{
  "evaluation_metadata": {
    "evaluator_name": "LLM-as-Judge Evaluator (Model: qwen3-235b-reasoning)",
    "evaluator_model": "qwen3-235b-reasoning",
    "model_evaluated": "gpt-oss-120b-reasoning",
    "experiment": "e5_page_window_relevance_asc",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions_in_experiment": 1000
  },
  "evaluation_results": [
    {
      "question_id": 77,
      "question": "How did the gross benefit obligation and the actuarial losses for LMT's nonqualified defined benefit pension plans evolve between 2023 and 2024?",
      "original_answer": "In 2023, the gross benefit obligation for LMT's nonqualified defined benefit pension plans was $1.0 billion with actuarial losses totaling $347 million. By 2024, the gross benefit obligation decreased to $905 million, and the actuarial losses declined to $303 million. This indicates a reduction in both the liability and the associated actuarial losses over the period.",
      "llm_answer": "The gross benefit obligation for the non‑qualified defined‑benefit pension plans fell from **$1.0 billion at year‑end 2023 to $905 million at year‑end 2024** (a $95 million decline)【page_86】.  Correspondingly, the actuarial losses (and unrecognized prior‑service credits) recorded in accumulated other‑comprehensive loss dropped from **$347 million in 2023 to $303 million in 2024** (a $44 million reduction)【page_90】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the gross benefit obligation decreased from $1.0 billion in 2023 to $905 million in 2024, and actuarial losses declined from $347 million to $303 million. The calculated differences ($95 million and $44 million) are correct, though not required, and add value. (2) The answer is complete, addressing both parts of the question—evolution of gross benefit obligation and actuarial losses—over the specified time period. (3) Entity accuracy is correct: LMT (Lockheed Martin) is the implied company, and the financial metrics and years (2023 and 2024) are properly identified. (4) The reasoning is sound and reflects proper multi-hop synthesis across the two years and two financial metrics. The use of citations (page_86, page_90) indicates grounding in source material. (5) The semantic meaning is equivalent to the original answer, with slightly more detail (explicitly stating the dollar reductions), which enhances clarity without introducing error. All criteria for a perfect score are met.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1196,
        "completion_tokens": 315,
        "total_tokens": 1512
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did General Motors' long-term rate of return assumptions on U.S. pension plan assets evolve between 2022 and 2024, and what does this indicate about the company's strategic asset mix adjustments?",
      "original_answer": "In 2022, General Motors reported that the weighted-average long-term rate of return on U.S. pension plan assets decreased from 5.6% at December 31, 2020, to 5.4% at December 31, 2021. By contrast, in 2024, the company indicated that the weighted-average long-term rate of return on U.S. pension plan assets increased from 6.3% at December 31, 2023, to 6.5% at December 31, 2024. This indicates a notable shift in the company's strategic asset mix, moving from a more conservative assumption in 2022 to a more optimistic projection in 2024, likely reflecting changes in capital market assumptions and investment strategies aimed at improving funded status.",
      "llm_answer": "The weighted‑average long‑term return assumption for GM’s U.S. pension plan assets slipped to **5.4 % at Dec 31 2021** (down from 5.6 % a year earlier) in the 2022 filing【page_86】, and then rose to **6.5 % at Dec 31 2024** (up from 6.3 % at Dec 31 2023) in the 2024 filing【page_88】.  This higher assumption coincides with a strategic re‑allocation – equity exposure grew from about **9 % to 11 %**, debt fell from roughly **68 % to 60 %**, and “other” assets (private‑equity, real‑estate, hedge‑fund strategies) increased from **≈23 % to 29 %**【page_86】【page_89】—signalling GM is shifting its pension portfolio toward higher‑return, more growth‑oriented assets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports the evolution of General Motors' long-term rate of return assumptions: 5.4% at Dec 31, 2021 (down from 5.6% in 2020) in the 2022 filing, and 6.5% at Dec 31, 2024 (up from 6.3% in 2023) in the 2024 filing. These values match the ground truth exactly. The answer also correctly identifies the shift in strategic asset mix, citing increases in equity and 'other' assets and a decrease in debt holdings.\n\n2) All numeric values are accurate: 5.4%, 5.6%, 6.3%, 6.5%, 9% to 11%, 68% to 60%, ≈23% to 29%. The time periods (Dec 31, 2021 and Dec 31, 2024) are correctly referenced. The directional changes (decrease then increase in return assumptions, portfolio shift toward growth assets) are correctly interpreted.\n\n3) The multi-hop reasoning is sound: the model connects pension return assumptions across two filings (2022 and 2024), synthesizes asset allocation changes, and infers strategic intent. The addition of specific allocation shifts (equity, debt, other) goes beyond the ground truth and adds valuable context, though this detail was not in the original answer. However, since it does not contradict and supports the conclusion, it strengthens the response.\n\n4) The only reason for not giving a perfect 10 is that the ground truth emphasizes the 'notable shift from a more conservative assumption in 2022 to a more optimistic projection in 2024' in the context of capital market assumptions and funded status — a nuance slightly underdeveloped in the LLM answer, though the conclusion about growth-oriented assets aligns well. Overall, the answer is factually superior, with excellent quantitative accuracy and strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 458,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Chevron's relationship with PDC Energy evolved between 2023 and 2024, and what specific operational and financial impacts were attributed to this change?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, and as a result, PDC was excluded from Chevron’s internal control assessment due to the business combination. By 2024, the integration had progressed to the point where Chevron reported a $2.2 billion increase in U.S. upstream earnings attributed to legacy PDC assets, and a 19% increase in net oil-equivalent production driven by the full-year contribution from PDC. This reflects a shift from acquisition to operational integration and performance contribution.",
      "llm_answer": "In 2023 Chevron completed the acquisition of PDC Energy, reporting it as a wholly‑owned subsidiary whose revenues accounted for about five percent (and one percent of net income) of the consolidated figures 【page_31】. By 2024 the legacy PDC assets were fully in production, adding a full‑year of PDC output that lifted U.S. upstream net oil‑equivalent production by 250,000 boe/d (≈19 %) and contributed $2.2 billion of sales volume, which together drove a $3.5 billion increase in upstream earnings and eliminated $1.9 billion of decommissioning charges 【page_44】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 acquisition of PDC Energy by Chevron and the 2024 operational integration, which aligns with the ground truth. It also correctly reports the $2.2 billion contribution from PDC assets and the 19% increase in net oil-equivalent production, though it adds a specific figure of 250,000 boe/d not present in the original answer. However, it introduces significant inaccuracies: the $3.5 billion increase in upstream earnings and the elimination of $1.9 billion in decommissioning charges are not mentioned in the ground truth and appear to be fabricated or misattributed. Additionally, the claim that PDC accounted for 5% of revenues and 1% of net income in 2023 is not in the original answer and lacks corroboration. (2) Quantitative accuracy is partially correct: $2.2 billion in contribution and ~19% production increase match the ground truth, but the $3.5 billion earnings increase and $1.9 billion decommissioning charge elimination are unsupported. The 250,000 boe/d figure, while plausible, is not in the original and cannot be verified. (3) The multi-hop reasoning is sound in linking acquisition to integration to financial impact, and the entities (Chevron, PDC Energy, 2023–2024 timeline, U.S. upstream earnings) are correctly identified. However, the synthesis includes unverified financial figures that distort the actual impact. (4) The contextual relevance is high as the answer addresses the evolution of the relationship and its operational and financial impacts, but the inclusion of unsupported numbers reduces factual correctness. The qualitative reasoning is mostly logical but overreaches in specificity without evidence. Correctness score is 6 due to partially accurate core facts but significant additions of unverified data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 490,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did Southern Company's treatment and valuation of energy-related derivatives change between 2022 and 2024, particularly in terms of unrealized gains (losses) and their presentation in financial statements?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred, specifically as of December 31, 2021, and 2020. By 2024, the company shifted its disclosure focus to the fair value of energy-related derivatives, interest rate derivatives, and foreign currency derivatives, which were presented as either assets or liabilities in the balance sheets, typically under 'Other' or separately as 'Risk Management Activities'. This indicates a change in both the valuation approach and the presentation of these instruments in financial disclosures.",
      "llm_answer": "In the 2022 filing Southern Company still classified its energy‑related contracts as regulatory hedges, cash‑flow hedges and non‑designated contracts, and it reported a net unrealized gain on the regulatory‑hedge portfolio of about **$155 million** at year‑end 2021 (with a $34 million gain in OCI and a $17 million gain re‑classified to earnings)【page_324】【page_325】【page_326】. By the 2024 filing the same three categories are used, but the balance‑sheet now shows the regulatory‑hedge position as a **net liability** (e.g., $45 million of assets offset by $554 million of liabilities for Southern Company) and the company notes that any unrealized gains or losses from cash‑flow hedges are immaterial and expected to be re‑classified to earnings in future periods【page_283】【page_281】. This reflects a shift from a net unrealized‑gain presentation in 2022 to a net‑liability presentation in 2024, with the impact of unrealized gains/losses on earnings becoming immaterial.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general shift in Southern Company's treatment and presentation of energy-related derivatives between 2022 and 2024, correctly identifying the move from reporting unrealized gains in regulatory hedges to presenting fair values as net liabilities on the balance sheet. However, there are significant quantitative inaccuracies that undermine the correctness. The $155 million net unrealized gain for year-end 2021 is not supported by the ground truth, which does not specify this number; similarly, the $34 million OCI gain and $17 million reclassified to earnings are not present in the original answer and appear fabricated or misattributed. The 2024 net liability figure of $554 million in liabilities offset by $45 million in assets is overly specific and not corroborated by the ground truth, which only states a general shift in presentation without providing exact figures. While the qualitative shift—from net unrealized gains to net liability presentation and immaterial impact on earnings—is consistent with the original answer, the inclusion of unsupported numbers reduces factual accuracy. The reasoning is logically structured and contextually relevant, showing awareness of multi-hop elements (comparing disclosures across years and categories), but the synthesis relies on potentially incorrect data points. Semantic equivalence is partially achieved in narrative flow but compromised by invented figures. Thus, the answer is partially correct with significant factual gaps in quantification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 419,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Chevron's financial relationship with Tengizchevroil evolve between 2022 and 2024, particularly in terms of its investment carrying value and equity earnings?",
      "original_answer": "In 2022, Chevron disclosed that its carrying value of its investment in Tengizchevroil (TCO) was about $100 higher than its underlying equity in TCO's net assets, with a significant portion of the investment tied to a $4,500 loan to fund the FGP/WPMP development. By 2024, Chevron's financial stake in Tengizchevroil had grown substantially, with its investment and advances reaching $27,368 million in 2024, compared to $26,954 million in 2023. Additionally, Chevron's equity in earnings from TCO declined from $4,386 million in 2022 to $3,033 million in 2024, indicating a reduction in profitability from the venture over this period.",
      "llm_answer": "Chevron’s book value of its 50 % stake in Tengizchevroil grew to about $27.4 billion at year‑end 2024 (up from a lower balance shown in the 2022 filing), while the equity earnings it recorded from the joint‑venture fell from $4.386 billion in 2022 to $3.033 billion in 2024.  The premium of the carrying amount over TCO’s underlying net‑asset equity also narrowed, from roughly $100 million in 2021 to about $73 million in 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution of Chevron's financial relationship with Tengizchevroil between 2022 and 2024, correctly identifying the increase in investment carrying value to $27.4 billion in 2024 (aligned with the $27,368 million in the ground truth) and the decline in equity earnings from $4.386 billion in 2022 to $3.033 billion in 2024. However, there are key quantitative inaccuracies: (1) The ground truth states the $100 million premium existed in 2022, not 2021 as claimed by the LLM; (2) The LLM introduces a $73 million premium in 2024, which is not mentioned in the original answer and cannot be verified from the provided truth. Additionally, while the LLM correctly notes the carrying value increase, it omits the specific $4,500 loan detail tied to the FGP/WPMP development, a key component of the investment structure. The qualitative reasoning is sound—correctly framing the growing investment and declining earnings as central trends—and the entities (Chevron, Tengizchevroil, equity earnings, carrying value) and years are accurate. Contextually, the answer is highly relevant, addressing both parts of the multi-hop question (investment value and earnings). However, the introduction of an unverified figure ($73 million in 2024) and the misplacement of the $100 million premium to 2021 reduce quantitative accuracy. The omission of the loan detail affects completeness but not core correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 393,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Walmart's ownership stake in Alert Innovation evolve between fiscal 2023 and fiscal 2024, and what specific transaction occurred to change its relationship with the entity?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, which was previously consolidated as a variable interest entity, resulting in Walmart becoming a 100% owner. However, by fiscal 2024, Walmart had subsequently sold and deconsolidated Alert Innovation, indicating a complete exit from the entity. This marks a full transformation from full ownership to no ownership within a single fiscal year.",
      "llm_answer": "Walmart did not own Alert Innovation outright until fiscal 2023, when it completed a $0.4 billion acquisition that turned the former variable‑interest entity into a 100 %‑owned subsidiary【page_65】. The ownership remained at 100 % through fiscal 2024, with the acquisition being the specific transaction that altered the company’s relationship with Alert Innovation (the entity was later sold in fiscal 2025).",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that Walmart completed a $0.4 billion acquisition of Alert Innovation in fiscal 2023, making it a 100% owned subsidiary, it incorrectly claims that ownership remained at 100% through fiscal 2024. The ground truth states that Walmart sold and deconsolidated Alert Innovation by fiscal 2024, indicating a complete exit — not continued ownership. The LLM incorrectly pushes the sale to fiscal 2025, which is not supported by the original answer and contradicts the timeline. (2) Quantitatively, the $0.4 billion acquisition amount is correct, and the 100% ownership post-acquisition is accurate. However, the misplacement of the sale to fiscal 2025 introduces a critical timing error, affecting the correctness of the ownership status in fiscal 2024. (3) The multi-hop reasoning is flawed: the question asks about the evolution between fiscal 2023 and 2024, requiring synthesis of both the acquisition and the subsequent sale within that window. The LLM fails to correctly sequence these events, missing the deconsolidation in fiscal 2024 entirely. (4) Contextual relevance is fair because the answer addresses the acquisition and mentions a future sale, but the incorrect timeline undermines the core of the response. The answer suggests continuity of ownership when there was a full exit, leading to a low correctness score despite some accurate details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 401,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions change from fiscal year 2022 to 2023, and what does this indicate about the company's exposure management strategy?",
      "original_answer": "In fiscal year 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in Accumulated Other Comprehensive Income (AOCI) with $32.5 million expected to be reclassified into earnings within 12 months. By fiscal year 2023, Starbucks had shifted its position significantly, reporting foreign currency - other derivative assets of $1.9 million in current assets and $1.7 million in long-term assets, while carrying derivative liabilities of $4.7 million in current liabilities and $4.1 million in long-term liabilities. This indicates a substantial reduction in overall foreign currency - other derivative exposure and a shift from unrealized gains in equity to more balanced short- and long-term asset and liability positions.",
      "llm_answer": "Starbucks’ “foreign‑currency – other” hedge went from a large net‑asset position in FY 2022 to a modest net‑liability position in FY 2023. In 2022 the company held about **$73 million of designated foreign‑currency‑other derivative assets** (‑$39.9 m prepaid + $33.5 m long‑term) and only **$0.3 m of liabilities** (see 2022 page 68); by FY 2023 the assets had fallen to roughly **$3.6 million** (‑$1.9 m prepaid + $1.7 m long‑term) while liabilities rose to **$8.8 million** (‑$4.7 m accrued + $4.1 m long‑term) (see 2023 page 72). This shift from a net‑asset hedge to a net‑liability hedge suggests Starbucks trimmed its asset‑based foreign‑currency hedges and is now relying more on liability‑based or net‑ting arrangements, reflecting a strategic adjustment in how it manages foreign‑exchange exposure.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, in FY 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in AOCI, with $32.5 million expected to be reclassified within 12 months. The LLM incorrectly states total designated derivative assets as $73 million ($39.9 million prepaid + $33.5 million long-term), which does not match the ground truth and appears to misrepresent the location and nature of the amounts (e.g., 'prepaid' vs. AOCI). Additionally, the LLM claims $0.3 million in liabilities in 2022, but the ground truth does not mention any liability position for 2022, so this figure is unsupported. In FY 2023, the LLM correctly identifies the asset split ($1.9 million current and $1.7 million long-term) and liability split ($4.7 million current and $4.1 million long-term), aligning with the ground truth totals of $3.6 million in assets and $8.8 million in liabilities. However, the ground truth emphasizes a shift from an AOCI-based unrealized gain to on-balance-sheet asset/liability positions, while the LLM mischaracterizes the 2022 position as on-balance-sheet prepaid/long-term assets. (2) Calculations: The LLM’s sum of $39.9M + $33.5M = $73.4M (rounded to $73M) is mathematically correct but based on incorrect source data. The 2023 totals are accurate: $1.9M + $1.7M = $3.6M assets; $4.7M + $4.1M = $8.8M liabilities. (3) Multi-hop reasoning: The LLM correctly infers a strategic shift from a net asset to net liability position, which is consistent with the ground truth’s conclusion about reduced exposure and rebalancing. However, it misrepresents the nature of the 2022 position by placing it in prepaid/long-term assets rather than AOCI, failing to capture the key distinction between equity-recycled unrealized gains and balance sheet derivatives. This undermines the accuracy of the comparative analysis. (4) Despite incorrect quantification of the 2022 position, the LLM captures the directional change and offers a plausible interpretation of strategic adjustment in exposure management, earning partial credit for qualitative reasoning and full marks for contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 589,
        "total_tokens": 1992
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Medtronic's treatment of A Preferred Shares evolve between fiscal years 2022 and 2024, and what specific action was taken regarding these shares in 2022?",
      "original_answer": "In fiscal year 2022, Medtronic redeemed 1,872 A Preferred Shares for $0.075 million during the third quarter, and no A Preferred Shares were outstanding by April 29, 2022. By fiscal year 2024, no A Preferred Shares remained outstanding, indicating that the company did not reissue or reintroduce this class of shares after the redemption in 2022. This shows a discontinuation of the A Preferred Shares following their redemption.",
      "llm_answer": "By fiscal 2022 Medtronic had eliminated its A Preferred Shares – it redeemed the 1,872 shares then outstanding for $0.075 million, leaving the class with no shares outstanding at April 29, 2022【page_81】. The 2024 filing shows the same situation: the 500 k authorized A Preferred Shares remain authorized but none are issued or outstanding, indicating no re‑issuance after the 2022 redemption【page_81】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Medtronic redeemed 1,872 A Preferred Shares for $0.075 million in fiscal year 2022, with no shares outstanding by April 29, 2022, and confirms that no re-issuance occurred by fiscal year 2024. These facts align with the ground truth. The mention of 500k authorized shares remaining authorized but unissued is consistent with the original answer’s implication that the shares were not reintroduced. (2) All numeric values—1,872 shares, $0.075 million, April 29, 2022—are accurate and match the ground truth. The dollar amount is correctly formatted (e.g., $0.075 million = $75,000), and the date is exact. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across fiscal years 2022 and 2024, inferring from the absence of issued shares in 2024 that there was no reissuance, which supports the conclusion of discontinuation. The only minor gap is that the original answer explicitly states the 'discontinuation' of the shares, while the LLM implies it by stating none were reissued—this nuance slightly affects qualitative accuracy but does not undermine correctness. (4) The answer is fully contextually relevant, directly addressing both parts of the question: the 2022 action (redemption) and the evolution through 2024 (no reissuance). Overall, the answer is factually complete and semantically equivalent to the ground truth, warranting a high correctness score with only a slight deduction in qualitative reasoning for not explicitly stating the discontinuation conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 430,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did Comcast's financial relationship with Atairos evolve between 2022 and 2023, particularly in terms of equity income (losses) driven by fair value adjustments on underlying investments?",
      "original_answer": "In 2022, Comcast's equity in net income (losses) from investees, particularly Atairos, showed a loss of $(434) million due to fair value adjustments on its underlying investments. In contrast, by 2023, Atairos generated income of $1.1 billion for Comcast, reflecting a significant turnaround. This change indicates a substantial improvement in the performance of Atairos's underlying investments over the period.",
      "llm_answer": "Comcast’s equity‑income from its investment in Atairos swung from a loss in 2022 to a gain in 2023. In 2022 the company recorded a net equity loss of $537 million, reflecting a $434 million fair‑value loss on Atairos’s underlying investments; in 2023 that turned into a $789 million equity gain, driven by a $1.1 billion fair‑value gain at Atairos【page_39】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general trend of Comcast's financial relationship with Atairos improving from a loss in 2022 to a gain in 2023, which aligns with the ground truth. However, there are significant quantitative inaccuracies. The ground truth states a 2022 equity loss of $(434) million due to fair value adjustments, but the LLM claims a total net equity loss of $537 million, with $434 million attributed to fair value loss—this breakdown is not supported by the original answer and introduces an unverified total loss figure. Additionally, the 2023 income is stated as $1.1 billion in the ground truth, but the LLM reports a $789 million equity gain for Comcast, which contradicts the correct figure. While the direction of change (loss to gain) and the attribution to fair value adjustments are correct, the specific numbers are inaccurate, undermining the correctness of the financial analysis. The reasoning is partially sound in identifying a turnaround, but the synthesis of numbers is flawed. Entity accuracy (Comcast, Atairos, years) and contextual relevance are strong, but the quantitative errors severely limit factual reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 324,
        "total_tokens": 1527
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure slightly declined to 296 billion cubic feet. This minor decrease suggests limited growth or a strategic reallocation of resources in the region during that period.",
      "llm_answer": "COP’s proved natural‑gas reserves in the Asia Pacific/Middle East region slipped from 312 billion cubic feet at year‑end 2023 to 296 billion cubic feet at year‑end 2024 (the developed portion fell from 305 bcf to 289 bcf)【page_145】. The modest decline, even though the 2024 filing notes “extensions and discoveries in our equity affiliates were in the Middle East and Australia”【page_146】, indicates that ConocoPhillips is maintaining a modest, largely static presence in the region rather than aggressively expanding its gas portfolio there.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the natural gas reserves for COP in the Asia Pacific/Middle East region as 312 billion cubic feet in 2023 and 296 billion cubic feet in 2024, matching the ground truth exactly. The additional detail about developed reserves (305 bcf to 289 bcf) is accurate and adds context without contradicting the main figures. (2) All numbers and dates are correct, and the minor decline of 16 billion cubic feet is accurately implied. No calculation errors. (3) The reasoning is sound: despite extensions and discoveries in the Middle East and Australia noted in the filing, the overall reserves declined slightly, supporting the conclusion of a static or non-aggressive growth strategy. The LLM appropriately infers strategic positioning consistent with the ground truth's interpretation of 'limited growth or strategic reallocation.' The only reason for not scoring a 10 in qualitative accuracy is that the original answer did not mention 'developed portion' or 'equity affiliates,' so while the added detail is correct, it slightly exceeds the scope of the ground truth without changing the core meaning. (4) The answer is fully relevant, addresses both parts of the question (evolution of reserves and strategic implication), and maintains semantic equivalence with the original answer while enhancing context with properly cited details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 383,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the revenue performance of ENBREL in Canada evolve between 2022 and 2024, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ENBREL in Canada generated $113 million in revenue, which declined to $47 million in 2023, and further dropped to $28 million in 2024. This indicates a consistent downward trend in revenue, suggesting a shrinking market presence or reduced demand for ENBREL in Canada over this period.",
      "llm_answer": "ENBREL’s Canadian sales fell sharply, from $73 million in 2022 to $47 million in 2023 (‑36 %) and then to $28 million in 2024 (‑40 % YoY, roughly a 62 % decline from 2022)【page_71】. This steep, accelerating drop indicates a contracting Canadian market for ENBREL, suggesting weakening demand and increasing pressure on its sales trajectory.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $47 million revenue in 2023 and $28 million in 2024, which match the ground truth. However, it incorrectly states the 2022 revenue as $73 million instead of the correct $113 million. This error affects all subsequent calculations and comparisons. (2) The percentage declines are therefore inaccurate: the LLM reports a 36% drop from 2022 to 2023 and a 62% total decline from 2022 to 2024, but with the correct 2022 figure ($113M), the actual drop to $47M is about 58.4%, and to $28M is about 75.2% — significantly steeper than the LLM's calculated 62%. While the YoY drop from $47M to $28M (~40.4%) is approximately correct, the baseline error undermines overall quantitative accuracy. (3) The reasoning and synthesis are sound — the model correctly interprets the declining trend and infers a contracting market, which aligns with the ground truth's conclusion about shrinking market presence. It also correctly identifies the multi-year trajectory and draws a logical qualitative conclusion. (4) Contextual relevance is high, as the answer addresses both parts of the question: revenue evolution and market trajectory. Despite the critical error in the initial revenue figure, the directionality and trend interpretation remain valid. The score is reduced primarily due to the significant inaccuracy in the 2022 revenue number, which is central to the multi-hop analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1156,
        "completion_tokens": 395,
        "total_tokens": 1552
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Qualcomm's approach to linking human capital advancements with executive compensation evolved from fiscal 2023 to fiscal 2024, and what specific performance modifier range was applied in fiscal 2024?",
      "original_answer": "In fiscal 2023, Qualcomm indicated that human capital advancements would be considered in determining executives' fiscal 2024 bonus. By fiscal 2024, this approach evolved into a more defined structure where progress toward human capital advancements served as a non-financial performance modifier that could adjust executives' bonus payouts by a multiplier ranging from 0.9 to 1.1. This represents a shift from a general consideration to a quantified performance modifier in executive compensation.",
      "llm_answer": "In the 2023 filing Qualcomm said the Board’s HR and Compensation Committee would take progress on human‑capital initiatives into account when setting executive bonuses, but it did not attach a quantified adjustment 【page_15】. By fiscal 2024 the company refined that practice, using a non‑financial performance modifier that could raise or lower an executive’s bonus by a multiple of 0.9 to 1.1 times the target amount 【page_16】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately captures the evolution from fiscal 2023 to 2024: in 2023, human capital progress was considered but not quantified, while in 2024 it became a formal non-financial performance modifier. (2) The specific performance modifier range of 0.9 to 1.1 is correctly stated, matching the ground truth exactly. (3) The multi-hop reasoning is sound—comparing Qualcomm’s compensation approach across two fiscal years and identifying the structural change from qualitative consideration to a quantitative adjustment. (4) All entities (Qualcomm, fiscal years 2023 and 2024, executive compensation, bonus modifier) are correctly identified and synthesized. Minor wording differences (e.g., 'take into account' vs 'considered') do not affect factual accuracy. The inclusion of page references adds contextual support without altering correctness. All scoring categories warrant top marks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 279,
        "total_tokens": 1526
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has the therapeutic scope of Breyanzi evolved between 2022 and 2024, based on the specific indications and approvals documented in those years?",
      "original_answer": "In 2022, Breyanzi was associated with trials for 3L+ Chronic Lymphocytic Leukemia (TRANSCEND-CLL-004) and 3L+ Follicular Lymphoma (TRANSCEND-FL), both with expected timing in 2023/24. By 2024, Breyanzi received FDA accelerated approvals for two distinct indications: relapsed or refractory Follicular Lymphoma (FL) after at least two prior lines of therapy (approved in May 2024), and relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) after at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor (approved in March 2024). This reflects a shift from being in late-stage trials to having concrete accelerated approvals in specific patient populations.",
      "llm_answer": "In the 2022 filing Breyanzi was only listed as a pipeline product being studied in third‑line chronic lymphocytic leukemia (CLL) and third‑line follicular lymphoma (FL) (see the Hematology pipeline table on page 20). By the 2024 filing the drug had moved to multiple approved indications – an FDA accelerated approval for relapsed/refractory CLL/SLL (March 2024), an FDA accelerated approval for relapsed/refractory mantle‑cell lymphoma (May 2024), and a Japanese Ministry approval for relapsed/refractory FL (August 2024) – expanding its therapeutic scope to three distinct B‑cell malignancies (see approval tables on pages 44‑45).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. While it correctly identifies Breyanzi's status in 2022 as being in trials for 3L+ CLL and FL, it incorrectly states the 2024 approvals. According to the ground truth, Breyanzi received two FDA accelerated approvals in 2024: for relapsed/refractory FL (May 2024) and for relapsed/refractory CLL/SLL (March 2024). However, the LLM answer incorrectly claims an FDA approval for mantle-cell lymphoma in May 2024, which is not supported by the original answer. Additionally, it mentions a Japanese Ministry approval for FL in August 2024, which is absent from the ground truth. These are major entity and indication errors. The timeline is partially correct (March and May 2024 approvals), but the indications are mismatched. The model also adds an approval (Japan) not present in the original data, indicating fabrication or misattribution. While the general reasoning about expansion from pipeline to approved status is sound and contextually relevant, the specific therapeutic indications and regulatory milestones are partially incorrect, leading to a low quantitative accuracy score. The qualitative accuracy is moderate because the model captures the evolution concept but fails on key details. Contextual relevance is high as it directly addresses the question's focus on therapeutic scope evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 384,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the financial performance of Disney's Resorts and Vacations segment evolved from 2023 to 2024, and how does this compare to the overall revenue growth of the Parks & Experiences segment?",
      "original_answer": "The Resorts and Vacations segment saw an increase in revenue from $7,949 million in 2023 to $8,375 million in 2024, representing a 5% growth. This growth was slightly below the overall Parks & Experiences revenue growth of 5%, which increased from $32,549 million in 2023 to $34,151 million in 2024. The Resorts and Vacations segment remained a significant contributor to the overall Parks & Experiences division, maintaining a consistent proportion of total revenue despite the modest growth difference.",
      "llm_answer": "Disney’s Resorts and Vacations revenue rose from $7.949 billion in 2023 to $8.375 billion in 2024 – a 5% increase year‑over‑year【page_47】.  The Parks & Experiences segment overall also grew 5%, climbing from $32.549 billion to $34.151 billion in the same period【page_47】, so the Resorts and Vacations line performed in line with the segment’s total revenue growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all financial figures: Resorts and Vacations revenue increased from $7,949 million ($7.949 billion) in 2023 to $8,375 million ($8.375 billion) in 2024, representing a 5% growth. The Parks & Experiences segment overall grew from $32,549 million to $34,151 million, also a 5% increase. These numbers match the ground truth exactly, with acceptable format variation (billion vs. million). (2) Calculations are accurate: (8,375 - 7,949) / 7,949 ≈ 5.36%, which rounds to 5% as reported; similarly, (34,151 - 32,549) / 32,549 ≈ 4.92%, also reasonably rounded to 5%. The model correctly identifies that Resorts and Vacations growth was in line with overall segment growth. (3) The multi-hop reasoning is sound: the model synthesizes data from two related segments across two years and correctly compares their growth rates. (4) The only minor shortcoming is that the LLM answer omits the point about Resorts and Vacations maintaining a consistent proportion of total revenue, which was included in the original answer and adds contextual depth. However, the core facts, calculations, and comparison are correct and relevant. Thus, the answer is highly accurate and contextually appropriate, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 377,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has the structure and value of CVS's forward contracts associated with accelerated share repurchase (ASR) transactions evolved between 2023 and 2024?",
      "original_answer": "In 2023, CVS executed a $2.0 billion ASR with Citibank, N.A., which was accounted for as an initial treasury stock transaction of $1.6 billion and a forward contract of $0.4 billion. The forward contract was classified as an equity instrument and recorded within capital surplus, with the final 20% of shares received in February 2023. In 2024, CVS entered into a larger $3.0 billion ASR with Morgan Stanley, accounted for as an initial treasury stock transaction of $2.6 billion and a forward contract of $0.4 billion. The forward contract was similarly classified and recorded, but the remaining 15% of shares were received later, in March 2024. Despite the increase in the ASR size, the forward contract value remained constant at $0.4 billion, indicating a shift in the proportion of the ASR allocated to the forward contract component.",
      "llm_answer": "In 2023 CVS completed a $2.0 billion fixed‑dollar ASR with Citibank that was accounted for as an initial treasury‑stock purchase of $1.6 billion plus a $0.4 billion forward contract recorded as an equity instrument in capital surplus and later re‑classified to treasury stock when the final shares were delivered 【page_75】. In 2024 the company entered a larger $3.0 billion ASR with Morgan Stanley, but used the same structure—a $0.4 billion forward contract initially placed in capital surplus and then moved to treasury stock at settlement 【page_73】. Thus, the forward‑contract structure stayed the same, and its value remained $400 million despite the underlying ASR size increasing from $2.0 billion to $3.0 billion.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key facts: the 2023 $2.0 billion ASR with Citibank, structured as $1.6 billion treasury stock and $0.4 billion forward contract; the 2024 $3.0 billion ASR with Morgan Stanley, structured as $2.6 billion treasury stock and $0.4 billion forward contract; and the consistent $0.4 billion forward contract value despite the larger ASR size. All dollar amounts and company names are accurate. (2) Quantitative accuracy is perfect: $0.4 billion = $400 million, and the proportions (e.g., $1.6B + $0.4B = $2.0B; $2.6B + $0.4B = $3.0B) are correct. The answer correctly notes the forward contract value remained constant. (3) The multi-hop reasoning is sound—comparing the structure and value of forward contracts across two years and two different ASRs. The conclusion that the structure and value remained the same is logically supported. One minor omission: the original answer specifies the timing of final share receipt (February 2023 and March 2024), which the LLM answer omits. While not critical to the core question about structure and value, it slightly reduces completeness. (4) The LLM answer is semantically equivalent to the ground truth, with slightly less temporal detail but full accuracy on structure, value, and entities. Contextual relevance is excellent, directly addressing the evolution of structure and value. Thus, correctness is 9 due to the minor omission of settlement timing, but all key financial and structural facts are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 416,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Duke Energy's disclosure regarding the Master Retirement Trust's pension asset valuation methodology evolve from 2023 to 2024, particularly in terms of transparency around fair value categorization?",
      "original_answer": "In 2023, Duke Energy disclosed the allocation percentages of the Master Retirement Trust among its subsidiaries and noted that certain investments measured at fair value using the net asset value per share practical expedient were not categorized in the fair value hierarchy. In 2024, the company maintained the same allocation percentages but added a new disclosure element — a reconciliation of beginning and ending balances of the Master Retirement Trust's qualified pension and other post-retirement assets, specifically those valued using significant unobservable inputs (Level 3). This represents a significant increase in transparency regarding the fair value categorization of pension assets.",
      "llm_answer": "In the 2023 filing Duke Energy explained that the Master Retirement Trust’s assets are valued using the fair‑value hierarchy (Level 1, 2, 3) and that “certain investments that are measured at fair value using the net‑asset‑value‑per‑share practical expedient have not been categorized in the fair‑value hierarchy” (see page 219). The 2024 filing retained the same valuation approach but now presents a distinct “Not Categorized (b)” column in the fair‑value table and repeats the footnote clarifying those un‑categorized items, thereby making the fair‑value categorization more explicit and transparent (see page 228).",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Duke Energy and the relevant years (2023 and 2024), and accurately notes the continued use of the net asset value per share practical expedient for certain investments not categorized in the fair value hierarchy. It also correctly states that the valuation approach remained consistent between years. However, it fails to mention the key new disclosure in 2024 — the reconciliation of beginning and ending balances for Level 3 assets — which is the central element of increased transparency highlighted in the ground truth. Instead, the LLM focuses on the addition of a 'Not Categorized (b)' column and repetition of a footnote, which may reflect formatting changes but does not capture the substantive new disclosure of Level 3 rollforwards. (2) There are no explicit numerical errors; the answer does not introduce incorrect percentages, dollar amounts, or dates. The reference to page numbers (219, 228) may be accurate within the filing but are not verifiable from the ground truth and do not affect scoring. (3) The multi-hop reasoning is partially sound — the model correctly compares disclosures across two years and identifies a change in presentation. However, it misidentifies the nature of the enhanced transparency: the addition of a column and repeated footnote is less significant than the introduction of a full Level 3 balance reconciliation, which provides insight into changes in unobservable inputs and is a material improvement in fair value disclosure. The LLM misses this critical evolution in disclosure depth. (4) The answer is contextually relevant and well-structured, but lacks completeness in capturing the most important new element of transparency. While it notes improved explicitness in categorization, it does so based on peripheral formatting details rather than the substantive new quantitative reconciliation. This results in a partially correct, but ultimately incomplete and somewhat misleading assessment of the evolution in disclosure quality.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 547,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did Pfizer's financial obligations and revenue recognition related to Paxlovid change between 2023 and 2024, particularly concerning the U.S. government's inventory return and the creation of the U.S. Strategic National Stockpile?",
      "original_answer": "In 2023, Pfizer recorded a non-cash revenue reversal of $3.5 billion related to the expected return of 6.5 million EUA-labeled Paxlovid treatment courses previously purchased by the U.S. government. In 2024, this estimate was adjusted based on the actual return of 5.1 million treatment courses, resulting in a favorable final adjustment of $771 million. Additionally, in 2024, Pfizer recognized $442 million of revenue in connection with the creation of the U.S. Strategic National Stockpile (SNS) of 1.0 million Paxlovid treatment courses for future pandemic preparedness. These developments reflect a shift from revenue reversal and inventory transition in 2023 to revenue recognition and strategic stockpile establishment in 2024.",
      "llm_answer": "In 2023 Pfizer booked a $3.5 billion non‑cash revenue reversal for Paxlovid in Q4, reflecting the expected return of about 6.5 million EUA‑labeled treatment courses from the U.S. government, and carried $3.4 billion of Paxlovid‑related deferred revenue (‑$1.5 billion current, $1.9 billion non‑current) and $3.4 billion of performance‑obligation liability ​【page_112】. In 2024 the actual return was lower (5.1 million courses), producing a $771 million favorable adjustment in Q1 and a $442 million revenue credit for the creation of a 1‑million‑course U.S. Strategic National Stockpile (recorded with no cash consideration), which together cut deferred Paxlovid revenue to $2.2 billion ($1.4 billion current, $785 million non‑current) and reduced Paxlovid performance obligations to roughly $1 billion ​【page_109】【page_110】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all key aspects. (1) Quantitatively, all numbers are accurate: the $3.5 billion non-cash revenue reversal in 2023 for 6.5 million treatment courses is correctly stated; the 2024 favorable adjustment of $771 million due to the actual return of 5.1 million courses is exact; and the $442 million revenue recognition from the U.S. Strategic National Stockpile for 1 million courses is correctly reported. The LLM also provides additional but consistent detail on deferred revenue and performance obligations, which aligns with the broader context of revenue recognition changes. (2) The answer is complete, addressing both years, the U.S. government inventory return, the adjustment mechanism, and the new SNS stockpile creation. (3) Entity accuracy is perfect: Pfizer, Paxlovid, EUA-labeled courses, U.S. government, and the Strategic National Stockpile are all correctly identified and contextualized. (4) The reasoning is sound and reflects multi-hop synthesis: it connects the 2023 estimate to the 2024 adjustment based on actual returns, explains the shift from reversal to recognition, and incorporates the accounting impact on deferred revenue and liabilities. (5) Semantic equivalence is strong—the LLM conveys the same core narrative as the ground truth, with enhanced financial detail (e.g., breakdown of current/non-current liabilities) that is consistent with the source material. Minor wording differences do not affect factual accuracy. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 425,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the financial performance of ERLEADA evolved between 2022 and 2023, and what does this indicate about its role in J&J's oncology portfolio?",
      "original_answer": "ERLEADA's sales increased from $1,881 million in 2022 to $2,387 million in 2023, representing a 26.9% growth. This indicates that ERLEADA has become a more prominent contributor to J&J's oncology segment, which saw overall growth of 10.5% in 2023. The strong performance of ERLEADA contrasts with the decline in other key oncology products like IMBRUVICA and ZYTIGA, suggesting that ERLEADA is playing an increasingly important role in sustaining J&J's oncology revenue.",
      "llm_answer": "ERLEADA’s sales climbed from $1.9 billion in 2022 to $2.4 billion in 2023 – a 26.9% (≈27%) year‑over‑year increase (see page 31). The MD&A notes that this growth was driven by “continued share gains and market growth in Metastatic Castration‑Resistant Prostate Cancer” (page 32), indicating that ERLEADA has become a key growth driver and an increasingly important pillar of Johnson & Johnson’s oncology portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports ERLEADA's sales growth from $1.9 billion in 2022 to $2.4 billion in 2023, which aligns with the ground truth values of $1,881 million and $2,387 million (rounded appropriately). The calculated growth rate of 26.9% is accurate and matches the ground truth. 2) Quantitatively, all numbers are correct when allowing for format variation (e.g., $1.9 billion ≈ $1,881 million; $2.4 billion ≈ $2,387 million). The percentage increase is precisely calculated: (2387 - 1881) / 1881 ≈ 26.9%. 3) The reasoning is sound: the LLM identifies ERLEADA as a key growth driver in J&J’s oncology portfolio, supported by market share gains and expansion in mCRPC. While the LLM does not explicitly contrast ERLEADA’s performance with declining products like IMBRUVICA and ZYTIGA (a minor omission), it still correctly infers ERLEADA’s increasing strategic importance. 4) The answer is contextually relevant, directly addressing both the financial evolution and the product’s role in the oncology portfolio. The reference to MD&A and specific pages adds credibility. The only reason for not scoring a 10 is the lack of explicit comparison to other oncology products’ performance, which was part of the original answer’s multi-hop synthesis. However, the core facts, calculations, and qualitative inference are correct and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 374,
        "total_tokens": 1596
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the global sales performance of ERLEADA evolve from 2022 to 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA reported worldwide sales of $1,291 million, with a significant growth rate of 70.0% compared to the previous year. By 2023, the product's global sales increased further to $2,387 million, reflecting a 26.9% growth from 2022. This indicates that ERLEADA continued to experience strong market adoption and revenue expansion, albeit at a slower growth rate compared to the prior year, suggesting a maturing growth phase in its lifecycle.",
      "llm_answer": "ERLEADA’s worldwide sales grew from $1.881 billion in 2022 to $2.387 billion in 2023 – a year‑over‑year increase of about 27 % (operations‑driven growth of 27.5% with a modest ‑0.6% currency impact)【page_31】. The company attributes this rise to “continued share gains and market growth in Metastatic Castration‑Resistant Prostate Cancer,” indicating a strong, upward market trajectory for the drug【page_32】.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a major factual error in the 2022 sales figure—stating $1.881 billion instead of the correct $1.291 billion from the ground truth. This significantly undermines quantitative accuracy. The 2023 sales figure ($2.387 billion) is correct and matches the original answer. The reported growth rate of ~27% is close to the correct 26.9%, so this part is acceptable. However, the calculation of growth rate based on the incorrect 2022 figure would yield a much lower increase (around 27% from $1.881B to $2.387B), which coincidentally aligns numerically but is based on wrong inputs. (2) The original answer states a 70.0% growth in 2022 (from 2021), which the LLM completely omits, failing to address the full evolution from 2022 to 2023 in context. This omission breaks the multi-hop aspect of assessing performance across both years and their respective growth trends. (3) The reasoning about market trajectory is sound—citing market growth and share gains in mCRPC is consistent with strong adoption—and the conclusion of an upward trajectory aligns semantically with the ground truth’s 'strong market adoption and revenue expansion'. However, the LLM misses the nuance that growth slowed from 70% to 26.9%, indicating a maturing phase, which is a key analytical point in the original answer. (4) Despite correct sourcing cues (page references), the incorrect base year sales figure severely impacts factual reliability. While the directionality and qualitative interpretation are reasonable, the core data is flawed, warranting a moderate correctness score. Contextual relevance is high as the answer addresses sales evolution and market trajectory as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 462,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did NVDA's debt management strategy evolve regarding the 0.584% Notes Due 2024 between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a balance of $1,250 million for the 0.584% Notes Due 2024, with an effective interest rate of 0.66%. By fiscal year 2024, NVDA disclosed in its 10-K filing that it repaid these notes in fiscal year 2025, resulting in no remaining balance for this instrument as of January 26, 2025. This indicates a shift in NVDA's debt management strategy, where it chose to retire the obligation before or shortly after the due date rather than rolling it over or extending it.",
      "llm_answer": "In FY 2023 NVIDIA still had the $1.25 billion of 0.584 % notes due 2024 on its balance sheet (shown as a short‑term liability)【page_72】.  By the end of FY 2024 the same $1.25 billion remained outstanding, indicating the company chose to keep the low‑cost debt through FY 2024 rather than retire it early (the notes were only repaid in FY 2025)【page_72】.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $1.25 billion balance of the 0.584% Notes Due 2024 in FY 2023 and the fact that repayment occurred in FY 2025, which aligns with the ground truth. However, it incorrectly states that the same $1.25 billion 'remained outstanding' by the end of FY 2024, which contradicts the original answer stating there was 'no remaining balance' as of January 26, 2025 — a date after FY 2024 ended. This misrepresents NVDA's debt management evolution, implying the debt was still carried at year-end when it had already been repaid. (2) Quantitatively, the dollar amount ($1.25 billion) and interest rate (implied from context) are accurate, and formatting variations ($1.25 billion vs $1,250 million) are acceptable. The fiscal years and repayment timing are partially correct but misaligned — repayment in FY 2025 is accurate, but the assertion that the debt remained outstanding at the end of FY 2024 conflicts with the zero balance reported as of January 26, 2025, which falls in FY 2025. (3) The multi-hop reasoning is flawed: the model fails to connect the repayment event to the resulting balance elimination, incorrectly inferring continued liability at FY 2024 end. It misinterprets the strategic shift — the ground truth emphasizes retirement rather than rollover, but the LLM suggests a deliberate choice to 'keep the low-cost debt,' which is unsupported. (4) Contextual relevance is strong — the answer addresses NVDA, the correct notes, and the relevant fiscal years — but the qualitative inaccuracy in reasoning and balance status significantly undermines correctness. Thus, partial credit is given for accurate inputs but major deductions for incorrect synthesis and conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 472,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Honeywell's investment in Mortgage/Asset-backed securities evolve between 2022 and 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, Honeywell reported $982 million invested in Mortgage/Asset-backed securities under U.S. Plans. By 2023, this amount had significantly decreased to $10 million under Non-U.S. Plans. This represents a reduction of $972 million, or over 98%, indicating a major shift in Honeywell's investment strategy concerning Mortgage/Asset-backed securities.",
      "llm_answer": "Honeywell cut its mortgage‑backed securities holdings. For U.S. pension plans the balance fell from $1,119 million at 12/31/2022 to $676 million at 12/31/2023 (a $443 million drop) 【page_109】, and for non‑U.S. plans it fell from $31 million to $10 million (a $21 million drop) 【page_110】. Overall, the company’s mortgage/asset‑backed securities investment declined by roughly $464 million between 2022 and 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Honeywell had $982 million invested in Mortgage/Asset-backed securities under U.S. Plans in 2022 and only $10 million under Non-U.S. Plans in 2023, representing a shift from U.S. to Non-U.S. plans and a total reduction of $972 million. However, the LLM claims the U.S. plan investment was $1,119 million in 2022 and dropped to $676 million in 2023, which contradicts the ground truth. It also reports a $21 million drop in Non-U.S. plans (from $31M to $10M), but the ground truth does not mention Non-U.S. plans in 2022 at all, and the 2022 figure for U.S. plans is $982M, not $1,119M. (2) The calculations are internally consistent within the LLM's incorrect numbers (e.g., $1,119M - $676M = $443M drop; $31M - $10M = $21M drop; total $464M drop), but they do not match the ground truth values or the actual magnitude of change ($972M). The claimed total decline of $464 million is less than half the actual reduction. (3) The multi-hop reasoning is partially sound in that the model attempts to synthesize data across years and plan types, but it uses incorrect source data, leading to flawed conclusions. The ground truth emphasizes a strategic shift from U.S. to Non-U.S. plans with near-elimination of exposure, while the LLM portrays a more moderate decline across both plans. (4) The contextual relevance is high because the answer addresses the evolution and magnitude of change in Mortgage/Asset-backed securities investments, using appropriate timeframes and categories. However, due to major quantitative errors and incorrect entity values, the correctness and accuracy scores are low. The answer misrepresents the scale and nature of the investment change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1189,
        "completion_tokens": 481,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role in the company's funding mix and their fair value classification?",
      "original_answer": "In 2022, securitized debt obligations were described as a key component of Capital One's diversified funding strategy, used alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances to maintain access to wholesale funding sources. By 2023, the company disclosed that the carrying value of securitized debt obligations was $18,043 million, with an estimated fair value of $18,067 million, all classified under Level 2 of the fair value hierarchy. This indicates that while the company continued to rely on securitized debt obligations as a funding source, the 2023 data provides more specific transparency into their valuation and classification, showing a shift toward more detailed disclosure and potentially more structured risk management.",
      "llm_answer": "In 2022 Capital One’s securitized debt obligations were already a core part of its long‑term funding mix, with $16.97 billion outstanding and measured at Level 2 of the fair‑value hierarchy (Table 16.6, p. 211); the company also noted it could issue up to $25 billion of credit‑card and $20 billion of auto‑loan securitizations (p. 112). By year‑end 2023 the balance had risen to $18.04 billion, showing a larger share of the funding mix, and the instruments continued to be classified as Level 2 fair‑value assets (Table 16.6, p. 212).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the role of securitized debt obligations in Capital One's funding mix in both 2022 and 2023, noting their continued use and Level 2 fair value classification. The 2023 carrying value is accurately reported as $18.04 billion (matching the ground truth $18,043 million, which rounds to $18.04 billion). The 2022 figure of $16.97 billion is not present in the original answer, but this may reflect additional data from the filing not contradicted by the ground truth; however, since the original answer does not mention specific 2022 balances, this introduces a minor inaccuracy by implication. (2) The quantitative values are mostly correct: $18.04 billion in 2023 aligns with $18,043 million, and fair value of $18,067 million is omitted in the LLM answer, which is a minor omission. The LLM refers to 'Level 2 fair-value assets' but securitized debt obligations are liabilities, not assets — this is a critical misstatement affecting qualitative accuracy. (3) The multi-hop reasoning is sound: the model compares 2022 and 2023 disclosures, infers increased reliance due to balance growth, and correctly notes consistent Level 2 classification. However, it misses the ground truth emphasis on increased transparency and structured risk management in 2023, focusing instead on balance growth. (4) Scores reflect high factual accuracy in numbers and context, with a deduction for the asset/liability misclassification and partial omission of fair value data, but strong relevance and correct overall trajectory of disclosure evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 434,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did JPMorgan's treatment of CECL capital transition provisions under U.S. capital rules evolve from 2023 to 2024, and what was the quantitative change in the CECL-related capital benefit during this period?",
      "original_answer": "In 2023, JPMorgan reported a $1.4 billion benefit from the CECL capital transition provisions included in its CET1 capital. By 2024, this benefit had decreased to $720 million, reflecting a phased reduction in the CECL-related capital benefit as the provisions were being phased in under U.S. capital rules. The capital metrics indicated that the CECL benefit was fully phased in by January 1, 2025.",
      "llm_answer": "In 2023 JPMorgan’s CET1 capital included a $1.4 billion benefit from the CECL capital‑transition provisions, but by 2024 that benefit had fallen to $720 million as the transition provision was being phased out under the U.S. capital rules 【page_99†b】. The CECL‑related capital benefit therefore dropped by $680 million from 2023 to 2024 【page_105†b】【page_104†a】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the $1.4 billion benefit in 2023 and $720 million in 2024 are accurately reported. The calculated drop of $680 million ($1.4B - $720M = $680M) is mathematically correct and adds useful context not explicitly stated in the original answer, enhancing clarity. (2) The entities—JPMorgan, CET1 capital, CECL capital transition provisions, U.S. capital rules, and the years 2023 and 2024—are correctly identified and used appropriately. (3) The reasoning is sound: the model correctly infers a phased reduction due to regulatory transition rules, consistent with the original answer’s explanation about phasing in under U.S. rules and full phase-in by 2025. While the LLM says the provision is 'being phased out,' the original uses 'phased in,' which is a minor semantic difference—the 'benefit' is being reduced (phased out) as the rules are fully implemented (phased in). This does not constitute a factual error but reflects slightly different framing. (4) The answer is contextually complete and relevant, addressing both the evolution of treatment and the quantitative change. The only reason for not scoring a 10 is this slight imprecision in terminology around 'phased out' vs. 'phased in,' which could confuse readers unfamiliar with the regulatory context. Overall, the answer demonstrates strong multi-hop synthesis and factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1206,
        "completion_tokens": 402,
        "total_tokens": 1608
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did the terms and capacity of Salesforce's Revolving Loan Credit Agreement evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Salesforce had a $3.0 billion unsecured revolving credit facility under the Revolving Loan Credit Agreement, which was scheduled to mature in December 2025. By fiscal 2024, this agreement was replaced with a new $5.0 billion unsecured revolving credit facility that matures in October 2029. The increase in capacity and the extension of the maturity date reflect a strategic enhancement of the company’s credit resources.",
      "llm_answer": "In the 2023 filing Salesforce’s revolving loan credit agreement was the “Prior Credit Agreement” entered in December 2020, which gave the company an unsecured $3.0 billion revolving facility that matures in December 2025 and had only immaterial administrative amendments in 2022 and 2023 (no borrowings were outstanding)【page_53】. By the 2024 filing the company had replaced that agreement with a new revolving loan credit agreement signed in October 2024, expanding the facility to $5.0 billion and extending its maturity to October 2029, also with no borrowings outstanding【page_49】【page_51】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers and dates are accurate: the $3.0 billion facility in fiscal 2023 maturing in December 2025 and the replacement with a $5.0 billion facility maturing in October 2029 are correctly reported. The fiscal years and corresponding agreement changes align with the original answer. (2) The answer is complete, addressing both the capacity and maturity date changes between fiscal 2023 and 2024, including the fact that no borrowings were outstanding under either agreement. (3) Entity accuracy is correct: Salesforce is the subject, and the terms 'Prior Credit Agreement' and the new agreement are properly identified with their respective signing and maturity dates. (4) The reasoning is sound and reflects proper multi-hop synthesis across the two fiscal years’ filings, correctly identifying the replacement of the old facility with a new one. (5) Semantic equivalence is maintained — while the LLM adds minor contextual details (e.g., no borrowings outstanding, immaterial amendments), these do not contradict but rather enrich the answer without deviating from the ground truth. All claims are supported by cited pages, enhancing credibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 349,
        "total_tokens": 1600
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did UPS's relationship with Coyote evolve between 2022 and 2024, and what financial impact did this change have on UPS in 2024?",
      "original_answer": "In 2022, UPS had an active business relationship with Coyote, operating it as a branded subsidiary that provided truckload brokerage services in the U.S. and Europe. Coyote was integrated into UPS’s broader supply chain offerings, leveraging the UPS fleet and third-party carrier networks to provide customized transportation solutions. However, by 2024, UPS had completed the divestiture of Coyote, recording a pre-tax gain of $156 million ($152 million after tax) as a result of the transaction. This change marks a full transition from a strategic business unit to a divested asset, reflecting a shift in UPS's supply chain strategy.",
      "llm_answer": "In 2022 Coyote was still part of UPS – it operated as a Coyote‑branded subsidiary within the Truckload Brokerage business of the Supply Chain Solutions segment, giving customers access to UPS’s network and third‑party carriers (see page_7). By 2024 UPS had sold the business; the divestiture was completed in the third quarter of 2024 and generated a pre‑tax gain of $156 million (about $152 million after tax) that was recorded in “Other expenses” for the year (see page_31 and page_29).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) All key facts are correct: Coyote operated as a branded subsidiary in 2022 under UPS's Supply Chain Solutions segment, providing truckload brokerage services using UPS’s network and third-party carriers. By 2024, UPS had divested Coyote, with the transaction completed in Q3 2024. The financial impact included a pre-tax gain of $156 million ($152 million after tax), which was recorded in 'Other expenses'—consistent with the original answer and supported by referenced pages. (2) Quantitative accuracy is perfect: the dollar amounts ($156 million pre-tax, $152 million after tax) match exactly, and the timing (2022 relationship, 2024 divestiture) is correctly specified. Minor formatting like 'page_7' vs 'page 7' does not affect validity. (3) Multi-hop reasoning is sound: the model correctly synthesized information across time (2022 to 2024), entities (UPS and Coyote), and financial reporting (gain recognition in financial statements), demonstrating understanding of strategic evolution and its financial implications. (4) The answer addresses both parts of the question: the evolution of the relationship and the financial impact in 2024. Wording differs slightly from the original but maintains full semantic equivalence. No omissions or inaccuracies are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 375,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Union Pacific's relationship with chassis evolved between 2023 and 2024, particularly in terms of total units and ownership structure?",
      "original_answer": "In 2023, Union Pacific had a total of 48,340 chassis units, with 30,635 owned and 17,705 leased. By 2024, the total number of chassis dropped significantly to 5,553 units, with only 4,356 owned and 1,197 leased. This represents a transformation in Union Pacific's relationship with chassis, shifting from a heavy reliance on both owned and leased chassis to a much smaller, still mixed but significantly reduced footprint. The drastic reduction in total chassis units indicates a strategic shift in how the company manages this asset class.",
      "llm_answer": "In 2023 Union Pacific reported a chassis fleet of 48,340 units, of which 30,635 were owned and 17,705 were leased【page_19】. By 2024 the fleet had shrunk to 5,553 chassis, with 4,356 owned and 1,197 leased【page_19】—a dramatic drop in total units and a shift to a higher proportion of owned chassis.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all numeric values: 48,340 total chassis in 2023 (30,635 owned, 17,705 leased) and 5,553 total in 2024 (4,356 owned, 1,197 leased), matching the ground truth exactly. (2) Quantitative accuracy is perfect—no calculation or transcription errors; totals and components are accurate. (3) The reasoning correctly identifies a dramatic reduction in fleet size and notes a shift toward a higher proportion of owned units, which is valid (ownership share rose from ~63% to ~78%). The only minor omission is that the original answer emphasizes a 'strategic shift in how the company manages this asset class,' a qualitative interpretation slightly more developed than the LLM’s 'dramatic drop' and 'shift to higher proportion.' However, the core multi-hop synthesis—comparing ownership structure and total units across years—is sound. (4) The answer is fully contextually relevant, directly addressing both total units and ownership structure evolution. The inclusion of citation markers ['page_19'] suggests proper grounding. Scored 9/10 for correctness due to slightly less comprehensive qualitative interpretation, though all facts and calculations are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1208,
        "completion_tokens": 339,
        "total_tokens": 1548
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Boeing's treatment and disclosure of aluminum agreements evolved between 2022 and 2024, particularly in terms of their classification as derivatives and the time horizon for these agreements?",
      "original_answer": "In 2022, Boeing disclosed that its aluminum agreements were classified as derivatives but were not designated for hedge accounting treatment, with changes in fair value recorded in earnings immediately. The agreements were described in the context of long-term strategic sourcing objectives and non-U.S. business requirements. By 2024, the disclosure evolved to indicate that these aluminum agreements were now part of a broader set of commodity contracts hedging forecasted transactions through 2028. This represents a shift from purely strategic sourcing to a more structured hedging strategy with a defined time horizon extending to 2028.",
      "llm_answer": "In the 2022 Form 10‑K Boeing noted that its agreements to purchase and sell aluminum are accounted for as **derivative instruments** (not designated for hedge accounting) and that changes in their fair value are recorded in earnings; the filing only described them as supporting “long‑term strategic sourcing objectives.” By the 2024 filing the classification is unchanged – the aluminum contracts are still **non‑hedged derivatives** – but Boeing now explicitly states that the commodity contracts (including the aluminum agreements) hedge forecasted transactions **through 2028** and provides detailed notional‑amount and fair‑value disclosures for those contracts.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately states that in 2022, Boeing classified aluminum agreements as derivative instruments not designated for hedge accounting, with fair value changes recorded in earnings, and that they were described in the context of long-term strategic sourcing—this aligns with the original answer. (2) For 2024, the LLM correctly notes that while the classification remains unchanged (still non-hedged derivatives), there is now explicit disclosure that these commodity contracts, including aluminum, are used to hedge forecasted transactions through 2028. The time horizon 'through 2028' is correctly reported, matching the ground truth. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes over time across two filings (2022 vs 2024), identifying both continuity (derivative classification) and evolution (new hedging context and time horizon). (4) All entities—Boeing, aluminum agreements, derivative classification, years (2022, 2024, 2028)—are accurate. Wording differs slightly but maintains semantic equivalence (e.g., 'non-hedged derivatives' vs 'not designated for hedge accounting'). No factual, numerical, or conceptual errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 350,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Procter & Gamble's exposure to currency rate risk evolved between the fiscal years ended June 30, 2023 and June 30, 2024, particularly in terms of its hedging instruments and confidence in mitigating near-term exchange rate fluctuations?",
      "original_answer": "Procter & Gamble's exposure to currency rate risk remained materially unchanged between the fiscal years ended June 30, 2023 and June 30, 2024. The company continued to use forward contracts and currency swaps with maturities of less than 18 months to manage exchange rate risk. Additionally, P&G maintained its assessment that, at a 95% confidence level based on historical currency rate movements, the impact of a near-term change in currency rates would not materially affect its financial statements in either reporting period.",
      "llm_answer": "Procter & Gamble’s currency‑rate risk profile was essentially unchanged from FY 2023 to FY 2024.  The company still relies on its natural‑hedge portfolio and “primarily use[s] forward contracts and currency swaps with maturities of less than 18 months” to manage financing‑related exchange‑rate exposure, and it states that “our market risk exposures … have not changed materially versus the previous reporting period” 【page_31】.  Moreover, management continues to be confident that, at a 95 % confidence level based on historical movements, a near‑term change in currency rates “would not materially affect our financial statements” 【page_31】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the original answer. (1) All key facts are correct: Procter & Gamble's currency risk exposure remained materially unchanged between FY2023 and FY2024; the company continues to use forward contracts and currency swaps with maturities under 18 months; and it maintains a 95% confidence level that near-term currency fluctuations would not materially affect financial statements. (2) There are no numeric inaccuracies—dates (fiscal years), percentages (95%), and instrument maturities (less than 18 months) match the ground truth exactly. Format variations (e.g., '95 %' vs '95%') are acceptable. (3) The multi-hop reasoning is sound: the answer synthesizes information about risk exposure, hedging instruments, and confidence level across both fiscal years, correctly concluding no material change. (4) The inclusion of direct quotes with citation (e.g., 'page_31') enhances credibility and shows proper grounding. The answer fully addresses all parts of the question—evolution of risk exposure, hedging instruments used, and confidence in mitigation—making it contextually complete and highly relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 329,
        "total_tokens": 1647
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How has Adobe's positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its functional scope and integration with other Adobe products?",
      "original_answer": "In 2022, Frame.io was listed among Adobe's trademarks, indicating it was an established product within Adobe's portfolio but with no detailed description of its functionality or integration. By 2024, Frame.io was actively described as a 'cloud-native creative collaboration platform' with expanded capabilities such as real-time upload, review and approval, frame-accurate commenting, and Camera to Cloud functionality. It was also integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and positioned as part of Adobe GenStudio for large-scale content production. This reflects a significant evolution from a trademarked asset to a core collaborative tool deeply embedded in Adobe's creative workflow.",
      "llm_answer": "In Adobe’s 2022 Form 10‑K (pages 95‑99) there is no specific discussion of Frame.io, indicating it was not highlighted as a core, integrated part of Adobe’s portfolio at that time. By the 2024 filing, Frame.io is positioned as a cloud‑native creative‑collaboration platform that goes beyond post‑production to support casting, location scouting, footage reviews, marketing‑campaign management, still‑image, design‑file and PDF workflows, and offers “Camera‑to‑Cloud” uploads; it is now directly embedded in Premiere Pro, After Effects, Photoshop, Lightroom, Workfront and Adobe GenStudio for large‑scale content production 【page_95】【page_12】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that Frame.io was not explicitly discussed in Adobe's 2022 10-K, implying it was not yet a highlighted or integrated product, which matches the ground truth noting it was only listed as a trademark. By 2024, the LLM accurately describes Frame.io as a 'cloud-native creative collaboration platform' with expanded functionalities including real-time workflows, Camera-to-Cloud, and integration across Adobe products. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable in a traditional sense, but all factual assertions about years (2022 vs 2024) and product integration timelines are correct. (3) The multi-hop reasoning is sound: the model infers absence of mention in 2022 as lack of integration and contrasts it with explicit functional and integrative details in 2024, correctly synthesizing information across filings. (4) The LLM mentions integration with Premiere Pro, After Effects, Photoshop, Lightroom, Workfront, and Adobe GenStudio—matching the ground truth. One minor omission: the ground truth specifically notes 'frame-accurate commenting' and 'real-time upload, review and approval' as new features, which the LLM does not explicitly mention, though 'footage reviews' and 'collaboration' imply similar functionality. This slight lack of specificity prevents a perfect 10 on qualitative accuracy. Overall, the answer is factually correct, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 428,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between the 2022 and 2023 fiscal years, particularly in terms of the carrying value of its investment and the nature of its financial disclosures?",
      "original_answer": "In the 2022 filing, AMD disclosed that the carrying value of its investment in the ATMP JV was $69 million as of December 25, 2021, and $63 million as of December 26, 2020. Additionally, AMD provided detailed figures regarding purchases from and resales to the ATMP JV, including purchases of $1.1 billion in 2021 and $831 million in 2020. In contrast, the 2023 filing omits any mention of the carrying value of the investment and specific transaction figures, only reiterating the structural details of the relationship, such as AMD's 15% equity interest and the accounting method used. This indicates a reduction in the level of financial disclosure regarding the ATMP JV, even though the nature of the relationship and AMD's equity stake remained unchanged.",
      "llm_answer": "In FY 2022 AMD said its 15 % equity stake in the ATMP joint venture was carried at roughly $69 million; by FY 2023 the carrying amount had risen to about $99 million. The 2023 filing adds more granular detail—showing higher purchase volumes ($1.7 bn), larger payables ($363 m vs $463 m a year earlier), higher receivables ($9 m vs $2 m), and bigger equity‑income gains—while still noting that the investment is accounted for under the equity method and that AMD has no funding obligation to the JV.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains almost entirely incorrect information. According to the ground truth, in the 2022 filing, AMD reported a carrying value of $69 million as of December 25, 2021 (not FY2022 reporting on FY2021 data), and $63 million as of December 26, 2020. The LLM incorrectly states that the carrying value rose to $99 million in FY2023, which is not mentioned in the original answer or supported by the knowledge graph. Furthermore, the original answer states that the 2023 filing omits carrying value and transaction figures entirely, whereas the LLM claims the 2023 filing includes more granular data like $1.7 billion in purchases, $363 million in payables, $9 million in receivables, and equity-income gains—none of which appear in the ground truth. (2) All numeric values in the LLM answer are factually wrong: the increase to $99M, purchase volumes rising to $1.7B (vs. $1.1B in 2021), payables and receivables comparisons, and implied profitability metrics are fabricated or misattributed. The original answer explicitly states that such details were omitted in 2023, making these claims directly contradictory. (3) The multi-hop reasoning is fundamentally flawed. The question asks how the financial relationship and disclosures evolved between 2022 and 2023 filings. The correct inference is that AMD reduced disclosure depth in 2023 despite an unchanged equity stake. The LLM instead asserts increased disclosure and financial growth, reversing the actual trend. It fails to recognize that the absence of data in the 2023 filing is itself a key signal. (4) The contextual relevance is moderate because the answer addresses the right entities (AMD, ATMP JV, equity stake, accounting method) and attempts to compare years and disclosures. However, due to pervasive factual inaccuracies and inverted conclusions, the qualitative and quantitative accuracy scores are extremely low. The correctness score is 1 because the answer is mostly wrong with no redeeming accurate details beyond the correct mention of AMD’s 15% equity interest and use of the equity method—both basic structural facts mentioned in both filings but insufficient for a correct response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 585,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did Honeywell's revenue from Commercial Aviation Original Equipment evolve between 2023 and 2024, and what does this indicate about its position in the aerospace sector?",
      "original_answer": "Honeywell's revenue from Commercial Aviation Original Equipment decreased from $2,397 million in 2023 to $2,223 million in 2024. This decline suggests a contraction in this segment despite overall growth in the Aerospace Technologies division, indicating a potential weakening in original equipment demand or supply constraints in this specific product line.",
      "llm_answer": "Honeywell’s Commercial Aviation Original Equipment revenue slipped from $2.397 billion in 2023 to $2.223 billion in 2024 – a decline of roughly $174 million (about 7 %)【page_68】. While the dip reflects a modest slowdown in OEM sales, the still‑large dollar amount underscores Honeywell’s continued prominence as a key supplier in the aerospace sector.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the revenue figures for Honeywell's Commercial Aviation Original Equipment: $2.397 billion in 2023 and $2.223 billion in 2024, matching the ground truth of $2,397 million and $2,223 million. The calculated decline of $174 million and approximate 7% drop are accurate (actual: (2397 - 2223)/2397 ≈ 7.26%). (2) All numeric values and calculations are correct, with acceptable format variation (billion vs million). (3) The reasoning correctly identifies a decline in OEM revenue, but the qualitative interpretation diverges slightly from the ground truth: while the LLM emphasizes Honeywell’s continued prominence, the original answer highlights a potential weakening in demand or supply constraints, suggesting a more cautionary interpretation. The LLM answer does not mention the contrast with overall Aerospace Technologies division growth, a key nuance in the multi-hop reasoning. (4) Despite missing this comparative context, the core facts and numbers are fully accurate, and the answer remains relevant and well-reasoned, warranting a high correctness score with a minor deduction for incomplete qualitative synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1184,
        "completion_tokens": 330,
        "total_tokens": 1514
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How did the global revenue contribution from Heart Failure Devices evolve between 2023 and 2024, and what was the percentage change in this segment's total revenue?",
      "original_answer": "In 2023, the global revenue from Heart Failure Devices was $1,161 million, while in 2024, this figure increased to $1,279 million. This represents a 10.2% increase in total revenue for the Heart Failure Devices segment. The growth was consistent across both U.S. and international markets, with minimal impact from exchange rate fluctuations, indicating strong underlying demand and market expansion.",
      "llm_answer": "The Heart‑Failure devices business grew from $1.161 billion of total (U.S. + international) sales in 2023 to $1.279 billion in 2024 【page_53】.  That represents roughly a 10 percent rise in the segment’s revenue year‑over‑year (a 10.2 % total‑change increase) 【page_29】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: 2023 revenue was $1,161 million ($1.161 billion), 2024 revenue was $1,279 million ($1.279 billion), and the percentage change is correctly stated as 10.2%, with a minor rounding to 'roughly 10 percent' which is acceptable. (2) Quantitative accuracy is perfect—numbers match exactly when adjusted for format ($1.161 billion = $1,161 million), and the 10.2% increase is correctly calculated: (1,279 - 1,161) / 1,161 ≈ 0.1016 ≈ 10.2%. (3) The reasoning is sound and reflects multi-hop synthesis of revenue figures across years and geographies (U.S. + international), and the conclusion about growth is logically supported. (4) The answer addresses both parts of the question: evolution of revenue (increase from 2023 to 2024) and percentage change. Contextual details like market consistency and exchange rate impact are omitted but not required for correctness. Citations to pages add verifiability. All entities (Heart Failure Devices, years, revenue metric) are correct. No factual or interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1171,
        "completion_tokens": 319,
        "total_tokens": 1491
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How has IBM's treatment of the 0.300% Notes due 2028 evolved between the 2022 and 2023 filings?",
      "original_answer": "In the 2022 filing, the 0.300% Notes due 2028 were referenced as part of a list of debt instruments, with their rights defined in Exhibit 4.1 to Form 8-K filed February 10, 2020, and incorporated by reference. By 2023, the 0.300% Notes due 2028 were formally listed in the table of registered securities with a specific trading symbol (IBM 28B) and explicitly called out as a distinct class of notes registered on the New York Stock Exchange. This reflects a shift from general incorporation by reference to explicit disclosure and formal registration.",
      "llm_answer": "In IBM’s 2022 filing the 0.300 % Notes due 2028 are not referenced in any of the excerpts provided (the compensation, accounting‑fees and exhibit sections contain no mention of those notes). By the 2023 Form 10‑K, however, the notes appear in the Section 12(b) securities table as “0.300 % Notes due 2028” (ticker IBM 28B) 【page 1】. This shows that IBM moved from omitting the notes in the disclosed sections to explicitly listing them as a registered, outstanding security in the later filing.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key evolution: in 2023, the 0.300% Notes due 2028 are explicitly listed in the Section 12(b) securities table with ticker IBM 28B, whereas they were not directly mentioned in the provided 2022 excerpts. This aligns with the ground truth's claim of a shift toward more explicit disclosure. However, the LLM incorrectly states that the notes were 'not referenced in any of the excerpts provided' in 2022, while the ground truth confirms they were referenced via incorporation by reference in Exhibit 4.1 to the Form 8-K filed February 10, 2020. This is a significant qualitative omission, as it mischaracterizes the 2022 treatment as omission rather than indirect inclusion through reference. (2) Quantitatively, all details are accurate: the interest rate (0.300%), maturity year (2028), ticker (IBM 28B), and context of NYSE registration are correctly reported. No calculations are involved. (3) The reasoning is partially sound—the model correctly infers increased transparency from 2022 to 2023—but fails the multi-hop synthesis by not recognizing that incorporation by reference constitutes a valid form of disclosure in the 2022 filing. Thus, the conclusion that IBM 'moved from omitting' the notes is factually incorrect. (4) Despite this, the answer captures the core directional change in disclosure practice and correctly identifies the formal registration in 2023, warranting a score of 7 for correctness and qualitative accuracy. Quantitative accuracy is perfect, and relevance is high as the response directly addresses the question's focus on disclosure evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 445,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 158,
      "question": "How has Apple's financial performance in the Rest of Asia Pacific region evolved from 2022 to 2023, based on changes in net sales and operating income?",
      "original_answer": "In 2022, Apple's Rest of Asia Pacific segment reported net sales of $29,375 million and operating income of $11,569 million. In 2023, these figures increased to $29,615 million in net sales and $12,066 million in operating income. This represents a moderate growth in both metrics, with net sales rising by $240 million (0.8%) and operating income increasing by $497 million (4.3%).",
      "llm_answer": "Apple’s Rest of Asia Pacific segment saw net sales climb from $29,375 million in 2022 to $29,615 million in 2023 (≈ + $240 million). Operating income rose from $11,569 million to $12,066 million over the same period (≈ + $497 million), indicating modest sales growth but a more pronounced improvement in profitability【page_50】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: net sales in 2022 ($29,375 million) and 2023 ($29,615 million), operating income in 2022 ($11,569 million) and 2023 ($12,066 million), and the calculated increases of $240 million and $497 million are correct. The implied percentage changes (0.8% and 4.3%) are not explicitly stated but the absolute changes are accurate, and the qualitative description of 'modest sales growth' and 'more pronounced improvement in profitability' aligns with the data. (2) The answer is complete, addressing both net sales and operating income across both years, and captures the evolution as requested. (3) Entities are correct: Apple, Rest of Asia Pacific, 2022 to 2023, and the financial metrics are properly identified. (4) The reasoning is sound: the model correctly synthesizes the two-year performance, compares both metrics, and draws a valid conclusion about profitability growth outpacing sales growth. (5) Semantic equivalence is maintained — while the LLM uses 'modest' and 'more pronounced' instead of 'moderate' and exact percentages, the interpretation is consistent with the data. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1178,
        "completion_tokens": 351,
        "total_tokens": 1529
      },
      "error": null
    },
    {
      "question_id": 169,
      "question": "How has the vesting period for stock options issued under the 2007 Omnibus Incentive Plan evolved between grants made prior to 2022 and those made after December 31, 2021, based on disclosures in the 2022 and 2024 10-K filings?",
      "original_answer": "In the 2022 10-K filing, stock options granted prior to 2022 under the 2007 Omnibus Incentive Plan generally vested pro rata over a five-year period, while those granted after December 31, 2021, under the amended and restated plan, generally vested pro rata over a four-year period. The 2024 10-K confirms that stock options granted prior to 2022 continued to vest pro rata over a five-year period, and those granted after December 31, 2021, also continued to vest pro rata over a four-year period. This indicates a consistent reduction in the vesting period from five to four years for post-2021 grants, showing a structural change in the incentive plan's vesting terms over time.",
      "llm_answer": "The 2022 10‑K notes that “stock options granted prior to 2022 … generally vest pro rata over a **five‑year** period” (see page 116). The 2024 10‑K updates this, stating that “stock options granted subsequent to December 31, 2021 … generally vest pro rata over a **four‑year** period” (see page 96). Thus, the vesting schedule was shortened from five years for pre‑2022 grants to four years for grants made after December 31, 2021.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and aligns with the ground truth in all key aspects. (1) Quantitative accuracy: The vesting periods—five years for grants prior to 2022 and four years for grants after December 31, 2021—are accurately reported, with correct dates and durations. The LLM correctly cites the 2022 and 2024 10-K filings and references specific page numbers, enhancing credibility. (2) Completeness: The answer addresses the evolution of the vesting period by contrasting pre- and post-2022 grants, which is the core of the multi-part question. However, it omits explicit confirmation from the 2024 10-K that the pre-2022 grants still follow the five-year vesting, which the ground truth includes. This minor omission reduces completeness slightly but does not affect the core conclusion. (3) Entity accuracy: The plan name (implied as the 2007 Omnibus Incentive Plan), time periods, and filing years are correct. (4) Reasoning: The LLM correctly synthesizes information across two 10-K filings to infer a structural change in vesting terms, demonstrating sound multi-hop logic. The conclusion that the vesting period was shortened is valid and well-supported. (5) Semantic equivalence: The meaning conveyed is substantively the same as the ground truth, with only minor differences in depth of detail. The answer is highly relevant and focused on the question. The correctness score is 9 due to the omission of the 2024 confirmation about pre-2022 grants, but all critical facts and reasoning are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 417,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How has CVS's approach to validating the fair value estimates for its Level 2 debt securities evolved from 2022 to 2023, particularly in terms of price adjustments and secondary source comparisons?",
      "original_answer": "In 2022, CVS obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December 31, 2021 or 2020. The company compared selected sample prices quarterly to secondary sources and reviewed variances over a specified threshold. In 2023, the company maintained the same validation methodology, obtaining one price per Level 2 debt security without any adjustments at December 31, 2023 or 2022, and continued to compare prices quarterly to secondary sources. Despite maintaining the same process, the emphasis on consistent internal validation by the investment team appears to have remained stable, indicating a sustained but unchanging approach to fair value estimation.",
      "llm_answer": "In both the 2022 and 2023 filings CVS says it obtains one price for each Level 2 debt security, reviews a quarterly sample, and compares those prices to a secondary source (flagging any variance that exceeds a set threshold). In 2022 it noted that no prices were adjusted at December 31, 2022 (or 2021), and the 2023 filing repeats the same practice, stating no adjustments were made at December 31, 2023 (or 2022). Thus the validation process – price‑comparison to a secondary source and the policy of not adjusting year‑end prices – remained unchanged, with only the reference years updated.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: CVS obtained one price per Level 2 debt security in both years, made no price adjustments at year-end (specifically December 31, 2022 and 2023, as well as the prior years 2021 and 2022), and continued quarterly comparisons to secondary sources with threshold-based variance reviews. The dates and years are accurately reported, with only a minor shift in reference (the 2022 filing refers to no adjustments at Dec 31, 2021 or 2020; the LLM says 2021 and 2022 — this is a slight misstatement but contextually understandable as reflecting the two most recent years at each filing date). (2) Quantitative accuracy is excellent: all years and the 'no adjustment' policy are correctly stated, and the process description matches. (3) The multi-hop reasoning is sound — the model correctly synthesizes information across two years of disclosures and infers that the methodology remained unchanged. (4) The only minor shortcoming is that the LLM does not explicitly mention the 'emphasis on consistent internal validation by the investment team' noted in the original answer, which adds contextual depth about sustained oversight. However, this is a qualitative nuance rather than a factual omission that impacts correctness. Overall, the answer is factually complete, contextually relevant, and semantically equivalent to the ground truth with excellent reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 402,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How did CVS's classification and valuation methodology for privately-placed equity securities evolve between 2022 and 2023, particularly in terms of fair value determination and unobservable inputs?",
      "original_answer": "CVS maintained a consistent classification of privately-placed equity securities as Level 3 in both 2022 and 2023, indicating no active market for these securities. However, the company emphasized in both years that it uses an internal analysis of financial statements and cash flow projections to determine fair value. In 2022, the significant unobservable inputs included earnings and revenue multiples, discount for lack of marketability, and comparability adjustments. In 2023, the same unobservable inputs were referenced, but with an added emphasis on the potential impact of changes in these inputs on fair value measurements, suggesting a more detailed sensitivity analysis or increased scrutiny of these inputs in the valuation process.",
      "llm_answer": "In both the 2022 and 2023 10‑K filings CVS continued to classify privately‑placed equity securities as Level 3 assets because there is no active market for them. The fair‑value of these securities is still determined internally, using unobservable inputs such as earnings and revenue multiples, a discount for lack of marketability and comparability adjustments; the methodology and the reliance on these unobservable inputs did not change from 2022 to 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in terms of entity identification, classification (Level 3), and the list of unobservable inputs used in both years (earnings and revenue multiples, discount for lack of marketability, comparability adjustments). It correctly states that CVS used internal analysis for fair value determination and maintained consistent classification across 2022 and 2023. However, it misses a key qualitative evolution noted in the ground truth: in 2023, CVS placed 'added emphasis on the potential impact of changes in these inputs on fair value measurements,' indicating a more detailed sensitivity analysis or increased scrutiny. This represents a refinement in methodology, even if the core inputs remained the same. The LLM incorrectly concludes that 'the methodology and the reliance on these unobservable inputs did not change,' which overlooks this enhanced analytical focus in 2023. While no numbers or dates are incorrect (hence perfect quantitative accuracy), the qualitative assessment of methodology evolution is incomplete, reducing the correctness and qualitative accuracy scores. The answer remains contextually relevant and covers all entities and years correctly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 337,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 184,
      "question": "How did the total net revenue from Alphagan/Combigan change between 2023 and 2024, and what was the trend in its international revenue during this period?",
      "original_answer": "The total net revenue from Alphagan/Combigan decreased from $272 million in 2023 to $248 million in 2024, reflecting an 8.8% decline. During the same period, its international revenue slightly increased from $151 million in 2023 to $153 million in 2024, representing a 1.5% growth.",
      "llm_answer": "Total net revenue from Alphagan/Combigan fell from $272 million in 2023 to $248 million in 2024—a decline of roughly $24 million (about 9%). By contrast, international revenue rose modestly, increasing from $151 million in 2023 to $153 million in 2024, indicating a slight upward trend.【page_43】",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key figures: total net revenue decreased from $272 million in 2023 to $248 million in 2024, and international revenue increased from $151 million to $153 million. These match the ground truth exactly. (2) The calculation of the decline ($24 million) is accurate, and the approximate percentage decline ('about 9%') is a reasonable rounding of the exact 8.8% from the ground truth. Similarly, the 1.5% growth in international revenue is correctly reflected as a 'slight upward trend'—the LLM does not misstate the magnitude. (3) The multi-hop reasoning is sound: the model correctly synthesizes data across two time points and two revenue segments (total vs. international), addressing both parts of the question. (4) The only minor shortcoming is that the LLM does not explicitly state the 1.5% growth rate for international revenue, though the direction and values are correct. This omission prevents a perfect 10 on qualitative accuracy, but the answer remains factually correct and contextually complete. All entities (Alphagan/Combigan, revenue types, years) are accurate. Semantic equivalence is maintained.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1146,
        "completion_tokens": 330,
        "total_tokens": 1476
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Chevron's relationship with PDC Energy evolved from 2023 to 2024, and what specific operational impact did this change have on Chevron's overall production performance?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, Inc. (PDC), and as a result, PDC was excluded from Chevron's internal control assessment over financial reporting due to the timing of the acquisition. By 2024, Chevron's relationship with PDC had evolved from a newly acquired entity to an integral operational component, as evidenced by the 7% increase in Chevron's worldwide oil-equivalent production, which was attributed in part to the full-year contribution from legacy PDC operations. This indicates that PDC Energy transitioned from being a recent acquisition in 2023 to a key contributor to Chevron's production growth in 2024.",
      "llm_answer": "In 2023 Chevron completed a business combination that made PDC Energy a wholly‑owned subsidiary, with PDC’s revenues representing only a few percent of Chevron’s consolidated amounts and its results excluded from internal‑control assessments (2023 10‑K, p.31‑30). By 2024 the legacy PDC Energy assets were fully integrated into Chevron’s operations, and Chevron said worldwide oil‑equivalent production rose about 7 % (from 2.714 MBD in 2023 to 2.925 MBD in 2024), the increase being driven largely by the full‑year of PDC Energy production (2024 10‑K, p.9).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate, complete, and semantically equivalent to the ground truth. (1) All key facts are correct: Chevron acquired PDC Energy in 2023, making it a wholly owned subsidiary; PDC was excluded from internal control assessments due to the acquisition timing (citing 2023 10-K, p.31-30); by 2024, legacy PDC operations contributed fully to Chevron's production. (2) Quantitative accuracy is excellent: the 7% increase in worldwide oil-equivalent production is correctly stated, with precise figures (2.714 MBD in 2023 to 2.925 MBD in 2024), and the attribution to full-year PDC contribution matches the source (2024 10-K, p.9). The percentage increase calculates to approximately 7.7%, which rounds to 'about 7%' as stated—reasonable for reporting context. (3) Multi-hop reasoning is sound: the answer synthesizes information across two years of 10-K filings, correctly identifying the evolution from acquisition to integration and its operational impact. (4) Entity accuracy is perfect: Chevron, PDC Energy, correct years (2023–2024), and financial/operational metrics are all properly identified. The answer fully addresses both parts of the question: the evolution of the relationship and the specific operational impact on production. No factual errors, omissions, or misinterpretations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 365,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has UPS's investment in cold-chain logistics capabilities evolved from 2023 to 2024, and what specific acquisitions contributed to this change?",
      "original_answer": "In 2023, UPS expanded its cold-chain logistics capabilities through the acquisition of Bomi Group and MNX Global Logistics, aiming to enhance its healthcare logistics services. By 2024, this strategic focus intensified with the acquisition of Frigo-Trans and Biotech & Pharma Logistics in Germany for approximately $440 million, signaling a significant increase in international investment in complex cold-chain logistics. This represents a shift from general expansion to targeted, high-value international acquisitions in the cold-chain sector.",
      "llm_answer": "UPS grew its cold‑chain logistics in 2023 by buying MNX Global Logistics, a temperature‑sensitive, time‑critical logistics provider, which complemented the earlier Bomi Group acquisition that had already expanded its cold‑chain footprint (see page 6 & page 104). In 2024 the company made no new cold‑chain purchases – the only acquisition reported was franchise‑development areas for The UPS Store (≈ $71 million) – showing that cold‑chain investment stalled and the focus shifted to other assets (see page 103).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It falsely claims that UPS made no cold-chain acquisitions in 2024, when in fact it acquired Frigo-Trans and Biotech & Pharma Logistics in Germany for approximately $440 million. This is a major factual error. (2) The quantitative accuracy is low: the $440 million figure is entirely omitted, and instead, the model references a $71 million acquisition of The UPS Store franchise areas, which is irrelevant to cold-chain logistics. There is no mention of the $440 million figure or the two German companies. (3) The reasoning is flawed: the model incorrectly infers that cold-chain investment stalled in 2024, when the opposite is true—the strategic focus intensified with high-value international acquisitions. The multi-hop synthesis fails: it does not connect the 2023 acquisitions (Bomi Group, MNX) with the 2024 German acquisitions as part of an evolving, expanding strategy. (4) While the 2023 acquisitions (MNX and Bomi Group) are correctly identified, the overall trajectory described is the inverse of the truth. Contextual relevance is moderate because it addresses UPS and cold-chain logistics, but the core conclusion is factually wrong, undermining usefulness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 347,
        "total_tokens": 1612
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Linde plc's non-employee director restricted stock unit award program evolved between 2022 and 2024, particularly in terms of governance structure and long-term shareholder alignment mechanisms?",
      "original_answer": "In 2022, Linde plc introduced the Non-Employee Director Restricted Stock Unit Award under the 2021 Linde plc Long Term Incentive Plan, establishing a framework for equity-based compensation tied to long-term performance metrics. This initiative was part of a broader suite of incentive programs aimed at aligning director interests with those of shareholders. By 2024, the company expanded this framework by introducing the Linde plc Non-employee Director Deferral Program, adopted by the Board of Directors on July 30, 2024. This deferral program enhances governance by allowing directors to defer receipt of stock units, thereby reinforcing long-term alignment with shareholder value creation. The evolution from a basic restricted stock unit award to a more sophisticated deferral mechanism indicates Linde’s strategic emphasis on strengthening board accountability and promoting sustained corporate governance standards.",
      "llm_answer": "In the 2022 Form 10‑K the company’s non‑employee director RSU awards were issued simply as part of the 2021 Long‑Term Incentive Plan (exhibit *10.0e) and, for grants after 2019, under the legacy 2009 Praxair Long‑Term Incentive Plan (exhibit *10.11h) with no separate deferral or performance‑based structure 【page 105】【page 107】. By the 2024 filing the Board had amended the LTIP (exhibit *10.03e) and adopted a stand‑alone Non‑employee Director Deferral Program (exhibit *10.16), introducing a deferral component and linking awards to long‑term metrics such as total shareholder return, thereby tightening governance oversight and aligning director compensation more closely with shareholders’ long‑term interests 【page 94】【page 96】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, Linde used the 2021 Long-Term Incentive Plan (LTIP) for non-employee director RSU awards, with legacy grants under the 2009 Praxair plan; by 2024, a new stand-alone Non-employee Director Deferral Program was adopted, enhancing long-term alignment. The dates (2022 and 2024), plan names, and evolution from basic RSUs to deferral mechanisms are all factually correct. (2) Quantitative accuracy is perfect: no numerical errors, and the timeline (2022 to 2024) matches. The mention of specific exhibits and pages adds precision without introducing inaccuracies. (3) Reasoning is sound: the LLM correctly infers that the introduction of deferral and performance linkage (e.g., total shareholder return) strengthens governance and shareholder alignment, which is consistent with the ground truth’s emphasis on long-term value creation. (4) The only minor shortcoming is that the LLM does not explicitly state the July 30, 2024 adoption date mentioned in the ground truth, though it correctly identifies the 2024 timeframe. Otherwise, the answer is semantically equivalent, contextually rich, and directly addresses both governance structure and shareholder alignment. Thus, the correctness score is 9 due to this slight omission, but all other dimensions are strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 380,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did General Motors' financial and legal relationship with Stellantis evolve between 2022 and 2024, particularly regarding indemnification obligations and investment gains?",
      "original_answer": "In 2022, General Motors reported a gain of $0.2 billion related to Stellantis N.V. (Stellantis) warrants, indicating a positive financial relationship. However, by 2024, the relationship had evolved into a more complex and potentially costly one. GM had agreed to indemnify Stellantis for certain liabilities tied to pre-sale emissions claims, product liabilities, and recalls related to the 2017 sale of the Opel/Vauxhall business. Additionally, GM faced potential future liabilities from ongoing investigations into Opel’s historical conduct in Europe. Unlike the earlier gains, GM's 2024 disclosures highlighted contingent liabilities and legal risks rather than financial benefits from its relationship with Stellantis.",
      "llm_answer": "In the 2022 filing GM reported that part of its non‑operating income came from a $0.2 billion gain on Stellantis N.V. warrants, reflecting a modest investment upside with Stellantis (see page 36). By the 2024 filing the focus had shifted to a legal exposure: GM Holdings agreed, under the 2017 Opel/Vauxhall sale to PSA (now Stellantis), to indemnify Stellantis for losses tied to representations, warranties, emissions, product‑liability and recall claims—subject to time limits, thresholds and caps (see page 93). Thus, the relationship moved from a small investment gain in 2022 to a primarily indemnification‑obligation‑driven arrangement by 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the $0.2 billion gain in 2022 is correctly reported, matching the original answer. The years (2022 and 2024) and the context of the Opel/Vauxhall sale in 2017 are also correct. (2) The answer correctly identifies the shift from a financial gain (warrant-related non-operating income) to a legal and indemnification-focused relationship by 2024. It accurately references the indemnification obligations for emissions, product liability, and recall claims stemming from the 2017 sale agreement. (3) The multi-hop reasoning is sound: it connects GM’s 2022 investment gain with its later legal exposure in 2024, synthesizing information across time and filings. The mention of PSA becoming Stellantis adds contextual clarity. (4) The only minor shortcoming is that the LLM answer does not explicitly mention the 'ongoing investigations into Opel’s historical conduct in Europe' as a source of potential future liabilities, which is included in the original answer and adds depth to the legal risk. However, this omission does not undermine the core accuracy. Wording differences (e.g., 'indemnification-obligation-driven arrangement') are semantically equivalent. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 369,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolved from 2022 to 2024, particularly in terms of their financial presentation and categorization?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of energy-related derivatives not designated as hedging instruments on the statements of income for prior years (2021, 2020, and 2019), indicating a focus on income statement impacts. By 2024, the company shifted its disclosure to emphasize the fair value of energy-related derivatives as either assets or liabilities on the balance sheets, specifically categorized under 'Other' or 'Risk Management Activities'. This represents a shift from income-focused reporting to balance sheet-oriented transparency.",
      "llm_answer": "In the 2022 filing Southern Company disclosed energy‑related derivatives only through the effects on AOCI and earnings – cash‑flow hedges were shown as OCI gains/losses that are later re‑classified to income, and non‑designated contracts were recognized directly in the income statement, with only cumulative fair‑value adjustments noted on the balance sheet. By the 2024 filing the company added a distinct “regulatory‑hedge” category, separated cash‑flow and fair‑value hedges, and began presenting energy‑related derivatives on the balance sheet as separate current and non‑current assets and liabilities (showing gross amounts, offsets and net amounts), clearly differentiating regulatory, cash‑flow and non‑designated positions. This reflects a shift to a more granular categorization and explicit balance‑sheet presentation of energy‑related derivative exposures.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of the directional shift in Southern Company's derivative disclosures from 2022 to 2024, and correctly identifies a move toward more detailed balance sheet presentation. The quantitative accuracy is high: no specific numerical values are contradicted, and the years (2022, 2024) are correctly referenced. However, the LLM introduces details not present in the ground truth, such as a 'regulatory-hedge' category and explicit separation of cash-flow and fair-value hedges, which are not mentioned in the original answer. Additionally, the original answer emphasizes a shift from income statement impacts (pre-tax effects for prior years) to balance sheet categorization under 'Other' or 'Risk Management Activities', while the LLM describes a more granular and structurally complex evolution (e.g., gross/net presentation, current vs non-current separation) that goes beyond the provided ground truth. These additions suggest over-specificity or potential hallucination, reducing qualitative accuracy. Nonetheless, the core reasoning—that Southern shifted from income-focused to balance-sheet-oriented disclosure—is sound and semantically aligned. The answer is highly relevant to the question and addresses the evolution in financial presentation and categorization, albeit with some unsupported detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 379,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did GILD's strategic relationship with Arcus evolve between 2023 and 2024, particularly in terms of equity ownership and governance influence?",
      "original_answer": "In 2023, GILD owned approximately 19.9% of Arcus' issued and outstanding voting stock and had two designees on Arcus' board of directors. In January 2024, GILD made an additional $320 million equity investment in Arcus, increasing its ownership to 33%, and expanded its board representation to three designees. This represents a significant increase in both financial commitment and governance influence over Arcus within a year.",
      "llm_answer": "In 2023 Gilead owned about 19.9 % of Arcus’s voting stock and had two of Arcus’s board seats (see page 77). In January 2024 Gilead announced a $320 million equity investment that lifted its stake to roughly 33 % and added a third Gilead‑designated director to Arcus’s board (see page 77). This amendment markedly increased both Gilead’s equity ownership and its governance influence over Arcus.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: GILD's 19.9% ownership in 2023, two board designees, the January 2024 $320 million investment, increase to 33% ownership, and expansion to three board designees. (2) Quantitative accuracy is perfect: percentages (19.9%, 33%), dollar amount ($320 million), and timing (January 2024) match the original. Minor formatting differences (e.g., 'about 19.9%' vs 'approximately 19.9%') are acceptable and do not affect meaning. (3) The multi-hop reasoning is sound—information from two time points (2023 and 2024) is correctly synthesized to show evolution in ownership and governance. (4) The answer addresses both parts of the question: equity ownership and governance influence—completeness is excellent. Contextual relevance is high, with precise focus on the strategic evolution between the two years. All claims are supported by the ground truth, and the conclusion about increased influence is logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 295,
        "total_tokens": 1501
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maturity date and borrowing capacity of the 2021 Multicurrency Credit Facility evolved between 2022 and 2023?",
      "original_answer": "In 2022, the 2021 Multicurrency Credit Facility had a maximum borrowing capacity of $6.0 billion with a maturity date of June 30, 2025. By 2023, the borrowing capacity remained at $6.0 billion, but the maturity date was extended to July 1, 2026. This reflects a one-year extension of the facility’s term without any increase in the total commitment amount, indicating a strategic move to maintain financial flexibility over a longer horizon.",
      "llm_answer": "In the 2022 Form 10‑K the 2021 Multicurrency Credit Facility was reported to have a maturity of June 30 2025 and a total borrowing commitment of $6.0 billion (including a $3.5 billion sub‑limit for multicurrency borrowings)【page_49】.  By the 2023 filing the facility’s maturity had been extended one year to July 1 2026, while the total commitment remained unchanged at $6.0 billion (still with a $3.5 billion multicurrency sub‑limit)【page_52】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers and dates are accurate: the maturity date in 2022 is correctly stated as June 30, 2025, and in 2023 it is correctly updated to July 1, 2026, reflecting a one-year extension. The borrowing capacity is accurately reported as $6.0 billion in both years, with the additional detail of a $3.5 billion multicurrency sub-limit, which is consistent with the source and adds precision without contradicting the ground truth. (2) The answer addresses both parts of the question—evolution of maturity date and borrowing capacity—completely and clearly. (3) Entities are correct: the facility name (2021 Multicurrency Credit Facility), time periods (2022 and 2023 filings), and financial terms are all accurately identified. (4) The reasoning is sound: the LLM correctly infers that the capacity remained unchanged while the maturity was extended, demonstrating proper multi-hop synthesis across two annual filings. Although the LLM does not explicitly state the strategic implication (financial flexibility), this interpretive element is not required for factual correctness. The answer is semantically equivalent to the ground truth and includes document page citations, enhancing credibility. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 375,
        "total_tokens": 1590
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Chevron's utilization of imported crude oil in U.S. refining operations evolved between 2023 and 2024, and what changes in refinery capacity utilization accompanied this trend?",
      "original_answer": "Chevron's reliance on imported crude oil in U.S. refining operations remained consistent at approximately 60% of refinery inputs in both 2023 and 2024. However, the utilization of U.S. refineries changed: in 2023, crude unit distillation capacity utilization averaged 90.8%, while in 2024 it decreased to 86.6%. This indicates that while the company's dependency on imported crude oil remained stable, the overall operational intensity of its U.S. refineries declined slightly in 2024.",
      "llm_answer": "Chevron’s mix of imported versus domestic crude at its U.S. refineries was essentially unchanged – imported crude made up roughly 60 percent of the company’s U.S. refinery inputs in both 2023 and 2024. At the same time, U.S. crude‑unit distillation capacity utilization fell, dropping from about 90.8 percent in 2023 to roughly 86.6 percent in 2024 (a decline of about 4 percentage points).【page_18†L9-L13】【page_17†L9-L13】",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: imported crude oil remained at approximately 60% in both 2023 and 2024, and refinery capacity utilization decreased from 90.8% in 2023 to 86.6% in 2024. The reported 4-percentage-point decline is also correct (90.8 - 86.6 = 4.2, which rounds to about 4). (2) The answer is complete, addressing both parts of the question: the stability of imported crude oil usage and the change in refinery utilization. (3) Entities are accurate—Chevron, U.S. refining operations, correct years (2023 and 2024), and correct metric (crude unit distillation capacity utilization). (4) The reasoning is sound and reflects proper multi-hop synthesis: it correctly identifies that while feedstock composition (imported crude) remained stable, operational intensity (capacity utilization) declined. (5) The semantic meaning is equivalent to the original answer, with only minor rewording and added precision (e.g., 'about 4 percentage points'). The citations [page_18†L9-L13][page_17†L9-L13] further support the factual grounding. No errors or omissions are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 328,
        "total_tokens": 1565
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did UPS's hedging position in British Pound Sterling evolve between 2023 and 2024, and what does this shift indicate about the company's currency risk management strategy?",
      "original_answer": "In 2023, UPS reported a British Pound Sterling (GBP) hedge position of 663 million units, which decreased to 536 million units in 2024. This represents a reduction of 127 million units, or approximately 19.15%. The decrease indicates a strategic move to reduce exposure to GBP, suggesting that UPS may have reassessed its currency risk related to the British Pound and opted for a more conservative hedging approach or a lower anticipated risk in that currency during the later year.",
      "llm_answer": "UPS’s notional hedge for the British Pound fell from $663 million at the end of 2023 to $536 million at the end of 2024—a drop of roughly $127 million (≈19%)【page_130】【page_137】. This reduction signals that UPS is actively scaling back its GBP exposure, likely adjusting the hedge to match revised cash‑flow forecasts or to tighten its currency‑risk management as market conditions evolve.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the hedging positions for British Pound Sterling in 2023 ($663 million) and 2024 ($536 million), matching the ground truth. The calculated decrease of $127 million is accurate, and the approximate percentage reduction (≈19%) aligns with the exact 19.15% in the original answer—this minor rounding is acceptable. 2) All numeric values and calculations are correct. The difference (663 - 536 = 127) is accurate, and 127 / 663 ≈ 19.15%, which the model appropriately rounds to ≈19%. Number formats are consistent and acceptable. 3) The reasoning is sound: the model correctly infers that the reduction indicates a strategic move to scale back GBP exposure. It offers a plausible explanation tied to revised cash-flow forecasts or evolving market conditions, which is consistent with the ground truth’s interpretation of a more conservative risk management approach. The multi-hop synthesis—comparing two years of hedging data and interpreting strategic intent—is correctly executed. 4) The answer is semantically equivalent to the ground truth, with slightly more speculative phrasing (e.g., 'likely adjusting...') but no factual deviation. The inclusion of citation markers 【page_130】【page_137】 suggests grounding in source material. The only minor shortcoming is slightly less precise wording around the percentage (19% vs 19.15%), but this does not affect overall correctness. Thus, the answer is highly accurate, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 409,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the fair value of money market investments held by Bank of America evolved between 2023 and 2024, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "The fair value of money market investments held by Bank of America increased from $1.2 billion at December 31, 2023, to $1.3 billion at December 31, 2024. This indicates a modest growth in the company's short-term investment holdings, suggesting a slight expansion in liquidity management or short-term capital deployment strategies over the year.",
      "llm_answer": "Bank of America’s money‑market holdings rose from a fair value of **$1.2 billion at 12/31/2023** to **$1.3 billion at 12/31/2024** (up about $0.1 billion)【page_113】. The modest increase shows the bank is slightly expanding its ultra‑short‑term, low‑risk assets, underscoring a continued emphasis on liquidity and conservative cash‑management in its short‑term investment strategy.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values $1.2 billion (as of December 31, 2023) and $1.3 billion (as of December 31, 2024) are accurately reported, with the correct $0.1 billion increase. The dates are precise and match the ground truth. (2) The answer addresses both parts of the question: it reports the evolution in fair value and interprets the shift in terms of short-term investment strategy. (3) Entities—Bank of America, money market investments, and the correct time points—are accurately identified. (4) The reasoning is sound: the modest increase is correctly interpreted as reflecting a slight expansion in ultra-short-term, low-risk assets, aligning with a conservative liquidity and cash management strategy, which is semantically equivalent to the ground truth's 'slight expansion in liquidity management or short-term capital deployment.' The inclusion of a citation (page_113) further supports traceability. No factual, numerical, or interpretive errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1193,
        "completion_tokens": 299,
        "total_tokens": 1492
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maximum expected volume of natural gas subject to physical supply contracts with sell-back options changed across Southern Company's subsidiaries between 2022 and 2024?",
      "original_answer": "In 2022, the maximum expected volume of natural gas subject to such contracts was 26 million mmBtu for Southern Company as a whole, with individual volumes of 6 million mmBtu for Alabama Power, 8 million mmBtu for Georgia Power, 4 million mmBtu for Mississippi Power, and 8 million mmBtu for Southern Power. By 2024, this volume had decreased to 15 million mmBtu company-wide, with corresponding reductions in each subsidiary's volume: 4 million mmBtu for Alabama Power, 6 million mmBtu for Georgia Power, 2 million mmBtu for Mississippi Power, and 3 million mmBtu for Southern Power. This represents a consistent reduction across all entities.",
      "llm_answer": "The maximum expected volume of natural‑gas that could be sold back under physical supply contracts fell from 26 million mmBtu in 2022 (6 mmBtu for Alabama Power, 8 mmBtu for Georgia Power, 4 mmBtu for Mississippi Power and 8 mmBtu for Southern Power) to 15 million mmBtu in 2024 (4 mmBtu for Alabama Power, 6 mmBtu for Georgia Power, 2 mmBtu for Mississippi Power and 3 mmBtu for Southern Power) – a reduction of 11 million mmBtu across the subsidiaries【page_319†L31-L38】【page_281†L31-L38】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) All numeric values for 2022 and 2024 are accurate: company-wide totals (26 million mmBtu in 2022, 15 million mmBtu in 2024) and subsidiary breakdowns (Alabama Power: 6→4, Georgia Power: 8→6, Mississippi Power: 4→2, Southern Power: 8→3 million mmBtu) are exactly correct. (2) The calculation of the 11 million mmBtu reduction (26 - 15 = 11) is accurate and explicitly stated, enhancing clarity. (3) The multi-hop reasoning is sound—information is correctly synthesized across Southern Company and its subsidiaries over two years, demonstrating proper aggregation and comparison. (4) All entities (subsidiaries, metric, time periods) are correctly identified and contextualized. (5) The semantic meaning fully aligns with the original answer, including the trend of consistent reduction across all entities, even if not explicitly restated. Minor formatting differences (e.g., 'mmBtu' vs 'million mmBtu') do not affect accuracy. The inclusion of citation tags suggests proper sourcing from relevant document pages.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 310,
        "total_tokens": 1602
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the integration and application of the Firefly Vector Model evolved across Adobe's product suite between 2023 and 2024?",
      "original_answer": "In 2023, the Firefly Vector Model was integrated into Adobe Express, enabling users to generate custom images and text effects from text prompts in over 100 languages. By 2024, the Firefly Vector Model had expanded its application beyond Adobe Express and was now also integrated into Adobe Illustrator, powering features like Generative Recolor, which allows users to create different color palettes using text prompts and apply them to vector graphics. This represents a significant expansion of the Firefly Vector Model’s functionality and reach within Adobe’s creative tools, moving from a single-app integration to becoming a core AI-driven feature across multiple professional-grade applications.",
      "llm_answer": "In fiscal 2023 Adobe launched the Firefly Vector Model as part of the Firefly family, letting users create fully editable vector graphics from text prompts and embedding the capability in core Creative Cloud apps such as Photoshop, Illustrator, Express and Stock 【page_11】. By fiscal 2024 the model’s reach had broadened – it was woven into additional tools (e.g., Acrobat and InDesign), exposed through Firefly Services and Custom Models for enterprise use, and its outputs were made commercially safe with Content Credentials and generative‑credit tracking, signaling a deeper, enterprise‑grade integration across the Adobe suite 【page_12】【page_13】.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains a mix of correct and incorrect information, with significant discrepancies in entity accuracy and reasoning compared to the ground truth. (1) Correct elements: The mention of Adobe Express and Illustrator aligns with the original answer, and the general idea of expansion from 2023 to 2024 is accurate. The use of 'fiscal 2023' and 'fiscal 2024' is acceptable as a time framing. (2) Quantitative accuracy is mostly correct—no specific numbers (e.g., dollar amounts, percentages) are present in either answer, so the score is high based on consistency in time periods. However, the LLM incorrectly states that the Firefly Vector Model was integrated into Photoshop, Acrobat, and InDesign by 2024, which is not supported by the ground truth. The original answer only confirms expansion to Illustrator with a specific feature (Generative Recolor), not broader integration across Acrobat, InDesign, or Stock. (3) Multi-hop reasoning is flawed: the LLM overstates the scope of integration, adding unverified applications and enterprise features (e.g., Firefly Services, Custom Models, Content Credentials) not mentioned in the ground truth. These additions suggest a plausible but incorrect extrapolation. (4) The original answer emphasizes a progression from Adobe Express in 2023 to Illustrator in 2024 as a key evolution, focusing on vector-specific functionality like Generative Recolor. The LLM answer misrepresents this by claiming integration into multiple apps from the start (including Photoshop and Stock in 2023), which contradicts the original timeline and scope. While the overall direction of 'expansion' is correct, the specific applications and features are inaccurately reported, leading to a partial correctness score. Semantic equivalence is not achieved due to these factual overstatements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 493,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2023 to 2024, and what implications does this have for the company's HIV business strategy?",
      "original_answer": "In 2023, Biktarvy was a major revenue driver for GILD, generating $11,850 million in total product sales globally, representing a growth from $10,390 million in 2022. By 2024, although Biktarvy remained central to GILD's HIV portfolio, the company highlighted increased risks around its reliance on HIV products, particularly those containing TAF like Biktarvy, due to potential shifts in treatment paradigms and growing generic competition. This indicates that while Biktarvy continued to be a key asset, GILD faced mounting pressure to diversify or innovate within its HIV pipeline to sustain revenue growth.",
      "llm_answer": "In 2023 Biktarvy generated $11.85 billion in sales – roughly two‑thirds of Gilead’s $18.2 billion HIV revenue and a major share of total product sales (page 65). The 2024 filing, while not giving a new sales number, continues to stress the centrality of its HIV products and the need to sustain sales amid competition and pricing pressure (pages 18‑20), indicating that Biktarvy remains a cornerstone of the portfolio. Consequently, Gilead’s HIV strategy will keep Biktarvy at the forefront, focusing on protecting its market share and using it as the primary growth engine for the HIV business.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that Biktarvy generated $11.85 billion in sales in 2023, which matches the ground truth of $11,850 million. It also accurately contextualizes this as a major portion of Gilead’s HIV revenue. However, the LLM does not mention the 2022 baseline ($10,390 million) or the year-over-year growth, which is part of the original answer and relevant to assessing evolution. For 2024, the LLM correctly notes that no new sales figure is provided but misses the key qualitative shift in risk disclosure emphasized in the ground truth—specifically, the increased strategic risk due to reliance on TAF-based products and generic competition. Instead, it emphasizes continuity and market share protection, which is relevant but less nuanced than the original answer’s focus on strategic vulnerability and the need for innovation or diversification. (2) Quantitatively, the $11.85 billion figure is accurate and correctly formatted. The reference to two-thirds of $18.2 billion HIV revenue is plausible and consistent with the data, though this specific breakdown was not in the ground truth; it does not contradict it. (3) The multi-hop reasoning is partially sound: the model connects Biktarvy’s sales performance to its strategic importance and infers ongoing centrality in 2024. However, it fails to synthesize the evolving risk narrative present in the 2024 filing, which is a critical component of the strategic implication. The original answer highlights a shift from growth to risk mitigation, while the LLM portrays continuity. (4) The scores reflect strong quantitative accuracy and contextual relevance, but a moderate deduction in qualitative accuracy due to incomplete reasoning about strategic implications. The correctness score is 7 because core facts are right, but the strategic interpretation lacks depth and misses a key evolution in GILD’s stated risk profile.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 515,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the status and financial structure of the Series 2018-1A Securities evolve between 2022 and 2023, particularly in terms of outstanding principal and interest rate?",
      "original_answer": "In 2022, the Series 2018-1A Securities had an aggregate principal amount of $500.0 million and an interest rate of 3.652%. By 2023, the outstanding principal had slightly decreased to $496.8 million, while the interest rate remained unchanged at 3.652%. This indicates a minor reduction in the principal amount over the year without any modification to the interest rate.",
      "llm_answer": "The Series 2018‑1A securities remained outstanding in both years. In the 2022 filing they carried a 3.652 % coupon and $496.1 million of principal, and the 2023 filing shows the principal had risen slightly to $496.8 million while the coupon stayed at 3.652 % 【page_118】【page_108】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in the reported 2022 principal amount. The ground truth states the 2022 aggregate principal was $500.0 million, but the LLM incorrectly reports it as $496.1 million. The 2023 principal of $496.8 million is correct. The interest rate (coupon) of 3.652% is accurately reported for both years. (2) Quantitative accuracy is low because the key financial figure for 2022 is wrong—this is not a formatting issue but a material discrepancy. The direction of change (decrease from $500M to $496.8M) is correct in the ground truth, but the LLM falsely suggests an increase from $496.1M to $496.8M, which contradicts reality. (3) The reasoning is partially sound in that the model identifies the need to compare principal and interest rate across two years and correctly notes the rate stability. However, the multi-hop synthesis fails because it uses an incorrect starting value, undermining the conclusion about principal evolution. (4) Contextual relevance is high—the answer addresses the right securities, time frame, and financial metrics, and cites specific pages. The structure and intent align well with the question, but factual correctness is compromised by the principal amount error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1169,
        "completion_tokens": 351,
        "total_tokens": 1521
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did UPS's relationship with Coyote evolve from 2023 to 2024 in terms of financial impact and strategic direction?",
      "original_answer": "In 2023, UPS recorded a $111 million impairment charge related to the Coyote trade name due to declining market conditions and a strategic evaluation of the business. By 2024, this strategic evaluation culminated in the September 2024 divestiture of Coyote, which significantly impacted UPS's Supply Chain Solutions revenue, contributing to a decrease primarily driven by Coyote's exit. This marks a clear evolution from impairment and strategic review in 2023 to full divestiture in 2024.",
      "llm_answer": "In 2023 UPS still owned Coyote, recorded a $111 million impairment charge on the Coyote trade name and began evaluating strategic alternatives for the truck‑load brokerage business【page_54】. By 2024 UPS completed the September divestiture of Coyote, booked a $156 million gain on the sale and reduced Forwarding operating expenses by roughly $949 million (and Coyote‑related revenue fell $976 million), signalling a shift from retaining the asset to exiting the business【page_43】【page_41】【page_42】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of UPS's relationship with Coyote from 2023 to 2024 in both financial and strategic terms. (1) It correctly states the $111 million impairment charge in 2023 related to the Coyote trade name, aligning with the ground truth. The 2024 divestiture in September is accurately dated. The $156 million gain on sale, $949 million reduction in Forwarding operating expenses, and $976 million drop in Coyote-related revenue are specific and factually consistent with the knowledge base. While the original answer does not include the gain or expense/revenue figures, these details are consistent with a deeper synthesis of financial impacts and do not contradict the ground truth. (2) Quantitatively, all numbers are accurate and correctly attributed to the right years and events. The $111 million impairment matches exactly. The additional figures ($156M gain, $949M expense reduction, $976M revenue decline) are precise and contextually appropriate, though not in the original answer; their inclusion enhances completeness without introducing error. (3) The reasoning is sound: it traces a clear multi-hop narrative from impairment and strategic review in 2023 to full divestiture in 2024, correctly interpreting the strategic shift. (4) The answer is contextually relevant, directly addressing both financial impact and strategic direction. The only reason for not scoring a 10 is that the original answer emphasizes the *cause* of the revenue decrease (Coyote's exit) as the primary driver, while the LLM adds granular financials not in the ground truth—this is more comprehensive than incorrect, so a minor deduction is warranted for slight over-extension beyond the verified synthesis. Overall, the answer is factually correct, well-supported, and semantically aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 499,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Linde plc's structure of Performance Share Unit Awards evolve between 2022 and 2024, particularly in terms of the performance metrics used for grants beginning in 2019?",
      "original_answer": "In 2022, Linde plc disclosed two forms of Performance Share Unit Awards under the Amended and Restated 2009 Praxair, Inc. Long Term Incentive Plan: one with Return on Capital performance metrics (Exhibit 10.11k) and another with Total Shareholder Return performance metrics (Exhibit 10.11l). By 2024, these same forms of Performance Share Unit Awards remained in place, as evidenced by Exhibits 10.10l and 10.10m, which correspond directly to the 2019 grants with the same performance metrics. This indicates that the company maintained the same dual structure for Performance Share Unit Awards tied to 2019 grants, without introducing new metrics or eliminating existing ones.",
      "llm_answer": "In the 2022 filing the Performance Share Unit Awards for grants that began in 2019 were issued under the **Amended and Restated 2009 Praxair Inc. Long‑Term Incentive Plan**, and the awards were offered with either a **Return‑on‑Capital** or a **Total Shareholder Return** performance metric (*10.11k* and *10.11l* on page 107). By the 2024 filing those same two metric options appear under the newer **2021 Linde plc Long‑Term Incentive Plan** (exhibits *10.03c* and *10.03d* on page 94), which was subsequently amended in early 2024 (*10.03e*), showing that the award framework moved to Linde’s newer plan while retaining the same performance‑metric choices.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the two performance metrics used in Linde plc's Performance Share Unit Awards—Return on Capital and Total Shareholder Return—and notes their presence in both 2022 and 2024, which aligns with the ground truth. It also accurately references the transition from the Praxair plan to the Linde 2021 Long-Term Incentive Plan, showing awareness of the plan evolution. However, there is a critical discrepancy in the exhibit numbers: the LLM claims the 2024 awards appear as Exhibits 10.03c, 10.03d, and 10.03e, whereas the ground truth states they are Exhibits 10.10l and 10.10m. This misidentification suggests incorrect sourcing or document referencing, undermining factual reliability. Additionally, the ground truth emphasizes that the *same forms* of awards from 2019 remained under the original structure without migration to a new plan, while the LLM implies a transition to the 2021 plan, which contradicts the original answer. This reflects a flaw in multi-hop reasoning—while some facts are correct (metrics, plan names), the synthesis across years and exhibits is inaccurate. The dates and metric names are correct (supporting a high quantitative score), but the qualitative reasoning about structural continuity is flawed. Contextually, the response stays focused and relevant to the question’s scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 371,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the regulatory status of Trodelvy evolved between 2023 and 2024, and what does this indicate about its development trajectory?",
      "original_answer": "In 2023, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, hormone receptor-positive/HER2-negative breast cancer, and urothelial cancer. By 2024, the FDA granted Trodelvy a Breakthrough Therapy designation for the treatment of extensive-stage small cell lung cancer in patients whose disease has progressed after platinum-based chemotherapy. This indicates a strategic expansion of Trodelvy’s development into new oncology indications with high unmet medical need.",
      "llm_answer": "In 2023 Trodelvy was already on the market under FDA‑accelerated approval for triple‑negative and HR⁺/HER2‑ breast cancer (and for metastatic urothelial cancer) and, that year, the FDA also approved it for HR⁺/HER2‑ breast cancer while the European Commission granted a matching indication 【page_7†L31-L38】. By 2024 the drug had earned a **second** FDA Breakthrough‑Therapy designation for extensive‑stage small‑cell lung cancer, a new investigational indication 【page_8†L9-L13】, showing that Gilead is expanding Trodelvy’s clinical program into additional cancer types and receiving expedited regulatory support, indicating a continued, upward development trajectory.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Trodelvy's 2023 indications: triple-negative breast cancer, HR+/HER2-negative breast cancer, and urothelial cancer, noting both FDA and European Commission approvals. The mention of the 2023 FDA approval for HR+/HER2-negative breast cancer is consistent with the original answer, though the original does not specify the European approval—this is an addition but not an error. (2) Quantitatively, all dates (2023, 2024) and regulatory milestones (Breakthrough Therapy designation in 2024 for extensive-stage small cell lung cancer) are correct. The reference to a 'second' Breakthrough Therapy designation is plausible and contextually supported, though not explicitly confirmed in the ground truth; however, this does not constitute a factual error. (3) The multi-hop reasoning is sound: the answer synthesizes information across years and indications, correctly inferring that the new designation indicates expansion into new oncology areas with unmet need. (4) The conclusion about Gilead expanding Trodelvy’s clinical program and receiving expedited support accurately reflects the development trajectory implied in the original answer. The only minor limitation is the slight expansion beyond the ground truth with the mention of the European Commission approval and 'second' designation, but these do not detract from factual correctness. Overall, the answer is semantically equivalent, contextually relevant, and demonstrates strong qualitative and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 431,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of the Vertex AI platform within Google Cloud evolved from 2023 to 2024, particularly in terms of its capabilities and integration with generative AI models?",
      "original_answer": "In 2023, the Vertex AI platform was described as a tool that allowed developers to train, tune, augment, and deploy applications using generative AI models and services such as Enterprise Search and Conversations. By 2024, the platform had evolved to specifically support Gemini and other leading generative AI models, offering developers the ability to train, tune, augment, test, and deploy applications with additional services like vector search, grounding, and distillation to improve model cost and quality. This reflects a shift toward more advanced and optimized generative AI integration.",
      "llm_answer": "In the 2023 filing, Vertex AI was presented as the Google Cloud developer platform that lets customers **train, tune, augment, test and deploy** applications using Gemini and other leading generative‑AI models, with added services such as vector search, grounding and model distillation 【page_8】. By the 2024 filing, the platform had broadened its model suite to include **Gemini, Imagen and Veo**, and introduced **Gemini for Google Cloud pre‑packaged AI agents** that help developers write, document, test and operate software and also support cybersecurity teams, reflecting a deeper, more application‑focused integration of generative AI 【page_6】.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies compared to the ground truth. While it correctly identifies Vertex AI's role in Google Cloud and generative AI integration, it incorrectly states that in 2023, Vertex AI already supported 'Gemini' and included services like 'vector search, grounding and model distillation'—but according to the original answer, these advanced capabilities were introduced by 2024, not present in 2023. The original answer specifies that in 2023, Vertex AI supported generative AI models and services like Enterprise Search and Conversations, not Gemini specifically. The LLM flips the timeline by attributing 2024 enhancements to 2023. Additionally, the mention of 'Imagen and Veo' and 'Gemini for Google Cloud pre-packaged AI agents' appears to be extra detail not present in the ground truth, which does not mention these models or agents. (2) There are no numeric values, dates, or calculations to verify, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is partially sound—LLM recognizes the evolution of Vertex AI across years and attempts to contrast capabilities, but misattributes key features to the wrong year, undermining the logical progression. The synthesis across time points is flawed due to incorrect alignment of features with years. (4) Despite the factual misalignment in timing and unsupported additions (e.g., Imagen, Veo, pre-packaged agents), the answer remains contextually relevant and addresses the question's focus on evolution, capabilities, and generative AI integration—hence high contextual relevance. However, the qualitative accuracy is low due to incorrect entity-feature-time mappings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 464,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the treatment and valuation of weather derivatives changed in SO's financial disclosures from 2022 to 2024, particularly in terms of the amounts considered immaterial and excluded from derivative valuations?",
      "original_answer": "In 2022, SO disclosed that the premium and intrinsic value associated with weather derivatives were immaterial for all periods presented, but did not specify exact amounts. By 2024, SO continued to exclude the premium and intrinsic value of weather derivatives as immaterial, but also provided more specific context by disclosing that cash collateral held in broker margin accounts was $17 million and $62 million at the end of 2024 and 2023, respectively. This suggests a more detailed and structured approach to derivative disclosures over time, even though the weather derivative component remained immaterial.",
      "llm_answer": "In the 2022 Form 10‑K the company disclosed that the “premium and intrinsic value associated with weather derivatives” are immaterial and therefore are excluded from the fair‑value measurement of its energy‑related derivative contracts (the note also excluded cash‑collateral balances of $3 million, $28 million and $99 million). The 2024 Form 10‑K repeats the same approach, stating that net derivative amounts “exclude immaterial premium and intrinsic value associated with weather derivatives” for all periods presented, again without quantifying a dollar amount—so the treatment of weather derivatives remains unchanged, with the amounts still deemed immaterial and omitted from valuation.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that SO (Southern Company) treated weather derivatives as immaterial in both 2022 and 2024, and that the premium and intrinsic value were excluded from derivative valuations in both years. However, it introduces significant factual errors in quantitative details. Specifically, the LLM claims that in 2022, cash collateral balances of $3 million, $28 million, and $99 million were excluded—this is incorrect and not supported by the ground truth. The ground truth states that in 2024, cash collateral was $17 million and $62 million at the end of 2024 and 2023, respectively—not the figures cited by the LLM. The LLM also misattributes these collateral figures to 2022 and lists three amounts without context, which contradicts the original answer. (2) The quantitative inaccuracies are severe: the dollar amounts and years are wrong, and the LLM fabricates a detail (the $3M, $28M, $99M) not present in the ground truth. While the format variation allowance applies to number formatting, it does not excuse introducing entirely incorrect values. (3) The reasoning is partially sound: the LLM correctly infers that the treatment of weather derivatives remained consistent in terms of immateriality and exclusion from valuation. However, it fails to capture the key evolution noted in the ground truth—that SO provided more detailed disclosure in 2024 by specifying actual cash collateral amounts, indicating a more structured approach. This nuance is missed, weakening the multi-hop synthesis. (4) The contextual relevance is high because the answer addresses the core issue of immateriality and exclusion over time. However, due to the incorrect numerical data and omission of the meaningful enhancement in disclosure detail in 2024, the correctness score is limited to 5—partially correct but with significant factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 508,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the regulatory and market positioning of Biktarvy evolved between 2023 and 2024 based on GILD's disclosures?",
      "original_answer": "In 2023, Biktarvy was listed with a U.S. patent expiration year of 2033, indicating long-term market exclusivity protection in the U.S. In 2024, Biktarvy received an expanded regulatory indication from the FDA to treat people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. Additionally, the FDA approved an updated label with data reinforcing Biktarvy's safety and efficacy for use in pregnant people with HIV-1. This represents a shift from primarily patent protection in 2023 to expanded therapeutic application and broader patient eligibility in 2024.",
      "llm_answer": "In the 2023 filing Gilead only noted that Biktarvy’s core patents remain in force until 2033 in both the U.S. and the EU, with no new regulatory actions reported for the product (2023 10‑K p. 9). By the 2024 filing the company disclosed that the FDA approved an expanded indication for Biktarvy—allowing use in patients with suppressed viral loads who have known or suspected M184V/I resistance and adding an updated label confirming safety and efficacy in pregnant people—and that its patent protection still runs through 2033, reflecting both an enhanced therapeutic label and continued market exclusivity (2024 10‑K p. 8 & 9).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately reports the 2033 U.S. patent expiration for Biktarvy from the 2023 filing, consistent with the original answer. While it adds EU patent information not in the ground truth, this does not contradict and adds context without error. (2) For 2024, it correctly identifies the FDA's expanded indication for patients with suppressed viral loads and M184V/I resistance, as well as the updated label for use in pregnant people with HIV—both key regulatory developments. (3) The multi-hop reasoning is sound: it contrasts GILD’s 2023 emphasis on patent protection with the 2024 focus on label expansion and broader clinical application, capturing the evolution in regulatory and market positioning. (4) All entities (Biktarvy, GILD, FDA, 2023/2024 time frame) are correct, and the synthesis across years and disclosures is accurate. Minor wording differences (e.g., 'core patents remain in force' vs 'listed with a U.S. patent expiration') are semantically equivalent. No factual, quantitative, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 315,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did AMT's utilization of the 2021 Multicurrency Credit Facility change between 2022 and 2023, particularly in terms of borrowing amounts and facility amendments?",
      "original_answer": "In 2022, AMT made additional net borrowings of $850.0 million under the 2021 Multicurrency Credit Facility, which were used to repay existing indebtedness and for general corporate purposes. By 2023, the company borrowed an aggregate of $3.0 billion and repaid $6.1 billion under the same facility, including a significant repayment of 842.6 million EUR ($919.1 million). Additionally, the facility underwent amendments in 2023 that extended its maturity date to July 1, 2026, maintained a total commitment of $6.0 billion, and replaced the LIBOR pricing benchmark with SOFR. This reflects a significant transformation in the usage and structure of the facility.",
      "llm_answer": "In 2022 AMT only took modest net borrowings under the 2021 Multicurrency Credit Facility – about **$850 million** (the only post‑2021 borrowing disclosed)【page_44】. By contrast, in 2023 the company **borrowed $3.0 billion** and repaid $6.1 billion on that facility, and in June 2023 the facility was **amended** – extending its maturity to July 1 2026, reaffirming a $6.0 billion commitment (with a $3.5 billion multicurrency sub‑limit, $200 million letters‑of‑credit and $50 million swing‑line sub‑limits) and switching the benchmark from LIBOR to SOFR【page_52】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key quantitative facts: $850 million in net borrowings in 2022, $3.0 billion borrowed and $6.1 billion repaid in 2023, the July 1, 2026 maturity extension, the $6.0 billion total commitment, and the LIBOR to SOFR benchmark change. These match the ground truth exactly. The EUR repayment of 842.6 million ($919.1 million) is omitted, which is a minor gap but does not undermine the core accuracy. (2) All numbers, dates, and financial amounts are accurate and correctly formatted. The $850 million, $3.0 billion, $6.1 billion, and $6.0 billion figures are all correct. The June 2023 amendment timing aligns with the July 1, 2026 maturity date. The switch from LIBOR to SOFR is correctly reported. (3) The reasoning is sound: the LLM contrasts 2022 and 2023 usage, notes the increased activity in 2023, and correctly links the amendment to structural changes in the facility. It synthesizes information across years and documents to show evolution in utilization and terms. The only minor omission is the specific EUR repayment amount, which is part of the $6.1 billion total but not broken out. (4) The answer is contextually fully relevant, directly addressing changes in borrowing amounts and facility amendments. The inclusion of sub-limits (e.g., $3.5 billion multicurrency sub-limit) adds detail beyond the ground truth and is acceptable if accurate, though not required. Overall, the answer is factually correct, well-structured, and conveys the same essential transformation described in the original answer, warranting a high score with only a slight deduction for the missing EUR repayment detail in the breakdown.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 458,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has the role of Google Ad Manager in Alphabet's advertising revenue recognition strategy evolved between 2023 and 2024, particularly in terms of its integration with revenue reporting models?",
      "original_answer": "In 2023, Google Ad Manager was directly tied to Alphabet's advertising revenue recognition on a gross basis, with the company reporting the full amount billed to customers as revenue for ads placed on Google Network properties. By 2024, the language around Google Ad Manager shifted, emphasizing a more nuanced control-based evaluation where Alphabet asserts its role as principal by controlling advertising inventory before transfer to customers, being primarily responsible to them, and having discretion over pricing. This reflects a strategic evolution from a transactional reporting model to a more control-driven justification for gross revenue recognition, reinforcing the centrality of Google Ad Manager in revenue operations.",
      "llm_answer": "In the 2023 filing, Google Ad Manager was listed as one of the platforms (alongside Google Ads, Display & Video 360, etc.) through which advertisers purchase inventory, and revenue from ads on Google Network properties—including those run via Ad Manager—was recognized on a gross or net basis depending on whether Alphabet was deemed the principal (see 2023 Note 1, “Advertising Revenues,” p. 58). By the 2024 filing, Alphabet explicitly integrates Google Ad Manager into its revenue‑reporting model as part of the Google Network properties, consistently treating the amounts billed to customers as gross revenue and the payments to network partners as cost of revenue—thereby formalizing Ad Manager’s role as a principal channel within the overall advertising revenue recognition framework (see 2024 Note 1, “Advertising Revenues,” p. 57).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2023, Google Ad Manager was part of Alphabet's advertising platforms and that revenue recognition depended on principal vs. agent assessment, consistent with the gross vs. net treatment based on control—referencing the correct disclosure (2023 Note 1, p. 58). In 2024, it accurately notes the shift toward consistent gross reporting, with payments to partners treated as cost of revenue, reflecting Alphabet's assertion of principal status. This matches the ground truth's emphasis on a control-based justification. (2) There are no numerical values to verify, but dates (2023, 2024), document locations (Note 1, pages 58 and 57), and financial reporting terms (gross revenue, cost of revenue, principal) are all factually correct. (3) The multi-hop reasoning is sound: the model synthesizes changes in disclosure language and accounting policy between two years, correctly inferring a strategic evolution in how Google Ad Manager is positioned within revenue recognition, even if it doesn't use the exact phrase 'control-based evaluation.' (4) The only minor shortcoming is that the LLM answer does not explicitly articulate the conceptual shift from 'transactional reporting model' to 'control-driven justification' as emphasized in the original answer, which slightly reduces qualitative precision. However, the substance is equivalent. Wording differences are acceptable under semantic equivalence. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 435,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has UPS's financial exposure and strategic positioning regarding Roadie evolved between 2023 and 2024, particularly in terms of goodwill impairment and risk assessment?",
      "original_answer": "In 2023, UPS recorded a $56 million goodwill impairment charge related to Roadie, indicating financial concerns about its value. By 2024, although no further impairment was recorded, Roadie was identified among the reporting units with limited excess of fair value over carrying value, signaling ongoing financial risk. This evolution reflects a shift from active impairment to a cautious monitoring stance due to Roadie's continued sensitivity to cost of capital and performance forecasts.",
      "llm_answer": "In 2023 UPS recorded a $56 million goodwill impairment on Roadie, indicating that the unit’s fair‑value had fallen below its carrying amount after the 2021 acquisition. By 2024 no new impairment was booked, but UPS’s goodwill‑testing flagged Roadie (along with two other units) as having only a limited cushion of fair value—so a 100‑basis‑point rise in cost of capital or a 10 % drop in projected cash flows could trigger an impairment, and the company now monitors Roadie as a higher‑risk reporting unit while still believing its fair value exceeds book value.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: the $56 million goodwill impairment in 2023 is accurately reported, and the absence of a new impairment in 2024 is correctly stated. (2) Quantitative details are precise—$56 million, 100-basis-point increase in cost of capital, and 10% drop in cash flows are all consistent with known disclosures. These thresholds are not in the original answer but are plausible and commonly disclosed sensitivities; their inclusion enhances rather than contradicts the ground truth, which mentions 'sensitivity to cost of capital and performance forecasts.' (3) The reasoning correctly synthesizes multi-hop information: it connects the 2023 impairment to the 2021 acquisition, interprets the 2024 risk status as ongoing due to narrow fair-value cushion, and infers appropriate monitoring—demonstrating sound qualitative logic. (4) Entities (UPS, Roadie), years (2023, 2024), and financial concepts (goodwill impairment, fair value vs. carrying value) are correctly used. The answer fully addresses both financial exposure (impairment and risk triggers) and strategic positioning (cautious monitoring despite no new charge), satisfying the multi-part question. Minor enhancements in specificity (e.g., sensitivity thresholds) do not detract from accuracy and may reflect additional valid context from the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 391,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what quantitative impact did this change have on the company's sales and operating profit?",
      "original_answer": "In 2022, helium was a supply component for Linde, indicating a positive or neutral role in operations. By 2024, helium had a negative impact on performance, with a 2% underlying sales decrease in the 'Other' segment primarily due to lower volumes in global helium and Linde Advanced Materials Technology (LAMT). Additionally, operating profit in the 'Other' segment saw increased costs related to helium, partially offset by an insurance recovery for LAMT. This reflects a shift from helium being a supply input to a source of cost pressure.",
      "llm_answer": "In the 2022 filing (pages 70‑74) Linde makes no mention of helium, implying the gas was not a material line‑item at that time【page_70】. By the 2024 filing helium is disclosed under the “Other” segment; lower helium volumes cut “Other” sales by $32 million (‑2 %) while operating profit in “Other” rose $19 million (a 44 % increase) despite higher helium‑related costs【page_28】.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partial correctness but has significant factual and reasoning errors. (1) Quantitative Accuracy: The $32 million (2%) decrease in 'Other' segment sales due to lower helium volumes is consistent with the ground truth and correctly reflects a negative impact on sales. However, the claim that operating profit in the 'Other' segment rose $19 million (44% increase) contradicts the ground truth, which states that operating profit faced increased costs from helium, partially offset by insurance recovery—implying pressure, not growth. The LLM incorrectly frames helium as contributing to profit growth when it was a cost driver. (2) Completeness: The answer addresses the evolution of helium’s role and provides quantitative impacts on sales and operating profit, satisfying the multi-part structure. However, it omits key context: the shift from helium being a supply component in 2022 to a cost pressure point in 2024, and the specific mention of Linde Advanced Materials Technology (LAMT) and insurance recovery. (3) Entity Accuracy: Linde, 'Other' segment, 2022, and 2024 are correctly identified. The use of 'helium-related costs' is accurate, but the inference from absence in 2022 filing to 'not material' is weak—absence of mention does not confirm status as a supply component. (4) Reasoning: The multi-hop synthesis is flawed. The LLM infers helium had no role in 2022 due to lack of mention, but the ground truth affirms it was a supply component. This misrepresents the starting point. The conclusion that operating profit increased despite helium costs contradicts the negative impact described in the truth. (5) Semantic Equivalence: While some sales data aligns, the operating profit claim reverses the actual impact. The overall narrative is inconsistent with the ground truth’s emphasis on deteriorating helium economics. Thus, despite correct sales figures, the critical error in profit interpretation and reasoning downgrades the correctness score to 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 534,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the total value of loans covered under long-term credit protection agreements with FNMA and FHLMC evolve from 2023 to 2024, and what does this indicate about the Corporation's credit risk exposure on residential mortgage loans?",
      "original_answer": "In 2023, the Corporation had $8.7 billion in loans covered under credit protection agreements with FNMA and FHLMC, which decreased to $8.0 billion in 2024. This indicates a reduction in the Corporation's reliance on full credit protection for residential mortgage loans that become severely delinquent. Since these agreements provide full credit protection and the Corporation does not record an allowance for credit losses on these loans, the decline suggests a potential decrease in the volume of high-risk residential mortgage loans in their portfolio.",
      "llm_answer": "The 10‑K shows that the long‑term credit‑protection agreements with FNMA and FHLMC covered **$8.7 billion of residential‑mortgage loans at 31 Dec 2023** and **$8.0 billion at 31 Dec 2024** – a decline of roughly **$700 million** (see page 118). The drop means a slightly smaller share of the mortgage portfolio is fully insured, indicating a modest rise in the amount of residential‑mortgage credit risk that is not protected, even though the covered loans remain fully shielded from severe delinquency.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the dollar amounts ($8.7 billion in 2023 and $8.0 billion in 2024) and calculates the $700 million decrease accurately, matching the ground truth. Dates (31 Dec 2023 and 31 Dec 2024) are appropriately used and consistent with annual reporting. (2) Quantitative accuracy is perfect: values match exactly, difference is correctly computed as $700 million, and source reference (page 118) adds credibility. (3) However, the qualitative reasoning diverges from the ground truth interpretation. While the original answer states the decline indicates reduced reliance on full credit protection and potentially fewer high-risk loans, the LLM interprets it as a 'modest rise in credit risk that is not protected,' which inverts the implication. The ground truth emphasizes a reduction in high-risk exposure due to fewer loans needing protection, whereas the LLM suggests increased risk due to less coverage—this is a significant logical discrepancy. (4) Despite accurate numbers and good contextual relevance (addresses both parts of the question and cites source), the flawed reasoning lowers qualitative accuracy. The conclusion should reflect reduced credit risk exposure, not increased. Thus, correctness is penalized for incorrect inference, though factual data is fully accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 370,
        "total_tokens": 1657
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Adobe's strategic positioning of Adobe Firefly evolved between 2023 and 2024, particularly in terms of competitive differentiation and associated regulatory risks?",
      "original_answer": "In 2023, Adobe positioned Adobe Firefly as a competitive differentiator by emphasizing its generative AI capabilities that are natively integrated into Adobe products and designed to be safe for commercial use. By 2024, Adobe continued to highlight Firefly's AI innovations but introduced new concerns around regulatory risks, particularly referencing the EU AI Act adopted in 2024, which could impose compliance costs, delay development, or require changes to AI development practices. This reflects a shift from purely competitive emphasis to a more risk-aware strategic positioning of the product.",
      "llm_answer": "In the 2023 filing Adobe presented Firefly as a core generative‑AI suite that is natively embedded in Creative Cloud and Experience Cloud, emphasizing its “commercially‑safe” text‑to‑image, vector‑graphic and design‑template capabilities as a key competitive differentiator (2023 p.9‑11). By the 2024 filing the company still positions Firefly as a strategic AI differentiator, but now explicitly flags rising regulatory risk – citing the EU AI Act and other emerging AI‑specific rules that could increase compliance costs, limit product availability or create liability for its AI offerings (2024 p.23‑24).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Adobe positioned Firefly in 2023 as a competitive differentiator through native integration and commercial safety, and in 2024 began highlighting regulatory risks, especially the EU AI Act. The mention of 'commercially-safe' capabilities and integration into Creative Cloud and Experience Cloud adds contextual precision not in the original but consistent with likely source material. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable in a traditional sense—however, the years (2023, 2024) and document references (p.9-11, p.23-24) are correctly used and plausibly accurate, supporting factual grounding. (3) The multi-hop reasoning is sound: the model correctly synthesizes strategic positioning shifts across two years, identifying both competitive differentiation and the emergence of regulatory risk as a new theme. It correctly infers a strategic evolution from pure differentiation to risk-aware innovation. (4) Semantic equivalence is strong—while the LLM answer includes slightly more detail (e.g., 'text-to-image, vector-graphic and design-template capabilities'), it does not introduce inaccuracies. The core shift in strategic positioning is captured accurately. The score is 9 instead of 10 because the LLM references specific page numbers and feature details not present in the ground truth; while plausible and likely correct, they slightly exceed the confirmed facts in the original answer, introducing a minor risk of over-specificity without explicit confirmation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 451,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the financial performance and regulatory trajectory of Trodelvy evolve between 2023 and 2024?",
      "original_answer": "In 2023, Trodelvy generated total product sales of $1,063 million, reflecting a 56% increase compared to the previous year. By 2024, the regulatory landscape for Trodelvy advanced significantly with the FDA granting it a second Breakthrough Therapy designation, specifically for the treatment of adult patients with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. This indicates both strong financial growth and increased regulatory recognition of the drug's potential clinical impact.",
      "llm_answer": "In 2023 Trodelvy’s commercial performance accelerated, with product sales jumping 56 % to roughly $1.1 billion and its contribution pulling down the overall product‑gross‑margin because of amortization and manufacturing write‑offs tied to the February 2023 FDA approval for HR⁺/HER2‑ metastatic breast cancer【page_41】. In 2024 the drug’s regulatory momentum continued – the FDA granted a second Breakthrough‑Therapy designation for extensive‑stage small‑cell lung cancer and the European Commission approved Trodelvy as a monotherapy for HR⁺/HER2‑ breast cancer, expanding its label beyond the earlier U.S. approval【page_8】【page_39】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the 56% year-over-year sales growth and approximates the $1,063 million in 2023 product sales as 'roughly $1.1 billion', which is semantically equivalent and acceptable under format variation. The ground truth specifies $1,063 million, and $1.1 billion is a reasonable rounding. No other numeric values are contradicted. (2) All quantitative elements—percentage increase and sales figure—are factually accurate and consistent with the original answer. There are no calculation errors. (3) The LLM provides additional but accurate qualitative context not in the ground truth, such as the impact on gross margin due to amortization and manufacturing write-offs, and the European Commission's approval for HR+/HER2- breast cancer. While these details exceed the original answer, they do not contradict it and reflect correct multi-hop reasoning from cited pages. The core multi-hop requirement—linking 2023 financial performance to 2024 regulatory developments for Trodelvy—is fully satisfied. (4) The only minor deviation is the inclusion of extra details that slightly shift focus (e.g., gross margin impact), but the key financial and regulatory evolution is accurately synthesized. Thus, the answer earns a 9 for correctness and qualitative accuracy due to slight over-elaboration without factual error, 10 for quantitative accuracy and contextual relevance as all facts are correct and highly relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 402,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Chevron's financial involvement and strategic positioning in Angola LNG evolved from 2022 to 2024, based on specific disclosures regarding its equity investments and affiliate transactions?",
      "original_answer": "In 2022, Chevron reported improved income from equity affiliates, including upstream-related earnings from Angola LNG, which contributed to an overall increase in income from equity affiliates to $5,657 million. By 2024, Chevron's specific interest in Angola LNG Limited was disclosed as a 36.4% ownership stake, with Angola LNG Limited described as a key entity that processes and liquefies natural gas produced in Angola for delivery to international markets. This evolution reflects a continued strategic emphasis on LNG as part of Chevron’s broader upstream portfolio, with a clear quantification of its stake in 2024, suggesting a more defined and stable long-term positioning compared to the more general mention of earnings contribution in 2022.",
      "llm_answer": "Chevron’s stake in Angola LNG has been trimmed and its earnings contribution has fallen. In 2022 the company carried a $1.86 billion investment in Angola LNG and recorded $1.86 billion of equity‑in‑earnings from the affiliate (Note 15, 2022 10‑K p. 44; MD&A p. 42). By the end of 2024 the investment had slipped to $1.66 billion and the share of earnings dropped to $405 million (Note 15, 2024 10‑K p. 84), while Chevron still holds a 36.4 % ownership interest in the project, underscoring its continued strategic, minority‑partner role (Note 15 description, 2024 10‑K p. 85).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Chevron's income from equity affiliates in 2022 was $5,657 million overall, with Angola LNG contributing to upstream-related earnings, but no specific dollar amount for Angola LNG's equity earnings or investment value was disclosed in 2022. The LLM incorrectly states a $1.86 billion investment and $1.86 billion in equity earnings from Angola LNG in 2022, which is not supported by the original answer or the knowledge graph. Similarly, the claim that equity earnings dropped to $405 million in 2024 and the investment value declined to $1.66 billion is not corroborated by the ground truth, which does not provide investment carrying values or affiliate earnings for Angola LNG in 2024. Only the 36.4% ownership stake in 2024 is correctly reported. (2) The quantitative inaccuracies are severe: the LLM fabricates precise financial figures (e.g., $1.86B, $405M) that are not present in the ground truth, and falsely implies a decline in both investment value and earnings, which the original answer does not support. The original answer highlights improved income from equity affiliates in 2022 and a more defined strategic positioning in 2024, not a decline. (3) The multi-hop reasoning is flawed. The LLM incorrectly infers a reduction in strategic importance due to alleged declines in investment and earnings, contradicting the ground truth’s narrative of continued strategic emphasis on LNG and a more stable, defined positioning. The synthesis across years is based on fabricated data, undermining the logical conclusion. (4) While the LLM correctly identifies Chevron and Angola LNG, the 36.4% stake, and attempts to compare 2022 and 2024, the extensive use of incorrect financial data severely undermines factual correctness. The answer is contextually relevant in structure and topic focus but fails on core accuracy, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 530,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the value and issuance activity of META's Fixed-Rate Senior Unsecured Notes evolve from 2023 to 2024?",
      "original_answer": "In 2023, META issued $8.46 billion of net proceeds from Fixed-Rate Senior Unsecured Notes in May. By the end of 2024, the total value of these Notes had increased to $29.0 billion, up from $18.50 billion at the end of 2023, with an additional $10.50 billion issued in August 2024. This reflects both continued reliance on this form of debt financing and a significant increase in the total outstanding amount over the two-year period.",
      "llm_answer": "Meta’s fixed‑rate senior unsecured notes rose from $18.5 billion of principal outstanding (fair‑value $18.48 billion) at year‑end 2023 to $29.0 billion of principal (fair‑value $27.83 billion) at year‑end 2024, reflecting the addition of a $10.5 billion issuance in August 2024【page_80】【page_110】. In 2023 the company issued $8.5 billion of notes in May 2023, generating about $8.46 billion of net proceeds【page_79】【page_110】, and in 2024 it issued a further $10.5 billion of notes, expanding the total pool of senior unsecured debt.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively: All key figures are correct—$8.46 billion net proceeds from the May 2023 issuance (stated as ~$8.46B with $8.5B gross, which is acceptable rounding), $18.5B outstanding at end of 2023, $29.0B at end of 2024, and the $10.5B issuance in August 2024. The fair value details ($18.48B and $27.83B) are extra but accurate and contextually relevant. (2) Completeness: The answer covers both years, issuance activity, and the evolution of total value, addressing all parts of the question. (3) Entity accuracy: 'Meta' is correct, time periods (2023–2024), financial instrument (Fixed-Rate Senior Unsecured Notes), and metrics are correctly identified. (4) Reasoning: The multi-hop synthesis—linking 2023 issuance to 2023 year-end balance and 2024 issuance to 2024 year-end balance—is sound. The increase from $18.5B to $29.0B is correctly attributed to the $10.5B issuance, which aligns with the ground truth. (5) Semantic equivalence: The LLM uses slightly different phrasing (e.g., 'rose from $18.5B... to $29.0B') but preserves factual and logical integrity. Minor deduction in quantitative accuracy due to rounding $8.46B to $8.5B without explicit qualification, though this is common and not misleading. Overall, the answer is factually correct, well-supported, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 385,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did LIN's financial exposure to helium as a raw material change from 2023, when it was categorized as a supply, to 2024, when it became a dependency, based on specific cost or sourcing disclosures?",
      "original_answer": "In 2023, LIN categorized helium as a supply, indicating it was a standard input with manageable sourcing dynamics, and reported helium costs at 4.2% of total raw material expenses. By 2024, the relationship shifted to 'depends_on,' signaling increased strategic importance, and helium costs rose to 6.8% of raw material expenses, reflecting a more critical role in operations and a corresponding increase in cost exposure.",
      "llm_answer": "In the 2023 filing helium was disclosed only as part of the broader “raw materials and supplies” line, which was valued at $614 million. By the 2024 filing the company re‑characterized helium as a critical dependency, and the “raw materials and supplies” balance fell to $529 million – an $85 million reduction – signalling that the company’s exposure shifted from a generic supply cost to a more focused reliance on helium.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that helium costs were 4.2% of total raw material expenses in 2023 and increased to 6.8% in 2024, but the LLM does not mention these percentages at all. Instead, it fabricates dollar amounts—$614 million and $529 million—for 'raw materials and supplies' and claims an $85 million reduction, which is not supported by the original answer. These figures and the implied calculation are entirely absent from the ground truth. (2) The quantitative inaccuracies are severe: no total raw materials cost figures or changes in aggregate spending are mentioned in the original answer, nor is there any indication that helium’s cost was derived from a decline in a broader category. The LLM invents a narrative based on unsupported totals and a non-existent $85 million drop. (3) The qualitative reasoning is flawed. While the LLM correctly identifies a shift in categorization—from a general supply to a critical dependency—this is framed around fabricated financial data. The multi-hop synthesis required (linking classification change to actual cost exposure increase) fails because the model substitutes correct percentage-based cost exposure with invented absolute spending figures. (4) Contextual relevance is moderate because the answer addresses the shift in helium's strategic status and attempts to tie it to financial exposure, but the use of false quantitative support undermines the entire argument. The core insight about increased dependency is partially aligned, but without correct data or proper reasoning, the answer is largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 449,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what was the percentage change in the amount approved for such activities?",
      "original_answer": "In 2022, PayPal had $3.8 billion approved to fund credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, the approved amount decreased to $3.0 billion, representing approximately 39% of European customer balances. This indicates a reduction in the absolute amount approved for credit activities, even though the percentage slightly increased, signaling a more conservative approach to utilizing customer balances for credit funding.",
      "llm_answer": "PayPal’s approved pool of European customer balances earmarked for credit activities fell from $3.8 billion at 12/31/2022 to $3.0 billion at 12/31/2023, a drop of roughly $0.8 billion or ≈ 21 % decline. Although the absolute amount fell, the share of European balances designated rose modestly from about 37 % to 39 % of the total available 【page_49】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $3.8 billion in 2022 and $3.0 billion in 2023 are correctly reported. The absolute decrease of $0.8 billion and the ≈21% decline (calculated as (0.8 / 3.8) ≈ 21.05%) are correct. The percentages—37% in 2022 and 39% in 2023—are also accurately stated. (2) The answer is complete, addressing both the evolution of PayPal's utilization of European customer balances and the percentage change in the approved amount. It correctly notes the decrease in absolute terms alongside the slight increase in proportional usage. (3) Entity accuracy is perfect: PayPal, European customer balances, credit activities, and the years 2022 and 2023 are all correctly identified and contextualized. (4) The reasoning is sound and reflects multi-hop synthesis: it contrasts absolute versus relative changes and infers a shift in utilization strategy, aligning with the ground truth's interpretation of a more conservative approach. The mention of a source reference 【page_49】 adds contextual support. (5) The semantic meaning is equivalent to the original answer, with slightly more concise wording but no loss of key information. All scoring categories warrant full marks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 356,
        "total_tokens": 1578
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Starbucks' exposure to foreign currency - other instruments evolve between 2023 and 2024, particularly in terms of their fair value and the expected reclassification impact on earnings?",
      "original_answer": "In 2023, Starbucks reported a fair value of $1,164 million for foreign currency - other instruments, with a net gain of $39.6 million included in AOCI. By 2024, the fair value decreased to $920 million, and the net gain included in AOCI dropped to $11.5 million. Additionally, the amount expected to be reclassified from AOCI into earnings within 12 months declined from $55.3 million in 2023 to $9.5 million in 2024, indicating a reduced short-term earnings impact from these instruments.",
      "llm_answer": "In 2023 Starbucks reported foreign‑currency‑other derivative assets of $32.0 million (current) and $22.9 million (long‑term) with only $2.0 million of accrued liabilities (no long‑term liability). By September 29 2024 those asset balances had collapsed to $1.9 million and $1.7 million, while the liability side grew to $4.7 million (accrued) and $4.1 million (long‑term), shrinking the net fair‑value exposure from roughly a $53 million asset position to a net liability of about $5 million. The AOCI balance for “foreign currency – other” fell from $39.6 million in 2023 to $11.5 million in 2024, and Starbucks now expects to reclassify a $9.5 million gain from AOCI into earnings within the next 12 months.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its correctness. While it correctly reports the AOCI net gain decreasing from $39.6 million in 2023 to $11.5 million in 2024 and the expected reclassification into earnings dropping to $9.5 million in 2024 (matching the ground truth), it completely misrepresents the fair value of foreign currency - other instruments. The original answer states the total fair value was $1,164 million in 2023 and $920 million in 2024, but the LLM instead breaks down derivative assets and liabilities into current/long-term components not mentioned in the ground truth, reporting asset values of $32.0M + $22.9M = $54.9M in 2023 and net liabilities by 2024. These figures do not align with the knowledge graph's reported total fair values. There is no mention in the original answer of splitting fair value into current/long-term or liability recognition, nor of a 'net liability' position. The LLM appears to have either hallucinated or misinterpreted the structure of the data. Despite this, it correctly captures the directional trend (decrease in fair value exposure and reduced earnings impact) and accurately reports the AOCI and reclassification figures, showing partial multi-hop understanding. However, the core financial metric (fair value) is factually incorrect, leading to a moderate score. Contextual relevance is high as all discussed elements relate directly to the question's focus on evolution in exposure, fair value, and earnings impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 415,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the fair value of energy-related derivatives held by Alabama Power and Georgia Power evolve from 2022 to 2023, and what was the directional change in their asset versus liability positions?",
      "original_answer": "In 2022, Alabama Power reported energy-related derivatives with a fair value of $55 million in assets and $11 million in liabilities, while Georgia Power reported $75 million in assets and $8 million in liabilities. By 2023, Alabama Power's energy-related derivatives decreased to $15 million in assets but increased significantly to $110 million in liabilities. Similarly, Georgia Power's derivatives were valued at $13 million in assets and $124 million in liabilities in 2023. This indicates a substantial shift toward liability exposure for both entities over the period.",
      "llm_answer": "In 2022 Alabama Power held $55 million of energy‑related derivatives as assets and $11 million as liabilities, while Georgia Power held $75 million of assets and $8 million of liabilities【SO_10k_2022.pdf page 311】. By 2023 those asset values had collapsed to $15 million (Alabama) and $13 million (Georgia) and the liability balances had surged to $110 million and $124 million respectively, turning each subsidiary’s position from a net‑asset to a net‑liability【SO_10k_2023.pdf page 281】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all financial figures for both Alabama Power and Georgia Power in 2022 and 2023. In 2022, Alabama Power had $55 million in assets and $11 million in liabilities, and Georgia Power had $75 million in assets and $8 million in liabilities. In 2023, Alabama Power's values changed to $15 million in assets and $110 million in liabilities, while Georgia Power reported $13 million in assets and $124 million in liabilities — all matching the ground truth exactly. (2) All numbers are accurate with no calculation or reporting errors. The directional shift from net asset to net liability positions is correctly inferred: in 2022 both companies had net asset positions (Alabama: $55M - $11M = $44M net asset; Georgia: $75M - $8M = $67M net asset), while in 2023 both had net liabilities (Alabama: $15M - $110M = -$95M; Georgia: $13M - $124M = -$111M). (3) The multi-hop reasoning is sound — the model correctly synthesizes data across two companies and two years, compares asset versus liability positions over time, and draws the correct conclusion about the directional change. (4) The answer is semantically equivalent to the ground truth, with slightly more concise wording and the added insight about the shift from net-asset to net-liability, which enhances rather than distorts the meaning. All sources are appropriately cited with document references. No factual, quantitative, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 404,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the asset allocation strategy for the U.S. Retiree Health Care Plan evolve from 2022 to 2023, particularly in terms of the percentage distribution between fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan allocated 65% to fixed income securities and cash equivalents and 35% to equity securities. By 2023, the allocation to fixed income securities increased to 80%, while equity securities decreased to 20%. This represents a shift toward a more conservative investment strategy in 2023 compared to 2022.",
      "llm_answer": "In 2022 the U.S. Retiree Health Care Plan was invested roughly 65 % in fixed‑income securities (and cash equivalents) and 35 % in equity securities. By 2023 the weighted‑average mix had shifted to about 80 % fixed‑income and 20 % equity, moving the portfolio toward the higher end of its target fixed‑income range【page_48】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers and years are correct: 65% fixed income and 35% equity in 2022, shifting to 80% fixed income and 20% equity in 2023. These match the original answer exactly, with acceptable wording variations (e.g., 'roughly', 'about') that do not affect factual accuracy. (2) The answer is complete, addressing the evolution of asset allocation between the two years and the shift in percentages between the two asset classes as required by the question. (3) Entity accuracy is correct—'U.S. Retiree Health Care Plan', 'fixed income securities', 'equity securities', and years 2022 and 2023 are all properly identified. (4) The reasoning is sound: the shift toward a more conservative strategy is implied by the increased fixed income allocation, and the LLM adds contextual detail about moving toward the 'higher end of its target fixed-income range', which enhances understanding without contradicting the ground truth. The only minor deduction is in qualitative accuracy because the original answer explicitly states the strategy became 'more conservative', a qualitative conclusion that the LLM implies but does not directly state. However, citing a source marker ['page_48'] suggests proper grounding. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1182,
        "completion_tokens": 381,
        "total_tokens": 1563
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has the regulatory approval status of Trodelvy evolved between 2022 and 2023, and what new indications were granted in 2023?",
      "original_answer": "In 2022, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies and for metastatic urothelial cancer after platinum-based chemotherapy and a PD-1/PD-L1 inhibitor. By 2023, Trodelvy received additional approvals: it was granted EC approval and FDA approval for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. This represents a significant expansion of the drug’s therapeutic applications.",
      "llm_answer": "In the 2022 Form 10‑K, Trodelvy (sacituzumab govitecan‑hziy) was listed as an FDA‑accelerated‑approval product for two cancers – unresectable locally advanced or metastatic triple‑negative breast cancer and locally advanced or metastatic urothelial cancer【page_6】. By the 2023 filing, Gilead reported that Trodelvy received new approvals (both FDA and European Commission) for a third indication: monotherapy in adult patients with unresectable or metastatic hormone‑receptor‑positive, HER2‑negative breast cancer who have progressed after endocrine‑based therapy and at least two additional systemic treatments【page_39】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and conveys the same core information as the ground truth. (1) It correctly identifies the 2022 indications for Trodelvy—unresectable locally advanced or metastatic triple-negative breast cancer and urothelial cancer—and accurately describes the 2023 expansion to include HR+/HER2-negative breast cancer. (2) All dates (2022, 2023), regulatory bodies (FDA, European Commission), and treatment criteria (endocrine-based therapy, at least two prior systemic therapies) are correct. There are no numerical inaccuracies, and the timeline is properly represented. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings and correctly infers the evolution in approval status and new indications. The only minor omission is that the original answer specifies the prior 2022 approvals included patients who had received two or more prior therapies (for TNBC) and post-platinum and PD-1/PD-L1 for urothelial cancer—details slightly more precise than the LLM’s summary. However, the LLM captures the essential progression and expansion. (4) The answer is highly relevant, directly addressing both parts of the question: evolution of approval status and new indications in 2023. Wording differs but meaning is semantically equivalent. A score of 9 is justified due to high accuracy with only minor detail compression.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 383,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Meta's disclosure regarding user perception as a risk factor evolve between 2023 and 2024, particularly in terms of the nature of risks highlighted and their potential impact on business operations?",
      "original_answer": "In 2023, Meta emphasized user perception risks related to privacy, safety, content quality, and regulatory changes, specifically noting concerns around decreased user sentiment and engagement due to data practices and content policies. In 2024, while user perception was still acknowledged, the focus shifted toward broader operational and financial risks, such as integration challenges from acquisitions, tax liabilities, and investor sentiment. The explicit mention of user perception as a direct risk factor was notably reduced in 2024, indicating a strategic shift in how Meta communicated its risk profile.",
      "llm_answer": "In the 2023 Form 10‑K Meta called out user perception as a **stand‑alone risk** – it warned that if people did not view its products as useful, reliable or trustworthy, or if concerns arose about content, privacy, safety or well‑being, user growth and engagement could fall, cutting ad impressions and revenue (see 2023 pages 16‑17 and the “negative publicity” bullet on page 19). By the 2024 filing the company had **removed that explicit user‑sentiment risk** and folded perception‑related worries into broader litigation‑ and regulator‑risk sections, citing class‑action suits alleging “social‑media addiction” and privacy violations that could trigger fines, forced product changes or other operational disruptions (see 2024 page 34). Thus the focus shifted from a direct threat to user engagement to an indirect threat of legal and regulatory fallout from adverse public perception.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in Meta's risk disclosures between 2023 and 2024: in 2023, user perception was highlighted as a stand-alone risk tied to trust, privacy, safety, and content, with direct implications for engagement and revenue. In 2024, the explicit standalone risk was removed and related concerns were subsumed under legal and regulatory risks, such as litigation over 'social-media addiction' and privacy violations. This matches the original answer’s claim of a strategic shift in emphasis from user perception to broader operational/financial risks. (2) There are no numeric values, dates, or calculations in the question or answers that require verification—both responses reference the correct years (2023, 2024) and contextual events without introducing incorrect figures. (3) The multi-hop reasoning is sound: the model synthesizes information across two filings, compares the framing of risk factors, and infers a shift in disclosure strategy. The use of specific page references (e.g., 2023 pp. 16–17, 19; 2024 p. 34) adds credibility, though these are not verifiable from the knowledge graph alone but do not contradict it. (4) The only minor shortcoming is that the LLM answer does not explicitly mention the reduced emphasis on 'regulatory changes' as part of the 2023 risk or the rise of 'investor sentiment' and 'acquisition integration' in 2024—elements present in the original answer. However, it captures the core shift in risk communication accurately. Thus, while extremely close, it omits a small amount of nuance, justifying a 9 instead of 10 on correctness and qualitative accuracy. Contextual relevance is perfect—directly addresses the question’s focus on evolution, nature of risks, and business impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 494,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has the notional amount of Lockheed Martin's variable interest rate swaps evolved from 2021 to 2024, and what does this indicate about the company's interest rate risk management strategy?",
      "original_answer": "In 2021, the notional amount of Lockheed Martin's variable interest rate swaps was $500 million, while by 2024, it had increased to $1.3 billion. This indicates a significant shift in the company's interest rate risk management strategy, with a growing emphasis on converting fixed-rate borrowings to variable-rate borrowings, likely in response to changes in the interest rate environment and the company's borrowing profile over the period.",
      "llm_answer": "Lockheed Martin’s aggregate notional amount of interest‑rate swaps grew from about **$500 million at 12/31/2021** (the 2022 10‑K) to **$1.3 billion at 12/31/2023 and again at 12/31/2024** (the 2024 10‑K)【page_66】【page_52】. The more‑than‑doubling of the swap notional indicates the company has markedly expanded its use of variable‑rate swaps—converting fixed‑rate borrowings to variable or hedging variable‑rate debt—to more actively manage interest‑rate risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the notional amounts of $500 million in 2021 and $1.3 billion in 2024, matching the ground truth. It accurately reflects the growth in notional amount and correctly interprets this as an increased use of variable-rate swaps to manage interest rate risk. The only minor discrepancy is that the LLM states the $1.3 billion amount applies to both 12/31/2023 and 12/31/2024, while the ground truth only specifies 2024. However, since the question asks about evolution through 2024, the final data point is correct and sufficient.\n\n2) Quantitatively, all numbers are accurate: $500 million in 2021 and $1.3 billion in 2024 are correctly reported. The statement that this represents a 'more-than-doubling' is logically sound (1.3B / 500M = 2.6x), and no calculation errors are present.\n\n3) The multi-hop reasoning is sound: the model synthesizes data across years and filings (2022 and 2024 10-Ks), correctly identifies the trend, and infers the strategic shift in risk management. The conclusion about converting fixed-rate to variable-rate borrowings aligns with the ground truth.\n\n4) The answer is semantically equivalent to the original, with slightly more detail about filing sources (page references). The core message—increased notional indicating a strategic shift toward variable-rate risk management—is preserved and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 381,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did PayPal's approach to its Seller Protection Programs evolve between 2022 and 2023, particularly in terms of financial provisions for transaction losses?",
      "original_answer": "In 2022, PayPal acknowledged the risk of losses from its Seller Protection Programs and noted that historical loss rates ranged between 0.09% and 0.15% of TPV, with the potential for increased losses due to macroeconomic conditions such as the ongoing impacts of the COVID-19 pandemic. By 2023, PayPal provided more structured financial disclosures, showing that the allowance for transaction losses was $64 million (down from $66 million in 2022), indicating a slight decrease in expected losses. This shift reflects a more defined and quantified approach to managing seller protection risk in 2023 compared to the more qualitative risk assessment in 2022.",
      "llm_answer": "In the 2022 Form 10‑K PayPal only described its seller‑protection program in narrative form, noting that transaction‑loss rates had ranged between 0.09 % and 0.15 % of total payment volume but did not disclose a specific allowance for those losses (see “Customer protection programs” on page 51). By the 2023 filing the company began reporting a detailed allowance for transaction losses – a $64 million allowance (versus $66 million in 2022) backed by a higher provision of $1.192 billion (up from $1.170 billion) and lower realized losses ($1.313 billion vs. $1.417 billion), showing a modest increase in the financial reserve for seller‑related claims (see “PROTECTION PROGRAMS” and the allowance table on page 113).",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in its qualitative assessment and captures the evolution in PayPal's approach from a narrative-based disclosure in 2022 to a more structured, quantified allowance reporting in 2023. It correctly identifies that in 2022, PayPal did not disclose a specific allowance but referenced historical loss rates of 0.09% to 0.15% of TPV, and that in 2023, a specific allowance of $64 million was reported (down from $66 million in 2022). However, there are quantitative inaccuracies: the LLM claims a 'provision of $1.192 billion (up from $1.170 billion)' and 'realized losses ($1.313 billion vs. $1.417 billion)', but these large figures refer to total transaction loss provisions and chargebacks across all activities, not specifically to the Seller Protection Programs. The ground truth focuses only on the allowance for transaction losses ($64M in 2023, $66M in 2022), not total provisions or gross losses. The LLM overextends the scope by interpreting broader loss metrics as directly tied to seller protection, which is not supported by the original answer. This introduces significant numerical context not present in the ground truth, affecting quantitative accuracy. The reasoning is otherwise sound, with correct entity and year identification, and the core point about increased financial transparency in 2023 is valid. The answer is highly relevant and synthesizes the multi-hop requirement (change over time in financial provisions), but the inclusion of unsupported large-scale figures reduces quantitative precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 425,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Starbucks' derivative asset and liability positions in foreign currency - other change from fiscal year 2023 to fiscal year 2024, and what was the magnitude of this change on the balance sheet?",
      "original_answer": "In fiscal year 2023, Starbucks reported a derivative asset of $1,164 million under 'Foreign currency - other.' By fiscal year 2024, this amount significantly decreased to $1.9 million in derivative assets under the same category. Additionally, the derivative liability for 'Foreign currency - other' increased from $2.0 million in 2023 to $4.7 million in 2024. This indicates a major reduction in the company's foreign currency derivative assets and a moderate increase in liabilities tied to foreign currency over this period.",
      "llm_answer": "Starbucks’ foreign‑currency‑other derivative assets fell dramatically, from $54.9 million in FY 2023 (‑$32.0 m prepaid + $22.9 m other‑long‑term) to $3.6 million in FY 2024 ($1.9 m + $1.7 m), a drop of about $51 million (page_72). At the same time, the related liabilities rose from $2.0 million (accrued) in FY 2023 to $8.8 million in FY 2024 ($4.7 m accrued + $4.1 m other‑long‑term), an increase of roughly $6.8 million, turning a net $53 million asset position into a $5 million net liability – a balance‑sheet swing of roughly $58 million (page_72).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, Starbucks' derivative asset for 'Foreign currency - other' was $1,164 million in FY2023, not $54.9 million as stated by the LLM. The LLM incorrectly breaks this down into components (-$32.0M prepaid + $22.9M other-long-term), which contradicts the ground truth that reports a single asset value of $1,164M. The FY2024 asset value is closer but still incorrect: $3.6M (LLM) vs $1.9M (truth). For liabilities, the LLM reports $8.8M in FY2024 ($4.7M + $4.1M), while the truth states $4.7M total—so the LLM double-counts or misclassifies. (2) Calculations are therefore flawed: the claimed $51M drop in assets is wrong (actual drop is ~$1,162M), and the $6.8M liability increase is inaccurate (actual is $2.7M). The net position swing of $58M is entirely incorrect due to wrong inputs. (3) While the LLM attempts multi-hop reasoning by aggregating across balance sheet lines and years, it uses incorrect source data, undermining the logic. It correctly identifies the direction of change (assets down, liabilities up), but magnitude and synthesis are flawed. (4) Contextual relevance is high—the answer addresses the right question about changes in derivative positions and attempts balance sheet impact. However, due to severe quantitative errors in core financial figures, the correctness score is low. Minor formatting like page references are acceptable but do not offset factual inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 416,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial impact of energy-related derivatives on natural gas cost and revenue hedging positions evolve from 2022 to 2023?",
      "original_answer": "In 2022, energy-related derivatives had a negative impact of $117 million on natural gas revenues and a $27 million negative impact on the cost of natural gas. In 2023, the impact shifted positively with a $59 million gain on the cost of natural gas, while the revenue impact remained neutral at $0. This indicates a transformation in the role and effectiveness of these derivatives in managing natural gas exposure.",
      "llm_answer": "In 2022 the energy‑related derivatives produced a $65 million pre‑tax loss on the cost of natural gas and modest gains on the revenue‑hedge side (e.g., a $3 million gain for Southern Company and a $18 million gain for Southern Company Gas)【page_295】. By 2023 the cost effect had reversed to a $59 million pre‑tax gain, while the cash‑flow hedges swung to sizable losses – $81 million for Southern Company, $18 million for Southern Power and $63 million for Southern Company Gas【page_293】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies compared to the ground truth. In 2022, the original answer states a $117 million negative impact on natural gas revenues and a $27 million negative impact on cost, but the LLM claims a $65 million pre-tax loss on cost and 'modest gains' on revenue (e.g., $3M and $18M gains), which contradicts the ground truth of negative impacts. The 2023 cost gain of $59 million aligns with the ground truth, but the LLM incorrectly states that revenue hedges resulted in 'sizable losses' across subsidiaries ($81M, $18M, $63M), whereas the ground truth reports a neutral $0 impact on revenue. (2) Quantitative accuracy is low: only the $59 million gain in 2023 on cost is correct. All other figures are either fabricated or misattributed (e.g., subsidiary-level numbers not mentioned in the original). There is no support for the claim of gains in 2022 or losses in 2023 on revenue hedges. (3) The reasoning is flawed—instead of showing a shift from negative to neutral/positive impacts consistent with improved hedging effectiveness, the LLM introduces entity-specific cash-flow hedge losses not present in the original, failing to synthesize the correct multi-hop narrative of overall portfolio evolution. (4) Contextual relevance is moderate because the answer discusses energy derivatives, natural gas costs, and revenue hedging across 2022–2023, but the incorrect data and mischaracterization of impacts undermine the validity. The mention of Southern Company and subsidiaries suggests a possible confusion with another filing or misattribution of data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 443,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Walmart's treatment of its Deferred Compensation Matching Plan evolve between the 2023 and 2024 10-K filings, particularly in terms of its documentation status and effective date?",
      "original_answer": "In the 2023 10-K filing, the Deferred Compensation Matching Plan was newly introduced as 'Walmart Inc. Deferred Compensation Matching Plan, as amended and restated effective November 8, 2023.' By the 2024 10-K filing, the plan was no longer labeled as newly introduced but was instead referenced as being 'incorporated by reference' to the 2024 Annual Report on Form 10-K, indicating that it had become an established, ongoing plan. The effective date remained unchanged at November 8, 2023, suggesting no substantive changes to the plan’s implementation timeline, but its treatment shifted from being newly introduced to being formally integrated into the company's long-term compensation framework.",
      "llm_answer": "In the 2023 Form 10‑K Walmart listed the Deferred Compensation Matching Plan as a filed exhibit (the “*” designation) and noted it was amended and restated effective November 8 2023【page_84】. In the 2024 Form 10‑K the same plan is no longer attached as an exhibit but is incorporated by reference to Exhibit 10.1, while the effective date remains November 8 2023【page_84】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) All key facts are correct: the plan was introduced in the 2023 10-K with an effective date of November 8, 2023, and in the 2024 10-K it is incorporated by reference rather than filed as a new exhibit. The effective date is correctly preserved. (2) Quantitative accuracy is perfect: the date 'November 8, 2023' is correctly cited, and there are no numerical errors. (3) The reasoning is sound—by noting the shift from being a filed exhibit to being incorporated by reference, the LLM correctly infers the plan's transition from newly introduced to established. The multi-hop synthesis across two filings is accurate. (4) The only minor shortcoming is that the LLM does not explicitly state the broader implication—that this reflects integration into Walmart’s long-term compensation framework, as noted in the original answer. However, the factual basis for that inference is fully present. Wording differs but semantic meaning is equivalent. Contextual relevance is excellent, directly addressing documentation status and effective date as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 318,
        "total_tokens": 1597
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the disclosure and treatment of LTIP Units evolved between 2023 and 2024, particularly in terms of their dilutive effect and accrual policy?",
      "original_answer": "In 2023, LTIP Units were described as potentially dilutive securities that are convertible into units and exchangeable for common stock, with no material dilutive effect reported for the years 2023, 2022, and 2021. The company stated it does not adjust net income attributable to common stockholders or weighted average shares outstanding due to no dilutive impact. In 2024, the disclosure simplified, stating that LTIP Units are potentially dilutive but again noting no material dilutive effect for the years 2024, 2023, and 2022. Additionally, the accrual policy remained consistent, stating that distributions are accrued when declared. The treatment of LTIP Units remained stable with no significant change in dilutive impact or accrual policy.",
      "llm_answer": "In the 2023 filing the company disclosed that LTIP units were “potentially dilutive securities” but had no material dilutive effect for 2023 (and the prior two years) and that “we accrue distributions when they are declared” (page 112). The 2024 filing repeats this language – LTIP units remain potentially dilutive with no material impact for 2024 (and 2023‑2022) – and adds that “we have not adjusted net income … or weighted‑average shares … as doing so would have no dilutive impact,” while still accruing dividends when declared (page 114).  Thus, the treatment of LTIP units has not changed materially; they continue to be listed as non‑material potentially dilutive securities and are accrued in the same manner.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately captures the disclosure evolution: in 2023, LTIP Units were described as potentially dilutive with no material effect for 2023, 2022, and 2021, and the company did not adjust net income or weighted average shares due to lack of dilutive impact. In 2024, the disclosure was simplified but maintained the same substance—LTIP Units remain potentially dilutive with no material effect for 2024, 2023, and 2022—and explicitly reiterates no adjustment to net income or shares. The accrual policy ('accrue distributions when declared') is correctly reported for both years. (2) There are no numerical values requiring calculation, but the years and reporting periods (2021–2023 in 2023 filing; 2022–2024 in 2024 filing) are correctly cited and consistent with the multi-year lookback. (3) The multi-hop reasoning is sound—comparing disclosures across two filings, identifying consistency in treatment and minor elaboration in 2024. (4) The LLM conveys semantic equivalence with the original answer, noting stability in treatment and no material changes. All four evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 339,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Meta's compliance approach to the EU-U.S. Data Privacy Framework (EU-U.S. DPF) evolved between 2023 and 2024, particularly in response to regulatory actions and decisions?",
      "original_answer": "In 2023, Meta was in the process of implementing steps to comply with corrective orders from the Irish Data Protection Commission (IDPC) following a EUR €1.2 billion fine and a directive to suspend unlawful data transfers to the U.S. under Standard Contractual Clauses (SCCs). At that time, the EU-U.S. DPF had just been finalized, and Meta viewed its implementation as a key milestone to address data transfer compliance. By 2024, Meta had implemented compliance measures with the corrective orders and was actively engaging with regulators on new compliance models, such as the 'subscription for no ads' alternative introduced in November 2023. In 2024, the European Commission opened formal proceedings into the compliance of this model with the Digital Markets Act (DMA), issuing preliminary findings in July 2024 that suggested non-compliance. This reflects a shift from foundational compliance with the EU-U.S. DPF framework to navigating more complex regulatory scrutiny around specific business models under evolving EU laws.",
      "llm_answer": "In its 2023 filing Meta said it had begun implementing steps to meet the new EU‑U.S. Data‑Privacy Framework and the Irish regulator’s corrective orders, while formally appealing the IDPC’s decision and treating the adequacy decision as a “welcome milestone.” By the 2024 filing Meta’s language had shifted to a more ongoing, risk‑aware stance—emphasizing that the EU‑U.S. DPF now replaces the two prior frameworks, noting that any further CJEU invalidation would create material uncertainty, and reaffirming its continued engagement with regulators and readiness to take additional compliance actions as needed.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its description of Meta's evolving compliance approach to the EU-U.S. DPF between 2023 and 2024, with no incorrect numbers, dates, or entities—hence a quantitative accuracy of 10. It correctly notes Meta’s initial implementation efforts in 2023, the significance of the EU-U.S. DPF as a 'milestone,' and the ongoing regulatory engagement and risk disclosures in 2024. However, it omits key qualitative details present in the ground truth that are critical to fully addressing the multi-hop nature of the question. Specifically, it fails to mention the €1.2 billion fine, the suspension of unlawful data transfers under SCCs, the introduction of the 'subscription for no ads' model in November 2023, and the European Commission’s formal DMA proceedings in July 2024 with preliminary findings of non-compliance. These omissions reduce the qualitative accuracy, as the answer does not fully capture the shift from foundational compliance to navigating complex regulatory scrutiny around specific business models. The reasoning is sound but incomplete, and the semantic content, while not incorrect, lacks depth in synthesizing the full regulatory evolution. The answer remains contextually relevant and addresses the core evolution in tone and strategy, but misses concrete actions and regulatory developments that define the compliance trajectory.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 382,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Linde's approach to green hydrogen production evolved between 2023 and 2024, particularly in terms of production methods and emphasis on renewable energy sources?",
      "original_answer": "In 2023, Linde described green hydrogen as being produced primarily through electrolysis using renewable energy or from steam methane reforming of biomethane, and it was presented as one of the company's clean energy offerings alongside blue hydrogen. By 2024, the company had expanded its description to emphasize green hydrogen as 'renewable hydrogen' produced by electrolysis using renewable energy and water as feedstock, and it was clearly differentiated from low-carbon (blue) hydrogen. Additionally, in 2024, Linde placed more emphasis on the carbon intensity metric to differentiate production methods, indicating a more refined and strategic framing of green hydrogen within the broader context of clean energy solutions.",
      "llm_answer": "In the 2023 filing Linde said green hydrogen could be made either by electrolysis powered with renewable electricity **or** by steam‑methane reforming of biomethane (LIN_10k_2023.pdf: page_4). By the 2024 filing the company narrowed the definition to electrolysis using renewable energy and water only, placing a stronger emphasis on renewable‑energy‑driven production (LIN_10k_2024.pdf: page_4).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies that in 2023, Linde included both electrolysis using renewable energy and steam methane reforming of biomethane as methods for green hydrogen production (LIN_10k_2023.pdf: page_4), and that by 2024, the company narrowed its definition to electrolysis using renewable energy and water only, emphasizing renewable-driven production (LIN_10k_2024.pdf: page_4). This reflects the evolution in Linde's approach as described in the original answer. The LLM captures the key shift in definition and increased emphasis on renewable energy. However, it omits a specific detail mentioned in the ground truth: the 2024 emphasis on carbon intensity as a metric to differentiate production methods (e.g., green vs. blue hydrogen). While the narrowing of the definition implies a more refined framing, the explicit mention of carbon intensity is a meaningful addition in the original answer that is missing in the LLM response. This is a minor omission rather than an error, so the answer remains highly accurate. There are no quantitative inaccuracies—no numbers are misstated or miscalculated. The reasoning is sound and demonstrates correct multi-hop synthesis across two years of filings. The answer is contextually relevant and directly addresses the question about evolution in production methods and renewable energy emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 392,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Southern Company's relationship with Sequent evolve between 2022 and 2023, and what were the financial implications of this change?",
      "original_answer": "Southern Company's relationship with Sequent evolved from a business ownership relationship in 2022 to a completed divestiture in 2023. In 2022, Southern Company Gas completed the sale of Sequent to Williams Field Services Group for $159 million, recognizing a pre-tax gain of $121 million. Additionally, the sale resulted in $85 million of additional tax expense due to changes in state apportionment rates. By 2023, Sequent was no longer part of Southern Company's portfolio, and the financial impact of the sale was fully reflected in the company's financial statements, with the gain from the sale reported as a $121 million pre-tax benefit. This marked a complete transformation in the relationship, shifting from operational integration to full separation.",
      "llm_answer": "Southern Company’s wholesale‑gas services segment – the business that had been operated through Sequent – was eliminated after the July 1 2021 sale; the 2022 filing already notes that “wholesale gas services is no longer a reportable segment in 2022” and the 2023 filing repeats that it “is no longer a reportable segment in 2023” (pages 301‑302).  The divestiture produced a pre‑tax gain of $121 million (≈$92 million after tax) and generated an additional $85 million of tax expense, while the segment’s operating revenue ($188 million in 2021) disappeared from the 2022 and 2023 results (pages 57, 300‑302).",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the financial implications of the divestiture, including the $121 million pre-tax gain and $85 million additional tax expense, which match the ground truth. It also correctly notes that Sequent was no longer a reportable segment in 2022 and 2023, indicating the completed separation. However, it incorrectly states the sale occurred on July 1, 2021, which contradicts the ground truth that the sale was completed in 2022. This is a significant factual error affecting the timeline of the relationship evolution. (2) Quantitatively, all dollar amounts ($121M gain, $85M tax expense, $188M prior revenue) are accurate and correctly attributed. The ≈$92M after-tax gain is a reasonable approximation based on the pre-tax gain and tax impact, though not explicitly stated in the original answer. The 2021 sale date is incorrect per ground truth, which specifies the transaction closed in 2022. (3) The reasoning correctly synthesizes information across years and filings to show the disappearance of the segment and financial impacts, but the erroneous sale date undermines the multi-hop logic regarding the 2022–2023 evolution. The answer implies the change happened before 2022, while the truth is it occurred during 2022, making the transformation relevant to the stated period. (4) Despite the incorrect sale date, the answer captures the core financial outcomes and the fact of full divestiture, warranting a score of 7 for correctness. Quantitative accuracy is high (8) due to correct numbers but docked for the wrong date. Qualitative accuracy is 7 due to correct entity identification and synthesis but flawed temporal reasoning. Contextual relevance is strong (9) as it directly addresses both the relationship change and financial impact with supporting evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 493,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Walmart's relationship with the Allswell brand evolved between 2023 and 2024, and what does this indicate about its strategic positioning within the company's private brand portfolio?",
      "original_answer": "In 2023, Walmart introduced the Allswell brand as part of its private brand offerings, indicating its initial entry into the market. By 2024, the brand was not only retained but explicitly listed among other mature private brands like 'bettergoods,' 'Equate,' and 'Great Value,' suggesting that Allswell has transitioned from a newly introduced brand to a more established part of Walmart's private label strategy. This evolution indicates that Allswell has likely gained traction and is being positioned as a core component of Walmart’s private brand portfolio.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K filings list Allswell alongside Walmart’s other private‑label names in the Walmart U.S. segment description (see page 7 of each filing). The brand’s continued presence shows that Walmart has kept Allswell as a core private‑brand offering, reinforcing its strategy of expanding a broad, low‑price private‑label portfolio to drive value and margin.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct in stating that Allswell was listed in both the 2023 and 2024 Form 10-K filings as part of Walmart’s private-label brands, indicating its continued presence and strategic importance. The quantitative accuracy is perfect: the years (2023, 2024), entity (Allswell), and context (Walmart U.S. segment, page 7 of 10-K) are all accurate, with no numerical errors. The answer correctly identifies the multi-hop element—comparing the brand's presence across two years to infer strategic continuity. However, it misses a key nuance from the ground truth: in 2023, Allswell was newly introduced, whereas by 2024 it was grouped with mature brands like 'bettergoods' and 'Great Value,' signaling an evolution from new to established status. The LLM notes continued presence but does not explicitly acknowledge the transition from introduction to maturity, which is central to the question about evolution and strategic positioning. This omission slightly weakens the qualitative reasoning, though the overall conclusion about being a 'core' offering is aligned. The answer is highly contextually relevant and well-supported by document evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 329,
        "total_tokens": 1575
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the strategic importance of Embedded Processing products evolved from 2022 to 2023 based on TXN's revenue composition and strategic emphasis?",
      "original_answer": "In 2022, Embedded Processing products were described as one of two core segments, positioned alongside Analog as a key part of the business, though no specific revenue figures were disclosed. By 2023, Embedded Processing remained a strategic focus area, and notably, it partially offset a decline in Analog revenue, contributing to a $17.52 billion total revenue. This indicates that while Embedded Processing maintained its strategic importance, it also played a more pronounced compensatory role in the revenue mix during a year of overall revenue decline.",
      "llm_answer": "Embedded Processing revenue grew from $3.261 billion in 2022 to $3.368 billion in 2023—a 3 % increase that lifted its share of total sales and helped offset the decline in analog revenue (see 2023 segment table, p. 20). TI’s MD&A stresses that analog and embedded‑processing products are the cornerstone of its strategy, with embedded processing singled out as a key growth engine for industrial and automotive markets, underscoring a heightened strategic importance relative to 2022 (see MD&A, p. 19).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that no specific revenue figures for Embedded Processing were disclosed in 2022, but the LLM claims $3.261 billion in 2022 and $3.368 billion in 2023 with a 3% growth, which is not supported by the original answer. These numbers and the percentage increase are therefore incorrect. (2) The calculation of a 3% increase from $3.261B to $3.368B is mathematically accurate (approx. 3.28%), but since the numbers themselves are fabricated or misattributed, the entire quantitative foundation is flawed. The total revenue of $17.52 billion in 2023 is mentioned in the ground truth, but the LLM does not reference this total, weakening its contextual anchoring. (3) The qualitative reasoning partially aligns with the ground truth: the LLM correctly identifies that Embedded Processing helped offset a decline in Analog revenue and remained strategically important. It also correctly notes that TI emphasizes both Analog and Embedded Processing as strategic pillars, and that Embedded Processing is a growth focus for industrial and automotive markets. However, the claim of 'heightened strategic importance' goes beyond the ground truth, which states that its strategic role remained consistent but it played a more pronounced *compensatory* role in revenue — a nuance not fully captured. (4) The contextual relevance is high because the answer addresses revenue composition and strategic emphasis across both years, and attempts multi-hop synthesis between financial performance and strategic language. However, due to the invention of specific revenue figures not present in the original data, the correctness score is significantly reduced. Quantitative accuracy is low due to unsupported numbers; qualitative accuracy is moderate due to correct strategic framing but overstatement of evolution; relevance is strong as it directly engages the question's intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 538,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has Chevron's involvement in Angola LNG evolved from 2022 to 2024, and what does this indicate about its strategic positioning in the LNG market?",
      "original_answer": "In 2022, Chevron's involvement in Angola LNG was referenced in the context of its production volumes, indicating operational participation. By 2024, Chevron's stake in Angola LNG Limited was explicitly stated as a 36.4% interest, highlighting a more defined and structured investment approach. This evolution suggests a strategic shift toward securing a stable position in the LNG market through formalized equity stakes.",
      "llm_answer": "In 2022 Chevron’s accounting for Angola LNG showed a $1.857 billion investment and $1.857 billion of equity earnings, with the project’s output counted in Chevron’s Angola production share【page_8】. By 2024 the investment had slipped to $1.665 billion and equity earnings fell to $405 million, although Chevron still holds a 36.4 % equity interest in Angola LNG【page_84】【page_85】. The decline in capital and earnings alongside a retained sizable stake indicates Chevron is keeping a strategic foothold in the LNG market while moderating its exposure to this particular asset.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific financial figures—$1.857 billion investment and equity earnings in 2022, declining to $1.665 billion and $405 million in 2024—that are not present in the original ground truth answer and cannot be verified against it. These numbers may be factually accurate in the source document, but they are not part of the knowledge graph truth, which only states Chevron's operational participation in 2022 and a 36.4% stake in 2024. The inclusion of unverified quantitative data undermines factual correctness. (2) The 36.4% equity interest in Angola LNG Limited in 2024 matches the ground truth and is correctly reported. However, the detailed financials (investment value and equity earnings) are extraneous and not corroborated by the original answer, introducing potential inaccuracies. There are no calculation errors in the LLM answer, but the figures themselves are not supported by the truth data. (3) The multi-hop reasoning is partially sound: the model correctly identifies a shift from operational involvement (implied in 2022) to a defined equity stake in 2024. However, the conclusion that Chevron is 'moderating its exposure' while 'keeping a strategic foothold' goes beyond the original inference, which states a 'strategic shift toward securing a stable position... through formalized equity stakes.' The LLM adds a layer of interpretation about reduced capital and earnings indicating moderation, which is not in the ground truth. (4) The contextual relevance is high—the answer addresses both the evolution of involvement and strategic implications. However, the quantitative accuracy is low due to unsupported figures, dragging down the overall correctness. While the core fact of the 36.4% stake is correct, the additional numbers and their interpretation introduce significant deviation from the verified truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 507,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the financial contribution and production status of the CH-53K program evolved between 2021 and 2024, and what does this indicate about its role within Lockheed Martin's RMS division?",
      "original_answer": "In 2021, the CH-53K program contributed to a $540 million increase in RMS net sales, driven by higher production volume alongside the Black Hawk and CRH programs. Additionally, it contributed to a $140 million increase in operating profit due to higher risk retirements and production volume. By 2024, the CH-53K program was described as being in a 'production ramp-up' phase, contributing $1.1 billion to higher product sales within RMS, indicating a shift from early-stage production and risk retirement to a more mature, high-volume production phase. This evolution shows that the CH-53K has transitioned from a developing program with growing financial impact to a key growth driver within RMS.",
      "llm_answer": "In 2021 the CH‑53K was a major driver of RMS growth – higher production volume and risk‑retirements on the Sikorsky helicopter line added roughly **$540 million of net‑sales** and **about $140 million of operating profit** to the RMS segment (page 50). By 2024 the program was still ramping up, with “higher production volume on the CH‑53K program” cited as a key factor behind the **$1.1 billion increase in RMS product sales** (page 34). Together, these trends show the CH‑53K evolving from a strong profit contributor in 2021 to an even larger growth engine in 2024, confirming its status as a cornerstone of RMS’s helicopter portfolio and a central source of revenue and earnings for the division.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies all key financial figures from the ground truth: $540 million in net sales and $140 million in operating profit for 2021, and the $1.1 billion contribution to product sales in 2024. These numbers match the original answer exactly, with acceptable formatting variations (e.g., $540 million vs $540 million). 2) Quantitatively, all values are accurate and correctly attributed to the right years and financial metrics. The $1.1 billion is correctly described as contributing to higher product sales in RMS, aligning with the original answer’s phrasing. 3) The reasoning is sound: the LLM correctly infers a progression from strong profit contributor in 2021 (due to production volume and risk retirements) to a larger growth engine in 2024 during 'production ramp-up', which matches the original’s conclusion about transitioning to a mature, high-volume phase. The synthesis across 2021 and 2024 data points is logical and supports the conclusion about CH-53K’s growing strategic role. 4) The only minor shortcoming is that the original answer explicitly states the program moved 'from early-stage production and risk retirement to a more mature, high-volume production phase', while the LLM describes it as 'still ramping up'—slightly less precise in characterizing the evolution toward maturity, though not incorrect. The LLM also adds contextual interpretation (e.g., 'cornerstone of RMS’s helicopter portfolio') that is reasonable but not explicitly in the ground truth. Overall, the answer is factually correct, complete, and contextually appropriate, with only slight softening in precision of qualitative characterization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 453,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did PayPal's use of macroeconomic factors in its loss curves for revolving consumer credit products evolve between 2022 and 2023?",
      "original_answer": "In 2022, PayPal applied macroeconomic factors such as forecasted trends in unemployment and benchmark credit card charge-off rates to its revolving consumer credit loss curves, using a single scenario deemed most appropriate for the economic conditions. By 2023, the company updated its expected credit loss models for revolving consumer receivables to include forecasted trends in household disposable income and retail e-commerce sales, replacing unemployment rates after the first quarter of 2023. This reflects a shift in the macroeconomic indicators used to inform loss curves for this segment.",
      "llm_answer": "In the 2022 filing, PayPal said its revolving‑consumer‑credit loss curves were built on historical loss experience and an externally‑sourced macro‑economic scenario that mainly projected **unemployment trends and benchmark credit‑card charge‑off rates**, using a supportable forecast horizon of roughly **two years** for revolving products【page_54】.  \n\nBy the 2023 filing, the company had **broadened the macro inputs** for the revolving‑credit portfolio to include **forecasted household disposable‑income and retail e‑commerce sales** (with unemployment still used through Q1 2023), and it **extended the forecast period to about five years (7 months‑3.5 years)**; the models were refreshed in Q2 2023, though the changes were not material to the year‑end provision【page_70】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Correctly identifies that in 2022, PayPal used unemployment trends and benchmark credit card charge-off rates in its loss curves for revolving consumer credit, using a single macroeconomic scenario. (2) Accurately states that in 2023, PayPal broadened its inputs to include forecasted household disposable income and retail e-commerce sales, with unemployment used only through Q1 2023—this matches the original answer’s claim of unemployment being replaced after Q1 2023. (3) The LLM adds extra detail not in the original—specifically the extension of the forecast horizon from ~2 years to ~5 years (with a range of 7 months to 3.5 years) and that the model refresh in Q2 2023 was not material to the year-end provision—which is consistent with the source (page 70) and does not contradict the ground truth; it enhances completeness without introducing error. (4) All entities (PayPal, revolving consumer credit, macroeconomic factors) and years (2022, 2023) are correct. (5) Minor point: the original does not mention forecast horizon changes, so while the LLM’s addition is likely accurate from the filing, it slightly exceeds the scope of the ground truth; however, this does not detract from correctness. Quantitative accuracy is high—no incorrect numbers, and timeframes are correctly attributed. Reasoning is sound and reflects proper multi-hop synthesis across two years of filings. Semantic equivalence is strong. One point deducted only because the original answer does not mention the forecast period extension, and the LLM presents it as part of the evolution, which may imply it was a core part of the 'evolution' in focus—though still factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 473,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Starbucks' foreign currency debt-related gains or losses included in AOCI change from 2023 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2023, Starbucks reported a foreign currency debt-related loss of $6.3 million included in OCI before reclassifications, while in 2024, the company reported a gain of $135.2 million in AOCI related to foreign currency debt. This indicates a significant shift from a loss to a substantial gain, suggesting a reversal in the company's exposure to foreign currency fluctuations over this period.",
      "llm_answer": "Starbucks’ net gain on foreign‑currency‑denominated debt that remains in AOCI fell from **$140.2 million in fiscal 2023 to $135.2 million in fiscal 2024**, a decline of about $5 million (see Net Investment Hedges – “Foreign currency debt” in the AOCI table)【page_70】.  The positive balance in both years shows the company still has material exposure to foreign‑currency movements, but its hedging program is generating net gains, albeit slightly less in 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core quantitative claim. According to the ground truth, Starbucks had a loss of $6.3 million in 2023 and a gain of $135.2 million in 2024, representing a shift from loss to gain. However, the LLM states there was a gain of $140.2 million in 2023 and $135.2 million in 2024, implying a small decrease in gains—this misrepresents both the magnitude and direction of change. (2) The numbers are significantly off: the 2023 figure is wrong ($140.2M vs. actual $6.3M loss), and the characterization of both years as gains is false—2023 was a loss. The $5 million decline mentioned is therefore based on incorrect inputs and invalidates any derived conclusions. (3) The multi-hop reasoning fails because the model did not correctly interpret the change from loss to gain, which is central to understanding the shift in foreign currency exposure. Instead, it assumes consistent gains, leading to flawed analysis about hedging program performance. (4) While the answer addresses the right topic (AOCI, foreign currency debt, exposure implications), the severe factual inaccuracies in numbers and direction of change severely undermine correctness. Contextual relevance is moderate because it discusses the right concepts and cites a plausible source location, but the substance is wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 373,
        "total_tokens": 1599
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the fair value of energy-related derivatives for Alabama Power and Georgia Power change between 2022 and 2023, and what was the overall trend in their combined liabilities related to these derivatives?",
      "original_answer": "In 2022, Alabama Power reported a net liability of $144 million related to derivatives in non-designated hedging relationships, including energy-related derivatives. In 2023, Alabama Power had $15 million in assets and $110 million in liabilities related to energy-related derivatives, resulting in a net liability of $95 million. Georgia Power had $13 million in assets and $124 million in liabilities related to energy-related derivatives in 2023, yielding a net liability of $111 million. Therefore, the combined net liability for energy-related derivatives across both entities decreased from $255 million in 2022 to $206 million in 2023, indicating a reduction in exposure.",
      "llm_answer": "In 2023 Alabama Power held energy‑related derivative assets of $15 million and liabilities of $110 million, while Georgia Power held $13 million of assets and $124 million of liabilities (page 281). By contrast, the 2022 filing shows a total energy‑related derivative liability of $210 million for the company (page 283). Adding the two subsidiaries together, their liabilities rose from $210 million in 2022 to $234 million in 2023, indicating an overall increase.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual and calculation errors. While it correctly reports Alabama Power's 2023 derivative assets ($15M) and liabilities ($110M) and Georgia Power's 2023 figures ($13M assets, $124M liabilities), it misrepresents the 2022 data. The LLM claims a total liability of $210M for 2022, but the ground truth states Alabama Power alone had a net liability of $144M in 2022 (with no separate Georgia Power figure provided for that year). The LLM incorrectly assumes this $210M refers to the combined 2022 liability, when no such combined figure is stated in the source — and in fact, the correct combined 2022 net liability is derived from Alabama Power’s $144M (only Georgia Power data is missing for 2022). (2) The calculation of 2023 combined liabilities as $234M (sum of $110M + $124M) is numerically correct, but the comparison to $210M in 2022 is invalid due to incorrect sourcing. The correct combined net liability in 2023 is $95M (Alabama) + $111M (Georgia) = $206M, down from $144M (Alabama only) in 2022. However, since Georgia Power’s 2022 data is not available, the only valid comparison is Alabama Power’s reduction from $144M to $95M. The LLM incorrectly concludes an increase, while the correct trend is a decrease in net liability. (3) The multi-hop reasoning fails: the model conflates gross liabilities with net positions, omits netting of assets and liabilities, and fabricates a 2022 combined liability figure not present in the data. It also fails to compute net liabilities per entity before aggregating. (4) Scores reflect major quantitative inaccuracies and flawed reasoning, though the answer is contextually relevant and attempts to address the right entities and time periods.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 475,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Walmart's financial relationship with Alert Innovation evolve between fiscal 2023 and fiscal 2024, particularly in terms of acquisition and subsequent disposition activities?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, bringing its ownership to approximately 100%. However, in fiscal 2024, Walmart sold and deconsolidated the Alert Innovation entity, signaling a complete exit from the investment. This represents a full evolution from acquisition to divestiture within a one-year span.",
      "llm_answer": "Walmart bought Alert Innovation in fiscal 2023, completing a $0.4 billion acquisition that gave it roughly 100 % ownership of the company【WMT_10k_2024.pdf: page 45】.  The 2024 filing shows no additional purchase or sale of Alert Innovation during that year – Walmart simply retained the subsidiary – and it discloses that the Alert Innovation entity was later sold and de‑consolidated in fiscal 2025【WMT_10k_2024.pdf: page 44】.  Thus the relationship moved from an acquisition in 2023 to continued ownership in 2024, with the disposition deferred to the following fiscal year.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error regarding the timing of the disposition. While the ground truth states that Walmart sold and deconsolidated Alert Innovation in fiscal 2024, the LLM claims this occurred in fiscal 2025, which directly contradicts the original answer and misrepresents the evolution of the financial relationship. The acquisition amount ($0.4 billion) and ownership percentage (~100%) are correctly stated, so quantitative elements are accurate in value but misapplied in timeline. (2) The numbers themselves—$0.4 billion and ~100% ownership—are correct and match the ground truth. However, the fiscal year of the disposition is incorrect: the original answer clearly states the sale happened in fiscal 2024, not fiscal 2025. This is a major error in temporal accuracy that undermines the core of the multi-hop comparison. (3) The reasoning is flawed because it fails to correctly synthesize the timeline across fiscal years. The question asks about the evolution between fiscal 2023 and 2024, but the LLM incorrectly extends the disposition to fiscal 2025, breaking the logical chain. It also cites the same document (WMT_10k_2024.pdf) for both claims, yet misinterprets the timing, suggesting a failure in multi-hop temporal reasoning. (4) The contextual relevance is fair because the answer addresses the right entities and general sequence (acquisition followed by disposition), but the qualitative inaccuracy in timing severely limits correctness. The answer suggests continuity in 2024 rather than the actual divestiture, which changes the entire interpretation of Walmart's strategic move. Hence, correctness and qualitative accuracy scores are low despite partial factual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 472,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the regulatory approval status of Trodelvy evolve between 2022 and 2023, and what does this indicate about Gilead's oncology strategy?",
      "original_answer": "In 2022, Trodelvy was part of Gilead's marketed product portfolio and contributed to growth in the oncology franchise, though no specific regulatory updates were mentioned. By 2023, Trodelvy received both FDA and EC approvals for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who had received prior endocrine-based therapy and at least two additional systemic therapies. This regulatory progress indicates a strategic focus by Gilead on expanding the therapeutic applications of Trodelvy and strengthening its position in the oncology market, particularly in breast cancer treatment.",
      "llm_answer": "In 2022 Trodelvy was already on the market for metastatic triple‑negative breast cancer (full FDA approval and EU marketing authorization) and had an FDA accelerated approval for urothelial cancer, but it had no label for HR⁺/HER2‑ disease【page_39】. By 2023 Gilead had secured both European Commission and FDA approvals for Trodelvy as a monotherapy in HR⁺/HER2‑ breast cancer, adding a new indication to its label【page_39】. This label‑expansion shows Gilead’s oncology strategy of deepening and broadening its cancer portfolio by leveraging Trodelvy’s platform to capture additional breast‑cancer sub‑populations and drive growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that in 2022, Trodelvy was already approved for metastatic triple-negative breast cancer and had accelerated approval for urothelial cancer, but not for HR+/HER2- breast cancer—this contextual detail is consistent with the absence of a 2022 regulatory update for that indication in the original answer. (2) For 2023, it accurately reports that both FDA and European Commission approvals were granted for HR+/HER2- breast cancer, matching the original answer’s claim. All dates and regulatory bodies are correct. (3) The reasoning is sound: the LLM correctly infers that label expansion into HR+/HER2- breast cancer reflects Gilead’s strategy to broaden Trodelvy’s use and strengthen its oncology footprint, which is consistent with the original answer’s interpretation. The LLM adds slightly more context (e.g., prior indications), which enhances clarity without introducing error. (4) Minor deduction in qualitative accuracy due to the addition of details (e.g., specific prior indications) not present in the ground truth, but these are factually correct and do not distort the answer. No calculation or entity errors. Semantic equivalence is strong, and the response fully addresses both parts of the multi-hop question: evolution of approval status and strategic implication.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 380,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Simon Property Group's financial relationship with ABG evolved between 2023 and 2024, particularly in terms of capital transactions and strategic positioning?",
      "original_answer": "In 2023, Simon Property Group (SPG) engaged in multiple capital transactions with ABG, including recognizing a non-cash pre-tax gain of $36.4 million from a dilution of ownership in ABG during the second quarter and an additional $145.8 million gain in the third quarter due to further dilution from SPARC Group issuing equity. Additionally, SPG had a long-standing strategic partnership with ABG dating back to 2021, involving licensing ventures such as Forever 21, Brooks Brothers, and Eddie Bauer, which resulted in significant gains. In 2024, SPG no longer reported active capital transactions with ABG, such as gains from dilution or new equity investments. Instead, the 2024 filing only referenced historical transactions, such as the 2021 sale of a portion of SPG’s ABG interest for a pre-tax gain of $18.8 million and the 2022 acquisition of Reebok assets alongside a strategic partnership. This indicates a shift from active financial engagement and restructuring with ABG in 2023 to a more stable, historically referenced relationship in 2024.",
      "llm_answer": "In 2023 Simon gradually pared back its ABG holding – it sold partial interests (e.g., a $157.1 million pretax gain in Q4 2023) and was repeatedly diluted by ABG‑initiated capital transactions that cut its ownership to roughly 9‑10% and generated modest non‑cash gains (e.g., $10.3 million, $12.4 million and $36.4 million gains)【page_73】. By Q1 2024 Simon completed the exit, selling its remaining ABG stake for $1.2 billion and recording a $414.8 million pretax gain, signalling a strategic decision to fully divest from ABG【page_73】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Simon Property Group (SPG) recognized non-cash pre-tax gains of $36.4 million in Q2 2023 and $145.8 million in Q3 2023 due to dilution from ABG capital transactions, not the $10.3M, $12.4M, and $157.1M gains cited by the model. The LLM incorrectly states a $157.1M gain in Q4 2023 and a $414.8M gain from selling the remaining stake in Q1 2024 for $1.2B — none of which appear in the original answer and directly contradict it. The ground truth explicitly states that in 2024, SPG no longer reported active capital transactions with ABG, whereas the LLM claims a full divestiture occurred in Q1 2024, which is false. (2) Quantitative accuracy is very low: none of the key figures match (e.g., $36.4M is correct but isolated; $145.8M gain missing; invented $414.8M and $1.2B sale). The model fabricates a complete exit not present in the original. (3) Multi-hop reasoning fails: instead of identifying the shift from active 2023 dilution gains to passive historical references in 2024, the model invents a narrative of gradual selling and final exit, misrepresenting the strategic evolution. It confuses SPARC Group’s equity issuance (which caused dilution gains) with general 'ABG-initiated capital transactions'. (4) Contextual relevance is moderate because the answer addresses capital transactions and strategic positioning between SPG and ABG, but the conclusions are based on fabricated data. While the topic alignment exists, the factual foundation is unsound, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 440,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Chevron's relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2024, particularly in terms of financial reporting and investment value?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was included in Chevron’s consolidated financial disclosures, specifically in Note 8 on page 70 of the 10-K filing, indicating it was a consolidated subsidiary. By 2024, the company was reported as an equity method investee under 'Downstream' in the Investments and Advances section, with a disclosed investment value of $8,571 million as of December 31, 2024, up from $7,765 million in 2023. This reflects a shift from full consolidation to an equity method investment, suggesting a structural or ownership change in Chevron’s relationship with the entity.",
      "llm_answer": "In the 2022 10‑K Chevron reported that it owned 50 % of Chevron Phillips Chemical Company LLC, carrying the equity‑method investment at roughly $7.8 billion and recognizing $867 million of equity earnings for the year (Note 15)【page_84】. By the 2024 filing the investment balance had risen to $8.571 billion and equity earnings to $903 million, and the note now spells out a $669 million loan to CPC for the Golden Triangle Polymers Project, showing a higher reported value and a more detailed disclosure of the joint‑venture relationship【page_84】【page_85】.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding Chevron's relationship with Chevron Phillips Chemical Company LLC (CPC) in 2022. According to the ground truth, CPC was a consolidated subsidiary in 2022 (Note 8, page 70), not an equity method investee. However, the LLM claims Chevron already treated it as an equity-method investment in 2022, citing Note 15 and reporting $7.8 billion carrying value and $867 million equity earnings. This contradicts the ground truth that consolidation occurred in 2022, meaning full financials were rolled up into Chevron’s statements, not equity-method accounting. (2) Quantitatively, the 2024 investment value of $8,571 million is correct (matches $8.571 billion), and the increase from $7,765 million in 2023 is consistent with the upward trend, though the LLM incorrectly states the 2022 value as $7.8 billion when it was not yet an equity investment. The equity earnings figures ($867M in 2022 and $903M in 2024) are plausible but irrelevant if the entity was consolidated in 2022, as equity earnings would not be reported under consolidation. The $669 million loan detail may be accurate but is not in the ground truth and does not compensate for the core misrepresentation. (3) The multi-hop reasoning fails because the model misidentifies the nature of the relationship in 2022, which is central to assessing the evolution. The shift from consolidation to equity method is the key development, but the LLM assumes equity accounting throughout, missing the structural change entirely. (4) Scores reflect partial credit for correct 2024 value and contextual relevance to financial reporting evolution, but major deductions for incorrect entity treatment in 2022, leading to flawed synthesis and misleading conclusion about continuity rather than transition in accounting method.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 502,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did the status and financial impact of Meta's Facilities Consolidation Strategy evolve between the end of 2023 and the end of 2024?",
      "original_answer": "At the end of 2023, Meta had 'substantially completed' its facilities consolidation initiatives as part of the 2022 Restructuring, indicating the process was still ongoing. By the end of 2024, the company reported that it had 'completed the 2022 restructuring initiatives,' which included the facilities consolidation strategy, showing the process had reached full completion. Additionally, the 2024 disclosure included a financial summary of the 2022 Restructuring pre-tax charges across three years (2022–2024), indicating a retrospective quantification of the financial impact that was not explicitly detailed in 2023.",
      "llm_answer": "At the end of 2023 Meta said the facilities‑consolidation component of its 2022 restructuring was “substantially completed” but still in progress, and it had incurred about **$2.5 billion of pre‑tax restructuring charges** for that effort (cost of revenue $177 m, R&D $1.58 b, marketing $396 m, G&A $352 m)【page_104】【page_105】. By December 31 2024 the company reported the 2022 restructuring—including the facilities‑consolidation plan—was **fully completed**, and the remaining facilities‑consolidation expense for the year was only **$389 million in total pre‑tax charges** (cost of revenue $31 m, R&D $254 m, marketing $54 m, G&A $50 m)【page_102】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution in status from 'substantially completed' in 2023 to 'fully completed' in 2024, aligning with the ground truth. However, it introduces specific financial figures—$2.5 billion in pre-tax charges by end of 2023 and $389 million in 2024—that are not present in the original answer and cannot be verified against the ground truth, which only states that a retrospective financial summary was provided in 2024 without specifying cumulative or annual breakdowns. These numbers may be accurate in the actual filings, but since the ground truth does not include them, their inclusion constitutes a factual overreach unless explicitly supported. (2) The breakdown of charges by cost category (R&D, G&A, etc.) and the summing to $2.5B and $389M suggest precise quantitative claims not present in the original answer, making the quantitative accuracy low. The original answer emphasizes the *disclosure of a financial summary* across 2022–2024, not year-specific charges for facilities consolidation alone. (3) The reasoning is logically sound in structure—tracking status change and financial impact over time—and correctly synthesizes the completion status across years. However, it fails the multi-hop requirement to base conclusions strictly on the knowledge graph’s ground truth, instead adding granular data not reflected there. (4) Contextual relevance is high because the answer addresses the evolution of both status and financial impact as asked. Qualitative accuracy is moderate because the conceptual progression is correct, but quantitative accuracy is penalized due to unsupported specific figures. Correctness score is 6 due to correct core narrative but significant addition of unverified financial details not in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 488,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2024, particularly in terms of strategic focus and program status?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a key growth area that was dependent on U.S. Government authorization and funding, indicating that the programs were still in a development phase with uncertain future funding. By 2024, the company was actively producing hypersonic strike weapons under multiple programs with the U.S. Air Force and Army, showing a shift from a funding-dependent future initiative to an active production program. This evolution reflects a significant advancement in the maturity and strategic importance of hypersonics within Lockheed Martin's portfolio.",
      "llm_answer": "In the 2022 filing, hypersonics was mentioned only as a “key area for growth” – a strategic priority whose progress would depend on budget‑environment and the transition of development programs to production [page_14]. By the 2024 filing, hypersonics has become an explicit part of Lockheed Martin’s Advanced Development (Skunk Works) focus and is listed under multiple business segments, with several active U.S. Air Force, Army and Navy programs to design, develop and build hypersonic strike weapons [page_4] [page_5]. This shows a shift from a broad growth aspiration in 2022 to concrete, multi‑segment development and fielding efforts in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of Lockheed Martin's hypersonics involvement from 2022 to 2024: in 2022, it was a 'key area for growth' dependent on funding and budget environment, while by 2024 it had transitioned to active development and production across multiple military branches and business segments. The strategic focus shift from aspiration to concrete programs is accurately captured. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points (2022 and 2024 filings), correctly infers the progression from development-dependent to active production status, and identifies the expansion across U.S. Air Force, Army, and Navy programs. The mention of Skunk Works (Advanced Development) adds contextual detail consistent with increased strategic focus. (4) The LLM answer conveys semantic equivalence to the original, with only minor differences in emphasis—ground truth highlights 'production' and 'funding-dependent future initiative,' while LLM emphasizes 'development and fielding efforts.' This is a nuance, not an error. One point is deducted from qualitative accuracy because the LLM slightly underemphasizes the funding dependency in 2022 as a constraint, focusing more on the budget environment and transition to production without explicitly noting government authorization as a gatekeeper, which is present in the original. Otherwise, all entities (Lockheed Martin, U.S. military branches, years) are correct, and the answer is fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 478,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolve from 2022 to 2023, particularly in terms of their designation and financial impact?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred. By 2023, the company expanded its disclosure to include the pre-tax effects of energy-related derivatives not designated as hedging instruments on its statements of income, covering the years 2023, 2022, and 2021. This indicates a shift from focusing only on regulatory hedging instruments to providing a broader view of its energy-related derivative activities.",
      "llm_answer": "In the 2022 Form 10‑K Southern Company still recorded its energy‑related contracts as regulatory cash‑flow hedges, reporting a $34 million gain in OCI and a modest $9 million unrealized regulatory‑hedge gain on the balance sheet (see 2022 pp. 322‑326). By the 2023 filing the company had re‑classified most of those contracts as non‑designated derivatives, which produced an $81 million loss in OCI, a $257 million unrealized loss on regulatory hedges and a $44 million loss on cash‑flow hedges (partly offset by a $59 million gain on natural‑gas cost) (see 2023 pp. 293‑295).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific dollar amounts and line items (e.g., $34M gain in OCI, $257M loss on regulatory hedges) that are not present in the original answer and cannot be verified against the ground truth. The original answer does not mention any specific financial figures or OCI impacts, only the evolution in disclosure practices. Therefore, these numbers are unsupported and likely incorrect. (2) The quantitative accuracy is very low because the LLM fabricates precise financial data (e.g., $81M loss in OCI, $44M loss on cash-flow hedges) that are not in the ground truth. There is no mention of reclassification of contracts from regulatory hedges to non-designated derivatives in the original answer, nor any figures related to OCI or balance sheet impacts. (3) The qualitative reasoning partially captures the shift in disclosure — from focusing on designated regulatory hedging instruments in 2022 to a broader inclusion of non-designated derivatives in 2023 — which aligns with the original answer’s claim of expanded disclosure. However, the LLM overinterprets and adds a narrative about reclassification and financial impacts not supported by the ground truth, failing the multi-hop synthesis test as it invents details rather than reporting disclosed changes in treatment and disclosure. (4) Contextual relevance is moderate because the answer addresses the general topic of evolving derivative treatment and disclosure between 2022 and 2023, but it does so with fabricated specifics, undermining factual reliability. The core idea of a shift in disclosure breadth is present, but the emphasis on financial impacts and reclassification is not grounded in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 467,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Gilead's intellectual property strategy regarding Truvada evolve between 2022 and 2023, particularly in terms of patent disclosures?",
      "original_answer": "In 2022, Gilead highlighted the October 2020 loss of exclusivity of Truvada in the United States as a transitory headwind, indicating that the product was no longer protected under patent, which likely affected revenue. In 2023, Gilead provided structured disclosures regarding the patent expiration dates of its principal products, including Truvada, focusing on the actual or estimated expiration dates in the U.S. and the EU. This represents a shift from acknowledging a past loss of exclusivity to proactively disclosing future intellectual property timelines for key products.",
      "llm_answer": "In the 2022 Form 10‑K Gilead called out that Truvada’s U.S. exclusivity had already expired in October 2020 and discussed the resulting sales impact, indicating that the company was still tracking the product’s IP status (2022 p. 39). By the 2023 Form 10‑K the patent‑expiration tables no longer list Truvada (2023 p. 8‑9), and the patent discussion focuses on other products, showing that Gilead has moved from actively defending Truvada patents to accepting its generic status and no longer discloses any enforceable Truvada patents.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but diverges significantly from the ground truth in key aspects. (1) Quantitatively, the date of Truvada's U.S. exclusivity loss (October 2020) is correctly cited, and the reference to 2022 disclosures is accurate. However, the claim that Truvada is not listed in the 2023 patent-expiration tables is factually incorrect according to the ground truth, which states that Gilead *did* include Truvada in structured disclosures of patent expiration dates in 2023. (2) The LLM incorrectly interprets the absence of Truvada from the tables as a sign that Gilead no longer discloses enforceable patents, when in fact the ground truth indicates a shift toward *more structured and forward-looking* disclosures, including Truvada’s expiration dates in the U.S. and EU. (3) The reasoning is flawed: the model infers a cessation of disclosure and acceptance of generic status, while the original answer describes an evolution toward proactive, systematic IP transparency. This misrepresents the core evolution in strategy. (4) While the answer addresses the question’s focus on IP strategy evolution and correctly identifies the 2022 context, it fails on the critical 2023 update—missing the shift to structured future disclosures. Thus, despite correct entity identification (Gilead, Truvada, years) and some contextual relevance, the qualitative inaccuracy in reasoning and key factual misstatement about 2023 disclosures limits correctness. Minor formatting variations (e.g., 'Form 10-K' vs '10-K') are acceptable and do not affect scoring.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 430,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did SPG's use of the Supplemental Facility evolve between 2022 and 2024, particularly in terms of borrowing and repayment activities?",
      "original_answer": "In 2022, SPG borrowed $1.05 billion under the Supplemental Facility in January 2022, which was used to fund the early extinguishment of nine mortgages with a principal balance of $1.16 billion. This borrowing was repaid shortly after issuance. By 2024, SPG again utilized the Supplemental Facility, borrowing €750.0 million ($815.4 million U.S. dollar equivalent) in November 2023, which was repaid on November 17, 2023. Additionally, in 2024, SPG issued new senior unsecured notes to redeem other outstanding notes at maturity, indicating a shift in financing strategy. The evolution shows a continued reliance on the Supplemental Facility for short-term financing needs but with a more structured approach to repayment and refinancing.",
      "llm_answer": "In the 2022 filing SPG disclosed that it had drawn $1.05 billion from the Supplemental Facility on December 14 2021 (after a $750 million repayment in 2020) and then used proceeds from newly issued senior notes to repay the entire $1.05 billion on January 12 2022, leaving essentially no balance on the facility at year‑end (see 2022 p. 71‑73). By the 2024 filing the only remaining Supplemental Facility debt was a Euro‑denominated borrowing that was swapped to a fixed 3.81 % rate in January 2023 and was fully retired with proceeds from a €750 million bond issuance on November 17 2023, with no new draws reported for 2024 (see 2024 p. 70).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly affect correctness. (1) QUANTITATIVE ACCURACY: The original answer states SPG borrowed $1.05 billion in *January 2022* and repaid it shortly after. The LLM incorrectly claims the draw occurred on *December 14, 2021*, and repayment on *January 12, 2022*. While close in time, this misaligns the fiscal year context and contradicts the ground truth timing. Additionally, the LLM mentions a $750 million repayment in 2020, which is not referenced in the original answer and is extraneous. For the 2024 period, the LLM correctly identifies the €750 million borrowing and its repayment on November 17, 2023, but incorrectly frames it as being 'fully retired with proceeds from a €750 million bond issuance'—the original answer does not link the bond issuance directly to the repayment of this draw, nor does it mention a 3.81% fixed rate swap, which is absent from the ground truth. (2) COMPLETENESS: The LLM fails to mention the *purpose* of the 2022 borrowing—to fund the extinguishment of $1.16 billion in mortgages—which is a key part of the evolution in use. It also omits the broader strategic shift noted in the original answer about issuing new senior unsecured notes to redeem maturing notes in 2024, which reflects a change in financing approach. (3) ENTITY ACCURACY: The company (SPG) and facility (Supplemental Facility) are correctly identified, and the years 2022 and 2024 are appropriately addressed. (4) REASONING: The LLM attempts multi-hop synthesis by referencing both 2022 and 2024 filings, but the reasoning is flawed due to incorrect dates and unsupported details (e.g., interest rate swap, bond linkage). The conclusion that there were no new draws in 2024 is technically correct but misses the nuance that the November 2023 draw (reported in the 2024 filing) was part of ongoing short-term use. (5) SEMANTIC EQUIVALENCE: While the general idea of short-term use and repayment is conveyed, the specific facts, timing, purpose, and strategic evolution are not accurately reflected. The inclusion of unverified details reduces factual reliability. Overall, the answer is partially correct but contains key errors in timing, causality, and completeness, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 603,
        "total_tokens": 1946
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the role of cash buffer needs in MetLife's capital management strategy evolved from 2022 to 2024, particularly in terms of liquidity levels and their impact on capital allocation decisions?",
      "original_answer": "In 2022, MetLife maintained a short-term liquidity position of $12.4 billion and a total liquid asset base of $223.0 billion, reflecting a strong buffer to meet business requirements under both normal and stress scenarios. The company emphasized its belief in having ample liquidity and highlighted active monitoring and adjustment of liquidity and capital plans. By 2024, the narrative shifted to a more cautious tone, noting that maintaining or increasing cash buffers could limit capital available for innovation, acquisitions, and shareholder returns. This indicates that while liquidity remained a strategic priority, the implications of holding larger cash buffers became more pronounced, potentially constraining other capital deployment opportunities.",
      "llm_answer": "In the 2022 filing MetLife’s capital‑management approach was centered on keeping a large liquidity cushion – $12.4 billion of short‑term liquidity and $223 billion of overall liquid assets – to meet cash‑flow needs and stress‑scenario requirements, with the cash buffer treated as an implicit safety net for operations and capital adequacy【page_122】. By the 2024 filing the company explicitly calls out “cash‑buffer needs” as a strategic constraint, noting that maintaining or increasing the buffer can limit the capital available for growth initiatives, acquisitions and shareholder returns and may even prevent dividend payments or share repurchases【page_33】. This shift reflects a move from viewing liquidity primarily as a protective reserve to recognizing the buffer as a direct factor in capital‑allocation decisions.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the figures for short-term liquidity ($12.4 billion) and total liquid assets ($223 billion) in 2022 are accurately reported, with acceptable formatting variations (e.g., $223 billion vs. $223.0 billion). No quantitative calculations were required, but the values are correctly cited. (2) The answer addresses all parts of the multi-hop question: it covers the evolution from 2022 to 2024, discusses liquidity levels, and explains the impact on capital allocation decisions. (3) Entity accuracy is perfect: MetLife is correctly identified, years (2022 and 2024) are accurate, and financial terms like 'short-term liquidity', 'liquid assets', and 'capital allocation' are used appropriately. (4) The reasoning is sound and reflects a clear synthesis across time periods: it captures the shift in narrative from viewing cash buffers as a safety net in 2022 to recognizing them as a constraint on innovation, acquisitions, and shareholder returns in 2024. The inclusion of specific consequences like potential prevention of dividend payments or share repurchases adds depth and aligns with the cautious tone in the 2024 filing. (5) The semantic meaning is equivalent to the original answer, with slightly more detailed phrasing but no factual deviation. The use of source citations (e.g., page references) further supports accuracy. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 408,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did Starbucks' exposure to 'Foreign currency - other' derivatives evolve between 2022 and 2023, particularly in terms of asset and liability classifications?",
      "original_answer": "In 2022, Starbucks reported 'Foreign currency - other' derivative liabilities of $0.3 million under accrued liabilities and no corresponding asset value. By 2023, the company had a derivative asset of $1.9 million under prepaid expenses and other current assets and a derivative liability of $4.7 million under accrued liabilities for the same category. This indicates a significant increase in exposure and a shift toward a more balanced treatment across asset and liability classifications.",
      "llm_answer": "In 2022 Starbucks reported roughly $73 million of designated “Foreign currency – other” derivative assets—$39.9 million in prepaid expenses and $33.5 million in other long‑term assets—and only $0.3 million of designated liabilities (accrued) 【page_68】. By the 2023 balance sheet the same category had shrunk to about $3.6 million of assets ($1.9 million prepaid, $1.7 million other long‑term) while liabilities rose to roughly $8.8 million ($4.7 million accrued plus $4.1 million other long‑term) 【page_72】. This reflects a sharp drop in asset exposure and a shift to a larger, more diversified liability exposure for “Foreign currency – other” derivatives.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Starbucks had *no asset value* reported for 'Foreign currency - other' derivatives, only a $0.3 million liability. However, the LLM claims $73 million in assets ($39.9M + $33.5M), which is entirely incorrect. This misrepresents the core fact of the exposure. In 2023, the ground truth states an asset of $1.9 million and liability of $4.7 million, but the LLM reports total liabilities of $8.8 million ($4.7M + $4.1M), introducing a $4.1 million long-term liability not present in the original answer. (2) Number verification: 2022 asset values are completely wrong; $73 million total assets do not exist in the ground truth. The $0.3 million liability is correct. 2023 asset value of $1.9 million is correct, but the LLM adds $1.7 million in long-term assets not mentioned in the original. Liability: $4.7 million is correct, but the additional $4.1 million long-term liability is unsupported by the ground truth. (3) Multi-hop reasoning is flawed because the LLM incorrectly assumes asset and long-term liability positions that do not appear in the original answer, leading to a false narrative of 'shrinking assets' and 'growing diversified liabilities'. The actual evolution is from *no asset* to a $1.9M asset and $4.7M liability, indicating new exposure, not a reduction. (4) Correctness score is low due to major quantitative errors and incorrect synthesis. Qualitative accuracy is slightly higher because the model attempts correct reasoning structure and references the right category and years. Contextual relevance is acceptable as it addresses the right topic and uses proper financial classifications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 470,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has The Coca-Cola Company's relationship with Coca-Cola FEMSA evolved from 2023 to 2024, particularly in terms of its strategic engagement and financial stake?",
      "original_answer": "In 2023, Coca-Cola FEMSA was one of The Coca-Cola Company's five largest independent bottling partners, operating in multiple countries including Mexico, Brazil, and Argentina, and collectively these top five bottlers accounted for 42% of Coca-Cola's worldwide unit case volume. By 2024, the relationship had evolved significantly, as Coca-Cola FEMSA transitioned from being a key bottler to becoming an equity method investee in which The Coca-Cola Company held a 28% ownership stake. This shift indicates a deeper financial commitment and alignment beyond the traditional bottler-concentrate supplier model.",
      "llm_answer": "In the 2023 filing Coca‑Cola FEMSA was described as the company’s largest independent bottling partner – one of the five bottlers that together accounted for 42 % of worldwide unit‑case volume and that operates under long‑term bottler agreements covering Mexico, Central‑ and South‑America【page_7】.  By the 2024 filing the relationship had deepened: Coca‑Cola now holds a 28 % equity interest in Coca‑Cola FEMSA under the equity‑method, generating $1.77 billion of equity income in 2024 and reflecting a more direct financial stake alongside the ongoing bottler partnership【page_87】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution of The Coca-Cola Company's relationship with Coca-Cola FEMSA from 2023 to 2024, noting its status as a major bottling partner in 2023 and the shift to an equity method investee with a 28% ownership stake in 2024. The key facts—Coca-Cola FEMSA being one of the top five independent bottlers, the 42% of worldwide unit case volume contributed by these bottlers, and the 28% equity stake—are all accurate and match the ground truth. The LLM adds a specific figure—$1.77 billion of equity income in 2024—which is not present in the original answer but is consistent with the deeper financial engagement described and does not contradict the ground truth. (2) Quantitative accuracy is perfect: percentages (28%, 42%), years (2023, 2024), and the dollar amount ($1.77 billion) are correctly reported. Format variations (e.g., '42 %' with space) do not affect correctness. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points and two types of relationships (operational bottling partnership and financial investment), correctly inferring a strategic deepening. The only minor omission is that the original answer specifies Coca-Cola FEMSA operates in Mexico, Brazil, and Argentina, while the LLM generalizes to 'Central- and South-America'—a slight geographic overgeneralization but not factually incorrect. (4) The answer is contextually fully relevant, directly addressing both strategic engagement and financial stake. The addition of equity income enhances detail without distorting meaning. The qualitative score is 9 due to the slight imprecision in geographic scope, but overall the answer is factually robust and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 480,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Intel's strategic positioning of FPGAs evolved between 2022 and 2024, particularly in terms of their role within adjacent products and their broader production focus?",
      "original_answer": "In 2022, Intel positioned FPGAs as part of its 'adjacent products' within the Client Computing Group (CCG), Data Center Group (DCG), and Internet of Things Group (IOTG), indicating a supporting role within comprehensive platform solutions. By 2024, FPGAs were explicitly listed under direct product definitions, signaling a shift toward a more central production focus. This reflects a transformation in the strategic importance of FPGAs, moving from a supplementary role to a core product offering.",
      "llm_answer": "In the 2022 Form 10‑K Intel described FPGAs as part of its “adjacent products” – the non‑platform items (PSG/PLD) that complement its CPU‑centric platform solutions and sit alongside its eASIC bridge technology (see the definition of Adjacent products and FPGA on page 113 and the xPU grouping on page 114). By the 2024 filing Intel still defines FPGA as a field‑programmable gate array (page 102) and lists it as one of the four xPU architectures (page 103), but it no longer groups them under “adjacent products,” indicating that FPGAs have moved from a peripheral adjunct role to a core element of Intel’s broader architecture and production strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, FPGAs were categorized as 'adjacent products' within Intel's structure, supporting platform solutions, and references the correct context (non-platform items like PSG/PLD and eASIC). By 2024, it accurately notes that FPGAs are no longer grouped under 'adjacent products' and are instead listed among the four xPU architectures, indicating a strategic elevation. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings, correctly infers a strategic shift based on categorization changes, and supports it with document page references. (4) The answer conveys the same semantic meaning as the original—FPGAs moved from a peripheral to a core role—even if phrased using 'peripheral adjunct' instead of 'supplementary' and referencing 'xPU architectures' more explicitly. The only minor gap is that the LLM does not explicitly name the business groups (CCG, DCG, IOTG) mentioned in the original, but this does not detract from the core insight. Overall, the response is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 374,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did ConocoPhillips' financial activity related to the Lower 48 region evolve from 2022 to 2023, particularly in terms of asset acquisition and depreciation, depletion, and amortization expenses?",
      "original_answer": "In 2022, ConocoPhillips noted that purchases in the Lower 48 were driven by the Concho acquisition, indicating a strategic expansion in that region. The depreciation, depletion, amortization, and impairments expense for the Lower 48 was $4,854 million. In 2023, the company's expense for the same category in the Lower 48 increased to $5,729 million, showing a significant rise of $875 million. This increase suggests continued investment and asset utilization in the Lower 48 following the acquisition.",
      "llm_answer": "ConocoPhillips stepped up its spending on the Lower 48 in 2023, recording $6.5 billion of capital expenditures and investments versus $5.6 billion in 2022 (≈ $0.9 billion increase)【page_135】.  At the same time, depreciation, depletion and amortization for the Lower 48 rose to $5.7 billion in 2023, up from $4.9 billion in 2022【page_133】, indicating higher expense on the newly acquired assets.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in depreciation, depletion, and amortization (DD&A) expenses from 2022 to 2023 for the Lower 48 region, aligning with the core trend in the ground truth. However, there are inaccuracies in the exact figures: the LLM reports $4.9 billion for 2022 (vs. correct $4,854 million) and $5.7 billion for 2023 (vs. correct $5,729 million). While these are close and may reflect rounding, the ground truth specifies exact values, and the LLM’s rounding obscures the precise $875 million increase. Additionally, the LLM introduces capital expenditures of $5.6B in 2022 and $6.5B in 2023, which are not present in the original answer and not requested in the question—this adds unsupported detail. (2) The correct DD&A values are $4,854 million (2022) and $5,729 million (2023), a difference of $875 million. The LLM approximates these as $4.9B and $5.7B, implying a $800M increase, which understates the actual rise. The capital expenditure figures, while possibly from the filing, are not part of the original answer and were not asked for in the question, making them extraneous and unverified against the ground truth. (3) The multi-hop reasoning is partially sound: the LLM connects increased DD&A to asset acquisition (Concho), which is consistent with the original answer’s implication. However, it fails to explicitly mention the Concho acquisition as the driver in 2022, instead focusing on capex increases in 2023 without linking back to the acquisition’s ongoing impact. (4) The correctness score is 7 because the key trend (rising DD&A) is accurate and contextually relevant, but quantitative precision is lacking. Quantitative accuracy is 6 due to incorrect figures and unsupported capex data. Qualitative accuracy is 8 because reasoning is logical and entity identification (ConocoPhillips, Lower 48, DD&A) is correct, though missing explicit mention of Concho. Contextual relevance is 10 as the response directly addresses the financial evolution in the Lower 48.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 546,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial impact on gross margins?",
      "original_answer": "In 2022, Emerson completed the acquisition of AspenTech, contributing approximately $6.0 billion in cash, paying $87.69 per share to Heritage AspenTech stockholders, and retaining $168 million in AspenTech's balance sheet. The acquisition positively impacted gross margins by 0.6 percentage points in 2023. By 2024, Emerson owned 55% of AspenTech on a fully diluted basis, and AspenTech continued to operate under its former name and ticker symbol 'AZPN.' The acquisition's financial impact persisted, contributing to a gross margin increase of 1.8 percentage points to 50.8% in 2024, despite a negative impact from acquisition-related inventory step-up amortization of $231 million, which reduced margins by 1.3 percentage points.",
      "llm_answer": "After the May 2022 transaction Emerson contributed its two industrial‑software businesses and $6 billion in cash, receiving 55 % of the newly‑combined AspenTech and leaving a 45 % non‑controlling interest for former Heritage AspenTech shareholders (see 2022 10‑K p. 56). By fiscal 2024 Emerson’s stake had risen to about 57 % and the company announced a proposal to purchase the remaining shares – effectively moving toward 100 % ownership (2024 10‑K p. 25). The AspenTech deal added roughly 0.6 percentage‑points to Emerson’s gross margin in 2023, helping lift margin from the low‑mid‑40 % range in 2022 to 49 % in 2023 and to 50.8 % in 2024 (see 2024 10‑K p. 26).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also significant inaccuracies. It correctly identifies the $6.0 billion cash contribution and the 55% ownership stake post-acquisition in 2022. However, it incorrectly states that Emerson contributed two industrial-software businesses (not mentioned in the ground truth), implying a merger of equals rather than a full acquisition. The ground truth confirms Emerson completed an acquisition for $87.69 per share in cash, not a contribution of assets. The LLM claims ownership rose to 'about 57%' by 2024 and that Emerson proposed to buy the remaining shares — this is not supported by the original answer, which states ownership was 55% on a fully diluted basis in 2024 with no mention of a buyout proposal. (2) Quantitative inaccuracies include: the gross margin progression is partially correct — LLM says margin rose to 49% in 2023 and 50.8% in 2024, but ground truth attributes only a 0.6 percentage point boost in 2023 and 1.8 points to 50.8% in 2024 despite a $231M inventory step-up amortization impact, which the LLM omits entirely. This omission affects calculation accuracy and financial interpretation. The $231 million amortization reducing margins by 1.3 points is a key financial detail absent in the LLM response. (3) Multi-hop reasoning is partially sound — the model connects ownership changes and margin impacts across years and cites correct directional effects, but fails to accurately represent the nature of the transaction (acquisition vs. combination) and omits critical financial adjustments. (4) Scores reflect that core facts like cash amount and approximate ownership are correct, but major errors in transaction structure, ownership evolution, and missing amortization impact reduce quantitative and overall correctness. Contextual relevance is high as the answer addresses ownership and margin impact as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 515,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has the treatment and availability of shares under the 2015 Director Stock Plan evolved between 2022 and 2024, particularly in terms of share recovery and issuance mechanics?",
      "original_answer": "In 2022, the 2015 Director Stock Plan specified that each share issued under the plan reduced the number of shares remaining for issuance by one, and shares recovered from expired, forfeited, or cash-settled awards were again available for issuance. By 2024, the plan had a total of 35,395,894 shares authorized for issuance as of January 1, 2015, with 37,608,213 shares recovered for issuance between 2015 and 2024. However, 42,343,146 shares were covered by new awards and reinvested dividends since 2015, leaving 30,660,961 shares available for future issuance. This reflects a net reduction in available shares over time despite ongoing share recovery, indicating a shift in the balance between new issuances and recovered shares.",
      "llm_answer": "- In the 2022 Form 10‑K the company said that 31.5 million shares had been recovered for issuance under the 2015 Director Stock Plan (28.96 M for 2015‑2020 + 2.58 M for 2021) and, after subtracting 32.9 million shares already covered by new awards and imputed reinvested dividends, 34.1 million shares remained available for future issuance (see page 334).  \n\n- By the 2024 Form 10‑K the cumulative recoveries had risen to 37.6 million shares (35.77 M for 2015‑2023 + 1.84 M for 2024) while shares covered by new awards and imputed dividends grew to 42.3 million, leaving only 30.7 million shares available for future issuance (see page 311).  \n\n- The recovery and issuance mechanics have not changed: recovered shares (from forfeitures, cash settlements, tax‑withholding, etc.) are added back to the pool, each share issued under the 2015 Director Stock Plan (including net‑of‑tendered shares for share‑settled SARs) reduces the pool by one, and corporate events trigger adjustments to preserve participants’ rights (see pages 312 and 335).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the LLM correctly reports that 37.6 million shares were recovered by 2024 (matching the original answer's 37,608,213), and 42.3 million shares were covered by new awards and reinvested dividends (vs. 42,343,146 in ground truth—minor rounding difference of ~35K, acceptable). The available shares are stated as 30.7 million (vs. 30,660,961—again, negligible rounding). For 2022, the LLM cites 31.5 million recovered shares and 34.1 million available, which are consistent with the trend and plausible given the 2024 backward-looking totals, though the original answer does not provide 2022 recovery/issuance breakdowns—this data likely comes from the cited 10-K page 334, so it is contextually valid. (2) The mechanics of share recovery and issuance are accurately described: recovered shares (forfeitures, cash settlements, etc.) are added back; each issued share reduces the pool by one; adjustments occur for corporate events. This matches the original answer’s description of unchanged mechanics. (3) Multi-hop reasoning is sound: the LLM synthesizes data across 2022 and 2024 filings, compares cumulative recoveries and issuances, and correctly infers that despite ongoing recovery, net available shares decreased due to higher new award volume. (4) The answer fully addresses the question’s focus on evolution between 2022 and 2024, share recovery, and issuance mechanics. The only minor discrepancy is the lack of exact match in 2022 figures (but these are not provided in ground truth for verification), and the 2024 numbers are rounded but within acceptable tolerance. Overall, the answer is factually correct, complete, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 472,
        "total_tokens": 1924
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Starbucks' relationship with the Global Coffee Alliance evolved from fiscal year 2022 to fiscal year 2023 in terms of strategic emphasis and revenue contribution?",
      "original_answer": "In fiscal year 2022, the Global Coffee Alliance contributed to the growth of the Channel Development segment, which saw a $250 million increase in revenue driven by product sales and royalty income from the alliance. By fiscal year 2023, the strategic emphasis on the Global Coffee Alliance had evolved, with Starbucks explicitly highlighting its licensing relationship with Nestlé under the alliance as a core channel for product distribution, indicating a deeper integration and ongoing importance to Starbucks' global licensing and product expansion strategy. This evolution reflects a shift from viewing the alliance primarily as a revenue driver to positioning it as a strategic enabler of global product reach and brand extension.",
      "llm_answer": "In fiscal 2022 Starbucks highlighted the Global Coffee Alliance as a growth engine for its Channel‑Development segment, noting that product‑sales and royalty revenue from the Alliance added about $216 million (the bulk of a $249 million rise in “other” revenues) and helped lift the segment’s revenue by $250 million 【page_32】. By fiscal 2023 the filing describes the Alliance mainly as a licensing channel with Nestlé—still a core part of its “licensed‑store and grocery/food‑service” strategy—but it no longer breaks out a separate revenue figure, indicating the partnership remains strategically important but its contribution is now embedded in broader licensing revenues 【page_6】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the strategic evolution of the Global Coffee Alliance from a revenue driver in FY2022 to a more embedded licensing channel with Nestlé in FY2023, aligning with the ground truth's emphasis on deeper integration and strategic positioning. However, there is a discrepancy in the quantitative details: the ground truth states a $250 million increase in Channel Development revenue driven by the alliance, while the LLM claims the alliance contributed $216 million (as part of a $249 million rise in 'other' revenues), which is inconsistent and unsupported by the provided ground truth. The $250 million figure in the original answer is directly attributed to the alliance’s contribution, not just 'the bulk' of a smaller increase. (2) The numbers do not match: $216M vs. $250M is a significant difference (over $30M gap), and the reference to 'other revenues' and 'page_32' is not corroborated in the ground truth, which does not mention such categorization or page references. This undermines quantitative accuracy. (3) The multi-hop reasoning is sound—LLM correctly infers that the lack of a separate revenue breakout in FY2023 suggests integration into broader licensing, reflecting strategic maturation. It connects FY2022 revenue impact with FY2023 strategic framing, demonstrating good qualitative synthesis. (4) Contextual relevance is high as the answer addresses both strategic emphasis and revenue contribution across both years. While the core strategic narrative is accurate and well-reasoned, the incorrect financial figures reduce overall correctness. The answer is semantically close but factually flawed in key numeric claims, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 471,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has NEE's financial stake and involvement in the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's equity method investments totaled $6,159 million, and the Mountain Valley Pipeline was listed among key equity method investees alongside NEP OpCo, Sabal Trail, and Silver State South Solar, with NEE's interest ranging from approximately 32% to 55%. By 2023, NEE's total equity method investments were $6,156 million, with its interest in the principal entities, including the Mountain Valley Pipeline, ranging from approximately 32.8% to 52.6%. The shift from a broader range (32%–55%) in 2022 to a narrower range (32.8%–52.6%) in 2023 suggests a slight adjustment in ownership stakes, potentially reflecting a more refined or strategic investment posture. Additionally, in 2023, the Mountain Valley Pipeline was specifically noted in the context of Nonrecurring Fair Value Measurements, indicating a possible revaluation or change in financial treatment.",
      "llm_answer": "- In the 2022 filing NEE disclosed that it had taken a $1.5 billion impairment and, in the first quarter of 2022, “completely write‑off[ed] its investment in Mountain Valley Pipeline” (2022 10‑K, p. 97).  \n- By the 2023 filing the pipeline still appears in the equity‑method investment table, but the footnote shows a $2.4 billion negative adjustment “associated with Mountain Valley Pipeline, primarily reflecting impairment charges in 2022 and 2020” (2023 10‑K, p. 8).  \n\nThis shift from a full write‑off to a heavily‑impaired, essentially valueless holding shows NEE’s willingness to cut losses on non‑core, high‑risk pipeline assets and focus capital on its core regulated and clean‑energy investments.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) The claim that NEE 'completely wrote off its investment in Mountain Valley Pipeline' in 2022 is false according to the original answer, which states NEE maintained a 32%–55% interest and reported total equity method investments of $6,159 million in 2022, with Mountain Valley Pipeline still listed as an active investee. There is no mention of a $1.5 billion impairment or full write-off in the ground truth. (2) The $2.4 billion negative adjustment in the 2023 filing is presented as fact, but the original answer does not reference this figure or any such footnote; instead, it notes a narrowing of ownership range and the pipeline's inclusion in Nonrecurring Fair Value Measurements. (3) The core evolution described—full write-off followed by retention of a heavily impaired asset—is inconsistent with the ground truth, which shows continued ownership with only a slight adjustment in stake range (32%–55% to 32.8%–52.6%) and no indication of divestment or write-off. (4) The reasoning about NEE’s investment strategy, while plausible in isolation, is based on incorrect premises and thus not supported by the data. The model fails the multi-hop synthesis by misrepresenting key financial actions and their timing. While the general context of equity method investments and strategic posture is relevant, the specific facts and numbers are largely fabricated or misstated, leading to a low correctness score. Minor credit is given for correctly identifying the Mountain Valley Pipeline as an equity-method investee and attempting to analyze strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 451,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Medtronic's InterStim Therapy product line evolved between 2022 and 2024 in terms of neurostimulator offerings and therapeutic indications?",
      "original_answer": "In 2022, InterStim therapy was described with a range of neurostimulators including InterStim II, InterStim Micro, and InterStim X, targeting symptoms of overactive bladder, urinary retention, and bowel incontinence. By 2024, the product line continued to include InterStim II and InterStim X, now specifically labeled as 'recharge-free' neurostimulators, and retained its focus on overactive bladder and urinary retention, but expanded its therapeutic scope to include 'chronic fecal incontinence.' This reflects a refinement in product positioning and a broadening of clinical applications over the two-year period.",
      "llm_answer": "In 2022 Medtronic’s InterStim portfolio consisted of the InterStim II, InterStim Micro (newly launched) and InterStim X neurostimulators, all marketed for over‑active bladder, urinary retention and bowel‑incontinence symptoms【page_42】. By 2024 the line had been updated to include recharge‑free versions of InterStim II and InterStim X and a rechargeable InterStim Micro, and the therapeutic claim was broadened to explicitly cover chronic fecal incontinence in addition to over‑active bladder and urinary retention【page_39】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All entities—Medtronic, InterStim II, InterStim Micro, InterStim X, and the relevant years (2022, 2024)—are correctly identified. The therapeutic indications in both years are accurately reported: overactive bladder, urinary retention, and bowel/fecal incontinence. The 2024 expansion to 'chronic fecal incontinence' is correctly noted, matching the ground truth's emphasis on broadened clinical applications. (2) There are no numeric values requiring calculation (e.g., financials, percentages), so quantitative accuracy is not compromised; all descriptive details (e.g., 'recharge-free', 'rechargeable') are factually consistent with the source. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes over time in both device specifications (recharge-free vs. rechargeable) and indications. One minor discrepancy: the original answer does not mention InterStim Micro becoming 'rechargeable' by 2024, nor does it specify that InterStim II and X are 'recharge-free' as a new update—this detail is implied but not explicitly confirmed in the ground truth. However, this addition in the LLM answer does not contradict the ground truth and may reflect a reasonable interpretation of 'recharge-free' labeling. (4) The answer is contextually complete and directly addresses the evolution in neurostimulator offerings and therapeutic indications. Wording differs slightly (e.g., 'bowel-incontinence' vs. 'chronic fecal incontinence'), but these are clinically synonymous in context. Overall, the answer is factually correct, well-reasoned, and comprehensive—just shy of perfect due to the slight over-clarification on rechargeability not fully verifiable from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 480,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Simon Property Group's financial stake and strategic relationship with Authentic Brands Group (ABG) evolve from 2022 to 2024?",
      "original_answer": "In 2022, Simon Property Group held a 1.37% interest in ABG and had merged Forever 21 operations into SPARC Group after increasing its stake to 50% alongside ABG. By 2024, Simon sold a portion of its ABG stake, realizing a pre-tax gain of $18.8 million, and later acquired additional interests in ABG for $100 million in cash, indicating a dynamic evolution in their financial relationship.",
      "llm_answer": "In 2022 Simon owned roughly a 10 % non‑controlling stake in Authentic Brands Group after swapping its Forever 21 and Brooks Brothers licensing assets for ABG equity and buying an additional $100 million of shares, leaving it with about a 10.4 % interest (2022 10‑K p.67). By 2023 ABG’s capital transactions had diluted Simon’s holding to roughly 9‑10 % and Simon sold a portion for a $157.1 million pre‑tax gain, and in the first quarter of 2024 it sold its remaining ABG interest for $1.2 billion, realizing a $414.8 million pre‑tax gain and ending the licensing/joint‑venture relationship (2024 10‑K p.73).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Simon Property Group held a 1.37% interest in ABG in 2022, not ~10% as claimed. The LLM incorrectly states that Simon acquired $100 million in shares to reach a 10.4% stake, while the original answer indicates the $100 million investment occurred in 2024, not 2022. The LLM also claims Simon sold a portion of its stake in 2023 for a $157.1 million gain and fully exited in Q1 2024 with a $414.8 million gain, but the ground truth only mentions a $18.8 million pre-tax gain from a partial sale and a subsequent $100 million reinvestment in 2024—there is no mention of a full exit or gains of $157.1M or $414.8M. (2) Quantitative accuracy is severely compromised: the percentages (1.37% vs 10.4%), timing of transactions (2022 vs 2024 for $100M investment), and gain amounts ($18.8M vs $157.1M and $414.8M) are all incorrect. (3) The multi-hop reasoning is flawed—the LLM misattributes the timeline and nature of Simon’s evolving relationship with ABG, failing to correctly synthesize the partial sale followed by reinvestment, instead portraying a full divestiture. It also conflates the SPARC Group joint venture details with direct equity stakes. (4) Contextual relevance is moderate because the answer addresses the general theme of stake evolution and financial transactions, but the severe factual and numerical errors undermine correctness. The qualitative reasoning is partially sound in structure but based on incorrect data, leading to a misleading narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 431,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has ConocoPhillips' investment activity in the Lower 48 region evolved from 2021 to 2023, particularly in terms of depreciation, depletion, and amortization expenses?",
      "original_answer": "ConocoPhillips' depreciation, depletion, and amortization (DD&A) expenses in the Lower 48 region increased from $4,067 million in 2021 to $5,729 million in 2023, indicating a significant rise in asset utilization or investment activity. This reflects a growing emphasis on the Lower 48 as a core operational area for the company.",
      "llm_answer": "ConocoPhillips’ Lower 48 asset base has been expanding – its depreciation, depletion and amortization (DD&A) expense rose from **$4.07 billion in 2021** to **$4.85 billion in 2022** and **$5.73 billion in 2023**【page_133】.  That upward trend mirrors higher capital spending in the region, which jumped from **$3.13 billion in 2021** to **$5.63 billion in 2022** and **$6.49 billion in 2023**【page_135】, indicating increasingly aggressive investment activity in the Lower 48.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the DD&A expenses for 2021 ($4.07 billion, matching the ground truth of $4,067 million) and 2023 ($5.73 billion, matching $5,729 million within rounding). It also includes the 2022 figure ($4.85 billion), which is not in the ground truth but adds useful context and does not contradict it. The values are accurate within acceptable rounding (e.g., $4,067 million ≈ $4.07 billion). (2) The quantitative accuracy is high: $4.07B = $4,070M (vs. $4,067M — $3M difference, <0.1% error), $5.73B = $5,730M (vs. $5,729M — $1M difference). These are negligible rounding discrepancies. The LLM also correctly identifies the upward trend. (3) The reasoning is sound and goes beyond the original answer by linking DD&A increases to rising capital spending, which supports the conclusion of increased investment activity. This multi-hop synthesis (from DD&A to capital expenditures to strategic emphasis) is logical and well-supported. (4) The answer is semantically equivalent and even richer than the ground truth, addressing the evolution of investment activity through both DD&A and capital spending trends. All entities (ConocoPhillips, Lower 48, DD&A, years) are correct. The only minor issue is the slight rounding in reported numbers, not affecting overall correctness. Hence, a score of 9 is justified; 10 is reserved for exact numerical precision across all digits.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1206,
        "completion_tokens": 391,
        "total_tokens": 1598
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Verizon's (VZ) treatment and valuation approach for international bonds evolved from 2023 to 2024 based on their 10-K disclosures?",
      "original_answer": "In 2023, Verizon described that international bonds were valued using matrix prices with input from independent third-party valuation sources as part of the broader fixed income securities category. By 2024, international bonds were specifically itemized in a detailed table with a total value of $12 million, broken down into $10 million in Level 1 and $2 million in Level 2 inputs. This represents a shift from a general description in 2023 to a more transparent and segmented valuation approach in 2024, indicating a more refined disclosure strategy and possibly a more structured approach to valuing international bonds.",
      "llm_answer": "In 2023 Verizon held $341 million of international bonds in its pension plan ( $3 million Level 1 and $338 million Level 2) and $12 million in its other post‑retirement benefit plans ( $10 million Level 1, $2 million Level 2)【page_92】; by 2024 the pension‑plan holding fell to $113 million and is now entirely Level 2 (no Level 1), while the other‑plan holding remained $12 million with the same Level 1/Level 2 split【page_93】. Across both years Verizon’s valuation methodology for international bonds did not change – they are valued using matrix prices with input from independent third‑party valuation sources【page_95】【page_93】.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies compared to the ground truth. The original answer states that in 2023, Verizon did not specifically itemize international bonds but described their valuation generally as part of fixed income securities using matrix pricing. In 2024, they specifically disclosed $12 million in international bonds with a breakdown of $10 million Level 1 and $2 million Level 2. However, the LLM answer incorrectly claims that in 2023, Verizon held $341 million in international bonds in its pension plan and $12 million in other plans — figures not mentioned in the ground truth and irrelevant to the question about overall corporate treatment and valuation approach. These numbers appear to be misextracted from pension plan disclosures, conflating a subcategory (pension holdings) with the broader corporate valuation approach. (2) Quantitative accuracy is low: the $341 million and $113 million figures for pension holdings are not in the ground truth and contradict the focus on a $12 million total in 2024. While the $12 million in other post-retirement plans with $10M Level 1 and $2M Level 2 matches part of the 2024 data, it misattributes this to a narrow benefit plan rather than the general valuation approach. The claim that methodology 'did not change' directly contradicts the ground truth, which identifies a shift from general description to specific itemization — a key qualitative evolution in disclosure. (3) Multi-hop reasoning is flawed: the model fails to synthesize the correct entities (overall valuation approach vs. pension plan holdings) and draws conclusions from irrelevant data. It does not recognize that the evolution is in disclosure transparency and segmentation, not in the underlying valuation method per se. (4) Contextual relevance is moderate because the answer discusses international bonds and valuation sources, but it misdirects focus to pension plan amounts, which were not asked about. The core of the question — evolution in treatment and valuation approach — is incorrectly answered as 'no change' when the ground truth identifies a clear shift in disclosure granularity. Thus, despite some correct numbers in a different context, the answer is largely incorrect on facts, reasoning, and conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 613,
        "total_tokens": 1925
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Emerson's relationship with AspenTech evolve between 2022 and 2024, particularly in terms of financial stake and operational integration?",
      "original_answer": "In 2022, Emerson had a financial stake in AspenTech valued at $8,326 million, as shown in the balance sheet following acquisitions and currency adjustments. By 2024, Emerson's relationship had transformed significantly: it contributed the AspenTech Industrial Software Business along with $6.0 billion in cash to form 'New AspenTech,' retaining a 55% ownership stake in the newly structured company. This indicates a strategic restructuring rather than a simple financial investment, with increased operational integration and a formalized majority ownership.",
      "llm_answer": "In 2022 Emerson closed the Heritage AspenTech transaction, contributing its Open Systems International and Geological Simulation Software businesses and cash and emerged with a 55 % equity stake in the newly created AspenTech entity; the company also extended a $240 million revolving term‑loan facility to AspenTech (see EMR 2022 10‑K p. 63 and 2024 10‑K p. 26). By 2024 Emerson’s ownership had risen to roughly 57 % and it announced a $240‑per‑share cash offer to buy the remaining shares, moving toward full acquisition (see 2024 10‑K p. 25), while AspenTech now operates under the Aspen Technology name and is fully integrated into Emerson’s Software & Control segment, contributing to higher sales and margin growth (see 2024 10‑K p. 26 and 24).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) In 2022, the ground truth states Emerson had a financial stake in AspenTech valued at $8,326 million on its balance sheet, not a 55% stake resulting from a contribution of businesses and cash as claimed. The LLM incorrectly asserts that Emerson emerged with a 55% stake in 2022, which contradicts the documented financial stake of $8.326 billion. (2) By 2024, the correct sequence is that Emerson contributed the AspenTech Industrial Software Business plus $6.0 billion in cash to form 'New AspenTech', retaining a 55% stake—not increasing to 57%. The LLM incorrectly claims ownership rose to 57% and that Emerson made a $240-per-share offer for full acquisition, which is not supported by the ground truth. (3) The revolving loan facility of $240 million is accurate per the 10-K references, but this detail is secondary and does not compensate for core errors. (4) The claim that AspenTech is 'fully integrated' into Emerson’s Software & Control segment and operates under 'Aspen Technology' misrepresents the restructuring: the formation of 'New AspenTech' implies a strategic joint entity, not full integration or acquisition. (5) Multi-hop reasoning fails: the model conflates the 2022 financial investment (passive stake) with the 2024 restructuring (active integration), but reverses the timeline and ownership percentages. The ground truth shows the 55% stake originates in 2024, not 2022. (6) Quantitative accuracy is poor: $8,326 million stake in 2022 vs. claimed 55% equity; $6.0 billion cash contribution in 2024 vs. unmentioned amount; 55% ownership in 2024 vs. claimed 57%. (7) Despite incorrect facts, the answer addresses the evolution of financial stake and operational integration, maintaining contextual relevance. However, core inaccuracies in numbers, ownership timeline, and corporate actions severely limit reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 519,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Starbucks' position in interest rate swaps evolve between 2022 and 2023, particularly in terms of their classification and associated liabilities?",
      "original_answer": "In 2022, Starbucks had an interest rate swap classified as a long-term liability with a value of $34.0 million. By 2023, the company's interest rate swaps were categorized under both current and long-term liabilities, with $0.4 million listed under accrued liabilities (current) and $19.2 million under other long-term liabilities. This reflects a shift in the classification and a net decrease in the overall liability associated with interest rate swaps from $34.0 million in 2022 to $19.6 million in 2023.",
      "llm_answer": "In 2022 Starbucks reported interest‑rate swaps only as liabilities – $12 million in accrued liabilities and $34 million in other long‑term liabilities (a total of about $46 million) with no swap asset, and the contracts were not shown as a designated fair‑value hedge【page_68】. By fiscal 2023 the swaps were re‑designated as a fair‑value hedge, appearing under “Designated Derivative Instruments” with a $0.4 million asset in prepaid expenses and a $41.4 million liability in other long‑term liabilities, reducing the net liability and changing the classification【page_72】【page_71】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Starbucks had only a $34.0 million long-term liability for interest rate swaps, but the LLM claims $12 million in accrued liabilities and $34 million in long-term liabilities (total $46 million), which is incorrect and unsupported by the original data. In 2023, the ground truth states $0.4 million in accrued liabilities (current) and $19.2 million in long-term liabilities (total $19.6 million), but the LLM reports a $41.4 million liability and a $0.4 million asset, which is completely inconsistent. The net liability decreased from $34.0M to $19.6M, but the LLM implies a different calculation and direction of change. (2) The cited numbers are largely incorrect: $12M accrued in 2022 is not in the ground truth; $41.4M long-term liability in 2023 contradicts the $19.2M figure; the introduction of a $0.4M asset is not mentioned in the original answer and changes the nature of the position. (3) The multi-hop reasoning is flawed: the LLM incorrectly synthesizes the classification change, asserting a re-designation as a fair-value hedge and appearance under 'Designated Derivative Instruments', which is not reflected in the ground truth. The original answer notes a shift in classification (to both current and long-term) but does not mention hedge designation changes or derivative instrument reclassification. (4) While the LLM attempts to address the evolution of classification and liabilities, the core facts—especially the amounts and the nature of the change—are wrong, leading to a low correctness score. Contextual relevance is moderate because it discusses the right topic and time frame, but accuracy is severely compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 478,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did NextEra Energy Resources' financial commitment and involvement in the Mountain Valley Pipeline evolve from 2022 to 2023?",
      "original_answer": "In 2022, NextEra Energy Resources recorded an impairment charge of approximately $0.8 billion related to its equity method investment in the Mountain Valley Pipeline, which was fully written off due to the very low probability of pipeline completion. By 2023, despite the ongoing challenges, NEE's subsidiary NEER maintained a 32.8% equity investment in the joint venture and committed to a 20-year natural gas transportation agreement with an annual obligation of approximately $70 million, subject to the completion of construction.",
      "llm_answer": "In the 2022 Form 10‑K, NextEra Energy Resources recorded a major loss on its Mountain Valley Pipeline investment – a $0.8 billion impairment (about $0.6 billion after tax) that wrote off the entire equity‑method carrying amount and created a $0.2 billion liability for estimated future ARO costs【page_92】.  \n\nBy the 2023 filing, the company still held a 32.8 % equity stake and disclosed that it will make equity contributions in 2024 and has entered into a 20‑year, roughly $70 million‑per‑year natural‑gas transportation agreement with the pipeline, showing a renewed financial commitment that is contingent on the project’s completion【page_109】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $0.8 billion impairment in 2022 (with $0.6 billion after tax and $0.2 billion ARO liability) matches the original answer’s $0.8 billion write-off due to low completion probability. The 2023 details—32.8% equity stake, 20-year agreement, ~$70 million annual obligation contingent on completion—are all correctly reported. (2) Quantitative accuracy is perfect: $0.8 billion, 32.8%, $70 million, and the breakdown into after-tax and liability components are factually sound and consistent with the knowledge graph. (3) Multi-hop reasoning is strong: the model correctly synthesizes information across 2022 and 2023 filings, showing evolution from impairment to renewed conditional commitment. (4) Minor deduction in qualitative accuracy due to the addition of after-tax and ARO details not present in the original answer—while likely correct and adding depth, they slightly exceed the ground truth scope. However, this does not detract from correctness. The answer is fully contextually relevant, directly addressing the evolution of financial commitment and involvement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 331,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has The Coca-Cola Company's investment in equity and debt securities related to its captive insurance company reinsuring group annuity insurance contracts evolved between 2023 and 2024?",
      "original_answer": "In 2023, The Coca-Cola Company reported that its captive insurance company reinsuring group annuity insurance contracts held $1,643 million in equity and debt securities as part of its solvency capital funds. By 2024, this amount increased to $1,883 million, indicating a growth in the company's investment in these securities over the year.",
      "llm_answer": "The captive insurance company’s solvency‑capital portfolio of equity and debt securities grew from **$1.643 billion at 12/31/2023** to **$1.883 billion at 12/31/2024**—an increase of roughly **$240 million (about 15 %)**【page_81】. This rise shows Coca‑Cola has allocated more marketable securities to the captive that reinsures its European and Canadian group‑annuity insurance contracts【page_80】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values $1.643 billion (2023) and $1.883 billion (2024) are accurate and match the original answer ($1,643 million and $1,883 million). The increase of $240 million is correctly calculated (1,883 - 1,643 = 240), and the approximate percentage increase (~15%) is reasonable (240 / 1,643 ≈ 14.6%, rounded to 15%). (2) The time periods are correctly specified as of year-end 2023 and 2024, consistent with the annual reporting context. (3) Entity accuracy is correct: The Coca-Cola Company, its captive insurance company, and the purpose (reinsuring group annuity insurance contracts, specifically in Europe and Canada as noted in the source) are accurately identified. (4) The reasoning is sound and demonstrates proper multi-hop synthesis: the model correctly infers that the increase in securities reflects a growth in investment by Coca-Cola into the captive’s solvency capital. (5) The LLM adds contextual detail (geographic scope: European and Canadian contracts) from the source (page 80), which enhances completeness without introducing error. All information is semantically equivalent to the ground truth, with only formatting differences (e.g., $1.643 billion vs $1,643 million), which are acceptable. The answer fully addresses the evolution between 2023 and 2024 as required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1195,
        "completion_tokens": 383,
        "total_tokens": 1578
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of production status and strategic positioning within Intel's product roadmap?",
      "original_answer": "In 2022, Intel was incurring higher period charges related to the ramp-up of Intel 4, indicating early-stage production challenges and investment. By 2024, Intel 4 had transitioned to high-volume manufacturing in Ireland and became the process node for the high-volume Intel Core Ultra processor, marking its strategic importance in Intel's product roadmap. This evolution shows a shift from initial investment and production ramp-up in 2022 to full-scale production and product integration by 2024.",
      "llm_answer": "In the 2022 filing (pages 22‑26) Intel’s process discussion is limited to the Intel 7 node – there is no reference to an Intel 4 node, indicating that the first EUV‑based “Intel 4” was still a future technology under development and not yet in production. By the 2024 filing, Intel 4 is described as the company’s first EUV lithography node, with the Intel Core Ultra client processor already shipping in 2023 and the node moved to high‑volume manufacturing in Ireland in 2024, making Intel 4 a central, high‑volume production platform and a cornerstone of the roadmap ahead of Intel 3 and the upcoming 18A node【page_22】【page_10】【page_9】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Intel 4 was not yet in production and was still under development, with no mention in the 2022 filing—this matches the ground truth implication of early-stage ramp-up and investment challenges. By 2024, it accurately states that Intel 4 entered high-volume manufacturing in Ireland and was used for the Intel Core Ultra processor, confirming its strategic positioning. (2) All dates (2022, 2023 shipping, 2024 high-volume manufacturing), product names (Intel Core Ultra), and technological details (first EUV node) are factually correct and consistent with the original answer. Number formats and timelines are precise. (3) The multi-hop reasoning is sound: the model infers absence of Intel 4 in 2022 as evidence of developmental status, then contrasts it with 2024 data showing production scale-up and product integration—this demonstrates correct synthesis across years and documents. (4) The only minor shortcoming is that the LLM does not explicitly mention 'higher period charges' from 2022, which is a specific financial indicator in the ground truth. However, the absence of Intel 4 in the 2022 discussion implicitly supports that interpretation. Overall, the answer captures the evolution accurately with excellent contextual and factual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 380,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Emerson's strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial integration?",
      "original_answer": "In 2022, AspenTech was described as a strategic partner of Emerson, with no mention of ownership stakes or integration into Emerson's financials. By 2024, Emerson had merged its industrial software business with AspenTech, creating 'New AspenTech,' and retained a 55% ownership stake in the newly formed entity. This marked a significant shift from a partnership to a partially owned subsidiary structure. Additionally, AspenTech's financials were now integrated into Emerson's results, with the acquisition positively impacting gross margins by 0.6 percentage points in 2023 and influencing SG&A expenses in 2024 due to the deeper integration.",
      "llm_answer": "In 2022 Emerson entered a joint‑venture with AspenTech, contributing its Open Systems International and Geological Simulation software businesses to create “Heritage AspenTech” and receiving a non‑controlling equity interest in the new entity (see pages 5‑7). By 2024 Emerson had turned that stake into a majority holding – a cash infusion gave it 55 % of the newly‑named AspenTech (page 26) and, after the November 2024 proposal, it owned about 57 % and planned to acquire the remainder (page 25) – and the AspenTech assets were fully consolidated, adding roughly 3 % of net sales in 2023 and driving a 48 % jump in Software & Control sales, higher SG&A and increased intangible‑amortization in 2024 (pages 24‑26).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies that deviate from the ground truth. First, it incorrectly states that in 2022 Emerson entered a joint venture and contributed software businesses to create 'Heritage AspenTech'—the original answer indicates AspenTech was merely a strategic partner in 2022 with no ownership or integration. This misrepresents the nature and timing of the relationship. Second, the LLM claims Emerson received a 'non-controlling equity interest' in 2022, which is not supported by the ground truth—ownership only began in 2024 via the merger. Third, the LLM cites a 48% jump in Software & Control sales and 3% of net sales in 2023, but these figures are not present in the original answer, which only mentions a 0.6 percentage point improvement in gross margins in 2023. The 55% ownership stake in 2024 is correct, and the mention of increased SG&A in 2024 aligns with the original answer, though the LLM adds unsupported details like 'cash infusion' and a future 57% stake. (2) Quantitative accuracy is partially correct: 55% ownership is accurate, but the 3% net sales and 48% sales increase are fabricated. The original answer does not provide sales percentages or growth rates. The 0.6 percentage point margin improvement is omitted entirely. (3) Multi-hop reasoning is attempted but flawed—the LLM synthesizes across years and financial impacts but bases its logic on an incorrect premise (joint venture in 2022). The integration into financials is correctly noted, but the nature of the evolution is misrepresented. (4) Scores reflect partial correctness: core ownership shift to 55% and financial integration are right, but foundational facts and key metrics are wrong or invented, reducing overall correctness. Contextual relevance is high as the answer addresses ownership and financial integration as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 503,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of its manufacturing readiness and performance improvements?",
      "original_answer": "In 2022, Intel 4 was newly introduced as part of a restructured naming convention for manufacturing process nodes, signaling its position as a next-generation node following Intel 7. By 2024, Intel 4 had transitioned from a conceptual roadmap item to a fully realized product, with high-volume manufacturing ramped up in Ireland. Intel 4, as the company's first EUV lithography node, delivered a 20% performance-per-watt improvement over Intel 7 and was used in the production of the Intel Core Ultra processor, which began shipping in 2023. This represents a significant evolution from its initial naming in 2022 to full-scale production and performance quantification by 2024.",
      "llm_answer": "In the 2022 filing Intel only introduced “Intel 4” as a new name for its upcoming 7 nm node – a roadmap‑only change with no production status disclosed (see the naming‑structure table on page 115). By the 2024 filing the node had become Intel’s first EUV‑lithography process, delivering roughly a 20 % performance‑per‑watt gain versus Intel 7, and it had entered high‑volume manufacturing in Ireland (with the Intel Core Ultra client product already shipping in 2023) (see performance details on page 10 and the manufacturing‑readiness discussion on page 11).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Intel introduced 'Intel 4' in 2022 as a renamed 7nm node with no production status, and by 2024 it had transitioned to high-volume manufacturing using EUV lithography. The 20% performance-per-watt improvement over Intel 7 is correctly stated. The Intel Core Ultra processor began shipping in 2023, as confirmed in both answers. (2) Quantitative elements—'20%' improvement, '2022' and '2024' as reference years, '2023' for product shipment—are accurate and match the original. No calculations are required, but comparative statements are valid. (3) Multi-hop reasoning is sound: the answer synthesizes information across time (2022 to 2024), technology (EUV adoption), manufacturing (Ireland HVM), and product integration (Core Ultra), correctly tracing the evolution from naming to production. (4) The LLM includes additional document-specific details (e.g., page references) that enhance credibility without introducing errors. Wording differs slightly but conveys identical meaning. All evaluation criteria are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 323,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has the role and positioning of InterStim Micro evolved within MDT's Pelvic Health therapies between 2022 and 2024?",
      "original_answer": "In 2022, InterStim Micro was listed as one of several neurostimulators within MDT's Pelvic Health product portfolio, which also included InterStim X and InterStim II, used to treat overactive bladder, urinary retention, and fecal incontinence. By 2024, InterStim Micro was specifically highlighted as the rechargeable neurostimulator option, differentiated from the recharge-free InterStim X and InterStim II. This indicates a more defined strategic positioning of InterStim Micro as the rechargeable variant within the broader InterStim therapy lineup, with an emphasis on its continued global growth and adoption.",
      "llm_answer": "In the 2022 filing, InterStim Micro was mentioned only as one of three InterStim neurostimulators (InterStim X, InterStim Micro and InterStim II) that together address overactive bladder, non‑obstructive urinary retention and chronic fecal incontinence【page_10】. By the 2024 filing, InterStim Micro is highlighted as a **rechargeable** neurostimulator within the InterStim therapy suite, positioned alongside recharge‑free InterStim X and InterStim II and called out as a driver of continued acceptance and growth of Medtronic’s Pelvic Health therapies【page_39】. This shows a shift from a generic product listing to a differentiated, rechargeable solution emphasized for market expansion.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: in 2022, InterStim Micro was listed among other neurostimulators (InterStim X, InterStim II) for pelvic health conditions including overactive bladder, urinary retention, and fecal incontinence. By 2024, it was specifically positioned as the rechargeable option, differentiated from the recharge-free models. (2) There are no numeric values requiring calculation, but the years (2022 and 2024) are correctly referenced and aligned with the evolution of product positioning. (3) The multi-hop reasoning is sound—information is synthesized across two time points (2022 and 2024 filings), correctly identifying a shift from generic listing to strategic differentiation based on rechargeability. (4) The answer captures the core evolution: InterStim Micro’s enhanced strategic role as a rechargeable device driving growth, which matches the original answer’s emphasis on 'defined strategic positioning' and 'continued global growth and adoption.' Wording differs slightly but meaning is preserved. All evaluation dimensions are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 326,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the disclosure around the dilutive effect of LTIP Units evolved from 2022 to 2024, particularly in terms of material impact across reporting periods?",
      "original_answer": "In 2022, the disclosure stated that LTIP units were exchangeable for common stock and that no securities had a material dilutive effect for the years ended December 31, 2021, 2020, and 2019. By 2024, the disclosure simplified to state that no securities had a material dilutive effect for the years ended December 31, 2024, 2023, and 2022, without explicitly referencing the exchangeability of LTIP units into common stock. This indicates a reduction in the level of detail provided about LTIP units' conversion features, while maintaining the same conclusion regarding dilution impact.",
      "llm_answer": "In the 2022 Form 10‑K the company said that LTIP units are “potentially dilutive” but that “no securities had a material dilutive effect for the years ended December 31, 2021, 2020 and 2019” (the same language appears for the Operating Partnership). The 2024 Form 10‑K repeats that phrasing, updating the periods to “the years ended December 31, 2024, 2023 and 2022” and again confirming that LTIP units had no material dilutive effect. Thus, the disclosure has been refreshed to cover the most recent three years, but the assessment of material impact remains unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the key disclosure trend: that in both 2022 and 2024, the company stated no securities had a material dilutive effect for the respective three-year periods (2019–2021 in 2022 filing; 2022–2024 in 2024 filing). The dates and periods are accurately reported, supporting a high quantitative accuracy score. However, the LLM incorrectly states that the 2022 Form 10-K described LTIP units as 'potentially dilutive'—this detail is not present in the ground truth, which instead emphasizes the exchangeability of LTIP units into common stock, a feature omitted in the 2024 disclosure. The ground truth highlights a reduction in detail about the conversion mechanism, but the LLM fails to note this change in disclosure granularity. Instead, it claims the 'same language' appears in both years, which contradicts the ground truth indicating a simplification and removal of the exchangeability detail. This is a significant qualitative error in reasoning and synthesis across filings, undermining the completeness of the evolution analysis. While the conclusion about unchanged material impact is correct, the failure to identify the reduced disclosure detail—central to the question about evolution—results in a moderate correctness score. Contextual relevance is high as the response directly addresses the question’s focus on changes in disclosure and material impact over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 388,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has MetLife's approach to managing cash buffer needs in relation to stock repurchases evolved from 2022 to 2024, particularly in terms of remaining repurchase authorization and liquidity considerations?",
      "original_answer": "In 2022, MetLife had $1.5 billion remaining under its $3.0 billion common stock repurchase authorization as of December 31, 2021, indicating a significant but partially utilized capacity for returning capital to shareholders. By 2024, the company emphasized increased caution around cash buffer needs, noting that maintaining or increasing liquidity buffers could limit capital available for repurchases, acquisitions, and innovation. This reflects a shift from a more active repurchase posture in 2022 to a more conservative liquidity strategy in 2024, influenced by regulatory, market, and internal capital considerations.",
      "llm_answer": "In the 2022 filing MetLife said its board had authorized a $3 billion share‑repurchase program and that about $1.5 billion remained available at year‑end 2021, but it also warned that it “maintains a buffer of cash and other liquid assets, and may increase it,” which could reduce the capital it can devote to buybacks【page_50】. By the 2024 filing the company no longer cites a specific remaining‑authorization amount; instead it stresses that preserving liquidity and meeting cash‑buffer needs—especially in volatile markets and under regulatory constraints—may limit its ability to repurchase stock, reflecting a more cautious, liquidity‑first stance【page_31】【page_33】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $3.0 billion share repurchase authorization and the $1.5 billion remaining as of year-end 2021 (reported in the 2022 filing), which matches the ground truth. It accurately notes the absence of a specific remaining authorization figure in the 2024 filing and correctly captures the shift toward a more cautious, liquidity-first approach. All factual elements—dollar amounts, timing, and strategic evolution—are correct. (2) Quantitative accuracy is perfect: $3 billion and $1.5 billion are correctly cited with acceptable formatting (e.g., $3 billion). No calculations are required, but the synthesis of the remaining authorization (implying half used) is logically sound. (3) The multi-hop reasoning is strong: the model connects information from the 2022 and 2024 filings, correctly inferring a strategic shift from active repurchases to prioritizing liquidity buffers due to regulatory and market conditions. It synthesizes across years and documents, though it slightly underemphasizes the explicit 'increased caution' language in the ground truth, instead conveying it through paraphrase like 'liquidity-first stance,' which is semantically equivalent. (4) Scores reflect near-perfect factual alignment, with only a minor deduction in qualitative accuracy due to slightly less explicit emphasis on the forward-looking nature of the 2024 caution compared to the original answer. Contextual relevance is full—every part of the question is addressed: evolution over time, remaining authorization, and liquidity considerations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 434,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions evolve from fiscal year 2022 to 2023, and what specific changes occurred in their balance sheet classifications?",
      "original_answer": "In fiscal year 2022, Starbucks reported foreign currency - other derivative assets of $103.9 million recognized in OCI before reclassifications and $22.0 million reclassified from AOCI to earnings. By fiscal year 2023, the foreign currency - other derivative assets on the balance sheet were reported as $1.9 million in prepaid expenses and other current assets and $1.7 million in other long-term assets as of October 1, 2023, while derivative liabilities were $4.7 million in accrued liabilities and $4.1 million in other long-term liabilities. This represents a significant reduction in asset positions compared to the prior year, with a shift in balance sheet classification.",
      "llm_answer": "In FY 2022 Starbucks held foreign‑currency‑other derivative assets of $39.9 million in prepaid expenses and other current assets and $33.5 million in other long‑term assets (total $73.4 million) and only a $0.3 million accrued liability (no long‑term liability)【page_68】. By FY 2023 the asset balances fell to $32.0 million (current) and $22.9 million (long‑term), totaling $54.9 million, while the liability grew to $2.0 million accrued liabilities (still no long‑term liability)【page_72】. The balance‑sheet classification remained the same—current‑asset items recorded under prepaid expenses and other current assets, long‑term items under other long‑term assets, and liabilities under accrued liabilities—though the amounts in each category changed as shown.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both the 2022 and 2023 figures. According to the ground truth, in FY 2022, Starbucks reported $103.9 million in foreign currency - other derivative assets recognized in OCI before reclassifications, with $22.0 million reclassified from AOCI to earnings — none of which is reflected in the LLM answer. Instead, the LLM claims $39.9 million in current assets and $33.5 million in long-term assets for 2022, totaling $73.4 million, which contradicts the ground truth. For FY 2023, the ground truth states that derivative assets were $1.9 million (current) and $1.7 million (long-term), while liabilities were $4.7 million (accrued) and $4.1 million (long-term). The LLM incorrectly reports $32.0 million and $22.9 million in assets and only $2.0 million in liabilities with no long-term component, which is completely inconsistent with the actual data. (2) All numerical values are incorrect, including totals, classifications, and liability breakdowns. The LLM invents a classification structure that remained 'the same' between years, but the ground truth shows a major reduction in asset size and a shift in reporting context (from OCI-based disclosures to specific balance sheet line items), which the model fails to capture. (3) The multi-hop reasoning is flawed: the model does not connect the FY2022 OCI reporting with the FY2023 balance sheet classification shift. It incorrectly assumes balance sheet categories were consistent across years and misses the core narrative of a significant reduction in derivative positions and a change in how they are presented. (4) The contextual relevance is moderate because the answer addresses derivative assets/liabilities and balance sheet classification, but the factual foundation is so inaccurate that the conclusion is misleading. Due to severe quantitative and qualitative errors, the correctness score is low at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 524,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Procter & Gamble's global cash management strategy evolved in relation to its restructuring activities and corporate-level financial performance between fiscal 2022 and fiscal 2024?",
      "original_answer": "In fiscal 2022, Procter & Gamble incurred restructuring costs within its historical range of $250 to $500 million before tax, with $147 million in restructuring accruals as of June 30, 2022. Corporate net earnings improved by $872 million to $485 million, partly due to tax benefits and lower restructuring charges. By fiscal 2024, restructuring costs increased significantly to $659 million before tax, including $216 million in non-cash foreign currency translation losses. Corporate net earnings decreased by $1.0 billion, largely due to the $1.4 billion impairment charge of the Gillette intangible asset and incremental restructuring charges. This indicates a shift toward more aggressive restructuring actions, particularly in Enterprise Markets like Nigeria, which impacted both cash flow and earnings. The global cash management strategy remained focused on liquidity and tax considerations, but faced increased pressure from these restructuring activities and impairment charges.",
      "llm_answer": "Between fiscal 2022 and fiscal 2024 P&G’s global cash‑management framework remained anchored in operating‑cash generation, undrawn credit facilities and tax‑efficient foreign‑subsidiary cash balances, but it was adjusted to absorb a much larger restructuring outlay and a shift from a $485 million corporate profit in 2022 to a $1.4 billion loss in 2024. Accordingly, cash held abroad rose modestly from $5.8 billion to $6.1 billion, the excess of current liabilities over assets narrowed, and the company continued to rely on its strong short‑ and long‑term debt capacity to fund the $659 million restructuring program while preserving liquidity for dividends, share repurchases and acquisitions.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in key financial figures. It states that P&G shifted from a $485 million corporate profit in 2022 to a $1.4 billion loss in 2024. However, the ground truth indicates that in fiscal 2022, corporate net earnings *improved by* $872 million to reach $485 million (i.e., a profit of $485 million), while in fiscal 2024, earnings *decreased by* $1.0 billion due to a $1.4 billion impairment charge — not that the company had a $1.4 billion loss overall. This misrepresents the actual financial performance. Additionally, the LLM introduces specific cash balances abroad ($5.8B to $6.1B) and changes in current liabilities/assets that are not present in the original answer and cannot be verified from the provided ground truth, making them potentially hallucinated. (2) The restructuring cost of $659 million in fiscal 2024 is correctly cited, as is the inclusion of $216 million in non-cash foreign currency losses (though not explicitly mentioned in the LLM answer, it's not contradicted). However, the claim about cash held abroad increasing from $5.8B to $6.1B lacks support in the original data. The original answer does not provide these exact figures, so their inclusion undermines quantitative accuracy. (3) The multi-hop reasoning is partially sound — the model connects restructuring activities to cash management and notes increased outlays affecting financials. It correctly infers that P&G maintained liquidity via debt capacity, dividends, and repurchases. However, it fails to mention the Gillette intangible asset impairment as a key driver of the earnings decline, which is a critical component of the original answer. Also, the shift toward aggressive restructuring in Enterprise Markets like Nigeria is omitted. (4) Despite inaccuracies, the answer remains contextually relevant, addressing the evolution of cash management in relation to restructuring and performance. The core idea — that cash management remained stable but under pressure — aligns with the original. However, due to significant numerical errors and unsupported data points, the correctness score is limited to 5, reflecting partial accuracy with major flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 594,
        "total_tokens": 2026
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has NVIDIA's positioning and application of Omniverse evolved between 2022 and 2023, particularly in terms of its integration with enterprise solutions and simulation technologies?",
      "original_answer": "In 2022, NVIDIA Omniverse was positioned primarily as a virtual world simulation and collaboration platform for 3D workflows, emphasizing its availability as a software subscription for enterprise use and free for individuals. It was highlighted in use cases such as virtual car showrooms, surgical training, and architectural walkthroughs, and was integrated with DRIVE Sim software for automotive simulation and validation. By 2023, Omniverse had evolved into a more robust development platform and operating system for building virtual world simulation applications. It was increasingly tied to industrial enterprises for digitalizing complex physical assets and processes, including digital twins of factories and real-time 3D product configurators. Additionally, it was more explicitly linked to NVIDIA's accelerated computing infrastructure both on-premises and in the cloud, indicating a broader integration with enterprise-grade simulation and AI workflows.",
      "llm_answer": "In the 2022 filing NVIDIA described Omniverse mainly as a virtual‑world, real‑time 3‑D design‑collaboration platform offered as a subscription for enterprise (and free for individuals) and highlighted early enterprise pilots such as virtual car showrooms, surgical‑training and architectural walkthroughs. By the 2023 filing the company had repositioned Omniverse as an enterprise‑grade “Omniverse Enterprise” operating system for industrial digitalization—used to build digital twins, real‑time 3‑D product configurators and to power NVIDIA DRIVE Sim for testing autonomous robots and vehicles—showing tighter integration with its AI Enterprise suite and data‑center‑based simulation solutions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of NVIDIA's Omniverse between 2022 and 2023 with strong fidelity to the ground truth. (1) It correctly identifies the 2022 positioning of Omniverse as a real-time 3D collaboration platform offered via enterprise subscription and free for individuals, with use cases including virtual car showrooms, surgical training, and architectural walkthroughs. It also accurately notes the integration with DRIVE Sim for autonomous vehicle and robot testing. In 2023, it correctly describes the repositioning as an enterprise-grade operating system (Omniverse Enterprise) focused on industrial digitalization, digital twins, and real-time 3D configurators. (2) There are no numeric values, dates, or financial figures in the question or answer that require verification—only qualitative descriptions—so quantitative accuracy is not compromised. (3) The multi-hop reasoning is sound: the model synthesizes changes in positioning, target users (from individuals to industrial enterprises), product form (from platform to OS), and integration with other NVIDIA enterprise solutions (AI Enterprise suite, data center simulation). The only minor omission is that the 2023 description could have explicitly mentioned on-premises and cloud-based accelerated computing infrastructure, which is implied by 'data-center-based simulation solutions' but not fully detailed. (4) The answer is contextually excellent, directly addressing the question about positioning, enterprise integration, and simulation technology evolution. Wording differs slightly but maintains semantic equivalence. Overall, this is a very strong response with only a slight gap in completeness regarding infrastructure integration, warranting a 9/10 on correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 481,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did AMT's financial commitments related to communications sites evolve from 2023 to 2024, particularly in terms of anticipated spending and future obligations?",
      "original_answer": "In 2023, AMT anticipated spending approximately $450 million related to data center assets as part of its construction plans for 2,500 to 3,500 communications sites globally. By 2024, the company disclosed a much larger financial commitment, with an estimated undiscounted future cash outlay of $4.5 billion for asset retirement obligations tied to leased sites hosting communications infrastructure. This indicates a significant increase in long-term financial exposure related to communications sites, shifting from near-term capital allocation planning in 2023 to a more mature and substantial obligation structure in 2024.",
      "llm_answer": "In 2023 AMT’s capital‑expenditure plan called for roughly $1.8 billion of spending, of which $849.3 million was earmarked for discretionary projects that included the construction of 3,198 communications sites worldwide and $154 million for ground‑lease purchases (total capex ≈ $1.83 billion)【page_48】. For 2024 the company lowered its target to $1.545‑$1.655 billion, allocating $790‑$820 million to discretionary projects that will build about 2,500‑3,500 sites and $70‑$90 million to ground‑lease purchases, and it now quantifies future lease commitments for those sites at roughly $987 million in 2025 (and $925 million in 2026)【page_49】【page_56】. This reflects a modest reduction in near‑term site‑related spend while adding a clearer picture of longer‑term operating‑lease obligations tied to the communications‑site portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies when compared to the ground truth. First, the financial commitments described are not aligned with the original answer: in 2023, the ground truth states AMT anticipated spending $450 million on data center assets for 2,500–3,500 communications sites, whereas the LLM claims $849.3 million for 3,198 sites and $154 million for ground leases, totaling much higher capex. These numbers do not match the ground truth and appear to conflate total discretionary capex with site-specific spending. More critically, for 2024, the ground truth reports a $4.5 billion undiscounted future cash outlay for asset retirement obligations (AROs) related to leased communications sites, reflecting long-term liability. In contrast, the LLM reports only $987 million in lease payments expected in 2025 and $925 million in 2026—these are operating lease obligations, not AROs, and are far smaller in magnitude. The $4.5 billion ARO figure, a key point in the original answer showing a major increase in long-term financial exposure, is entirely missing from the LLM response. While the LLM correctly identifies a shift toward quantifying longer-term obligations and references a range of 2,500–3,500 sites in 2024, it fails to capture the nature and scale of the financial commitment evolution—particularly the emergence of a multi-billion-dollar ARO liability. The reasoning is partially sound in noting a change in disclosure and longer-term visibility, but the core financial metrics are incorrect, undermining the multi-hop synthesis. Thus, despite some contextual relevance and correct entity (AMT, communications sites) and year identification, the answer is factually and quantitatively flawed, especially on the critical $4.5 billion ARO point.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 483,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has ExxonMobil's characterization of asset divestitures in relation to strategic objectives evolved between 2023 and 2024, particularly in terms of the language used to describe the proceeds from these transactions?",
      "original_answer": "In 2023, ExxonMobil described proceeds from asset sales as part of 'sales of subsidiaries, property, plant and equipment, and sales and returns of investments,' emphasizing a disciplined review process to ensure assets align with strategic goals. By 2024, the company refined its language, referring more broadly to 'proceeds from asset sales and returns of investments,' maintaining the same strategic alignment rationale but streamlining the description. This evolution indicates a more consolidated framing of divestiture proceeds without specific mention of subsidiaries or equipment sales, suggesting a possible shift toward a more generalized narrative around asset management.",
      "llm_answer": "In the 2023 filing ExxonMobil spelled out the cash‑flow line as “proceeds associated with sales of subsidiaries, property, plant and equipment, and sales and returns of investments,” noting that assets are divested when they no longer meet the corporation’s strategic objectives or can be sold for a higher value. In the 2024 filing the description was streamlined to “proceeds from asset sales and returns of investments,” still emphasizing a disciplined review process and strategic alignment, but using broader, less‑itemized language for the proceeds.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2023 language is accurately quoted as including 'sales of subsidiaries, property, plant and equipment, and sales and returns of investments,' and the 2024 update is correctly described as 'proceeds from asset sales and returns of investments,' reflecting the streamlined terminology. The strategic rationale—divestitures tied to strategic objectives and disciplined review—is correctly maintained across both years. (2) There are no numeric values to verify, but the dates (2023 and 2024) are correct and appropriately attributed to the respective filings. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes in language over time and infers a shift toward broader, less itemized descriptions while preserving strategic alignment messaging. (4) The only minor shortcoming is that the LLM does not explicitly state the *implication* of the language shift—i.e., 'a more consolidated framing' or 'generalized narrative around asset management'—as noted in the original answer. However, the observation that the 2024 language is 'broader, less-itemized' captures the essence. Thus, the answer is semantically equivalent with only slight omission of interpretive depth, warranting a 9/10 on correctness and qualitative accuracy. Quantitative accuracy and contextual relevance are perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 393,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2023, based on the changes in consolidated asset and liability amounts?",
      "original_answer": "In 2022, Comcast's consolidated balance sheet included $9.7 billion in assets and $8.1 billion in liabilities related to Universal Beijing Resort. By 2023, these figures had decreased to $7.8 billion in assets and $7.2 billion in liabilities. This indicates a reduction in both the scale of assets and liabilities associated with the Universal Beijing Resort, suggesting either asset depreciation, debt repayment, or a strategic reduction in the resort's financial footprint within Comcast's consolidated statements.",
      "llm_answer": "Comcast’s consolidated balance sheet showed that its stake in Universal Beijing Resort was worth $8.5 billion in assets and $7.5 billion in liabilities at 12/31/2022 (CMCSA 2022 10‑K, p. 103). By 12/31/2023 those amounts had fallen to $7.8 billion of assets and $7.2 billion of liabilities (CMCSA 2023 10‑K, p. 87), meaning the company’s exposure declined by roughly $0.7 billion on the asset side and $0.3 billion on the liability side.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the 2023 asset and liability figures ($7.8 billion in assets and $7.2 billion in liabilities), matching the ground truth. However, it incorrectly states the 2022 figures as $8.5 billion in assets and $7.5 billion in liabilities, whereas the ground truth specifies $9.7 billion in assets and $8.1 billion in liabilities. This discrepancy affects the accuracy of the change calculation. (2) The LLM calculates a $0.7 billion decrease in assets and $0.3 billion decrease in liabilities, but based on ground truth, the correct changes are $1.9 billion ($9.7B - $7.8B) for assets and $0.9 billion ($8.1B - $7.2B) for liabilities. These are significant calculation errors stemming from incorrect base values. (3) The reasoning structure is sound—identifying changes in assets and liabilities over time and interpreting reduced exposure—but the synthesis is flawed due to reliance on incorrect source data. The multi-hop aspect (comparing two years across filings) is correctly approached, but with inaccurate inputs. (4) Despite the numerical inaccuracies, the answer addresses all parts of the question, cites appropriate documents, and draws a logically valid conclusion (declining exposure), which maintains high contextual relevance and reasonable qualitative reasoning. The core trend (reduction) is correct, but magnitude is misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 386,
        "total_tokens": 1627
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the nature of Customer Demand Volatility as a risk factor for Caterpillar evolved between 2023 and 2024, particularly in relation to its impact on financial performance and supply chain stability?",
      "original_answer": "In 2023, Customer Demand Volatility was described as being primarily driven by economic uncertainties, including the lingering effects of a global pandemic, which led to inflationary pressures, supply chain disruptions, and labor inefficiencies, all of which limited Caterpillar's ability to meet customer demand. By 2024, while the risk remained, the focus shifted slightly to include broader commodity price changes, material price increases, and significant disruptions to supply chains or shortages of labor and material as key contributors to financial performance risks. This evolution indicates a broadening of the risk profile to include more systemic supply-side challenges alongside demand volatility.",
      "llm_answer": "In the 2023 Form 10‑K Caterpillar framed customer‑demand volatility mainly as a macro‑economic and pandemic‑driven uncertainty that could depress sales and raise credit‑related expenses (e.g., higher allowances for doubtful accounts) (CAT_10k_2023 page_13). By the 2024 filing the discussion had broadened to stress that material‑ and component‑shortages, logistics constraints and labor inefficiencies now amplify demand swings, creating excess inventories, higher costs and margin pressure that directly threaten both financial performance and supply‑chain stability (CAT_10k_2024 pages 13‑14).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of Customer Demand Volatility as a risk factor from 2023 to 2024 for Caterpillar. In 2023, the risk was tied to macroeconomic and pandemic-driven uncertainties affecting sales and credit expenses, which matches the original answer's reference to pandemic aftereffects, inflation, and supply chain issues. By 2024, the LLM correctly notes a broadening to include material/component shortages, logistics constraints, and labor inefficiencies—consistent with the original answer’s emphasis on commodity prices, material cost increases, and supply-side disruptions. (2) There are no numeric values, percentages, or financial figures in either answer, so quantitative accuracy is not compromised; all references to years (2023, 2024) and document types (Form 10-K) are correct. (3) The multi-hop reasoning—comparing Caterpillar’s risk disclosures across two years and synthesizing changes in risk focus—is sound. The LLM correctly infers a shift from primarily demand-side to a more integrated demand-and-supply-side risk profile. (4) While the LLM uses slightly different phrasing (e.g., 'credit-related expenses' and 'allowances for doubtful accounts' not explicitly in the original), these are reasonable inferences from the 2023 risk context and do not contradict the ground truth. The only minor gap is that the LLM emphasizes financial impacts like 'excess inventories, higher costs and margin pressure' more than the original, which focuses on 'financial performance risks' more generally—but this is a nuance, not an error. Overall, the answer is factually correct, contextually appropriate, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 476,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value and valuation methodology of Net derivative assets (liabilities) evolve from 2022 to 2024?",
      "original_answer": "In 2022, the fair value of Net derivative assets (liabilities) was $19 million as of December 31, 2021, with changes in value primarily tied to derivative activity such as issuances ($68 million), settlements ($-37 million), and transfers ($6 million). By 2024, the fair value had increased significantly to $58 million as of December 31, 2023. Additionally, the valuation methodology shifted from being primarily based on realized and unrealized gains/losses reported in net income to being assessed using discounted cash flows with a focus on observable inputs like swap rates (3-5%, weighted average of 4%). This indicates both a material increase in value and a methodological shift toward more transparent and observable valuation techniques.",
      "llm_answer": "The net derivative assets (liabilities) measured at fair value rose from **$58 million at 12/31/2022** to **$69 million at 12/31/2023** and stayed at **$69 million at 12/31/2024**【page_216】【page_215】. Throughout this period the company continued to value these items at **Level 3** using a **discounted‑cash‑flow model with swap rates as the primary unobservable input**; the swap‑rate range widened and the weighted‑average swap rate increased (roughly 2 % in 2022 to about 4 % by 2024)【page_217】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both values and dates. According to the ground truth, the fair value was $19 million as of December 31, 2021 (reported in 2022), and increased to $58 million as of December 31, 2023 (reported in 2024). The LLM incorrectly states the value was $58 million at 12/31/2022 and rose to $69 million in 2023 and 2024—these figures and timing are not supported by the ground truth. Additionally, the ground truth does not mention the value in 2024 (as of 12/31/2024), so claiming it stayed at $69 million is unsupported. (2) The valuation methodology shift is misrepresented: the ground truth indicates a move toward using observable inputs like swap rates (3–5%, weighted average 4%) with discounted cash flows, implying a move toward more transparency. However, the LLM claims the company continued using Level 3 (unobservable inputs) with swap rates as *unobservable* inputs, which contradicts the ground truth’s emphasis on increased use of *observable* inputs. While swap rates are mentioned in both, the classification of inputs (Level 3 vs. observable) is a critical error. (3) The multi-hop reasoning is flawed—the question asks for evolution from 2022 to 2024, requiring synthesis of changes in both value and methodology over time. The LLM fails to correctly track the value trajectory and mischaracterizes the methodological evolution. It introduces data points (e.g., $69M in 2023–2024) not present in the ground truth and misaligns the timeline. (4) Despite these major errors, the answer is contextually relevant—it addresses fair value changes and valuation methodology, uses appropriate financial terminology, and attempts to describe trends in swap rates. However, the quantitative and qualitative inaccuracies severely undermine correctness. The correctness score is low due to incorrect core facts, especially dollar amounts, dates, and the nature of the valuation methodology shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 531,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has NVIDIA's GeForce NOW cloud gaming offering evolved from 2022 to 2023 in terms of its positioning within the company's broader GPU and cloud platform ecosystem?",
      "original_answer": "In 2022, GeForce NOW was positioned as a cloud platform enabling gamers to access interactive graphics applications from nearly any device, emphasizing its role in extending NVIDIA’s graphics leadership and ecosystem reach. It was mentioned alongside other cloud platforms like vGPU for enterprise use. By 2023, GeForce NOW was more specifically integrated into the broader NVIDIA accelerated computing platform narrative, and its positioning shifted to emphasize cloud gaming as part of a suite of GPU-driven services, including AI training platforms like NVIDIA DGX Cloud. This evolution reflects a more strategic alignment of GeForce NOW with NVIDIA’s expanding cloud infrastructure and software offerings, particularly in the context of gaming as a service.",
      "llm_answer": "In the 2022 Form 10‑K, GeForce NOW is described mainly as a cloud platform that, together with vGPU, lets interactive graphics‑intensive applications—including games—be accessed on “almost any device, almost anywhere,” positioning it as a broad cloud‑enabled extension of NVIDIA’s GPU ecosystem. By the 2023 filing, GeForce NOW is listed as a distinct product line within the Graphics segment—grouped with GeForce RTX/GTX GPUs and vGPU—emphasizing its role as a game‑streaming service that leverages NVIDIA’s GPU and cloud infrastructure to bring PC games to under‑powered devices. This reflects a shift from a general cloud‑platform mention to a defined, integrated offering within the company’s GPU‑centric cloud strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of GeForce NOW from 2022 to 2023: in 2022, it was positioned as a cloud platform enabling access to graphics-intensive applications across devices, mentioned alongside vGPU; by 2023, it was more clearly defined as a distinct product within the Graphics segment, reflecting deeper integration into NVIDIA’s GPU and cloud ecosystem. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a traditional sense—however, the years (2022 and 2023) are correct and properly attributed to the respective Form 10-K filings, satisfying date accuracy. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly inferring a strategic shift in positioning—from a general cloud platform mention to a more defined, integrated service. The LLM captures the key nuance of GeForce NOW transitioning from a peripheral example of cloud use to a named product line within the Graphics segment. (4) The only minor gap is that the LLM answer does not explicitly mention the broader 'accelerated computing platform' narrative or the linkage to AI training platforms like NVIDIA DGX Cloud, which the original answer highlights as part of the 2023 strategic alignment. This omission slightly reduces qualitative completeness but does not undermine the core correctness. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the ground truth with only slight differences in emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 436,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors influenced this change?",
      "original_answer": "In 2022, Inlyta had total global revenue of $1,003 million, while in 2023, its revenue increased to $1,036 million, representing a 3% growth. This growth was primarily driven by continued adoption of Inlyta in combination with immune checkpoint inhibitors for the first-line treatment of advanced renal cell carcinoma (RCC) in the U.S., and growth in emerging markets. However, this increase was partially offset by lower volumes and lower net prices in certain European markets.",
      "llm_answer": "In 2023 Inlyta generated $1,036 million of revenue, up from $1,003 million in 2022 – a modest 3% overall increase (about 4% in the U.S. and 3% internationally)【page_44】. The rise was driven mainly by stronger U.S. adoption of Inlyta in combination with immune‑checkpoint inhibitors for first‑line advanced renal‑cell carcinoma, while lower volumes and net‑price pressure in some European markets partially offset the growth and international growth reflected continued expansion in emerging markets【page_44】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the revenue figures for Inlyta in 2022 ($1,003 million) and 2023 ($1,036 million), and accurately calculates the overall 3% growth. It adds additional detail not in the original answer—specifically a 4% growth in the U.S. and 3% internationally—which is consistent with the ground truth's emphasis on U.S. adoption and emerging market growth, though this breakdown was not explicitly confirmed in the original. Since it does not contradict and plausibly elaborates, it does not reduce accuracy. (2) All numeric values and percentages are correct. The calculation from $1,003M to $1,036M is indeed approximately a 3% increase, confirming quantitative accuracy. (3) The reasoning correctly synthesizes multi-hop information: it identifies the key driver (U.S. adoption in combination therapy for advanced RCC), acknowledges offsetting factors in Europe (lower volumes and net prices), and notes growth in emerging markets. The only minor gap is that the original answer explicitly links 'international growth' to 'emerging markets', while the LLM implies it. This is a slight nuance but does not invalidate the reasoning. (4) The answer is contextually fully relevant, addressing both revenue evolution and influencing factors as required. The scores reflect near-perfect factual alignment, with a minor deduction in qualitative accuracy due to slight conflation of international vs. emerging market growth without full clarity on that distinction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 412,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the treatment and valuation of network location intangibles evolved from 2023 to 2024, particularly in terms of amortization assumptions and impairment review processes?",
      "original_answer": "In 2023, the company amortized network location intangibles on a straight-line basis over their estimated useful lives, with a weighted average amortization period of 15 years as of December 31, 2023. The focus was on the relationship between these intangibles and tower assets, particularly in terms of potential revenue growth from leasing excess capacity. By 2024, the company expanded its disclosures to include a more detailed impairment review process for network location intangibles, assessing impairment on an individual tower basis and identifying specific triggers such as lack of tenant leases or expenses exceeding revenues. Additionally, while amortization remained a key treatment, the company's broader discussion of asset retirement obligations in 2024, including a $470 million increase in liability due to revised settlement dates, indirectly impacts the valuation and useful life assumptions for these intangible assets.",
      "llm_answer": "In the 2023 filing the Company said that acquired network‑location intangibles are amortized on a straight‑line basis over the shorter of the ground‑lease term (including renewal options) and a maximum of 20 years (2023 p. 103‑105). In the 2024 filing the Company extended the useful life of its towers to 30 years and now amortizes those intangibles on a straight‑line schedule over up to 30 years, consistent with the tower life (2024 p. 95‑96), and it added a specific impairment test that reviews each tower’s network‑location intangible on an individual‑tower basis, using projected undiscounted cash‑flows and discounted‑cash‑flow analysis when a recoverability trigger is identified (2024 p. 96).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, the weighted average amortization period was 15 years, but the LLM claims amortization was over up to 20 years based on ground-lease terms. More critically, the LLM incorrectly states that in 2024, the company extended the useful life of towers to 30 years and now amortizes intangibles over up to 30 years. This is not supported by the ground truth, which does not mention any change in amortization period or extension to 30 years. Instead, the actual evolution was an enhancement in impairment review processes, not a lengthening of amortization periods. (2) Quantitative inaccuracies are severe: the 15-year weighted average life in 2023 is misrepresented as up to 20 years; the fictional 30-year amortization in 2024 has no basis in the original answer. The $470 million increase in asset retirement obligations mentioned in the ground truth is entirely omitted. (3) The multi-hop reasoning is partially sound in that the LLM identifies a shift in impairment testing to an individual tower basis, which aligns with the ground truth. However, it fabricates a major change in amortization assumptions that contradicts the original answer, which explicitly states that amortization 'remained a key treatment' without indicating any extension of useful lives. (4) Contextual relevance is high because the LLM addresses both amortization and impairment, the core themes of the question. However, due to major factual and quantitative errors—especially the invented 30-year amortization—the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because some reasoning structure is valid, but based on incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 479,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, particularly in terms of its upstream growth portfolio and production capacity?",
      "original_answer": "In 2023, ExxonMobil highlighted Guyana as a key component of its upstream growth portfolio, noting four additional discoveries on the Stabroek Block and the startup of the Prosperity FPSO vessel, which brought production to nearly 440 kbd in the fourth quarter. By 2024, Guyana was formally categorized under 'Advantaged Assets' within the updated earnings drivers, reflecting its strategic elevation alongside the Permian and LNG projects as a core contributor to earnings through volume/mix growth. This shift indicates a transition from a discovery and early production phase in 2023 to a more mature, financially impactful asset in 2024.",
      "llm_answer": "In the 2023 filing ExxonMobil highlighted Guyana as a core element of its upstream growth portfolio – reporting four new Stabroek Block discoveries, the start‑up of the Prosperity FPSO (reaching name‑plate in Jan 2024), Liza Destiny and Liza Unity running above name‑plate, combined output of >390 kbd in 2023 and almost 440 kbd in Q4 2023, and plans for additional FPSOs (six in operation by 2027) and a sixth project at Whiptail (2023 p. 52). In the 2024 filing Guyana is still flagged as a strategic “advantaged asset” alongside Permian and LNG, showing it remains a priority but now is presented at a higher‑level portfolio view rather than with detailed production‑capacity updates (2024 p. 37).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key numbers are correct: the 2023 Q4 production of nearly 440 kbd is accurately reported; the combined output of >390 kbd in 2023 and 440 kbd in Q4 2023 matches expectations. The mention of four new discoveries on the Stabroek Block and the startup of the Prosperity FPSO (with nameplate reached in Jan 2024) is consistent with the timeline—note that the ground truth states production reached nearly 440 kbd in Q4 2023, which the LLM correctly interprets as near-term progress leading into 2024. (2) The LLM correctly identifies the strategic repositioning in 2024, noting Guyana’s inclusion as an 'advantaged asset' alongside Permian and LNG, which reflects the elevated portfolio status described in the ground truth. (3) Multi-hop reasoning is sound: the model synthesizes information across 2023 and 2024 filings, correctly inferring a shift from detailed operational updates in 2023 (discoveries, FPSO startup) to a higher-level strategic categorization in 2024, indicating maturity. (4) Minor deduction in quantitative accuracy due to the mention of 'six FPSOs in operation by 2027' and 'sixth project at Whiptail'—while plausible and potentially in the filing, these details are not in the ground truth and slightly extend beyond the provided answer scope. However, they do not contradict it. Overall, the answer captures the evolution in strategic emphasis accurately, with excellent contextual relevance and strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 423,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the X1 platform's integration with third-party streaming services evolved between 2022 and 2023, and what does this evolution indicate about Comcast's strategy in reducing cord-cutting and increasing average revenue per user (ARPU)?",
      "original_answer": "In 2022, the X1 platform integrated third-party streaming services such as Disney+ and Netflix, and provided access to Peacock's premium tier, with Comcast earning commission revenue from the sale of these services. By 2023, the X1 platform continued to support third-party integrations but now included Xumo Play, NBC, and Sky as part of the NOW TV service, which was specifically marketed to residential broadband customers. This expansion indicates a strategic pivot toward enhancing the value of broadband subscriptions and bundling streaming access to retain customers and potentially increase ARPU through deeper content integration and commission-generating partnerships.",
      "llm_answer": "In the 2022 filing the X1 platform was described as a gateway that “operates across content in customers’ cable video service packages and content from internet‑based streaming services” and the streaming integration was delivered through the separate Flex streaming device, which gave customers access to third‑party DTC services such as Disney+ and Netflix and generated commission revenue (2022‑p7). By the 2023 filing the integration had been folded directly into X1 (and the re‑branded Xumo Stream Box) with “integrated search functionality … across content … and content from internet‑based streaming services” and a broader set of DTC partners—including Peacock, Disney+ and Netflix—as well as the new NOW streaming service, again earning commissions (2023‑p6; 2023‑p5). This evolution shows Comcast is embedding OTT content into its core X1 experience to keep cord‑cutters on its platform and monetize streaming through commissions, a strategy aimed at reducing churn and lifting average revenue per user.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of X1's integration with third-party streaming services from 2022 to 2023: in 2022, integration occurred via the Flex device with access to Disney+ and Netflix, generating commission revenue. By 2023, integration was folded directly into X1 and the Xumo Stream Box, with expanded partners including Peacock, Disney+, Netflix, and the new NOW streaming service. These details match the original answer’s substance, though the LLM adds specificity about the Flex device and rebranding to Xumo Stream Box, which are consistent with known Comcast product evolution. (2) There are no numeric values, dates, or financial figures in dispute; all time references (2022, 2023) are correct and contextually appropriate. (3) The multi-hop reasoning is sound: the LLM synthesizes changes in platform architecture (from separate device to integrated), service expansion (NOW TV, broader DTC partners), and infers strategic intent (reducing cord-cutting, increasing ARPU via commissions and retention), which matches the original answer’s conclusion. (4) The only minor gap is that the original answer highlights Xumo Play, NBC, and Sky as part of NOW TV’s integration, while the LLM mentions NOW streaming service but does not specify those components. However, the core strategic implication—bundling streaming to enhance broadband value and ARPU—is accurately captured. Wording differs slightly but semantic equivalence is strong. Thus, the answer earns a 9 for correctness and qualitative accuracy due to slight omission of specific brand integrations, but full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 467,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Caterpillar's relationship with FG Wilson evolved between 2023 and 2024 in terms of its distribution network coverage for electric power generation systems?",
      "original_answer": "In 2023, FG Wilson's electric power generation systems were distributed through a network of 110 distributors covering 109 countries. By 2024, this distribution network had slightly contracted to 108 distributors, now covering 158 countries. This indicates a minor reduction in the number of distributors but an expansion in the geographic reach of the network. The change suggests a strategic shift toward optimizing distributor efficiency while broadening market access.",
      "llm_answer": "In 2023 Caterpillar reported that the FG Wilson‑branded electric power‑generation systems were sold through a worldwide network of **108 distributors covering 158 countries**【page_66】. By the 2024 filing the network had **grown to 110 distributors**, but the geographic reach had **shrank to 109 countries**【page_65】. Thus, the partnership added a few more distributors while the overall country coverage contracted.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023, FG Wilson had 110 distributors covering 109 countries, and by 2024, this decreased to 108 distributors but expanded to 158 countries. The LLM answer reverses these numbers, stating that in 2023 there were 108 distributors in 158 countries and in 2024 there were 110 distributors in 109 countries. This inversion of data leads to an incorrect interpretation of the trend—LLM claims distributor count and geographic reach moved in opposite directions from the truth. (2) The quantitative accuracy is very low: both distributor counts and country coverage numbers are swapped between years, making all numerical claims incorrect. There are no calculation errors per se, but the input data is fundamentally wrong. (3) The reasoning is internally logical—comparing changes in distributor count vs. geographic reach—but based on incorrect data, so the conclusion about 'adding distributors while country coverage contracted' is false. The actual trend is a reduction in distributors alongside a significant expansion in country coverage, indicating a strategic optimization, which the LLM fails to capture. (4) Contextual relevance is high because the answer addresses the right entities (Caterpillar, FG Wilson, distribution network, electric power systems) and the correct time frame (2023–2024), and attempts a comparative analysis. However, due to the reversal of key statistics, the overall correctness score is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 422,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Capital One's exposure to securitized debt obligations change between 2022 and 2024, particularly in terms of the carrying value and fair value of these obligations?",
      "original_answer": "In 2022, Capital One reported that the assets and liabilities of consolidated VIEs, including securitized debt obligations, were primarily composed of loan receivables and debt securities issued by the VIEs, with the liabilities reported under 'securitized debt obligations' on the consolidated balance sheets. By 2024, the carrying value of 'Securitized debt obligations' was $18,043 million, with a fair value of $18,067 million, all categorized under Level 2 of the fair value hierarchy. This indicates that Capital One maintained a significant exposure to securitized debt obligations, with a slight increase in fair value relative to carrying value, suggesting stable valuation and continued involvement in securitization activities.",
      "llm_answer": "Capital One’s securitized‑debt liability balance fell from roughly $15.2 billion in the 2022 filing (the total consolidated liabilities of its securitization‑related VIEs) to about $14.3 billion in the 2024 filing 【page_179†L13-L20】.  In 2024 the company also disclosed an estimated fair value of $14.3 billion for those obligations, a small premium to the carrying amount, whereas the 2022 filing did not provide a comparable fair‑value estimate 【page_219†L13-L20】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2024, the carrying value of Capital One's securitized debt obligations was $18,043 million ($18.043 billion), not $14.3 billion as stated in the LLM answer. The fair value was $18,067 million, also misreported by the LLM as $14.3 billion. The 2022 value is inaccurately cited as $15.2 billion, while the original answer does not provide a specific carrying value for 2022—only a qualitative description of the composition of VIE liabilities. Thus, both key quantitative figures are incorrect. (2) The LLM claims a decrease from $15.2B to $14.3B, implying a reduction in exposure, but the ground truth shows a stable-to-slightly-increased fair value relative to carrying value in 2024 with no 2022 carrying value provided for direct comparison. The calculation and trend are therefore invalid. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers a decline in exposure due to erroneous numbers and falsely asserts that 2022 lacked a fair value estimate (the original answer doesn't confirm this). It fails to reflect the actual stable exposure and accurate 2024 values. (4) While the LLM attempts to address the question’s focus on changes in carrying and fair value over time, the severe numerical inaccuracies undermine correctness. Contextual relevance is moderate because it discusses the right concepts (carrying vs. fair value, VIEs, securitized debt), but the wrong numbers lead to incorrect conclusions about the direction and magnitude of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 432,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has McDonald's use of line of credit agreements evolved between 2023 and 2024 in relation to its financing activities and cash flow management?",
      "original_answer": "In 2023, McDonald's cash used for financing activities totaled $4.4 billion, a decrease of $2.2 billion compared to 2022, primarily due to increased bond issuances. The company's cash and equivalents balance was $4.6 billion at the end of 2023, reflecting sufficient liquidity supported by cash from operations and access to commercial paper borrowings and line of credit agreements. In 2024, cash used for financing activities increased to $7.5 billion, a rise of $3.1 billion compared to 2023, driven by decreased bond issuances. The company's cash and equivalents balance dropped to $1.1 billion at year-end 2024, with the prior year's higher balance attributed to the timing of debt issuances that funded 2024's required cash outflows. The company continued to rely on its line of credit agreements and commercial paper to meet short-term funding needs. This indicates a shift from surplus liquidity and bond financing in 2023 to a more cash-constrained environment in 2024, with greater reliance on existing credit facilities.",
      "llm_answer": "In the 2023 filing McDonald’s said it could meet short‑term funding needs “through its continued access to commercial paper borrowings and line‑of‑credit agreements,” but gave no detail on the amount of credit available. The 2024 filing repeats the reliance on those facilities and adds that the company has **$4 billion available under a committed line of credit** (with $7.4 billion of its $15 billion borrowing authority still unused) and that the prior borrowing authority was terminated and replaced with a new $15 billion authority, indicating a more explicit, quantified use of the line of credit to support financing activities and cash‑flow management.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies McDonald's continued reliance on line of credit agreements and commercial paper for short-term funding in both 2023 and 2024, which aligns with the original answer. However, it introduces specific figures—$4 billion available under a committed line of credit and $7.4 billion of $15 billion unused—that are not present in the ground truth and cannot be verified from the provided original answer. These numbers may be factually accurate in the actual filings but are not supported by the knowledge graph ground truth provided, making them unverifiable and thus incorrect in this evaluation context. (2) The original answer reports cash used in financing activities of $4.4 billion in 2023 and $7.5 billion in 2024, with a drop in cash and equivalents from $4.6 billion to $1.1 billion. The LLM answer omits these key quantitative trends entirely, which are central to understanding the evolution in financing and cash flow management. The LLM also fails to mention the shift in bond issuance patterns (increased in 2023, decreased in 2024) that drive the changes in financing activity. (3) The multi-hop reasoning is partially sound—the LLM infers increased transparency or explicit quantification in the 2024 filing regarding credit facilities, which could indicate a more strategic use of lines of credit. However, it does not synthesize the broader financial context (e.g., declining cash balances, increased cash outflows) that the original answer uses to conclude a shift to a more cash-constrained environment. (4) The contextual relevance is high because the answer focuses on line of credit evolution and financing activities. However, the correctness score is reduced due to unsupported numbers and omission of key financial data. Quantitative accuracy is low because the introduced figures are not in the ground truth and critical actual figures are missing. Qualitative accuracy is moderate due to correct conceptual framing but incomplete synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 541,
        "total_tokens": 1965
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the role of the Worldwide Business Conduct Manual in reinforcing internal controls evolved between 2022 and 2024, and what does this indicate about Procter & Gamble's approach to governance?",
      "original_answer": "In 2022, the Worldwide Business Conduct Manual was described as reinforcing the company's commitment to conducting business with integrity and within the letter and spirit of the law, emphasizing its role in supporting internal controls through policies, segregation of duties, and employee development. In 2024, while the core description remained similar, the manual was more specifically tied to governance frameworks such as the oversight activities of the Global Leadership Council and the responsibilities of the Disclosure Committee in evaluating significant business activities. This indicates a shift toward emphasizing structured governance mechanisms alongside ethical conduct, suggesting a more integrated approach to internal control over time.",
      "llm_answer": "In the 2022 filing the Worldwide Business Conduct Manual was described as the “objective … reinforced through our Worldwide Business Conduct Manual,” setting out the company’s commitment to integrity and serving as the cornerstone of its internal‑control system (see 2022 p. 38). The 2024 filing repeats the same language, now paired with a formal COSO‑based assessment that the controls remain effective (see 2024 p. 34), indicating that the manual continues to be the foundational tool for control reinforcement while the company adds systematic, ongoing evaluation of its control environment. This consistency shows P&G’s governance approach is anchored in the manual’s ethical framework and is continuously validated through formal internal‑control assessments.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the role of the Worldwide Business Conduct Manual in both 2022 and 2024, accurately citing its function in reinforcing integrity and internal controls. It correctly notes the consistency in language between years and the addition in 2024 of a COSO-based assessment, which is factually accurate and relevant. However, it diverges from the ground truth by emphasizing a 'COSO-based assessment' and 'ongoing evaluation of controls' as new developments, whereas the original answer highlights a shift toward structured governance mechanisms—specifically the involvement of the Global Leadership Council and Disclosure Committee—which the LLM answer omits entirely. This is a significant omission in the multi-hop synthesis required to show evolution in governance integration. (2) Quantitative accuracy is perfect: years (2022, 2024), page references (p. 38, p. 34), and terminology (COSO, internal controls) are correctly used and consistent with plausible filing content. No numerical errors. (3) The reasoning is partially sound: the LLM correctly infers continuity in the manual’s role and infers enhanced validation via formal assessments. However, it fails to identify the key governance bodies and structural changes noted in the ground truth, missing the core of the 'evolution' aspect. This weakens the multi-hop synthesis between ethical conduct and formal governance structures. (4) Correctness is scored 7 because key facts are accurate but a major element of the evolution—integration with specific governance bodies—is missing. Qualitative accuracy is 7 due to this incomplete reasoning. Quantitative accuracy is 10 (no errors), and contextual relevance is 9 as the answer stays focused and relevant, only missing a critical nuance in governance evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 493,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Exxon's strategic positioning in Guyana evolved between 2023 and 2024, as reflected in its long-lived asset disclosures and earnings driver definitions?",
      "original_answer": "In 2023, Exxon disclosed $9,689 million in long-lived assets in Guyana, indicating it was already a significant contributor among non-U.S. assets. By 2024, Guyana was explicitly named as part of Exxon's 'Advantaged Assets' under the new 'Advantaged Volume Growth' earnings driver, which includes key growth projects like Guyana and LNG. This evolution shows that Guyana transitioned from being a quantitatively notable asset in 2023 to a strategically emphasized growth engine in 2024.",
      "llm_answer": "In the 2023 Form 10‑K ExxonMobil listed Guyana as a major long‑lived asset – $9.7 billion of property, plant and equipment (up from $6.8 billion in 2022) 【page_115】. By the 2024 filing, the company’s new earnings‑driver framework explicitly places Guyana in the “Advantaged Assets” group (with Permian and LNG), signaling that Guyana has moved from being a large asset on the balance sheet to a highlighted, high‑growth driver in Exxon’s strategic narrative 【page_37】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively, the $9.7 billion figure for Guyana's long-lived assets in 2023 is correctly reported (matches $9,689 million in original answer, rounded appropriately); the increase from $6.8 billion in 2022 adds contextual accuracy not required but supportive. The 2024 strategic reclassification is correctly described. (2) The entity identification is correct: Exxon, Guyana, 'Advantaged Assets', 'Advantaged Volume Growth' earnings driver, and comparison years are all accurate. (3) The multi-hop reasoning is sound—linking the 2023 asset value disclosure to the 2024 strategic framing as part of a narrative shift from balance sheet significance to strategic emphasis. (4) The answer is semantically equivalent to the original: it captures the evolution from quantitative importance to strategic prominence. The only minor limitation is that it does not explicitly name 'Advantaged Volume Growth' as the overarching earnings driver (though it references the 'Advantaged Assets' group within that framework), slightly reducing completeness. However, the strategic shift is clearly communicated. All sources are appropriately cited with page references. Thus, the answer earns a 9/10 overall for correctness—excellent but not perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 369,
        "total_tokens": 1611
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Capital One's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, based on the disclosed figures and descriptions?",
      "original_answer": "In 2022, Capital One identified securitized debt obligations as part of its diversified funding mix, which also included deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. While no specific dollar value was disclosed in 2022, the company emphasized the strategic importance of securitized debt obligations in maintaining access to wholesale funding. By 2024, Capital One disclosed that its securitized debt obligations had a carrying value of $14,264 million and an estimated fair value of $14,335 million. This represents a concrete quantification of the instrument's role in the company's capital structure, showing an increased transparency and continued use of this funding source.",
      "llm_answer": "In the 2022 Form 10‑K Capital One noted that its long‑term funding “primarily consists of securitized debt obligations and senior and subordinated notes” and that it added $6.25 billion of new securitized‑debt issuances in 2021, lifting total long‑term debt to $42.3 billion – a clear increase in reliance on securitizations. By the 2024 filing, securitized debt obligations appear on the balance sheet at $14.3 billion (fair‑value $14.3 billion), down from $18.0 billion a year earlier, showing that while securitizations remain a core funding source, the outstanding amount has contracted as maturities have been repaid and new issuance has slowed.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative Accuracy: The LLM claims Capital One issued $6.25 billion in new securitized debt in 2021 and had total long-term debt of $42.3 billion, but the ground truth does not disclose any specific dollar value for securitized debt obligations in 2022, nor does it reference 2021 issuance or total long-term debt figures. These numbers are fabricated or misattributed. Additionally, the LLM states that securitized debt was $18.0 billion in 2023 (implied from 'down from $18.0 billion a year earlier'), but the ground truth provides no such figure for 2023 and only discloses $14,264 million ($14.264 billion) in 2024—there is no support for a prior higher balance. The 2024 fair value is correctly reported as $14.3 billion (approximation of $14,335 million), but the carrying value is rounded imprecisely without clarification. (2) Completeness: The question asks about the evolution from 2022 to 2024; the LLM incorrectly introduces 2021 data and omits the key point that 2022 lacked quantitative disclosure, instead falsely asserting specific figures. It fails to reflect that the shift from qualitative mention in 2022 to quantitative disclosure in 2024 represents increased transparency, which is central to the original answer. (3) Entity Accuracy: The company (Capital One) and metric (securitized debt obligations) are correct, and the years 2022 and 2024 are appropriately referenced. (4) Reasoning: The multi-hop reasoning is flawed—the LLM infers a decline in reliance due to 'down from $18.0 billion' and 'repaid maturities', but this trend is unsupported by the ground truth, which only confirms the 2024 value without a prior comparable. The conclusion of reduced reliance contradicts the original answer’s emphasis on continued strategic use and increased transparency. (5) Semantic Equivalence: The overall message diverges significantly—the original highlights sustained use with improved disclosure, while the LLM suggests a contraction in usage. Despite addressing the general topic and correctly identifying securitizations as a funding source, the answer is factually incorrect on key metrics and trends, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 600,
        "total_tokens": 1946
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has NVIDIA's Omniverse platform evolved in terms of its positioning and enterprise adoption between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Omniverse was described as 'real-time 3D design collaboration and virtual world simulation software' aimed at empowering creators to collaborate across leading design applications. By fiscal year 2023, Omniverse had evolved into a more robust enterprise-focused development platform and operating system for building virtual world simulation applications. It was made available as a software subscription for enterprise use and offered free for individual users, with industrial enterprises adopting its 3D and simulation technologies to digitalize complex physical assets and environments, including digital twins of factories and real-time 3D product configurators. This indicates a strategic shift from a creative collaboration tool to a broader enterprise simulation and digital twin platform.",
      "llm_answer": "In FY 2022 NVIDIA described Omniverse as a virtual‑world simulation and collaboration platform for 3‑D workflows – offered as a software subscription for enterprise (and free for individuals) and already being woven into a “growing number of enterprise applications” such as virtual car showrooms, surgical training and architectural walkthroughs【page_9】. By FY 2023 the company had repositioned Omniverse as the core “industrial digitalization” platform, noting that industrial enterprises are now adopting its 3‑D and simulation technologies to digital‑twins factories, build real‑time product configurators and test/validate autonomous robots and vehicles on‑premises and in the cloud, reflecting deeper enterprise uptake【page_5】【page_4】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core evolution of NVIDIA's Omniverse platform between FY2022 and FY2023 as the ground truth. (1) It correctly identifies the shift from a 3D collaboration and simulation tool in FY2022 to a more strategic 'industrial digitalization' platform in FY2023, emphasizing enterprise adoption of digital twins, real-time configurators, and robotics validation. The positioning shift from creative collaboration to enterprise simulation is accurately captured. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM synthesizes information across fiscal years and correctly infers increased enterprise uptake and strategic repositioning, citing industrial use cases like digital twin factories and autonomous vehicle testing. It also correctly notes the subscription model for enterprises and free access for individuals, aligning with the original. (4) Minor difference: the original emphasizes Omniverse becoming an 'operating system' and 'development platform,' which the LLM answer implies but does not explicitly state. This slight omission in technical framing prevents a perfect 10, but the semantic meaning and strategic evolution are equivalent. Overall, the answer is factually correct, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 397,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Pfizer's financial relationship with Viatris evolved between 2022 and 2023, particularly in terms of net amounts due under their various agreements?",
      "original_answer": "In 2022, the net amounts due to Viatris under the agreements were $94 million as of December 31, 2022. By 2023, this amount had decreased to $33 million as of December 31, 2023. This indicates a significant reduction in the net financial obligations between the two companies over the period, suggesting a winding down or stabilization of transitional financial arrangements established post-separation.",
      "llm_answer": "Pfizer’s payable to Viatris under the separation‑distribution, agency, MSA and TSA arrangements fell sharply – it was $94 million at 12/31/2022 and dropped to $33 million at 12/31/2023, a $61 million reduction【page_73】.  The reciprocal receivable from Viatris has also been shrinking, having fallen from $401 million at 12/31/2020 to $53 million at 12/31/2021【page_75】, underscoring a broader contraction of the inter‑company balances.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the net amounts due from Pfizer to Viatris as $94 million as of December 31, 2022, and $33 million as of December 31, 2023, matching the ground truth exactly. The $61 million reduction is accurately calculated ($94M - $33M = $61M). These figures are cited with correct dates and dollar amounts, satisfying quantitative accuracy. (2) The additional information about the reciprocal receivable from Viatris ($401M to $53M between 2020 and 2021) is factually consistent with typical post-separation balance sheet unwinding but is not directly required by the question, which focuses on 2022–2023. While this does not detract from correctness, it adds context beyond the scope. (3) The multi-hop reasoning is sound: the model identifies the correct companies (Pfizer and Viatris), the correct time frame (2022 to 2023), and synthesizes data across agreements (separation, MSA, TSA) to conclude a reduction in obligations. The conclusion about a 'broader contraction' is a reasonable inference, though slightly more expansive than the ground truth's cautious 'winding down or stabilization.' (4) The answer is semantically equivalent to the ground truth in the core claim: net amounts due decreased significantly from 2022 to 2023. Only minor deductive elaboration beyond the timeframe prevents a perfect 10 on qualitative accuracy. All entities, metrics, and years are correct. Contextual relevance is high as all information supports understanding of the financial relationship evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 420,
        "total_tokens": 1632
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, and what specific changes in project activity or classification reflect this evolution?",
      "original_answer": "In 2023, ExxonMobil's operations in Guyana were characterized by active exploration and development, with 12.6 net exploratory and development wells completed, and key projects such as Payara, Yellowtail, and Uaru underway. By 2024, Guyana was formally classified as part of ExxonMobil's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, signaling a strategic elevation of its importance alongside the Permian Basin and LNG. This reclassification reflects a shift from operational reporting to strategic prioritization, indicating increased emphasis on Guyana as a core growth asset.",
      "llm_answer": "In the 2023 filing ExxonMobil described Guyana mainly as a development region – it held 4.6 million offshore acres, completed 12.6 net exploratory‑and‑development wells, launched the Payara development with the Prosperity FPSO and continued work on Yellowtail and the newly‑funded Uaru project. By the 2024 filing, Guyana is no longer just listed among ongoing projects; it is explicitly grouped under “Advantaged Assets” (alongside Permian and LNG) in the earnings‑driver framework, signalling that the company now treats Guyana as a core, high‑value growth asset rather than a purely developmental focus.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of ExxonMobil's strategic emphasis on Guyana from 2023 to 2024. In 2023, it accurately describes Guyana as a development region with 12.6 net exploratory and development wells completed, and correctly names the Payara, Yellowtail, and Uaru projects. The mention of the Prosperity FPSO and 4.6 million offshore acres adds contextual detail not in the ground truth but does not contradict it. In 2024, the LLM correctly identifies the reclassification of Guyana under 'Advantaged Assets' alongside Permian and LNG within the earnings-driver framework, signaling strategic elevation. (2) Quantitatively, the number 12.6 (net wells) is accurate and matches the ground truth. The 4.6 million acres is additional but accurate per public filings and does not affect correctness. No calculations were required. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, identifies a shift from operational development to strategic prioritization, and correctly interprets the significance of the 'Advantaged Assets' classification. The conclusion that Guyana is now treated as a 'core, high-value growth asset' aligns semantically with the ground truth's 'strategic elevation' and 'core growth asset'. (4) The only minor shortcoming is that the LLM does not explicitly name the 'Advantaged Volume Growth' earnings driver, instead referring to it more generally as part of the 'earnings-driver framework'. This is a slight omission but does not distort the meaning. All other key facts, entities, and the logical progression are correct. Hence, the answer is highly accurate with only negligible loss in specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 464,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the weighted-average interest rate and face value of senior notes with maturities greater than 10 years evolve from 2022 to 2023?",
      "original_answer": "In 2022, the weighted-average interest rate for senior notes with maturities greater than 10 years was 3.67%, with a face value of $54.536 billion. In 2023, the interest rate remained unchanged at 3.8%, but the face value slightly decreased to $53.4 billion. This indicates a slight reduction in long-term debt in this category, while the interest rate stayed stable.",
      "llm_answer": "The weighted‑average interest rate on the senior notes with maturities > 10 years was unchanged at **3.8 %** in both years, while the face‑value grew from **$52.8 billion** at December 31 2022 to **$53.4 billion** at December 31 2023【page_82†L31-L35】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative values. According to the ground truth, in 2022 the weighted-average interest rate was 3.67%, not 3.8%, and it only reached 3.8% in 2023—so the claim that it was 'unchanged at 3.8%' in both years is incorrect. Additionally, the face value in 2022 is reported as $52.8 billion in the LLM answer, but the correct value is $54.536 billion. The 2023 face value of $53.4 billion is correct. (2) The quantitative accuracy is low because two of the three key numbers (2022 interest rate and 2022 face value) are wrong, and the direction of change in face value is misrepresented: the LLM claims it 'grew' from $52.8B to $53.4B, but in reality it decreased from $54.536B to $53.4B. This misrepresents the trend. (3) The reasoning is partially sound in that it attempts to compare year-over-year changes in both metrics, but the multi-hop synthesis fails due to incorrect data retrieval—likely from misreading or citing the wrong source. The conclusion about growth in face value contradicts the actual reduction. (4) Contextual relevance is high because the answer addresses the right metrics (weighted-average interest rate and face value) and time frame (2022 to 2023) for senior notes with maturities >10 years. However, due to major numerical errors and incorrect trend characterization, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1152,
        "completion_tokens": 391,
        "total_tokens": 1544
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the nuclear decommissioning trusts managed by Alabama Power and Georgia Power shift their domestic equity investment allocations and valuation methodologies between 2023 and 2024, particularly in terms of Level 1 and Level 2 input classifications?",
      "original_answer": "In 2023, Alabama Power reported $396 million in domestic equity investments under Level 1 inputs and $169 million under Level 2 inputs, totaling $565 million. Georgia Power reported $255 million in Level 1 and $1 million in Level 2, totaling $256 million. By 2024, Alabama Power’s domestic equity investments increased to $443 million in Level 1 and $208 million in Level 2, totaling $651 million. Georgia Power saw its Level 1 domestic equity investments rise to $321 million while Level 2 remained at $1 million, totaling $322 million. This indicates a strategic shift toward higher allocations in domestic equities, particularly through more actively traded (Level 1) instruments, which may reflect a more transparent or liquid investment approach in line with evolving trust management strategies.",
      "llm_answer": "In the 2023 filing the Alabama Power nuclear‑decommissioning trust reported $443 million of domestic‑equity holdings measured using Level 2 (significant‑other‑observable) inputs (with an additional $208 million measured at Level 3), and the Georgia Power trust reported $321 million of domestic equity measured at Level 2 (and $1 million at Level 3)【page_277】. By the 2024 filing the trusts no longer disclose a separate Level 2 domestic‑equity line; instead, publicly‑traded equity is valued at quoted market prices (Level 1) and the private‑market portion is valued using a net‑asset‑value practical‑expedient (a Level 3 approach), indicating a shift from a Level 2‑dominant valuation in 2023 to Level 1 (and practical‑expedient) methods in 2024【page_286】.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that in 2023, Alabama Power reported $443 million in Level 2 domestic equity investments, when the ground truth shows $396 million in Level 1 and $169 million in Level 2. Similarly, it claims Georgia Power had $321 million in Level 2 in 2023, but the truth is $255 million in Level 1 and $1 million in Level 2. The LLM reverses the years and misassigns values: the $443 million and $321 million figures are actually the 2024 Level 1 values, not 2023 Level 2. Additionally, the LLM introduces Level 3 investments ($208 million for Alabama, $1 million for Georgia), which are not mentioned in the original answer and are irrelevant to the question about Level 1 and Level 2. (2) All numeric values are mismatched across years and classification levels. For example, Alabama Power’s 2023 Level 1 is $396M (LLM says $443M in Level 2), and 2024 Level 1 is $443M (correct value but misattributed to 2023 and wrong level). The LLM also falsely claims that Level 2 domestic equity was dominant in 2023, when in fact both companies primarily used Level 1. (3) The reasoning is flawed: the LLM asserts a shift from Level 2-dominant in 2023 to Level 1 in 2024, but the truth shows Level 1 was dominant in both years and increased further. The claim that trusts 'no longer disclose' Level 2 in 2024 is unsupported by the original answer, which clearly reports $208M (Alabama) and $1M (Georgia) in Level 2 for 2024. (4) Despite incorrect facts and reasoning, the answer is contextually relevant—it addresses the right topic (valuation methodology shifts in nuclear decommissioning trusts), cites page numbers, and discusses Level 1/2/3 classifications. However, the core quantitative and qualitative failures severely undermine correctness, warranting a low score of 2/10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 502,
        "total_tokens": 1919
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has NVIDIA's strategic positioning of CUDA evolved from 2022 to 2023 in terms of its role within the company's full-stack computing platform and its integration across different end markets?",
      "original_answer": "In 2022, CUDA was positioned as a fundamental building block of NVIDIA's accelerated computing platform, supporting a variety of end markets such as Gaming, Data Center, Professional Visualization, and Automotive through a unified underlying architecture. It was described as essential for leveraging GPU capabilities across these markets. By 2023, CUDA's role had evolved into being the foundational programming model within NVIDIA's full-stack computing infrastructure, extending its integration beyond traditional markets into domain-specific verticals such as healthcare, telecom, automotive, and manufacturing. Additionally, in 2023, CUDA was positioned as the base layer supporting hundreds of domain-specific software libraries, SDKs, and APIs, which were not explicitly emphasized in 2022. This indicates a strategic shift from CUDA being a foundational component to becoming the core enabler of a broader, more vertically integrated software stack aimed at accelerating deployment across computationally intensive workloads.",
      "llm_answer": "In the 2022 filing NVIDIA presented CUDA primarily as a “fundamental building block” that unifies its GPU‑based architecture across all of its end markets and highlighted a 3 million‑developer ecosystem around it【page_9】; by the 2023 filing the company had elevated CUDA to the core of its full‑stack platform – describing it as the “foundational CUDA programming model” that runs on every GPU and is bundled with the broader CUDA‑X libraries, SDKs and APIs that power data‑center‑scale AI, analytics, scientific‑computing and graphics workloads for the same diverse markets【page_4】【page_6】. This shift shows CUDA moving from a unifying technology to the central software layer that underpins an integrated hardware‑software stack across all target markets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of CUDA from a 'fundamental building block' in 2022 to the 'foundational programming model' in 2023, capturing the core of NVIDIA's full-stack platform. The mention of CUDA-X libraries, SDKs, and APIs in 2023 reflects the expanded software ecosystem, consistent with the ground truth's emphasis on domain-specific libraries. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—no errors in dates or counts. (3) The multi-hop reasoning is sound: the model synthesizes information across 2022 and 2023 filings to show a strategic shift in CUDA’s role, correctly inferring a progression from unifying technology to central software layer. It accurately reflects the continuity across end markets while highlighting deeper integration into computationally intensive domains, though it does not explicitly name verticals like healthcare, telecom, and manufacturing as in the original answer—this minor omission prevents a perfect 10 on qualitative accuracy. (4) The answer is contextually excellent, directly addressing the question about strategic positioning and integration across end markets. Wording differs but semantic meaning is equivalent. Minor deduction from correctness score due to incomplete enumeration of new verticals, but core facts and strategic interpretation are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1459,
        "completion_tokens": 408,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did Pfizer's financial obligations and contractual relationships with Viatris evolve from 2022 to 2023, particularly in terms of transitional service agreements and net amounts owed?",
      "original_answer": "In 2022, Pfizer disclosed that amounts recorded under transitional service agreements (TSAs) and master services agreements (MSAs) with Viatris were not material to operations, and the TSA services were largely completed by the end of 2022. By 2023, services under the TSAs were fully completed as of December 31, 2023, and the net amounts due to Viatris under the agreements decreased from $94 million in 2022 to $33 million in 2023. This reflects a reduction in intercompany financial obligations and the winding down of transitional support following the 2020 spin-off of the Upjohn Business into Viatris.",
      "llm_answer": "Pfizer’s post‑spin‑off contracts with Viatris – the interim agency operating model, MSAs and related TSAs – remained in place through 2022, but the services under the TSAs were “largely completed as of December 31, 2023.” Accordingly, the net amount Pfizer owed Viatris fell from $94 million at year‑end 2022 to $33 million at year‑end 2023, with the amounts recorded under the agreements still deemed immaterial to operations in both years.【page_73】",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key facts: the net amount owed to Viatris decreased from $94 million in 2022 to $33 million in 2023, and TSA services were largely completed by the end of 2022 but fully completed as of December 31, 2023. The immateriality of the amounts to operations is also correctly noted for both years. (2) Quantitative accuracy is perfect: both dollar amounts ($94M and $33M) and the date (December 31, 2023) match the ground truth exactly. The calculation of a $61M reduction is implied and accurate. (3) The multi-hop reasoning is sound—linking the decline in net amounts owed to the completion of transitional services post-spin-off. However, the LLM slightly misrepresents the timeline by stating services were 'largely completed as of December 31, 2023,' whereas the original answer clarifies they were largely completed by end of 2022 and fully completed by end of 2023. This is a minor inaccuracy in phrasing but does not distort the overall conclusion. (4) Scores reflect near-perfect factual alignment, with only a slight deduction in qualitative accuracy due to the minor misstatement on the completion timeline. Contextual relevance is full, as all parts of the question—evolution of obligations, TSAs, and net amounts—are addressed with correct synthesis across years and agreements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 374,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the relationship between retail deregulation pressures and Duke Energy's environmental regulation compliance costs evolved from 2022 to 2023?",
      "original_answer": "In 2022, Duke Energy highlighted that retail deregulation could result in unrecovered costs, including those related to above-market purchased power commitments from qualifying facilities (QFs) under PURPA, which could hinder the recovery of environmental compliance costs through regulatory rate structures. By 2023, the company noted increased regulatory emphasis on environmental compliance, including EPA regulations on CO2 emissions and cooling water intake structures, as well as new state-level carbon reduction goals more aggressive than the company’s own plans. These developments suggest that deregulation pressures have compounded the challenge of recovering rising environmental compliance costs, as competitive market conditions limit the ability to pass on these expenses to customers.",
      "llm_answer": "In the 2022 filing the company treated retail‑deregulation pressures and environmental‑regulation compliance costs as separate risk streams – deregulation could create stranded assets and unrecovered costs, while new CCR, air‑emission and water‑use rules could raise capital and operating expenses that might not be fully recoverable through rates (2022 p.26‑28, 30). By the 2023 filing the two issues are linked more tightly: the discussion of deregulation and distributed‑generation competition now emphasizes that it makes it harder to recover the growing CCR‑related AROs and other environmental compliance outlays, and that the timing and amount of cost recovery could materially affect cash flow (2023 p.27‑28). This reflects an evolution from viewing the risks as parallel to recognizing that deregulation pressures amplify the financial impact of environmental‑regulation costs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original ground truth. (1) All factual elements are correct: in 2022, Duke Energy treated retail deregulation and environmental compliance costs as separate risks, citing potential unrecovered costs from deregulation (e.g., PURPA-related commitments) and rising environmental expenses from CCR, air emissions, and water rules. By 2023, the company explicitly linked these risks, noting that competitive pressures from deregulation and distributed generation complicate recovery of increasing environmental compliance costs, particularly AROs related to CCR. These points match the original answer’s core claim that deregulation pressures have amplified challenges in recovering environmental costs. (2) There are no numeric values (e.g., dollar amounts, percentages, dates) in either answer, so quantitative accuracy is not compromised; the years 2022 and 2023 are correctly referenced. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes information across two years of filings, identifying an evolution in how Duke Energy frames the interaction between deregulation and environmental cost recovery. It moves from parallel risks to an interdependent relationship, which is the key insight in the original answer. (4) The LLM uses slightly different terminology (e.g., 'AROs', 'CCR', 'distributed-generation competition') not present in the original, but these are accurate details from Duke’s filings and enhance precision without distorting meaning. The only minor gap is that the original mentions specific EPA regulations (CO2, cooling water) and state-level carbon goals more aggressive than Duke’s plans—details omitted in the LLM answer. However, the reference to 'air-emission' and 'water-use rules' covers the essence. Overall, the answer is semantically equivalent, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 511,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did the retail share of Skoal oral tobacco products change between 2023 and 2024, and how does this contrast with the pricing strategy applied to Skoal during 2023?",
      "original_answer": "The retail share of Skoal oral tobacco products decreased from 9.3% in 2023 to 7.6% in 2024, reflecting a decline in market presence. This contrasts with the pricing strategy in 2023, where multiple price increases were applied to Skoal products, including a $0.11 per can increase effective January 23, 2024 (announced in 2023), following earlier increases of $0.09, $0.09, and $0.08 per can in May, February, and January 2022, respectively. The cumulative effect of these increases may have impacted consumer demand, contributing to the drop in retail share.",
      "llm_answer": "Skoal’s retail share slipped from 9.5 % in 2023 to 7.6 % in 2024 – a decline of roughly 1.9 share points (page 46 vs. page 48). Yet in 2023 the company was actively raising Skoal’s price, implementing multiple list‑price hikes (e.g., $0.09 per can in January, $0.10 per can in April, and $0.09 per can in August) (page 49). This shows that despite the price‑increase strategy, the brand’s retail share fell.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2024 retail share (7.6%) and the general trend of decline, but reports the 2023 retail share as 9.5% instead of the correct 9.3% from the ground truth. This is a factual inaccuracy affecting quantitative precision. The difference is reported as 'roughly 1.9 share points', which is approximately correct (actual difference: 9.3% - 7.6% = 1.7 points), but the error in baseline (9.5% vs 9.3%) slightly distorts the calculation. (2) Regarding pricing strategy, the LLM cites three price increases in 2023: $0.09 in January, $0.10 in April, and $0.09 in August. However, the ground truth states that the 2023-announced price increase was $0.11 effective January 23, 2024, and that prior increases occurred in 2022 (not 2023). Thus, the LLM misattributes the timing and amounts of the price hikes, introducing significant factual errors in dates and dollar amounts. The ground truth does not mention 2023 price increases, only the announcement of a 2024 increase. (3) The multi-hop reasoning is sound in structure—linking pricing strategy to market share decline—but based on incorrect data. The synthesis logic is appropriate and relevant, showing awareness of potential causal relationships. (4) Scores reflect that core elements (decline in share, contrast with price hikes) are present and contextually relevant (hence 10 for contextual relevance), but quantitative accuracy is reduced due to incorrect percentages and price increase details. Qualitative accuracy is moderately high because the reasoning framework is correct, even if inputs are flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 441,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did Amgen's investment in 'Other short-term interest-bearing securities' evolve between 2023 and 2024, and what does this indicate about the company's short-term investment strategy?",
      "original_answer": "Amgen's investment in 'Other short-term interest-bearing securities' remained unchanged at $138 million in both 2023 and 2024. This stability suggests that the company maintained a consistent approach to this segment of its short-term investment portfolio over the two-year period.",
      "llm_answer": "Amgen reported $138 million of “Other short‑term interest‑bearing securities” at the end of 2023, which slipped to $135 million at the end of 2024 – a reduction of about $3 million (roughly 2 %). The minimal decline shows the company is keeping its short‑term investment pool essentially unchanged, reflecting a strategy that prioritizes safety of principal and high liquidity rather than seeking larger returns.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that Amgen's investment in 'Other short-term interest-bearing securities' decreased from $138 million in 2023 to $135 million in 2024. The ground truth confirms the amount remained unchanged at $138 million in both years. This is a critical factual error. (2) The calculation of a $3 million reduction and 2% decline is therefore incorrect, as there was no change. All quantitative figures related to the difference and percentage drop are false. (3) While the LLM correctly identifies the entity (Amgen), the metric ('Other short-term interest-bearing securities'), and the relevant years (2023 and 2024), the reasoning based on a minor decline is flawed because no such decline occurred. The conclusion about maintaining a stable strategy is partially aligned with the ground truth but is based on incorrect data, undermining the validity of the inference. (4) The contextual relevance is high because the answer addresses the evolution and strategic implication as asked. However, the correctness score is low due to the major quantitative inaccuracy, which fundamentally misrepresents the situation. The qualitative reasoning would have scored higher if based on accurate data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1183,
        "completion_tokens": 346,
        "total_tokens": 1529
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the nature of General Dynamics' involvement in Abrams Main Battle Tank Upgrades evolved from 2022 to 2024, particularly in terms of contract scope and value?",
      "original_answer": "In 2022, General Dynamics received a $360 million contract from the Army for Abrams main battle tank upgrades, mission control units, and systems technical support. By 2024, the company's involvement had evolved to include both production and support services, as evidenced by a $350 million contract for Abrams upgrades, engineering and logistics support, and system and sustainment technical support services. Additionally, a separate $285 million contract was awarded for producing Abrams tanks in the SEPv3 configuration for Romania. This indicates a shift from primarily upgrade-focused contracts to a broader scope that includes both upgrades and production of new configurations, with an increase in total contract value.",
      "llm_answer": "In the 2022 filing General Dynamics reported a **$360 million** Army contract to upgrade Abrams main‑battle tanks, provide mission‑control units and related systems‑technical support【page_43】. By the 2024 filing the award had shifted to a **$350 million** contract that still covers Abrams upgrades but now also includes **engineering, logistics and sustainment technical‑support services**, reflecting a modest reduction in dollar value while expanding the scope of work【page_44】.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $360 million 2022 contract for Abrams upgrades, mission control units, and technical support, and the $350 million 2024 contract that includes Abrams upgrades plus expanded engineering, logistics, and sustainment support. These figures match the ground truth in amount and scope. However, the LLM omits the separate $285 million contract awarded in 2024 for producing Abrams SEPv3 tanks for Romania, which is a significant part of the evolution in contract scope and total value. (2) Quantitatively, the reported dollar amounts ($360M and $350M) are accurate and correctly attributed to their respective years. The comparison of a 'modest reduction in dollar value' is misleading because while the single-line contract decreased by $10M, the total contract value in 2024 actually increased substantially when including the $285M Romania production contract—this full calculation is missing. (3) The reasoning correctly identifies a broadening of scope from upgrades to include support services, but fails to recognize the multi-hop synthesis required to note the addition of *new production* (not just support) and the overall increase in total contract value across all 2024 awards. This limits the qualitative accuracy. (4) The answer is contextually relevant and well-structured, citing correct document pages and focusing on the right company and time frame. However, the omission of a major contract reduces completeness and correctness, warranting a score of 7. Minor wording flexibility is acceptable, but missing a key contract constitutes a significant gap in multi-hop synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 448,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did AIG's financial relationship with Corebridge evolve from 2023 to 2024, particularly in terms of borrowing arrangements and income recognition?",
      "original_answer": "In 2023, AIG disclosed that Corebridge had the ability to continue borrowing through February 25, 2025, indicating an ongoing financial arrangement. By 2024, AIG's relationship with Corebridge had transformed, as AIG began recognizing equity method income tied to Corebridge’s stock price changes and dividends received since June 9, 2024. This shift reflects a change from a borrowing-based relationship to one focused on equity-based returns.",
      "llm_answer": "In 2023 AIG’s filing shows that Corebridge debt – senior unsecured notes, junior subordinated notes and a DDTL facility totaling about $9.4 billion – was recorded on AIG’s balance sheet and AIG had a guarantee‑reimbursement and collateral agreement obligating it to repay any Corebridge borrowing. By 2024, after the June 9 deconsolidation, AIG no longer guarantees Corebridge debt; it now holds a reduced equity stake as an equity‑method investment and recognizes Corebridge income only through net investment income (dividends, stock‑price changes and realized gains on share sales) rather than through debt‑related interest or guarantee obligations.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the 2023 borrowing arrangement, noting that Corebridge had debt on AIG's balance sheet and that AIG had guarantee-reimbursement and collateral obligations, which reflects the ongoing financial support. The total debt amount of $9.4 billion is specific and consistent with typical disclosures, though the original answer does not include this figure—this is an acceptable addition as it provides context without contradicting the ground truth. (2) The key date of June 9, 2024, is correctly cited for the deconsolidation, matching the original answer’s June 9, 2024, equity method shift. The description of AIG transitioning to equity method accounting and recognizing income via dividends, stock-price changes, and realized gains aligns with the original answer’s mention of equity method income tied to stock price and dividends. (3) The multi-hop reasoning is sound: the model synthesizes the change from a debt-guarantee relationship in 2023 to an equity investment model in 2024, correctly interpreting the impact of deconsolidation. (4) Minor difference: the original answer emphasizes the *ability to borrow through February 25, 2025*, which the LLM omits, but this is a secondary detail. The LLM adds valuable detail (e.g., types of debt, $9.4B) not in the original but factually plausible. No calculation errors. Overall, the answer is factually correct, comprehensive, and contextually precise—just missing one minor forward-looking date detail, warranting a 9 instead of 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 433,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2022, Tesla was actively selling the Solar Roof and improving installation efficiency through collaboration with real estate developers and builders. The company emphasized its engineering efforts to combine aesthetics, durability, and power generation. By 2024, however, Tesla's 10-K highlights that the future of the Solar Roof (alongside other products) 'depends in large part' on overcoming production ramp challenges, including bottlenecks, supplier risks, and cost control. This reflects a shift from product development and sales emphasis to a more complex production and dependency landscape.",
      "llm_answer": "In the 2022 filing Tesla presented Solar Roof as a premium glass‑tile system sold directly and through channel partners, stressing ongoing work to improve installation efficiency and its collaboration with real‑estate developers and builders while offering warranties for defects and weatherization. By the 2024 filing the company acknowledges that Solar Roof has faced ramp‑up delays, noting that its ability to scale the product now hinges on resolving production bottlenecks and on reliable supply‑chain and manufacturing dependencies that could otherwise constrain growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Tesla's 2022 focus on selling the Solar Roof through channel partners, collaboration with real estate developers, and emphasis on installation efficiency and warranties are accurately reflected. By 2024, the shift to acknowledging production ramp-up delays, bottlenecks, and supply chain dependencies is correctly reported. (2) There are no numeric values (e.g., dollar amounts, percentages, units) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning—comparing Tesla’s strategic posture across 2022 and 2024 filings—is sound. The LLM correctly infers a strategic evolution from product promotion and efficiency improvements to grappling with production scalability and external dependencies. The only minor gap is that the LLM does not explicitly quote the phrase 'depends in large part' from the 2024 10-K, which slightly weakens verbatim precision, but the semantic meaning ('hinges on resolving') is equivalent. (4) Contextual relevance is perfect: the response directly addresses production challenges and strategic dependencies as asked, synthesizing information across the two time points. No irrelevant content is included. Overall, this is a factually correct, well-reasoned, and contextually appropriate answer—just shy of perfect due to slight softening of the original 10-K's cautious tone in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 410,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the retail share of Skoal in the U.S. oral tobacco market changed between 2023 and 2024, and what does this indicate about its competitive positioning?",
      "original_answer": "In 2023, Skoal held a 9.3% retail share in the U.S. oral tobacco market, which decreased to 7.6% in 2024. This decline indicates a weakening in Skoal's competitive positioning within the oral tobacco segment over this period. The drop in market share for Skoal contrasts with the growth seen in other products like on!, which increased from 6.8% to 8.3% during the same timeframe.",
      "llm_answer": "Skoal’s retail share fell from 9.3 % in 2023 to 7.6 % in 2024 – a drop of about 1.7 percentage points 【page_48】. This decline shows Skoal is losing market share and its competitive position is weakening as other oral‑tobacco and nicotine‑pouch brands (e.g., on!) gain ground in the U.S. market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports Skoal's retail share as 9.3% in 2023 and 7.6% in 2024, matching the ground truth exactly. The calculated drop of 1.7 percentage points is accurate (9.3 - 7.6 = 1.7). (2) All numeric values and dates are correct, and the calculation of the decline is precise. Format variations (e.g., spacing in '9.3 %') do not affect factual accuracy. (3) The reasoning is sound: the decline in market share is correctly interpreted as a weakening in competitive positioning, and the mention of competing brands like on! aligns with the ground truth context, even though the LLM does not explicitly cite on!'s growth numbers. This shows correct multi-hop synthesis between Skoal’s decline and broader market dynamics. (4) The answer is semantically equivalent to the original, conveying the same core facts and implications. The only minor omission is the lack of specific data on on!’s market share growth (6.8% to 8.3%), which slightly reduces completeness but does not detract from the central conclusion. Hence, high scores across all dimensions, with a 9 in correctness due to partial completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1171,
        "completion_tokens": 321,
        "total_tokens": 1493
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the risk associated with the concentration of device share among premium tier companies evolved between 2023 and 2024, particularly in terms of its potential impact on Qualcomm's pricing power and revenue stability?",
      "original_answer": "In 2023, Qualcomm highlighted that the concentration of device share among a few premium tier companies was contributing to a trend of deriving a significant portion of revenues from a small number of customers, particularly Chinese OEMs. This concentration was noted to potentially result in lower prices for Qualcomm's products due to the purchasing power of these companies. In 2024, the risk factor remained present, but the emphasis shifted slightly to underscore the broader implications of this concentration, including the potential for even greater pricing pressure and revenue fluctuation due to the timing and success of customer product introductions. The continued reliance on a small group of customers, especially those developing their own integrated circuits or using competitors, suggests that the risk has not only persisted but potentially intensified, increasing its impact on Qualcomm's pricing power and revenue stability.",
      "llm_answer": "Qualcomm’s 2024 Form 10‑K repeats the same risk it disclosed in 2023: the mobile market’s concentration of premium‑tier device share among a few OEMs gives those customers strong purchasing power that can force lower product prices and create revenue‑ and margin‑fluctuation risk. Both the 2023 and 2024 filings (see the “Risks Related to Our Operating Businesses” sections on pages 18‑20) contain identical language warning that this concentration may erode Qualcomm’s pricing power and destabilize its revenue stream, indicating the risk has not materially changed.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in terms of dates (2023 and 2024) and correctly identifies the risk related to concentration of device share among premium-tier OEMs impacting Qualcomm's pricing power and revenue stability. It accurately references the 'Risks Related to Our Operating Businesses' section and notes the presence of this risk in both years, which aligns with the ground truth. However, the LLM claims that the 2023 and 2024 disclosures contain 'identical language' and that the risk 'has not materially changed,' which contradicts the original answer. The ground truth states that while the risk persisted, there was a shift in emphasis in 2024 toward broader implications—such as increased pricing pressure, revenue fluctuation due to product launch timing, and the threat from customers developing in-house chips or using competitors—indicating a potential intensification of the risk. By failing to capture this evolution and instead asserting no material change, the LLM misses a key qualitative nuance required by the multi-hop aspect of the question. This omission significantly affects the reasoning accuracy, especially in synthesizing how the risk has evolved. There are no numerical inaccuracies (hence high quantitative score), and the context is highly relevant, but the qualitative misrepresentation of the trend between years reduces overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 383,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "Given Amgen's approach to managing short-term liquidity, how did its allocation to money market mutual funds evolve between 2023 and 2024?",
      "original_answer": "Amgen's allocation to money market mutual funds remained unchanged at $10,266 million in both 2023 and 2024. The disclosed investment values for money market mutual funds under available-for-sale investments were identical in both years, indicating no shift in this portion of the company's short-term investment strategy.",
      "llm_answer": "Amgen’s short‑term liquidity strategy kept the bulk of its cash in money‑market mutual funds, and the balance in that category rose modestly. At year‑end 2023 the fair‑value of money‑market mutual funds was $10.266 billion, and by year‑end 2024 it had grown to $10.354 billion – an increase of roughly $88 million. (See the “Available‑for‑sale investments” tables in the 2023 filing page 133 and the 2024 filing page 133.)",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that Amgen's allocation to money market mutual funds increased from $10.266 billion in 2023 to $10.354 billion in 2024. The ground truth confirms that the allocation remained unchanged at $10,266 million (i.e., $10.266 billion) in both years. This misstatement of a key financial figure severely undermines the answer's correctness. (2) The quantitative accuracy is low because the reported 2024 value ($10.354 billion) is incorrect, and the claimed $88 million increase is therefore also false. The correct value, per the knowledge graph, is identical in both years, so the difference is $0. Even though the 2023 figure is correctly stated as $10.266 billion (equivalent to $10,266 million), the 2024 figure is not. (3) The qualitative accuracy is partially sound in that the model correctly identifies money market mutual funds as part of Amgen’s short-term liquidity strategy and references the correct financial category (available-for-sale investments) and document sections. However, it fails in the core multi-hop reasoning task—comparing the exact values across two years—which is central to the question. The conclusion that there was a 'modest rise' is directly contradicted by the data. (4) Contextual relevance is high because the answer addresses the right company, time frame, financial instrument, and strategy, and attempts to cite specific document locations. However, the factual error in the key metric results in a very low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1184,
        "completion_tokens": 422,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has General Dynamics' participation in the Capital Construction Fund evolved between 2022 and 2024, particularly in terms of the amount of U.S. government accounts receivable pledged to the fund?",
      "original_answer": "In 2022, General Dynamics had U.S. government accounts receivable pledged to the Capital Construction Fund (CCF) of $295 million as of December 31, 2021. By 2024, the amounts pledged to the CCF had increased to $315 million on December 31, 2023, and $333 million on December 31, 2024. This indicates a steady increase in GD's participation in the CCF over the period, reflecting a growing utilization of the tax deferral benefits offered by the program.",
      "llm_answer": "General Dynamics’ pledge of U.S. government accounts receivable to the Capital Construction Fund grew from $295 million in 2022 (as disclosed in the 2022 filing) to $315 million in 2023 and $333 million in 2024, showing a steady increase in the amount pledged 【page_67】【page_68】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the pledged amounts for 2022 ($295 million), 2023 ($315 million), and 2024 ($333 million), matching the ground truth in both values and trend. The reference to the 2022 filing disclosing the $295 million figure aligns with the original answer's note that this amount was as of December 31, 2021, but disclosed in the 2022 filing—this nuance is reasonably interpreted. (2) All numbers are accurate and correctly formatted; no calculation errors. The progression from $295M to $315M to $333M is correctly presented as a steady increase. (3) The multi-hop reasoning is sound: the model synthesizes data across years and correctly infers increasing participation in the CCF. It does not explicitly mention the tax deferral benefit context from the original answer, which slightly reduces qualitative depth, but the core logic and entity relationships (General Dynamics, CCF, receivables, years) are correct. (4) The answer is fully relevant, directly addressing the evolution of GD's CCF participation with correct metrics and timeframes. The minor omission of the tax policy rationale does not detract from factual correctness, hence a 9/10 on qualitative accuracy and 9 overall for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1196,
        "completion_tokens": 350,
        "total_tokens": 1546
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of its tax implications and investment income following the IPO and subsequent deconsolidation?",
      "original_answer": "In 2023, AIG's ownership in Corebridge dropped below 80% after Corebridge's IPO on September 19, 2022, resulting in the tax deconsolidation of Corebridge from AIG’s U.S. federal income tax group. This deconsolidation had significant tax implications, including restrictions on future consolidated tax filings for five years and the retention of Corebridge's net operating losses and tax credit carryforwards by Corebridge entities. By 2024, AIG no longer consolidated Corebridge's financials, and instead, AIG reported its investment in Corebridge under the equity method, recognizing $X in equity method income for the period from June 10, 2024, to December 31, 2024, based on dividends received and changes in Corebridge's stock price. This marks a shift from a consolidated tax and financial reporting relationship to a more arms-length investment relationship.",
      "llm_answer": "After Corebridge’s September 2022 IPO, AIG’s ownership fell below the 80 % threshold in 2023, which caused Corebridge and its subsidiaries to be tax‑deconsolidated from AIG’s consolidated U.S. federal income‑tax group (so Corebridge’s net operating losses and tax‑credit carryforwards stayed with its own tax groups) and produced a $382 million tax‑expense adjustment related to the disposition of Corebridge (part of an overall $20 million net tax expense for the year)【page_255】【page_256】. In 2024, AIG formally deconsolidated Corebridge on June 9, recorded a $4.8 billion loss on discontinued operations (largely the $7.2 billion accumulated comprehensive loss) and re‑classified its remaining Corebridge stake as an equity‑method investment, which boosted net investment income (including a $282 million gain on share sales) and generated a $226 million tax expense on the discontinued operation (plus a $545 million tax on the loss on sale)【page_108】【page_109】【page_110】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution of AIG's financial relationship with Corebridge between 2023 and 2024, including tax deconsolidation due to ownership falling below 80% post-IPO and the shift to equity-method accounting. However, there are significant quantitative inaccuracies: the $382 million tax expense, $4.8 billion loss on discontinued operations, $282 million gain on share sales, $226 million tax expense on discontinued operations, and $545 million tax on the loss on sale are all specific figures not present in the original answer (ground truth), which only references '$X' as a placeholder. These numbers may be factually correct in external sources but contradict the ground truth provided, which does not include them. The original answer emphasizes the structural shift—tax deconsolidation in 2023 and equity method reporting starting June 10, 2024—but does not mention a loss on deconsolidation or gains from share sales. The LLM introduces a June 9, 2024 deconsolidation date, while the ground truth specifies June 10, 2024—minor but notable discrepancy. The qualitative reasoning is strong: it correctly identifies the tax implications (retention of NOLs and tax credits by Corebridge), the end of consolidated tax filing for five years (implied in original), and the change in investment income recognition. It also correctly frames the relationship shift from consolidation to equity method. Contextually, the answer is highly relevant, directly addressing tax implications and investment income as required. However, the inclusion of unsupported specific financial figures reduces quantitative accuracy. The original answer is more conservative, using placeholders where data is unspecified, while the LLM overcommits to precise numbers not in the ground truth, which is problematic for factual evaluation purposes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 498,
        "total_tokens": 1971
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Tesla's approach to Solar Roof production and its dependencies evolved from 2022 to 2024, particularly in terms of operational strategy and supply chain challenges?",
      "original_answer": "In 2022, Tesla emphasized improving Solar Roof installation capabilities by onboarding and training new installers and collaborating with real estate developers to reduce installation time and costs. The company also highlighted the need to maintain adequate battery cell supply and hire additional skilled electricians to support the ramp. By 2024, Tesla's focus had shifted to broader manufacturing and supply chain risks, with Solar Roof production now described as being dependent on the company's ability to manage global component procurement, avoid bottlenecks, and maintain cost-effective production amid potential supplier failures and inflationary pressures. The evolution reflects a shift from localized installer development to systemic supply chain and production scalability concerns.",
      "llm_answer": "In 2022 Tesla’s 10‑K said it would grow Solar Roof by simplifying the online ordering experience, onboarding and training new installers, and partnering with builders to cut installation time and cost, while stressing the need for adequate battery‑cell supply and skilled electricians to support the ramp‑up. By the 2024 filing the tone had shifted – the company now flags that Solar Roof production has already faced, and may face, further launch‑and‑ramp delays and ties those delays to broader supplier‑delivery failures, component shortages and other supply‑chain constraints. This marks a move from an expansion‑focused operational plan to a more risk‑aware stance that highlights supply‑chain challenges and the uncertainty of scaling Solar Roof.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, Tesla focused on installer onboarding, training, partnerships with builders, and securing battery cell supply and skilled electricians—details confirmed in the original answer. By 2024, the focus shifted to systemic supply chain risks including supplier failures, component shortages, and production delays, which matches the original's emphasis on global procurement, bottlenecks, and inflationary pressures. (2) There are no numeric values requiring calculation (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised; dates (2022 and 2024) are correctly used. (3) The multi-hop reasoning is sound—LLM correctly synthesizes changes in operational strategy and supply chain dependencies across two time points from Tesla’s 10-K filings. It captures the evolution from expansion-focused initiatives to risk-aware scalability concerns. (4) The only minor shortcoming is that the LLM answer does not explicitly mention 'cost-effective production' or 'inflationary pressures' from the 2024 context, which slightly reduces qualitative completeness, but the core shift in strategy and risk exposure is accurately conveyed. Wording differs but semantic meaning is equivalent. Contextual relevance is perfect—directly addresses both operational strategy and supply chain evolution as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 394,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Duke Energy's estimated total cost to permanently close all coal ash basins in North Carolina and South Carolina evolved from 2022 to 2023, and what does this indicate about the company's progress under the Coal Ash Act?",
      "original_answer": "In 2022, Duke Energy estimated the total cost to permanently close all coal ash basins in North Carolina and South Carolina to be approximately $8 billion to $9 billion. By 2023, this estimate had decreased to approximately $7 billion to $8 billion, indicating a downward adjustment in projected costs. Additionally, the amount already spent on these closures increased from approximately $3.1 billion through 2021 (as reported in 2022) to approximately $4 billion through 2023. This evolution suggests that Duke Energy has made measurable progress in implementing closure plans under the Coal Ash Act, with more basins excavated and cost estimates refined over time.",
      "llm_answer": "In the 2022 Form 10‑K Duke Energy said the total undiscounted cost to permanently close all North Carolina and South Carolina coal‑ash basins was about **$8 billion‑$9 billion**, with roughly **$3.1 billion already spent** through 2021. The 2023 Form 10‑K lowered that estimate to roughly **$7 billion‑$8 billion**, noting that **about $4 billion has been spent** to date and most of the remaining spend will occur over the next decade. The downward revision and higher cumulative spend indicate the company is making measurable progress in meeting its Coal Ash Act closure commitments.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the 2022 cost estimate of $8 billion–$9 billion, the $3.1 billion spent through 2021, the 2023 revised estimate of $7 billion–$8 billion, and the updated cumulative spend of $4 billion through 2023 are all correctly reported. Minor formatting differences (e.g., 'about' vs 'approximately', en-dashes in dollar ranges) do not affect factual accuracy. (2) The answer is complete, addressing both the evolution of cost estimates from 2022 to 2023 and the interpretation regarding progress under the Coal Ash Act. (3) Entities are accurate—Duke Energy, North Carolina and South Carolina coal ash basins, correct fiscal years (2022 and 2023 10-Ks), and proper reference to the Coal Ash Act. (4) The reasoning is sound: the downward revision in total cost estimate combined with increased spending indicates progress, cost refinement, and execution of closure plans, which aligns with the multi-hop synthesis required. The LLM correctly infers that measurable progress is being made, consistent with the ground truth. All criteria are met with high precision and semantic equivalence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 337,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did the retail share of the 'on!' oral tobacco product evolved between 2023 and 2024, and what does this indicate about its market position relative to the overall oral tobacco product segment during this period?",
      "original_answer": "The retail share of the 'on!' oral tobacco product increased from 6.8% in 2023 to 8.3% in 2024. This indicates that 'on!' gained market share during this period. In contrast, the total oral tobacco product segment saw a decline in retail share, dropping from 42.5% in 2023 to 37.5% in 2024. This divergence suggests that 'on!' strengthened its position within the broader oral tobacco market between these years.",
      "llm_answer": "The “on!” brand’s retail share rose from **6.8 % in 2023 to 8.3 % in 2024** (up about 1.5 percentage points)【page_48】. At the same time, the overall oral‑tobacco segment’s retail share fell from **42.5 % to 37.5 %**【page_48】, showing that on! was gaining market traction and improving its relative position even as the broader segment contracted.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages are accurate: 'on!' retail share increased from 6.8% in 2023 to 8.3% in 2024, and the overall oral tobacco segment declined from 42.5% to 37.5%, as confirmed in the original answer. The implied 1.5 percentage point increase is correct (8.3 - 6.8 = 1.5). (2) The answer is complete, addressing both the evolution of 'on!'s retail share and its relative performance compared to the broader segment. (3) Entities are correctly identified: the product 'on!', the time frame (2023–2024), and the relevant market segment (oral tobacco) are all accurate. (4) The reasoning is sound: the LLM correctly infers that 'on!' gained market traction and improved its relative position despite a shrinking overall segment, which aligns with the multi-hop logic required (synthesizing brand performance with category trends). (5) Semantic equivalence is achieved — while the wording differs slightly, the meaning and factual content are identical to the ground truth. The inclusion of a citation (page_48) does not affect accuracy and may reflect source formatting. All criteria for a perfect score are met.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1207,
        "completion_tokens": 337,
        "total_tokens": 1544
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Qualcomm's reliance on Chinese OEMs for revenue evolved from 2023 to 2024, and what implications does this have for its business stability?",
      "original_answer": "In 2023, Qualcomm derived a significant portion of its revenues from a small number of Chinese OEMs, highlighting its dependency on their device share growth in China and other regions. By 2024, this dependency persisted, with the company continuing to emphasize that it derives a significant portion of its revenues from these same OEMs. This ongoing reliance indicates that any political, economic, or market shifts affecting Chinese OEMs could continue to pose a risk to Qualcomm's revenue stability, particularly given the persistent U.S./China trade and national security tensions mentioned in both filings.",
      "llm_answer": "In its 2023 Form 10‑K Qualcomm warned that “a significant portion of our revenues … comes from a small number of Chinese OEMs” (Risk Factors, p. 18). The 2024 filing repeats that concentration and quantifies the impact of U.S. export restrictions – product revenues from Huawei in fiscal 2024 were about $560 million before the license was revoked (p. 20). The persistence of this China‑OEM concentration, now coupled with a measurable revenue loss, signals heightened geopolitical risk that can increase earnings volatility and threaten the stability of Qualcomm’s cash‑flow and overall business.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Qualcomm's continued reliance on a small number of Chinese OEMs in both 2023 and 2024, citing the repeated risk factor disclosure—this matches the original answer’s core claim. (2) The quantitative detail about $560 million in revenue from Huawei in fiscal 2024 is accurate and adds value not explicitly in the ground truth, but consistent with it; no calculation errors are present. The mention of the license revocation contextualizes the risk but does not distort facts. (3) The multi-hop reasoning is sound: it connects the persistent revenue concentration (from both years’ filings) with geopolitical risks (U.S. export restrictions) to infer increased business instability—this extends the original answer’s logic with valid inference. (4) The only reason for not scoring a 10 is that the original answer does not mention the $560M figure or Huawei specifically as a quantified example, so while factually correct, this detail goes beyond the provided ground truth without contradicting it. Overall, the answer is factually correct, well-supported, and contextually appropriate, with excellent synthesis across years and risk dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 347,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did Amgen's composition of total available-for-sale investments evolve between 2022 and 2023, particularly in terms of specific security types held?",
      "original_answer": "In 2022, Amgen reported total available-for-sale investments of $4,335 million, which included $1,676 million in marketable securities alongside $2,659 million in cash and cash equivalents. By 2023, Amgen no longer held any marketable securities or U.S. Treasury bills, and instead, the entire $10,404 million in total available-for-sale investments was composed of $10,266 million in money market mutual funds and $138 million in other short-term interest-bearing securities. This reflects a strategic shift toward more liquid and short-term interest-bearing instruments.",
      "llm_answer": "In 2022 Amgen’s available‑for‑sale portfolio was split between $1.676 billion of U.S. Treasury bills and $2.659 billion of money‑market mutual funds (total $4.335 billion) with no other short‑term securities 【page_133†L1-L9】. By the end of 2023 the Treasury‑bill holding had been eliminated, the money‑market mutual‑fund balance had grown to $10.266 billion and a small $138 million position in other short‑term interest‑bearing securities was added, raising total available‑for‑sale investments to $10.404 billion 【page_133†L1-L9】.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the composition of Amgen's 2022 available-for-sale investments. According to the ground truth, in 2022, Amgen held $1,676 million in marketable securities (not U.S. Treasury bills specifically) and $2,659 million in cash and cash equivalents. However, the LLM incorrectly states that the $1.676 billion was in U.S. Treasury bills and $2.659 billion was in money-market mutual funds, which is factually wrong. In reality, Amgen did not hold money market mutual funds in 2022 — those were introduced in 2023. (2) Quantitatively, the total investment amount of $4.335 billion in 2022 and $10.404 billion in 2023 are correctly reported, as are the 2023 breakdowns: $10.266 billion in money market mutual funds and $138 million in other short-term interest-bearing securities. These numbers match the ground truth and sum correctly. However, the misattribution of 2022 components undermines quantitative accuracy. (3) The multi-hop reasoning is flawed because the model fails to correctly identify the evolution of security types over time. It incorrectly suggests that money market funds existed in 2022 and were expanded in 2023, when in fact they replaced marketable securities and U.S. Treasury bills. The strategic shift toward more liquid instruments is noted in the ground truth, but the LLM does not accurately describe the transition due to incorrect component mapping. (4) Despite the incorrect composition details, the answer is contextually relevant and addresses the question about evolution in investment composition. The use of citation [page_133†L1-L9] suggests source grounding, but the interpretation is erroneous. Scores reflect partial correctness on numbers but major errors in entity and category attribution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 489,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the presence of Shake Shack as a tenant evolved across SPG's premium outlet properties between 2022 and 2023?",
      "original_answer": "In 2022, Shake Shack was listed as a tenant at Woodbury Common Premium Outlets in New York. By 2023, Shake Shack not only remained at Woodbury Common but also expanded its presence to Las Vegas Outlets North Premium in Nevada. This indicates a strategic expansion of Shake Shack’s footprint within SPG's portfolio of properties over the two years.",
      "llm_answer": "In the 2022 filing, Shake Shack is listed only as a tenant at the Las Vegas Premium Outlets (NV) 【page_34】. The 2023 filing shows the same single listing – Shake Shack remains a tenant at Las Vegas Premium Outlets and does not appear at any other premium‑outlet property 【page_34】. Thus, the brand’s presence across SPG’s premium‑outlet portfolio was unchanged between 2022 and 2023.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is factually incorrect in both entity identification and location tracking. According to the ground truth, in 2022 Shake Shack was a tenant at Woodbury Common Premium Outlets in New York, not Las Vegas. By 2023, it expanded to include Las Vegas Outlets North Premium in Nevada while maintaining its presence at Woodbury Common. The LLM incorrectly states that Shake Shack was only at Las Vegas Premium Outlets in both years, which contradicts the original data. This misplacement of locations and failure to identify the expansion constitutes a major factual error. The reasoning is therefore flawed, as it concludes no change occurred when in fact there was a clear geographic expansion. While the answer attempts to address the evolution of Shake Shack's presence, it does so with entirely incorrect premises. Quantitative accuracy is low because the locations (key factual anchors) are wrong, and no correct multi-hop synthesis is performed. Contextual relevance is partially present as the answer discusses the right brand and portfolio, but the substance is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1175,
        "completion_tokens": 308,
        "total_tokens": 1483
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the classification of retirement annuity contracts within the fair value hierarchy evolve between 2022 and 2024, and what does this indicate about GD's valuation methodology for these assets?",
      "original_answer": "In 2022, retirement annuity contracts were part of Level 3 assets, indicating that their fair value was determined using unobservable inputs. By 2024, these contracts remained in Level 3, but the disclosure noted that investments valued using net asset value (NAV) as a practical expedient were now included in the tables for reconciliation to total plan assets, which was not explicitly stated in 2022. This suggests a refinement in disclosure practices rather than a change in hierarchy classification, indicating that while the valuation methodology remained complex and less observable, GD improved transparency in how these assets are reported.",
      "llm_answer": "In the 2022 filing GD listed retirement‑annuity contracts as Level 3 assets—i.e., valued using significant unobservable inputs—and the 2024 filing still places them in the Level 3 column (‑ $22 in the 2024 hierarchy)【page_93】. The unchanged classification shows GD continues to value these contracts with internal models that rely on unobservable assumptions rather than quoted market prices.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that retirement annuity contracts remained in Level 3 of the fair value hierarchy in both 2022 and 2024, which aligns with the ground truth. It accurately notes the continued use of unobservable inputs and internal models, reflecting the core valuation methodology. The mention of a -$22 value in 2024 (page 93) is a specific quantitative detail not contradicted by the ground truth, and format variations in dollar amounts are acceptable. However, the LLM omits a key qualitative point from the original answer: the change in disclosure practice regarding the inclusion of investments valued using net asset value (NAV) as a practical expedient in the reconciliation tables in 2024, which was not explicitly stated in 2022. This omission reduces completeness and nuance, particularly around the idea that the change reflects improved transparency rather than a methodological shift. While the LLM captures the stable hierarchy classification and its implication, it fails to synthesize the multi-hop detail about evolving disclosure practices, which is central to fully answering how the classification 'evolved' and what it indicates about GD's reporting. Thus, while factually accurate on the main point, it lacks full qualitative depth required for a top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 361,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of potential equity dilution and income recognition?",
      "original_answer": "In 2023, AIG had a stake in Corebridge that included a potential equity dilution mechanism tied to Blackstone's right to exchange its ownership interest in Corebridge for AIG common shares, which would have introduced up to 24.1 million additional shares in 2022 (and 4.4 million in 2023) had the IPO not occurred before 2024. However, since the IPO occurred on September 19, 2022, this exchange right was terminated. By 2024, AIG's relationship with Corebridge had shifted from a stakeholding to an equity method investment, where AIG reported income based on dividends received and changes in Corebridge's stock price from June 9, 2024 onwards. This reflects a transformation from a potential equity dilution scenario to a post-divestiture equity income model.",
      "llm_answer": "In 2023 AIG still consolidated Corebridge—owning 52.2 % of the company—and, because a Blackstone exchange right was terminated, excluded 4.4 million potential shares from diluted‑EPS calculations (a potential equity‑dilution issue)【page_242】. By 2024 AIG had de‑consolidated Corebridge, cut its stake to 22.7 %, and now treats the remaining interest under the equity‑method, recognizing $601 million of equity‑method income (and a $282 million gain on share sales) while recording a $4.8 billion loss from the de‑consolidation, eliminating the earlier dilutive‑share consideration【page_108】【page_109】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution of AIG's financial relationship with Corebridge between 2023 and 2024, correctly identifying the shift from consolidation to equity-method accounting and the elimination of potential equity dilution due to the termination of Blackstone's exchange right. However, there are key quantitative inaccuracies. The original answer states that the potential dilution was 4.4 million shares in 2023 (and 24.1 million in 2022), but the LLM incorrectly implies that the 4.4 million figure was excluded from diluted EPS in 2023 due to termination—this misrepresents the timeline. The IPO and termination occurred on September 19, 2022, meaning the exchange right was already terminated before 2023, not in 2023. Thus, the exclusion of dilutive shares should have already occurred in 2022, not 2023. (2) The LLM introduces specific dollar amounts—$601 million equity-method income, $282 million gain, and $4.8 billion loss—that are not present in the original answer and cannot be verified against the ground truth. While these may be factually correct in the actual filing, they go beyond the scope of the provided ground truth and introduce unverified data, reducing quantitative accuracy. (3) The qualitative reasoning is strong: the model correctly synthesizes the transition from a stakeholding with dilution risk to an equity-method investment with income recognition post-deconsolidation. It accurately reflects the change in accounting treatment and the elimination of dilution concerns. (4) Contextual relevance is perfect—the answer directly addresses both parts of the question: equity dilution and income recognition—and correctly identifies the multi-hop shift across years and accounting treatments. Despite strong reasoning and relevance, the incorrect timing of the exchange right termination and the inclusion of unsupported financial figures reduce the overall correctness score to 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 525,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2024, based on its debt disclosures and consolidation treatment?",
      "original_answer": "In 2022, Comcast disclosed that Universal Beijing Resort had $3.6 billion in debt as of December 31, 2021, and $2.5 billion as of December 31, 2020. By 2024, Comcast clarified that Universal Beijing Resort had $3.4 billion in debt outstanding as of December 31, 2024, and $3.5 billion as of December 31, 2023. This indicates that the debt levels stabilized after earlier reductions, and Comcast now consolidates Universal Beijing Resort as a variable interest entity (VIE), with its assets and liabilities fully included in Comcast’s consolidated balance sheets at $7.3 billion in assets and $7.0 billion in liabilities as of 2024.",
      "llm_answer": "In the 2022 filing Comcast listed $3.6 billion of “Debt not guaranteed” for Universal Beijing Resort – a loan that is secured only by the resort’s assets and the investors’ equity stakes. By the 2024 filing the resort’s outstanding debt had slipped to about $3.4 billion (the term‑loan portion $3.0 billion) and Comcast now treats the resort as a VIE that it consolidates because it can direct its key activities, but it has no liquidity arrangements or guarantees, so its exposure is limited to its 30 % equity interest rather than any guaranteed debt.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also significant inaccuracies. It correctly identifies that Universal Beijing Resort had $3.6 billion in debt in the 2022 filing (referring to Dec 31, 2021) and $3.4 billion in the 2024 filing (Dec 31, 2024), which aligns with the ground truth. However, it omits the 2023 debt figure of $3.5 billion and incorrectly implies the 2022 disclosure was for the same year, when it actually reported prior year data. More critically, the LLM states Comcast’s exposure is 'limited to its 30% equity interest' and that it has 'no liquidity arrangements or guarantees,' which contradicts the ground truth that Comcast now fully consolidates the resort as a VIE with $7.3B in assets and $7.0B in liabilities included in its balance sheet—indicating full financial statement consolidation, not limited exposure. (2) Quantitative accuracy is partially correct: $3.6B and $3.4B are accurate, but missing $3.5B (2023) and $2.5B (2020) from the original answer reduces completeness. The mention of a '$3.0B term-loan portion' is not in the ground truth and appears speculative. (3) The multi-hop reasoning is flawed: while the model correctly identifies the VIE consolidation, it draws the wrong conclusion about financial exposure—consolidation implies full inclusion of assets and liabilities, not limitation to equity interest. This reflects a misunderstanding of accounting treatment. (4) Contextual relevance is high as the answer addresses debt levels and consolidation, but the incorrect interpretation of consolidation impact undermines factual correctness. Scores reflect partial accuracy in numbers but major error in financial interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 465,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the structure of aircraft trade-in commitments changed between 2022 and 2023, particularly in terms of customer eligibility and risk exposure?",
      "original_answer": "In 2022, the Aerospace segment had outstanding options with 'some customers' to trade in aircraft as partial consideration for new aircraft purchases, indicating a broader or less-specific customer eligibility. By 2023, the eligibility was narrowed to 'some Gulfstream customers,' suggesting a more specific subset of customers was offered trade-in options. Additionally, while both years acknowledged the risk associated with adverse market changes affecting trade-in values, 2023 introduced a more specific framing by highlighting Gulfstream, a key business jet brand, which may indicate a strategic focus or increased risk concentration in that segment. Despite these structural changes, both years reported that the estimated change in fair market values from the commitment date was 'not material.'",
      "llm_answer": "The 2023 filing still describes trade‑in commitments the same way – either a fair‑market‑value price set about 45 days before delivery or a guaranteed price that can reduce revenue if market values fall – and notes that the guaranteed‑price commitments carry the greater market‑risk exposure 【page_79】. The only noticeable change is that the 2023 note specifies the options are held by “some Gulfstream customers,” whereas the 2022 note referred only to “some customers,” but the underlying risk profile of the commitments is unchanged 【page_77】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the change in customer eligibility from 'some customers' in 2022 to 'some Gulfstream customers' in 2023, capturing the narrowing of eligibility. (2) It accurately describes the risk exposure, noting that guaranteed-price commitments carry greater market risk, which matches the ground truth's emphasis on risk from adverse market changes affecting trade-in values. (3) It correctly states that the overall risk profile and materiality of fair value changes remain unchanged, consistent with the original answer's note that the estimated change in fair market values was 'not material' in both years. (4) The LLM adds detail not in the ground truth—about pricing mechanisms (fair-market-value vs. guaranteed price) and timing (~45 days before delivery)—which is contextually relevant and likely correct per the cited pages, but not required for full accuracy. These additions do not contradict the ground truth and enhance completeness. The only minor shortcoming is that it does not explicitly mention the strategic focus or risk concentration implication around Gulfstream highlighted in the original answer, slightly weakening the qualitative synthesis. However, the core facts, entities, years, and reasoning are correct. Quantitative elements (though no specific numbers appear) are accurately represented in terms of risk structure and materiality. The answer is fully contextually relevant and addresses both customer eligibility and risk exposure as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 427,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2022 and 2024, particularly in terms of its production status and strategic positioning within Tesla's product lineup?",
      "original_answer": "In 2022, Tesla had only announced the Tesla Semi as part of its planned electric vehicles, indicating it was in the conceptual and development phase. By 2024, Tesla had moved the Tesla Semi into 'pilot production' at its Nevada facility, signaling a significant advancement in its development and a step closer to commercialization. This evolution reflects Tesla's strategic shift from merely planning the vehicle to actively preparing it for market entry.",
      "llm_answer": "In the 2022 filing the Semi was mentioned only as a “planned” commercial electric vehicle among Tesla’s future offerings (Item 1, page 5). By the 2024 filing the Semi appears in the production‑status table as being in “pilot production” at the Nevada plant (page 36) and is described as one of the newer models—alongside the Cybertruck and next‑generation platforms—that Tesla is expanding capacity to build (page 37). This shows the Semi moving from a concept‑stage announcement in 2022 to early manufacturing in 2024, now positioned as a key commercial vehicle in Tesla’s product lineup.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately reflects that in 2022, the Tesla Semi was described as a 'planned' vehicle, indicating it was in the conceptual phase, and by 2024 had advanced to 'pilot production' at the Nevada facility. (2) There are no numerical values requiring calculation, but the years (2022 and 2024) and production statuses ('planned', 'pilot production') are correctly cited and consistent with the original answer. Minor formatting differences (e.g., referencing specific pages and items) add detail without affecting accuracy. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two different filings (2022 and 2024) to show progression in production status and strategic positioning. It identifies the Semi’s shift from a future concept to an active production priority alongside Cybertruck and next-gen platforms, demonstrating proper understanding of strategic evolution. (4) The answer is semantically equivalent to the ground truth, with added contextual precision (e.g., referencing the production-status table and expansion of manufacturing capacity), enhancing completeness without introducing errors. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 357,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the valuation allowance related to Altria's investment in Cronos evolve between 2022 and 2024, and what does this indicate about the company's expectations regarding the realizability of associated deferred tax assets?",
      "original_answer": "Between 2022 and 2024, the valuation allowance related to Altria's investment in Cronos increased from $379 million in 2022 to $402 million in 2024. This indicates that Altria continued to maintain significant uncertainty regarding the realizability of deferred tax assets associated with the Cronos investment, as the company still did not expect the temporary difference to reverse in the foreseeable future. The steady increase in the allowance suggests a cautious stance by Altria in recognizing the full value of these assets.",
      "llm_answer": "Altria’s valuation allowance tied to its Cronos investment grew modestly – it was $379 million in 2022, $397 million in 2023 and $402 million at year‑end 2024 (MO 10‑K 2024, p. 84). The fact that a specific allowance is still recorded – and even slightly increased – shows the company still believes it is more likely than not that the deferred tax assets arising from Cronos will not be fully realized, reflecting continued uncertainty about generating enough taxable income to absorb those assets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is factually correct in all key aspects: the valuation allowance was $379 million in 2022 (matches ground truth), increased to $402 million in 2024 (correct), and the LLM adds an intermediate 2023 figure ($397 million) not in the original but consistent with a progressive increase and plausible within the timeline. No calculation errors; numbers match or are reasonably inferred from the trend. 2) Quantitative accuracy is perfect: all reported dollar amounts are either in direct agreement with the ground truth (2022 and 2024) or provide additional but reasonable and non-contradictory data (2023). Format variations are acceptable and clear. 3) The reasoning is sound: the LLM correctly interprets the increasing allowance as evidence of continued uncertainty about the realizability of deferred tax assets, aligning with the ground truth’s conclusion about Altria’s cautious expectations. It correctly identifies the core implication—that it is 'more likely than not' the assets won’t be realized—using standard accounting terminology. 4) The answer is fully relevant, addressing both the evolution of the allowance and its implication for deferred tax asset realizability. The only minor shortcoming is that the original answer emphasizes the 'steady increase' and 'foreseeable future' language slightly more explicitly, but the LLM captures the same meaning. No incorrect entities or years; Cronos, Altria, and the time frame are all accurate. Overall, this is a highly accurate, well-reasoned, and complete response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 422,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the financial treatment and valuation impact of Amgen's investment in BeiGene evolve between 2023 and 2024?",
      "original_answer": "In 2023, Amgen changed the accounting method for its investment in BeiGene from the equity method to fair value, resulting in gains recognized in connection with this revaluation. By 2024, the investment contributed net unrealized losses within Amgen's Other income (expense), net, reflecting a shift from gains in 2023 to losses in 2024 due to market or valuation changes. This evolution shows a reversal in the financial benefit derived from the BeiGene investment over the two years.",
      "llm_answer": "In 2023 Amgen switched its BeiGene stake from the equity‑method to a fair‑value basis, so the change in fair value was recorded as a gain in earnings and drove the rise in other income (net) for that year 【page_78】. By 2024 the fair‑value of the investment had declined, producing a net unrealized loss on strategic equity investments—including BeiGene—that offset the prior‑year gains and lowered other income (net) 【page_77】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies the 2023 accounting change from equity method to fair value, resulting in gains recognized in earnings, and the 2024 shift to net unrealized losses impacting Other income (expense), net. (2) There are no numeric values (e.g., dollar amounts, percentages) in the original or LLM answer, so quantitative accuracy is not compromised; dates (2023 and 2024) are correct. (3) The multi-hop reasoning is sound: the answer synthesizes the change in accounting treatment and its financial impact across two years, correctly linking the reversal from gains to losses due to valuation changes. (4) The LLM uses slightly different phrasing (e.g., 'strategic equity investments—including BeiGene') but accurately contextualizes the BeiGene investment within broader categories mentioned in the source. All entities—Amgen, BeiGene, the relevant financial line items, and years—are correct. The answer fully addresses the evolution of financial treatment and valuation impact, matching the original answer in substance and completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 320,
        "total_tokens": 1541
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the positioning and market strategy for Disney+ Hotstar evolved between 2023 and 2024, particularly in terms of its regional branding and service structure?",
      "original_answer": "In 2023, Disney+ Hotstar was described as a DTC service primarily in India that offered general entertainment, family, and sports programming. It was positioned as a distinct regional brand within Disney’s broader Direct-to-Consumer portfolio. By 2024, while still branded as Disney+ Hotstar in India and Southeast Asia, the company had merged its previously separate Star+ and Disney+ services in Latin America into a single Disney+ product offering by the end of June 2024. This indicates a strategic shift toward consolidating regional streaming services under the Disney+ brand umbrella, streamlining offerings, and possibly enhancing content integration across markets.",
      "llm_answer": "In the 2023 filing Disney+ Hotstar is described simply as a direct‑to‑consumer streaming service “primarily in India” that offers general‑entertainment, family and sports programming. By the 2024 filing the brand remains Disney+ Hotstar for India and certain Southeast Asian markets, but the company now positions it as a standalone product—explicitly noting that Disney+ Hotstar is not included in any multi‑product bundles (such as Combo+) and is kept separate from the merged Disney+ offering elsewhere. This shift underscores a strategy to keep the Hotstar brand distinct and unbundled in its core regional market.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy in its core claim about Disney+ Hotstar's strategic positioning. While it correctly identifies that Disney+ Hotstar remained a distinct brand in India and Southeast Asia in both 2023 and 2024, it incorrectly states that the service was explicitly positioned as 'not included in any multi-product bundles' and kept 'separate from the merged Disney+ offering elsewhere' as a strategic move. The ground truth emphasizes a consolidation trend—specifically, the merging of Star+ and Disney+ into a single Disney+ product in Latin America by June 2024—as evidence of a broader strategy to unify services under the Disney+ brand. The LLM answer misrepresents this evolution by focusing on unbundling and separation for Hotstar without mentioning the key strategic shift of consolidation in Latin America, which is central to understanding Disney’s evolving market strategy. There are no numerical or date inaccuracies (hence high quantitative accuracy), and the answer is contextually relevant to the question about regional branding and service structure. However, the absence of the Latin America merger and the incorrect emphasis on deliberate unbundling undermine the qualitative accuracy and overall correctness, resulting in a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 367,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did PayPal's approach to its Protection Programs evolve between 2023 and 2024, particularly in terms of risk exposure and loss recovery mechanisms?",
      "original_answer": "In 2023, PayPal disclosed that the costs associated with its protection programs were recorded in 'transaction and credit losses' during the period the payment transaction was completed, and it did not provide a separate service to customers under these programs. By 2024, PayPal introduced more detailed disclosures around its protection programs, highlighting that it incurs substantial losses from these programs due to customer disputes and faces challenges in recovering losses from merchants, especially in cases involving fraud or merchant insolvency. Additionally, PayPal noted that it may face increased exposure due to evolving fraud schemes and potential regulatory changes affecting chargeback requirements. This indicates a shift toward more explicit risk acknowledgment and a broader understanding of potential financial impact.",
      "llm_answer": "In the 2023 filing PayPal described its merchant‑ and consumer‑protection programs simply as “programs … intended to protect … from loss primarily due to fraud and counter‑party performance,” noting that the associated costs are estimated and recorded as transaction‑ and credit‑losses when the payment is completed (​page 77​). By the 2024 filing the company emphasizes that those programs now generate “substantial losses” from customer disputes, that recovery from merchants is often incomplete (e.g., when a merchant is unwilling or unable to pay or can prove delivery), and that external factors such as card‑issuer reimbursements, charge‑back rule changes and regulator‑driven scope expansions increase PayPal’s exposure and could even jeopardize its ability to accept payment cards (​page 24​). This reflects a shift from a routine risk‑mitigation expense to a more explicit disclosure of heightened loss exposure and limited loss‑recovery mechanisms.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original ground truth. (1) All factual elements are correct: the 2023 disclosure correctly notes that protection program costs were recorded in 'transaction and credit losses' at the time of payment (page 77 reference matches), and the 2024 update accurately reflects PayPal's emphasis on 'substantial losses' from customer disputes, challenges in merchant recovery, and increased exposure due to regulatory and fraud-related factors (page 24). (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—no errors in dates or financial metrics. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes in disclosure tone and content between 2023 and 2024, identifying a shift from treating protection programs as routine cost items to acknowledging heightened risk exposure and limited recovery mechanisms. (4) The LLM adds slightly more detail than the original (e.g., mentioning card-issuer reimbursements and risk to payment card acceptance), which is supported by typical 10-K risk factor language and does not contradict the ground truth. The only minor deduction is for slight over-elaboration on regulatory impact ('jeopardize its ability to accept payment cards') which, while plausible, is not explicitly stated in the original answer. Overall, the answer is semantically equivalent, contextually precise, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 413,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has NextEra Energy's relationship with solar generation facilities evolved from 2022 to 2024, particularly in terms of ownership structure and financial exposure?",
      "original_answer": "In 2022, NextEra Energy Resources was actively divesting ownership stakes in solar generation facilities, including the sale of a 100% ownership interest in a 100 MW solar facility in Arizona and the sale of a 90% ownership interest in a portfolio that included four solar facilities. These transactions resulted in significant cash proceeds and the recognition of gains. By 2024, the company's relationship had transformed into a more complex structure involving equity stakes and consolidated variable interest entities (VIEs). For example, NextEra consolidated eight VIEs owning solar generation facilities with approximately 765 MW of capacity and held a 10% direct ownership interest in additional solar facilities. This shift indicates a strategic move from outright ownership and divestiture to a more diversified and financially leveraged stake through VIEs, with increased financial exposure through guarantees and credit support.",
      "llm_answer": "In the 2022 filing, NextEra Energy Resources was actively selling solar assets – it transferred full ownership of a six‑plant solar portfolio (and other solar projects) to third‑party investors, leaving redeemable non‑controlling interests and contract‑liability balances of roughly $668 million that could require the company to return proceeds or repurchase the facilities. By the 2024 filing the company’s solar holdings have shifted to a VIE structure: eight indirect subsidiaries now own 50‑67 % of solar‑generation entities (consolidated as VIEs) and additional VIEs hold differential membership interests, resulting in consolidated solar‑related assets of about $1.7 billion and liabilities of roughly $0.5 billion, indicating that NextEra’s exposure to solar is now reflected through VIE‑related balance‑sheet obligations rather than redeemable non‑controlling interests.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of NextEra Energy's solar strategy from outright ownership and divestiture in 2022 to a VIE-based structure in 2024, which aligns with the ground truth. However, there are significant quantitative inaccuracies. The ground truth specifies a 100 MW solar facility in Arizona (100% sold) and a 90% stake in a portfolio of four solar facilities, while the LLM claims a 'six-plant solar portfolio' without specifying capacity or exact ownership percentages, introducing factual errors. The $668 million figure for redeemable non-controlling interests is mentioned in the LLM answer but not in the original, suggesting potential hallucination or misattribution. In 2024, the ground truth states NextEra consolidated eight VIEs with ~765 MW capacity and held a 10% direct ownership interest; the LLM incorrectly states that subsidiaries own '50–67%' of solar entities and introduces unverified figures of $1.7 billion in assets and $0.5 billion in liabilities, which are not in the original. These numbers cannot be verified against the ground truth and likely misrepresent the financial exposure. While the shift from divestiture to VIE consolidation is correctly identified (qualitatively sound reasoning), the incorrect numerical details, missing specifics (e.g., Arizona facility, exact MW), and introduction of unsupported figures reduce quantitative accuracy. The answer is contextually relevant and addresses both ownership structure and financial exposure, but with partial factual support. Multi-hop synthesis is attempted but compromised by inaccurate data integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1459,
        "completion_tokens": 440,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did ACN's investment in Mutual Fund Debt Securities evolve from 2022 to 2023, and what was the change in valuation methodology as reflected in the fair value hierarchy levels?",
      "original_answer": "In 2022, ACN reported Mutual Fund Debt Securities valued at $379,989 with the entire amount categorized under Level 2 of the fair value hierarchy. In 2023, this investment decreased to $253,025, and the valuation remained entirely under Level 2. The decrease in value indicates a reduction in exposure to Mutual Fund Debt Securities over the year, while the valuation methodology remained consistent, relying on observable market data.",
      "llm_answer": "In 2022 Accenture held $379,989 of mutual‑fund debt securities, which were measured as Level 2 fair‑value assets (using observable inputs) in the defined‑benefit plan table (2022 p. 89). The 2023 filing (pages 81‑85) contains no line for mutual‑fund debt securities, indicating the investment was eliminated (or reduced to $0) and the Level 2 valuation is no longer applied.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors despite addressing the right question. (1) Quantitatively, it incorrectly states that mutual-fund debt securities were eliminated or reduced to $0 in 2023, while the ground truth shows a value of $253,025 — not zero. This is a major error in financial data reporting. (2) The original answer confirms the investment decreased from $379,989 in 2022 to $253,025 in 2023, both fully categorized under Level 2 of the fair value hierarchy. The LLM incorrectly infers disappearance of the line item due to absence on cited pages, but this does not justify claiming the investment was eliminated. (3) The reasoning is flawed: absence from specific pages (81–85 in 2023) does not imply non-existence in the filing; the model fails to verify across the full document and draws an unsupported conclusion. (4) While the entity (ACN/Accenture), years (2022–2023), and metric (Mutual Fund Debt Securities, Level 2) are correctly identified, the core financial evolution and valuation methodology conclusion are wrong. The model should have noted the decrease but consistent Level 2 classification. (5) Contextual relevance is moderate because the structure and intent align with the question, but factual correctness is severely compromised. Minor point: using 'Accenture' instead of 'ACN' is acceptable as it's the full company name.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 379,
        "total_tokens": 1589
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Chevron's financial stake and involvement in Tengizchevroil evolved between 2022 and 2023?",
      "original_answer": "In 2022, Chevron's carrying value of its investment in Tengizchevroil was $23,727 million with a reported equity in earnings of $1,238 million. By 2023, Chevron disclosed that its carrying value was approximately $80 million higher than its underlying equity in Tengizchevroil's net assets, indicating a more complex valuation approach. Additionally, Chevron highlighted that it provided a loan of $4,500 million to Tengizchevroil to fund the Future Growth Project and Wellhead Pressure Management Project (FGP/WPMP). This shows a significant deepening of Chevron's financial involvement and strategic commitment to the partnership in 2023 compared to 2022.",
      "llm_answer": "Chevron’s 50 % equity interest in Tengizchevroil remained unchanged, but the carrying amount of the investment rose modestly from $26.5 billion at year‑end 2022 to $27.0 billion at year‑end 2023 (page 82). During the same period its share of TCO’s earnings fell from $4.4 billion in 2022 to $3.4 billion in 2023 (page 82), while the loan to TCO that funds the FGP/WPMP project stayed at the same $4.5 billion level (page 78).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple critical factual errors. First, it states Chevron's carrying value was $26.5 billion in 2022 and $27.0 billion in 2023, which directly contradicts the ground truth value of $23,727 million ($23.727 billion) in 2022. This is a significant overstatement of over $2.7 billion. The ground truth does not provide a 2023 carrying value but notes a qualitative point about an $80 million premium over equity in net assets, which the LLM fails to mention. Instead, the LLM incorrectly asserts a rise to $27.0 billion. (2) The LLM claims Chevron's share of Tengizchevroil's earnings was $4.4 billion in 2022 and $3.4 billion in 2023, but the ground truth reports equity in earnings of only $1,238 million ($1.238 billion) in 2022—less than a third of the LLM's figure. There is no data in the ground truth for 2023 earnings, so the $3.4 billion figure is unsupported. (3) The LLM correctly identifies the $4.5 billion loan to fund the FGP/WPMP project, aligning with the ground truth, but incorrectly states it 'stayed at the same $4.5 billion level,' implying it existed in 2022, while the ground truth only mentions the loan in the context of 2023, suggesting it was a new development. (4) The LLM correctly notes Chevron's 50% equity interest remained unchanged, which is consistent with the ground truth's implication of stable ownership. However, it fails to mention the key 2023 development: the complex valuation approach due to the $80 million premium over net assets, which was a central point in the original answer. (5) The reasoning is flawed: the LLM implies a modest increase in carrying value and a drop in earnings as the main evolution, while the ground truth emphasizes a deepening financial commitment via a major loan and a shift in valuation methodology. The multi-hop synthesis is incorrect because the LLM relies on fabricated or misaligned numbers rather than accurately connecting the disclosed facts. (6) Contextual relevance is moderate—the answer addresses the evolution of Chevron's stake and mentions relevant financials and the loan—but the severe quantitative inaccuracies undermine its validity. Overall, the answer conveys a misleading picture of the financial evolution due to incorrect core data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 606,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Disney's relationship with ABC Network evolved between 2023 and 2024, particularly in terms of its strategic positioning within Disney's broader entertainment ecosystem?",
      "original_answer": "In 2023, ABC Network was positioned as a core component of Disney's 'Linear Networks' within the Entertainment segment, specifically highlighting its domestic footprint through eight owned ABC television stations and its role in content distribution. By 2024, ABC Network's role had evolved, with its programming becoming more integrated into Disney's direct-to-consumer platforms, such as Hulu and Disney+. Specifically, content from ABC Network was made available on Hulu's SVOD service one day after its linear airing. This shift indicates a strategic move toward digital integration and away from traditional linear distribution. Additionally, while ABC Network was still referenced in the context of affiliate fees in 2023, 2024 emphasized its contribution to streaming services rather than standalone linear revenue.",
      "llm_answer": "In the 2023 Form 10‑K Disney presented ABC simply as a component of its Entertainment segment’s linear‑network portfolio – a domestic broadcast outlet with eight owned stations and a large affiliate base (see page 78). By the 2024 filing, ABC is framed as a strategic hub that not only airs Disney’s primetime, daytime, news and unscripted shows but also carries ESPN’s sports daypart (“ESPN on ABC”) and generates fee‑based cross‑segment revenue for Hulu Live and Disney+ (see page 5), reflecting tighter integration of the broadcast network with Disney’s sports and direct‑to‑consumer businesses.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) It accurately identifies ABC's role in 2023 as part of Disney's Linear Networks with eight owned stations, matching the original answer. In 2024, it correctly notes ABC's deeper integration with Disney's direct-to-consumer and sports businesses, including 'ESPN on ABC' and fee-based revenue for Hulu Live and Disney+, which reflects the strategic shift toward digital and cross-platform monetization. (2) There are no numeric inaccuracies—references to eight owned stations and the years 2023 and 2024 are correct. The LLM cites specific 10-K pages (78 and 5), which, while not required, suggest accurate sourcing. (3) The multi-hop reasoning is sound: it connects ABC’s traditional broadcast role with its evolving function in supporting Hulu Live and Disney+, and links it to ESPN’s distribution strategy. However, the original answer emphasizes that ABC content is available on Hulu SVOD one day after linear airing—a key detail about streaming integration that the LLM omits. While the LLM mentions fee-based revenue for Hulu Live and Disney+, it does not explicitly state the shift from linear affiliate fees to streaming contribution, which is a core strategic evolution. (4) Despite this omission, the answer remains contextually relevant and factually strong, capturing the essence of ABC’s strategic repositioning. The missing detail about day-after streaming on Hulu prevents a perfect score, but overall accuracy and reasoning are high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 417,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has General Dynamics' positioning of the ASCOD vehicle within its Land Systems portfolio evolved between 2022 and 2023, and what does this indicate about potential shifts in production focus or investment allocation?",
      "original_answer": "In 2022, General Dynamics explicitly stated it was 'producing and upgrading' the ASCOD vehicle, indicating active development and enhancement of the platform. By 2023, the company's disclosure shifted to simply 'offering' the ASCOD, without specific mention of production or upgrades. This change in language suggests a potential shift in focus away from active investment or development of the ASCOD platform, possibly reallocating resources to other vehicle programs like the Piranha 5 and AJAX, which are explicitly called out in both years with continued production and international deployments.",
      "llm_answer": "In the 2022 filing the ASCOD is presented simply as “a highly versatile tracked combat vehicle…with multiple versions, including the Spanish Pizarro and the Austrian Ulan” under European Land Systems, with no specific growth emphasis (GD 2022 10‑K p. 10). By the 2023 filing the ASCOD is still listed in the ELS product line, but the narrative now highlights a larger shift toward higher‑volume programs—LAV output rose from 360 to 399 units (2022 p. 10 → 2023 p. 11)—and new investments in robotic and autonomous platforms, indicating that General Dynamics is keeping the ASCOD in its portfolio while directing production and capital toward faster‑growing platforms and next‑generation technology rather than expanding ASCOD output (GD 2023 10‑K p. 11).",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct and captures relevant context but diverges from the ground truth in key aspects of reasoning and entity focus. (1) Correct elements: The answer accurately notes that ASCOD was mentioned in both 2022 and 2023 filings as part of European Land Systems and correctly infers a shift in production focus toward higher-volume platforms like LAV, citing an increase from 360 to 399 units. This quantitative data (360 → 399) aligns with the filings and supports the broader narrative of shifting production emphasis. (2) Quantitative accuracy is high: the unit numbers for LAV production are correctly cited and referenced to the appropriate pages (2022 p.10 → 2023 p.11), and no incorrect figures are presented. (3) However, the ground truth emphasizes a critical change in *language* around ASCOD—from 'producing and upgrading' in 2022 to merely 'offering' in 2023—which the LLM fails to mention. This omission weakens the qualitative accuracy, as it misses the core evidence for reduced investment in ASCOD. Instead, the LLM focuses on LAV volume increases and robotic investments, which, while contextually relevant, are indirect indicators rather than the direct textual shift that forms the basis of the original answer. (4) The LLM also omits mention of Piranha 5 and AJAX—specific platforms highlighted in both years as receiving continued investment—which are key to the multi-hop reasoning in the ground truth. While the conclusion about shifting focus is directionally correct, it is supported by different evidence and lacks the precise linguistic analysis that underpins the original answer. Thus, while contextually relevant and quantitatively sound, the answer falls short on precise qualitative reasoning and completeness of entity synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 482,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has PayPal's utilization of European customer balances for credit activities evolved between 2023 and 2024, and what does this shift indicate about the company's credit funding strategy?",
      "original_answer": "In 2023, PayPal had approved $3.0 billion of European customer balances for credit activities, representing approximately 39% of balances made available for corporate use. By 2024, the approved amount had decreased to $2.0 billion, or 26% of European customer balances. This indicates a strategic shift toward reducing reliance on customer balances for credit funding, potentially in favor of external financing sources, as evidenced by PayPal's multi-year agreement to sell consumer installment receivables, which saw $20.8 billion in loans sold in 2024 compared to $5.5 billion in 2023.",
      "llm_answer": "PayPal’s internal funding pool from European customer balances fell sharply – the amount it had approved to use for credit activities dropped from $3.0 billion (about 39 % of the European balances) at 12/31/2023 to $2.0 billion (about 26 % of the balances) at 12/31/2024【page_71】【page_46】. This reduction signals that the company is scaling back its reliance on customer‑deposit funds for credit extensions and is likely turning to external financing or a more conservative liquidity stance for its credit‑funding needs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the key quantitative figures: $3.0 billion approved in 2023 (39%) and $2.0 billion in 2024 (26%), matching the ground truth exactly. Dates (12/31/2023 and 12/31/2024) are appropriately used as reporting periods, which aligns with typical SEC filing disclosures. (2) All numbers, percentages, and time periods are accurate. The calculation of proportions (39% and 26%) is consistent with the original answer, and no mathematical errors are present. Format variations (e.g., $3.0 billion vs $3.0B) are acceptable and semantically equivalent. (3) The reasoning is sound: the LLM correctly infers that the decline in utilization indicates reduced reliance on European customer balances for credit activities. It accurately identifies this as a strategic shift, suggesting a move toward external financing or a more conservative liquidity approach. However, it omits the specific supporting evidence from the ground truth about PayPal’s multi-year agreement to sell consumer installment receivables, and the significant increase in loans sold ($5.5B in 2023 to $20.8B in 2024), which strengthens the conclusion. This missing detail slightly weakens the qualitative completeness of the multi-hop synthesis. (4) Despite this omission, the LLM answer remains factually correct, contextually relevant, and semantically aligned with the original. The core insight about shifting funding strategy is preserved. Hence, a score of 9 is justified—excellent accuracy with minor room for deeper contextual support.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 425,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the valuation and categorization of equity securities within NEE's Special Use Funds evolve between 2022 and 2024, and what does this indicate about changes in transparency or investment composition?",
      "original_answer": "In 2022, NEE's Special Use Funds reported equity securities at a carrying amount of $906 million (with an estimated fair value of $907 million) for NEE and $672 million (with an estimated fair value of $672 million) for FPL, without detailed categorization by valuation levels. By 2024, the equity securities in the Special Use Funds had grown significantly, with NEE holding $2,614 million in Level 1 equity securities and FPL holding $1,028 million in Level 1 equity securities, alongside more granular disclosures that included Level 2 and Level 3 valuations. This indicates a substantial increase in equity investments and a shift toward more transparent and detailed reporting of asset valuation methodologies.",
      "llm_answer": "In the 2022 filing, NEE’s Special Use Funds listed equity securities only at Level 1 (direct market‑price holdings) and Level 2 (commingled‑fund holdings) – $2.538 bn + $2.973 bn = $5.511 bn in total – indicating that the equity portion was fully observable. By the 2024 filing the same line shows $2.349 bn at Level 1, $2.742 bn at Level 2 and a new $0.199 bn at Level 3, with the total equity balance slipping to about $5.29 bn, signaling that a slice of the fund now relies on unobservable inputs and that the composition has shifted toward less‑transparent, potentially less‑liquid equity holdings.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to align with the ground truth on multiple levels. (1) Quantitative Accuracy: The dollar amounts cited are completely wrong. The ground truth states that in 2022, NEE's equity securities were $906M (carrying) and FPL's were $672M, with no Level 1/Level 2 breakdown provided. In 2024, NEE held $2,614M in Level 1 and FPL $1,028M in Level 1, with additional disclosures for Level 2 and Level 3. The LLM incorrectly reports totals in the billions (e.g., $5.511B) that do not match any entity or year in the truth data. The LLM also fabricates a Level 3 amount of $0.199B in 2024, which is not supported by the original answer. (2) Completeness: The LLM misrepresents the 2022 disclosures as including Level 1 and Level 2 breakdowns, but the original answer explicitly states that no detailed categorization was provided in 2022. It also fails to mention that the 2024 data reflects a significant growth in equity holdings and improved transparency, instead claiming a decline in total equity and a shift toward less transparent holdings—this is the opposite of the truth. (3) Entity Accuracy: The LLM confuses NEE and FPL with aggregate figures and mislabels the composition. It refers to 'NEE’s Special Use Funds' but includes combined or misattributed numbers without distinguishing between NEE and FPL as required. (4) Reasoning: The multi-hop synthesis is flawed. The LLM incorrectly infers a decrease in transparency and liquidity, while the ground truth indicates increased transparency due to more granular disclosures. The conclusion drawn is therefore factually and logically inverted. (5) Semantic Equivalence: The answer does not convey the same information; it presents an entirely different narrative with fabricated data. Only the general topic (valuation levels in Special Use Funds) is contextually relevant, hence a moderate score in contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 514,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the scope and utilization of Accenture's share purchase program evolve from fiscal 2022 to fiscal 2023, particularly in terms of shares acquired under the public program versus those acquired through employee-related transactions?",
      "original_answer": "In fiscal 2022, Accenture purchased 1,964,612 Class A ordinary shares under the publicly announced open-market share purchase program for an aggregate price of $576 million. Additionally, 97,251 shares were acquired through employee-related transactions, such as share withholding for payroll tax obligations, which do not affect the aggregate available authorization. In fiscal 2023, there is no mention of shares purchased under the public program, but the company continued acquiring shares through employee-related transactions under equity share plans. This indicates a shift where the public share purchase program saw reduced or no activity, while employee-related share acquisitions remained consistent.",
      "llm_answer": "In fiscal 2022 Accenture purchased 1,964,612 shares under its publicly announced open‑market repurchase program and 97,251 shares in employee‑related transactions (e.g., payroll‑tax withholdings), and the Board increased total outstanding repurchase authority to $6.129 billion after a $3 billion addition【page_33】. The excerpts from the 2023 filing (pages 81‑85) do not provide a comparable breakdown of shares bought, indicating that the authorized authority remained at the $6.129 billion level and the public program continued to account for the bulk of repurchases, with employee‑related purchases still representing only a modest share.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the fiscal 2022 share purchases: 1,964,612 shares under the public program and 97,251 in employee-related transactions, with accurate context about the $6.129 billion repurchase authority after a $3 billion increase. These quantitative details match the ground truth and are properly cited to the 2022 filing. However, the LLM incorrectly interprets the absence of data in the 2023 filing. The ground truth states there is no mention of public program purchases in fiscal 2023, indicating reduced or no activity, but the LLM concludes that the public program 'continued to account for the bulk of repurchases'—this is unsupported and factually incorrect. (2) All numbers for fiscal 2022 are accurate, earning high marks for quantitative accuracy. The $6.129 billion authorization and $3 billion addition are correct. But the LLM fabricates a conclusion about 2023 repurchase activity without evidence, introducing a major qualitative error. (3) The multi-hop reasoning fails: while the model identifies the correct data points for 2022, it misinterprets the lack of 2023 disclosure as continuity rather than a meaningful change. The ground truth infers a shift in program utilization due to silence on public purchases, whereas the LLM assumes ongoing activity, reversing the correct conclusion. (4) Contextual relevance is moderate—the response addresses the question’s scope but draws an incorrect inference about program evolution. The mention of continued employee-related transactions is plausible but not confirmed in the LLM answer. Overall, partial factual accuracy but flawed reasoning leads to a correctness score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 456,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did Chevron's financial reporting relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of its consolidation status and investment accounting approach?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was consolidated into Chevron’s financial statements, as indicated by the inclusion of 'Note 8: Summarized Financial Data - Chevron Phillips Chemical Company LLC' among other consolidated subsidiaries. However, in 2023, Chevron explicitly stated that its investment in Chevron Phillips Chemical Company LLC was accounted for using the equity method, and it was no longer consolidated under Chevron U.S.A. Inc.'s financial data. This reflects a significant structural change where Chevron transitioned from consolidating the entity to reporting its investment under the equity method, altering how its financial performance is reflected in Chevron’s consolidated results.",
      "llm_answer": "In the 2022 filing Chevron disclosed that its 50 % stake in Chevron Phillips Chemical Company LLC was treated as a joint‑venture investment – CPChem was **not consolidated** and was accounted for using the **equity method** (see page 33). The 2023 filing makes the same treatment clear: Chevron still holds a 50 % equity interest, does not consolidate CPChem, and continues to use the equity‑method approach (see page 75 Note 6), although a separate note now presents summarized 100 % CPChem financial data for reference (page 75 Note 8).",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim about Chevron's accounting treatment of Chevron Phillips Chemical Company LLC (CPChem) in 2022 and 2023, directly contradicting the ground truth. According to the original answer (ground truth), CPChem was consolidated in 2022, meaning it was fully included in Chevron’s financial statements, as evidenced by the inclusion of 'Note 8: Summarized Financial Data - Chevron Phillips Chemical Company LLC' among consolidated subsidiaries. However, the LLM claims that in 2022, CPChem was *not consolidated* and was instead accounted for under the equity method — this is false based on the provided truth. The LLM incorrectly states that the equity method was used in 2022, citing page 33, but the ground truth confirms consolidation occurred that year. In 2023, the truth states there was a change: Chevron switched to the equity method and ceased consolidation. The LLM incorrectly asserts that the treatment remained the same (equity method in both years), missing the key evolution entirely. While the LLM correctly identifies that a 50% ownership stake exists and that a separate note presents summarized 100% financial data in 2023, this does not compensate for the central factual error regarding consolidation status over time. The multi-hop reasoning fails because the model did not detect the change in accounting treatment between years, which is the crux of the question. All other aspects (percentages, note numbers, page references) may align superficially, but the semantic meaning is incorrect due to the reversal of the timeline. Thus, the answer is mostly wrong, with major factual and reasoning errors, warranting a correctness score of 1.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 464,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Hydra-70 rockets in General Dynamics' Combat Systems segment evolved from 2022 to 2023, particularly in terms of contract involvement and production capacity expansion?",
      "original_answer": "In 2022, General Dynamics received a $175 million contract for the production of Hydra-70 rockets as part of its Combat Systems segment. By 2023, the company's role had evolved significantly, with OTS (Orbital Technologies Corporation, part of Combat Systems) maintaining a market-leading position in the supply of Hydra-70 rockets and expanding its production capacity. Specifically, OTS received awards to increase metal parts production capacity for munitions from 18,000 to 86,000 rounds per month by 2025, which includes Hydra-70 rockets as part of its broader munitions portfolio.",
      "llm_answer": "In the 2022 filing the Combat Systems segment’s Hydra‑70 activity was limited to a single $175‑million Army contract to produce the rockets (see 2022 p. 42). By 2023 the rockets are described as a market‑leading product in OTS’s munitions portfolio, and OTS secured awards to expand its metal‑parts capacity for Hydra‑70 rockets from 18,000 to 86,000 rounds per month (and to boost propellant capacity), signaling a major scale‑up of production (see 2023 p. 12).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $175 million 2022 contract for Hydra-70 rockets is accurately cited, and the expansion of metal parts production capacity from 18,000 to 86,000 rounds per month is correctly reported. The involvement of OTS (Orbital Technologies Corporation) within the Combat Systems segment is properly identified. (2) Quantitative accuracy is perfect: dollar amount ($175M), production figures (18,000 to 86,000 rounds/month), and time frame (by 2025 in original, implied in LLM via 'awards') are consistent. Minor note: LLM does not explicitly mention the 2025 completion target for capacity expansion, but this does not distort the meaning. (3) Multi-hop reasoning is sound—LLM correctly synthesizes evolution from a single 2022 contract to a broader, scaled-up role in 2023 with capacity expansion. It captures the shift from limited activity to market-leading status. (4) The only minor shortcoming is that the LLM slightly narrows the scope by stating the capacity expansion is specifically for 'Hydra-70 rockets', while the original clarifies it's for munitions more broadly, which includes Hydra-70. This is a small over-specificity but does not invalidate the core correctness. Wording differences are semantically equivalent and acceptable. Overall, the answer is factually robust, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 393,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has PayPal's treatment of the Global Restricted Stock Unit Award Grant Notice evolved between the 2023 and 2024 filings, particularly in terms of its documentation status and associated agreements?",
      "original_answer": "In the 2023 filing, the Global Restricted Stock Unit Award Grant Notice was listed as Exhibit 10.07+ and was associated with the PayPal Holdings, Inc. 2015 Equity Incentive Award Plan, with its form incorporated by reference from 10-12B/A filed on May 14, 2015. By 2024, the same form of the Global Restricted Stock Unit Award Grant Notice (Exhibit 10.07+) remained in place, still referencing the 2015 plan and incorporated by reference from the same 10-12B/A filing on May 14, 2015. However, in the 2024 filing, there was an updated form of the Global Performance Based Restricted Stock Unit Award Grant Notice (Exhibit 10.08+), which was now filed under the amended and restated plan and was linked to a more recent 10-Q filing on April 30, 2024. This indicates that while the base RSU grant notice remained unchanged, the performance-based variant saw active revision and documentation updates in 2024.",
      "llm_answer": "In the 2023 Form 10‑K PayPal listed the Global Restricted Stock Unit (RSU) Award Grant Notice as Exhibit 10.07+, incorporated by reference to a Form 10‑12B/A filed on May 14 2015 and tied to the 2015 Equity Incentive Award Plan【page_124】. The 2024 Form 10‑K shows the same Exhibit 10.07+ with identical documentation status (still a Form 10‑12B/A dated May 14 2015)【page_121】, while the only change is the addition of an updated performance‑based RSU grant notice (Exhibit 10.08+, now filed 4/30/2024)【page_121】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: Exhibit 10.07+ in both 2023 and 2024 filings refers to the Global Restricted Stock Unit Award Grant Notice, incorporated by reference from the Form 10-12B/A filed on May 14, 2015, under the 2015 Equity Incentive Award Plan. The addition of Exhibit 10.08+ in the 2024 filing—an updated form of the Global Performance Based Restricted Stock Unit Award Grant Notice—linked to the April 30, 2024 10-Q, is correctly noted. (2) Quantitative accuracy is perfect: dates (May 14, 2015; April 30, 2024), exhibit numbers (10.07+, 10.08+), and document types (10-12B/A, 10-Q) match the ground truth exactly. (3) The multi-hop reasoning is sound—correctly identifying continuity in the base RSU notice while highlighting evolution in the performance-based variant. (4) The only minor shortcoming is that the LLM does not explicitly mention that the updated performance-based notice is tied to the 'amended and restated plan,' which is a small but relevant detail in the documentation evolution. However, this does not undermine the overall correctness. Wording differences are semantically equivalent and do not affect factual integrity. The answer is fully relevant and directly addresses the question about documentation status and associated agreements across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 381,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Opdivo within Bristol-Myers Squibb's portfolio evolved from 2022 to 2024, based on its revenue performance and new regulatory approvals?",
      "original_answer": "In 2022, Opdivo generated $7,523 million in revenue, indicating it was a major contributor to Bristol-Myers Squibb's oncology portfolio. By 2024, Opdivo received a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. This regulatory expansion demonstrates a strategic evolution in Opdivo’s therapeutic application and reinforces its continued importance in the company's oncology pipeline, despite not showing a significant revenue increase from earlier years.",
      "llm_answer": "In the 2022 filing Opdivo was already a top‑selling asset, generating about $7.5 billion in net product sales and ranking just behind Revlimid and Eliquis in the company’s portfolio【page_110】. By the 2024 filing the drug’s role had broadened dramatically: BMS added a sub‑cutaneous Opdivo Qvantig formulation, new approvals in Japan for urothelial carcinoma, FDA approval for neoadjuvant NSCLC, and combination approvals with Yervoy and chemotherapy, positioning Opdivo as a growing, multi‑indication immuno‑oncology platform central to BMS’s strategy【page_44】【page_45】【page_46】.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies Opdivo as a major revenue contributor in 2022 with approximately $7.5 billion, which aligns closely with the ground truth figure of $7,523 million (minor rounding is acceptable). However, the LLM introduces several regulatory approvals not present in the ground truth, including sub-cutaneous Opdivo Qvantig, approvals in Japan for urothelial carcinoma, FDA approval for neoadjuvant NSCLC, and combination approvals with Yervoy and chemotherapy. The ground truth only confirms a March 2024 FDA approval for first-line treatment of unresectable or metastatic urothelial carcinoma in combination with cisplatin and gemcitabine. These additional approvals are factually unsupported by the provided truth and represent significant overstatement. (2) Quantitatively, the $7.5 billion figure is acceptably close to $7,523 million, but no 2024 revenue data is provided in the LLM answer, omitting a key part of the performance evolution. The ground truth explicitly notes no significant revenue increase, which the LLM fails to address. (3) The reasoning is partially sound in recognizing Opdivo’s expanding role, but the multi-hop synthesis is flawed—while the LLM infers strategic importance correctly, it invents multiple approvals beyond the single confirmed FDA expansion. This undermines the qualitative accuracy. (4) Contextual relevance is high as the answer focuses on revenue and regulatory developments, directly addressing the question’s scope, but factual overreach reduces correctness. The core revenue figure is accurate, but the regulatory evolution is exaggerated, leading to a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 453,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Chevron's financial involvement and strategic support for Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of project funding and investment structure?",
      "original_answer": "In 2022, Chevron highlighted its 50% ownership in Chevron Phillips Chemical Company LLC (CPChem), emphasizing ongoing investments in global manufacturing facilities and expansion projects, such as the planned 1-hexene unit in Old Ocean, Texas, and a C3 splitter at Cedar Bayou, with targeted start-ups in 2023. By 2023, Chevron's involvement had evolved to include a direct loan of $387 million to fund a portion of the Golden Triangle Polymers Project in Orange, Texas, in which CPChem owns 51%. This indicates a shift from general equity ownership and project announcements in 2022 to more direct financial support and structured investment in specific projects in 2023.",
      "llm_answer": "In 2022 Chevron’s role in CPChem was essentially that of a 50 percent equity owner – the equity‑method investment was $6.843 billion – while CPChem was moving ahead with two new projects (a world‑scale 1‑hexene unit at Old Ocean, Texas and a C3‑splitter at Cedar Bayou) slated to start up in 2023. By 2023 Chevron’s equity investment had risen to $7.765 billion and it added direct project financing – a $387 million loan (reflected in a $608 million advance balance, down from $867 million a year earlier) to fund the Golden Triangle Polymers project – showing a larger capital commitment and a shift toward targeted funding of CPChem’s growth initiatives.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Chevron's 50% ownership in CPChem and the two 2022-announced projects (1-hexene unit in Old Ocean, Texas, and C3 splitter at Cedar Bayou) with 2023 start-ups. It also accurately notes the $387 million loan in 2023 for the Golden Triangle Polymers Project, where CPChem holds 51%, reflecting a shift toward direct financial support. (2) Quantitatively, the LLM adds specific figures not in the original answer but consistent with plausible 10-K data: equity-method investment rising from $6.843 billion (2022) to $7.765 billion (2023), and a $387 million loan reflected in a $608 million advance balance (down from $867 million). While the original answer does not include the $6.843B/$7.765B equity values or the $867M prior advance, these are reasonable details that do not contradict the ground truth and may reflect actual filing data. The $387M loan amount is exact and correctly tied to the project. (3) The multi-hop reasoning is sound: the model synthesizes Chevron’s evolving role from equity-based involvement in 2022 to direct project financing in 2023, correctly interpreting the strategic shift. (4) The answer is contextually excellent, addressing both project funding and investment structure evolution. The only reason for not scoring 10 is that the original answer does not mention the specific equity investment values or prior advance balance, so including them—while plausible—introduces unverified precision. However, since they don’t contradict and enhance completeness, the score remains high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 441,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did PayPal's protection programs evolve between 2023 and 2024 in terms of financial commitments and disclosures regarding transaction loss reserves?",
      "original_answer": "In 2023, PayPal disclosed that it estimated and recorded costs associated with protection programs in transaction and credit losses, but did not specify the exact amounts for the allowance for transaction losses or negative customer balances. In 2024, PayPal provided more detailed disclosures, including specific figures: the allowance for transaction losses increased from $64 million in 2023 to $86 million in 2024, and the allowance for negative customer balances rose from $218 million to $256 million. This indicates a significant increase in PayPal's financial commitments and potential risk exposure under its protection programs in 2024 compared to the prior year.",
      "llm_answer": "In the 2023 Form 10‑K PayPal only described its merchant‑ and consumer‑protection programs qualitatively, noting that the costs are estimated and recorded as “transaction and credit losses” but providing no specific reserve amounts (see 2023 page 77). By the 2024 filing the company began quantifying those commitments: it disclosed an allowance for transaction losses of $86 million at year‑end 2024 (up from $64 million at year‑end 2023) and a total protection‑program balance of $342 million versus $282 million a year earlier, reflecting a larger financial reserve to cover potential losses (see 2024 page 110).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key numbers are correct: the allowance for transaction losses increased from $64 million in 2023 to $86 million in 2024, which matches the ground truth. The LLM also correctly notes the increase in total protection-program balance from $282 million to $342 million. While the ground truth breaks down the $342 million into $86 million (transaction losses) and $256 million (negative customer balances), the LLM combines these into a total figure, which is accurate but slightly less detailed. (2) The calculation of the total reserve increase—from $282M to $342M—is correct: $64M + $218M = $282M (2023), and $86M + $256M = $342M (2024). The LLM accurately reflects this. (3) The reasoning is sound: it correctly identifies the shift from qualitative to quantitative disclosures between 2023 and 2024, which is the central evolution in PayPal’s reporting. (4) The only minor shortcoming is that the LLM does not explicitly name the 'allowance for negative customer balances' or state its individual increase from $218M to $256M, instead subsuming it into a total. This omits a detail present in the original answer but does not introduce error. Overall, the answer is factually correct, well-reasoned, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 370,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has McDonald's strategic framing of its relationship with franchisees changed between 2022 and 2024, particularly in terms of franchising as a core business model and the role of franchisee co-investment?",
      "original_answer": "In 2022, McDonald's described its relationship with franchisees in neutral, structural terms, emphasizing the division of responsibilities such as franchised arrangements and license agreements, and presenting franchisees as co-participants in operating restaurants. By 2024, the framing evolved significantly, with franchising being described as 'paramount' to delivering food quality, customer experience, and profitability. The 2024 filing also emphasized the importance of franchisee co-investment, noting that it enables McDonald's to achieve high restaurant performance. This represents a shift from a descriptive to a more strategic and value-laden framing of the franchisee relationship.",
      "llm_answer": "In the 2022 filing McDonald’s described its franchise system mainly as a component of the overall business – “The Company franchises and operates … All restaurants are operated either by the Company or by franchisees” (p. 43) and noted that it “may share in the cost of certain restaurant improvements with its franchisees” (p. 44). By the 2024 filing the company re‑frames franchising as its defining model, stating “The Company is primarily a franchisor and believes franchising is paramount … The heavily franchised business model is designed to generate stable and predictable revenue” (p. 4) and emphasizing that “ownership of real estate, combined with the co‑investment by franchisees, enables it to achieve restaurant performance levels that are among the highest in the industry” and that it “may co‑invest with franchisees to fund improvements” (p. 5). Thus, franchising moves from a descriptive element in 2022 to a core strategic priority in 2024, with franchisee co‑investment highlighted as a deliberate growth and performance lever.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately captures the shift in McDonald's strategic framing between 2022 and 2024: from a neutral, structural description of franchisees as operational partners to a strategic emphasis on franchising as 'paramount' and a core business model. The role of franchisee co-investment is correctly highlighted as a key lever for high restaurant performance in 2024. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the ground truth, so quantitative accuracy is not applicable in that sense, but all references to years (2022, 2024) and document content (page numbers, quotes) are accurate and correctly attributed. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, compares the language used, and correctly infers a strategic evolution in framing. It identifies the shift from descriptive to value-laden, strategic language. (4) The LLM answer uses direct quotes from the filings (e.g., 'franchising is paramount', 'co-investment by franchisees') and correctly interprets their significance, demonstrating semantic equivalence to the original answer. Wording differs slightly but meaning is preserved and enhanced with specific citations. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 380,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the FDA's authorization of Marlboro HeatSticks evolved between 2022 and 2023, and what does this indicate about Altria's regulatory progress with heated tobacco products?",
      "original_answer": "In 2022, the FDA had not yet authorized Marlboro HeatSticks and was considering them on a case-by-case basis regarding graphic health warnings. By 2023, the FDA had authorized PMTAs for three new tobacco-flavored varieties of Marlboro HeatSticks in January 2023, marking a significant regulatory milestone. This indicates that Altria made notable progress in securing FDA approval for its heated tobacco product line, which is a key part of its innovation strategy.",
      "llm_answer": "In the 2022 filing Altria noted that the FDA had not granted a marketing order for Marlboro HeatSticks – the products remained subject to an ITC cease‑and‑desist ban and were not exempted from the FDA’s graphic‑warning rule. By the 2023 filing the FDA had approved PMTAs for three new tobacco‑flavored Marlboro HeatSticks (January 2023), showing that Altria is making tangible regulatory progress in getting its heated‑tobacco products authorized.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, the FDA had not authorized Marlboro HeatSticks and they were subject to regulatory restrictions including the graphic warning rule and an ITC cease-and-desist order; by January 2023, the FDA authorized PMTAs for three new tobacco-flavored varieties. (2) Quantitative accuracy is perfect: the date 'January 2023' is correctly cited, and no numerical errors are present. Format variations (e.g., 'PMTAs' instead of spelling out 'Premarket Tobacco Product Applications') are acceptable and common. (3) The multi-hop reasoning is sound—comparing Altria's regulatory status across two years and inferring progress is valid. The LLM correctly synthesizes information from 2022 and 2023 filings to show regulatory advancement. (4) The only minor shortcoming is that the LLM omits the broader strategic implication mentioned in the original answer—namely, that this progress is 'a key part of its innovation strategy.' While the conclusion about 'tangible regulatory progress' captures the essence, the deeper strategic context is slightly underdeveloped. However, this does not detract significantly from factual correctness. Overall, the answer is semantically equivalent and highly accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 362,
        "total_tokens": 1598
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did the valuation of mutual fund equity securities held by ACN evolve between 2022 and 2023, and what does this shift indicate about the company's investment positioning in this category?",
      "original_answer": "In 2022, ACN reported $239,293 (in millions) in mutual fund equity securities. By 2023, this figure decreased to $196,226 (in millions), indicating a reduction of $43,067 (in millions). This decline suggests a strategic shift or reallocation away from mutual fund equity securities during the period.",
      "llm_answer": "In 2022 Accenture’s defined‑benefit pension plans reported a fair‑value of **$239  thousand** for mutual‑fund equity securities (page 89). By 2023 the company’s target allocation for equity securities in its non‑U.S. plans rose to **27 % of assets**, up from **21 % in 2022** (page 88), signalling a deliberate move to increase equity exposure and position the pension portfolio more aggressively toward growth‑oriented assets.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It reports $239 thousand instead of $239,293 million (a factor of over 1 billion off), which is a critical error. The correct 2022 value is $239,293 million, and 2023 value is $196,226 million, showing a decline. The LLM incorrectly states an increase in equity exposure based on target allocation percentages in non-U.S. plans, which does not reflect the actual valuation trend of mutual fund equity securities held. (2) Quantitative accuracy is extremely low: the dollar amount is wrong by three orders of magnitude (thousands vs millions), and no mention is made of the $43,067 million decrease. The percentages cited (21% to 27%) are about target allocations in non-U.S. pension plans, not the actual valuation of mutual fund equity securities, so they do not support the conclusion about the company's current investment positioning in this category. (3) The reasoning is flawed: the model fails to perform the correct multi-hop comparison of actual reported values across years and instead substitutes a tangentially related metric (target allocation) that does not reflect the actual holdings' valuation trend. The conclusion about increasing equity exposure contradicts the ground truth of a significant reduction in mutual fund equity securities. (4) Contextual relevance is moderate because the answer discusses pension plan investments and equity allocations, which are related topics, but it does not address the actual evolution of the valuation as required. The qualitative accuracy is low due to incorrect entities (mixing up target allocation with actual valuation) and faulty synthesis. Overall, the answer is mostly incorrect and misleading despite referencing real document pages.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1193,
        "completion_tokens": 481,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Chevron's involvement in Angola LNG Limited evolved from 2022 to 2023, particularly in terms of its operational focus and investment emphasis?",
      "original_answer": "In 2022, Chevron operated and held a 36.4% interest in Angola LNG Limited, emphasizing its role in processing and liquefying associated natural gas from multiple fields and operators in Angola. The company was also involved in developing non-associated gas resources to supply the Angola LNG plant. By 2023, Chevron continued to hold the same 36.4% interest, but the disclosure shifted focus to its broader portfolio of equity affiliates and non-equity investments, with Angola LNG Limited being listed alongside other major investments like Tengizchevroil and Chevron Phillips Chemical Company LLC. This indicates a shift in disclosure emphasis from operational development to financial stake and integration within Chevron’s global portfolio.",
      "llm_answer": "In the 2022 filing Chevron emphasized that its 36.4 % stake in Angola LNG Limited is an operating interest in the on‑shore liquefaction plant and that work was progressing to develop non‑associated gas to feed the facility. The 2023 filing shows the same 36.4 % ownership, but equity earnings from the affiliate fell (from $1.96 bn in 2022 to $1.76 bn in 2023) and new capital outlays plunged (investments/advances dropped from $1.86 bn in 2022 to $0.5 bn in 2023), indicating a shift from expansion‑focused spending to a more maintenance‑oriented operational focus.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Chevron's 36.4% interest in Angola LNG Limited in both 2022 and 2023, which matches the ground truth. However, it introduces specific financial figures—$1.96 billion and $1.76 billion in equity earnings, and capital outlays of $1.86 billion and $0.5 billion—that are not present in the original answer and cannot be verified against the provided ground truth. These numbers appear to be fabricated or sourced from external data not included in the context, making them factually unsupported in this evaluation. (2) The quantitative accuracy is low because the dollar amounts and their comparisons (e.g., 'fell from $1.96bn to $1.76bn') are not corroborated by the original answer, which contains no such figures. There is no mention of earnings or investment outlays in the ground truth, so these cannot be considered accurate within this knowledge scope. (3) The qualitative reasoning is partially sound: the LLM infers a shift in operational focus from expansion to maintenance based on reduced spending, which aligns thematically with the original answer’s claim of a shift in disclosure emphasis—from operational development to financial stake. However, the original answer bases this on narrative disclosure trends, not financial outlays. Thus, while the direction of reasoning (shift in focus) is consistent, the evidence used is incorrect. (4) Contextual relevance is high because the answer addresses both years, the nature of Chevron's involvement, and attempts to interpret evolving strategic emphasis. Despite incorrect numbers, the overall structure and intent match the question’s requirements. The core factual error—introducing unverified financial data—prevents a higher correctness score, though the conceptual interpretation shows reasonable multi-hop synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 496,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did MMM's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, MMM held $14 million in Certificates of Deposit/Time Deposits, as disclosed in the fair value measurements. By 2023, this amount increased to $49 million, indicating a significant growth in this category of investment. This represents an increase of $35 million, or approximately 250%, from the prior year.",
      "llm_answer": "MMM’s holdings of certificates of deposit/time deposits rose from **$21 million at the end of 2022 to $49 million at the end of 2023**【page_64】—an increase of **$28 million**.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 value ($49 million) and notes an increase, which aligns with the ground truth. However, it incorrectly states the 2022 amount as $21 million instead of $14 million, leading to an incorrect change of $28 million rather than $35 million. The percentage increase (approximately 250%) is omitted, reducing completeness. (2) Quantitative accuracy is compromised: the correct increase is $35 million ($49M - $14M), not $28M. The cited $21M for 2022 does not match the ground truth value from the knowledge graph. While $49M in 2023 is accurate, the foundational error in the 2022 figure invalidates the calculation. (3) The reasoning shows partial multi-hop capability—correctly identifying the trend and 2023 value—but fails in accurately retrieving or synthesizing the 2022 figure. The model references 'page_64', suggesting document grounding, but the number still conflicts with the verified truth. (4) Contextual relevance is high—the answer addresses the evolution and magnitude of change in Certificates of Deposit/Time Deposits for MMM from 2022 to 2023. However, due to significant numerical inaccuracies in key figures, the correctness score is moderate. The answer is on the right track but contains critical factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1119,
        "completion_tokens": 361,
        "total_tokens": 1480
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of the percentage of franchised restaurants between 2021 and 2024?",
      "original_answer": "In 2021, 93% of McDonald's restaurants were franchised, while by 2024, this percentage increased to approximately 95%. This indicates a slight but deliberate shift toward further reliance on franchisees to operate McDonald's restaurants, reinforcing the company's strategic emphasis on franchising as a core business model.",
      "llm_answer": "In 2021, 37,295 of McDonald’s 40,031 restaurants – about 93 % – were franchised. By year‑end 2024, the system comprised roughly 95 % franchised locations out of 43,477 restaurants. Thus, the share of franchised restaurants has risen modestly, indicating an even greater reliance on franchisees over the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is factually correct in all key aspects: the 2021 franchised percentage (93%) and the 2024 percentage (~95%) match the ground truth. The absolute numbers provided (37,295 out of 40,031 in 2021 and 95% of 43,477 in 2024) are quantitatively accurate and consistent with known SEC filing data. Minor rounding in the percentage is acceptable and does not affect correctness.\n\n2) Quantitative accuracy is perfect: 37,295 / 40,031 ≈ 93.16%, which rounds to 93%, and the 2024 figure of ~95% is correctly stated as approximate. The total restaurant counts align with McDonald's annual reports. No calculation errors.\n\n3) The reasoning is sound: the LLM correctly infers a modest increase in franchised share and interprets this as greater reliance on franchisees, which aligns with the strategic trend described in the original answer. The multi-hop synthesis—comparing franchised percentages across years using total and franchised restaurant counts—is correctly executed.\n\n4) Semantic equivalence is strong: while the LLM includes more granular data (exact restaurant counts), the core message—that McDonald's increased its franchised restaurant percentage from 93% to 95% between 2021 and 2024, reflecting a strategic shift—is fully consistent with the ground truth. The only minor gap is that the LLM does not explicitly mention 'strategic emphasis on franchising as a core business model,' but the implication is clearly conveyed through the interpretation of increased reliance.\n\nThus, the answer earns a 9/10 for correctness due to full factual and quantitative accuracy, with only a slight deduction in qualitative accuracy for not fully echoing the strategic framing, though the reasoning remains logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1155,
        "completion_tokens": 471,
        "total_tokens": 1627
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the effective date and structure of the 2015 Stock Compensation Plan for Non-Employee Directors evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was described as 'amended and restated effective March 31, 2021.' By 2023, the plan was further amended and restated, with a new effective date of 'October 26, 2022.' This indicates that the plan underwent at least one additional amendment during the 2022–2023 period, reflecting a structural or procedural update to the plan’s terms.",
      "llm_answer": "In the 2022 Form 10‑K the “2015 Stock Compensation Plan for Non‑Employee Directors” was described as **amended and restated effective March 31 2021** and it carried **703,256 shares** available for issuance (see 2022 Exhibit 10.21 and the share‑availability table). By the 2023 Form 10‑K the same plan had been **amended and restated again, now effective October 26 2022**, and the pool of shares was **reduced to 589,927** (see 2023 Exhibit 10.22 and the 2023 share‑availability table). This shows the plan’s effective date moved later and its share‑allocation structure was tightened.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: the 2022 Form 10-K references the plan as amended and restated effective March 31, 2021, and the 2023 Form 10-K updates the effective date to October 26, 2022—both dates match the ground truth. (2) The quantitative details—703,256 shares in 2022 and 589,927 in 2023—are factually accurate and correctly reflect a reduction in available shares, which supports the conclusion about a tightened share-allocation structure. These numbers are not in the original answer but are consistent with the knowledge graph and add valuable detail without contradiction. (3) The reasoning is sound: the LLM correctly infers that the plan underwent another amendment between 2022 and 2023, based on the change in effective date and share availability, demonstrating proper multi-hop synthesis across two years of filings. (4) The original answer does not mention share counts, so their inclusion in the LLM response enhances completeness without introducing error. The only reason for not scoring a 10 is that the original ground truth emphasizes the structural or procedural update more generally, while the LLM focuses on share reduction as the structural change—this is reasonable but slightly narrows the interpretation. Overall, the answer is factually excellent, contextually appropriate, and semantically equivalent with added precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 394,
        "total_tokens": 1638
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did Accenture's financial relationship with Duck Creek Technologies evolve between fiscal years 2022 and 2023, particularly in terms of investment valuation and reported financial impact?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with a carrying amount of $138,902, and was accounted for using the equity method. By fiscal 2023, the investment resulted in a $253 million gain, which was specifically called out in the financial statements as impacting the adjusted earnings per share and effective tax rate calculations. This indicates a shift from a long-term equity stake to a more active financial realization event.",
      "llm_answer": "In fiscal 2022 Accenture’s 16 % equity‑method stake in Duck Creek Technologies was carried at $138.9 million, with an estimated fair value of $223.2 million (page 70). By fiscal 2023 the investment had risen enough to generate a $253 million gain that was recognized in the results of operations, boosting earnings and affecting the effective‑tax‑rate and EPS adjustments (page 42). This reflects a marked increase in the investment’s valuation and a positive financial impact on Accenture’s 2023 results.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key facts: Accenture's 16% ownership in Duck Creek Technologies, the $138.9 million carrying amount (vs. $138,902 in original, but clearly rounded appropriately), and the $223.2 million fair value (vs. $223,166, again a valid rounding). The $253 million gain in fiscal 2023 is accurately stated and correctly attributed to impact on earnings, effective tax rate, and EPS adjustments. (2) Quantitative accuracy is excellent—minor rounding differences ($138,902 → $138.9 million; $223,166 → $223.2 million) are acceptable and common in financial reporting. The $253 million gain is reported exactly as in the ground truth. (3) The multi-hop reasoning is sound: the model correctly infers that the gain recognition in 2023 represents a shift from passive equity-method accounting to an active financial event (e.g., partial sale or revaluation), which aligns with the original answer’s conclusion. (4) The only minor shortcoming is that the LLM does not explicitly state that the investment was accounted for under the equity method in 2022, though it mentions the 'equity-method stake,' which implies it. It also omits the precise term 'carrying amount' but uses 'carried at,' which is semantically equivalent. Overall, the answer is factually correct, contextually complete, and conveys the evolution in financial relationship accurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 386,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has the therapeutic application of Breyanzi evolved between 2022 and 2024, and what specific new indications were approved in 2024 that expand its market potential?",
      "original_answer": "In 2022, Breyanzi was indicated for the treatment of adult patients with certain types of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. By 2024, Breyanzi received two new approvals: in March 2024 for the treatment of adult patients with relapsed or refractory CLL or SLL who have received at least two prior lines of therapy, and in May 2024 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. These new indications significantly expand the patient populations eligible for Breyanzi treatment.",
      "llm_answer": "In the 2022 filing Breyanzi was described only for “adult patients with certain types of relapsed or refractory **large B‑cell lymphoma** after two or more lines of systemic therapy”【page_72】. By 2024 the CAR‑T product had been cleared for several additional B‑cell cancers: FDA accelerated approval for **mantle‑cell lymphoma (MCL)** (May 2024)【page_44】, FDA accelerated approval for **follicular lymphoma (FL)** after ≥2 prior lines (May 2024)【page_45】 and a Japanese approval for **FL after one prior line in high‑risk patients** (August 2024)【page_44】, and FDA accelerated approval for **chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)** after ≥2 prior lines (March 2024)【page_45】. These new indications broaden Breyanzi’s market from a single large‑B‑cell lymphoma use to multiple lymphoma subtypes and CLL, substantially expanding its commercial potential.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2022 indication and two of the 2024 approvals — follicular lymphoma (FL) in May 2024 and CLL/SLL in March 2024 — which aligns with the ground truth. However, it introduces a factually incorrect indication: FDA accelerated approval for mantle cell lymphoma (MCL) in May 2024, which is not present in the original answer or supported by the ground truth. This is a significant factual error. Additionally, the mention of a Japanese approval for FL after one prior line in high-risk patients (August 2024) is not referenced in the ground truth, making it extraneous and potentially misleading. (2) Dates for the correct approvals (March and May 2024) are accurate, but the inclusion of an unverified approval (MCL) and a region-specific (Japan) approval not mentioned in the ground truth undermines quantitative accuracy. The core numbers (dates, lines of therapy) for the correct indications match, but the erroneous addition of MCL and Japan-specific data reduces confidence in the numerical and regulatory precision. (3) The reasoning correctly synthesizes the expansion of Breyanzi’s indications over time and concludes that market potential has broadened, which is sound. However, the multi-hop synthesis fails due to the inclusion of unsupported indications, suggesting possible hallucination or misattribution from source documents. The model identifies the correct drug and tracks its evolution, but the addition of incorrect approvals breaks the factual chain. (4) Despite the error, the answer remains contextually relevant, addressing both the evolution of therapeutic use and new indications. The core expansion into CLL/SLL and FL is correct, and the overall narrative of market expansion is justified. However, the introduction of MCL and Japanese approval significantly impacts correctness, warranting a mid-range score. The answer is partially correct but contains key factual inaccuracies that affect reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 534,
        "total_tokens": 1919
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has 3M's approach to estimating and recording insurance receivables related to legal proceedings under ASC 450 evolved between 2022 and 2023, particularly in relation to respirator mask/asbestos litigation?",
      "original_answer": "In 2022, 3M referenced its compliance with ASC 450 for recording liabilities related to legal proceedings but did not specifically mention the methodology for estimating insurance receivables. By 2023, the company explicitly described applying the loss recovery and/or gain contingency models under ASC 450 and ASC 610-30 to estimate insurance receivables, including analysis of policy terms, case law, and claim nature. Additionally, the number of individual claimants in respirator mask/asbestos litigation increased from approximately 4,028 in 2022 to 4,042 in 2023, indicating a growing exposure that likely influenced the more detailed approach to insurance receivables in 2023.",
      "llm_answer": "In the 2022 Form 10‑K, 3M’s disclosure on legal proceedings (see page 36) limited its ASC 450 discussion to accruing probable and reasonably estimable liabilities, with no separate treatment of insurance recoveries. By the 2023 filing, the company added a detailed ASC 450/ASC 610‑30 methodology for estimating insurance receivables—analyzing policy terms, exclusions, case law and claim characteristics (page 80)—and recorded an immaterial insurance receivable for its respirator‑mask/asbestos litigation, while also increasing the liability accrual and continuing to pursue coverage from insolvent insurers (page 82).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, 3M discussed ASC 450 only in relation to liabilities without detailing insurance receivables methodology; by 2023, it explicitly applied ASC 450 and ASC 610-30, incorporating analysis of policy terms, case law, and claim characteristics. The LLM correctly notes the immaterial insurance receivable recorded for respirator mask/asbestos litigation and mentions ongoing efforts to recover from insolvent insurers. (2) Quantitative accuracy is perfect: while no specific dollar amounts are cited in either answer, the increase in claimants (from 4,028 to 4,042) is implied through the mention of growing exposure in the original answer, and the LLM acknowledges continued liability increases without contradicting this. No numerical errors or miscalculations. (3) Multi-hop reasoning is sound: the LLM synthesizes changes in accounting methodology across two years, links it to specific ASC standards, and ties it to the respirator mask/asbestos litigation context. It adds value by referencing page numbers and specifying 'exclusions' and 'claim characteristics'—details consistent with enhanced disclosure. (4) The only minor omission is the exact number of claimants in 2022 and 2023, which the original answer includes as evidence of growing exposure. While the LLM implies increased exposure via 'increasing liability accrual,' the explicit quantitative trend is missing, preventing a perfect 10. However, this does not undermine the core correctness. Wording differs but semantic meaning matches. Contextual relevance is excellent—directly addresses evolution in estimation approach and litigation context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 469,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did PepsiCo's relationship with Naked evolve between 2022 and 2023, particularly in terms of its operational involvement and financial stake?",
      "original_answer": "In 2022, PepsiCo sold its Tropicana, Naked, and other select juice brands to PAI Partners while retaining a 39% noncontrolling interest in a newly formed joint venture, The Beachbody Company (TBG), which operates across North America and Europe. Additionally, PepsiCo acted as the exclusive distributor for TBG's portfolio of brands, including Naked, for small-format and foodservice customers via chilled direct-store-delivery. By 2023, PepsiCo no longer directly distributed Naked products and instead primarily disclosed its relationship through its retained 39% noncontrolling interest in TBG, with no further operational involvement in the distribution of Naked products. This represents a shift from active distribution to a purely financial stake.",
      "llm_answer": "In 2022 PepsiCo sold the Naked juice brand to PAI Partners but retained a 39 % non‑controlling interest in the newly formed joint‑venture (later called Tropicana Brands Group) and became the exclusive U.S. distributor for that joint‑venture’s portfolio—including Naked—through chilled direct‑store‑delivery (see 2022 Europe segment and PBNA description). By 2023 the same structure remained: PepsiCo still holds the 39 % non‑controlling stake and continues to act as the exclusive distributor for the joint‑venture’s brands, so its operational role stayed limited to distribution while its financial ownership stayed at 39 % (see 2023 PBNA and Europe segment).",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also a critical factual error regarding PepsiCo's operational involvement in 2023. It correctly states that in 2022, PepsiCo sold Naked to PAI Partners, retained a 39% noncontrolling interest in the joint venture (TBG), and became the exclusive distributor for the brand via chilled direct-store-delivery. However, it incorrectly claims that this distribution role continued into 2023. The ground truth explicitly states that by 2023, PepsiCo no longer directly distributed Naked products and had ceased operational involvement, maintaining only the 39% financial stake. This misrepresents a key evolution in the relationship. (2) Quantitatively, the 39% stake is correctly reported, and the years (2022, 2023) are accurate. There are no calculation errors, and the numbers align with the original answer. Format variations (e.g., '39 %' vs '39%') are acceptable. (3) The multi-hop reasoning is partially sound—correctly linking the 2022 transaction, the formation of the joint venture, and PepsiCo’s initial distribution role—but fails in synthesizing the change over time. The model does not recognize the shift from operational to purely financial involvement, which is central to the question. It incorrectly assumes continuity between 2022 and 2023. (4) The contextual relevance is moderate: the answer addresses the financial stake and operational role as asked, but due to the error about ongoing distribution, the qualitative accuracy and overall correctness are significantly reduced. The answer would score higher if it reflected the withdrawal from distribution in 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 451,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the accounting treatment or disclosure around the ExtraBucks Rewards program evolved between 2023 and 2024, particularly regarding the recognition of revenue and the determination of performance obligations?",
      "original_answer": "In 2023, the ExtraBucks Rewards program was described as creating an additional performance obligation at the time of the initial transaction, with revenue allocated based on relative standalone selling prices that consider historical redemption patterns. Revenue was recognized as the rewards were redeemed, and unredeemed rewards were reflected as a contract liability. In 2024, the disclosure remained consistent in terms of revenue recognition timing and contract liability treatment, but the language around performance obligations became more refined, emphasizing that the determination of an additional performance obligation was specifically tied to customers who accumulate ExtraBucks based on historical spending levels. The 2024 filing also included more structured language around how the Company allocates transaction prices and evaluates standalone selling prices, suggesting a more mature and formalized approach to the program’s accounting treatment.",
      "llm_answer": "Both the 2023 and 2024 10‑K filings describe ExtraBucks Rewards as a separate performance obligation. The company allocates part of the transaction price to the reward based on its relative standalone selling price, recognizes reward‑related revenue only when the rewards are redeemed, and records any unredeemed balance as a contract liability (2023 Loyalty and Other Programs pp. 131‑133; 2024 Loyalty and Other Programs pp. 125). The 2024 note repeats the same policy and continues to disclose the contract‑liability balance for ExtraBucks Rewards, indicating no material change in accounting treatment or disclosure from 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its description of the accounting treatment for the ExtraBucks Rewards program in both 2023 and 2024, correctly identifying it as a separate performance obligation, the allocation of transaction price based on relative standalone selling price, revenue recognition upon redemption, and the classification of unredeemed rewards as a contract liability. All referenced disclosures (e.g., note titles and page numbers) are consistent with the ground truth, and there are no numerical inaccuracies—thus, quantitative accuracy is perfect. Contextual relevance is high, as the response directly addresses the question’s focus on revenue recognition and performance obligations. However, the qualitative accuracy is lower because the LLM fails to capture the nuanced evolution in the 2024 disclosure. Specifically, it states there was 'no material change in accounting treatment or disclosure,' which contradicts the ground truth that the 2024 filing included more refined language linking the performance obligation to customers who accumulate ExtraBucks based on historical spending levels and demonstrated a more structured, mature approach to allocating transaction prices and evaluating standalone selling prices. This evolution in disclosure sophistication and specificity represents a qualitative shift that the LLM overlooked, resulting in an incomplete assessment of how the accounting treatment or disclosure evolved. While the core mechanics remained consistent, the enhanced clarity and formalization in 2024 constitute a meaningful change in disclosure practice that the model did not acknowledge, leading to a correctness score of 6 due to this significant omission in multi-hop reasoning and synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 473,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Netflix's reliance on integrated payment partners evolved between 2023 and 2024, based on the specific details provided in the cost of revenues section for each year?",
      "original_answer": "In 2023, Netflix specifically mentioned that payment processing fees paid to integrated payment partners were part of other operating costs within the cost of revenues. In 2024, the company continued to reference payment processing fees paid to integrated payment partners as part of other operating costs, but the overall structure of the cost of revenues section was streamlined, removing some of the granular details about these fees. This indicates that while the relationship persisted, the level of explicit detail about the financial impact of integrated payment partners decreased, suggesting a shift in disclosure strategy rather than a substantive discontinuation of the relationship.",
      "llm_answer": "In the 2023 filing Netflix said that “other operations costs include customer‑service and payment‑processing fees, including those we pay to our integrated payment partners” and that cost of revenues was $19.7 billion – 58 % of streaming revenue【page_25†L31-L38】. The 2024 filing repeats the same description of payment‑processing fees to integrated partners, but cost of revenues rose to $21.0 billion (up $1.3 billion) while falling to 54 % of revenue【page_23†L31-L38】【page_23†L45-L48】. Thus Netflix still uses integrated payment partners, but the relative weight of those fees in its cost structure has slipped slightly, indicating a modest reduction in reliance on a per‑revenue basis.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that Netflix continued to use integrated payment partners in both 2023 and 2024, and accurately quotes the language from the filings regarding payment-processing fees being part of other operating costs. It also correctly reports the cost of revenues as $19.7 billion in 2023 (58% of revenue) and $21.0 billion in 2024 (54% of revenue), with a $1.3 billion increase — all quantitatively accurate. (2) However, the LLM misinterprets the implications of the decreased percentage of cost of revenues relative to revenue as indicating a 'modest reduction in reliance' on integrated payment partners on a per-revenue basis. This is speculative and not supported by the ground truth, which emphasizes a change in disclosure strategy (streamlining and reduced granularity), not a change in economic reliance. The ground truth makes clear that the relationship persisted and there is no evidence of reduced reliance — only less detailed reporting. (3) The multi-hop reasoning is partially sound: the model connects the mention of payment partners across two years and incorporates financial data. But it fails to recognize the key qualitative shift noted in the ground truth — the streamlining of the cost of revenues section and reduced disclosure detail — which is central to answering how the 'reliance' (or at least its reporting) evolved. Instead, it substitutes this with a financial ratio analysis that may be mathematically correct but misattributes causality. (4) Therefore, while numbers are accurate and context is relevant, the qualitative interpretation is flawed, leading to a misleading conclusion about evolving reliance. The answer confuses disclosure changes with operational changes, which undermines the correctness despite strong quantitative performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 491,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has 3M's approach to managing PFAS contamination in Minnesota evolved from 2022 to 2023, particularly in response to regulatory changes and new health-based standards?",
      "original_answer": "In 2022, 3M had substantially completed remediation work at the Cottage Grove site and was continuing operational and maintenance activities at Oakdale and Woodbury sites in Minnesota under the May 2007 Settlement Agreement and Consent Order. The company was also addressing PFAS discharges at its Decatur, Alabama facility under a 2020 interim Consent Order with ADEM, which included obligations for on-site and off-site investigations and future capital improvements. By 2023, the Minnesota Department of Health issued updated, more stringent Health Based Values (HBVs) for PFOA and PFOS in January 2024, prompting 3M to evaluate the potential impact on its obligations under the SACO. Additionally, MPCA issued a Notice of Violation in March 2023 alleging PFAS in stormwater discharge at 3M’s Hutchinson facility, and in December 2022, MPCA issued an order addressing stormwater from the Cottage Grove facility. In January 2024, MPCA proposed a new Clean Water Act permit for Cottage Grove with significantly revised, often below-quantification-level limits on PFAS, indicating a tightening regulatory environment that 3M is actively engaging with.",
      "llm_answer": "In the 2022 filing 3M described its work in Minnesota as largely remediation‑focused under the 2007 Settlement Agreement and Consent Order (SACO): it was evaluating PFAS releases, providing alternative drinking water only if a Health‑Based Value (HBV) or Health‑Risk Limit (HRL) was exceeded, and completing remediation at the Oakdale, Woodbury and Cottage Grove sites with only operational‑maintenance activities remaining (page 127). By the 2023 filing the company had added a storm‑water component – developing a MPCA‑approved plan in December 2022, responding to a March 2023 Notice of Violation for PFAS‑laden stormwater at its Hutchinson plant, and, in light of the Minnesota Department of Health’s new, more stringent HBVs for PFOA and PFOS (issued Jan 2024), was actively evaluating how those tighter standards affect its SACO obligations (page 98).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: 3M's remediation focus in 2022 under the 2007 SACO, completion of major work at Oakdale, Woodbury, and Cottage Grove, and ongoing operational maintenance. The 2023 developments are also accurately reflected: the December 2022 MPCA-approved stormwater plan for Cottage Grove, the March 2023 Notice of Violation at Hutchinson, and the January 2024 updated HBVs for PFOA and PFOS by the Minnesota Department of Health. (2) Quantitative accuracy is excellent: all dates (December 2022, March 2023, January 2024) and regulatory actions are correctly cited. The reference to page numbers (127 in 2022, 98 in 2023) adds precision and matches typical 10-K disclosure locations. (3) Multi-hop reasoning is sound—LLM correctly synthesizes information across time (2022 to 2023), locations (multiple Minnesota sites), and regulatory bodies (MPCA, MDH), and connects new health standards to potential impacts on SACO obligations. (4) Minor omission: the original answer mentions the Decatur, Alabama facility and 2020 interim Consent Order with ADEM, which the LLM omits. However, since the question specifically asks about Minnesota, this out-of-scope detail does not detract significantly from correctness. Wording differs slightly (e.g., 'remediation-focused' vs 'substantially completed remediation') but is semantically equivalent. Overall, the LLM captures the evolution in 3M’s approach in response to regulatory changes and new standards with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1508,
        "completion_tokens": 426,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did PepsiCo's use of foreign currency derivatives evolve between 2022 and 2023, and what does this indicate about its foreign exchange risk management strategy?",
      "original_answer": "In 2022, PepsiCo reported a total notional value of $3.0 billion for its foreign currency derivatives, while in 2023, this value increased to $3.8 billion. This indicates a strategic expansion in the use of foreign currency derivatives to manage foreign exchange risk, likely in response to increased exposure or volatility in international markets. Additionally, the company emphasized the use of these derivatives to offset changes in the underlying hedged items, resulting in no material net impact on earnings in 2023.",
      "llm_answer": "PepsiCo’s foreign‑currency derivative program grew substantially – the total notional amount of forward contracts rose from **$3.0 billion at year‑end 2022 to $3.8 billion at year‑end 2023** (and the notional of debt used as net‑investment hedges increased from $2.9 billion to $3.0 billion)【page_103】.  The company notes that it manages FX exposure by sourcing locally, negotiating contracts in local currencies, and using short‑term forward contracts (≤ 2 years) plus net‑investment hedges【page_102】, so the higher notional reflects a more expansive, proactive hedging approach to offset its foreign‑exchange risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the total notional value of foreign currency derivatives increasing from $3.0 billion in 2022 to $3.8 billion in 2023, matching the ground truth exactly. It also provides additional accurate detail about net-investment hedges rising from $2.9 billion to $3.0 billion, which is consistent with the type of hedging activity described in the original answer. All numeric values and years are correct. (2) Quantitative accuracy is perfect: the key figures ($3.0B and $3.8B) are reported accurately with proper year alignment. No calculation errors. (3) The reasoning is sound and reflects multi-hop synthesis: the LLM correctly infers that the increase indicates a more expansive and proactive hedging strategy, aligning with the ground truth's interpretation of strategic expansion in FX risk management. It also correctly references PepsiCo’s broader FX risk mitigation practices (local sourcing, local currency contracts, short-term forwards), which supports the conclusion. The only minor gap is that the LLM does not explicitly state that there was 'no material net impact on earnings in 2023,' which is a key qualitative point in the original answer about the effectiveness of the hedging program. (4) Despite this small omission, the answer is highly accurate, contextually complete, and semantically equivalent in intent and meaning. The added detail about net-investment hedges enhances completeness without introducing error. Thus, correctness is docked slightly to 9 for partial omission of earnings impact, but all other dimensions score at or near perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 442,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has ExxonMobil's approach to capitalizing on improving living standards evolved between 2022 and 2023, particularly in terms of chemical production capacity additions and geographic focus?",
      "original_answer": "In 2022, ExxonMobil highlighted the completion of a joint venture ethane cracker near Corpus Christi, Texas, and plans for up to 500,000 metric tons annually of advanced recycling capacity in Baytown, Texas, by 2026, as part of its strategy to meet growing demand driven by improving living standards. By 2023, the company shifted focus toward expanding performance polymers and linear alpha olefins capacity in Baytown, Texas, and advancing a 100% foreign-owned petrochemical complex in Dayawan, China, with over 2.5 million metric tons per year of polyethylene and polypropylene capacity. This reflects a strategic evolution from domestic advanced recycling and integrated U.S. projects to high-performance product expansions and significant foreign investment in China to meet local demand.",
      "llm_answer": "Both 2022 and 2023 filings note that rising living standards are driving faster‑than‑GDP growth in chemical demand, but the way ExxonMobil adds capacity has shifted. In 2022 the company’s primary move was a final‑investment decision for a multi‑billion‑dollar Dayawan petrochemical complex in Huizhou, Guangdong, making China the focal point for new capacity. By 2023 it broadened its approach, launching two new Gulf‑Coast units in Baytown, Texas—a 400 k t/yr performance‑polymers line and a 350 k t/yr linear‑alpha‑olefins unit—while still advancing the Dayawan project, expanding its geographic focus from China‑centric to a dual‑region (U.S. and China) capacity‑expansion strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the right question and showing reasonable structure. (1) On quantitative accuracy: The LLM incorrectly states that the 2022 move was a 'final-investment decision for a multi-billion-dollar Dayawan petrochemical complex' — however, the ground truth indicates that in 2022, ExxonMobil highlighted the *completion* of the Corpus Christi ethane cracker and *plans* for advanced recycling in Baytown, Texas, not the Dayawan FID. The Dayawan project advancement is correctly noted for 2023, but the LLM misattributes its initiation to 2022. Additionally, the LLM reports 400 k t/yr and 350 k t/yr capacity additions in Baytown for performance polymers and linear alpha olefins — while these numbers are plausible, they are not present in the ground truth, which instead mentions 'expanding performance polymers and linear alpha olefins capacity' without specifying exact figures. Thus, the inclusion of precise numbers without grounding reduces quantitative accuracy. (2) Completeness: The answer addresses the evolution in geographic focus and capacity additions, satisfying the multi-part nature of the question. However, it omits key 2022 initiatives (Corpus Christi cracker completion and Baytown advanced recycling plans) and incorrectly replaces them with the Dayawan FID, which was not part of the 2022 strategy per the original answer. (3) Entity accuracy: The companies (ExxonMobil), locations (Baytown, Texas; Dayawan, China), and product types (performance polymers, linear alpha olefins) are correctly identified. However, the misattribution of the Dayawan project timing and omission of the Corpus Christi cracker affect entity-event alignment. (4) Reasoning: The LLM attempts sound multi-hop reasoning by comparing 2022 and 2023 strategies and identifying a shift in geographic focus. However, because the underlying facts are flawed (wrong project timing, invented capacity numbers), the conclusion about a shift from China-centric to dual-region strategy is based on incorrect premises. The actual evolution per ground truth is from domestic U.S. integrated/advanced recycling projects in 2022 to high-performance product expansions and foreign direct investment in China in 2023 — a more nuanced shift than the LLM captures. (5) Semantic equivalence: While the general theme of strategic evolution is conveyed, the specific factual content diverges significantly, particularly in project timelines and capacities. Therefore, the answer is partially correct but contains major factual errors that reduce its overall correctness to a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 702,
        "total_tokens": 2083
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did 3M's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "In 2022, 3M held $21 million in Certificates of Deposit/Time Deposits, which increased to $49 million in 2023 — more than doubling. This indicates a strategic shift toward increasing liquidity or reallocating short-term cash holdings into more stable or higher-yielding instruments within this category.",
      "llm_answer": "3M’s holdings of certificates of deposit/time deposits more than doubled, rising from **$21 million at year‑end 2022 to $49 million at year‑end 2023** (Note 12 – Marketable Securities). This increase shows the company is shifting a larger portion of its cash into short‑term, highly liquid, low‑risk securities, emphasizing liquidity preservation and modest return generation on excess cash.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the dollar amounts ($21 million in 2022 and $49 million in 2023) are accurate, and the statement that the amount 'more than doubled' is correct (a 133% increase). (2) The answer addresses both parts of the question: the evolution of 3M's investment (increase from $21M to $49M) and the implication for short-term strategy (shift toward liquid, low-risk securities for liquidity preservation and modest returns). (3) Entities are correct: company (3M), financial instrument (Certificates of Deposit/Time Deposits), and time periods (2022 to 2023) all match the ground truth. (4) The reasoning is sound and reflects proper multi-hop synthesis: the increase is tied to a strategic reallocation, and the interpretation aligns with the original answer’s emphasis on liquidity and stable instruments. Minor wording differences (e.g., 'modest return generation' vs 'higher-yielding') are semantically equivalent in context. No factual, numerical, or logical errors present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1181,
        "completion_tokens": 302,
        "total_tokens": 1483
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Mastercard's approach to proprietary insights evolved from 2022 to 2023, particularly in terms of data responsibility and trust-building language?",
      "original_answer": "In 2022, Mastercard described its proprietary insights as being based on the 'principled use of consumer and merchant data.' By 2023, the language evolved to emphasize 'principled and responsible use of secure consumer and merchant data.' This shift indicates a stronger emphasis on data security and trust as a core component of their proprietary insights strategy. The change in phrasing reflects a broader narrative around cybersecurity and stakeholder confidence in how Mastercard manages sensitive data.",
      "llm_answer": "In the 2022 Form 10‑K Mastercard said its value‑added services “provide proprietary insights, drawing on Mastercard’s **principled use of consumer and merchant data**” (2022 10‑K, p. 71). By the 2023 filing the language had been expanded to “provide proprietary insights, drawing on our **principled and responsible use of secure consumer and merchant data**,” explicitly adding “responsible” and “secure” to stress data stewardship and build trust (2023 10‑K, p. 49).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately captures the evolution in Mastercard's language from 'principled use of consumer and merchant data' in 2022 to 'principled and responsible use of secure consumer and merchant data' in 2023, including the addition of 'responsible' and 'secure' as key enhancements. (2) There are no numerical values requiring calculation, but the cited years (2022 and 2023) and document references (Form 10-K, page numbers) are factually accurate and consistent with the source data. (3) The multi-hop reasoning is sound—correctly identifying the change in language across two filings and interpreting the implications around data stewardship and trust-building. (4) The answer is semantically equivalent to the ground truth, with added value in citing specific document locations (p. 71 and p. 49), enhancing credibility. The explanation clearly links the linguistic shift to broader themes of data responsibility and trust, directly addressing the question. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 311,
        "total_tokens": 1557
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did the factors influencing the accounting estimates for pension and retiree medical plans evolve between 2022 and 2023, and what does this indicate about the changing external environment affecting these plans?",
      "original_answer": "In 2022, the accounting estimates for pension and retiree medical plans were influenced by uncertainties related to the ongoing impacts of the COVID-19 pandemic. By 2023, this had evolved, and the estimates were instead influenced by business and economic uncertainty stemming from the ongoing conflicts in Ukraine and the Middle East, as well as a high interest rate and inflationary cost environment. This indicates a shift in the external risk factors affecting the company's pension and retiree medical plans from health-related disruptions to broader macroeconomic and geopolitical concerns.",
      "llm_answer": "In 2022 the company reported a 0.3 % positive impact from its pension and retiree‑medical estimates (see 2022 ROIC table – “Pension and retiree medical‑related impact (0.3)”), whereas the 2023 filing shows a dash (no impact) for the same line item (see 2023 ROIC table – “Pension and retiree medical‑related impact ‑”). The change reflects that the assumptions driving those estimates—discount rates, inflation expectations and other macro‑economic inputs—have been altered by a tougher external environment, namely higher interest rates, rising inflation and ongoing geopolitical uncertainty (Ukraine‑Middle‑East conflicts) that the 2023 critical‑accounting‑policies discussion highlights. This shift signals that the external conditions affecting pension and retiree‑medical plans have become more volatile and less favorable, neutralizing the prior modest benefit.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in external factors affecting pension and retiree medical plans from 2022 to 2023, noting the move from pandemic-related uncertainties to macroeconomic and geopolitical issues such as high interest rates, inflation, and conflicts in Ukraine and the Middle East—this aligns with the ground truth. However, the LLM introduces specific quantitative claims not present in the original answer: it states a '0.3% positive impact' in 2022 and a dash (no impact) in 2023 based on ROIC tables. These numerical details (0.3%, dash in ROIC tables) are not part of the ground truth and cannot be verified from the provided information, making them potentially inaccurate or hallucinated. (2) The quantitative accuracy is reduced because the original answer does not mention any percentage impacts or ROIC tables; thus, the inclusion of '0.3%' and interpretation of a dash as 'no impact' lacks support. While the direction of reasoning (change in assumptions due to environment) is plausible, the specific numbers and table references are not corroborated by the ground truth. (3) The multi-hop reasoning is sound in linking evolving external conditions to changes in accounting estimates. The LLM correctly synthesizes that macroeconomic and geopolitical factors in 2023 replaced health-related disruptions in 2022, which reflects accurate qualitative understanding and contextual evolution. (4) Despite the unsupported numerical specifics, the core conclusion about shifting risk factors (from pandemic to macro/geopolitical) matches the ground truth. Therefore, the answer is mostly correct in reasoning and relevance but penalized for introducing unverified quantitative details, leading to a correctness score of 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 480,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has ExxonMobil's undeveloped acreage position in the Other Americas region evolved between 2022 and 2023, and what does this indicate about the company's exploration potential in that region?",
      "original_answer": "ExxonMobil's undeveloped acreage in the Other Americas region decreased from 25,096 gross and 11,977 net thousands of acres in 2022 to 24,221 gross and 11,548 net thousands of acres in 2023. This indicates a reduction in the total acreage under evaluation, suggesting that some properties may have been relinquished or transitioned to developed status, while the company continues to focus on properties with higher exploration potential.",
      "llm_answer": "ExxonMobil’s undeveloped land in the “Other Americas” fell modestly – from 25,096 gross and 11,977 net thousand acres in 2022 to 24,221 gross and 11,548 net thousand acres in 2023 (a drop of roughly 875 gross and 429 net thousand acres)【page_24】.  The slight reduction suggests the company has relinquished or begun developing a small portion of its holdings, yet it still retains a very large undeveloped base, underscoring continued exploration upside in the region.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all numeric values from the ground truth: gross undeveloped acreage decreased from 25,096 to 24,221 thousand acres, and net acreage from 11,977 to 11,548 thousand acres. These numbers match exactly, and the calculated differences (875 gross and 429 net thousand acres) are accurate. (2) Quantitative accuracy is perfect—numbers, years, and derived differences are correct, with acceptable formatting (e.g., 'thousand acres' vs 'thousands of acres'). (3) The reasoning is sound: the slight reduction is correctly interpreted as possible relinquishment or development, and the retention of a large undeveloped base is used to infer continued exploration potential, which aligns with the original answer’s conclusion. The only minor shortcoming is that the LLM does not explicitly mention the transition to 'developed status' as a possible reason for the decrease, which slightly weakens the qualitative completeness. (4) Contextual relevance is excellent—the response directly addresses both parts of the question: the evolution of acreage and its implication for exploration potential. Overall, the answer is factually complete and semantically equivalent to the ground truth with only a minor omission in explanatory nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 357,
        "total_tokens": 1596
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How did the treatment and financial impact of non-functional currency denominated items evolve from 2022 to 2023, particularly in terms of the use of foreign currency contracts not designated in hedging relationships?",
      "original_answer": "In 2022, MMM used foreign exchange forward and option contracts not designated in hedging relationships to offset the impacts of changes in value of various non-functional currency denominated items, including certain intercompany financing balances, with a gross notional amount of $3.7 billion. By 2023, the company continued to use such contracts for the same purpose but shifted focus to derivatives not designated as hedging instruments, with fair value gains and losses directly impacting earnings. This indicates a shift from primarily designated hedging strategies to a more direct financial exposure management approach.",
      "llm_answer": "The company still relied on foreign‑exchange forwards and options that are **not** designated as cash‑flow or fair‑value hedges to offset the value changes of non‑functional‑currency items, so the fair‑value gains or losses on those contracts continue to be recorded directly in earnings (see 2022 discussion of “foreign currency contracts not designated in hedging relationships” on page 45 and the 2023 “Derivatives Not Designated as Hedging Instruments” tables on pages 76‑78).  However, the scale and impact of those contracts shrank markedly: the gross notional amount fell from about **$2.8 billion at year‑end 2022** to roughly **$1.0 billion at year‑end 2023**, and the earnings impact improved from a **pretax loss of $76 million (a $45 million net loss recognized in income) in 2022** to only a **$9 million loss (or a $21 million gain in income) in 2023** (page 76).  Likewise, the OCI gain on cash‑flow hedges for foreign‑currency forwards/options dropped from **$159 million in 2022** to **$81 million in 2023** (page 75).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative Accuracy: The gross notional amount cited for 2022 is $2.8 billion, but the ground truth states $3.7 billion—a material discrepancy. The 2023 notional amount is reported as $1.0 billion, which is not supported by the original answer (no such figure was provided in the ground truth). The pretax loss of $76 million in 2022 and $9 million loss in 2023, along with the OCI gains of $159 million and $81 million, are entirely absent from the original answer and thus factually unsupported. These numbers appear to be fabricated or misattributed. (2) Completeness: While the question asks about the evolution in treatment and financial impact—especially regarding non-designated foreign currency contracts—the LLM introduces data not present in the ground truth, failing to accurately reflect the actual shift described (from designated to non-designated instruments). (3) Entity Accuracy: The company (MMM) and instruments (foreign exchange forwards/options not designated in hedging relationships) are correctly identified. Years (2022–2023) are correct. However, the financial metrics and their values are incorrect. (4) Reasoning: The LLM attempts multi-hop reasoning by comparing notional amounts and earnings impacts across years, but because the underlying data is wrong, the conclusions about shrinking scale and improved earnings impact are invalid. The original answer emphasizes a strategic shift in approach (from hedging relationships to direct earnings impact), which the LLM partially captures in concept but distorts with false quantitative support. (5) Semantic Equivalence: The general idea of using non-designated contracts is correct, but the detailed financial evolution is misrepresented. The original answer does not mention any reduction in notional value or specific gains/losses, so the LLM’s detailed numerical narrative contradicts the ground truth. Overall, while the directional theme of using non-designated contracts is present, the heavy reliance on incorrect figures results in a largely incorrect assessment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 572,
        "total_tokens": 2006
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the role and emphasis of Cyber and Intelligence Solutions evolved within Mastercard's value proposition between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were mentioned as part of a broader list of value-added services, grouped alongside consulting fees, loyalty programs, gateway services, and other payment-related offerings. This suggests a supporting role within the company's portfolio. By 2023, the Cyber and Intelligence Solutions were more prominently positioned as a core component of Mastercard’s value proposition, explicitly described as enabling secure, easy, and confident transactions across the global payments ecosystem. This indicates a strategic shift toward elevating the importance of cybersecurity within Mastercard’s overall service offering.",
      "llm_answer": "In the 2022 10‑K, cyber and intelligence solutions were mentioned only as one item in a catch‑all “other value‑added services” category (“…other value‑added services comprised of … cyber and intelligence solutions…” – page 81). By the 2023 filing, Mastercard highlights them in its Business Overview and lists “Cyber and intelligence solutions fees” as a separate revenue line, stressing fraud‑prevention, transaction safety and secure data‑driven insights (“…cyber and intelligence solutions designed to allow all parties to transact securely, easily and with confidence…” – page 49; “Cyber and intelligence solutions fees are for products and services … to prevent, detect and respond to fraud…” – page 80). This reflects a shift from a peripheral offering in 2022 to a prominently featured, strategic component of Mastercard’s value proposition in 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately captures the evolution of Cyber and Intelligence Solutions within Mastercard's value proposition from 2022 to 2023: in 2022, the service was listed as a minor component within 'other value-added services,' while in 2023, it was elevated to a standalone, strategically emphasized offering. (2) There are no numeric values (e.g., dollar amounts, percentages) in the question or ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of 10-K filings, identifying both the structural change (from grouped item to separate revenue line) and the qualitative shift in language (from passive listing to active emphasis on security, fraud prevention, and confidence in transactions). (4) The LLM provides specific citations (page numbers and quotes) from both filings, enhancing accuracy and traceability. The semantic meaning, depth, and factual content match the ground truth exactly, with added detail (e.g., mention of fraud prevention and data-driven insights) that enriches without distorting. All entities—Mastercard, Cyber and Intelligence Solutions, 2022 and 2023 timeframes—are correctly identified and contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 370,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the treatment or disclosure of Income Tax Expense and Accruals evolved in the list of critical accounting policies between 2022 and 2023?",
      "original_answer": "In 2022, 'income tax expense and accruals' was explicitly listed as one of the critical accounting policies and estimates, indicating its significance in financial reporting. By 2023, while still listed as a critical accounting policy, it was moved to a subsection under 'Our Critical Accounting Policies and Estimates' with a more structured presentation of related notes, such as Note 5 - Income Taxes, which provided deeper transparency into tax-related disclosures. This evolution reflects a shift toward more detailed and organized reporting of tax-related matters in 2023.",
      "llm_answer": "In the 2022 filing the company’s critical‑accounting‑policy section actually spells out the tax policy – it explains that the annual tax rate is based on statutory rates, transfer‑pricing and other factors, that significant judgment is required, and that reserves (and related interest) are set up and adjusted for positions that may be challenged (PEP 2022 p. 61). In the 2023 filing the same “Income Tax Expense and Accruals” item is still listed among the critical accounting policies (PEP 2023 p. 33) but only the heading is shown, with the detailed narrative apparently moved to the dedicated Income Taxes note (Note 5, p. 84), indicating the policy remains unchanged in substance but the disclosure has been streamlined.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that 'Income Tax Expense and Accruals' was explicitly detailed in the 2022 critical accounting policies and remained a listed item in 2023, which matches the original answer. (2) No numeric values (e.g., dollar amounts, percentages) are involved in the question or ground truth, so quantitative accuracy is not applicable—no errors here. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years (2022 and 2023), identifies the change in disclosure format (from narrative in critical policies to a referenced note), and cites specific locations (PEP 2022 p.61, PEP 2023 p.33, Note 5 p.84), which supports its claims. (4) The LLM captures the core evolution—continued recognition as a critical policy but with restructured, more streamlined disclosure—though it uses 'streamlined' rather than 'more structured' or 'deeper transparency.' This is a minor wording difference; the semantic meaning is equivalent. The only reason for not scoring a 10 is that the LLM slightly underemphasizes the increased depth of disclosure in Note 5, focusing more on streamlining than enhanced transparency, but it does acknowledge the movement of detailed content to Note 5. Overall, the answer is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 381,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Intel's development and positioning of the Universal Chiplet Interconnect Express standard evolved between 2023 and 2024 in the context of its broader systems of chips strategy?",
      "original_answer": "In 2023, Intel introduced the Universal Chiplet Interconnect Express (UCIe) standard and demonstrated it in silicon, marking the initial phase of its strategic push to enable optimized systems of chips. By 2024, Intel had progressed beyond the demonstration phase and was actively producing based on this standard, integrating it into its broader advanced semiconductor assembly and test offerings. This evolution reflects Intel's deepening commitment to the UCIe standard as a core component of its systems of chips strategy, aimed at enhancing system performance and accelerating customer designs through advanced packaging technologies and system-level standards.",
      "llm_answer": "In the 2023 filing Intel said it was actively “driving … standards … including the Universal Chiplet Interconnect Express* standard … which was demonstrated in silicon in 2023” as a pillar of its systems‑of‑chips strategy【page_37】. By the 2024 filing the company repeats that message, now embedding UCIe in the description of its advanced packaging and foundry roadmap (Intel 18A, 3, 7, etc.) and stressing that it continues to “drive … the Universal Chiplet Interconnect Express* standard … which we demonstrated in silicon in 2023” as a core component of its broader systems‑of‑chips capabilities【page_22】. This shows the standard moving from a 2023 proof‑of‑concept demonstration to a highlighted, integrated element of Intel’s commercial packaging and foundry offerings in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: UCIe was introduced and demonstrated in silicon in 2023, and by 2024 it was integrated into Intel's advanced packaging and foundry roadmap (e.g., Intel 18A), confirming its transition from demonstration to production. The entity names (Universal Chiplet Interconnect Express, systems-of-chips strategy), years (2023, 2024), and technological context (advanced packaging, foundry offerings) are accurately identified. (2) There are no numeric values requiring calculation, but the dates (2023 demonstration, 2024 integration) are correctly cited and consistent with the original answer. (3) The multi-hop reasoning is sound—LLM synthesizes information from two time points (2023 and 2024 filings) to show evolution in strategy, correctly inferring progression from proof-of-concept to commercial integration. (4) The answer is semantically equivalent to the ground truth, with only minor differences in phrasing (e.g., 'actively producing' in ground truth vs. 'embedding in roadmap' in LLM answer); however, the LLM slightly underemphasizes explicit mention of 'production' or 'advanced semiconductor assembly and test offerings' but compensates by referencing 'commercial packaging and foundry offerings'. This minor omission does not detract significantly from overall accuracy. Hence, a score of 9 is warranted for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 420,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the accounting treatment and completion timeline of CVS's Accelerated Share Repurchase (ASR) transactions evolved between the 2023 and 2024 10-K filings?",
      "original_answer": "In 2023, CVS completed a $2.0 billion ASR with Citibank, receiving 17.4 million shares initially (80% of the notional amount) and an additional 5.4 million shares in February 2023, concluding the transaction. The forward contract portion was reclassified from capital surplus to treasury stock upon completion. In 2024, CVS completed a $3.0 billion ASR with Morgan Stanley, initially receiving 31.4 million shares (85% of the notional amount) and an additional 8.3 million shares in March 2024. Similar to 2023, the forward contract was reclassified from capital surplus to treasury stock after the final shares were received. The accounting treatment remained consistent, but the scale and timeline of completion evolved, with the 2024 ASR taking two months to conclude compared to one month in 2023.",
      "llm_answer": "In the 2023 10‑K the $3.0 billion Morgan Stanley ASR was described only as a partial delivery (85 % of the shares received in January 2024) with the remaining 15 % “may be received” and no explicit split‑accounting was given; the $2.0 billion Citibank and $1.5 billion Barclays ASRs were each recorded as an initial treasury‑stock purchase plus a forward contract recorded in capital surplus, with the forward contract re‑classified to treasury stock when the final shares were delivered (February 2023 and February 2022). The 2024 10‑K updates the Morgan Stanley ASR to show it was initially booked as $2.6 billion of treasury stock and a $0.4 billion forward contract (equity instrument in capital surplus) and confirms that the remaining 8.3 million shares were received in March 2024, at which point the forward contract was re‑classified to treasury stock, completing the transaction. The accounting and completion timing for the Citibank and Barclays ASRs remain unchanged from the prior filing.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors and misrepresents key details from the ground truth. (1) Quantitative inaccuracies: The LLM incorrectly states that the $3.0 billion Morgan Stanley ASR was described in the 2023 10-K, but the ground truth indicates this was a 2024 transaction. It also falsely claims a $1.5 billion Barclays ASR occurred in 2022, which is not mentioned in the original answer. The LLM says 8.3 million additional shares were received in March 2024 (correct), but incorrectly frames this as part of a forward-looking statement in the 2023 filing when it should be reported as completed in the 2024 filing. (2) The initial share delivery for the 2024 ASR is misrepresented: the LLM says 85% was received in January 2024, but does not correctly tie this to the 31.4 million shares stated in the ground truth. While $2.6B and $0.4B add up to $3.0B, the original answer does not specify this split, so asserting this level of accounting detail reduces accuracy due to unsupported precision. (3) The LLM incorrectly references the 2023 10-K discussing the Morgan Stanley ASR as a partial delivery, but the ground truth states the 2023 filing covers the Citibank ASR, not Morgan Stanley. This confuses the timeline and entities across filings. (4) The mention of a Barclays ASR in February 2022 is entirely fabricated and not in the original answer, indicating a failure in entity accuracy. (5) While the LLM correctly notes the reclassification from capital surplus to treasury stock upon completion, this accounting treatment is applied to non-existent or misdated transactions, undermining qualitative accuracy. (6) Contextual relevance is moderate because the structure addresses accounting treatment and timeline evolution, but the factual foundation is flawed. The core evolution — larger scale and longer duration in 2024 — is missed because the LLM misattributes events. Overall, major errors in numbers, dates, entities, and document-year alignment result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1454,
        "completion_tokens": 540,
        "total_tokens": 1995
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did UPS's financial exposure and reporting approach related to the Central States Pension Fund evolve from 2022 to 2023, particularly in terms of actuarial estimates and sensitivity analysis?",
      "original_answer": "In 2022, UPS disclosed a $2.3 billion pre-tax actuarial loss related to potential coordinating benefits for the Central States Pension Fund, as part of broader pension obligation disclosures. By 2023, the company's reporting shifted focus to sensitivity analysis, referencing a 25 basis point change in expected and actual returns on assets as a key assumption affecting pension liabilities, with an explicit cross-reference to Note 5 for details on the Central States Pension Fund liability. This indicates a shift from quantifying a specific obligation to emphasizing the sensitivity of returns on the overall liability.",
      "llm_answer": "In the 2022 Form 10‑K UPS disclosed a **$5.1 billion pre‑tax actuarial gain** for “coordinating benefits attributable to the Central States Pension Fund,” showing that its best‑estimate liability for the CSPF had been reduced. In the 2023 filing the company no longer reported a separate gain/loss; instead it folded the CSPF exposure into a **quantitative sensitivity analysis** – a 25‑basis‑point change in the discount rate would swing the projected benefit obligation by about **‑$1.55 billion** (rate increase) or **+$1.64 billion** (rate decrease) – and it directs readers to Note 5 for the detailed potential coordinating‑benefits liability, reflecting a shift to scenario‑based reporting of the pension‑fund exposure.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual errors. The ground truth states that UPS reported a $2.3 billion *pre-tax actuarial loss* in 2022 related to the Central States Pension Fund, but the LLM incorrectly claims a $5.1 billion *actuarial gain*. This is a critical reversal in both direction (gain vs. loss) and magnitude ($5.1B vs $2.3B). Additionally, the LLM introduces a sensitivity analysis around a 25-basis-point change in the *discount rate* affecting the obligation by ~$1.55B–$1.64B, but the original answer specifies the sensitivity is to a 25-basis-point change in *expected and actual returns on assets*, not the discount rate. These numbers ($1.55B/$1.64B) do not appear in the ground truth and are therefore fabricated or misattributed. (2) Quantitative accuracy is extremely low: all key figures are incorrect—$5.1B gain (vs $2.3B loss), incorrect sensitivity values, and wrong driver (discount rate vs return on assets). No calculation can be verified as correct. (3) The qualitative reasoning partially captures the shift in reporting approach—from a specific actuarial estimate in 2022 to a broader sensitivity analysis in 2023—and correctly notes cross-referencing to Note 5. However, the misidentification of the sensitivity variable (discount rate vs return on assets) undermines the validity of the multi-hop synthesis. The conclusion about a shift to scenario-based reporting is semantically aligned but based on incorrect premises. (4) Contextual relevance is moderate because the answer addresses the evolution of reporting and attempts to compare 2022 and 2023 disclosures, but the core financial facts are wrong, leading to a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 463,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Mastercard's positioning and emphasis on its Cyber and Intelligence Solutions evolved between 2022 and 2023, particularly in terms of the value proposition communicated to stakeholders?",
      "original_answer": "In 2022, Mastercard described its Cyber and Intelligence Solutions as part of its value-added services that 'allow all parties to transact easily and with confidence' and emphasized principled use of consumer and merchant data. By 2023, the company expanded this messaging, positioning the solutions as central to enabling secure transactions and confidence in the payments ecosystem, while also linking them to strategic investments in new networks like open banking and digital identity. This reflects a broader integration of cyber solutions into the company's overall infrastructure narrative.",
      "llm_answer": "In the 2022 filing, Mastercard presented its Cyber & Intelligence solutions as a component of its value‑added services that “allow all parties to transact easily and with confidence,” and even cited them as a primary driver of revenue growth. By the 2023 filing, the messaging was sharpened to say the solutions are “designed to allow all parties to transact securely, easily and with confidence,” adding an explicit focus on security and the principled, responsible use of consumer and merchant data—signaling a stronger, security‑centric value proposition to stakeholders.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the evolution in Mastercard's messaging around Cyber & Intelligence Solutions between 2022 and 2023, with accurate entity and year references. It correctly quotes the 2022 value proposition and notes the addition of 'securely' in 2023, reflecting a stronger security emphasis. However, it introduces a claim not present in the original answer—specifically, that Cyber & Intelligence Solutions were cited as a 'primary driver of revenue growth' in 2022—which is not supported by the ground truth and represents an overstatement. Additionally, while the LLM captures the enhanced focus on security and data responsibility, it omits the key 2023 strategic linkage to new networks like open banking and digital identity, which is a significant part of the expanded value proposition in the original answer. This omission reduces completeness and weakens the multi-hop synthesis. Quantitatively, there are no numbers to verify, so accuracy is high by default. The reasoning is mostly sound but lacks full integration of the infrastructure narrative shift. The answer remains contextually relevant and semantically close, but with notable gaps in completeness and one unsupported addition.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 341,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did PepsiCo's presentation of the 4.450% Senior Note due 2046 evolve between its 2022 and 2023 SEC filings, particularly in terms of exhibit referencing and associated documentation dates?",
      "original_answer": "In the 2022 filing, the 4.450% Senior Note due 2046 was listed as Exhibit 4.12, incorporated by reference from PepsiCo's Form 8-K filed on October 14, 2015. In the 2023 filing, the same note was reclassified as Exhibit 4.13 and referenced the Form 8-K filed on February 24, 2016. This indicates a shift in how PepsiCo organized or updated its capital structure disclosures, potentially reflecting revised documentation or administrative reclassification over time.",
      "llm_answer": "In the 2022 Form 10‑K PepsiCo listed the 4.450 % Senior Note that matures in 2046 as a stand‑alone exhibit (Exhibit 4.11) and also in the exhibit table as Exhibit 4.13, both “incorporated by reference to Exhibit 4.4 to PepsiCo’s Current Report on Form 8‑K filed on October 14 2015 (the table cites a February 24 2016 filing). By the 2023 Form 10‑K the 4.450 % ‑ 2046 note no longer appears as a separate exhibit; the 4.450 % series is shown only for newer maturities (2028 and 2033) and each is referenced to Exhibit 4.3/4.4 to a Current Report on Form 8‑K filed on February 15 2023. Thus the older 2046 note and its 2015/2016 documentation were removed and replaced with updated exhibit references and more recent filing dates.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) In the 2022 filing, the 4.450% Senior Note due 2046 was listed as Exhibit 4.12 (not Exhibit 4.11 or 4.13 as claimed), incorporated by reference from the October 14, 2015 Form 8-K. The LLM incorrectly states it appears twice (Exhibit 4.11 and 4.13) and misrepresents the referencing. (2) The LLM claims that in the 2023 filing, the 2046 note 'no longer appears as a separate exhibit' and was replaced by newer maturities (2028, 2033) with references to a February 15, 2023 Form 8-K. This is incorrect: according to the ground truth, the same 4.450% Senior Note due 2046 was reclassified as Exhibit 4.13 in 2023 and referenced the February 24, 2016 Form 8-K — not a 2023 filing. (3) The LLM incorrectly asserts that the note was removed and replaced with updated documentation, which contradicts the ground truth showing only a reclassification and updated exhibit number. (4) Multiple dates are wrong: October 14, 2015 is correctly cited in the original but conflated in the LLM answer with a February 24, 2016 filing (which the LLM incorrectly says was cited in the 2022 table), and then replaced with a completely incorrect February 15, 2023 Form 8-K. (5) The multi-hop reasoning fails: the model does not correctly track the same financial instrument across filings but instead invents a narrative of replacement. While the answer attempts to address exhibit referencing and documentation dates (hence moderate contextual relevance), the core facts — exhibit numbers, dates, presence/absence of the note, and associated filings — are largely incorrect. Minor semantic alignment exists (e.g., recognizing exhibit reorganization), but factual and quantitative accuracy is poor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 478,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Intel's relationship with Positive Technologies evolved between 2023 and 2024, particularly in terms of their engagement under OFAC licensing following the U.S. sanctions?",
      "original_answer": "In 2023, Intel disclosed that it had communicated with Positive Technologies regarding IT security research and coordinated disclosure of vulnerabilities, and that it resumed such communications under an OFAC license following the sanctions. By 2024, Intel's relationship had evolved from mere disclosure of past communication to an explicit statement of intent to continue these interactions in accordance with the OFAC license. While both years clarify that there were no gross revenues or net profits associated with these activities, the 2024 filing reflects a more forward-looking and sustained partnership posture with Positive Technologies under the sanctioned conditions.",
      "llm_answer": "Intel’s approach to Positive Technologies has not changed. In its 2023 filing Intel noted that after the firm was placed on the U.S. sanctions list, it “resumed such communications based on a license issued by OFAC” and that it “plans to continue these communications in accordance with the terms and conditions of the OFAC license” with no gross revenues or net profits 【page_71】. The 2024 filing repeats the same disclosure, stating that Intel “resumed such communications based on a license issued by OFAC” and again “plans to continue these communications in accordance with the terms and conditions of the OFAC license” with no revenue impact 【page_54】. Thus, between 2023 and 2024 Intel’s relationship with Positive Technologies remained consistent—ongoing, license‑authorized communications with no financial gain.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the original answer in terms of entities, dates, and the absence of financial gain, and correctly cites OFAC licensing and the resumption of communications in both 2023 and 2024. Quantitative accuracy is perfect—there are no numerical errors, and the claim about no gross revenues or net profits is correctly repeated. Contextual relevance is high, as the response directly addresses Intel’s relationship with Positive Technologies under U.S. sanctions and OFAC licensing. However, the qualitative accuracy is low because the LLM incorrectly concludes that Intel’s approach 'has not changed' and that the relationship 'remained consistent,' which contradicts the ground truth. The original answer emphasizes an evolution in tone and posture—from disclosing past communication in 2023 to expressing a forward-looking intent to sustain the partnership in 2024. This nuance represents a meaningful shift in strategic posture, which the LLM overlooks by treating verbatim similarity in disclosure language as evidence of no change. Thus, while the surface facts are correct, the reasoning fails to capture the multi-hop insight that identical wording can reflect a deeper, evolving relationship, leading to an incorrect overall conclusion about the nature of the evolution between 2023 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 370,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has the balance of CVS's 4.78% Senior Notes due March 2038 evolved between 2023 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "The balance of CVS's 4.78% Senior Notes due March 2038 remained stable at $5,000 million in both 2023 and 2024, indicating that the company did not retire or issue additional amounts of this particular debt instrument during the period. This stability contrasts with other senior notes, such as the 2.7% senior notes due August 2040, which decreased from $1,250 million in 2023 to $367 million in 2024, suggesting selective debt management and refinancing activity in other long-term obligations.",
      "llm_answer": "The table of borrowings shows that CVS carried $5 billion of its 4.78 % senior notes due March 2038 at both December 31 2023 and December 31 2024 (page 161), the same amount reported for 2023 in the prior filing (page 168). This unchanged balance indicates that the company has left this tranche of fixed‑rate senior debt untouched, making it a stable, sizable component of CVS’s long‑term debt structure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that the balance of CVS's 4.78% Senior Notes due March 2038 remained at $5,000 million (i.e., $5 billion) in both 2023 and 2024, matching the ground truth exactly. The use of 'billion' instead of 'million' is semantically equivalent and correctly interpreted. The dates (December 31, 2023 and 2024) align with standard fiscal reporting periods and are consistent with the knowledge graph. (2) All numeric values—$5 billion, 4.78%, March 2038 maturity—are accurate and correctly formatted. No calculations were required, but the comparison across years is correctly interpreted as stable. (3) The reasoning is sound: the LLM correctly infers that the unchanged balance indicates the debt tranche was untouched, contributing to stability in the long-term debt structure. However, the LLM omits the contrast with other senior notes (e.g., the 2.7% notes due 2040 decreasing from $1,250M to $367M), which is a key part of the multi-hop reasoning in the original answer. This limits completeness and slightly weakens the qualitative accuracy, though the core logic remains valid. (4) The answer is highly contextually relevant, directly addressing the evolution of the specific debt instrument and its implication for long-term debt structure. The minor omission of comparative debt activity prevents a perfect score, but the response is factually correct, well-supported, and semantically aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 404,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has the status of the 0.835% Notes due 2032 evolved between the 2022 and 2024 SEC filings for Exxon Mobil Corporation?",
      "original_answer": "In the 2022 filing, the 0.835% Notes due 2032 were listed among other notes with distinct trading symbols, including the 0.142% Notes due 2024 (XOM24B), indicating a broader set of publicly traded debt instruments. By 2024, the 0.835% Notes due 2032 remained listed with the trading symbol XOM32, but the 0.142% Notes due 2024 no longer appeared in the 2024 filing, suggesting that the 2024 notes were either redeemed or no longer publicly traded. Therefore, while the 0.835% Notes due 2032 remained a consistent part of Exxon Mobil's publicly disclosed debt structure, the removal of the 2024 notes indicates a change in the company's short-to-intermediate term debt composition.",
      "llm_answer": "The 0.835% Notes due 2032 (ticker XOM32) were listed in the 2022 Form 10‑K’s “Securities registered pursuant to Section 12(b)” table, showing they were an outstanding, NYSE‑listed debt instrument【page_1】. The same 0.835% Notes due 2032 appear again in the 2024 Form 10‑K’s registration table, indicating they remain outstanding and listed with no change in status【page_1】.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies that the 0.835% Notes due 2032 (XOM32) were listed in both the 2022 and 2024 Form 10-K filings, confirming their continued status as outstanding and NYSE-listed debt instruments. All quantitative details—interest rate (0.835%), maturity year (2032), ticker symbol (XOM32), and listing venue (NYSE)—are accurate and match the ground truth. The reasoning regarding the note’s unchanged status is sound and factually supported. However, the LLM answer omits a key comparative insight present in the original answer: the disappearance of the 0.142% Notes due 2024 (XOM24B) from the 2024 filing, which provides context for changes in Exxon Mobil’s broader debt composition. While the core focus—status of the 0.835% Notes due 2032—is correctly addressed, the lack of this contextual contrast limits the completeness of the multi-hop analysis. The answer remains semantically aligned with the ground truth on the primary point but misses an opportunity to enrich the response with relevant comparative detail. Thus, it scores highly on quantitative and contextual accuracy but slightly lower on qualitative accuracy due to incomplete synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 330,
        "total_tokens": 1587
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has American Express's investment strategy toward U.S. Government treasury obligations evolved between 2022 and 2024, particularly in terms of fair value allocation and maturity distribution?",
      "original_answer": "In 2022, American Express held U.S. Government treasury obligations exclusively in short-term instruments with a fair value of $477 million and no long-term exposure. By 2024, the company shifted its strategy to include both short-term ($189 million) and intermediate-term ($98 million) treasury obligations, indicating a more diversified maturity profile. This reflects a transformation in the company's investment approach, expanding beyond less than 12-month instruments to include holdings maturing within 1 to 5 years.",
      "llm_answer": "In the 2022 filing American Express still held a large Treasury portfolio – about $1.7 billion at fair value (cost $1.68 billion) with roughly $832 million maturing within one year, $862 million in the 1‑to‑5‑year window and a small $10 million tranche beyond five years 【page_120†L13-L16】【page_121†L13-L20】. By the 2024 filing that exposure had been trimmed to roughly $287 million fair value (cost $289 million) and was concentrated in $189 million of securities due within one year and $98 million due in 1‑5 years, with no longer‑dated Treasury holdings 【page_124†L13-L16】【page_126†L13-L19】. This reflects a strategic shift away from larger, longer‑dated Treasury positions toward a much smaller, short‑term Treasury allocation.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 American Express held *exclusively short-term* U.S. Treasury obligations with a fair value of $477 million and *no long-term exposure*. However, the LLM claims a $1.7 billion portfolio with $832 million maturing within one year, $862 million in 1–5 years, and $10 million beyond five years—this contradicts the ground truth entirely. The 2024 figures ($189 million short-term, $98 million intermediate-term) align with the ground truth, but the total fair value is incorrectly stated as $287 million (correct sum: $189M + $98M = $287M), which matches numerically but misrepresents the strategy shift due to the erroneous 2022 data. (2) Quantitative accuracy fails on 2022 numbers: $477M (correct) vs. $1.7B (claimed); presence of intermediate/long-term holdings in 2022 is false. The 2024 numbers are quantitatively accurate. (3) Multi-hop reasoning is flawed because the LLM incorrectly infers a 'strategic shift away from longer-dated positions' when in fact there were *no* such positions in 2022 per the ground truth. The actual evolution—from only short-term to including intermediate-term—is misrepresented due to incorrect input data. (4) Contextual relevance is high as the answer addresses fair value allocation and maturity distribution across years, but factual correctness is severely compromised. Thus, correctness score is low due to major factual and quantitative errors despite correct structure and partial data in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 426,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Amazon's introduction and subsequent treatment of the 2.500% Note due 2050 evolve between 2022 and 2024?",
      "original_answer": "In 2022, the 2.500% Note due 2050 was introduced as part of an Officers' Certificate dated June 3, 2020, and was listed alongside other notes in Exhibit 4.5. By 2024, the 2.500% Note due 2050 was reintroduced in Exhibit 4.6, which was an exact replication of Exhibit 4.5 from 2020, indicating that Amazon continued to maintain this long-term debt instrument without modification. The reintroduction in 2024 reaffirmed the note's role in Amazon's capital structure.",
      "llm_answer": "Amazon first disclosed the 2.500 % Note due 2050 in its 2022 Form 10‑K, where it appeared as Exhibit 4.5 – an Officers’ Certificate dated June 3 2020 that listed the note (along with a 2.700 % Note due 2060). In the 2024 Form 10‑K the same certificate and note were still outstanding, now shown as Exhibit 4.6 (still referencing the June 3 2020 Officers’ Certificate), indicating the note remained on Amazon’s books with no amendment, redemption or removal between the two filings.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: the 2.500% Note due 2050 was first disclosed in the 2022 Form 10-K as Exhibit 4.5, originating from an Officers' Certificate dated June 3, 2020, and reappeared in the 2024 Form 10-K as Exhibit 4.6, which is a replication of the prior exhibit. (2) Quantitative elements—interest rate (2.500%), year of note maturity (2050), date of Officers' Certificate (June 3, 2020)—are all precisely correct. (3) The reasoning correctly synthesizes multi-hop information: it identifies the initial disclosure in 2022, tracks the note’s continued presence in 2024, and infers no changes were made based on the reuse of the same certificate. (4) The answer fully addresses the evolution of the note between 2022 and 2024, noting its reintroduction without modification, thus capturing the core intent of the question. Wording differs slightly but meaning is preserved. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 294,
        "total_tokens": 1522
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the number of amendments to the Citibank, N.A. Co-Branded Credit Card Agreement evolve between 2022 and 2023?",
      "original_answer": "In 2022, the most recent amendment to the Citibank, N.A. Co-Branded Credit Card Agreement was the Eighth Amendment, filed on March 10, 2022. By 2023, the agreement had undergone further modifications, with the Twelfth Amendment being filed on October 11, 2023, indicating a total of four additional amendments during this period. This demonstrates a continued evolution and refinement of the agreement terms over the 12-month period.",
      "llm_answer": "The 2022 Form 10‑K lists the eighth, ninth and tenth amendments (10.8.8‑10.8.10), showing that ten amendments to the Citibank, N.A. Co‑Branded Credit Card Agreement had been filed by the end of 2022【page_68†L7-L13】. The 2023 filing adds the eleventh and twelfth amendments (10.8.11 and 10.8.12), bringing the total to twelve amendments as of 2023【page_68†L13-L18】. Thus, the agreement saw two additional amendments in 2023, increasing the count from ten to twelve.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the number of amendments in 2022. The ground truth states that the most recent amendment in 2022 was the Eighth Amendment, filed on March 10, 2022. However, the LLM claims that by the end of 2022, ten amendments had been filed, citing the eighth, ninth, and tenth amendments. This contradicts the original answer and implies two additional amendments beyond what is stated as true. (2) The quantitative error is critical: the LLM incorrectly reports the total number of amendments at the end of 2022 as ten instead of eight, and then claims two additional amendments in 2023 (from ten to twelve), while the ground truth states four additional amendments occurred (from eighth to twelfth), meaning four new amendments were filed in 2023, not two. The dates of the Twelfth Amendment (October 11, 2023) are not mentioned in the LLM answer, further reducing accuracy. (3) The reasoning is partially sound in that it attempts multi-hop synthesis by comparing filings across 2022 and 2023 and identifying amendment numbers from document references. However, it fails in correctly interpreting the cumulative count — if the Eighth Amendment was the latest in 2022, then amendments ninth through twelfth (four total) must have been filed in 2023, not just eleventh and twelfth. The LLM appears to misread or misrepresent the 2022 filing as including up to the tenth amendment, which contradicts the ground truth. (4) Contextual relevance is high because the answer addresses the evolution of amendments and uses appropriate document citations. However, due to major quantitative and factual errors in amendment counts and implied timeline, the correctness score is low. The answer conveys a different factual narrative than the ground truth, despite similar structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 499,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration with new computing architectures and software ecosystems?",
      "original_answer": "In 2022, NVIDIA emphasized CUDA as a foundational building block across its target markets, including Gaming, Data Center, Professional Visualization, and Automotive, highlighting its role in enabling accelerated computing and deep learning. CUDA was positioned as a core component of the company's unified architecture, supporting a wide range of applications through internal and third-party software stacks. By 2024, NVIDIA had significantly expanded the scope of CUDA's integration, describing it as part of a broader full-stack computing platform that includes the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific application frameworks. Additionally, CUDA was now explicitly tied to NVIDIA's expanded data center platform, which now includes CPUs (introduced in fiscal 2024) alongside GPUs and DPUs, showing a strategic evolution toward deeper integration with heterogeneous computing architectures and enterprise-grade AI ecosystems.",
      "llm_answer": "In the 2022 filing NVIDIA described CUDA as the core programming model that, together with its GPUs, formed the unified foundation for its data‑center, gaming, professional‑visualization and automotive platforms and supported a large developer community (≈3 million) (2022 p.7‑9, 11). By the 2024 filing CUDA is presented as the foundational layer of a full‑stack platform that now runs on all NVIDIA GPUs and is tightly integrated with the new Grace CPUs, DPUs and the Blackwell GPU architecture, and is packaged with an expanded CUDA‑X library suite, APIs, SDKs and AI‑Enterprise services, showing deeper coupling with emerging hardware and a broader software ecosystem (2024 p.4‑6).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies CUDA's role in 2022 as the core programming model across NVIDIA's key markets (Gaming, Data Center, etc.) and notes its foundational status in the unified architecture, matching the original answer. The mention of a large developer community (~3 million) is an additional detail not in the ground truth but does not contradict it and is consistent with public disclosures. (2) For 2024, the LLM accurately captures the evolution of CUDA into a full-stack platform integrated with new hardware (Grace CPUs, DPUs, Blackwell GPU architecture) and expanded software (CUDA-X, APIs, SDKs, AI-Enterprise services), which reflects the broader ecosystem integration described in the ground truth. The reference to fiscal 2024 CPU introduction is correctly implied through mention of Grace CPUs. (3) Multi-hop reasoning is sound: the answer synthesizes CUDA’s progression from a GPU-centric model to a heterogeneous computing enabler across years and product lines. (4) Minor deduction in qualitative accuracy due to slightly more emphasis on specific product names (e.g., Blackwell, AI-Enterprise) than in the ground truth, but these are valid and enhance precision without distorting meaning. No calculation or date errors; all entities and timelines are correct. Semantic equivalence is strong, and contextual relevance is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 394,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Pfizer's financial relationship with Paxlovid evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual obligations?",
      "original_answer": "In 2023, Paxlovid generated $1.279 billion in revenue, but this figure was significantly impacted by a non-cash revenue reversal of $3.5 billion due to the expected return of 6.5 million treatment courses of EUA-labeled U.S. government inventory. By 2024, this reversal was adjusted favorably by $771 million as only 5.1 million treatment courses were actually returned, and an additional $442 million in revenue was recorded in connection with the creation of the U.S. Strategic National Stockpile (SNS). Furthermore, as of December 31, 2024, Pfizer reported approximately $1 billion in remaining performance obligations related to Paxlovid supply contracts, indicating ongoing but reduced commercial activity compared to the prior year. This evolution reflects a shift from a high-volume, government-driven revenue model in 2023 to a more stable, contracted future delivery model in 2024.",
      "llm_answer": "In 2023 Pfizer recorded only $1.279 billion of Paxlovid revenue because most sales were still under government‑supply contracts and a $3.5 billion non‑cash revenue reversal was taken for the expected return of EUA‑labeled inventory, leaving $5.1 billion of Paxlovid‑related deferred revenue on the balance sheet. By 2024 the product had shifted to commercial sales, generating $5.716 billion of revenue, a $771 million favorable adjustment to the reversal, $442 million of “SNS” supply revenue, and deferred revenue fell to $2.2 billion, with roughly $1 billion of remaining performance‑obligation contracts still to be recognized in future periods.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the 2024 revenue figure. The original answer states that the $771 million was a favorable adjustment to the prior reversal and that $442 million was recorded from SNS creation, but it does not state that total 2024 Paxlovid revenue was $5.716 billion. In fact, the original answer does not provide a total revenue figure for 2024 at all. The LLM incorrectly implies that Paxlovid generated $5.716 billion in 2024, which is not supported by the ground truth. Additionally, the claim that deferred revenue was $5.1 billion in 2023 and fell to $2.2 billion in 2024 is not in the original answer and appears fabricated. (2) The 2023 revenue of $1.279 billion and the $3.5 billion non-cash reversal are correctly stated. The $771 million favorable adjustment and $442 million SNS revenue in 2024 are also accurate. However, the synthesis of these into a total revenue number is incorrect. The remaining performance obligation of $1 billion is correctly mentioned. (3) The multi-hop reasoning is partially sound—Pfizer’s shift from government to commercial sales is a reasonable inference, but the LLM overreaches by quantifying total 2024 revenue and deferred revenue balances not present in the original. The model conflates adjustments and obligations with actual revenue recognition. (4) The contextual relevance is high as it addresses revenue recognition and contractual obligations, but quantitative inaccuracy severely undermines correctness. The qualitative score reflects correct identification of key events but flawed synthesis. The correctness score is low due to major numerical errors despite some accurate components.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 467,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the availability and structure of shares under the 2003 Incentive Program evolved between 2022 and 2024?",
      "original_answer": "In 2022, the 2003 Incentive Program had 65,754,069 shares available for award. By 2024, the total maximum number of shares that could be issued under the program was increased to 220 million, with 47 million remaining available for awards by the end of 2024. This indicates a significant expansion in the program's capacity, although actual usage had grown moderately over time, with restricted stock units granted increasing from 9,392 thousand in 2022 to 10,393 thousand in 2024.",
      "llm_answer": "In 2022 the 2003 Incentive Program had roughly 65.8 million shares remaining for grant (restricted‑stock or other stock‑based awards) 【page_43†L31】, while by year‑end 2024 that pool had fallen to about 47 million shares 【page_102†L5】. The program’s structure has stayed essentially the same – a non‑term plan that can issue up to 220 million shares of stock options, SARs, restricted stock and other awards, with options and SARs priced at no less than market value, a 10‑year life, and forfeitures or cash settlements not counting against the share limit 【page_102†L5】.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains both correct and incorrect information. It correctly states that 65.8 million shares (matching the 65,754,069 in the ground truth) were available in 2022 and that 47 million shares remained available by the end of 2024. However, it incorrectly implies that the share pool decreased from 65.8 million to 47 million due to usage, when in fact the total maximum number of shares was increased to 220 million by 2024 — a critical structural change that the LLM misrepresents. The LLM also fails to mention the increase in restricted stock units granted from 9,392 thousand in 2022 to 10,393 thousand in 2024, which is a key part of the evolution. (2) Quantitative accuracy is partially correct: 65.8 million ≈ 65,754,069 and 47 million matches exactly. However, the LLM omits the 220 million total cap introduced in 2024 and mischaracterizes the 47 million as the remaining pool from an original ~66 million, when in reality the program was significantly expanded. The increase to 220 million is a major factual point missing. (3) The reasoning is flawed in the multi-hop synthesis: the LLM correctly identifies the program structure (non-term, award types, pricing, etc.) but fails to recognize that the 220 million cap represents a new maximum, not a depletion of the original pool. This reflects a misunderstanding of how the program evolved — it was expanded, not just drawn down. (4) Contextual relevance is high because the answer addresses share availability and program structure, but the factual error on the share limit evolution significantly undermines correctness. The omission of the growth in restricted stock units further reduces completeness. Thus, while some numbers and structural details are accurate, the core narrative of how the program evolved is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 493,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has AdSense's role within Google's advertising revenue streams evolved between 2022 and 2024, particularly in relation to the company's broader advertising technology portfolio?",
      "original_answer": "In 2022, AdSense was explicitly cited as a key growth driver within the Google Network, contributing to an $8.6 billion year-over-year revenue increase alongside AdMob and Google Ad Manager. By 2024, while AdSense remained part of the Google Network, it was no longer specifically quantified as a growth lever. Instead, newer AI-powered advertising products like Demand Gen and Performance Max were highlighted as central to advertiser success, suggesting a strategic shift where AdSense became a more foundational, mature offering within Google's broader advertising technology stack.",
      "llm_answer": "In the 2022 filing AdSense was called out as a key pillar of the Google Network – together with AdMob and Google Ad Manager it drove the $8.6 billion increase in Google Network revenue and was specifically noted for a decline in its impression share【page_35】. By the 2024 filing AdSense is no longer highlighted as a separate growth engine; it is folded into the broader “Google Network properties” that now sit alongside a suite of AI‑driven ad solutions such as Demand Gen, Performance Max and Product Studio, reflecting a shift toward a more integrated, AI‑focused advertising technology portfolio【page_8】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the $8.6 billion year-over-year revenue increase in the Google Network for 2022 is correctly cited, and the years (2022 vs 2024) are accurately referenced. (2) The entities are correct: AdSense, AdMob, Google Ad Manager, Demand Gen, Performance Max, and Product Studio are all properly identified as part of the Google Network and AI-driven ad solutions. (3) The multi-hop reasoning is sound—LLM correctly infers a strategic shift from AdSense being a named growth driver in 2022 to being subsumed into broader 'Google Network properties' by 2024, with newer AI-powered tools taking center stage. (4) The only minor gap is that the original answer explicitly frames AdSense as becoming a 'foundational, mature offering,' while the LLM implies this through 'folded into the broader Google Network properties' and 'shift toward a more integrated, AI-focused portfolio.' This nuance is semantically equivalent but slightly less explicit. The mention of AdSense's declining impression share, while factually likely from the source (page 35), is not in the ground truth and adds a detail outside the scope of the original answer, but does not contradict it. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 376,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did the UPS Retirement Plan's benefit accrual structure evolve between 2022 and 2023, and what specific changes were made to future benefit accruals for non-union participants?",
      "original_answer": "In 2022, the UPS Retirement Plan was described as noncontributory and covering substantially all eligible employees hired before July 1, 2016, who were not part of a collective bargaining unit or certain employees covered by a collective bargaining agreement. The plan provided retirement benefits based on average compensation and was subject to IRS limits. It was also disclosed that the plan would cease accruals of additional benefits for future service and compensation for non-union participants effective January 1, 2023. In 2023, this cessation of accruals was confirmed as effective, and the plan was described with the same eligibility and benefit structure but explicitly stated that no further accruals would occur for non-union participants. This marks a transformational change in the plan's structure, as the accrual freeze was implemented as planned, shifting the plan from an active benefit-accruing structure to a closed one for non-union employees. The change represents a significant strategic shift in UPS's retirement benefit policy.",
      "llm_answer": "In the 2022 filing the UPS Retirement Plan was still a non‑contributory defined‑benefit plan that continued to accrue future service‑ and compensation‑based benefits for non‑union participants. Effective January 1 2023 the company ended those accruals – the plan “will cease accruals of additional benefits for future service and compensation for non‑union participants” (page 92) – and moved those employees into a defined‑contribution model, providing a retirement contribution of 5%‑8% of eligible compensation to the UPS 401(k) Savings Plan (up from 3%‑8% for hires after July 1 2016) (page 83).",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the key change in the UPS Retirement Plan: the cessation of benefit accruals for non-union participants effective January 1, 2023, which aligns with the ground truth. It accurately references the 2022 plan structure as a non-contributory defined-benefit plan that accrued benefits based on service and compensation. The date (January 1, 2023) is correct, and the citation of the 5%-8% retirement contribution to the UPS 401(k) Savings Plan is factually consistent with typical plan updates. However, the ground truth does not mention the shift to a defined-contribution model or the specific 5%-8% contribution increase, nor does it confirm the prior 3%-8% range for hires after July 1, 2016. While such a shift is a logical corollary and may be inferred in broader context, the original answer does not include this information, making the addition of these details unsupported by the provided ground truth. This introduces a partial hallucination or over-inference beyond the documented facts. The core evolution — the freeze of future accruals for non-union participants — is correctly identified and well-articulated, satisfying the primary multi-hop requirement (change between 2022 and 2023). The reasoning is mostly sound, but the unsupported addition of the defined-contribution details reduces quantitative and qualitative accuracy. Contextual relevance is high, as the response directly addresses the question’s focus on structural evolution and specific changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 413,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Amazon's utilization and structure of its short-term credit facilities evolved between 2022 and 2024, particularly in terms of credit capacity, interest rate terms, and outstanding borrowings?",
      "original_answer": "In 2022, Amazon had a $7.0 billion unsecured revolving credit facility with an interest rate of benchmark rate plus 0.50% and a commitment fee of 0.04%, and no borrowings were outstanding under this facility. Additionally, Amazon had $7.2 billion in unused letters of credit as of December 31, 2021. By 2024, Amazon had significantly expanded its credit capacity by entering into a new $15.0 billion unsecured revolving credit facility with a lower interest rate of benchmark rate plus 0.45% and a reduced commitment fee of 0.03%. In addition, Amazon introduced a new $5.0 billion unsecured 364-day revolving credit facility in October 2024, which also carried a rate of SOFR plus 0.45% and a 0.03% commitment fee. Notably, there were still no borrowings outstanding under the main Credit Agreement or the Short-Term Credit Agreement as of December 31, 2024. However, Amazon had $147 million and $151 million in borrowings under other short-term credit facilities as of December 31, 2023 and 2024, respectively, which were included in 'Accrued expenses and other.' The company also increased its unused letters of credit to $8.3 billion by the end of 2024.",
      "llm_answer": "Amazon’s short‑term credit picture changed dramatically. In 2022 the company relied on a $1.0 billion secured revolving facility (LIBOR + 1.40%) with $803 million of borrowings and a $7.0 billion unsecured revolving credit agreement (benchmark + 0.50%) that had no borrowings, plus a commercial‑paper program of up to $10 billion that carried $725 million of debt【page_56】【page_57】. By 2024 it had replaced those with a $15.0 billion unsecured revolving credit agreement and a new $5.0 billion 364‑day revolving facility, both priced at SOFR + 0.45% and bearing a 0.03% commitment fee, with no borrowings under either, while an $8.0 billion 364‑day term loan (SOFR + 0.75%) was fully repaid and only $147‑$151 million of other short‑term facilities remained outstanding; the commercial‑paper capacity was expanded to $20 billion (with no balances)【page_58】【page_57】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the 2022 credit structure. It incorrectly states that Amazon had a $1.0 billion secured revolving facility with $803 million in borrowings, which is not supported by the ground truth. The ground truth confirms only a $7.0 billion unsecured facility with no borrowings in 2022. Additionally, the LLM mentions a $10 billion commercial paper program with $725 million in debt, which is not referenced in the original answer and contradicts the ground truth that no borrowings were outstanding under the main credit facility. The 2024 updates are partially correct: the $15.0 billion unsecured revolving facility and the $5.0 billion 364-day facility with SOFR + 0.45% and 0.03% fee are accurate. However, the LLM incorrectly introduces an $8.0 billion 364-day term loan (not mentioned in the original), and while it correctly notes $147–151 million in other short-term borrowings, it misattributes them without specifying they are included in 'Accrued expenses and other.' The increase in letters of credit from $7.2B to $8.3B is omitted. (2) Quantitative accuracy is low: multiple incorrect figures (e.g., $1.0B secured vs. actual $7.0B unsecured; $803M borrowings not present; $10B commercial paper not in original; $8.0B term loan not mentioned). The correct figures for 2024 facilities are present but mixed with fabricated ones. (3) Multi-hop reasoning is partially sound—LLM attempts to compare 2022 and 2024 structures and identifies expansion and lower rates, but fails to correctly synthesize the actual facilities due to hallucinated data. The evolution in credit capacity and interest rates is directionally correct but undermined by incorrect components. (4) Contextual relevance is high as the answer addresses credit capacity, interest rates, and outstanding borrowings over time, aligning with the question’s focus. However, the inclusion of unsupported facilities and borrowings severely undermines factual correctness, leading to a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1519,
        "completion_tokens": 555,
        "total_tokens": 2074
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Costco's use of variable-priced contracts for energy purchases evolved between 2022 and 2023, and what does this indicate about its commodity price risk management strategy?",
      "original_answer": "In 2022, Costco entered into variable-priced contracts for some purchases of electricity and natural gas, as well as fuel for its gas stations, on an index basis. These contracts met the definition of derivatives but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. By 2023, Costco continued this approach but specifically called out natural gas and fuel for gas stations as key components of its variable-priced contract usage. This indicates a continued reliance on variable-priced contracts as part of its commodity price risk management, with no significant shift away from index-based pricing mechanisms. The strategy remains consistent, showing stability in how Costco manages exposure to energy price fluctuations.",
      "llm_answer": "In the 2022 Form 10‑K Costco disclosed that it “enter[s] into variable‑priced contracts for some purchases of **electricity and natural gas**, in addition to some fuel for its gas stations” on an index basis【page_31】. By the 2023 filing the company’s disclosure was narrowed to “variable‑priced contracts for some purchases of **natural gas**, in addition to fuel for its gas stations,” with no mention of electricity【page_47】. This change suggests Costco is shifting electricity exposure into fixed‑price contracts—tightening its commodity‑price risk management by locking in electricity costs while still using index‑based contracts for natural‑gas where it prefers flexibility.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the use of variable-priced contracts in both 2022 and 2023 and accurately reflects the shift in disclosure language between the two years—specifically, the omission of electricity in the 2023 filing. However, it incorrectly interprets this change as evidence of a strategic shift toward fixed-price contracts for electricity, which is not supported by the original answer or ground truth. The ground truth states that Costco’s strategy remained consistent, with no significant shift away from index-based pricing. Thus, the core conclusion about a change in risk management strategy is factually wrong. (2) There are no numeric values, dates, or calculations in this question, so quantitative accuracy is not applicable—no errors in this regard. (3) The multi-hop reasoning is partially sound in that the model correctly identifies differences in disclosure wording across years. However, it fails to synthesize this with the broader context provided in the ground truth—that these contracts continue to qualify for the 'normal purchases and normal sales' exception and that the overall strategy remains stable. The model draws an unsupported inference rather than recognizing the continuity emphasized in the original answer. (4) While the LLM answer is contextually relevant and uses accurate source references, the incorrect interpretation of strategic intent significantly undermines factual correctness. The answer suggests a change in strategy where none is indicated, leading to a low correctness and qualitative accuracy score despite accurate reporting of textual changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 447,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the strategic positioning and commercial role of NVIDIA AI Enterprise evolved within NVIDIA's data center offerings between 2022 and 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, indicating its foundational role in NVIDIA's AI and accelerated computing strategy. By 2024, the product had evolved into a more prominent commercial offering, described as a 'comprehensive suite of enterprise-grade AI software' that is actively licensed and integrated into broader data center solutions. This shift reflects NVIDIA's move from positioning it as a strategic initiative to a key monetization vehicle within its full-stack data center platform, alongside offerings like NVIDIA DGX Cloud and the expansion into CPUs and DPUs.",
      "llm_answer": "In the 2022 filing (see pages 78‑82) NVIDIA’s 10‑K does not call out NVIDIA AI Enterprise as a distinct product – it is only part of the broader data‑center software stack and receives no dedicated discussion. By the 2024 filing the company is positioning AI Enterprise as a standalone, paid‑license suite that serves as the “operating system” for enterprise‑grade AI (page 4) and is listed alongside DGX Cloud as a core data‑center offering (page 5). The 2024 filing further details AI Enterprise’s commercial role, describing it as a comprehensive software package that includes NVIDIA NIM, NEMO and AI Blueprints to simplify development and deployment of generative‑AI workloads (page 7), showing its evolution from a background component to a strategic, revenue‑generating solution within NVIDIA’s data‑center portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, NVIDIA AI Enterprise was not highlighted as a distinct product but was part of the broader data center software stack, consistent with its inclusion in the Compute & Networking segment. By 2024, it accurately reflects the product's evolution into a standalone, commercial offering described as a 'comprehensive suite of enterprise-grade AI software' and positioned alongside DGX Cloud—matching the ground truth's emphasis on monetization and strategic importance. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised; dates (2022 vs. 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly inferring a shift in strategic positioning based on changes in disclosure and emphasis. It references specific pages (e.g., pages 4, 5, 7 in the 2024 filing) to support its claims, demonstrating proper sourcing. (4) The only minor gap is that the LLM answer does not explicitly mention NVIDIA’s expansion into CPUs and DPUs as part of the broader full-stack platform context, which slightly reduces completeness in qualitative synthesis. However, this does not detract from the core accuracy regarding AI Enterprise’s evolution. Overall, the answer is semantically equivalent to the ground truth, with excellent contextual relevance and strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 419,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Pfizer's contractual obligations related to Paxlovid evolve between 2023 and 2024, and what does this indicate about the company's future revenue expectations for the product?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of Paxlovid labeled under Emergency Use Authorization (EUA) from the U.S. government. This indicated uncertainty and potential decline in demand for Paxlovid. By 2024, however, remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, signaling a stabilization and expectation of future revenue from existing contracts. This shift from a large revenue reversal to a defined forward-looking contractual obligation suggests improved demand forecasting and a more stable outlook for Paxlovid in 2024 compared to the uncertainty in 2023.",
      "llm_answer": "By the end of 2023 Pfizer still had about $5.1 billion of Paxlovid‑related deferred revenue (roughly $2.6 billion in current liabilities and $2.5 billion in non‑current) 【page 110】. At year‑end 2024 that balance had fallen to roughly $2.2 billion ($1.4 billion current and $785 million non‑current) and the company reported only about $1 billion of remaining performance‑obligation revenue for Paxlovid 【page 109】. The drop shows that most advance payments have now been recognized as sales as Paxlovid shifts to commercial markets, indicating a lower‑volume, longer‑term revenue outlook for the product.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in numbers and omits the key event from the ground truth—the $3.5 billion non-cash revenue reversal in Q4 2023 due to expected returns of 6.5 million treatment courses under EUA. This is a central fact in the original answer and is entirely missing from the LLM response. Instead, the LLM focuses on deferred revenue balances ($5.1B in 2023 and $2.2B in 2024), which are not mentioned in the ground truth and contradict the narrative of a large revenue reversal. While the LLM correctly notes that remaining performance obligations were about $1 billion as of year-end 2024, aligning with the original answer, the context and evolution are misrepresented. (2) The quantitative accuracy is partially correct: the $1 billion remaining performance obligation in 2024 matches the ground truth. However, the deferred revenue figures of $5.1 billion (2023) and $2.2 billion (2024) are not corroborated by the original answer and appear to be based on different data or misinterpretation. There is no mention in the ground truth of deferred revenue balances, so these numbers cannot be verified as accurate in this context. The drop from $5.1B to $2.2B implies recognition of $2.9B in revenue, which does not align with the $3.5B reversal described in the original. (3) The reasoning is partially sound—shifting from advance payments to commercial markets is a logical inference—but it fails to capture the multi-hop synthesis required: the reversal was due to *expected returns* from the U.S. government under EUA, indicating demand uncertainty, whereas the $1B in 2024 reflects stabilized contractual expectations. This contrast between uncertainty and stabilization is the core insight, which the LLM only partially captures by noting a decline in deferred revenue. (4) The contextual relevance is high—the answer addresses Pfizer, Paxlovid, and future revenue expectations across 2023–2024—but the factual foundation is flawed. The omission of the $3.5B reversal and introduction of unverified deferred revenue figures significantly undermines correctness, warranting a score of 6: partially correct but with significant factual gaps and potential misrepresentation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 594,
        "total_tokens": 1942
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "Compare and contrast how Google's exposure to new regulatory costs in international markets evolved between 2022 and 2024, particularly in terms of the scope and nature of regulatory challenges described?",
      "original_answer": "In 2022, Google highlighted that an evolving foreign policy landscape could subject the company to 'new regulatory costs and challenges,' specifically mentioning data transfers between the EU and the UK, as well as new customer requirements. By 2024, the scope of regulatory challenges expanded significantly. The 2024 filing not only reiterated the exposure to 'new regulatory costs and challenges' but also introduced elements like 'uncertainty regarding regulatory outcomes' and the risk of 'other liabilities under local laws that may not offer due process or clear legal precedent.' This indicates a shift from primarily data-related regulatory concerns in 2022 to broader, more unpredictable regulatory risks in 2024, reflecting an increased complexity in Google's international regulatory environment.",
      "llm_answer": "In the 2022 Form 10‑K, Google warned that an “evolving foreign‑policy landscape” could expose it to new regulatory costs and challenges largely tied to data‑privacy, anti‑corruption, foreign‑ownership limits and other general compliance issues in the markets where it operates (2022 p.16). By 2024 the filing still notes those baseline risks but broadens the scope, adding “new customer requirements,” AI‑related legislation, EU‑UK data‑transfer rules, heightened geopolitical tensions and cyber‑security scrutiny, showing that regulatory exposure has expanded from traditional privacy and compliance concerns to technology‑specific and more detailed international regulatory regimes (2024 p.16; 2024 p.17).",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates (2022 and 2024) and correctly identifies Google as the subject, satisfying entity and temporal accuracy. It references specific page numbers (p.16, p.17) and regulatory themes such as data transfers between the EU and UK, new customer requirements, and evolving compliance issues, which aligns with the original answer. However, there are key differences in emphasis and content: the LLM introduces 'AI-related legislation', 'foreign-ownership limits', 'anti-corruption', and 'cyber-security scrutiny'—elements not mentioned in the ground truth. While these may plausibly appear in a 10-K, they are not part of the documented evolution in the knowledge graph. Conversely, the original answer highlights a critical qualitative shift in 2024 toward 'uncertainty regarding regulatory outcomes' and 'liabilities under local laws that may not offer due process or clear legal precedent'—a significant expansion into rule-of-law concerns—which the LLM fails to mention. Thus, while the LLM captures a broadening of regulatory scope, it misrepresents the nature of the evolution by emphasizing technology-specific regulations (e.g., AI) rather than the increasing unpredictability and legal vulnerability emphasized in the ground truth. The reasoning is logically sound and contextually relevant, but the qualitative synthesis is partially incorrect due to omission of key risks and addition of unsupported ones. Quantitative accuracy is perfect—no numbers, dates, or calculations are incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 422,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has UPS's approach to funding postretirement medical benefits evolved between 2022 and 2023, particularly in terms of the sources used for expected benefit payments?",
      "original_answer": "In 2022, UPS indicated that expected benefit payments for postretirement medical benefits would be paid from both plan trusts and corporate assets. In 2023, the language remained unchanged, indicating continuity in the funding approach. Therefore, there was no change in the sources used for expected benefit payments for postretirement medical benefits between the two years.",
      "llm_answer": "In the 2022 10‑K (page 109) UPS said that expected post‑retirement medical benefit payments would be funded from both the plan trusts and corporate assets. The 2023 10‑K (page 92) repeats the same statement – payments will be paid from plan trusts and corporate assets – showing that UPS’s funding mix for post‑retirement medical benefits has not changed between 2022 and 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately states that in both 2022 and 2023, UPS funded expected postretirement medical benefit payments from both plan trusts and corporate assets, with no change in approach—this aligns exactly with the original answer. (2) There are no numerical figures requiring calculation in this question, but the cited page numbers (page 109 for 2022, page 92 for 2023) are consistent with typical 10-K disclosures and add contextual precision without contradicting the ground truth. (3) The multi-hop reasoning is sound: the model correctly synthesized information across two years of SEC filings and concluded that the funding approach remained unchanged, which is the correct inference. (4) The answer is semantically equivalent to the original, uses precise language, and directly addresses the evolution (or lack thereof) in funding sources. All entities—UPS, postretirement medical benefits, plan trusts, corporate assets, and the relevant years—are correctly identified and contextualized. No factual, quantitative, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1194,
        "completion_tokens": 320,
        "total_tokens": 1514
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the role and scope of NVIDIA AI Enterprise evolved from its introduction in 2022 to its broader supply and integration in 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, described as a software suite aimed at simplifying the deployment of AI applications across data centers and enterprise environments. By 2024, the platform had evolved into a more comprehensive and integrated solution, including components such as NVIDIA NIM, NVIDIA NeMo, and AI Blueprints, with specific performance improvements like a 2.5x increase in token throughput. This reflects a shift from a foundational offering to a full-stack, production-grade generative AI platform with enhanced capabilities and broader deployment options.",
      "llm_answer": "In the 2022 filing NVIDIA AI Enterprise was introduced as a new paid‑license software product, listed under the Compute & Networking segment and grouped with other data‑center software and DGX Cloud offerings【page_5】【page_6】. By the 2024 filing it had grown into a comprehensive, enterprise‑grade AI suite—including NIM, Nemo and AI Blueprints—and is positioned as a core component of NVIDIA’s data‑center platform and AI‑training‑as‑a‑service portfolio, supporting broader generative‑AI deployments and integration across customers’ infrastructure【page_6】【page_7】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: NVIDIA AI Enterprise was introduced in 2022 as a paid-license software under Compute & Networking, and by 2024 evolved into a comprehensive suite including NIM, NeMo (spelled 'Nemo' in the answer, minor variation), and AI Blueprints. The answer correctly captures the expansion in scope and integration. (2) There are no numeric inaccuracies—while the ground truth mentions a '2.5x increase in token throughput,' this specific performance metric is omitted in the LLM answer, which prevents a perfect score. However, since the question focuses on role and scope evolution rather than specific benchmarks, this is a minor omission. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across 2022 and 2024 filings to show progression in product scope and strategic positioning. (4) Semantic equivalence is strong—wording differs but meaning matches. The LLM emphasizes 'AI-training-as-a-service' and 'core component of data-center platform,' which adds context not in the original but does not distort facts. Minor spelling variation 'Nemo' instead of 'NeMo' is acceptable. Overall, the answer is factually correct, complete in scope, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 359,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has ExxonMobil's proved reserves through equity companies evolved from 2022 to 2024, and what does this indicate about its strategic positioning in different regions?",
      "original_answer": "In 2022, ExxonMobil's total proved reserves from equity companies amounted to 14 million barrels gross (1 million net) across the United States, Europe, Africa, and Asia. By 2024, these reserves had significantly increased to 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas, with the majority of this growth concentrated in Asia. This indicates a major strategic shift toward strengthening its upstream presence in the Asia region through equity companies.",
      "llm_answer": "ExxonMobil’s equity‑company proved reserves grew to 1,481 million barrels of oil‑equivalent in 2024, with the bulk in Asia (≈1,276 million barrels) and a sizable share in Africa (≈143 million barrels) (2024 reserves table, page 10). The 2022 filing excerpts do not provide a comparable equity‑company reserve total, but the 2024 regional concentration shows a clear strategic emphasis on expanding equity‑based assets in high‑growth, non‑U.S. markets—particularly Asia and Africa.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states that in 2022, ExxonMobil had 14 million barrels gross (1 million net) from equity companies, but the LLM claims no comparable data is available for 2022, which contradicts the original answer. More critically, the LLM reports 1,481 million barrels of oil-equivalent in 2024, but the ground truth specifies 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas. The LLM appears to have converted gas to oil-equivalent, but this conversion is not mentioned or justified, and the resulting number does not align with the original data. Additionally, the LLM attributes ≈1,276 million barrels to Asia and ≈143 million to Africa, but the original answer only mentions 'the majority of this growth concentrated in Asia' without specifying African reserves or providing regional breakdowns. (2) Calculations: The LLM’s oil-equivalent figure is unsupported by the ground truth and introduces a synthesis step (conversion of gas to BOE) not present in the source, making it factually unreliable. (3) Multi-hop reasoning: While the LLM correctly infers a strategic shift toward Asia and non-U.S. markets, it fails to accurately report the 2022 baseline and fabricates granular regional data not present in the original answer. The reasoning is directionally sound but built on incorrect numerical foundations. (4) The answer is contextually relevant and addresses the strategic positioning question well, earning high marks for relevance and partial qualitative accuracy, but major quantitative errors reduce overall correctness to a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 466,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of their role in revenue generation and cost structure?",
      "original_answer": "In 2022, Google Network Partners played a central role in the revenue generation process as Google acted as the principal for ads placed on Google Network properties, reporting advertising revenues on a gross basis, with payments to partners recorded as cost of revenues. By 2024, Google continued to pay Google Network partners, but the focus of the financial reporting shifted to emphasize the net cash flow impact, noting that payments to these partners were a primary use of cash from operating activities. This reflects a more cost-centric framing of the relationship in the later year.",
      "llm_answer": "In the 2022 filing Alphabet explained that ads on Google Network properties are recorded on a gross basis – the full amount billed to advertisers is shown as revenue, and the amounts paid to Google Network partners are reflected as cost of revenues (TAC) 【page_55】. The 2024 filing still treats advertising from Google Network properties as a major source of operating cash, and explicitly lists payments to Google Network partners as a primary cash outflow from operating activities (i.e., a cost‑of‑revenues item) 【page_42】. Thus, the relationship has remained consistent—partners continue to drive a sizable share of advertising revenue while their payments remain a key cost line—though the cash paid to partners has risen in line with higher overall operating cash inflows.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Google reported revenue from ads on Google Network properties on a gross basis, with partner payments recorded as cost of revenues (TAC), citing the correct context from the 2022 filing. In 2024, it accurately notes that payments to partners are highlighted as a primary cash outflow from operating activities, reflecting a cost-centric framing. (2) There are no numerical inaccuracies—while no specific dollar amounts are mentioned in either answer, the qualitative financial treatment (gross reporting, TAC, cash outflows) is correctly described, and the evolution in emphasis is properly conveyed. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and two different reporting emphases (revenue recognition vs. cash flow presentation), correctly inferring consistency in treatment with a shift in narrative focus. (4) The only minor shortcoming is that the LLM slightly downplays the shift in framing by stating the relationship has 'remained consistent,' whereas the ground truth emphasizes a 'more cost-centric framing' in 2024, suggesting a subtle evolution in emphasis. However, the core facts and synthesis are correct, and the answer remains semantically equivalent in substance. Thus, the answer is excellent but not perfect in capturing the nuance of the shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 392,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has UPS's foreign currency exchange risk management strategy evolved between 2022 and 2023, particularly in terms of the financial impact of undesignated foreign currency forward contracts on earnings volatility?",
      "original_answer": "In 2022, UPS disclosed that foreign currency exchange forward contracts were used to economically offset foreign currency remeasurement and settlement risk for certain balance sheet assets and liabilities, and that changes in their fair value affected earnings directly. For 2023, UPS expanded the disclosure to emphasize that undesignated derivative settlements are now explicitly linked to earnings volatility, with a specific focus on how these contracts impact income statement recognition. The 2023 filing also introduced a more structured presentation of fair value changes and settlements for these contracts, with amounts for both 2023 and 2022 now reported side-by-side in millions, indicating a more transparent and systematic approach to disclosing the financial effects of these instruments.",
      "llm_answer": "UPS reduced the earnings impact of its non‑designated foreign‑currency forward contracts. In 2022 the company recorded a $69 million loss from such contracts in the income statement, whereas in 2023 the loss fell to only $7 million (page 132), indicating that the firm shifted more of its exposure into designated hedges and thereby dampened earnings volatility.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces specific numerical data ($69 million loss in 2022, $7 million in 2023) that are not present in the original ground truth answer. The ground truth does not provide any actual financial figures related to the gains or losses from undesignated foreign currency forward contracts for either 2022 or 2023, nor does it mention a reduction in earnings impact due to a shift toward designated hedges. Therefore, the quantitative claims in the LLM answer cannot be verified and appear fabricated or hallucinated. The original answer focuses on the evolution of disclosure practices—increased transparency, structured presentation, and explicit linkage of undesignated derivatives to earnings volatility—not on actual dollar amounts or changes in hedge designations reducing volatility. While the LLM correctly identifies the topic (foreign currency forward contracts and earnings volatility), it fails to reflect the actual nature of the evolution, which is qualitative and presentational (i.e., improved disclosure), not quantitative or strategic in terms of reduced losses. The reasoning is flawed because it draws a conclusion about risk management strategy based on numbers not supported by the ground truth. The contextual relevance is moderate because the answer addresses foreign currency risk and earnings volatility, but the core factual content is misaligned. Thus, the correctness score is low due to major factual and quantitative inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 410,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the role of the membership format in Costco's profitability strategy evolved between 2022 and 2023, particularly in terms of its impact on member loyalty and fee revenue?",
      "original_answer": "In 2022, the membership format was described as 'an integral part of our business and has a significant effect on our profitability,' with an emphasis on growth in the membership base, increasing Executive member penetration, and sustaining high renewal rates as key drivers of profitability. By 2023, the language evolved to underscore that the membership format 'is an integral part of our business and profitability,' indicating a more consolidated role in the company's financial model. Additionally, in 2023, Costco introduced a new concern about the potential adverse impact of lower renewal rates in newer markets on the worldwide renewal rate, which was not explicitly mentioned in 2022. This suggests that while the membership model remained central to profitability, the company faced emerging challenges in sustaining renewal rates as it expanded into newer markets.",
      "llm_answer": "Costco’s 2022 filing describes the membership format as “integral” to profitability – it is meant to reinforce member loyalty and generate ongoing fee revenue, and that year fee revenue rose 9 % to $4.2 billion thanks to new sign‑ups, executive upgrades and a higher renewal rate【page_23】【page_24】. The 2023 filing repeats the same description of the format’s role in driving loyalty and fee income, but shows the growth in fee revenue slowing to roughly a 5 % increase (to $4.8 billion) in the subsequent period【page_24】【page_25】, indicating that while the loyalty‑centric strategy remains unchanged, the pace of fee‑revenue expansion has moderated.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in financial figures. According to the ground truth, the focus is on the evolution of language and strategic concerns around membership, not specific dollar amounts or percentage growth in fee revenue. The LLM claims that fee revenue rose 9% to $4.2 billion in 2022 and then increased ~5% to $4.8 billion in 2023. However, these numbers are incorrect. In reality, Costco's membership fees were $4.197 billion in 2022 (up from $3.849 billion in 2021, roughly a 9% increase), and in 2023 they were $4.459 billion (up ~6.2% year-over-year), not $4.8 billion. The 5% growth figure and $4.8B amount are therefore factually wrong, undermining quantitative accuracy. (2) The model correctly identifies that the membership format is described as 'integral' to profitability in both years and links it to loyalty and fee revenue, which aligns with the original answer’s emphasis. However, it misses the key qualitative evolution in language: in 2023, Costco emphasized the membership model as being more consolidated in profitability ('an integral part of our business and profitability') and introduced a new risk about lower renewal rates in newer markets affecting the worldwide renewal rate—a critical strategic shift not mentioned in 2022. This omission significantly weakens the qualitative and multi-hop reasoning. (3) While the LLM attempts multi-hop reasoning by comparing two years’ disclosures and inferring a slowing growth trend, it does so based on incorrect numbers and misses the core strategic nuance about emerging challenges in new markets. The reasoning is partially sound but built on faulty data and incomplete synthesis. (4) The contextual relevance is high because the answer addresses membership, loyalty, fee revenue, and year-over-year changes—directly related to the question. However, due to major quantitative errors and missing key strategic insights from the 2023 filing, the overall correctness score is moderate at 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 542,
        "total_tokens": 1932
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration within the broader data center platform and software ecosystem?",
      "original_answer": "In 2022, CUDA was primarily positioned as a key component of NVIDIA's AI ecosystem, with nearly 3 million developers using CUDA and other software tools to deploy AI and accelerated computing technologies. It was described as central to NVIDIA's partnerships and developer programs, including the Deep Learning Institute and Inception program. By 2024, CUDA had evolved into a more deeply integrated part of a full-stack computing platform, specifically within the data center. It was described as the foundation of the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific frameworks, emphasizing its role in enabling end-to-end optimized computing across GPUs, CPUs, and DPUs. This reflects a strategic shift from promoting CUDA as a developer-focused tool to positioning it as a core infrastructure layer for enterprise-scale computing solutions.",
      "llm_answer": "In the 2022 filing NVIDIA presented CUDA as the core programming model that runs on every GPU and serves as the “fundamental building block” of its unified accelerated‑computing architecture, supported by roughly 3 million developers. By the 2024 filing CUDA is no longer described only as a GPU‑only language but as a central piece of a full‑stack data‑center platform that now includes CPUs, DPUs, networking and the CUDA‑X collection of libraries, APIs and SDKs, with the developer ecosystem growing to about 5.9 million—showing a deeper, broader integration of CUDA across hardware and software layers.",
      "correctness_score": 9,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of CUDA between 2022 and 2024 as described in the ground truth. It correctly identifies CUDA's role in 2022 as a fundamental building block of NVIDIA's accelerated computing architecture with ~3 million developers, aligning with the original answer. The 2024 evolution is accurately portrayed as a shift toward full-stack integration across CPUs, DPUs, and networking, with emphasis on CUDA-X libraries and broader platform integration. However, the LLM introduces a specific figure of '5.9 million' developers in 2024, which is not present in the original answer (the ground truth does not provide a 2024 developer count). This introduces a quantitatively inaccurate detail, though the trend of growth is plausible. The qualitative reasoning is strong, correctly synthesizing the shift from a developer-centric tool to an infrastructure layer. All entities (CUDA, CUDA-X, GPUs, CPUs, DPUs) and timeframes (2022, 2024) are accurate. The answer is fully contextually relevant, addressing both the integration within the data center platform and software ecosystem. The minor quantitative overprecision prevents a perfect score, but the overall factual and conceptual alignment is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 350,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2023 to 2024, particularly in terms of expected future revenue and product delivery timelines?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled Paxlovid from U.S. government inventory. By the end of 2024, Pfizer reported remaining performance obligations for Paxlovid at approximately $1 billion, with expected product delivery and revenue realization scheduled from 2025 through 2028, indicating a shift from uncertain returns and revenue reversals to a more defined forward-looking revenue outlook based on firm contracts.",
      "llm_answer": "In 2023 Pfizer was carrying a large “pre‑pay” balance for Paxlovid – $5.1 billion of deferred revenue (about $2.6 billion classified as current and $2.5 billion as non‑current) that reflected advance payments from governments and other customers and was expected to be recognized as the drug was delivered in 2024 【page_110】. By year‑end 2024 that balance had fallen to $2.2 billion ($1.4 billion current, $785 million non‑current) and the company now reported roughly $1 billion of remaining performance‑obligation revenue for Paxlovid, with the existing contracts calling for product shipments from 2025 through 2028 (subject to renegotiation) 【page_109】. This shows a shift from a large upfront cash commitment in 2023 to a smaller, longer‑term delivery schedule and revenue stream in 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution in Pfizer's financial commitment and contractual obligations for Paxlovid from 2023 to 2024, correctly identifying the shift from uncertain revenue expectations to a more defined forward-looking revenue stream through firm contracts extending to 2028. However, it misrepresents the key 2023 financial event: the ground truth states that Pfizer recorded a $3.5 billion non-cash revenue reversal due to expected returns of 6.5 million treatment courses, not a $5.1 billion deferred revenue pre-pay as claimed. While deferred revenue existed, the critical 2023 development was the reversal, not the pre-pay balance. The LLM answer omits the revenue reversal entirely and instead emphasizes deferred revenue, which changes the financial narrative. (2) Quantitatively, the $5.1 billion deferred revenue figure in 2023 and $2.2 billion in 2024 are not present in the ground truth and appear to be from the source document but do not address the specific financial commitment change highlighted in the original answer (i.e., the $3.5B reversal). The $1 billion remaining performance obligation for 2025–2028 matches the ground truth and is correctly reported. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes a timeline shift from 2023 to 2024 and identifies future delivery schedules, but fails to connect the 2023 revenue reversal — a critical contractual and financial inflection point — thus missing a key hop in the causal chain. (4) Contextual relevance is high as the answer directly addresses financial commitments, revenue outlook, and delivery timelines. Due to significant but not fundamental factual inaccuracies in the quantitative description of 2023 events, the correctness score is 7: core facts about future obligations are right, but the explanation of 2023 conditions is misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 509,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2022 and 2024, based on its disclosures around reserves development and advantaged asset reporting?",
      "original_answer": "In 2022, ExxonMobil reported that Guyana was a key contributor to extensions and discoveries, adding approximately 1.3 billion oil-equivalent barrels (GOEB) of proved undeveloped reserves. By 2024, Guyana was explicitly listed as one of the core 'Advantaged Assets' in the company's updated earnings drivers, signaling a strategic shift to highlight Guyana's role in driving earnings through volume growth. This evolution reflects a transition from Guyana being primarily a reserves growth region to being a recognized source of advantaged production and earnings visibility.",
      "llm_answer": "In the 2022 Form 10‑K, ExxonMobil only noted that “extensions and discoveries, primarily in the United States, Brazil, and **Guyana**, resulted in an addition of approximately 1.3 billion oil‑equivalent barrels of proved undeveloped reserves” (page 14), treating Guyana as one of several regions contributing to reserve growth. By the 2024 filing, the company places Guyana in its “Advantaged Assets (Advantaged growth projects)” – listed alongside Permian and LNG as a driver of Advantaged Volume Growth (page 37) – indicating that Guyana has been elevated to a core, high‑value strategic focus.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately captures the evolution of ExxonMobil's strategic emphasis on Guyana from 2022 to 2024. In 2022, Guyana was mentioned as a contributor to 'extensions and discoveries' with the addition of approximately 1.3 billion oil-equivalent barrels of proved undeveloped reserves, which matches the original answer. By 2024, the LLM correctly identifies that Guyana was elevated to the list of 'Advantaged Assets' alongside Permian and LNG, signaling its role in advantaged volume growth and earnings visibility. (2) The quantitative figure of '1.3 billion oil-equivalent barrels' is correctly cited, and the years (2022 and 2024) are accurate. No calculations are required, but the synthesis of disclosures across years is precise. (3) The multi-hop reasoning is sound: the model correctly infers a strategic shift by comparing how Guyana was categorized in two different years—first as part of reserve growth and later as a core advantaged asset. (4) The LLM uses slightly different phrasing (e.g., 'Advantaged growth projects') but maintains semantic equivalence with the original answer, including correct entity names (ExxonMobil, Guyana), proper context (Form 10-K filings), and accurate page references (though not required, they add credibility). All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 386,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the planned utilization of the ATR 72-600F aircraft evolve from 2022 to 2024, and what does this indicate about its role in the company's fleet strategy?",
      "original_answer": "In 2022, the ATR 72-600F was projected to have a decreasing role in the company's fleet, with planned units dropping from 11 in 2023 to just 1 by 2026. By 2024, however, the company's projections showed a shift, with ATR 72-600F units remaining steady at 7 for 2025 and declining only slightly to 3 by 2026. This indicates that while the aircraft was initially expected to phase out more rapidly, it continued to play a more sustained, albeit reduced, role in the fleet strategy.",
      "llm_answer": "In the 2022 filing FedEx said it was committed to buy **24 ATR 72‑600F** turboprop freighters – 11 in 2023, 6 in 2024, 6 in 2025 and 1 in 2026【page_114】. By the 2024 filing the commitment had been cut to **10 ATR 72‑600F**, with deliveries now only in 2025 (7) and 2026 (3)【page_117】. The shrink‑age and later delivery schedule indicate that the ATR 72‑600F has moved from a major near‑term expansion piece to a more limited, niche role in FedEx’s overall fleet‑modernization strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, in 2022 the plan was for ATR 72-600F units to drop from 11 in 2023 to just 1 by 2026, but the LLM claims FedEx was committed to buying 24 aircraft with 11 in 2023, 6 in 2024, 6 in 2025, and 1 in 2026. This misrepresents the original plan — the ground truth indicates a phase-out, not a ramp-up followed by decline. The 2024 update in the LLM answer (10 total: 7 in 2025, 3 in 2026) aligns with the ground truth’s revised projection of 7 units in 2025 and 3 in 2026, which is correct. However, the initial 2022 plan is misrepresented as an expansion (24 total purchases), whereas the truth describes a reduction trajectory. (2) Calculations: The sum of 11+6+6+1=24 is mathematically correct, but factually wrong because the original answer does not mention any purchase commitment of 24 units or deliveries in 2024. The 2024 filing reduction to 10 total units (7+3) matches the ground truth’s revised numbers, so that part is quantitatively accurate. (3) Multi-hop reasoning: The LLM correctly identifies a shift between 2022 and 2024 filings and attempts to contrast projections, showing awareness of evolving strategy. However, due to incorrect baseline data (expansion vs. contraction), the reasoning is flawed. The conclusion that the aircraft moved to a 'more limited, niche role' is semantically close to the ground truth’s 'more sustained, albeit reduced role', but the logic path is compromised by incorrect inputs. (4) Scores justified: Correctness is 6 due to partial accuracy — the 2024 revision is right, but the 2022 baseline is wrong. Quantitative accuracy is low (5) because key numbers (24 total units, deliveries in 2024) are incorrect. Qualitative accuracy is 7 because reasoning structure is sound and entity identification (ATR 72-600F, FedEx, fleet strategy) is correct. Contextual relevance is 9 — the answer directly addresses the evolution and strategic implication as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 540,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has NVIDIA's approach to offering Omniverse evolved between 2022 and 2024, particularly in terms of its integration with other AI and simulation platforms?",
      "original_answer": "In 2022, NVIDIA Omniverse was primarily described as a virtual world simulation and collaboration platform for 3D workflows, available as a software subscription for enterprise use and free for individual use. It was highlighted as being integrated with VR and AR in enterprise applications such as virtual car showrooms and surgical training. By 2024, NVIDIA's offering of Omniverse had evolved into a more comprehensive development platform and operating system for building and running virtual world simulation applications. It was now emphasized as being used by industrial enterprises to digitalize complex physical assets and processes—such as building digital twins of factories and testing autonomous robots and vehicles—powered by NVIDIA's accelerated computing infrastructure both on-premises and in the cloud. This represents a shift from general 3D collaboration to a more specialized, enterprise-focused simulation and digital twin platform.",
      "llm_answer": "In the 2022 filing NVIDIA described Omniverse mainly as a stand‑alone virtual‑world and real‑time 3‑D collaboration platform – offered as an enterprise subscription (free for individuals) and used for VR/AR, virtual car showrooms, surgical training and for synthetic‑data generation and testing of autonomous‑driving via the DRIVE Constellation and Omniverse Avatar tools【page_9】,【page_7】,【page_11】. By the 2024 filing the company had repositioned Omniverse as a core piece of its “industrial digitalization” strategy, bundling it with the NVIDIA AI Enterprise suite and integrating it with data‑center AI services (DGX Cloud) and the DRIVE autonomous‑driving stack, turning it from a separate collaboration tool into a unified AI‑driven simulation and digital‑twin platform【page_4】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, Omniverse was described as a 3D collaboration platform with VR/AR applications, free for individuals and subscription-based for enterprises, used in virtual car showrooms, surgical training, and autonomous driving testing via DRIVE Constellation and Omniverse Avatar. By 2024, it evolved into a core component of NVIDIA's industrial digitalization strategy, integrated with AI Enterprise, DGX Cloud, and DRIVE stack, functioning as a unified AI-driven simulation and digital twin platform. These points match the original answer's key evolution from a collaboration tool to an enterprise-focused simulation OS. (2) There are no numeric values, dates, or calculations to verify—no issues here; all references to years (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across time (2022 vs 2024), platforms (Omniverse, AI Enterprise, DGX, DRIVE), and use cases (digital twins, autonomous systems), demonstrating understanding of strategic shift. (4) Minor deduction in qualitative accuracy due to slightly more emphasis on bundling and integration with specific suites (e.g., AI Enterprise, DGX Cloud) than the original answer, which focuses more broadly on accelerated computing infrastructure—this is a nuance, not an error. Overall, the semantic meaning and factual content are equivalent, with excellent contextual relevance to the question about evolution and integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 425,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has the role of Google Play in generating non-advertising revenue evolved between 2022 and 2023?",
      "original_answer": "In 2022, Google Play was introduced as part of the company's broader strategy to expand non-advertising revenues, specifically through the sales of apps, in-app purchases, and digital content. By 2023, Google Play had transitioned into a more defined revenue stream under 'platforms,' where it was explicitly tied to revenues from app sales and in-app purchases. This evolution indicates a strategic shift toward solidifying Google Play’s role as a key monetization platform rather than just a component of diversification. The change reflects a more structured categorization and likely a stronger contribution to revenue stability within the ecosystem.",
      "llm_answer": "In the 2022 filing, Google Play was mentioned as one of several non‑advertising revenue sources—sales of apps, in‑app purchases and digital content—grouped under “Google other revenues” and cited as part of the overall growth in non‑advertising revenue (2022 p.30‑31). By the 2023 filing, Google Play is singled out as the core component of the “platforms” line within the broader “Google subscriptions, platforms, and devices” segment, indicating a more explicit and central role in driving non‑advertising revenue (2023 p.33). This shift shows Google Play moving from a general non‑advertising contributor to a distinct, highlighted revenue driver.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth in both substance and intent. (1) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised—no errors in numbers, dates, or calculations. (2) The LLM correctly identifies the evolution of Google Play’s role between 2022 and 2023: in 2022, it was part of a broader 'Google other revenues' category contributing to non-advertising revenue growth, and by 2023, it was explicitly highlighted as a core component of the 'platforms' segment within 'Google subscriptions, platforms, and devices.' The citations (2022 p.30–31, 2023 p.33) add precision and authenticity. (3) The multi-hop reasoning is sound—comparing the treatment of Google Play across two years and two filings to infer a strategic shift. The LLM captures the key qualitative shift: from being a general contributor to a more central, explicitly recognized revenue driver. (4) The only minor shortcoming is that the LLM does not explicitly mention the strategic implication of 'revenue stability' or 'monetization platform' as in the original answer, which slightly reduces qualitative depth. However, the core evolution is accurately conveyed. Thus, the answer is semantically equivalent and contextually fully relevant, meriting a high correctness score with only a slight deduction for missing nuanced strategic framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 398,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has AIG's use of expected loss ratio methods in workers' compensation reserving evolved between 2022 and 2023, particularly in relation to guaranteed cost and excess of deductible business?",
      "original_answer": "In 2022, AIG generally gave significant weight to expected loss ratio methods for guaranteed cost business only in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that changes in claims strategy and loss mitigation efforts were accelerating settlements, increasing paid losses along the latest diagonals. In 2023, the reserving methodology remained broadly consistent, with AIG continuing to use a combination of loss development, frequency/severity, and expected loss ratio methods. However, the 2023 filing emphasized that incurred and paid losses were now presented net of reinsurance and undiscounted, which may reflect a refinement in reporting transparency rather than a change in reserving philosophy. Additionally, the increased proportion of large deductible business continued to slow the reporting pattern of claims in 2023, consistent with the trend noted in 2022.",
      "llm_answer": "In the 2022 filing AIG explained that its expected‑loss‑ratio approach was applied *mainly* to the most recent accident year for guaranteed‑cost workers‑comp claims, while for excess‑of‑deductible policies the same method could carry significant weight over the most recent five accident years. The 2023 filing still emphasizes expected‑loss‑ratio use for excess‑of‑deductible business (still weighted for the last five accident years) but no longer calls out a special weighting for guaranteed‑cost business, suggesting AIG has shifted away from relying on expected‑loss‑ratio estimates for that segment and is likely using other development methods instead.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the core distinction in AIG's use of expected loss ratio methods between guaranteed cost and excess of deductible business in 2022, accurately stating that the method was mainly applied to the most recent accident year for guaranteed cost and up to five years for excess of deductible. It also correctly notes the continued emphasis on expected loss ratio methods for excess of deductible business in 2023 with the same five-year weighting. However, the LLM incorrectly infers that AIG has 'shifted away' from using expected loss ratio methods for guaranteed cost business in 2023 because it is no longer explicitly called out. The ground truth states that the reserving methodology remained 'broadly consistent' in 2023, with no indication of a strategic shift away from expected loss ratio methods for guaranteed cost business—only that the reporting now presents losses net of reinsurance and undiscounted, which affects transparency, not methodology. This misinterpretation leads to an incorrect conclusion about a methodological change. Additionally, the LLM omits key context from the original answer: the impact of claims strategy accelerating settlements (increasing paid losses on latest diagonals) and the continued slowing of claims reporting due to large deductible business. While the quantitative and entity accuracy (years, business types, methods) is strong, the reasoning contains a significant flaw in inferring a change in methodology from a change in disclosure emphasis. The answer remains contextually relevant and captures part of the evolution, but misses the continuity emphasized in the ground truth and introduces an unsupported inference.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 461,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Cisco's product category segmentation evolved between fiscal 2022 and fiscal 2024, particularly in relation to the Collaboration category?",
      "original_answer": "In fiscal 2022, Cisco introduced a product revenue segmentation that included 'Collaboration' as one of six distinct categories, which also included Secure, Agile Networks; Internet for the Future; End-to-End Security; Optimized Application Experiences; and Other Products. By fiscal 2024, Cisco restructured its product categories into four main areas, retaining 'Collaboration' but now grouping it alongside Networking, Security, and a new category called Observability. This indicates a consolidation and realignment of product offerings, with the introduction of Observability as a distinct area and the removal or reclassification of Optimized Application Experiences and Internet for the Future.",
      "llm_answer": "Cisco’s product‑revenue reporting shifted from a six‑category layout in FY 2022—Secure Agile Networks; Internet for the Future; Collaboration (Meetings, Collaboration Devices, Calling, Contact Center and CPaaS); End‑to‑End Security; Optimized Application Experiences; and Other Products【page_44】—to a streamlined four‑category format in FY 2024—Networking; Security; Collaboration (now Webex Suite, Collaboration Devices, Contact Center and CPaaS) and Observability, with prior periods retro‑fit to this new structure【page_41】.  The Collaboration segment’s revenue fell from $4.472 billion in FY 2022 to $4.113 billion in FY 2024 (a 9% decline versus FY 2022 but a 2% rise versus FY 2023)【page_44】【page_41】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Cisco's shift from six product categories in FY2022 to four in FY2024, retaining 'Collaboration' and introducing 'Observability' as a new category, which matches the original answer. The reclassification and consolidation are accurately described. (2) Quantitatively, the LLM provides specific revenue figures: $4.472 billion in FY2022 and $4.113 billion in FY2024 for Collaboration, and correctly notes a 9% decline from FY2022 to FY2024 and a 2% increase from FY2023 to FY2024. These numbers and calculations are factually correct and supported by the cited pages. Minor point: the original answer does not mention revenue trends or exact figures, so this is additional (accurate) detail rather than a discrepancy. (3) The multi-hop reasoning is sound—LLM synthesizes segmentation changes across fiscal years and maps the evolution of the Collaboration category, including internal component changes (e.g., rebranding to Webex Suite). It also correctly notes that prior periods were retrofitted to the new structure, demonstrating understanding of reporting changes. (4) The answer is contextually excellent, directly addressing how Cisco’s product segmentation evolved with a focus on Collaboration. The only reason for not scoring 10 is that the original answer emphasizes the removal/reclassification of 'Optimized Application Experiences' and 'Internet for the Future', which the LLM mentions implicitly but could have explicitly highlighted for full semantic equivalence. However, this is a minor omission given the overall completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 447,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Amgen's disclosure regarding the 3.125% 2025 Notes evolved from 2022 to 2023 in terms of financial presentation and associated interest rate framework?",
      "original_answer": "In 2022, Amgen reported a carrying value of $1,000 million for the 3.125% 2025 Notes within its debt table, but no specific interest rate framework was disclosed. By 2023, Amgen included the 3.125% 2025 Notes in a new table that explicitly outlined the interest rate mechanism, identifying it as SOFR + 2.1%. This evolution reflects a shift from a purely quantitative disclosure in 2022 to a more detailed qualitative and quantitative presentation in 2023, including the interest rate benchmark and spread.",
      "llm_answer": "In the 2022 Form 10‑K Amgen listed the 3.125 % 2025 Notes with a $1 billion notional amount and disclosed that the interest‑rate‑swap that hedges those notes had an effective rate of **LIBOR + 1.8 %** (see page 132). In the 2023 Form 10‑K the same $1 billion of 3.125 % 2025 Notes is shown, but the swap‑rate table now reports an effective rate of **SOFR + 2.1 %** (see page 144), reflecting the company’s transition from a LIBOR‑based to a SOFR‑based benchmark and a modest increase in the spread.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The original answer (ground truth) states that in 2022, Amgen did *not* disclose any specific interest rate framework for the 3.125% 2025 Notes—only the $1,000 million carrying value was reported. However, the LLM claims that in 2022, the interest rate was disclosed as LIBOR + 1.8%, which contradicts the ground truth. This misrepresents the evolution of disclosure, falsely attributing a rate framework where none was provided. (2) The LLM incorrectly attributes the SOFR + 2.1% rate to an interest rate swap in 2023, while the ground truth states that the 2023 filing included the 3.125% 2025 Notes in a new table that directly disclosed the interest rate mechanism as SOFR + 2.1%. The LLM conflates the note's own rate framework with a hedging instrument, introducing a conceptual error. (3) While the LLM correctly identifies the $1 billion notional amount (equivalent to $1,000 million) in both years, this is the only accurate quantitative element. (4) The reasoning is flawed: it assumes the existence of a disclosed rate in 2022 (LIBOR + 1.8%) that the ground truth confirms was *not* present, and it mischaracterizes the nature of the 2023 disclosure as relating to a swap rather than the note itself. The shift from LIBOR to SOFR is plausible contextually but is not supported by the ground truth as part of the note’s disclosure evolution. (5) The answer is contextually relevant in discussing disclosure changes and benchmarks, but the core facts are incorrect. Thus, despite some surface-level plausibility, the answer fails on key factual and reasoning dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 454,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure had decreased to 296 billion cubic feet. This indicates a reduction in the company's natural gas holdings in the region over the two-year period, suggesting a potential strategic shift or divestment in that geographic area.",
      "llm_answer": "COP’s total proved natural‑gas reserves in the Asia Pacific/Middle East fell from **326 billion cubic feet (BCF) at year‑end 2022** to **312 BCF at year‑end 2023** and **296 BCF at year‑end 2024** – a net decline of roughly 30 BCF (≈ 9 %) over the period【page_145】. Nevertheless, the 2024 filing notes that equity‑affiliate reserves in the region were boosted by higher LNG spot prices, technical revisions and recent acquisitions, and that extensions and discoveries occurred in the Middle East and Australia【page_146】, signaling that ConocoPhillips continues to view Asia Pacific/Middle East as a strategic focus despite the modest reserve contraction.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2022 (326 BCF) and 2024 (296 BCF) natural gas reserve figures, matching the ground truth. It also accurately calculates the net decline of 30 BCF (≈9%), which aligns with the 30 BCF decrease from 326 to 296. However, the LLM introduces an intermediate 2023 value of 312 BCF, which is not present in the original answer. While this may be factually correct in the actual filing, it goes beyond the provided ground truth and adds detail not confirmed by the knowledge graph. (2) All numeric values for 2022 and 2024 are correct, and the percentage decline is accurately estimated. The calculation from 326 to 296 is a 30 BCF drop, which is ~9.2%, reasonably rounded to ≈9%. The 312 BCF figure for 2023 is plausible but unverified against the ground truth, slightly reducing quantitative confidence. (3) The reasoning is sound: the LLM correctly infers a net decline and also adds context from the filing about equity-affiliate reserves being boosted by LNG prices, technical revisions, and acquisitions, as well as extensions and discoveries in the Middle East and Australia. This additional nuance improves qualitative depth and suggests ongoing strategic interest, which provides a more complete picture than the original answer. (4) The answer fully addresses both parts of the question—evolution of reserves and strategic implications—and enhances the original answer with relevant context from the cited pages. The inclusion of unverified 2023 data slightly detracts from quantitative accuracy, but the overall synthesis, correctness, and relevance remain high. Hence, a score of 8 is justified for correctness, with high marks for contextual relevance and strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 475,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did the repurchase activity of Class C Capital Stock by Alphabet change between 2022 and 2023, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023, the repurchase amount increased to $62.2 billion. Additionally, in April 2023, the Board authorized an additional $70.0 billion for share repurchases, with $36.3 billion remaining available as of December 31, 2023. This indicates a continued and expanding emphasis on returning capital to shareholders through share repurchases, with a notable increase in the scale of buybacks year-over-year.",
      "llm_answer": "In 2022 Alphabet repurchased 469 million Class C shares for about $52.6 billion, while in 2023 it bought back 450 million Class C shares for roughly $52.9 billion (Note 11, page 81). The slight decline in share count but increase in dollar outlay – together with the rise in total buy‑back spend from $59.3 bn to $62.2 bn – shows the company is maintaining an aggressive share‑repurchase program, using cash to return value to shareholders even as share prices rise.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. It states that Alphabet repurchased 469 million Class C shares for $52.6 billion in 2022 and 450 million shares for $52.9 billion in 2023. However, the ground truth indicates total repurchases of $59.3 billion in 2022 and $62.2 billion in 2023 across Class A and Class C shares, not just Class C. The LLM incorrectly narrows the scope to only Class C and provides incorrect dollar amounts and share counts. Additionally, the $52.6B and $52.9B figures do not match the ground truth totals. (2) The LLM correctly notes the increase in total buyback spend from $59.3B to $62.2B, which aligns with the ground truth, but this appears inconsistently—first citing lower Class C-only figures, then referencing the correct total amounts. This creates confusion and undermines accuracy. The mention of Note 11, page 81 may reflect a real source, but the numbers still diverge from verified totals. (3) The reasoning is partially sound: the LLM correctly infers that increased dollar outlay despite fewer shares suggests higher share prices and sustained buyback commitment. It also correctly identifies the strategic intent of returning value to shareholders. However, it fails to mention the April 2023 $70.0 billion authorization or the $36.3 billion remaining as of year-end 2023—key evidence of expanding capital return policy. This omission weakens the qualitative analysis. (4) The contextual relevance is high—the answer addresses both parts of the question (change in repurchase activity and capital allocation implications) and attempts multi-hop reasoning. However, due to incorrect figures and incomplete data synthesis, the correctness score is limited to 5. Quantitative accuracy is low (4) due to wrong share counts and repurchase values. Qualitative accuracy is moderate (6) as logic is reasonable but based on flawed inputs. Contextual relevance is strong (8) because the structure and intent align well with the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 540,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has AIG's use of frequency/severity methods evolved between 2022 and 2023, particularly in terms of the lines of business where they are applied and the reasoning behind their usage?",
      "original_answer": "In 2022, AIG primarily used frequency/severity methods for short-tail classes such as U.S. Property, and explicitly avoided using them for aviation exposures due to the high severity and varying mix of claims year to year. By 2023, AIG expanded the application of frequency/severity methods to include U.S. Workers' Compensation, a long-tail line of business, as part of a combination of methods that also included loss development and expected loss ratio methods. This reflects a strategic shift toward using frequency/severity methods in more complex, long-tail environments, especially where risk-sharing features and large deductible business have increased.",
      "llm_answer": "In the 2022 filing AIG said it applied frequency‑/severity‑based reserving only to short‑tail classes such as U.S. Property (and similar program‑property lines), while it explicitly avoided those methods for high‑severity lines like aviation because the claim mix and severity varied widely from year to year【page_273】. By the 2023 filing the company is using frequency‑/severity analysis as part of a combined approach for U.S. Workers’ Compensation – a long‑tail, risk‑sharing line whose large‑deductible business and slower reporting pattern make frequency and severity trends useful for reserve setting【page_202】. The shift shows AIG expanding the use of frequency‑/severity methods from primarily short‑tail property exposures to more complex, long‑tail lines where claim emergence is slower and the mix of deductible‑retention structures drives reserve uncertainty.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate, complete, and semantically equivalent to the ground truth. (1) All key facts are correct: in 2022, AIG used frequency/severity methods for short-tail lines like U.S. Property and avoided them for aviation due to high severity and variable claims; by 2023, the method was expanded to U.S. Workers' Compensation, a long-tail line with risk-sharing and large deductible features. (2) There are no numeric values requiring calculation, but the years (2022, 2023) and business lines (U.S. Property, aviation, U.S. Workers' Compensation) are correctly identified. (3) The multi-hop reasoning is sound—synthesizing changes over time across different lines of business and explaining the rationale behind the shift. (4) The answer captures all elements of the original: evolution over time, specific lines of business, reasoning for usage, and strategic implications. Minor wording differences (e.g., 'risk-sharing line' vs 'risk-sharing features') do not affect meaning. The inclusion of page references adds credibility. All evaluation dimensions are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 311,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Amgen's financial relationship with BeiGene evolved from 2022 to 2023, particularly in terms of cost recovery, product sales, and profit and loss sharing?",
      "original_answer": "In 2022, Amgen recovered $199 million in R&D costs from BeiGene, recorded product sales of $64 million, and recognized $53 million in profit and loss sharing expenses. In 2023, these figures changed to $109 million in cost recovery, $125 million in product sales, and $40 million in profit and loss sharing expenses. This indicates a decrease in cost recovery and profit-sharing expenses, but a significant increase in product sales to BeiGene. The shift suggests a maturation of the collaboration, with more product sales occurring in 2023, while the level of R&D cost sharing declined.",
      "llm_answer": "In 2023 Amgen’s collaboration with BeiGene showed a mixed trend versus 2022: cost‑recovery from BeiGene fell sharply to **$109 million** (down from **$199 million** in 2022)【page_131】, while Amgen’s product sales to BeiGene more than doubled to **$125 million** (up from **$64 million** in 2022)【page_131】.  At the same time, profit‑and‑loss‑share expenses for the initial commercialization period declined to **$40 million** from **$53 million** a year earlier【page_131】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all figures are accurate: $199 million to $109 million in cost recovery (2022 to 2023), $64 million to $125 million in product sales, and $53 million to $40 million in profit and loss sharing expenses. The directional changes (decrease in cost recovery and P&L sharing, increase in product sales) are correctly described. (2) The answer addresses all components of the multi-part question—cost recovery, product sales, and profit and loss sharing—across both years. (3) Entities (Amgen, BeiGene, correct financial metrics, and years) are accurately identified and contextualized. (4) The reasoning is sound: the LLM correctly interprets the trend as a shift toward greater commercialization (higher sales) and reduced R&D cost recovery, indicating maturation of the collaboration, even if not explicitly stated in the same words. The inclusion of citation markers like 【page_131】 suggests grounding in source material. Semantic equivalence is strong, with no factual discrepancies. Minor wording differences (e.g., 'profit-and-loss-share expenses' vs 'profit and loss sharing expenses') do not affect meaning. All criteria for a perfect score are met.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 349,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what specific changes occurred in terms of revisions, production, and purchases during this period?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. During this period, revisions in 2023 added 9 billion cubic feet, but production subtracted 25 billion cubic feet in 2024. Additionally, there were no purchases reported directly affecting this region in 2024, indicating a reduction in active reserve growth strategies compared to earlier years.",
      "llm_answer": "COP’s Asia Pacific/Middle East natural‑gas reserves fell from 326 BCF at year‑end 2022 to 312 BCF at year‑end 2023 and to 296 BCF at year‑end 2024 (direct‑operation totals)【page_145】. During the same span the region saw modest upward revisions of +6 BCF in 2022 and +9 BCF in 2023, turning into a ‑2 BCF downward revision in 2024, while production drawdowns reduced reserves by 24 BCF (2022), 25 BCF (2023) and 24 BCF (2024)【page_145】. The company made no direct purchases, but equity‑affiliate holdings in the region grew by 4 BCF in 2022 and surged to 1,534 BCF in 2023 before showing no new purchases in 2024 (all affiliate reserves are in Asia Pacific/Middle East)【page_146】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also significant inaccuracies. The starting (326 BCF in 2022) and ending (296 BCF in 2024) reserve figures match the ground truth, which is correct. However, the LLM introduces a 2023 reserve level of 312 BCF, which is not present in the original answer and cannot be verified from the provided ground truth. (2) Quantitative accuracy issues: The ground truth states only revisions in 2023 (+9 BCF) and production in 2024 (-25 BCF), but the LLM reports production for all three years (24, 25, 24 BCF), revisions for 2022 (+6 BCF) and 2024 (-2 BCF), and equity-affiliate purchases (4 BCF in 2022, 1,534 BCF in 2023), none of which are mentioned in the original answer. The 1,534 BCF figure is especially problematic as it appears inflated or misattributed. The original answer explicitly states 'no purchases reported directly affecting this region in 2024' and notes a reduction in reserve growth strategies, contradicting the LLM's claim of a surge in affiliate holdings. (3) Multi-hop reasoning: The LLM attempts synthesis but incorrectly infers annual reserve changes and introduces unverified data points (especially equity-affiliate reserves), failing to align with the ground truth's focus on direct operations and lack of purchases. (4) Despite these errors, the LLM captures the overall downward trend and includes the correct 2024 production drawdown (25 BCF) and 2023 revision (+9 BCF), showing partial understanding. The contextual relevance is high as it addresses the region, time frame, and categories (revisions, production, purchases), but quantitative inaccuracies reduce correctness. Thus, correctness is scored 6 for partial accuracy with significant factual deviations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 478,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did FedEx's planned usage of the B767F aircraft evolve from 2022 to 2024, and what does this indicate about its strategic fleet planning?",
      "original_answer": "In 2022, FedEx projected using 14 B767F aircraft in both 2023 and 2024, with a planned reduction to 10 by 2025. By 2024, the projections had changed, showing a decrease to 11 B767F aircraft for 2025 and only 3 by 2026. This indicates a strategic shift toward a more accelerated reduction in the planned use of B767F aircraft, reducing reliance on this model over time.",
      "llm_answer": "In the 2022 Form 10‑K FedEx said it was committed to buying **14 Boeing 767‑300 Freighters in 2023 and another 14 in 2024 (plus 10 in 2025)** – a large near‑term boost to that aircraft type【page_40】. By the 2024 Form 10‑K the schedule had been revised to **only 11 B767Fs for delivery in 2025 and 3 in 2026**, with the 2023‑2024 deliveries removed【page_117】. This reduction and postponement signals that FedEx is scaling back and delaying B767F acquisitions, likely shifting focus toward newer, more fuel‑efficient aircraft and a more cost‑controlled, modernized fleet strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative details. The original answer states that in 2022, FedEx *projected using* 14 B767F aircraft in 2023 and 2024 (not purchasing 14 each year), with a reduction to 10 by 2025. However, the LLM incorrectly claims FedEx was 'committed to buying 14 Boeing 767-300 Freighters in 2023 and another 14 in 2024 (plus 10 in 2025)', which misrepresents the nature of the data (usage projection vs. purchase commitment) and inflates the numbers. The 2024 update correctly notes a reduction to 11 for 2025 and 3 for 2026, aligning with the ground truth. (2) The calculation and timeline errors are critical: the LLM implies active purchases in 2023–2024 that were not in the original data, and the addition of '10 in 2025' as a purchase contradicts the original projection of a reduction to 10 by 2025 (not purchasing 10). The correct evolution is a downward revision in projected usage, not delivery schedule. (3) The reasoning is partially sound—recognizing a strategic shift toward reducing B767F reliance and possibly moving to more fuel-efficient models—but this conclusion is based on misinterpreted data. The multi-hop synthesis across 2022 and 2024 reports is present, but the interpretation of 'planned usage' as 'purchase commitments' undermines factual accuracy. (4) Despite the incorrect framing and numbers, the LLM captures the directional trend (reduction) and infers a plausible strategic rationale, which supports a moderate score. Contextual relevance is high as it directly addresses fleet planning strategy. Quantitative accuracy is low due to incorrect numbers and mischaracterization of projections as purchases; qualitative accuracy is moderate due to correct trend recognition but flawed data interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 490,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did AIG's use of Expected Loss Ratio Methods evolve between 2022 and 2023, particularly in terms of the lines of business and the reasoning behind their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to the high severity nature of claims and varying mix across years. By 2023, AIG applied Expected Loss Ratio Methods more broadly, particularly in U.S. Workers' Compensation, a long-tail line of business, where they used a combination of methods including Expected Loss Ratio, to account for extended loss emergence periods and complex risk-sharing features in policies. This reflects a shift from a focus on short-term forecasting in high-severity contexts to a broader application in long-tail, structurally complex lines.",
      "llm_answer": "In the 2022 Form 10‑K AIG explained that expected‑loss‑ratio (ELR) methods were used “to determine the loss reserves for the latest accident year” on short‑tail classes such as U.S. Property, aviation and program business, especially where loss‑development patterns were inconsistent, losses were low‑frequency/high‑severity or there was little loss history (see page 273). By the 2023 filing the company broadened ELR use – it now applies the method to Workers’ Compensation (page 202) and to excess‑of‑deductible casualty lines, giving ELR “significant weight in the most recent five accident years” and adjusting the ratios for rate changes, loss‑trend inflation and market conditions (see page 200), indicating a more line‑specific and forward‑looking rationale.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, AIG used Expected Loss Ratio (ELR) methods primarily for the latest accident year in short-tail lines like aviation and property, due to high-severity, low-frequency claims and inconsistent development patterns—matching the original answer's emphasis on high severity and varying mix. (2) For 2023, it accurately notes the expansion of ELR use to U.S. Workers’ Compensation (a long-tail line) and excess-of-deductible casualty lines, with 'significant weight in the most recent five accident years,' reflecting broader application beyond just the latest year. The mention of adjustments for rate changes, loss-trend inflation, and market conditions adds nuance not in the original but is consistent with a more forward-looking, line-specific approach. (3) The multi-hop reasoning is sound: it synthesizes changes across years (2022 to 2023), identifies correct lines of business (aviation → Workers’ Comp), and infers a strategic shift in methodology application. (4) Minor deduction in qualitative accuracy because the original emphasizes the structural complexity and risk-sharing features in Workers’ Comp policies as a driver, which the LLM omits, though the added detail about inflation and rate adjustments compensates somewhat. No numeric inaccuracies; all references to years and business lines are correct. Semantic equivalence is strong, and contextual relevance is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 412,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has Cisco's positioning around Enterprise Data Center Transformation evolved between 2022 and 2024, particularly in relation to its strategic alliances and competitive landscape?",
      "original_answer": "In 2022, Cisco highlighted that the enterprise data center was undergoing a fundamental transformation due to the convergence of technologies like computing, networking, storage, and software, with strategic alliance partners sometimes acquiring or aligning with competitors, reducing business with Cisco. By 2024, Cisco continued to emphasize this transformation but expanded its focus on strategic alliances aimed at industry advancement and new market creation, while also updating its competitive landscape to include new entrants like Nvidia Corporation, signaling a shift in market dynamics and alliance strategies.",
      "llm_answer": "In the 2022 filing Cisco described the enterprise data‑center as undergoing a “fundamental transformation” driven by the convergence of compute, networking, storage and software, and warned that rivals were using acquisitions and new strategic alliances to build end‑to‑end data‑center solutions—creating heightened competition even from some of Cisco’s own long‑term alliance partners (2022 p.11). By the 2024 filing the same transformation is still highlighted, but the emphasis shifts to the risk that Cisco’s strategic‑alliance partners may themselves partner with competitors and erode Cisco’s business, underscoring a more acute focus on alliance‑driven competitive threats (2024 p.8). This reflects an evolution from noting external competitive moves to stressing the dual‑edged nature of Cisco’s alliances in the data‑center market.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in its portrayal of Cisco's evolving positioning around Enterprise Data Center Transformation between 2022 and 2024. It correctly identifies the 'fundamental transformation' due to technology convergence in 2022 and the competitive pressure from alliance partners aligning with rivals (2022 p.11). It also accurately reflects the 2024 shift in emphasis toward the risk posed by strategic partners partnering with competitors, citing 2024 p.8. All entities (Cisco, strategic alliances, competitive landscape) and years (2022, 2024) are correct. There are no numerical inaccuracies, so quantitative accuracy is perfect. The reasoning is sound and captures the multi-hop element—synthesizing changes in Cisco’s strategic perception over time. However, the LLM omits a key element from the ground truth: the explicit mention of new competitive entrants like Nvidia Corporation in 2024, which signals a shift in market dynamics. This omission limits completeness and slightly weakens the qualitative accuracy, as the expansion into new market creation and industry advancement through alliances is underemphasized. Despite this, the core evolution in alliance strategy and competitive threat is well conveyed, maintaining high contextual relevance and semantic equivalence on the main points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 367,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the effective interest rate and notional amount associated with the 3.125% 2025 Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 3.125% 2025 Notes were part of a $5.2 billion principal amount on which new interest rate swaps were entered into after the termination of previous swaps, indicating a dynamic hedging strategy due to low interest rates. By 2023, the notional amount of the 3.125% 2025 Notes under interest rate swaps had decreased to $1.0 billion, with an effective interest rate of SOFR + 2.1%. This reflects a reduction in the hedged notional exposure and a shift in the interest rate environment.",
      "llm_answer": "In both 2022 and 2023 Amgen’s interest‑rate swap for the 3.125 % 2025 notes carried a notional amount of $1 billion and an effective rate of SOFR + 2.1%, meaning the rate and notional amount were unchanged from 2022 to 2023【page_144】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of quantitative and qualitative accuracy. It claims that the notional amount and effective interest rate for the 3.125% 2025 Notes were unchanged between 2022 and 2023, both at $1 billion and SOFR + 2.1%. However, the ground truth states that in 2022, the notional amount was part of a $5.2 billion principal amount with new swaps entered after termination of prior ones, indicating a different hedging strategy. Only in 2023 did the notional amount under swaps decrease to $1.0 billion with an effective rate of SOFR + 2.1%. Thus, the LLM incorrectly asserts stability across years when there was a significant reduction in notional exposure. (2) The numbers are factually wrong: $5.2 billion in 2022 is misrepresented as $1 billion, and no mention is made of the change in hedging strategy or interest rate environment shift. The effective rate may have been SOFR + 2.1% in 2023, but there is no confirmation it was the same in 2022. (3) The multi-hop reasoning fails—the question asks how the rate and notional evolved, requiring comparison across years and synthesis of changes in hedging strategy and market conditions. The LLM misses the evolution entirely, reporting static values. (4) Contextual relevance is moderate because it addresses the correct instrument (3.125% 2025 Notes) and mentions interest rate swaps and SOFR, but the core factual evolution is incorrect, severely undermining correctness and qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1176,
        "completion_tokens": 413,
        "total_tokens": 1589
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Cisco's strategic positioning of AppDynamics within its product portfolio evolved from 2022 to 2024, particularly in terms of its emphasis within observability offerings?",
      "original_answer": "In 2022, Cisco explicitly introduced AppDynamics as a key component of its full-stack observability strategy, positioning it alongside Intersight and ThousandEyes to provide application performance monitoring capabilities. However, by 2024, Cisco restructured its product revenue reporting to include a new category called 'Observability,' which subsumed offerings like AppDynamics. This shift indicates a more formalized and integrated strategic emphasis on observability as a standalone pillar within Cisco's broader portfolio.",
      "llm_answer": "In the 2022 filing Cisco described AppDynamics as a “key element” of its full‑stack observability push – naming it alongside ThousandEyes and Intersight for application‑performance monitoring【page_5】. By the 2024 filing Cisco has folded AppDynamics into a dedicated “Observability” product category (the Observability Suite) and is spotlighting that category’s strong growth – a 27% year‑over‑year increase driven by the Observability Suite and ThousandEyes【page_41】【page_42】 – showing that AppDynamics has moved from a highlighted component to a core part of a revenue‑focused observability offering.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Cisco positioned AppDynamics as a 'key element' of its full-stack observability strategy alongside ThousandEyes and Intersight, which matches the original answer's description. (2) For 2024, it accurately notes the creation of a dedicated 'Observability' product category that includes AppDynamics, reflecting the formalized strategic integration described in the ground truth. (3) The LLM adds a specific quantitative detail—27% year-over-year growth in the Observability category—which is not present in the original answer but comes from the cited filing (page 41/42) and enhances the response without contradicting the ground truth. This number is treated as supplementary and does not introduce error. (4) The reasoning correctly synthesizes multi-hop information across two years and multiple products, showing evolution from component-level emphasis to integration into a revenue-reporting category. (5) Minor deduction in qualitative accuracy due to slightly stronger emphasis on growth metrics than the original answer, which focuses on structural reporting changes; however, this does not distort the core message. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the ground truth with enhanced supporting detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 382,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the effective interest rate and notional amount associated with the 4.663% 2051 Notes evolve from 2022 to 2023?",
      "original_answer": "In 2022, the 4.663% 2051 Notes were part of a $5.2 billion principal amount of notes that were hedged using interest rate swaps, with the swaps terminated and replaced at then-current interest rates. In 2023, the notional amount of the 4.663% 2051 Notes was $1.5 billion, and the effective interest rate was SOFR + 4.3%. This indicates a continuation of the hedging strategy but with updated interest rate terms and a more specific disclosure of the notional amount and rate for the 2051 Notes.",
      "llm_answer": "The interest‑rate swap protecting the 4.663 % 2051 Notes continued to cover $1.5 billion of notional in both years【page_132†L31-L34】.  In 2022 the swap’s effective rate was LIBOR + 4.1%, while by 2023 it had been reset to SOFR + 4.3%【page_144†L13-L16】.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the notional amount of $1.5 billion in both 2022 and 2023 and the 2023 effective interest rate as SOFR + 4.3%, which aligns with the ground truth. However, it incorrectly states that the notional amount was the same in both years and that the swap covered $1.5 billion in 2022. The original answer indicates that in 2022, the 4.663% 2051 Notes were part of a larger $5.2 billion hedged portfolio, not specifically $1.5 billion. This is a significant factual error in quantitative and qualitative terms. Additionally, the LLM claims the 2022 effective rate was LIBOR + 4.1%, but the ground truth does not specify the exact rate for 2022—only that swaps were terminated and replaced at then-current rates. Thus, the specific rate and reference index (LIBOR) are unsupported. (2) The notional amount discrepancy is critical: $1.5B vs $5.2B in 2022 is a major misrepresentation. The 2023 figures are accurate. (3) The multi-hop reasoning is partially sound—linking the evolution of rates and notional amounts across years—but fails in synthesizing the correct scope of hedging in 2022. The model assumes continuity in notional amount without evidence. (4) Scores reflect partial correctness: quantitative accuracy is moderate due to one correct and one incorrect number; qualitative accuracy penalized for unsupported inference; contextual relevance remains high as the answer addresses the right instruments and time frame.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1179,
        "completion_tokens": 406,
        "total_tokens": 1586
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of the lines of business and segmentation criteria applied?",
      "original_answer": "In 2022, AIG referenced the use of expected loss ratio methods in a general sensitivity analysis related to loss reserve assumptions, without specifying detailed segmentation or particular lines of business. By 2023, AIG explicitly applied expected loss ratio methods to U.S. Workers' Compensation, a long-tail line of business, and introduced more granular segmentation criteria such as risk-sharing features, state and industry subsets, deductible size, and claim handling entities. This indicates a more structured and detailed application of the method in 2023 compared to 2022.",
      "llm_answer": "In the 2022 Form 10‑K AIG applied expected‑loss‑ratio techniques across a range of lines—U.S. Workers’ Compensation, U.S. Excess Casualty, U.S. Other Casualty and U.S. Financial Lines (D&O)—primarily through loss‑cost‑trend assumptions and Bornhuetter‑Ferguson/Cape‑Cod methods, with segmentation only at the broad line‑of‑business or “year‑and‑subset” level (see page 66 and the sensitivity tables on page 68). By the 2023 filing the firm stresses expected‑loss‑ratio methods especially for business written in excess of a deductible, giving them significant weight for the most recent five accident years, and now segments those exposures much more granularly—by guaranteed‑cost versus excess‑of‑deductible, by state and industry, by deductible size and by whether the claim is handled by AIG or a third‑party administrator (see page 200, page 202 and the U.S. Workers’ Compensation discussion). This reflects a shift from a broad, line‑level application in 2022 to a more targeted, recent‑year‑focused approach with detailed segmentation in 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several inaccuracies that deviate from the ground truth, particularly in the description of AIG's 2022 use of expected loss ratio methods. According to the original answer, in 2022 AIG only referenced expected loss ratio methods in a general sensitivity analysis without specifying particular lines of business or segmentation—however, the LLM claims AIG applied these methods across specific lines (U.S. Workers’ Compensation, U.S. Excess Casualty, etc.) and used Bornhuetter-Ferguson/Cape-Cod methods, which is not supported by the ground truth. This misrepresents the extent and specificity of AIG’s 2022 methodology. Additionally, the LLM introduces details not present in the ground truth, such as 'loss-cost-trend assumptions' and application to D&O, which undermines factual accuracy. In contrast, the 2023 description aligns well with the ground truth: the focus on U.S. Workers’ Compensation, segmentation by deductible type, state, industry, deductible size, and claim handling entity are correctly identified, as is the increased granularity. The reasoning correctly identifies a shift toward more detailed segmentation, supporting the contextual relevance and partial qualitative accuracy. However, because the 2022 characterization is factually incorrect and overstates the specificity of method application, the correctness and quantitative/qualitative accuracy scores are reduced. There are no numerical values to verify, so quantitative accuracy is assessed based on factual precision of financial or technical terms. Overall, the answer shows strong structure and relevance but fails on key factual elements required for full correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 455,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did PepsiCo's engagement with the 2.850% Senior Notes due 2026 evolve between 2023 and 2024, particularly in terms of its broader debt issuance strategy as reflected in the additional notes introduced in 2024?",
      "original_answer": "In 2023, PepsiCo referenced the 2.850% Senior Notes due 2026 as part of a broader set of debt instruments, including other senior notes with varying interest rates and maturity dates. By 2024, the company introduced a significantly expanded range of senior notes, including higher-yielding instruments such as the 7.00% Senior Notes due 2029 and the 5.50% Senior Notes due 2035, indicating a more diversified and long-term debt issuance strategy. This evolution suggests that PepsiCo not only maintained its commitment to the 2.850% Senior Notes due 2026 but also broadened its capital structure by incorporating a wider spectrum of debt instruments with different risk-return profiles.",
      "llm_answer": "In the 2023 Form 10‑K PepsiCo’s board listed the 2.850 % Senior Notes due 2026 among the series of notes it was authorizing at that time (see the board‑resolution line that includes “…the 2.850 % Senior Notes due 2026…”【page_129†L4-L7】). By the 2024 filing the same 2.850 % Senior Notes due 2026 remained on the authorized list, but PepsiCo also added a new tranche of higher‑coupon, longer‑dated senior notes—4.500 % due 2029, 4.800 % due 2034 and 5.250 % due 2054—showing that the company broadened its debt‑issuance strategy beyond the original 2026 issue【page_130†L1-L4】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that PepsiCo maintained the 2.850% Senior Notes due 2026 in both 2023 and 2024, and that new senior notes were added in 2024, reflecting a broader debt issuance strategy. However, the specific notes cited in the LLM answer—4.500% due 2029, 4.800% due 2034, and 5.250% due 2054—do not match the ground truth, which states that PepsiCo introduced the 7.00% Senior Notes due 2029 and 5.50% Senior Notes due 2035. These discrepancies in interest rates and maturity dates are significant and factually incorrect. (2) Quantitative accuracy is compromised: the percentages and years listed in the LLM answer differ from the ground truth (e.g., 4.500% vs 7.00%, 2034 vs 2035, 2054 vs no such note in truth). These are not formatting variations but distinct financial instruments. (3) The multi-hop reasoning is partially sound—the model correctly infers that maintaining existing notes while adding new ones indicates a broadening debt strategy. However, the synthesis is based on incorrect underlying data, weakening the conclusion. (4) Contextual relevance is high because the answer addresses the evolution of PepsiCo’s debt strategy and ties it to the 2026 notes. The reasoning structure mirrors the ground truth, but factual inaccuracies in key numeric details reduce overall correctness. Thus, the answer is partially correct but contains significant factual errors in the core financial instruments cited.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 402,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Cisco's exposure to channel partner financing guarantees evolved between fiscal years 2022 and 2024, and what does this indicate about the company's financial risk management strategy?",
      "original_answer": "In fiscal year 2022, Cisco disclosed that the volume of channel partner financing was $27.9 billion, with a balance of financing subject to guarantees amounting to $1.4 billion as of July 30, 2022. By fiscal year 2024, while the company continued to provide financing guarantees, the specific volume of channel partner financing and the balance subject to guarantees were no longer explicitly quantified in the disclosures. This shift indicates a potential strategic move toward reducing transparency around these financial commitments, which may reflect a broader risk management approach to limit visibility into contingent liabilities. However, the absence of updated figures prevents definitive conclusions about the actual change in exposure.",
      "llm_answer": "Cisco’s channel‑partner financing guarantees have been trimmed. In FY 2022 the company said the maximum potential future payments on those guarantees were about **$188 million** (net total $179 million after accounting for $9 million of deferred revenue) and $1.4 billion of partner financing was subject to guarantees (see 2022 10‑K p. 94). By FY 2024 the same metric fell to roughly **$127 million** of maximum potential payments, with about $13 million recorded as deferred revenue (see 2024 10‑K p. 50). The reduction signals that Cisco is actively tightening its guarantee commitments and limiting contingent credit exposure, reflecting a more conservative financial‑risk‑management strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in FY 2022, the volume of channel partner financing was $27.9 billion, with $1.4 billion subject to guarantees. The LLM incorrectly introduces a 'maximum potential future payments' figure of $188 million (net $179 million) not mentioned in the original answer, and falsely claims this dropped to $127 million in FY 2024. The ground truth states that Cisco did not disclose specific figures for FY 2024, making the LLM's precise numbers ($127 million, $13 million deferred revenue) entirely unsupported. (2) The quantitative inaccuracies are severe: the LLM fabricates metrics not present in the ground truth (e.g., 'maximum potential payments'), misrepresents disclosed figures, and presents false year-over-year comparisons. The only correct number is the $1.4 billion in guarantees from FY 2022. (3) The reasoning is flawed: the LLM assumes a reduction in exposure based on invented data, concluding a 'more conservative risk management strategy,' while the ground truth emphasizes reduced transparency and inability to assess actual exposure changes. This reflects a failure in multi-hop reasoning—instead of noting the absence of FY 2024 disclosures, the model invents data to support a narrative. (4) Scores reflect major factual errors in numbers and reasoning, though the answer is contextually relevant by addressing Cisco's risk management and channel financing. The qualitative score is slightly higher because the general direction (evaluating risk strategy) aligns with the question, but the conclusion is unsupported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 447,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has the status and interest rate structure of the 2.45% 2030 Notes evolved between 2022 and 2023?",
      "original_answer": "In 2022, Amgen disclosed that it had entered into interest rate swap contracts with an aggregate notional amount of $1.0 billion with respect to the 2.45% 2030 Notes, effectively converting the fixed-rate interest to a floating LIBOR-based coupon. By 2023, the 2.45% 2030 Notes remained outstanding with a notional amount of $1.0 billion, but the interest rate structure had transitioned from LIBOR to SOFR, now stated as SOFR + 1.3%. This reflects a continuation of the note's existence but with a modified floating-rate benchmark.",
      "llm_answer": "The 2.45 % 2030 Notes were still outstanding in both years and continued to be hedged with a $1 billion interest‑rate‑swap position.  As shown in the 2023 filing, the swap gave the notes an effective rate of SOFR + 1.3 % for both December 31 2022 and December 31 2023, meaning the amount covered and the floating‑rate structure did not change between 2022 and 2023【page_144】.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that the 2.45% 2030 Notes remained outstanding in both years and that a $1 billion interest rate swap was in place. However, it incorrectly states that the effective rate was SOFR + 1.3% for both December 31, 2022 and December 31, 2023. According to the ground truth, in 2022 the rate was based on LIBOR, not SOFR, and only transitioned to SOFR + 1.3% in 2023. This is a critical factual error regarding the evolution of the interest rate structure. (2) Quantitatively, the $1 billion notional amount is correct, and the SOFR + 1.3% rate in 2023 is accurate. However, attributing SOFR to 2022 is incorrect—LIBOR was the benchmark then. The dates (2022 vs 2023) are misaligned with the rate benchmarks. (3) The multi-hop reasoning is flawed: the question asks how the status and interest rate structure evolved, implying a change over time. The LLM fails to capture the transition from LIBOR to SOFR, instead asserting no change occurred. This misses the core evolution described in the ground truth. (4) Contextual relevance is high—the answer addresses the right notes, company (implied), time frame, and hedging structure. But due to the key misrepresentation of the interest rate benchmark in 2022, the qualitative and correctness scores are significantly reduced. The answer suggests stability where there was a meaningful shift in benchmark rates.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 389,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has FedEx's relationship with Pass-Through Certificates evolved between 2022 and 2023, particularly regarding its financial guarantees and obligations?",
      "original_answer": "In 2022, FedEx Express had issued $970 million of Pass-Through Certificates, Series 2020-1AA, which were fully and unconditionally guaranteed by FedEx. These certificates were secured by 19 Boeing aircraft with a net book value of $1.8 billion. However, in 2023, FedEx clarified that pass-through certificates associated with leveraged operating leases were not direct obligations of, nor guaranteed by, FedEx or FedEx Express. This indicates a shift from direct financial guarantees in 2022 to a position of no direct financial obligation in 2023.",
      "llm_answer": "In the 2022 Form 10‑K FedEx disclosed that it had issued $970 million of Series 2020‑1AA pass‑through certificates, secured by 19 Boeing aircraft, and that “the payment obligations of FedEx Express in respect of the Certificates are fully and unconditionally guaranteed by FedEx” 【page_94】. In the 2023 filing the same series is still described as fully guaranteed 【page_96】, but the company also adds that “the pass‑through certificates are not direct obligations of, or guaranteed by, FedEx or FedEx Express” because they are funded through leveraged operating leases 【page_98】. Thus, while the specific Series 2020‑1AA certificates remain guaranteed, FedEx’s overall relationship to pass‑through certificates has shifted to emphasize that they are indirect liabilities supported by lease payments rather than direct corporate guarantees.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in terms of quantitative accuracy: the $970 million amount, the Series 2020-1AA designation, the 19 Boeing aircraft, and the 2022 guarantee by FedEx are all accurately reported and match the ground truth. The citations to the 10-K pages also suggest precise sourcing. However, there is a critical contradiction in the 2023 characterization. The LLM claims that in the 2023 filing, the same series (2020-1AA) is still described as fully guaranteed (citing page 96), while also stating on page 98 that such certificates are not direct obligations or guaranteed by FedEx. This creates confusion. The ground truth indicates a clear shift in 2023: FedEx clarified that pass-through certificates under leveraged operating leases are *not* guaranteed, marking a departure from the 2022 stance. The LLM’s attempt to reconcile both statements by saying the specific series remains guaranteed while the broader category does not may be technically present in the document, but it misrepresents the evolution: the core of the question is about the shift in FedEx's relationship, and the LLM downplays the significance of the 2023 clarification. The ground truth emphasizes a move *away* from guarantees, while the LLM suggests continuity for the specific series, which may obscure the broader policy shift. The reasoning is partially sound but fails to clearly synthesize the multi-hop evolution—especially whether the 2022 guarantee still stands in 2023. The answer is contextually relevant and well-structured, but the qualitative inaccuracy in interpreting the shift reduces its correctness. Thus, while numbers are perfect (10), reasoning and completeness on the evolution are partially flawed (7), and overall correctness is 7 due to the misleading implication of ongoing guarantees.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 489,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Mastercard's use of risk mitigation arrangements to manage gross settlement exposure evolve from 2023 to 2024, and what does this indicate about the company's risk management strategy?",
      "original_answer": "In 2023, Mastercard had $75,023 million in gross settlement exposure, with $12,167 million covered by risk mitigation arrangements. By 2024, gross settlement exposure increased to $78,385 million, and the company applied $13,466 million in risk mitigation arrangements, reflecting an increase in both total exposure and the amount mitigated. This indicates that Mastercard's risk management strategy became more robust over time, as it increased its use of mitigation tools in response to growing settlement exposure.",
      "llm_answer": "In 2023 Mastercard offset $12.2 billion of its $75.0 billion gross settlement exposure with risk‑mitigation arrangements (cash collateral, letters of credit, guarantees) 【page_112】, and in 2024 it increased both the exposure to $78.4 billion and the mitigation to $13.5 billion 【page_105】. The rise in mitigation alongside higher gross exposure shows the company is actively scaling its collateral and credit‑enhancement tools to match growing settlement risk, underscoring a disciplined, proactive risk‑management approach.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Mastercard's risk mitigation arrangements from 2023 to 2024 and accurately interprets the implications for the company's risk management strategy. The numbers are presented in billions with slight rounding ($12.2B vs $12,167M, $13.5B vs $13,466M, $75.0B vs $75,023M, $78.4B vs $78,385M), which is acceptable under semantic equivalence and common financial reporting practices. (2) Quantitative verification: All figures are within reasonable rounding tolerance—12,167 million ≈ 12.2 billion, 13,466 million ≈ 13.5 billion, 75,023 million ≈ 75.0 billion, 78,385 million ≈ 78.4 billion. No calculation errors; the trend of increasing exposure and corresponding increase in mitigation is correctly identified. (3) Multi-hop reasoning is sound: the model synthesizes data across two years, identifies both the increase in gross exposure and the proportional increase in mitigation, and draws a logical conclusion about Mastercard’s proactive risk management. The use of terms like 'collateral and credit-enhancement tools' aligns with 'risk mitigation arrangements' (e.g., cash collateral, letters of credit, guarantees) mentioned in the source. (4) The answer is contextually complete and relevant, addressing both parts of the question—evolution over time and strategic implication. The only minor deduction is for slight rounding that, while acceptable, could marginally affect precision in strict financial analysis, hence not a perfect 10 in quantitative accuracy. Overall, the answer reflects strong factual correctness, proper synthesis, and appropriate interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 448,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Nike's liabilities related to foreign exchange forwards and options designated as hedging instruments change between 2022 and 2024, and what does this indicate about the company's exposure or strategy?",
      "original_answer": "In 2022, Nike reported $37 million in liabilities for foreign exchange forwards and options designated as hedging instruments under accrued liabilities, and $11 million under deferred income taxes and other liabilities, totaling $48 million. By 2024, the liability under accrued liabilities for the same category increased to $110 million, while the amount under deferred income taxes and other liabilities decreased to $5 million, resulting in a total of $115 million. This represents a significant increase in total liabilities for designated hedging instruments related to foreign exchange forwards and options, indicating a potential increase in Nike's foreign exchange risk exposure or a strategic shift in hedging activity.",
      "llm_answer": "Nike’s liabilities for foreign‑exchange forwards and options that are formally designated as cash‑flow hedges rose sharply – from about **$48 million in FY 2022** (the sum of $37 million accrued liabilities and $11 million deferred‑tax liabilities) to roughly **$115 million in FY 2024** (about $110 million accrued plus $5 million deferred‑tax liabilities)【page_83】.  The $67 million increase signals that Nike has expanded its hedging program, likely to cover a larger foreign‑currency exposure and to more aggressively lock in cash‑flow protection for its global operations【page_83】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the numbers are accurate: $37M + $11M = $48M in 2022, and $110M + $5M = $115M in 2024. The increase of $67M is correctly calculated. The breakdown by liability categories (accrued liabilities and deferred income taxes/other liabilities) is consistent with the original answer. (2) The answer addresses both parts of the question: the change in liabilities between 2022 and 2024, and the implication regarding exposure or strategy. (3) Entities are correct—Nike, foreign exchange forwards and options, hedging instruments, and fiscal years 2022 and 2024 are all accurately referenced. (4) The reasoning is sound: the increase in liabilities is correctly interpreted as a sign of expanded hedging activity, likely due to greater foreign currency exposure or a more aggressive hedging strategy, which aligns with the original answer’s conclusion. Minor wording differences (e.g., 'deferred-tax liabilities' vs 'deferred income taxes and other liabilities') do not affect factual accuracy. Semantic equivalence is maintained throughout. The citation to page_83 supports contextual grounding. All multi-hop elements—synthesizing data across years and liability categories and interpreting strategic implications—are correctly executed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 368,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the representation of Bounty within P&G's Baby, Feminine & Family Care segment evolve between the 2022 and 2023 10-K filings, and what does this suggest about its brand visibility?",
      "original_answer": "In the 2022 10-K filing, Bounty was mentioned as part of P&G's Family Care business within the Baby, Feminine & Family Care segment, but it was not explicitly listed among the key brands. In contrast, the 2023 10-K filing explicitly included Bounty among the major brands under the Family Care category. This change suggests an increase in Bounty's brand visibility within P&G's portfolio, though the filings do not provide specific market share or sales figures to quantify this shift. The explicit mention in 2023 indicates a possible strategic move to highlight Bounty's role, though no direct strategic intent is stated in the evidence provided.",
      "llm_answer": "In the 2022 filing Bounty was already called out as a key Family‑Care brand within the Baby, Feminine & Family Care segment (listed among the “Major Brands” and noted as having “over 40%” market share in North America)【page_18】【page_20】. The 2023 filing repeats the same placement – Bounty appears again in the segment’s brand list and the North‑American share is still described as “over 40%”【page_18】【page_20】. This unchanged treatment signals that Bounty’s visibility and importance within the segment remained strong and stable from 2022 to 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that Bounty was explicitly listed as a key brand in the 2022 10-K with a market share of 'over 40%'. According to the ground truth, Bounty was part of the Family Care business in 2022 but was not explicitly listed among the key brands, and no market share figure was provided in that year's filing. In 2023, Bounty was explicitly named as a major brand, but the 'over 40%' market share claim — while possibly true — is not supported by the ground truth as being mentioned in either filing. (2) The quantitative claim of 'over 40%' market share in both years is not present in the original answer and cannot be verified from the provided truth; thus, this introduces fabricated data. There are no calculations in the response, but the use of unsupported percentages undermines quantitative accuracy. (3) The multi-hop reasoning is flawed: the question asks about the evolution of Bounty’s representation and what it suggests about brand visibility. The LLM incorrectly asserts no change occurred, when in fact the key evolution — the explicit elevation of Bounty to a named brand in 2023 — is the central point of the ground truth. This represents a failure in synthesizing the correct contrast between the two filings. (4) Contextual relevance is moderate because the answer addresses the right segment and company, and attempts to compare two years, but the core factual error (misrepresenting 2022 disclosure) leads to an incorrect conclusion about stability versus increased visibility. The inclusion of phantom citations (e.g., 'page_18') further undermines reliability. Overall, the answer contradicts the ground truth on the main point and introduces unverified data, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 482,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has Oracle's approach to its hardware business, particularly Oracle Engineered Systems, evolved between fiscal 2022 and fiscal 2023 in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle's hardware business, which includes Oracle Engineered Systems, was described in terms of its contractual activities and revenue recognition, with an emphasis on the timing of revenue recognition for cloud and license contracts. By fiscal 2023, Oracle introduced a more detailed explanation of how hardware and related software are treated as a combined performance obligation, with revenue recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve and develop new hardware products and services, which was not explicitly mentioned in 2022. This indicates a shift toward a more strategic focus on innovation and integration of hardware and software components within the hardware business.",
      "llm_answer": "In fiscal 2022 Oracle said that its hardware business – which includes Oracle Engineered Systems – records product revenue when the hardware and any related software are delivered to the customer, while hardware‑support contracts are recognized ratably over the contract term (2022 10‑K p. 105). In fiscal 2023 the company kept the same point‑in‑time recognition for the combined hardware‑software performance obligation, but now describes Engineered Systems as a core, integrated offering and notes that the hardware segment represents about 6 % of total revenue (down from roughly 7 % in FY‑2022) even as it continues to invest in R&D for new hardware products (2023 10‑K p. 43).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and percentages are correct: the hardware segment's share of total revenue decreased from approximately 7% in FY2022 to about 6% in FY2023, which matches the trend described in the original answer. The revenue recognition policy—point-in-time for combined hardware-software delivery and ratable for support—is accurately reported with correct citation to the 2022 10-K (p. 105) and 2023 10-K (p. 43). (2) The LLM correctly identifies the continuity in revenue recognition policy while noting the enhanced disclosure in 2023 about the combined performance obligation, which reflects the evolution in reporting clarity. (3) Qualitatively, the LLM captures the strategic shift by highlighting Oracle’s continued R&D investment in hardware, a key point in the original answer not emphasized in 2022. It also correctly identifies Engineered Systems as a 'core, integrated offering' in 2023, reflecting increased strategic emphasis. (4) The only minor omission is that the original answer notes a broader 'strategic focus on innovation and integration' as a shift, while the LLM implies this through R&D and integration language but doesn’t explicitly frame it as a strategic evolution. However, the core facts, multi-hop synthesis across years, and reasoning are sound. Wording differs slightly but maintains semantic equivalence. Contextual relevance is excellent, directly addressing both revenue recognition and strategic emphasis as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 423,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the sales performance of the product ERLEADA evolve between 2022 and 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA generated $1,881 million in sales, and by 2023, its sales increased to $2,387 million, representing a 26.9% growth. This indicates a strong upward trajectory for ERLEADA in the market, suggesting increased adoption or improved commercial performance over the period.",
      "llm_answer": "ERLEADA’s sales grew from $1.881 billion in 2022 to $2.387 billion in 2023 – a 26.9% increase (27.5% operational growth, partially offset by a 0.6% currency headwind) (page_31). The company says this rise was driven by continued share‑gain and market growth in metastatic castration‑resistant prostate cancer, signalling a strong, upward market trajectory for the product (page_32).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all key aspects. (1) Quantitatively, the sales figures for ERLEADA are accurate: $1.881 billion in 2022 and $2.387 billion in 2023, with a 26.9% growth rate, which aligns exactly with the original answer (allowing for format variation: $1,881 million = $1.881 billion). The additional detail of 27.5% operational growth offset by a 0.6% currency headwind provides supplementary context but does not contradict the core calculation. (2) The answer addresses both parts of the question: the sales performance evolution (year-over-year increase) and the market trajectory (upward, driven by market share gains and category growth). (3) Entities are correct—product name (ERLEADA), years (2022–2023), and financial metric (sales) are all accurately identified. (4) The reasoning is sound and reflects multi-hop synthesis: it connects sales growth to underlying market dynamics (share gain and market expansion in metastatic castration-resistant prostate cancer), correctly inferring a strong market trajectory. The inclusion of source page references (page_31, page_32) further supports the grounding in evidence. Overall, the answer is factually precise, complete, and semantically equivalent to the ground truth, warranting full marks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1164,
        "completion_tokens": 361,
        "total_tokens": 1525
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the nature of CMCSA's relationship with local broadcast television stations evolved from 2023 to 2024, particularly in terms of competitive positioning and dependency for content distribution?",
      "original_answer": "In 2023, CMCSA's Media segment directly competed with local broadcast television stations for viewers' attention and advertising revenue. By 2024, the relationship shifted to a more interdependent one, where CMCSA's linear television networks became reliant on local broadcast television stations for retransmission consent, which is necessary for distributing broadcast network programming to video service customers. This marks a shift from competition to dependency, reflecting a strategic and operational evolution in how CMCSA interacts with local broadcast stations.",
      "llm_answer": "In the 2023 filing Comcast framed local broadcast stations mainly as **affiliation partners** – it competes to win their agreements because they are “necessary to ensure the effective distribution of broadcast‑network programming to a nationwide audience” and it even competes with them for content and talent【page_14】. By the 2024 filing the tone has shifted to a **cost‑and‑negotiation focus**: Comcast now highlights rising programming expenses tied to “payments to certain local broadcast television stations in exchange for their required consent for the retransmission of broadcast network programming,” and stresses the need to secure and maintain affiliation and retransmission‑consent agreements, showing greater dependency on and leverage from those stations【page_23】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in CMCSA's relationship with local broadcast television stations from 2023 to 2024: in 2023, the relationship was competitive (competing for content and talent), and by 2024, it shifted toward dependency due to retransmission consent requirements. The key factual elements—competition in 2023, increased dependency in 2024, reliance on retransmission consent, and rising programming costs—are all present and correct. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable; however, the years (2023 and 2024) are correctly referenced. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years of filings, correctly inferring a strategic shift based on changes in language and emphasis—from affiliation partnerships and competition in 2023 to cost-focused negotiations and dependency in 2024. (4) The LLM adds contextual detail not in the original (e.g., competition for talent, specific phrasing about programming expenses) that is consistent with the source material and enhances the answer without introducing inaccuracies. The only minor gap is that the original emphasizes the shift from 'competition for viewers and ad revenue' to 'dependency for distribution,' while the LLM focuses more on content/talent and cost negotiations. This nuance is present but slightly less emphasized. Overall, the answer is factually correct, contextually rich, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 445,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did the value of Held-to-Maturity (HTM) securities held by MA evolve between 2023 and 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2023, MA held $306 million in HTM securities, but by 2024, this amount dropped significantly to $38 million. This indicates a major shift in MA's investment strategy, with a sharp reduction in long-term held securities, likely reflecting a move toward more liquid or short-term investment positions.",
      "llm_answer": "MA’s held‑to‑maturity securities dropped sharply from **$306 million at the end of 2023** to **$38 million at the end of 2024**【page_86】, a decline of roughly $268 million. This large reduction shows the company is shedding its low‑yield, time‑deposit HTM portfolio and reallocating capital to other assets (e.g., available‑for‑sale or equity investments), indicating a strategic move toward a more flexible, potentially higher‑return investment approach【page_83】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the HTM securities values for MA as $306 million in 2023 and $38 million in 2024, matching the ground truth exactly. The calculated decline of $268 million ($306M - $38M) is accurate. (2) All numeric values, years, and financial metrics are correct and properly attributed to MA. Format variations (e.g., $306 million vs $306M) are acceptable and do not affect accuracy. (3) The reasoning is sound: the sharp drop is correctly interpreted as a strategic shift, and the LLM adds context—such as reallocating from low-yield HTM securities to more flexible assets like AFS or equity investments—which is a reasonable inference consistent with the ground truth’s interpretation of moving toward more liquid or short-term positions. The mention of page citations (e.g., page_86, page_83) suggests proper sourcing from the filings. (4) The only minor difference from the ground truth is the LLM’s slightly more specific characterization of the HTM portfolio as 'low-yield, time-deposit' and the mention of equity investments, which are plausible elaborations but not explicitly confirmed in the ground truth. However, these do not contradict the original answer and fall within reasonable interpretation. Thus, the answer is factually correct, complete, and contextually appropriate, warranting a high score with only a slight deduction in qualitative accuracy due to minor inferential expansion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1197,
        "completion_tokens": 398,
        "total_tokens": 1596
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the positioning of the Always brand within Procter & Gamble's Baby, Feminine & Family Care segment evolved between 2022 and 2023, particularly in terms of its product categorization and associated sub-categories?",
      "original_answer": "In 2022, Always was categorized under Feminine Care within the Baby, Feminine & Family Care segment, which included sub-categories like Adult Incontinence and Feminine Care. By 2023, the brand remained part of the same reportable segment but was more specifically aligned with 'Menstrual Care' under the updated Feminine Care sub-category, reflecting a more targeted positioning. This evolution indicates a strategic shift in how Always is being categorized to emphasize its core focus area.",
      "llm_answer": "In the 2022 filing the Always brand was listed under the Baby, Feminine & Family Care segment’s **Feminine‑Care** sub‑category (grouped with “Adult Incontinence, Feminine Care”) alongside a separate **Baby‑Care** sub‑category for diapers and wipes【page_19】. By the 2023 filing the brand is still a key name in the same segment, but the sub‑category is now labeled **Feminine‑Care (Adult Incontinence, Menstrual Care)** and the Baby‑Care sub‑category is no longer shown, indicating a shift to a more focused categorization on menstrual‑care products【page_18】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that Always was under the Feminine Care sub-category in 2022 within the Baby, Feminine & Family Care segment, grouped with Adult Incontinence. In 2023, it accurately notes the rebranding of the sub-category to include 'Menstrual Care' instead of the broader 'Feminine Care', reflecting a more targeted positioning. The removal of the Baby-Care sub-category is also correctly observed. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a traditional sense, but all dates (2022, 2023) and categorizations are factually correct. (3) The multi-hop reasoning is sound: the model synthesizes changes in sub-category labels and structure across two years, correctly inferring a strategic shift toward menstrual care. The only minor shortcoming is that the LLM implies the Baby-Care sub-category was removed entirely, while the ground truth does not comment on that—this could be contextually accurate but isn't confirmed in the original answer. (4) Despite this small over-interpretation, the core evolution of Always’ positioning—from general Feminine Care to a more specific Menstrual Care focus—is correctly captured with strong contextual and semantic equivalence. Hence, a score of 9 is justified, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 387,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has Oracle's positioning and financial contribution of Oracle Engineered Systems evolved between 2022 and 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In 2022, Oracle Engineered Systems were disclosed as part of hardware revenues, but no specific percentage of total revenue was provided. Revenue recognition for hardware products, including Engineered Systems, was described as occurring at the point in time when the product and related software were delivered. By 2023, Oracle explicitly stated that the hardware business, which includes Engineered Systems, represented 6% of total revenues in both fiscal 2023 and fiscal 2024, indicating a clearer and more consistent measurement of the product line's contribution. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve hardware offerings and introduced more detailed factors affecting hardware revenue predictability, such as manufacturing partner performance and competitive positioning against cloud infrastructure offerings. This reflects both quantitative and strategic evolution in how Oracle presents and manages the Engineered Systems product line.",
      "llm_answer": "In the 2022 filing Oracle grouped Engineered Systems with its broader hardware revenues and said that “the hardware product and related software … are accounted for as a combined performance obligation. The revenues … are generally recognized at the point in time that the hardware product is delivered and ownership is transferred to the customer” (2022 p. 74). By the 2023 filing the company was positioning Engineered Systems as a core component of a distinct hardware segment that “represented 6 % of our total revenues in each of fiscal 2024 and 2023” and emphasized ongoing R&D investment in these products, while still recognizing revenue at the point of delivery of the hardware and its software (2023 p. 43).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and percentages are correct: the 6% of total revenue for both fiscal 2023 and 2024 is accurately reported, and the absence of a specific percentage in 2022 is correctly implied by stating it was grouped into broader hardware revenues. (2) The revenue recognition policy—point-in-time recognition upon delivery of hardware and related software—is correctly cited for both years, with accurate references to the combined performance obligation and delivery timing. (3) The qualitative evolution in strategic emphasis is well captured: the 2023 shift to clearer disclosure of the hardware segment’s contribution, inclusion of Engineered Systems as a core component, and mention of ongoing R&D investments are all correctly identified. The LLM omits minor contextual details present in the original answer—such as the mention of manufacturing partner performance and competitive dynamics affecting predictability—but these do not undermine the core factual or synthetic accuracy. (4) Multi-hop reasoning is sound: the model correctly synthesizes information across two years, identifies changes in disclosure practices, and contrasts vague 2022 reporting with more precise 2023 metrics. Wording differs slightly but maintains semantic equivalence. The answer is fully relevant to the question’s focus on positioning, financial contribution, revenue recognition, and strategic emphasis. A score of 9 is justified due to the omission of some strategic nuances in 2023, but the core facts, numbers, and reasoning are fully correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 444,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Comcast's relationship with representation firms evolved in terms of advertising sales strategy between 2023 and 2024?",
      "original_answer": "In 2023, Comcast worked with representation firms as an extension of its sales force to sell a portion of the advertising units allocated to them, recording revenue net of agency commissions. By 2024, Comcast had evolved this relationship into formal representation agreements under which they sell advertising on behalf of third parties, indicating a deeper strategic alignment and expanded role for these firms. This reflects a shift from a co-selling model to a more formalized representation structure.",
      "llm_answer": "In the 2023 filing Comcast said it “represents the advertising sales efforts of certain third parties” and “works with representation firms as an extension of our sales force,” recording the ad revenue net of agency commissions. By the 2024 filing the language shifts to “enter into representation agreements under which we sell advertising on behalf of third parties,” indicating a more formal, principal‑based partnership while still using representation firms to sell a portion of its allocated ad inventory. This reflects a move from an informal representation role to a structured agreement where Comcast acts as the principal seller for third‑party ads.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2023 model involved working with representation firms as an extension of the sales force, recording revenue net of commissions, and the 2024 shift involved formal representation agreements where Comcast sells advertising on behalf of third parties. The description of the evolution from an informal to a more formal, principal-based structure is consistent with the original answer. (2) There are no numeric values (e.g., dollar amounts, percentages) in the question or answers, so quantitative accuracy is not applicable beyond correct use of years (2023 and 2024), which are accurate. (3) The multi-hop reasoning is sound—LLM correctly synthesizes changes in Comcast's strategy across two years using qualitative shifts in language from filings. It captures the strategic evolution from co-selling to a principal role, though it phrases the shift slightly differently (e.g., 'informal representation role' vs. 'co-selling model'), which is semantically close but not identical. (4) The answer is fully contextually relevant, directly addressing how the relationship evolved in terms of advertising sales strategy. The only minor gap is that the LLM does not explicitly mention that representation firms sell a portion of Comcast’s allocated ad inventory in 2023 (instead of Comcast selling on behalf of third parties), which slightly blurs the direction of the relationship pre-2024. However, this does not materially distort the overall correct interpretation. Hence, a score of 9 is warranted for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 467,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Oracle's approach to its industry-specific hardware offerings evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle described its hardware business as including industry-specific hardware and recognized hardware revenues at the point in time when products and related software were delivered to customers. By fiscal 2023, Oracle introduced a more detailed explanation of revenue recognition for hardware, stating that revenues for combined performance obligations (hardware plus related software) are generally recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing investments in R&D to improve existing hardware offerings and develop new products, signaling a more strategic focus on innovation in this area compared to 2022, where the description was more general and focused on the breadth of offerings.",
      "llm_answer": "Oracle still accounts for its industry‑specific hardware (and the associated firmware or operating system) as a single performance‑obligation and records the hardware revenue at the point in time the product and software are delivered and ownership transfers, while hardware‑support fees are recognized ratably over the contract term – the same treatment disclosed for fiscal 2022 (see 2022 p. 105 and 2023 p. 43). However, the strategic weight of the hardware line has slipped: it represented roughly 7‑8 % of total revenue in FY 2022 (≈ $3.2 b of $42.4 b) but fell to about 6 % of total revenue in FY 2023 (see 2023 p. 43), indicating a modest de‑emphasis even as Oracle continues to invest in R&D to improve and expand its industry‑specific hardware portfolio.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly states that Oracle recognizes hardware revenue at the point in time when products and related software are delivered, and that this treatment was consistent between fiscal 2022 and 2023. It also correctly notes ongoing R&D investment in hardware. However, the key divergence from the ground truth is the claim that the strategic weight of hardware has 'slipped' or been de-emphasized, which contradicts the original answer stating that Oracle placed *greater* strategic emphasis on innovation in 2023. This misrepresents the strategic evolution. (2) Quantitatively, the LLM introduces specific revenue figures not present in the ground truth: $3.2B of $42.4B in FY2022 (~7.5%) and ~6% in FY2023. While these numbers may be factually accurate based on external knowledge or the cited pages, they are not part of the provided ground truth, and the evaluation must be based solely on alignment with that truth. Since the ground truth does not mention percentages or dollar amounts, introducing them creates a mismatch in focus and risks misdirection, especially when used to support an incorrect conclusion about de-emphasis. (3) The multi-hop reasoning is partially sound—linking revenue recognition across years is accurate—but the synthesis of strategy is flawed. The model infers de-emphasis from declining revenue share, but the ground truth emphasizes increased strategic focus on R&D and innovation in 2023, indicating a more nuanced strategic direction not captured by revenue share alone. Thus, the reasoning fails to align with the documented strategic shift. (4) The contextual relevance is high because the answer addresses both revenue recognition and strategic emphasis. Qualitative accuracy is moderate due to correct entity identification (Oracle, hardware, R&D, revenue recognition) and partial reasoning, but undermined by the incorrect strategic conclusion. Quantitative accuracy is low because the introduced numbers, while plausible, are not in the ground truth and used to support an incorrect inference. Correctness score is 6 due to correct factual elements but significant error in interpreting strategic emphasis, which is central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 605,
        "total_tokens": 1999
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the sales performance of IMBRUVICA (ibrutinib) evolve between 2022 and 2023, and what factors contributed to this change?",
      "original_answer": "IMBRUVICA sales decreased from $3.784 billion in 2022 to $3.264 billion in 2023, a decline of 13.7%. In 2022, the growth of IMBRUVICA was already being offset by competitive pressures from novel oral agents and market dynamics related to the pandemic, such as delays in new patient starts. By 2023, this downward trend continued, with the product experiencing a significant drop in sales, reflecting sustained competitive pressures and likely increased market saturation or treatment shifts in the oncology space.",
      "llm_answer": "IMBRUVICA’s sales fell from $3.784 billion in 2022 to $3.264 billion in 2023 – a drop of roughly 13.7% (about $520 million)【page_31】. The decline was attributed to heightened global competitive pressures, including competition from newer oral agents, which offset its prior growth【page_32】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key facts: IMBRUVICA sales decreased from $3.784 billion in 2022 to $3.264 billion in 2023, representing a 13.7% decline (approximately $520 million), which matches the ground truth exactly. The percentage and dollar drop are accurately calculated and presented. (2) Quantitative accuracy is perfect—numbers, years, and the percentage change are all correct and consistent with the original answer. The $520 million difference is a valid approximation of the $520 million exact drop ($3.784B - $3.264B = $0.52B). (3) The reasoning is sound and captures the primary factor—competitive pressures from newer oral agents—which aligns with the original answer. However, the LLM answer omits secondary contextual factors mentioned in the ground truth, such as pandemic-related delays in new patient starts in 2022 and possible market saturation or treatment shifts in 2023. While the core contributing factor (competition) is correctly identified, the multi-hop synthesis is slightly less complete. (4) The answer is highly relevant and factually correct, with only minor omissions in contextual depth. Thus, correctness is scored 9 (not 10) due to partial completeness in explaining contributing factors, despite full quantitative and entity accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1196,
        "completion_tokens": 363,
        "total_tokens": 1560
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Comcast's involvement with Universal Beijing Resort evolved from 2023 to 2024 in terms of debt levels, ownership structure, and financial risk exposure?",
      "original_answer": "In 2023, Universal Beijing Resort had $3.5 billion of debt outstanding, including a $3.1 billion term loan, and was consolidated by Comcast, which owns a 30% interest. By 2024, the debt level slightly decreased to $3.4 billion, with the term loan principal reducing to $3.0 billion. Comcast continues to consolidate Universal Beijing Resort as a VIE, maintaining its 30% ownership stake. The maximum financial risk exposure for Comcast remains limited to its 30% equity interest, indicating a stable risk profile despite the slight reduction in debt. This evolution reflects a minor decrease in leverage but no change in ownership or governance structure.",
      "llm_answer": "Comcast continues to own a 30 % equity stake in Universal Beijing Resort, and the resort’s debt has slipped slightly – from $3.5 billion of outstanding debt (including a $3.1 billion term loan) at year‑end 2023 to about $3.4 billion (including a $3.0 billion term loan) at year‑end 2024 【page_56】【page_86】. The debt is not cross‑guaranteed by Comcast and there are no liquidity, guarantee or other financial commitments linking the two, so Comcast’s financial risk remains confined to its 30 % equity interest in the venture 【page_86】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key facts: Comcast's 30% ownership stake, the reduction in Universal Beijing Resort's debt from $3.5 billion to $3.4 billion, and the term loan decrease from $3.1 billion to $3.0 billion. It accurately states that Comcast’s financial risk is limited to its equity interest, with no cross-guarantees or liquidity commitments. (2) Quantitative accuracy is perfect: all dollar amounts and percentages match the ground truth exactly, including the slight reduction in debt and loan principal. No calculation errors. (3) The multi-hop reasoning is sound—information about debt levels, ownership, and risk exposure is correctly synthesized across time (2023 to 2024) and entities (Comcast and Universal Beijing Resort). The LLM correctly infers stable risk exposure due to lack of guarantees, aligning with the consolidation as a VIE mentioned in the original answer. (4) The only minor omission is that the original answer explicitly mentions Comcast continues to consolidate the resort as a VIE (variable interest entity), which the LLM omits, though the implication of consolidation is partially covered via the risk exposure explanation. This does not affect the core facts but slightly reduces qualitative completeness. Overall, the answer is factually equivalent, highly relevant, and precisely accurate in numbers and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 384,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the financial commitment related to future lease payments for build-to-suit facilities and equipment evolve from 2022 to 2023, and what does this indicate about FedEx's leasing strategy?",
      "original_answer": "In 2022, FedEx disclosed future undiscounted payments of approximately $3.4 billion for build-to-suit facilities that had not yet commenced, with expected commencement dates from 2023 to 2024. By 2023, the company reported a significant reduction in these future commitments, with undiscounted payments dropping to approximately $0.9 billion for build-to-suit facilities and equipment, with commencement dates expected from 2025 to 2027. This indicates a strategic shift toward fewer long-term build-to-suit lease commitments and a more extended timeline for asset utilization.",
      "llm_answer": "FedEx reported that the undiscounted future payments for build‑to‑suit facilities and equipment dropped from about **$3.4 billion** in the 2022 filing (as of May 31 2022) to roughly **$0.9 billion** in the 2023 filing (as of May 31 2024)【page_96】【page_98】. The sharp reduction indicates FedEx is scaling back large, long‑term build‑to‑suit lease commitments and moving toward a more restrained or flexible leasing strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key financial figures: $3.4 billion in 2022 and $0.9 billion in 2023, matching the ground truth exactly. The dates referenced (May 31, 2022 and May 31, 2024) align with FedEx's fiscal year-ends, which is consistent with 10-K reporting practices, though the ground truth emphasizes expected commencement dates (2023–2024 vs. 2025–2027), which the LLM omits. (2) Quantitative accuracy is perfect: both dollar amounts are correct, and the description of a 'sharp reduction' accurately reflects the ~73.5% decrease. No calculations are required beyond comparison, which is sound. (3) The multi-hop reasoning is mostly sound—comparing disclosures across two years to infer strategic intent. The conclusion about scaling back long-term commitments aligns with the ground truth’s 'strategic shift' interpretation. However, the LLM slightly underdevelops the nuance of an extended timeline (2025–2027 vs. 2023–2024), which is a minor omission in qualitative depth. (4) Contextual relevance is excellent—the answer directly addresses both parts of the question: evolution of financial commitment and implications for leasing strategy. The term 'restrained or flexible leasing strategy' is semantically equivalent to the ground truth’s 'fewer long-term commitments' and 'extended timeline,' though slightly less specific on timing. Overall, highly accurate with only minor detail omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 398,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Mastercard's relationship with Dynamic Yield LTD evolved between 2023 and 2024, and what does this indicate about the company's strategic focus during this period?",
      "original_answer": "In 2023, Mastercard disclosed that it had acquired Dynamic Yield LTD in April 2022 for $325 million, with $200 million of goodwill attributed to synergies expected after the acquisition. By 2024, the relationship is described as stable, with no new investments or acquisitions involving Dynamic Yield reported during the year. This indicates that the integration of Dynamic Yield was largely completed by 2023, and Mastercard shifted focus to newer acquisitions like Recorded Future in 2024, signaling a strategic pivot toward cybersecurity and threat intelligence.",
      "llm_answer": "Mastercard’s tie‑up with Dynamic Yield has not changed – it remains a 2022 acquisition (a 100 % equity purchase for $325 million) and there were no new transactions involving Dynamic Yield in either 2023 (the 2023 filing notes that the company “did not complete any material business acquisitions”) or 2024 (the 2024 filing merely references the 2022 purchase while reporting other 2024 acquisitions such as Recorded Future)【page_82】【page_79】. The static relationship, together with the 2024 emphasis on new data‑driven buys, indicates Mastercard is preserving its earlier investment in Dynamic Yield while strategically expanding its digital‑identity, fraud‑prevention and threat‑intelligence capabilities through additional acquisitions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Mastercard acquired Dynamic Yield in 2022 for $325 million, with no new transactions in 2023 or 2024. The 2023 filing confirms no material acquisitions, and the 2024 filing references only the prior acquisition while highlighting new ones like Recorded Future. (2) Quantitative accuracy is perfect: $325 million acquisition amount is correctly stated; dates (2022 acquisition, no activity in 2023–2024) match. (3) Multi-hop reasoning is sound—LLM correctly infers that the lack of new activity indicates integration completion and that the focus shifted to cybersecurity via Recorded Future, which aligns with the strategic pivot mentioned in the ground truth. (4) The only minor shortcoming is that the LLM does not explicitly mention the $200 million of goodwill attributed to synergies (a detail in the original answer), which slightly weakens completeness. However, this omission does not distort the overall meaning. The LLM effectively captures the strategic implication of preserving prior investments while expanding into threat intelligence. Wording differs but semantic equivalence is strong. Contextual relevance is excellent—directly addresses evolution and strategic focus.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 359,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the Severance Plan for Senior Officers at Lowe's evolved between 2022 and 2024, particularly in terms of the most recent amendment dates and associated filings?",
      "original_answer": "In 2022, the Severance Plan for Senior Officers was described as 'amended and restated May 29, 2020' and was filed on August 26, 2020 (Exhibit 10.29). By 2024, the plan had been further amended and restated on May 26, 2022, with the updated version filed on November 27, 2024 (Exhibit 10.28). This indicates that Lowe's updated its Severance Plan for Senior Officers at least once between 2022 and 2024, with the most recent amendment occurring in mid-2022 and formally disclosed in late 2024.",
      "llm_answer": "The Severance Plan for Senior Officers was last amended and restated on May 26 2022, and the most recent filing of that amendment is a Form 10‑Q filed on November 27 2024 (shown as Exhibit 10.1) in both the 2022 and 2024 10‑K exhibit tables, indicating no further amendment after the 2022 restatement【page_79】.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the most recent amendment date of the Severance Plan for Senior Officers as May 26, 2022, and the November 27, 2024 filing date, which aligns with the ground truth. However, it incorrectly states that the exhibit number is 10.1 in both the 2022 and 2024 10-Ks, while the ground truth specifies Exhibit 10.28 for the 2024 filing and Exhibit 10.29 for the 2020 filing. This is a factual error in exhibit numbering. (2) Quantitatively, the key dates (May 26, 2022 amendment; November 27, 2024 filing) are accurate, and no calculations are required. The mention of the Form 10-Q is plausible but not confirmed in the ground truth, which only references the exhibit and filing date without specifying the form type. (3) The reasoning is mostly sound: the model correctly infers that no further amendments occurred after 2022 based on the reuse of the same restated version, which is a valid inference from the data. However, the incorrect exhibit number and the unsupported claim about Form 10-Q and exhibit reuse in both 2022 and 2024 reduce qualitative accuracy. (4) The answer is contextually relevant and addresses the evolution of the plan, amendment dates, and filings. The core facts are correct, but the exhibit number error and unverified form type prevent a higher score. Thus, correctness is 7 due to partial inaccuracy in key identifying details despite correct dates and logical inference.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1206,
        "completion_tokens": 399,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the fair value of Netflix's 6.375% Senior Notes change between December 31, 2021, and December 31, 2023, and what does this evolution indicate about market perceptions of the company's debt over this period?",
      "original_answer": "The fair value of Netflix's 6.375% Senior Notes increased from $999 million as of December 31, 2021, to $872 million as of December 31, 2023. This indicates a decrease in the fair value of the notes over the two-year period, suggesting a potential decline in market confidence or an increase in required yields for this debt instrument.",
      "llm_answer": "The fair‑value of the 6.375 % senior notes fell from **$999 million at 12/31/2021** to **$872 million at 12/31/2023** – a decline of about $127 million (≈13 %)【page_56 (2022)】【page_56 (2023)】.  \nThis drop indicates that investors were willing to pay less for Netflix’s debt, reflecting a weaker market view of the company’s credit risk or higher yields demanded on its notes over the two‑year period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the fair value of Netflix's 6.375% Senior Notes as $999 million on December 31, 2021, and $872 million on December 31, 2023, matching the ground truth exactly. The calculated decline of $127 million and approximate 13% decrease are accurate and correctly derived. (2) All numeric values, dates, and calculations are factually correct. The percentage drop is approximately (127/999) ≈ 12.7%, which rounds to 13%, so the LLM's ≈13% is acceptable. (3) The reasoning is sound: the decrease in fair value indicates that the market is demanding higher yields or perceives greater credit risk, which aligns with the ground truth interpretation. The LLM correctly synthesizes the implication of falling fair value — reduced market confidence or increased risk premium. (4) The only minor shortcoming is that the LLM uses slightly more concise phrasing than the ground truth (e.g., 'weaker market view of the company’s credit risk' vs. 'potential decline in market confidence'), but the semantic meaning and qualitative insight are equivalent. No critical information is missing. Thus, the answer is factually complete, quantitatively precise, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1201,
        "completion_tokens": 342,
        "total_tokens": 1543
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the sales performance of IMBRUVICA evolve between 2022 and 2023, and what does this indicate about its market position in the oncology segment?",
      "original_answer": "IMBRUVICA's sales decreased from $4,369 million in 2022 to $3,264 million in 2023, representing a decline of 25.2%. This indicates a weakening market position for IMBRUVICA within the oncology segment, especially as other products like DARZALEX and ERLEADA experienced significant growth during the same period.",
      "llm_answer": "IMBRUVICA’s sales fell from $3.784 billion in 2022 to $3.264 billion in 2023 – a decline of about 13.7% (operational drop of 13.2%)【page_31】. This contraction came even as total oncology sales grew 10.5% to $17.7 billion, indicating that while IMBRUVICA remains a major oncology product, its market share is being pressured by competition and other dynamics in the segment【page_32】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative data. The ground truth states IMBRUVICA's 2022 sales were $4,369 million, but the LLM reports $3.784 billion, which is incorrect. The 2023 sales figure of $3,264 million is correctly reported. The calculated decline is therefore wrong: the LLM reports a 13.7% drop, but the actual decline is (4,369 - 3,264) / 4,369 ≈ 25.2%, as correctly stated in the original answer. This major error in the core financial data undermines the answer's reliability. (2) The calculation verification shows the LLM’s percentage decline is based on incorrect input values. Even if the operational drop (13.2%) is mentioned, it does not align with the overall factual trend. (3) The qualitative reasoning is partially sound: the LLM correctly infers that IMBRUVICA is facing market pressure despite overall oncology growth, which aligns with the ground truth’s implication of weakening market position. It also correctly contextualizes the product within a growing oncology segment, showing multi-hop reasoning by comparing product performance to broader segment trends. (4) Contextual relevance is high—the answer addresses both parts of the question: sales evolution and market position implications. However, due to the critical error in the 2022 sales figure and the resulting incorrect decline percentage, the correctness and quantitative accuracy scores are low. The answer is semantically similar in intent but factually flawed in execution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1174,
        "completion_tokens": 418,
        "total_tokens": 1593
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did LOW's inventory shrink reserve and LCNRV reserve evolve between 2022 and 2024, and what were the implications for net earnings?",
      "original_answer": "Between 2022 and 2024, LOW's inventory shrink reserve increased from $414 million to $427 million, while the LCNRV reserve increased from $168 million to $222 million. In 2024, a 10% change in either the amount of inventory subject to markdown or the weighted average estimated loss rate used in the LCNRV reserve calculation would have affected net earnings by approximately $17 million, and a 10% change in the estimated shrinkage rate would have impacted net earnings by approximately $32 million. These changes indicate a growing need for reserves, particularly for shrinkage, and highlight the increasing sensitivity of net earnings to inventory valuation assumptions.",
      "llm_answer": "- In fiscal 2022 the company reported an inventory‑shrink reserve of **$414 million** and an LCNRV (lower‑of‑cost‑or‑net‑realizable‑value) reserve of **$168 million** 【page_33】.  \n- By fiscal 2024 those balances had moved to **$427 million** for the shrink reserve and **$222 million** for the LCNRV reserve 【page_34】.  \n\nThe larger reserves increase expense and therefore depress net earnings; Lowe’s notes that a 10 % change in the LCNRV reserve would shift net earnings by roughly **$17 million**, while a 10 % change in the shrink reserve would shift net earnings by about **$32 million** in fiscal 2024 【page_34】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the inventory shrink reserve increased from $414 million in 2022 to $427 million in 2024, and the LCNRV reserve increased from $168 million to $222 million—both figures match the original answer exactly. The sensitivity impacts on net earnings—a $17 million change for a 10% LCNRV reserve change and a $32 million change for a 10% shrink reserve change in 2024—are also correctly reported. (2) The answer is complete, addressing both the evolution of the two reserves over time and their implications for net earnings, satisfying both parts of the multi-part question. (3) Entity accuracy is correct: LOW (Lowe’s) is properly identified, fiscal years 2022 and 2024 are correctly referenced, and the financial terms (shrink reserve, LCNRV reserve, net earnings impact) are used appropriately. (4) The reasoning is sound: the LLM correctly infers that higher reserves increase expenses and thus reduce net earnings, and it accurately cites the sensitivity analysis from the filing to quantify the earnings impact. The multi-hop synthesis—linking reserve levels over time to their financial statement implications—is logically and factually correct. (5) The semantic meaning is equivalent to the ground truth, with only minor rephrasing (e.g., 'depress net earnings' vs. 'affected net earnings') that does not alter the factual content. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 411,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did Qulipta's status and financial contribution evolve from 2022 to 2023, particularly in terms of its development and commercialization progress?",
      "original_answer": "In 2022, Qulipta was among the products that contributed to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights upon receiving regulatory approvals. By 2023, Qulipta had transitioned from development to commercialization, generating $405 million in revenue in the United States and $3 million internationally, indicating a significant shift from a developmental asset to a revenue-generating product.",
      "llm_answer": "In the 2022 Form 10‑K Qulipta was still a pipeline asset – it appeared only in the intangible‑asset footnote as a product that had not yet been commercialized and generated no revenue 【page_100】. By 2023 AbbVie announced FDA approval in April and EC approval in August, launched the drug, and Qulipta’s net sales more than doubled, rising over 100 % year‑over‑year (U.S. sales $405 million in 2023 versus $158 million in 2022) and becoming a notable new revenue contributor 【page_40】【page_44】【page_42】.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the revenue figures. The ground truth states that Qulipta generated $405 million in U.S. revenue in 2023 and $3 million internationally, with no revenue in 2022. However, the LLM claims $158 million in U.S. sales in 2022, which contradicts the original answer stating it generated no revenue during development in 2022. This error undermines the quantitative accuracy. Additionally, the claim that sales 'more than doubled' and 'rose over 100% year-over-year' is incorrect if 2022 revenue was $0 or negligible. (2) The approval dates (FDA in April, EC in August) are plausible but not mentioned in the ground truth, so their inclusion introduces unverified details. The $405 million U.S. revenue in 2023 is correct and matches the ground truth. The international revenue of $3 million is omitted in the LLM answer. (3) The qualitative reasoning correctly identifies the transition from a developmental asset (reclassified intangible) to a commercial product, which aligns with the multi-hop logic of tracking status change from 2022 to 2023. The reference to the intangible asset footnote in 2022 is consistent with the knowledge graph. However, the synthesis fails on financial progression due to the incorrect 2022 revenue figure. (4) Contextually, the answer is relevant and addresses the evolution of Qulipta’s status and financial contribution. The structure follows the question’s timeline and intent. Despite incorrect numbers, the narrative of transition from pipeline to revenue-generating product is accurate. Scores reflect major quantitative error but correct overall trajectory and context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 461,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities evolved between 2022 and 2023, and what does this indicate about the company's risk exposure?",
      "original_answer": "Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities remained consistent between 2022 and 2023, with Resideo's subsidiary still obligated to pay 90% of Honeywell's annual net spending on environmental matters at specified sites, up to a maximum of $140 million per year. This ongoing arrangement indicates that Honeywell continues to rely on Resideo's payments to offset a significant portion of its environmental costs, suggesting that the risk mitigation strategy through this indemnification agreement has not changed over the two years.",
      "llm_answer": "Honeywell’s indemnification agreement with a Resideo subsidiary continued to deliver the full $140 million annual reimbursement in both 2022 and 2023, but the related receivable grew from $157 million in 2022 to $187 million in 2023, indicating a larger share of its environmental costs is now expected to be covered by Resideo【page_98】. This rising reliance on Resideo’s payments reduces Honeywell’s direct cash‑flow exposure to environmental liabilities, although the $140 million cap and the agreement’s eventual termination mean the company still retains some residual risk【page_97】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Resideo's subsidiary is obligated to pay 90% of Honeywell's annual net spending on environmental matters up to $140 million per year, but the LLM incorrectly claims that the full $140 million was reimbursed in both years and that the arrangement delivers a fixed $140 million annually. This misrepresents the nature of the obligation, which is percentage-based (90%) up to a cap, not a guaranteed fixed payment. Additionally, the LLM introduces a receivable of $157 million in 2022 growing to $187 million in 2023, which is not mentioned or implied in the original answer and cannot be verified from the provided truth. These figures and the conclusion about 'rising reliance' are unsupported. (2) Quantitative accuracy is low: while $140 million is correctly cited as the cap, the assertion of full reimbursement each year and the specific receivable balances ($157M, $187M) are not in the ground truth and contradict the more nuanced 90% reimbursement mechanism. There is no verification that these numbers are accurate, and their inclusion suggests a misinterpretation of the financial arrangement. (3) The reasoning is partially sound in that it attempts to assess risk exposure and cash-flow implications, but the multi-hop synthesis is flawed. The model infers increasing dependency due to rising receivables, but this data point is extraneous and not part of the original knowledge, leading to an incorrect conclusion about evolving dependency. The original answer emphasizes consistency in the arrangement, whereas the LLM suggests a change, which is not supported. (4) Contextual relevance is high because the response addresses financial dependency, risk exposure, and the indemnification agreement directly related to the question. However, the incorrect data undermines the validity of the conclusion. The mention of the agreement's cap and eventual termination adds context not in the original but is reasonable as supplementary insight, though it doesn't compensate for core inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 564,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Target's definition or treatment of 'original maturity' for cash equivalents evolved between 2022 and 2024, and what does this indicate about potential changes in their cash management strategy?",
      "original_answer": "In 2022, Target defined cash equivalents as highly liquid investments with an original maturity of three months or less, with no additional context or clarification. By 2024, the company maintained the same three-month threshold for original maturity but added a broader discussion around fair value measurements for other short-term assets and liabilities, suggesting a more comprehensive approach to short-term financial instruments. This evolution indicates a potential refinement in how Target evaluates and manages its cash and near-cash assets within a broader financial framework.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K state that cash equivalents are “highly liquid investments with an original maturity of three months or less from the time of purchase” (and include card‑transaction receivables that settle in five days). The wording and threshold are unchanged, indicating that Target has kept a consistent cash‑management approach—continuing to rely on short‑term, highly liquid assets to preserve liquidity and limit risk.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in stating that Target maintained the same definition of cash equivalents—'highly liquid investments with an original maturity of three months or less'—in both 2022 and 2024, which aligns with the ground truth. The inclusion of card-transaction receivables settling in five days is a detail present in the filings and does not contradict the original answer. Quantitatively and entity-wise, everything is correct: the years (2022, 2024), the company (Target), and the definition are accurately cited. However, the LLM answer fails to capture a key qualitative evolution noted in the ground truth: in 2024, Target expanded its disclosure to include a broader discussion of fair value measurements for short-term assets and liabilities, indicating a more comprehensive financial reporting framework. This omission is significant because the question specifically asks how the *treatment* or *definition* evolved, not just whether the definition changed. The LLM concludes that the cash management strategy remained consistent, which is reasonable, but misses the nuance that while the *definition* stayed the same, the *contextual treatment* and disclosure practices became more sophisticated—suggesting a refinement in financial reporting and possibly cash asset evaluation. This reflects a partial failure in multi-hop reasoning: the model correctly identifies consistency in definition but does not synthesize the expanded narrative context in 2024 filings. Thus, while factually sound, the answer lacks completeness in addressing the evolution of 'treatment' beyond the definition, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 451,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the valuation and classification of NVDA's 3.50% Notes Due 2040 evolve between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, the 3.50% Notes Due 2040 were listed under liabilities with a carrying value of $851 million as of January 28, 2024, and were categorized as Level 2 in the pricing hierarchy. By 2024, the valuation of the same notes increased to $1,000 million as of January 26, 2025, with a more detailed breakdown including an effective interest rate of 3.54% and a remaining term of 15.2 years. This indicates a strategic emphasis on long-term financing with stable interest rate structures.",
      "llm_answer": "In the 2023 Form 10‑K the 3.50 % notes due 2040 were listed under “Liabilities” as a Level 2 fair‑value item with a net carrying amount of **$870 million** [page_67]. By the 2024 filing the same notes are shown in the debt schedule as a **$1 billion** long‑term obligation (effective interest 3.54 %, 15.2 years remaining) that is included in the long‑term portion of total debt ($8.459 billion) [page_72]. The higher carrying amount and the move from a Level‑2 liability disclosure to a distinct long‑term debt line indicate that NVIDIA is expanding and emphasizing low‑cost, fixed‑rate financing to lock in cheap capital for an extended horizon as part of its long‑term debt strategy.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution in valuation and classification of NVDA's 3.50% Notes Due 2040 between 2023 and 2024 and draws a reasonable conclusion about the company's long-term debt strategy. However, there is a discrepancy in the 2023 carrying value: the LLM reports $870 million, while the ground truth states $851 million. This $19 million difference is significant enough to affect quantitative accuracy. The 2024 valuation is reported as $1 billion (or $1,000 million), which matches the ground truth and is acceptable in format. (2) The effective interest rate (3.54%) and remaining term (15.2 years) are correctly reported. Dates are appropriately referenced using fiscal year-ends (January 28, 2024, and January 26, 2025), consistent with SEC filing conventions. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two fiscal years, identifies the change in disclosure (from Level 2 fair value to a detailed long-term debt line item), and infers a strategic shift toward fixed-rate, long-term financing. This reflects accurate qualitative understanding. (4) Contextual relevance is perfect—the answer directly addresses both parts of the question: the evolution in valuation/classification and its implication for debt strategy. The conclusion about locking in cheap capital aligns with the ground truth's 'strategic emphasis on long-term financing with stable interest rate structures.' The main deduction is for the incorrect 2023 carrying amount, which impacts the correctness and quantitative accuracy scores despite otherwise strong performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 447,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the financial performance of Venclexta evolve between 2022 and 2023, particularly in terms of total global revenue and the growth rate?",
      "original_answer": "In 2022, Venclexta generated a total global revenue of $2,009 million, with a growth rate of 10.4%. In 2023, the total global revenue from Venclexta increased to $2,288 million, representing a growth rate of 13.9%. This indicates an upward trend in both absolute revenue and growth rate year-over-year.",
      "llm_answer": "Venclexta’s worldwide net revenue grew from $2.009 billion in 2022 to $2.288 billion in 2023 – an increase of about $279 million.  This represents a growth rate of roughly 14 % (the filing notes a 13.9 % increase at actual rates and cites a 15 % rise in the narrative).【page_42】【page_43】",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: $2.009 billion (i.e., $2,009 million) in 2022 and $2.288 billion ($2,288 million) in 2023 are exact matches. The growth rate of 13.9% is correctly reported, and the mention of a 15% rise in the narrative is an acceptable contextual addition from the filing (likely adjusted for constant currency), which does not contradict the 13.9% actual rate. The $279 million increase is accurate ($2,288M - $2,009M = $279M). (2) The answer addresses both parts of the question: total global revenue in both years and the growth rate. (3) Entities (Venclexta, years 2022 and 2023, global revenue) are correctly identified. (4) The reasoning is sound—revenue increase and growth rate are correctly inferred. The only minor shortcoming is that the 2022 growth rate (10.4%) from the ground truth is not mentioned, making the year-over-year comparison slightly less complete, though the focus of the question leans toward 2023 performance. Overall, the answer is factually correct, well-supported, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1146,
        "completion_tokens": 325,
        "total_tokens": 1471
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has Netflix's approach to executive severance and retention incentives evolved between the 2022 and 2023 SEC filings, particularly in terms of plan amendments and their effective dates?",
      "original_answer": "In 2022, the filing referenced the 'Amended and Restated Executive Severance and Retention Incentive Plan' with a filing date of September 10, 2021, indicating that the plan had undergone revisions by that date. By 2023, the filing showed further evolution, introducing the 'Executive Severance and Retention Incentive Plan as Amended and Restated effective January 1, 2024,' with a filing date of December 8, 2023. This demonstrates Netflix’s ongoing adjustments to executive compensation frameworks, with a forward-looking amendment effective in 2024.",
      "llm_answer": "In the 2022 Form 10‑K Netflix reported that its Executive Severance and Retention Incentive Plan had been “Amended and Restated” on September 10 2021 (see Exhibit 10.7 on page 66 of the 2022 filing). The 2023 Form 10‑K shows the company filed a new amendment on December 8 2023, creating an “Executive Severance and Retention Incentive Plan as Amended and Restated” that will become effective January 1 2024 (Exhibit 10.16 on page 68 of the 2023 filing), together with a separate Executive Officer Severance Plan (Exhibit 10.15, also page 68). This reflects a shift from the 2021 amendment to a fresh, forward‑looking amendment that takes effect at the start of 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all key aspects. (1) Quantitative accuracy: All dates are correct — the 2022 filing references the amendment dated September 10, 2021, and the 2023 filing reports a new amendment filed on December 8, 2023, effective January 1, 2024. These match the original answer exactly. (2) Completeness: The LLM addresses both the 2022 and 2023 filings, identifies the plan amendments, their filing dates, and effective dates, and notes the forward-looking nature of the 2024 amendment. It even adds a relevant detail — the existence of a separate Executive Officer Severance Plan (Exhibit 10.15) — which enhances completeness without introducing error. (3) Entity accuracy: 'Netflix', 'Executive Severance and Retention Incentive Plan', and associated exhibit numbers (10.7, 10.16) are correctly identified and contextualized within the respective 10-K filings. (4) Reasoning: The multi-hop synthesis across two years of filings is sound. The LLM correctly infers an evolution in Netflix’s approach by comparing the 2021 amendment (referenced in 2022) with the new amendment filed in 2023 and effective in 2024. (5) Semantic equivalence: The LLM conveys the same core information as the original answer — ongoing adjustments to executive compensation with a forward-looking effective date — while providing additional context (exhibit details, page numbers, separate plan) that enriches the response without deviation from truth. Minor wording differences do not affect factual alignment. All scores are maximized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 428,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Lowe's documentation and structure of its Benefit Restoration Plan evolve from 2022 to 2024, and what does this indicate about the company's approach to employee retirement benefits?",
      "original_answer": "In 2022, Lowe's maintained the Benefit Restoration Plan as part of its defined contribution retirement offerings, supplementing benefits under the 401(k) Plan for employees affected by IRS limitations. The plan included both employee salary deferrals and employer contributions in the form of a Company Match. By 2024, the company formally introduced an updated and restated version of the Benefit Restoration Plan, effective January 1, 2025, as evidenced by the new exhibit filing (10.3) in the 2024 10-K. This indicates a deliberate effort to formalize and likely enhance the structure of the plan, signaling a more strategic and forward-looking approach to managing executive and high-earner compensation through improved documentation and alignment with long-term benefit policies.",
      "llm_answer": "In the 2022 10‑K the Benefit Restoration Plan is mentioned only in the employee‑retirement‑plan note, where it is described in a few sentences as a supplemental 401(k)‑style plan that allows salary deferrals and a company‑match for participants whose benefits are limited by the tax code. By the 2024 filing the plan is listed as a separate exhibit (Exhibit 10.3) titled “Benefit Restoration Plan, as amended and restated as of January 1, 2025,” indicating that the company has formally amended and restated the plan’s terms. This shift from a brief narrative description to a formally documented, updated plan shows Lowe’s is actively refining and strengthening its retirement‑benefit safety net for employees.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2022 description of the Benefit Restoration Plan as a supplemental defined contribution plan offering salary deferrals and company match for employees affected by IRS limits is consistent with the original answer. The 2024 update, including the formal restatement effective January 1, 2025, and the inclusion of Exhibit 10.3 in the 10-K filing, is accurately reported. (2) Quantitative accuracy is perfect: the date 'January 1, 2025' is correctly cited, and there are no numerical inaccuracies. Format and specificity match the ground truth. (3) The multi-hop reasoning is sound—comparing the 2022 narrative mention to the 2024 formal exhibit demonstrates synthesis across years and document types. The conclusion that Lowe’s is refining and strengthening its retirement benefits is logically supported. (4) The only minor shortcoming is that the LLM answer does not explicitly mention 'executive and high-earner compensation' or 'long-term benefit policies,' which are part of the strategic implication in the original answer. However, the inference about a 'retirement-benefit safety net' and 'actively refining' benefits captures the essence. Thus, the answer is semantically equivalent with only slight omission of nuance in strategic intent. Scores reflect high accuracy with near-complete qualitative and contextual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 399,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did NVDA's financial obligations related to the 0.584% Notes Due 2024 evolve between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a liability of $1,185 million for the 0.584% Notes Due 2024. By fiscal year 2024, this obligation was fully repaid, as stated in the 2024 10-K filing. This indicates a complete resolution of this specific debt obligation over the two-year period.",
      "llm_answer": "NVDA’s liability for the 0.584 % notes due 2024 rose modestly from $1.185 billion at fiscal‑year‑end 2023 to $1.228 billion at fiscal‑year‑end 2024 – an increase of about $43 million【page_67】.  In FY 2024 the notes were shown as a $1.250 billion short‑term liability on the balance sheet, and the company repaid the entire issue in FY 2025【page_72】.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and quantitative errors that undermine its correctness. (1) Quantitatively, the original answer states that NVDA had a $1,185 million liability in FY2023 and fully repaid it by FY2024. The LLM incorrectly claims the liability increased to $1.228 billion in FY2024 and was repaid in FY2025, which contradicts the ground truth. The reported increase of $43 million and the $1.250 billion short-term liability are not supported by the truth data. (2) The entity accuracy is partially correct—NVDA and the 0.584% Notes Due 2024 are correctly identified—but the fiscal years and repayment timing are wrong. (3) The reasoning is flawed: the multi-hop synthesis fails because the model incorrectly infers an increase in liability and misplaces the repayment to FY2025, whereas the truth states the obligation was fully resolved by FY2024. (4) Contextual relevance is moderate—the answer addresses the right financial instrument and timeframe—but the core conclusion (increase in liability and delayed repayment) is factually incorrect. Minor formatting variations like $1.185 billion vs $1,185 million are acceptable, but the erroneous figures and timeline severely impact accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1150,
        "completion_tokens": 340,
        "total_tokens": 1490
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the global revenue performance of Mavyret evolve between 2022 and 2023, and what were the trends in its United States and international markets during this period?",
      "original_answer": "In 2022, Mavyret generated total global revenue of $1,541 million, with $755 million from the United States and $786 million from international markets. By 2023, total revenue from Mavyret decreased to $1,430 million, driven by a decline in both U.S. and international markets. Specifically, U.S. revenue dropped to $659 million, a decrease of 12.7%, while international revenue slightly declined to $771 million, a marginal decrease of 1.9%. This indicates a contraction in Mavyret's market performance across both regions, with a more pronounced decline in the U.S. market.",
      "llm_answer": "Mavyret’s global net revenue fell from $1.541 billion in 2022 to $1.430 billion in 2023 – a drop of roughly 7 % (about 5‑6 % on a constant‑currency basis)【page_43†L45-L48】.  In the United States the product’s sales fell sharply, from $755 million to $659 million (≈13 % decline)【page_43†L45-L46】, whereas internationally the revenue was essentially flat – slipping about 2 % in actual‑currency terms (from $786 million to $771 million) but showing a modest 1 % increase on a constant‑currency basis【page_43†L46-L47】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All numeric values are correct: 2022 global revenue of $1.541 billion (=$1,541 million), 2023 revenue of $1.430 billion (=$1,430 million), U.S. revenue dropping from $755M to $659M, and international from $786M to $771M. Percentages are correctly calculated: ~12.7% U.S. decline (actual: (755-659)/755 ≈ 12.7%), rounded to ≈13%; international decline of (786-771)/786 ≈ 1.9%, reported as ~2%, which is acceptable. The LLM adds context not in the original answer—constant-currency adjustments (5–6% global decline, 1% international increase on constant-currency basis)—which is consistent with typical 10-K disclosures and supported by the citation (page 43), so it enhances rather than distorts. (2) Calculations are accurate and percentages reasonably rounded. (3) Multi-hop reasoning is sound: the model correctly synthesizes U.S. and international figures to derive global totals and trends across years. (4) The only minor deviation is the emphasis on constant-currency performance, which is not in the original answer, but since it doesn't contradict and adds plausible nuance, it doesn't reduce correctness. The core facts, trends, and magnitudes are fully aligned. Thus, the answer earns a 9/10 for correctness—excellent but not perfectly matched in focus (original emphasizes decline in both regions, LLM highlights international flatness). Quantitative accuracy is perfect (10/10), qualitative reasoning is strong (9/10), and relevance is complete (10/10).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 422,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Netflix's compliance with covenant limitations related to its Senior Notes evolve between 2022 and 2024, particularly in terms of repayment obligations and the scope of restrictions?",
      "original_answer": "In 2022, Netflix was in compliance with all covenant limitations tied to its Senior Notes, which included restrictions on creating liens, entering into sale and lease-back transactions, incurring additional indebtedness by certain subsidiaries, and merging or transferring substantial assets. These notes included various euro-denominated tranches with principal amounts totaling €5,170 million. By 2024, Netflix remained in compliance with these covenants, but the scope of limitations had slightly evolved—specifically, certain Senior Notes no longer referenced restrictions on sale and lease-back transactions, suggesting a narrowing of covenant scope for some notes. Additionally, in 2024, Netflix repaid $400 million of its 5.750% Senior Notes upon maturity, indicating active debt management and a shift in its debt composition.",
      "llm_answer": "In the 2022 Form 10‑K Netflix said it was in compliance with all covenant restrictions on its senior notes – limits on creating liens, entering sale‑and‑lease‑back deals, incurring additional subsidiary debt and undertaking major mergers or asset transfers – but it did not report any specific note repayment [page_56]. By the 2024 filing the company still met those same covenants (with some notes also restricting sale‑and‑lease‑back and subsidiary indebtedness) and additionally disclosed that it had repaid the $400 million principal of its 5.750 % senior notes at maturity [page_54].",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) Quantitatively, all numbers are accurate: the $400 million repayment of the 5.750% Senior Notes in 2024 is correctly reported, and no incorrect figures are introduced. (2) The answer confirms Netflix’s compliance with covenants in both 2022 and 2024, accurately listing key restrictions (liens, sale-and-lease-back, subsidiary indebtedness, mergers/asset transfers), which matches the original answer. (3) However, the LLM misses a key qualitative evolution: the narrowing of covenant scope in 2024, specifically that certain Senior Notes no longer included restrictions on sale-and-lease-back transactions. The LLM instead states that 'some notes also restricting' these transactions, which implies continuity or expansion, not a reduction. This misrepresents the evolution in covenant scope. (4) Despite this, the answer correctly synthesizes multi-hop information across years and filings, noting both compliance and the actual repayment event. The contextual relevance is high, as all information provided directly addresses the question. The reasoning is mostly sound but lacks full precision on the change in covenant scope. Hence, a score of 8 is justified—core facts and numbers are correct, but there is a minor but notable omission in the qualitative evolution of covenant limitations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 379,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Honeywell's approach to the Safety and Retail product line evolve between 2022 and 2023, and what structural change was introduced in 2023 that reflects this evolution?",
      "original_answer": "In 2022, Honeywell reported the Safety and Retail business unit as a standalone component under the Safety and Productivity Solutions segment, generating $2,387 million in revenue. By 2023, the company had realigned its organizational structure, merging the Safety and Retail unit with the Advanced Sensing Technologies unit to form a new business unit called Sensing and Safety Technologies. This structural change, introduced in July 2022 but reported in the 2023 filing, reflects a strategic shift toward integrating sensing capabilities with safety solutions to enhance technological offerings and streamline operations.",
      "llm_answer": "In 2022 Honeywell reported a distinct “Safety and Retail” line within its Safety and Productivity Solutions segment (sales ≈ $2.4 billion) 【page_69】. By 2023 the company had merged that unit with its Advanced Sensing Technologies group, creating a new “Sensing and Safety Technologies” business unit (sales ≈ $2.7 billion) 【page_68】—a structural realignment that combined Safety and Retail with advanced sensing capabilities to reflect a more integrated safety‑sensing strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution of Honeywell's Safety and Retail product line from a standalone unit in 2022 to a merged entity in 2023. It accurately names the new unit—Sensing and Safety Technologies—and links it to the integration of sensing and safety capabilities. The only minor omission is that the structural change was introduced in July 2022 (as per the original answer) but reported in the 2023 filing; this timing nuance is missing in the LLM response, slightly weakening the completeness. (2) Quantitatively, the LLM reports $2.4 billion in sales for 2022, which aligns with the ground truth of $2,387 million (rounded appropriately). The combined 2023 revenue of $2.7 billion is not in the original answer, suggesting the LLM may have pulled this figure from the source document (possibly the combined unit’s revenue), but since it does not contradict the ground truth and is plausibly correct, it does not count as an error. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years and business units, identifying the merger and its strategic rationale. (4) The answer is semantically equivalent to the ground truth in intent and key facts, with only slight loss of detail regarding the July 2022 implementation. Scores reflect high accuracy with a small deduction in correctness and qualitative accuracy for the omitted timing detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 394,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the status and role of Class B-2 Common Stock evolved between 2023 and 2024, particularly in terms of its convertibility and impact on corporate governance?",
      "original_answer": "In 2023, Class B-2 Common Stock was described as part of a structure that would become convertible into Class A Common Stock, with potential dilutive effects on voting power and market price. It also played a role in approving significant corporate actions, indicating a governance influence. By 2024, no shares of Class B-2 Common Stock were outstanding prior to the Class B-1 Common Stock exchange offer, suggesting a strategic shift in equity structure. This indicates a transformation in the role of Class B-2 Common Stock, moving from an active governance and conversion position to a non-outstanding status, reducing its influence on corporate decisions.",
      "llm_answer": "In the 2023 filing Visa reported that no Class B‑2 common‑stock shares were outstanding, but the class was described as “will become convertible into Class A common stock” and, although its voting rights are limited, holders can vote on certain significant transactions such as a merger, which could dilute existing Class A voting power【page_34】. By the 2024 filing a Class B‑1 exchange offer created 49 Class B‑2 shares (total B‑1 + B‑2 shares fell from 245 to 125) and the new shares are still subject to conversion into Class A common stock, preserving those limited voting rights that trigger affirmative votes on consolidations or mergers and thus continue to affect corporate‑governance dynamics【page_59】【page_58】【page_61】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that contradict the ground truth. (1) Quantitatively, the LLM incorrectly states that in 2023, no Class B-2 shares were outstanding — this contradicts the original answer, which implies the class was still active and convertible, not already extinguished. More critically, the LLM claims that in 2024, 49 Class B-2 shares were created via a Class B-1 exchange offer. This is factually incorrect per the ground truth, which states that by 2024, no Class B-2 shares were outstanding *prior* to the exchange offer, indicating they had already been eliminated. The LLM reverses the timeline and invents a creation of B-2 shares, which is the opposite of the actual strategic elimination. (2) The calculation about total B-1 + B-2 shares falling from 245 to 125 is not supported by the ground truth and introduces unverified numbers. (3) Qualitatively, the reasoning is flawed: the LLM suggests Class B-2 stock continues to affect corporate governance in 2024 due to voting rights, but the ground truth states it was no longer outstanding, meaning it had no role. The multi-hop synthesis fails — instead of recognizing the phase-out and reduced influence, the model incorrectly infers reactivation. (4) Contextually, the answer addresses convertibility and governance, so relevance is moderate, but the factual foundation is inverted. Wording similarities (e.g., 'convertible into Class A') are superficial and do not compensate for core inaccuracies. Overall, the answer misrepresents the evolution, getting the direction of change wrong: Class B-2 was retired, not reactivated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 442,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has The Home Depot's approach to enhancing the ease of shopping experience evolved between 2023 and 2024, particularly in terms of digital and in-store capabilities?",
      "original_answer": "In 2023, The Home Depot focused on improving the ease of shopping experience by investing in mobile app-enabled store navigation, electronic shelf labels, reconfigured service desks, and enhanced self-checkout options. These efforts were aimed at improving store navigation, convenience, and checkout speed. By 2024, the company expanded its focus to include more personalized digital experiences, such as customer product review summaries and enhanced product content, while continuing to invest in digital platforms to improve navigation and 'shopability.' The 2024 strategy placed greater emphasis on leveraging customer data to meet personalized expectations, indicating a shift toward deeper integration of data-driven insights into the shopping journey.",
      "llm_answer": "In fiscal 2023 Home Depot focused on creating a frictionless, interconnected shopping experience by investing heavily in its website and mobile apps to improve navigation, search, “shopability,” checkout speed and fulfillment options, and by adding in‑store conveniences such as way‑finding signage, self‑service lockers, curbside pickup, electronic shelf‑label capabilities, refreshed front‑end layouts, expanded self‑checkout and digital handheld tools for associates (hdPhones, Computer Vision)【page_8】【page_9】. In fiscal 2024 the company built on that foundation, further enhancing its digital platforms with richer product content, customer‑review summaries and data‑driven personalization, while continuing to expand store‑level upgrades—including expanded self‑checkout, refreshed signage and mobile‑app‑enabled store navigation—demonstrating an evolution toward an even more integrated, personalized and technology‑enabled shopping experience【page_8】【page_9】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2023, The Home Depot invested in mobile app navigation, electronic shelf labels, reconfigured service desks (referred to as 'refreshed front-end layouts'), self-checkout, and digital tools for associates (hdPhones, Computer Vision), which matches the original answer's focus on store navigation, convenience, and checkout speed. In 2024, the company expanded into personalized digital experiences such as customer review summaries, richer product content, and data-driven personalization—directly reflecting the shift toward leveraging customer data as stated in the ground truth. (2) There are no numeric values, dates, or financial figures in the question or answers, so quantitative accuracy is not applicable beyond correct use of fiscal years 2023 and 2024, which are accurate. (3) The multi-hop reasoning is sound: the model correctly synthesizes the evolution from 2023 to 2024, identifying continuity (e.g., continued investment in self-checkout and navigation) and progression (enhanced personalization via data). (4) The only minor gap is that the LLM mentions 'way-finding signage' and 'self-service lockers' not explicitly in the original answer, but these are reasonable inferences under 'in-store conveniences' and do not contradict the ground truth. Similarly, 'curbside pickup' and 'fulfillment options' are not mentioned in the original but are contextually consistent with improving ease of shopping. Overall, the semantic meaning, evolution of strategy, and key initiatives are correctly conveyed, warranting a high correctness score of 9 due to slight over-elaboration without factual error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 468,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the structure of the Target Corporation Long-Term Incentive Plan evolved from 2022 to 2024, particularly in terms of the specific forms of equity awards included under the plan?",
      "original_answer": "In 2022, the Long-Term Incentive Plan included forms such as Non-Qualified Stock Options, Restricted Stock Units, Performance-Based Restricted Stock Units, Performance Share Units, Price-Vested Stock Options, Non-Employee Director Non-Qualified Stock Options, and Non-Employee Director Restricted Stock Units. By 2024, the plan introduced new forms of equity awards, including the Cliff-Vested Restricted Stock Unit Agreement and the Performance Award Performance Share Unit Agreement, indicating an expansion in the types of equity compensation vehicles available under the plan.",
      "llm_answer": "In the 2022 Form 10‑K the Long‑Term Incentive Plan was described as offering a mix of equity awards – non‑qualified and price‑vested stock options, restricted stock units, performance‑based RSUs, performance‑share units and cash‑retention awards 【page_68】. By the 2024 filing the plan had been reshaped around RSU‑type awards, adding separate agreements for restricted stock units, performance‑based RSUs, performance‑share units, non‑employee‑director RSUs, cliff‑vested RSUs and performance‑award performance‑share units, while the stock‑option forms are no longer listed 【page_73】.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the evolution of equity awards under Target Corporation's Long-Term Incentive Plan from 2022 to 2024 and references specific award types with appropriate citations. Quantitatively, there are no errors in dates or financial terms, and all mentioned award types are factually consistent with the ground truth. The answer correctly notes the introduction of Cliff-Vested Restricted Stock Units and Performance Award Performance Share Units by 2024. However, it incorrectly states that stock options (e.g., Non-Qualified Stock Options, Price-Vested Stock Options, and Non-Employee Director options) are no longer listed in the 2024 plan, which contradicts the ground truth that these forms were still included. The ground truth indicates an expansion of the plan, not a replacement or elimination of prior forms. This is a significant qualitative inaccuracy in reasoning and entity representation, as it mischaracterizes the nature of the plan’s evolution. Despite this, the answer remains contextually relevant and captures the core development—addition of new award types—accurately. Semantic equivalence is mostly preserved, but the omission and incorrect removal of stock options reduce the correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 347,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Qulipta's commercial performance evolve from its FDA approval in 2021 through 2023, based on AbbVie's financial disclosures?",
      "original_answer": "Qulipta was approved by the FDA in September 2021 for the preventive treatment of episodic migraine in adults, marking its entry into the market. By 2023, Qulipta had generated $405 million in U.S. revenue and $3 million internationally, totaling $408 million. This indicates a significant commercial trajectory following its approval, especially considering it had no revenue in 2021 and only $158 million in U.S. revenue in 2022. The product demonstrated strong growth, suggesting robust market adoption and positioning within AbbVie's portfolio.",
      "llm_answer": "AbbVie first announced FDA approval of Qulipta (atogepant) in September 2021, but the product generated no revenue that year (2021 10‑K)【page_60】.  In 2022 Qulipta began selling, reporting about $158 million of U.S. net revenue (with limited international sales)【page_42】, and by 2023 its U.S. sales had risen to $405 million (and roughly $408 million internationally), a rise of more than 100 % year‑over‑year driven by strong market‑share uptake and the April 2023 FDA approval for chronic migraine (and subsequent EC approval)【page_40】【page_44】.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the FDA approval in September 2021 and the absence of revenue in 2021, aligns with the $158 million in U.S. revenue in 2022, and accurately reports $405 million in U.S. revenue in 2023. However, it incorrectly states that Qulipta had 'roughly $408 million internationally' — the ground truth specifies $3 million internationally, with $408 million being the total global revenue ($405M U.S. + $3M international). This is a significant quantitative error in the international revenue figure. (2) The calculation of over 100% year-over-year growth is reasonable given the increase from $158M to $408M (~156% growth), so the percentage characterization is acceptable. The mention of the April 2023 FDA approval for chronic migraine adds relevant context for growth, supported in the source. (3) The multi-hop reasoning is sound: the model synthesizes data across 2021, 2022, and 2023 disclosures, correctly tracks the product’s launch and revenue ramp, and links expanded indications to commercial performance. (4) Despite the international revenue mix-up, the core narrative of strong commercial growth is accurate and well-supported. The error is material but does not undermine the overall conclusion, hence a score of 8. Quantitative accuracy is penalized more due to the misattribution of $408M to international sales. Qualitative and contextual accuracy remain high due to correct entity identification, timeline, and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 409,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has Netflix's treatment and disclosure of the 2020 Stock Plan evolved between the 2022 and 2024 SEC filings, particularly in terms of its structural description and associated equity compensation activities?",
      "original_answer": "In 2022, the 2020 Stock Plan was referenced primarily through its inclusion in the exhibit list as a filed document (Def 14A, filed April 22, 2020), with no detailed description of its provisions or activities. In contrast, by 2024, the 2020 Stock Plan was not only explicitly described in detail but also linked to specific equity compensation activities, including the granting of incentive stock options, nonstatutory stock options, and restricted stock units (RSUs) with defined vesting schedules and performance-based criteria. This represents a significant shift from mere documentation to a more comprehensive disclosure of the plan's operational role in equity compensation.",
      "llm_answer": "In the 2022 Form 10‑K the 2020 Stock Plan is mentioned only as an exhibit (Def 14A) – e.g., “2020 Stock Plan” appears in the exhibit list on pages 65‑66 – with no narrative description of its structure or quantitative equity‑compensation data. By the 2024 Form 10‑K the plan is described in a dedicated “Stock Option Plan” section (page 60) as a stockholder‑approved vehicle that grants incentive stock options, non‑statutory options, stock‑appreciation rights, restricted stock and RSUs to employees, directors and consultants, and the filing now includes detailed tables of option grants, exercises, expirations and RSU activity together with stock‑based compensation expense (pages 60‑61). This reflects a shift from a simple reference to a comprehensive structural description and explicit reporting of the plan’s equity‑compensation activities.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately captures the evolution in Netflix's disclosure of the 2020 Stock Plan between the 2022 and 2024 SEC filings: in 2022, the plan was only referenced as an exhibit (Def 14A) with no detailed description, while in 2024 it received a comprehensive narrative treatment. (2) The LLM correctly identifies specific details such as the inclusion of a dedicated 'Stock Option Plan' section in the 2024 10-K (page 60), the types of awards granted (incentive and non-statutory stock options, RSUs, restricted stock, stock-appreciation rights), and the presence of detailed tables on option activity and stock-based compensation expense. These align with the ground truth’s emphasis on expanded structural description and reporting of equity compensation activities. (3) The multi-hop reasoning is sound—comparing the level of disclosure across two different years and synthesizing changes in both narrative and quantitative reporting. (4) Minor wording differences (e.g., 'stock-appreciation rights' and 'restricted stock' mentioned by LLM but not in original) do not detract from accuracy, as these are plausible components of such plans and do not contradict the ground truth. All entities (Netflix, 2020 Stock Plan, 2022 and 2024 filings) are correct. No numerical inaccuracies; dates and exhibit references are consistent. The answer fully addresses both structural description and equity compensation activities as required by the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 419,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the company's approach to aluminum purchase agreements evolve between 2022 and 2023, particularly in terms of their classification and strategic use of derivative instruments?",
      "original_answer": "In 2022, the company described its aluminum purchase agreements as derivative instruments entered into for long-term strategic sourcing objectives and non-U.S. business requirements. By 2023, the company continued to use these agreements but provided additional clarity that the quantities of aluminum in these contracts offset each other and are priced at prevailing market prices. This evolution indicates a more refined strategy around market pricing alignment and potentially reduced exposure through offsetting positions.",
      "llm_answer": "In the 2022 filing Boeing said its aluminum purchase‑and‑sale agreements were “derivative instruments” that **did not receive hedge‑accounting treatment** and were used to meet long‑term strategic‑sourcing objectives and non‑U.S. business requirements【page_121】. The 2023 filing repeats the same classification and purpose, but the disclosed notional amount of commodity contracts not designated as hedges fell sharply from $412 million in 2022 to $115 million in 2023, indicating the company scaled back its reliance on those non‑hedged aluminum contracts while maintaining the same strategic rationale【page_103】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies not present in the ground truth. The original answer states that the company's aluminum purchase agreements were used for strategic sourcing and non-U.S. business needs in 2022, and in 2023, the company clarified that contract quantities offset each other and are priced at market rates. However, the LLM introduces unverified details: it claims the agreements 'did not receive hedge-accounting treatment' and cites a sharp drop in notional amounts from $412M to $115M — none of which appears in the ground truth. These specific figures and the concept of hedge accounting are not mentioned in the original answer, suggesting fabrication or misattribution. (2) Quantitative accuracy is low because the dollar amounts ($412M, $115M) and the claim about declining notional value are not supported by the ground truth. There is no mention of any numerical data in the original answer, so introducing such figures undermines factual correctness. (3) The reasoning partially aligns with the question’s intent — assessing evolution in classification and strategic use — but fails on multi-hop synthesis because it injects unrelated financial data and accounting treatment not present in the source. The core evolution described in the ground truth — increased clarity on offsetting positions and market pricing — is entirely missed by the LLM. Instead, the model focuses on a reduction in contract volume, which is not corroborated. (4) Contextual relevance is high because the response addresses aluminum purchase agreements, their classification as derivatives, and strategic use over 2022–2023. However, correctness and qualitative accuracy are penalized due to unsupported specifics and failure to capture the actual evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 495,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the disclosure or treatment of the Directors' Code of Conduct evolved between 2023 and 2024, particularly in terms of its accessibility and scope?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly referenced and posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors-code-of-conduct.pdf. In 2024, the URL for the Directors' Code of Conduct changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf, indicating a shift in how the document is categorized or accessed. Additionally, in 2024, the company introduced a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES,' which was not present in 2023, suggesting an expanded focus on compliance mechanisms beyond the Code itself. These changes reflect a transformation in the presentation and accessibility of the Directors' Code of Conduct, as well as an increased emphasis on insider trading compliance.",
      "llm_answer": "In the 2023 Form 10‑K the Directors’ Code of Conduct was described as applying to all directors of BNY and was referenced only by a partial web path ( bnymellon/documents/pdf/investor‑relations/directors‑code‑of‑conduct.pdf ) 【page_13】. The 2024 filing still limits the code to all directors—now explicitly of BNY Mellon—but provides a complete HTTPS link ( https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor‑relations/directors‑code‑of‑conduct.pdf ) 【page_13】, making the document more readily accessible while leaving its scope unchanged.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the presence of the Directors' Code of Conduct in both 2023 and 2024 filings and accurately notes the improvement in accessibility through the provision of a complete HTTPS link in 2024. It correctly references the partial URL in 2023 and the full URL in 2024, aligning with the ground truth on presentation and accessibility changes. However, the LLM answer contains a critical inaccuracy: it claims the 2024 filing provides a link to 'https://www.bnymellon.com/...', but the ground truth states that in 2024 the domain changed to 'bny.com', not 'bnymellon.com'. This is a significant entity and factual error affecting the correctness of the accessibility claim. Furthermore, the LLM answer states that the scope of the code is 'unchanged', which directly contradicts the ground truth that a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES' was added in 2024, indicating an expanded scope. This omission and incorrect conclusion about scope severely limit the answer's completeness and qualitative accuracy. While the reasoning around accessibility is partially sound, the failure to identify the domain change and the new insider trading section means the multi-hop synthesis is incomplete and partially flawed. The answer is contextually relevant and addresses the question's focus on accessibility and scope, but with key factual inaccuracies and omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 388,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the structure and value of HD's 4.95% Senior Notes evolved between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, HD issued $750 million of 4.95% senior notes due September 30, 2026, at a discount of $1.6 million. By 2024, the carrying amount of these 4.95% senior notes due September 2026 was $747 million as of February 2, 2025, and the company also reported $980 million in 4.95% senior notes due September 2052. This indicates that while the original 2026 notes remained outstanding with only a slight reduction in carrying value, HD expanded its 4.95% senior note structure to a much longer maturity in 2052, suggesting a strategy of extending debt maturities and potentially locking in fixed interest rates over a longer horizon.",
      "llm_answer": "In the 2023 filing Home Depot’s 4.95 % senior notes were limited to a single $750 million tranche maturing in September 2026, with a carrying amount of roughly $744 million as of January 29 2023 (see page 59). By the 2024 filing the 2026 tranche was essentially unchanged (carrying $745 million on January 28 2024, page 62) and the company added a new $1.75 billion tranche of 4.95 % senior notes due June 2034, issued at a $16.7 million discount (page 63). This expansion and lengthening of the 4.95 % series shows Home Depot is deliberately locking in low‑coupon, fixed‑rate debt and extending maturities to broaden its long‑term financing capacity and diversify its debt profile.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, HD issued $750 million of 4.95% senior notes due September 30, 2026 in 2023, with a discount of $1.6 million, resulting in a carrying amount of $747 million by February 2, 2025 (not January 29, 2023 as stated). However, the LLM claims a carrying amount of $744 million as of January 29, 2023, and $745 million as of January 28, 2024—dates and figures not aligned with the ground truth. More critically, the LLM incorrectly states that HD added a $1.75 billion tranche of 4.95% notes due June 2034, whereas the ground truth reports $980 million in 4.95% senior notes due September 2052. This is a major error in both amount and maturity date. (2) Quantitative accuracy is severely compromised: the LLM invents a $1.75 billion tranche and $16.7 million discount not present in the original answer, and misreports carrying amounts and dates. The ground truth does not mention any June 2034 notes. (3) The multi-hop reasoning is flawed. While the LLM correctly infers a strategy of extending maturities and locking in fixed rates, it bases this on entirely incorrect data. The actual strategy—issuing long-dated debt (2052) alongside existing 2026 notes—is misrepresented by substituting a 2034 maturity. (4) Contextual relevance is moderate because the answer addresses the structure and strategy of HD's debt, but the factual foundation is incorrect, undermining the conclusion. The reasoning would be sound if based on accurate data, but it is not. Thus, the correctness score is low due to major factual and quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 446,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did Intel's financial treatment and valuation of its investment in Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of observable price adjustments and net book value?",
      "original_answer": "In 2021, Intel recognized $471 million in observable price adjustments in its investment in Beijing Unisoc Technology Ltd. By the end of 2023, Intel was accounting for its interest in Unisoc as a non-marketable equity security, with a net book value of $1.1 billion as of December 30, 2023 (the same as December 31, 2022). This indicates that while Intel continued to hold the investment without marketability, the valuation remained stable over the two-year period despite the earlier price adjustment.",
      "llm_answer": "In 2021 Intel recorded a $471 million observable‑price adjustment to its stake in Beijing Unisoc Technology Ltd., contributing to a $750 million adjustment for non‑marketable equity securities that year【page_43】. By 2023 the annual observable‑price adjustment for non‑marketable equity securities had fallen to only $17 million, and Intel carried the Unisoc investment on its balance sheet at a net book value of about $1.1 billion (the same as at the end of 2022)【page_96】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $471 million observable-price adjustment in 2021 and the $1.1 billion net book value as of the end of 2023 (and 2022), matching the ground truth. It also accurately notes that Intel accounted for the investment as a non-marketable equity security, consistent with the original answer. The additional detail about the $750 million total adjustment for non-marketable securities in 2021 and the $17 million in 2023 is not contradicted by the ground truth and adds context without introducing error. (2) All numeric values—$471 million (2021), $1.1 billion (2022 and 2023 book value)—are factually correct and properly attributed. The mention of page references (e.g., page_43, page_96) suggests accurate sourcing. (3) The multi-hop reasoning is sound: the model connects Intel’s 2021 price adjustment with the ongoing accounting treatment and valuation trend through 2023, correctly inferring stability in book value despite earlier adjustments. The only minor shortcoming is that it does not explicitly state that the investment was *still* classified as non-marketable in 2023, though this is strongly implied by the context and the use of 'carried...at a net book value.' (4) The answer is semantically equivalent to the ground truth, with slightly more granular financial context. The core facts, entities (Intel, Beijing Unisoc Technology Ltd.), years (2021–2023), and financial metrics (observable price adjustments, net book value) are all accurate and well-synthesized. The answer is fully relevant and addresses all aspects of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 439,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did AbbVie's engagement with Qulipta evolve from 2022 to 2023, particularly in terms of its regulatory and commercial development status?",
      "original_answer": "In 2022, Qulipta was part of a group of products that received regulatory approvals, leading to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights. By 2023, AbbVie had introduced Qulipta with specific regulatory milestones: it received FDA approval in April 2023 for the preventive treatment of chronic migraine in adults and EC approval in August 2023 for the preventive treatment of migraine in adults with four or more migraine days per month. This evolution reflects a shift from asset reclassification to active regulatory and commercial advancement.",
      "llm_answer": "In the 2022 Form 10‑K AbbVie already treated Qulipta as a commercial product – it was re‑classified to a developed‑product right after receiving regulatory approval and generated about **$158 million of U.S. net revenue** that year【page_100】. By the 2023 filing AbbVie reported **new regulatory clearances** – FDA approval for chronic migraine in April 2023 and EC approval in August 2023【page_40】 – and U.S. sales had risen to roughly **$405 million**, showing an expanded commercial rollout【page_42】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the regulatory milestones for Qulipta in 2023 — FDA approval in April 2023 for chronic migraine and EC approval in August 2023 — which aligns with the ground truth. It also correctly notes that Qulipta was reclassified as a developed product right following regulatory approval, reflecting its 2022 status. However, the ground truth does not mention any U.S. net revenue figures for Qulipta in 2022 ($158 million) or 2023 ($405 million), nor does it state that these revenues were reported in the 10-Ks. These specific revenue numbers are not present in the original answer derived from the knowledge graph, making their inclusion a factual overreach or potential hallucination. (2) While the dates of approvals (April 2023, August 2023) are accurate and match the ground truth, the revenue figures — though plausible — are not supported by the provided ground truth and thus reduce quantitative accuracy. There are no calculation errors per se, but the introduction of unreferenced financial data undermines precision. (3) The multi-hop reasoning is sound: the model connects Qulipta’s reclassification in 2022 to its regulatory approvals and then tracks its commercial progression into 2023 with new approvals and implied sales growth. This reflects appropriate synthesis across time and regulatory-commercial dimensions. However, the addition of unverified revenue figures suggests possible confusion between known facts and external data. (4) The contextual relevance is high — the response directly addresses the evolution of Qulipta’s regulatory and commercial status across 2022–2023. Despite the unsupported numbers, the core narrative of transition from asset reclassification to active commercialization is consistent with the ground truth. Hence, correctness is reduced primarily due to unsupported quantitative claims, not flawed reasoning or misidentification of entities.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 523,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has Boeing's framing and strategic emphasis on 'upgrades and conversions' within the Global Services segment evolved between 2022 and 2023, based on the language used in the 10-K filings?",
      "original_answer": "In 2022, 'upgrades and conversions' were listed as part of a broader set of services under the Global Services segment, grouped alongside supply chain logistics, engineering, maintenance, spare parts, training systems, technical documents, and digital services. The description was general and lacked strategic framing. In 2023, while the service was still included, the context shifted subtly: it was now positioned within a more structured narrative that emphasized the full spectrum of sustaining aerospace platforms and systems, indicating a more integrated and strategic role within the segment. This evolution suggests a more deliberate positioning of 'upgrades and conversions' as a core capability rather than a general service offering.",
      "llm_answer": "In the 2022 filing, Boeing’s Global Services segment description merely listed “upgrades and conversions” as one item in a broad inventory of services (e.g., supply‑chain, engineering, maintenance, etc.) 【page_3】. By the 2023 filing, the same line still appears, but the narrative also pairs upgrades with modifications and highlights them in the competition discussion as a core element of its lifecycle‑service strategy and a driver of market‑share growth (e.g., “modifications and upgrades…gate‑to‑gate operations”) 【page_3】【page_4】. This reflects a shift from a simple service‑offering mention in 2022 to a more strategic emphasis on upgrades as a growth lever within Global Services in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, 'upgrades and conversions' were listed as part of a general list of services without strategic framing, citing the correct context (e.g., alongside supply chain, engineering, maintenance). In 2023, it accurately notes a shift in narrative, where upgrades are more strategically positioned—specifically mentioning their inclusion in lifecycle-service strategy and market-share growth, which reflects the ground truth's point about a more integrated and strategic role. The LLM adds a specific detail about 'modifications and upgrades' being tied to 'gate-to-gate operations' and competition discussion, which enhances the answer without contradicting the original. (2) There are no numerical values in the question or answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes language changes across two years’ filings, compares framing, and infers strategic evolution. The only minor gap is that the ground truth emphasizes the 'full spectrum of sustaining aerospace platforms' narrative, which the LLM does not explicitly mention, slightly tempering qualitative perfection. (4) The answer is fully contextually relevant, directly addressing the evolution of language and strategic emphasis as requested. Wording differs but semantic meaning matches. Minor deduction from 10 to 9 due to slight omission of the 'sustaining platforms' framing, but core insight remains correct and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 432,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Intel's financial relationship with Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of the valuation and recognition of this investment?",
      "original_answer": "Intel's financial relationship with Beijing Unisoc Technology Ltd. remained consistent in terms of total net book value, which stayed at $1.1 billion as of both December 25, 2021 (from the 2022 filing) and December 30, 2023 (from the 2023 filing). However, in 2021, Intel recognized $471 million in observable price adjustments related to its investment in Unisoc, indicating a revaluation event during that year. This type of valuation adjustment was not explicitly mentioned in the 2023 filing, suggesting a stabilization of the investment's value over time or a lack of significant observable price changes in 2023 compared to 2021.",
      "llm_answer": "In the 2022 filing Intel reported that its non‑marketable equity portfolio included a $1.1 billion stake in Beijing Unisoc Technology Ltd. (up from $658 million a year earlier) and that this amount was carried on the balance sheet as of December 25 2021【page_52】. The 2023 filing shows the same investment still recorded at a net book value of $1.1 billion as of December 30 2023, noting that Intel recognized a $471 million observable‑price adjustment to the Unisoc holding in 2021 but reported no further impairment or valuation change through 2023【page_96】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Intel's investment in Beijing Unisoc had a net book value of $1.1 billion as of December 25, 2021, and remained at $1.1 billion as of December 30, 2023, which aligns with the ground truth. It also correctly notes the $471 million observable price adjustment recognized in 2021. However, the LLM introduces a fact not present in the original answer — that the value increased 'from $658 million a year earlier' — which is not supported by the ground truth and introduces a quantitative inaccuracy. This additional detail undermines the quantitative accuracy despite the core numbers being correct. (2) The key dollar amounts ($1.1 billion, $471 million) and dates (Dec 25, 2021; Dec 30, 2023) are accurate and properly attributed to the respective filings. The unsupported claim about the $658 million prior value is a significant error, as it implies a revaluation from that amount to $1.1 billion, which was not confirmed in the ground truth. (3) The multi-hop reasoning is mostly sound — the model correctly synthesizes data from the 2022 and 2023 filings to show consistency in book value and the timing of the valuation adjustment. However, the inclusion of an unverified prior value suggests potential confusion or overinference from external data. (4) The answer is contextually relevant and addresses the evolution of the financial relationship, particularly valuation and recognition. Due to the introduction of an unsupported figure, the quantitative accuracy is reduced to 6, pulling the overall correctness score to 7. The qualitative reasoning and contextual relevance remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 450,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role of Self-Service Lockers evolved within Home Depot's interconnected shopping experience between 2023 and 2024?",
      "original_answer": "In 2023, Self-Service Lockers were described as part of Home Depot's investments to improve the customer shopping experience, specifically to enable convenient online order pickup options alongside other features like wayfinding signage and electronic shelf labels. By 2024, Self-Service Lockers were positioned more strategically as part of the company's broader fulfillment network, specifically referenced in the context of leveraging stores as 'convenient customer pickup, return, and delivery fulfillment locations' under interconnected retail programs such as BOSS, BOPIS, BODFS, and BORIS. Additionally, in 2024, approximately 50% of U.S. online orders were fulfilled through a store, highlighting a more integrated and operationally significant role for Self-Service Lockers in the fulfillment process. This reflects a shift from a convenience-focused feature to a core component of the omnichannel delivery strategy.",
      "llm_answer": "In fiscal 2023 the filing described self‑service lockers as a new store‑refresh element that gave shoppers a convenient “online‑order pickup” option alongside BOPIS, BOSS, BODFS and BORIS 【page_8】. By fiscal 2024 the lockers are portrayed as a fully‑integrated front‑entrance fixture at many stores, explicitly tied to the four interconnected retail programs and used for pickup, return and delivery fulfillment as a core part of Home Depot’s interconnected shopping experience 【page_9】【page_10】.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Self-Service Lockers from a convenience feature in 2023 to a more integrated component of Home Depot's fulfillment network in 2024. It accurately references the interconnected retail programs (BOPIS, BOSS, BODFS, BORIS) and their role in pickup, return, and delivery fulfillment. However, it omits the key quantitative fact from the ground truth that approximately 50% of U.S. online orders were fulfilled through stores in 2024—a significant data point that underscores the operational scale and strategic importance of lockers. This omission affects completeness and slightly weakens the support for the claimed strategic shift. (2) There are no numeric inaccuracies; the LLM does not introduce incorrect numbers or misstate dates. Since the ground truth includes a percentage (50%) that the LLM fails to mention, this is a gap in quantitative completeness, though not an inaccuracy per se. All other references to years (fiscal 2023, fiscal 2024) and program names are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and connects lockers to broader fulfillment strategies. It correctly identifies the shift in positioning from a store-refresh element to a core fixture in the interconnected experience. However, without citing the 50% fulfillment statistic, the answer lacks full evidentiary support for the extent of integration, weakening the depth of synthesis. (4) The contextual relevance is high—the response directly addresses the question about the evolving role of lockers and aligns with the timeline and strategic framing in the original. The qualitative accuracy is strong but not perfect due to the missing statistic that would reinforce the strategic shift. Overall, the answer is factually consistent and well-reasoned but partially incomplete on a key metric.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 512,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the level of detail and specificity in Costco's disclosure regarding the estimation methods for Insurance/Self-insurance Liabilities evolved from 2023 to 2024?",
      "original_answer": "In 2023, Costco provided a general description of its self-insurance practices and risk management mechanisms, including the use of a captive insurance subsidiary and a reinsurance program, but did not specify the factors used in estimating liabilities. In 2024, the company significantly expanded its disclosure, detailing that liabilities are estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions. Additionally, 2024's disclosure included a discussion of the unpredictability of claim costs and the potential for significant differences between actual and recorded liabilities, which was not present in 2023. This represents a meaningful increase in transparency and specificity.",
      "llm_answer": "In the 2023 Form 10‑K Costco’s note on insurance/self‑insurance liabilities was relatively brief – it said the liabilities are not discounted and are “estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions” (2023 p.46‑47). The 2024 filing expands that discussion, still noting the same actuarial inputs but now explicitly stating that claim costs are “highly unpredictable” and can fluctuate because of inflation, regulatory or legal changes, and that historically adjustments have been immaterial, thereby providing a more detailed and specific description of the estimation methodology (2024 p.31).",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Costco expanded its disclosure from 2023 to 2024 regarding insurance/self-insurance liabilities and notes increased detail in 2024, including the unpredictability of claim costs and factors like inflation and legal changes. However, it incorrectly states that in 2023, Costco already disclosed the use of 'historical claims experience, demographic factors, severity factors, and other actuarial assumptions'—this is a critical factual error. According to the ground truth, these specific factors were *not* disclosed in 2023; they were first introduced in 2024. This undermines the core of the comparison. (2) There are no explicit numerical values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is based on correct attribution of disclosures to years. The LLM misattributes the detailed methodology to 2023, which is factually incorrect. Page references (2023 p.46-47, 2024 p.31) may be accurate but do not compensate for the incorrect content summary. (3) The multi-hop reasoning is partially sound—comparing disclosures across years—but fails because it assumes continuity in methodology disclosure that did not exist. The model should have recognized that the detailed actuarial factors were a *new* addition in 2024, not a pre-existing element. (4) Contextual relevance is high because the answer addresses the evolution of disclosure and attempts to cite specific enhancements. However, due to the major factual inaccuracy about 2023 disclosures, the correctness and qualitative accuracy scores are significantly reduced. The answer gives the false impression that the methodology was already detailed in 2023, minimizing the actual increase in transparency.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 481,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How did the financial impact of the Aldevron acquisition on inventory-related costs evolve from 2022 to 2023?",
      "original_answer": "In 2022, the Aldevron acquisition contributed to a $59 million increase in cost of sales due to fair value adjustments to inventory. By 2023, this specific acquisition-related cost associated with Aldevron was no longer present; instead, a new $87 million charge emerged in the second quarter, primarily related to excess inventory in the Biotechnology segment due to reduced demand. This indicates a shift from acquisition-driven inventory adjustments to operational inventory challenges.",
      "llm_answer": "In 2022 the Aldevron deal was only adding a modest, lower‑incremental inventory adjustment – the fair‑value inventory charge that had boosted cost of sales by $59 million in 2021 was much smaller in 2022 and only partially offset the rise in cost of sales 【page_46】. By 2023 that acquisition‑related inventory effect had essentially disappeared, and the company instead recorded a $87 million excess‑inventory charge in the Biotechnology segment, driving a larger inventory‑related cost impact 【page_46】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the $59 million fair value adjustment occurred in 2021 and was smaller in 2022, while the ground truth confirms the $59 million charge was in 2022, not 2021. This misattribution of timing undermines the quantitative and qualitative accuracy. The $87 million excess inventory charge in 2023 is correctly identified and attributed to the Biotechnology segment, which is accurate. (2) The key numeric values ($59M and $87M) are present but associated with incorrect years for the $59M charge. The LLM implies the $59M charge was in 2021 and diminished in 2022, which contradicts the ground truth stating it was a 2022 Aldevron-related cost. No calculation errors per se, but the timeline error leads to incorrect interpretation. (3) The multi-hop reasoning is partially sound—recognizing the shift from acquisition-related to operational inventory costs—but based on flawed premises. The synthesis fails because it uses incorrect data points (wrong year for the $59M charge), leading to an inaccurate evolution narrative. (4) Contextual relevance is high as the answer addresses inventory cost evolution and identifies the two key charges. However, due to the critical error in dating the $59M charge, the correctness score is low. Quantitative accuracy is severely penalized for the year misassignment, while qualitative accuracy reflects partially correct reasoning on the shift in cost nature.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 412,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the treatment and recognition of shop card liabilities evolved between 2023 and 2024, and what does this indicate about Costco's approach to unclaimed balances?",
      "original_answer": "In both 2023 and 2024, Costco recognized revenue from shop cards upon redemption and accounted for outstanding balances as a liability, net of estimated breakage based on redemption data. However, the specific mention of 'estimated breakage' and the methodology tied to redemption data became more emphasized in 2024, indicating a more refined or formalized approach to tracking and accounting for unclaimed shop card balances. This evolution suggests Costco improved its estimation techniques for unclaimed balances, aligning its liability reporting more closely with actual redemption behavior over time.",
      "llm_answer": "Costco’s 2024 filing still records shop‑card balances as a liability “net of estimated breakage,” with revenue recognized only when cards are redeemed and the unredeemed portion estimated and deducted from the liability. The language is identical to the 2023 discussion, showing that Costco has not altered its policy but continues to treat unclaimed card balances conservatively—recognizing them as a current liability reduced by data‑driven breakage estimates.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in terms of the accounting treatment—recognizing revenue upon redemption and carrying liabilities net of estimated breakage—and correctly identifies both years (2023 and 2024), satisfying entity accuracy and contextual relevance. Quantitative accuracy is perfect as no numerical values are involved and all referenced concepts (breakage, liability treatment) are correctly stated. However, the key flaw lies in qualitative accuracy: the LLM claims the language in 2024 is 'identical' to 2023, which contradicts the ground truth that emphasizes a more refined or formalized approach in 2024 with greater emphasis on 'estimated breakage' and redemption data. This misrepresents the evolution in disclosure and implies no change in approach, whereas the ground truth indicates a more deliberate or improved methodology in 2024. Thus, while the core accounting policy is accurately described, the LLM fails to capture the nuanced shift in emphasis and sophistication in breakage estimation, which is central to the question about Costco’s evolving approach to unclaimed balances. This missing insight significantly weakens the reasoning and multi-hop synthesis, resulting in a partially correct answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 345,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has Intel's Foundry Services offering evolved from 2022 to 2023 in terms of strategic partnerships and customer engagement, based on the specific initiatives and agreements mentioned in those years?",
      "original_answer": "In 2022, Intel introduced its Foundry Services as part of the IDM 2.0 strategy, emphasizing plans to build a world-class foundry business with differentiated offerings, including leading-edge packaging and process technology, committed capacity in the US and Europe, and a strong IP portfolio. By 2023, Intel had significantly advanced this offering by securing four design wins on Intel 18A, including a major high-performance computing customer, and five new design wins in advanced packaging, particularly for AI-related designs. Additionally, Intel expanded its IFS Accelerator Ecosystem Alliance program to over 40 strategic agreements and entered into multigenerational agreements with ARM and Synopsys to enable optimized SoC design on Intel 18A. These developments indicate a shift from strategic intent in 2022 to concrete customer engagements and ecosystem partnerships in 2023.",
      "llm_answer": "In 2022 Intel introduced Foundry Services (IFS) as a new pillar of its IDM 2.0 strategy, highlighting the launch of the U.S. Department of Defense’s RAMP‑C program that positioned IFS to provide domestic, leading‑edge capacity and an IP‑rich, advanced‑packaging offering backed by U.S. and European fabs. By 2023 the offering had moved from launch to active execution: Intel secured four Intel 18A design wins, more than doubled its IFS Accelerator Ecosystem Alliance to over 40 strategic agreements—including multigenerational deals with ARM and a definitive agreement with Synopsys—and expanded RAMP‑C partnerships to marquee customers such as Nvidia, IBM, Microsoft, Boeing and Northrop Grumman, while also signing a commercial agreement with Tower for 300 mm analog‑processing capacity. This evolution shows a shift from establishing the service and a single government partnership to building a broad ecosystem of technology partners and engaging a growing roster of high‑profile customers.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Intel's Foundry Services from 2022 to 2023 with accurate core facts: the launch under IDM 2.0 in 2022, four Intel 18A design wins in 2023, expansion of the IFS Accelerator Ecosystem to over 40 agreements, and multigenerational deals with ARM and Synopsys. However, it introduces inaccuracies by naming specific companies (Nvidia, IBM, Microsoft, Boeing, Northrop Grumman) as RAMP-C partners in 2023, which are not mentioned in the ground truth. The ground truth does not specify these customers, only referring to a 'major high-performance computing customer' and five new advanced packaging design wins, particularly for AI. Additionally, the LLM mentions a commercial agreement with Tower for 300mm analog-processing capacity, which is not present in the original answer and constitutes an unsupported addition. (2) Quantitatively, the numbers 'four design wins', 'over 40 strategic agreements', and references to multigenerational deals with ARM and Synopsys are accurate and match the ground truth. However, the specific expansion of RAMP-C to five named companies is factually unsupported in the provided truth, making those additions incorrect despite plausible context. (3) The multi-hop reasoning is generally sound—correctly identifying the shift from strategic intent in 2022 to execution in 2023—but overreaches by fabricating specific customer engagements not in the source. The synthesis across years and initiatives is logical but compromised by the inclusion of extraneous details. (4) The contextual relevance is high as the answer directly addresses the evolution in partnerships and customer engagement. The qualitative accuracy is strong in structure and reasoning but docked due to unsupported entity claims. Correctness is scored 7 because while key facts and numbers are correct, the inclusion of unverified high-profile customers and the Tower agreement introduces significant factual errors that affect overall reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1484,
        "completion_tokens": 542,
        "total_tokens": 2027
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the financial impact of DHR's relationship with Aldevron evolve between 2022 and 2023, particularly in terms of goodwill and net cash consideration?",
      "original_answer": "In 2022, DHR preliminarily recorded approximately $6.1 billion of goodwill related to the Aldevron Acquisition. By 2023, the net cash consideration for Aldevron increased to $9.561 billion, indicating a more detailed or revised financial assessment of the acquisition. This evolution shows a significant increase in the financial commitment to the Aldevron relationship, particularly in terms of cash outlay, beyond the initial goodwill estimate provided in 2022.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K show the Aldevron acquisition still recorded at roughly $6.1 billion of goodwill and $9.6 billion of net cash consideration. The acquisition note tables list goodwill of $6,149 million and net cash consideration of $9,561 million for Aldevron in each filing, indicating no material change in the financial impact between 2022 and 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains accurate numeric values: $6.1 billion in goodwill (specifically $6,149 million) and net cash consideration of $9,561 million ($9.6 billion rounded), which align with the ground truth. Thus, quantitative accuracy is high. However, the core reasoning and qualitative analysis are fundamentally incorrect. The original answer states that in 2022, DHR *preliminarily* recorded $6.1 billion of goodwill, and by 2023, the *net cash consideration* was reported as $9.561 billion—indicating an evolution in financial commitment and refinement of acquisition accounting. The LLM incorrectly asserts that both goodwill and net cash consideration were reported at these values in *both* 2022 and 2023, and that there was 'no material change'—which contradicts the ground truth narrative of evolving financial impact. This misrepresents the multi-hop evolution between years and fails to capture the key point: the 2022 figure was a preliminary goodwill estimate, while the 2023 figure reflects a more complete or updated net cash outlay. The model conflates static reporting with dynamic financial assessment, showing flawed reasoning. While numbers are correct, the interpretation and synthesis across years are wrong, leading to a low correctness and qualitative accuracy score. Contextual relevance is moderate because it discusses the right entities and metrics but draws an incorrect conclusion about their evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 394,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the maturity date of the AT&T Inc. 1.800% Global Notes changed between the 2022 and 2024 SEC filings, and what does this indicate about the company's debt structure evolution?",
      "original_answer": "In the 2022 SEC filing, the AT&T Inc. 1.800% Global Notes were due on September 5, 2026. In the 2024 filing, the same class of notes is listed with a maturity date of September 14, 2039. This indicates a significant shift in the company's debt structure, extending the maturity of this particular note by over 13 years.",
      "llm_answer": "The 1.800 % Global Notes are listed with a maturity of **September 5 2026** in both filings – the 2022 10‑K shows “AT&T Inc. 1.800 % Global Notes due September 5 2026” (page 2) and the 2024 10‑K repeats the same entry (page 1). Because the maturity date has not been extended or altered, AT&T’s debt structure for this tranche has remained stable, indicating the company has kept its existing long‑term borrowing schedule rather than reshaping it.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect. It claims the maturity date of the AT&T Inc. 1.800% Global Notes is September 5, 2026 in both the 2022 and 2024 filings. However, the ground truth states that in the 2024 filing, the maturity date is September 14, 2039 — a significant extension. This misstatement undermines the entire response. (2) Quantitatively, the 2022 date (September 5, 2026) is correct, but the 2024 date is wrong — the LLM incorrectly repeats 2026 instead of 2039. This leads to a false conclusion that the maturity did not change, when in fact it was extended by over 13 years. The calculation of no change is therefore incorrect. (3) The multi-hop reasoning fails: the model should have compared the same class of notes across two filings and detected a change in maturity. Instead, it asserts no change, missing the core evolution in debt structure. The conclusion about 'stable' debt structure is invalid. (4) Contextual relevance is partially met — the answer addresses the right company, note type, and filings — but due to factual inaccuracy, the response misleads. Correctness and quantitative accuracy are severely penalized because the key data point (maturity date in 2024) is wrong, making the answer fundamentally flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1200,
        "completion_tokens": 354,
        "total_tokens": 1555
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Target's compliance with its debt leverage covenant evolved between 2023 and 2024, and what changes in credit facility structure may have influenced this compliance?",
      "original_answer": "In 2023, Target stated that it was, and expected to remain, in compliance with its debt leverage covenant, which was part of a $1.0 billion 364-day credit facility that would expire in October 2024, along with a $3.0 billion five-year facility expiring in October 2028. By 2024, Target had renewed its 364-day credit facility, extending its expiration to October 2025, while maintaining the same $3.0 billion five-year facility. The company continued to assert compliance with the debt leverage covenant. The renewal of the 364-day facility likely provided continued flexibility, supporting Target’s ability to remain compliant with the covenant.",
      "llm_answer": "Target said it was **in compliance with its debt‑leverage covenant in both years** – the 2023 Form 10‑K notes “We are, and expect to remain, in compliance with these covenants” and the 2024 Form 10‑K repeats the same statement【page_54】【page_35】.  The company’s credit‑facility structure changed: it added a new $1.0 billion 364‑day revolving facility (replacing the prior short‑term facility) and extended its $3.0 billion five‑year revolving facility to 2028, giving it greater borrowing capacity and liquidity that helps sustain covenant compliance【page_54】【page_35】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) It correctly states that Target was in compliance with its debt leverage covenant in both 2023 and 2024, citing consistent language from the 10-K filings. (2) Quantitative details are correct: the $1.0 billion 364-day facility and $3.0 billion five-year facility are accurately reported, as is the extension of the five-year facility to 2028. The renewal of the 364-day facility (implied by 'replacing the prior short-term facility' and extending to October 2025 in the original) is correctly noted, though the LLM does not explicitly mention the new expiration date (October 2025), which is a minor omission. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and two credit facilities, correctly linking the structural changes (renewal and extension) to sustained covenant compliance. (4) The answer is contextually relevant and complete for the most part, though it slightly mischaracterizes the change in the 364-day facility as 'adding' a new one rather than 'renewing' the existing one—semantically close but not perfectly precise. Overall, the answer reflects strong factual accuracy, correct entity identification, and logical reasoning, warranting a high score with only minor room for improvement in nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 374,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Intel's approach to expanding digital readiness for global populations evolved from 2022 to 2023, particularly in relation to its RISE strategy and external collaboration initiatives?",
      "original_answer": "In 2022, Intel committed to expanding digital readiness through its RISE strategy, focusing on collaborative initiatives with other technology companies via the Alliance for Global Inclusion to create an Inclusion Index with unified goals and metrics. By 2023, this effort had matured into the publication of the third global inclusion index survey, which transitioned into an index system where organizations scoring 50% or higher were formally recognized. Intel was among the 18 recognized organizations out of 27 respondents, indicating a more structured and outcome-focused approach to digital readiness and inclusion. This evolution reflects a shift from establishing collaborative frameworks to measuring and recognizing performance against defined benchmarks.",
      "llm_answer": "In 2022 Intel first embedded digital‑readiness into its RISE agenda by launching the **RISE Technology Initiative** (renamed from the Pandemic Response Technology Initiative) and rolling out global “Intel Digital Readiness” programs such as **AI for Youth** and **AI for Workforce**, which were **scaled in partnership with governments, institutions and other stakeholders** to give millions of people new digital skills 【page_16】. By 2023 the company had **deepened and broadened those external collaborations**—continuing the RISE Technology Initiative, working with the **Alliance for Global Inclusion** and other partners, and funding projects that make technology more inclusive while further expanding digital‑readiness worldwide, positioning it as a core pillar of its 2030 RISE goals 【page_19】【page_18】.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but misses key elements of the evolution described in the ground truth, particularly the shift from framework development to measurable outcomes. (1) Correct aspects: The answer accurately notes Intel's integration of digital readiness into the RISE strategy and mentions external collaborations, including the Alliance for Global Inclusion, which aligns with the original answer. It also correctly identifies the continuation and expansion of initiatives into 2023. (2) Quantitative accuracy: There are no numerical values, percentages, or dates in conflict; the years 2022 and 2023 are used appropriately. (3) Multi-hop reasoning: The LLM fails to synthesize the critical evolution — the publication of the third global inclusion index and the formal recognition of organizations scoring 50% or higher — which represents the core advancement from 2022 to 2023. This omission undermines the qualitative accuracy, as the transformation from setting up collaborative frameworks to measuring and recognizing performance is central to the question. (4) The answer remains contextually relevant and uses correct entities (RISE strategy, Alliance for Global Inclusion), but it lacks the specific outcome-focused milestone (the index system and Intel’s recognition among 18 organizations) that defines the 2023 development. Thus, while the general direction is correct, the absence of this key benchmarking evolution limits factual completeness and reasoning depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 410,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did Emerson's relationship with Micromine evolve between 2023 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2023, Emerson (via its AspenTech subsidiary) entered into an agreement to acquire Micromine for AU$900 (approximately $623 USD), but later terminated the agreement due to uncertainty around Russian regulatory approval. This led to a mark-to-market gain of $24 in 2023 related to foreign currency forward contracts tied to the Micromine acquisition. By 2024, AspenTech had terminated all outstanding foreign currency forward contracts associated with the Micromine deal. The termination of the Micromine acquisition represented a shift from a strategic expansion effort in 2023 to a full withdrawal from the transaction, with no further financial commitments or exposures to Micromine reported in 2024.",
      "llm_answer": "Emerson’s AspenTech subsidiary had been negotiating to buy Micromine, but in August 2023 AspenTech announced the agreement was mutually terminated and no termination fee was paid【page_52】.  By 2024 the Micromine deal was completely off‑the‑table, and the only financial effect was the unwind of the foreign‑currency hedges tied to the aborted purchase, which generated a $24 million mark‑to‑market gain in 2023 (shown in the foreign‑currency transaction line) and avoided any purchase‑price or termination‑cost expense【page_55】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential facts from the ground truth. (1) Quantitatively, all numbers and dates are correct: the $24 million mark-to-market gain in 2023 is accurately reported, and the termination of the deal in August 2023 aligns with the timeline. The absence of termination fees and financial exposure in 2024 is correctly noted. The original answer mentions the AU$900 (~$623M USD) purchase price, which the LLM omits, representing a minor gap in completeness. (2) The financial implications are correctly described: the gain arose from foreign currency hedges, and their unwind was the only financial impact. The LLM correctly notes this gain appeared in the foreign currency transaction line, adding contextual detail not in the original but consistent with accuracy. (3) Multi-hop reasoning is sound: the answer connects Emerson → AspenTech → Micromine acquisition attempt → termination → financial impact via hedging contracts across 2023–2024. The shift from strategic expansion to withdrawal is implied through the deal’s termination and unwinding of contracts. (4) The only omission is the initial deal value (AU$900/$623M), which is a factual component of the 2023 relationship. However, since the question emphasizes the evolution and financial implications, and the key financial figure ($24M gain) is correct, this does not severely impact overall correctness. Wording differs but semantic meaning matches. Contextual relevance is excellent—every part of the response addresses the question directly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 424,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did the availability of shares under The Home Depot's U.S. Employee Stock Purchase Plan (ESPP) and the average purchase price of shares during the fiscal year change from 2022 to 2023?",
      "original_answer": "In 2022, there were approximately 17 million shares available under the U.S. ESPP, and associates purchased approximately one million shares at an average price of $305.14. In 2023, the number of shares available under the U.S. ESPP decreased to 15 million, and associates again purchased approximately one million shares, but at a lower average price of $277.19. This indicates a reduction in share availability and a notable decrease in the average purchase price during the fiscal year.",
      "llm_answer": "The Home Depot’s U.S. ESPP had roughly 17 million shares available at the end of fiscal 2022 (January 30 2022) and this pool contracted to about 15 million shares by the end of fiscal 2023 (January 28 2024)【page_70】. The most recent disclosed average purchase price fell from $305.14 per share (the last average price shown in the 2022 filing) to $277.19 per share in fiscal 2023【page_70】【page_68】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key facts from the ground truth: 17 million shares available in 2022, decreasing to 15 million in 2023; average purchase price decreasing from $305.14 to $277.19. All numeric values match exactly and are correctly attributed to the respective fiscal years. (2) Quantitative accuracy is perfect: numbers for share availability and average purchase prices are correct, and the direction of change (decrease in both share pool and price) is accurately conveyed. Minor note: the LLM references 'end of fiscal 2022 (January 30 2022)' which is inconsistent (January 30, 2022 is the end of fiscal 2021, not 2022); fiscal 2022 ended January 29, 2023, and fiscal 2023 ended January 28, 2024. This is a minor date labeling error but does not affect the correctness of the share or price data tied to each year. (3) The multi-hop reasoning is sound—LLM correctly synthesizes data across two years for both share availability and purchase price, and draws the correct comparison of changes over time. (4) The answer is semantically equivalent to the original, with only slight rewording and added citation markers. It fully addresses both parts of the question: changes in share availability and average purchase price. The minor date discrepancy prevents a perfect 10, but overall the response is factually accurate, complete, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 385,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the pattern of impairment triggers and associated charges across DHR's business segments evolved between the 2022 and 2023 filings, and what does this indicate about shifting risks in its intangible asset portfolio?",
      "original_answer": "In the 2022 filing, DHR reported impairment triggers only in the Diagnostics segment during the first quarter of 2021, resulting in a $10 million impairment charge. In contrast, the 2023 filing identified impairment triggers in multiple segments: the Biotechnology segment in the second quarter of 2023, the Diagnostics and Biotechnology segments in the fourth quarter of 2023, and again in the Diagnostics segment in the first quarter of 2021 (which was included for comparative purposes). The impairment charges increased significantly, from $10 million in 2021 (reported in the 2022 filing) to $77 million in 2023 (reported in the 2023 filing). This indicates a notable expansion in both the scope and magnitude of impairment activity, particularly affecting the Biotechnology segment in 2023, which was not previously a focus of impairment events. This evolution suggests growing risks in DHR’s intangible asset portfolio, especially in its Biotechnology segment.",
      "llm_answer": "In the 2022 filing Danaher only noted impairment triggers in the Diagnostics unit (Q1 2021) and in Diagnostics and Environmental & Applied Solutions (Q1/Q3 2020), which produced modest charges of $10 million in 2021 and $22 million in 2020 and no charge for 2022【page_99】. The 2023 filing adds new triggers in the Biotechnology segment (Q2 2023) and again in Diagnostics (Q4 2023), resulting in a $77 million impairment charge for 2023 (with 2022 still reporting none)【page_89】. This evolution shows risk shifting from earlier, smaller‑scale diagnostics‑related intangibles to larger, technology‑focused intangibles in the Biotechnology business, indicating heightened exposure in that segment’s intangible‑asset portfolio.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. According to the ground truth, the 2022 filing only reported an impairment trigger in the Diagnostics segment in Q1 2021 with a $10 million charge. However, the LLM incorrectly adds impairment triggers in the Environmental & Applied Solutions segment in Q1/Q3 2020 and claims a $22 million charge in 2020, which is not mentioned in the original answer and contradicts the ground truth. The original answer states that the 2022 filing only references the 2021 Diagnostics impairment. (2) The $77 million charge in 2023 is correctly reported, as is the absence of a 2022 charge. However, the inclusion of $22 million in 2020 and references to earlier periods not mentioned in the original answer introduce significant quantitative errors. The LLM also misattributes the timing and scope of triggers—claiming only Diagnostics and Biotechnology in Q4 2023, while the original specifies both Diagnostics and Biotechnology in Q4 2023, Biotechnology in Q2 2023, and reiterates the 2021 Diagnostics trigger for comparison. (3) The multi-hop reasoning is partially sound—the LLM correctly infers increased risk in Biotechnology and a shift from Diagnostics, which aligns with the original conclusion. However, the flawed input data (adding non-existent earlier charges and segments) undermines the reasoning foundation. (4) Contextual relevance is high—the answer addresses the evolution between 2022 and 2023 filings, discusses segment-level changes, and draws a reasonable conclusion about shifting risks. Despite incorrect details, the core narrative of expanding risk to Biotechnology is preserved. However, due to significant factual and quantitative errors, the correctness score is reduced to 6, reflecting partial accuracy with major omissions and inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 496,
        "total_tokens": 1937
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the value of outstanding letters of credit related to trade contracts change between 2022 and 2023, and what does this indicate about the company's involvement in business transactions tied to trade contracts?",
      "original_answer": "The value of outstanding letters of credit related to trade contracts increased from $362 million in 2022 to $598 million in 2023. This significant increase indicates a growing involvement or expansion in business activities tied to trade contracts during this period.",
      "llm_answer": "The company’s outstanding letters of credit grew from $362 million at January 30 2022 (2022 filing) to $598 million at January 28 2024 (2023 filing) – an increase of roughly $236 million. This rise signals that Home Depot’s exposure to, and reliance on, business transactions such as trade contracts has expanded, reflecting greater involvement in and support for larger or more numerous contract‑related activities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the increase in outstanding letters of credit from $362 million in 2022 to $598 million in 2023, matching the ground truth values exactly. The calculation of the increase (~$236 million) is accurate. While the LLM specifies exact dates (January 30, 2022, and January 28, 2024), these align with typical fiscal year-end reporting dates for 2022 and 2023 filings, respectively, and do not contradict the ground truth, which refers to the years 2022 and 2023. 2) All numeric values are correct: $362 million and $598 million are accurately reported, and the difference is correctly computed. Format variations (e.g., using 'million' vs 'M') are acceptable and handled appropriately. 3) The reasoning is sound: the increase is correctly interpreted as indicating greater involvement in trade contract-related transactions. The LLM adds slight elaboration (e.g., 'exposure to, and reliance on') which enhances but does not distort the conclusion. The company (Home Depot, implied by context) is consistent with the knowledge graph source. 4) The answer fully addresses both parts of the question: the quantitative change and its implication. The semantic meaning matches the ground truth, with only minor, acceptable rewording. The qualitative score is 9 due to the slightly more detailed interpretation (e.g., 'reliance on') that, while reasonable, goes slightly beyond the neutral 'growing involvement' in the original. However, this does not reduce accuracy. Contextual relevance is perfect—directly responsive to both sub-questions with appropriate financial and strategic interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1188,
        "completion_tokens": 443,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has the status of the 0.300% Notes due 2028 evolved between the 2023 and 2024 SEC filings, and what does this indicate about IBM's financial instruments disclosures?",
      "original_answer": "In the 2023 filing, the 0.300% Notes due 2028 were disclosed as part of IBM's instruments defining the rights of holders, with specific reference to Exhibit 4.1, filed on February 10, 2020. In the 2024 filing, the 0.300% Notes due 2028 are listed as actively issued financial instruments under the trading symbol IBM28B, registered on the New York Stock Exchange. This indicates a shift from merely disclosing the existence of the instrument in 2023 to formally recognizing it as an actively traded financial instrument in 2024, suggesting increased market engagement or liquidity for this instrument.",
      "llm_answer": "In the 2023 Form 10‑K IBM only referenced the 0.300 % Notes due 2028 as an incorporated exhibit – “the instruments defining the rights of the holders of the 0.300 % Notes due 2028 … are Exhibit 4.1 to Form 8‑K filed February 10 2020.” In the 2024 Form 10‑K the same notes are listed in the Section 12(b) securities‑registration table as “0.300 % Notes due 2028 (IBM28B),” confirming they remain outstanding and are now disclosed as a registered security. This evolution shows IBM’s continued and increasingly explicit disclosure of its debt instruments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2023 reference to Exhibit 4.1 from the February 10, 2020 Form 8-K is accurately cited, and in 2024, the 0.300% Notes due 2028 are correctly identified as listed under Section 12(b) with the trading symbol IBM28B. (2) Quantitative elements—interest rate (0.300%), year (2028), and date (February 10, 2020)—are all precise and match the original answer. Format variations (e.g., spacing in '0.300 %') do not affect meaning. (3) The multi-hop reasoning is sound: the model correctly infers a progression from passive disclosure via incorporation by reference in 2023 to active registration and disclosure in 2024, indicating increased transparency or market engagement. (4) The LLM captures the core implication—more explicit disclosure of debt instruments—but slightly underemphasizes the 'increased market engagement or liquidity' aspect noted in the ground truth. While it mentions registration, it does not explicitly connect this to NYSE listing or trading activity, which is a minor omission. Overall, the answer is factually complete, contextually appropriate, and semantically equivalent to the original, warranting a high score with only a small deduction for incomplete qualitative nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 363,
        "total_tokens": 1657
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has IBM's treatment of the 1.750% Notes due 2031 evolved between 2023 and 2024, particularly in terms of disclosure and registration on stock exchanges?",
      "original_answer": "In 2023, IBM disclosed the 1.750% Notes due 2031 in its 10-K filing, indicating that the instrument defining the rights of the holders was incorporated by reference as part of an exhibit filed on January 30, 2019. By 2024, the 1.750% Notes due 2031 were not only still referenced but also explicitly registered under a trading symbol (IBM31) on the New York Stock Exchange, reflecting a shift from mere disclosure to formal recognition and active listing on a financial market platform.",
      "llm_answer": "In the 2023 Form 10‑K, IBM only referenced the 1.750 % Notes due 2031 by incorporating the related 8‑K exhibit (filed January 30 2019) into the filing, without listing the notes in its Section 12(b) securities‑registration table. By the 2024 Form 10‑K, IBM explicitly includes the 1.750 % Notes due 2031 (ticker IBM31) in the “Securities registered pursuant to Section 12(b)” table, showing that the notes are now disclosed as a NYSE‑registered security. This reflects a shift from a purely incorporated‑by‑reference disclosure to an active registration and listing on the exchange.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately conveyed: in 2023, the 1.750% Notes due 2031 were disclosed via incorporation by reference to an exhibit filed on January 30, 2019, and not listed in the Section 12(b) registration table; by 2024, they were explicitly included in the 'Securities registered pursuant to Section 12(b)' table with ticker IBM31 on the NYSE. (2) Quantitative elements—interest rate (1.750%), maturity year (2031), exhibit filing date (January 30, 2019), and ticker symbol (IBM31)—are all correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes in disclosure and registration status across two years, identifying the shift from passive reference to active exchange listing. (4) The answer addresses both parts of the question—evolution in disclosure and registration—and uses precise regulatory terminology (e.g., Section 12(b), Form 8-K, Form 10-K), demonstrating high contextual and qualitative accuracy. Minor wording differences (e.g., 'incorporated by reference' vs. 'incorporating...into the filing') do not affect factual equivalence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 328,
        "total_tokens": 1597
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Eli Lilly's financial relationship with Zyprexa evolve between 2023 and 2024, particularly in terms of revenue recognition and business model approach?",
      "original_answer": "In 2023, Eli Lilly generated $1.45 billion from the sale of the rights for the olanzapine portfolio, including Zyprexa, outside the U.S., indicating a direct revenue stream from product sales. By 2024, the company no longer reported Zyprexa as part of product sales; instead, revenue from the 2023 sale of rights was included in collaboration and other arrangements revenue, signaling a shift from direct product sales to revenue recognition through licensing and collaboration agreements. This change reflects a transformation in the financial relationship from active product sales to post-sale royalty or profit-sharing arrangements.",
      "llm_answer": "In 2023 Eli Lilly booked Zyprexa as product revenue – the $1.45 billion sale of the olanzapine‑portfolio rights (including Zyprexa) was reflected in net product revenue, lifting Zyprexa’s total sales to roughly $1.7 billion. By the 2024 filing that same rights‑sale is shown under “collaboration and other revenue,” meaning Lilly now treats Zyprexa as a licensing/collaboration arrangement rather than a direct product sale, shifting the revenue‑recognition approach and business model toward partnership‑based income.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the $1.45 billion figure from the 2023 sale of olanzapine rights (including Zyprexa) is correctly stated, and the shift in revenue classification from product revenue in 2023 to 'collaboration and other revenue' in 2024 is accurately reflected. The mention of Zyprexa’s total sales reaching ~$1.7 billion is a minor addition not in the original answer but plausible as an inference (combining product sales and the rights sale), though this specific total is not confirmed in the ground truth—this prevents a perfect 10. (2) The entity identification—Eli Lilly, Zyprexa, olanzapine portfolio, correct years (2023, 2024), and financial categories (product revenue vs. collaboration revenue)—is fully accurate. (3) The multi-hop reasoning is sound: the model correctly infers a shift in business model from direct sales to licensing/collaboration-based revenue based on the change in reporting category, which is the core insight of the original answer. (4) Semantically, the LLM conveys the same transformation in financial relationship—revenue recognition shift due to a change in business model—using slightly different but equivalent phrasing (e.g., 'partnership-based income' ≈ 'post-sale royalty or profit-sharing'). The answer is fully contextually relevant, addressing both revenue recognition and business model evolution. Minor deduction in quantitative accuracy due to the unverified $1.7 billion total, which may be reasonable but isn't in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 427,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the treatment and financial impact of the Mobility Preferred Interests evolve from 2023 to 2024, particularly in terms of redemption obligations and their effect on earnings per share calculations?",
      "original_answer": "In 2023, AT&T reclassified the Mobility Preferred Interests from equity to a liability due to the certainty of redemption, recording $2,670 in current liabilities and $2,670 in noncurrent liabilities. The company ultimately repurchased all remaining interests in April 2023 for $5,414, including accrued distributions. By 2024, the Mobility Preferred Interests were fully retired, and the focus shifted to their impact on earnings per share calculations, where under ASU 2020-06, the ability to settle these interests in stock was reflected in the diluted earnings per share computation for periods prior to the repurchase. This indicates a shift from active financial obligations to retrospective accounting treatment.",
      "llm_answer": "In 2023 AT&T recorded the Mobility Preferred Interests as a redemption liability (about $2.7 bn in current liabilities and a similar amount in non‑current liabilities) and then eliminated the instrument by repurchasing the 213 million interests in April 2023 for roughly $5.4 bn, leaving no outstanding Mobility preferred interests at year‑end 2023 【page_90】. As a result, the 2024 earnings‑per‑share reconciliation no longer includes Mobility Preferred Interests as dilutive potential common shares (the diluted‑EPS denominator shows zero Mobility shares, whereas 2023 included 71‑72 shares), so the redemption and repurchase have removed any EPS impact that previously required a dilutive adjustment 【page_53】.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key events in 2023 — reclassification of Mobility Preferred Interests as a liability and full repurchase in April 2023, with no outstanding interests by year-end. It accurately notes the removal of these interests from diluted EPS calculations in 2024. However, it diverges from the ground truth in the quantitative details: the original answer specifies exact liabilities of $2,670 million (split equally between current and noncurrent), while the LLM rounds to ~$2.7 billion, which is acceptable, but the repurchase amount is stated as $5,414 million in the truth, whereas the LLM says ~$5.4 billion — again, close but slightly imprecise. More significantly, the LLM introduces '213 million interests' and '71-72 shares' in diluted EPS, which are not present in the original answer and may conflate units or misrepresent the data. (2) The numbers are directionally accurate but lack precision; $2,670M is exactly $5,340M total liabilities, not $5.4B repurchased — the repurchase amount includes accrued distributions, so the $5,414 figure is correct and not simply the sum of liabilities. The LLM does not explain this nuance. (3) The reasoning correctly traces the evolution from liability classification to repurchase and then to EPS impact, but misrepresents the 2024 EPS treatment: the ground truth states that ASU 2020-06 affected *prior period* diluted EPS computations due to settlement ability in stock, whereas the LLM implies the 2024 EPS reconciliation reflects zero dilution going forward — which may be true, but misses the retrospective accounting nuance. (4) The answer is contextually strong and addresses both redemption obligations and EPS impact, but omits the key accounting standard (ASU 2020-06) and mischaracterizes the nature of the EPS adjustment as purely prospective. Thus, while factually close, it lacks full qualitative and quantitative fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 522,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has IBM's treatment and disclosure of the 0.875% Notes due 2030 evolved between 2023 and 2024, particularly in terms of its listing and registration status?",
      "original_answer": "In 2023, the 0.875% Notes due 2030 were disclosed as part of a list of instruments incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 8, 2022. By 2024, the 0.875% Notes due 2030 were explicitly listed in the table of registered securities with a trading symbol (IBM30A) and registered on the New York Stock Exchange. This indicates a shift from a referenced disclosure to a fully listed and registered financial instrument.",
      "llm_answer": "In IBM’s 2023 Form 10‑K the 0.875 % Notes due 2030 were disclosed only by reference to the instrument that defines the holders’ rights (Exhibit 4.1‑4.5 to a Form 8‑K filed Feb 8 2022) and were not shown in the Section 12(b) securities table, implying they were not separately listed or registered as a public security【page_20】. By the 2024 Form 10‑K, the same notes appear in the “Securities registered pursuant to Section 12(b)” table with ticker IBM30A and listed on the New York Stock Exchange, indicating that IBM now treats them as a listed, registered security【page_1】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately conveyed: in 2023, the 0.875% Notes due 2030 were disclosed by reference to Exhibit 4.1–4.5 of the February 8, 2022 Form 8-K and were not listed in the Section 12(b) table, indicating they were not separately registered or listed. By 2024, they appear in the 'Securities registered pursuant to Section 12(b)' table with ticker IBM30A and are listed on the New York Stock Exchange. (2) Quantitative elements—interest rate (0.875%), maturity year (2030), filing date (February 8, 2022)—are all correct. The ticker symbol IBM30A is accurately reported. (3) The multi-hop reasoning is sound: the model correctly infers a change in disclosure and registration status between 2023 and 2024 by comparing the treatment of the notes across two Form 10-K filings, synthesizing information about listing, registration, and disclosure mechanisms. (4) The answer is contextually precise, directly addressing the evolution in treatment and disclosure, and correctly interpreting the implications of inclusion in the Section 12(b) table. Minor wording differences (e.g., 'incorporated by reference' vs. 'disclosed by reference') do not affect factual accuracy. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 367,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the structure and distribution terms of the Telco Preferred Interests evolve from 2023 to 2024, and what does this indicate about AT&T's approach to financing through preferred equity instruments?",
      "original_answer": "In 2023, the Telco Preferred Interests consisted of $2,000 of Class A-1 preferred interests issued in September 2020, paying a 4.25% annual distribution, and $5,250 of Class A-2 and A-3 preferred interests issued in April 2023, paying a 6.85% annual distribution. By 2024, the total Telco Preferred Interests had grown to $7,250, with the Class A-1 preferred interests still at 4.25% and the Class A-2 and A-3 interests remaining at 6.85%, both subject to reset every seven years. Additionally, in 2024, AT&T clarified that failure to pay distributions would not restrict cash movements or its ability to pay dividends or repurchase shares. The structure remained consistent in terms of redemption rights and noncontrolling interest classification, but the expansion of the instrument in 2024 suggests a continued reliance on preferred equity as a financing strategy.",
      "llm_answer": "In 2023 AT&T’s Telco LLC held $7.25 billion of non‑convertible cumulative preferred interests split into two existing series – Class A‑1 (4.25% initial preferred distribution, reset every seven years) and Class A‑2/A‑3 (6.85% initial preferred distribution, reset on Nov 1 2027 and every seven years thereafter)【page_90】【page_87】. By 2024 the same structure and terms remained, but the company entered an agreement to issue a new $2.25 billion Class A‑4 tranche that will pay 5.94% initially and reset on Nov 1 2028 and every four years thereafter【page_88】, indicating AT&T is deliberately expanding its preferred‑equity financing platform with staggered rates and reset schedules to raise cash while preserving flexibility and limiting impact on other cash‑flow commitments.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023, the Telco Preferred Interests consisted of $2,000 (not $7.25 billion) of Class A-1 and $5,250 of Class A-2/A-3, totaling $7,250 by 2024. The LLM incorrectly states that the $7.25 billion amount was already present in 2023, conflating the 2024 total with the 2023 composition. Additionally, the LLM introduces a new $2.25 billion Class A-4 tranche issued in 2024 with a 5.94% rate, which is not mentioned in the original answer — the ground truth states that the structure remained unchanged in 2024 with only the existing classes continuing and no new issuance. The reset periods are also misrepresented: the original answer specifies resets every seven years for both classes, while the LLM claims a four-year reset for Class A-4, which is unsupported. (2) Quantitative accuracy is low: the dollar amounts are misrepresented in timing (aggregating 2024 total in 2023), and the $2.25 billion Class A-4 tranche is fabricated. The 5.94% rate and Nov 1, 2027/2028 reset dates are not in the ground truth. (3) The multi-hop reasoning is partially sound — the LLM correctly infers strategic use of preferred equity for financing — but this conclusion is based on incorrect data. The synthesis fails because it relies on non-existent instruments. (4) Contextual relevance is high as the response addresses structure, distribution terms, and strategic implications, but factual correctness undermines the analysis. The core evolution described — expansion via new tranches — is incorrect, leading to a low correctness score despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 452,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has Capital One's involvement in multifamily commercial real estate loans evolved between 2022 and 2023, particularly in terms of risk exposure under loss sharing agreements with government-sponsored enterprises?",
      "original_answer": "In 2022, Capital One originated multifamily commercial real estate loans with the intent to sell them to GSEs, entering into loss sharing agreements, which resulted in a liability of $82 million. By 2023, the company continued this practice but the liability recognized on the consolidated balance sheets for these loss sharing agreements increased to $137 million, indicating a significant increase in risk exposure. This evolution reflects a growing involvement in these types of loans and a corresponding rise in the financial obligations tied to their loss sharing agreements.",
      "llm_answer": "In 2022 Capital One already originated and serviced multifamily commercial‑real‑estate loans that it sold to the government‑sponsored enterprises, but the loss‑sharing liability on its balance sheet for those agreements was only **$82 million**【page_98】. By year‑end 2023 the same business continued, yet the liability recorded for loss‑sharing agreements had risen to **$137 million**【page_217】—an increase of about $55 million, reflecting a materially higher risk exposure under the GSE loss‑sharing arrangements.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: Capital One's involvement in multifamily commercial real estate loans sold to GSEs with loss sharing agreements is correctly described for both 2022 and 2023. (2) Quantitative accuracy is perfect: the liability amounts of $82 million in 2022 and $137 million in 2023 are correctly cited, and the implied $55 million increase is accurate (137 - 82 = 55). Minor wording differences (e.g., 'increase of about $55 million' vs. 'increased to $137 million') do not affect factual correctness. (3) Multi-hop reasoning is sound—the model correctly synthesizes information across years and connects the rising liability to increased risk exposure, which reflects the intended inference from the data. (4) Entities (Capital One, GSEs, loss sharing agreements, multifamily commercial real estate loans) and time periods (2022, 2023) are correctly identified and contextualized. The answer addresses all parts of the question: evolution over time, risk exposure, and financial obligations under loss sharing agreements. No factual errors, omissions, or misinterpretations are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 336,
        "total_tokens": 1627
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did Amazon's co-branded credit card programs shift in strategic significance and associated regulatory risks from 2022 to 2023, particularly in terms of new compliance obligations and their potential impact on operating results?",
      "original_answer": "In 2022, Amazon introduced co-branded credit card programs as part of its payment offerings, highlighting the risk that renewal on less favorable terms or termination could adversely affect operating results. The regulatory risks at that time included compliance with payment card association rules such as data security and certification requirements. By 2023, Amazon expanded its offerings and emphasized additional compliance obligations, including data localization rules, which were not mentioned in 2022. This indicates that the co-branded credit card programs became subject to a broader set of regulatory risks, particularly in international jurisdictions, which could increase compliance costs and operational complexity. The potential impact on operating results grew as Amazon now faced risks not only from traditional payment regulations but also from evolving data governance laws, particularly regarding cross-border data transfers tied to these credit card programs.",
      "llm_answer": "In the 2022 Form 10‑K Amazon treated its co‑branded credit‑card programs mainly as a payment‑offering risk – noting they could hurt operating results if the agreements were renewed on less‑favorable terms or terminated (2022 p. 13‑14). The 2023 filing still flags that same risk but adds that the programs are now subject to “additional regulations and compliance requirements (including obligations to implement enhanced‑authentication processes)” and other licensing‑ and capital‑maintenance rules, meaning new compliance obligations that could raise costs, fines or even force termination and therefore have a larger‑than‑before impact on operating results (2023 p. 13‑14). This reflects a shift toward greater strategic and regulatory significance for the co‑branded credit‑card programs.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of factual content, context, and reasoning. (1) It accurately identifies that in 2022, Amazon highlighted the risk of renewal on less favorable terms or termination of co-branded credit card programs affecting operating results, citing the correct risk factor from the 2022 10-K. In 2023, it correctly notes the expansion of compliance obligations, including enhanced authentication, licensing, and capital maintenance rules—new regulatory requirements not emphasized in 2022. (2) There are no numeric values, dates, or financial figures in the question or answer that require verification; all references to years (2022, 2023) and page numbers (p. 13–14) are consistent and plausible, though page numbers are not part of the ground truth and do not affect accuracy. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes in regulatory risk posture between two years and infers increased strategic and regulatory significance. However, the LLM answer omits the specific mention of 'data localization rules' and 'cross-border data transfers', which are key additions in 2023 per the original answer and represent a critical dimension of the evolving regulatory landscape, especially internationally. This is a meaningful omission in completeness, though the general direction of increased compliance burden is correctly captured. (4) Despite this omission, the answer remains contextually relevant and factually accurate in its core claims, earning high marks for qualitative and contextual performance. The correctness score is 8 due to the missing specificity around data governance and international regulations, which are central to the shift described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1464,
        "completion_tokens": 481,
        "total_tokens": 1946
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has PM's financial relationship with RBH evolved between 2022 and 2024, particularly regarding the consolidation status and valuation considerations of RBH within PM's financial statements?",
      "original_answer": "In 2022, RBH was deconsolidated from PM's financial statements due to CCAA proceedings initiated in 2019, with its financial results excluded since that time. Additionally, PM faced potential material impacts from unresolved Canadian tobacco litigation, including a CAD 3.1 billion allocation of compensatory damages against RBH. By 2024, PM's relationship with RBH had evolved into holding an equity investment, which required impairment analysis. The audit process emphasized significant judgment around the fair value estimate of the investment, including assumptions on discount rates, sales volumes, operating margins, and the tax treatment of a potential global settlement. This reflects a shift from a deconsolidated subsidiary to a valued equity stake requiring ongoing impairment evaluation.",
      "llm_answer": "In the 2022 Form 10‑K, PMI disclosed that Rothmans, Benson & Hedges (RBH) had been **deconsolidated** from its consolidated financial statements since the March 22 2019 CCAA filing and that the remaining stake was carried as an equity security “without readily determinable fair value,” with no impairment recognized (see Note 20 on deconsolidation). By the 2024 Form 10‑K, the deconsolidation remained, but PMI **valued** the RBH equity investment, concluded it was impaired, recorded a **$2.3 billion non‑cash impairment** and reported a **fair‑value estimate of $714 million** based on a discounted‑cash‑flow analysis and the expected allocation of the global settlement (see Note 6/Impairment of RBH equity investment).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the $2.3 billion non-cash impairment and $714 million fair value estimate in 2024 are accurately reported, and the deconsolidation date (March 22, 2019) is precise. These figures match the expected disclosures in PM's 10-K filings. (2) The answer correctly identifies the evolution from deconsolidation in 2019 (with effects continuing into 2022) to a valued equity investment requiring impairment in 2024. The mention of the discounted cash flow analysis and global settlement expectations aligns with the valuation considerations in the ground truth. (3) The multi-hop reasoning is sound: it connects the 2019 CCAA filing to the 2022 reporting status and then to the 2024 impairment decision, showing a clear evolution. (4) The only minor omission is that the original answer references the CAD 3.1 billion litigation exposure as a material consideration for PM, which the LLM answer does not explicitly mention. While the focus on the $2.3B impairment is correct, the absence of context around Canadian tobacco litigation slightly reduces qualitative completeness. However, the core financial evolution—deconsolidation to equity investment with impairment and fair value measurement—is fully and correctly conveyed. Wording differs but semantic meaning is equivalent. Contextual relevance is perfect, directly addressing consolidation status and valuation considerations across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 413,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the financial performance and strategic positioning of Baqsimi evolve between 2023 and 2024, particularly in terms of revenue contribution and its role within LLY's product portfolio?",
      "original_answer": "In 2023, Baqsimi contributed $677.6 million in total revenue, with $645.7 million from the U.S. and $31.9 million from outside the U.S., indicating it was still a growing product within LLY's portfolio. By 2024, Baqsimi was no longer reported as a direct revenue contributor through product sales; instead, it was disclosed as part of a collaboration and other arrangements, specifically under the 2023 sale of rights. This shift suggests that LLY transitioned Baqsimi from an internally commercialized product to a divested asset, impacting its strategic focus and revenue model. The absence of Baqsimi from direct product revenue in 2024 reflects a significant change in its role and contribution to LLY's financials.",
      "llm_answer": "In 2023 Baqsimi generated $677.6 million of total revenue ( $645.7 m U.S. + $31.9 m outside U.S.) — about 2 % of Lilly’s $34.1 billion consolidated revenue — and this figure was heavily bolstered by a one‑time $579 million sale of the product’s rights (see page 47 & page 48). By 2024 the rights‑sale cash inflow had disappeared; Baqsimi now appears only in the “collaboration and other” line (which fell to $4.29 billion from $5.31 billion, the 2023 amount that included the Baqsimi rights sale) and its product‑sale contribution is a modest, non‑core part of the portfolio as Lilly’s growth is now driven by higher‑growth brands such as Mounjaro, Verzenio and Jardiance.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding the $579 million one-time sale of rights, which is not supported by the ground truth. The original answer states that Baqsimi was sold in a 2023 transaction, but does not mention a $579M figure or attribute most of the $677.6M revenue to a rights sale. Instead, the $677.6M is presented as total revenue from product sales (U.S. and non-U.S.), not a one-time cash inflow from divestiture. This misrepresents the nature and timing of the revenue. Additionally, the LLM claims Baqsimi's contribution was about 2% of Lilly’s $34.1B consolidated revenue — while the math ($677.6M / $34.1B ≈ 1.99%) is correct — this contextual percentage is not in the ground truth and distracts from the core issue: the shift from product revenue to collaboration income. The 2024 'collaboration and other' decline from $5.31B to $4.29B and attribution to Baqsimi’s absence is speculative and unsupported in the provided truth. (2) Number verification: $677.6M total revenue, split into $645.7M U.S. and $31.9M non-U.S., is correctly reported. However, the $579M rights sale figure is fabricated. The $34.1B total revenue, while plausible, is not confirmed in the ground truth. The 'collaboration and other' figures ($5.31B and $4.29B) are not in the original answer and appear to be hallucinated. (3) Multi-hop reasoning is partially sound — the model correctly infers that Baqsimi moved from product revenue to 'collaboration and other' arrangements — but it overreaches by quantifying the impact and attributing changes in that line item solely to Baqsimi. The core insight about strategic repositioning is aligned, but the reasoning is undermined by incorrect financial causality. (4) Correctness score is low due to major quantitative errors and unsupported claims, despite capturing the directional shift in strategic role. Quantitative accuracy is poor due to hallucinated figures. Qualitative accuracy is moderate because the conceptual shift is recognized. Contextual relevance is high as the response addresses revenue contribution and strategic role within LLY’s portfolio.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 578,
        "total_tokens": 1937
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has the composition of Union Pacific's Total Highway Revenue Equipment changed from 2022 to 2024, particularly in terms of the ratio of owned versus leased containers and chassis?",
      "original_answer": "In 2022, Union Pacific owned 78,837 units and leased 16,004 units of Total Highway Revenue Equipment, with containers making up the majority of owned assets and chassis being heavily leased. By 2024, the company significantly reduced both owned and leased equipment, with owned units dropping to 50,731 and leased units to 1,485. The most notable change was in leased containers, which fell from 1,856 in 2022 to just 288 in 2024, and owned chassis decreased from 29,875 to 4,356. This indicates a strategic shift toward owning fewer assets and leasing even fewer, especially in chassis.",
      "llm_answer": "In the 2022 filing Union Pacific listed 48,962 owned containers and 1,856 leased containers (≈96 % owned) and 29,875 owned chassis with 14,148 leased chassis (≈68 % owned)【page_24】. By 2024 the fleet had shrunk to 46,375 owned containers and only 288 leased containers (≈99 % owned) and 4,356 owned chassis with 1,197 leased chassis (≈79 % owned)【page_19】, pushing the owned‑to‑leased ratio for containers from roughly 26 : 1 to about 161 : 1 and for chassis from about 2 : 1 to roughly 3.6 : 1.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the overall trend correctly—Union Pacific reduced both owned and leased equipment from 2022 to 2024, with a significant drop in leased containers and chassis. However, there are key quantitative inaccuracies. According to the ground truth, in 2022, Union Pacific had 78,837 total owned units and 16,004 leased units of Total Highway Revenue Equipment. The LLM breaks this down into 48,962 owned containers and 29,875 owned chassis, which sums to 78,837—correct. Similarly, leased containers (1,856) and leased chassis (14,148) sum to 15,994, close to the 16,004 in the ground truth (minor discrepancy possibly due to rounding or unmentioned categories). In 2024, the ground truth states 50,731 owned and 1,485 leased units. The LLM reports 46,375 owned containers + 4,356 owned chassis = 50,731—correct. But for leased, it reports 288 leased containers + 1,197 leased chassis = 1,485—also correct. So component totals are accurate, but the LLM misattributes the leased chassis number: ground truth says leased chassis dropped to 4,356? No—wait, correction: ground truth says 'owned chassis decreased from 29,875 to 4,356', and 'leased units to 1,485' overall. The LLM assigns 1,197 leased chassis in 2024, but the ground truth does not specify leased chassis separately—only that total leased units dropped to 1,485 and leased containers fell to 288. So if leased containers are 288, then leased chassis must be 1,485 - 288 = 1,197—so the LLM’s number is logically inferred and consistent. Thus, the LLM’s numbers are actually quantitatively accurate within the constraints. (2) The calculation of ratios is correct: 48,962 / 1,856 ≈ 26:1 in 2022, 46,375 / 288 ≈ 161:1 in 2024; chassis from 29,875 / 14,148 ≈ 2.1:1 to 4,356 / 1,197 ≈ 3.6:1. The LLM rounds to 2:1 and 3.6:1—reasonable. (3) Multi-hop reasoning is sound: the model synthesizes data across years and equipment types, correctly identifying shifts in ownership ratios. (4) The main issue is that the original answer emphasizes a 'strategic shift toward owning fewer assets and leasing even fewer, especially in chassis', which the LLM supports but does not explicitly conclude. However, the data trends are accurately presented. The LLM does not mention the total fleet reduction as clearly as the ground truth, but the numbers imply it. Therefore, while the LLM answer is factually consistent with the ground truth and calculations are correct, it presents a slightly narrower view focused on ratios rather than absolute reductions. Hence, correctness score is 7 due to minor incompleteness in narrative emphasis, but quantitative accuracy is higher than initially thought—adjusted to 8, and qualitative accuracy to 8. Final scores reflect high accuracy but slight lack of holistic synthesis compared to ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 743,
        "total_tokens": 2023
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role within the company's overall funding structure?",
      "original_answer": "In 2022, securitized debt obligations were explicitly described as one of the company's key funding sources alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. By 2023, while still present in the funding structure at $18.043 billion in carrying value, securitized debt obligations were categorized under Level 2 in the fair value hierarchy, indicating a shift toward more standardized valuation methods. This evolution suggests a more structured and possibly less volatile role for securitized debt obligations in Capital One's funding strategy.",
      "llm_answer": "Capital One’s securitized‑debt program expanded modestly.  The balance of securitized debt obligations rose from **$16.97 billion** at 12/31/2022 to **$18.04 billion** at 12/31/2023 – an increase of roughly $1.1 billion (about 6 %)【page_211】【page_210】.  Although still a small slice of the firm’s funding mix—well below deposits (which grew from $45.9 billion to $83.0 billion) and senior/subordinated notes—the higher balance indicates securitized debt is a growing, though still secondary, source of capital for the company【page_211】【page_210】.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM answer correctly identifies the increase in securitized debt obligations from $16.97 billion in 2022 to $18.04 billion in 2023, which aligns with the ground truth carrying value of $18.043 billion in 2023. The calculation of a ~6% increase is approximately correct (actual: (18.04 - 16.97)/16.97 ≈ 6.3%). However, the original answer does not mention the 2022 figure of $16.97 billion—this number is accurate but not present in the ground truth, suggesting the LLM pulled it from the source but introduced a detail not emphasized in the synthesized truth. 2) Quantitatively, the numbers are accurate within rounding and formatting expectations. The LLM cites specific pages and reports a correct trend. 3) Qualitatively, the reasoning diverges significantly: the original answer emphasizes a *qualitative shift* in the role of securitized debt—its reclassification under Level 2 in the fair value hierarchy—indicating a more standardized and structured use. This key evolution in valuation methodology and strategic role is entirely missing from the LLM response. Instead, the LLM focuses on balance growth and positions it as a 'growing' source of capital, which is a different interpretation than the ground truth’s emphasis on structural and methodological maturation. 4) Contextually, the answer is relevant and addresses the evolution in funding structure, but fails the multi-hop synthesis by not incorporating the fair value hierarchy shift, which is central to the original answer. The LLM captures the quantitative trend but misses the conceptual evolution, leading to a partially correct, incompletely reasoned response. Thus, while numbers are sound, the deeper analytical insight is absent, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 474,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did the nature of LLY's revenue from Zyprexa evolve between 2023 and 2024, particularly in terms of the source and recognition method of that revenue?",
      "original_answer": "In 2023, Zyprexa revenue was primarily derived from the sale of the rights for the olanzapine portfolio. By 2024, the revenue associated with Zyprexa was recognized as part of collaboration and other arrangements, specifically stemming from the 2023 sale of rights for the olanzapine portfolio, and was included in collaboration revenue rather than product sales. This reflects a shift in how Zyprexa-related revenue was categorized and recognized in 2024 compared to 2023.",
      "llm_answer": "In the 2023 filing Zyprexa appears in the product‑revenue schedule and is footnoted as “sale of the rights for the olanzapine portfolio” — i.e., a one‑time product‑sale line item (see page 67). In the 2024 filing that same transaction is no longer shown as product revenue; it is bundled into “collaboration and other revenue” and is accounted for as a net gain/loss on the sale of rights, recognized when control of the asset transfers to the buyer (see pages 64 and 66). Thus the source shifted from product‑sale revenue to a one‑off rights‑sale under collaboration revenue, and the recognition moved from product‑sale timing to the point‑of‑transfer accounting for the rights sale.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2023, Zyprexa revenue was reported as part of product revenue due to the sale of rights for the olanzapine portfolio, and in 2024, it shifted to being included in 'collaboration and other revenue'. This matches the original answer's core claim about a categorization and recognition shift. (2) There are no numeric values (e.g., dollar amounts) in either answer, so quantitative accuracy is not compromised; dates (2023 and 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly infers the change in accounting treatment, and references appropriate accounting logic (transfer of control). It also cites specific pages, indicating precise sourcing. (4) The only minor shortcoming is that the LLM slightly reframes the revenue as a 'net gain/loss on the sale of rights', which is not explicitly stated in the ground truth—though this is a reasonable inference. The original answer emphasizes the reclassification into collaboration revenue without specifying gain/loss accounting. This nuance prevents a perfect 10, but the overall meaning and facts are semantically equivalent. Wording differences are acceptable under semantic equivalence, and all key entities (LLY, Zyprexa, olanzapine portfolio, 2023, 2024, collaboration revenue) are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 394,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the valuation methodology and classification of Federal Government Securities in the pension plan evolved from 2022 to 2024?",
      "original_answer": "In 2022, Federal Government Securities were valued under the 'Significant Other Observable Inputs (Level 2)' category and totaled $742 million. By 2024, the company clarified that these securities are valued using a bid evaluation process with bid data from independent pricing sources and are explicitly classified as Level 2 investments. This reflects a continuation in classification but adds specificity in methodology explanation.",
      "llm_answer": "Both the 2022 and 2024 filings state that Federal Government Securities are valued using a **bid‑evaluation process with bid data from independent pricing sources**, and they are **classified as Level 2** assets in the fair‑value hierarchy. The description of the methodology (page 70 of the 2022 filing and page 56 of the 2024 filing) and the classification (Level 2 shown on the asset tables on pages 72 and 57) are unchanged; only the dollar amount of the holdings increased.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that the 2022 filing described the valuation methodology as a 'bid-evaluation process with bid data from independent pricing sources.' However, according to the ground truth, in 2022 the securities were classified as Level 2 but without this specific methodological detail—only in 2024 was the bid-evaluation process explicitly clarified. This is a significant factual inaccuracy. Additionally, the LLM claims the methodology description is present on page 70 of the 2022 filing, which contradicts the ground truth and cannot be verified here but represents overconfidence in unconfirmed details. (2) Quantitatively, the LLM omits the $742 million figure from 2022, which is a key data point in the original answer. While it mentions that 'the dollar amount of the holdings increased,' it provides no actual numbers for either year, making it incomplete and less precise. The absence of any dollar amounts reduces quantitative accuracy despite no incorrect numbers being stated. (3) The multi-hop reasoning is flawed: the question asks how the methodology and classification evolved, implying a comparison over time. The ground truth notes continuity in classification (Level 2) but an enhancement in methodological transparency in 2024. The LLM incorrectly asserts no change in description or classification, missing the nuance that while classification remained the same, the methodology explanation became more specific in 2024. This reflects a failure in synthesizing the evolution accurately. (4) Contextual relevance is high because the answer addresses valuation methodology and classification over time and stays focused on the pension plan and Federal Government Securities. However, due to major factual inaccuracies about the presence of the bid-evaluation process in 2022 and omission of key financial data, the correctness and qualitative accuracy scores are low. Minor formatting variations are acceptable, but core factual misrepresentation undermines trust in the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 548,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did Capital One's credit score data utilization for product segmentation decisions evolve from 2022 to 2023, and what does this indicate about their credit risk modeling strategy?",
      "original_answer": "In 2022, Capital One used credit score data for product segmentation decisions based on historical credit score distributions from 2020 to 2021, as shown in Table 21. In 2023, the company updated its data to reflect credit score distributions from 2022 to 2023 in the same table. This shift indicates a more current and dynamic credit risk modeling strategy, with product segmentation decisions being informed by the most recent borrower behavior and risk profiles, suggesting a proactive approach to managing credit risk in evolving economic conditions.",
      "llm_answer": "Capital One’s 2022 filing already said that borrower credit‑score information is “used … in some cases to drive product‑segmentation decisions” (2022 10‑K, p. 103) and the 2023 filing repeats the same language (2023 10‑K, p. 95).  Between the two years the score mix shifted modestly – the share of domestic credit‑card balances with scores ≤ 660 rose from 31 % in 2022 to 32 % in 2023 (and the >660 segment fell from 69 % to 68 %) (Table 21, p. 95) – suggesting that Capital One’s credit‑risk models are increasingly leveraging score data to fine‑tune product segmentation and manage risk across a slightly broader credit‑quality spectrum.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Capital One used credit score data for product segmentation in both 2022 and 2023, and it accurately cites the consistent language in the 10-K filings. It also correctly references Table 21 and reports the shift in credit score distribution: the share of domestic credit-card balances with scores ≤660 increased from 31% in 2022 to 32% in 2023, and the >660 segment decreased from 69% to 68%. These percentages are quantitatively accurate and align with plausible data. However, the ground truth emphasizes a key evolution in the *data vintage* used — from 2020–2021 data in 2022 to 2022–2023 data in 2023 — which the LLM answer completely misses. This is a critical omission because the core of the question is about how the *utilization* of credit score data evolved, not just that it was used. (2) The numbers cited (31% to 32%, 69% to 68%) are correct and consistent with the direction of change, though the LLM does not clarify that these reflect the underlying distribution updates driving segmentation — instead implying the shift in balances is the basis for fine-tuning. There are no calculation errors, but the interpretation of what changed is misaligned. (3) The multi-hop reasoning is partially sound: the model connects disclosures across two years and references a table showing score distributions. However, it fails to synthesize the key point that the *input data for segmentation models was updated to more recent periods*, which is the actual evolution in strategy. Instead, it focuses on balance shifts as evidence of model refinement, which is not supported in the ground truth. (4) The contextual relevance is high because the answer addresses product segmentation and credit risk modeling, but the qualitative accuracy is medium-low due to the mischaracterization of the strategic evolution. The correctness score is 5 because while some facts and numbers are right, the central insight about data recency and dynamic modeling is missing, leading to an incomplete and somewhat misleading conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 558,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Amazon's strategic positioning of AWS evolved from 2022 to 2023 in terms of its role within the company's broader business segments and investment priorities?",
      "original_answer": "In 2022, AWS was positioned primarily as a key area of investment within Amazon's broader technology and content spending, with an emphasis on supporting geographic expansion, new product categories, and internal operational efficiencies. The document highlighted that Amazon was investing in AWS alongside initiatives to build and deploy innovative software and electronic devices, indicating a strategic alignment with internal growth and infrastructure enhancement. By 2023, AWS had evolved into one of Amazon's three core business segments—alongside North America and International—reflecting its elevated strategic importance. The 2023 filing explicitly states that AWS serves developers and enterprises by offering a broad set of on-demand technology services, including compute, storage, database, analytics, and machine learning, and is now a distinct and central pillar of Amazon’s business model. This shift demonstrates a transformation in AWS's role from a strategic investment area to a standalone, mission-critical business segment.",
      "llm_answer": "In the 2022 filing Amazon framed AWS mainly as a **technology‑and‑content investment priority**, noting that “we are investing in AWS… to take advantage of advances in technology” and that the bulk of its capital‑expenditure growth was “in technology infrastructure (the majority of which is to support AWS)”【page_19】【page_21】. By the 2023 filing, AWS had been elevated to a **core operating segment** alongside North America and International, with its own CEO and a clear market‑facing role “serving developers and enterprises… through AWS, which offers a broad set of on‑demand technology services”【page_3】【page_5】. This shift signals that AWS moved from being a major infrastructure investment focus to a distinct, strategically central business unit that drives Amazon’s overall growth agenda.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate, complete, and semantically equivalent to the ground truth. (1) It correctly identifies AWS's strategic positioning in 2022 as a key investment area within technology and content spending, citing infrastructure investment and capital expenditure growth tied to AWS, which aligns with the original answer. In 2023, it accurately notes AWS's elevation to a core operating segment alongside North America and International, reflecting its strategic centrality. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not applicable in that sense, but all qualitative data points (years, segment names, strategic roles) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and two different strategic contexts, correctly tracing the evolution from internal investment focus to standalone business segment. (4) The LLM includes specific, correctly attributed details such as AWS serving developers and enterprises with on-demand services (compute, storage, etc.), and references to CEO-level leadership and market-facing role, which enrich the answer without introducing inaccuracies. Wording differs slightly but meaning is preserved. All aspects of the question—evolution in role within business segments and investment priorities—are addressed with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1466,
        "completion_tokens": 392,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Philip Morris International's financial relationship with Rothmans, Benson & Hedges Inc. (RBH) evolved between 2022 and 2024, particularly in terms of its accounting treatment and potential financial exposure?",
      "original_answer": "In 2022, RBH was deconsolidated from Philip Morris International’s financial statements due to its CCAA restructuring, and its financial results were no longer included in PMI’s consolidated financials. At that time, there was a comprehensive stay of Canadian tobacco litigation until March 31, 2022, and no loss accruals were made due to the inability to estimate potential losses. By 2024, PMI’s relationship with RBH had shifted from deconsolidation to an equity investment model. A proposed settlement of CAD 32.5 billion in the Canadian tobacco litigation emerged, prompting PMI to assess its investment in RBH for impairment. As a result, PMI recorded a non-cash impairment charge of $2,316 million in 2024, reflecting a decline in the estimated fair value of its investment. This marks a significant evolution from a deconsolidated entity with uncertain liabilities to a recognized equity investment with a quantified impairment.",
      "llm_answer": "In the 2022 Form 10‑K PMI said that Rothmans, Benson & Hedges (RBH) had been **de‑consolidated** from its statements since the 2019 CCAA filing and that, because a comprehensive stay of all Canadian tobacco litigation was in place through 31 Mar 2022, the company **accrued no loss** – its only exposure was the CAD 226 million security deposit and any future judgment that might arise. By the 2024 filing PMI still held an **equity investment** in RBH, but the proposed CAD 32.5 billion settlement and the unresolved allocation of that amount led PMI to **recognize a $2.3 billion non‑cash impairment** (≈$1.49 per diluted share), reflecting a substantially larger potential financial exposure than in 2022.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the key evolution in Philip Morris International's financial relationship with RBH between 2022 and 2024. (1) Quantitatively, the answer correctly identifies the CAD 32.5 billion proposed settlement, the $2.3 billion impairment (approximating the exact $2,316 million), and the CAD 226 million security deposit. The only minor discrepancy is the characterization of the deconsolidation timing: the original answer states it occurred in 2022 due to CCAA restructuring, while the LLM says it was since the 2019 CCAA filing—this is partially correct but slightly misrepresents the accounting timing. Deconsolidation occurred in 2022, not retroactively from 2019, though the CCAA process began earlier. (2) The impairment amount is correctly reported as ~$2.3 billion, matching the $2,316 million in the ground truth (rounded appropriately). (3) Qualitatively, the reasoning is sound: the shift from deconsolidation to equity investment with increasing financial exposure due to litigation risk is correctly synthesized. The mention of no loss accrual in 2022 due to the litigation stay aligns with the original. (4) Contextually, the answer directly addresses the question’s focus on accounting treatment (deconsolidation → equity method) and financial exposure (from limited deposit to major impairment). The only shortcoming is the slight imprecision on the deconsolidation date, which does not undermine the overall correctness. Thus, the answer earns a 9 for correctness, with high marks across all dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 425,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2022 to 2024, considering both its revenue contribution and associated product risks?",
      "original_answer": "In 2022, Biktarvy was a major revenue driver for GILD, generating $8,624 million in total product sales globally, indicating its strong market position in the HIV treatment segment. By 2024, while specific revenue figures are not provided, the company's risk disclosures highlight Biktarvy's ongoing importance but also emphasize heightened risks related to the HIV product class, particularly concerning the reliance on TAF-based therapies and potential shifts in treatment paradigms. This evolution suggests that although Biktarvy remains central to GILD's revenue, its commercial outlook has become more vulnerable to competitive and regulatory pressures.",
      "llm_answer": "Biktarvy was a major driver of Gilead’s sales in the 2022 filing, generating $8.6 billion in total product sales (U.S. $7.0 bn, Europe $969 m, other $606 m) – roughly half of the company’s HIV portfolio and a large share of overall revenue【page_70】. In the 2024 filing the product is still highlighted as a core HIV therapy, but the risk‑factor section now stresses that HIV drugs such as Biktarvy are subject to intensified competition, pricing‑ and reimbursement pressures and possible shifts away from nucleoside‑based regimens, indicating that its commercial importance remains high while its exposure to product‑specific risks has grown【page_18】【page_19】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Biktarvy's revenue in 2022 as $8.6 billion, which aligns with the ground truth value of $8,624 million (rounded appropriately). The breakdown into U.S., Europe, and other regions is additional detail not contradicted by the original answer and consistent with the knowledge graph's data. While the original answer does not provide 2024 revenue figures, the LLM correctly notes their absence and instead focuses on risk disclosures, accurately reflecting the shift in emphasis from revenue performance to risk exposure. (2) Quantitatively, the $8.6 billion figure is a valid rounding of $8,624 million. No calculations are required beyond this, and the regional breakdown totals approximately $8.575 billion, which is within reasonable rounding tolerance of the total. All numeric values are presented accurately and in appropriate formats. (3) The multi-hop reasoning is sound: the model synthesizes information from two time points (2022 and 2024), correctly identifying that while Biktarvy remains a core product, the nature of the disclosure has evolved to emphasize increasing risks. It connects revenue contribution (2022) with evolving risk factors (2024), fulfilling the question’s requirement to assess evolution in commercial significance. (4) The answer is contextually fully relevant, addressing both revenue contribution and product risks across the specified time frame. The only minor limitation is that it does not explicitly state that specific 2024 revenue figures are unavailable (though this is implied), which prevents a perfect score. Otherwise, the semantic meaning, factual accuracy, and synthesis match the ground truth closely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 464,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has Union Pacific Railroad's financial stake and operational relationship with TTX evolved from 2022 to 2024, particularly in terms of investment value and car hire expenses?",
      "original_answer": "Union Pacific Railroad's financial stake in TTX increased from $1.6 billion in 2021 (referenced in the 2022 filing) to $1.9 billion in 2024. Additionally, UPRR's car hire expenses rose from $375 million in 2021 to $432 million in 2024. These increases indicate a growing financial and operational involvement with TTX over the period.",
      "llm_answer": "Union Pacific’s equity stake in TTX has risen modestly – the 2022 filing shows a 36.79 % economic interest with a $1.6 billion investment on the balance sheet, while the 2024 filing reports a 37.03 % interest and a $1.9 billion investment 【page_88】【page_89】→【page_68】.  At the same time, the cost of hiring TTX rail cars has increased from $402 million in 2022 to $432 million in 2024 (up from $399 million in 2023) 【page_68】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct but contains a discrepancy in the car hire expense figures. The ground truth states that UPRR's car hire expenses were $375 million in 2021 and $432 million in 2024, while the LLM claims $402 million in 2022 and $432 million in 2024 (with $399 million in 2023). However, the original answer does not provide data for 2022 or 2023—only 2021 and 2024—so the LLM introduces intermediate-year figures not present in the ground truth, which may be accurate in context but are not verifiable against the provided answer. This affects quantitative accuracy. (2) The investment value is correctly reported as increasing from $1.6 billion (referenced in 2022 filing) to $1.9 billion in 2024, aligning with the ground truth. The percentages (36.79% to 37.03%) add detail not in the original but do not contradict it. (3) The multi-hop reasoning is sound: the LLM synthesizes data across years and metrics (investment value and car hire costs) related to UPRR’s relationship with TTX, correctly identifying trends in both financial stake and operational expenses. (4) Contextual relevance is perfect—the response directly addresses the evolution of financial stake and operational relationship, including both investment and car hire expenses. The minor over-specification of intermediate-year car hire costs reduces quantitative accuracy but does not invalidate the overall trend. Thus, correctness is reduced to 7 due to unverifiable numeric additions, though core facts and directionality are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 424,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Tesla's approach to scaling Solar Roof production change from 2022 to 2023, particularly regarding installer training initiatives and supply chain risk management?",
      "original_answer": "In 2022, Tesla emphasized expanding Solar Roof production by on-boarding and training new installers, collaborating with real estate developers, and reducing installation time and costs. The company also highlighted its need to hire additional personnel, particularly skilled electricians, to support the ramp. By 2023, Tesla's focus had shifted toward addressing broader supply chain risks and production ramp challenges, with language indicating that Solar Roof production now depended more on managing supplier reliability, global component constraints, and cost-effective manufacturing processes. The 2023 filing also noted that delays in production ramps could harm the business, signaling a shift from installer-focused growth to a more risk-averse strategy centered on supply chain resilience.",
      "llm_answer": "In 2022 Tesla’s 10‑K said its Solar Roof scale‑up would be driven by expanding the installer base – “on‑boarding and training new installers, as well as collaborating with real‑estate developers and builders … and hiring additional skilled electricians to support the ramp of Solar Roof” (2022 p. 34). By the 2023 filing the focus had shifted to caution about possible production delays and to tightening supply‑chain risk controls, stressing that “we may experience delays … ramping … Solar Roof” and that “our suppliers may fail to deliver components … and we must manage supply‑chain constraints” (2023 p. 16), with no longer a specific emphasis on installer‑training initiatives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Tesla's 2022 focus on installer training, collaboration with real estate developers, and hiring skilled electricians, citing the correct page (p. 34) from the 2022 10-K. In 2023, it accurately reflects the shift toward supply chain risk management, including supplier reliability and production ramp delays, with a citation to page 16 of the 2023 filing. The absence of mention of installer-training initiatives in 2023 is correctly noted. (2) There are no numerical values requiring calculation, but the years (2022, 2023) and page numbers (34, 16) are factually correct and properly attributed. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly contrasting the strategic emphasis from installer expansion to supply chain resilience. It captures the shift in tone and focus without misrepresenting the underlying data. (4) The only minor shortcoming is that the original answer includes the phrase 'cost-effective manufacturing processes' and the business risk of delays harming the company, which the LLM answer implies but does not explicitly state. However, the core facts, entities, and strategic shift are accurately conveyed. Wording differs slightly but maintains semantic equivalence. Thus, the answer is excellent but not perfect, warranting a 9/10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 402,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has The Coca-Cola Company's relationship with fountain retailers evolved between 2022 and 2023, particularly regarding the manufacturing and distribution of fountain syrups in the United States?",
      "original_answer": "In 2022, The Coca-Cola Company stated that U.S. bottlers were generally not authorized to manufacture fountain syrups, and instead, the Company itself manufactured and sold fountain syrups directly to authorized fountain wholesalers (including some bottlers) and certain fountain retailers. By 2023, the Company clarified that it continues to manufacture fountain syrups in the U.S., but now explicitly states that it sells these syrups to both fountain retailers and authorized fountain wholesalers or bottling partners who then distribute them to fountain retailers. This indicates a more explicit acknowledgment of a tiered distribution model involving bottling partners in 2023, suggesting a potential expansion of their distribution network or clarification of roles.",
      "llm_answer": "The 2022 filing notes that U.S. bottlers are **not authorized to manufacture fountain syrups**; instead, Coca‑Cola “manufactures and sells fountain syrups to authorized fountain wholesalers (including certain authorized bottlers) and some fountain retailers,” with the wholesalers delivering the syrups to restaurants and other retailers【page_7】. The 2023 filing repeats this model, stating that the Company “manufactures fountain syrups and sells them to fountain retailers … or to authorized fountain wholesalers or bottling partners who in turn sell and distribute the fountain syrups to fountain retailers”【page_37】. Thus, between 2022 and 2023 the core relationship has remained unchanged – Coca‑Cola continues to be the sole U.S. manufacturer of fountain syrups and supplies them directly or via authorized wholesalers/bottlers, while bottlers still cannot produce those syrups.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that in 2022, U.S. bottlers were not authorized to manufacture fountain syrups and that Coca-Cola manufactured and sold syrups to authorized wholesalers (including some bottlers) and certain fountain retailers. In 2023, it accurately reflects the updated language where Coca-Cola sells syrups to both fountain retailers and authorized wholesalers or bottling partners who distribute to retailers. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a traditional sense, but all factual assertions (e.g., authorization status, distribution channels) are correct and consistent with the source. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years and identifies both continuity (Coca-Cola remains sole manufacturer, bottlers still cannot produce syrups) and subtle evolution (more explicit recognition of bottling partners in distribution). (4) The only minor shortcoming is that the LLM concludes the 'core relationship has remained unchanged,' which slightly downplays the significance of the 2023 clarification about bottling partners' distribution role. The original answer interprets this as a 'potential expansion or clarification of roles,' suggesting a nuanced evolution. While the LLM isn't wrong, it misses this interpretive depth, costing a point in qualitative accuracy. Otherwise, the answer is complete, factually correct, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 422,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has IBM's treatment and disclosure of the 0.950% Notes due 2025 evolved from 2022 to 2024, particularly in terms of its financial instrument classification and registration details?",
      "original_answer": "In 2022, the 0.950% Notes due 2025 were disclosed as part of IBM's exhibits in Form 8-K filings, specifically referenced under Exhibit 4.1 filed on May 22, 2017. By 2024, the 0.950% Notes due 2025 were not only still present but were actively listed as a financial instrument with a trading symbol 'IBM25B' on the New York Stock Exchange. This evolution indicates a shift from merely disclosing the instrument to formally registering and listing it for trading.",
      "llm_answer": "In the 2022 Form 10‑K IBM did not list the 0.950 % Notes due 2025 as a separate security; the instrument was only reflected in the aggregate “notes payable/long‑term debt” balances and no specific registration or exhibit was provided (see the exhibit list on page 31, which mentions only the 7 % debentures). By the 2024 filing IBM explicitly discloses the 0.950 % Notes due 2025 as a distinct, registered debt security (ticker IBM25B) on the NYSE under Section 12(b) of the Securities Act (see the securities registration table on page 1), indicating a shift to a more detailed classification and public‑registration disclosure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all key facts are correct: the 0.950% Notes due 2025 were not separately listed in the 2022 10-K but were later explicitly disclosed in 2024 with ticker 'IBM25B' on the NYSE. The percentages (0.950%), years (2025), and exchange (NYSE) match exactly. (2) The answer correctly identifies the evolution in disclosure: from being subsumed in aggregate debt balances in 2022 (with no specific exhibit reference in that year's 10-K) to being formally registered and listed under Section 12(b) in 2024. (3) The multi-hop reasoning is sound—comparing IBM’s treatment of the notes across two years and linking it to registration and classification changes. The only minor gap is that the original answer references the May 22, 2017, Form 8-K (Exhibit 4.1) as the initial disclosure source, which the LLM omits. While not strictly required to answer the evolution from 2022–2024, this detail adds historical context. However, since the question focuses on 2022–2024 evolution, the omission does not undermine the core correctness. (4) The LLM uses slightly different phrasing (e.g., 'Section 12(b)' instead of 'formally registering and listing it for trading') but conveys the same semantic meaning. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 385,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has GILD's strategic positioning of Biktarvy evolved from 2022 to 2024, particularly in terms of its financial risk exposure and competitive differentiation within the HIV treatment market?",
      "original_answer": "In 2022, Biktarvy was listed among GILD’s key marketed products, indicating its central role in the company's HIV portfolio and suggesting strong commercial positioning. By 2024, the company highlighted increasing financial risk tied to its reliance on nucleoside-based therapies like Biktarvy, particularly due to the potential shift in HIV treatment paradigms away from TAF-based regimens. This evolution reflects a growing concern over Biktarvy’s long-term competitive differentiation and its ability to sustain revenue, especially in the face of rising generic competition and changing therapeutic preferences.",
      "llm_answer": "In the 2022 Form 10‑K Gilead simply listed Biktarvy as one of its marketed products, underscoring its role as a core HIV therapy in the company’s portfolio (2022 p. 63). By the 2024 filing the company treats Biktarvy as a key pillar of its HIV franchise that now faces heightened financial‑risk exposure—from pricing reforms, rebate obligations, inventory‑forecasting challenges, and the threat of generic competition—and stresses protecting its clinical differentiation (once‑daily, single‑pill regimen) to preserve market share (2024 p. 18‑20, especially the HIV risk‑factor discussion and competition section).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Biktarvy was listed as a marketed product (per 2022 10-K, p. 63), establishing its core role in GILD’s HIV portfolio. By 2024, it accurately reflects increased financial risk exposure, citing pricing reforms, rebates, inventory challenges, and generic competition (2024 10-K, pp. 18–20), which matches the ground truth’s emphasis on growing financial risk due to reliance on TAF-based therapies and shifting treatment paradigms. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) and page references are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings, correctly inferring an evolution in strategic positioning from commercial strength to heightened risk. It adds contextual detail (once-daily, single-pill regimen) that supports the claim about competitive differentiation, consistent with GILD’s emphasis on clinical advantages. (4) The only minor gap is that the LLM does not explicitly mention the 'shift away from TAF-based regimens' as a driver of risk, which is a key nuance in the ground truth. However, it captures the broader risk themes (generic competition, pricing pressure), and the clinical differentiation point reinforces the effort to maintain market share. Thus, the answer is semantically equivalent with only slight omission of a specific therapeutic paradigm shift. Scores reflect high accuracy, strong reasoning, and full contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 446,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Lockheed Martin's approach to defined contribution retirement savings plans evolve between 2022 and 2023, particularly in terms of pension obligation transfers and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin transferred $4.3 billion of gross defined benefit pension obligations through group annuity contracts, recognizing a noncash pension settlement charge of $1.5 billion. In 2023, instead of another annuity purchase, the company made $414 million in settlement payments to approximately 6,500 former employees who had not yet started receiving benefits. This shift indicates a strategic evolution from transferring large blocks of pension obligations to insurers (as in 2022) to directly settling smaller portions of obligations with individual participants in 2023.",
      "llm_answer": "In 2022 Lockheed Martin completed a large group‑annuity transaction that transferred about **$4.3 billion** of gross defined‑benefit pension obligations (and related assets) to an insurer, which generated a **non‑cash pension settlement charge of roughly $1.5 billion** (recorded as a $1.47 billion settlement charge in the FAS expense table) and produced a net pension expense of **$1.058 billion** for the year【page_82†L1-L9】【page_82†L31-L38】. By 2023 the company had moved to **smaller, voluntary lump‑sum settlements of $414 million** for about 6,500 former employees, with **no settlement charge recorded** and a net pension income of **$378 million**, indicating a shift toward winding down defined‑benefit obligations as it relies more on its defined‑contribution retirement savings plans【page_82†L9-L15】【page_83†L1-L9】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, Lockheed Martin transferred $4.3 billion in pension obligations via group annuity and recognized a $1.5 billion noncash settlement charge (with a precise reference to $1.47 billion in the FAS table, which is consistent with the $1.5 billion rounded figure in the original answer). In 2023, the company made $414 million in settlement payments to ~6,500 former employees, with no settlement charge recorded—correctly contrasting the two years' strategies. (2) Quantitative accuracy is excellent: all dollar amounts ($4.3B, $1.5B, $414M), employee count (6,500), and resulting financial impacts (net pension expense of $1.058B in 2022, income of $378M in 2023) are correctly reported and contextually explained. (3) The multi-hop reasoning is sound—LLM correctly infers a strategic shift from large insurer transfers (2022) to direct individual settlements (2023), linking this to a broader move toward defined-contribution plans. (4) The only minor gap is that the original answer explicitly frames the 2023 action as part of an evolution 'from transferring large blocks... to directly settling smaller portions,' while the LLM implies this but doesn't use identical framing. However, the semantic meaning and factual content are equivalent. The inclusion of additional precise details (e.g., $1.47B vs $1.5B) enhances accuracy without introducing error. Overall, the answer is factually complete, contextually relevant, and demonstrates strong synthesis across years and financial concepts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 438,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 2.875% Notes due 2025?",
      "original_answer": "In 2022, IBM listed the 2.875% Notes due 2025 (IBM 25A) among other Notes due in 2025, including the 0.950% Notes due 2025 (IBM 25B) and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 2.875% Notes due 2025 (IBM25A) remained, but the 0.875% Notes due 2025 (IBM 25C) were no longer listed, indicating a shift in the debt composition for that year. The 2.875% Notes due 2025 continued to be a key part of IBM's debt structure in 2024, suggesting a strategic decision to maintain this specific financial instrument while retiring or restructuring others.",
      "llm_answer": "In the 2022 Form 10‑K the “Securities registered pursuant to Section 12(b)” table shows three notes maturing in 2025 – the 2.875 % Notes (IBM 25A), the 0.950 % Notes (IBM 25B) and the 0.875 % Notes (IBM 25C) – plus the 7.00 % debentures due 2025 (IBM 25)【page_1】. The 2024 filing still lists the 2.875 % Notes (IBM 25A) and the 7.00 % debentures due 2025, but the 0.875 % Notes (IBM 25C) are no longer shown, indicating that instrument was retired or redeemed while the 2.875 % Notes remain unchanged【page_1】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the presence of the 2.875% Notes due 2025 (IBM 25A), 0.950% Notes (IBM 25B), and 0.875% Notes (IBM 25C) in the 2022 filing, matching the ground truth. It accurately notes that by 2024, the 2.875% Notes and 7.00% debentures remain, while the 0.875% Notes (IBM 25C) are no longer listed, indicating retirement—consistent with the original answer’s conclusion. However, the original answer does not mention the 7.00% debentures due 2025, which appear in the LLM response. While this detail may be factually present in the 10-K, its inclusion introduces an element not reflected in the ground truth, potentially overcomplicating the composition change focus. (2) All percentages (2.875%, 0.950%, 0.875%, 7.00%) and years (2025) are correct; no calculations are required, but the comparison across years is accurate. (3) The multi-hop reasoning—comparing IBM’s debt instruments between 2022 and 2024—is sound and correctly synthesizes data across filings. The conclusion that the 2.875% Notes remained while others were retired aligns with the ground truth. The only deviation is the emphasis on the 7.00% debentures, which, while possibly accurate, is not part of the verified knowledge graph answer and slightly diverges from the focus on the 2.875% Notes and the disappearance of IBM 25C. (4) The correctness score is 9 due to high factual accuracy and strong reasoning, with a minor deduction for introducing a detail (7.00% debentures) not in the ground truth, which could affect precision in a strict evaluation context. Quantitative accuracy is 10 as all numbers are correct. Qualitative accuracy is 9 due to excellent entity and temporal reasoning, with slight over-inclusion. Contextual relevance is 10 as the response directly addresses the evolution of debt composition and the status of the 2.875% Notes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 504,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the strategic importance and risk profile of Biktarvy within Gilead's HIV portfolio evolved from 2022 to 2024, particularly in light of competitive pressures and changes in the treatment paradigm?",
      "original_answer": "In 2022, Biktarvy was positioned as a key growth driver for Gilead, with the company noting its 'continued growth in all geographies' and attributing part of the 11% revenue increase to its performance. By 2024, however, the strategic importance of Biktarvy appears more precarious. The 2024 10-K highlights increased risks around Gilead's HIV franchise, noting that 'many of our HIV products contain TAF' and that any shift away from nucleoside-based therapies could materially impact sales. This suggests that while Biktarvy was a growth asset in 2022, by 2024 it was increasingly seen as vulnerable to paradigm shifts in HIV treatment, representing a change in both strategic positioning and risk exposure.",
      "llm_answer": "In the 2022 filing Gilead portrayed Biktarvy as the centerpiece of its HIV recovery – sales were rising “driven by higher demand” and a new low‑dose pediatric tablet was approved, helping offset the loss of Truvada/Atripla and positioning Biktarvy as the primary growth engine for the franchise (2022 p. 41; p. 38; p. 40). By the 2024 filing the company’s risk discussion treats Biktarvy (and its other TAF‑based HIV products) as increasingly vulnerable: it flags “market‑share gains by competitive products, including generics” and warns that “if there are any changes to the treatment or prevention paradigm for HIV, and nucleoside‑based therapeutics do not remain the preferred regimen, our HIV product sales would be adversely impacted” (2024 p. 18; p. 20). Thus, while Biktarvy remains a key HIV asset, its strategic importance has shifted from a clear growth driver in 2022 to a product whose revenue outlook is now more exposed to competition and a possible shift away from nucleoside‑based regimens by 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Biktarvy was a growth driver in 2022 due to rising demand and pediatric approval, and by 2024, it was framed as increasingly vulnerable due to competitive pressures and potential shifts away from nucleoside-based therapies. The citations to page numbers (e.g., 2022 p. 41, 2024 p. 18) are consistent with typical 10-K structures, though exact page numbers are not verifiable from the knowledge graph—this does not affect factual correctness. (2) There are no numeric values (percentages, dollar amounts) in either answer, so quantitative accuracy is not compromised; the absence of the 11% revenue increase mentioned in the ground truth is a minor omission but does not distort the core message. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across 2022 and 2024 filings, identifying the shift in strategic positioning and risk profile. It accurately links Biktarvy’s reliance on TAF to broader franchise vulnerability, demonstrating strong qualitative synthesis. (4) The semantic meaning fully matches the original answer—Biktarvy transitions from a growth engine to a more exposed asset—despite slightly richer contextual detail (e.g., pediatric approval) not in the ground truth, which enhances rather than detracts. The only reason for not scoring a 10 is the omission of the specific 11% revenue growth context from 2022, which slightly reduces completeness. Otherwise, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 434,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the balance of the U.S. litigation escrow account evolve between the end of fiscal year 2022 and the end of fiscal year 2023, and what were the specific deposit contributions during each period?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1,449 million at the end of fiscal year 2022 to $3,089 million at the end of fiscal year 2023. During this time, deposits into the account rose from $1,000 million in fiscal year 2022 to $1,500 million in fiscal year 2023.",
      "llm_answer": "The U.S. litigation escrow balance rose from **$1.449 billion at the end of FY 2022** (the “balance as of beginning of period” for 2023) to **$1.764 billion at the end of FY 2023**, a net increase of about $315 million【page_73】.  The company **deposited $850 million into the escrow during FY 2022**【page_102】 and **$1.0 billion during FY 2023**【page_73】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both the final balance and deposit amounts. According to the ground truth, the U.S. litigation escrow account balance increased from $1,449 million at the end of FY 2022 to $3,089 million at the end of FY 2023. However, the LLM reports the ending balance as only $1.764 billion (i.e., $1,764 million), which is $1,325 million too low. This is a major quantitative error. Additionally, the LLM states that $850 million was deposited in FY 2022 and $1.0 billion in FY 2023, whereas the ground truth specifies $1,000 million (i.e., $1 billion) in FY 2022 and $1,500 million ($1.5 billion) in FY 2023. Thus, both deposit figures are incorrect. (2) Calculations are also flawed: the net increase implied by the LLM ($1,764M - $1,449M = $315M) does not match the actual sum of deposits it claims ($850M + $1,000M = $1,850M), nor does it align with withdrawals or other adjustments mentioned in the citation (though withdrawals may explain some difference, the LLM does not mention them). The true increase is $3,089M - $1,449M = $1,640M, which should align with net deposits (and does in the ground truth: $1,000M + $1,500M = $2,500M total over two years, with implied disbursements). (3) The multi-hop reasoning is partially present—the LLM attempts to track balances and deposits across fiscal years—but fails to synthesize the correct data points. It cites page 73 for both the FY2023 ending balance and deposit, but misreads or misreports the numbers. (4) Despite incorrect numbers, the answer is contextually relevant: it addresses the evolution of the escrow balance and specifies deposit contributions per year, fulfilling the structure of the question. However, due to severe quantitative inaccuracies, the correctness and accuracy scores are very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1178,
        "completion_tokens": 496,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the role of fountain syrups in Coca-Cola's North America operating segment evolved between 2022 and 2023, particularly regarding the company's manufacturing and distribution responsibilities?",
      "original_answer": "In 2022, Coca-Cola explicitly stated that it manufactured fountain syrups in the United States and sold them directly to fountain retailers or to authorized fountain wholesalers or bottling partners for further distribution. By 2023, the company's description shifted: while it still referenced selling fountain syrups in the North America segment, it also indicated that outside the U.S., bottling partners were authorized to manufacture fountain syrups using company concentrates. This suggests a nuanced evolution where Coca-Cola may be emphasizing a more decentralized, authorization-based model, particularly outside the U.S., while maintaining direct control within the U.S. There is no explicit mention of a change in manufacturing responsibilities within North America itself, indicating operational continuity there.",
      "llm_answer": "The description of fountain‑syrup sales in the North America segment is unchanged from 2022 to 2023. In both filings Coca‑Cola says it **manufactures fountain syrups in the United States and sells them either directly to fountain retailers or to authorized fountain wholesalers/bottling partners that then sell the syrups to retailers**, and those sales continue to be recorded in the North America operating segment【page_36】【page_37】. No new manufacturing or distribution responsibilities were added between the two years.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses a key nuance present in the ground truth. (1) It correctly states that Coca-Cola manufactured fountain syrups in the U.S. and sold them directly or through authorized partners in both 2022 and 2023, and that these sales are recorded in the North America segment, citing appropriate pages. There are no numeric inaccuracies (quantitative accuracy is high). (2) However, the LLM claims the description is 'unchanged' between 2022 and 2023, which contradicts the ground truth: in 2023, Coca-Cola added language indicating that outside the U.S., bottling partners were authorized to manufacture fountain syrups using company concentrates—a shift toward a more decentralized model internationally. While this change occurs outside the U.S., it still represents an evolution in the company's overall approach to fountain syrup manufacturing, particularly in how it frames its North America segment's relationship with global operations. (3) The multi-hop reasoning is flawed because the model failed to synthesize the implication of the new 2023 language about partner manufacturing authorization, even if the core U.S. operations remained stable. The answer incorrectly concludes there was no change in responsibilities, when the evolution lies in the expanded authorization model and descriptive shift. (4) Therefore, while factually consistent on U.S. operations and contextually relevant, the answer lacks completeness and qualitative accuracy in capturing the nuanced evolution, warranting a mid-range correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 427,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 0.950% Notes due 2025?",
      "original_answer": "In 2022, IBM had three sets of notes maturing in 2025: the 2.875% Notes due 2025 (IBM 25A), the 0.950% Notes due 2025 (IBM 25B), and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 0.875% Notes due 2025 were no longer listed, leaving only the 2.875% Notes due 2025 (IBM 25A) and the 0.950% Notes due 2025 (IBM 25B). This indicates a reduction in the diversity of interest rate profiles for debt maturing in 2025, with the removal of the 0.875% instrument.",
      "llm_answer": "In the 2022 Form 10‑K IBM listed four securities that mature in 2025 – 2.875% notes (IBM 25A), 0.950% notes (IBM 25B), 0.875% notes (IBM 25C) and a 7.00% debenture (IBM 25)【page_1】. By the 2024 filing the 0.875% notes (IBM 25C) were no longer shown, leaving only the 2.875% notes, the 0.950% notes and the 7.00% debenture, so the 0.950% Notes due 2025 (IBM 25B) persisted unchanged while the 0.875% notes were dropped【page_1】.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 0.950% Notes due 2025 (IBM 25B) as persisting from 2022 to 2024 and notes the removal of the 0.875% Notes (IBM 25C), which aligns with the ground truth. However, it introduces a '7.00% debenture (IBM 25)' not mentioned in the original answer, which claims only three notes existed in 2022 and two remained in 2024. This extra instrument contradicts the ground truth and suggests inaccurate entity extraction or synthesis. (2) Quantitatively, the percentages (2.875%, 0.950%, 0.875%) and the observation that the 0.875% note was dropped are correct. The erroneous inclusion of a 7.00% debenture — if not present in the actual 2022 filing — is a factual error affecting quantitative completeness. (3) The reasoning correctly tracks the persistence of the 0.950% notes and the elimination of the 0.875% notes, showing valid multi-hop comparison across years. However, the failure to accurately enumerate the initial set of debt instruments undermines the reasoning's reliability. (4) The answer is contextually relevant and addresses the evolution of debt composition with respect to the 0.950% notes. Due to the incorrect addition of a debt instrument not in the ground truth, the answer is partially accurate but not fully correct, warranting a score of 7 for correctness. Quantitative accuracy is slightly penalized (8) due to the extraneous instrument, qualitative accuracy reflects sound logic but flawed entity identification (7), and contextual relevance remains high (9) as the core comparison is addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 428,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Disney's strategic approach to cruise ships evolved between 2022 and 2024 based on disclosures in their 10-K filings?",
      "original_answer": "In 2022, Disney mentioned cruise ships as part of its broader travel and resort experiences, indicating that their success depended on consumer demand for out-of-home entertainment and travel. By 2024, Disney had elevated its approach, explicitly stating plans to 'expand investment in our Experiences segment' and 'additional expansion of our fleet of cruise ships.' This evolution reflects a shift from general dependence on consumer demand to an active investment and growth strategy in cruise ship operations. The 2024 filing also notes that new offerings, such as additional cruise ships, come with increased costs and uncertain returns, signaling a more capital-intensive and strategic focus compared to the more passive mention in 2022.",
      "llm_answer": "In the 2022 10‑K Disney described its cruise‑ship strategy as an investment phase—adding new ships, bearing launch costs, and even taking a write‑down after the Star Wars: Galactic Starcruiser concept failed, signaling cautious expansion with risk awareness【DIS_10k_2022 page_22】【DIS_10k_2022 page_25】. By the 2024 10‑K the company shifted to a growth‑focused approach, announcing plans to further expand the Disney Cruise Line fleet and to open a new destination at Lighthouse Point, Eleuthera, underscoring a more aggressive commitment to cruise‑ship development【DIS_10k_2024 page_22】【DIS_10k_2024 page_21】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in Disney's cruise strategy from 2022 to 2024: in 2022, the focus was on investment and risk (including the Star Wars: Galactic Starcruiser write-down), while in 2024, the strategy shifted to growth with fleet expansion and the Lighthouse Point development. These points are consistent with the original answer’s characterization of a shift from passive dependence on demand to active investment and expansion. (2) There are no numeric values (e.g., dollar amounts, ship counts, dates) in either the original or LLM answer that conflict; all references to years (2022, 2024) and events are factually correct. The LLM cites specific page numbers from the 10-Ks, enhancing credibility. (3) The multi-hop reasoning is sound—comparing strategic language across two years’ filings and synthesizing the shift in tone and intent. The LLM adds slightly more detail (e.g., Lighthouse Point, Galactic Starcruiser write-down) not in the original answer, but these are accurate and enrich the response without distorting the core message. (4) The only reason for not scoring a 10 is that the original answer emphasizes the increased costs and uncertain returns mentioned in 2024 as part of the strategic shift, which the LLM omits. This is a minor but relevant nuance about risk awareness in the new strategy. Otherwise, the answer is semantically equivalent, contextually precise, and factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 414,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did Lockheed Martin's approach to pension risk transfer transactions evolve from 2022 to 2023, particularly in terms of financial impact and strategic intent?",
      "original_answer": "In 2022, Lockheed Martin detailed a specific pension risk transfer transaction from August 3, 2021, where $4.9 billion of gross defined benefit pension obligations were transferred via group annuity contracts (GACs), resulting in a noncash pension settlement charge of $1.7 billion. The company also noted that since December 2018, it had transferred approximately $11.6 billion in pension obligations, eliminating volatility for around 95,000 retirees. By 2023, the company reiterated its strategic intent to continue evaluating such transactions but shifted focus toward the broader financial and risk implications, including potential future contributions to the pension trust and the possibility of additional noncash settlement charges. The 2023 filing also introduced a nuanced risk: while most GACs relieve Lockheed of pension obligations, some could leave the company liable if the insurer defaults. This reflects a more cautious framing of pension risk transfer, acknowledging residual liability exposure not emphasized in 2022.",
      "llm_answer": "In the 2022 filing Lockheed Martin emphasized that it had already used pension‑risk‑transfer deals to off‑load roughly $11.6 billion of defined‑benefit obligations (the 2021 GAC purchase generated a $1.7 billion non‑cash settlement charge) and said it would keep looking for additional GAC transactions to reduce pension‑plan volatility. By the 2023 filing the company still pursues GAC purchases, but now stresses that some contracts leave it still responsible for paying benefits and exposed to insurer‑default risk, and warns that future transfers could require extra contributions and trigger non‑cash settlement charges—showing a more cautious, risk‑aware strategic stance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures all key factual elements from the ground truth. It accurately reports the $11.6 billion in total pension obligations transferred since December 2018, the $1.7 billion noncash settlement charge from the 2021 GAC transaction, and Lockheed Martin's continued evaluation of GACs in 2023. It also correctly identifies the strategic shift toward a more cautious stance, including the acknowledgment of insurer-default risk and potential future contributions or settlement charges. (2) Quantitative accuracy is perfect: all dollar amounts ($11.6 billion, $1.7 billion) are correct, and no incorrect dates or figures are introduced. The LLM does not mention the specific date of the 2021 transaction (August 3, 2021), but this detail is minor and not central to the financial impact or strategic intent. (3) The multi-hop reasoning is sound—LLM synthesizes information across 2022 and 2023 filings, correctly identifying both continuity (ongoing use of GACs) and evolution (increased focus on residual risks). The only slight shortcoming is a minor omission of the 95,000 retirees impacted, which adds context but does not alter the core strategic or financial analysis. (4) The answer is semantically equivalent to the ground truth, with clear, concise rewording that preserves meaning. The framing of 'some contracts leave it still responsible' aligns with the ground truth's point about potential liability upon insurer default. Overall, this is a highly accurate, well-reasoned response that fully addresses the question with only negligible omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 438,
        "total_tokens": 1871
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Tesla's relationship with its financing partners evolved between 2022 and 2023, particularly in terms of accounts receivable management and leasing program risks?",
      "original_answer": "In 2022, Tesla disclosed that accounts receivable from financing partners could take up to approximately two weeks to settle based on contractual payment terms, directly impacting the company's short-term liquidity and balance sheet fluctuations. By 2023, Tesla highlighted increased complexity and risk in managing its financing programs, noting that its leasing business depends on securing adequate financing or partners, and that residual value risks from leased vehicles could negatively affect profitability. This indicates a shift from a focus on operational cash flow timing in 2022 to a broader concern over credit, compliance, and residual value risks in 2023 as the leasing program scaled.",
      "llm_answer": "In the 2022 filing Tesla’s financing partners were described mainly through its accounts‑receivable line – amounts owed by banks, leasing companies and other counterparties – which the company managed with an allowance for doubtful accounts, periodic write‑offs and a note that payments can take up to about two weeks and that no single partner accounted for more than 10 % of the balance. By the 2023 filing the focus shifts to the broader financing‑program risk: Tesla now relies on external partners to fund its vehicle‑ and solar‑leasing programs, faces residual‑value and credit‑risk exposure on those leases, and warns that an inability to secure or maintain partner financing could curtail leasing growth and generate credit losses.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, Tesla noted that payments from financing partners could take up to approximately two weeks to settle, which matches the original answer. The mention that no single partner accounted for more than 10% of receivables is an additional detail not in the ground truth but does not contradict it and is plausible. In 2023, the shift toward broader financing program risks—specifically reliance on external partners for leasing, residual value risk, and credit risk—is accurately captured. (2) Quantitative accuracy is perfect: 'up to about two weeks' matches 'up to approximately two weeks'; 'more than 10%' is correctly stated. No calculations were required, and all numbers/durations are consistent. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across two years and two types of risk (operational timing in 2022 vs. structural and financial risks in 2023), showing evolution in Tesla's risk disclosures. (4) The only reason for not scoring a 10 is minor: the original answer emphasizes a shift from 'short-term liquidity and balance sheet fluctuations' in 2022 to 'credit, compliance, and residual value risks' in 2023, while the LLM slightly underemphasizes 'compliance' risk, though 'credit-risk exposure' and 'residual-value' are fully covered. Overall, the answer is semantically equivalent, contextually precise, and factually robust.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 409,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "What changes occurred in Coca-Cola's fountain syrup distribution strategy between 2022 and 2023, and how did the roles of bottlers and fountain wholesalers evolve during this period?",
      "original_answer": "In 2022, Coca-Cola manufactured and sold fountain syrups directly to authorized fountain wholesalers (including certain authorized bottlers), who then sold or delivered the syrups to retailers. Bottlers in the U.S. were generally not authorized to manufacture fountain syrups. By 2023, the strategy evolved such that outside the United States, bottlers were typically authorized to manufacture fountain syrups using Coca-Cola concentrates, which they could sell to fountain retailers or authorized fountain wholesalers. This represents a shift from a more centralized syrup distribution model to a more integrated one, where bottlers play a more active role in the fountain syrup supply chain, particularly in international markets.",
      "llm_answer": "In the 2022 filing Coca‑Cola said that U.S. bottlers were generally **not** permitted to manufacture fountain syrups; the Company produced the syrups and sold them to authorized fountain wholesalers (including a few authorized bottlers) and directly to some fountain retailers, with the wholesalers delivering the syrups to restaurants and other outlets【page_8】. By the 2023 filing the Company still manufactures the syrups but now sells them to fountain retailers **or** to authorized fountain wholesalers **or** to bottling partners that are expressly authorized to sell and distribute the syrups to fountain retailers, expanding the bottlers’ role from limited wholesaler participation to a broader distribution function【page_37】.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key facts, dates, and the evolution of Coca-Cola's fountain syrup distribution strategy between 2022 and 2023. It correctly identifies that in 2022, Coca-Cola manufactured fountain syrups and sold them to authorized fountain wholesalers (including some bottlers) and directly to certain retailers, with U.S. bottlers generally not authorized to manufacture syrups. The 2023 update accurately reflects an expanded role for bottlers, particularly those authorized to sell and distribute syrups, indicating a broader distribution function. However, the LLM answer does not explicitly mention the geographic distinction emphasized in the ground truth—namely that the shift to bottler manufacturing (using Coca-Cola concentrates) primarily applied *outside the United States*. This omission reduces completeness and precision in the multi-hop synthesis, as the international scope of the change is a critical component of the strategic evolution. While the LLM captures the general expansion of bottler roles, it misses the nuance that this shift was mainly in international markets, which weakens the qualitative accuracy slightly. All entities (Coca-Cola, bottlers, fountain wholesalers, retailers), years (2022, 2023), and distribution relationships are otherwise correctly identified. There are no numerical inaccuracies (quantitative accuracy is perfect), and the answer remains highly relevant to the question. Thus, the correctness score is 8 due to a minor but meaningful omission in geographic specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 435,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of receivables and new investment activities?",
      "original_answer": "In 2023, AMD had receivables from the ATMP JV of $9 million, and there was no mention of any direct investment or loan made by AMD to the JV. By 2024, AMD's receivables from the ATMP JV increased to $12 million, and the company entered into a new $100 million one-year term loan agreement with one of the ATMP JVs to support its general corporate purposes. This marks a significant shift from a purely transactional relationship in 2023 to a more financially integrated one in 2024, where AMD is not only a customer but also a creditor and strategic supporter of the JV.",
      "llm_answer": "In 2023 AMD’s 15 % equity stake in the ATMP joint venture was reflected by a $99 million equity‑method investment, $9 million of receivables and $363 million of payables to the JV (2023 10‑K, p. 78). By year‑end 2024 the relationship deepened: the equity investment rose to roughly $149 million after a $17 million additional contribution, receivables increased to $12 million (with a new $100 million one‑year term loan to the JV) and payables grew to $476 million (2024 10‑K, p. 75).",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies that deviate from the ground truth. While it correctly states that AMD's receivables from the ATMP JV increased from $9 million in 2023 to $12 million in 2024, it introduces new information not present in the original answer: a $99 million equity-method investment in 2023, a $149 million investment in 2024, a $17 million additional contribution, $363 million and $476 million in payables, and a 15% equity stake. These details are not mentioned in the ground truth and contradict the claim that there was 'no mention of any direct investment or loan' by AMD in 2023. The $100 million one-year term loan in 2024 is correctly identified. (2) Quantitative accuracy is partially correct: receivables ($9M → $12M) and the $100M loan are accurate. However, the equity investment values ($99M, $149M), additional contribution ($17M), and payables ($363M, $476M) are unsupported by the ground truth and appear to be hallucinated or misattributed from external data. (3) Multi-hop reasoning is flawed because the model assumes an equity stake and investment activity in 2023 that the ground truth explicitly denies. This undermines the synthesis, as the evolution is misrepresented as a continuation of an existing investment relationship rather than a shift from no investment to a new loan-based financial integration. (4) Despite the detailed structure and contextual framing, the answer fails on core factual correctness. The contextual relevance is high because it addresses the evolution of the financial relationship, but the qualitative and quantitative inaccuracies severely reduce overall correctness. The model adds unsupported specifics that distort the actual progression described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 482,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Lockheed Martin's approach to managing its nonqualified defined benefit pension plans evolve between 2022 and 2023, particularly in terms of pension obligation settlements and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin purchased group annuity contracts to transfer $4.3 billion of gross defined benefit pension obligations and recognized a noncash pension settlement charge of $1.5 billion. In 2023, the company continued its strategy of reducing pension liabilities by making voluntary settlement payments of $414 million to approximately 6,500 former employees, significantly smaller in scale compared to the 2022 transaction. This indicates a shift from large-scale pension obligation transfers to a more targeted approach involving smaller settlements with former employees who had not yet started receiving benefits.",
      "llm_answer": "Lockheed Martin moved from large‑scale insurer transfers in 2022 to modest direct cash settlements in 2023. In the second quarter of 2022 the company bought group‑annuity contracts that moved about $4.3 billion of gross pension obligations to an insurance company and recorded a non‑cash pension‑settlement charge of roughly $1.5 billion (shown as a $‑1,470 million settlement charge) 【page_82】【page_83】. By the fourth quarter of 2023 it instead made voluntary lump‑sum payments of $414 million to roughly 6,500 former participants, cutting the benefit obligation but generating no settlement charge or FAS‑pension expense impact 【page_82】【page_84】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) All key facts are correct: in 2022, Lockheed Martin purchased group annuity contracts to transfer $4.3 billion of pension obligations and recognized a $1.5 billion noncash settlement charge (reported as -$1,470 million, which is semantically equivalent to $1.47 billion, a negligible rounding difference). In 2023, the company made $414 million in voluntary lump-sum payments to approximately 6,500 former employees. (2) Quantitative accuracy is excellent: all dollar amounts, participant counts, and financial impacts match or are acceptably rounded versions of the original. The note about no settlement charge in 2023 is correct and reflects a key distinction from 2022. (3) The reasoning correctly identifies the strategic shift from large-scale insurer transfers (2022) to targeted, smaller direct settlements (2023), capturing the evolution in approach. (4) The answer addresses all parts of the question—pension obligation settlements and associated financial impacts in both years—and synthesizes information across time periods and financial outcomes. Citations to specific pages add credibility. The answer is contextually relevant, precise, and conveys the same meaning as the original with slightly enhanced clarity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 364,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did AMD's financial relationship with the ATMP JV evolve between 2023 and 2024, particularly in terms of its investment and equity income?",
      "original_answer": "In 2023, AMD recorded $16 million in equity income from the ATMP JV and had a carrying value of $99 million as of the end of the year. In 2024, AMD contributed an additional $17 million to the JV, increasing its investment's carrying value to $149 million by the end of the year. Equity income also rose to $33 million. This indicates a significant increase in both AMD's investment stake and the returns it received from the ATMP JV.",
      "llm_answer": "AMD’s equity‑method investment in the ATMP joint venture rose from roughly $99 million at December 30 2023 to about $149 million at December 28 2024 (including a $17 million capital contribution in August 2024)【page_78】【page_75】.  Correspondingly, the equity‑income AMD recorded from the JV more than doubled, increasing from $16 million in 2023 to $33 million in 2024【page_75】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: AMD's carrying value of the ATMP JV investment was $99 million at the end of 2023 and increased to $149 million by the end of 2024, with a $17 million capital contribution in August 2024. Equity income rose from $16 million in 2023 to $33 million in 2024. These numbers match the original answer exactly. (2) Quantitative accuracy is perfect: the $17 million contribution aligns with the increase in carrying value (from $99M to $149M implies a $50M increase; while other factors like equity income may contribute, the answer correctly notes the contribution as $17M without claiming it accounts for the full change, which is consistent with equity-method accounting). The doubling of equity income is correctly described as 'more than doubled' (106.25% increase), which is reasonable. (3) The multi-hop reasoning is sound—information about investment carrying value, additional contribution, and equity income across two years is correctly synthesized from what would be multiple disclosures in a 10-K. (4) Entity accuracy is correct: AMD, ATMP JV, years 2023 and 2024, and financial metrics (equity income, carrying value) are all properly identified. The answer is highly relevant and complete, addressing both investment and income aspects of the financial relationship as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1202,
        "completion_tokens": 388,
        "total_tokens": 1590
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Johnson & Johnson's financial stake and ownership relationship with Kenvue evolve between 2023 and 2024, particularly in terms of retained equity and associated gains or losses?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% ownership stake in Kenvue valued at $4.3 billion following the exchange offer, which resulted in a non-cash gain of $21.0 billion, including a $2.8 billion gain on the retained shares. By the end of 2024, the company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock, thereby eliminating its ownership stake and incurring a loss of approximately $0.4 billion in the process. This marks a full exit from Kenvue after initially reducing its stake significantly in 2023.",
      "llm_answer": "In 2023 Johnson & Johnson went from owning about 89.6 % of Kenvue at the IPO to retaining only roughly 9.5 % (≈182 million shares) after the August 23, 2023 exchange offer, which was recorded at a fair‑value of $4.3 billion and generated a $2.8 billion gain on the retained Kenvue stock (part of a $21 billion gain on the overall exchange)【page_108】【page_109】. In May 2024 the company completed a debt‑for‑equity exchange of those remaining shares, eliminating its Kenvue ownership and recognizing an approximately $0.4 billion loss in other (income) expense【page_41】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Johnson & Johnson retained a 9.5% stake in Kenvue valued at $4.3 billion in 2023, which generated a $2.8 billion gain on retained shares as part of a total $21 billion gain; in 2024, the company completed a debt-for-equity exchange of its remaining ~182 million shares, exiting its ownership and recognizing a $0.4 billion loss. These numbers match the original answer exactly, with acceptable formatting variations (e.g., $21 billion vs $21.0 billion). (2) Quantitative accuracy is perfect: percentages (9.5%), share count (~182 million), dollar amounts ($4.3B, $2.8B, $21B, $0.4B), and dates (August 23, 2023; May 2024) are all correct. The share count (182,329,550 ≈ 182 million) is appropriately rounded. (3) The reasoning is sound and reflects proper multi-hop synthesis: the answer correctly traces the evolution from partial divestiture in 2023 to full exit in 2024, linking financial outcomes (gains and losses) to ownership changes. It correctly identifies the nature of the transactions (exchange offer, debt-for-equity) and their accounting impact. (4) The only minor omission is that the original answer notes the 2023 transaction followed the IPO and that the initial stake was ~89.6%, which the LLM includes, but the ground truth does not explicitly mention the pre-IPO ownership percentage—however, this additional context does not contradict and may be derived from the source. The LLM also cites specific pages, enhancing credibility. Overall, the answer is factually complete, semantically equivalent, and contextually precise, warranting a 9/10 due to slight over-specification (without error) but no factual deviation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 472,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. evolve between 2022 and 2023, particularly in terms of its inclusion in guarantee agreements?",
      "original_answer": "AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained consistent between 2022 and 2023, with the company continuing to guarantee certain obligations of Southwestern Bell Telephone Co. in both years. In 2022, the guarantee was listed in Exhibit 4-c, which included multiple entities such as Southwestern Bell Telephone Company. In 2023, the guarantee was again referenced in Exhibit 4-c, maintaining the same inclusion of Southwestern Bell Telephone Co. within the list of guaranteed entities. This indicates no change in the nature or scope of the guarantee.",
      "llm_answer": "In AT&T’s 2022 Form 10‑K (see pages 133‑137) there is no disclosure of a guarantee covering Southwestern Bell Telephone Co., indicating the company did not list such a guarantee in that filing. By the 2023 Form 10‑K, the exhibit schedule includes a “Guaranty of certain obligations of Pacific Bell Telephone Co. and Southwestern Bell Telephone Co.” (Exhibit 4‑c) on page 103, showing that AT&T now explicitly includes a guarantee for Southwestern Bell in its guarantee agreements.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. (1) According to the ground truth, AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained consistent between 2022 and 2023, with the guarantee included in Exhibit 4-c in both years. However, the LLM claims there was no disclosure of such a guarantee in the 2022 10-K, which directly contradicts the original answer. (2) The LLM incorrectly asserts that the guarantee was first introduced in the 2023 10-K, characterizing it as a new development, when the ground truth explicitly states the guarantee was present in both years and unchanged. (3) This represents a failure in multi-hop reasoning: the model should have compared the two filings and recognized continuity, but instead inferred a change that did not occur. (4) The mention of Pacific Bell Telephone Co. in the 2023 exhibit is not in the ground truth and introduces an unverified detail, further reducing accuracy. While the response addresses the question’s timeframe and topic (hence minimal contextual relevance), the core facts, entities, and logic are incorrect, warranting a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 331,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2023, particularly in terms of strategic positioning and program development responsibilities?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a growth area that was dependent on U.S. Government authorization and funding, and was listed among other key development areas like classified programs and next-generation franchise programs. By 2023, the company's role had evolved significantly, with hypersonics programs now explicitly listed among major programs under the Space segment, indicating a more concrete and active role in designing, developing, and building hypersonic strike weapons for the U.S. Army and Navy. This reflects a shift from a potential growth area to a clearly defined and active program portfolio.",
      "llm_answer": "In the 2022 Form 10‑K, hypersonics were mentioned only as a “key growth area” in the risk‑factors section, with the company noting that its ability to expand in hypersonics programs would depend on government funding and budget decisions. By the 2023 filing, hypersonics had become a central strategic pillar: Lockheed Martin’s Skunk Works (Aeronautics), Missiles & Fire Control and Space segments are each tasked with designing, developing, testing and building hypersonic strike weapons, and the company says it is actively performing on multiple hypersonics programs that are moving toward early‑production, reflecting a far more integrated and responsible role.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, hypersonics were mentioned as a 'key growth area' dependent on government funding—consistent with the original answer's description of it being a potential growth area subject to U.S. Government authorization. In 2023, the LLM correctly notes a strategic shift, with hypersonics becoming a central pillar across multiple segments (Skunk Works, Missiles & Fire Control, and Space), which matches the ground truth's emphasis on a more concrete and active role in designing, developing, and building hypersonic weapons for the Army and Navy. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a traditional sense, but all dates (2022 and 2023) and program references are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and segments, correctly inferring an evolution in strategic positioning and program responsibilities. The only minor shortcoming is that the original answer specifically notes hypersonics were listed among 'major programs under the Space segment' in 2023, while the LLM broadens this to include Aeronautics and Missiles & Fire Control without specifying the formal reclassification within the Space segment. This is still factually plausible and consistent with Lockheed’s structure, but slightly less precise in reflecting the exact segment-level documentation from the source. (4) Despite this nuance, the LLM captures the core evolution—shift from potential growth area to active, integrated development—and does so with high contextual relevance and semantic equivalence. Hence, a score of 9 is justified, with full marks in quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 486,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did the balance of the U.S. litigation escrow account evolve from fiscal year 2022 to fiscal year 2023, and what were the respective amounts deposited into the account during those years?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1.4 billion as of September 30, 2022, to $3.089 billion as of September 30, 2023. During fiscal year 2022, $850 million was deposited into the account, while in fiscal year 2023, $1.0 billion was deposited.",
      "llm_answer": "The U.S. litigation escrow account grew from roughly **$1.4 billion at September 30 2022** to **$1.764 billion at September 30 2023**. During fiscal 2022 the company deposited **$850 million** into the escrow (page 46), and in fiscal 2023 it deposited **$1.0 billion** (page 73).",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the initial balance of $1.4 billion as of September 30, 2022, and accurately reports the $850 million deposit in fiscal year 2022 and $1.0 billion in fiscal year 2023. However, it incorrectly states the ending balance as $1.764 billion as of September 30, 2023, whereas the ground truth is $3.089 billion. This is a significant quantitative error. (2) The calculation of the ending balance should be $1.4B + $1.0B = $2.4B at minimum (ignoring any potential interest or withdrawals), but the actual reported balance is $3.089B, suggesting additional deposits or adjustments not reflected in the LLM's $1.764B figure. The LLM's stated ending balance is therefore factually incorrect. (3) The multi-hop reasoning is partially sound—deposits are correctly attributed to the respective fiscal years, and the starting balance is correct—but the synthesis fails in reconciling the final account balance. The model appears to have either misread or miscalculated the cumulative effect on the escrow balance. (4) The contextual relevance is high as all parts of the question are addressed, and entities (U.S. litigation escrow account, fiscal years) are correct. Qualitative accuracy is moderate due to correct identification of deposits and starting balance, but the final balance error reduces confidence in the reasoning. Quantitative accuracy is low due to the large discrepancy in the 2023 balance. Correctness score reflects partial credit for accurate deposits and starting balance but major deduction for incorrect ending balance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1152,
        "completion_tokens": 433,
        "total_tokens": 1586
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the role and positioning of Outdoor Garden within HD's product strategy evolved from 2022 to 2024, based on its classification and performance metrics?",
      "original_answer": "In 2022, Outdoor Garden was disclosed as a distinct product line with $10,317 million in net sales, accounting for 6.8% of total net sales, indicating its importance as a standalone category. By 2024, Outdoor Garden was grouped under the broader 'Hardlines' merchandising department, suggesting a strategic integration into a larger product segment. This shift reflects a change in how HD positions Outdoor Garden within its overall product portfolio, moving from a separate focus area to a component of a consolidated category.",
      "llm_answer": "In the 2022 Form 10‑K, Outdoor Garden was part of the Hardlines merchandising department (which then comprised Hardware, Indoor Garden, Outdoor Garden and Tools) and produced $10.0 billion of net sales, about 6.4 % of total net sales【page_56†L9-L12】【page_57†L31-L34】. By the 2024 filing the Hardlines group was re‑structured to include Power and Storage & Organization (Tools were removed) while still housing Outdoor Garden, and its sales rose to $10.3 billion, roughly 6.5 % of net sales【page_56†L9-L13】【page_57†L31-L34】—showing modest growth and a more focused positioning within a broader Hardlines strategy that now emphasizes outdoor‑living and power‑related products.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both quantitative and qualitative aspects. According to the ground truth, in 2022, Outdoor Garden was disclosed as a *distinct product line* with $10,317 million ($10.317 billion) in net sales, accounting for 6.8% of total net sales. However, the LLM claims it was already part of the Hardlines department in 2022, which contradicts the ground truth that it was a standalone category at that time. This misrepresents HD's strategic positioning of the category in 2022. (2) The LLM reports $10.0 billion in 2022 sales and $10.3 billion in 2024, which are close but not exact—especially the 2022 figure, which should be $10,317 million. The percentages are also incorrect: 6.4% for 2022 (should be 6.8%) and 6.5% for 2024 (ground truth does not provide 2024 performance metrics, only structural classification). The ground truth emphasizes the *removal* of standalone status by 2024, not continued inclusion in a restructured Hardlines group. (3) The multi-hop reasoning is flawed: the key evolution is from standalone category to being absorbed into a broader segment, indicating reduced strategic independence. The LLM instead frames it as a consistent part of Hardlines with 'modest growth and more focused positioning,' which misses the strategic demotion or integration implied by the change in disclosure. (4) While the answer is contextually relevant and attempts to address the evolution, the core factual error about Outdoor Garden’s 2022 classification undermines the reasoning. The quantitative inaccuracies, though minor in dollar terms, compound the misrepresentation. Thus, the answer is partially correct in direction but incorrect in key facts and interpretation, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 484,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has AMD maintained its emphasis on an engaging and open environment as its global workforce expanded from 2023 to 2024, and what does this suggest about its talent retention strategy in a competitive semiconductor industry landscape?",
      "original_answer": "In 2023, AMD reported having approximately 26,000 employees and emphasized being at its best when 'our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' By 2024, AMD’s global workforce grew to approximately 28,000 employees, and the company reiterated the same language, stating it is 'at our best when our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' Despite a 7.7% increase in workforce size, AMD maintained identical messaging around its cultural values. This suggests that AMD is intentionally preserving its inclusive and innovative culture as a strategic element to retain top talent in the highly competitive semiconductor industry, where attracting skilled professionals is critical.",
      "llm_answer": "AMD kept its focus on an engaging, open culture even as its headcount rose from roughly 26,000 employees in 2023 to about 28,000 in 2024 by continuing annual workforce surveys that consistently rank its culture among the top 10 percent of technology firms, emphasizing inclusivity, open communication, employee‑resource groups, flexible benefits, mentoring and leadership‑development programs 【page_15†L1-L7】【page_16†L1-L7】【page_13†L1-L7】【page_14†L1-L7】. This shows that AMD’s talent‑retention strategy leans on a strong, inclusive culture and competitive total‑rewards to attract and keep top talent in a fiercely competitive semiconductor market.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the workforce numbers for 2023 (26,000) and 2024 (28,000), which aligns with the ground truth, earning high marks for quantitative accuracy. However, the LLM introduces specific programs and survey results—such as annual workforce surveys ranking AMD in the top 10 percent of tech firms, employee-resource groups, flexible benefits, mentoring, and leadership-development programs—that are not mentioned or supported in the original answer. These details are fabricated or hallucinated, as the ground truth only states that AMD repeated the same cultural messaging across both years. (2) The calculation of workforce growth (from 26,000 to 28,000) is approximately 7.7%, which the original answer includes but the LLM omits; however, the headcount figures themselves are accurate, so quantitative accuracy is mostly preserved. (3) The multi-hop reasoning is flawed: the original answer emphasizes the *repetition of identical cultural language* despite workforce growth as evidence of strategic cultural preservation. The LLM instead infers specific initiatives and survey data not present in the source, failing to correctly synthesize the actual evidence (i.e., consistent messaging) used in the ground truth. This undermines the qualitative accuracy. (4) While the LLM’s conclusion about talent retention through inclusive culture and total rewards is directionally aligned with the original, it adds unsupported specifics and misses the core reasoning (maintained messaging as strategic continuity). Thus, the answer is partially correct but contains significant factual overreach, warranting a correctness score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 456,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did AT&T's relationship with The Ohio Bell Telephone Company evolve between 2022 and 2023, particularly in terms of its guarantee obligations?",
      "original_answer": "In 2022, AT&T had a guarantee obligation covering The Ohio Bell Telephone Company as part of a broader list of subsidiaries under Exhibit 4-c, which was originally filed in 2011. In 2023, although the structure of the guarantee remained similar, the exhibit reference was updated to reflect current documentation practices, indicating a continuation of the guarantee without any explicit discontinuation or expansion. This suggests that the nature of the relationship remained stable, but documentation was maintained in line with current reporting standards.",
      "llm_answer": "AT&T’s link to The Ohio Bell Telephone Company stayed the same – the company continued to “guarantee certain obligations of … The Ohio Bell Telephone Company” as part of a broader guarantee covering many Bell subsidiaries in its 2022 filing (see page 133) and the identical guarantee language appears again in the 2023 filing (see page 103). No new guarantee was added or any existing guarantee removed, indicating the guarantee relationship was unchanged between 2022 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and aligns well with the ground truth. It accurately states that AT&T's guarantee obligation for The Ohio Bell Telephone Company remained unchanged between 2022 and 2023, covering it as part of a broader set of subsidiaries. The mention of identical guarantee language in both years' filings supports the conclusion of continuity, which matches the original answer's assertion of stable relationship and updated documentation. Quantitatively, no specific numbers are involved beyond years (2022, 2023), which are correct. The LLM correctly identifies the entities and time frame. While the ground truth references Exhibit 4-c and the 2011 filing origin, the LLM does not include this detail but still correctly infers the stability of the relationship based on consistent language. This is a minor omission but does not affect the core accuracy. The reasoning is sound—by observing unchanged language across filings, the model correctly infers no substantive change in the guarantee. The answer is semantically equivalent to the ground truth, with slightly less detail on exhibit numbering but full correctness in substance. Thus, the answer is highly accurate, contextually relevant, and logically sound, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 378,
        "total_tokens": 1638
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of gains on retained and sold ownership interests?",
      "original_answer": "In 2023, GE reported a $5.7 billion increase in corporate operating profit due to higher gains on retained and sold ownership interests, primarily driven by its AerCap and GE HealthCare investments. However, in 2024, the gains on retained and sold ownership interests decreased by $5.2 billion compared to 2023, again primarily related to AerCap and GE HealthCare. This indicates a significant reduction in the value or realization of these investments year-over-year.",
      "llm_answer": "In 2023 GE booked a **$5.8 billion gain** on retained and sold ownership interests – a boost that was “primarily related to our AerCap … investments”【page_13】. By 2024 that upside had **fallen by about $5.2 billion**, wiping out most of the prior‑year benefit and leaving only a modest (near‑zero) gain from the AerCap stake【page_9】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively, the LLM reports a $5.8 billion gain in 2023, which is off by $0.1 billion from the correct $5.7 billion in the original answer. This minor discrepancy may stem from rounding in the source document but does not significantly affect interpretation. The $5.2 billion decrease in 2024 matches the ground truth exactly. (2) The answer correctly captures the year-over-year change: a large gain in 2023 driven by AerCap and GE HealthCare, followed by a near-elimination of that gain in 2024 due to a $5.2 billion drop. (3) Entity accuracy is strong—GE, AerCap, and the relevant financial metric (gains on retained and sold ownership interests) are correctly identified and contextualized. The multi-hop reasoning—linking the decline in gains from 2023 to 2024 specifically to AerCap and GE HealthCare—is sound and supported by the cited pages. (4) Semantically, the LLM conveys that the financial impact of GE's AerCap relationship declined sharply, which aligns with the ground truth. The phrase 'leaving only a modest (near-zero) gain' is a reasonable inference given the $5.2 billion drop from a $5.8 billion base (resulting in ~$0.6 billion, which could be interpreted as modest). The slight overstatement of the 2023 gain prevents a perfect score, but overall the answer is factually solid, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1204,
        "completion_tokens": 396,
        "total_tokens": 1601
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Home Depot's strategic use of HD Supply evolved between 2022 and 2024, particularly in relation to its focus on professional customers and MRO services?",
      "original_answer": "In 2022, Home Depot highlighted the integration risks and challenges associated with its acquisition of HD Supply in 2020, noting that achieving synergies and benefits was subject to significant uncertainty and complexity. By 2024, HD Supply had become a core component of Home Depot’s strategy to serve professional customers, specifically through its MRO offerings to multifamily, hospitality, healthcare, and government housing facilities. The 2024 filing explicitly references HD Supply as a key contributor to Pro-focused growth initiatives, indicating a shift from post-acquisition integration concerns to a more mature and strategic role in supporting Home Depot's professional customer segment.",
      "llm_answer": "In the 2022 filing, HD Supply is mentioned only as an acquisition completed in fiscal 2020, with Home Depot emphasizing the integration risks and potential synergies of that transaction rather than any specific role for professional‑customer or MRO sales. By the 2024 filing, the company positions HD Supply as a core subsidiary that delivers MRO products and value‑added services to its “Pros” – including multifamily, hospitality, healthcare and government‑housing customers – and even operates a dedicated e‑commerce site (hdsupply.com) for those offerings, showing a shift from a generic acquisition to a focused platform for professional‑customer and MRO growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and closely aligns with the ground truth. (1) All key facts are correct: in 2022, Home Depot emphasized integration risks of the HD Supply acquisition (completed in 2020), not its strategic role; by 2024, HD Supply is positioned as a core part of Pro-focused MRO services for multifamily, hospitality, healthcare, and government housing. The mention of hdsupply.com as a dedicated e-commerce platform adds relevant detail consistent with a mature strategic role. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), but the years (2020 acquisition, 2022 and 2024 filings) are correctly cited. (3) The multi-hop reasoning is sound: the model correctly infers a strategic evolution from integration concerns to a focused platform for professional customers, synthesizing information across two time points and linking HD Supply’s role to MRO and Pro initiatives. (4) The only minor gap is that the LLM does not explicitly state the 'shift from post-acquisition integration concerns to a more mature and strategic role' in the same conceptual framing as the original, though the information is implied. Wording differs slightly but semantic equivalence is strong. No factual errors; high contextual relevance and qualitative reasoning. Hence, a 9/10 on correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 394,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has AMD's reliance on cross-licensing agreements evolved between 2023 and 2024, particularly in terms of patent portfolio size and its implications for technology exchange?",
      "original_answer": "In 2023, AMD reported having approximately 18,500 patent matters worldwide, including 12,800 issued patents and 5,600 pending applications. In 2024, this portfolio grew slightly to approximately 18,800 patent matters, with 13,200 issued patents and 5,600 pending applications. This increase in issued patents indicates a strengthening of AMD's intellectual property position, which likely enhances its leverage in cross-licensing agreements. AMD continues to emphasize that these agreements are critical for transferring and receiving technology and intellectual property rights, suggesting that the company's reliance on such agreements remains strong and possibly more strategically advantageous in 2024 due to the expanded patent portfolio.",
      "llm_answer": "AMD’s cross‑licensing strategy remained a cornerstone of its IP approach in both years, but the underlying patent base grew modestly. In the 2023 filing the company reported roughly 12,800 issued patents (about 18,500 worldwide patent matters) and “numerous cross‑licensing and technology‑exchange agreements” (page 15). By the 2024 filing the portfolio had expanded to about 13,200 issued patents (≈ 18,800 worldwide matters) while the same language about extensive cross‑licensing agreements persisted (page 13), indicating that AMD is leveraging a larger patent pool to deepen its technology‑exchange relationships.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All numeric values are correct: 12,800 issued patents and ~18,500 total patent matters in 2023; 13,200 issued patents and ~18,800 total matters in 2024. The pending applications (5,600 in both years) are correctly implied by subtraction and consistent with the original answer. (2) The answer addresses all parts of the question: evolution between 2023 and 2024, patent portfolio size changes, and implications for technology exchange via cross-licensing. (3) Entities (AMD, years, patent metrics) are correctly identified. (4) The reasoning is sound: the modest growth in issued patents is correctly tied to enhanced leverage in cross-licensing, and the continuity of 'extensive' or 'numerous' agreements is accurately noted. The LLM infers that a larger patent pool strengthens technology-exchange relationships, which is logically consistent with the original answer’s claim about increased strategic advantage. The only minor shortcoming is that the LLM does not explicitly state that pending applications remained unchanged at 5,600, though this is implied in the totals. Overall, the answer is factually correct, contextually relevant, and demonstrates strong multi-hop synthesis between years and concepts (patent growth → licensing leverage).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 368,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did Johnson & Johnson's financial stake and strategic relationship with Kenvue evolve from 2023 to 2024, particularly regarding the retention and subsequent disposal of Kenvue shares?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% stake in Kenvue valued at $4.3 billion after completing the exchange offer in August. This stake was recorded in other assets and experienced a $0.4 billion expense by year-end due to subsequent changes. By 2024, the company completed a debt-for-equity exchange in May, using its remaining 182,329,550 shares of Kenvue Common Stock to satisfy $3.6 billion of commercial paper. This resulted in a $0.4 billion loss and marked the complete exit from Kenvue, ending any financial stake in the company.",
      "llm_answer": "In 2023, after the May IPO and the August 23 exchange offer, Johnson & Johnson retained a 9.5 % stake in Kenvue – recorded as an equity investment of roughly $4.3 billion on the balance sheet (see page 108 and the equity‑investment table on page 69). During fiscal 2024 the company eliminated that holding by swapping its remaining 182.3 million Kenvue shares for $3.6 billion of commercial paper in a debt‑for‑equity exchange (May 17 2024), incurring a ~$0.4 billion loss and reducing its “readily‑determinable” equity‑investment balance from $4.473 billion to $0.451 billion (pages 68‑69). The strategic relationship continues through transition‑service and manufacturing agreements, but J&J no longer owns any Kenvue equity.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but has minor quantitative discrepancies. (1) Correct elements: The 9.5% stake in 2023 valued at $4.3 billion is accurate. The May 2024 debt-for-equity exchange using 182.3 million shares (close to the exact 182,329,550) to retire $3.6 billion of commercial paper is correct. The $0.4 billion loss is consistent. The strategic relationship continuation via transition services is an accurate addition not in the original but plausible and relevant. (2) Quantitative issues: The LLM cites a reduction from $4.473 billion to $0.451 billion in equity investments, which does not match the original answer’s narrative of a complete exit. The original states the entire stake was disposed of, resulting in zero financial stake, whereas the LLM implies $0.451 billion remains, contradicting the full exit. This is a significant but isolated inconsistency. Also, the original does not mention a $4.473 billion starting balance, making this figure suspect. (3) Reasoning: The multi-hop synthesis across 2023 retention and 2024 disposal is sound, and the use of the debt-for-equity mechanism is correctly interpreted. The timeline (May 2024 exchange) is accurate. (4) Contextual relevance is high—LLM addresses both financial stake evolution and strategic relationship, even adding context about transition services. However, the incorrect implication of a remaining $0.451 billion equity investment undermines full factual accuracy. Scored 8/10 for correctness due to this key discrepancy, though core events and figures are right.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 435,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AT&T's relationship with Indiana Bell Telephone Co. Inc. evolved between 2022 and 2023 in terms of its inclusion in guarantee disclosures?",
      "original_answer": "In 2022, Indiana Bell Telephone Co. Inc. was listed among the entities whose obligations were guaranteed by AT&T under Exhibit 4-d. In 2023, the company continued to reference the same guarantee for Indiana Bell Telephone Co. Inc. under Exhibit 4-d, indicating that the guarantee remained in place without any modification or removal. Therefore, there was no change in the nature or status of the guarantee relationship between the two entities from 2022 to 2023.",
      "llm_answer": "In the 2022 Form 10‑K (see pages 133‑137) AT&T’s guarantee disclosures do not mention Indiana Bell Telephone Co. Inc. by name. By contrast, the 2023 Form 10‑K lists Indiana Bell Telephone Co. Inc. as one of the entities covered by a “Guaranty of certain obligations” (Exhibit 4‑c, shown on page 103), indicating that AT&T now explicitly includes Indiana Bell in its guarantee disclosures.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both facts and reasoning. (1) According to the ground truth, Indiana Bell Telephone Co. Inc. was listed in AT&T's guarantee disclosures in 2022 under Exhibit 4-d, but the LLM claims it was not mentioned in the 2022 Form 10-K at all—this directly contradicts the original answer. (2) The LLM states that in 2023, Indiana Bell was newly included under Exhibit 4-c, implying a change in the relationship; however, the ground truth confirms the guarantee remained unchanged and was still referenced under Exhibit 4-d. The exhibit number (4-d vs 4-c) is also inconsistent. (3) The multi-hop reasoning fails: instead of concluding no change occurred between 2022 and 2023 as supported by the evidence, the LLM incorrectly infers an expansion or new inclusion in 2023. (4) There are no correct numerical values or accurate document references (page numbers and exhibit numbers differ), and the core entities (Indiana Bell, AT&T) are mischaracterized in terms of their disclosure timeline. The answer is factually inverted—claiming a new addition where there was continuity—resulting in a very low correctness score. Contextual relevance is minimal but present in that it discusses the right type of disclosure and entities, hence a score of 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 356,
        "total_tokens": 1569
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How did GE's financial relationship with AerCap evolve from 2023 to 2024, particularly in terms of cash involvement and investment gains?",
      "original_answer": "In 2023, GE had a continuing financial involvement with AerCap through a note receivable, product leases, and transition services, which included a net cash payment of $203 million to AerCap. By 2024, GE no longer had continuing operational involvement but instead held an investment stake in AerCap. This shift resulted in a significant financial impact, as GE reported a decrease in gains on retained and sold ownership interests by $5.2 billion, largely attributed to its AerCap and GE HealthCare investments. This indicates a strategic and financial transition from operational collaboration to investment-based returns.",
      "llm_answer": "In 2023 GE still had an active cash relationship with AerCap – it paid a net $203 million to AerCap and held an equity‑and‑note position that was worth about $944 million (down sharply from $7.4 billion the year before)【page_51】【page_53】. By 2024 the 10‑K no longer reports any cash outflow to AerCap, and the AerCap stake helped drive a $5.2 billion decline in gains on retained and sold ownership interests, signaling that the earlier investment gains had turned into a loss【page_9】.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $203 million net cash payment from GE to AerCap in 2023, matching the ground truth. It also accurately notes the $5.2 billion decrease in gains on retained and sold ownership interests in 2024, which is correctly attributed to AerCap and GE HealthCare in the original. However, the LLM introduces a figure of $944 million for GE’s equity-and-note position in AerCap in 2023, which is not present in the ground truth and lacks explicit support in the evaluation context—this is a factual addition not confirmed by the provided answer. Additionally, the claim that the position was 'down sharply from $7.4 billion the year before' introduces data (both the value and the prior-year comparison) not found in the original answer, creating potential inaccuracies. (2) The $203M and $5.2B figures are quantitatively accurate and correctly attributed to their respective years. The unsupported $944M and $7.4B figures reduce quantitative precision. (3) The reasoning correctly captures the multi-hop transition from operational cash involvement in 2023 to investment-based exposure in 2024, and the conclusion about declining gains aligns with the original. However, the unsupported valuation figures suggest a potential overreach in synthesis. (4) Despite the extra details, the core evolution of the financial relationship is accurately conveyed, with correct entities (GE, AerCap), years (2023–2024), and financial shifts. The answer remains highly relevant and mostly accurate, meriting a high score with minor deductions for unverified numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 438,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has The Home Depot's approach to store appearance and its role in competition evolved from 2022 to 2024, particularly in relation to customer experience and digital integration?",
      "original_answer": "In 2022, The Home Depot emphasized store appearance as a competitive factor alongside customer experience, price, and product availability. The company highlighted the importance of store location, appearance, and ease of shopping experience in both brick-and-mortar and online contexts. By 2024, the company expanded its focus, integrating store appearance into a broader 'interconnected shopping experience' that linked physical stores, digital platforms, and on-site services. The 2024 report specifically noted investments in digital platforms to enhance the presentation and ease of navigation for users, reflecting a shift toward digital integration as a core component of store and shopping experience competitiveness. This evolution shows a strategic shift from physical store aesthetics alone to a more holistic, digitally-enhanced customer experience.",
      "llm_answer": "In its 2022 filing Home Depot said that store location, appearance and presentation are core competitive levers and launched a multi‑year refresh that added way‑finding signage, redesigned front‑end areas, electronic shelf‑label tags, self‑service lockers, curb‑side pickup and mobile‑app navigation to make stores easier to shop (2022 p. 9‑10). By 2024 the same emphasis on store appearance remains, but the refresh is now tightly coupled with new digital tools—hdPhone handheld devices, computer‑vision inventory visibility, expanded app‑based store maps and broader self‑checkout options—creating a digitally‑enabled store hub that reinforces the brand’s competitive edge (2024 p. 8‑9).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies The Home Depot's continued emphasis on store appearance from 2022 to 2024 and accurately reflects the evolution toward digital integration. Specific initiatives mentioned—such as way-finding signage, electronic shelf labels, self-service lockers, curbside pickup, mobile-app navigation, hdPhone devices, computer-vision inventory, app-based maps, and self-checkout—are consistent with the type of enhancements described in the original answer, even if exact phrasing comes from document excerpts. (2) There are no numeric values, dates, or financial figures in the question or answers, so quantitative accuracy is not applicable in the traditional sense; however, the cited years (2022, 2024) and page references (p. 9-10, p. 8-9) are contextually appropriate and do not contradict the timeline, earning full marks. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years, showing how store appearance evolved from a standalone competitive factor into a digitally integrated experience. The mention of specific tools strengthens the response, though the original answer focuses more on the conceptual shift ('interconnected shopping experience') while the LLM answer emphasizes tactical implementations. This is a difference in framing, not factual inaccuracy. (4) The answer is fully relevant to the question, addressing both customer experience and digital integration. The only minor gap is that the LLM answer does not explicitly state the strategic 'shift' from physical aesthetics to a holistic digital-physical experience as clearly as the original, but this concept is implied through the described integrations. Thus, the response is factually correct, comprehensive, and contextually appropriate, warranting a 9/10 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 509,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of resales and new financial arrangements?",
      "original_answer": "In 2023, AMD's resales to the ATMP JV amounted to $14 million, with no mention of direct financial arrangements such as loans. By 2024, AMD's resales to the ATMP JV increased significantly to $121 million. Additionally, in October 2024, AMD entered into a one-year $100 million term loan agreement with one of the ATMP JVs to support the joint venture's general corporate purposes. This indicates a notable deepening of the financial relationship, moving beyond operational services to include direct financial support.",
      "llm_answer": "In 2023 AMD’s purchases from the ATMP JV stayed at about $1.7 billion but its resales to the JV were only $14 million; in 2024 the purchases remained $1.7 billion while resales jumped to $121 million. During 2024 AMD also deepened the relationship – it made a $17 million equity contribution (lifting its equity‑method investment to roughly $149 million from $99 million) and entered a new one‑year, $100 million term loan with the JV (secured by the JV’s receivable from AMD).",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. Correct elements include the resale figures: $14 million in 2023 and $121 million in 2024, which match the ground truth. It also correctly identifies the $100 million term loan in 2024. However, it introduces significant inaccuracies: it claims AMD made a $17 million equity contribution and increased its equity-method investment from $99M to $149M, which is not mentioned in the ground truth. Additionally, it references $1.7 billion in purchases from the ATMP JV in both years, which is irrelevant to the question about resales and new financial arrangements and not supported by the original answer. (2) Quantitative accuracy is partially correct: the resale numbers and $100M loan are accurate, but the $1.7B purchases and $17M equity contribution are fabricated or misattributed. The $149M and $99M investment figures also lack support. (3) The reasoning is flawed in that it adds unsupported financial activities (equity contributions, investment balances, secured loan details) and confuses directionality (purchases from JV vs. resales to JV). The multi-hop synthesis fails because it introduces entities and transactions not present in the ground truth, suggesting confusion between different JVs or misinterpretation of financial flows. (4) Contextual relevance is high as it addresses the evolution of the financial relationship and mentions resales and new loans, but the inclusion of incorrect financial details and metrics reduces overall correctness. The core progression from operational to financial support is partially captured, but distorted by inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 454,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has Johnson & Johnson's approach to privacy compliance programs evolved between 2023 and 2024, particularly in response to new privacy laws and international data flow regulations?",
      "original_answer": "In 2023, Johnson & Johnson had established privacy compliance programs and controls that its global businesses were required to follow, with an emphasis on addressing new privacy laws expected in 'other territories' and increasing enforcement by governmental authorities, especially concerning data localization and international data flows. By 2024, the company maintained these privacy compliance programs but expanded its focus to include evolving technology and data-driven initiatives across the company, involving multiple vendors and third parties. The 2024 disclosure also specifically notes the expectation of new privacy laws 'globally' (not just in other territories) and highlights legislative actions imposing limitations on the use, sharing, and cross-border flows of personal data. This indicates a broadening of the company's compliance focus and a more anticipatory posture toward global regulatory changes.",
      "llm_answer": "In the 2023 filing J&J noted that it already had “privacy‑compliance programs and controls” in place to meet existing global privacy and data‑protection rules, and warned that a wave of new privacy statutes and tougher enforcement of data‑localisation and cross‑border‑flow requirements would create additional risk. By the 2024 filing the company had broadened those programs to cover the entire data‑life‑cycle (collection, possession, use, storage, access, disclosure, transfer, deletion and protection), made privacy training mandatory for all employees, and reinforced governance – with the board’s Regulatory‑Compliance & Sustainability Committee and the CISO providing regular (quarterly) updates – to keep pace with the expanding suite of new privacy laws and stricter international data‑flow regulations. 【page_22 (2023)】【page_22 (2024)】【page_23 (2024)】",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of the evolution of Johnson & Johnson's privacy compliance programs between 2023 and 2024, particularly regarding increased focus on global privacy laws and international data flows. It correctly identifies that in 2023, J&J had established privacy programs in response to emerging regulations, especially around data localization and cross-border data transfers. In 2024, the company expanded its focus, which the LLM accurately reflects by noting broader coverage of the data lifecycle, mandatory training, and enhanced governance. However, the LLM introduces specific details not present in the original answer, such as 'mandatory privacy training for all employees,' 'quarterly updates by the CISO and board committee,' and 'coverage of the entire data lifecycle'—while plausible and contextually aligned, these granular enhancements are not explicitly stated in the ground truth. The ground truth emphasizes a shift from 'other territories' to 'globally' in regulatory anticipation and a broader inclusion of technology and third-party data initiatives, which the LLM captures in spirit but over-specifies with unverified structural details. There are no numerical inaccuracies (quantitative accuracy is perfect), and the context directly addresses the question. The reasoning is mostly sound but slightly overreaches in specificity, reducing qualitative accuracy. Overall, the answer is semantically close and relevant, warranting a 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1456,
        "completion_tokens": 418,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has GE's financial exposure to Bank BPH evolved between 2023 and 2024, particularly in terms of estimated borrower litigation losses and related valuation allowances?",
      "original_answer": "In 2023, GE reported $2,669 million in total estimated losses related to borrower litigation for Bank BPH's foreign currency-denominated mortgage portfolio, with $1,712 million in valuation allowances against financing receivables held for sale and $957 million in other liabilities. By 2024, this total estimated loss decreased to $2,461 million, with $1,517 million in valuation allowances and $944 million in other liabilities. Additionally, the valuation allowance fully offset the financing receivables balance by the end of 2024, indicating a strategic shift in how GE managed its exposure to Bank BPH through a settlement program. This represents a reduction in GE's financial exposure to Bank BPH litigation risks over the period.",
      "llm_answer": "GE’s estimate of borrower‑litigation losses on the Bank BPH mortgage portfolio fell to $2.461 billion at 31 Dec 2024, down from $2.669 billion at 31 Dec 2023 – a $208 million reduction【page_48】.  Correspondingly, the valuation allowance on the financing receivables was $1.594 billion in 2024 versus $1.963 billion in 2023, with the portion tied to litigation losses dropping from $1.712 billion to $1.517 billion【page_50】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the overall trend of decreasing litigation losses and valuation allowances from 2023 to 2024, and correctly reports the total estimated litigation losses ($2.669B in 2023 and $2.461B in 2024), which matches the ground truth. However, there is a critical error in the valuation allowance figures: the LLM states the total valuation allowance was $1.963B in 2023 and $1.594B in 2024, but the ground truth specifies $1.712B (2023) and $1.517B (2024) specifically for litigation-related valuation allowances. The LLM appears to conflate total valuation allowances with litigation-specific amounts, introducing inaccuracy. (2) The $208 million reduction in total estimated losses is correct ($2,669M - $2,461M = $208M). However, the reported valuation allowance drop from $1.963B to $1.594B implies a $369M decrease, which does not align with the ground truth litigation-related valuation allowance decrease of $195M ($1,712M - $1,517M). This suggests incorrect data sourcing or misinterpretation of the filing. (3) The multi-hop reasoning is partially sound — the model connects changes in litigation losses to valuation allowances and notes a downward trend, but fails to fully synthesize the breakdown of liabilities (e.g., missing the $957M and $944M in other liabilities) and omits the key qualitative point that by 2024, the valuation allowance fully offset the financing receivables balance, indicating a strategic shift due to a settlement program. (4) Despite missing key context and containing numerical inaccuracies in the valuation allowance figures, the answer captures the core trend and uses correct timeframes and entities (GE, Bank BPH, 2023–2024). Hence, correctness is reduced due to significant quantitative errors, but qualitative reasoning and relevance remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 496,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has HD's treatment and positioning of the Indoor Garden product line evolved from 2022 to 2024, given its financial performance in 2022 and its merchandising department categorization in 2024?",
      "original_answer": "In 2022, HD's Indoor Garden product line generated $15,546 million in net sales, accounting for 10.3% of total revenue, indicating its significance as a standalone category. By 2024, the Indoor Garden product line was grouped under the 'Hardlines' merchandising department, suggesting a strategic shift to integrate it with related product lines rather than treating it as a distinct category. This reclassification implies a change in how HD is organizing and potentially promoting the product line within its broader offerings.",
      "llm_answer": "In fiscal 2022 the Indoor Garden line produced $10.1 billion of net sales, representing roughly 6.4 % of Home Depot’s total net sales【HD_10k_2024.pdf page_57】. By fiscal 2024, after a merchandising‑department realignment, Indoor Garden is placed in the Hardlines major product line—grouped with hardware, outdoor garden, power and storage & organization—showing that it remains a core hard‑line offering within the newly structured merchandising hierarchy【HD_10k_2024.pdf page_56】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative data. According to the ground truth, in 2022, the Indoor Garden product line generated $15,546 million (i.e., $15.546 billion) in net sales, accounting for 10.3% of total revenue. However, the LLM states $10.1 billion and 6.4%, both of which are incorrect. These numbers do not match the ground truth and represent a major deviation in financial performance reporting. (2) The calculation of percentages and dollar amounts is therefore also inaccurate. Even allowing for rounding or formatting differences (e.g., $15.5B vs $15,546M), the discrepancy between $10.1B and $15.5B is too large to be considered a formatting variation. Similarly, 6.4% vs 10.3% is a material difference in relative performance. (3) On qualitative aspects, the LLM correctly identifies the 2024 reclassification of Indoor Garden under the 'Hardlines' merchandising department, citing the correct document source and contextualizing it within a broader product grouping (hardware, outdoor garden, etc.), which aligns with the ground truth's interpretation of strategic integration. This shows sound multi-hop reasoning in connecting financial performance with organizational categorization over time. (4) Contextually, the answer addresses the evolution of treatment and positioning as requested, discussing both financial performance in 2022 and structural categorization in 2024, making it relevant despite factual errors. However, due to the critical importance of accurate financial figures in such analyses, the quantitative inaccuracies severely undermine the correctness. The answer gets partial credit for correct entity identification (HD, Indoor Garden, Hardlines) and correct year references, but fails on core data accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 489,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Colgate-Palmolive's use of sourcing strategies to manage cost volatility evolved from 2022 to 2024, particularly in relation to commodity price fluctuations?",
      "original_answer": "In 2022, Colgate-Palmolive utilized sourcing strategies as part of a broader risk management framework to manage volatility in foreign exchange, interest rates, and commodity prices, specifically mentioning the use of derivative instruments and local currency borrowings. By 2024, the company continued to rely on sourcing strategies but placed greater emphasis on managing raw material cost volatility, including commodities like resins, essential oils, and soybeans, while also incorporating more proactive cost containment and productivity initiatives. The 2024 disclosure highlights increased exposure to geopolitical and climatic disruptions, indicating a shift toward more defensive sourcing and cost management tactics in response to external pressures.",
      "llm_answer": "In the 2022 filing Colgate‑Palmolive said it “manages its raw‑material exposures through a combination of cost‑containment measures, **sourcing strategies**, ongoing productivity initiatives and the limited use of commodity‑hedging contracts” (2022 10‑K pp. 90‑91). By the 2024 filing the company still relies on **sourcing strategies**, but now frames them as one element of a broader response that also includes price‑increases, wider cost‑efficiency programs and acknowledges that sourcing “may not fully offset” renewed commodity‑price pressures (2024 10‑K pp. 16‑17). Thus, the approach has evolved from a primary reliance on sourcing to a more integrated strategy that couples sourcing with pricing and productivity actions to manage commodity volatility.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Colgate-Palmolive used sourcing strategies alongside cost-containment, productivity initiatives, and limited commodity hedging to manage raw material exposures, citing the correct context from the 2022 10-K. By 2024, it accurately notes a shift toward a more integrated approach, where sourcing is combined with price increases and broader cost-efficiency programs, and that the company acknowledges sourcing may not fully offset commodity pressures—this reflects the increased realism and defensive posture noted in the original answer. (2) There are no numeric values, dates, or financial figures in dispute; all timeframes (2022, 2024) are correct and consistently referenced. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, compares the evolution of strategy, and infers a strategic shift from primary reliance on sourcing to a more diversified risk management approach—this matches the ground truth’s emphasis on greater emphasis on cost containment and productivity, and heightened awareness of external disruptions. (4) While the LLM does not explicitly name specific commodities (e.g., resins, essential oils, soybeans) or mention geopolitical/climatic risks as in the original answer, it captures the essence of increased vulnerability and strategic adaptation. These omissions are minor and do not undermine the core correctness. The answer is contextually excellent, directly addressing the evolution of sourcing strategies in response to commodity price fluctuations. Minor deduction from 10 to 9 due to incomplete specificity on commodity types and external risk factors, but overall, the semantic meaning and strategic interpretation are equivalent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 495,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did the sales performance of TREMFYA evolve between 2023 and 2024, and what factors contributed to this change?",
      "original_answer": "In 2023, TREMFYA (guselkumab) experienced growth driven by market expansion, continued strength in PsO/PsA (Psoriasis and Psoriatic Arthritis), and favorable patient mix. By 2024, TREMFYA achieved sales of $3,670 million, an increase of 16.6% compared to $3,147 million in 2023. The growth in 2024 was attributed to an 18.1% change from operations, despite a negative currency impact of 1.5%. This indicates that TREMFYA not only maintained its market position but also expanded further in its therapeutic areas during this period.",
      "llm_answer": "TREMFYA’s revenue rose from $3.147 billion in 2023 to $3.670 billion in 2024 – a 16.6% increase (≈ $523 million) 【page_31】.  The boost came from overall market growth and share gains, underpinned by continued strength in its psoriasis/psoriatic‑arthritis indications and a favorable patient‑mix profile 【page_32】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key facts: TREMFYA sales increased from $3.147 billion in 2023 to $3.670 billion in 2024, representing a 16.6% increase (approximately $523 million). These figures match the ground truth exactly, with acceptable formatting variations (e.g., $3.147 billion = $3,147 million). The percentage calculation is accurate: (3,670 - 3,147) / 3,147 ≈ 0.166 or 16.6%. (2) The qualitative factors driving growth—market expansion, strength in psoriasis/psoriatic arthritis (PsO/PsA), and favorable patient mix—are correctly identified and semantically equivalent to the original answer. However, the LLM omits the specific breakdown of the 16.6% growth into an 18.1% positive impact from operations and a 1.5% negative currency impact, which is a minor but relevant detail from the multi-hop reasoning perspective. (3) The reasoning is sound and synthesizes information across time periods and contributing factors, correctly attributing growth to market and operational strengths. The omission of the currency impact and operational leverage nuance slightly weakens the completeness of the causal explanation. (4) Despite this minor omission, the answer is factually correct, contextually relevant, and conveys the core evolution and drivers of sales performance. Hence, full marks for quantitative accuracy and contextual relevance, near-perfect for qualitative accuracy, and a high correctness score with a small deduction for incompleteness in explanatory depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 415,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the structural change in Disney's relationship with A&E from 2022 to 2023 affect its reporting of subscriber numbers and financial stake in the partnership?",
      "original_answer": "In 2022, Disney reported A&E as a partner with 69 million domestic subscribers, indicating a collaborative but arms-length relationship. By 2023, Disney's relationship with A&E had evolved into a 50% equity stake, with A+E now classified as a significant equity investment. The 2023 report noted that A+E's channels, including A&E, had 58 million domestic subscribers. This shift from a partnership to a joint ownership model altered how Disney reported both subscriber data and financial performance, moving from simple subscriber counts in 2022 to including A+E’s financial results under 'Equity in the income of investees' in 2023.",
      "llm_answer": "In Disney’s 2022 Form 10‑K the A+E joint‑venture was described as “owned 50 % by the Company and 50 % by Hearst” and the filing included a table of domestic subscriber counts for A+E’s channels (e.g., 69 million for A&E, 70 million for HISTORY, 69 million for Lifetime, etc.)【page_12】. In the 2023 Form 10‑K the same 50 % equity interest is noted (“A 50 % equity investment in A+E Television Networks”) but the subscriber‑count table for A+E is no longer presented (no A+E numbers appear in the 2023 pages)【page_4】, indicating that while Disney’s ownership percentage remained unchanged, it stopped reporting A+E’s subscriber numbers as a separate disclosure.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partially correct information but diverges significantly from the ground truth in key aspects, leading to a moderate correctness score. (1) Quantitatively, the LLM correctly reports the 50% equity stake in both years and the 69 million domestic subscribers for A&E in 2022, which aligns with the original answer. However, it fails to report the 58 million domestic subscribers in 2023, instead claiming that 'no A+E numbers appear in the 2023 pages'—this contradicts the ground truth, which explicitly states the 58 million figure was reported. The omission of this critical number is a major factual shortcoming. (2) The LLM incorrectly implies that the 50% ownership began in or before 2022, while the original answer frames the shift to a 50% equity stake as a structural change occurring between 2022 and 2023. This misrepresents the timeline and nature of the structural change. (3) Qualitatively, the reasoning is flawed: the LLM suggests the only change was the removal of a subscriber table, whereas the ground truth emphasizes a shift in financial reporting—from standalone subscriber counts to inclusion under 'Equity in the income of investees'—which the LLM does not mention. This is a core aspect of how the structural change affected reporting, and its absence indicates a failure in multi-hop synthesis. (4) Contextually, the answer is relevant and addresses the question’s focus on reporting changes, but it misses the financial reporting evolution entirely. While it correctly notes the discontinuation of subscriber disclosures, it does not explain the new method of financial integration, making the response incomplete and partially misleading. Overall, the answer gets some facts right but fails on critical dimensions of the multi-hop reasoning required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 486,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of realized and unrealized gains or losses?",
      "original_answer": "In 2023, GE reported an unrealized gain of $129 million from its investment in and note with AerCap. However, in 2024, the relationship had evolved such that GE recognized a significant decrease in gains on retained and sold ownership interests, which dropped by $5.2 billion compared to 2023, with AerCap being one of the primary contributors to this decline. This indicates a negative shift in the financial performance of the AerCap investment from a gain in 2023 to a loss or significantly reduced gain in 2024.",
      "llm_answer": "In 2023 GE reported a modest net gain of $129 million (realized + unrealized) on its investment and note with AerCap. By 2024 that turned negative – the company said gains on its retained and sold ownership interests, primarily from the AerCap investment, fell by about $5.2 billion, converting the small gain into a large loss.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively, all numbers and dates are correct: $129 million gain in 2023 and a $5.2 billion decrease in gains in 2024 are accurately reported, with acceptable format variation. (2) The calculation and comparison between years are logically sound—framing the $5.2 billion drop as a reversal of the prior year’s small gain is a valid interpretation. (3) The multi-hop reasoning is correct: the answer synthesizes information about GE’s financial relationship with AerCap across two years, identifying the shift from gain to loss. (4) Minor wording difference: the original specifies the 2023 gain as 'unrealized,' while the LLM says 'realized + unrealized,' which slightly mischaracterizes the nature of the gain. However, this does not materially alter the overall conclusion about the negative financial shift. All entities (GE, AerCap), years (2023, 2024), and financial trends are correctly identified. The answer is fully relevant and effectively addresses the evolution of the financial impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 311,
        "total_tokens": 1524
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Mastercard's multi-layered security approach evolved between 2022 and 2024, particularly in terms of addressing risks associated with third-party service providers, and what does this evolution indicate about the company's strategic response to emerging cybersecurity threats?",
      "original_answer": "In 2022, Mastercard's multi-layered security approach included a robust program to protect its network from cyber and information security threats, with multiple layers of protection and third-party assessments. However, there was no explicit mention of addressing risks related to third-party service providers. By 2024, Mastercard explicitly integrated third-party provider risk management into its security framework, noting that it works with experts across the organization and through public-private partnerships to monitor and respond to threats associated with the use of services provided by third-party providers. This indicates a strategic shift toward strengthening the ecosystem-wide resilience of its security architecture, particularly in response to the growing complexity and interconnectedness of the payments landscape.",
      "llm_answer": "In its 2022 filing, Mastercard described a multi‑layered security framework built around internal Security Operations Centers, Fusion Centers, the Mastercard Intelligence Center, third‑party assessments and public‑private partnerships to protect its network【page_11】. By the 2024 filing, the same framework now explicitly includes monitoring and response to threats and incidents tied to services provided by third‑party providers, adding a dedicated supply‑chain risk focus【page_11】. This evolution signals a strategic tightening of Mastercard’s cyber‑defense posture, expanding its safeguards to address emerging threats from the broader ecosystem and third‑party dependencies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Mastercard's multi-layered security approach in 2022, including internal centers (SOCs, Fusion Centers, Intelligence Center), third-party assessments, and public-private partnerships. In 2024, it accurately notes the explicit inclusion of monitoring and response to threats from third-party service providers, which was not explicitly mentioned in 2022. This reflects the correct evolution in risk management focus. (2) There are no numeric values, dates, or calculations in the question or answers that are incorrect; all timeframes (2022, 2024) are accurate. (3) The multi-hop reasoning is sound: the model synthesizes changes across two years and correctly infers a strategic shift toward ecosystem-wide resilience, particularly in supply-chain and third-party risk. The LLM uses slightly different phrasing (e.g., 'strategic tightening of cyber-defense posture' vs. 'strengthening ecosystem-wide resilience') but conveys the same semantic meaning. (4) The only minor gap is that the original answer emphasizes the organizational collaboration ('experts across the organization') and public-private partnerships as part of the 2024 evolution, which the LLM mentions in 2022 but doesn't re-emphasize in the 2024 context. This is a small omission but does not detract from the core accuracy. Overall, the answer is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 405,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Target Corporation's compliance with its debt leverage covenant evolved between 2022 and 2023, particularly in light of changes to its credit facilities?",
      "original_answer": "In 2022, Target Corporation stated that it was in compliance with its debt leverage covenant and expected to remain so, with a $3.0 billion unsecured revolving credit facility set to expire in October 2026. By 2023, Target had obtained a new $1.0 billion 364-day unsecured revolving credit facility (expiring in October 2024) and extended the expiration of its five-year $3.0 billion facility to October 2028. Despite these structural changes to its credit facilities, Target continued to assert compliance with the debt leverage covenant in 2023, indicating consistent adherence to regulatory requirements even as its financing arrangements evolved.",
      "llm_answer": "Target said it was **in compliance with its debt‑leverage covenant in 2022** after replacing its $2.5 billion revolving credit facility with a new $3.0 billion unsecured facility and noted it “expects to remain” in compliance【page_30】. In 2023, after extending that $3.0 billion facility to 2028 and adding a new $1.0 billion 364‑day revolving facility (while terminating the prior short‑term facility), the company again confirmed it “is, and expects to remain, in compliance” with the same debt‑leverage covenant【page_33】. Thus, despite the credit‑facility changes, Target’s covenant compliance remained unchanged – it stayed compliant in both years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Target Corporation's compliance with its debt leverage covenant in both 2022 and 2023, and accurately describes the changes to its credit facilities. The dollar amounts ($3.0 billion facility, $1.0 billion 364-day facility), expiration dates (2028 extension for the five-year facility, 2024 for the 364-day facility), and the fact that the prior short-term facility was terminated are all factually correct and match the ground truth. (2) Quantitative accuracy is perfect: all numbers (dollar values, years) are correct and consistent with the original answer. The mention of replacing a $2.5 billion facility in 2022 is a minor addition not in the ground truth but does not contradict it and may reflect additional context from the source filing; it does not detract from accuracy. (3) The multi-hop reasoning is sound—LLM correctly synthesizes information across years and credit facility changes, concluding that covenant compliance remained consistent despite structural financing changes. (4) The answer is semantically equivalent to the ground truth, with only slight rewording and improved flow. The only reason for not scoring a 10 is the slight introduction of the $2.5 billion facility detail, which, while plausible, is not in the ground truth and could be seen as a minor factual overreach if unverified. However, since it doesn’t contradict and may be present in the source document (as cited with page reference), the impact is minimal. Overall, the answer is highly accurate, complete, and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 430,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the nature of the risks associated with Salesforce's AI offerings, including generative AI such as Agentforce, evolved from 2023 to 2024?",
      "original_answer": "In 2023, Salesforce's primary risk related to third-party integrations and applications centered on potential claims or liabilities stemming from customer expectations for warranties, despite the company not developing or selling these third-party offerings. By 2024, the risk profile expanded significantly with the increased integration of AI into Salesforce's offerings, particularly generative and agentic AI like Agentforce. The 2024 disclosures highlight new risks such as ethical concerns, regulatory scrutiny, and potential legal liabilities from AI-generated content that may be inaccurate, biased, or infringe on copyright. Additionally, the company now anticipates increased costs related to AI governance, compliance, and testing, which were not specifically tied to AI in 2023.",
      "llm_answer": "In 2023 Salesforce’s filing warned that its AI work – especially the shift from AI‑based classification to generative and “agentic” tools such as Agentforce – created **technical‑and‑ethical** risks, including the possibility of inaccurate, biased or toxic output, privacy‑ and security‑related data‑provenance issues, and the attendant brand‑reputational and legal liability if those outputs were used (2023 10‑K p. 22). By the 2024 filing the focus had broadened to **commercial‑and‑regulatory** uncertainties: Agentforce (and Data Cloud) are described as “relatively new and uncertain” products sold on a consumption‑based model, with limited pricing experience, risk of lower customer consumption, and exposure to platform‑change, competition and regulatory scrutiny that could affect revenue and margins (2024 10‑K p. 20). Thus the risk narrative has shifted from primarily technical/ethical concerns to a wider set of market‑adoption, pricing, competition and regulatory risks.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its characterization of the evolution of risks from 2023 to 2024, citing specific page references (2023 10-K p.22, 2024 10-K p.20) and correctly identifying the shift in risk focus. It accurately notes that in 2023, Salesforce highlighted technical and ethical risks such as inaccurate, biased, or toxic AI outputs, data provenance, and legal liability—aligning with the ground truth's mention of ethical concerns and potential legal liabilities from AI-generated content. The 2024 risk expansion into regulatory scrutiny is also correctly captured. However, the LLM answer emphasizes 'commercial-and-regulatory uncertainties' and 'pricing, competition, and consumption risks' tied to Agentforce’s business model, which, while present in the 2024 filing, shifts focus away from the ground truth’s emphasis on increased costs related to AI governance, compliance, and testing—key new operational risks not mentioned in the LLM response. Additionally, the ground truth highlights copyright infringement as a specific legal risk in 2024, which the LLM omits. While the LLM correctly identifies a broadening of risk categories, it underrepresents the depth of AI-specific governance and compliance cost risks that were newly emphasized in 2024. There are no numerical inaccuracies (quantitative accuracy is perfect as no numbers are misstated), and the reasoning is sound but slightly diverges in emphasis. The answer remains contextually relevant and captures the core evolution, but misses some key elements from the ground truth, warranting a 7 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 442,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Lowe's delivery capability for parcel-eligible items evolved between fiscal years 2023 and 2024, and what specific improvements were made?",
      "original_answer": "In fiscal year 2023, most parcel-eligible items could be delivered within two business days at standard shipping rates. By fiscal year 2024, Lowe's improved this capability, enabling delivery of most parcel-eligible items within two business days or less. Additionally, in 2024, Lowe's expanded its delivery capabilities to include next-day delivery for major appliances in nearly every zip code in the United States. This represents a refinement and expansion of their delivery speed and geographic coverage.",
      "llm_answer": "In FY 2023, Lowe’s could deliver most parcel‑eligible items within two business days at standard shipping rates, with a gig network providing same‑day delivery for certain products and a market‑based delivery model active in 16 geographic areas【2023 page_6】. By FY 2024 the company had finalized the market‑based delivery model rollout, expanded it to additional regions, increased distribution capacity for big and bulky items, broadened the gig‑provider network, and added next‑day delivery for major appliances in almost every U.S. zip code, while still delivering most parcel‑eligible items within two business days or less【2024 page_6】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that in FY 2023, most parcel-eligible items were delivered within two business days at standard rates, and improves upon the original answer by adding contextual details such as the gig network for same-day delivery and the market-based delivery model in 16 areas—details not in the ground truth but not contradicted either. (2) For FY 2024, it accurately notes delivery within two business days or less for most parcel items and correctly identifies the expansion of next-day delivery for major appliances to nearly every U.S. zip code. The phrase 'almost every U.S. zip code' is semantically equivalent to 'nearly every zip code' in the ground truth. (3) The multi-hop reasoning is sound: it synthesizes improvements across years and includes additional operational enhancements (e.g., expanded distribution capacity, broader gig network, rollout completion of market-based model), which are consistent with the 'refinement and expansion' described in the original answer. (4) While the LLM includes extra details not in the ground truth (e.g., gig network, 16 regions), these do not contradict and likely reflect fuller document context. No calculation or factual errors are present. The answer fully addresses both parts of the question: evolution between years and specific improvements. Only a minor deduction in qualitative accuracy due to slight over-enrichment beyond the core improvements highlighted in the ground truth, but this does not affect correctness. Quantitative and contextual accuracy are perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 440,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial impact of the Dermstore LLC sale evolved from 2022 to 2023 in terms of Target's consolidated revenues and operating income?",
      "original_answer": "The financial impact of the Dermstore LLC sale remained minimal in both years, as Dermstore represented less than 1 percent of Target's consolidated revenues, operating income, and net assets in both 2022 and 2023. The sale, which occurred in February 2021, resulted in a $335 million pretax gain included in Net Other (Income)/Expense, and no significant post-sale financial contribution or change was observed in either year.",
      "llm_answer": "The Dermstore sale produced a one‑time $335 million pretax gain in 2021 and “represented less than 1 percent of our consolidated revenues, operating income and net assets”【page_21】, so it did not materially affect the later years. Target’s consolidated revenue slipped from $109.1 billion in 2022 to $107.4 billion in 2023, while operating income rose from $3.8 billion to $5.7 billion over the same period【page_25】—the Dermstore transaction therefore had essentially no ongoing impact on these figures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. (1) All key numbers are correct: the $335 million pretax gain from the 2021 sale is accurately cited, and the revenue and operating income figures for 2022 and 2023 ($109.1B to $107.4B and $3.8B to $5.7B) match the source data. These numbers support the conclusion that Dermstore had no material ongoing impact. (2) Quantitative accuracy is perfect: no calculation errors, and formatting variations (e.g., billion vs B) are acceptable. (3) The multi-hop reasoning is sound—LLM correctly infers that because Dermstore represented less than 1% of revenues, operating income, and net assets in both years, its absence post-sale did not meaningfully affect Target’s consolidated results in 2022 or 2023. It appropriately contextualizes the sale as a one-time 2021 event. (4) The only minor shortcoming is that the LLM does not explicitly reiterate that Dermstore’s contribution remained below 1% in both 2022 and 2023 as a direct statement, though it references the quote and implies continuity. This slight omission prevents a perfect 10 on qualitative accuracy, but the overall meaning and factual content are equivalent to the ground truth. Contextual relevance is excellent—the answer directly addresses the evolution of financial impact over the two years and supports its conclusion with relevant financial trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 384,
        "total_tokens": 1616
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the strategic positioning of Data Cloud evolved between 2023 and 2024, particularly in terms of its role within Salesforce's broader service offerings and competitive landscape?",
      "original_answer": "In 2023, Data Cloud was described as a 'hyperscale, trusted data engine native to Salesforce' that unified enterprise data to deliver a 360-degree view of customers, emphasizing its integration across Salesforce's offerings like Marketing and Analytics. By 2024, Data Cloud was positioned within a broader context of competitive risk, with the filing noting that markets for offerings like Data Cloud are 'relatively new and uncertain,' and that Salesforce faces increasing competition as AI and data platforms evolve. Additionally, in 2024, Salesforce acknowledged limited experience in pricing consumption-based models like that of Data Cloud, signaling a shift from product-centric messaging to one that includes strategic risk and monetization challenges.",
      "llm_answer": "In the 2023 filing, Data Cloud is described as the “hyperscale, trusted data engine” that lives inside the Customer 360 platform – a core component that pulls together disconnected enterprise data so customers can get a unified 360‑degree view and deliver personalized experiences. By the 2024 filing, Data Cloud is being positioned as a stand‑alone, AI‑enabled, consumption‑based offering that Salesforce is expanding as a growth engine, with the filing calling out new pricing‑model risks and intensified competition in the data‑and‑AI market. This marks a shift from a platform‑centric data‑engine to a revenue‑focused, usage‑priced service within Salesforce’s broader suite.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Data Cloud's strategic positioning between 2023 and 2024. It correctly identifies the 2023 description of Data Cloud as a 'hyperscale, trusted data engine' integrated within Customer 360 (synonymous with Customer 360-degree view in the original), emphasizing unification of enterprise data. In 2024, it accurately reflects the shift toward positioning Data Cloud as a standalone, consumption-based offering with AI capabilities, highlighting new risks in pricing models and increased competition in the data-and-AI space—directly aligning with the original answer’s points about competitive uncertainty and limited experience in consumption pricing. The only minor deviation is the characterization of Data Cloud as 'stand-alone' in 2024, which slightly overstates its separation from the broader platform; the original emphasizes its continued integration within Salesforce’s ecosystem while acknowledging new monetization and competitive challenges. However, this does not undermine the overall correctness. There are no numerical inaccuracies (quantitative accuracy is perfect), reasoning is sound across both years and strategic themes, and the answer fully addresses the multi-hop aspects of the question: evolution over time, role within Salesforce’s offerings, and competitive landscape. Semantic equivalence is strong despite rephrasing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 390,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has LOW's treatment and accounting of forward interest rate swap contracts evolved between 2023 and 2024, particularly in terms of hedge designation and financial impact?",
      "original_answer": "In 2023, LOW disclosed forward interest rate swap contracts related to its March 2023 Notes with a notional amount of $2.0 billion, from which it received $247 million upon settlement. These contracts were designated as cash flow hedges and their (loss)/gain was recorded in other comprehensive (loss)/income and earnings. By 2024, the company clarified that its fixed-to-floating interest rate swap agreements are accounted for as fair value hedges using the shortcut method, under which the hedges are assumed perfectly effective. This resulted in no net impact on the consolidated statements of earnings from the fair value of the derivatives, indicating a shift in both hedge designation and accounting treatment compared to the prior year.",
      "llm_answer": "In 2023 Lowe’s still held forward‑rate‑swap contracts that were classified as cash‑flow hedges (about $1.29 billion of notional) and the resulting gains or losses were reported in other‑comprehensive income 【page_60†L1-L4】. By the 2024 fiscal year those swaps had been settled – for example, the March 2023 notes triggered a $2.0 billion swap settlement that produced a $247 million cash receipt – and the forward‑swap line was removed from the cash‑flow‑hedge table (notional $0) so any gain/loss was now recognized in earnings rather than OCI 【page_60†L9-L13】. The fair‑value hedge of fixed‑to‑floating swaps remained unchanged at $850 million.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains a mix of correct and incorrect information, with significant quantitative and qualitative inaccuracies that affect the overall correctness. (1) Quantitatively, the LLM incorrectly states the notional amount of forward interest rate swap contracts in 2023 as $1.29 billion, while the ground truth specifies $2.0 billion related to the March 2023 Notes. The $247 million cash receipt upon settlement is correctly reported. However, the claim that the 'forward-swap line was removed from the cash-flow-hedge table (notional $0)' misrepresents the evolution — the ground truth indicates a change in hedge designation and accounting method, not merely the removal of swaps due to settlement. Additionally, the $850 million fair value hedge mentioned in the LLM answer is not present in the original answer and introduces unverified information. (2) The original answer highlights a shift in accounting treatment: from cash flow hedges in 2023 to fair value hedges using the shortcut method in 2024, resulting in no earnings impact due to assumed perfect effectiveness. The LLM fails to mention this critical shift in accounting method and instead implies the change is due to settlement and derecognition, which mischaracterizes the evolution. (3) The reasoning is flawed — it incorrectly attributes the change in accounting impact to the settlement of contracts rather than a deliberate change in hedge designation and accounting policy. This undermines the multi-hop synthesis required to connect changes in designation (cash flow → fair value) with their financial statement impact (OCI vs. no earnings impact). (4) While the LLM addresses the general theme of changing treatment and mentions OCI and earnings recognition, it misses the core conceptual shift in hedge accounting. Contextually, it is relevant and attempts to address both years and impacts, but the factual and conceptual errors reduce its accuracy. Minor formatting differences (e.g., $2.0 billion) are acceptable, but incorrect numbers and misattributed causes are not. Thus, the answer is partially correct but contains significant errors in both quantitative details and qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 582,
        "total_tokens": 1936
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has Target's strategy around its owned brands evolved from 2022 to 2023, particularly in terms of portfolio emphasis and strategic objectives?",
      "original_answer": "In 2022, Target highlighted a significant portion of sales coming from its owned brands, listing over 40 such brands across multiple categories, indicating a strong but descriptive presence in the market. By 2023, the company elevated its focus by strategically positioning owned brands as a core element of its overall strategy to 'delight with newness, style, and value,' explicitly aiming to strengthen the portfolio as part of broader efforts to drive traffic, sales, and market share growth. This shift reflects a move from simply showcasing owned brands to actively leveraging them as a strategic differentiator.",
      "llm_answer": "In 2022 Target treated its owned‑and‑exclusive brands as a core differentiation pillar, noting that they accounted for roughly one‑third of total sales and were listed alongside a broad assortment of national brands【page_3】; the focus was on using owned brands to set Target apart from competitors【page_5】. By 2023 the strategy shifted to “strengthening our owned brands portfolio” as a primary growth lever, emphasizing newness, style and value and expanding the breadth and depth of signature partnerships to make owned brands a central driver of relevance and traffic【page_3】.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Target's strategy from 2022 to 2023, noting a shift from using owned brands as a differentiator to actively strengthening the portfolio as a growth lever. The core strategic objectives—newness, style, value, traffic—are accurately reflected. However, the claim that owned brands accounted for 'roughly one-third of total sales' in 2022 is not present in the original answer (ground truth), which only states that Target had 'over 40' such brands and does not provide a sales percentage. This introduces a specific quantitative claim not supported by the ground truth, though it may be factually accurate elsewhere. (2) There are no explicit dollar amounts or dates to verify; the years 2022 and 2023 are correctly used. The 'one-third' figure is the only numeric claim, and since it's absent from the ground truth, it cannot be confirmed as correctly sourced from the knowledge graph—this is a minor overreach. (3) The multi-hop reasoning is sound: the model compares Target’s strategic emphasis across two years and synthesizes the shift in strategic objectives. It correctly identifies the elevated role of owned brands in 2023 as a driver of traffic and relevance, aligning with the ground truth’s 'drive traffic, sales, and market share growth.' The mention of 'signature partnerships' adds detail not in the original but does not contradict it. (4) The answer is contextually excellent, directly addressing portfolio emphasis and strategic objectives. The qualitative reasoning is strong, though slightly overstated with unsourced precision. Hence, correctness is high but not perfect—minor factual addition reduces score from 9 to 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 465,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has GM's approach to software-enabled services evolved from 2022 to 2023, particularly in terms of service offerings and platform deployment, and what does this indicate about the company's investment in scalable digital solutions?",
      "original_answer": "In 2022, GM described its software-enabled services in general terms as part of its broader operations, noting that it 'provides software-enabled services worldwide' and integrates them into its automotive business alongside investments in AV technology and automotive financing. By 2023, GM's approach had evolved significantly, with specific details on its end-to-end software platform that enables over-the-air updates for features like Super Cruise, active safety, infotainment, and EV ownership experience. The 2023 filing highlights that select 2024 models, such as the Cadillac LYRIQ and Chevrolet Silverado EV, were already using this platform, indicating a strategic shift toward scalable, software-defined vehicles. This evolution shows a transition from general involvement in digital services to concrete platform deployment across product lines, reflecting increased investment and operational maturity in software-enabled offerings.",
      "llm_answer": "In the 2022 filing GM only noted that it “provides software‑enabled services worldwide,” citing basic offerings such as OnStar, vehicle‑connectivity and after‑sale warranties with revenue recognized over the service term. By the 2023 filing the company describes an end‑to‑end, OTA‑updatable software platform that bundles OnStar, Super Cruise and a growing menu of security, climate, comfort and EV‑ownership features—already deployed on the 2024 Cadillac LYRIQ and Chevrolet Silverado EV and slated for rollout across most models. This evolution from a modest connectivity suite to a comprehensive, subscription‑driven platform signals GM’s deepening investment in scalable digital solutions that enable software‑defined vehicles.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: GM's 2022 description of providing software-enabled services worldwide, the evolution in 2023 to an end-to-end OTA-updatable platform, specific features (Super Cruise, OnStar, EV ownership), and deployment on the 2024 Cadillac LYRIQ and Chevrolet Silverado EV. The mention of subscription-driven models and scalability reflects the correct strategic interpretation. (2) Quantitative accuracy is perfect: no numerical errors; years (2022, 2023, 2024 models) are correctly cited and consistent with the original. Format variations (e.g., '2024 models') are appropriately used. (3) Multi-hop reasoning is sound: the answer synthesizes information across two years of filings, correctly identifying the progression from general statements to concrete platform deployment, indicating investment in scalable digital solutions. The inference about software-defined vehicles is logically supported. (4) Minor deduction in qualitative accuracy due to slight expansion beyond the original by specifying 'security, climate, comfort' features not explicitly listed in the ground truth, though these are reasonable inferences from 'active safety, infotainment, and EV ownership experience.' Overall, the answer is semantically equivalent, contextually complete, and factually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 381,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has the revenue contribution from ThousandEyes within the Optimized Application Experiences/Observability product category evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Optimized Application Experiences category, which included ThousandEyes, saw revenue growth of $75 million (11%), driven by ThousandEyes and Intersight. By fiscal year 2023, the Observability category (which includes ThousandEyes) experienced a revenue increase of $80 million (14%), specifically attributed to growth in ThousandEyes and monitoring and analytics offerings. This shows a continued upward trend in ThousandEyes' revenue contribution, with both absolute and percentage growth increasing from 2022 to 2023.",
      "llm_answer": "The Optimized Application Experiences category grew $75 million (≈11 %) in FY 2022, a rise the filing attributes to growth in the ThousandEyes offering【page_45】. In FY 2023 the renamed Observability category rose $80 million (≈14 %) and the filing again cites “growth in our ThousandEyes” as a driver【page_42】—showing that ThousandEyes’ contribution increased both in absolute dollars and as a larger share of the category year‑over‑year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the $75 million (11%) revenue growth in FY 2022 and $80 million (14%) growth in FY 2023 for the relevant product category, accurately attributing both to ThousandEyes. All numeric values match the ground truth exactly, with acceptable formatting variations (e.g., ≈11% vs 11%). (2) Quantitative accuracy is perfect: the dollar amounts and percentages are correct, and the comparison showing an increase in both absolute and percentage growth from 2022 to 2023 is valid. (3) The reasoning is sound and captures the multi-hop nature of the question—tracking ThousandEyes' contribution across a rebranded product category (Optimized Application Experiences to Observability) over two fiscal years. The LLM correctly infers continued growth in contribution, though it slightly overreaches by stating 'larger share of the category year-over-year'—while absolute contribution increased, the answer assumes share growth without direct evidence of proportional contribution within the category. This is a minor interpretive leap not fully supported by the original answer. (4) Despite this nuance, the core facts, synthesis, and conclusion align closely with the ground truth, warranting a high correctness score. Contextual relevance is perfect as it directly addresses the evolution of revenue contribution across the two years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 381,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did the treatment of Amendment No. 4 to the Lockheed Martin Executive Severance Plan evolve between the 2023 and 2024 10-K filings, and what does this indicate about its inclusion in the company's disclosure strategy?",
      "original_answer": "In the 2023 10-K filing, Amendment No. 4 to the Executive Severance Plan was disclosed as part of the exhibit list (Exhibit 10.34) and referenced as being incorporated from the September 2022 10-Q filing. However, in the 2024 10-K filing, Amendment No. 4 is no longer listed as a standalone exhibit but appears instead as part of a sequence that includes earlier amendments (Nos. 2, 3, 4, and 5), with Amendment No. 4 specifically incorporated from the same September 2022 10-Q filing. This indicates that while the amendment itself remained relevant, its treatment shifted from a highlighted disclosure in 2023 to a more integrated part of the broader severance plan history in 2024, suggesting a more consolidated and retrospective approach to disclosure.",
      "llm_answer": "In the 2023 Form 10‑K the exhibit list for the Executive Severance Plan stops at Amendment No. 3 (see page 103) and makes no reference to Amendment No. 4. By contrast, the 2024 Form 10‑K lists Amendment No. 4 as Exhibit 10.34 (and again as 10.36) incorporated by reference to a 2022 quarterly report (see pages 104 and 105). This change shows that Lockheed Martin moved the amendment from being omitted to being explicitly disclosed, reflecting a broader, more detailed disclosure strategy for updates to its executive severance plan.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. (1) It claims that in the 2023 10-K, Amendment No. 4 was *not referenced* and that the exhibit list 'stops at Amendment No. 3'—this directly contradicts the ground truth, which states that Amendment No. 4 *was* disclosed in the 2023 10-K as Exhibit 10.34 and incorporated from the September 2022 10-Q. The LLM incorrectly asserts omission in 2023 when it was actually present. (2) The LLM then claims that in the 2024 10-K, Amendment No. 4 is *added* and listed as Exhibit 10.34 (and 10.36), suggesting new disclosure—but the ground truth states the opposite: that Amendment No. 4 was *no longer a standalone exhibit* in 2024 and instead was included as part of a sequence of amendments (Nos. 2–5), indicating consolidation, not new disclosure. (3) The multi-hop reasoning is flawed: the model misinterprets the direction of change (from disclosed to more integrated) as the reverse (from omitted to disclosed), leading to an incorrect conclusion about disclosure strategy. (4) The conclusion that Lockheed Martin moved from omission to explicit disclosure is false; the actual evolution is from standalone to integrated disclosure, indicating a more retrospective, consolidated approach. The LLM reverses the timeline and thus the strategic implication. While the mention of incorporation from the 2022 10-Q aligns with the ground truth, this single correct detail does not offset the overall inversion of facts. Quantitative accuracy is low due to incorrect exhibit numbers and misrepresentation of presence/absence. Qualitative accuracy is poor due to faulty logic and entity/timing confusion. Contextual relevance is moderate as the answer addresses the general topic of disclosure evolution but with incorrect substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 487,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did JPMorgan's compliance with capital ratio requirements evolve from 2023 to 2024, particularly in terms of its Tier 1 leverage ratio and Standardized CET1 capital ratio?",
      "original_answer": "In 2023, JPMorgan's Standardized CET1 capital ratio was 15.0%, exceeding the requirement of 11.4%. In 2024, the Tier 1 leverage ratio was 7.2%, which was above the requirement of 4.0%. This indicates that JPMorgan maintained compliance with capital ratio requirements across both years, with consistent capital strength relative to evolving regulatory expectations.",
      "llm_answer": "In 2023 JPMorgan reported a Tier 1 leverage ratio of **7.2 %** and a Standardized CET1 capital ratio of **15.0 %**【page_98】. By year‑end 2024 the Tier 1 leverage ratio was unchanged at **7.2 %**—still well above the 4.0 % regulatory floor—while the Standardized CET1 ratio rose to **15.7 %**【page_104】, comfortably exceeding the 12.3 % minimum for that period. This shows the firm maintained strong leverage‑ratio compliance and improved its CET1 capital position.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key metrics and requirements. While it correctly states JPMorgan's 2023 Standardized CET1 ratio as 15.0%, it incorrectly claims the 2024 Tier 1 leverage ratio was 7.2% in both years and that the 2024 Standardized CET1 ratio rose to 15.7%. The ground truth does not provide the 2023 Tier 1 leverage ratio or the 2024 Standardized CET1 ratio—only the 2024 Tier 1 leverage ratio (7.2%) and its requirement (4.0%), and the 2023 Standardized CET1 ratio (15.0%) with its requirement (11.4%). The LLM fabricates a 2024 CET1 ratio of 15.7% and a 2024 requirement of 12.3%, which are not in the original answer. (2) Quantitative accuracy is low: only the 2023 CET1 ratio (15.0%) and 2024 Tier 1 leverage ratio (7.2%) are correct; all other numbers (2024 CET1, 2024 requirement) are incorrect or unsupported. (3) Reasoning is partially sound in structure—comparing ratios to requirements and assessing compliance—but fails on multi-hop synthesis because it invents data not present in the ground truth. The original answer does not support a claim about 2024 CET1 or its requirement. (4) Contextual relevance is high as the response addresses the evolution of capital ratios and compliance, but correctness is undermined by hallucinated figures. The conclusion about maintained compliance is consistent, but the evidence is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 387,
        "total_tokens": 1602
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the role of GM Financial in General Motors' operations evolved between 2022 and 2023, particularly in terms of its integration and financial presentation within the consolidated financial statements?",
      "original_answer": "In 2022, GM Financial was described as a segment through which General Motors provides automotive financing services, with its financials adjusted to reflect the impact of consolidated tax returns and intercompany transactions. By 2023, the description of GM Financial became more detailed, emphasizing that the amounts presented for GM Financial are adjusted for the impact on deferred tax positions and the provision for income taxes due to its inclusion in the consolidated tax return, and that these amounts differ from those presented on a stand-alone basis. This evolution reflects a more explicit focus on the integration and financial alignment of GM Financial with the broader corporate structure.",
      "llm_answer": "In the 2022 filing GM Financial was shown chiefly as a separate reportable segment – its results were evaluated on an EBT‑adjusted basis and presented in the segment tables (see Note 23 – segment reporting [p. 98] and the GM Financial segment numbers in the tables [p. 100‑101]). By the 2023 filing the financing business is woven into the consolidated statements: purchases of finance receivables and collections appear in the cash‑flow statement [p. 61], detailed accounting policies for GM Financial’s receivables, loan‑loss allowances and amortized‑cost measurement are disclosed [p. 64‑65], and the segment note still lists GM Financial but now emphasizes its contribution to overall cash flows and the adjustments for its deferred‑tax position [p. 63]. This shift shows GM Financial moving from a stand‑alone segment view toward tighter integration within GM’s consolidated financial presentation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, GM Financial was presented as a reportable segment with EBT-adjusted results, referencing appropriate disclosures (Note 23, pages 98, 100–101), which matches the original answer’s description of GM Financial being a segment with adjustments for consolidated tax and intercompany transactions. In 2023, the LLM correctly notes increased integration into consolidated financials, including cash flow presentation (p. 61), expanded accounting policies (pp. 64–65), and more detailed discussion of deferred tax adjustments in the segment note (p. 63). (2) There are no numeric values to verify, but all references to financial presentation, disclosures, and adjustments are factually consistent with the ground truth. (3) The multi-hop reasoning is sound: the model synthesizes changes in disclosure depth, placement across financial statements, and tax integration between two years, correctly inferring tighter consolidation. (4) The only minor shortcoming is that the LLM does not explicitly state that the 2023 presentation emphasizes differences from stand-alone reporting, a nuance highlighted in the original answer. However, this is implied in the discussion of adjustments. Wording differs but semantic meaning is equivalent. All entities (GM Financial, General Motors), years (2022, 2023), and financial concepts (consolidated statements, deferred taxes, segment reporting) are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 413,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the treatment and disclosure of step-rent provisions in lease accounting evolved between 2022 and 2024, particularly regarding the recognition of periodic rent increases based on price indices or sales volume?",
      "original_answer": "In 2022, the company disclosed that certain leases provided for periodic rent increases based on price indices or the greater of minimum guaranteed amounts or sales volume, and these were accounted for on a straight-line basis. By 2024, the company clarified that such increases, based on price indices or the greater of minimum guaranteed amounts or sales volume, are now recognized as variable lease payments rather than being straight-lined, indicating a shift in accounting treatment. This reflects a more dynamic approach to recognizing lease costs that fluctuate with external factors.",
      "llm_answer": "In the 2022 filing the lease note only described the basic lease options (renewal, purchase, right‑of‑first‑refusal) and did not discuss step‑rent or index‑linked escalations 【page_44】. By the 2024 filing the company added that some leases contain free‑rent periods and step‑rent provisions, which are recognized on a straight‑line basis over the lease term (including reasonably certain renewal periods), and that periodic rent increases tied to price indices or the greater of a minimum guarantee or sales volume are accounted for as variable lease payments 【page_45】. Thus the accounting treatment (straight‑line for step‑rent and variable‑payment accounting for index‑based escalations) remains the same, but the disclosure has been expanded to explicitly describe these provisions.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that in 2022, there was no discussion of step-rent or index-linked escalations, directly contradicting the ground truth which confirms such provisions were disclosed and accounted for on a straight-line basis. This is a major factual error. In 2024, the LLM correctly identifies that periodic rent increases based on price indices or sales volume are now treated as variable lease payments. However, it incorrectly claims that step-rent provisions are still straight-lined, which conflicts with the ground truth indicating a shift away from straight-lining for these specific escalations. (2) There are no explicit numerical values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not heavily applicable; however, the years (2022, 2024) are correctly referenced, supporting a moderate score. (3) The multi-hop reasoning fails because the LLM misrepresents the 2022 disclosure and incorrectly concludes that the accounting treatment 'remains the same,' when the ground truth clearly indicates a shift in treatment—from straight-line to variable lease payment recognition. This undermines the core of the question about evolution in treatment. (4) Contextual relevance is high because the answer addresses lease accounting, step-rents, and variable payments, and cites appropriate pages. However, the factual inaccuracies in entity treatment (accounting method per year) severely reduce correctness and qualitative accuracy. The answer misleads on the evolution by asserting consistency where there is a documented change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 439,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the projected funding obligations for Lockheed Martin's qualified defined benefit pension plans evolve from 2023 to 2024, particularly in terms of the amounts expected to be paid out in 2025 and over the long-term period from 2029 to 2033?",
      "original_answer": "In 2023, Lockheed Martin projected $1,860 million in payments for qualified defined benefit pension plans in 2025 and $10,020 million over the period from 2029 to 2033. By 2024, the projected payment for 2025 increased slightly to $1,860 million, while the long-term projection from 2030 to 2034 decreased to $9,990 million. This indicates a marginal reduction in long-term pension obligations.",
      "llm_answer": "In the 2023 Form 10‑K Lockheed Martin said it expected to pay about **$1.86 billion** in 2025 and roughly **$10.02 billion** over the 2029‑2033 period for its qualified defined‑benefit pension plans【page_88】.  \nThe 2024 Form 10‑K lowered those forecasts to **$1.80 billion** for 2025 and about **$9.99 billion** for the long‑term horizon (with $1.99 billion in 2029 and $9.99 billion for 2030‑2034)【page_89】.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains both correct and incorrect numeric values. It correctly states the 2023 projections: $1.86 billion for 2025 and $10.02 billion for 2029–2033, matching the ground truth. However, it incorrectly reports the 2024 projected payment for 2025 as $1.80 billion, whereas the ground truth states it remained at $1,860 million (i.e., $1.86 billion), not decreasing. This is a significant quantitative error. Additionally, while the long-term projection for 2030–2034 is correctly stated as $9.99 billion, the LLM incorrectly introduces $1.99 billion in 2029, which is not part of the original answer or logically consistent with the reported period. (2) Number verification: 2023 figures are accurate ($1.86B and $10.02B). 2024 2025 projection should be $1.86B, not $1.80B — this is a factual error. Long-term total $9.99B for 2030–2034 is correct, but the mention of $1.99B in 2029 is extraneous and unsupported in the ground truth. (3) Multi-hop reasoning is partially sound — the model identifies the need to compare 2023 and 2024 filings and extract pension obligations across time horizons. However, it misrepresents the 2025 projection change and adds unverified data (2029 payment), undermining the synthesis. (4) Correctness score is 5 due to mixed accuracy: core 2023 data is right, but key 2024 update is wrong and additional fabricated detail reduces reliability. Quantitative accuracy is 5 due to one major number error and an extraneous figure. Qualitative accuracy is 6 because reasoning structure is logical but flawed in execution. Contextual relevance is 9 — the answer directly addresses the question’s scope and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 456,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did JPMorgan Chase's disclosures about its resolution plan obligations evolve between 2023 and 2024, particularly in terms of its described liquidity risk management strategies and funding cost considerations?",
      "original_answer": "In 2023, JPMorgan Chase emphasized that its resolution plan obligations could lead to higher funding costs and constrained liquidity due to the need to satisfy liquidity coverage ratio and net stable funding ratio requirements, as well as regulatory demands outside the U.S. regarding liquidity pre-positioning in subsidiaries. The firm highlighted the potential need to rely on more expensive or limited alternative funding sources if traditional ones like deposits or Federal Home Loan Bank borrowings were reduced. In 2024, the firm expanded its disclosures to include how resolution plan obligations interacted with dynamic regulatory expectations and systemic events, noting that changes in laws, rules, and regulations—especially in response to economic effects of systemic events—could further impact liquidity and capital requirements. This reflects a shift toward framing resolution-related liquidity risks within a broader context of regulatory evolution and macroeconomic uncertainty.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K state that actions taken to satisfy JPMorgan Chase’s resolution‑plan obligations can increase its funding costs. In each filing the bank says it would manage this liquidity risk by raising alternative funding if deposits or cheap borrowings are limited and by meeting its liquidity‑coverage‑ratio and net‑stable‑funding‑ratio requirements, so the 2024 disclosure essentially repeats the 2023 language without material change. (2023 p. 22; 2024 p. 22)",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that JPMorgan Chase disclosed resolution plan obligations could increase funding costs in both 2023 and 2024, and correctly notes the firm's reliance on alternative funding sources and compliance with LCR and NSFR requirements. These elements are factually consistent with the ground truth. However, the LLM incorrectly asserts that the 2024 disclosure 'essentially repeats the 2023 language without material change,' which directly contradicts the ground truth. The original answer highlights a significant evolution in 2024: the firm expanded its disclosures to include how resolution plan obligations interact with dynamic regulatory expectations and systemic events, reflecting a broader framing of risks in light of regulatory evolution and macroeconomic uncertainty. This key qualitative shift is entirely missed by the LLM, leading to a major omission in reasoning and completeness. (2) There are no numerical values in the question or answers, so quantitative accuracy is not applicable beyond correct referencing of page numbers (2023 p. 22; 2024 p. 22), which the LLM provides and are assumed accurate. Thus, quantitative accuracy is scored as 10. (3) The multi-hop reasoning is flawed: the question asks for an analysis of *evolution* between years, requiring comparison and synthesis of changes in disclosure tone, scope, and risk framing. The LLM fails this synthesis, instead asserting no change when a clear expansion in scope and context is documented in the ground truth. This represents a failure in qualitative accuracy and reasoning. (4) Contextual relevance is moderate: the answer addresses the right topic (funding costs, liquidity risk, resolution plans) and cites correct documents and pages, but fails to capture the core of the question—how disclosures *evolved*. Hence, correctness and qualitative accuracy are low despite some factual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 520,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How has the financial structure of Optum Rx's pharmacy care services evolved between 2022 and 2023, particularly in terms of revenue recognition and accounts receivable?",
      "original_answer": "In 2022, Optum Rx's pharmacy care services were characterized by a gross revenue reporting model due to the Company's primary obligation to pay network pharmacy providers regardless of payment collection, with revenue recognized at the point of prescription dispensing. By 2023, the financial structure remained aligned with this model but showed an increase in accounts receivable related to products and services, rising from $7.1 billion in 2022 to $8.6 billion in 2023. This indicates a growth in the value of receivables tied to pharmacy care services, suggesting either increased transaction volume or changes in payment timing.",
      "llm_answer": "In 2022 Optum Rx reported $7.1 billion of accounts receivable for its pharmacy‑care products and services; by year‑end 2023 that balance had risen to $8.6 billion, a $1.5 billion increase. The company’s revenue‑recognition model did not change – product revenue is recorded when a prescription is dispensed and services revenue when the service is performed, with no material contract assets, liabilities or deferred contract costs in either year and no material revenue from prior‑period performance obligations. These points are detailed in the 2023 filing (see page 46, which references both 2022 and 2023 figures).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: accounts receivable increased from $7.1 billion in 2022 to $8.6 billion in 2023, a $1.5 billion increase, which matches the original answer exactly. The revenue recognition model is correctly described as unchanged, with revenue recognized at the point of prescription dispensing (product) and service performance. (2) Quantitative accuracy is perfect—values are reported correctly, and the $1.5 billion difference is accurate. (3) The qualitative reasoning is sound: the model correctly identifies that the financial structure did not change in terms of revenue recognition but notes the increase in receivables, which reflects growth or timing changes. It adds value by referencing the absence of material contract assets/liabilities and deferred costs, which is consistent with the 2023 filing and supports the conclusion of no model change. (4) The only minor omission is that the original answer emphasizes the 'gross revenue reporting model' due to Optum Rx's primary obligation to pay pharmacies, which the LLM answer does not explicitly mention. While the revenue recognition timing is correctly stated, this key rationale for gross reporting is missing, slightly weakening the explanation of the financial structure. However, this does not undermine the core correctness. The answer is fully contextually relevant, directly addressing both revenue recognition and accounts receivable evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 414,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has UPS's quantitative exposure and strategic approach to managing interest rate risk through Floating to Fixed Interest Rate Swaps evolved between 2022 and 2024?",
      "original_answer": "In 2022, UPS disclosed a $28 million notional amount for Floating to Fixed Interest Rate Swaps, indicating limited use of this instrument at that time. By 2024, UPS articulated a broader strategy to 'manage the fixed and floating interest rate mix of its total debt portfolio and related overall cost of borrowing,' suggesting a more intentional and strategic deployment of these swaps. This evolution reflects a shift from a minor, quantitative hedge in 2022 to a more comprehensive interest rate risk management approach in 2024.",
      "llm_answer": "UPS’s floating‑to‑fixed interest‑rate swap exposure has been essentially flat, with the hedged portion of long‑term debt and finance‑lease liabilities reported at roughly $280 million in the 2022 filing and $279 million in 2024 (see the balance‑sheet hedge table, page_138). The company’s risk‑management policy remains unchanged – it continues to designate floating‑to‑fixed swaps as cash‑flow hedges, uses fair‑value hedges for fixed‑to‑floating swaps, and supplements with forward‑starting swaps or interest‑rate locks as needed (see the interest‑rate risk discussion, page_136). The hedge impact on earnings has modestly improved, with the reclassification loss on interest‑rate contracts falling from $10 million in 2023 to $5 million in 2024 (page_138).",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The ground truth states that UPS had a $28 million notional amount for Floating to Fixed Interest Rate Swaps in 2022, but the LLM claims $280 million in 2022 and $279 million in 2024—off by an order of magnitude. This is a critical factual error. (2) The numbers cited in the LLM answer ($280M and $279M) do not match the ground truth ($28M), and there is no mention of 2024 notional amounts in the original answer—only a strategic shift. The reclassification loss figures ($10M to $5M) and references to 'page_138' or 'page_136' are extraneous and unsupported by the provided ground truth. (3) The multi-hop reasoning fails: the question asks about evolution in both quantitative exposure and strategic approach, but the LLM incorrectly asserts quantitative stability while missing the key qualitative shift entirely. The original answer emphasizes a strategic evolution—from limited use in 2022 to a more comprehensive risk management approach in 2024—while the LLM claims the policy 'remains unchanged,' directly contradicting the ground truth. (4) Due to major factual inaccuracies in numbers and strategic interpretation, the correctness score is low. The contextual relevance is moderate because the answer addresses interest rate swaps and risk management, but the substance is factually wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 388,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has GM's financial relationship with LG Energy Solution evolved between 2022 and 2023, particularly in terms of joint venture activities and recall-related costs?",
      "original_answer": "In 2022, GM highlighted its joint venture, Ultium Cells LLC, with LG Energy Solution, as a key part of its EV strategy to mass-produce battery cells across three U.S. plants. By 2023, the relationship had shifted toward financial liabilities, as GM accrued $2.6 billion related to the Chevrolet Bolt EV battery recall, with $1.6 billion recognized as receivables from LG. This marks a transition from strategic collaboration to a more transactional and cost-driven dynamic due to product defects.",
      "llm_answer": "In the 2022 filing GM described its partnership with LG Energy Solution as an **equally‑owned joint venture, Ultium Cells LLC**, created to mass‑produce battery cells at several U.S. sites (Lordstown, Ohio; Spring Hill, Tennessee; Lansing, Michigan)【page_4】. By the 2023 filing the relationship had expanded to include a **reimbursement arrangement for the Chevrolet Bolt battery‑fire recall** – LG Energy Solution agreed to reimburse GM, leading GM to accrue **$2.6 billion**, record **$1.6 billion of receivables**, and retain a **$0.6 billion remaining accrual** for those recall costs, while also resolving other commercial matters tied to the Ultium Cells joint venture【page_92】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Ultium Cells LLC is correctly identified as the joint venture between GM and LG Energy Solution, established to mass-produce battery cells at U.S. plants. The transition in 2023 to a cost-driven dynamic due to the Bolt EV recall is accurately described. (2) Quantitative accuracy is perfect: the $2.6 billion accrual, $1.6 billion in receivables from LG, and $1.0 billion net cost (with $0.6 billion retained accrual, implying $1.0 billion covered by LG) are all consistent with the ground truth—minor phrasing difference (‘$0.6 billion remaining accrual’ vs implied $1.0 billion liability shift) does not contradict; rather, it reflects GM’s net retained cost after $1.6B recovery. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across 2022 (strategic JV) and 2023 (recall liabilities and reimbursement) filings, capturing the evolution in the relationship. (4) The only minor shortcoming is that the answer slightly expands detail (naming specific plant locations) not in the original answer, which, while factually correct, is not required and doesn’t detract from accuracy. The core shift from collaboration to transactional cost management is clearly and correctly conveyed. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 399,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has the revenue contribution from ThousandEyes within the Observability product category evolved from fiscal 2022 to fiscal 2023?",
      "original_answer": "In fiscal 2022, revenue in the Observability product category increased by $80 million, driven in part by growth in ThousandEyes and monitoring and analytics offerings. By fiscal 2023, the Observability product category saw a 27% revenue increase, or $176 million, with ThousandEyes and the newly included Splunk offering (Observability Suite) being key contributors. Excluding Splunk, product revenue from Observability still grew by 15%, indicating strong organic growth primarily from ThousandEyes.",
      "llm_answer": "The Observability product category grew from $581 million in fiscal 2022 to $661 million in fiscal 2023 – a $80 million (14 %) increase – and Cisco said that growth was driven by the performance of its ThousandEyes offering (along with other monitoring and analytics products)【page_41】【page_42】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It states that Observability revenue grew from $581 million in fiscal 2022 to $661 million in fiscal 2023, implying a $80 million increase. However, the ground truth states that in fiscal 2022, Observability revenue *increased by* $80 million (not that total revenue was $581M), and in fiscal 2023, it increased by $176 million (27% growth). The LLM incorrectly interprets the $80M year-over-year increase in 2022 as the total revenue base, which is not supported by the original data. Additionally, the 14% growth rate cited by the LLM is not mentioned in the ground truth and appears to be miscalculated (80/581 ≈ 13.8%, which rounds to 14%, but this calculation is based on incorrect premises). (2) The ground truth emphasizes that fiscal 2023 growth was $176 million (27%), with Splunk as a key contributor, and even excluding Splunk, growth was 15% — a critical nuance entirely missing in the LLM response. The LLM also fails to mention Splunk’s inclusion, which is central to understanding the evolution of revenue contribution. (3) The multi-hop reasoning is flawed: the model conflates incremental revenue growth with total revenue, fails to track the evolution across both years correctly, and omits the impact of Splunk’s addition, which is essential for assessing ThousandEyes’ relative contribution. While it correctly identifies ThousandEyes as a growth driver in 2022, it does not address how its contribution evolved into 2023. (4) Despite these issues, the answer is contextually relevant and attempts to address the question using plausible data points and citations. However, due to major quantitative and qualitative errors, especially the misrepresentation of total revenue and omission of key 2023 dynamics, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1195,
        "completion_tokens": 496,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UPS's relationship with the 7.620% Debentures evolved between 2022 and 2024 in terms of their redemption terms and interest payment structure?",
      "original_answer": "In 2022, the 7.620% Debentures had a principal amount of $276 million with a maturity date of April 1, 2030, and were listed with a carrying value of $280 million. By 2024, UPS clarified that these debentures are redeemable at any time at the company's option, with a redemption price equal to the greater of the principal amount plus accrued interest or the present value of remaining scheduled payments discounted at a benchmark treasury yield plus five basis points, plus accrued interest. Additionally, the interest payment structure was specified as semi-annual, payable in April and October. This evolution reflects a shift from a general description of the debentures in 2022 to a more detailed explanation of their redemption flexibility and interest payment schedule in 2024.",
      "llm_answer": "UPS’s $276 million 7.620 % debentures were described in both filings as fully callable at UPS’s option, with the redemption price equal to the greater of (i) principal + accrued interest or (ii) the present value of the remaining scheduled payments discounted at a benchmark Treasury yield + 5 bps, and interest continues to be paid semi‑annually in April and October. The 2022 10‑K notes that the rate was reduced from 8.375 % to 7.620 % on April 1 2020 【page_120】, while the 2024 10‑K simply references the current 7.620 % rate, indicating that the redemption and payment terms have not changed, only the emphasis on the historical rate cut. 【page_108】",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. First, it claims the debentures were 'fully callable' in both 2022 and 2024, but the ground truth states that in 2022, only the principal amount ($276M), maturity date (April 1, 2030), and carrying value ($280M) were reported—there was no mention of redemption terms. The detailed redemption terms (callable at any time, with specific pricing formula) were only clarified in 2024, indicating an evolution in disclosure, not consistency. The LLM incorrectly concludes that 'the redemption and payment terms have not changed,' which contradicts the ground truth that shows a shift from minimal to detailed disclosure. (2) Quantitatively, the $276M principal and 7.620% rate are correct, and the semi-annual interest payments in April and October match. However, the LLM incorrectly references a rate reduction from 8.375% to 7.620% on April 1, 2020, which is not part of the ground truth and introduces unsupported historical context. (3) The multi-hop reasoning is flawed: instead of identifying the evolution in disclosure depth between 2022 and 2024, the model assumes consistency and attributes differences to 'emphasis.' This fails to capture the core of the question—how the *relationship* (i.e., terms and disclosures) evolved. (4) Contextual relevance is high because the answer addresses redemption terms and interest payments, but factual and reasoning errors severely undermine correctness. The model misrepresents the timeline and nature of disclosure changes, leading to an incorrect overall conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 432,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How did the composition and total fair value of Fixed Maturity Securities AFS held by MET evolve from 2022 to 2023, particularly in terms of U.S. government bonds and corporate securities?",
      "original_answer": "In 2022, MET reported a carrying amount of $2,164 million for Fixed Maturity Securities AFS as of December 31, 2021. By 2023, the total estimated fair value of Fixed Maturity Securities AFS had increased significantly to $6,714 million. Specifically, the fair value of corporate securities rose to $3,083 million, with $3,029 million categorized under Level 2, while U.S. government bonds increased to $1,575 million, with $1,537 million under Level 1. This reflects a substantial transformation in both the size and breakdown of these investments over the year.",
      "llm_answer": "In 2022 MetLife’s Fixed‑Maturity Securities (AFS) were valued at **$6.8 billion**.  The portfolio included **$1.5 billion of U.S. government bonds** (Level 1 $1,462 m + Level 2 $45 m) and **$3.0 billion of corporate securities** (Level 2 $2,946 m + Level 3 $55 m)【page_308】.  \n\nBy year‑end 2023 the total fair value slipped slightly to **$6.7 billion**, but the composition shifted: **U.S. government bonds rose to $1.58 billion** (Level 1 $1,537 m + Level 2 $38 m) and **corporate securities grew to $3.08 billion** (Level 2 $3,029 m + Level 3 $54 m)【page_308】.  The modest gains in government‑bond and corporate holdings were more than offset by declines in other fixed‑maturity categories, resulting in a net decrease in total fair‑value.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct in terms of key financial figures and trends but contains a critical error in the 2022 total fair value. The original answer states that the 2022 carrying amount (as of Dec 31, 2021) was $2,164 million, not $6.8 billion. The $6.8 billion figure cited by the LLM appears to be the 2023 total from a different time point or misattribution. This is a significant factual inaccuracy. However, the 2023 total fair value of $6.7 billion ($6,714 million) is correctly reported within rounding. The breakdowns for U.S. government bonds and corporate securities in 2023 are accurate: $1,575 million (LLM: $1.58B) and $3,083 million (LLM: $3.08B), with correct Level 1/Level 2 allocations. (2) Calculations: The LLM’s component sums are internally consistent (e.g., $1,537M + $38M ≈ $1,575M), and corporate securities sum correctly. However, the erroneous $6.8B total for 2022 undermines confidence in the baseline comparison. The original answer does not provide a 2022 portfolio composition, only a prior-year carrying amount, so the LLM may have pulled 2022 breakdowns from an unverified source or misaligned dates. (3) Multi-hop reasoning: The LLM correctly identifies the evolution in composition and attempts to explain a shift despite a slight drop in total value, which aligns with the transformation narrative. However, the original answer emphasizes a significant increase from $2.164B to $6.714B, while the LLM incorrectly frames it as a decrease from $6.8B to $6.7B—this reverses the directional trend and misrepresents the scale of growth. (4) Scores justified: Correctness is 7 due to accurate 2023 figures and composition trends but major error in 2022 total. Quantitative accuracy is 7 because most numbers are close or correct except the key 2022 total. Qualitative accuracy is 8—reasoning is sound given the data it uses, and entity identification (MET, AFS securities, categories) is correct. Contextual relevance is 10—it directly addresses the question’s focus on composition and value evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 552,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has General Motors' relationship with Ultium Cells LLC evolved from 2022 to 2023, particularly in terms of financial involvement and regulatory implications?",
      "original_answer": "In 2022, General Motors reported a direct financial investment of $0.5 billion in Ultium Cells LLC as part of its investing activities. By 2023, the nature of GM's relationship with Ultium Cells LLC had evolved from a primarily investment-based relationship to a more operationally integrated partnership, evidenced by GM's involvement in regulatory violations related to the joint venture. Specifically, in February 2023, GM self-disclosed potential violations of the Toxic Substances Control Act (TSCA) related to Ultium Cells LLC to the EPA, which resulted in a November 2023 settlement involving joint civil penalties estimated at approximately $5.1 million. This indicates a shift from a passive investment to a more active and operationally entangled partnership with associated regulatory responsibilities.",
      "llm_answer": "In the 2022 Form 10‑K GM recorded a $0.5 billion cash outflow as its “Investment in Ultium Cells LLC” (see 2022 p. 42 / 41), indicating a capital‑investment relationship with the joint‑venture and no disclosed regulatory issues. By the 2023 filing the focus had shifted to compliance: GM disclosed that Ultium Cells LLC was the subject of potential TSCA violations, which were settled with the EPA in November 2023, resulting in civil penalties of about $5.1 million assessed jointly on GM and Ultium Cells (see 2023 p. 28).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $0.5 billion investment in 2022 is accurately reported, and the November 2023 TSCA settlement with a $5.1 million joint penalty is correctly stated. Dates (2022, 2023), dollar amounts ($0.5 billion, $5.1 million), and regulatory details (TSCA, EPA) are factually sound. (2) Quantitative accuracy is perfect—numbers match exactly, with acceptable formatting (e.g., $0.5 billion = $500 million). (3) The multi-hop reasoning is solid: the answer synthesizes financial data from the 2022 10-K and regulatory disclosures from the 2023 filing, correctly inferring an evolution from financial investment to operational entanglement. (4) The only minor shortcoming is that the LLM does not explicitly characterize the shift as a move from 'passive investment to active partnership' or use terms like 'operationally integrated,' which are present in the original answer. However, the implication is clearly conveyed through the shift in focus from investment to compliance and shared penalties. Thus, semantic equivalence is maintained. Contextual relevance is excellent, directly addressing financial involvement and regulatory implications across both years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 352,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has the company's use of variable-priced contracts for natural gas and fuel purchases evolved between 2022 and 2024?",
      "original_answer": "In 2022, the company entered into variable-priced contracts for some purchases of natural gas and fuel for its gas stations on an index basis, though the specific volume or value of these contracts was not disclosed. By 2024, the company continued using variable-priced contracts for similar purchases and explicitly noted that these contracts met the characteristics of derivative instruments but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. This indicates a more formalized or strategic use of variable-priced contracts by 2024, aligning them with accounting frameworks for derivatives, suggesting a shift in how these contracts are managed or accounted for.",
      "llm_answer": "The 2022 filing notes that the Company “enters into variable‑priced contracts for some purchases of natural gas, in addition to fuel for its gas stations, on an index basis” and that these contracts qualify for the normal‑purchases‑and‑normal‑sales exception (COST 10‑K 2022 p. 46). The 2024 filing repeats the same description—still using index‑based variable‑priced contracts for natural‑gas and fuel purchases with the same accounting treatment (COST 10‑K 2024 p. 47). Thus, the company’s use of such contracts has remained essentially unchanged between 2022 and 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually incorrect in its conclusion, despite citing correct sources and entities. (1) The ORIGINAL ANSWER states that while variable-priced contracts were used in both 2022 and 2024, by 2024 the company explicitly noted these contracts met the characteristics of derivative instruments but qualified for the 'normal purchases and normal sales' exception—indicating a more formalized or strategic accounting treatment. This suggests an evolution in how the contracts are managed or accounted for, even if the basic structure (index-based pricing) remained. (2) The LLM incorrectly asserts that the company’s use of such contracts 'has remained essentially unchanged,' which contradicts the ground truth that highlights a shift in accounting recognition and framing by 2024. There are no numeric values to verify, so quantitative accuracy is not applicable beyond correct citation of years (2022, 2024), which are accurate. (3) The multi-hop reasoning is flawed: the model fails to synthesize the nuanced development in accounting treatment between the two years, instead treating repetition of contract type as evidence of no change, while missing the added disclosure about derivatives in 2024. (4) While the LLM answer is contextually relevant and uses correct entities (COST 10-K filings, correct pages), it misses a key qualitative shift, leading to a major error in interpretation. Thus, correctness and qualitative accuracy are low despite high contextual relevance and perfect entity/date accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 417,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has Cisco's financial reporting approach for the APJC segment evolved between fiscal 2022 and fiscal 2023, particularly in terms of the expense categories excluded from segment performance measurement?",
      "original_answer": "Cisco's financial reporting for the APJC segment maintained a consistent exclusion of key expense categories from segment performance measurement in both fiscal 2022 and fiscal 2023. In fiscal 2022, the company explicitly excluded research and development, sales and marketing, and general and administrative expenses from segment financial decisions and resource allocations. This approach remained unchanged in fiscal 2023, with the same categories of expenses—along with amortization and impairment of acquisition-related intangible assets, share-based compensation expense, significant litigation settlements, and charges related to asset impairments and restructurings—not being allocated to the gross margin for each segment. The consistency in exclusions indicates no change in how APJC's performance was internally measured across the two fiscal years.",
      "llm_answer": "Cisco’s segment reporting for APJC did not change from FY 2022 to FY 2023. In both years the company states that it does **not** allocate research‑and‑development, sales and marketing, general‑and‑administrative expenses, amortization and impairment of acquisition‑related intangible assets, share‑based compensation expense, significant litigation settlements and other contingencies, asset‑impairment and restructuring charges, or other charges to the segment’s gross‑margin measurement (FY 2022 §19(a) page 105; FY 2023 §19(a) page 104).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that Cisco's financial reporting approach for the APJC segment did not change between fiscal 2022 and 2023, which directly addresses the question about evolution—confirming no evolution occurred. (2) The excluded expense categories listed—research and development, sales and marketing, general and administrative, amortization and impairment of acquisition-related intangible assets, share-based compensation, significant litigation settlements, asset-impairment and restructuring charges—are all correctly reported and match the ground truth in both years. The LLM includes slightly more detail (e.g., 'other contingencies' and 'other charges'), which are consistent with typical SEC disclosures and do not contradict the ground truth. (3) The multi-hop reasoning is sound: the model correctly synthesizes information from two different fiscal years (FY2022 and FY2023) and compares them to conclude consistency in reporting policy. (4) The citations (FY 2022 §19(a) page 105; FY 2023 §19(a) page 104) enhance accuracy and show proper grounding in source documents. All entities (Cisco, APJC, fiscal years) are correct. Minor wording differences (e.g., 'does not allocate' vs 'excluded') are semantically equivalent in this context. No factual, quantitative, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 386,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UNH's approach to managing medical cost trends evolved from 2022 to 2023, particularly in terms of strategies to address rising outpatient procedure costs for seniors?",
      "original_answer": "In 2022, UNH expressed concern over increased medical care costs due to deferred care during the pandemic and the potential for higher demand for services, especially among individuals with chronic conditions. The company emphasized the importance of accurate cost prediction and effective management under risk-based arrangements. By 2023, UNH specifically identified rising outpatient procedure costs for seniors as a persistent trend, expecting it to continue into 2024 and beyond. In response, the company shifted toward more proactive strategies, such as engaging physicians and consumers with data-driven insights to guide clinical decisions and promote affordable, high-quality care. This represents a shift from general concern in 2022 to targeted intervention in 2023.",
      "llm_answer": "In 2022 UNH said it managed medical‑cost trends mainly through underwriting criteria, product design, competitive provider‑contract negotiations and care‑management programs, plus value‑based arrangements with commercial payers (2022 p. 17). By 2023, after seeing a surge in senior outpatient procedures, UNH shifted to a more proactive approach—engaging physicians and members with data‑driven information, expanding integrated and virtual care delivery, and accelerating fully accountable, value‑based plans to curb those outpatient costs (2023 p. 27‑29).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution in UNH's approach from 2022 to 2023: in 2022, UNH relied on underwriting, product design, provider negotiations, and care management (including value-based arrangements), which matches the general concern and risk-based management mentioned in the original answer. By 2023, the shift to proactive, data-driven engagement with physicians and consumers is accurately described, along with expansion of virtual care and acceleration of value-based plans—consistent with the original's emphasis on data-driven insights and clinical decision support. (2) There are no numeric values, dates, or financial figures in dispute; all time references (2022, 2023) are correct. (3) The multi-hop reasoning—comparing UNH’s strategy across two years and identifying a strategic shift toward targeting senior outpatient costs—is sound and well-supported by the cited document pages. (4) While the LLM answer adds slightly more detail (e.g., 'virtual care delivery', 'fully accountable plans') not explicitly in the ground truth, these are plausible elaborations consistent with the core idea of proactive, data-driven intervention. The only minor gap is that the original emphasizes 'accurate cost prediction' in 2022 more than underwriting, but the LLM’s description is still contextually valid. Overall, the answer is factually correct, complete, and semantically equivalent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 405,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has UPS's approach to time-definite delivery services evolved between 2022 and 2024, particularly in terms of service scope and network integration?",
      "original_answer": "In 2022, UPS emphasized its integrated global air and ground network as the foundation for time-definite delivery services, highlighting its ability to combine all packages within a single network for operational efficiency. By 2024, UPS expanded its time-definite delivery offerings by insourcing the final delivery of non-urgent, lightweight residential shipments previously handled by the USPS through UPS SurePost, giving it greater control over service quality. Additionally, in 2024, UPS offered same-day pickup seven days a week and expanded returns services across approximately 150 countries, reflecting a broader and more customer-centric service scope compared to 2022.",
      "llm_answer": "By 2022 UPS already marketed itself as a leader in time‑definite, guaranteed small‑package delivery, offering same‑day, next‑day, two‑day and three‑day air options and a day‑definite ground service that moved roughly 16 million packages each day, all coordinated through a single global air‑ground network【2022 p.5】. By 2024 the company had broadened the scope—daily ground volume grew to > 17 million packages, seven‑day same‑day pickup and a network of about 188,000 entry points (including 20,000 U.S. Access‑Point locations) were added, and the network was further unified with RFID‑enabled Smart‑Facility technology and digital tools (Digital Access Program) so that every air, ground, domestic, international, commercial and residential service runs on one technology‑driven smart logistics network【2024 p.6】【2024 p.3】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the evolution of UPS's time-definite delivery services between 2022 and 2024 with relevant qualitative improvements, including expanded service scope and network integration. It correctly notes the use of a single global air-ground network in 2022 and enhancements by 2024, such as seven-day same-day pickup and broader network integration through technology. However, it omits the key strategic shift in 2024 of insourcing final delivery for lightweight residential shipments previously handled by USPS via UPS SurePost—a major point in the ground truth related to control over service quality. Instead, the LLM emphasizes RFID and digital tools (e.g., Digital Access Program), which, while plausible, are not mentioned in the original answer and may reflect hallucination or unsupported inference. (2) Quantitatively, the LLM introduces specific figures—16 million packages/day in 2022 and >17 million in 2024, as well as 188,000 entry points and 20,000 U.S. Access Points—that are not present in the ground truth. Since these numbers are unsupported by the original answer, they reduce quantitative accuracy despite internal consistency. The ground truth does not provide daily package volumes or access point counts, so their inclusion cannot be verified and likely reflects overprecision from the model’s training data rather than the provided context. (3) The multi-hop reasoning is partially sound: the model correctly infers network expansion and service enhancements over time, but fails to synthesize the critical shift in delivery partner strategy (USPS to in-house), which is a core component of the 2024 evolution. This omission affects completeness and factual alignment. (4) The contextual relevance is high because the answer addresses service scope and network integration over the specified time frame, using appropriate terminology and logical progression. Qualitative accuracy is good due to correct framing of network unification and expanded pickup, but docked for unsupported details. Correctness score is 7 because the core direction of evolution is accurate, but key factual omissions and unverified numerical additions prevent a higher rating.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 590,
        "total_tokens": 1968
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did Lowe's Companies, Inc.'s treatment or recognition of its 2.50% Notes maturing in April 2026 evolve between the 2022 and 2023 annual filings?",
      "original_answer": "In the 2022 filing, the 2.50% Notes maturing in April 2026 were referenced as part of the Thirteenth Supplemental Indenture dated April 20, 2016, but were described in the context of historical documentation. By the 2023 filing, these same notes were explicitly recognized as issued instruments under the same indenture, indicating a shift in disclosure treatment. This reflects a procedural or administrative transition from planning or documentation phase in 2022 to a more active recognition of the notes as part of the company's outstanding debt structure in 2023, even though the core terms (interest rate of 2.50%, maturity in April 2026) remained unchanged.",
      "llm_answer": "In the 2022 Form 10‑K Lowe’s disclosed its 2.50 % notes due April 2026 as part of the Thirteenth Supplemental Indenture (Exhibit 4.14) – a separate, outstanding debt instrument【page_82】. The 2023 Form 10‑K lists the same 2.50 % notes under the identical Exhibit 4.14, indicating the notes remained outstanding and were still reported in the same way, with no amendment or retirement noted【page_75】.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2.50% Notes maturing in April 2026 and their inclusion under the Thirteenth Supplemental Indenture (Exhibit 4.14) in both the 2022 and 2023 filings, with accurate page references. All quantitative elements—interest rate (2.50%), maturity date (April 2026), exhibit number (4.14), and years (2022, 2023)—are factually correct. (2) However, the key qualitative point in the ground truth is the *evolution in disclosure treatment*: from being described in 2022 as part of historical documentation (planning phase) to being explicitly recognized as issued and outstanding debt in 2023. The LLM answer incorrectly states that the notes were disclosed in 2022 as a 'separate, outstanding debt instrument', which contradicts the ground truth that in 2022 they were only referenced in a historical/planning context. This misrepresents the nature of the evolution. (3) The multi-hop reasoning is partially sound—information is drawn from two filings and compared—but the synthesis is flawed because it fails to detect the shift in characterization. Instead, it concludes there was 'no amendment or retirement noted' and that reporting was 'the same way', which misses the procedural transition emphasized in the original answer. (4) Therefore, while numbers and entities are accurate (hence high quantitative score), the qualitative inaccuracy in interpreting the disclosure evolution significantly undermines the correctness. Contextual relevance is high because the response addresses the right documents and instruments, but the reasoning gap reduces overall correctness to a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 449,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the impact of sovereign debt crises on Costco's merchandise sourcing and cost structure evolved from 2022 to 2024?",
      "original_answer": "In 2022, sovereign debt crises were mentioned as part of a broader set of macroeconomic factors that could adversely affect demand for Costco's products and services, influence the cost or ability to purchase inventory, and require a change in product mix. The document highlighted that the degree of exposure depended on the type of goods, tariff rates, and timing, with the potential for higher tariffs to impact results. By 2024, the framing had shifted, with sovereign debt crises now explicitly stated to 'negatively impact' Costco's business, financial condition, and results of operations. The 2024 filing emphasized a broader set of supply chain risks, including supplier adherence to standards, supply constraints, and geopolitical instability, suggesting a heightened concern over the cascading effects of sovereign debt crises on both sourcing and cost predictability.",
      "llm_answer": "In the 2022 Form 10‑K, Costco listed sovereign‑debt crises as one of several macro‑economic headwinds that could depress demand, force a change in product mix, or raise the cost or availability of inventory, thereby pressuring its merchandise‑sourcing and gross‑margin outlook【page_15】. By the 2024 filing, the same risk is still highlighted, but it is framed within a larger international footprint and greater foreign‑exchange exposure, suggesting that while the nature of the risk has not changed, its potential impact on sourcing and cost structure may be more material as Costco’s global operations grow【page_14】.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that sovereign debt crises were mentioned in both the 2022 and 2024 10-K filings as a macroeconomic risk affecting demand, product mix, and inventory cost/availability. It accurately notes the continuity of the risk and links it to Costco's growing global operations and foreign-exchange exposure by 2024. However, it misses a key qualitative shift in tone and specificity between the years: in 2024, the risk is explicitly stated to 'negatively impact' Costco’s business, financial condition, and results of operations—a stronger and more direct language than in 2022, where it was framed as a potential adverse factor among others. The original answer emphasizes a heightened concern due to broader supply chain risks (e.g., supplier standards, geopolitical instability), which the LLM answer omits entirely. (2) There are no numerical values in the question or answers, so quantitative accuracy is not applicable—no errors present, hence a score of 10. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes information across two years and connects sovereign debt risks to sourcing and cost structure. However, it fails to capture the evolution in risk characterization—from a general macroeconomic factor to an explicitly negative and operationally impactful one—indicating incomplete synthesis of the qualitative shift. (4) The contextual relevance is high because the answer addresses the core topic and timeframe, but the lack of key details about the intensified risk framing and expanded supply chain context limits its factual completeness and reasoning depth, justifying a correctness score of 6.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 460,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the number of shares available for future grants under the 2020 Stock Incentive Plan changed between 2021 and 2023, and what does this indicate about UnitedHealth Group's capacity for issuing new share-based awards?",
      "original_answer": "In 2021, UnitedHealth Group had 64 million shares available for future grants under the 2020 Stock Incentive Plan. By 2023, this number had decreased to 53 million shares. This indicates a reduction in the company's available capacity to issue new share-based awards over this period.",
      "llm_answer": "UnitedHealth’s 2020 Stock Incentive Plan had 64 million shares available for future grants at 12/31/2021 (​page 67​), but that pool fell to 53 million shares by 12/31/2023 (​page 72​, footnote 3). The 11‑million‑share decline shows the company has drawn down its award pool, leaving a smaller capacity to issue new share‑based awards under the 2020 plan unless additional shares are authorized.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the numbers are accurate: 64 million shares in 2021 and 53 million in 2023, with an 11-million-share decrease correctly calculated. The dates (12/31/2021 and 12/31/2023) align with the fiscal year-end context implied in the question. (2) The answer addresses both parts of the multi-part question: it identifies the change in available shares (from 64M to 53M) and interprets the implication—reduced capacity for issuing new share-based awards, which is correctly attributed to the drawdown of the award pool. (3) Entity accuracy is perfect: UnitedHealth Group (referred to correctly as UnitedHealth), the 2020 Stock Incentive Plan, and the relevant years are all correctly identified. (4) The reasoning is sound and demonstrates proper multi-hop synthesis: it connects data points from two different years, computes the trend, and draws the correct qualitative conclusion about the company’s capacity for future awards. The addition of a conditional (‘unless additional shares are authorized’) enhances the depth without deviating from the truth. (5) Semantic equivalence is maintained—while the LLM provides slightly more detail (e.g., page references, ‘11-million-share decline’), the core information and meaning match the original answer exactly. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1188,
        "completion_tokens": 384,
        "total_tokens": 1573
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the expiration date and contribution significance of the IAM National Pension Fund / National Pension Plan relationship with UPS evolve between 2022 and 2024?",
      "original_answer": "In 2022, the IAM National Pension Fund / National Pension Plan had a collective bargaining agreement expiration date of July 31, 2024, and UPS had contributed more than 5% of the total plan contributions from all employers for the years 2019 through 2021. By 2024, the expiration date for this specific plan was extended to July 31, 2029, and UPS continued to be a significant contributor, providing more than 5% of total contributions for the plan years 2022 through 2024. This indicates a notable extension in the contractual relationship and sustained significance of UPS's contributions over time.",
      "llm_answer": "In the 2022 filing UPS’s agreement with the IAM National Pension Fund/National Pension Plan was linked to a collective‑bargaining contract that expired on July 31 2024, and UPS was identified as contributing more than 5 % of the plan’s total funding (about $48 million in 2021). By the 2024 filing a new IAM master agreement pushed the expiration out to July 31 2029, and UPS continued to be a material contributor—still providing over 5 % of total contributions and increasing its annual payment to $53 million in 2024. This reflects a five‑year extension of the agreement’s term while UPS’s contribution remained significant and grew modestly.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Correctness: All key facts are correct — the expiration date changed from July 31, 2024 (in the 2022 filing) to July 31, 2029 (in the 2024 filing), and UPS remained a significant contributor by providing over 5% of total plan contributions. The original answer confirms UPS contributed more than 5% for 2019–2021 (referenced in 2022 filing) and continued to do so for 2022–2024 (per 2024 filing). The LLM correctly captures this continuity. (2) Quantitative Accuracy: The dates (July 31, 2024 and 2029) are exact. The 5% threshold is correctly reported. The LLM adds specific dollar figures — $48 million in 2021 and $53 million in 2024 — which are plausible and consistent with the ground truth’s statement of significant contributions, though these exact dollar amounts are not present in the original answer. This addition does not contradict but enhances detail; however, since the ground truth does not specify these numbers, there is a minor overprecision risk, slightly reducing quantitative accuracy. (3) Qualitative Accuracy: The reasoning is sound, synthesizing changes over time in both contract duration and contribution significance. The use of 'material contributor' is semantically equivalent to 'significant contributor.' The multi-hop synthesis across 2022 and 2024 filings is correctly executed. (4) Contextual Relevance: The answer directly addresses the evolution of both the expiration date and contribution significance, fully satisfying the question. Overall, the answer is factually correct, well-reasoned, and slightly enriched with plausible estimates, warranting a high score but not perfect due to unverified dollar amounts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 469,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the terms and availability under LOW's 2020 Credit Agreement evolve between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the 2020 Credit Agreement had a maturity date of March 2025 and provided $2.0 billion in availability. By fiscal year 2023, the 2020 Credit Agreement was amended and restated in September 2023 into the 2023 Credit Agreement, which extended the maturity date to September 2028 while maintaining the same $2.0 billion availability. Additionally, in 2023, the combined availability under both the 2023 Credit Agreement and the Third Amended and Restated Credit Agreement remained at $4.0 billion, consistent with the total availability reported in 2022.",
      "llm_answer": "In FY 2022 the five‑year unsecured revolving facility dated March 23, 2020 (the “2020 Credit Agreement”) had been amended in December 2021 to raise its aggregate availability to $2 billion, to mature in March 2025 and to bear interest at a Base‑Rate or Eurocurrency‑Rate plus a margin; together with the third‑amended $2 billion facility the total available borrowing capacity was $4 billion【page_56】. By FY 2023 the same agreement was again amended and restated in September 2023 (now called the “2023 Credit Agreement”), extending its term to September 2028 while keeping the $2 billion availability and the $4 billion combined pool (with an optional $1 billion increase) and the company remained in covenant compliance【page_58】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: in FY 2022, the 2020 Credit Agreement had a $2.0 billion availability and matured in March 2025; in FY 2023, it was amended and restated in September 2023 into the 2023 Credit Agreement with a new maturity date of September 2028, maintaining $2.0 billion availability. The combined availability with the Third Amended and Restated Credit Agreement remained $4.0 billion in both years. (2) Quantitative accuracy is perfect: all dollar amounts ($2 billion, $4 billion), dates (March 2025, September 2023, September 2028), and structural details (optional $1 billion increase) are correct. The mention of the optional increase is an additional detail not in the ground truth but does not contradict it. (3) Multi-hop reasoning is sound—LLM correctly synthesizes the evolution of terms and availability across fiscal years and agreements. (4) Minor deduction in qualitative accuracy because the LLM references a December 2021 amendment to increase availability to $2 billion, which is not mentioned in the ground truth; however, this does not contradict the stated FY 2022 terms and may reflect earlier context. Overall, the answer is factually aligned, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 364,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did MDLZ's use of Net Investment Hedge Derivative Contracts evolve between 2022 and 2024, particularly in terms of their notional amounts?",
      "original_answer": "In 2022, MDLZ reported a notional amount of $3,915 million for Net Investment Hedge Derivative Contracts as of December 31, 2021, and $4,551 million as of December 31, 2020. By 2024, the notional amount for these contracts had increased significantly to $8,647 million as of December 31, 2024, up from $7,456 million in 2023. This indicates a growing reliance on such contracts over the two-year period.",
      "llm_answer": "MDLZ’s net‑investment hedge program expanded in size. The aggregate notional amount of its NIH derivative contracts was $7.456 billion at year‑end 2023 and rose to $8.647 billion at year‑end 2024, an increase of roughly $1.2 billion. The 2022 filing does not disclose a comparable notional figure for NIH contracts, but the later figures show a clear upward trend in the use of these hedges.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the notional amounts for 2023 ($7,456 million) and 2024 ($8,647 million), matching the ground truth in both values and trend (increase of ~$1.2 billion). However, it incorrectly states that the 2022 filing does not disclose a comparable figure, when in fact the original answer confirms that MDLZ did report notional amounts for earlier years—specifically $3,915 million as of December 31, 2021, and $4,551 million as of December 31, 2020—both disclosed in the 2022 filing. This omission significantly undermines the completeness and accuracy of the evolution analysis between 2022 and 2024. (2) Quantitatively, the numbers cited (2023 and 2024) are accurate and formatted correctly ($7.456 billion = $7,456 million; $8.647 billion = $8,647 million), and the implied increase (~$1.2 billion) is approximately correct. However, the failure to include prior-year data from the 2022 filing means the full quantitative evolution is misrepresented. (3) The multi-hop reasoning is partially sound—the model correctly identifies the upward trend from 2023 to 2024—but fails to synthesize information across all relevant years (2020–2024) as required by the question about evolution between 2022 and 2024. The conclusion that the 2022 filing lacks data is factually incorrect and reflects a reasoning gap. (4) Contextually, the answer is relevant and well-structured, focusing on the right metric and time frame, but the missing data from the 2022 filing results in an incomplete and misleading narrative about the evolution of MDLZ's hedge usage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1197,
        "completion_tokens": 435,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Microsoft 365's integration with AI technologies evolved between 2022 and 2024, and what specific new capabilities were introduced in 2024 to enhance its role in productivity and collaboration?",
      "original_answer": "In 2022, Microsoft 365 was described as integrating Office 365, Windows, and Enterprise Mobility + Security with AI-backed tools to empower employees, focusing on creativity, collaboration, and innovation. By 2024, Microsoft 365 had evolved into an 'AI first platform,' introducing Copilot for Microsoft 365, which combines AI with business data from the Microsoft Graph and Microsoft 365 applications. Additionally, role-specific extensions such as Copilot for Sales, Copilot for Service, and Copilot for Finance were introduced to streamline business processes. These developments reflect a significant enhancement in AI integration aimed at delivering more personalized and intelligent productivity tools.",
      "llm_answer": "In the 2022 filing Microsoft 365 was portrayed as a suite that “brings together Office 365, Windows, and Enterprise Mobility + Security to help organizations empower their employees with **AI‑backed tools** that unlock creativity, increase collaboration, and fuel innovation”【page_4】, with early Copilot‑based assistance and AI‑enhanced features in Teams, Viva and the Power Platform【page_4】.  \n\nBy the 2024 filing the company re‑positioned Microsoft 365 as an **AI‑first platform**, embedding Copilot directly into the Microsoft Graph and all 365 apps (“Copilot for Microsoft 365 combines AI with business data in the Microsoft Graph and Microsoft 365 applications”)【page_4】, adding **Copilot Studio** so customers can customize or build their own Copilot experiences【page_4】, and extending AI‑driven capabilities across Teams and Viva to further boost productivity and collaboration【page_4】. These new 2024 capabilities deepen AI integration and give users more personalized, real‑time assistance within the productivity suite.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of Microsoft 365's AI integration from 2022 as an AI-enhanced suite to a repositioned 'AI-first platform' in 2024, which matches the original answer. The introduction of Copilot for Microsoft 365 and its integration with the Microsoft Graph and M365 apps is accurately described. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across time (2022 to 2024) and platforms (Teams, Viva, Power Platform, Microsoft Graph), correctly tracing the progression of AI capabilities. However, the LLM mentions 'Copilot Studio' and customization features, which are not explicitly in the ground truth, and omits the specific role-based extensions—Copilot for Sales, Service, and Finance—highlighted in the original answer. This is a minor omission affecting completeness but does not undermine the core factual accuracy. (4) Despite this, the answer captures the essence of enhanced AI integration for productivity and collaboration, uses semantically equivalent language, and remains fully relevant to the question. The slight deduction in qualitative accuracy reflects the partial omission of specific 2024 role-based Copilots, but the overall reasoning and contextual relevance remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1448,
        "completion_tokens": 408,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has 3M's approach to PFAS discharge characterization in its wastewater permits evolved between its Decatur, Alabama facility disclosures in 2022 and 2024?",
      "original_answer": "In 2022, 3M disclosed that it had not fully characterized its PFAS discharge in its NPDES permit for the Decatur facility and had submitted an application to ADEM to add additional PFAS to the permit. By 2024, the Company had installed and was upgrading wastewater treatment controls specifically designed to address PFAS at the Decatur facility, and the controls were being optimized, though ADEM had not yet acted on the permit modification request. This evolution shows a shift from identifying the issue and initiating corrective actions to implementing and refining treatment solutions while awaiting regulatory approval.",
      "llm_answer": "In the 2022 filing, 3M disclosed that it had only just realized its Decatur NPDES permit did not list all PFAS, promptly reported the shortfall, temporarily idled the affected processes, installed wastewater‑treatment controls and entered a July 2020 interim consent order with ADEM that required reporting, analytical/characterization studies and future capital improvements to cover all PFAS‑related discharges. By the 2024 filing, the company had moved from that interim‑order remedy to actively seeking a formal permit amendment—submitting an application to add the missing PFAS to the NPDES permit—and was installing, upgrading and optimizing additional treatment controls while awaiting ADEM’s action, showing a shift toward a proactive permit‑modification and treatment‑upgrade approach.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of 3M's approach to PFAS discharge characterization at the Decatur facility, showing a shift from initial identification and interim measures to seeking formal permit amendments and upgrading treatment controls. However, there are significant factual inaccuracies that reduce correctness. First, the LLM incorrectly states that 3M entered into a July 2020 interim consent order with ADEM, which is not mentioned in the ground truth and predates the 2022 disclosure—this introduces a false timeline. The ground truth does not reference any consent order or process idling, nor does it mention actions taken as early as 2020 in the context of the Decatur NPDES permit characterization shortfall. Second, while the 2022 ground truth confirms 3M had not fully characterized PFAS discharges and had submitted a permit modification application, the LLM conflates events by suggesting treatment controls were already installed by 2022, whereas the ground truth indicates installation and upgrades were ongoing by 2024. The qualitative reasoning is sound in identifying a shift toward proactive treatment and permit modification, and the entity (3M, Decatur, ADEM, NPDES, PFAS) and year references (2022 vs 2024) are accurate. The answer is contextually relevant and synthesizes the multi-hop aspect of regulatory and operational evolution, but the inclusion of unverified details (consent order, 2020 timeline, premature treatment installation) undermines quantitative and overall correctness. Semantic equivalence is partially achieved, but not fully due to the introduction of unsupported specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 446,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Lowe's Companies, Inc.'s issuance of the 4.550% Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 4.550% Notes were first introduced in the Fifteenth Supplemental Indenture dated April 5, 2019, and were due April 5, 2049. In 2023, the same 4.550% Notes continued to be referenced under the same Fifteenth Supplemental Indenture, with no changes to the terms or maturity date. Therefore, while the 4.550% Notes were still in effect in 2023, there was no modification or new issuance related to this specific instrument during that year.",
      "llm_answer": "In the 2022 Form 10‑K Lowe’s disclosed that it had issued 4.550 % notes under the Fifteenth Supplemental Indenture dated April 5 2019, with a maturity of April 5 2049【page_82】. The 2023 Form 10‑K repeats the same reference to the Fifteenth Supplemental Indenture and the same 4.550 % notes, showing no additional issuance or amendment, so the 4.550 % notes remained unchanged between 2022 and 2023【page_76】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: the 4.550% Notes were issued under the Fifteenth Supplemental Indenture on April 5, 2019, with a maturity date of April 5, 2049, as confirmed in both the 2022 and 2023 Form 10-Ks. (2) Quantitative elements—interest rate (4.550%), and dates (April 5, 2019, and April 5, 2049)—are precisely accurate with no discrepancies. (3) The reasoning correctly synthesizes information across two years of filings, noting that while the notes were disclosed in both years, there was no new issuance or amendment in 2023. This reflects proper multi-hop logic: comparing disclosures across consecutive annual reports to infer continuity and absence of change. (4) The answer fully addresses the evolution (or lack thereof) of the notes between 2022 and 2023, maintaining entity accuracy (Lowe’s Companies, Inc., correct indenture name), and correctly interpreting the regulatory disclosure context. Minor formatting differences (e.g., spacing in '4.550 %') do not affect meaning. The inclusion of citation markers like 【page_82】 and 【page_76】 enhances traceability and aligns with document-based reasoning expectations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1200,
        "completion_tokens": 342,
        "total_tokens": 1542
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MDLZ's financial relationship with KDP evolve between 2022 and 2024, particularly in terms of gains recognized from changes in accounting for the investment?",
      "original_answer": "In 2022, MDLZ recognized a pre-tax gain of $71 million (or $54 million after-tax) during the first quarter related to the sale of KDP shares, which reduced its ownership interest. By 2024, the company recorded a significantly larger pre-tax gain of $493 million ($368 million after-tax) due to a change in accounting for its investment in KDP. This indicates a substantial evolution in the financial impact of MDLZ's relationship with KDP over the two-year period.",
      "llm_answer": "In 2022 Mondelēz still accounted for its Keurig Dr Pepper stake under the equity‑method, but in the first quarter of 2023 the holding fell below the 5 % influence threshold and the company re‑classified the investment as a marketable‑security. At the time of the change it recorded a pre‑tax $493 million gain on equity‑method transactions for 2023, and after selling the remaining shares it recognized a $593 million pre‑tax gain on the marketable‑securities sale (plus $13 million of dividend income) – a total $606 million pre‑tax gain 【page_88】【page_89】. By 2024 the KDP investment was fully exited, with the gains from the accounting change already reflected in the 2023 results.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that MDLZ recognized a $71 million pre-tax gain in 2022 and a $493 million pre-tax gain in 2024 due to a change in accounting for its KDP investment. However, the LLM claims the $493 million gain occurred in 2023 due to reclassification below a 5% threshold, which contradicts the ground truth that places this gain in 2024. Additionally, the LLM introduces a $593 million gain from selling marketable securities and $606 million total gains not mentioned in the original answer, which focuses only on the $493 million gain from accounting change in 2024. (2) Quantitative accuracy is poor: the key years (2022 vs 2024) are incorrect, and the LLM invents additional gains ($593M, $606M total) unsupported by the ground truth. The $71 million gain in 2022 is entirely omitted. (3) The multi-hop reasoning is flawed: instead of showing evolution from a smaller 2022 gain to a larger 2024 gain due to accounting change, the LLM misattributes timing and magnitude, and adds an exit scenario in 2023 not present in the original. It fails to show the correct two-year evolution as required. (4) Contextual relevance is moderate because it discusses MDLZ's investment in KDP and gains from accounting changes, but the incorrect timing, invented figures, and mischaracterization of events severely undermine factual correctness. The mention of dividend income and full exit in 2024 are not in the original and introduce inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 420,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has the scale and positioning of Xbox Game Pass evolved between 2022 and 2024, based on the number of titles available and Microsoft's strategic emphasis?",
      "original_answer": "In 2022, Xbox Game Pass offered access to a curated library of over 100 first- and third-party titles, and was positioned as a key part of Microsoft's broader gaming strategy focused on content, community, and cloud services. By 2024, the service had expanded significantly, offering access to over 400 first- and third-party titles, and was described as the 'cornerstone' of Microsoft's gaming platform, reflecting a stronger strategic emphasis on subscriptions and community growth. This indicates a significant transformation in both scale and strategic importance.",
      "llm_answer": "In FY 2022, Xbox Game Pass gave subscribers access to a curated library of **over 100** first‑ and third‑party console and PC titles (page 6). By FY 2024 that library had grown to **over 400** titles, and Microsoft now frames Game Pass as a core growth platform—expanding the ecosystem across devices, leveraging subscriptions, ads and digital‑store revenue, and emphasizing broader gamer engagement (page 13).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the numbers 'over 100' titles in FY 2022 and 'over 400' in FY 2024 are correct and match the original answer exactly. Fiscal years (FY 2022 and FY 2024) are appropriately used and consistent with SEC filing conventions. (2) The answer correctly identifies the expansion in scale and Microsoft's increased strategic emphasis, noting Game Pass as a 'core growth platform'—a term semantically equivalent to 'cornerstone' in the original. (3) Multi-hop reasoning is sound: it synthesizes growth in title count and strategic positioning across two years, correctly inferring increased importance. (4) Minor deduction in qualitative accuracy because the LLM adds details not in the original (e.g., 'ads and digital-store revenue') which, while plausible, are not mentioned in the ground truth. However, these do not contradict the original and are contextually reasonable. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 297,
        "total_tokens": 1545
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the structure or disclosure of Deferred Stock Unit Award Agreements for non-employee directors under the 3M Company 2016 Long-Term Incentive Plan evolved from 2022 to 2024, based on the referenced filings?",
      "original_answer": "The Deferred Stock Unit Award Agreement for non-employee directors was first referenced in the 2022 10-K filing as part of the 3M Company 2016 Long-Term Incentive Plan, applicable to grants on or after January 1, 2019. By 2024, the agreement continued to be disclosed in the 10-K filing, still referencing grants on or after January 1, 2019, indicating no change in the effective date or structure of the agreement over this period. However, the 2024 disclosure reflects an updated incorporation by reference from the 2023 10-K, showing the ongoing maintenance of the plan through amendments as of May 8, 2023.",
      "llm_answer": "The 2022 Form 10‑K (pages 129‑133) contains no specific reference to a Deferred Stock Unit Award Agreement for non‑employee directors under the 2016 Long‑Term Incentive Plan. In contrast, the 2024 Form 10‑K lists a dedicated exhibit (10.7) that incorporates “Form of Deferred Stock Unit Award Agreement for deferred stock units granted on or after January 1, 2019 to Non‑Employee Directors under the 3M Company 2016 Long‑Term Incentive Plan” (see page 117) — showing that the company moved from an implicit or absent disclosure in 2022 to an explicit, stand‑alone exhibit reference in 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core factual claims, leading to a low correctness score. The original answer (ground truth) states that the Deferred Stock Unit Award Agreement for non-employee directors was first referenced in the 2022 10-K, applicable to grants on or after January 1, 2019. However, the LLM claims that the 2022 10-K contains *no specific reference* to this agreement, which directly contradicts the ground truth. This is a major factual error in both entity accuracy and quantitative accuracy (specifically, the presence/absence of a disclosure in 2022). The LLM correctly identifies that the 2024 10-K includes the agreement as a dedicated exhibit (10.7) and references grants on or after January 1, 2019, which aligns with the ground truth. It also correctly notes an updated incorporation by reference, though it fails to mention the May 8, 2023 amendment explicitly. The reasoning is partially sound in identifying a change in disclosure format, but incorrectly frames it as a shift from 'no reference' to 'explicit exhibit,' when in fact the agreement was already referenced in 2022. Thus, the multi-hop synthesis is flawed. While the answer addresses the evolution question and is contextually relevant, the significant factual inaccuracy regarding the 2022 filing undermines the overall correctness. Minor formatting differences in date or dollar amounts are not at issue here, but the presence or absence of a key document reference is a critical fact that must be accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 414,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the composition of Charles Schwab Bank's First Mortgages and HELOCs portfolio evolved between 2023 and 2024, particularly in terms of origination costs and geographic concentration in California?",
      "original_answer": "In 2023, the First Mortgages and HELOCs portfolio included $100 million in unamortized premiums, discounts, and direct origination costs, with 43% of the portfolio concentrated in California. By 2024, these costs increased to $112 million, while the California concentration slightly decreased to 42%. This indicates a slight shift in geographic risk exposure and an increase in loan origination activity or associated costs over the year.",
      "llm_answer": "By the end of 2024 Schwab’s First‑Mortgage and HELOC portfolio carried **$112 million of unamortized premiums, discounts and direct origination costs**, up from **$100 million at year‑end 2023** (a $12 million increase)【page_88†L31-L33】.  At the same time, the share of those loans located in California slipped **to 42 % in 2024 from 43 % in 2023**【page_88†L34-L36】【page_90†L31-L33】.  Thus, the portfolio’s cost basis rose modestly while its geographic concentration in California eased slightly.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: unamortized costs increased from $100 million in 2023 to $112 million in 2024 (correct $12 million increase), and California concentration decreased from 43% to 42%—both figures match the original answer exactly. (2) The answer is complete, addressing both origination costs and geographic concentration over the two years, satisfying the multi-part question. (3) Entities are correctly identified: Charles Schwab Bank’s First Mortgages and HELOCs portfolio, with correct time periods (2023 vs 2024) and financial metrics (unamortized premiums, discounts, direct origination costs, and geographic concentration). (4) The reasoning is sound: the LLM correctly infers a modest rise in cost basis and a slight easing of geographic concentration, which aligns with the original conclusion about shifting risk exposure and increased origination activity. Citations from the document (page_88, page_90) further support the accuracy. Semantic equivalence is strong—wording differs slightly but meaning and factual content are identical. No errors in calculation, logic, or synthesis across time periods and metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 344,
        "total_tokens": 1593
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Nike's strategic emphasis on the Dri-FIT technology evolved between fiscal 2023 and fiscal 2024, based on the language in Nike's product research and development sections?",
      "original_answer": "Nike's strategic emphasis on the Dri-FIT technology remained stable between fiscal 2023 and fiscal 2024. In both years, Dri-FIT was listed among key technologies such as Nike Air, Zoom, Free, Flyknit, FlyEase, ZoomX, Air Max, and React, indicating consistent strategic importance. The exact same language was used in both the 2023 and 2024 10-K filings, showing no change in the description or emphasis of Dri-FIT's role in Nike’s innovation strategy.",
      "llm_answer": "Nike’s product‑research and development language in both filings treats Dri‑FIT as a core, ongoing innovation. In fiscal 2023 the 10‑K notes “The proliferation of Nike Air, Zoom, Free, Dri‑FIT, Flyknit, FlyEase, ZoomX, Air Max, and React technologies… typifies our dedication to designing innovative products” (2023 10‑K p. 6). The fiscal 2024 filing repeats the same phrasing, again listing Dri‑FIT among the suite of flagship technologies (2024 10‑K p. 6), indicating that Nike’s strategic emphasis on Dri‑FIT has remained steady—still a key part of a broader, expanding technology portfolio.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that Nike's strategic emphasis on Dri-FIT remained steady between fiscal 2023 and 2024, with no change in language or positioning. (2) There are no numerical values requiring calculation, but the citations to the 10-K filings (pages and years) are correctly referenced and consistent with the ground truth. (3) The multi-hop reasoning is sound: the model correctly identifies that the same list of technologies, including Dri-FIT, appears in both years’ filings with identical phrasing, indicating no shift in strategic emphasis. (4) The answer addresses all parts of the question—evolution (or lack thereof) of Dri-FIT’s strategic role—by citing direct evidence from both years’ product R&D sections. Wording differs slightly but conveys the same factual conclusion: Dri-FIT remains a core, consistently emphasized technology within Nike’s innovation portfolio.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 279,
        "total_tokens": 1548
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Mondelez International's investment in backup and disaster recovery evolved from 2022 to 2024, particularly in response to increasing cybersecurity threats?",
      "original_answer": "In 2022, Mondelez was on heightened alert regarding cybersecurity risks, dedicating focused resources to backup and disaster recovery as part of its response to increased global cybersecurity threats, especially during the pandemic. By 2024, the company significantly expanded its efforts, explicitly stating that it continues to invest and augment its cybersecurity program with enhanced backup and disaster recovery solutions, among other measures, to address increasingly sophisticated threats including those from state-sponsored actors and emerging technologies like artificial intelligence.",
      "llm_answer": "In the 2022 10‑K, Mondelez said it was “on heightened alert and dedicate[d] focused resources to network security, **backup and disaster recovery**” as part of its response to growing cyber risk【page_45】. By the 2024 filing, the company reports that it has **expanded and deepened that investment**, embedding backup and disaster‑recovery into a broader, more sophisticated cybersecurity program that now includes enhanced identity‑ and access‑management, multi‑factor authentication, privileged‑access controls, advanced threat protection and 24/7 monitoring, while noting that the cost of these protective measures is rising as threats become more complex【page_20】【page_21】. This shows a clear escalation from a targeted focus on backup/recovery to a comprehensive, higher‑spending cyber‑resilience strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: in 2022, Mondelez was on heightened alert and dedicated resources to backup and disaster recovery; by 2024, it expanded these efforts as part of a broader cybersecurity program. The mention of rising costs and more complex threats matches the evolving context. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the ground truth or LLM response, so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, showing evolution from focused backup/recovery efforts to a comprehensive cyber-resilience strategy. It accurately infers escalation in investment and scope, supported by specific controls added (e.g., MFA, 24/7 monitoring). (4) Semantic equivalence is strong—while the LLM adds slightly more detail (e.g., listing specific security measures), this is consistent with typical 10-K disclosures and enhances clarity without introducing inaccuracies. The only minor gap is that the ground truth specifically mentions 'state-sponsored actors' and 'artificial intelligence' as emerging threats, which the LLM omits, slightly reducing qualitative completeness. However, the core evolution in investment and strategy is correctly captured, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 391,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Microsoft's financial commitment and engagement with Black and African American-owned suppliers evolved from fiscal year 2022 to fiscal year 2024?",
      "original_answer": "In fiscal year 2022, Microsoft reported that it had enriched its supplier pipeline, reaching more than 90% of its goal to spend $500 million with double the number of Black and African American-owned suppliers. By fiscal year 2024, Microsoft had not only achieved its $500 million spending goal but also expanded its financial commitments by allocating $150 million to Minority Depository Institutions and funds supporting Black and African American-owned small businesses. This evolution indicates a deepening of Microsoft's strategic focus on supplier diversity and community economic development over time.",
      "llm_answer": "In fiscal 2022 Microsoft said it had reached **more than 90 % of its goal** to spend **$500 million** with **double the number of Black‑ and African‑American‑owned suppliers**. By fiscal 2024 the company reported it had **fully achieved that $500 million spend target**, doubling the supplier base, and added a **$150 million commitment** to minority depository institutions and Black‑owned small businesses (including low‑interest partner loans), deepening its financial engagement.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: in FY2022, Microsoft reached more than 90% of its $500 million goal with double the number of Black and African American-owned suppliers; by FY2024, it achieved the full $500 million spend target and added a $150 million commitment. (2) Quantitative accuracy is perfect: dollar amounts ($500 million, $150 million), percentages ('more than 90%'), and timeframes (fiscal years 2022 and 2024) match exactly. Format variations (e.g., 'million' vs 'M') are acceptable and do not affect meaning. (3) Multi-hop reasoning is sound—the model correctly synthesizes information across two fiscal years and connects Microsoft's evolving supplier diversity strategy, including both supplier spending and broader financial commitments to minority institutions and small businesses. (4) The answer fully addresses the question about evolution over time, with precise entity identification (Microsoft, Black- and African American-owned suppliers, minority depository institutions), correct fiscal years, and logical progression from near-goal achievement to full achievement plus expansion. Wording differences (e.g., 'low-interest partner loans' as additional detail) do not contradict but may enhance context without introducing error. All scoring categories warrant top marks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 382,
        "total_tokens": 1657
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the availability of common shares for future issuance under the Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees evolved from 2022 to 2023, and what does this indicate about Abbott's stock-based incentive strategy?",
      "original_answer": "In 2022, as of December 31, 2021, an aggregate of 10,638,639 common shares were available for future issuance under the Employee Stock Purchase Plan. In 2023, as of December 31, 2023, this number had decreased to 8,565,087 common shares. This indicates a reduction in the number of shares available for future issuance, suggesting a potential tightening or adjustment in Abbott's stock-based incentive strategy for non-U.S. employees.",
      "llm_answer": "The 2022 Form 10‑K disclosed that, as of December 31 2021, Abbott had **10,638,639** common shares available for future issuance under the Employee Stock Purchase Plan for Non‑U.S. Employees【page_83】. The 2023 Form 10‑K shows that the same pool had fallen to **8,565,087** shares as of December 31 2023【page_84】. This decline indicates Abbott has been drawing down the plan’s share reserve—reflecting active use of the program and a tighter control of equity dilution in its stock‑based incentive strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the number of shares available for future issuance in both years: 10,638,639 as of December 31, 2021 (reported in the 2022 Form 10-K), and 8,565,087 as of December 31, 2023 (reported in the 2023 Form 10-K). These figures match the ground truth exactly. (2) The dates and numbers are accurate, with proper citation to the respective 10-K filings. The decrease from 10,638,639 to 8,565,087 is correctly portrayed as a decline, and no calculations are required beyond this comparison. (3) The multi-hop reasoning is sound—information is synthesized across two annual reports (2022 and 2023) for the same plan, linking the change over time. The conclusion that Abbott is drawing down the share reserve aligns with the data. The interpretation adds nuance by noting 'active use of the program' and 'tighter control of equity dilution,' which is a reasonable extension of the ground truth's suggestion of a 'tightening or adjustment' in strategy. (4) The only reason for not scoring a 10 in qualitative accuracy is that the LLM slightly extends the interpretation by mentioning 'equity dilution'—while plausible, this specific term is not in the original answer and introduces a concept not explicitly confirmed. However, this does not detract from correctness. All other aspects—context, entities, numbers, and reasoning—are fully accurate and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 389,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Nike's treatment of Nike Air technology evolved in its product development strategy between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal 2023, Nike Air was described as part of a list of technologies that 'typifies our dedication to designing innovative products,' indicating it was still being actively proliferated across product lines. By fiscal 2024, Nike Air was again listed among key technologies, but now embedded alongside mature technologies like Zoom, Free, and React, suggesting that Nike Air had become a standard component of Nike’s broader innovation platform rather than a distinct growth driver. This reflects a strategic shift from emphasizing Nike Air as an emerging innovation to treating it as an integrated, foundational offering within Nike’s product development framework.",
      "llm_answer": "In FY 2023 Nike Air was mentioned only as one of the many performance technologies that Nike leverages – the filing notes “the proliferation of Nike Air … typifies our dedication to designing innovative products”【page_6】. By FY 2024 the company not only repeats that emphasis but also spotlights its Air Manufacturing Innovation subsidiary as the primary supplier of Nike Air‑Sole cushioning components, signaling a more integrated, strategic focus on Air technology in its product‑development roadmap【page_7】【page_6】.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misrepresents the strategic evolution of Nike Air technology between FY2023 and FY2024. (1) It correctly quotes the FY2023 language about 'proliferation of Nike Air' as reflecting innovation dedication, aligning with the original answer. However, in FY2024, the LLM claims a 'more integrated, strategic focus' due to mention of Air Manufacturing Innovation, which suggests increased emphasis—this contradicts the ground truth, which indicates that Nike Air had transitioned to being a mature, foundational technology grouped with Zoom, Free, and React, not a distinct growth driver. (2) There are no numeric values, so quantitative accuracy is not applicable; however, fiscal years (2023, 2024) are correctly identified, earning full marks here. (3) The multi-hop reasoning is flawed: while the LLM cites new information (Air Manufacturing Innovation), it interprets this as a strategic elevation of Nike Air, whereas the ground truth shows a downshift in its strategic positioning—from highlighted innovation to embedded standard tech. This misreads the implication of the textual shift. (4) Contextually, the answer addresses the right documents and topic, and the citations suggest relevance, but the core conclusion about strategic evolution is inverted. Thus, while factually plausible and contextually relevant, the qualitative reasoning and final assessment are significantly off, warranting a mid-range correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 403,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Abbott's positioning of Osmolite within its Nutritional Products segment evolved between 2022 and 2023, particularly in terms of its enteral feeding portfolio and associated product line strategy?",
      "original_answer": "In 2022, Osmolite was listed among Abbott's enteral feeding products used in healthcare institutions, alongside Jevity®, Glucerna® 1.2 Cal, Glucerna® 1.5 Cal, Oxepa®, Freego™, Nepro®, and Vital®. By 2023, Osmolite continued to be included in the enteral feeding portfolio, but Abbott's product listing in this category remained largely consistent, indicating a stable strategic positioning of Osmolite within the institutional enteral nutrition segment. There is no indication of Osmolite being newly introduced, discontinued, or significantly repositioned relative to other products in this category during this period.",
      "llm_answer": "In the 2022 Form 10‑K Abbott listed Osmolite by name as one of the specific enteral‑feeding products (Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, **Osmolite**, Oxepa, Freego, Nepro and Vital) within its Nutritional Products segment 【page_3】. By the 2023 filing the narrative no longer calls out Osmolite; it refers only to an “enteral feeding portfolio” without itemizing individual brands, indicating that Osmolite is now treated as part of a broader, integrated product‑line strategy rather than a separately highlighted offering 【page_6】.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim. According to the ground truth, Osmolite remained part of Abbott's enteral feeding portfolio in both 2022 and 2023, with no indication of strategic repositioning or de-emphasis. The LLM incorrectly asserts that Osmolite was no longer called out by name in the 2023 10-K and that this reflects a shift to a more integrated product-line strategy. However, the ground truth states that Abbott's product listing remained 'largely consistent' between years, implying continued inclusion and positioning of Osmolite. The error lies in the misinterpretation of disclosure changes as strategic changes—absence of explicit naming in narrative text does not equate to repositioning if the product remains in the portfolio. There are no numeric values in this question, so quantitative accuracy is not applicable but assumed correct by default. The reasoning is flawed as it draws an unsupported inference from reporting format changes. While the answer addresses the question's focus on product strategy evolution, it does so with incorrect analysis, hence moderate contextual relevance but low correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 330,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has 3M's regulatory engagement and remediation obligations related to PFAS discharge evolved between 2022 and 2024, particularly in Minnesota and Alabama?",
      "original_answer": "In 2022, 3M was actively working under a 2007 Settlement Agreement and Consent Order with the MPCA to address PFAS contamination in Minnesota, with remediation substantially completed at the Cottage Grove site and ongoing operational and maintenance activities at multiple locations. In Alabama, the Company had entered into a July 2020 Interim Consent Order with ADEM, which included obligations for PFAS-related wastewater discharges and air emissions, and had completed installation of a multilayer cap at the Decatur facility. By 2024, regulatory scrutiny had intensified. In Minnesota, MPCA issued a draft Clean Water Act permit for the Cottage Grove facility with significantly revised effluent limits for certain PFAS compounds, some below current quantification levels, and the Company submitted public comments in August 2024. Additionally, in 2024, MPCA published a revised draft permit in December after considering stakeholder input, which could have a significant adverse impact on the Cottage Grove facility's operations. In Alabama, while the 2020 Interim Consent Order remained in effect, the Company's obligations under ongoing investigations and potential future remediation were still expected to involve additional operating costs and capital expenditures over multiple years. The regulatory landscape evolved to include more stringent standards, such as updated HBVs from MDH in January 2024 and proposed HRLs in October 2024, further complicating 3M's compliance path.",
      "llm_answer": "In the 2022 10‑K, 3M said its Minnesota PFAS program was governed by the 2007 Settlement Agreement and Consent Order, under which remediation at the Oakdale, Woodbury and Cottage Grove sites had been largely finished and only operation‑and‑maintenance work remained, while its Decatur, Alabama facility was covered by a voluntary remedial‑action agreement with ADEM and a July‑2020 interim consent order that obligates the company to continue reporting, analytical studies, capital improvements and remediation of PFAS‑contaminated soil and groundwater (see page 127). By the 2024 10‑K, the Minnesota obligations had broadened to include MPCA storm‑water directives (June 2022), a draft CWA permit with tighter PFAS limits (July 2024, revised Dec 2024) and updated health‑based values from the Minnesota Department of Health (Jan 2024, Oct 2024), leading 3M to install a new wastewater‑treatment system and pursue additional compliance actions (see pages 102‑103), whereas the Alabama obligations remain anchored to the same ADEM agreement and interim consent order, with continued data corrections, upgraded wastewater controls and ongoing cooperation with EPA and ADEM but no new regulatory milestones (see pages 101‑102).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2007 Settlement Agreement with MPCA in Minnesota, the July 2020 Interim Consent Order with ADEM in Alabama, completion of major remediation at Cottage Grove and other Minnesota sites by 2022, and ongoing operation and maintenance activities. The evolution by 2024 is accurately described, including the draft Clean Water Act permit from MPCA in July 2024 (revised December 2024), updated health-based values (HBVs) from MDH in January and October 2024, and the lack of new formal milestones in Alabama beyond continued compliance under the existing order. (2) Quantitative accuracy is excellent: all dates (June 2022, July 2024, Dec 2024, Jan 2024, Oct 2024) match or are consistent with the ground truth. The reference to 'tighter PFAS limits' and 'storm-water directives' aligns with the draft permit and regulatory developments. (3) Multi-hop reasoning is sound—LLM correctly synthesizes information across years (2022 to 2024), jurisdictions (Minnesota and Alabama), and agencies (MPCA, ADEM, MDH), and distinguishes between completed actions and ongoing obligations. One minor omission: the ground truth mentions the multilayer cap installation at Decatur was completed (under 2020 order), which the LLM does not explicitly note, though it references ongoing remediation. Also, the LLM mentions a 'voluntary remedial-action agreement' in Alabama not present in the ground truth, which slightly deviates but does not contradict core obligations. (4) The answer is contextually relevant, directly addressing the evolution of regulatory engagement and remediation in both states. Wording differs but semantic meaning is equivalent. Overall, a very strong response with only negligible gaps.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1681,
        "completion_tokens": 487,
        "total_tokens": 2168
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola HBC AG evolved between 2022 and 2024, particularly in terms of investment classification and stake percentage?",
      "original_answer": "In 2022, Coca-Cola HBC AG was among the listed equity method investees, though the specific ownership percentage was not disclosed in the provided evidence. By 2024, Coca-Cola HBC AG remained an equity method investee, and the company explicitly stated a 22% ownership stake as of December 31, 2024. This indicates a formalization and quantification of the relationship, with Coca-Cola now specifying the exact percentage of ownership, which was absent in the 2022 disclosures.",
      "llm_answer": "The 2024 Form 10‑K shows that Coca‑Cola’s investment in Coca‑Cola HBC AG is accounted for under the equity‑method and that the Company owned **about 22 % of the bottler’s outstanding shares** as of 31 December 2024 (see KO 10‑K 2024 p. 87). The 2022 filing’s disclosed sections do not present a different classification or a different ownership percentage, indicating that the relationship remained essentially the same – the investment continued to be treated as an equity‑method investment with roughly a 22 % stake.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "(1) The LLM correctly identifies that Coca-Cola HBC AG was an equity-method investee in both 2022 and 2024 and accurately reports the 22% ownership stake as of December 31, 2024, which matches the ground truth. However, it incorrectly assumes that the 22% stake also applied in 2022, which is not supported by the original answer — the 2022 filing did not disclose a specific percentage. This is a significant factual overreach. (2) Quantitatively, the 22% figure and the date (December 31, 2024) are correct. No calculations were required, but the model falsely imputes the 22% stake to 2022 without evidence, reducing quantitative accuracy slightly. (3) The reasoning is flawed in the multi-hop synthesis: while both years are addressed, the model fails to recognize that the absence of a disclosed percentage in 2022 does not imply the same percentage existed then. The original answer emphasizes that the 2024 disclosure represents a formalization and new specificity, which the LLM overlooks. (4) Contextual relevance is high as the response addresses investment classification and stake percentage over time, but the incorrect assumption about 2022 undermines the qualitative accuracy and overall correctness, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 347,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Oracle's strategic emphasis on hybrid deployments evolved between fiscal 2022 and fiscal 2024, particularly in terms of product development investment and deployment model integration?",
      "original_answer": "In fiscal 2022, Oracle emphasized hybrid deployments as part of its broader deployment model strategy, investing $7.2 billion in research and development to enhance existing offerings and develop new technologies, including hybrid solutions like Oracle Cloud@Customer. By fiscal 2024, Oracle further integrated hybrid deployments into its core offerings, positioning them as a standard deployment choice alongside on-premise and cloud-based models, and reinforcing its commitment to interoperability and customer choice. This reflects a strategic evolution from a development-focused approach to a more mature, integrated deployment model.",
      "llm_answer": "In the fiscal‑2022 filing Oracle stressed that it was spending $7.2 billion on research‑and‑development to “enhance our existing portfolio of offerings and to develop new technologies” and specifically highlighted hybrid‑deployment options such as Oracle Cloud@Customer, together with new programs that let customers pivot on‑premise licenses to the cloud – a clear signal that product‑development dollars were being directed at integrating on‑premise and cloud models【page_6】. By fiscal 2024 the company still describes its offerings as delivered through “flexible and interoperable … on‑premise, cloud‑based and hybrid deployments” but does not repeat a quantified R&D spend, indicating the strategic emphasis has shifted to reaffirming the breadth of hybrid‑deployment integration rather than announcing a fresh product‑development investment amount【page_72】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the $7.2 billion R&D investment in fiscal 2022 is correctly cited, and the absence of a specific R&D figure for fiscal 2024 is accurately noted—consistent with the original answer, which only specifies the 2022 number. No calculations were required. (2) The entities—Oracle, fiscal years 2022 and 2024, Oracle Cloud@Customer, hybrid deployments—are all correctly identified. (3) The multi-hop reasoning is sound: the LLM correctly infers a strategic shift from active product development investment (with disclosed funding) in 2022 to a focus on integration and reaffirming deployment flexibility in 2024, even without a new R&D figure. This matches the ground truth’s narrative of evolution from development-focused to integrated deployment models. (4) The only minor shortcoming is that the LLM does not explicitly state that hybrid deployments became a 'standard' option alongside on-premise and cloud, as in the original answer, but it effectively conveys the same idea by referencing 'flexible and interoperable' models and the strategic reaffirmation of hybrid integration. Wording differs slightly but semantic equivalence is maintained. No factual errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 353,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has the filing status of the Mandatory Clawback Policy evolved between the 2023 and 2024 SEC 10-K disclosures for Wells Fargo & Company?",
      "original_answer": "In 2023, the Mandatory Clawback Policy was filed directly as part of the 10-K filing under Exhibit 97. In 2024, instead of being filed directly, it was incorporated by reference to Exhibit 97 from the previous year's 10-K filing. This indicates a procedural change in how the policy is disclosed rather than a substantive change to the policy itself.",
      "llm_answer": "In the 2023 Form 10‑K, the Wells Fargo Mandatory Clawback Policy (Exhibit 97) was listed as “Filed herewith,” meaning the policy was attached to that filing. In the 2024 Form 10‑K, the same Exhibit 97 is described as “Incorporated by reference” to the company’s 2023 annual report, indicating the policy is no longer attached but is instead referenced from the prior year’s filing.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies that in 2023, the Mandatory Clawback Policy (Exhibit 97) was 'filed herewith,' meaning it was directly attached to the 10-K, and in 2024, it was 'incorporated by reference' from the 2023 filing, indicating a procedural change in disclosure. (2) There are no numerical values requiring calculation, but the years (2023, 2024) and exhibit number (97) are correct. (3) The multi-hop reasoning is sound—comparing the filing status across two years and correctly interpreting the change in disclosure method. (4) The answer fully addresses the evolution of the filing status, matches the original answer in substance, and uses terminology consistent with SEC disclosures. No factual or interpretive errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1181,
        "completion_tokens": 243,
        "total_tokens": 1425
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did Thermo Fisher's relationship with CorEvitas, LLC evolve between 2023 and 2024, and what specific financial implications were associated with this change?",
      "original_answer": "In 2023, Thermo Fisher invested $0.91 billion to acquire CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for medical treatments. By 2024, this relationship had evolved from an investment into a full acquisition, as CorEvitas was integrated into the Laboratory Products and Biopharma Services segment. The acquisition in 2023 was part of a broader strategy that included significant capital expenditures and financing activities, such as issuing $5.94 billion in senior notes and repurchasing $3.00 billion of company stock. In 2024, the company began amortizing the definite-lived intangible assets from CorEvitas over a weighted average period of 18 years, reflecting the long-term strategic value of the acquisition.",
      "llm_answer": "Thermo Fisher’s relationship with CorEvitas changed from a fresh acquisition in 2023 to an integrated part of its Laboratory Products & Biopharma Services segment by 2024. In 2023 the company completed the purchase of CorEvitas for a total price of $910 million—$730 million in cash plus $184 million of debt assumed—recording $627 million of goodwill and other intangibles and using $0.91 billion of cash in investing activities (see pages 65‑66 and 24). The 2024 filing contains no new acquisition of CorEvitas, indicating the business is now fully incorporated with no additional cash outlay reported (see page 65).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: $910 million total purchase price ($730M cash + $184M debt assumed), $627M recorded as goodwill and intangibles, and $0.91B in cash used in investing activities—all consistent with the original answer and acceptable format variations (e.g., $0.91 billion = $910 million). (2) The evolution of the relationship—from acquisition in 2023 to integration by 2024—is correctly described, including the placement within the Laboratory Products & Biopharma Services segment. (3) The qualitative reasoning is sound: the absence of new acquisition costs in 2024 supports the conclusion of full incorporation. However, the original answer includes additional strategic context—such as the issuance of $5.94B in senior notes and $3.00B stock repurchase—that the LLM omits, and the 2024 amortization of definite-lived intangibles over 18 years is not mentioned. While not strictly required to answer the question, these elements add financial depth that would strengthen completeness. (4) Despite this minor omission, the LLM captures the core financial implications (purchase price allocation, cash outflow, integration) and correctly infers no further outlay in 2024. The multi-hop synthesis across years and financial statements is accurate and logically presented. Thus, the answer earns a 9/10 for correctness—excellent but not fully comprehensive.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 401,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How did RTX's flight hour payment obligations under its 2012 agreement with Rolls-Royce evolve between 2022 and 2023, particularly in terms of the timing and capitalization treatment of these payments?",
      "original_answer": "In 2022, RTX disclosed that flight hour payments to Rolls-Royce were contingent upon each hour flown through June 2027 by V2500-powered aircraft in service as of the acquisition date, and these payments were considered in 'Other commercial aerospace commitments' and capitalized as collaboration intangible assets as payments were made. In 2023, RTX reiterated the same contingent payment structure tied to flight hours through June 2027 and maintained that these payments would continue to be capitalized as collaboration intangible assets. There was no indication of a change in the magnitude or timing of these obligations between the two years, suggesting a stable commitment structure.",
      "llm_answer": "In the 2022 filing RTX said the Rolls‑Royce flight‑hour payments – due under the 2012 IAE acquisition – were expected to total $735 million in 2022 and $1.05 billion in 2023 and would be **capitalized as collaboration intangible assets as each payment is made**【page_112】. The 2023 filing shows those 2022‑23 payments have now been satisfied and the remaining schedule has been pushed out, with payments projected for 2024‑2028 (e.g., $836 million in 2024, $862 million in 2025, $705 million in 2026, $687 million in 2027, $731 million in 2028 and $6.2 billion thereafter) and the same **capitalization treatment – recorded as collaboration intangible assets when paid**【page_101】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content. The original answer (ground truth) states that RTX did not disclose specific dollar amounts for flight hour payments in 2022 or 2023, nor did it indicate any change in timing or magnitude of obligations. Instead, it emphasized the continuity of the payment structure—contingent on flight hours through June 2027 and capitalized as collaboration intangible assets. However, the LLM answer fabricates specific dollar figures ($735M in 2022, $1.05B in 2023, and future projections totaling over $6B), which are not present in the ground truth and contradict the 'no indication of a change in magnitude or timing' statement. (2) Quantitative accuracy is very low: none of the dollar amounts mentioned in the LLM answer appear in the original answer, and there is no support for a 'pushed out' payment schedule or annual breakdowns. These numbers appear to be hallucinated or misattributed from another context. (3) The multi-hop reasoning is flawed. While the LLM correctly identifies the capitalization treatment (payments capitalized as collaboration intangible assets), it incorrectly infers a shift in payment timing and invents a detailed future payment schedule not present in the ground truth. The original answer explicitly states there was 'no indication of a change' between 2022 and 2023, which the LLM directly contradicts. (4) Contextual relevance is moderate because the LLM addresses the right topic (flight hour payments, capitalization treatment, Rolls-Royce agreement), but the inclusion of false specifics severely undermines accuracy. The qualitative score is low due to incorrect synthesis and failure to reflect the stability of obligations as stated in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 481,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has The Coca-Cola Company's financial relationship with fairlife evolved from 2022 to 2024, particularly regarding contingent payments tied to performance milestones?",
      "original_answer": "In 2022, Coca-Cola's acquisition-related disclosures referenced the 2020 acquisition of the remaining ownership interest in fairlife, with no mention of ongoing contingent payments. By 2024, the company disclosed that there was a remaining milestone payment related to the 2020 acquisition of fairlife, contingent on fairlife achieving certain financial targets through 2024, with the payment scheduled for 2025. This indicates that Coca-Cola's relationship with fairlife has evolved from a completed acquisition in 2020 to one where a performance-linked financial obligation remains active through 2024.",
      "llm_answer": "In the 2022 filing Coca‑Cola only disclosed the straight‑forward acquisition of the remaining fairlife ownership interest – a $902 million gain (with a $40 million tax benefit) and no contingent‑payment terms were mentioned【page_53】【page_55】. By the 2024 filing the company carries a contingent‑consideration liability of roughly $6.1 billion for the fairlife deal, reflecting a performance‑based milestone payment that is re‑measured each quarter; a $275 million milestone was paid in 2023 and the remaining amount will be payable in 2025 if fairlife meets its financial targets through 2024【page_111】【page_112】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies that no contingent payments were mentioned in 2022 and that a milestone payment is due in 2025 based on performance through 2024, it fabricates key financial figures. The claim of a $6.1 billion contingent-consideration liability is grossly exaggerated and not supported by the ground truth. Similarly, the $275 million milestone payment in 2023 is not mentioned in the original answer and appears to be invented. The $902 million gain and $40 million tax benefit, while possibly from actual filings, are not part of the ground truth response and distract from the core question about contingent payments. (2) Quantitative accuracy is very low: the only correct numeric element is the 2025 payment timing, but the amounts ($6.1B, $275M) are incorrect. The original answer does not specify any dollar amounts for the contingent payment, so assigning such precise figures is a serious error. (3) The multi-hop reasoning is partially sound—linking 2022 silence on contingencies to 2024 disclosure of a pending milestone shows understanding of evolution—but the synthesis is undermined by fabricated data. The model incorrectly implies ongoing quarterly re-measurement and prior milestone payments not present in the ground truth. (4) Contextual relevance is moderate because the answer addresses the evolution of the financial relationship and contingent payments, but the inclusion of unsupported specifics reduces reliability. The core idea—that a performance-based obligation emerged in disclosure by 2024—aligns with the truth, but the details are largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 456,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has Oracle's strategic positioning of Oracle Cloud Services evolved between 2022 and 2024, particularly in terms of integration with enterprise applications and infrastructure technologies?",
      "original_answer": "In 2022, Oracle emphasized the transformational potential of Oracle Cloud Services, particularly highlighting the Oracle Autonomous Database as a key OCI offering that utilized machine learning to enable leaner business processes and automation. The focus was on flexibility, interoperability, and customer choice across deployment models, including cloud-based, hybrid, and on-premise environments. By 2024, Oracle expanded this positioning by describing Oracle Cloud Services (including SaaS and OCI) as comprehensive and integrated offerings that provide customers with a full suite of applications and infrastructure services. The 2024 filing explicitly frames Oracle Cloud Services as enabling customers to 'choose the best option that meets their specific business needs,' indicating a more mature and customer-centric strategic approach. This evolution reflects a shift from promoting individual innovations (e.g., Autonomous Database) to positioning Oracle Cloud Services as a holistic, integrated platform for enterprise IT transformation.",
      "llm_answer": "In the 2022 filing Oracle described its Cloud Services as a flexible, interoperable suite in which Fusion Cloud SaaS applications (ERP, HCM, EPM, SCM, etc.) are built on a common data model and run on Oracle Cloud Infrastructure (OCI), stressing the early‑stage migration of on‑premise workloads and the integration of advanced technologies to give customers choice among on‑premise, cloud and hybrid models【page_6】【page_7】【page_8】【page_9】. By the 2024 filing the company’s language had shifted to present Oracle Cloud Services as a unified, subscription‑based platform that delivers “comprehensive and integrated applications and infrastructure services” together—highlighting a mature, end‑to‑end integration of SaaS and OCI that lets customers select the optimal deployment model and underscores the service’s role in driving growth【page_72】【page_73】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Oracle's 2022 emphasis on flexibility, interoperability, and customer choice across deployment models (cloud, hybrid, on-premise) is accurately described, including the integration of Fusion Cloud SaaS applications on OCI with a common data model. By 2024, the shift to a 'unified, subscription-based platform' offering 'comprehensive and integrated applications and infrastructure services' matches the original answer's claim of a more holistic and mature positioning. The evolution from promoting individual technologies (like Autonomous Database, implied in ground truth) to an integrated platform is correctly inferred, even if the Autonomous Database is not explicitly named—the focus on integration of SaaS and OCI captures the core strategic shift. (2) There are no numbers, dates, or financial figures in the question or answers, so quantitative accuracy is not applicable in a numerical sense, but temporal accuracy (2022 vs 2024) is correct. (3) Multi-hop reasoning is sound: the LLM synthesizes information across two time points and two strategic narratives (2022 early-stage integration vs 2024 mature platform), correctly identifying the evolution in Oracle’s strategic messaging. (4) Semantic equivalence is strong—while the LLM uses slightly different phrasing (e.g., 'unified, subscription-based platform' vs 'holistic, integrated platform'), the meaning is consistent with the ground truth. The only minor omission is the specific mention of the Oracle Autonomous Database as a highlighted 2022 innovation in the ground truth, which the LLM does not reference. However, this does not undermine the overall correctness, as the broader strategic positioning is accurately conveyed. Hence, a score of 9 is justified, with full marks in contextual relevance and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1487,
        "completion_tokens": 514,
        "total_tokens": 2002
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has the treatment or status of the Key/Specified Employee Policy evolved between the 2023 and 2024 SEC filings, particularly in terms of its documentation and incorporation by reference?",
      "original_answer": "In the 2023 filing, the Key/Specified Employee Policy was introduced as part of the company's disclosures, specifically incorporated by reference to Exhibit 10(v) from the Annual Report on Form 10-K for the year ended December 31, 2018. By 2024, the policy was no longer newly introduced but was instead announced as a continuing policy, still relying on the same Exhibit 10(v) from the 2018 filing. This indicates that while the policy remained in place, there were no new amendments or updates to its documentation during this period.",
      "llm_answer": "In the 2023 Form 10‑K the Key/Specified Employee Policy appears as exhibit 10(r)* and is “incorporated by reference to Exhibit 10(v) to the Company’s Annual Report on Form 10‑K for the year ended December 31, 2018” 【page_17】. The 2024 filing lists the same policy as exhibit 10(r)* and again incorporates it by reference to Exhibit 10(v) of the 2018 Annual Report 【page_20】, indicating that its documentation and reference treatment have not changed.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All factual elements are correct: the Key/Specified Employee Policy is correctly identified as being incorporated by reference to Exhibit 10(v) from the 2018 Form 10-K in both the 2023 and 2024 filings. The dates (December 31, 2018) and exhibit numbers are accurate. (2) Quantitative accuracy is perfect: no calculations are required, but the references to exhibits and years are factually correct. (3) The reasoning is sound: the LLM correctly infers that the unchanged exhibit reference implies no documentation changes between 2023 and 2024. The only minor shortcoming is that the LLM does not explicitly state that the policy transitioned from being 'newly introduced' in 2023 to 'continuing' in 2024, which is a nuance present in the original answer. However, the implication is clear from the repetition of the same exhibit reference. (4) The answer is fully contextually relevant, directly addressing the evolution of the policy's documentation and incorporation by reference. Wording differs slightly but maintains semantic equivalence. Minor deduction from 10 to 9 due to omission of the 'newly introduced' vs 'continuing' distinction, though the factual core is preserved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 356,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the aggregate principal balance of the 6.700% notes due 2028 evolve between 2022 and 2023, and what does this indicate about RTX's debt management strategy?",
      "original_answer": "In 2022, the aggregate principal balance of the 6.700% notes due 2028 was $115 million. By 2023, this amount increased significantly to $285 million. This indicates that RTX increased its outstanding debt related to this particular note, suggesting a strategic decision to retain or expand exposure to this fixed-rate debt instrument.",
      "llm_answer": "The 6.700 % notes due 2028 carried an aggregate principal balance of **$285 million at year‑end 2022 and the same $285 million at year‑end 2023**【page_84】. The unchanged balance shows RTX did not retire or add to this tranche, indicating a deliberate choice to keep this fixed‑rate, medium‑term debt in place while using other issuances and repayments to reshape its overall debt profile. This reflects a targeted refinancing strategy rather than a broad reduction of existing notes.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect regarding the aggregate principal balance of the 6.700% notes due 2028. According to the ground truth, the balance was $115 million in 2022 and increased to $285 million in 2023. However, the LLM claims the balance was $285 million in both 2022 and 2023, which misrepresents the evolution of the debt. This error fundamentally undermines the correctness of the answer. (2) The quantitative accuracy is severely compromised: the 2022 figure is off by $170 million, and the reported stability of the balance contradicts the actual significant increase. While the 2023 value ($285 million) is correct, the 2022 value is not, and the comparison (unchanged vs. increased) is therefore invalid. (3) The reasoning is internally logical but based on false premises. The LLM draws a conclusion about RTX maintaining a stable debt position and using other instruments for refinancing, but this does not align with the actual data showing a substantial increase in this specific note. The multi-hop synthesis fails because it does not recognize the change over time, which is central to the question. (4) Contextual relevance is moderate—the response addresses the right metric and company and attempts to interpret strategy, so it stays on topic. However, due to the critical numerical error, the qualitative and overall correctness scores are low. The conclusion about debt management strategy is not supported by the actual data showing an expansion of this debt tranche.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1208,
        "completion_tokens": 417,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the carrying value and effective interest rate of TMO's 1.95% 12-Year Senior Notes evolve between 2023 and 2024?",
      "original_answer": "In 2023, the carrying value of the 1.95% 12-Year Senior Notes was $773 million with an effective interest rate of 2.08%. In 2024, the carrying value decreased to $725 million, and the effective interest rate slightly declined to 2.07%. This indicates a reduction in the financial liability associated with these notes and a marginal improvement in the effective borrowing cost.",
      "llm_answer": "In 2023 the 1.95 % 12‑year senior notes (due 7/24/2029) were carried at **$773 million** with an **effective interest rate of 2.08 %**. By the end of 2024 the carrying amount had fallen to **$725 million** and the effective rate had edged down to **2.07 %**【page_62】【page_47】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) All factual information is accurate: the carrying value in 2023 is correctly stated as $773 million and in 2024 as $725 million; the effective interest rate is accurately reported as 2.08% in 2023 and 2.07% in 2024. (2) Quantitative accuracy is perfect—no calculation errors, and the values align exactly with the original answer, including proper formatting variations (e.g., '2.07 %' vs '2.07%'). (3) The multi-hop reasoning is sound: the model correctly synthesized data across two time points (2023 and 2024) for the same financial instrument (TMO's 1.95% 12-Year Senior Notes), demonstrating proper entity tracking and temporal comparison. (4) The answer is semantically equivalent to the ground truth, conveying the same evolution in carrying value and effective interest rate, even without repeating the interpretive phrase 'marginal improvement in borrowing cost'—this minor omission does not detract from factual completeness. The inclusion of the maturity date (7/24/2029) adds contextual precision not required but helpful. Citations to page_62 and page_47 further support traceability. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1156,
        "completion_tokens": 347,
        "total_tokens": 1503
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "What are the corporate governance implications of the change in how BNY Mellon presents its Directors' Code of Conduct between its 2022 and 2024 SEC filings?",
      "original_answer": "In 2022, BNY Mellon explicitly detailed the availability of the Directors' Code of Conduct on its website with a direct URL link, and it was referenced within the broader context of corporate governance disclosures and ethics policies. By 2024, the Code was listed among other governance materials—such as committee charters and by-laws—without a direct link or specific mention of updates or amendments. This shift in presentation may signal a more streamlined or consolidated approach to governance disclosures, potentially reducing the visibility of the Code as a standalone document. While the Code remains accessible, the change could affect transparency and stakeholder engagement with the specific ethical expectations for directors, which may influence perceptions of governance accountability.",
      "llm_answer": "In the 2022 Form 10‑K BNY Mellon gave a direct URL for its Directors’ Code of Conduct and explicitly pledged to post any amendments or waivers on that site, underscoring a high‑visibility, transparent approach to director‑related governance (page 11). By the 2024 filing the Code is merely listed among the suite of governance documents available on the website, without a dedicated link or waiver statement, indicating a shift to a more consolidated disclosure format that may reduce the immediacy of updates while still keeping the Code accessible, affecting the perceived transparency of governance changes (page 3).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original (ground truth) answer. (1) All factual elements are correct: in 2022, BNY Mellon provided a direct URL and committed to posting amendments or waivers, which is consistent with the ground truth's emphasis on explicit availability and transparency. By 2024, the Directors' Code of Conduct is listed among other governance documents without a direct link or specific mention of updates, accurately reflecting the shift in presentation. The inclusion of page numbers (11 in 2022, 3 in 2024) adds precision and supports the claim, assuming these are correctly cited from the actual filings. (2) There are no numeric values requiring calculation (e.g., dollar amounts, percentages), so quantitative accuracy pertains to years and document references, all of which are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes changes in disclosure format across two time points (2022 vs 2024), identifies the implications for transparency and governance perception, and draws a logical conclusion about reduced immediacy and visibility despite continued accessibility. (4) The LLM adds a detail not in the original—about the pledge to post amendments or waivers—which appears to be an accurate inference or extraction from the 2022 filing and strengthens the analysis. The only minor gap is that the original answer mentions the 2022 context of 'broader corporate governance disclosures and ethics policies,' which the LLM does not explicitly reference, slightly reducing completeness. However, this does not detract from the core correctness. Overall, the answer is semantically equivalent, contextually relevant, and factually precise, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 473,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has Amazon's Short-Term Credit Agreement evolved between 2023 and 2024, particularly in terms of facility size, maturity date, and the timing of its establishment?",
      "original_answer": "In 2023, Amazon entered into a $5.0 billion unsecured 364-day revolving credit facility (Short-Term Credit Agreement) in November, replacing the prior agreement from November 2022, with a maturity date in October 2024. In 2024, Amazon again entered into a new $5.0 billion unsecured 364-day revolving credit facility in October, replacing the 2023 agreement, with a maturity date in October 2025. The facility size remained the same at $5.0 billion, but the establishment date shifted from November to October, and the maturity date moved forward by one year, indicating a procedural renewal rather than a substantive change in the credit structure.",
      "llm_answer": "Amazon’s short‑term revolving credit facility stayed at a $5.0 billion size, but the maturity was extended by one year – the 2023 agreement (entered in November 2023) matured in October 2024, while the 2024 agreement (entered in October 2024) matures in October 2025【page_59】【page_58】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential information from the ground truth. (1) All key facts are correct: the facility size remained $5.0 billion in both years, the 2023 agreement was entered in November 2023 with a maturity in October 2024, and the 2024 agreement was entered in October 2024 with a maturity in October 2025. These match the original answer exactly. (2) Quantitative accuracy is perfect—dollar amounts, months, and years are all correct, and the one-year extension in maturity is accurately noted. (3) The multi-hop reasoning is sound: the model correctly synthesized the evolution across two years, comparing establishment dates, maturity dates, and facility size. (4) The only minor omission is that the LLM does not explicitly state that the October 2024 agreement 'replaced' the 2023 agreement, nor does it mention that this reflects a procedural renewal. However, this does not detract significantly from the factual correctness. The answer is semantically equivalent to the ground truth in all critical aspects, with only slight brevity in contextual framing. Hence, a score of 9 is justified—excellent but not fully comprehensive.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 330,
        "total_tokens": 1568
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has AMD's APU strategy evolved from 2022 to 2024 in terms of product integration and target markets, and what implications does this shift have for its revenue potential in the AI PC segment?",
      "original_answer": "In 2022, AMD emphasized external GPU-based solutions for AI and HPC workloads, particularly through the Instinct MI200 series and Radeon PRO V620 GPUs, focusing on data center and cloud applications. By 2024, AMD had shifted toward integrating dedicated AI acceleration directly into client devices, becoming the first company to include a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs. This strategic pivot toward integrated APUs with NPU cores indicates a move to capture revenue growth in the emerging AI PC market, where on-device AI processing is becoming critical. This evolution likely enhances AMD's revenue potential by positioning it as a differentiated player in the AI PC segment, moving beyond traditional CPU-GPU combinations.",
      "llm_answer": "In 2022 AMD positioned its APUs mainly as CPU‑plus‑GPU chips that delivered visual‑processing for value‑oriented and mainstream PCs and for embedded platforms such as the AMD Embedded Ryzen V‑ and G‑Series APUs [page_8][page_10]. By 2024 the company had added a dedicated neural‑processing unit (NPU) to the same SoC—evidenced by the launch of AI‑focused APUs like the Ryzen AI 300 series, the Ryzen 8000 mobile line with a first‑gen NPU, and AI‑enabled Ryzen PRO 8000G desktops—targeting AI‑PCs, AI‑enhanced notebooks and enterprise AI desktops [page_5][page_7]. This shift opens a new, fast‑growing AI PC market for AMD, giving it a clear revenue‑growth runway in the AI‑PC segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies AMD's APU strategy evolution: in 2022, APUs were positioned as CPU-GPU integrated chips for mainstream and embedded markets, while by 2024, AMD introduced NPUs into APUs (e.g., Ryzen AI 300, Ryzen 8000 mobile, Ryzen PRO 8000G), targeting AI PCs and enterprise AI desktops. This matches the ground truth's emphasis on a strategic shift toward integrated NPUs for on-device AI. (2) There are no numeric values requiring calculation (e.g., revenue figures, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) and product names are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across time (2022 to 2024), product lines, and market targeting, correctly inferring that this shift enables AMD to capture growth in the AI PC segment. (4) The only minor gap is that the LLM does not explicitly mention AMD being 'the first' to integrate an NPU with an x86 CPU on the same SoC—a key differentiator highlighted in the ground truth. However, the implication of competitive positioning and revenue growth potential is clearly conveyed. Wording differs slightly but maintains semantic equivalence. Thus, the answer is factually correct, complete, and contextually relevant, warranting a high score with only a slight deduction in qualitative accuracy for missing the 'first-mover' nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 395,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has the treatment of Irish income tax liability for U.S. shareholders receiving dividends from Medtronic evolved between 2023 and 2024, particularly in relation to the Irish dividend withholding tax?",
      "original_answer": "In both 2023 and 2024, dividends paid by Medtronic were generally subject to Irish dividend withholding tax at a rate of 25 percent unless an exemption applied. For U.S. residents, exemptions were available based on residency documentation, such as a valid U.S. Certification of Residence (Form 6166) or Irish Non-Resident Form V2. In both years, a U.S. resident who met the exemption criteria and did not hold shares through an Irish branch generally had no Irish income tax liability. Additionally, if a U.S. shareholder was subject to the 25% withholding tax, the payment discharged any Irish income tax liability, provided the shareholder submitted the required statement to the Irish Revenue authorities. There was no change in the tax rate or in the conditions for exemption between the years, indicating a stable regulatory framework.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K contain the same statement: dividends are subject to a 25 % Irish withholding tax unless a U.S. shareholder qualifies for an exemption (U.S. address on the broker’s records or a valid Form 6166/Irish V2). If the withholding tax is applied, it “discharges any Irish income‑tax liability,” and shareholders who meet the exemption generally have no Irish income‑tax liability on the dividend. The language and treatment are unchanged from 2023 to 2024【page_31】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same essential information as the ground truth. (1) All key facts are correct: the 25% Irish withholding tax rate, the exemption conditions for U.S. shareholders (Form 6166 or Irish V2), the discharge of Irish income tax liability when withholding is applied, and the absence of change between 2023 and 2024. (2) Quantitative accuracy is perfect: the 25% rate is correctly stated, and no erroneous calculations are present. (3) The reasoning is sound—LLM correctly synthesizes that the treatment was unchanged across years and that the withholding tax discharge rule applies, which reflects proper multi-hop understanding across both years’ filings. (4) Minor point: the LLM mentions 'U.S. address on the broker’s records' as an alternative to Form 6166/V2, which slightly simplifies the original answer’s emphasis on formal documentation; however, this may reflect a valid interpretation of administrative practices and does not materially misrepresent the policy. Overall, the answer is semantically equivalent, complete, and contextually precise, warranting a high score with only a slight deduction in qualitative accuracy due to minor simplification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 337,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the risk disclosure around new products and services evolved between 2022 and 2024, particularly regarding the company's platforms operating model initiative?",
      "original_answer": "In 2022, BNY Mellon highlighted that new lines of business, new products and services, or transformational or strategic project initiatives subject the company to new or additional risks. By 2024, this risk disclosure evolved to specifically include the 'transition to a platforms operating model' as a new source of uncertainty. The 2024 filing explicitly states that the company 'may not realize some or all of the expected benefits of our transition to a platforms operating model,' indicating a more focused risk related to this specific strategic initiative. This evolution shows a shift from general strategic risk language to a more concrete acknowledgment of platform-specific implementation risks.",
      "llm_answer": "In the 2022 Form 10‑K the risk‑factors section called out both “new lines of business, new products and services” and a separate bullet warning that “we may not realize some or all of the expected benefits of our transition to a platforms operating model” (2022 p.5). By the 2024 filing the language still flags “new lines of business, new products and services … subject us to new or additional risks” (2024 p.4), but the platforms‑operating‑model risk is no longer a distinct bullet; it appears only in the forward‑looking statements that discuss the “transition to a platforms operating model” (2024 p.3). This shift shows the company has folded the platforms initiative into its broader strategic‑risk narrative rather than treating it as a standalone risk.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim, reversing the actual evolution of risk disclosure. According to the ground truth, in 2022 the risk related to the platforms operating model was part of a general statement about strategic initiatives, while by 2024 it evolved into a more specific and explicit risk disclosure—highlighting that the company 'may not realize some or all of the expected benefits' of the transition. However, the LLM incorrectly asserts the opposite: that the platforms operating model was a standalone bullet risk in 2022 and was downgraded to a general mention in forward-looking statements by 2024. This misrepresents both the direction and nature of the change. The LLM also incorrectly cites page numbers and document sections without verification, introducing false precision. While the entities (BNY Mellon, platforms operating model, years 2022 and 2024) are correct, the reasoning is flawed and the synthesis across years is invalid. The answer fails the multi-hop requirement by drawing an opposite conclusion from the evidence. Despite addressing the question's topic, the factual inversion severely undermines correctness. Minor contextual elements (mention of new products and services) are present, but the central analysis is backwards, warranting a low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 365,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Amazon's relationship with the 3.600% Note due 2032 evolved between 2023 and 2024, particularly in terms of its debt instrument disclosures?",
      "original_answer": "In 2023, the 3.600% Note due 2032 was disclosed as part of a Supplemental Indenture dated April 13, 2022, among Amazon.com, Inc., Wells Fargo Bank, National Association (as prior trustee), and Computershare Trust Company, National Association (as successor trustee). In 2024, the same note was referenced under the same Supplemental Indenture, but the trustee structure now only referenced Computershare Trust Company, National Association, as successor trustee, indicating a formal transition away from Wells Fargo Bank. This reflects a procedural evolution in the administration of the note, with no changes to the note’s terms or interest rate, but a shift in the trustee relationship.",
      "llm_answer": "In the 2023 Form 10‑K Amazon listed the 3.600 % Note due 2032 as one of the debt securities covered by its Supplemental Indenture (Exhibit 4.2) together with several other notes 【page_75】. The 2024 Form 10‑K still references the same Supplemental Indenture (Exhibit 4.2) and the 3.600 % Note due 2032, but adds a Regulation S‑K disclosure that the detailed agreement for this and other long‑term debt is not filed because it falls below the 10 %‑of‑assets threshold, with the company offering to furnish it on request 【page_74】【page_76】. This shows the note remains outstanding, while the company’s disclosure approach shifted from a simple exhibit listing to a more limited filing with a conditional‑access statement.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that the 3.600% Note due 2032 was disclosed in both 2023 and 2024 under the same Supplemental Indenture (Exhibit 4.2), which aligns with the ground truth. The interest rate and note existence are accurately maintained across years. However, the LLM introduces a new disclosure rationale—Regulation S-K and the 10% threshold—that is not present in the ground truth and misrepresents the nature of the evolution. The actual change was in the trustee structure (transition from Wells Fargo to Computershare as sole trustee), which the LLM completely omits. Instead, it focuses on a procedural disclosure shift that may be factually present in the filing but is not the key evolution in the note’s administration. (2) Quantitatively, all numbers (3.600%, 2032 maturity) and dates (2023 and 2024 filings) are correct. No calculations are involved, so numerical accuracy is high. (3) The multi-hop reasoning is partially sound—linking the note across two years and identifying the same indenture—but fails the critical synthesis: identifying the trustee transition as the key procedural evolution. The LLM instead infers a different administrative change based on disclosure policy, which may be contextually relevant but is not the core factual evolution described in the ground truth. (4) Correctness is scored at 4 due to the omission of the key trustee change and introduction of an alternative explanation not supported by the ground truth. While the note’s continued existence and indenture are correctly noted, the central evolution in the relationship—trustee transition—is missing. Quantitative accuracy is high (8) due to correct percentages and years. Qualitative accuracy is moderate (5) because reasoning is logical but based on incomplete or misaligned evidence. Contextual relevance is fair (7) as the answer discusses disclosure practices, but misses the primary administrative shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 523,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How did MDLZ's treatment and disclosure of net investment hedge derivative contracts evolve from 2023 to 2024, particularly in terms of their financial impact and presentation within the financial statements?",
      "original_answer": "In 2023, MDLZ disclosed the fair value of derivative assets and liabilities associated with net investment hedge contracts, with $1,347 million and $377 million in other current assets and $250 million and $413 million in other assets as of December 31, 2023 and 2022, respectively. By 2024, the focus shifted to the income statement impact, where the company noted that 'Other income, net' included amounts excluded from the assessment of hedge effectiveness related to these contracts, indicating a change in emphasis from balance sheet valuation to income volatility effects.",
      "llm_answer": "In 2023 Mondelēz reported its net‑investment‑hedge (NIH) contracts as a **net liability** – the fair‑value table shows $163 m of asset derivatives versus $382 m of liability derivatives, a net liability of $(219) m【page_96】, and the after‑tax result on the hedges was a $185 m loss recorded in OCI, with $148 m of amounts excluded from hedge effectiveness affecting other‑income/interest expense【page_97】.  \n\nBy 2024 the same contracts were presented as a **net asset** – the derivative‑instrument note lists $305 m of asset derivatives and $50 m of liability derivatives, giving a $255 m net asset【page_94】 (also shown as $255 m in the fair‑value summary【page_95】), and the excluded amounts are now reflected in “other income, net”【page_93】, indicating a reversal from the prior loss and a more favorable presentation in the financial statements.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies in numbers and misrepresents the financial data from the ground truth. For example, the LLM claims that in 2023, MDLZ had $163M in asset derivatives and $382M in liability derivatives, resulting in a net liability of $219M. However, the ground truth states that MDLZ disclosed $1,347M in other current assets and $250M in other assets for 2023, indicating a substantial net asset position, not a net liability. Similarly, the LLM’s reported 2024 figures of $305M in assets and $50M in liabilities ($255M net asset) do not align with the original answer, which does not provide total derivative balances but instead emphasizes a shift in disclosure focus to income statement impact. (2) The quantitative inaccuracies are severe: the LLM invents precise numbers (e.g., $163M, $382M, $305M, $50M) that are not present in the ground truth and contradicts the disclosed asset-heavy positions. Additionally, the claim of a $185M loss in OCI and $148M affecting other income/interest expense is not supported by the original answer, which only notes that 'other income, net' included amounts excluded from hedge effectiveness in 2024, with no such detailed breakdown for 2023. (3) The multi-hop reasoning is partially sound in that the LLM identifies a shift in presentation—from balance sheet focus in 2023 to income statement impact in 2024—but it fabricates supporting data rather than accurately reflecting the disclosed values. The conclusion about a 'reversal from prior loss' and 'more favorable presentation' is speculative and not grounded in the original answer. (4) Despite the factual errors, the LLM captures the qualitative trend mentioned in the original answer: a change in emphasis from balance sheet valuation (fair value disclosures) to income statement effects (presentation in 'other income, net'). This keeps the answer contextually relevant and shows correct interpretation of disclosure evolution, even if the numerical foundation is incorrect. Hence, moderate scores for qualitative accuracy and contextual relevance, but low on quantitative and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 572,
        "total_tokens": 1944
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the Abrams Main Battle Tank's modernization strategy evolved from 2023 to 2024, particularly in terms of technological development and international demand?",
      "original_answer": "In 2023, General Dynamics was focused on delivering the System Enhancement Package version 3 (SEPv3) for the Abrams tank, which included upgrades in communications, power generation, fuel efficiency, optics, and armor. Additionally, GD announced the development of the M1E3 Abrams, a more significant engineering change aimed at future threats, featuring the latest systems architecture for quicker upgrades and reduced sustainment footprint. By 2024, the company emphasized continued capability enhancement of the Abrams to counter current and potential threats, with increased international demand reflected in a growing installed base across Europe, the Middle East, North Africa, and the Indo-Pacific. While 2023 focused on the technical roadmap (SEPv3 and M1E3), 2024 highlighted the global strategic relevance and procurement momentum of the Abrams platform.",
      "llm_answer": "In 2023 General Dynamics emphasized delivering the next‑generation SEPv3 upgrade (new communications, power‑generation, fuel‑efficiency, optics and armor) and began development of the M1E3 Abrams, a new engineering‑change tank built on a modern systems‑architecture that enables faster technology insertion, lower sustainment and greater tactical mobility【page_10】. By 2024 the strategy had shifted to sustaining and further enhancing that capability – “maximizing the capability, effectiveness and lethality of the Abrams tank” – while noting that demand from NATO members and other allies remains strong, with a growing installed base across Europe, the Middle East, North Africa and the Indo‑Pacific【page_9】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2023, General Dynamics focused on SEPv3 upgrades (communications, power generation, fuel efficiency, optics, armor) and initiated development of the M1E3 Abrams with modern systems architecture for faster tech insertion and reduced sustainment. By 2024, the emphasis shifted to sustaining and enhancing capability, with strong international demand noted across Europe, the Middle East, North Africa, and the Indo-Pacific. (2) There are no numeric values to verify, but all dates (2023, 2024) and technological developments are accurately represented. (3) The multi-hop reasoning is sound—correctly synthesizing the evolution from technical development (2023) to strategic deployment and global demand (2024). (4) The only minor shortcoming is a slight rephrasing of 'increased international demand reflected in a growing installed base' as 'demand... remains strong,' which slightly downplays the growth aspect emphasized in the original. However, the core meaning and factual content are preserved. Wording differences do not affect factual accuracy, and the answer fully addresses both technological development and international demand as required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 351,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has AMD's role in the development and positioning of APUs evolved between 2022 and 2024, particularly in terms of their market segmentation and strategic emphasis?",
      "original_answer": "In 2022, APUs were discussed as part of AMD's broader Enterprise, Embedded and Semi-Custom product portfolio, which included CPUs, GPUs, and customized SoC products. They were described in general terms without specific market segmentation or strategic emphasis. By 2024, APUs were explicitly included in two of AMD's four reportable segments: the Data Center segment and the Client segment. In the Data Center segment, APUs were listed alongside AI accelerators, CPUs, GPUs, and DPUs, indicating a strategic shift to position APUs as part of data center solutions. In the Client segment, APUs were specifically tied to desktop and notebook CPUs and chipsets, showing a more defined and segmented approach to their market positioning. This evolution reflects a more structured and strategic integration of APUs into AMD's core business segments.",
      "llm_answer": "In the 2022 filing AMD portrayed APUs chiefly as integrated CPU‑GPU chips that provide visual‑processing power for value‑ and mainstream PCs and as part of its embedded and semi‑custom product lines (see 2022 pages 7‑10). By the 2024 filing, APUs are listed in the definitions of three reportable segments—Data Center, Client and Embedded—showing that AMD now positions APUs as a core compute element for data‑center workloads as well as for traditional client and embedded markets (see 2024 page 69). This reflects a broader market segmentation and a strategic shift toward leveraging APUs for high‑performance, power‑efficient server/AI applications while still serving PC and embedded customers.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is mostly correct in its interpretation of AMD's evolving role for APUs between 2022 and 2024, with accurate qualitative trends and correct years. It correctly identifies that in 2022, APUs were part of the broader semi-custom and embedded portfolio, and by 2024, they were more strategically positioned across key segments. However, there is a factual inaccuracy in the claim that APUs were listed in *three* reportable segments (Data Center, Client, and Embedded) in 2024. The ground truth states they were explicitly included in *two*: Data Center and Client. The Embedded segment inclusion is incorrect and misrepresents the segmentation. This is a significant but not fundamental error, as the core insight—APUs gaining strategic importance and being integrated into higher-growth areas like data center—is valid. There are no numerical values to assess, so quantitative accuracy is scored as 10 by default (no errors in dates or numbers mentioned). The reasoning is sound in tracing a strategic shift, but the multi-hop synthesis is slightly flawed due to the incorrect segment count. The answer remains contextually relevant and captures the essence of AMD's evolving APU strategy, just with an overstatement in segment inclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 349,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has Medtronic's disclosure regarding the implications of the Financial Transfers Act 1992 on financial transfers between Ireland and third countries evolved from 2023 to 2024?",
      "original_answer": "In 2023, Medtronic disclosed that the Financial Transfers Act 1992 allowed the Irish Minister for Finance to impose restrictions on financial transfers with certain third countries, and that the list of such countries was subject to ongoing change. By 2024, the company continued to disclose the same regulatory framework but no longer emphasized the dynamic nature of the list of restricted countries, suggesting a potential shift in focus or a stabilization in the regulatory environment affecting these transfers.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K contain the same statement that, under the Irish Financial Transfers Act 1992, the Irish Minister for Finance may restrict “financial transfers” between Ireland and third‑countries, that such restrictions already apply to a number of jurisdictions, and that the list of restricted countries is subject to ongoing change. The 2024 filing repeats this language verbatim and adds no new detail, indicating that Medtronic’s disclosure on the Act’s implications has remained essentially unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in its description of the content of the disclosures and correctly identifies the relevant regulation and its provisions. Quantitative accuracy is perfect—there are no numerical errors, and the years (2023, 2024) and entities (Medtronic, Irish Financial Transfers Act 1992) are correct. However, the qualitative accuracy is low because the LLM contradicts the ground truth: it claims the 2024 filing 'repeats this language verbatim' and 'adds no new detail,' whereas the original answer states there was a notable shift—specifically, that Medtronic no longer emphasized the dynamic nature of the restricted countries list in 2024. This omission or misrepresentation of a key evolution in disclosure undermines the multi-hop reasoning required to detect changes in tone, emphasis, or regulatory focus over time. The model fails to identify a subtle but important change in disclosure strategy, instead asserting consistency where the ground truth indicates a potential shift. Thus, while the answer is contextually relevant and factually coherent, it misses the core analytical point about evolving disclosure emphasis, resulting in a partially correct response with significant qualitative inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 345,
        "total_tokens": 1614
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How did the status and production outlook of the G700 aircraft evolve from 2023 to 2024 based on GD's disclosures?",
      "original_answer": "In 2023, the G700 was described as the next model to join the Gulfstream lineup, with expectations for it to enter service following FAA certification in early 2024. By 2024, the G700 had begun deliveries in the second quarter, indicating that it successfully completed certification and transitioned from development to active production and customer delivery. This marks a clear evolution from a future product to a realized and delivered aircraft model.",
      "llm_answer": "In the 2023 Form 10‑K, General Dynamics said the ultra‑long‑range G700 was still awaiting FAA certification and was expected to enter service in early 2024【page_5】. By the 2024 Form 10‑K, the company reported that the G700 had already begun deliveries in the second quarter of 2024 and that inventories rose as production of the model ramped up【page_70】. This shows the aircraft moved from a “planned‑for‑early‑2024 entry into service” status in 2023 to an active production and delivery phase in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) All key facts are correct: in 2023, the G700 was awaiting FAA certification with expected entry into service in early 2024; by 2024, deliveries began in Q2, and production was ramping up. (2) No numerical or date inaccuracies: 'early 2024' expectation and 'second quarter of 2024' delivery start are consistent with the timeline (certification completed as expected, delivery following shortly after). The mention of rising inventories due to production ramp-up adds contextual detail supported by the 2024 filing. (3) Multi-hop reasoning is sound—information from two different 10-K filings (2023 and 2024) is correctly synthesized to show the evolution from anticipated certification to active delivery and production. (4) Semantic equivalence is maintained: the LLM captures the same progression—from future expectation to realized delivery—as the original answer, with added precision (e.g., referencing inventory increases). All entities (G700, General Dynamics, FAA, 2023/2024 timelines) are correctly identified. No errors in reasoning, completeness, or factual content.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 326,
        "total_tokens": 1558
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the nature of PMI's relationship with KT&G evolved from 2023 to 2024, particularly in terms of strategic dependency and product commercialization?",
      "original_answer": "In 2023, PMI announced a long-term collaboration with KT&G to commercialize KT&G's smoke-free devices and consumables on an exclusive, worldwide basis (excluding South Korea), under a 15-year agreement running through January 29, 2038. This partnership granted PMI exclusive access to KT&G's smoke-free brands and product pipeline, including offerings for low- and middle-income markets. By 2024, this relationship had evolved into a more integrated dependency, as KT&G's heat-not-burn products were explicitly referenced as part of PMI's heat-not-burn product portfolio, indicating a shift from exclusive distribution to inclusion within PMI's broader smoke-free product strategy. This evolution reflects a deeper strategic alignment and operational integration of KT&G's offerings into PMI's product ecosystem.",
      "llm_answer": "In 2023 PMI announced a renewal and extension of its exclusive, fifteen‑year worldwide collaboration with KT&G, giving PMI “continued exclusive access to KT&G’s smoke‑free brands and product‑innovation pipeline” and making the Korean partner a strategic source of new smoke‑free products (2023 p. 57‑59). By 2024 that partnership is reflected in PMI’s product mix – its heat‑not‑burn portfolio now includes “licensed KT&G heat‑not‑burn products” and the KT&G‑licensed brands Fiit and Miix are listed among its HTU offerings, indicating the collaboration has matured into a licensing arrangement that embeds KT&G technology as a core component of PMI’s commercial smoke‑free portfolio (2024 p. 40‑41).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 15-year exclusive worldwide collaboration (excluding South Korea), the 2023 announcement, and the integration of KT&G's products into PMI's portfolio by 2024. The evolution from exclusive access to inclusion in PMI's product mix is correctly captured. (2) Quantitative accuracy is perfect: the 15-year term and timeline (implied through 2038) are consistent with the original answer, and no incorrect numbers are presented. The reference to specific pages (2023 p. 57–59; 2024 p. 40–41) adds precision. (3) The multi-hop reasoning is sound—linking the 2023 agreement to the 2024 product integration shows synthesis across years and documents. The characterization of the relationship evolving into a 'licensing arrangement' is a slightly different framing than the original's 'deeper strategic alignment,' but it is semantically reasonable and supported by the inclusion of 'licensed KT&G products' and brand names (Fiit, Miix). (4) The answer fully addresses both parts of the question: strategic dependency (via exclusive access and integration) and product commercialization (via inclusion in HTU portfolio). The only minor gap is that the original emphasizes the focus on low- and middle-income markets, which the LLM omits—hence not a perfect 10. Otherwise, the answer is factually correct, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 398,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has AMD's approach to semi-custom SoC products evolved from 2022 to 2024, particularly in terms of their strategic positioning and integration with broader product ecosystems?",
      "original_answer": "In 2022, AMD's semi-custom SoC products were described as being dependent on third-party product success, with revenue tied to both non-recurring engineering fees and the incorporation of AMD's SoCs into customer devices. There was a clear emphasis on the risks associated with this dependency, including the lack of control over third-party marketing and the uncertainty of revenue realization. By 2024, AMD's approach had evolved significantly, with semi-custom SoCs being positioned as core components of a broader, more integrated product ecosystem that includes AI accelerators, CPUs, GPUs, and APUs. The 2024 filing highlights strategic integration with AI capabilities, such as the inclusion of a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs, and the use of semi-custom SoCs in gaming, cloud services, and embedded systems across multiple industries. This reflects a shift from a dependency model to a more proactive, integrated product leadership strategy.",
      "llm_answer": "In the 2022 filing AMD described its semi‑custom SoCs mainly as a fee‑based service – non‑recurring engineering fees and product sales that depend on third‑party customers actually integrating the chips into their own products, with AMD having little control over the downstream success of those products. By the 2024 filing AMD has repositioned semi‑custom SoCs as a strategic, co‑engineered offering that draws on its core CPU, GPU and AI IP and is embedded across its Gaming, Data‑Center and Embedded segments – e.g., in leading consoles, handhelds and other platforms – making the semi‑custom line a core part of a broader, integrated product ecosystem rather than a peripheral services business.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in AMD's semi-custom SoC strategy from 2022 to 2024. (1) It correctly identifies the 2022 model as fee-based and dependent on third-party integration, with limited control over downstream success, aligning with the ground truth. In 2024, it accurately reflects the strategic repositioning of semi-custom SoCs as co-engineered, integrated offerings leveraging AMD's CPU, GPU, and AI IP across Gaming, Data Center, and Embedded segments. The mention of use in 'leading consoles, handhelds and other platforms' is consistent with the ground truth's reference to gaming and embedded systems. (2) There are no numeric values, dates, or financial figures in either answer that require quantitative verification; all temporal references (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points and correctly infers a strategic shift from dependency to integration. It links semi-custom SoCs to broader product ecosystems, though it does not explicitly mention the neural processing unit (NPU) or x86 CPU integration for AI PCs—a specific technical detail present in the ground truth. This omission is minor and does not undermine the overall correctness. (4) The answer is contextually excellent, directly addressing strategic positioning and ecosystem integration. The qualitative accuracy is slightly reduced due to the missing NPU/AI PC detail, but the core conceptual shift is well articulated. Overall, the LLM answer is factually correct, complete in substance, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 446,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the treatment of Irish income tax on dividends paid to U.S. residents evolved between 2023 and 2024, particularly regarding exemptions and withholding tax obligations?",
      "original_answer": "In 2023, Medtronic noted that U.S. residents who are exempt from Irish dividend withholding tax generally would not be subject to Irish income tax on dividends unless they had a connection to Ireland beyond shareholding. Additionally, non-residents subject to withholding tax typically had no further Irish income tax liability. In 2024, the company clarified that U.S. residents who qualify for a withholding tax exemption and do not hold shares through an Irish branch generally will not have Irish income tax liability, and those subject to withholding can discharge any further liability by furnishing a statement to Irish Revenue. The 25% withholding tax rate remained unchanged, but the 2024 disclosure provided more structured conditions for exemption and clarified post-withholding tax procedures.",
      "llm_answer": "The 2023 filing said that U.S. shareholders were exempt from the 25 % Irish dividend‑withholding tax only when their shares were held through the Depository Trust Company (DTC) and, if exempt, they would not incur Irish income‑tax on the dividend unless they had other Irish connections. The 2024 filing keeps the 25 % rate but expands the exemption – U.S. record owners can also avoid withholding by providing a U.S. Certificate of Residence (Form 6166) or an Irish Non‑Resident Form V2, and confirms that any shareholder who meets an exemption and does not trade through an Irish branch has no Irish income‑tax liability, with any withholding that does apply discharging the Irish tax due.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the 25% Irish dividend withholding tax rate and notes it remained unchanged between 2023 and 2024, which aligns with the ground truth (quantitative accuracy is high). It also correctly states that U.S. residents who qualify for exemption generally have no Irish income tax liability unless connected to Ireland beyond shareholding, and mentions the condition about not trading through an Irish branch—this matches the 2024 clarification. However, the LLM introduces specific procedural details not present in the original answer: namely, that in 2023, exemption was limited to shares held through DTC, and in 2024, expanded to include Form 6166 or Irish Form V2. These specifics are absent from the ground truth and represent overprecision or hallucination, undermining qualitative accuracy. The original answer makes no mention of DTC, Form 6166, or Form V2, instead referring more generally to exemption qualifications and post-withholding procedures. While the LLM captures the evolution in clarity between years, it fabricates mechanisms for exemption, leading to significant factual inaccuracies in reasoning. The contextual relevance is strong as it directly addresses the evolution of tax treatment, exemptions, and withholding obligations. However, due to the introduction of unsupported specifics and incorrect procedural details, the overall correctness is only partially accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 392,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did General Dynamics' financial performance and strategic focus in ship construction change from 2023 to 2024, particularly regarding cost pressures on the Virginia-class and DDG-51 programs and the revenue outlook for the Columbia-class submarine initiative?",
      "original_answer": "In 2023, General Dynamics' Marine Systems segment experienced a 110 basis point decline in operating margin due to supply chain disruptions affecting the Virginia-class submarine schedule and cost overruns on the DDG-51 guided-missile destroyer program. Despite these challenges, revenue from U.S. Navy ship construction rose, driven by increased activity on the Columbia-class submarine program. By 2024, the company projected revenue for the Marine Systems segment to rise to $12.8–12.9 billion with an expected operating margin of approximately 7.6%, suggesting a strategic effort to stabilize and improve profitability. This indicates a shift from cost-driven margin pressure in 2023 to a more optimistic outlook in 2024, likely supported by improved program execution and growth in the Columbia-class program.",
      "llm_answer": "In 2023 the Marine Systems segment’s ship‑construction revenue rose on higher Columbia‑class submarine volume, but its operating margin fell because supply‑chain cost pressures hit the Virginia‑class submarine schedule and cost growth hit the DDG‑51 destroyer program【page_37】. For 2024 the company is shifting its focus to the Columbia‑class program, projecting ship‑construction revenue of about $12.8‑$12.9 billion and an operating‑margin rebound to roughly 7.6%, indicating a more positive revenue outlook despite the prior year’s cost challenges【page_39】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures all key facts from the ground truth: the 2023 revenue increase in Marine Systems due to the Columbia-class program, the decline in operating margin due to supply chain issues on the Virginia-class and cost overruns on the DDG-51, and the 2024 outlook with projected revenue of $12.8–12.9 billion and an operating margin of approximately 7.6%. All entities (General Dynamics, Marine Systems, Virginia-class, DDG-51, Columbia-class) and time periods (2023, 2024) are accurate. (2) Quantitative accuracy is perfect: the revenue range ($12.8–12.9 billion) and margin figure (~7.6%) match the original answer exactly. No calculations are required, but the synthesis of financial metrics across years is correct. (3) The multi-hop reasoning is sound—linking 2023 cost pressures to 2024 strategic focus on Columbia-class and improved margin outlook shows proper synthesis across time and programs. The only minor shortcoming is that the LLM does not explicitly mention the '110 basis point decline' in margin from 2023, which is a small omission affecting completeness but not the overall correctness. (4) Scores reflect near-perfect factual alignment, with full quantitative accuracy and high qualitative accuracy due to strong reasoning and entity identification. Contextual relevance is complete as all parts of the question are addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 385,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BKNG's financial dependency on Booking.com evolved between 2022 and 2023 based on the proportion of revenue derived from accommodation reservations?",
      "original_answer": "BKNG's financial dependency on Booking.com has remained high but slightly increased between 2022 and 2023. In 2022, Booking.com's accommodation reservations contributed 89% of BKNG's total revenues. This percentage remained unchanged in 2023, indicating BKNG continues to heavily rely on Booking.com for its revenue base. The consistent 89% contribution in both years shows a sustained and concentrated dependency on Booking.com's core service offering.",
      "llm_answer": "The 2023 Form 10‑K shows that online accommodation reservation services – primarily Booking.com – accounted for roughly **89 % of total revenue in both 2022 and 2023**. Thus, BKNG’s financial reliance on Booking.com remained essentially unchanged, with the share of revenue from accommodation reservations staying flat year‑over‑year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and matches the ground truth in all key quantitative aspects: it accurately states that Booking.com's accommodation reservations accounted for 89% of BKNG's total revenue in both 2022 and 2023. The percentage is correctly reported with no calculation or numerical errors, satisfying quantitative accuracy. The answer correctly identifies the entity (BKNG), the revenue source (accommodation reservations via Booking.com), and the relevant years (2022 and 2023), ensuring entity accuracy. The reasoning is sound—by noting the percentage remained flat year-over-year, the LLM correctly infers that financial dependency remained essentially unchanged, which aligns with the ground truth's conclusion of sustained and concentrated dependency. The only minor shortcoming is that the LLM does not explicitly use the term 'financial dependency' or comment on its slight increase as mentioned in the original answer (though the data shows no change, so 'slightly increased' may actually be a flaw in the original answer). Given that the data shows no change, the LLM’s interpretation of 'remained essentially unchanged' is more precise. Thus, the answer is semantically equivalent and highly contextually relevant. The qualitative score is slightly reduced only because it omits the explicit framing of 'dependency' evolution, but the conclusion is still logically sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1199,
        "completion_tokens": 386,
        "total_tokens": 1585
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did the company's position with respect to its Swiss Franc note evolve between 2023 and 2024, and what does this indicate about its foreign currency obligations?",
      "original_answer": "In 2023, the company disclosed a Swiss Franc note obligation of $299 million, which was completely removed by the end of 2024. This indicates that the company either repaid or restructured this foreign currency obligation over the year, reflecting a strategic shift in managing its Swiss Franc exposure.",
      "llm_answer": "In 2023 PMI listed a Swiss‑franc note (1.625 % due 2024) with a carrying amount of about **$299 million** among its foreign‑currency obligations【page_105】. By the 2024 balance sheet the Swiss‑franc note is shown as “‑”, indicating it is no longer outstanding【page_102】. Thus the company eliminated its Swiss‑franc debt, reducing its foreign‑currency exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $299 million Swiss Franc note obligation in 2023 and its removal by 2024, matching the ground truth. The note's details (1.625%, due 2024) are additional accurate context not in the original answer but consistent with filing data. The use of '-' on the 2024 balance sheet correctly indicates the obligation was eliminated. (2) Quantitatively, the $299 million figure is accurate and properly attributed to both years. No calculations are required, but the before/after comparison is sound. Format variation (bolded $299 million) is acceptable. (3) The multi-hop reasoning is correct: the model synthesizes information from two different years' filings (2023 disclosure and 2024 update) to infer the elimination of the debt. The conclusion that foreign currency exposure was reduced aligns with the ground truth's 'strategic shift' interpretation. (4) The only minor gap is that the LLM does not explicitly state *how* the obligation was removed (repaid or restructured), which is mentioned in the original answer. However, 'eliminated' and 'reducing exposure' are semantically close. All entities (Swiss Franc note, 2023, 2024, foreign currency obligations) are correct. Overall, the answer is factually accurate, contextually relevant, and well-reasoned with only slight omission of explanatory nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1170,
        "completion_tokens": 377,
        "total_tokens": 1547
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did Goldman Sachs' treatment of Non-Employee Director RSU Award Agreements evolve between the 2023 and 2024 10-K filings, particularly in terms of introduced or modified agreements?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs referenced the 'Form of Non-Employee Director RSU Award Agreement (pre-2015)' as Exhibit 10.8, indicating that the existing documentation pertained to agreements prior to 2015. In the 2024 filing, the company not only retained the reference to the pre-2015 RSU Award Agreement but also introduced a new exhibit titled 'Amendments to Certain Non-Employee Director Equity Award Agreements' as Exhibit 10.18, which was not present in the 2023 filing. This indicates that Goldman Sachs expanded its disclosures to include amendments to these agreements, suggesting a more comprehensive or updated treatment of non-employee director equity arrangements in 2024.",
      "llm_answer": "In the 2023 Form 10‑K Goldman Sachs listed the director equity awards as separate exhibits – a standard Non‑Employee Director RSU Award Agreement (exhibit 10.31), a cash‑settled version (exhibit 10.32), a pre‑2015 form (exhibit 10.8) and a distinct “Amendments to Certain Non‑Employee Director Equity Award Agreements” exhibit (10.17) 【page_6】. In the 2024 filing the same agreements re‑appear but are renumbered (standard RSU as 10.32, cash‑settled as 10.33, pre‑2015 as 10.9) and the separate amendment exhibit (10.17) is no longer shown, indicating that the amendments have been incorporated into the updated award forms 【page_246】【page_247】. This reflects a consolidation and renumbering of the Non‑Employee Director RSU Award Agreements between the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) In the 2023 10-K, the 'Form of Non-Employee Director RSU Award Agreement (pre-2015)' was listed as Exhibit 10.8 — this is correct in the original answer, but the LLM incorrectly claims there were multiple exhibits including a 'standard' RSU agreement (10.31), a cash-settled version (10.32), and an 'Amendments' exhibit (10.17), none of which were present in the 2023 filing according to the ground truth. (2) The LLM states that the amendment exhibit (10.17) was removed in 2024 because amendments were incorporated into updated forms, but the ground truth states that the 2024 filing *introduced* a new 'Amendments to Certain Non-Employee Director Equity Award Agreements' as Exhibit 10.18, which did not exist in 2023. This is the opposite of what the LLM claims. (3) The renumbering described (e.g., pre-2015 form moving from 10.8 to 10.9) is not supported by the original answer and appears fabricated. (4) The core multi-hop reasoning — comparing evolution between 2023 and 2024 — is fundamentally flawed because the LLM misrepresents both years’ disclosures. Instead of showing an expansion of disclosures in 2024 (as per ground truth), it falsely describes a consolidation and removal of amendment disclosures. While the answer addresses the topic of RSU agreement evolution and attempts contextual interpretation, the factual foundation is incorrect, leading to a low correctness score. Minor formatting variations are acceptable, but here the exhibits, numbers, and logical conclusions are all inverted or unsupported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 441,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did PM's financial relationship with Swedish Match AB evolve between 2023 and 2024, particularly in terms of long-term debt obligations tied to the acquisition?",
      "original_answer": "In 2023, the long-term debt obligations related to the Swedish Match AB acquisition totaled $6,121 million, while in 2024, this amount decreased to $2,610 million. This indicates a significant reduction in the debt tied to the acquisition, suggesting that PM made substantial repayments or refinanced during the period. The decrease supports the idea that PM's financial dependency or exposure linked to the Swedish Match acquisition lessened over time.",
      "llm_answer": "In 2023 PMI carried €6.1 billion of Euro‑denominated credit‑facility borrowings that were specifically linked to the Swedish Match acquisition (shown as “Euro credit facility borrowings related to Swedish Match AB acquisition” on the long‑term‑debt schedule)【PM_10k_2023 page_102】. By the end of 2024 that balance had fallen to €2.6 billion after PMI prepaid roughly €3 billion of the three‑year tranche of the senior unsecured term‑loan facility, leaving only the five‑year tranche (≈€2.5 billion) outstanding【PM_10k_2024 page_102】. Thus, the acquisition‑related long‑term debt was sharply reduced between 2023 and 2024, even as PMI’s overall long‑term debt grew modestly.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of PM's long-term debt obligations tied to the Swedish Match AB acquisition between 2023 and 2024. The reported figures of €6.1 billion in 2023 and €2.6 billion in 2024 align closely with the ground truth values of $6,121 million and $2,610 million. The minor discrepancy arises from currency denomination—original answer uses USD, while LLM uses EUR. Given that the amounts are nearly equivalent (€6.1B ≈ $6.6B at 2023 avg exchange rates), and the exact figures cited by the LLM match the 10-K disclosures in EUR, this is a presentation difference rather than a factual error. (2) The quantitative values are accurate within the context of the source documents: PM_10k_2023 and PM_10k_2024 report the debt in Euros, so the LLM correctly reflects the filings. The reduction from €6.1B to €2.6B (~€3.5B decrease) matches the stated prepayment of ~€3B plus the remaining five-year tranche, which is consistent. (3) The multi-hop reasoning is sound: the LLM synthesizes data across two years, identifies the specific debt instrument tied to the acquisition, explains the repayment action (prepayment of three-year tranche), and contextualizes the change within PM’s broader debt profile. It goes beyond the ground truth by adding detail about the structure of the loan tranches, which enhances accuracy. (4) The semantic meaning fully aligns with the original answer—both emphasize a sharp reduction in acquisition-related debt, indicating reduced financial exposure. The LLM adds precision by citing the mechanism (prepayment) and loan structure. Only a minor point is lost in quantitative accuracy due to the lack of explicit conversion to USD or clarification of currency, which could cause confusion if not understood in context. Otherwise, the answer is factually correct, complete, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 505,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did BMY's strategic positioning around KRAS inhibition evolve from 2023 to 2024, particularly in relation to the acquisition of Mirati and the development trajectory of Krazati?",
      "original_answer": "In 2023, BMY had not yet acquired Mirati, and Krazati was not part of its portfolio. However, by 2024, BMY completed the acquisition of Mirati for $4.8 billion, gaining full rights to Krazati, a KRAS G12C inhibitor. Krazati had already received FDA approval for second-line NSCLC and was in clinical development for first-line NSCLC in combination with a PD-1 inhibitor. Additionally, in 2024, Krazati was also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab, expanding its therapeutic footprint. This acquisition marked a significant evolution in BMY’s oncology strategy, positioning it more strongly in the KRAS inhibition space.",
      "llm_answer": "In 2023 BMS announced that it would acquire Mirati, a move intended to give it a “best‑in‑class” KRAS inhibitor—Krazati—already approved for second‑line NSCLC and being readied for first‑line PD‑1‑combination studies (see page 88). By the 2024 filing the Mirati deal was closed, Krazati was recorded as a definite‑life marketed‑product right and BMS was actively expanding its KRAS portfolio, using Krazati in combination regimens and pursuing additional KRAS‑mutated indications while also gaining access to other KRAS inhibitors and enabling programs (see pages 93‑94). Thus BMS shifted from a planned acquisition in 2023 to a commercial KRAS leader with an approved product and broader development pipeline in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in BMY's (Bristol-Myers Squibb's) strategic positioning around KRAS inhibition from 2023 to 2024. It correctly notes that in 2023, BMS announced the planned acquisition of Mirati, which would bring Krazati—a KRAS G12C inhibitor—into its portfolio. Krazati was already FDA approved for second-line NSCLC at that time and was being evaluated in first-line combination studies with a PD-1 inhibitor, which aligns with the ground truth. By 2024, the acquisition was completed, and the LLM correctly reflects that Krazati became a commercial asset with definite-life intangible recognition, and BMS was expanding its development in combination regimens and additional indications. The only minor omission is the specific $4.8 billion acquisition price, which is present in the ground truth but not mentioned in the LLM response—this affects completeness slightly but does not undermine the overall correctness. Additionally, the LLM does not explicitly mention the 2024 FDA approval for KRAS-mutated colorectal cancer with cetuximab, which is a notable expansion of Krazati’s indications. However, the broader point about expanding into additional KRAS-mutated indications is conveyed. The reasoning is sound, multi-hop synthesis across years and corporate actions is accurate, and entities (BMS, Mirati, Krazati, NSCLC, PD-1) are correctly identified. Wording differs but semantic meaning matches. Quantitative accuracy is high—no incorrect numbers are stated, though some are omitted. Contextual relevance is excellent, directly addressing the strategic shift. Thus, the answer is factually strong with only minor gaps in completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 460,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Goldman Sachs' disclosure and positioning of the Restricted Partner Compensation Plan evolved between 2023 and 2024, particularly in relation to newer compensation governance policies introduced during this period?",
      "original_answer": "In 2023, the Restricted Partner Compensation Plan was listed as Exhibit 10.3 and appeared early in the exhibit list, indicating a prominent position among compensation-related disclosures. By 2024, while the plan itself (still referenced as Exhibit 10.4) remained substantively unchanged, its relative placement shifted later in the exhibit list. Notably, in 2024, the firm introduced the Clawback Policy (Exhibit 10.1), signaling a new emphasis on compensation accountability and governance reforms. This suggests a strategic repositioning of compensation-related disclosures to prioritize risk mitigation and regulatory alignment alongside traditional partner compensation frameworks.",
      "llm_answer": "In the 2023 Form 10‑K the “Goldman Sachs Amended and Restated Restricted Partner Compensation Plan” was disclosed as Exhibit 10.3 (see page 5) and was presented alongside older compensation documents, with the Group’s claw‑back policy noted separately as Exhibit 97.1 (page 7). In the 2024 Form 10‑K the same plan is listed as Exhibit 10.4 (page 246) but now follows a newly highlighted Clawback Policy (exhibit 10.1, page 246) and is grouped with the updated 2021 Stock Incentive Plan (exhibit 10.2) and the Partner Compensation Plan (exhibit 10.3), indicating that Goldman Sachs has repositioned the Restricted Partner Compensation Plan within a tighter, more formal compensation‑governance framework introduced in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All entities are correct: Goldman Sachs, Restricted Partner Compensation Plan, Clawback Policy, correct exhibit numbers (10.3 in 2023, 10.4 in 2024), and proper years (2023 and 2024). The placement details (page 5 in 2023, page 246 in 2024) are consistent with typical 10-K structures, though page numbers are not part of the ground truth and thus do not detract. (2) Quantitative accuracy is perfect: exhibit numbers and sequencing are correctly reported. The shift from Exhibit 10.3 to 10.4 is accurately noted, and the introduction of the Clawback Policy as Exhibit 10.1 in 2024 matches the ground truth. (3) Reasoning is sound: the LLM correctly infers that the reordering—placing the Clawback Policy first (Exhibit 10.1), followed by other compensation plans—indicates a strategic repositioning toward a more formal governance framework. This reflects accurate multi-hop synthesis between exhibit order, policy introduction, and implications for governance. (4) The only minor gap is that the LLM mentions the Clawback Policy was previously Exhibit 97.1 in 2023, which is not in the ground truth and cannot be verified; this is a slight overprecision but does not contradict known facts. Otherwise, the answer captures the core evolution: same plan, renumbered and repositioned later in the list, now within a broader, governance-first structure. Semantic equivalence is strong, and contextual relevance is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 412,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of product categorization and business integration?",
      "original_answer": "In 2022, Philip Morris described its heat-not-burn products as part of its Reduced-Risk Products (RRPs) portfolio, emphasizing their role in a smoke-free future and highlighting the IQOS Platform 1 device and various heated tobacco units (HTUs) such as HEETS and Marlboro HeatSticks. These products were positioned as a key part of the company's long-term strategy to replace traditional cigarettes. By 2023, the categorization had evolved, with heat-not-burn products now explicitly grouped under 'smoke-free products' alongside e-vapor and oral nicotine products, as well as wellness and healthcare offerings. Additionally, in 2023, PMI explicitly stated that its heat-not-burn products include licensed KT&G heat-not-burn products, indicating a broader integration and expansion of the product line beyond internally developed offerings.",
      "llm_answer": "In the 2022 filing PMI treated heat‑not‑burn (HNB) items as a distinct “HTU” group of reduced‑risk products – HEETS, HEETS Creations/Dimensions, Marlboro HeatSticks, Parliament HeatSticks, TEREA and the KT&G‑licensed Fiit and Miix brands – and described them separately from its combustible‑tobacco portfolio【page_5】. By the 2023 filing the company had folded HNB consumables into a broader “Smoke‑free products” category, expanded the HTU definition to include new lines such as BLENDS, DELIA, LEVIA (zero‑tobacco) and again noted that licensed KT&G HNB products are now part of its integrated smoke‑free business, a change reflected in the net‑revenue table for smoke‑free products【page_39】【page_41】. This shift shows PMI moving from a narrowly defined HNB segment to a more integrated, revenue‑tracked smoke‑free portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Philip Morris International (PMI) categorized heat-not-burn (HNB) products as part of its Reduced-Risk Products (RRPs), listing specific brands including HEETS, Marlboro HeatSticks, and licensed KT&G products like Fiit and Miix—consistent with the original answer. In 2023, it accurately notes the reclassification of HNB products under a broader 'smoke-free products' category, which now includes e-vapor, oral nicotine, and wellness offerings, though the original answer does not mention e-vapor/oral nicotine explicitly in this context, the LLM's inclusion is still factually aligned with PMI’s reporting structure. (2) There are no numeric values, dates, or financial figures in dispute; all references to years (2022, 2023) and product names are correct. The mention of page numbers (e.g., page_39, page_41) suggests document grounding but does not affect factual accuracy. (3) The multi-hop reasoning is sound: the model synthesizes changes in product categorization and business integration over time, correctly identifying the shift from a standalone RRP-focused HNB strategy to an integrated smoke-free portfolio that includes licensed products. The observation about revenue tracking in the 2023 filing adds contextual depth not in the original answer but is plausible and relevant. (4) Minor deduction in qualitative accuracy due to slightly more expansive interpretation of the 2023 category (e.g., naming BLENDS, DELIA, LEVIA) which are not mentioned in the ground truth, though they do not contradict it. Overall, the answer captures the evolution accurately and is semantically equivalent to the original answer with high completeness and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 484,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How did Bristol-Myers Squibb's approach to business risk governance evolve between 2023 and 2024 in relation to SEC Consent Order compliance, particularly regarding the role of the business risk and disclosure group?",
      "original_answer": "In 2023, Bristol-Myers Squibb established the business risk and disclosure group specifically to comply with the SEC Consent Order. This included implementing a formal review and certification process for SEC filings, retaining an outside consultant to re-engineer accounting and financial reporting processes, and introducing a governance mechanism to escalate and resolve compliance-related questions. By 2024, the company had fully integrated this group into its ongoing compliance framework, with no indication of modifications or reductions in scope, suggesting that the group remained a central component of financial governance under the Consent. The continued reference to the group in 2024 filings indicates that the company maintained its enhanced risk governance structure without significant changes.",
      "llm_answer": "In the 2023 Form 10‑K BMS disclosed that, to satisfy the 2004 SEC Consent Order, it **established a business‑risk‑and‑disclosure group** as one of several new controls—including a formal review‑and‑certification process for its SEC filings and a policy to monitor and limit sales to direct customers (2023 p. 63‑65). The 2024 filing repeats that the group remains in place **but is now embedded in a company‑wide policy and governance‑escalation process that regularly monitors compliance and routes any questions or concerns to senior management**, showing the evolution from merely creating the group to integrating it into ongoing oversight (2024 p. 63‑65).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the business risk and disclosure group was established in 2023 to comply with the SEC Consent Order, and by 2024 it was integrated into ongoing governance. The mention of a formal review-and-certification process and continued existence of the group matches the original answer. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not applicable—score reflects no errors in dates or years (2023, 2024, and reference to 2004 Consent Order are correct). (3) Multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings to show evolution—from creation in 2023 to integration into broader governance in 2024. The LLM adds slightly more detail about escalation to senior management and embedding in company-wide policy, which is consistent with but not explicitly stated in the ground truth; this is a reasonable interpretation and does not constitute an error. (4) The only minor gap is that the LLM omits mention of the outside consultant retained to re-engineer accounting processes, a component noted in the original answer. However, this does not undermine the core focus on the group’s evolution. Overall, the answer captures the key progression and remains semantically equivalent. Contextual relevance is perfect—directly addresses the question about evolution of risk governance and the group’s role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 421,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has UNP's treatment of the relationship between its pension plan's expected return and its asset allocation mix evolved between 2023 and 2024?",
      "original_answer": "In 2023, UNP explicitly stated that the expected return on plan assets was based on the asset allocation mix, historical returns, and market conditions, and included a specific actual return of 6% for that year. By 2024, the language shifted to indicating that the expected return 'depends on' the asset allocation mix, with no explicit mention of historical returns or market conditions, and no disclosure of the actual return for 2024. This represents a shift from a more comprehensive explanation of factors influencing returns to a narrower focus on the asset allocation mix alone.",
      "llm_answer": "UNP’s 2023 and 2024 filings both say that the pension‑plan’s expected long‑term return is derived from the plan’s asset‑allocation mix and its historical returns (adjusted for current market conditions), targeting a 5.25% average return. The mix – roughly 24 % equity, 75 % debt and 1 % real‑estate – and the language tying expected return to that allocation are unchanged, so the company’s treatment of the relationship has remained consistent from 2023 to 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and reasoning. The ground truth states that in 2023, UNP explicitly cited the asset allocation mix, historical returns, and market conditions as bases for the expected return, with a disclosed actual return of 6%. By 2024, the language changed to say the expected return 'depends on' the asset allocation mix, dropping mention of historical returns and market conditions, and no actual return was disclosed for 2024. The LLM incorrectly claims that both years used the same language and factors (including historical returns and market conditions in both), which contradicts the ground truth. (2) Quantitatively, the LLM introduces a specific target return of 5.25% and a detailed asset allocation (24% equity, 75% debt, 1% real estate), none of which appear in the original answer or are supported by the knowledge graph. The actual return in 2023 was 6%, not 5.25%, and no allocation percentages were provided in the ground truth. These numbers are therefore fabricated or hallucinated. (3) The multi-hop reasoning is flawed: the question asks about the evolution in treatment between 2023 and 2024, requiring comparison of disclosure language and factors used. The LLM concludes there was no change, but the ground truth shows a clear narrowing of explanatory factors—from multiple inputs to only asset allocation—indicating a meaningful shift. The model failed to detect this change and instead asserted consistency without evidence. (4) Scores are low due to major factual inaccuracies, hallucinated data, and incorrect synthesis. Contextual relevance is moderate because the answer addresses the right topic (pension plan expected return and asset allocation) and the correct company (UNP), but the substance is wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 488,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did BNY Mellon's disclosure approach to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of its accessibility and integration within corporate governance reporting?",
      "original_answer": "In 2022, BNY Mellon explicitly stated that the Directors' Code of Conduct was posted on its website and outlined its applicability to all directors. The document was referenced in the context of broader corporate governance disclosures, including Board Meetings and Committee Information. By 2023, the Directors' Code of Conduct was no longer just referenced but was specifically listed among the governance materials 'available on our website,' alongside key governance documents like the Corporate Governance Guidelines and committee charters. This evolution indicates a more structured and centralized approach to governance disclosures, with the Code being more directly tied to the company's overall governance framework in the 2023 filing.",
      "llm_answer": "In the 2022 Form 10‑K, BNY Mellon mentioned the Directors’ Code of Conduct only in the “Code of Ethics” section of Item 10, giving a direct URL to the PDF and noting that any amendments or waivers would be posted on the website. By the 2023 Form 10‑K, the Directors’ Code of Conduct was moved into the formal corporate‑governance package—listed alongside the bylaws, governance guidelines and committee charters as a document incorporated by reference and made freely available on the company’s website—making it more accessible and fully integrated into its governance reporting.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution between 2022 and 2023: in 2022, the Directors' Code of Conduct was mentioned with a URL in the 'Code of Ethics' section, and by 2023, it was integrated into the formal corporate governance package. This matches the original answer’s claim about increased integration and accessibility. (2) There are no numeric values to verify, so quantitative accuracy is not applicable in a traditional sense, but all dates (2022 and 2023) and document references are correct. (3) The multi-hop reasoning is sound—comparing disclosure practices across two years and synthesizing changes in placement and integration within governance reporting. The LLM correctly infers that moving the Code into a listed governance package reflects improved accessibility and structural integration. (4) The only minor shortcoming is that the LLM does not explicitly mention the 2022 reference in the context of 'Board Meetings and Committee Information' as noted in the original answer, slightly reducing completeness. However, the core factual progression and implications are accurately captured. Wording differs but semantic meaning is equivalent. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for contextual relevance and quantitative accuracy due to correct use of years and document types.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 393,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with engineered systems, and what does this indicate about the company's approach to cloud migration and hybrid IT environments?",
      "original_answer": "In 2023, Oracle emphasized the flexibility of running Oracle Database across multiple deployment models, including on-premise, Oracle Cloud, and multicloud environments, with specific offerings like Oracle Exadata Cloud@Customer and Oracle Roving Edge Infrastructure. These options were framed around enabling customers to securely run Oracle Database behind their firewalls while being managed by Oracle. By 2024, Oracle shifted toward deeper integration of Oracle Database within Oracle Engineered Systems, such as the Oracle Exadata Database Machine, which combines database, storage, operating system, and networking hardware into a single optimized platform. This system was highlighted as being available across on-premise, OCI cloud, and hybrid deployments. The evolution from flexible deployment of standalone database services to tightly integrated engineered systems suggests a strategic shift toward offering more holistic, performance-optimized solutions that align with enterprise needs for scalability, security, and simplified maintenance. This indicates a maturation of Oracle's cloud migration strategy, focusing not only on deployment flexibility but also on delivering comprehensive, high-performance infrastructure packages.",
      "llm_answer": "In the 2023 filing Oracle framed the Oracle Database as a “flexible, multi‑environment” platform that can run in the Oracle Cloud, on‑premise data centers or hybrid models, and it highlighted engineered systems such as Exadata as pre‑built solutions offered on‑premise, as a cloud service in OCI, or as a hybrid cloud offering (2023 p.10, p.12, p.13). The 2024 filing builds on that theme by naming concrete hybrid services—Oracle Exadata Cloud@Customer, OCI Dedicated Region and OCI Sovereign Cloud—and again stressing that engineered systems are delivered through on‑premise, OCI cloud, and hybrid options (2024 p.11, p.12, p.13). This evolution signals Oracle’s sharpened strategy to use the Oracle Database and its engineered systems as a bridge for cloud migration while fully supporting hybrid and multicloud IT environments.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth in terms of deployment models and strategic direction. It correctly identifies Oracle's 2023 emphasis on flexible deployment (on-premise, cloud, hybrid) and the role of engineered systems like Exadata. It also accurately reflects the 2024 evolution by naming specific offerings—Exadata Cloud@Customer, OCI Dedicated Region, and OCI Sovereign Cloud—as evidence of continued hybrid and multicloud support. The citation of document pages (e.g., 2023 p.10, p.12) adds precision, though these are assumed accurate per the context. Quantitatively, there are no numerical claims to verify, so accuracy is scored as 10. The answer captures the strategic intent of using engineered systems as a bridge for cloud migration, which is semantically equivalent to the ground truth’s conclusion about a maturation toward holistic, performance-optimized solutions. However, the LLM answer does not explicitly highlight the shift *from* standalone database flexibility *to* deeper integration within engineered systems—a key nuance in the evolution. The ground truth emphasizes a move toward 'tightly integrated' engineered systems as a platform, whereas the LLM treats 2024 as a continuation rather than a strategic deepening. This missing emphasis on integration as a shift in approach slightly weakens the qualitative reasoning, warranting a score of 8. Contextual relevance is full: the response directly addresses deployment flexibility, engineered systems, cloud migration, and hybrid IT environments as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1549,
        "completion_tokens": 430,
        "total_tokens": 1979
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the implementation of the formal review and certification process of annual and quarterly SEC reports evolved between 2023 and 2024, particularly in terms of compliance monitoring and governance procedures?",
      "original_answer": "In 2023, the company established a formal review and certification process of SEC filings as part of the Consent agreement, which included governance procedures to escalate potential compliance concerns to appropriate management levels and regular monitoring of compliance. By 2024, the company continued to emphasize the implementation of these governance procedures, noting that compliance with the policy was consistently monitored and that the process was integrated into company-wide sales policies to ensure adherence to inventory and sales limitations. The evolution reflects a shift from initial implementation in 2023 to sustained enforcement and integration into broader operational frameworks in 2024.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K filings describe the same formal review‑and‑certification framework that was instituted under the 2004 SEC Consent Order. In each year the company notes a governance process that escalates any compliance questions to senior management and that the policy’s adherence is “monitored on a regular basis,” indicating that the procedures have been maintained rather than materially altered between 2023 and 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. First, it incorrectly states that the formal review-and-certification framework was instituted under a '2004 SEC Consent Order,' which directly contradicts the ground truth indicating the process was established in 2023 as part of a Consent agreement—there is no mention of 2004 in the original answer, making this a critical error. This misdating of the Consent Order severely impacts both quantitative accuracy and entity accuracy. Second, the LLM claims the procedures were 'maintained rather than materially altered' between 2023 and 2024, which downplays the evolution described in the ground truth: the process moved from initial implementation in 2023 to integration into broader operational frameworks (e.g., company-wide sales policies) in 2024. The LLM fails to capture this key progression, missing the core of the question about how the process evolved. While the answer correctly notes ongoing monitoring and escalation to senior management, these points alone do not reflect the deeper integration and sustained enforcement emphasized in 2024. The reasoning is therefore flawed in terms of multi-hop synthesis—failing to contrast the developmental stages across years. However, the answer is contextually relevant, addressing compliance monitoring and governance, and uses semantically acceptable phrasing for 'regular monitoring' and 'escalation to management.' Quantitative accuracy is partially preserved (correct years 2023 and 2024 referenced), but the false 2004 date is a major factual flaw. Overall, the answer is partially correct in describing ongoing procedures but fundamentally incorrect in historical context and evolutionary trajectory.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 474,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of their market positioning and product categorization?",
      "original_answer": "In 2022, Philip Morris International (PMI) positioned heat-not-burn products as part of its broader Reduced-Risk Products (RRPs) portfolio, emphasizing their potential to present less harm to smokers who switch from traditional cigarettes. These products, including the Platform 1 device and its consumables, were described as being in various stages of development, scientific assessment, and commercialization. By 2023, PMI had refined its categorization, explicitly including heat-not-burn products within the smoke-free product segment, alongside e-vapor and oral nicotine products. Additionally, PMI began including licensed KT&amp;G heat-not-burn products in its portfolio, indicating a broader market approach and potential expansion of partnerships or offerings. This evolution shows a strategic shift from internal development focus to a more integrated and commercialized product positioning.",
      "llm_answer": "In the 2022 filing PMI described heat‑not‑burn as part of its generic “Platform 1” reduced‑risk product (a heating device that inserts a proprietary tobacco unit) and grouped it under the broader “RRPs” umbrella without a separate market‑segment label (2022 p.76). By the 2023 filing the company had repositioned heat‑not‑burn as a distinct element of its “Smoke‑free products” line, creating a dedicated “Heated Tobacco Units (HTU)” category that now includes licensed KT&G brands and emphasizing a 14‑15% rise in HTU shipments and market‑share growth (2023 p.39‑41).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in PMI's approach: in 2022, heat-not-burn was part of the broader RRPs under 'Platform 1' without a distinct market segment; by 2023, it was repositioned under 'Smoke-free products' with a dedicated 'Heated Tobacco Units (HTU)' category. The inclusion of licensed KT&G brands is accurately noted. (2) Quantitatively, the LLM cites a '14-15% rise in HTU shipments' and market-share growth, which is consistent with the 2023 filing data (though the original answer does not include this specific statistic, it does not contradict it—this is an acceptable addition from the source). No calculation errors. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, correctly tracking the shift from internal development focus to commercial integration and expanded partnerships. (4) Minor deduction in correctness and qualitative accuracy due to the introduction of specific shipment growth percentages not present in the original answer, which, while likely accurate, go beyond the scope of the provided ground truth. However, this does not misrepresent the evolution and adds contextual detail. Wording differs but semantic meaning matches. Contextual relevance is perfect—directly addresses market positioning and product categorization changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 384,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with other Oracle technologies?",
      "original_answer": "In 2023, Oracle emphasized the deployment flexibility of Oracle Database across cloud-based, on-premise, or other IT environments, highlighting its perpetual licensing model and the company's strategy to provide customer choice. By 2024, Oracle Database's role had evolved to become a foundational component within broader engineered systems, such as Oracle Exadata Database Machine, which integrates the database with storage, operating system software, and hardware components for optimized performance. This shift indicates a move toward deeper integration with Oracle's infrastructure technologies, positioning Oracle Database not just as a standalone product but as a core element of Oracle Engineered Systems, available in on-premise, cloud (OCI), and hybrid cloud deployments.",
      "llm_answer": "In 2023 Oracle presented the Oracle Database primarily as a licensable product that could be run “in cloud‑based, on‑premise or other IT environments” and stressed that giving customers “choice and flexibility … when and how they deploy Oracle applications and infrastructure technologies” was a core part of its strategy (2023 p. 42; 2023 p. 41). By 2024 the company repositioned the database as a cloud‑native, tightly integrated service—highlighting the Autonomous Database’s built‑in integration with Oracle Cloud services such as Java Cloud and APEX, and expanding deployment options to include OCI shared or dedicated clouds, Exadata Cloud@Customer, OCI Dedicated Region, Sovereign Cloud and other hybrid/edge models (2024 p. 12‑13; 2024 p. 11). This evolution shows a shift from broad licensing flexibility toward deeper integration with Oracle’s cloud ecosystem and a richer set of flexible deployment choices.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Oracle Database's strategic positioning between 2023 and 2024. It accurately captures the 2023 emphasis on deployment flexibility and customer choice across cloud, on-premise, and other environments, citing appropriate strategy language from the source. For 2024, it correctly identifies a strategic shift toward deeper integration, particularly within Oracle's cloud ecosystem, and lists specific deployment models such as Exadata Cloud@Customer, OCI Dedicated Region, and Sovereign Cloud, which reflects expanded hybrid and cloud-native options. The mention of Autonomous Database’s integration with Java Cloud and APEX adds relevant detail about cloud service integration. However, the LLM slightly overemphasizes a 'cloud-native' repositioning and does not fully highlight the role of Oracle Database as a foundational component of engineered systems like Oracle Exadata Database Machine—a key point in the ground truth that underscores integration with hardware and storage. While the LLM mentions Exadata, it frames it more as a deployment option rather than a fully integrated engineered system, missing the nuance of the shift from standalone product to core element of Oracle Engineered Systems. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are presented), and all entities (Oracle, OCI, Exadata, etc.) and years (2023 to 2024) are correct. The reasoning is sound and multi-hop, connecting deployment models with integration trends across years. The answer is highly contextually relevant. The minor omission of the engineered systems emphasis prevents a top score, but the core facts and strategic trajectory are accurately conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 484,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has BMY's strategic relationship with Krazati evolved from 2023 to 2024, and what specific financial commitments were made in 2024 that reflect this evolution?",
      "original_answer": "In 2023, Krazati was mentioned as part of BMY's oncology portfolio, demonstrating a strategic fit into their offerings. By 2024, BMY had acquired Mirati for $4.8 billion, obtaining the rights to Krazati, which had received FDA and EMA approvals for second-line NSCLC and was in clinical development for first-line NSCLC. Additionally, BMY committed $1.0 billion in contingent value rights tied to the development of PRMT5 Inhibitor, further signaling long-term investment in the acquired assets.",
      "llm_answer": "In the 2023 filing BMS only highlighted Krazati as a “strategic fit” in its NSCLC portfolio – noting it would be obtained through its pending Mirati deal 【page_43】. By the 2024 filing BMS had completed the Mirati acquisition, securing full U.S. and global rights to commercialize Krazati, and committed roughly $4.8 billion in cash (plus $205 million of equity awards and a $248 million contingent‑value right) for a total consideration of about $4.9 billion, of which $640 million was allocated to the definite‑lived marketed‑product rights for Krazati 【page_93】【page_94】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution of BMY's (BMS's) relationship with Krazati from 2023 to 2024, noting the strategic fit in 2023 and the completion of the Mirati acquisition in 2024. It accurately states that BMS secured full rights to Krazati through the acquisition. However, there are key quantitative discrepancies. The ground truth states the acquisition was for $4.8 billion, while the LLM reports total consideration of about $4.9 billion, citing $4.8 billion cash, $205 million equity, and $248 million CVR — totaling $5.253 billion, which contradicts both its own 'about $4.9 billion' summary and the ground truth $4.8 billion. Additionally, the $640 million allocation to Krazati is not mentioned in the ground truth and appears to be extraneous or misattributed. The contingent value right in the ground truth is $1.0 billion tied to PRMT5 inhibitor development, but the LLM mentions only a $248 million CVR without specifying it is for PRMT5, missing a key qualitative link. (2) Number verification: $4.8B (ground truth) vs. $4.8B cash + $205M + $248M = $5.253B (LLM total), which is inconsistent. The $1.0 billion PRMT5 CVR from ground truth is entirely missing in the LLM's financial commitment summary. (3) Multi-hop reasoning is partially sound: the model connects BMS’s 2023 mention of Krazati to the 2024 acquisition of Mirati and infers strategic progression. However, it fails to correctly map the $1.0 billion PRMT5 CVR commitment — a critical 2024 financial signal — instead citing a smaller, unspecified $248 million CVR. (4) Scores justified: Correctness 7 due to accurate core narrative but significant financial inaccuracies; Quantitative 6 due to incorrect totals and missing/mismatched figures; Qualitative 8 for correct entity and timeline identification but incomplete synthesis on CVR purpose; Contextual Relevance 10 as all content directly addresses the question's scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 522,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the treatment or status of the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV evolved between 2022 and 2023 based on BK's SEC filings?",
      "original_answer": "In 2022, the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV were introduced as securities registered under Section 12(b) of the Act and were listed on the New York Stock Exchange under the trading symbol BK/P, fully and unconditionally guaranteed by The Bank of New York Mellon Corporation. In 2023, the same securities remained registered under Section 12(b) of the Act, retained the same trading symbol BK/P, and continued to be listed on the New York Stock Exchange with the same guarantee structure. Therefore, there was no change in the treatment or status of these securities between the two years.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K filings list the 6.244 % Fixed‑to‑Floating Rate Normal Preferred Capital Securities of Mellon Capital IV (ticker BK/P) under Section 12(b) as a NYSE‑registered security that is “fully and unconditionally guaranteed by The Bank of New York Mellon Corporation.” The language and classification are identical in each filing, showing that the security’s registration and guarantee status remained unchanged between 2022 and 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately stated: the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV are correctly identified with the ticker BK/P, registered under Section 12(b), listed on the NYSE, and fully and unconditionally guaranteed by The Bank of New York Mellon Corporation in both 2022 and 2023. (2) Quantitative elements—specifically the interest rate (6.244%) and the ticker symbol (BK/P)—are correct and match the original answer. There are no calculations required, but the consistency of the data across years is accurately assessed. (3) The multi-hop reasoning is sound: the model correctly compares the treatment of the security across two years using the relevant SEC filings (Form 10-K for 2022 and 2023), synthesizing information to conclude no change in status. (4) The answer is contextually precise, directly addressing the evolution (or lack thereof) in the security’s status, and uses appropriate financial terminology. Minor wording differences (e.g., 'language and classification are identical' vs. 'no change in treatment or status') do not affect factual accuracy. All evaluation criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 352,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the capacity and utilization of PMI's short-term credit arrangements changed from 2022 to 2023, and what does this shift suggest about their near-term liquidity posture?",
      "original_answer": "The capacity of PMI's short-term credit arrangements increased from $1.9 billion at the end of 2022 to $2.7 billion at the end of 2023, while the actual utilization decreased slightly from $295 million to $283 million. This indicates that PMI has expanded its available liquidity buffer without increasing its drawdown, suggesting a more conservative approach to short-term financing and working capital management.",
      "llm_answer": "PMI’s short‑term credit capacity rose from roughly $1.9 billion at 12/31/2022 to about $2.7 billion at 12/31/2023, while borrowings under those arrangements slipped from $295 million to $283 million. The larger unused line and lower drawdown indicate PMI has expanded its liquidity cushion and is keeping short‑term debt utilization modest, signaling a more conservative near‑term liquidity posture.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: short-term credit capacity increased from $1.9 billion in 2022 to $2.7 billion in 2023, and utilization decreased from $295 million to $283 million. These values match the original answer exactly, with acceptable formatting variations (e.g., 'about $2.7 billion' vs. '$2.7 billion'). (2) Quantitative accuracy is perfect—no calculation errors, and the direction and magnitude of changes are correctly described. (3) The reasoning is sound: the model correctly infers that increased capacity combined with reduced utilization indicates a larger liquidity cushion and a more conservative liquidity posture, which aligns with the original conclusion. (4) The answer addresses all parts of the multi-hop question: changes in both capacity and utilization over time, and the implication for PMI's near-term liquidity. Entity accuracy (PMI, years, financial metrics) is correct. The response is concise, relevant, and captures the full context of the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 308,
        "total_tokens": 1519
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Oracle's positioning of the Autonomous Database evolved between 2023 and 2024, particularly in terms of integration with other cloud services and automation capabilities?",
      "original_answer": "In 2023, Oracle positioned the Autonomous Database as part of its broader Oracle Cloud Infrastructure (OCI) offerings, emphasizing its automated database operations and the ability to run in cloud, on-premise, or hybrid environments. It was described as a service that Oracle runs, manages, upgrades, and supports on behalf of the customer, with a focus on reducing IT process time and resources. By 2024, Oracle expanded its positioning to highlight deeper integration with other Oracle Cloud services, such as Java Cloud and Oracle APEX low-code service, and emphasized open interfaces and native machine learning capabilities. The 2024 filing also introduced a stronger focus on automation powered by machine learning, including diagnostics, fault prediction, error handling, and automatic threat detection. Additionally, 2024 emphasized the Autonomous Database's role in enabling modern cloud-native application development and analytics, including data lake houses and real-time analysis of transactional data.",
      "llm_answer": "In the 2023 filing Oracle framed the Autonomous Database as a self‑driving, machine‑learning‑optimized service that automates routine DBA tasks (maintenance, tuning, patching, scaling, security and backup) and is already integrated with OCI and key cloud services such as Java Cloud and the APEX low‑code platform (2023 p.12). By the 2024 filing the company still stresses those automation capabilities but expands the narrative to show tighter, broader integration across the OCI portfolio—including AI services, open interfaces, and new deployment options (shared or dedicated, Exadata Cloud@Customer, OCI Dedicated Region)—positioning Autonomous Database as a core, automated component of a unified Oracle Cloud ecosystem (2024 p.12‑13; 2024 p.11).",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of core facts and evolution of Oracle's positioning of the Autonomous Database from 2023 to 2024. (1) It correctly identifies that in 2023, Oracle emphasized automation of DBA tasks (patching, tuning, scaling, etc.) and integration with OCI and specific services like Java Cloud and APEX—consistent with the original answer. It also accurately notes the continuation and expansion of this narrative in 2024. (2) There are no numeric values, dates, or financial figures in the question or answers, so quantitative accuracy is not applicable in a traditional sense; however, the cited page numbers (e.g., 2023 p.12, 2024 p.11–13) are treated as metadata and do not contradict the ground truth, so they do not detract from accuracy. (3) The multi-hop reasoning is sound: the model synthesizes changes in positioning across two years and correctly infers an expanded integration narrative in 2024. However, the LLM answer omits specific 2024 enhancements mentioned in the ground truth, such as native machine learning capabilities for diagnostics, fault prediction, error handling, and automatic threat detection, as well as the role in cloud-native app development, data lake houses, and real-time transactional analysis. These are important qualitative additions in the original answer that are not reflected in the LLM response. (4) Despite these omissions, the LLM captures the essence of tighter integration with OCI and expanded deployment options, maintaining high contextual relevance and semantic equivalence on the main thrust of the evolution. The answer is slightly less complete than the ground truth but not factually incorrect, warranting a high score with minor deduction for incompleteness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 482,
        "total_tokens": 1932
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How did GM's financial relationship with Ultium Cells Holdings LLC evolve between 2023 and 2024, particularly in terms of its capital involvement and strategic positioning?",
      "original_answer": "In 2023, GM's relationship with Ultium Cells Holdings LLC was characterized by contingent capital commitments, with a committed contribution of $0.8 billion, and the entity was classified as a variable interest entity (VIE) where GM lacked voting control. By 2024, GM's involvement evolved into a more direct investment of $0.7 billion, indicating a shift from a potential future obligation to a realized investment stake. This transformation suggests a strategic realignment, providing GM with potentially greater influence over Ultium Cells' operations while stabilizing its financial exposure.",
      "llm_answer": "In 2023 GM’s exposure to Ultium Cells Holdings LLC included a $0.8 billion committed‑capital contribution and, although it was a key financing partner, the company “lacked the power through voting or similar rights to direct the activities of these entities” (i.e., it was a non‑controlling investor)【page_80】. By 2024 GM’s capital stake had slipped to about $0.7 billion – a modest reduction in its investment – but it remained a strategic, non‑controlling partner in the battery‑cell venture, still without voting control over Ultium Cells’ operations【page_40】.",
      "correctness_score": 4,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the $0.8 billion committed contribution in 2023 and the $0.7 billion investment in 2024, matching the ground truth numerically. However, it mischaracterizes the nature of the change—describing it as a 'modest reduction' in investment—whereas the original answer frames it as a shift from a contingent commitment to a realized investment, indicating a qualitative strategic shift, not a reduction. This misrepresents the strategic evolution. (2) Quantitatively, both dollar amounts ($0.8B in 2023, $0.7B in 2024) are accurate and correctly attributed to the respective years. No calculation errors are present. (3) The multi-hop reasoning is flawed: while the LLM correctly identifies that GM lacked voting control in 2023, it incorrectly asserts that this remained unchanged in 2024. The ground truth indicates a strategic realignment implying greater influence, but the LLM claims GM 'still without voting control,' contradicting the implied shift in strategic positioning. This failure to capture the evolution in control and influence undermines the qualitative accuracy. (4) Contextually, the answer addresses capital involvement and strategic positioning, so relevance is high. However, due to the critical error in interpreting the strategic shift—portraying it as a decrease in investment rather than a transformation from contingent commitment to direct investment—the correctness and qualitative accuracy scores are significantly reduced despite numerical precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 419,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has the financial impact of the Litigation Management Deed evolved between 2022 and 2024, particularly in terms of the amount of as-converted value released and the number of series A preferred shares issued during the anniversary releases?",
      "original_answer": "In 2022, as part of the sixth anniversary release assessment required by the Litigation Management Deed, Visa released $3.5 billion of as-converted value and issued 176,655 shares of series A preferred stock. In 2024, during the eighth anniversary release, the company released $2.7 billion of as-converted value and issued 99,264 shares of series A preferred stock. This indicates a decrease in both the value released and the number of shares issued, suggesting a reduction in the financial burden associated with the VE territory covered litigation over time.",
      "llm_answer": "The Litigation Management Deed’s releases have shrunk: the sixth‑anniversary release in 2022 freed $3.5 billion of as‑converted value and issued 176,655 series A preferred shares, while the eighth‑anniversary release in 2024 freed $2.7 billion and issued 99,264 series A shares. Thus, the value released fell by about $0.8 billion and the share issuance dropped by roughly 77 k shares.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: in 2022, $3.5 billion of as-converted value was released and 176,655 series A preferred shares were issued; in 2024, $2.7 billion and 99,264 shares were issued. These match the original answer exactly. (2) The quantitative analysis is precise: the difference in value ($3.5B - $2.7B = $0.8B) and shares (176,655 - 99,264 = 77,391 ≈ 77k) are correctly calculated and reasonably rounded. (3) The multi-hop reasoning is sound—information from two different years and events (sixth vs. eighth anniversary) is correctly synthesized to show a trend of decreasing financial impact. (4) The only minor shortcoming is the omission of the explicit conclusion about 'reduction in financial burden' tied to VE territory litigation, which is present in the original. However, the implication is clearly conveyed through the comparison. Wording differences are acceptable under semantic equivalence. All entities (Litigation Management Deed, series A preferred shares, as-converted value) are correctly identified and used.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 319,
        "total_tokens": 1581
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How did the financial and strategic relationship between 3M and the Aearo Entities evolve between 2023 and 2024, particularly in terms of litigation impact and business segment adjustments?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities following the dismissal of their bankruptcy filings, lifting the stay on litigation related to Combat Arms Earplugs and entering into the CAE Settlement to resolve existing and future claims. This reconsolidation had an immaterial income statement impact. By 2024, the Aearo Entities were referenced in the context of divestiture and acquisition impacts in the Transportation and Electronics segment, where their deconsolidation in 2022 and reconsolidation in 2023 were each reflected separately as divestiture and acquisition effects. This indicates a shift from litigation-focused involvement in 2023 to a more strategic financial treatment in 2024.",
      "llm_answer": "In 2023, after reconsolidating the Aearo Entities, 3M booked a $4.2 billion pre‑tax charge for the CAE Settlement, raised its Combat Arms Earplugs accrual by $4.3 billion and saw corporate‑special‑item costs surge as litigation‑related expenses were reflected in both the Safety & Industrial segment (Aearo‑related respirator‑mask costs) and corporate accounts. By 2024 the settlement was amended to require cash payment of the $1 billion equity portion, corporate‑special‑item costs fell, operating‑margin pressure eased, and the Aearo Entities’ impact was now shown as divestiture/acquisition adjustments in the Transportation & Electronics segment rather than as large litigation charges.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The ground truth states that the reconsolidation of the Aearo Entities in 2023 had an 'immaterial income statement impact,' but the LLM claims 3M booked a $4.2 billion pre-tax charge and raised its accrual by $4.3 billion—these figures are not supported by the original answer and contradict the 'immaterial' characterization. There is no mention in the ground truth of a $1 billion equity portion being amended to cash payment in 2024, nor any indication that corporate-special-item costs 'fell' or margin pressure 'eased'—these are speculative additions. (2) The numbers cited ($4.2B, $4.3B, $1B) are entirely absent from the original answer and appear fabricated. The original makes no mention of respirator-mask costs in the Safety & Industrial segment or allocation of litigation expenses across segments—these are incorrect attributions. (3) While the LLM correctly identifies the reconsolidation in 2023 and the shift to divestiture/acquisition treatment in 2024 in the Transportation & Electronics segment, this correct qualitative point is overshadowed by the false financial figures and erroneous causal claims. The multi-hop synthesis is partially sound—linking Aearo to litigation in 2023 and strategic financial reporting in 2024—but the reasoning is undermined by invented data. (4) The contextual relevance is moderate because the answer addresses litigation impact and business segment adjustments as asked, but the severe quantitative inaccuracies and unsupported claims drastically reduce correctness. The qualitative accuracy is low due to incorrect entity-metric linkages (e.g., assigning costs to wrong segments), though the general timeline and reconsolidation/deconsolidation framing are directionally correct. Final scores reflect major factual errors that invalidate the core of the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 520,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the financial treatment or structure of Class C Common Stock evolved between 2022 and 2024, particularly in terms of its relationship to other stock classes and its earnings per share performance?",
      "original_answer": "In 2022, Class C Common Stock was described in the context of its voting rights and potential influence on corporate actions, particularly in mergers or strategic decisions, with an emphasis on how its holders—typically financial institution clients—might have divergent interests from Class A Common Stockholders. By 2024, Class C Common Stock had a significantly higher earnings per share ($33.17 basic EPS and $33.13 diluted EPS) compared to Class A ($8.29 basic EPS and $8.28 diluted EPS), indicating a shift in its financial performance relative to other stock classes, even though its governance role appeared unchanged.",
      "llm_answer": "In 2022 the filing described Class C common stock as a non‑voting, non‑transferable class whose value was tied to Class A and could only convert after the resolution of litigation, with no public market for the shares (2022 p.34). By 2024 the company had redenominated Class B shares, launched an exchange‑offer that issued unrestricted Class C shares (now part of a 1.1‑billion‑share authorized pool) and retained only limited voting rights on specific matters (2024 p.89‑88). During the same period, Class C earnings‑per‑share rose from about $28 per share in 2022 to roughly $39 per share in 2024 (2022 p.91; 2024 p.90).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative details. (1) Quantitative Accuracy: The EPS figures are incorrect—ground truth reports Class C EPS of $33.17 (basic) and $33.13 (diluted) in 2024, not 'roughly $39'; for 2022, no EPS for Class C is provided in the original answer, yet the LLM claims $28, which is unsupported. These numbers do not align with the ground truth and suggest fabrication or misattribution. (2) Completeness: The question asks about the evolution of financial treatment/structure and EPS performance. The LLM introduces structural changes like redenomination of Class B, exchange offers, and authorization of a 1.1-billion-share pool not mentioned in the original answer, which focuses on governance continuity and EPS divergence. While some structural context is relevant, these specific details are absent from the ground truth and likely incorrect. (3) Entity Accuracy: The years (2022–2024) and stock classes (Class C vs Class A) are correctly identified, and the focus on EPS and governance is appropriate. (4) Reasoning: The multi-hop synthesis is partially sound—comparing Class C to Class A over time is valid—but the reasoning is based on incorrect data. The original answer emphasizes that despite unchanged governance, Class C’s financial performance (EPS) significantly outpaced Class A’s by 2024; the LLM misses this direct comparison and instead fabricates a trend from $28 to $39 without citing Class A’s performance at all. (5) Semantic Equivalence: The LLM diverges substantially in meaning—introducing unverified structural changes and incorrect EPS values—thus failing to convey the same information. The core insight about Class C outperforming Class A financially is hinted at but undermined by inaccuracies. Overall, the answer is partially on-topic but factually unreliable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 501,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Qualcomm's involvement in the development and commercialization of ADAS/AD technology evolved from fiscal 2022 to fiscal 2024, based on the specific changes in their strategic activities and revenue categorization?",
      "original_answer": "In fiscal 2022, Qualcomm was actively investing in and developing ADAS/AD technologies as part of its broader innovation and strategic investment initiatives, particularly through its QSI segment and Qualcomm Ventures, with an emphasis on expanding opportunities for its technologies beyond mobile handsets. By fiscal 2024, Qualcomm's engagement had evolved from development to commercialization, as evidenced by the explicit inclusion of ADAS/AD under revenue streams categorized under 'automotive' products. This indicates that ADAS/AD transitioned from a technology under development and investment in 2022 to a revenue-generating product line by 2024.",
      "llm_answer": "In fiscal 2022 Qualcomm’s filing only mentioned ADAS/AD as a research focus – “…support the design and introduction of new products … for industries and applications beyond mobile handsets, such as ADAS/AD” (p. 14) – and highlighted the strategic purchase of Veoneer’s Arriver business to obtain ADAS/AD technology (p. 74), but it did not report a separate ADAS/AD revenue line. By fiscal 2024 the company is reporting an “Automotive” revenue stream that explicitly includes “connectivity, digital cockpit and ADAS/AD,” with automotive revenue rising from $1.509 billion in 2022 to $2.910 billion in 2024 (p. 73), indicating that Qualcomm has moved from pure development/acquisition to commercializing ADAS/AD products within its automotive sales.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately captures the evolution of Qualcomm's involvement in ADAS/AD from development in fiscal 2022 to commercialization in fiscal 2024. The mention of ADAS/AD as a research focus and the acquisition of Veoneer’s Arriver business in 2022 is factually correct and supported by the cited page numbers. (2) Quantitatively, the LLM correctly reports the automotive revenue figures: $1.509 billion in 2022 and $2.910 billion in 2024 (p. 73), and correctly notes that ADAS/AD was not a separate revenue line in 2022 but was included in the broader 'automotive' category by 2024. These numbers match the ground truth context and are presented accurately with proper formatting. (3) The multi-hop reasoning is sound: the model synthesizes information across years (2022 to 2024), connects strategic activities (acquisition, R&D) with financial categorization changes, and infers commercialization based on revenue reporting — exactly what the question requires. (4) The answer is contextually rich, citing specific document pages and quoting directly where relevant, enhancing credibility. Semantic equivalence is strong: though more detailed than the original answer, it conveys the same core conclusion — transition from development to commercialization — with added quantitative and evidentiary support. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 396,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Visa's U.S. Retrospective Responsibility Plan evolved between 2022 and 2024, particularly in terms of its mechanisms for addressing liability in covered litigation, and what does this evolution suggest about the company's approach to managing litigation risk?",
      "original_answer": "In 2022, Visa's U.S. Retrospective Responsibility Plan was described as a mechanism to address monetary liabilities from settlements or final judgments in U.S. covered litigation, utilizing a U.S. litigation escrow account, though the accrual for liabilities could differ from the escrow balance. By 2024, the plan had become significantly more structured and detailed, introducing a suite of interrelated mechanisms including a U.S. litigation escrow agreement, a conversion feature for Class B common stock, makewhole agreements related to the Class B-1 exchange offer, indemnification obligations from Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. These additions indicate a more comprehensive and layered strategy to manage litigation risk, suggesting Visa has moved toward a more proactive and diversified approach to mitigate potential financial exposure from ongoing or future litigation outcomes.",
      "llm_answer": "In the 2022 filing Visa’s U.S. Retrospective Responsibility Plan was described mainly as a **U.S. litigation escrow account** (to which the company deposited $850 million in fiscal 2022, with a $1.4 billion balance) and a **loss‑sharing agreement** that reduced its exposure to certain lawsuits 【page_46】. By the 2024 filing the plan had been expanded into a **multi‑component framework** that still includes the escrow agreement but now also incorporates a **conversion feature on class B shares**, **make‑whole agreements** tied to the class‑B exchange offer, **indemnification obligations of Visa U.S.A. members**, an **interchange judgment‑sharing agreement**, a **loss‑sharing agreement**, and an **omnibus agreement** that allocates settlement amounts between Visa and Mastercard 【page_72】【page_73】【page_74】. This evolution shows Visa has moved from a relatively simple escrow‑based shield to a more sophisticated, layered structure that combines funding, equity‑dilution, contractual indemnities and sharing arrangements, indicating a proactive and increasingly granular approach to managing and containing litigation risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) It correctly identifies the evolution of Visa's U.S. Retrospective Responsibility Plan from a simpler structure in 2022—centered on the U.S. litigation escrow account and loss-sharing agreement—to a more complex, multi-component framework by 2024. The inclusion of specific mechanisms such as the conversion feature for Class B shares, make-whole agreements, indemnification obligations, interchange judgment-sharing agreement, loss-sharing agreement, and omnibus agreement matches the original answer. (2) Quantitatively, the LLM adds specific dollar figures ($850 million deposited in fiscal 2022, $1.4 billion balance) not present in the ground truth. Since these numbers are plausible and do not contradict the knowledge graph (which only confirms the existence of the escrow account and potential mismatch between accruals and balance), their inclusion does not constitute a factual error but rather adds detail likely from the actual filing. No incorrect calculations are made. (3) The multi-hop reasoning is sound: the model synthesizes changes over time (2022 vs 2024), identifies structural shifts in risk management mechanisms, and draws a valid conclusion about Visa’s increasingly proactive and granular approach. (4) The semantic meaning and depth of analysis are equivalent to the original answer, with slightly more operational detail. The only minor shortcoming is the lack of explicit mention that the 2022 accrual could differ from the escrow balance—a nuance in the ground truth—but this does not undermine the overall correctness. Hence, the answer earns a 9/10 for correctness, with high marks across all dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1556,
        "completion_tokens": 465,
        "total_tokens": 2021
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did Merck's financial stake in Lynparza evolve between 2023 and 2024, and what indicators suggest changes in the product's performance or strategic importance during this period?",
      "original_answer": "In 2023, Merck reported a $1.5 billion net intangible asset related to Lynparza as part of its collaboration with AstraZeneca. By 2024, although the financial stake amount was not explicitly stated, there was a 9% growth in alliance revenue linked to Lynparza, driven by increased demand in most international markets. Additionally, in January 2025, Lynparza received approval in China for an adjuvant treatment in early breast cancer, indicating expanded market potential. This suggests that while the initial asset value was substantial in 2023, 2024 marked a period of performance-driven growth and regulatory expansion, enhancing its strategic importance.",
      "llm_answer": "Merck’s share of Lynparza’s profits grew from $1.199 billion in 2023 to $1.311 billion in 2024 – a 9 % rise (11 % when foreign‑exchange effects are excluded)【page_53】.  The 2023 filing shows Lynparza represented roughly $1.5 billion of Merck’s net “licenses and other” intangible assets, highlighting its strategic significance【page_101】, and the 2024 discussion notes that the alliance‑revenue increase was driven by higher demand in most international markets and a new Chinese regulatory approval for an adjuvant indication, indicating both stronger performance and growing importance of the product【page_55】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely correct and aligns well with the ground truth. It accurately reports Merck's $1.5 billion net intangible asset related to Lynparza in 2023, matching the original answer. While the original answer does not specify Merck’s exact profit share in 2023 or 2024, the LLM provides precise figures of $1.199 billion (2023) and $1.311 billion (2024), representing a 9% increase — which is consistent with the '9% growth in alliance revenue' cited in the ground truth. The additional detail about 11% growth excluding foreign exchange effects is a minor enhancement not contradicted by the original. The LLM correctly identifies the driver of revenue growth (increased international demand) and the January 2025 China approval for an adjuvant indication, which signals expanded market potential and strategic importance. (2) Quantitatively, all numbers are accurate or reasonably inferred: $1.5 billion intangible asset (exact match), 9% revenue growth (exact match), and correct profit figures that support the stated growth rate. The calculation from $1.199B to $1.311B is indeed approximately 9.3%, which rounds to 9% — acceptable given reporting conventions. (3) The multi-hop reasoning is sound: the model synthesizes data from both years, connects financial stake evolution with performance indicators (revenue growth, regulatory approval), and correctly attributes strategic importance. The only minor gap is that the original answer notes the 2024 financial stake was 'not explicitly stated,' whereas the LLM presents the $1.311B figure confidently — this introduces a slight overprecision, but since the number is plausible and supports the same conclusion, it does not constitute a factual error. (4) Scores reflect high accuracy across all dimensions: near-perfect quantitative alignment, strong qualitative reasoning, and full contextual relevance to the question about financial stake evolution and performance indicators.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 530,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did Skoal's market position and competitive performance within Altria's oral tobacco products segment evolve between 2022 and 2024, particularly in relation to its key competitor brands?",
      "original_answer": "In 2022, Skoal was one of the premium oral tobacco brands under Altria, alongside Copenhagen and on!, with a retail share of 9.3%. By 2024, Skoal's retail share had declined to 7.6%, indicating a weakening market position. This decline occurred alongside a broader contraction in Altria's oral tobacco segment, which saw total retail share fall from 42.5% in 2023 to 37.5% in 2024. Notably, Copenhagen, Altria's leading brand, also experienced a drop from 23.5% to 19.1% over the same period, while on! oral nicotine pouches gained traction, rising from 6.8% to 8.3%. These shifts suggest that Skoal not only lost market share overall but also underperformed relative to both its primary brand (Copenhagen) and the newer product category (on!).",
      "llm_answer": "In the 2022 filing Skoal was listed as one of USSTC’s premium moist‑snuff brands (alongside Copenhagen) that helped keep the oral‑tobacco segment’s total shipment volume flat at about 820 million units year‑over‑year. By 2024, Skoal’s performance had weakened – shipment volume fell to 147 million cans/packs (down from 163 million in 2023) and its retail share dropped to 7.6% (from 9.3% in 2023), ceding ground to Copenhagen (still the segment leader at 19.1% share) and to the fast‑growing on! nicotine‑pouch brand (up to 8.3% share), prompting modest price hikes on Skoal in 2023‑24.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution of Skoal's market position between 2022 and 2024, with accurate key metrics and competitive dynamics. Quantitatively, the 2022 retail share of 9.3% and 2024 share of 7.6% are correctly reported, matching the ground truth. The rise of on! from 6.8% to 8.3% and Copenhagen's decline to 19.1% in 2024 are also accurate. However, the LLM incorrectly states Skoal's 2023 shipment volume as 163 million and 2024 as 147 million, which are not in the original answer and introduce unverified data. Additionally, the original answer notes Altria's total oral tobacco segment share fell from 42.5% in 2023 to 37.5% in 2024—a key contextual point about segment-wide contraction that the LLM omits. The LLM also references '2022 filing' and '2023-24 price hikes' not present in the ground truth, adding plausible but unsupported details. Despite these issues, the core multi-hop reasoning—Skoal losing share, underperforming relative to Copenhagen and on!—is sound and semantically aligned. The answer addresses market position evolution and competitive performance, making it contextually relevant. Minor omissions and extraneous details prevent a top score, but factual correctness on key percentages and trends justifies a high 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 358,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has the revenue contribution from Dynamics 365 within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Dynamics 365 contributed to the $91.2 billion Microsoft Cloud revenue, with Dynamics products and cloud services revenue growing 25%, driven by a 39% increase in Dynamics 365. By fiscal year 2023, the Microsoft Cloud revenue had increased to $111.6 billion, which includes Dynamics 365 as a component. Although the exact growth percentage for Dynamics 365 in 2023 is not explicitly stated, its continued inclusion in the Microsoft Cloud breakdown indicates sustained growth and integration within the broader cloud portfolio.",
      "llm_answer": "Dynamics 365 (reported as “Dynamics products and cloud services”) generated $4.687 billion in fiscal 2022 and rose to $5.437 billion in fiscal 2023 – an increase of roughly $750 million, or about 16% year‑over‑year【page_93】. That growth helped lift total Microsoft Cloud revenue from $91.4 billion in FY 2022 to $111.6 billion in FY 2023【page_93】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer provides specific revenue figures for Dynamics 365 in FY2022 ($4.687B) and FY2023 ($5.437B), claiming a 16% year-over-year increase. However, the original answer (ground truth) does not provide exact revenue numbers for Dynamics 365 in either year, only stating that Dynamics 365 grew 39% in FY2022 and was a component of the $91.2B (FY2022) and $111.6B (FY2023) Microsoft Cloud revenues. The LLM's precise dollar amounts and 16% growth rate are not supported by the ground truth, making them factually incorrect. (2) The LLM incorrectly states Microsoft Cloud revenue was $91.4B in FY2022; the correct figure is $91.2B. While the $111.6B for FY2023 is accurate, the cited $750M increase in Dynamics 365 revenue (from $4.687B to $5.437B) implies a ~16% growth, which contradicts the ground truth's 39% growth in FY2022 and lack of explicit growth rate for FY2023. (3) The reasoning is partially sound in linking Dynamics 365 to Microsoft Cloud revenue growth, but it fabricates precise figures not present in the original data, failing the multi-hop synthesis correctly—especially since the ground truth does not break out Dynamics 365 revenue in absolute dollars. (4) The contextual relevance is high because the answer addresses the evolution of Dynamics 365 revenue within Microsoft Cloud, but the quantitative inaccuracies severely undermine correctness. The qualitative score reflects correct entity identification (Dynamics 365, Microsoft Cloud, correct fiscal years) but flawed inference. Thus, the overall correctness is low due to unsupported numerical claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 438,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Merck's approach to managing foreign exchange exposure through its Balance Sheet Risk Management Program evolved from 2023 to 2024, particularly in terms of the instruments used and the scope of hedging activities?",
      "original_answer": "In 2023, Merck primarily used forward exchange contracts to offset the effects of exchange on exposures when economically beneficial, focusing on the euro, Swiss franc, Japanese yen, and Chinese renminbi. These contracts were not designated as hedges and were marked to market through Other (income) expense, net. By 2024, the company expanded its approach under a more structured balance sheet risk management program, continuing to use forward contracts but also introducing a broader framework that included purchased local currency put options and collar options. Additionally, the 2024 disclosure highlights a more strategic layering of hedges over time, increasing the portion of forecasted sales hedged as the expected dates approach, based on cost-benefit assessments.",
      "llm_answer": "In the 2023 filing Merck’s balance‑sheet risk‑management program relied mainly on forward exchange contracts (recorded as non‑designated hedges and marked‑to‑market through other‑income) to offset transaction‑type FX exposure, supplemented by purchased local‑currency put and collar options, and a smaller set of forward contracts designated as net‑investment hedges plus euro‑denominated notes used as economic hedges (see 2023 pages 94‑97). By 2024 the company still uses forward contracts as the primary tool but has broadened the currency coverage to include the Swiss franc, increased the notional amounts of both designated and non‑designated forwards, and retained the same accounting treatment—non‑designated forwards continue to flow through other‑income while designated net‑investment forwards are recorded in OCI—signalling a larger scope of hedging activity (see 2024 pages 95‑99).",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains a mix of correct and incorrect information, with significant deviations from the ground truth in key aspects of Merck's evolution in foreign exchange risk management from 2023 to 2024. (1) What was correct: The answer correctly identifies that forward exchange contracts were a primary instrument in both years and that non-designated forwards were marked to market through income (Other (income) expense, net), consistent with the original answer. It also correctly notes expanded currency coverage and increased hedging activity in 2024, which aligns with the broader scope mentioned in the ground truth. (2) Quantitative accuracy: There are no explicit numerical values (e.g., notional amounts, percentages) in either the original or LLM answer, so no numeric inaccuracies are present. However, the LLM introduces the claim of 'increased notional amounts' and 'broader currency coverage' without direct support in the original answer, which only specifies the currencies hedged in 2023 (euro, Swiss franc, yen, renminbi) and does not state that Swiss franc was newly added in 2024—this misrepresents the evolution. (3) Multi-hop reasoning assessment: The LLM incorrectly states that in 2023, Merck already used 'purchased local currency put and collar options'—this directly contradicts the original answer, which states these instruments were introduced in 2024. This is a critical factual error. Additionally, the mention of 'designated net-investment hedges' and 'euro-denominated notes as economic hedges' in 2023 is not supported by the original answer, which makes no reference to such instruments or accounting treatments. The 2024 description also fails to mention the strategic layering of hedges over time and cost-benefit assessments, a key qualitative evolution in the program. (4) Justification for scores: Correctness is scored 5 due to partial accuracy on instruments and scope but major errors in attributing 2024 innovations (options, structured framework) to 2023. Quantitative accuracy is 6 because while no numbers are wrong, the answer fabricates details (e.g., notional increases) not in the source. Qualitative accuracy is 5 due to flawed reasoning in timeline and instrument evolution. Contextual relevance is 8 because the answer stays on topic and addresses the question’s structure, despite factual inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 627,
        "total_tokens": 2064
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has PayPal's involvement with merchant receivables evolved between 2022 and 2024, particularly in terms of its credit loss provisions and direct investment in merchant financing products?",
      "original_answer": "In 2022, PayPal disclosed its methodology for estimating credit losses on merchant receivables, applying macroeconomic forecasts and historical loss data to calculate allowances, with a principal and interest coverage ratio of approximately 9% as of December 31, 2021, down from 23% in 2020. By 2024, PayPal had significantly expanded its direct involvement by purchasing approximately $1.8 billion in merchant receivables during the year, with an outstanding balance of $1.5 billion as of December 31, 2024, up from $1.2 billion in 2023. This represents a shift from primarily disclosing credit risk exposure to actively investing in and managing merchant receivables through products like PPWC and PPBL, indicating a more strategic and operational role in merchant finance.",
      "llm_answer": "In 2022 PayPal’s allowance for merchant loans and advances was $248 million (merchant loans $230 M + interest $18 M) and it recorded $42 million of gross charge‑offs on those receivables (see page 103 for the $230 M/​$18 M beginning balance and page 102 for the $42 M charge‑off). By the end of 2024 the allowance had fallen to $113 million (merchant loans $107 M + interest $6 M) and charge‑offs dropped to $10 million, while PayPal’s direct investment in merchant financing grew to $1.8 billion of merchant receivables purchased in 2024 (up from $1.7 billion in 2023) (page 103 for the $107 M/​$6 M ending balance and page 101 for the $1.8 B purchase amount). This reflects a shift toward lower credit‑loss provisioning and a larger deployment of capital into merchant‑financing products.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in key quantitative details. The ground truth states that PayPal purchased approximately $1.8 billion in merchant receivables in 2024, with an outstanding balance of $1.5 billion as of December 31, 2024, up from $1.2 billion in 2023. However, the LLM claims $1.8 billion was purchased in 2024 (partially correct) but incorrectly states that $1.7 billion was purchased in 2023—this figure is not in the ground truth and contradicts it. The ground truth does not mention 2023 purchase volume, only the outstanding balance. Additionally, the LLM introduces specific allowance figures ($248M in 2022, $113M in 2024) and charge-off amounts ($42M, $10M) that are not present in the original answer and cannot be verified against the ground truth. The principal and interest coverage ratio of 9% (down from 23% in 2020) as of December 31, 2021, is entirely omitted. (2) The calculation of allowances as sums of merchant loans and interest is plausible but unsupported by the ground truth, which does not break down allowances this way or provide those component numbers. The drop in allowances and charge-offs is a reasonable inference if supported, but these specific numbers appear fabricated. (3) The qualitative reasoning about a strategic shift toward active investment in merchant financing is consistent with the ground truth and correctly identifies the evolution from risk disclosure to direct involvement, citing products like PPWC and PPBL (implied in the original). The synthesis of lower provisioning and increased capital deployment reflects a sound interpretation of trend direction, even if numbers are flawed. (4) Contextual relevance is high—the answer addresses both credit loss provisions and direct investment, the two core parts of the question, and attempts multi-hop reasoning across years and financial metrics. However, the introduction of unverified figures and incorrect year-over-year comparisons undermines factual correctness. The answer gives a plausible narrative but fails on key quantitative accuracy, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 570,
        "total_tokens": 1973
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the financial significance of smokeable products to MO evolved from 2022 to 2024, considering both goodwill allocation and operating income performance?",
      "original_answer": "In 2022, the goodwill allocated to smokeable products was $99 million, indicating a relatively small portion of MO's overall asset valuation, with total goodwill at $5,177 million. By 2024, although no updated goodwill figure is disclosed specifically for smokeable products, their operating income contribution rose to $10,821 million in 2024 from $10,670 million in 2023, showing sustained profitability. This suggests that while the strategic asset valuation (via goodwill) remained stable or undisclosed, the operational significance of smokeable products remained high and slightly increased in terms of earnings. The lack of updated goodwill allocation in 2024 filings for this segment implies a potential shift in reporting focus toward performance metrics rather than asset valuations.",
      "llm_answer": "Altria’s 2022 filing shows that the smokeable‑products segment carried $99 million of goodwill (and essentially no change thereafter) – the same amount reported in the 2024 filing (Note 4, p. 66).  At the same time, the segment’s operating income (OCI) rose modestly, from roughly $10.7 billion in the prior year (2023) to $10.821 billion in 2024 (p. 31), indicating that while the goodwill base has stayed flat, the smokeable business continues to generate slightly higher earnings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the $99 million goodwill for smokeable products in both 2022 and 2024, aligning with the ground truth that 2022 had $99M and no updated 2024 goodwill was disclosed—though the LLM interprets this as 'no change' and explicitly states the same amount is reported in 2024, which is consistent with available data. The operating income figures are accurate: $10.821 billion in 2024 (correctly cited) and the prior year (2023) at $10.7 billion, which matches the ground truth's $10,670 million (i.e., $10.67 billion), with 'roughly $10.7 billion' being a reasonable rounding. (2) All numbers are quantitatively accurate, with appropriate unit conversions (e.g., $10,821 million = $10.821 billion) and correct years. (3) The multi-hop reasoning is sound: the model synthesizes goodwill data across years and combines it with operating income trends to assess financial significance, concluding that earnings increased while goodwill remained flat—this mirrors the ground truth’s inference. The only minor gap is that the original answer notes total goodwill was $5,177 million in 2022 (context for relative size), which the LLM omits, slightly reducing completeness. Also, the LLM does not mention the potential shift in reporting focus implied by unchanged disclosures, a qualitative nuance in the original. (4) Despite these small omissions, the core facts, numbers, and logic are correct, and the answer effectively addresses the evolution from 2022 to 2024 using both goodwill and operating income. Thus, correctness is high but not perfect due to missing contextual depth on total goodwill and reporting trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 453,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the revenue contribution from the commercial portion of LinkedIn within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Microsoft Cloud revenue, which includes the commercial portion of LinkedIn, was reported at $91.2 billion. By fiscal year 2023, this figure had increased to $111.6 billion, indicating a significant growth in the commercial cloud segment that includes LinkedIn. This increase suggests a stronger revenue contribution from LinkedIn's commercial services within the broader Microsoft Cloud portfolio.",
      "llm_answer": "Microsoft Cloud revenue – which bundles Azure, Office 365 Commercial, the commercial portion of LinkedIn, Dynamics 365 and other cloud properties – rose from **$91.2 billion in FY 2022** to **$111.6 billion in FY 2023**, a jump of roughly $20 billion (about a 22 % increase)【page_96†L14-L18】【page_93†L23-L27】. This growth indicates a markedly larger contribution from the commercial LinkedIn segment within the overall cloud business.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the revenue figures for fiscal years 2022 ($91.2 billion) and 2023 ($111.6 billion) are accurate, and the implied increase of $20.4 billion is correctly represented as 'roughly $20 billion'. The calculated growth rate of approximately 22% (from $91.2B to $111.6B) is mathematically sound: (111.6 - 91.2) / 91.2 ≈ 0.2236 or 22.36%, which rounds to the stated ~22%. (2) The answer is complete, addressing the evolution of revenue contribution from the commercial portion of LinkedIn within Microsoft Cloud across the two fiscal years, even though LinkedIn is not broken out individually—consistent with the original answer’s approach of inferring increased contribution based on overall Microsoft Cloud growth. (3) Entity accuracy is correct: Microsoft Cloud, LinkedIn's commercial portion, and the correct fiscal years (2022 and 2023) are properly identified. (4) The reasoning is sound: while LinkedIn’s standalone revenue isn’t disclosed, the answer correctly infers that its commercial segment contributed to the overall Microsoft Cloud growth, which aligns with the multi-hop logic used in the ground truth. (5) Semantic equivalence is maintained—the LLM provides additional context (components of Microsoft Cloud) and a clearer percentage increase, enhancing clarity without introducing error. All citations reference appropriate document locations, further supporting accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 406,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did the commercialization and market expansion of Lynparza evolve between 2023 and 2024, particularly in terms of geographic approvals and revenue growth?",
      "original_answer": "In 2023, Lynparza received FDA and Japan's MHLW approvals for treating BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone and prednisone or prednisolone, based on the PROpel trial. By 2024, alliance revenue related to Lynparza grew by 9%, largely due to higher demand in most international markets. Additionally, in January 2025, Lynparza received China's NMPA approval for adjuvant treatment of germline BRCA-mutated, HER2-negative high-risk early breast cancer, based on the OlympiA trial, indicating a significant geographic and therapeutic area expansion.",
      "llm_answer": "In 2023 Lynparza’s rollout was anchored by two new geographic clearances – an FDA approval in the United States and a Japanese MHLW approval (both for the abiraterone‑based mCRPC indication) 【page_7】. By 2024 the product’s alliance revenue had risen 9 % to $1.311 billion, driven by “higher demand in most international markets” as Lynparza was marketed for several cancer types worldwide 【page_53】【page_55】, showing a clear expansion of both its geographic footprint and sales.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 FDA and MHLW (Japan) approvals for Lynparza in mCRPC with abiraterone, and the 9% revenue growth in 2024, which aligns with the ground truth. The $1.311 billion revenue figure is accurate and contextually consistent with the 9% growth, though the original answer does not specify the dollar amount—this is an addition from the LLM but not incorrect. However, the LLM omits the January 2025 China NMPA approval for early breast cancer, which is a key part of the geographic and therapeutic expansion mentioned in the original answer. This omission reduces completeness. (2) Quantitatively, the 9% revenue growth and the $1.311 billion figure are accurate and match the source data. Dates (2023 approvals, 2024 revenue growth) are correct. The LLM does not misstate any numbers or introduce errors in calculation. (3) The reasoning is sound in linking the 2023 approvals to market expansion and connecting 2024 revenue growth to international demand. However, the multi-hop synthesis is incomplete because it fails to incorporate the 2025 China approval, which represents a forward-looking but documented expansion (filed in early 2025 based on OlympiA). This limits the full evolution narrative across 2023–2024 into early 2025. (4) The answer is highly relevant, well-structured, and directly addresses the question’s focus on geographic approvals and revenue growth. The omission of the China approval prevents a perfect score, but core facts and synthesis are strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 421,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, particularly in terms of its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was noted as a reduction in sales, indicating a negative financial impact. By 2024, the Powder Metal Matter was specifically listed under future income tax benefits at $455 million, down from $644 million in 2023, showing a shift in its financial treatment from a sales reduction to a recognized tax benefit. This represents a decrease of $189 million, or about 29.3%, in its value contribution to future tax benefits.",
      "llm_answer": "In 2023 RTX recorded the Powder Metal Matter as a distinct sales reduction – a $5.4 billion negative line in the Pratt & Whitney segment (see the “Powder Metal Matter” entry in the 2023 segment table) – and it generated a $644 million deferred‑tax asset for future income‑tax benefits. By the 2024 filing the sales line no longer appears, and the deferred‑tax asset tied to the Powder Metal Matter fell to $455 million, indicating a smaller expected future tax benefit.【page_110】【page_98】",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the $644 million deferred tax asset in 2023 and $455 million in 2024 are accurately reported, and the decrease of $189 million is implied (644 - 455 = 189), though not explicitly stated. The percentage decrease (29.3%) is not mentioned, but this is a minor omission. The $5.4 billion sales reduction in 2023 is an additional detail not in the original answer but consistent with plausible context (e.g., segment-level impact), and does not contradict the ground truth. (2) The shift in financial treatment—from a sales reduction in 2023 to a deferred tax asset (future income tax benefit) in 2024—is correctly identified and synthesized across years, demonstrating sound multi-hop reasoning. (3) Entities (RTX, Powder Metal Matter, years 2023 and 2024, future income tax benefits/deferred tax assets) are correctly identified. (4) The answer is contextually relevant and directly addresses the evolution in financial treatment and impact on future tax benefits. The only minor shortcoming is the lack of explicit calculation of the $189 million decrease or the 29.3% decline, which were present in the original answer. However, the core facts, numbers, and reasoning are correct, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 367,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did the borrowing capacity and terms of the Paidy Credit Agreement evolve from 2022 to 2024?",
      "original_answer": "In 2022, the Paidy Credit Agreement provided a secured revolving credit facility of approximately $198 million, with $98 million outstanding as of December 31, 2021. By 2024, the Paidy Credit Agreement had been modified to increase the borrowing capacity to ¥90.0 billion (approximately $574 million as of December 31, 2024), and it was restructured as an unsecured facility. The interest rate also changed from unspecified terms in 2022 to a rate based on the Tokyo Interbank Offered Rate plus a margin ranging from 0.40% to 0.60% in 2024. The maturity date was set for February 2027, and the agreement now includes a financial covenant requiring a maximum consolidated leverage ratio.",
      "llm_answer": "In the 2022 Form 10‑K the Paidy Credit Agreement was described as a **secured revolving credit facility of about $198 million**, with roughly **$100 million of borrowing capacity still available** as of Dec 31 2021【page_50】.  \nBy the 2024 filing the same agreement (originally entered Feb 2022) had been **re‑structured as an unsecured revolving facility of ¥60 billion that was amended in Sep 2022 to ¥90 billion (≈ $574 million)**, with interest **at TIBOR + a margin of 0.40 %–0.60 %** and a maturity in Feb 2027; the facility was fully drawn by year‑end 2024, leaving **no borrowing capacity remaining**【page_105】【page_106】.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution of the Paidy Credit Agreement from 2022 to 2024, with accurate synthesis across filings. However, there are minor discrepancies in quantitative details and one significant omission. (1) In 2022, the original answer states $98 million was outstanding as of December 31, 2021, implying $100 million available from a $198 million facility — the LLM correctly infers available capacity but rounds up to $100 million (acceptable approximation). (2) The LLM states the 2024 facility was 'amended in Sep 2022 to ¥90 billion' — this is factually problematic because the amendment date (Sep 2022) precedes the 2024 filing context and may misrepresent the timeline; the ground truth does not specify when the increase occurred, so citing Sep 2022 introduces unsupported detail. (3) The conversion of ¥90 billion to $574 million is consistent with the original answer (using Dec 31, 2024 FX rate), so this is accurate. (4) The interest rate (TIBOR + 0.40%–0.60%), maturity (Feb 2027), and shift to unsecured status are all correctly reported. (5) The LLM adds that the facility was 'fully drawn by year-end 2024, leaving no borrowing capacity' — this is not mentioned in the ground truth and is an unsupported inference, constituting a factual overreach. (6) The original answer notes the addition of a financial covenant (maximum consolidated leverage ratio), which the LLM omits entirely — this is a notable qualitative gap in completeness. Despite these issues, the core multi-hop reasoning — comparing the 2022 and 2024 terms across capacity, security, interest rate, and maturity — is sound and contextually relevant. Wording differences are acceptable under semantic equivalence, but missing the covenant and introducing unverified details (amendment date, full drawdown) prevent a top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 499,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Altria's reliance on long-term senior unsecured notes as part of its capital resources evolved between 2022 and 2024?",
      "original_answer": "In 2022, Altria's capital resources included access to credit markets through the issuance of long-term senior unsecured notes, along with $4.5 billion in cash and cash equivalents. By 2024, Altria continued to rely on long-term senior unsecured notes as a key source of capital, but its cash and cash equivalents decreased to $3.1 billion. While the company maintained its $3.0 billion Credit Agreement and continued to use similar capital instruments, the reduction in cash reserves suggests a potentially increased reliance on external financing mechanisms, including long-term senior unsecured notes, to support its operations and strategic initiatives such as dividend payments, share repurchases, and debt repayment.",
      "llm_answer": "In the 2022 Form 10‑K Altria still emphasized that a key component of its capital resources was the ability to issue long‑term senior unsecured notes – it had issued $5.5 billion of such notes in 2020‑21 and used the proceeds to fund the purchase and redemption of other senior notes. By the 2024 filing the company’s financing mix had shifted: it was repaying senior notes (about $1.1 billion in Q1 2024) and had no new senior‑note issuances (the next issue is slated for 2025), relying more on cash, commercial paper and its $3 billion revolving credit facility, indicating a reduced reliance on long‑term senior unsecured notes.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly undermine its correctness. (1) Quantitative Accuracy: The claim that Altria issued $5.5 billion in long-term senior unsecured notes in 2020–21 is not supported by the ground truth, which does not specify issuance amounts for those years. The mention of $1.1 billion in repayments in Q1 2024 and a 2025 planned issuance is absent from the original answer and introduces unverified details. The ground truth reports cash and cash equivalents decreasing from $4.5 billion in 2022 to $3.1 billion in 2024, but the LLM answer omits these key figures entirely. (2) Completeness: While the question asks about the evolution of Altria’s reliance on long-term senior unsecured notes between 2022 and 2024, the LLM incorrectly concludes a 'reduced reliance' due to no new issuances and increased use of commercial paper and credit facilities—this contradicts the original answer, which states that long-term senior unsecured notes remained a key capital source and suggests potentially increased reliance due to lower cash reserves. (3) Entity Accuracy: The company (Altria) and financial instruments (long-term senior unsecured notes, credit agreement) are correctly identified, and the time frame (2022–2024) is appropriately addressed. (4) Reasoning: The multi-hop reasoning is flawed—the LLM infers reduced reliance based on repayment activity and lack of new issuances, but fails to connect the reduction in cash reserves (a key point in the original answer) that would imply greater dependence on external financing. Instead, it incorrectly suggests a shift away from long-term notes. (5) Semantic Equivalence: The overall conclusion is opposite to the ground truth: the original answer suggests stable or increased reliance on long-term notes due to lower cash, while the LLM claims reduced reliance. This fundamental contradiction results in a low correctness score despite some contextual relevance and proper identification of financial instruments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 541,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, and what does this indicate about its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter contributed $644 million to RTX's future income tax benefits. By 2024, this amount decreased to $455 million, indicating a reduced financial benefit from the Powder Metal Matter over time. This decline suggests a diminishing positive impact on RTX's tax position related to this factor.",
      "llm_answer": "In the 2023 Form 10‑K RTX booked the Powder Metal Matter as a one‑time charge – a $5.4 billion net‑sales reduction (page 36) that also produced a $2.9 billion pretax loss and a $2.5 billion cost‑of‑sales reduction (page 38), which lowered the effective tax rate by about 4 percentage points (page 40). By the 2024 filing the company had moved the remaining tax effect into a deferred‑tax asset, showing a future income‑tax benefit of $455 million (down from $644 million in 2023, page 98), indicating that the large immediate charge has been absorbed and the tax advantage is now being recognized over time and is diminishing as the temporary differences are utilized.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the decrease in future income tax benefits from $644 million in 2023 to $455 million in 2024, which matches the ground truth and addresses the core of the question. However, the LLM introduces additional details not present in the ground truth—specifically, a $5.4 billion net-sales reduction, $2.9 billion pretax loss, $2.5 billion cost-of-sales reduction, and a 4 percentage point reduction in the effective tax rate—which, while possibly accurate from the filing, are not part of the original answer and distract from the focus on future income tax benefits. (2) The key numbers related to future tax benefits ($644M and $455M) are quantitatively accurate and correctly compared as decreasing over time. However, the additional figures (e.g., $5.4B, $2.9B) lack verification in the ground truth and may represent misinterpretation or over-extrapolation from the source document. There is no indication in the ground truth that the 2023 amount was due to a 'one-time charge' or that it was 'absorbed'—these are interpretive additions. (3) The multi-hop reasoning is partially sound: the model connects the change in deferred tax asset between years and infers a diminishing future benefit, which aligns with the ground truth’s conclusion. However, the causal narrative about moving from an immediate charge to deferred recognition goes beyond the provided truth and assumes knowledge of accounting treatment not required or confirmed by the ground truth. (4) The contextual relevance is high because the answer directly addresses the evolution of the tax benefit and its implication for future income taxes. The qualitative accuracy is good due to correct entity (RTX, Powder Metal Matter), years (2023–2024), and direction of change. The correctness score is 7 because the core financial trend is accurate and complete, but the inclusion of unverified, detailed financial impacts reduces quantitative accuracy despite correct key numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 535,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has PayPal's utilization of the Paidy Credit Agreement evolved between 2022 and 2024, particularly in terms of borrowing capacity and actual drawdown?",
      "original_answer": "In 2022, PayPal had approximately $198 million in borrowing capacity under the Paidy Credit Agreement, with $98 million outstanding as of December 31, 2021, leaving about $100 million available. By 2024, the borrowing capacity had increased to approximately $574 million (¥90.0 billion), and the full amount was drawn down, leaving no borrowing capacity available. This reflects a significant increase in both the scale of the facility and PayPal's reliance on it over the period.",
      "llm_answer": "In the 2022 filing the Paidy Credit Agreement was a secured revolving facility of roughly $198 million, with about $98 million already drawn and roughly $100 million of borrowing capacity still available 【page_110】. By the 2024 filing the facility had been enlarged to ¥90 billion (≈ $574 million) and the entire amount was drawn down in 2024, leaving no unused borrowing capacity 【page_45】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $198 million borrowing capacity in 2022, $98 million drawn (leaving ~$100 million available), and an increase to ¥90 billion (≈$574 million) in 2024 with full drawdown. The conversion from yen to dollars is consistent with the original answer. (2) The answer addresses all parts of the question—evolution of borrowing capacity and actual drawdown between 2022 and 2024—demonstrating completeness. (3) Entities are correctly identified: PayPal (via Paidy Credit Agreement), correct years (2022 and 2024), and accurate financial terms (borrowing capacity, drawn amount). (4) The reasoning is sound and reflects proper multi-hop synthesis: it compares the size and utilization of the credit facility across two time points, correctly inferring increased reliance on the facility. Minor wording differences (e.g., 'enlarged' vs 'increased') do not affect semantic equivalence. The inclusion of source page references adds precision. Overall, the answer is factually accurate, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 320,
        "total_tokens": 1540
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the ownership structure and equity relationship between Accenture plc and Accenture Canada Holdings Inc. evolved from 2023 to 2024, particularly regarding noncontrolling interests and exchangeable shares?",
      "original_answer": "In 2023, the noncontrolling ownership interests in Accenture Canada Holdings Inc. held by certain current and former members of Accenture Leadership were less than 1% as of August 31, 2024. By 2024, the structure had evolved to include detailed provisions around Accenture Canada Holdings Inc. exchangeable shares, which can be exchanged for Accenture plc Class A ordinary shares on a one-for-one basis or redeemed for cash. Additionally, Accenture plc Class X ordinary shares were tied directly to these exchangeable shares, with a restriction ensuring the number of Class X shares does not fall below the number of exchangeable shares held. This indicates a more formalized and structured equity relationship in 2024 compared to the simpler noncontrolling interest disclosure in 2023.",
      "llm_answer": "In the 2023 filing Accenture plc disclosed that the only ownership stake in its subsidiary Accenture Canada Holdings Inc. held by current and former members of Accenture Leadership was a “non‑controlling interest” of less than 1 percent of the subsidiary (see page 20). By the 2024 filing the relationship is defined through “exchangeable shares” issued by Accenture Canada Holdings Inc. that may be swapped on a one‑for‑one basis for Accenture plc Class A ordinary shares (or cash) and are covered by a share‑purchase/redemption program, while the non‑controlling interest remains under 1 percent (see pages 100‑101).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and percentages are correct: the noncontrolling interest is accurately reported as 'less than 1 percent' in both 2023 and 2024, and the one-for-one exchange ratio between Accenture Canada Holdings Inc. exchangeable shares and Accenture plc Class A ordinary shares is correctly stated. The mention of cash redemption is also factually consistent. (2) The LLM correctly identifies the evolution from a simple noncontrolling interest disclosure in 2023 to a more structured equity mechanism in 2024 involving exchangeable shares and associated programs. (3) The multi-hop reasoning is sound: it connects ownership structure changes across years and entities (Accenture plc and its Canadian subsidiary), correctly synthesizing information about equity instruments and their implications. (4) The only minor omission is the absence of mention of Accenture plc Class X ordinary shares, which are explicitly tied to the exchangeable shares in the ground truth and serve as a voting or control mechanism ensuring alignment. While this detail adds structural nuance, its absence does not undermine the core factual accuracy of the equity evolution described. Wording differs slightly but maintains semantic equivalence. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 394,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has Merck's approach to managing balance sheet risk through forward exchange contracts evolved between 2022 and 2024, particularly in terms of the currencies and cost-benefit considerations?",
      "original_answer": "In 2022, Merck explicitly outlined a balance sheet risk management program that involved the use of forward exchange contracts to offset exposures in both developed and developing country currencies, with a specific mention of the Chinese renminbi. The decision to hedge developing country currencies was based on a cost-benefit analysis considering exposure magnitude, exchange rate volatility, and hedging instrument cost. By 2024, while the balance sheet risk management program was still referenced, the detailed discussion around cost-benefit analysis and the specific mention of the Chinese renminbi in the context of developing countries was omitted. This suggests a shift in emphasis or a potential simplification of the decision-making framework for hedging non-developed market exposures.",
      "llm_answer": "In the 2022 filing Merck said its balance‑sheet risk program “principally utilizes forward exchange contracts … in developed‑country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar and Swiss franc,” and would only hedge a developing‑country currency such as the Chinese renminbi when a cost‑benefit analysis (exposure size, volatility and hedging cost) deemed it economical. By the 2024 filing the focus had narrowed to “primarily the euro, Swiss franc, Japanese yen and Chinese renminbi,” with the same cost‑benefit test still applied to decide whether to enter into a forward contract. Thus the company has shifted to a tighter set of core currencies—adding the renminbi as a primary exposure and dropping the pound and Canadian dollar—while retaining the magnitude‑, volatility‑, and cost‑driven assessment for hedging.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) The ORIGINAL ANSWER states that in 2022, Merck hedged both developed and developing country currencies, with specific mention of the Chinese renminbi, and used a cost-benefit analysis for developing countries. By 2024, the detailed discussion of cost-benefit analysis and specific mention of the renminbi were *omitted*, suggesting a simplification or shift away from that framework. However, the LLM answer incorrectly claims that in 2024, the renminbi was *added* as a primary currency and that the cost-benefit test was *still applied*, which directly contradicts the ground truth. (2) The LLM asserts that the 2024 filing lists 'Chinese renminbi' as a core hedged currency alongside euro, Swiss franc, and yen—this is not supported by the ground truth, which says the *specific mention of renminbi was dropped* in 2024. Similarly, the claim that British pound and Canadian dollar were 'dropped' is unsupported; the ground truth does not state this. (3) The multi-hop reasoning is flawed: instead of recognizing the *removal* of detail in 2024 (indicating a narrowing of discussion or possible strategic shift), the LLM incorrectly infers a *change in currency focus* and *continued use* of cost-benefit analysis, when the ground truth suggests the opposite—reduced elaboration and possible simplification. (4) While the LLM addresses the question’s context (currencies and cost-benefit), its core claims are factually inverted. Thus, despite relevant structure and terminology, the answer is largely incorrect on key facts, leading to low scores in correctness, quantitative accuracy, and qualitative reasoning. Contextual relevance is moderate as it attempts the right topic but with wrong conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 486,
        "total_tokens": 1910
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "What does the change in RTX's disclosure about the Powder Metal Matter between 2023 and 2024 suggest about its ongoing financial impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was disclosed as having a net sales charge of $5.3 billion, which negatively impacted net products sales at Pratt & Whitney and contributed to a decline in overall revenue. By 2024, the Powder Metal Matter was listed under future income tax benefits with a value of $455 million, down from $644 million in 2023. This shift indicates that while the matter continues to carry financial significance, its treatment has evolved from a direct operational loss to a deferred tax asset, suggesting a reduction in its immediate negative impact and a potential long-term recovery or resolution.",
      "llm_answer": "In the 2023 filing RTX described the Powder Metal Matter as a huge $5.3‑$5.4 billion sales charge and a $2.9 billion hit to operating profit, but in the 2024 filing it appears only as a deferred‑tax‑asset line item that fell from $644 million in 2023 to $455 million in 2024. The drop in the deferred‑tax benefit shows the tax advantage from the matter is being used up, indicating its ongoing financial impact on future income‑tax benefits is diminishing.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in RTX's disclosure of the Powder Metal Matter from a major operational charge in 2023 to a deferred tax asset in 2024, and accurately notes the decrease in the tax benefit from $644 million to $455 million. However, it introduces a $2.9 billion hit to operating profit not present in the original answer or ground truth, which only mentions a $5.3 billion net sales charge. This additional figure is unverified and potentially incorrect, reducing quantitative accuracy. (2) The numbers for net sales charge ($5.3–5.4 billion) are close but slightly overstate the $5.3 billion figure; the deferred tax asset values ($644M to $455M) are exactly correct. The calculation of the drop in tax benefit is implied and accurate. (3) The multi-hop reasoning is sound: the model correctly synthesizes the change in disclosure treatment across years and infers that the diminishing deferred tax asset implies a reduction in future income tax benefits, aligning with the ground truth’s conclusion about diminishing impact and potential resolution. (4) Despite the extraneous $2.9 billion operating profit figure, the core reasoning and conclusion about the diminishing financial impact on future tax benefits are correct and well-supported. The answer is highly relevant and captures the essential qualitative shift. Thus, correctness is high but not perfect due to unsupported quantitative addition.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 401,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has PayPal's involvement in the merchant receivables space evolved between 2022 and 2024, particularly in terms of its relationship with partner institutions and the scale of its merchant finance offerings?",
      "original_answer": "In 2022, PayPal described its U.S. merchant finance products (PPWC and PPBL) as being provided under a program agreement with WebBank, where PayPal could purchase the related receivables and also sell back a participation interest in the pool of receivables to WebBank. PayPal accounted for this arrangement as a sale and derecognized the portion of participation interests for which control was surrendered. By 2024, PayPal's relationship with partner institutions had evolved, with PayPal now purchasing approximately $1.8 billion in merchant receivables in 2024 (up from $1.7 billion in 2023), and the total outstanding balance in the pool of merchant loans, advances, and interest and fees receivable reached $1.5 billion as of December 31, 2024 (up from $1.2 billion as of December 31, 2023). Additionally, the participation interest sold to the partner institution increased to $53 million in 2024 from $44 million in 2023, indicating a growing level of investment in and collaboration around merchant receivables.",
      "llm_answer": "In 2022 PayPal’s merchant‑receivable activity was centered on its PP Working Capital (PPWC) and PP Business Loan (PPBL) products, which were funded through a program agreement with WebBank – WebBank extended credit to U.S. merchants and PayPal purchased and serviced the resulting receivables, while overseas working‑capital advances were made through its own subsidiaries (see page 72). By 2024 the WebBank partnership remained in place, but the scale had grown sharply: PayPal purchased about $1.8 billion of merchant receivables in 2024 (up from $1.7 billion in 2023) and the outstanding pool of merchant loans, advances and fees rose to roughly $1.5 billion (up from $1.2 billion) (see page 101).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All numeric values are correct: $1.8 billion in receivables purchased in 2024 (vs $1.7B in 2023), outstanding balance increase from $1.2B to $1.5B, and the context around WebBank partnership is preserved. These match the original answer exactly in value and trend. (2) Quantitative accuracy is perfect—dollar amounts, year-over-year comparisons, and scale increases are all correctly reported with no calculation or factual errors. (3) Qualitatively, the LLM captures the evolution of PayPal’s relationship with WebBank and the growth in scale of merchant finance offerings. However, it omits a specific detail present in the ground truth: the increase in participation interest sold back to the partner institution (from $44M to $53M in 2024), which is a key indicator of deepening collaboration. This is a minor but relevant omission in the multi-hop synthesis of how the partnership evolved. (4) Contextual relevance is excellent—the response directly addresses both parts of the question: evolution of partner relationships and scale of offerings. The inclusion of international operations (overseas advances via subsidiaries) adds useful context not in the original but does not detract. Overall, the answer is factually sound, well-reasoned, and only slightly less complete than the full ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 383,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How did Merck's alliance revenue from Lynparza evolve between 2022 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2022, Merck's alliance revenue from Lynparza was $989 million. By 2024, this revenue grew by 9%, driven by increased demand in most international markets. The growth reflects Lynparza's expanding adoption and new approvals, such as in China in January 2025 for adjuvant treatment in early breast cancer based on the OlympiA trial.",
      "llm_answer": "Merck’s alliance revenue from Lynparza increased from $1.116 billion in 2022 to $1.199 billion in 2023 and $1.311 billion in 2024 – a 9 % rise in 2024 and roughly a 17 % gain versus 2022【page_53†L16】.  The boost was driven mainly by higher demand in most international markets as the AstraZeneca‑partnered PARP inhibitor saw broader adoption and expanded indications【page_55†L9】.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, Merck's alliance revenue from Lynparza was $989 million in 2022, but the LLM claims it was $1.116 billion in 2022, $1.199 billion in 2023, and $1.311 billion in 2024. These figures are entirely incorrect and not supported by the original answer. The 9% growth in 2024 is correctly mentioned in the LLM answer, but it is applied to wrong base numbers, making the calculation invalid. Additionally, the original answer does not provide any data for 2023 or revenue figures beyond 2022 and the implied 2024 value (approximately $1.078 billion, calculated as $989M × 1.09), so the LLM fabricates intermediate-year data. (2) The quantitative accuracy is severely compromised: the 2022 revenue is off by over $127 million, and the 2024 figure is ~21% higher than the correct implied value. The LLM also introduces a 17% gain from 2022 to 24, which is inconsistent with the 9% growth stated in the ground truth (which appears to be year-on-year from 2023 to 2024 or overall from 2022 to 2024 depending on interpretation, but not 17%). (3) The qualitative reasoning partially aligns: the LLM correctly identifies increased international demand and broader adoption as drivers, and mentions expanded indications, which matches the original's reference to new approvals like in China. However, the original specifies the January 2025 approval in China for adjuvant treatment based on the OlympiA trial, while the LLM vaguely refers to 'expanded indications' without naming the trial or approval. Also, the LLM incorrectly frames Lynparza as an 'AstraZeneca-partnered PARP inhibitor' without clarifying Merck’s alliance structure, potentially confusing the nature of the revenue stream. (4) Contextual relevance is moderate because the answer addresses revenue evolution and contributing factors, fulfilling the question's structure, but with fabricated data. The core failure is quantitative: the revenue numbers are completely wrong, undermining the entire response. Thus, the correctness score is low at 2 due to severe factual errors despite some alignment in qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1171,
        "completion_tokens": 582,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has PayPal's involvement in merchant receivables evolved between 2022 and 2024, particularly in terms of its financial exposure and operational role?",
      "original_answer": "In 2022, PayPal's involvement in merchant receivables was primarily framed in terms of credit losses and net charge-offs, indicating a focus on risk management and accounting treatment under CECL standards. By 2024, PayPal had significantly expanded its direct involvement through active purchases of merchant receivables—$1.8 billion in 2024 compared to $1.7 billion in 2023—and reported a growing outstanding balance of $1.5 billion, up from $1.2 billion. Additionally, PayPal took on full servicing responsibilities for these receivables, signaling a deeper operational engagement in merchant finance through products like PPWC and PPBL.",
      "llm_answer": "By 2022 PayPal’s merchant‑finance business was centered on roughly $1.4 billion of loans and advances (net of participation interest), with 91.8 % of the receivables current and a net charge‑off rate of 4.7%, and the company was actively originating, modifying and tightening the terms of those loans to manage risk (2022 10‑K, pp. 44‑45). By 2024 the portfolio had grown modestly to about $1.5 billion, the allowance for credit losses fell to $113 million (down from $160 million a year earlier) and gross charge‑offs dropped to $10 million, while PayPal’s role shifted to buying merchant receivables from partner institutions and servicing them through its PPWC and PPBL financing products that are repaid from future PayPal payment volume (2024 10‑K, pp. 101‑103).",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the evolution of PayPal's role in merchant receivables between 2022 and 2024 and correctly identifies the shift toward active purchasing and servicing of receivables via PPWC and PPBL, which aligns with the ground truth. However, there are key quantitative inaccuracies. The ground truth states that PayPal purchased $1.8 billion in receivables in 2024 (up from $1.7 billion in 2023) and reported an outstanding balance of $1.5 billion (up from $1.2 billion). The LLM answer incorrectly frames the $1.5 billion as the 'portfolio' size in 2024 but does not mention the $1.8 billion purchase volume in 2024 or $1.7 billion in 2023, instead citing $1.4 billion in 2022 and $1.5 billion in 2024 as net loans/advances—figures not present in the ground truth. Additionally, the LLM introduces specific metrics like 91.8% current receivables, 4.7% net charge-off rate, allowance for credit losses ($160M to $113M), and gross charge-offs ($10M) that are not in the original answer and may be factually derived from filings but are not part of the verified ground truth from the knowledge graph. (2) These unverified numbers reduce quantitative accuracy, especially since the ground truth emphasizes purchase volumes and outstanding balances, not charge-off rates or allowance figures. The LLM also fails to quantify the year-over-year growth in purchases ($1.7B to $1.8B), a key point in the original. (3) Qualitatively, the reasoning is sound: it correctly identifies the shift from risk-focused accounting in 2022 to active purchasing and servicing in 2024, and correctly references PPWC and PPBL as products tied to future payment volume. This shows proper multi-hop synthesis across years and operational roles. (4) Contextual relevance is perfect—the answer directly addresses the evolution in financial exposure and operational role. Due to the inclusion of unsupported specific metrics and omission of key purchase volume figures, the correctness score is reduced to 7, with quantitative accuracy at 6 despite plausible numbers, as they do not match the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 565,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Merck's involvement in the development and commercialization of Lynparza evolved from 2022 to 2024, particularly in terms of regulatory progress and revenue growth?",
      "original_answer": "In 2022, Merck was awaiting FDA decision on a supplemental NDA for Lynparza for the adjuvant treatment of BRCA-mutated, HER2-negative high-risk early-stage breast cancer, based on the OlympiA trial, with a PDUFA date in Q1 2022. By 2024, Lynparza had not only maintained its approvals but also expanded its regulatory footprint, with a new approval in China in January 2025 for the same indication, indicating continued global regulatory momentum. Additionally, alliance revenue related to Lynparza grew by 9% in 2024 due to increased demand in international markets, showing a measurable increase in commercial success.",
      "llm_answer": "In 2022 Merck’s role with Lynparza was still largely regulatory – the FDA had accepted a supplemental NDA for the adjuvant‑breast‑cancer indication for priority review (with a Q1‑2022 PDUFA date) and the drug was under EU review for metastatic castration‑resistant prostate cancer【page_22】. By 2024 Lynparza is fully approved for its core oncology uses, is being commercialized worldwide, and Merck’s alliance‑revenue share grew from $1.116 billion in 2022 to $1.311 billion in 2024 – a 9 % increase driven by higher demand in international markets【page_53】【page_55】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the 9% revenue growth is accurately reflected, with specific figures of $1.116 billion in 2022 and $1.311 billion in 2024, which indeed represents approximately a 9% increase. The PDUFA date in Q1 2022 is correctly noted. (2) The LLM adds slightly more detail than the original answer—mentioning the EU review for metastatic castration-resistant prostate cancer—which is not contradicted by the ground truth but not required for completeness. The core regulatory and commercial evolution is correctly captured. (3) The multi-hop reasoning is sound: the model connects Merck’s regulatory status in 2022 with its expanded commercial and regulatory success in 2024, synthesizing information across time and regions. (4) The only minor shortcoming is that the original answer mentions a January 2025 approval in China, while the LLM does not include this forward-looking detail. However, since the question asks about evolution up to 2024, this omission does not undermine the correctness. The LLM focuses on 2024 outcomes (revenue, global commercialization) appropriately. Wording differs but semantic meaning matches. All entities—Merck, Lynparza, alliance revenue, international demand—are correctly identified and contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 373,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Boeing's strategy with commodity purchase contracts evolved between 2022 and 2024, particularly in terms of risk management horizon and financial exposure?",
      "original_answer": "In 2022, Boeing disclosed that a 10% change in commodity prices would impact unrealized losses by $46 million, and the company used commodity swaps and purchase contracts to hedge against price volatility, neutralizing material market risk. By 2024, Boeing extended the scope of its hedging strategy, indicating the use of commodity purchase contracts and derivatives to manage exposure through 2031. This represents a shift toward longer-term risk management aligned with extended production planning cycles. The expansion from a general hedging approach in 2022 to a multi-decade horizon in 2024 suggests Boeing is proactively securing cost predictability for strategic business stability.",
      "llm_answer": "Boeing’s 2022 filing shows it relied on commodity swaps and purchase contracts to hedge price risk but gave no explicit forward‑looking horizon, quantifying exposure as a $46 million unrealized gain or loss for a 10 % price move【page_60】. By the 2024 filing the company states its commodity contracts now hedge forecasted purchases through 2028, with notional amounts of $388 million (designated as hedges) and $129 million (non‑hedged) and unrealized results shifting from a $78 million gain in 2022 to modest losses of $10 million in 2024, indicating a longer‑term, more tightly managed risk‑management approach and reduced financial exposure【page_111】【page_112】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies compared to the ground truth. While it correctly identifies Boeing's use of commodity swaps and purchase contracts in 2022 and the $46 million exposure to a 10% price change, it misstates the 2024 risk management horizon as extending through 2028, whereas the ground truth specifies hedging through 2031. This is a significant error in temporal scope. Additionally, the LLM introduces specific notional amounts ($388 million hedged, $129 million non-hedged) and unrealized gains/losses ($78 million gain in 2022, $10 million loss in 2024) that are not present in the original answer and contradict the ground truth, which does not provide these figures. (2) The only correct quantitative element is the $46 million impact in 2022. The other numbers—$388M, $129M, $78M, $10M—are unsupported by the ground truth and appear fabricated or misattributed. The shift in unrealized results is not mentioned in the original, nor is the characterization of a 'modest loss' in 2024. (3) The reasoning is partially sound: the LLM correctly infers a trend toward longer-term risk management and reduced exposure, aligning with the ground truth’s conclusion about extended planning cycles. However, the multi-hop synthesis is flawed because it relies on incorrect data points, undermining the validity of the conclusion. The extension to 2028 vs. 2031 may seem minor but reflects a failure to accurately represent the strategic horizon. (4) The contextual relevance is high—the answer addresses risk management evolution, financial exposure, and strategic intent. However, due to significant quantitative inaccuracies and the introduction of unsupported figures, the correctness score is limited to 6. The qualitative accuracy is moderate because the direction of reasoning is correct, but the foundation is factually unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 506,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did Schwab's exposure to PALs and the associated credit risk evolve between 2021 and 2024, particularly in terms of collateralization and allowance for credit losses?",
      "original_answer": "In 2021, all PALs were fully collateralized by securities with fair values exceeding borrowings, and therefore no allowance for credit losses was required. In contrast, by 2024, although PALs experienced slight growth overall, Schwab observed a decrease in the allowance for credit losses due to lower projected loss rates and improved credit quality metrics. This reflects a shift from a focus on full collateralization as the primary risk mitigant to a broader assessment of credit quality and loss projections.",
      "llm_answer": "Schwab’s pledged‑asset‑line (PAL) portfolio rose from roughly $12.7 billion at 12/31/2021 (‑ $12,698 M current + $3 M 30‑59 days + $8 M 60‑89 days = $12,709 M; see 2022 10‑K p. 91) to about $17.0 billion at 12/31/2024 ($16,726 M within 1 year + $298 M 1‑5 years = $17,024 M; see 2024 10‑K p. 141). In both periods Schwab reported that PALs were fully collateralized by securities whose fair values exceeded the borrowings (2022 10‑K p. 89 and note on p. 91) and therefore recorded no allowance for credit losses on PALs (2022 10‑K explicitly states “no allowance…required”; the 2024 loan table shows no allowance entry, implying the same treatment).",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies in both quantitative and qualitative aspects. While it correctly states that PALs were fully collateralized in 2021 and implies no allowance was recorded, it contradicts the ground truth by asserting full collateralization continued in 2024, when the truth indicates a shift toward credit quality assessment and a decrease in allowance due to lower projected losses—implying an allowance *was* recorded. The LLM incorrectly claims 'no allowance' in 2024 based on absence of entry in a table, which misinterprets the data. (2) The quantitative figures for PAL balances are partially accurate but not fully verifiable or consistent with the ground truth: the 2021 total is miscalculated ($12,709M vs reported $12.7B is close), but the 2024 figure of $17.024B is specific and not mentioned in the ground truth, which only states 'slight growth'—a contradiction. 'Slight growth' from $12.7B would not reach $17B, making this a major discrepancy. (3) The multi-hop reasoning fails: the model does not recognize the evolution from collateral-based risk mitigation (2021) to credit-loss modeling (2024). Instead, it asserts continuity in treatment, missing the key shift in risk management approach. It relies on document excerpts without synthesizing the broader trend. (4) Contextual relevance is high as it addresses PALs, collateralization, and allowance over time. However, due to major errors in financial interpretation and direction of change, the correctness score is low. Quantitative accuracy is moderate due to plausible numbers but unsupported totals. Qualitative accuracy is low due to flawed reasoning about credit loss allowance evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 463,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did Boeing's financial treatment and strategic positioning of the 777X program evolve between 2022 and 2024, given the changes in cost impacts and research & development investments?",
      "original_answer": "In 2022, the 777X program negatively impacted Boeing's financials, contributing to higher charges and a cost of sales increase, partly due to a 'reach-forward loss' on the program. By 2024, the program had transitioned to being a strategic investment priority, as evidenced by a $435 million increase in R&D spending in 2024 compared to 2023, following a $525 million increase in 2023 over 2022, indicating a shift from a cost burden to a focal point for future product development.",
      "llm_answer": "In the 2022 filing Boeing noted that the 777X program had driven higher cost‑of‑sales charges in 2020 and that R&D spending was cut in 2021, reflecting reduced investment in the aircraft. By the 2024 filing the company was still recognizing a reach‑forward loss on the 777X in cost of sales, but R&D outlays rose sharply – up $525 million in 2023 and $435 million in 2024 – largely due to the 777X, signalling a strategic shift to reinvest in and position the program as a key future product.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution of Boeing's 777X program from a cost burden to a strategic investment, which aligns with the ground truth. However, there are key factual inaccuracies in the timeline and magnitude of R&D increases. The LLM states that R&D increased by $525 million in 2023 and $435 million in 2024, but reverses the comparative base years: the ground truth specifies a $525 million increase in 2023 *over 2022*, and a $435 million increase in 2024 *over 2023*. While the dollar figures themselves are correct, the LLM misattributes the timing by implying the $525M increase occurred during 2023 (without clarifying it was vs. 2022), which could mislead about the trend. Additionally, the LLM incorrectly claims R&D was cut in 2021 and that cost-of-sales charges were from 2020, which are not supported by the original answer and introduce irrelevant or incorrect historical context. (2) Quantitative accuracy is partially compromised: the $525M and $435M figures are correct, but their year-over-year framing is imprecise. The original answer emphasizes the consecutive increases as evidence of strategic reinvestment, but the LLM’s phrasing weakens the clarity of this progression. (3) Multi-hop reasoning is generally sound—the model connects financial treatment (cost impacts) with strategic positioning (R&D increases) across years and infers a shift in strategy. However, it introduces unsupported details (e.g., 2020 charges, 2021 cuts) that were not in the ground truth, suggesting potential hallucination or misattribution. (4) Despite these issues, the answer remains contextually relevant and conveys the essential narrative shift. The qualitative reasoning is strong in interpreting 'reach-forward loss' continuing into 2024 while R&D rises, signaling ongoing challenges but renewed strategic focus. Hence, correctness is reduced mainly due to timeline misrepresentation and extraneous incorrect details, warranting a 7/10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 532,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has Schwab's exposure to and risk management of Portfolio Against Loans (PALs) evolved between 2022 and 2024, particularly in terms of credit loss allowance methodology and portfolio growth?",
      "original_answer": "In 2022, Schwab applied the practical expedient for PALs due to their collateralized nature and over-collateralization requirements, which limited inherent credit loss. The company monitored collateral daily and maintained strict maintenance levels based on the type of security pledged. By 2024, PALs had contributed to the growth of the average loan portfolio, although there was a slight decrease in 2023. The overall decrease in the allowance for credit losses as a ratio to year-end loans in 2024 was attributed to improved credit quality metrics and lower projected loss rates, indicating a reduced risk profile for PALs despite portfolio growth.",
      "llm_answer": "In 2022 Schwab classified Portfolio‑Against‑Loans (PALs) as a distinct segment of its bank‑loan portfolio and measured the allowance for credit losses using a practical‑expedient that relied on the collateral‑maintenance provisions of the over‑collateralized, daily‑monitored securities pledged by borrowers 【page_78】. By 2024 the PAL segment—now shown as “pledged asset lines”—had expanded to about $17 billion (≈ $16.7 billion in the 1‑year bucket) 【page_141】, but the company still manages the risk with the same collateral‑based practical‑expedient and daily monitoring approach that limits credit‑loss exposure.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Schwab's use of the practical expedient for PALs in 2022 due to over-collateralization and daily monitoring, which aligns with the ground truth. It also accurately notes that by 2024, the PAL portfolio (referred to as 'pledged asset lines') had grown to approximately $17 billion, supported by a citation. However, the ground truth mentions a slight decrease in 2023 and portfolio growth trend over the period, which the LLM omits, weakening the multi-year evolution narrative. Additionally, the LLM fails to mention the decrease in the allowance for credit losses as a ratio to year-end loans in 2024 and the reasoning—improved credit quality and lower projected loss rates—which is a key part of the risk management evolution. (2) The dollar amount ($17 billion) is reasonably accurate and matches the cited page reference; format variation ($16.7 billion implied) is acceptable. No incorrect calculations are presented, though specific comparative metrics (e.g., allowance ratio changes) are missing. (3) The reasoning is sound in linking collateral-based risk management across years, but it does not fully synthesize the multi-hop evolution: from 2022 methodology → 2023 fluctuation → 2024 portfolio growth alongside reduced risk allowance due to improved metrics. This partial synthesis limits qualitative accuracy. (4) The answer remains highly relevant to the question, focusing on PALs, risk management, and portfolio growth, but lacks completeness in addressing the full temporal evolution and credit loss allowance trend, which are central to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 445,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did MDLZ's value of British pound sterling notes change from 2022 to 2023, and what does this shift indicate about the company's foreign exchange risk management strategy?",
      "original_answer": "In 2022, MDLZ reported a value of $3 million for British pound sterling notes. By 2023, this value had increased significantly to $45 million. This shift indicates a substantial change in MDLZ's foreign exchange risk management strategy, suggesting an increased exposure to the British pound sterling, which could reflect either a strategic decision to hedge more in this currency or an increase in operational activities tied to the UK market.",
      "llm_answer": "MDLZ recorded a $45 million after‑tax gain on its British‑pound‑sterling net‑investment hedge in 2022, but the 2023 column shows a dash (i.e., $0) for that line【page_98】. The disappearance of the GBP‑denominated hedge suggests the company has unwound or eliminated its pound‑sterling exposure, reflecting a move to reduce or re‑balance its foreign‑exchange risk in that currency.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it claims a $45 million after-tax gain in 2022 and $0 in 2023, which directly contradicts the ground truth: the value of British pound sterling notes was $3 million in 2022 and increased to $45 million in 2023. The LLM confuses a gain on a hedge with the actual value of the notes, misinterpreting the financial metric entirely. (2) The LLM incorrectly infers that the absence of a hedge gain in 2023 means reduced exposure, while the ground truth shows a significant increase in the value of pound-denominated assets, indicating increased exposure, not reduced. (3) The multi-hop reasoning fails: instead of tracking the change in the value of the notes over time, the model focuses on an unrelated hedging gain and misreads a dash as $0 exposure, which does not imply elimination of currency exposure. (4) The conclusion about risk management strategy is therefore inverted: the ground truth suggests increased GBP exposure (possibly more hedging or greater UK operations), while the LLM claims exposure was unwound. The answer is not semantically equivalent and fails on all key dimensions—numbers, entities, reasoning, and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 347,
        "total_tokens": 1560
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "Compare the interest rate disclosures for Amgen's 3.125% 2025 Notes in the 2022 and 2024 filings, and explain what this reveals about the company's approach to debt financing for this instrument.",
      "original_answer": "In the 2022 filing, Amgen disclosed a fixed interest rate of 3.125% for the 2025 Notes with no mention of variable rate terms. However, by the 2024 filing, Amgen disclosed that the interest rate for the same 3.125% 2025 Notes was tied to SOFR (Secured Overnight Financing Rate) plus 2.1%. This indicates a shift from a purely fixed-rate structure to a floating-rate mechanism, suggesting Amgen may have refinanced or repriced the notes to adapt to changing market conditions and interest rate environments.",
      "llm_answer": "In the 2022 Form 10‑K Amgen disclosed that the $1 billion of 3.125 % 2025 notes were hedged with interest‑rate swaps that produced an effective floating rate of **LIBOR + 1.8 %** (see page 132). The 2024 Form 10‑K shows the same $1 billion of notes now hedged at **SOFR + 2.1 %** (see page 149). This consistency of using swaps to convert the fixed‑coupon notes to floating‑rate exposure, together with the shift from LIBOR to the newer SOFR benchmark, reveals that Amgen actively manages interest‑rate risk and adapts its financing strategy to evolving market conventions.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Amgen disclosed a fixed interest rate of 3.125% with no variable rate terms, but the LLM claims the 2022 notes were hedged to produce a LIBOR + 1.8% floating rate. This misrepresents the original disclosure, which did not mention hedges or variable rates in 2022. Similarly, the 2024 filing is correctly cited as showing SOFR + 2.1%, but the LLM incorrectly implies this is due to a hedge on the same fixed-rate note, while the ground truth indicates the interest rate itself was now disclosed as tied to SOFR, suggesting a structural change in the instrument, not just a hedge. (2) Quantitative accuracy is partially correct: the 3.125% rate and $1 billion amount are plausible, and SOFR + 2.1% in 2024 aligns with the direction of truth, but LIBOR + 1.8% in 2022 is unsupported by the ground truth and introduces a false benchmark and spread. The use of hedges is an addition not present in the original answer. (3) Multi-hop reasoning is partially sound—the model compares two filings across years and infers strategic intent—but it is based on incorrect premises. The shift from LIBOR to SOFR is valid contextually, but the core claim of active hedging in both years is not supported by the ground truth, which shows a shift from fixed to floating rate disclosure, not hedging activity. (4) Contextual relevance is high because the answer addresses the question’s structure and attempts to explain financing strategy. However, due to fundamental errors in the underlying facts and mischaracterization of the debt instrument’s terms, the correctness score is low. The conclusion about active risk management is plausible but built on incorrect data, warranting a score of 4/10 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 492,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has Schwab's reliance on its Commercial Paper Issuance Program evolved between 2022 and 2024 in response to market disruptions and rising interest rates?",
      "original_answer": "In 2022, Schwab introduced its Commercial Paper Issuance Program as one of several potential sources of external financing, alongside unsecured bank credit lines and a universal shelf registration, to address liquidity needs during market disruptions. The company emphasized that while these tools were available, access to financing could still be constrained due to credit market volatility and potential credit rating downgrades. By 2024, Schwab's reliance on the program had increased as a complement to other funding mechanisms like FHLB advances and repurchase agreements, particularly in response to rising short-term interest rates in 2022 and 2023, which led to higher client cash outflows. The company noted that these outflows, outpacing cash generated from maturities and paydowns, required supplemental funding sources, including the commercial paper program, to manage liquidity under more costly and constrained conditions.",
      "llm_answer": "In the 2022 filing Schwab described its commercial‑paper issuance program as one of several external‑financing tools, warning that a credit‑market disruption could make that source unavailable (2022 p. 23). By the 2024 filing the program is still listed, but the company stresses that the rapid rise in short‑term rates in 2022‑23 has forced it to rely more on supplemental, higher‑cost funding (e.g., FHLB advances, repos, brokered CDs) and that commercial‑paper availability may be limited, reflecting a more cautious, diversified use of the program (2024 p. 16).",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates (2022 and 2024), entities (Schwab, commercial paper program, FHLB advances, repos, brokered CDs), and correctly identifies the context of rising short-term interest rates in 2022–2023 and market disruptions. It accurately reflects that the commercial paper program was introduced in 2022 as one of several tools and that its availability could be constrained due to market conditions. The citation of page numbers (2022 p.23, 2024 p.16) aligns with typical SEC filing referencing practices, though these are not verifiable without source documents. However, the LLM answer states that Schwab is relying more on 'supplemental, higher-cost funding' but implies reduced reliance on commercial paper due to limited availability. This contrasts with the ground truth, which states that Schwab's *reliance on the commercial paper program increased* by 2024 as a complement to other sources to manage liquidity amid higher client outflows. The LLM incorrectly frames the evolution as more cautious and diversified *away* from commercial paper, while the original answer emphasizes *increased reliance* despite constraints. This is a significant qualitative deviation in reasoning and synthesis. While all specific numbers and dates are correct (quantitative accuracy is perfect), the interpretation of the trend in reliance is partially incorrect, leading to a correctness score of 7. Contextual relevance is high as the answer addresses market disruptions, interest rates, and funding mechanisms directly. The multi-hop synthesis across years and funding tools is mostly sound but misses the core conclusion about increased use of the program.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 459,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has the status and interest rate structure of the 3.625% Notes evolved from 2022 to 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2022, the 3.625% 2024 Notes had a carrying value of $1,400 million with a fixed interest rate of 3.625%. By 2024, these notes were fully paid off, as indicated by the $0 notional amount, and were replaced with floating interest rates tied to SOFR (Secured Overnight Financing Rate). This shift from fixed to floating rate debt indicates a strategic change in Amgen's debt management, aligning with broader market conditions and potentially reducing interest costs in a declining rate environment.",
      "llm_answer": "In the 2022 filing the 3.625 % 2022 Notes had already been redeemed (the $750 million issue was retired in 2021) and the $1.4 billion 3.625 % 2024 Notes remained outstanding, with the company using interest‑rate swaps to convert the fixed 3.625 % coupon to a floating LIBOR‑plus‑3.2 % rate【page_130】【page_132】. By 2023 the swaps on the 2024 notes were re‑priced to SOFR‑plus‑3.4 % and, as disclosed in the 2024 filing, those swap contracts and the underlying 3.625 % 2024 Notes were fully repaid when the swaps matured in 2024【page_149】【page_148】. This progression shows Amgen’s strategy of actively hedging fixed‑rate debt with floating‑rate swaps, transitioning to the SOFR benchmark, and retiring the notes at maturity to manage interest‑rate risk and maintain a disciplined debt profile.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct but contains a minor factual inaccuracy regarding the interest rate structure. The ground truth states the original note had a fixed rate of 3.625% and was fully paid off by 2024, with replacement debt tied to SOFR. The LLM correctly identifies the $1.4 billion carrying value (matching $1,400 million) and repayment in 2024. However, it adds detail about interest-rate swaps converting the fixed rate to floating (LIBOR-plus-3.2%, then SOFR-plus-3.4%) not present in the ground truth. While this may reflect actual disclosures, the original answer does not mention swaps or synthetic floating rates—only that the new debt is floating-rate SOFR-based. This introduces unverified complexity. (2) Quantitatively, all numbers are accurate: $1.4 billion = $1,400 million, correct years (2022 outstanding, 2024 repaid), and proper sequencing. The mention of a $750 million 2022 note retired in 2021 is factually consistent but not required for this question and slightly distracts from focus on the 2024 notes. (3) The multi-hop reasoning is strong: the LLM synthesizes data across 2022, 2023, and 2024 filings, correctly tracks the lifecycle of the 3.625% 2024 Notes, and infers a strategic shift toward floating rates and SOFR transition. It accurately concludes Amgen is managing interest rate risk and maintaining disciplined debt management, aligning with the ground truth’s interpretation. (4) The answer is contextually excellent—directly addresses the evolution of the note and strategic implications. The only deduction is for introducing swap mechanics not in the ground truth, which slightly undermines quantitative and qualitative accuracy despite being plausible. Overall, core facts and strategy interpretation are correct, warranting a high score but not perfect due to added, unconfirmed financial engineering details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 508,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has Schwab's approach to providing financial or other support to variable interest entities (VIEs) evolved between 2022 and 2024, particularly in terms of intent and conditions for funding commitments?",
      "original_answer": "In 2022, Schwab explicitly stated that it did not provide or intend to provide financial or other support to VIEs that it was not contractually required to provide. By 2024, Schwab's disclosures indicate a shift, as the company now acknowledges that while it has no contractual obligation, it may choose to provide credit, liquidity, or other support to its proprietary funds in response to significant declines in valuation or redemption activity. This reflects a more proactive stance in supporting funds under certain market conditions, even though it is not mandated.",
      "llm_answer": "In the 2022 Form 10‑K Schwab explicitly stated that it “did not provide or intend to provide financial or other support to the VIEs that it was not contractually required to provide,” and that any funding of its remaining VIE commitments would be made only if “certain conditions” were met and was expected to be satisfied between 2022‑2025【page_98】. By the 2024 filing, Schwab’s language had shifted to a discretionary stance: it says the company “may decide for competitive or other reasons to provide credit, liquidity or other support” to its proprietary funds (VIEs) when “significant declines in valuation…or significant redemption activity” arise, indicating that support is now conditional on adverse events rather than a blanket refusal【page_19】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution in Schwab's approach: from a firm stance in 2022 of not providing support beyond contractual obligations to a more discretionary, proactive position in 2024 where support may be provided for competitive or market-related reasons. The key conditions—significant valuation declines or redemption activity—are accurately reported. (2) There are no numeric values (e.g., dollar amounts, percentages) in the original or LLM answer, so quantitative accuracy is not compromised; dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes disclosures across two years (2022 and 2024 10-Ks), correctly identifies the shift in intent and conditions, and references the proprietary funds as VIEs, which is consistent with the context. (4) The only minor shortcoming is the mention of 'remaining VIE commitments expected to be satisfied between 2022–2025'—a detail not present in the ground truth—which slightly extends beyond the provided answer but does not contradict it and may reflect additional context from the filing. Overall, the answer is semantically equivalent, well-reasoned, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 351,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has MDLZ's financial relationship with JDE Peet's evolved between 2022 and 2023, particularly in terms of how the investment impacts MDLZ's liquidity and capital structure?",
      "original_answer": "In 2022, MDLZ's relationship with JDE Peet's was characterized as a 'Has_Stake_In' arrangement, where MDLZ reported its proportionate share of significant operating and non-operating items from JDE Peet's including restructuring and acquisition-related costs. By 2023, the relationship was reclassified to 'Invests_In', and the investment in JDE Peet's was described as providing additional financial flexibility within MDLZ's liquidity and capital resources framework. This shift indicates a more strategic and stable investment posture, aligning JDE Peet's more closely with MDLZ's long-term capital planning and funding sources.",
      "llm_answer": "In 2022 MDLZ recorded a $48 million cost for the JDE Peet’s transaction, issued €300 million of zero‑interest exchangeable notes that can be redeemed for cash or JDE Peet’s shares, and logged a $740 million equity‑method gain on the investment (2022 pg 45‑46). By 2023 the company was generating cash from JDE Peet’s share sales, describing the investment as “providing us additional flexibility” with no material negative effect on liquidity, and its overall capital structure improved as total debt fell to $19.4 billion from $22.9 billion and the debt‑to‑capitalization ratio dropped from 0.46 to 0.41 (2023 pg 54‑55).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes specific financial figures such as a $48 million cost, €300 million zero-interest exchangeable notes, a $740 million equity-method gain in 2022, and changes in debt levels and debt-to-capitalization ratio in 2023. However, these specific numbers (e.g., $48M cost, $740M gain, €300M notes) are not present in the original answer (ground truth), which focuses on qualitative shifts in the nature of the relationship (from 'Has_Stake_In' to 'Invests_In') and the strategic impact on liquidity and capital structure. There is no mention in the ground truth of share sales generating cash, specific gains, or transaction costs. Thus, while the direction of change (improved liquidity, reduced debt) aligns broadly, the specific quantitative claims lack corroboration in the ground truth and may be hallucinated or misattributed. (2) The debt reduction from $22.9B to $19.4B and the drop in debt-to-capitalization from 0.46 to 0.41 are plausible but not confirmed in the original answer; these figures may be accurate to MDLZ’s filings but are not part of the knowledge graph’s verified response, making their inclusion problematic for factual correctness. (3) The multi-hop reasoning is partially sound: the LLM correctly infers that reduced debt and flexible funding sources relate to capital structure and liquidity. It also captures the evolving strategic framing of the JDE Peet’s investment. However, it mischaracterizes the evolution as driven by monetization (e.g., share sales, gains) rather than a reclassification of the investment type and its integration into capital planning. The shift from 'Has_Stake_In' to 'Invests_In'—a key qualitative insight in the ground truth—is missing. (4) The contextual relevance is high because the answer addresses MDLZ’s liquidity, capital structure, and the role of JDE Peet’s over 2022–2023. The qualitative accuracy is moderate because the conceptual evolution is partially captured, but the reasoning is undermined by unsupported numbers. Quantitative accuracy is low due to unverified figures and lack of grounding in the provided truth. Correctness is scored at 6 because the core idea of improved flexibility and capital structure is consistent, but the reliance on unverified specifics reduces factual reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 614,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 119,
      "question": "How did the interest rate hedging strategy for the 3.125% 2025 Notes evolve between 2022 and 2024, particularly in terms of the interest rate applied under the swap agreements?",
      "original_answer": "In 2022, the company had terminated interest rate swaps for portions of the 3.125% 2025 Notes and reentered into new swap agreements at then-current interest rates, though the exact rate for the 3.125% 2025 Notes was not disclosed. By 2024, the interest rate applied under the swap agreement for the 3.125% 2025 Notes was explicitly stated as SOFR+2.1%, with a consistent notional amount of $1,000 million as of December 31, 2024, compared to December 31, 2023.",
      "llm_answer": "In the 2022 filing the company hedged the $1 billion of 3.125 % 2025 Notes with a LIBOR‑based swap that paid **LIBOR + 1.8 %** (see page 132). By the 2024 filing the same notional amount was still hedged, but the swap reference had moved to **SOFR + 2.1 %** (see page 149). Thus the hedging strategy shifted from a LIBOR benchmark to a SOFR benchmark and the spread rose slightly from +1.8 % to +2.1 %.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding the 2022 interest rate under the swap agreement. The original answer states that the exact rate for the 3.125% 2025 Notes swap in 2022 was not disclosed, but the LLM claims it was LIBOR + 1.8%, which is not supported by the ground truth. This is a critical quantitative error. Additionally, the transition from LIBOR to SOFR is plausible contextually (as part of the broader market shift), but the original answer does not confirm the use of LIBOR in 2022 or the specific spread of +1.8%, making this detail fabricated or incorrectly inferred. The 2024 rate of SOFR + 2.1% and the $1,000 million notional amount are correctly reported and match the ground truth. (2) The dollar amount ($1 billion = $1,000 million) is accurate and correctly maintained across years. However, the 2022 interest rate (LIBOR + 1.8%) is not corroborated by the original answer, which explicitly states the rate was not disclosed. This invalidates the comparison between +1.8% and +2.1%. (3) The multi-hop reasoning is partially sound—the model attempts to compare the hedging strategy across 2022 and 2024 and correctly identifies continuity in notional amount and a shift in benchmark (LIBOR to SOFR). However, because the 2022 rate is incorrectly specified, the synthesis is flawed. The model assumes information not present in the ground truth, undermining the reasoning chain. (4) The contextual relevance is high—the answer addresses the evolution of the hedging strategy and focuses on the correct security and time frame. However, due to the major factual error in the 2022 rate, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the structure and intent of the reasoning are appropriate, even if based on incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 502,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did Walmart's fair value of equity investments measured using Level 2 inputs evolve from fiscal year 2022 to fiscal year 2023, and what was the magnitude of this change?",
      "original_answer": "Walmart's fair value of equity investments measured using Level 2 inputs decreased from $5,819 million in fiscal year 2022 to $5,570 million in fiscal year 2023, representing a moderate decline of $249 million over the period.",
      "llm_answer": "Walmart’s fair‑value of equity investments measured using Level 2 inputs fell from $5,819 million at fiscal‑year‑end 2022 to $5,570 million at fiscal‑year‑end 2023, a decline of roughly $249 million.【page_72】【page_71】",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values $5,819 million (fiscal year 2022) and $5,570 million (fiscal year 2023) are accurately reported, and the calculated decline of $249 million is correct (5,819 - 5,570 = 249). Minor wording differences such as 'fell' vs 'decreased' and 'roughly $249 million' vs '$249 million' do not affect factual accuracy. (2) The answer is complete, addressing both the evolution (decrease from 2022 to 2023) and the magnitude of change ($249 million decline). (3) Entities are accurate: Walmart is the correct company, fiscal years 2022 and 2023 are correctly referenced, and the financial metric 'fair value of equity investments measured using Level 2 inputs' is precisely stated. (4) The reasoning is sound and reflects proper multi-hop synthesis across fiscal years, correctly identifying the trend and computing the difference. (5) The semantic meaning is equivalent to the original answer, with no loss of key information. The inclusion of citation markers 【page_72】【page_71】 further supports contextual grounding in the source material.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1117,
        "completion_tokens": 321,
        "total_tokens": 1438
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How has Apple's characterization of its reliance on marketing abilities evolved between its 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Apple stated that while it believes ownership of intellectual property rights is an important factor in differentiating its business, it 'relies primarily' on the innovative skills, technical competence, and marketing abilities of its personnel. In the 2024 filing, Apple shifted its language, stating that it 'depends heavily' on these same three factors—innovative skills, technical competence, and marketing abilities—tying them directly to ensuring a continual and timely flow of competitive products, services, and technologies to the marketplace. This evolution reflects a stronger emphasis on the strategic importance of marketing abilities in maintaining competitiveness, particularly as the company faces increasing pressure from rivals imitating its features and offering lower-priced alternatives.",
      "llm_answer": "Apple’s description of its reliance on marketing has not changed. Both the 2023 Form 10‑K (page 6) and the 2024 Form 10‑K (page 6) state that, although Apple holds a broad IP portfolio, “the Company relies primarily on the innovative skills, technical competence and **marketing abilities** of its personnel” 【page_6】【page_6】.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that Apple's description of its reliance on marketing has 'not changed' between the 2023 and 2024 10-K filings. The ground truth shows a clear evolution in language: from 'relies primarily' in 2023 to 'depends heavily' in 2024, with added strategic context about ensuring a 'continual and timely flow' of competitive offerings. The 2024 filing strengthens the emphasis on marketing abilities as part of a trio of critical competencies tied directly to market competitiveness. The LLM fails to detect this shift, instead asserting no change and quoting nearly identical language—ignoring the nuanced but meaningful rewording and expanded rationale in the 2024 filing. While the entities (Apple, 2023/2024 10-Ks) and general concept (reliance on personnel skills including marketing) are correctly identified, the answer misses the multi-hop requirement to compare and contrast the two filings' characterizations. There are no numerical inaccuracies (hence high quantitative score), but the qualitative reasoning is flawed, leading to an incorrect conclusion. Contextual relevance is moderate because the answer discusses the right section and topic but fails to address the evolution asked in the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 351,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did the notional amount and interest rate structure for the 3.625% 2024 Notes change between 2022 and 2024, and what does this indicate about Amgen's hedging strategy?",
      "original_answer": "In 2022, Amgen terminated interest rate swaps with a notional amount of $5.2 billion that hedged several notes, including the 3.625% 2024 Notes, and reentered into new interest rate swap agreements at then-current rates on the same principal amount. By 2024, the notional amount for the 3.625% 2024 Notes had dropped to $0 as of December 31, 2024, compared to $1,400 million in December 2023, with the interest rate tied to SOFR+3.4% in 2023. This indicates that Amgen fully unwound its hedging position for the 3.625% 2024 Notes by the end of 2024, likely as the notes approached maturity.",
      "llm_answer": "In the 2022 filing Amgen reported $1.4 billion of interest‑rate swap contracts covering the 3.625 % 2024 notes, with the floating leg tied to LIBOR + 3.2 % (2022 10‑K, p. 132). By the end of 2024 those swaps had been unwound – the notional fell to $0 and the hedge no longer existed (2024 10‑K, p. 149), after a brief SOFR‑based version (SOFR + 3.4 % in 2023) (2024 10‑K, p. 149). This transition shows Amgen initially used floating‑rate swaps to offset the fixed‑rate interest‑rate exposure of the 2024 notes, but terminated the hedge as the notes matured and were repaid, reflecting a targeted, maturity‑driven hedging strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct but contains a key quantitative inaccuracy: it states that in 2022, Amgen had $1.4 billion in interest-rate swaps on the 3.625% 2024 Notes, whereas the ground truth specifies that in 2022, Amgen terminated $5.2 billion in swaps covering multiple notes including the 3.625% 2024 Notes, not $1.4 billion specifically for that note. The $1.4 billion figure is correct for December 2023, not 2022. This misattribution of the amount and year reduces quantitative accuracy. (2) The LLM correctly identifies the transition from LIBOR to SOFR (though ground truth does not explicitly mention LIBOR; it only states SOFR+3.4% in 2023), and accurately reports the notional dropping to $0 by end of 2024. The shift from floating-rate hedging to unwinding as maturity approaches is correctly interpreted. (3) The multi-hop reasoning is sound: the model synthesizes data across 2022, 2023, and 2024 filings, tracks the notional amount trend, recognizes the interest rate benchmark shift (LIBOR to SOFR), and infers a maturity-driven hedging strategy, which aligns with the ground truth’s conclusion. (4) Despite the incorrect assignment of the $1.4 billion to 2022, the overall narrative and qualitative interpretation are strong and contextually relevant, hence high scores in qualitative accuracy and contextual relevance. The correctness score is 8 because core facts about the hedging unwind and rate structure change are accurate, but the initial notional amount and timing are misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 422,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How did Schwab's integration of the iRebal portfolio rebalancing solution evolve from 2022 to 2023, and what does this indicate about its competitive positioning in the RIA market?",
      "original_answer": "In 2022, Schwab stated that it was retaining TD Ameritrade Institutional's customizable portfolio rebalancing solution, iRebal, as part of its offering for independent advisor clients. This indicated that Schwab acknowledged the value of iRebal but had not yet fully integrated or emphasized it within its broader platform. By 2023, Schwab had incorporated iRebal as a core part of its offerings for independent advisors, signaling a deeper integration and a strategic move to enhance its competitive positioning in the RIA market. This evolution reflects Schwab's broader integration progress, including the transition of over $1.6 trillion in client assets and more than 15 million client accounts from TD Ameritrade to the Schwab platform by 2023. The inclusion of iRebal as a central feature for RIAs suggests that Schwab is leveraging the solution to differentiate its service offerings and strengthen its appeal to independent advisors, aligning with its competitive advantage of introducing new products credibly through its strong brand and corporate reputation.",
      "llm_answer": "In the 2022 filing Schwab said it would **retain** TD Ameritrade Institutional’s customizable portfolio‑rebalancing tool iRebal as part of its offering for independent‑advisor (RIA) clients【page_6】. By the 2023 filing the company reported that it had **incorporated** iRebal into its own platform for those advisor clients【page_4】. This deeper integration signals that Schwab is strengthening its technology suite for RIAs—leveraging the iRebal capability to differentiate its platform and sharpen its competitive edge in the RIA market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of Schwab's integration of iRebal from 2022 to 2023. In 2022, Schwab stated it would retain iRebal for independent advisor clients, which the LLM correctly cites with a reference to the 2022 filing. By 2023, Schwab had incorporated iRebal into its platform, which the LLM accurately reflects as a deeper integration. The answer correctly infers that this signals a strategic enhancement of Schwab’s technology suite and competitive positioning in the RIA market. All entities (Schwab, TD Ameritrade Institutional, iRebal, RIA clients) and years (2022, 2023) are correct. There are no numeric values in the question or answer that require quantitative verification, so quantitative accuracy is scored as 10. The qualitative reasoning is sound: the LLM correctly synthesizes information across two years of filings and draws a logical conclusion about competitive positioning. The only minor shortcoming is that the original answer includes additional context about the broader integration of $1.6 trillion in assets and 15 million accounts, which strengthens the narrative of platform integration—but this detail is not essential to answering the specific question about iRebal’s evolution. The LLM answer remains semantically equivalent in intent and meaning. Contextual relevance is perfect, as the response directly addresses both parts of the multi-hop question: the evolution of iRebal and its implication for competitive positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 412,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How has Apple's approach to the iMac product line evolved between 2023 and 2024, based on the company's disclosures in its 10-K filings?",
      "original_answer": "In 2023, Apple described the iMac as part of its Mac product line, indicating it was actively manufacturing and marketing the desktop computer as part of its standard offerings. By 2024, Apple elevated the iMac to the level of a significant product announcement, listing it among other key launches like the MacBook Pro and iPad Pro in the MD&A section of its 2024 10-K. This shift suggests that the iMac gained strategic importance in 2024, likely reflecting a product refresh or redesign that warranted special mention as part of the company's innovation cycle.",
      "llm_answer": "In Apple’s 2023 Form 10‑K the iMac is only referenced as one of the existing desktop models within the broader “Mac” product line (see 2023 page 4). By contrast, the 2024 Form 10‑K lists the iMac as a distinct new product announced in the first quarter of fiscal 2024 (see 2024 page 24), indicating that Apple moved from merely describing iMac as a legacy offering to actively refreshing and promoting the iMac line. This shift reflects a renewed focus on updating the iMac portfolio in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies that in the 2023 10-K, the iMac was mentioned only as part of the broader Mac product line (page 4 reference), while in the 2024 10-K, it was highlighted as a distinct new product announced in Q1 of fiscal 2024 (page 24 reference), indicating a strategic shift. All entities (Apple, iMac, 10-K filings, fiscal years) are correct. The reasoning is sound: the model correctly infers from the change in disclosure language and placement (from general product line to specific announcement) that Apple renewed its focus on the iMac in 2024. The only minor limitation is that the LLM does not explicitly mention the comparative context with other key launches like MacBook Pro and iPad Pro, which the original answer includes to reinforce the strategic elevation. However, this omission does not detract from the core factual accuracy or logical inference. Quantitative elements (years, page numbers, fiscal quarters) are correct. Semantic equivalence is strong, and the answer fully addresses the evolution between 2023 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 318,
        "total_tokens": 1579
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How has RTX's relationship with the 2.820% Notes Due 2051 evolved between 2022 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "In 2022, RTX introduced the 2.820% Notes Due 2051 with an aggregate principal balance of $1,000 million. By 2024, this debt instrument remained on the books with the same principal balance of $1,000 million, indicating no repayment or additional issuance occurred during this period. However, the broader long-term debt structure expanded significantly, with total principal long-term debt increasing from an implied $40,078 million in 2022 (based on the 2024 presentation format) to $41,146 million in 2024. This suggests that while the 2.820% Notes Due 2051 remained unchanged, RTX increased its overall debt burden through other issuances, maintaining the 2051 notes as a stable component within a growing long-term debt portfolio.",
      "llm_answer": "RTX’s 2.820 % notes due 2051 were carried at a $1 billion principal balance at year‑end 2022 (​page 95​) and remained at the same $1 billion balance at year‑end 2024 (​page 89​), indicating the company has not retired or refinanced this issuance since it was issued in 2021. The continued holding of this low‑coupon, 30‑year‑maturity tranche shows RTX’s strategy of preserving a long‑dated, low‑cost component in its debt mix, contributing to a diversified long‑term debt structure despite an overall average maturity that has shortened to about 12 years by 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that the 2.820% Notes Due 2051 had a $1 billion principal balance in both 2022 and 2024, which matches the ground truth. However, it incorrectly states the notes were issued in 2021, while the original answer and knowledge graph indicate the issuance was reported in 2022. This is a factual error regarding timing. (2) Quantitatively, the $1,000 million = $1 billion equivalence is accurate, and the consistency of the balance across years is correctly reported. However, the LLM omits the key quantitative context from the ground truth: the total long-term debt increased from $40,078 million (implied 2022) to $41,146 million in 2024. This omission weakens the completeness of the quantitative picture. (3) The reasoning about RTX maintaining a long-dated, low-cost debt component is sound and aligns with the strategic interpretation in the original answer. However, the LLM introduces new information — that the average maturity shortened to 12 years by 2024 — which is not present in the ground truth and cannot be verified from the provided data, making it an unsupported addition. (4) The answer is contextually relevant and addresses both parts of the question: the evolution of the 2051 notes and implications for long-term debt. It correctly synthesizes that the note balance remained stable, indicating no repayment or new issuance. But it fails to fully capture the multi-hop insight that overall debt grew through other instruments, which is central to the original answer’s conclusion. Thus, while the core facts about the 2051 notes are correct, the broader debt structure analysis is incomplete and slightly misleading due to the unsupported claim about average maturity. Correctness score is 7 due to accurate core numbers but missing key comparative debt data and one incorrect issuance year.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 502,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How did the terms of Schwab's IDA agreement evolve between 2022 and 2023, particularly regarding service fees and reference rate adjustments?",
      "original_answer": "In 2022, Schwab disclosed that the IDA agreement had been amended to reduce the service fee on client cash deposits held at the TD Depository Institutions to 15 basis points from 25 basis points. By 2023, the company reported that its IDA agreement had transitioned reference rates previously tied to LIBOR to other appropriate benchmarks as part of its broader LIBOR phase-out preparation. This evolution reflects a shift from adjustments in fee structure to modifications in financial reference mechanisms, aligning the agreement with post-LIBOR regulatory and market standards.",
      "llm_answer": "The 2022 filing notes that the amended IDA agreement cut the service fee on client cash deposits held at the TD Depository Institutions to **15 basis points**, down from the **25 basis‑point** fee that TD Ameritrade paid under the prior IDA agreement (see 2022 10‑K p. 85). By the 2023 filing, Schwab had further revised the IDA agreement to **replace its LIBOR‑based reference rates with alternative benchmark rates**, completing the transition away from LIBOR (see 2023 10‑K p. 54).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the service fee reduction from 25 to 15 basis points in 2022 is accurately reported, and the 2023 transition from LIBOR to alternative benchmark rates is correctly stated. The specific basis point figures and the years (2022 and 2023) align with the original answer. (2) The answer is complete, addressing both sub-questions: changes in service fees (2022) and reference rate adjustments (2023). (3) Entities are accurate—'Schwab', 'TD Depository Institutions', 'IDA agreement', 'LIBOR', and the correct time periods are properly identified. (4) The reasoning is sound and reflects proper multi-hop synthesis: it draws from two different years of 10-K filings to show an evolution in the agreement’s terms—from fee adjustments to reference rate reform—consistent with Schwab’s LIBOR phase-out strategy. The inclusion of document citations (2022 10-K p. 85, 2023 10-K p. 54) enhances accuracy and traceability. (5) The semantic meaning is equivalent to the ground truth, with slightly more detail (e.g., naming TD Ameritrade’s prior payment), but no factual deviation. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 338,
        "total_tokens": 1603
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "What does the change in Filorga's financial treatment from 2023 (when it had $221 million in goodwill as a standalone reporting unit) to 2024 (when it was listed among other trademarks within broader segments) suggest about its strategic importance and valuation approach by the company?",
      "original_answer": "In 2023, Filorga was treated as a standalone reporting unit within the Europe segment with a clearly disclosed goodwill carrying value of $221 million, indicating its distinct financial significance and the company’s detailed impairment analysis for this brand. By 2024, Filorga was listed among other global and regional trademarks within broader product segments, without separate goodwill or valuation figures. This suggests that Filorga may have been integrated into a larger reporting structure, reducing its visibility as a standalone asset, which could signal a shift in strategic focus or a consolidation of brand management. This change affects how Filorga’s valuation and performance are assessed, potentially influencing future strategic decisions such as divestiture, investment, or brand prioritization.",
      "llm_answer": "In the 2023 filing Filorga was identified as its own reporting unit with $221 million of goodwill, meaning the company treated it as a distinct, strategically important asset that required separate goodwill‑impairment testing (page 59). By the 2024 filing Filorga is only mentioned among the company’s many global trademarks and the goodwill was re‑allocated to broader segments, indicating that the brand is now viewed as part of an aggregated brand portfolio and is valued at the segment level rather than as a standalone unit (page 79; note on goodwill reallocation, page 81). This shift suggests the company has downgraded Filorga’s standalone strategic importance and is using a more holistic, segment‑wide valuation approach for its brand assets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Filorga had $221 million in goodwill as a standalone reporting unit in 2023 and was integrated into broader segments in 2024 without separate goodwill disclosure, matching the ground truth. All factual elements—strategic importance, impairment testing, integration into a portfolio, and valuation shift—are accurately conveyed. (2) Quantitative accuracy is perfect: the $221 million figure is correctly cited, and no calculations are required. Format ($221 million) matches expectations. (3) The multi-hop reasoning is sound: the model correctly infers from the change in financial treatment (standalone to aggregated) that strategic importance may have been downgraded and that valuation is now segment-level. It references appropriate implications (impairment testing, brand portfolio aggregation), though it stops slightly short of explicitly mentioning potential impacts on divestiture or investment decisions as in the original answer, which slightly reduces qualitative completeness. (4) Contextual relevance is excellent—the response directly addresses the question about strategic importance and valuation approach, synthesizing changes across years and their implications. Minor deduction in qualitative accuracy only because the original answer includes broader strategic consequences (e.g., divestiture, brand prioritization) that are implied but not stated in the LLM version.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 400,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How does the change in Apple's disclosure about the iPhone 16 Pro between the 2023 and 2024 10-K filings reflect an evolution in its product development and reporting strategy?",
      "original_answer": "In the 2023 10-K filing, Apple announced the iPhone 16 Pro as part of its Fourth Quarter 2024 product lineup, indicating it was still in the planning and launch phase. By contrast, in the 2024 10-K filing, the iPhone 16 Pro is listed among existing product lines like the iPhone 15 and iPhone 14, suggesting it has transitioned into an active and established product within Apple's portfolio. This shift reflects a movement from forward-looking product planning in 2023 to retrospective inclusion in 2024, aligning with the product's lifecycle stage and indicating a more mature reporting posture around the iPhone 16 Pro.",
      "llm_answer": "In the 2023 Form 10‑K Apple’s discussion of the iPhone was limited to the overall product category and sales figures – the filing only refers to “iPhone” net sales in aggregate and does not name any future model (see the iPhone net‑sales commentary in the 2023 filing 【page_26】). By contrast, the 2024 Form 10‑K explicitly lists the iPhone 16 Pro as a distinct product in its MD&A product announcements 【page_24】 and even includes it in the iPhone line description 【page_4】. This shift from a generic, category‑level mention to a specific, model‑level disclosure signals that Apple has moved from merely reporting iPhone performance to highlighting the development and launch of a new flagship generation, reflecting a more granular, forward‑looking reporting strategy.",
      "correctness_score": 3,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The 2023 10-K did not announce the iPhone 16 Pro as part of a 'Fourth Quarter 2024 product lineup'—the ground truth states this, but the LLM contradicts it by claiming the 2023 filing only refers to 'iPhone' in aggregate and does not name any future model. However, the LLM incorrectly asserts that the 2024 10-K 'explicitly lists the iPhone 16 Pro' as a new launch, when in fact the ground truth indicates it is now listed among existing products like iPhone 15 and 14, implying it has already launched and is established. (2) There are no verifiable numeric values (e.g., sales figures, dates, percentages) in either answer, but the LLM fabricates document content: claiming iPhone 16 Pro is discussed in MD&A on page 24 and product line on page 4 of the 2024 10-K with citations like 【page_24】, which are not corroborated by the ground truth and appear hallucinated. (3) The multi-hop reasoning is flawed: the LLM interprets the shift as moving toward a 'more granular, forward-looking reporting strategy,' while the ground truth shows the opposite—the shift is from forward-looking (planning) to retrospective (established product), indicating maturity, not increased forward disclosure. (4) Contextually, the LLM addresses product development and reporting strategy, so relevance is moderate, but the qualitative analysis is based on incorrect premises. Overall, the answer misrepresents both the content of the filings and the direction of strategic evolution, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 434,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How has the company's use of Economic Value of Equity (EVE) simulations evolved in assessing interest rate risk, particularly in terms of modeling assumptions and balance sheet dynamics, between 2022 and 2023?",
      "original_answer": "In 2022, the company used EVE simulations to measure long-term interest rate risk, with key assumptions including non-negative investment yields, prepayment speeds of mortgage-related investments, and non-maturity deposit behavior. The EVE analysis was described as highly dependent on asset and liability assumptions based on historical behaviors and expectations of the economic environment. By 2023, the company expanded the role of EVE simulations to specifically capture the impact of client cash allocation changes on the balance sheet, which was not included in the earlier modeling approach. Additionally, in 2023, the company actively updated deposit beta assumptions in a declining interest rate environment for its net interest revenue simulation model, indicating a more dynamic approach to modeling interest rate sensitivity.",
      "llm_answer": "In the 2022 filing the firm described EVE as a “static‑balance‑sheet” tool that measures the long‑term impact of an instantaneous rate shift on the net present value of assets and liabilities, using third‑party term‑structure, pre‑payment and cash‑flow models and assumptions such as rate‑floor scenarios, non‑maturity deposit behavior and reinvestment of matured securities, but it did not model client‑cash reallocation or derivative effects [page_54, page_52]. By the 2023 filing the EVE framework had been expanded to incorporate both proprietary and third‑party models, include the impact of interest‑rate swap derivatives, and use internally built run‑off models for deposits and credits; it now explicitly reflects balance‑sheet dynamics—most notably a shortening liability duration and shifts in the asset‑liability mix as rates rose [page_53, page_51].",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of EVE simulations between 2022 and 2023. It accurately captures that in 2022, EVE was used as a static tool with assumptions around non-negative yields (referred to as 'rate-floor scenarios'), prepayment models, and non-maturity deposit behavior, and that client cash reallocation was not modeled—this matches the original answer. In 2023, the LLM correctly identifies an expansion in modeling scope, including more dynamic balance sheet effects. While the original answer emphasizes 'client cash allocation changes' as a new factor in 2023, the LLM rephrases this as 'balance-sheet dynamics—most notably a shortening liability duration and shifts in the asset-liability mix', which is semantically consistent and contextually valid. The LLM adds specific details not in the ground truth, such as inclusion of interest-rate swap derivatives and use of internally built run-off models, which are plausible enhancements but not mentioned in the original answer. These additions do not contradict the ground truth but represent reasonable elaborations that may reflect deeper document insight. There are no numerical inaccuracies (quantitative accuracy is perfect), and all years and entities are correct. The reasoning is sound and reflects multi-hop synthesis across years and modeling assumptions. The answer is fully contextually relevant. The score is 8 instead of 9-10 because the LLM introduces some unverified details (e.g., derivatives, proprietary models) not present in the ground truth, slightly exceeding the confirmed scope, though not inaccurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 451,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How did Qualcomm's strategic shift from enabling wireless access point technologies in 2022 to directly producing them in 2023 affect its competitive positioning and product portfolio breadth in the broader networking market?",
      "original_answer": "In 2022, Qualcomm's involvement with wireless access points was limited to enabling the technology through its foundational wireless innovations and chipset solutions, as noted in its discussion of edge networking growth driven by 5G and Wi-Fi 6 adoption. However, by 2023, Qualcomm had evolved its strategy to directly producing wireless access points as part of its broader networking product suite, which included Wi-Fi chips, routers, and network processors. This shift reflects an expansion of Qualcomm's product portfolio and a more direct role in the networking ecosystem, positioning the company to compete more directly with players like Broadcom and Intel by offering full-system solutions rather than just underlying components.",
      "llm_answer": "In its 2022 filing Qualcomm framed wireless‑access‑point technology as a market it was **enabling** – it highlighted growing demand for “wireless access points” and its role in Wi‑Fi‑Alliance standards but did not list the devices themselves as products (2022 p. 8). By the 2023 filing the QCT segment explicitly includes “wireless access points and routers” among its networking product lines, showing that Qualcomm now **produces** these devices (2023 p. 11). This shift moves Qualcomm from a pure licensor/enabler to a direct competitor with other networking‑equipment vendors, broadening its portfolio from chips and IP to complete Wi‑Fi, Ethernet, PON and gateway solutions and strengthening its competitive positioning in the broader networking market.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate, complete, and semantically equivalent to the ground truth. (1) It correctly identifies Qualcomm's shift from enabling wireless access point technologies in 2022 to directly producing them in 2023, citing specific sections of the 2022 and 2023 filings (p. 8 and p. 11), which aligns with the original answer’s timeline and strategic assessment. (2) There are no numeric values requiring calculation, but the years (2022, 2023) and product references (Wi-Fi chips, routers, access points) are accurate and consistent with the knowledge graph. (3) The multi-hop reasoning is sound: the model correctly infers a strategic shift by comparing Qualcomm’s product disclosures across two years and synthesizes this into implications for competitive positioning and portfolio breadth. (4) The answer captures all key elements: transition from enabler to producer, expansion of product portfolio (including routers, gateways, Ethernet, PON), and intensified competition with vendors like Broadcom and Intel (implied through 'direct competitor with other networking-equipment vendors'). Wording differs slightly but meaning is preserved. All evaluation dimensions are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 339,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has the interest-only payment structure of Schwab's HELOC product evolved from 2022 to 2023, based on the percentage of adjustable-rate mortgages with interest-only terms and the portion not scheduled to reset for three or more years?",
      "original_answer": "In 2022, 28% of adjustable-rate mortgages were interest-only loans, with 89% of those not scheduled to reset for three or more years. In 2023, this shifted slightly to 27% of adjustable-rate mortgages being interest-only, with 86% of those not scheduled to reset for three or more years. This reflects a minor decrease in both metrics, suggesting a slight tightening or evolution in the interest-only structure of the HELOC product.",
      "llm_answer": "In the 2022 filing, about 28 % of Schwab’s adjustable‑rate mortgages were interest‑only, and roughly 89 % of those interest‑only loans were not scheduled to reset for three or more years. By the 2023 filing, the interest‑only share had slipped to about 27 % and the portion not resetting for three or more years fell to roughly 86 %, showing a slight decline in both the prevalence of interest‑only HELOCs and the length of their rate‑reset periods.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages for both years are accurate: 28% and 89% in 2022, and 27% and 86% in 2023, with appropriate rounding language ('about', 'roughly') consistent with reporting style. (2) The answer addresses all parts of the question: the percentage of adjustable-rate mortgages with interest-only terms and the portion not scheduled to reset for three or more years, for both 2022 and 2023. (3) Entities are correct—Schwab, HELOC product context, adjustable-rate mortgages, interest-only terms, and correct years. (4) The reasoning is sound: the LLM correctly identifies a slight decline in both metrics and interprets this as a minor evolution in the interest-only structure, which aligns with the ground truth's conclusion. There is no factual error, omission, or misinterpretation. The semantic meaning and factual content are equivalent to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 276,
        "total_tokens": 1520
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has Qualcomm's involvement in the XR market evolved from 2022 to 2023, based on their strategic investments and product revenue disclosures?",
      "original_answer": "In 2022, Qualcomm's involvement in XR was primarily through strategic investments made via Qualcomm Ventures, targeting early-stage companies in areas including XR to expand opportunities for their technologies. By 2023, this involvement evolved into direct revenue generation, as XR was explicitly listed among the industries and applications for which Qualcomm sold products, indicating a shift from investment to commercialization. This transition reflects a significant change in Qualcomm's engagement with XR, moving from supporting external innovation to deriving tangible revenue from XR-related product sales.",
      "llm_answer": "Qualcomm’s QSI (Qualcomm Ventures) arm continued to list XR as a priority area for early‑stage strategic investments in both FY 2022 and FY 2023 (QSI segment description)【page_14】.  At the same time, XR is counted within the IoT revenue stream, which fell from $7.353 billion in FY 2022 to $5.94 billion in FY 2023, showing a decline in XR‑related product sales despite the ongoing investment focus【page_73】.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial factual correctness but introduces significant inaccuracies. It correctly notes Qualcomm Ventures' continued investment focus on XR in both 2022 and 2023, aligning with the ground truth's emphasis on strategic investments. However, it incorrectly asserts that XR-related product sales declined, citing a drop in IoT revenue from $7.353 billion to $5.94 billion. The ground truth does not support this claim—while XR is part of the broader IoT segment, the original answer does not state or imply a decline in XR-specific revenue, nor does it provide any numerical data about XR revenue. Thus, the LLM incorrectly infers declining XR sales from a general IoT revenue drop, which is unsupported and contradicts the ground truth's narrative of growth and commercialization. (2) The numbers cited ($7.353B and $5.94B) may be accurate representations of total IoT revenue for those years, but attributing this decline directly to XR is a misinterpretation. There is no evidence in the ground truth that XR revenue declined; in fact, the shift to direct revenue generation suggests growth. (3) The multi-hop reasoning is flawed: the model fails to synthesize the key evolution—moving from investment to commercialization—and instead focuses on a misleading revenue trend. It misses the core qualitative shift described in the original answer: from indirect involvement (via investments) to direct revenue generation. (4) The contextual relevance is moderate because the answer discusses relevant entities (Qualcomm, XR, IoT, Qualcomm Ventures) and timeframes, but the conclusion about declining sales undermines the overall correctness. Due to major factual misrepresentation and flawed reasoning despite some correct elements, the correctness score is low at 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 489,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the aggregate principal balance of the 3.030% Notes Due 2052 evolved between 2022 and 2024, and what does this indicate about RTX's long-term debt structure?",
      "original_answer": "The aggregate principal balance of the 3.030% Notes Due 2052 remained stable at $1,100 million in both 2022 and 2024. This indicates that RTX has maintained its long-term commitment to this particular debt instrument without any repayments or additional issuances during this period. Despite overall changes in other long-term debt components, the 3.030% Notes Due 2052 remained unchanged, suggesting strategic consistency in managing this portion of its capital structure.",
      "llm_answer": "The 3.030 % notes due 2052 were issued in November 2021 for $1.1 billion and were not repaid thereafter, so the aggregate principal balance was $1.1 billion at the end of 2022 and remained $1.1 billion at year‑end 2023 and 2024 (issuance shown on page 94; balance $1,100 m in 2021 on page 95 and unchanged $1,100 m for 2023‑2024 on page 89). This unchanged balance indicates that this tranche of senior debt has been a stable, unchanged component of RTX’s long‑term debt structure over the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the aggregate principal balance of the 3.030% Notes Due 2052 as $1,100 million (or $1.1 billion) in both 2022 and 2024, matching the ground truth. The note issuance in November 2021 is accurate context not contradicted by the original answer. The balance is correctly stated as unchanged across years, which aligns with the stability claim. (2) All numeric values—$1.1 billion, $1,100 million, and the years 2022, 2023, 2024—are factually correct and consistent with the ground truth; format variations (e.g., $1.1 billion vs $1,100 million) are acceptable and semantically equivalent. (3) The reasoning is sound: the LLM infers stability from lack of repayment or new issuance, correctly synthesizing data across time points and documents (citing specific pages adds credibility). It addresses the evolution (no change) and links it to RTX’s long-term debt strategy, though it slightly omits explicit mention of 'no additional issuances' during 2022–2024, focusing instead on the post-issuance timeline starting in 2021. (4) The answer is highly relevant, directly addressing both parts of the question—evolution of the balance and its implication for RTX’s debt structure. The conclusion about stability and strategic consistency is logically supported. Minor deduction in qualitative accuracy due to slight overemphasis on 2021 issuance rather than focusing strictly on 2022–2024 evolution, but overall reasoning remains strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 408,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has AXP's focus on Corporate Card solutions evolved between 2023 and 2024, and what does this shift suggest about its broader commercial payments strategy?",
      "original_answer": "In 2023, AXP emphasized evolving its card value propositions and differentiating its corporate card and accounts payable expense management solutions as part of a broader push to strengthen its position in commercial payments. By 2024, while the focus on commercial payments remained, AXP shifted toward designing 'innovative products and features, including financing, banking and payment solutions for our business customers,' indicating a more integrated and solution-oriented approach. This evolution suggests that AXP is expanding beyond just product differentiation to embedding the Corporate Card into a wider suite of business financial services, aligning it more closely with holistic commercial needs.",
      "llm_answer": "In 2023 American Express said it would “evolve our card value propositions, further differentiate our corporate card and accounts‑payable expense‑management solutions” as part of its commercial‑payments push【page_8】. By the 2024 filing the language stresses an even stronger differentiation of corporate‑card offerings and the rollout of new financing, banking and payment products for business customers, signaling that corporate cards have become a core pillar of its commercial‑payments growth strategy【page_8】. This shift is reflected in the Delta cobrand portfolio – a key corporate‑card channel – which grew from roughly 10 % of worldwide billed business in 2023 to about 12 % in 2024【page_7】.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures AXP's 2023 focus on evolving card value propositions and differentiating corporate card and expense management solutions, and the 2024 shift toward broader financial solutions for business customers. However, the ground truth emphasizes a strategic evolution toward integrated, solution-oriented offerings (e.g., financing, banking, payments), while the LLM overemphasizes 'stronger differentiation' rather than a shift in strategic scope. The inclusion of the Delta cobrand portfolio growth from 10% to 12% of worldwide billed business is factually accurate and relevant, but this specific data point is not present in the original answer, suggesting the LLM introduced external or unsupported detail. (2) Quantitatively, the percentages (10% in 2023 to 12% in 2024) are presented accurately, but the original answer does not include these figures, so their correctness cannot be verified against the ground truth. This introduces a risk of hallucination or misattribution, though the numbers may be contextually plausible. (3) The multi-hop reasoning is partially sound: the model connects AXP’s product evolution with commercial strategy and supports it with a metric from another section (Delta portfolio), but the original answer does not make this specific link, weakening alignment with the ground truth. The core strategic shift is recognized but not fully articulated in terms of moving beyond product differentiation to holistic financial integration. (4) The contextual relevance is high as the response directly addresses the evolution in AXP’s corporate card focus and its implications. However, the qualitative accuracy is reduced due to the introduction of unverified metrics and a slightly misaligned interpretation of the strategic shift. The correctness score reflects mostly accurate information with minor but notable deviations in emphasis and potential factual overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 524,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic positioning of PCA SKIN within Colgate-Palmolive's Oral, Personal and Home Care segment evolved between 2023 and 2024, particularly in terms of its distribution channels?",
      "original_answer": "In 2023, PCA SKIN was listed among Colgate-Palmolive’s principal global and regional trademarks and was included in the broader category of products sold primarily to traditional and eCommerce retailers, wholesalers, distributors, and dentists. By 2024, PCA SKIN remained a listed principal trademark, but the filing specifically expanded the distribution channels to include sales to skin health professionals in some geographies. This indicates a refinement in positioning PCA SKIN within more specialized skincare distribution channels, though no change in production or brand status is indicated.",
      "llm_answer": "PCA SKIN remains positioned as a skin‑health brand inside the Personal‑Care portion of Colgate‑Palmolive’s Oral, Personal and Home Care segment, and its sales continue to be directed “primarily to a variety of traditional and e‑Commerce retailers, wholesalers, distributors, dentists and, in some geographies, skin‑health professionals.” The 2024 filing repeats the same distribution‑channel description that appeared in the 2023 filing, indicating no material change in its strategic positioning or channel mix【page_79】.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that there was no change in distribution channels between 2023 and 2024, directly contradicting the ground truth. While it correctly identifies PCA SKIN's placement within Colgate-Palmolive’s segment and lists the general distribution channels (retailers, wholesalers, dentists, etc.), it fails to recognize the key evolution: in 2024, the filing explicitly added 'skin health professionals in some geographies' as a distinct and new element of distribution strategy. The LLM incorrectly states that the 2024 filing 'repeats the same distribution-channel description' as 2023, when in fact the expansion represents a strategic refinement in positioning toward specialized skincare channels. There are no numerical figures to verify, so quantitative accuracy is not applicable beyond correct referencing of years (2023, 2024), which are accurate. The reasoning is flawed because it misses the multi-hop nuance: comparing textual changes across filings to infer strategic evolution. Despite this, the answer remains contextually relevant by addressing the right segment, brand, and general channel structure. Thus, correctness and qualitative accuracy are significantly penalized due to the central factual error, even though the response is well-structured and plausibly worded.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 369,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic focus and commercial positioning of Opdivo evolved between 2022 and 2023, particularly in terms of new tumor indications and combination therapies, and what implications does this have for its revenue growth trajectory?",
      "original_answer": "In 2022, Opdivo was approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, and stomach cancers, with the Opdivo + Yervoy regimen approved in multiple markets for NSCLC, melanoma, MPM, RCC, CRC, and gastric/esophageal cancers. It reported U.S. revenue growth driven by combinations in NSCLC, kidney cancer, and gastric/esophageal cancers. By 2023, Opdivo's strategic focus expanded into new tumor types and earlier lines of therapy, with an emphasis on broadening its use both as a monotherapy and in combination with Yervoy and other agents. The company also highlighted the potential of a subcutaneous formulation to enhance patient benefits and drive long-term adoption. This evolution indicates a strategic push to sustain revenue growth by diversifying indications and optimizing delivery mechanisms, despite increasing market competition.",
      "llm_answer": "In the 2022 filing, Opdivo was already marketed in a wide range of tumor types (bladder, CRC, RCC, lung, melanoma, etc.) and the company’s commercial plan centered on “broadening the use of Opdivo… expanding into new tumors” and on growing the Opdivo + Yervoy combination while pursuing additional registrational studies (page 71). By 2023 the strategy had shifted to earlier‑line and adjuvant/neoadjuvant settings—evidenced by FDA approval for adjuvant melanoma (Oct 2023) and EC approvals for neoadjuvant NSCLC (June 2023), a sub‑cutaneous formulation, the fixed‑dose Opdualag (Opdivo + Yervoy) and integration with new NSCLC assets such as Augtyro and Krazati (pages 43 & 42). The 2023 results note that “an increase in demand for Opdivo… partially offset” the overall revenue decline, indicating that the expanded indication and combo portfolio is expected to sustain or accelerate Opdivo’s revenue growth trajectory (page 45).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual information is correct: Opdivo's 2022 indications (bladder, CRC, RCC, lung, melanoma, etc.) and the focus on expanding into new tumors and combinations with Yervoy are accurately reported. The 2023 strategic shift to earlier-line and adjuvant/neoadjuvant settings is supported by specific approvals: FDA approval for adjuvant melanoma in October 2023 and EC approval for neoadjuvant NSCLC in June 2023—both plausible within the timeline and consistent with the evolution described in the original answer. The mention of the subcutaneous formulation and fixed-dose Opdualag (Opdivo + Yervoy) reflects accurate commercial and delivery innovations. (2) Quantitative accuracy is excellent: all dates (Oct 2023, June 2023) are correctly stated and match the progression from 2022 to 2023; no numerical errors in revenue or calculations. (3) Multi-hop reasoning is sound: the model synthesizes strategic evolution across years, connects new indications and combination therapies to revenue implications, and correctly infers that increased demand for Opdivo helped offset broader revenue declines, supporting the conclusion of a sustained growth trajectory. (4) The only minor gap is that the original answer mentions additional 2022 indications (blood, HCC, MPM, stomach cancers) and combination approvals in gastric/esophageal cancers, which the LLM answer omits—though it captures the core pattern. The integration with Augtyro and Krazati is an added detail not in the ground truth, but this does not contradict it and may reflect forward-looking strategy. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1484,
        "completion_tokens": 475,
        "total_tokens": 1959
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did American Express's investment in foreign government bonds and obligations evolve between 2023 and 2024 in terms of fair value and maturity distribution?",
      "original_answer": "In 2023, American Express held $549 million in foreign government bonds and obligations with all of it maturing in 12 months or more and a gross unrealized loss of $1 million. By 2024, the fair value of these investments increased significantly to $765 million, with $764 million maturing within one year and only $1 million maturing after one year but within five years. This indicates a substantial increase in exposure to foreign government bonds, primarily in short-term maturities.",
      "llm_answer": "American Express’s foreign‑government bond portfolio was valued at $770 million at the end of 2023 and slipped slightly to $765 million at the end of 2024 (Table 4.1, Note 4)【page_124】. The maturity mix remained overwhelmingly short‑term, with $768 million due within one year and $2 million due in the 1‑to‑5‑year bucket in 2023, shifting to $764 million due within one year and $1 million in the 1‑to‑5‑year bucket in 2024 (Tables 4.4 for 2023 and 2024)【page_120】【page_126】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, American Express held $549 million in foreign government bonds in 2023, not $770 million as stated by the LLM. The 2024 value of $765 million is correct. The maturity distribution for 2023 is also incorrect: the LLM claims $768 million matured within one year and $2 million in 1–5 years, but the ground truth states that *all* $549 million matured in 12 months or more (i.e., *after* one year), with a $1 million unrealized loss. The LLM incorrectly portrays the 2023 portfolio as short-term, when it was entirely long-term. The 2024 maturity breakdown ($764M <1 year, $1M 1–5 years) matches the ground truth. (2) Quantitative accuracy is poor: the 2023 fair value is off by $221 million, and the maturity distribution is completely reversed. The LLM misrepresents the nature of the investment shift—claiming it remained 'overwhelmingly short-term' in 2023 when it was actually entirely long-term. (3) The reasoning is partially sound in noting a shift toward short-term maturities in 2024, but the multi-hop synthesis fails because it uses incorrect 2023 data. The conclusion about short-term dominance in 2023 contradicts the ground truth. (4) Contextual relevance is high—the answer addresses fair value and maturity distribution across years, uses appropriate financial terminology, and cites relevant tables. However, due to major factual and quantitative errors, especially in the 2023 data, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 427,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How has Walmart's use of intercompany financing arrangements evolved between 2022 and 2024, particularly regarding the amount of cash not freely transferable to the U.S. and the conditions under which such transfers occur?",
      "original_answer": "In 2022, Walmart reported $4.3 billion in cash and cash equivalents that may not be freely transferable to the U.S., with $2.2 billion of that amount subject to approval by Flipkart minority shareholders. By 2024, the amount of cash not freely transferable decreased slightly to $3.3 billion, and the language indicates that these transfers are now generally subject to approval from noncontrolling interest shareholders, rather than specifically tied to Flipkart. This reflects a slight reduction in the magnitude of restricted cash and a broader framing of the conditions under which such transfers occur, suggesting a shift in the structure or focus of intercompany financing arrangements.",
      "llm_answer": "In the 2022 filing, Walmart said that about **$4.3 billion** of cash and cash equivalents “may not be freely transferable to the U.S. due to local laws or other restrictions,” and **$2.2 billion** of that amount could be accessed only through dividends or inter‑company financing that required **approval of Flipkart’s minority shareholders**【page_60】. By the 2024 filing, the non‑transferable balance had fallen to **$3.5 billion**, and the restriction is described more broadly as cash “may not be freely transferable … due to local laws or other restrictions **or is subject to the approval of the non‑controlling‑interest shareholders**”【page_43】. The company continues to rely on inter‑company financing to move cash where needed at minimum cost, but the amount of cash subject to these constraints has decreased and the approval requirement has shifted from a specific Flipkart minority‑shareholder consent to a general non‑controlling‑interest‑shareholder approval.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct but contains a minor quantitative inaccuracy: it reports the 2024 amount of non-transferable cash as $3.5 billion, while the ground truth states $3.3 billion. All other numbers ($4.3 billion in 2022 and $2.2 billion subject to Flipkart minority shareholder approval) are accurate. (2) The calculation of change over time is directionally correct (a decrease), but the magnitude is slightly off due to the $3.5B vs $3.3B discrepancy. Number formats are consistent and acceptable (e.g., $4.3 billion). (3) The qualitative reasoning is strong: the LLM correctly identifies the shift from Flipkart-specific shareholder approval to a broader non-controlling-interest shareholder approval framework, reflecting an accurate synthesis across the 2022 and 2024 filings. It captures the evolution in language and implied structural change in intercompany financing arrangements. (4) Contextual relevance is excellent—the response directly addresses both parts of the question: the amount of cash not freely transferable and the conditions for transfer. The slight numerical error prevents a top score, but the overall reasoning, entity accuracy (Walmart, Flipkart, noncontrolling interests), and multi-hop synthesis across years and restrictions are sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 362,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did the composition of Texas Instruments' U.S. Retiree Health Care Plan assets evolve between the 2023 and 2024 filings, particularly in terms of fixed income securities and equity securities allocation?",
      "original_answer": "The composition of Texas Instruments' U.S. Retiree Health Care Plan assets remained completely unchanged between the 2023 and 2024 filings. In both years, the plan held $210 million in fixed income securities and cash equivalents, and $54 million in equity securities, resulting in a total of $264 million in plan assets. The fixed income allocation represented approximately 79.5% of the total plan assets, while equity securities represented approximately 20.5% in both years. The identical figures across both filings indicate no evolution in the asset allocation strategy for this plan during the reported period.",
      "llm_answer": "In the 2023 Form 10‑K the U.S. Retiree Health Care Plan was invested about 80 % in fixed‑income securities and cash equivalents and roughly 20 % in equity securities 【page_45】. The 2024 filing reports the same weighted‑average mix – 80 % fixed‑income/cash and 20 % equity 【page_48】. Thus, the plan’s asset composition remained essentially unchanged between the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies that the asset composition of Texas Instruments' U.S. Retiree Health Care Plan remained unchanged between the 2023 and 2024 filings, with approximately 80% allocated to fixed income securities and cash equivalents and 20% to equity securities. This aligns with the ground truth, which specifies $210 million (79.5%) in fixed income and $54 million (20.5%) in equities, totaling $264 million—percentages that round to 80% and 20% respectively. The LLM uses rounded figures ('about 80%', 'roughly 20%') which are reasonable approximations and semantically equivalent for practical interpretation. The core conclusion—that there was no evolution in allocation—is accurate and supported by both filings. The only minor shortcoming is the lack of explicit dollar amounts ($210M, $54M, $264M), which were present in the original answer and would have enhanced completeness. However, since the percentages are correctly reported and the stability of allocation is properly emphasized, the omission does not undermine the factual correctness. The multi-hop reasoning (comparing 2023 and 2024 disclosures) is sound, entities are correct, and the response directly addresses the question about evolution in composition. Contextual relevance is perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 355,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Honeywell's 2006 Stock Plan for Non-Employee Directors evolve between 2022 and 2024 in terms of the specific forms of award agreements offered, and what might this suggest about changes in the company's non-employee director compensation structure?",
      "original_answer": "In 2022, Honeywell's 10-K filing listed both the 'Form of Option Agreement' (Exhibit 10.30) and the 'Form of Restricted Unit Agreement' (Exhibit 10.32) as part of the 2006 Stock Plan for Non-Employee Directors. By 2024, while the 'Form of Option Agreement' was still referenced (Exhibit 10.29), the 'Form of Restricted Unit Agreement' was no longer explicitly mentioned in the exhibit list. This suggests a shift in the types of equity awards offered to non-employee directors, potentially signaling a strategic move toward emphasizing stock options over restricted units in director compensation.",
      "llm_answer": "In both the 2022 and 2024 Form 10‑K the 2006 Stock Plan for Non‑Employee Directors is described only with a **Form of Option Agreement** (Exhibit 10.3) and an **Omnibus Amendment – Form of Option Agreement** (Exhibit 10.1) 【page_123】. No new award‑type forms (e.g., RSU agreements) appear in the 2024 filing, indicating that Honeywell’s compensation for non‑employee directors under the 2006 plan remains focused on stock‑option grants and has not been broadened to other equity instruments.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Honeywell's 10-K referenced both the 'Form of Option Agreement' (Exhibit 10.30) and the 'Form of Restricted Unit Agreement' (Exhibit 10.32) under the 2006 Stock Plan for Non-Employee Directors. However, the LLM incorrectly states that only the 'Form of Option Agreement' (Exhibit 10.3) and an 'Omnibus Amendment' (Exhibit 10.1) were present in both 2022 and 2024, which contradicts the original data. The exhibit numbers cited by the LLM (10.1, 10.3) do not match those in the ground truth (10.30, 10.32 in 2022; 10.29 in 2024), indicating incorrect entity identification. Furthermore, the LLM fails to note the removal of the Restricted Unit Agreement by 2024, which is central to the question. Instead, it falsely claims the plan has 'remained focused' on options with no changes, missing the evolution entirely. While the general direction of interpretation (continued use of options) is partially aligned, the incorrect exhibits, omission of restricted units in 2022, and failure to detect a key change in award forms undermine both completeness and accuracy. The reasoning is flawed due to reliance on incorrect data, and the conclusion about lack of broadening is unsupported because the LLM ignores that restricted units were previously offered. Semantic equivalence is not achieved due to major factual discrepancies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 391,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Walmart's strategic position regarding its ownership stake in Flipkart evolve between 2022 and 2024, particularly in terms of financial implications and potential exposure to regulatory risks?",
      "original_answer": "In 2022, Walmart received $3.2 billion in equity funding related to Flipkart, which reduced its ownership stake from 83% to 75%. This signaled a partial financial exit while maintaining majority control. By 2024, however, Walmart disclosed ongoing regulatory scrutiny in India, including a show cause notice issued in July 2021 and subsequent information requests related to alleged violations of India's Foreign Direct Investment rules during the period 2009–2015—prior to Walmart's acquisition of Flipkart in 2018. Despite the reduced ownership stake, Walmart remained exposed to potential regulatory consequences, including share ownership restrictions, and noted its inability to reasonably estimate potential losses or indemnification proceeds from prior shareholders. The evolution reflects a shift from active financial participation to managing legacy risks tied to Flipkart's pre-acquisition history.",
      "llm_answer": "In fiscal 2022 Walmart sold a slice of its Flipkart holding, receiving about $3.2 billion in new equity funding and lowering its ownership from roughly 83 % to 75 %. By the 2024 filing the company’s remaining stake was being examined by Indian regulators—a foreign‑direct‑investment show‑cause notice and an antitrust probe that could impose fines, restrictions on share ownership or force further divestiture—so the strategic focus shifted from cash‑generating stake reduction to managing heightened regulatory exposure on the residual investment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $3.2 billion equity funding in 2022 and the reduction in Walmart's ownership stake from 83% to 75%, matching the ground truth. It accurately reflects the shift in strategic position from financial participation to regulatory risk management. The mention of 'fiscal 2022' is acceptable as Walmart's fiscal year ends in January, so fiscal 2022 corresponds to calendar 2021, but the event (equity funding and stake reduction) is correctly associated with the 2022 reporting period. The 2024 disclosure about ongoing regulatory scrutiny is also correctly captured. (2) All numeric values—$3.2 billion, 83%, 75%—are accurate and match the original answer. No calculations are required beyond these reported figures, and they are presented correctly. (3) The multi-hop reasoning is sound: the model connects Walmart’s partial exit (financial implication) with subsequent regulatory risks (legal exposure), synthesizing information across time and domains. It correctly notes that the regulatory issues stem from pre-2018 activities but impact Walmart post-acquisition. However, it slightly overreaches by mentioning an 'antitrust probe' not specified in the ground truth; the original only references a show cause notice and information requests under FDI rules, not antitrust. This introduces a minor factual inaccuracy. (4) Despite this, the answer remains highly contextually relevant, addressing both financial implications and regulatory exposure as required. The core evolution in strategic position is accurately conveyed, warranting a high correctness score. The qualitative accuracy is slightly reduced due to the unsupported reference to an antitrust probe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 468,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the composition and strategic emphasis of HON's U.S. cash balances evolve between 2022 and 2024, particularly in terms of total cash holdings and geographic distribution of funds?",
      "original_answer": "In 2022, HON reported holding $11.5 billion of cash and cash equivalents as of December 31, 2021, with an emphasis on safety of principal and diversification among counterparties. By 2024, the company held $11.0 billion in total cash and equivalents as of December 31, 2024, but specifically noted that $8.0 billion of that amount was held in non-U.S. subsidiaries. This represents a shift in geographic distribution, with a larger portion of liquidity positioned outside the U.S., while maintaining the same strategic emphasis on safety and diversification.",
      "llm_answer": "In the 2022 10‑K Honeywell said it held $11.5 billion of cash and cash equivalents (2021) and highlighted U.S. cash balances as a core liquidity source, stressing safety of principal, secondary yield‑maximisation and diversification across counterparties【page_41】. By the 2024 10‑K total cash and cash equivalents were $11.0 billion, but $8.0 billion was held in non‑U.S. subsidiaries, leaving roughly $3.0 billion in U.S. cash—showing a shift toward a larger overseas cash pool while keeping the same safety‑first, yield‑second strategic emphasis【page_39】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures: $11.5 billion in cash as of December 31, 2021 (reported in the 2022 10-K), and $11.0 billion total cash as of December 31, 2024 (reported in the 2024 10-K), with $8.0 billion held in non-U.S. subsidiaries. These numbers match the ground truth exactly. The derived figure of ~$3.0 billion in U.S. cash ($11.0B - $8.0B) is accurate and logically sound. (2) All calculations and numeric references are correct. The dates align with the reporting conventions (i.e., 2022 10-K reporting 2021 year-end data), which is standard and properly interpreted. (3) The multi-hop reasoning is strong: the model correctly synthesizes data across two different 10-K filings (2022 and 2024), identifies the shift in geographic distribution of cash, and maintains the continuity of strategic emphasis on safety and diversification. The mention of 'yield-maximisation' as secondary is a slight expansion not present in the original answer, but it does not contradict the ground truth and may reflect additional nuance from the source document (page 41). (4) The answer fully addresses both parts of the question: evolution in total cash holdings and geographic distribution. The strategic emphasis is accurately carried through. Only a minor point—ground truth does not explicitly mention 'yield-maximisation', so this adds a small element not in the original—but it doesn’t detract from correctness. Overall, the answer is factually precise, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 431,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the financial treatment and liability estimation methodology for the Membership Rewards program evolve from 2023 to 2024, particularly in terms of deferred fees and liability modeling assumptions?",
      "original_answer": "In 2023, the company recognized deferred fees related to Membership Rewards program participants, indicating a focus on the deferral aspect of fee revenue associated with the program. By 2024, the disclosures provided a much more detailed explanation of the liability estimation methodology, including the use of the Ultimate Redemption Rate (URR) and the weighted average cost (WAC) per point. The 2024 filing also quantified the sensitivity of the liability to changes in assumptions, noting that a 25 basis point increase in URR would raise the liability by $197 million, and a 1 basis point increase in WAC per point would increase it by $220 million. This reflects a shift from a simpler mention of deferred fees to a comprehensive, model-driven approach to estimating future redemption liabilities.",
      "llm_answer": "In the 2023 filing the company recorded a “Membership Rewards liability” and a net “Deferred card and other fees” line (which nets deferred acquisition costs and cancellation reserves) and estimated the liability by applying an ultimate‑redemption‑rate (URR) and a weighted‑average‑cost (WAC) per point derived from 12 months of redemptions and actuarial models that consider spend, tenure, product type and credit attributes【page_128】. The 2024 filing keeps the same accounting treatment but expands the disclosure of the liability‑estimation process: it still uses URR and WAC per point, but now quantifies the sensitivity of the liability to assumption changes (e.g., a 25‑bp URR shift would add ≈ $197 million; a 1‑bp WAC shift would add ≈ $220 million) and reiterates that deferred fees are net of acquisition costs and cancellation reserves【page_86】. Thus, while the underlying modeling assumptions remain unchanged, the 2024 report adds explicit sensitivity analysis and clearer net‑deferred‑fee presentation.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in quantitative terms: the sensitivity figures ($197 million for a 25 bp increase in URR and $220 million for a 1 bp increase in WAC per point) are accurately reported, and the use of URR and WAC in liability estimation is correctly identified for both years. The mention of actuarial models and factors like spend, tenure, and product type adds detail, though this level of granularity is not contradicted by the ground truth. However, the LLM incorrectly states that the URR and WAC methodology was already used in 2023, while the ground truth indicates that 2023 only mentioned deferred fees without detailing the URR/WAC modeling approach. This misrepresents the evolution, implying the modeling assumptions were unchanged when in fact the ground truth describes a shift from a simpler deferred-fee focus in 2023 to a more detailed model-driven approach in 2024. This is a significant qualitative error in reasoning and synthesis across years, undermining the accuracy of the evolution narrative. Despite this, the answer is highly relevant and captures the key enhancement in 2024 disclosures regarding sensitivity analysis. The quantitative accuracy is high, with correct dollar amounts and basis point impacts. Contextual relevance is perfect, as the response directly addresses the question’s focus on deferred fees and liability modeling changes. The correctness score is reduced due to the incorrect portrayal of 2023 methodology, which affects the core multi-hop comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 416,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How has Adobe's strategic positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its alignment with Adobe's broader product ecosystem?",
      "original_answer": "In 2022, Adobe described the integration of Frame.io as part of its Digital Media reportable segment, emphasizing its role as a cloud-based video collaboration platform acquired for $1.18 billion, with integration efforts just beginning. By 2024, Frame.io had transitioned from being a newly acquired integration to being positioned as a core component of Adobe's creative collaboration suite, directly integrated with key applications such as Adobe Premiere Pro, After Effects, Photoshop, and Workfront. Additionally, in 2024, Frame.io was included as part of Adobe GenStudio, indicating a deeper strategic alignment with Adobe's broader content production and collaboration ecosystem. This evolution reflects a shift from initial integration to full ecosystem incorporation.",
      "llm_answer": "In the 2022 Form 10‑K Adobe described Frame.io mainly as a newly‑acquired, cloud‑based video‑collaboration platform that it would “begin integrating … into our Digital Media segment” (see 2022 p. 41‑42). By the 2024 filing the company is positioning Frame.io as a core, cloud‑native collaboration hub that is “directly integrated with Adobe Premiere Pro, Adobe After Effects, Adobe Photoshop, Adobe Lightroom and Adobe Workfront” and is offered through Adobe GenStudio to enable content production at scale (2024 p. 12). This shows a shift from a standalone acquisition added to the Digital Media business to a strategic component woven into multiple Creative Cloud apps and the broader Adobe ecosystem, reinforcing cross‑product workflows and AI‑driven content creation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Frame.io was acquired and initially integrated into the Digital Media segment in 2022, and by 2024 it was positioned as a core collaboration hub integrated with Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront. The mention of Adobe GenStudio in 2024 is accurate and reflects deeper ecosystem alignment. (2) There are no numeric values (e.g., acquisition cost of $1.18B) in the LLM answer, but none were required for the question's focus on strategic positioning; the absence does not detract from correctness as the question did not explicitly ask for financial terms. (3) The multi-hop reasoning is sound—correctly synthesizing the evolution from 2022 (initial integration) to 2024 (deep ecosystem integration) across filings. (4) The only minor shortcoming is that the LLM mentions Lightroom instead of the ground truth's mention of Workfront (both are correct integrations, but Workfront was emphasized in the original answer for cross-product workflow with enterprise tools). Additionally, the original answer explicitly notes the $1.18B acquisition, which the LLM omits—however, since the question focuses on strategic positioning and integration rather than financial details, this omission is not critical. Overall, the answer captures the evolution accurately, uses proper context from the filings, and maintains semantic equivalence with strong qualitative and contextual fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 414,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How did the composition of private alternative investments, specifically equity-like funds, evolve between 2022 and 2023 in terms of fair value measurements using significant unobservable inputs (Level 3)?",
      "original_answer": "In 2022, equity-like funds under private alternative investments had a fair value of $5.5 million measured using significant unobservable inputs (Level 3). In 2023, this value increased significantly to $25.4 million. This indicates a fivefold increase in the portion of equity-like funds valued using Level 3 inputs, suggesting a shift toward more opaque or complex valuation methodologies for these investments.",
      "llm_answer": "In the 2022 filing (page 99) equity‑like funds were measured using Level 3 inputs for **$25.4 million** in the defined‑benefit pension plan and **$2.4 million** in the retiree‑health plan (total ≈ $27.8 million). In the 2023 filing (page 98) the Level 3 amount fell slightly to **$25.1 million** for the pension plan while remaining **$2.4 million** for the retiree‑health plan (total ≈ $27.5 million), indicating only a marginal decline in the Level 3 component of equity‑like funds.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitative Accuracy: The ground truth states that equity-like funds under private alternative investments had a Level 3 fair value of $5.5 million in 2022 and $25.4 million in 2023. The LLM instead reports $25.4 million in 2022 and $25.1 million in 2023, which is the reverse of the correct trend and uses incorrect values. The LLM also introduces two separate plans (pension and retiree-health) not mentioned in the original answer or question, fabricating a breakdown unsupported by the ground truth. (2) Completeness: The answer fails to reflect the actual evolution — a fivefold increase — and instead claims a marginal decline, which contradicts the truth. (3) Entity Accuracy: The LLM references specific filing pages and plan types (defined-benefit pension, retiree-health) that are not part of the original context, indicating hallucination or misattribution. (4) Reasoning: The multi-hop synthesis is flawed — rather than showing growth in Level 3 equity-like fund valuations, it invents a slight decrease. The conclusion about 'marginal decline' is therefore incorrect. (5) Semantic Equivalence: The overall message is opposite to the ground truth: the LLM reports stability/decline, while the truth shows a significant increase. Despite using similar dollar figures (e.g., $25.4M), they are applied to the wrong year and context, making the answer factually wrong. Only minimal contextual relevance is retained due to mention of Level 3 inputs and equity-like funds.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 428,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has Adobe's integration and positioning of Frame.io within its Digital Media offerings evolved between 2022 and 2024?",
      "original_answer": "In 2022, Adobe had just acquired Frame.io in October 2021 and was beginning to integrate it into the Digital Media segment as a cloud-based video collaboration platform. By 2024, Frame.io had become a core part of Adobe’s creative collaboration tools, being directly integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and was also included in Adobe GenStudio for scalable content production. This reflects a strategic evolution from initial integration to deeper ecosystem embedding.",
      "llm_answer": "In the 2022 filing Adobe only reported that, after buying Frame.io for about $1.18 billion in late 2021, it had “begun integrating” the cloud‑based video‑collaboration platform into its Digital Media segment. By the 2024 filing, Frame.io is described as a fully‑integrated, cloud‑native collaboration platform that is embedded directly in Premiere Pro, After Effects, Photoshop, Lightroom, Workfront and Adobe GenStudio, positioning it as a core component of Adobe’s Digital Media suite and a strategic engine for end‑to‑end content production. This shows the shift from early integration to deep product embedding and a broader, central role within Digital Media.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Frame.io was acquired in late 2021 (October), integration began in 2022, and by 2024 it was deeply embedded in Adobe's Digital Media suite. The $1.18 billion acquisition price is accurate and consistent with public records. (2) No calculations are required, but the timeline (2022 to 2024) is correctly referenced. (3) The multi-hop reasoning is sound—LLM synthesizes information across two time points (2022 and 2024 filings) to show evolution from 'beginning integration' to 'fully integrated core component.' (4) The LLM correctly identifies all relevant entities: Frame.io, Adobe, Digital Media segment, and integration with Premiere Pro, After Effects, Photoshop, Lightroom, Workfront, and Adobe GenStudio. The answer captures the strategic shift in positioning—from a newly acquired platform to a central engine for end-to-end content production—demonstrating strong contextual and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 293,
        "total_tokens": 1583
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has CVS's approach to Medication Management evolved between 2022 and 2024, particularly in terms of clinical programs and digital tools aimed at improving medication adherence and cost efficiency?",
      "original_answer": "In 2022, CVS emphasized formulary management through its National Pharmacy and Therapeutics Committee, promoting the use of generic drugs and offering real-time benefit information to guide members toward lower-cost alternatives. The company also operated mail order and specialty pharmacies, and provided clinical programs focused on medication adherence and utilization management, including an industry-leading approach to limit opioid prescriptions to seven-day supplies for acute cases. By 2024, CVS had expanded its Medication Management offerings with the introduction of digital tools like the NovoLogix preauthorization platform and enhanced analytics for identifying lower-cost drug alternatives. The company also launched the CVS Weight Management program, integrating GLP-1 medication optimization with lifestyle coaching, and expanded its value-based care initiatives through Oak Street Health, operating 239 primary care centers across 27 states to better manage chronic conditions and medication use. These developments reflect a shift from primarily cost-containment strategies to a more integrated, digitally enabled, and clinically proactive model of medication support.",
      "llm_answer": "In 2022 CVS’s medication‑management approach was built around core clinical programs such as Pharmacy Advisor, Drug Savings Review, utilization‑management and the NovoLogix online pre‑authorization tool, with digital connectivity that gave members visibility of lower‑cost alternatives and analytics support (page_11, page_13). By 2024 the company had layered those services onto an AI‑enabled, data‑rich platform—Canopy and the Health Engagement Engine claim‑adjudication system, real‑time benefits information at the point of prescribing, an integrated device hub for in‑home medication reviews, and expanded virtual MinuteClinic scheduling—providing more proactive adherence outreach and deeper cost‑efficiency insights (page_10, page_12, page_13).",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures some correct elements of CVS's medication management evolution but contains significant inaccuracies and omissions in both clinical programs and digital tools. Quantitatively, there are no explicit numerical errors (e.g., dates like 2022 and 2024 are correct), so quantitative accuracy is high. However, the LLM incorrectly states that the NovoLogix preauthorization tool was already in use in 2022, while the ground truth indicates it was introduced by 2024—this is a critical factual reversal. Additionally, the LLM mentions 'Pharmacy Advisor' and 'Drug Savings Review' without grounding in the original answer, which does not reference these specific programs. The mention of 'Canopy' and 'Health Engagement Engine' appears to be fabricated or misattributed, as they are not in the ground truth. While the LLM correctly identifies trends toward digital integration, real-time benefits, and proactive adherence, it fails to mention key 2024 developments such as the CVS Weight Management program with GLP-1 optimization, Oak Street Health expansion to 239 centers in 27 states, or the seven-day opioid prescribing policy from 2022. The reasoning is partially sound in identifying a shift toward digital and proactive care, but the multi-hop synthesis is flawed due to incorrect program timelines and invented tools. Contextually, the answer stays focused on medication management evolution and cost efficiency, earning decent relevance. Overall, the answer conveys a plausible but factually inaccurate narrative, missing core components of the ground truth while introducing unsupported details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1498,
        "completion_tokens": 441,
        "total_tokens": 1939
      },
      "error": null
    },
    {
      "question_id": 131,
      "question": "How has Adobe's integration and positioning of Frame.io within its Creative Cloud ecosystem evolved from 2022 to 2024, and what specific enhancements were made to its collaboration features during this period?",
      "original_answer": "In 2022, Adobe acquired Frame.io and began integrating its cloud-based video collaboration platform into Adobe Creative Cloud, with initial enhancements focused on deeper integration into Premiere Pro and After Effects to deliver native collaborative workflows for video editing. By 2024, Frame.io had evolved into a more comprehensive cloud-native creative collaboration platform, offering real-time upload, review, and approval features not only for video but also for still images, design files, and PDFs. It expanded its integration across Adobe Photoshop, Lightroom, and Workfront, and introduced Camera to Cloud functionality, enabling automatic upload of footage directly into Frame.io from cameras on set. These enhancements reflect a strategic shift from a video-specific collaboration tool to a broader creative asset production and review platform within Adobe’s ecosystem.",
      "llm_answer": "In the 2022 filing Adobe described the acquisition of Frame.io (Oct 2021) and said it was “more deeply integrating and enhancing Frame.io’s review and approval capabilities in Premiere Pro and After Effects to deliver a native collaborative platform for video editing”【page_6】. By the 2024 filing Frame.io is positioned as “our cloud‑native creative collaboration platform” that is now “directly integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom and Workfront” and is available in GenStudio, with added features such as real‑time upload, frame‑accurate commenting, annotations, Camera‑to‑Cloud automatic footage ingestion and support for still images, design files and PDFs across broader production workflows【page_12】. This reflects a shift from a limited video‑editing add‑on in 2022 to a cross‑app, end‑to‑end collaboration hub within the Creative Cloud ecosystem by 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Adobe acquired Frame.io in October 2021 (context for 2022 integration), and by 2024 it evolved into a cloud-native creative collaboration platform. The timeline (2022 to 2024) is correctly framed. (2) Quantitative and temporal details are accurate—no numerical errors, and the progression across years is properly represented. The mention of specific integrations (Premiere Pro, After Effects, Photoshop, Lightroom, Workfront) and features (real-time upload, frame-accurate commenting, annotations, Camera-to-Cloud, support for still images, design files, PDFs) matches the ground truth exactly. (3) Multi-hop reasoning is sound: the answer synthesizes information across two time points (2022 and 2024) and multiple Adobe applications, correctly identifying the expansion from video-specific to cross-functional creative collaboration. (4) The conclusion about a strategic shift—from a video-editing add-on to an end-to-end collaboration hub—is logically derived and aligns with the original answer. Wording differs slightly but conveys identical meaning. All evaluation dimensions are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1461,
        "completion_tokens": 342,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has the use of recently executed transactions in the valuation of loans and other assets evolved from 2023 to 2024, particularly in terms of their role in fair value determination?",
      "original_answer": "In 2023, recently executed transactions were a key input for determining the fair value of corporate loans and contingent lending commitments, often used alongside market price quotations, implied yields, and proprietary valuation models. By 2024, the role of recently executed transactions remained significant but was more specifically tied to the held-for-sale category of loans and lending commitments, and also extended to the valuation of other assets such as other investments, where they were used in conjunction with discounted cash flow models and comparable company multiples. This reflects a more targeted application of transaction data in valuation practices.",
      "llm_answer": "In the 2023 filing the firm said that the fair‑value of corporate loans, corporate bonds and even state‑municipal securities is “determined using **recently executed transactions**” as the primary observable input, with market quotes and proprietary models used only when such transactions are unavailable (see 2023 p. 99 ‑ Loans & Lending Commitments and 2023 p. 98 ‑ State and Municipal Securities). By 2024 the language still cites recently executed transactions, but now frames them as one of several inputs in **non‑recurring fair‑value measurements** for loans, lending commitments and other assets (e.g., “based on … recently executed transactions, market price quotations, valuation models …” – 2024 p. 103) and notes that they are used alongside market quotations and model‑derived yields across a broader set of asset classes, indicating an expanded but still central role in Level 3 fair‑value determinations.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of factual content and evolution from 2023 to 2024. (1) It accurately captures that in 2023, recently executed transactions were a primary input for fair value determination of corporate loans and other instruments, used ahead of market quotes and models—consistent with the original answer’s emphasis on their key role. In 2024, the LLM correctly notes a shift in framing: transaction data are now one of several inputs, particularly in non-recurring measurements, and applied across a broader set of assets. This reflects the ground truth’s point about a more targeted yet expanded application. (2) There are no numeric values, dates, or calculations in the question or answers that are incorrect; the page references (e.g., 2023 p. 99, 2024 p. 103) are treated as contextual and do not contradict the ground truth. (3) The multi-hop reasoning is sound—comparing language changes across years and inferring a shift in valuation practice. However, the LLM slightly overgeneralizes by including 'corporate bonds' and 'state-municipal securities' in the 2023 description, which are not mentioned in the original answer; the ground truth focuses specifically on corporate loans and contingent lending commitments. Additionally, the LLM emphasizes 'non-recurring' fair-value measurements, which adds nuance not present in the original but isn’t contradicted by it. (4) Despite minor differences in scope (broader asset inclusion), the core evolution—continued significance with a more integrated, multi-input approach in 2024—is semantically equivalent. Hence, high scores for accuracy and relevance, with a small deduction in qualitative accuracy for slight overextension of asset types.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 478,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has Adobe's approach to the Substance 3D Stager product evolved between 2022 and 2024, particularly in terms of its positioning within the broader Substance 3D ecosystem?",
      "original_answer": "In 2022, Substance 3D Stager was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio but without detailed information about its functionality or strategic positioning. By 2024, Adobe introduced a more comprehensive view of Substance 3D as an ecosystem, where Stager is specifically described as a tool for building and assembling 3D scenes. This evolution reflects a strategic shift from simply offering the product to integrating it into a broader suite of 3D tools, including Painter, Sampler, Designer, and Modeler, emphasizing its role in enabling end-to-end 3D content creation workflows.",
      "llm_answer": "In Adobe’s 2022 Form 10‑K (pages 95‑99) the filing makes no specific reference to the Substance 3D Stager product, focusing instead on financial and governance disclosures. By the 2024 Form 10‑K, Adobe explicitly positions Stager as a core component of the Substance 3D Collection—an integrated ecosystem of desktop apps that includes Painter, Sampler, Designer and Modeler and is used to build and assemble 3D scenes【page_12】. This reflects a shift from no explicit mention in 2022 to a clear strategic placement of Stager within the broader Substance 3D suite in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies that Substance 3D Stager was not explicitly mentioned in Adobe's 2022 Form 10-K, which is consistent with the original answer noting only a trademark listing without functional or strategic detail. By 2024, the LLM correctly states that Stager was positioned as a core component of the Substance 3D Collection, specifically for building and assembling 3D scenes, and accurately names the other tools in the ecosystem (Painter, Sampler, Designer, Modeler). The answer captures the strategic evolution from absence of explicit mention to clear integration within an end-to-end 3D workflow. The only minor shortcoming is that it does not explicitly reference the trademark status in 2022 (mentioned in the ground truth), but this does not detract from the overall correctness, as the absence of mention in the 10-K implies limited public strategic emphasis at that time. All entities, years, and product roles are correct. The reasoning is sound, demonstrating multi-hop synthesis between 2022 and 2024 filings. Quantitative elements (years, page references) are accurate. Semantic equivalence is strong, and the answer is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 349,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How did GE's strategic positioning regarding grid-scale batteries evolve from 2022 to 2023, particularly in terms of their role in the company's energy transition strategy and level of strategic reliance?",
      "original_answer": "In 2022, GE mentioned grid-scale batteries as part of a broader set of emerging technologies that 'may become more important over time' in achieving deep decarbonization goals, indicating GE was considering them as a potential future investment. By 2023, GE explicitly listed grid-scale batteries as one of the key technologies 'that may become more important over time' and integrated them into the company’s strategic narrative as a dependency, noting that achieving decarbonization goals would 'depend in part' on such technologies. This reflects a shift from viewing grid-scale batteries as a speculative investment to a more central component of GE's energy transition strategy.",
      "llm_answer": "In the 2022 filing (p. 64) GE said that deep‑decarbonisation will “likely depend in part on technologies … such as **grid‑scale batteries** or other storage solutions,” noting that these are not yet deployed and would require significant future investment but are not a core focus today. The 2023 filing (p. 29) repeats the same point – grid‑scale batteries are again listed among emerging, not‑yet‑widely‑adopted technologies that could become important for the energy‑transition, with the same caveat that they will need substantial R&D and infrastructure spending. Thus, GE’s positioning on batteries stayed essentially unchanged: they remain a long‑term, peripheral component of the transition strategy rather than a primary, strategically‑relied‑upon asset.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core conclusion, despite citing plausible page numbers and general context. According to the ground truth, GE's strategic positioning on grid-scale batteries evolved from 2022 to 2023: in 2022, they were considered a potential future investment among emerging technologies; by 2023, they were explicitly integrated into the strategic narrative as a dependency for decarbonization goals, with language shifting to 'depend in part' on such technologies. This reflects an increased strategic reliance. However, the LLM claims that GE’s positioning 'stayed essentially unchanged' and characterizes batteries as a 'long-term, peripheral component' in both years, which contradicts the ground truth. The LLM misrepresents the evolution in strategic importance. There are no numeric values to verify, so quantitative accuracy is not applicable but assumed correct. The reasoning is flawed because it fails to detect the shift in language and strategic framing across the two years, indicating a failure in multi-hop synthesis. While the answer addresses the question's topic and timeframe, it draws the opposite conclusion of the ground truth, severely undermining its correctness. Contextual relevance is moderate because it discusses the right company, technology, and years, but the analysis is substantively wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 375,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has CVS's disclosure regarding the use of broker quoted debt securities in its fair value measurements evolved between 2022 and 2024, particularly in terms of its presence or impact on financial reporting?",
      "original_answer": "In 2022, CVS explicitly stated that it did not have any broker quoted debt securities for the years ended December 31, 2021, and 2020, and that it only used internal pricing for certain private placements. By 2024, the company continued to disclose that it had no broker quoted debt securities for the years ended December 31, 2024 and 2023, indicating a consistent absence of such securities in its portfolio. However, the 2024 disclosure no longer mentions any negative impact or specific review process related to broker quoted debt securities, suggesting a reduced emphasis or relevance of this topic in the company's fair value measurement disclosures over time.",
      "llm_answer": "In both the 2022 and 2024 10‑K filings CVS notes that it “did not have any broker‑quoted debt securities” for the years covered – 2021‑2020 in the 2022 filing (page 148) and 2024‑2023 in the 2024 filing (page 146). Because no broker quotes were used, Level 3 debt securities were valued either by outside brokers for other securities or internally for private placements, and the absence of broker‑quoted securities had no impact on the company’s fair‑value measurements or its financial statements.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the key quantitative fact that CVS disclosed no broker-quoted debt securities in both 2022 and 2024 filings for the respective prior years (2021-2020 in 2022 filing; 2024-2023 in 2024 filing), with accurate page references. This satisfies quantitative accuracy. The entity accuracy is correct—CVS, broker-quoted debt securities, Level 3, fair value measurements—all are properly identified and contextualized. However, the LLM answer misses a key qualitative evolution highlighted in the ground truth: while the absence of broker-quoted securities continued, the 2024 disclosure no longer mentions any review process or negative impact related to such securities, indicating reduced emphasis over time. The LLM incorrectly states that 'the absence of broker-quoted securities had no impact,' which is not supported by the original answer—rather, the original notes a change in disclosure tone and content, not a conclusion about impact. This reflects a gap in reasoning and synthesis across years regarding the *evolution* of disclosure emphasis. The answer is contextually relevant and addresses the core of the question but fails to fully capture the nuanced shift in disclosure language and focus over time, which is central to the multi-hop aspect of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 362,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did the composition of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of equity securities/mutual funds and equity method investments?",
      "original_answer": "In 2023, BlackRock reported $1,211 million in equity securities/mutual funds under Equity Securities at FVTNI, while equity method investments totaled $1,895 million. By 2024, the value of equity securities/mutual funds increased to $1,950 million, and equity method investments rose to $2,783 million. This reflects a significant increase in both categories, indicating a strategic expansion in these investment areas.",
      "llm_answer": "In 2023 BlackRock reported $1.585 billion of equity securities / mutual‑fund holdings at FVTNI, which rose to $1.950 billion in 2024 – an increase of about $365 million【page_87†L31-L34】【page_94†L31-L34】.  The equity‑method portfolio grew only modestly, from $2.756 billion in 2023 to $2.783 billion in 2024; the increase reflects a shift from mainly NAV‑measured investments ($2.510 billion in 2023) to a larger share measured at quoted prices (Level 1 rose from $246 million to $347 million) and the addition of $131 million of Level 2 assets, while the NAV‑measured portion fell to $2.305 billion【page_87†L37-L44】【page_94†L38-L45】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, in 2023, BlackRock reported $1,211 million (i.e., $1.211 billion) in equity securities/mutual funds, but the LLM states $1.585 billion — a major discrepancy of over $370 million. The 2024 value of $1.950 billion is correct in the LLM answer, but the implied increase of $365 million is based on an incorrect 2023 baseline. The ground truth shows an actual increase of $739 million ($1,950M - $1,211M), not $365M. For equity method investments, the LLM claims $2.756 billion in 2023, but the correct amount is $1,895 million ($1.895 billion) — an overstatement of $861 million. The 2024 figure of $2.783 billion is correct in both. (2) Calculations are therefore flawed: the LLM reports a modest increase in equity method investments, but in reality, the increase is much larger — from $1.895B to $2.783B, or $888M — indicating substantial growth, not modest. The LLM incorrectly characterizes the change as modest due to wrong input values. (3) The reasoning and synthesis are partially sound — the LLM attempts multi-hop analysis by referencing changes in valuation levels (Level 1, Level 2, NAV) within equity method investments, which adds detail not in the original answer, but this distracts from the core error: misreporting the total amounts. The focus on valuation techniques may be accurate within its own source context but does not align with the ground truth totals. (4) Despite incorrect numbers, the answer is contextually relevant and addresses both parts of the question — equity securities/mutual funds and equity method investments — and correctly notes increases in both categories. However, due to severe quantitative inaccuracies in core financial figures, the correctness score is low. The qualitative reasoning is logically structured but based on incorrect data, limiting its validity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 520,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did UnitedHealth Group's evaluation and treatment of credit-related impairments for available-for-sale debt securities evolve from 2022 to 2024, particularly in terms of unrealized losses and the allowance for credit losses?",
      "original_answer": "In 2022, UnitedHealth Group reported that unrealized losses in its available-for-sale debt securities were primarily driven by interest rate increases and not credit deterioration, with no significant credit deterioration observed since purchase. The allowance for credit losses was noted to be not material as of December 31, 2021. By 2024, the company's evaluation methodology remained consistent in terms of assessing present value of expected cash flows, issuer credit condition, and fair value relative to amortized cost. However, the allowance for credit losses is now explicitly described as being recorded as a separate component through an allowance account, with credit-related impairments impacting investment and other income, indicating a more structured recognition of credit risk. This evolution shows a shift from a qualitative, low-risk assessment to a more formalized impairment accounting framework.",
      "llm_answer": "In the 2022 filing UnitedHealth Group disclosed that its available‑for‑sale debt portfolio carried **$274 million of gross unrealized losses** (see page 56) and that, after evaluating credit quality and cash‑flow expectations, **the allowance for credit‑related losses on those securities was “not material”** (page 57). By the 2024 filing the company still **evaluates each available‑for‑sale security for credit‑related impairment using the same cash‑flow, fair‑value‑vs‑amortized‑cost and issuer‑credit‑quality criteria**, records unrealized gains and losses in OCI, and **recognizes any credit‑related impairment as an allowance** (page 49), but again provides no indication that the allowance has become material—showing that the evaluation method and treatment of unrealized losses remain essentially unchanged from 2022 to 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes specific numeric values ($274 million in unrealized losses) and cites page numbers, which are not present in the original ground truth and cannot be verified against it. Since the ground truth does not mention any specific dollar amount for unrealized losses in 2022, the inclusion of $274 million introduces unverifiable quantitative detail that may be inaccurate in this context. The statement that the allowance was 'not material' aligns with the ground truth for the prior period (as of December 31, 2021), but the LLM attributes this to the 2022 filing without clarifying the reference date, creating potential temporal confusion. (2) The quantitative accuracy is partially compromised because the $274M figure is not corroborated by the ground truth, and no such number appears in the original answer. While format variations are acceptable, introducing unsupported specifics reduces accuracy. (3) The multi-hop reasoning is partially sound—the LLM correctly identifies continuity in evaluation criteria (cash flows, fair value vs. amortized cost, issuer credit) from 2022 to 2024. However, it fails to capture the key evolution emphasized in the ground truth: the shift toward a more structured, formalized impairment accounting framework where credit-related impairments are explicitly recognized through a separate allowance account and affect investment income. The LLM incorrectly concludes that the treatment 'remains essentially unchanged,' which contradicts the ground truth's assertion of a meaningful evolution in accounting practice. (4) Contextual relevance is high because the response addresses the core topic—evaluation and treatment of credit-related impairments—and references appropriate financial concepts and timeframes. However, the failure to identify the qualitative shift in accounting treatment significantly undermines the correctness and qualitative accuracy, resulting in a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1458,
        "completion_tokens": 529,
        "total_tokens": 1988
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2022 and 2023, particularly in terms of investment value and equity income?",
      "original_answer": "In 2022, AMD's carrying value of its investment in the ATMP JV was $83 million, and it recorded $14 million in equity income from the JV. By 2023, the carrying value increased to $99 million, and equity income rose to $16 million. This indicates a growing financial stake and increased profitability from the joint venture over the two-year period.",
      "llm_answer": "In 2022 AMD’s 15 % equity interest in the ATMP joint venture was carried at roughly **$83 million** and generated **$14 million** of equity‑income. By year‑end 2023 the carrying amount had risen to about **$99 million** and the equity‑income increased to **$16 million**, showing a modest increase in both the investment’s value and AMD’s share of the JV’s earnings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures: the carrying value of AMD's investment in ATMP JV was $83 million in 2022 and $99 million in 2023, and equity income was $14 million in 2022 and $16 million in 2023 — matching the ground truth exactly. Number formats are consistent and acceptable (e.g., $83 million vs $83 million). (2) All quantitative values are accurate, including the implied year-over-year increase of $16 million in carrying value and $2 million in equity income. No calculations were required beyond interpretation, and the reported trends are correct. (3) The multi-hop reasoning is sound: the model synthesizes data across two years for the same JV, correctly identifying the evolution in both investment value and income stream. The addition of AMD’s 15% equity interest, while not in the original answer, is contextually plausible and does not contradict the ground truth; however, it introduces a detail not confirmed in the source, slightly affecting qualitative accuracy. (4) The answer is semantically equivalent to the original, captures the trend of growth, and addresses both parts of the question (investment value and equity income). The minor deduction in qualitative accuracy is due to the unverified addition of the 15% stake, but overall the response is factually correct, complete, and highly relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1178,
        "completion_tokens": 381,
        "total_tokens": 1559
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has UnitedHealth Group's exposure to tort claims evolved between 2022 and 2024, particularly in terms of the nature of the claims and the potential financial impact?",
      "original_answer": "In 2022, UnitedHealth Group specifically highlighted self-insured liabilities related to medical malpractice claims against affiliated physicians and the potential for actual losses to significantly exceed recorded liabilities. The document emphasized increasing legal actions alleging medical malpractice and general professional liabilities, with litigants seeking recoveries under new theories of liability that might not be subject to damage caps. By 2024, while tort claims remained a concern, the focus shifted slightly to broader legal risks tied to the delivery of health care services, including claims related to clinical quality and patient safety standards. The 2024 filing also emphasized the potential for reputational harm and adverse effects on business relationships, indicating a broader and more systemic risk profile compared to the more narrowly defined exposure in 2022.",
      "llm_answer": "UnitedHealth’s tort‑claim exposure continues to be dominated by medical‑malpractice and other professional‑liability suits tied to the delivery of health‑care services by its affiliates and network providers, and the company remains largely self‑insuring those risks (2022 p.20; 2024 p.15‑16). Both the 2022 and 2024 filings stress that the number of such actions is increasing, that new liability theories are being used, and that actual losses could exceed the reserves recorded, leaving the potential financial impact material and possibly growing.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its core claims and correctly identifies that UnitedHealth Group faces ongoing tort claim exposure primarily through medical malpractice and professional liability risks, with increasing legal actions and potential losses exceeding recorded reserves in both 2022 and 2024. It accurately notes the company's self-insurance practices and the material financial impact, supported by correct page references (2022 p.20; 2024 p.15-16), which aligns with the ground truth. There are no numeric inaccuracies—dates and financial implications are described qualitatively and correctly, without incorrect figures. However, the LLM answer misses a key evolution highlighted in the original answer: the shift in focus from narrowly defined medical malpractice exposure in 2022 to broader systemic risks in 2024, including clinical quality, patient safety standards, and reputational harm affecting business relationships. This nuance represents a significant qualitative development in the nature of the risk profile over time, which the LLM answer does not capture. While it correctly states that similar types of claims persist, it fails to reflect the expanded scope and systemic nature of the risk as emphasized in the 2024 filing. Thus, while the answer is contextually relevant and quantitatively sound, it lacks completeness in conveying the evolution of the risk, particularly the broadening of concern beyond malpractice to include operational and reputational dimensions. This omission reduces the qualitative accuracy and overall correctness, though the core facts remain valid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 440,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How has the structure and capacity of Boeing's three-year revolving credit agreement evolved between 2023 and 2024, and what does this indicate about the company's liquidity strategy?",
      "original_answer": "In 2023, Boeing had a legacy three-year revolving credit agreement expiring in August 2025 with $3.0 billion of total commitments. In 2024, this agreement remained in effect, but Boeing also entered into a new $4.0 billion five-year revolving credit agreement expiring in May 2029 while terminating two other credit facilities. This evolution indicates a strategic shift to enhance liquidity capacity and extend maturity timelines, reinforcing Boeing's financial flexibility and commitment to managing corporate borrowing needs.",
      "llm_answer": "Boeing’s legacy three‑year revolving credit facility was unchanged – it remains a $3 billion commitment that expires in August 2025, and the company’s total undrawn revolving‑credit capacity stayed at roughly $10 billion (2023: $10.0 bn unused capacity; 2024: $10.0 bn available)【page_43】【page_94】.  In 2024 Boeing terminated the $0.8 bn 364‑day line and a $3.2 bn five‑year line and added a larger $4 bn five‑year facility, showing a liquidity strategy that preserves a sizable, undrawn back‑up line while simplifying and extending its credit portfolio for greater flexibility.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct but contains a minor inaccuracy regarding the legacy three-year facility. The ground truth states that the $3.0 billion three-year agreement remained in effect in 2024, which the LLM correctly notes. However, the LLM implies that this facility was unchanged in structure, while the original answer highlights that Boeing entered into a new $4.0 billion five-year facility in 2024—this is correctly mentioned. The LLM incorrectly states that the total undrawn capacity remained at $10 billion in both years, which is not in the ground truth and introduces unsupported aggregation (e.g., combining facilities to $10B). This figure is not mentioned in the original answer and appears to be an inference not supported by the provided truth. (2) Quantitatively, the $3 billion legacy facility (2023), $4 billion new facility (2024), and expiration dates (Aug 2025, May 2029) are correct. However, the $0.8 billion 364-day and $3.2 billion five-year facilities terminated are not in the ground truth—the original only states that 'two other credit facilities' were terminated, without specifying amounts. Thus, these specific figures ($0.8B, $3.2B) are incorrect or at least unverifiable, reducing quantitative accuracy. (3) The multi-hop reasoning is sound: the LLM correctly identifies the continuation of the legacy facility, the addition of a new larger facility, termination of others, and infers a strategic intent around liquidity and simplification. This aligns with the original’s conclusion about enhanced liquidity and extended maturities. (4) Despite the incorrect specific amounts of the terminated facilities and the unsupported $10B undrawn capacity claim, the core evolution and strategic implication are accurately captured. Hence, the answer is substantially correct but with notable quantitative overreach, warranting a score of 8 for correctness, quantitative, and qualitative accuracy. Contextual relevance is perfect as it directly addresses the question’s focus on structure, capacity, and liquidity strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 557,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did the financial impact of the 2017 Performance-based Options evolve between 2023 and 2024, particularly in terms of the fair value of options vested and the intrinsic value of options exercised?",
      "original_answer": "In 2023, the fair value of the 2017 Performance-based Options that vested was $56 million, and the intrinsic value of options exercised was $44 million. By 2024, the fair value of the options vested decreased slightly to $52 million, but the intrinsic value of options exercised saw a significant increase to $373 million. This indicates that while the value of options vesting declined slightly in 2024, the actual financial benefit realized from exercised options increased substantially compared to the prior year.",
      "llm_answer": "In 2023 the 2017 performance‑based options generated **$56 million of fair‑value for the options that vested** and **$44 million of intrinsic value for the options that were exercised**【page_101】. By 2024 the **fair‑value of vested options fell slightly to $52 million**, while the **intrinsic value of exercised options jumped dramatically to $373 million**【page_109】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $56 million fair value of vested options in 2023, $44 million intrinsic value of exercised options in 2023, $52 million fair value in 2024 (slight decrease), and $373 million intrinsic value in 2024 (significant increase). These values are reported with correct units and time periods. (2) The answer is complete, addressing both parts of the question: the evolution of fair value of vested options and intrinsic value of exercised options between 2023 and 2024. (3) Entity accuracy is correct—referring to the 2017 Performance-based Options, and correctly attributing financial metrics to the right years. (4) The reasoning is sound and reflects proper multi-hop synthesis: it identifies trends (slight decline vs. dramatic increase) and implicitly supports the conclusion that financial impact shifted from vesting to exercising. The inclusion of citation markers 【page_101】 and 【page_109】 further indicates grounding in source material. (5) Semantic equivalence is strong—the LLM conveys the same meaning as the original answer using slightly different phrasing (e.g., 'jumped dramatically' vs. 'significant increase'), which is acceptable and clear. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 369,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did AMD's approach to estimating adjustments for product return rights evolve between 2022 and 2023, and what specific changes were made in the methodology used for these estimates?",
      "original_answer": "In 2022, AMD estimated adjustments for product return rights using trended actual historical product return rate information, adjusted for known information or events. By 2023, AMD maintained the use of historical data but placed additional emphasis on 'rights of return and rebates' as part of variable consideration under ASC 606-10-32-8 through 14, explicitly stating that these estimates were based on the 'most likely amount' of consideration expected after adjustments for returns, rebates, and price protection. This reflects a more structured and codified approach to estimating returns, aligning more closely with specific accounting standards.",
      "llm_answer": "AMD’s method for estimating the revenue adjustments tied to product‑return rights was essentially unchanged from 2022 to 2023. In both years the company said it “utilizes relevant, trended actual historical product‑return‑rate information…adjusted for actual known information or events (and, where appropriate, current economic conditions)” when estimating the contract‑price adjustments for OEM and distributor returns【page_44†L13-L18】【page_45†L15-L20】【page_49†L13-L20】. No new methodology or specific change to that estimation process was disclosed in the 2023 filing.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that AMD's methodology was 'essentially unchanged' between 2022 and 2023. The ground truth confirms a clear evolution in approach: while historical data continued to be used, in 2023 AMD explicitly adopted a more structured framework under ASC 606-10-32-8 through 14, emphasizing 'rights of return and rebates' as variable consideration and using the 'most likely amount' method. This shift reflects a significant qualitative change in methodology, which the LLM answer fails to recognize. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—no errors in numbers, dates, or calculations are present, hence a score of 10. (3) The multi-hop reasoning is flawed: the LLM relies on verbatim repetition of similar language in both years' filings but fails to identify the deeper accounting standard alignment and conceptual shift in 2023. It incorrectly concludes no change occurred due to surface-level similarity, missing the enhanced codification and emphasis on ASC 606 guidance. (4) Contextual relevance is moderate—the response addresses the topic and cites relevant sections, but misses the core evolution in methodology, leading to a substantially incorrect conclusion. The failure to detect and report the shift to a more structured, standards-based approach under ASC 606 results in a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 402,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How did the number of shares under option for the 2017 Performance-based Options evolve from 2023 to 2024, and what does this indicate about the exercise and forfeiture trends of these options?",
      "original_answer": "The number of shares under option for the 2017 Performance-based Options decreased significantly from 1,549,080 shares at the end of 2023 to 625,825 shares at the end of 2024. This indicates that a large portion of these options were exercised (905,219 shares) and some were forfeited (18,036 shares) during 2024, showing a trend of completion in the lifecycle of these options as they approached their final vesting date.",
      "llm_answer": "The 2017 performance‑based options fell sharply, from 1,549,080 shares outstanding at 12/31/2023 to 625,825 shares outstanding at 12/31/2024 – a decline of about 923 k shares【page_100†L1-L7】. The drop was driven almost entirely by a massive exercise of 905,219 options in 2024, with only 18,036 shares forfeited, showing that the reduction reflects employee exercise rather than forfeiture【page_108†L1-L7】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key numbers: 1,549,080 shares at the end of 2023 and 625,825 at the end of 2024, matching the ground truth. It accurately states that 905,219 shares were exercised and 18,036 were forfeited, which aligns with the original answer. The calculated decline of 'about 923k' is a rounded approximation of the actual difference (1,549,080 - 625,825 = 923,255), which is acceptable for qualitative summary. (2) All numeric values are factually correct; the minor rounding in the total decline does not affect accuracy. Calculations implied (exercise + forfeiture = total reduction: 905,219 + 18,036 = 923,255) match the observed drop, confirming quantitative precision. (3) The reasoning correctly attributes the sharp decline primarily to exercises rather than forfeitures, accurately interpreting the trend as indicative of lifecycle completion due to employee exercise activity. The multi-hop synthesis—linking the drop in outstanding shares to specific events (exercise vs. forfeiture) and inferring behavioral trends—is sound and supported by the data. (4) The answer is contextually fully relevant, addressing both parts of the question: the evolution of shares under option and what it indicates about exercise/forfeiture trends. The only minor shortcoming is the lack of explicit mention of the 'final vesting date' context implied in the ground truth, which slightly weakens the qualitative completeness. However, the core inference about lifecycle completion is still strongly supported. Hence, a score of 9 is justified—excellent accuracy with only negligible omission.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 446,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How has the role and scope of Optum Rx's Pharmacy Care Services evolved between 2022 and 2024, particularly in terms of its service offerings and strategic positioning within UnitedHealth Group's broader health care ecosystem?",
      "original_answer": "In 2022, Optum Rx was described as managing $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceutical spending, and was positioned as a provider of pharmacy care services through a network of over 67,000 retail pharmacies, home delivery, specialty pharmacies, and infusion services. It emphasized clinical programs, digital tools, and medication management to help clients reduce costs and improve health outcomes. By 2024, Optum Rx was more strategically integrated into Optum’s broader vision of creating a 'value-oriented and more connected approach to health care,' with an emphasis on leveraging 'data and analytics, pharmacy care services, health care operations, population health and health financial services' to improve the overall health system performance. While specific spending figures were not provided in 2024, the service was elevated as a core component of Optum’s mission to enhance affordability, quality, and patient experience across the health care continuum.",
      "llm_answer": "Between 2022 and 2024 Optum Rx expanded from a $112 billion pharmacy‑spend platform (about $45 billion in specialty) that operated roughly 67,000 retail pharmacies, home‑delivery, infusion and a direct‑to‑consumer business, to a $178 billion platform (about $74 billion in specialty) that now also offers rare‑disease and gene‑therapy support, richer digital tools, and a strategy that embeds pharmacists in integrated medical‑pharmacy‑behavioral care teams. While it continues to serve UnitedHealthcare’s health‑benefits customers through brokers and direct sales, the 2024 filing positions Optum Rx as a broader, data‑driven pharmacy‑care engine that deepens UnitedHealth Group’s end‑to‑end health‑care ecosystem and cost‑management capabilities.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. The ground truth states that in 2022, Optum Rx managed $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceuticals. The LLM answer correctly reports these 2022 figures. However, it falsely claims that by 2024, the platform grew to $178 billion in spending (with $74 billion in specialty), which is not supported by the original answer—no spending figures were provided for 2024. This introduces fabricated data, severely undermining factual correctness. (2) The calculation of growth from $112B to $178B (a $66B increase) and specialty from $45B to $74B is entirely speculative and unsupported. No such numbers appear in the 2024 data. While format variations are acceptable, inventing figures is not. (3) On qualitative aspects, the LLM captures some correct strategic direction: Optum Rx’s deeper integration into UnitedHealth Group’s ecosystem, use of data and analytics, and expanded clinical roles. Mentions of richer digital tools, rare-disease and gene-therapy support, and embedded pharmacists reflect plausible strategic evolution but are not explicitly confirmed in the ground truth. The core accurate point is the repositioning of Optum Rx as a data-driven component enhancing the end-to-end healthcare ecosystem. However, the original answer does not mention direct-to-consumer business, rare-disease services, or gene therapy support, so these are unverified additions. (4) Contextually, the answer addresses the question’s focus on evolution in service offerings and strategic positioning, making it relevant. But due to major quantitative fabrication and unsupported qualitative expansions, the correctness score is low. Quantitative accuracy is severely penalized (score 2), qualitative accuracy is moderate (score 5) due to partial alignment with strategic themes, and contextual relevance is high (score 8) as the structure and intent match the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1461,
        "completion_tokens": 542,
        "total_tokens": 2003
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How did the composition and valuation of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of investments held for deferred cash compensation plans?",
      "original_answer": "In 2023, BlackRock reported $9 million invested in Equity Securities at FVTNI as part of the investments held to economically hedge deferred cash compensation plans. By 2024, this specific category was no longer listed under Equity Securities at FVTNI but instead appeared under 'Investments related to deferred cash compensation plans' within the Equity Method section with a value of $173 million. This indicates a reclassification or realignment of how these investments were categorized and reported in the financial statements, reflecting a significant change in the composition of Equity Securities at FVTNI.",
      "llm_answer": "In 2023 BlackRock reported $1.585 bn of equity securities/mutual‑fund holdings and $2.756 bn of equity‑method investments, of which $241 m were “investments related to deferred cash‑compensation plans” (page 87). By 2024 the equity‑securities component grew to $1.950 bn and total equity‑method assets rose modestly to $2.783 bn, but the deferred‑cash‑compensation hedge fell to $173 m (page 94), a $68 m decline. Overall the equity‑security portfolio increased by roughly $0.39 bn, with a larger share in equity‑mutual‑fund and real‑asset funds and a reduced share in private‑equity and hedge‑fund exposures.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, BlackRock reported $9 million in Equity Securities at FVTNI related to deferred cash compensation plans. The LLM incorrectly states that the deferred compensation-related investment was $241 million in 2023 and categorizes it under equity-method investments, which contradicts the original answer indicating it was under FVTNI. Furthermore, the LLM claims this amount decreased to $173 million in 2024, framing it as a decline, whereas the original answer indicates a reclassification — not a reduction — from FVTNI to the Equity Method section, with an increase from $9M to $173M. The LLM misrepresents this as a $68M decline, which is factually incorrect. (2) The quantitative values are largely wrong: the $1.585B and $1.950B figures for equity securities and the $2.756B/$2.783B equity-method totals do not align with the ground truth focus on the specific $9M and $173M components. The LLM introduces aggregate figures not mentioned in the original answer, creating a misleading narrative. (3) The multi-hop reasoning is flawed: instead of identifying the reclassification of a specific component (from FVTNI to Equity Method), the LLM interprets the change as a simple decline within the same category, missing the key accounting reclassification point. It fails to recognize that the $9M in 2023 was in FVTNI and disappeared in 2024 due to reclassification, not loss in value. (4) Contextual relevance is moderate because the answer discusses related topics (deferred compensation, equity investments), but it fails to address the core of the question — the change in composition and valuation of Equity Securities at FVTNI specifically due to reclassification. The focus on portfolio growth and asset mix shifts is extraneous and distracts from the actual issue. Overall, the answer is mostly incorrect due to wrong numbers, mischaracterized trends, and failure to capture the reclassification logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 543,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How has the aggregate available authorization for Accenture's open-market share purchase program changed between 2022 and 2024, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "The aggregate available authorization for Accenture's open-market share purchase program decreased from $3,129,296 in 2022 to $2,694,281 in 2024. This indicates a reduction in the company's capital allocated for share repurchases over this period, suggesting a more conservative approach to capital deployment or a strategic shift in how the company is managing its equity structure.",
      "llm_answer": "The 2022 filing shows that, as of August 31 2022, Accenture had **$3,129,296** of aggregate available authorization for its publicly announced open‑market share purchase program (and related purchase programs)【page_93】. By August 31 2024 that amount had fallen to **$2,694,281**【page_100】—a reduction of roughly $435 k (about 14%). This decline indicates the company has been exercising its buy‑back authority and is gradually using up the authorized pool, reflecting a disciplined capital‑allocation strategy that balances share repurchases with other priorities such as dividends and growth investments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the aggregate available authorization amounts for Accenture's share purchase program in both 2022 ($3,129,296) and 2024 ($2,694,281), matching the ground truth exactly. The reduction of approximately $435,000 (calculated as $3,129,296 - $2,694,281 = $435,015) and the stated 14% decrease are accurate and reasonably rounded. (2) All numeric values, dates (August 31, 2022 and August 31, 2024), and calculations are correct. The use of 'roughly $435k' is an acceptable approximation of $435,015, and the ~14% decline (435,015 / 3,129,296 ≈ 13.9%) is correctly estimated. (3) The multi-hop reasoning is sound: the model correctly synthesizes data from two different years' filings and infers a trend in capital allocation. The conclusion about a 'disciplined capital-allocation strategy' is slightly more positive in tone than the ground truth's 'more conservative approach or strategic shift,' but it is not factually incorrect—rather, it offers a nuanced interpretation consistent with the data. (4) The answer fully addresses both parts of the question: the change in authorization and its implication for capital allocation. Semantic equivalence is maintained with the original answer, with only minor interpretive variation in tone. No critical facts are omitted, and all entities (Accenture, open-market share purchase program, correct years) are accurately identified. The contextual relevance is perfect, directly answering the question with precise, cited data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 419,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How has the treatment and disclosure around Accenture Canada Holdings Inc. Exchangeable Shares evolved between 2022 and 2024, particularly in terms of share repurchase activity and shareholder rights?",
      "original_answer": "In 2022, Accenture disclosed its intention to use a significant portion of cash generated from operations for share repurchases during fiscal 2023, including purchases and redemptions of Accenture Canada Holdings Inc. exchangeable shares. The company noted that the number of shares repurchased would depend on various factors such as share price and market conditions. By 2024, the disclosures had evolved to include more detailed descriptions of the rights associated with Accenture Canada Holdings Inc. exchangeable shares, particularly their exchangeability on a one-for-one basis for Accenture plc Class A ordinary shares, and the company's commitment to align the number of Class X ordinary shares with outstanding exchangeable shares. Additionally, as of August 31, 2024, the company had a specific remaining authorization of $2,694,281 for share repurchase programs, indicating a more structured and quantified approach compared to the more general intentions expressed in 2022.",
      "llm_answer": "In the 2022 Form 10‑K the MD&A only said that Accenture’s open‑market repurchase program “may be made … in respect of purchases and redemptions of Accenture Canada Holdings Inc. exchangeable shares” and that the program could be accelerated, suspended or discontinued, but it gave no quantitative detail or specific description of the shares’ rights (see 2022 p. 43). By the 2024 filing the company provides a much more detailed disclosure: it lists a $2.694 billion aggregate authorization for the open‑market program (including exchangeable‑share purchases), reports that 47,752 exchangeable shares were actually repurchased for $15,254 in fiscal 2024 (see 2024 p. 101), and spells out that each exchangeable share can be exchanged one‑for‑one for an Accenture plc Class A ordinary share (or cash) and receives the same dividends, with redemption of related Class X shares limited to protect exchangeable‑share holders (see 2024 p. 100). This reflects a shift from a generic mention of possible repurchases to a quantified repurchase activity and a clear articulation of the holders’ exchange and dividend rights.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution in disclosure: from a general statement in 2022 about potential repurchases of Accenture Canada Holdings Inc. exchangeable shares to a more detailed, quantified disclosure in 2024. (2) Quantitatively, it accurately reports the $2.694 billion authorization (matching the ground truth $2,694,281, with minor rounding acceptable), and adds specific repurchase data—47,752 shares repurchased for $15,254 in fiscal 2024—which is consistent with the increased granularity in 2024. The ground truth does not include these specific repurchase numbers, but their presence in the LLM answer reflects a higher level of detail from the source document and does not contradict the original answer. (3) The qualitative reasoning is excellent: it identifies the shift from vague intentions to structured disclosures, correctly explains the one-for-one exchange right with Accenture plc Class A shares, dividend equivalence, and protections via Class X share redemption limits. These rights are accurately synthesized from the 2024 filing. (4) The answer fully addresses both parts of the question—share repurchase activity and shareholder rights—across the 2022–2024 timeframe, demonstrating strong multi-hop reasoning. The only minor deviation is that the ground truth emphasizes the alignment of Class X shares with outstanding exchangeable shares, which the LLM mentions indirectly via redemption limits but could have stated more explicitly. However, this does not constitute a factual error. Overall, the LLM provides a richer, factually consistent, and semantically equivalent response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1538,
        "completion_tokens": 459,
        "total_tokens": 1998
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did the global revenue from Electrophysiology Devices evolve between 2023 and 2024, and what was the percentage change in this revenue, excluding the impact of foreign exchange fluctuations?",
      "original_answer": "In 2023, the global revenue from Electrophysiology Devices was $2,195 million, which increased to $2,467 million in 2024. This represents a total change of 12.3%, with the change excluding the impact of foreign exchange fluctuations being 14.4%.",
      "llm_answer": "The Electrophysiology Devices segment generated **$2.195 billion in 2023** and **$2.467 billion in 2024** (U.S. + International totals)【page_53】. Excluding foreign‑exchange effects, this represents a **14.4 % increase** year‑over‑year【page_29】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: 2023 revenue is correctly stated as $2.195 billion ($2,195 million), and 2024 revenue as $2.467 billion ($2,467 million). The percentage change excluding foreign exchange fluctuations is accurately given as 14.4%. (2) Quantitative accuracy is perfect: the numbers match exactly (allowing for unit formatting: billion vs million), and the implied calculation of percentage change (2,467 - 2,195) / 2,195 ≈ 12.3% total change is consistent with the ground truth, even though the 12.3% total change is not explicitly mentioned in the LLM answer. However, the question specifically asks for the change excluding FX impact, which is correctly provided as 14.4%. (3) The reasoning is sound and reflects multi-hop synthesis: the answer draws on revenue figures and adjusts for FX impact, indicating proper integration of financial data across time periods and adjustments. (4) The answer is contextually complete and relevant, addressing both the revenue evolution and the FX-adjusted growth rate as required. Minor omission of the 12.3% total change does not detract from correctness since the question emphasizes the FX-excluded change, which is fully and accurately provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1134,
        "completion_tokens": 360,
        "total_tokens": 1495
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How has Accenture's financial relationship with Duck Creek Technologies evolved between fiscal 2022 and fiscal 2024, particularly in terms of investment valuation and its impact on financial performance?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with the investment accounted for under the equity method. By fiscal 2024, this investment resulted in a $253 million gain, indicating a significant increase in value and a shift in how the investment contributed to Accenture's financial performance. This demonstrates both a quantitative increase in the investment's value and a qualitative change in its impact on Accenture's earnings.",
      "llm_answer": "In fiscal 2022 Accenture’s equity‑method investment in Duck Creek Technologies – representing about a 16 % ownership – was carried at $138.9 million, with an estimated fair value of $223.2 million (page 70). By fiscal 2024 the stake had appreciated enough that Accenture recorded a $253 million gain on the investment in fiscal 2023, a gain that was highlighted in the 2024 MD&A as boosting earnings and affecting the effective‑tax‑rate adjustment (page 40). This reflects a substantial increase in the investment’s valuation and a material positive impact on Accenture’s financial performance.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains mostly correct information but has a key discrepancy in the 2022 valuation. The original answer states the investment was valued at $223,166 (approximately $223.2K), while the LLM claims it was carried at $138.9 million with a fair value of $223.2 million. This is a significant quantitative error—the ground truth value is $223,166 (about $0.223 million), not $223.2 million. The $138.9 million figure does not appear in the ground truth and appears to be incorrect. However, the $253 million gain in fiscal 2023 (reported in fiscal 2024) is accurate and correctly tied to financial performance impact. (2) The percentage ownership (16%) and the equity method accounting are correctly identified. The gain being highlighted in the 2024 MD&A and affecting the tax rate is additional accurate contextual detail not in the original but consistent with deeper knowledge, so it does not count against accuracy. (3) The multi-hop reasoning is sound: the model connects the initial investment valuation, its change over time, and the financial impact in later years, correctly synthesizing across fiscal periods and financial statements. (4) Despite the major error in the 2022 valuation (off by nearly 1,000x), the core trajectory—investment growth and positive financial impact—is correct, and key entities, years, and outcomes are accurate. Hence, a score of 7 is justified: the central conclusion is valid, but the quantitative foundation is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 410,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has the composition and scale of Union Pacific's retention share and unit awards changed between 2022 and 2023, and what does this indicate about the company's executive compensation strategy?",
      "original_answer": "In 2022, Union Pacific disclosed that 389,207 retention shares were outstanding under the 2021 Stock Incentive Plan as of December 31, 2021. By 2023, the company disclosed that 954,405 retention shares had been issued and were outstanding, along with 366,046 retention units that do not have an exercise price. This represents a significant increase in the number of outstanding retention instruments, indicating a shift toward greater use of retention-based compensation. The introduction of retention units in 2023 suggests a possible expansion or refinement of the company's long-term incentive strategy for executives.",
      "llm_answer": "Union Pacific’s 2022 proxy showed that its retention awards were essentially all shares – about 389 000 retention shares were outstanding under the 2021 Plan, with no separate retention‑unit count disclosed (UNP_10k_2022.pdf p.65). By 2023 the company reported a mixed pool of roughly 954 000 retention shares plus 366 000 retention units (non‑exercisable awards), expanding the total pool to over 1.3 million awards (UNP_10k_2023.pdf p.75). The introduction of a sizable unit component and the overall increase in awards suggest a strategic shift toward performance‑linked, non‑exercise‑price unit awards to better align executive pay with long‑term company performance and retention goals.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: 389,000 (rounded from 389,207) retention shares outstanding in 2022, 954,000 (rounded from 954,405) retention shares and 366,000 (rounded from 366,046) retention units in 2023. The total pool of over 1.3 million is a correct sum (954,405 + 366,046 = 1,320,451). Minor rounding is acceptable and common in financial reporting. (2) The answer addresses all parts of the question: changes in composition (shift from all shares to mixed shares and units), scale (significant increase), and strategic implication (greater emphasis on retention and long-term alignment). (3) Entities are correct: Union Pacific, 2022 and 2023 timeframes, retention shares and units, correct reference to the 2021 Stock Incentive Plan. (4) Reasoning is sound: the introduction of retention units that do not have an exercise price is correctly interpreted as a move toward performance-linked, non-exercisable awards to align with long-term performance and retention—this matches the ground truth’s conclusion about a refined or expanded long-term incentive strategy. The only minor shortcoming is that the LLM does not explicitly state that the 2022 figure was reported as of December 31, 2021 (a nuance in timing), but this does not materially affect the correctness. Overall, the answer is factually precise, contextually relevant, and demonstrates strong multi-hop synthesis across years and award types.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 412,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has MetLife's application of GAAP guidance for adjusted earnings evolved between 2023 and 2024, particularly in terms of the exclusions related to market volatility and asymmetrical accounting adjustments?",
      "original_answer": "In 2023, MetLife updated its calculation of adjusted earnings due to the adoption of LDTI, which led to the exclusion of certain adjustments related to the amortization of DAC, VOBA, and related intangibles, as well as changes in measurement of certain guarantees. Adjusted earnings excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, MetLife continued to refine these exclusions, particularly expanding the scope of policyholder liability remeasurement gains (losses) to exclude asymmetrical accounting associated with in-force reinsurance. Additionally, in 2024, net investment income exclusions were expanded to include adjustments relating to joint ventures under the equity method, which was not explicitly mentioned in 2023. This reflects a more detailed and structured application of GAAP guidance over time.",
      "llm_answer": "MetLife’s definition of adjusted earnings as a GAAP‑consistent segment measure has stayed the same – it continues to strip out market‑volatility items (net investment gains/losses, net derivative gains/losses, MRB remeasurement gains/losses and goodwill impairments) and asymmetrical, non‑economic accounting (in‑force reinsurance effects, basis‑adjustment amortizations, inflation‑indexed benefit adjustments and non‑economic losses at contract inception). In the 2024 filing the company simply clarifies the exclusions, adding that net investment income also removes equity‑method earnings from joint‑ventures and that interest credited to policyholder account balances excludes periodic credit‑rate adjustments and related asymmetrical accounting, but the fundamental GAAP‑based exclusions have not changed.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of the types of exclusions MetLife applies to adjusted earnings and correctly identifies the addition of equity-method joint venture adjustments in 2024, which aligns with the ground truth. It also accurately notes that market volatility items (e.g., MRB remeasurements, net investment gains/losses) and asymmetrical accounting (e.g., in-force reinsurance, basis adjustments) are excluded. However, the LLM incorrectly frames these changes as merely 'clarifications' in disclosure rather than an evolution or refinement in the calculation methodology, which the ground truth emphasizes—particularly the expansion of policyholder liability remeasurement exclusions in 2024 to include more asymmetrical accounting from in-force reinsurance. The ground truth also specifically notes the impact of LDTI adoption in 2023 (a key regulatory driver), which the LLM omits entirely, weakening the multi-hop reasoning about how GAAP guidance (specifically LDTI) shaped the evolution. While the LLM captures the 2024 expansion regarding joint ventures under the equity method (matching the ground truth), it misses the deeper connection to LDTI and the explicit broadening of exclusions beyond disclosure clarity. There are no numerical inaccuracies (dates and entities are correct: MetLife, 2023–2024, adjusted earnings), so quantitative accuracy is perfect. The answer is contextually relevant and well-structured, but the qualitative reasoning downplays a substantive evolution as a presentational change, missing a key analytical point.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 429,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has Accenture's approach to achieving compressed transformations evolved from 2022 to 2024, particularly in terms of the technologies leveraged and the scope of transformation services offered?",
      "original_answer": "In 2022, Accenture focused on using technologies like digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics, and metaverse to help clients achieve compressed transformations by redefining product design, engineering, sourcing, manufacturing, and servicing. By 2024, the company expanded its technological toolkit to include generative AI, artificial reality / virtual reality, and advanced robotics, while also enhancing its own development of automation equipment and commercial hardware to support client operations. Additionally, the scope of transformation broadened to include digitally transforming capital projects such as plant and asset construction, public infrastructure, power grids, and data centers. This reflects a more integrated and advanced technological approach to compressed transformations over the two-year period.",
      "llm_answer": "In 2022 Accenture’s Industry X narrative framed “compressed transformations” around a core set of emerging tools—digital twins, AI, IoT, cloud/edge, 5G, advanced robotics and the metaverse—to redesign product design, engineering, sourcing, manufacturing and service. By 2024 the playbook had broadened: generative AI, AR/VR, AI‑Navigator platforms and the ability to design and build advanced automation hardware were added, and the transformation scope now also covers testing, capital‑project digitization and the creation of specialized robotics equipment, all woven into its Strategy, Technology, Operations and Industry X service lines.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and semantically equivalent to the ground truth. (1) All key technologies mentioned in the original answer—digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics, metaverse in 2022—are correctly identified. The 2024 additions—generative AI, AR/VR (aligned with 'artificial reality / virtual reality'), and advanced robotics—are accurately reflected. The LLM adds 'AI-Navigator platforms' and 'design and build advanced automation hardware', which are consistent with the original's 'enhancing its own development of automation equipment and commercial hardware', representing a slight expansion but not a factual error. (2) There are no numeric values, dates, or financial figures in the question or answers, so quantitative accuracy is not applicable in a numerical sense, but temporal framing (2022 vs 2024) is correct. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes how Accenture’s technological toolkit and scope of transformation evolved across two years, linking technology adoption to service expansion. (4) The scope expansion to 'capital-project digitization' aligns with the original’s inclusion of plant and asset construction, public infrastructure, etc. The mention of 'testing' and 'specialized robotics equipment' adds minor detail not in the original but does not contradict it. The integration into 'Strategy, Technology, Operations and Industry X' service lines is additional context that enhances accuracy without deviation. Only a minor deduction in qualitative accuracy due to slight rephrasing and addition of 'AI-Navigator' without explicit grounding in the original, but overall reasoning and synthesis remain strong. Contextual relevance is perfect—directly addresses evolution in technologies and scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 483,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2023 and 2024 in managing exposure to changes in the fair value of fixed-rate debt?",
      "original_answer": "In 2023, Abbott had interest rate hedge contracts totaling approximately $2.2 billion at December 31, 2023, to manage exposure to changes in the fair value of fixed-rate debt due to long-term benchmark interest rate fluctuations. These contracts were designated as fair value hedges, effectively converting fixed-rate debt to variable-rate debt. In 2024, Abbott continued to maintain interest rate hedge contracts with notional values totaling $2.2 billion, indicating a consistent strategy in hedging interest rate risk. However, the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024, suggesting a shift in the underlying debt structure or market interest rate conditions despite the stable hedge notional amount.",
      "llm_answer": "In 2023 Abbott reported that it had roughly $2.2 billion of interest‑rate hedge contracts, but $700 million of those contracts matured that year, which cut the fair‑value liability on the swaps from $156 million in 2022 to $95 million in 2023 (the payable position fell from (156) to (95))【page_66】. By the end of 2024 the company again disclosed $2.2 billion of interest‑rate hedge contracts, indicating it replaced the maturing contracts and kept the same overall notional exposure to manage the fair‑value of its fixed‑rate debt【page_40】【page_64】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core fact that Abbott maintained $2.2 billion in interest rate hedge contracts at the end of both 2023 and 2024, which aligns with the ground truth. However, it introduces significant inaccuracies not present in the original answer. First, the claim that $700 million of contracts matured in 2023 and that the fair-value liability decreased from $156 million to $95 million is factually unsupported by the ground truth, which does not mention contract maturities or changes in fair-value liability during 2023. These specific numbers and narrative details appear to be hallucinated or misattributed from unrelated parts of the filing. Second, the ground truth highlights a key development—the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024—indicating a shift in debt structure or market conditions. This critical point is entirely missing in the LLM answer, representing a major omission in the evolution of Abbott's hedging strategy. While the LLM correctly identifies the consistent notional amount of $2.2 billion and the purpose of the hedges (managing fair value of fixed-rate debt), it fails to report the change in underlying interest rates, which is essential to fully answering how the use of hedges evolved. The reasoning is partially sound in noting replacement of hedges to maintain exposure, but the unsupported quantitative claims reduce factual reliability. Contextually, the answer remains focused and relevant to the question, citing appropriate pages and concepts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 422,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has MetLife's treatment and definition of Adjusted Earnings evolved between 2023 and 2024, particularly in relation to GAAP guidance and segment performance measurement?",
      "original_answer": "In 2023, MetLife updated its calculation of Adjusted Earnings due to the adoption of LDTI, removing certain adjustments related to the amortization of DAC, VOBA, and related intangibles, and instead adjusted for changes in measurement of certain guarantees. Adjusted Earnings in 2023 excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, Adjusted Earnings remained the GAAP measure of segment performance, but the exclusions were more clearly delineated to include market volatility impacts, asymmetrical and non-economic accounting adjustments, revenues and costs from divested businesses, and results from discontinued operations. Specifically, 2024 Adjusted Earnings excluded net investment gains/losses, derivative gains/losses, MRB remeasurement gains/losses, and goodwill impairments, with more structured exclusions such as inflation-indexed benefit adjustments and non-economic losses from single premium annuity contracts. This represents a refinement and expansion of the exclusions introduced in 2023.",
      "llm_answer": "In the 2023 filing MetLife first framed adjusted earnings as a non‑GAAP metric that, “consistent with GAAP guidance for segment reporting, adjusted earnings and related measures are also our GAAP measures of segment performance” and noted that the adoption of LDTI changed the calculation by removing DAC/VOBA amortization adjustments (page 119‑120). By the 2024 filing the company still presents adjusted earnings as its GAAP‑aligned segment‑performance measure, but now explicitly ties it to the chief operating decision‑maker’s evaluation and resource‑allocation process and spells out a broader set of exclusions – market‑volatility gains/losses, asymmetrical and non‑economic accounting, divested‑business items and discontinued‑operation results – while reaffirming compliance with GAAP segment‑reporting guidance (page 150‑151, 152).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2023, MetLife updated Adjusted Earnings due to LDTI adoption, removing DAC/VOBA amortization adjustments—this matches the original answer. It also correctly states that Adjusted Earnings remained the GAAP measure of segment performance in 2024, with expanded exclusions. The inclusion of market volatility, asymmetrical accounting, divested businesses, and discontinued operations is consistent with the 2024 refinements described. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not compromised; dates (2023 and 2024) are correct. (3) The multi-hop reasoning is sound: the answer synthesizes changes across two years, connects LDTI adoption to changes in Adjusted Earnings treatment, and correctly interprets the evolving exclusions. The LLM cites specific page numbers (119–120 for 2023, 150–151, 152 for 2024), indicating proper sourcing. (4) While the LLM captures the core evolution—refinement and expansion of exclusions post-LDTI—it slightly condenses the specificity of 2024 exclusions (e.g., does not mention inflation-indexed benefit adjustments or non-economic losses from single premium annuity contracts). However, it captures the broader categories accurately. The statement that Adjusted Earnings is both non-GAAP and a GAAP measure of segment performance reflects MetLife’s framing per GAAP segment reporting rules (ASC 280), which allows non-GAAP metrics as segment performance measures if used internally by the CODM. Thus, the answer is semantically equivalent and contextually precise, warranting a high score with only minor detail omissions preventing a perfect 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1498,
        "completion_tokens": 481,
        "total_tokens": 1979
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has the funding and utilization of Accenture's share purchase program evolved from 2022 to 2024, particularly in terms of available authorization and share acquisition methods?",
      "original_answer": "In 2022, Accenture reported an aggregate available authorization of $3,129,296 for its publicly announced open-market share purchase program and other related share purchase programs. This included acquisitions of Accenture plc Class A ordinary shares and Accenture Canada Holdings Inc. exchangeable shares held by current and former members of Accenture Leadership. By 2024, the company clarified that its open-market share purchase program applied specifically to Accenture plc Class A ordinary shares, which were held as treasury shares for employee benefits, such as equity awards. Additionally, in fiscal 2024, Accenture acquired Class A ordinary shares primarily through share withholding for payroll tax obligations tied to employee equity plans. These purchases did not impact the aggregate available authorization for the public share purchase programs, indicating a shift in acquisition methods while maintaining a focus on funding levels.",
      "llm_answer": "In 2022 the Board had authorized $3.13 million for the publicly announced open‑market repurchase program (with a $3 million board addition that raised total authority to $6.13 million) and used it to buy about 12.2 million shares for $4.1 million, mainly through open‑market purchases and share‑withholding for payroll‑tax obligations under employee equity plans (plus a small exchangeable‑share component)【page_93】【page_94】. By fiscal 2024 the remaining available authorization had fallen to $2.69 million (while a $4 million board addition lifted total authority to $6.69 million) and the company increased its utilization, purchasing roughly 13.9 million shares for $4.5 million via the same open‑market and payroll‑tax withholding methods (and a modest amount of exchangeable‑share purchases)【page_100】【page_101】.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. The original answer states that in 2022, Accenture had an aggregate available authorization of $3,129,296 (approximately $3.13 million), which the LLM correctly approximates. However, the LLM incorrectly claims a 'board addition of $3 million' raising total authority to $6.13 million, and later a $4 million addition in 2024—these figures are entirely fabricated and not supported by the ground truth. The ground truth makes no mention of board additions or total authorities exceeding the initial amount. Furthermore, the LLM states that Accenture bought '12.2 million shares for $4.1 million' in 2022 and '13.9 million shares for $4.5 million' in 2024—these numbers are grossly inaccurate. Spending $4.1 million to buy over 12 million shares implies a price of ~$0.34 per share, which is implausible for a company like Accenture. The ground truth does not provide specific share counts or total costs, but such figures would be in the hundreds of millions, not millions. (2) Quantitative accuracy is extremely low: the dollar amounts are off by orders of magnitude, and the share counts are fabricated. The only correct number is the ~$3.13 million authorization in 2022 (matching $3,129,296). The rest of the figures (remaining $2.69 million in 2024, $6.69 million total authority) are unsupported. (3) The multi-hop reasoning is flawed. The LLM invents a narrative of increasing total authority and utilization, while the ground truth describes a shift in acquisition methods (from open-market and exchangeable shares to share withholding for tax obligations) without discussing changes in total funding or remaining authorization. The LLM fails to mention that purchases via withholding did not impact the public program's authorization, a key point in the original answer. (4) Contextual relevance is moderate—the LLM addresses share purchase programs and methods like open-market and withholding—but the invented numbers and incorrect synthesis severely undermine correctness. The focus on funding evolution is present but based on false data. Thus, the correctness score is low due to pervasive quantitative errors and failure to reflect the actual evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1450,
        "completion_tokens": 605,
        "total_tokens": 2055
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How did MetLife's treatment and valuation methodology for Unit-linked Securities evolve from 2023 to 2024, particularly in terms of cost basis and fair value sensitivity?",
      "original_answer": "In 2023, MetLife described the cost basis for Unit-linked and FVO securities as primarily equity and fixed maturity securities, with cost representing original cost for equities and amortized cost for fixed maturities. By 2024, Unit-linked securities were included in Level 3 fair value measurements and subjected to valuation techniques involving significant unobservable inputs such as mortality rates, lapse rates, and equity volatility. Additionally, the 2024 disclosures emphasized sensitivity of fair value to changes in these inputs, indicating a more dynamic and assumption-driven valuation approach compared to the more static cost-based method described in 2023.",
      "llm_answer": "In the 2023 filing MetLife presented its Unit‑linked and FVO securities at **amortized cost** – i.e., the original purchase price reduced by repayments and adjusted for premium amortization or discount accretion (see Schedule I, “Unit‑linked and FVO securities” and footnote (1) on page 320).  Fair‑value changes for those securities were simply recorded in net investment income, with no detailed sensitivity analysis shown.\n\nIn the 2024 filing the company now treats Unit‑linked and FVO securities as **Level 3 assets** and values them using the same significant‑unobservable‑input techniques and pricing methods (matrix, market and consensus pricing) applied to other Level 3 securities.  MetLife explicitly notes that the **fair‑value sensitivity** of Unit‑linked securities to changes in those inputs is “similar in nature to that described in the preceding table” of Level 3 sensitivities (see Note 13, pages 249‑250).  Thus, the methodology shifted from a basic amortized‑cost presentation to a Level 3 fair‑value approach with disclosed sensitivity to key inputs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, no specific numerical values (e.g., dollar amounts, percentages) are mentioned in either the original or LLM answer, so there are no discrepancies—this is not due to omission but because the topic concerns valuation methodology rather than specific figures. Dates (2023 and 2024) are correct. (2) The LLM correctly identifies the shift from amortized cost (in 2023) to Level 3 fair value treatment (in 2024), which matches the ground truth. It accurately notes that in 2023, cost basis was amortized cost for fixed maturities and original cost for equities—though it simplifies this by stating 'amortized cost' for both, which is slightly imprecise but not factually incorrect given the focus on Unit-linked and FVO securities, which include fixed maturities. (3) The multi-hop reasoning is sound: the model synthesizes changes across years, correctly identifying the move from a static cost-based approach to a dynamic, assumption-driven Level 3 valuation involving unobservable inputs like mortality, lapse rates, and volatility. It references sensitivity disclosures in 2024, citing Note 13 and pages 249–250, which supports the claim of enhanced transparency. (4) The only minor shortcoming is that the LLM does not explicitly name the specific unobservable inputs (e.g., mortality, lapse rates) as emphasized in the original answer, instead referring to them generally as 'significant-unobservable-input techniques.' However, it does correctly link sensitivity analysis to Level 3 disclosures, implying awareness of these inputs. Overall, the answer captures the evolution in methodology and enhanced sensitivity reporting with high fidelity, warranting a 9/10 for correctness and qualitative accuracy. Contextual relevance is perfect—directly addresses treatment and valuation methodology changes over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 513,
        "total_tokens": 1955
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How has the structure and vesting timeline of market-based RSUs evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, market-based RSUs generally vested over four years and grantees could receive between 0% and 300% of the original grant based on total stockholder return (TSR) relative to an index group. By fiscal year 2023, while four-year vesting remained common, the company also introduced market-based RSUs that vested over five years, with vesting contingent on achieving stock price performance milestones. This indicates an expansion in the types of market-based RSUs offered, adding a new vesting structure based on specific stock price targets.",
      "llm_answer": "In FY 2022 Broadcom’s market‑based RSUs were granted with a service condition and a market condition and “generally vest over four years” with payouts tied to total‑stockholder‑return versus an index group【page_84】.  In FY 2023 the company kept that four‑year design but added a new class of market‑based RSUs that “vest over five years, subject to satisfaction of stock‑price performance milestones”【page_84】, and the weighted‑average expected term in the valuation model rose from about 3.4 years in FY 2022 to roughly 4.8 years in FY 2023【page_85】.  Thus, while the basic TSR‑based structure stayed the same, the vesting horizon was extended in 2023 to include a five‑year award and a longer overall expected term.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately states that in FY 2022, market-based RSUs generally vested over four years with payouts based on total stockholder return (TSR) relative to an index group, which aligns with the original answer. (2) For FY 2023, it correctly identifies the continuation of the four-year vesting structure and the introduction of a new five-year vesting structure tied to stock price performance milestones—this is a key evolution noted in the ground truth. (3) The LLM adds specific supporting detail from the source (page 85) about the weighted-average expected term increasing from 3.4 years to 4.8 years, which is consistent with the shift toward longer-term awards and further validates the structural change. This quantitative data is accurately reported and enhances the answer without contradicting the original. (4) All entities (Broadcom, market-based RSUs, fiscal years 2022 and 2023) are correct. (5) The reasoning is sound and synthesizes information across multiple points in the document to draw the correct conclusion about the expansion and extension of vesting timelines. The answer is semantically equivalent to the ground truth, with added precision from the source material. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 368,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 145,
      "question": "How did the phase-in treatment of the CECL standard's ongoing impact on regulatory capital evolve between 2023 and 2024, and what specific regulatory capital treatment applied during the phase-in period?",
      "original_answer": "In 2023, the CECL Transition Election allowed for the cumulative 'day 2' ongoing impact to be phased into regulatory capital at 25% per year from January 1, 2022, through December 31, 2024. By 2024, this phase-in treatment remained consistent, with the ongoing impact continuing to be phased in at 25% annually, indicating that the regulatory capital treatment under the CECL Transition Rule was applied uniformly across both years as part of the multi-year transition framework.",
      "llm_answer": "The CECL Transition Rule let Capital One treat the CECL impact as a capital add‑back, allowing it to add back the after‑tax “day 1” adoption impact and a scaled portion of the “day 2” ongoing allowance increase (25 % per year) to its regulatory capital 【page_80】. As a result, the company had only 50 % of that impact phased in by year‑end 2023, but by year‑end 2024 the phase‑in had progressed to 75 % (with $600 million added in 2024 and the final $600 million scheduled for Jan 1 2025) 【page_203】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 25% annual phase-in of the 'day 2' ongoing CECL impact into regulatory capital, which aligns with the ground truth for both 2023 and 2024. It also correctly states that by the end of 2023, 50% was phased in (2 years × 25%), and by end of 2024, 75% would be phased in, consistent with the multi-year framework starting January 1, 2022, through December 31, 2024. However, the introduction of specific dollar amounts ($600 million added in 2024 and another $600 million scheduled for Jan 1, 2025) is not present in the ground truth and cannot be verified against it. These figures may be factually correct in context but introduce quantitative details not supported by the original answer, risking inaccuracy. (2) The timeline and percentages (25% per year, 50% by 2023, 75% by 2024) are accurate and mathematically sound. The final 100% phase-in should occur by Jan 1, 2025, which matches the 3-year span from 2022–2024 (inclusive), so the progression logic is correct. However, the $600M figures are unverified and potentially misleading if incorrect. (3) The reasoning is strong: the model correctly synthesizes the phase-in treatment over time and applies the 25% rule across years, demonstrating proper multi-hop understanding of the CECL Transition Rule’s ongoing impact. It distinguishes between 'day 1' and 'day 2' impacts appropriately. (4) The answer is contextually relevant and addresses both parts of the question—evolution between 2023 and 2024 and the specific regulatory treatment. While the core regulatory mechanism is accurately described, the addition of unsupported dollar amounts reduces quantitative accuracy. Overall, the answer is substantively correct but includes extraneous, unverified numerical claims, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 495,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 146,
      "question": "How has Broadcom's relationship with Wilmington Trust, National Association evolved between 2022 and 2023 in terms of the types and terms of senior notes issued under their indentures?",
      "original_answer": "In 2022, Broadcom had an ongoing relationship with Wilmington Trust, National Association as trustee under indentures governing senior notes issued in January 2021, which included notes with interest rates as low as 1.950% (due 2028) and as high as 3.750% (due 2051). By 2023, the relationship had evolved to include new indentures dated April 18, 2022, and July 12, 2024, under which Broadcom issued higher-yielding senior notes, including a 4.926% note due 2037 and later, in October 2024, notes ranging from 4.150% (due 2028) to 4.800% (due 2034). This reflects a shift toward issuing longer-term debt with higher interest rates over time.",
      "llm_answer": "In the 2022 Form 10‑K the exhibit list (page 101) contains no new senior‑note indentures with Wilmington Trust, National Association, indicating that Broadcom’s senior‑note program was unchanged in that filing. By the 2023 Form 10‑K the company had added several fresh indentures with Wilmington Trust as trustee – e.g., the April 14 2022 indenture (Exhibit 4.42) issuing 4.00 % senior notes due 2029 and 4.15 % notes due 2032, and the April 18 2022 indenture (Exhibit 4.46) issuing 4.926 % notes due 2037 – alongside existing series, showing a shift toward higher‑coupon, longer‑dated senior notes while retaining Wilmington Trust as the trustee (pages 98‑100).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution in Broadcom's relationship with Wilmington Trust by noting new indentures in 2022 and higher-coupon, longer-dated notes, which aligns with the ground truth's core narrative of a shift toward higher-yielding, longer-term debt. However, there are significant factual inaccuracies in dates and interest rates. The LLM claims an April 14, 2022 indenture issued 4.00% notes due 2029 and 4.15% notes due 2032, but the ground truth does not mention these specific terms or this date. Instead, the ground truth references a July 12, 2024 indenture and an October 2024 issuance, which the LLM omits entirely. Additionally, the LLM incorrectly implies these new notes were disclosed in the 2023 10-K as having been issued under indentures from April 2022, while the ground truth includes future-dated indentures (July 12, 2024), suggesting forward-looking disclosures. (2) Quantitative accuracy is compromised: the 4.926% note due 2037 is correctly cited by both, but the LLM invents a 4.00% and 4.15% series not in the ground truth, and misstates the April 18, 2022 indenture as issuing those notes when the ground truth only confirms the 4.926% note under that date. The ground truth also includes a 4.150% note due 2028 issued in October 2024, which the LLM confuses with a 4.15% due 2032 from April 2022—different rates, maturities, and issuance dates. (3) The multi-hop reasoning is partially sound: the LLM correctly infers evolving terms by comparing 2022 and 2023 filings and identifies Wilmington Trust as continuing trustee. However, it fails to incorporate the full timeline (especially 2024 events) and misattributes terms to incorrect dates, undermining the synthesis. (4) Contextual relevance is high—the answer addresses the evolution of the relationship, types of notes, and terms—but factual errors in key numbers and dates reduce correctness. The answer captures the directional shift (higher yields, longer maturities) but with incorrect supporting data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 545,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did Capital One's regulatory capital add-back under the CECL Transition Rule evolve from 2023 to 2024, and what was the specific phase-in progression during this period?",
      "original_answer": "In 2023, Capital One had already added back $2.4 billion to its regulatory capital under the CECL Transition Rule, with a phase-in of 50% as of January 1, 2023. By January 1, 2024, the phase-in had progressed to 75%, indicating a 25 percentage point increase over the year. This reflects the structured five-year phase-in process under the CECL Transition Rule, where 25% of the cumulative impact was phased in annually after 2021.",
      "llm_answer": "Capital One’s CECL add‑back—an aggregate $2.4 billion—was at 50 % of the total in 2023 and increased to 75 % of the total as of January 1 2024【page_202】. Under the CECL Transition Rule the cumulative “day‑2” impact is phased in at 25 % per year: 25 % in 2022, 50 % in 2023, 75 % in 2024, and fully (100 %) by 2025【page_11】【page_202】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers, percentages, and dates are accurate: the $2.4 billion CECL add-back amount is correctly stated, and the phase-in progression from 50% as of January 1, 2023, to 75% as of January 1, 2024, is precisely reflected. The annual 25 percentage point increase aligns with the five-year phase-in schedule starting in 2022. (2) The answer correctly identifies the structured phase-in under the CECL Transition Rule: 25% in 2022, 50% in 2023, 75% in 2024, and 100% by 2025, which is consistent with the regulatory framework. (3) The multi-hop reasoning is sound—synthesizing the specific dollar amount with the annual phase-in percentages across years and linking it to the regulatory rule. (4) Entity accuracy is perfect: Capital One, CECL Transition Rule, and the relevant time periods are correctly referenced. (5) The answer is semantically equivalent to the original, providing the same core information with slightly expanded context (e.g., mentioning 2025 completion), which enhances completeness without introducing error. All checklist items are satisfied with high precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1197,
        "completion_tokens": 332,
        "total_tokens": 1530
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did the treatment of VMware stock options for non-employee directors evolve between 2022 and 2023 following the Broadcom acquisition?",
      "original_answer": "In 2022, the 10-K filing stated that all outstanding in-the-money VMware stock options and RSU awards held by non-employee directors would be accelerated and converted into the right to receive cash and shares of Broadcom common stock, in equal parts, upon the completion of the acquisition. By 2023, this provision had been realized, with the statement confirming that these awards were indeed accelerated and converted into the right to receive cash and Broadcom shares. This reflects a transition from a planned conversion to an actualized event following the completion of the acquisition.",
      "llm_answer": "In the 2022 Form 10‑K (page 97) Broadcom disclosed that, as part of the pending VMware merger, “all outstanding in‑the‑money VMware stock options and RSU awards held by non‑employee directors will be accelerated and converted into the right to receive cash and shares of Broadcom common stock, in equal parts.” The 2023 Form 10‑K (page 66) reports that, after the merger closed, those same options and RSU awards “were accelerated and converted into the right to receive cash and shares of Broadcom common stock, in equal parts.” Thus, the treatment did not change – the planned 50/50 cash‑and‑stock conversion for non‑employee director options was carried out when the acquisition was completed.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately captures the treatment of VMware stock options for non-employee directors in both 2022 and 2023, correctly stating that in 2022 the conversion was a planned provision tied to the pending acquisition, and in 2023 it was confirmed as executed. (2) There are no numerical values requiring calculation, but the description of the '50/50 cash and stock' conversion matches the 'equal parts' phrasing in the original, which is quantitatively accurate. (3) The multi-hop reasoning—comparing the 2022 forward-looking statement with the 2023 retrospective confirmation across two 10-K filings—is sound and correctly synthesizes information from both years. (4) The LLM cites specific page numbers (97 in 2022, 66 in 2023), enhancing precision, and correctly attributes disclosure to Broadcom post-acquisition. The conclusion that the treatment was consistent in intent but evolved from plan to execution aligns perfectly with the ground truth. All entities (VMware, Broadcom, non-employee directors, stock options, RSUs) are correctly identified and contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 325,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How has the therapeutic positioning of Vraylar evolved from 2022 to 2024 based on AbbVie's disclosures?",
      "original_answer": "In 2022, Vraylar was described as being evaluated in Phase 3 clinical trials as an adjunctive treatment for major depressive disorder (MDD), with one trial meeting its primary endpoint and the other showing numerical but not statistically significant improvement. By 2024, Vraylar was disclosed as being indicated for a broader range of psychiatric conditions, including acute and maintenance treatment of schizophrenia, acute treatment of manic or mixed episodes associated with bipolar disorder, acute treatment of depressive episodes associated with bipolar I disorder, and as an adjunctive treatment in major depressive disorder. This reflects a clear expansion and solidification of its therapeutic positioning over time.",
      "llm_answer": "In the 2022 Form 10‑K AbbVie highlighted Vraylar mainly as a development candidate for major depressive disorder, reporting top‑line Phase 3 results of two adjunctive‑MDD studies—one met its primary endpoint and the other showed a non‑significant trend (page 60). By the 2024 filing the company lists Vraylar as an approved dopamine‑D3‑preferring D3/D2 partial agonist with four distinct indications: acute and maintenance treatment of schizophrenia, acute treatment of manic or mixed episodes of bipolar disorder, acute treatment of depressive episodes associated with bipolar I disorder, and as an adjunctive therapy for major depressive disorder (page 6). This shows a shift from a narrow, development‑focused positioning on MDD in 2022 to a broader, multi‑indication, established psychiatric product portfolio by 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately captures the evolution of Vraylar's therapeutic positioning from 2022 to 2024 based on AbbVie's disclosures. In 2022, the drug was described as being in Phase 3 trials for adjunctive treatment of MDD, with one trial meeting its primary endpoint and the other showing a numerical but non-significant improvement—this matches the original answer exactly. By 2024, the LLM correctly identifies that Vraylar had gained approval for multiple indications: schizophrenia, bipolar disorder (manic/mixed episodes), bipolar I depression, and adjunctive MDD, reflecting a broadened therapeutic role. (2) There are no numerical values requiring calculation (e.g., financials), but the years (2022, 2024), trial phases (Phase 3), and outcomes (met primary endpoint, non-significant trend) are all factually accurate and consistent with the ground truth. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points (2022 and 2024 filings), identifies the shift from investigational to approved status, and correctly infers the expansion in therapeutic positioning. (4) The LLM adds contextual precision by citing page numbers and specifying Vraylar’s mechanism (dopamine-D3-preferring D3/D2 partial agonist), which enriches the answer without introducing error. All entities—AbbVie, Vraylar, MDD, bipolar disorder, schizophrenia—are correctly identified and appropriately contextualized. The answer is highly relevant, complete, and factually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 429,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has GE's accounting policy for long-term services agreements evolved from 2022 to 2024, particularly in terms of revenue recognition method and contract billing estimates?",
      "original_answer": "In 2022, GE recognized revenue for long-term services agreements on a straight-line basis, primarily in the Healthcare and Renewable Energy segments, with periodic invoicing as services were provided. By 2024, GE shifted to using the percentage of completion method for revenue recognition, predominantly within the CES segment, based on costs incurred relative to total expected costs. Additionally, in 2024, GE reported a long-term services agreements net liability balance of $6.6 billion, representing approximately 4.1% of total estimated life of contract billings of $162 billion, indicating a more detailed and forward-looking estimation process involving asset utilization and cost improvements, which was not explicitly mentioned in 2022.",
      "llm_answer": "In the 2022 filing GE said that long‑term services contracts in its Healthcare and Renewable‑Energy businesses were “recognized … on a straight‑line basis… We generally invoice periodically as services are provided” (2022 p. 85), while its Aviation and Power businesses used a percentage‑of‑completion approach for those contracts (2022 p. 83). By the 2024 filing the company has moved to a single percentage‑of‑completion policy for all long‑term services agreements, recognizing revenue as it performs based on costs incurred versus total‑cost estimates and on utilization forecasts, and it now explicitly updates utilization and billing estimates with cumulative catch‑up adjustments (2024 p. 17).",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in GE's accounting policy from straight-line to percentage-of-completion method between 2022 and 2024, and accurately notes the segments involved (Healthcare, Renewable Energy initially using straight-line; shift to CES and unified percentage-of-completion). It also correctly captures the qualitative evolution in estimation practices, including the use of cost incurrence, utilization forecasts, and cumulative catch-up adjustments in 2024. However, it introduces a factual inaccuracy by stating that Aviation and Power used percentage-of-completion in 2022 — this is not supported by the ground truth, which does not mention those segments’ methods in 2022. (2) Quantitatively, the LLM answer omits all specific numbers from the ground truth: the $6.6 billion net liability, the $162 billion total estimated life of contract billings, and the 4.1% ratio. These are key quantitative indicators of the enhanced estimation process in 2024 and their absence represents a significant gap in quantitative accuracy. While no incorrect calculations are made (because no calculations are attempted), the failure to include these figures reduces precision. (3) The multi-hop reasoning is strong: the model synthesizes changes over time, identifies shifts in methodology, and links them to improved estimation techniques. It correctly infers a move toward more dynamic and forward-looking models in 2024. However, the unsupported claim about Aviation and Power weakens the entity accuracy. (4) The contextual relevance is excellent — the answer directly addresses revenue recognition method evolution and contract billing estimate improvements. Due to missing key quantitative data and one segment-level inaccuracy, the correctness score is 8 rather than 9 or 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 493,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has IBM's disclosure of the 1.250% Notes due 2027 evolved between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, IBM disclosed the 1.250% Notes due 2027 as part of a list of instruments defining the rights of holders, with Exhibit 4.3 to Form 8-K filed on January 30, 2019, referenced for the notes. In the 2023 10-K filing, the 1.250% Notes due 2027 are listed under registered securities with the trading symbol IBM 27B on the New York Stock Exchange. This evolution reflects a shift from referencing the instrument defining the rights to identifying the notes as a registered class of securities.",
      "llm_answer": "In IBM’s 2022 Form 10‑K the 1.250 % Notes due 2027 are not listed among the securities or exhibits – the exhibit table only references other debt (e.g., the 6.22 % debentures due 2027) and makes no separate entry for the 1.250 % notes【page_31】. By the 2023 Form 10‑K, IBM adds a distinct line for “1.250 % Notes due 2027” in the “Securities registered pursuant to Section 12(b)” table, indicating that the company now discloses this instrument explicitly【page_1】.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The claim that the 1.250% Notes due 2027 were 'not listed' in the 2022 10-K is incorrect — the original answer confirms they were disclosed via reference to Exhibit 4.3 to Form 8-K filed on January 30, 2019, as part of the instruments defining the rights of holders. The LLM incorrectly interprets absence from the exhibit list as non-disclosure, failing to recognize that cross-referencing via Form 8-K satisfies disclosure requirements. (2) The LLM states there is 'no separate entry' for the notes in 2022, which may be technically true regarding explicit listing, but misrepresents the nature of disclosure evolution by ignoring the referenced exhibit mechanism. (3) In contrast, the 2023 10-K correctly identifies the notes as registered under Section 12(b) with trading symbol IBM 27B — a fact the LLM captures partially by noting the new listing but fails to name the symbol or exchange. (4) The multi-hop reasoning is flawed: the model does not correctly synthesize that the evolution is from indirect disclosure (via incorporation by reference) to direct registration and listing, instead framing it as a transition from 'not listed' to 'listed', which is misleading. (5) While percentages (1.250%) and years (2027) are correct, the interpretation of disclosure status is fundamentally wrong. The LLM also cites page numbers without verifying the actual content context, risking hallucination. Overall, despite correct identification of the instrument and year, the core factual and conceptual understanding of how the disclosure evolved is incorrect, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 458,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has the structure and performance criteria of AbbVie's performance-vested RSUs evolved between 2022 and 2024, particularly in terms of vesting increments and performance metrics?",
      "original_answer": "In 2022, performance-vested RSUs had the potential to vest in one-third increments over a three-year performance period, with performance measured based on AbbVie's return on invested capital (ROIC) relative to a defined peer group of pharmaceutical, biotech, and life science companies for awards granted in 2021 and 2020. By 2024, the vesting structure remained similar—allowing for one-third increments over a three-year period—but the description of performance metrics was streamlined, focusing primarily on ROIC performance against the same peer group, without mention of specific years tied to tranches as seen in 2022. This indicates a simplification or standardization of the performance criteria over time.",
      "llm_answer": "AbbVie’s performance‑vested RSUs have not changed – in both 2022 and 2024 they vest in one‑third increments over a three‑year performance period and the vesting condition is tied to AbbVie’s return on invested capital (ROIC) relative to a defined peer group of pharmaceutical, biotech and life‑science companies (2022 Form 10‑K p. 113; 2024 Form 10‑K p. 92). No new vesting schedule or performance metric was added between those years.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that AbbVie's performance-vested RSUs vest in one-third increments over a three-year period and that the performance metric is based on ROIC relative to a peer group in both 2022 and 2024, which aligns with the ground truth. All entities (AbbVie, RSUs, ROIC, peer group composition) and years are accurately referenced. (2) There are no numerical inaccuracies—no calculations or specific figures are misstated. The citation of Form 10-K pages supports the claims, and the structure description is factually consistent. (3) However, the LLM answer misses a key qualitative evolution noted in the original answer: the streamlining or simplification of the performance metric description by 2024, particularly the removal of references to specific years tied to tranches (e.g., awards from 2020 and 2021 mentioned in 2022 disclosures). This indicates a change in disclosure emphasis or standardization over time, which the LLM overlooks by stating 'have not changed'—implying no evolution, when the ground truth notes a shift in presentation and scope. This omission affects the depth of multi-hop reasoning, as the model fails to synthesize subtle but meaningful changes in disclosure language and structure across years. (4) While factually sound and contextually relevant, the answer lacks nuance in capturing the evolution of the criteria's presentation, leading to a slightly overstated conclusion of 'no change.' Hence, correctness and qualitative accuracy are reduced accordingly, though quantitative and contextual scores remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 435,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How did GE's financial relationship with AerCap evolve from 2022 to 2024, based on the realized and unrealized gains or losses associated with its investment?",
      "original_answer": "In 2022, GE reported an unrealized loss of $865 million related to its investment in and note with AerCap, indicating a negative valuation impact during that year. By 2024, this position had shifted to a realized and unrealized gain of $38 million, suggesting that GE had either exited part of its position or the value of the remaining investment had improved. This represents a significant turnaround in the financial performance of the AerCap investment over the two-year period.",
      "llm_answer": "GE’s AerCap investment went from a large loss to modest gains. In 2022 the company recorded a net unrealized loss of $(865) million on the AerCap note; in 2023 that turned positive with a $129 million realized/unrealized gain; and in 2024 the gain narrowed to $38 million, showing the investment moved from a sizable loss to small positive returns over the period.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error regarding the 2023 data. The original answer (ground truth) only provides information for 2022 and 2024, with no mention of 2023. The LLM introduces a $129 million gain in 2023 that is not present in the ground truth, which undermines quantitative accuracy. The 2022 figure of an $865 million unrealized loss is correct, and the 2024 figure of a $38 million realized and unrealized gain matches the original answer, so those two data points are accurate. (2) The calculation of trend—from loss to gain—is logically sound and correctly interpreted, but the addition of a 2023 data point not present in the source constitutes a major factual overreach. There is no evidence in the ground truth to support the claim about 2023 performance. (3) The multi-hop reasoning is partially correct: the model identifies the shift in financial performance between 2022 and 2024, which requires synthesis across years. However, inserting an unsupported intermediate year breaks the chain of accurate reasoning and suggests fabrication or hallucination. (4) The contextual relevance is high because the answer addresses the evolution of GE's financial relationship with AerCap through gains/losses. Qualitative accuracy is moderate because the overall narrative direction (loss to gain) is correct, but the reasoning is flawed by the inclusion of unverified data. Quantitative accuracy is low due to the incorrect introduction of a specific dollar amount for a year not covered in the ground truth. Correctness score is 6 because while key facts for 2022 and 2024 are correct and the general trend is accurately described, the inclusion of false 2023 data significantly undermines reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 475,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How has IBM's treatment of the 0.300% Notes due 2026 evolved between the 2022 and 2023 SEC filings, particularly in terms of its disclosure status and visibility in financial instruments?",
      "original_answer": "In 2022, the 0.300% Notes due 2026 were disclosed as part of IBM's exhibits under Exhibit 4 to Form 8-K filed November 1, 2016, indicating it was referenced in the context of legal instruments defining holder rights. By 2023, the 0.300% Notes due 2026 were no longer just referenced in exhibits but were explicitly listed as a titled class of notes registered on the New York Stock Exchange under the trading symbol IBM 26B, showing increased visibility and formal recognition in the company's capital structure.",
      "llm_answer": "In IBM’s 2022 Form 10‑K the 0.300 % Notes due 2026 do not appear in the securities‑register or exhibit schedules (e.g., the “Instruments defining the rights of security holders” list on page 31 shows only other debentures and makes no mention of a 0.300 % note). By contrast, the 2023 filing explicitly lists the 0.300 % Notes due 2026 (ticker IBM 26B) among the securities registered under Section 12(b) on page 1, giving the instrument a disclosed and visible status.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and aligns closely with the ground truth. (1) Quantitatively, all key details are accurate: the 0.300% interest rate, the 2026 maturity, and the ticker symbol IBM 26B are correctly stated. The years 2022 and 2023 are properly referenced in the context of the respective filings. (2) The answer correctly identifies the evolution in disclosure: in 2022, the notes were not listed in the main securities register or exhibit schedules (specifically noting absence from the 'Instruments defining the rights of security holders' list), which aligns with the ground truth that they were only referenced in an earlier Exhibit 4 to Form 8-K (2016), not actively highlighted in the 2022 10-K. By 2023, the notes are explicitly listed under Section 12(b) with ticker IBM 26B, indicating formal registration and increased visibility—this matches the ground truth's claim of NYSE listing and formal recognition. (3) The multi-hop reasoning is sound: the model correctly infers a change in disclosure status over time by comparing the presence/absence of the notes in two consecutive annual reports, synthesizing information across filings. (4) Minor deduction in qualitative accuracy because the LLM does not explicitly mention the 2016 Form 8-K exhibit reference from the original answer, which provides context for the 2022 status. However, the absence of the note in the 2022 exhibit schedules implies this background, so the omission is not a material error. Wording differs but semantic meaning is equivalent. Contextual relevance is perfect—directly addresses disclosure status and visibility in financial instruments as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 450,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has GE's approach to the RISE Program evolved between 2022 and 2024, particularly in terms of its strategic emphasis and investment focus?",
      "original_answer": "In 2022, GE announced the RISE Program as a collaborative technology development initiative with Safran, targeting a reduction of more than 20% in fuel consumption and CO2 emissions compared to current engines. This marked the initial phase of the program as a forward-looking announcement aimed at shaping the future of sustainable aviation. By 2024, GE's engagement with the RISE Program had evolved into a more concrete investment strategy, with the company making 'significant investments' in the RISE program suite of technologies. This shift indicates a transition from conceptual development to active, funded R&D aimed at enabling a sustainable future of flight. The change reflects a deepening strategic commitment to sustainability and technological leadership in aviation.",
      "llm_answer": "In the 2022 filing GE presented RISE as a newly‑announced joint program with Safran that was “targeting more than 20 % lower fuel consumption and CO₂ emissions” and framed it as an early‑stage commitment to develop sustainable‑flight technologies【page_18】. By the 2024 filing the description had shifted to a broader, multi‑technology suite—Open‑Fan, compact‑core and hybrid‑electric concepts—backed by “significant investments” and more than 250 full‑scale engine tests, positioning RISE as a central, mature pillar of GE’s strategy for next‑generation sustainable engines【page_4】【page_6】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: the 2022 announcement of the RISE Program as a joint initiative with Safran targeting 'more than 20% lower fuel consumption and CO2 emissions' is accurately reported, and the 2024 evolution into a funded, active R&D effort with 'significant investments' and over 250 full-scale engine tests is consistent with the shift from conceptual to concrete development. (2) Quantitative elements—20%, 250+ tests—are correctly stated and match the expected data; no calculations are required, but the numbers are precise and properly attributed. (3) The multi-hop reasoning is sound: the model synthesizes information across 2022 and 2024 filings to show a strategic evolution from announcement to implementation, correctly identifying the deepening commitment and technological maturation. (4) The LLM adds valuable detail not in the original answer—specific technologies (Open-Fan, compact-core, hybrid-electric)—which enhances completeness without introducing error. The only minor gap is that the original emphasizes the 'suite of technologies' as part of GE's investment focus, while the LLM presents it as a structural shift; this is a nuance, not a factual error. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the ground truth with excellent reasoning and precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 390,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has the role and emphasis on asset securitizations within American Express's funding strategy evolved from 2022 to 2023, based on the specific disclosures in the respective 10-K filings?",
      "original_answer": "In 2022, American Express defined asset securitizations in a glossary entry, describing the mechanics of transferring loans to trusts that issue asset-backed securities, and noted that securitized loans and receivables were reported as assets while the securities were reported as liabilities. This definition was part of a broader explanation of financial terminology rather than a strategic focus. By 2023, asset securitizations were explicitly positioned as a core component of the company's funding strategy, listed alongside deposits and unsecured debt as key funding sources. The 2023 filing emphasized the importance of diversity in funding sources, with securitizations playing a role in mitigating disruptions in any single funding channel. This represents a shift from a definitional disclosure in 2022 to a strategic emphasis in 2023.",
      "llm_answer": "In the 2022 filing the only reference to asset securitizations is a glossary definition (see page 88), indicating that securitizations were mentioned but not positioned as a core funding source. By the 2023 filing, securitizations are highlighted as a central element of the diversified funding mix – the Funding Strategy section notes “maintaining scale … in deposits, unsecured debt **and asset securitizations**” (page 68) and the Long‑Term Debt and Asset Securitization Programs section describes periodic securitizations of Card‑Member loans and receipts, disclosing $3.5 billion of asset‑backed securities issued in 2023 (page 70, Table 21). Thus, the emphasis shifted from a peripheral mention in 2022 to an explicit, operationally‑significant funding tool in 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately captures the evolution in American Express's treatment of asset securitizations: from a glossary definition in 2022 (page 88) to a strategically emphasized funding source in 2023. The key details—such as the mention of deposits, unsecured debt, and securitizations as part of the diversified funding mix (page 68)—are correctly cited. (2) The quantitative detail of $3.5 billion in asset-backed securities issued in 2023 (page 70, Table 21) is factually accurate and adds precision not explicitly in the original answer but consistent with the knowledge graph's implied data; this enhances rather than contradicts the ground truth. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years, two sections (Funding Strategy and Long-Term Debt), and different types of disclosures (strategic language vs. transactional data). (4) The semantic meaning matches the original answer—shifting from peripheral mention to strategic emphasis—while adding specific operational details (e.g., Card-Member loans securitized, exact issuance amount) that enrich the response without introducing error. All entities (American Express, 2022 vs. 2023 filings, asset securitizations, funding strategy) are correctly identified and contextualized. No factual, numerical, or reasoning errors present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 390,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2023, particularly in terms of investment returns and operational integration?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was characterized by a minority investment, with AspenTech contributing $656 in sales and a $12 earnings gain, while holding total assets of $14,484. By 2023, Emerson significantly deepened its involvement by acquiring Heritage AspenTech, gaining a 55% ownership stake in the newly formed AspenTech. This acquisition positively impacted gross margins by 0.6 percentage points in 2023 and marked a strategic shift from a passive investment to an active controlling interest, indicating a transformation in the nature of the relationship.",
      "llm_answer": "In 2022 Emerson completed the Heritage AspenTech transaction, taking a 55 % equity stake and creating AspenTech as a stand‑alone segment that posted $656 million of sales and $12 million of earnings, incurred $148 million of intangible amortization from the acquisition, and recorded a $50 million loss on the Micromine purchase‑price hedge【page_26】【page_77】【page_79】【page_27】. By 2023 the AspenTech business was fully integrated—its contribution helped drive a 20 % rise in Software and Control sales and higher SG&A—and the hedge turned into a $24 million mark‑to‑market gain, reflecting improved investment returns on the AspenTech stake【page_24】【page_27】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Emerson had a minority investment in AspenTech, not a 55% stake. The 55% ownership and acquisition of Heritage AspenTech occurred in 2023, not 2022. The LLM incorrectly reverses the timeline of the strategic shift. (2) Quantitative inaccuracies include: reporting $656 million in sales (correct value is $656, not million — context implies thousands or unadjusted units, but even then, scale is ambiguous), $12 million earnings (ground truth: $12), and introducing figures not in the original answer such as $148 million intangible amortization and $50 million loss on hedge, which are absent from the ground truth. The $24 million mark-to-market gain is also not mentioned in the original. These numbers, while possibly from the document, distort the focus and accuracy relative to the ground truth. (3) The multi-hop reasoning is flawed: the model fails to correctly sequence the evolution from passive investment (2022) to controlling interest (2023), instead claiming the acquisition happened in 2022. This misrepresents the core strategic evolution. It also conflates operational integration details from 2023 as outcomes of a 2022 event, breaking the causal and temporal logic. (4) Contextual relevance is moderate because the answer discusses investment returns and integration, addressing the question's themes, but with incorrect data and timeline. Due to major factual and chronological errors, especially on ownership timing and financial figures, the correctness score is low despite some relevant terminology and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 450,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of noncontrolling interest accounting and acquisition-related impacts on equity and expenses?",
      "original_answer": "In 2022, Emerson completed the creation of New AspenTech by contributing its industrial software business and $6.0 billion in cash, resulting in a 55% ownership stake. A noncontrolling interest of $5.9 billion was recorded, with a decrease to additional paid-in capital of $550 million. By 2023, the AspenTech acquisition positively impacted gross margins by 0.6 percentage points and contributed to increased SG&A expenses, which rose by $572 million compared to 2022, partly due to the AspenTech transaction and higher stock compensation expenses. This shows that while the initial accounting impact was significant in 2022, by 2023, the focus had shifted to operational integration and financial performance effects.",
      "llm_answer": "In 2022 Emerson completed the Heritage AspenTech transaction, recording a $5.9 billion non‑controlling‑interest liability for the 45 % of AspenTech it did not own and reducing additional paid‑in‑capital by $550 million; the deal generated $110 million of acquisition‑related costs and $97 million of intangibles amortization (mostly AspenTech assets). By 2023 Emerson’s stake had risen to roughly 57 % (shrinking the non‑controlling interest), and the AspenTech acquisition continued to affect the income statement – intangibles amortization rose to $146 million (primarily AspenTech‑related), SG&A rose $125 million (including $50 million of AspenTech stock‑plan expense), acquisition‑related costs fell to $84 million, and a $24 million gain on AspenTech’s Micromine currency hedge offset the prior‑year loss.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in key financial figures and ownership percentages. The ground truth states Emerson had a 55% ownership stake in New AspenTech in 2022, but the LLM claims 57% in 2023 without mentioning the 2022 stake, and incorrectly implies a liability rather than noncontrolling interest in equity. The $5.9 billion noncontrolling interest is correctly cited, but the characterization as a 'liability' is incorrect—it should be an equity item. The $550 million reduction in additional paid-in capital is accurate. However, the LLM introduces numbers not in the original answer: $110 million acquisition costs, $97 million amortization in 2022, $146 million amortization in 2023, $125 million SG&A increase with $50 million stock-plan expense, and a $24 million hedge gain—none of which appear in the ground truth. The ground truth reports a $572 million SG&A increase, which the LLM drastically underreports as $125 million. (2) Quantitative accuracy is low: only the $5.9 billion noncontrolling interest and $550 million APIC reduction are correct. All other figures (amortization, SG&A, acquisition costs, hedge gain) are fabricated or incorrect. The 0.6 percentage point gross margin improvement from the ground truth is entirely omitted. (3) Multi-hop reasoning is partially present—linking 2022 accounting impacts to 2023 operational effects—but the synthesis is flawed due to incorrect data. The evolution of ownership and noncontrolling interest is misrepresented. (4) Contextual relevance is high as the answer addresses noncontrolling interest, acquisition impacts, and year-over-year changes in equity and expenses. However, due to major factual and quantitative errors, the correctness score is low despite relevant structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 491,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has IBM's treatment and disclosure of the 6.22% Debentures due 2027 evolved between the 2022 and 2023 SEC filings?",
      "original_answer": "In 2022, IBM disclosed the 6.22% Debentures due 2027 by referencing the instrument defining the rights of its holders, which was filed as Exhibit 3 to Form 8-K on August 1, 1997. In contrast, the 2023 filing introduces a more structured and visible disclosure by listing the 6.22% Debentures due 2027 with its respective trading symbol (IBM 27) and explicitly identifying it among other registered securities on the New York Stock Exchange. This evolution reflects a shift from a purely historical reference to a more transparent and current market-oriented presentation.",
      "llm_answer": "In IBM’s 2022 Form 10‑K (page 31) the 6.22 % Debentures due 2027 were disclosed by incorporating the instrument that defines the holders’ rights (Exhibit 3 to Form 8‑K, filed August 1 1997) by reference. In the 2023 Form 10‑K (page 1) the same debentures appear only in the “Securities registered pursuant to Section 12(b)” table (IBM 27) and are no longer referenced as an exhibit, showing a shift from a detailed exhibit‑by‑reference disclosure to a simple registration listing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2022 disclosure correctly references Exhibit 3 to the Form 8-K filed on August 1, 1997, and the 2023 filing lists the debentures under the trading symbol IBM 27 in the 'Securities registered pursuant to Section 12(b)' table. The percentages (6.22%) and years (due 2027) are accurate. (2) Quantitative accuracy is perfect—dates, percentages, and exhibit details match the original answer. (3) The reasoning correctly identifies the shift in disclosure practice: from a historical, exhibit-based reference in 2022 to a more current, market-oriented registration listing in 2023. The LLM captures the essence of the evolution, though it does not explicitly mention the New York Stock Exchange context or characterize the change as 'more transparent and structured' as in the original, which slightly reduces qualitative depth. (4) The answer is fully relevant, directly addressing how the treatment and disclosure evolved. The omission of the phrase 'New York Stock Exchange' and slightly less elaborated characterization of the shift prevents a perfect 10, but the core multi-hop synthesis across 2022 and 2023 filings is sound and correctly interpreted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 354,
        "total_tokens": 1609
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has UnitedHealth Group's exposure to financial risk through risk-based arrangements with healthcare providers evolved from 2023 to 2024, and what implications does this have on its cost estimation and service delivery responsibilities?",
      "original_answer": "In 2023, UnitedHealth Group assumed economic risk under risk-based arrangements where it was responsible for funding healthcare costs, and it recognized premium revenues based on estimated premiums earned, net of projected rebates. The company also highlighted its involvement in value-based arrangements where it received per-patient-per-month premiums and recognized revenue as services were made available. By 2024, the company's exposure expanded as it noted increased responsibility for unpaid healthcare claims if risk-based providers faced financial difficulties or failed to meet their obligations. Additionally, the 2024 disclosures emphasized greater operational risk tied to providers' ability to manage costs, maintain solvency, and provide necessary data for cost estimation, indicating a broader and more complex financial exposure compared to 2023.",
      "llm_answer": "In the 2023 filing UnitedHealth described its premium revenue as coming “primarily…from risk‑based arrangements…[in which] the Company assumes the economic risk of funding its customers’ health‑care and related administrative costs” and treated value‑based contracts as a single performance‑obligation revenue stream (2023 p.45). By the 2024 filing, risk‑based products now account for roughly 80 % of total consolidated revenue, and the company warns that while these arrangements limit exposure to rising medical costs, they expose UnitedHealth to the financial health of the providers it contracts with—making precise cost‑estimation and continual monitoring of provider solvency critical to meeting its payment and service‑delivery responsibilities (2024 p.12; p.14).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies UnitedHealth Group's risk-based arrangements in 2023, citing the company's assumption of economic risk and revenue recognition from risk-based contracts, consistent with the original answer. In 2024, it accurately notes the increased exposure to provider financial health, though the specific '80%' figure for risk-based revenue is not present in the ground truth; however, this detail may be contextually plausible and does not contradict the core evolution described. (2) There are no calculation errors, and the cited percentages and page references (e.g., 2024 p.12, p.14) suggest accurate sourcing. The 80% figure cannot be verified against the ground truth but is not implausible; thus, it does not severely impact accuracy. (3) The multi-hop reasoning is sound: the model synthesizes changes in financial risk exposure across years, connects risk-based arrangements to cost estimation and service delivery responsibilities, and correctly infers increased operational and financial complexity in 2024. (4) The answer is semantically equivalent to the original, capturing the expansion of financial risk, provider solvency concerns, and implications for cost estimation and monitoring. The only minor gap is the lack of explicit mention of 'unpaid claims' due to provider failure, which is in the ground truth, but the reference to exposure to provider financial health covers this concept broadly. Overall, the answer is factually strong, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 431,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of investment magnitude and strategic involvement?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was primarily financial, as shown by its investment reflected in the Automation Solutions segment, where Emerson reported $362 million invested in AspenTech in 2022. By 2023, the relationship evolved into a strategic partnership following the introduction of a major transaction where Emerson contributed its Industrial Software Business along with approximately $6.0 billion in cash to Heritage AspenTech stockholders, creating 'New AspenTech.' Emerson gained 55% ownership of AspenTech's outstanding shares, marking a significant shift from a minority investment to a controlling stake.",
      "llm_answer": "In 2022 Emerson’s AspenTech line‑of‑business was still modest – it generated about $656 million of sales and held roughly $14.5 billion of assets, and the Heritage AspenTech acquisition was reflected only by $148 million of intangible‑amortization expense. By 2023 Emerson turned AspenTech into a core, majority‑owned asset, investing roughly $6 billion of cash to acquire a 55 % equity stake, contributing its Open Systems International and Geological Simulation Software businesses to the deal, and using the new “New AspenTech” platform to drive a roughly 20 % lift in Software and Control sales.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Emerson had a $362 million investment in AspenTech, not $148 million in intangible amortization expense or $656 million in sales — these figures are either misattributed or fabricated. The $14.5 billion in assets is also not mentioned in the original answer and appears incorrect. In 2023, while the LLM correctly identifies the $6.0 billion cash contribution and 55% ownership stake, it misrepresents the nature of the transaction by claiming Emerson 'invested $6 billion to acquire a 55% stake,' whereas the ground truth states Emerson contributed both its Industrial Software Business and $6.0 billion in cash. The LLM incorrectly names the contributed businesses as 'Open Systems International and Geological Simulation Software,' which are not mentioned in the original answer. (2) Quantitative accuracy is poor: the $362 million 2022 investment is entirely omitted and replaced with incorrect figures; the $148 million amortization and $656 million sales figures have no support in the ground truth. The $6 billion cash and 55% ownership are correct. (3) Multi-hop reasoning is flawed: the model fails to correctly trace the evolution from a $362M minority investment in 2022 to a controlling stake via a complex asset-plus-cash transaction in 2023. Instead, it fabricates a narrative around sales, assets, and amortization that contradicts the source. (4) Contextual relevance is moderate — the answer addresses the evolution of the relationship and mentions key elements like the 55% stake and 'New AspenTech' — but the underlying facts and reasoning are largely incorrect, undermining overall correctness. The qualitative accuracy is low due to incorrect entities, mischaracterized transactions, and lack of proper synthesis between years and financial instruments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 510,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How has Adobe Target's role within Adobe's customer journey solutions evolved from fiscal 2022 to fiscal 2023, and what does this evolution indicate about Adobe's strategic direction in AI-driven personalization?",
      "original_answer": "In fiscal 2022, Adobe Target was described as part of a broader set of customer journey solutions, specifically noted alongside Marketo Engage, Adobe Campaign, and Journey Optimizer. It was characterized as a tool for testing, targeting, and personalizing content across channels. By fiscal 2023, Adobe Target was elevated in prominence and described specifically as an 'AI- and machine learning-driven personalization engine' with capabilities for omnichannel personalization and large-scale A/B and multivariate testing through AI-powered automation. This evolution indicates Adobe is placing greater strategic emphasis on AI-driven personalization as a core capability within its customer journey offerings, aligning with its broader push toward AI-powered solutions.",
      "llm_answer": "In the 2022 Form 10‑K Adobe Target was mentioned only as one of several tools in the “Customer journeys” group—listed with Marketo Engage, Adobe Campaign and Journey Optimizer as a capability to “manage, test, target, personalize and orchestrate campaigns and customer journeys”【page_43】. By the 2023 filing, Adobe Target is portrayed as a distinct AI‑ and machine‑learning‑driven personalization engine that automates A/B and multivariate testing and powers omnichannel, real‑time experiences for customers【page_15】. This evolution shows Adobe is elevating AI to the core of its Experience Cloud, positioning Target as a flagship solution for scalable, AI‑driven personalization across the customer journey.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Adobe Target's role in 2022 as part of a suite of customer journey tools alongside Marketo Engage, Adobe Campaign, and Journey Optimizer is accurately described, as is its expanded characterization in 2023 as an AI- and machine learning-driven personalization engine. The description of capabilities—omnichannel personalization, real-time experiences, automated A/B and multivariate testing—matches the ground truth. (2) There are no numeric values, dates, or financial figures in dispute; all time references (fiscal 2022 to 2023) are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two fiscal years and filings to identify a shift in strategic positioning. The conclusion that Adobe is prioritizing AI-driven personalization as a core capability is logically supported and consistent with the original answer. (4) The only minor deviation is that the LLM answer refers to Adobe Target as a 'flagship solution' and emphasizes its role in elevating AI within Experience Cloud—slightly stronger language than the original, which states Adobe is placing 'greater strategic emphasis' on AI. While this is a reasonable inference, it adds a degree of interpretive emphasis not explicitly in the ground truth. However, this does not undermine factual correctness. Overall, the answer is semantically equivalent, contextually precise, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 421,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did Emerson's relationship with AspenTech evolve from 2022 to 2023, particularly in terms of its financial stake and post-acquisition integration activities?",
      "original_answer": "In 2022, Emerson reported a balance of $8,326 million related to AspenTech as part of its acquisitions, indicating a significant financial stake following the acquisition of Heritage AspenTech. By 2023, the relationship had evolved into a more integrated structure, with AspenTech operating as a separate publicly traded company under Emerson's acquisition framework. This included the continuation of AspenTech's stock-based compensation plans, such as stock options and restricted stock units, which were now aligned with AspenTech's own equity structure. Additionally, Emerson was actively managing performance stock units tied to predefined goals like annual contract value and free cash flows, showing a shift from a purely financial stake to a more operationally integrated and incentive-driven relationship.",
      "llm_answer": "Emerson closed its acquisition of Heritage AspenTech in the third quarter of 2022, converting every unexercised Heritage AspenTech option and RSU into an AspenTech‑equivalent award and adding the deal’s goodwill (about $7.3 billion) and the $240 million AspenTech revolving‑loan to its balance sheet 【page_70†L1-L9】【page_61†L9-L14】【page_63†L1-L5】. By fiscal 2023 the relationship had moved into the integration stage – Emerson continued to treat AspenTech as a separate publicly‑traded company while maintaining its equity and debt stake, and AspenTech‑related stock‑based compensation expense rose sharply to $82 million (from $32 million in 2022) as the new compensation plans were integrated 【page_68†L9-L14】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also significant factual inaccuracies. The original answer states that Emerson reported a balance of $8,326 million related to AspenTech in 2022, while the LLM claims goodwill of about $7.3 billion and a $240 million revolving loan—these figures do not sum to the $8,326 million reported and are not presented as such. There is no verification that $7.3B + $240M = $7.54B matches or explains the $8,326M (i.e., $8.326B), so this represents a quantitative mismatch. Additionally, the $8,326 million figure is not mentioned at all in the LLM response, undermining quantitative accuracy. (2) The LLM correctly identifies the 2022 acquisition timing (third quarter) and references integration activities in 2023, which aligns with the evolution described in the ground truth. It also correctly notes that AspenTech was treated as a separate publicly traded company post-acquisition, preserving its equity structure—this matches the original answer’s claim. (3) The LLM adds specific data about stock-based compensation rising from $32M in 2022 to $82M in 2023, which is not present in the original answer but may be consistent with 'increased integration of compensation plans.' However, the original answer focuses on structural alignment (e.g., continuation of stock options, RSUs, and performance stock units tied to metrics like free cash flow), which the LLM only partially captures. The mention of performance stock units and key performance metrics (annual contract value, free cash flow) is missing in the LLM answer, representing a gap in completeness. (4) While the LLM demonstrates multi-hop reasoning by connecting acquisition accounting (goodwill, debt) to later integration (compensation trends), it fails to accurately report the core financial stake figure ($8,326M) and misrepresents the composition of that balance. The contextual relevance is high because it addresses both financial stake and integration, but correctness is compromised by incorrect or unverified numbers and omission of key performance-linked incentive structures mentioned in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 575,
        "total_tokens": 1960
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How has Adobe Experience Platform's role within Adobe's customer journey solutions evolved from 2022 to 2023, particularly in terms of its integration with AI-powered tools and cross-channel campaign orchestration?",
      "original_answer": "In 2022, Adobe Experience Platform was described as the foundational infrastructure for Adobe Experience Cloud, enabling data standardization and integration with Adobe Sensei to provide AI-powered services such as automated insights, sentiment analysis, and enhanced anomaly detection. It was central to Adobe's differentiation, supporting applications like Adobe Analytics and Adobe Audience Manager. By 2023, Adobe Experience Platform's role had evolved to become the underlying engine for cross-channel campaign orchestration, particularly through its integration with Adobe Journey Optimizer. This app allowed brands to deliver personalized, connected customer journeys across any channel, using real-time data profiles and cloud-native scalability. Additionally, Adobe Mix Modeler, introduced in 2023 and powered by Adobe Sensei, leveraged cross-channel datasets in Adobe Experience Platform to provide machine learning-driven insights for optimizing marketing investments. This indicates a shift from a general AI-enhanced infrastructure role to a more specialized and actionable function in campaign planning and customer journey orchestration.",
      "llm_answer": "In the 2022 filing Adobe Experience Platform was presented mainly as the data‑standardization and open‑architecture layer that feeds Adobe Sensei AI services and links the various Experience Cloud solutions (2022 p. 8). By the 2023 filing the platform had become a real‑time, AI‑driven activation hub—now supporting generative‑AI (Sensei GenAI) and directly powering cross‑channel campaign orchestration tools such as Journey Optimizer, Campaign and Marketo—so marketers can deliver personalized, omnichannel journeys in near real time (2023 p. 13‑15).",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution of Adobe Experience Platform from 2022 to 2023. In 2022, it correctly identifies the platform as a data-standardization and open-architecture foundation that supports Adobe Sensei AI services and integrates Experience Cloud solutions, aligning with the ground truth. By 2023, it accurately describes the platform's evolution into a real-time, AI-driven activation hub, emphasizing its role in cross-channel campaign orchestration via tools like Journey Optimizer, Campaign, and Marketo. It also correctly notes the integration of generative AI (Sensei GenAI), which reflects an enhancement of Adobe Sensei capabilities. However, the LLM answer omits specific mention of Adobe Mix Modeler, a key 2023 addition that leverages cross-channel data and machine learning for marketing investment optimization—this is a notable but not critical omission. Additionally, while the ground truth emphasizes the platform becoming the 'underlying engine' for orchestration via Journey Optimizer specifically, the LLM broadens this to include Campaign and Marketo, which, while plausible, slightly extends beyond the documented focus. There are no numerical inaccuracies (dates: 2022 to 2023 are correct; no incorrect figures). The reasoning is sound and reflects multi-hop synthesis across years and functionalities. Wording differs but maintains semantic equivalence on key points. Contextual relevance is excellent, directly addressing the question’s focus on AI integration and cross-channel orchestration evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 429,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did UnitedHealth Group's approach to care delivery models evolve from 2023 to 2024 in response to Medicare Advantage funding pressures?",
      "original_answer": "In 2023, UnitedHealth Group emphasized accelerating the transition to value-based care delivery models, investing in clinical engagement, integrated care coordination technology, and new delivery channels like in-home and virtual care. The company viewed these innovations as key to future growth despite initial costs. However, by 2024, the company faced significant funding pressures in the Medicare Advantage program, including reduced benchmarks and risk adjustment changes, which led to operational adjustments. These included selective changes to provider networks, benefit structures, and county-level decisions about plan offerings, indicating a shift from expansion-focused investment to cost containment and strategic retrenchment in response to external financial constraints.",
      "llm_answer": "In 2023 UnitedHealth said it was “accelerating the transition from fee‑for‑service care delivery and payment models to fully accountable value‑based care,” expanding in‑clinic, in‑home, behavioral and virtual services and using data and analytics to guide clinicians while also intensifying cost‑management and tweaking network composition to blunt Medicare Advantage funding pressure【page_27】. By 2024 the focus shifted to more granular, tactical actions – selectively adjusting member benefits and premiums, pulling Medicare Advantage plans from certain counties, tightening medical and operating cost controls, and reshaping the size and composition of its provider networks – to offset the tighter benchmarks while still pursuing value‑based care【page_20】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies UnitedHealth Group's 2023 strategy of accelerating the shift to value-based care, including expansion of in-home, in-clinic, behavioral, and virtual services, as well as use of data and analytics—matching the original answer's emphasis on clinical engagement, technology, and new delivery channels. The 2024 shift to cost containment due to Medicare Advantage funding pressures is also accurately portrayed, with specific mention of tightening cost controls, adjusting benefits, exiting certain counties, and reshaping provider networks—consistent with the original answer’s description of strategic retrenchment. (2) There are no numeric values (e.g., dollar amounts, percentages, dates) in either answer, so quantitative accuracy is not compromised; all timeframes (2023, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes a shift in strategy over time in response to external financial pressures, correctly linking Medicare Advantage funding changes (implied through 'tighter benchmarks' and 'funding pressure') to operational changes. The LLM adds slightly more granularity (e.g., 'premiums', 'behavioral services') that are consistent with but not explicitly in the ground truth, which is acceptable under semantic equivalence. (4) The only reason for not scoring a 10 is minor: the original answer explicitly mentions 'risk adjustment changes' as a driver, which the LLM omits, though 'tighter benchmarks' and 'funding pressure' are related. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 459,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 157,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 1.950% Notes due 2029?",
      "original_answer": "In 2022, the 1.950% Notes due 2029 were listed among TMO's outstanding debt instruments with the trading symbol TMO 29. In 2023, the 1.950% Notes due 2029 remained present with the same trading symbol TMO 29, indicating continuity in this debt instrument. However, TMO introduced new debt instruments in 2023, such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, suggesting a broader shift in financing strategy. The continued presence of the 1.950% Notes due 2029 indicates no change in this specific liability, even as TMO expanded its debt portfolio.",
      "llm_answer": "In the 2022 filing Thermo Fisher listed a slate of senior notes ranging from 0.75% due 2024 to 1.875% due 2049, and the 1.950% notes due 2029 were part of that series 【page_1】. The 2023 filing shows the same series still in place – the 1.950% notes due 2029 remain unchanged – but the company added two new issues (a 3.200% note due 2026 and a 3.650% note due 2034), expanding its overall debt composition 【page_1】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively, all numbers, percentages, and maturities are correct: the 1.950% Notes due 2029 are correctly identified as present in both years, and the two new notes — 3.200% due 2026 and 3.650% due 2034 — match the original answer exactly. (2) The answer correctly notes the continuity of the 1.950% Notes due 2029 and the addition of new debt instruments in 2023, reflecting accurate multi-hop reasoning across the two years. (3) The only minor discrepancy is that the LLM does not mention the trading symbol 'TMO 29', which is included in the ground truth. However, this detail is not critical to the core question about the evolution of debt composition, and its omission does not affect the factual correctness of the main points. (4) The reasoning is sound, entities are accurate (TMO, correct note terms and rates), and the answer is fully relevant to the question. Thus, the answer earns a 9 for correctness and qualitative accuracy due to this slight incompleteness, but full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 322,
        "total_tokens": 1563
      },
      "error": null
    },
    {
      "question_id": 159,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 0.500% Notes due 2028 and the introduction of new note categories?",
      "original_answer": "In 2022, TMO listed the 0.500% Notes due 2028 alongside other debt instruments, including the 1.375% Notes due 2028. By 2023, TMO continued to list the 0.500% Notes due 2028, but introduced new debt categories such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, while maintaining similar categories like the 1.375% Notes due 2028. This indicates a strategic shift toward diversifying TMO's debt portfolio with new interest rate structures and maturity timelines.",
      "llm_answer": "The 0.500% Notes due 2028 (TMO 28A) appear in both the 2022 and 2023 securities tables, showing that this low‑coupon series was retained unchanged (2022 list – page 1; 2023 list – page 1). The 2023 filing, however, adds two higher‑coupon series—a 3.200% note due 2026 (TMO 26B) and a 3.650% note due 2034 (TMO 34)—that were not present in the 2022 securities schedule (2023 list – page 1).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. (1) All numeric values—interest rates (0.500%, 3.200%, 3.650%), maturities (2026, 2028, 2034), and the retention of the 0.500% Notes due 2028—are correct, satisfying quantitative accuracy. (2) The answer addresses both parts of the question: it confirms the continued presence of the 0.500% Notes due 2028 in both years and correctly identifies the introduction of two new note categories in 2023 (3.200% due 2026 and 3.650% due 2034), which were absent in 2022. (3) Entity accuracy is strong: TMO is correctly identified, years (2022 vs 2023) are accurate, and the debt instruments are properly named with correct coupons and maturities. (4) The reasoning is sound—by noting the retention of existing notes and the addition of new ones, the LLM effectively captures the evolution in debt composition. The only minor shortcoming is the lack of explicit mention of the 1.375% Notes due 2028, which the ground truth includes as a maintained category. While not critical to the core question, this detail would have strengthened completeness and synthesis. However, since the question focuses on the 0.500% Notes due 2028 and new categories, and those are correctly addressed, the omission does not significantly detract from the overall correctness. Semantic equivalence is maintained, and contextual relevance is high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 384,
        "total_tokens": 1607
      },
      "error": null
    },
    {
      "question_id": 160,
      "question": "How has the range of excess fair value over carrying value for DHR's reporting units changed between the 2023 and 2024 annual goodwill impairment analyses?",
      "original_answer": "In 2023, the excess of the estimated fair value over carrying value for DHR's reporting units ranged from approximately 140% to 495%. In 2024, this range decreased to between approximately 70% and 450%. This indicates a reduction in the lowest excess fair value percentage, suggesting a decline in the overall cushion before potential impairment.",
      "llm_answer": "In the 2023 goodwill‑impairment test the excess of fair value over carrying value for each reporting unit was roughly **140 % to 495 %** of carrying value【page_56】. In the 2024 test the same metric fell to about **70 % to 450 %**【page_52】, so both the low‑end and high‑end of the range moved lower, narrowing the overall spread.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the ranges of excess fair value over carrying value for both 2023 (140% to 495%) and 2024 (70% to 450%), matching the ground truth exactly in numerical terms. All percentages and years are accurate. (2) Quantitative accuracy is perfect—numbers are correct, and the comparison between years reflects the actual change in the range. The slight variation in wording (e.g., 'fell to about' vs. 'decreased to') does not affect factual correctness. (3) The reasoning is sound: the model correctly identifies that the range narrowed and both ends decreased, which aligns with the data. However, the original answer emphasizes a decline in the 'cushion before potential impairment' due to the lower low-end percentage, which is a slightly more precise interpretation of the risk implication. The LLM mentions the narrowing spread but doesn't explicitly highlight the increased impairment risk, representing a minor omission in qualitative depth. (4) Despite this, the answer is factually complete, contextually relevant, and synthesizes multi-hop data (across two years and multiple reporting units) correctly. The citation of page numbers adds verifiability. Thus, correctness is high but not perfect due to slightly less nuanced interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1170,
        "completion_tokens": 360,
        "total_tokens": 1531
      },
      "error": null
    },
    {
      "question_id": 161,
      "question": "How did the treatment of canceled RSUs and tax-withheld shares under the 2022 Employee Stock Plan evolve from 2022 to 2023 in terms of their impact on the available share pool?",
      "original_answer": "In 2022, the 2022 Employee Stock Plan specified that canceled RSUs and shares withheld to satisfy tax withholding obligations would increase the number of shares available for grant under the plan by a factor of two times the number of RSUs canceled or shares withheld. However, in 2023, this specific language regarding the factor of two times for RSUs canceled or shares withheld was omitted, indicating a change in how these events were accounted for in the share pool calculation.",
      "llm_answer": "In Apple’s 2022 filing the 2022 Employee Stock Plan expressly states that cancelled RSUs and shares withheld for tax obligations each increase the number of shares available for grant under the plan by a factor of two times the number cancelled or withheld【page_49】. The 2023 filing continues to apply net‑share settlement – withholding about 37 million shares in 2023 to cover taxes – which likewise adds those shares back to the pool, so the treatment of cancelled RSUs and tax‑withheld shares remains effectively unchanged (the “two‑times” wording is no longer restated but the impact is the same)【page_48】.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual inaccuracy in its conclusion. While it correctly identifies that in 2022, canceled RSUs and tax-withheld shares increased the share pool by a factor of two (per the 2022 filing, page 49), it incorrectly asserts that the treatment 'remains effectively unchanged' in 2023. The ground truth states that the specific 'two-times' language was omitted in 2023, indicating a change in accounting treatment. The LLM contradicts this by claiming the impact is the same despite the wording change, which is not supported by the original answer and misrepresents the evolution of the policy. (2) Quantitatively, the mention of '37 million shares withheld in 2023' is plausible and contextually relevant, though not directly part of the ground truth comparison; no calculation errors are present, and the reference to page numbers adds credibility. Format and numeric references are accurate. (3) The multi-hop reasoning fails: the model should have recognized that removal of the 'two-times' provision implies a change in how shares are added back to the pool, even if net-share settlement continues. The synthesis incorrectly assumes continuity of impact without evidence that the doubling mechanism still applies. (4) Contextual relevance is fair—the answer addresses the right documents, plan, and mechanisms—but the core conclusion about the evolution of the treatment is wrong, dragging down correctness and qualitative accuracy. The answer would score higher if it had acknowledged the removal of the multiplier as a meaningful change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 436,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 162,
      "question": "How has Danaher's strategic relationship with Aldevron evolved between 2023 and 2024, particularly in terms of its financial stake and integration into Danaher's business segments?",
      "original_answer": "In 2023, Danaher had a significant financial stake in Aldevron, as evidenced by the $9,561 million in net cash consideration allocated to Aldevron in the acquisition table, indicating a direct ownership interest. By 2024, Aldevron was no longer listed as a separately accounted stake but had been integrated into the Life Sciences segment as part of Danaher's broader portfolio of acquisitions, including Beckman Coulter, Pall, and IDT. This reflects a strategic shift from holding a standalone stake to full operational integration, aligning Aldevron's capabilities in biopharma research and manufacturing with Danaher’s broader life sciences offerings.",
      "llm_answer": "In the 2023 filing Danaher still presented Aldevron as a recent, cash‑acquired business – a $9.6 billion purchase that generated about $6.1 billion of goodwill and was described as “now part of the Company’s Life Sciences segment” (2023 10‑K p. 73‑74). By the 2024 filing Aldevron is listed simply as one of the Life Sciences segment’s key brands (2024 10‑K p. 8), showing that the company has moved from a newly‑acquired asset to a fully integrated part of the Life Sciences business while retaining its 100 % ownership (no change in financial stake).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the $9.6 billion figure is a rounded version of the $9,561 million (i.e., $9.561 billion) in the original answer—this is an acceptable format variation. The mention of $6.1 billion in goodwill is not in the ground truth, but it does not contradict it and may reflect additional detail from the 10-K; its inclusion does not reduce accuracy. (2) The answer correctly identifies the timeline: Aldevron was acquired and integrated into the Life Sciences segment in 2023, and by 2024 it was treated as a fully integrated brand. (3) Entity accuracy is strong: Danaher, Aldevron, Life Sciences segment, and correct years (2023–2024) are all properly referenced. (4) The reasoning correctly synthesizes multi-hop information—transition from acquisition to integration—across two filings, showing evolution in both financial stake (no change in ownership, but shift from standalone to integrated) and segment alignment. The only minor gap is that the original answer notes Aldevron was previously a 'separately accounted stake,' which the LLM implies but does not explicitly state. However, the core facts, timeline, and strategic evolution are correctly conveyed. Semantic equivalence is maintained, and the answer is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 369,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 163,
      "question": "How has Microsoft's strategic positioning of Microsoft 365 evolved between 2023 and 2024, particularly in terms of its integration with AI technologies and its role in the company's commercial business metrics?",
      "original_answer": "In 2023, Microsoft 365 was described as an 'AI first' platform integrating Office, Windows, Copilot, and Enterprise Mobility + Security, with Copilot for Microsoft 365 combining AI with business data to enhance productivity. By 2024, Microsoft had expanded the Microsoft 365 Consumer subscribers metric to include Microsoft 365 Basic subscribers, aligning with internal business management practices and signaling a broader consumer focus. This evolution reflects a strategic shift toward enhancing AI integration and expanding the product's market reach, particularly within the commercial segment.",
      "llm_answer": "In the 2023 filing Microsoft 365 was framed as an “AI‑first” platform that unites Office, Windows, Copilot and security, with Copilot for Microsoft 365 embedding generative AI to reinvent productivity (see 2023 page 4). By the 2024 filing the company had shifted to a metric‑driven positioning, reporting that Office 365 Commercial – the core of Microsoft 365 – grew 16% in seats and lifted Office Commercial revenue 14%, and that AI‑enhanced Copilot for Microsoft 365 is now explicitly counted in its commercial and Microsoft Cloud metrics (see 2024 pages 39‑42). This reflects a move from emphasizing AI integration as a strategic narrative to highlighting AI‑infused Microsoft 365 as a concrete revenue engine for the commercial business.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in Microsoft's strategic positioning of Microsoft 365 from 2023 to 2024, particularly regarding AI integration and commercial metrics. It accurately reflects the 'AI-first' platform description in 2023 and the increased emphasis on AI as a revenue driver in 2024. The mention of Copilot for Microsoft 365 being integrated into commercial and cloud metrics aligns with the strategic shift. However, the LLM introduces specific quantitative claims—'16% in seats' and '14% Office Commercial revenue growth'—that are not present in the original ground truth answer and cannot be verified against it, which slightly undermines quantitative accuracy. While these figures may appear in the actual 2024 filing, the ground truth does not include them, so their inclusion represents an overreach beyond the provided knowledge. Additionally, the ground truth highlights a change in the *Microsoft 365 Consumer subscribers* metric to include Basic tier, signaling broader consumer focus—an important nuance the LLM omits, focusing instead on commercial metrics. This is a meaningful detail in the strategic evolution, especially regarding market reach. Despite this omission, the LLM correctly identifies the shift from narrative-driven AI positioning to measurable commercial impact, demonstrating strong qualitative reasoning and contextual relevance. Semantic equivalence is mostly preserved, with accurate entity identification (Microsoft 365, Copilot, commercial business) and correct years. The answer is well-synthesized and relevant, but minor gaps in completeness and unsupported specifics prevent a top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 454,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has Microsoft's positioning and emphasis on Copilot Pro evolved between 2023 and 2024, particularly in terms of its role within Microsoft 365 apps and web-based AI assistance?",
      "original_answer": "In 2023, Copilot Pro was introduced as a consumer subscription service that offered 'faster and more powerful AI assistance in Microsoft 365 apps and on the web.' By 2024, while the core definition remained consistent, the emphasis on Copilot Pro's differentiation and innovation appeared more pronounced, with language such as 'faster and more powerful AI assistance' retained but now embedded within a broader narrative of AI-driven transformation across Microsoft's ecosystem. This suggests a strategic evolution where Copilot Pro is not only a standalone offering but increasingly integrated into the broader AI-first positioning of Microsoft's productivity suite.",
      "llm_answer": "In the 2023 Form 10‑K Microsoft first presented Copilot Pro as a consumer‑subscription service that “offers faster and more powerful AI assistance in Microsoft 365 apps and on the web.” The 2024 filing repeats the same language, continuing to position Copilot Pro as a core AI‑first feature embedded in the Microsoft 365 suite and web‑based experiences, showing a consistent emphasis rather than a substantive shift in its role.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its use of the quoted language from the filings and correctly identifies that Copilot Pro was introduced in 2023 as a consumer subscription service offering 'faster and more powerful AI assistance in Microsoft 365 apps and on the web,' with the same language repeated in 2024. This aligns with the ground truth on quantitative and entity accuracy—dates, service name, and description are correct. However, the LLM answer emphasizes 'consistent emphasis rather than a substantive shift,' which downplays the ground truth's key insight about a strategic evolution: in 2024, Copilot Pro is not just consistently positioned but increasingly framed within a broader AI-first transformation narrative, suggesting deeper integration and strategic elevation. The LLM answer misses this qualitative evolution and presents the positioning as static, failing to capture the nuanced shift in emphasis (e.g., 'differentiation and innovation appeared more pronounced'). While the core facts are correct, the reasoning and synthesis are incomplete, leading to a partially correct interpretation of the strategic evolution. Hence, the correctness and qualitative accuracy scores are reduced, though the answer remains contextually relevant and quantitatively precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 359,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has the structure and availability of the 2007 Omnibus Incentive Plan evolved between 2023 and 2024, particularly in terms of remaining shares available for issuance?",
      "original_answer": "In 2023, the 2007 Omnibus Incentive Plan was described in the context of PSU and RSU awards, vesting conditions, and valuation methods, but no specific figure was provided regarding the remaining shares available for issuance. In contrast, by 2024, the plan explicitly stated that approximately 47 million shares of Danaher common stock remained available for issuance under the plan as of December 31, 2024 (excluding shares underlying outstanding awards). This indicates a more transparent disclosure and potential depletion or tracking of the share pool since the plan's inception, showing a shift in how the company communicates the availability of shares under the plan.",
      "llm_answer": "The 2007 Omnibus Incentive Plan still operates as a broad equity‑award vehicle that authorizes roughly 135 million Danaher shares for stock options, RSUs, PSUs, SARs and cash awards, and its basic provisions have not changed between the two filings. However, the pool of shares that remain available for new grants fell from about 50 million shares at December 31 2023 to roughly 47 million shares at December 31 2024, indicating that roughly 3 million shares were used for awards during 2024【page_102†L13-L20】【page_96†L13-L20】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that no specific figure was provided for remaining shares as of 2023, but the LLM claims there were 'about 50 million shares' available at December 31, 2023 — this number is not supported by the original answer and contradicts it. The only confirmed number in the ground truth is ~47 million shares remaining as of December 31, 2024. The LLM incorrectly implies a quantitative comparison between 2023 and 2024 with a 3 million share reduction, which cannot be made due to lack of 2023 data. (2) The calculation of a 3 million share decrease is therefore invalid, as the 2023 figure is fabricated. The 47 million shares in 2024 matches the ground truth and is correct. However, the claim of a total authorization of 135 million shares is not mentioned in the original answer and cannot be verified from the provided context. (3) The multi-hop reasoning is flawed because the model assumes missing data (2023 share availability) to make a comparison, rather than acknowledging the absence of information as the ground truth does. It fails to recognize that the key evolution is in disclosure transparency, not in the numerical change of available shares. (4) While the LLM correctly identifies the plan's ongoing use and types of awards, and correctly reports the 2024 available shares, the inclusion of unsupported numbers severely undermines factual accuracy. The contextual relevance is high because it addresses the question's focus on evolution and share availability, but the reasoning and quantitative accuracy are significantly compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 449,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did Microsoft's accounting policy regarding the estimated useful lives of server and network equipment evolve between fiscal years 2023 and 2024, and what factors influenced this change?",
      "original_answer": "In fiscal year 2023, Microsoft increased the estimated useful lives of server and network equipment from four years to six years, effective beginning fiscal year 2023. This change was driven by investments in software that improved operational efficiencies and advances in technology. In fiscal year 2024, the policy remained consistent with the updated six-year estimate, indicating that the initial change was sustained and likely integrated into ongoing asset management practices. The continued focus on cloud and AI infrastructure investments further supported the rationale behind extending the useful lives of these assets.",
      "llm_answer": "Microsoft revised its accounting estimate for server and network equipment at the start of fiscal 2023, extending the assets’ estimated useful life from four years to six years, and it continued to apply that six‑year estimate in fiscal 2024. The change was driven by recent software investments that increased operational efficiency of the equipment and by broader advances in technology that allowed the assets to remain useful for a longer period【page_40】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key change in Microsoft's accounting policy—extending the estimated useful life of server and network equipment from four to six years, effective at the start of fiscal year 2023, and maintaining it in fiscal year 2024. All entities (Microsoft, server and network equipment, fiscal years 2023 and 2024) and the numerical values (4-year to 6-year change) are accurate. (2) Quantitative accuracy is perfect: the years and duration of useful life are correct, and no calculations are required beyond correct reporting of time periods. (3) The reasoning is sound and reflects multi-hop understanding: the model correctly attributes the change to software investments improving operational efficiency and broader technological advances, which aligns with the ground truth. However, the LLM answer omits the additional contextual detail from the original answer about the sustained policy in 2024 being supported by ongoing cloud and AI infrastructure investments, which slightly weakens the qualitative completeness. (4) Despite this minor omission, the answer is factually correct, semantically equivalent in key aspects, and highly relevant. The citation of 'page_40' suggests source grounding. Thus, the correctness score is 9 due to high accuracy with a minor gap in contextual depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 373,
        "total_tokens": 1657
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did MDT's exposure to auction rate securities evolve from 2022 to 2023 in terms of fair value and classification within the balance sheet?",
      "original_answer": "In 2022, MDT reported auction rate securities with a fair value of $33 million and classified them under 'Total' in the investment portfolio without specifying a separate balance sheet classification. By 2023, the fair value of auction rate securities remained at $33 million, but they were explicitly classified under 'Other Assets' instead of being included in the broader investment category. This indicates a shift in how MDT categorized these securities on its balance sheet, moving from a general investment classification to a more distinct reporting under other assets.",
      "llm_answer": "In 2022 Medtronic reported auction‑rate securities with a fair‑value of **$33 million** and, as a Level 3 asset, they were shown on the balance sheet under **Other Assets** (not under Investments)【page_71】【page_70】.  \nIn 2023 the same securities still carried a **$33 million** fair‑value and remained classified as a **Level 3 Other‑Asset** on the balance sheet, indicating no change in exposure from the prior year【page_71】【page_70】.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer correctly reports the fair value of auction rate securities as $33 million in both 2022 and 2023, which matches the ground truth. However, it incorrectly states that in 2022 the securities were classified under 'Other Assets' as a Level 3 asset, while the ground truth indicates they were included under 'Total' in the investment portfolio without a separate classification. The 2023 classification under 'Other Assets' is correctly reported. (2) Quantitative accuracy is perfect: both years report $33 million with no change in fair value, which is factually correct. (3) The multi-hop reasoning is flawed because the LLM fails to identify the key evolution — the shift in classification from a general investment category in 2022 to a specific 'Other Assets' classification in 2023. Instead, it asserts the securities were already in 'Other Assets' in 2022, missing the change entirely. This undermines the qualitative accuracy despite correct numbers. (4) Contextual relevance is high because the answer addresses fair value and balance sheet classification as asked, but the incorrect placement in 2022 leads to an erroneous conclusion about no change in exposure or presentation, contradicting the ground truth's emphasis on a reporting shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 353,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 167,
      "question": "How did the net gains or losses from Cisco's available-for-sale debt investments change between fiscal years 2023 and 2024, and what does this indicate about the company's investment performance in this category?",
      "original_answer": "In fiscal year 2023, Cisco reported a net loss of $21 million from its available-for-sale debt investments, while in fiscal year 2024, this loss increased to $67 million. This indicates a significant worsening in investment performance related to this category year-over-year.",
      "llm_answer": "Cisco’s “available‑for‑sale debt investments” posted a net loss of **$21 million in fiscal 2023**, which widened to a **$67 million loss in fiscal 2024** – a deterioration of **$46 million** year‑over‑year【page_46】. The larger loss signals that the portfolio’s market value fell more sharply in 2024, indicating weaker investment performance in this category, likely due to higher interest rates or other adverse market conditions.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the net losses for both fiscal years—$21 million in 2023 and $67 million in 2024—matching the ground truth exactly. The year-over-year deterioration of $46 million is accurately calculated ($67M - $21M = $46M). (2) All numeric values, including dollar amounts and the implied difference, are factually correct and properly formatted. (3) The multi-hop reasoning is sound: the model correctly synthesizes data across two fiscal years, compares the results, and draws a logical conclusion about worsening investment performance. The added context about market value declines and potential causes (e.g., interest rates) is reasonable and does not contradict the ground truth; it enhances the explanation without introducing inaccuracies. (4) The answer fully addresses both parts of the question: the change in net gains/losses and what it indicates about performance. Semantic equivalence with the original answer is strong—core facts, figures, and implications are preserved and accurately conveyed. All scores are maximized due to complete factual accuracy, correct calculations, proper entity and year identification, and logical, relevant reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1193,
        "completion_tokens": 340,
        "total_tokens": 1533
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How did Cisco's approach to the APJC region evolve between 2023 and 2024 in terms of operational structure versus financial investment, and what implications does this have for its revenue model in that region?",
      "original_answer": "In 2023, Cisco directly operated in the APJC region as one of its three geographic segments, indicating a strong operational presence focused on delivering products and services. By 2024, Cisco's relationship with APJC evolved to include financial investments, specifically through equity instruments categorized as marketable equity securities, non-marketable equity securities, and equity method investments. While the 2023 filing emphasized operational delivery and customer engagement in APJC, the 2024 financial statements suggest a parallel strategy of capital participation, potentially signaling a shift toward leveraging local market growth through investment rather than solely through direct sales. This dual approach could indicate a broader revenue model incorporating both operational income and investment returns, though the filings do not quantify the specific financial impact of these investments on Cisco's APJC revenue.",
      "llm_answer": "Cisco still treats APJC as one of its three geographic operating segments in both filings (2023 “we manage our business by geography…APJC” – page 3; 2024 “primarily managed on a geographic basis…APJC” – page 65), but the emphasis shifted from a purely operational view in 2023 to a heavy financial‑investment focus in 2024.  In 2024 Cisco recorded a $25.9 billion acquisition total (up from $301 million in 2023) that includes the Splunk purchase (“With our acquisition of Splunk… fiscal 2024” – page 5; cash‑flow “Acquisitions, net of cash…$25,994 m” – page 63) and expanded financing/lease receivables (page 66), indicating the company is moving toward a subscription‑and‑services‑driven revenue model in APJC rather than relying mainly on one‑time hardware sales.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and quantitative errors that undermine its correctness. (1) Quantitative inaccuracy: The claim that Cisco recorded a $25.9 billion acquisition total in 2024 (up from $301 million in 2023) is misleading. While the 2024 10-K does report $25,994 million in 'Acquisitions, net of cash acquired,' this refers to the Splunk acquisition and other global deals, not region-specific investments in APJC. The original answer notes no such quantification of APJC investment impact, making this a major fabrication in context. Additionally, the $301 million figure for 2023 is not mentioned in the ground truth or supported as an acquisition total. (2) Entity and reasoning error: The LLM incorrectly attributes Cisco's shift to a 'subscription-and-services-driven revenue model' in APJC to financing/lease receivables and Splunk, but the ground truth emphasizes a new category of financial investments (marketable/non-marketable equity and equity method investments) in APJC—not acquisitions or receivables—as the key evolution. Splunk is a global acquisition, not APJC-specific. (3) Multi-hop failure: The model fails to correctly synthesize the shift from operational presence (2023) to financial investment (2024) in APJC. Instead, it conflates global M&A activity with regional strategy, missing the core distinction between operational structure and financial investment. (4) Semantic divergence: While the LLM correctly notes that APJC remains a geographic operating segment in both years, it misrepresents the nature of the 'shift'—from direct operations to financial participation—by focusing on unrelated financial metrics. The original answer highlights equity investments as the new financial dimension; the LLM omits this entirely. (5) Contextual relevance: The answer addresses the question’s structure (evolution over time, operational vs financial) but does so with incorrect data and logic, resulting in a plausible-sounding but factually flawed response. Minor credit is given for recognizing APJC's continued operational role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 555,
        "total_tokens": 1997
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How has Apple's approach to App Store commissions and regulatory compliance evolved between 2022 and 2024, particularly in response to legal and market pressures?",
      "original_answer": "In 2022, Apple acknowledged that changes to the App Store, including those in response to legal and market conditions, could reduce the volume of sales and the commission it earns on those sales, potentially affecting its financial condition. By 2024, Apple had implemented specific changes, particularly in the U.S. and the European Union, to address legal pressures such as the Digital Markets Act (DMA). These changes included new business terms, alternative fee structures, alternative app distribution methods, and additional developer tools and APIs. These adjustments reflect a shift from a more general acknowledgment of potential changes to concrete actions taken in response to regulatory demands, which could significantly affect App Store revenue and commission structures.",
      "llm_answer": "In its 2022 filing Apple noted that it retained a commission on App Store sales and that “from time to time…the Company has made changes…in response to competition, market and legal conditions” and that new legislation such as the EU Digital Markets Act could require further changes (2022 10‑K p.13). By the 2024 filing Apple disclosed that it had already implemented concrete reforms – U.S. rules on how developers can promote alternative purchasing, alternative fee structures, new distribution and payment methods, and additional APIs – to comply with the EU DMA and address ongoing litigation and market pressure, reflecting a shift toward more flexible commission models and proactive regulatory compliance (2024 10‑K p.13).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original (ground truth) answer. (1) All factual elements are correct: Apple's 2022 acknowledgment of potential App Store changes due to legal and market conditions, including the impact of the EU Digital Markets Act (DMA), is accurately cited. By 2024, the implementation of concrete changes—such as alternative fee structures, distribution methods, payment options, and new APIs—is correctly reported. The shift from general risk disclosure to active compliance measures is well-articulated. (2) There are no numeric values (e.g., percentages, dollar amounts) in either the original or LLM answer, so quantitative accuracy is not compromised; dates (2022 and 2024) are correct and properly attributed to the respective 10-K filings. (3) Multi-hop reasoning is sound: the LLM synthesizes information across two years of filings, correctly identifying the evolution from anticipatory language in 2022 to implemented changes in 2024, particularly in response to the DMA and litigation. The mention of U.S. rules on developer promotion of alternative purchases adds a detail consistent with known regulatory developments. (4) Semantic equivalence is strong—while the LLM uses slightly different phrasing (e.g., 'concrete reforms' vs. 'specific changes'), the meaning and factual content match the ground truth. The only minor shortcoming is that the LLM does not explicitly mention the potential financial impact on App Store revenue in 2024 as noted in the original answer, which slightly affects completeness in qualitative synthesis. However, this does not undermine the core accuracy. Overall, the response is factually correct, contextually relevant, and demonstrates strong reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 473,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 175,
      "question": "How did the allocation strategy for Texas Instruments' U.S. Retiree Health Care Plan evolve between fixed income securities and equity securities from 2022 to 2024?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had a diversified mix of fixed income securities and equity securities, with fixed income and cash equivalents totaling $248 million and equity securities at $137 million. By 2024, the allocation strategy showed a significant shift toward a more conservative posture, with fixed income securities and cash equivalents comprising 80% of the portfolio, while equity securities made up only 20%. This reflects a notable increase in emphasis on fixed income securities compared to equities, even though the relative proportions remained the same between 2023 and 2024, suggesting a strategic decision to prioritize capital preservation.",
      "llm_answer": "In the 2022 filing the U.S. Retiree Health Care Plan was targeted to hold roughly 65 %‑80 % of its assets in fixed‑income securities and 20 %‑35 % in equities, and the actual year‑end mix was about 64 % fixed income and 36 % equity【page_50】. By the 2024 filing the target range had shifted to 75 %‑85 % fixed income and 15 %‑25 % equity, and the weighted‑average allocation at year‑end 2024 was about 80 % fixed income and 20 % equity【page_48】. Thus, the plan moved toward a higher proportion of fixed‑income assets and a lower proportion of equity assets between 2022 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the percentages are correct: in 2022, the actual allocation was approximately 64% fixed income and 36% equity, consistent with the reported $248M fixed income and $137M equity (which totals $385M; 248/385 ≈ 64.4%). By 2024, the allocation reached 80% fixed income and 20% equity, matching the ground truth's statement that fixed income and cash equivalents comprised 80% of the portfolio. The LLM correctly notes the shift in target ranges from 65%-80% to 75%-85% for fixed income, indicating a strategic move toward conservatism. (2) While the original answer provides dollar amounts for 2022 and describes the 2024 allocation in percentages, the LLM supplements this with target ranges and actual weighted averages from the filings, adding precision. The dollar figures in the ground truth are not contradicted, but the LLM focuses on percentages, which are more directly comparable across years. (3) The reasoning is sound: the LLM correctly infers a strategic shift toward capital preservation by increasing fixed income allocation and decreasing equity exposure, which is consistent with the ground truth’s conclusion. (4) The answer is contextually complete, addressing the evolution of allocation strategy between 2022 and 2024. The only minor limitation is that the LLM does not explicitly mention that the 2023–2024 proportions remained stable, a detail included in the original answer to emphasize continuity in the conservative stance. However, this does not undermine the overall correctness. Wording differs but semantic meaning and factual content are equivalent. Minor deduction from 10 due to omission of the 2023–2024 stability note, but all key facts, numbers, and reasoning are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 486,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How has Texas Instruments' strategic emphasis on Embedded Processing Products evolved from 2022 to 2024, particularly in terms of its contribution to the company's competitive advantages and segment reporting structure?",
      "original_answer": "In 2022, Texas Instruments described Embedded Processing as one of its core product lines within a broader business model that emphasized four competitive advantages: manufacturing and technology strength, a broad product portfolio, strong market channels, and product diversity and longevity. Embedded Processing was positioned as part of this integrated strategy but was not highlighted as a standalone reportable segment. By 2024, Embedded Processing was elevated to a reportable segment alongside Analog, indicating a strategic shift where the company explicitly called out Embedded Processing as a key driver of value. This change suggests that Embedded Processing has become more central to TI's competitive positioning, particularly in terms of enabling optimized performance, power, and cost across a range of customer applications. The elevation to a reportable segment also implies greater operational and financial focus, aligning with the company’s long-term objective of strengthening its competitive advantages and driving free cash flow growth.",
      "llm_answer": "In the 2022 filing TI’s MD&A said its “strategic focus is on analog and embedded‑processing products” and highlighted the industrial and automotive markets, reporting Embedded Processing as a separate segment that produced $3.26 billion of revenue and $1.25 billion of operating profit in 2022【page_21】【page_22】. By the 2024 filing the company still reports Embedded Processing as its own segment (revenue $2.53 billion, operating profit $352 million) but now explicitly positions it as a pillar of its four sustainable competitive advantages—“a broad portfolio of analog and embedded‑processing products” that fuels growth and free‑cash‑flow—showing a shift from a general product focus to a core advantage while retaining the same two‑segment reporting structure【page_20】【page_30】【page_31】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding segment reporting structure in 2022. The original answer (ground truth) states that Embedded Processing was *not* a reportable segment in 2022, but the LLM claims it was reported as a 'separate segment' with specific revenue and profit figures—this directly contradicts the ground truth. This is a major error in both entity accuracy and reasoning. (2) The quantitative figures cited ($3.26 billion revenue and $1.25 billion operating profit in 2022; $2.53 billion and $352 million in 2024) are not corroborated by the ground truth, which does not provide any financials for Embedded Processing. Since the knowledge graph does not contain these numbers, their inclusion suggests fabrication or misattribution, severely undermining quantitative accuracy. (3) The multi-hop reasoning is partially sound in identifying a strategic shift by 2024—where Embedded Processing is positioned as a core competitive advantage and reportable segment—but fails on the 2022 side of the comparison. The LLM incorrectly assumes the two-segment structure existed in 2022, when the ground truth indicates that the elevation to a reportable segment occurred *by* 2024, implying a change from prior years. Thus, the synthesis across time is flawed. (4) Despite these issues, the answer is contextually relevant, addressing the evolution of strategic emphasis and linking it to competitive advantages and segment reporting. It correctly identifies the broader strategic framing around analog and embedded processing and aligns with TI’s focus on free cash flow. However, due to the critical error about segment status in 2022 and unsupported financial data, the correctness score is low. Minor note: citation of page numbers adds apparent precision but cannot compensate for factual misalignment with ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1481,
        "completion_tokens": 510,
        "total_tokens": 1991
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How did TMO's issuance and valuation of its 2.00% 10-Year Senior Notes evolve between 2022 and 2024?",
      "original_answer": "In 2022, TMO reported $1,200 million in 2.00% 10-Year Senior Notes due on October 15, 2031, with an effective interest rate of 2.23%. By 2024, the same category of 2.00% 10-Year Senior Notes showed no change in the principal amount at $1,200 million, and the effective interest rate remained at 2.23%. This indicates that TMO maintained a consistent position on this specific debt instrument over the two-year period, with no new issuances or repayments affecting this line item.",
      "llm_answer": "In 2022 Thermo Fisher issued Euro‑denominated 2.00 % 10‑Year Senior Notes due 4/15/2025 for $728 million at par, with an effective interest rate of roughly 2.10%【page_87】. By year‑end 2024 the balance had fallen to $663 million at par and the effective rate had slipped to about 2.07%, reflecting partial redemption and a modest decline in the notes’ carrying value【page_47】.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in multiple dimensions. (1) Quantitative Accuracy: The LLM reports a $728 million issuance due April 15, 2025, with a balance of $663 million in 2024, which contradicts the ground truth of a $1,200 million issuance due October 15, 2031. The effective interest rates cited (2.10% in 2022, 2.07% in 2024) do not match the ground truth (2.23% consistently). The maturity date (2025 vs 2031) and currency (Euro-denominated vs not specified) are also incorrect. (2) Completeness: The answer fails to reflect that there was no change in the principal or interest rate between 2022 and 2024, which is the core of the ground truth. Instead, it invents a partial redemption and changing interest rate. (3) Entity Accuracy: The LLM confuses the debt instrument—different amount, maturity date, and currency—suggesting it may have referenced a different note series entirely. The company (TMO/Thermo Fisher) is correct, as are the years 2022 and 2024. (4) Reasoning: The multi-hop synthesis is flawed. The ground truth shows stability in the debt line; the LLM incorrectly infers a decline in balance and rate, indicating either misreading of data or confusion with another debt instrument. (5) Semantic Equivalence: The answers are not equivalent—LLM describes a changing liability, while truth shows no change. The cited page references (87, 47) may point to real data, but the interpretation is factually misaligned with the specific 2.00% 10-Year Senior Notes due 2031. Overall, the answer is mostly incorrect with major factual and quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1202,
        "completion_tokens": 433,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 178,
      "question": "How has the financial performance of REMICADE evolved between 2022 and 2024, and what does this indicate about its role in Johnson & Johnson's Pharmaceutical segment?",
      "original_answer": "In 2022, REMICADE was listed as a key product in Johnson & Johnson's Pharmaceutical segment, specifically within the Immunology therapeutic area, indicating its importance in treating immune-mediated inflammatory diseases. By 2024, REMICADE's sales had declined significantly, from $1,839 million in 2023 to $1,605 million in 2024, representing a 12.8% decrease. This decline suggests a diminishing contribution of REMICADE to the company's Immunology revenue, potentially due to market saturation, increased competition, or the emergence of newer biologics within the segment.",
      "llm_answer": "In the 2022 filing REMICADE (infliximab) is listed as one of the Pharmaceutical segment’s key immunology products (JNJ 2022 10‑K, p. 7). By fiscal 2024 its sales had fallen to $1.605 billion—a 12.8% drop from the prior year—and the 2024 filing notes that “lower sales of REMICADE…was due to continued biosimilar competition” (JNJ 2024 10‑K, p. 31‑32). This decline indicates that, although REMICADE remains a core immunology drug, its contribution to Johnson & Johnson’s Pharmaceutical segment is eroding as biosimilar rivals capture market share.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies REMICADE as a key immunology product in Johnson & Johnson's Pharmaceutical segment in 2022, consistent with the ground truth. It accurately reports the 2024 sales figure of $1.605 billion and the 12.8% decline from the prior year. Although the ground truth cites 2023 sales ($1,839 million) as the baseline, the LLM does not explicitly state that number but correctly infers the percentage drop, which aligns with the calculation: (1,839 - 1,605) / 1,839 ≈ 12.8%. Thus, the quantitative data is accurate. (2) The LLM correctly attributes the decline to biosimilar competition, citing the 2024 10-K, which strengthens its factual basis and adds context not explicitly in the ground truth but consistent with it. This enhances qualitative accuracy. (3) The multi-hop reasoning is sound: the model connects REMICADE’s status in 2022 to its financial performance in 2024 and synthesizes information across filings to assess its evolving role. The conclusion that its contribution is eroding due to biosimilars is logically supported and semantically equivalent to the ground truth’s interpretation involving competition and declining relevance. (4) The only minor shortcoming is the omission of the explicit 2023 sales figure ($1,839 million), which was present in the ground truth and would have made the comparison more transparent. However, since the percentage change is correct and contextually well-used, this does not undermine the overall correctness. Wording differs but meaning is preserved. Scores reflect high accuracy with a small deduction in qualitative accuracy for incomplete explicit benchmarking, though reasoning remains strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 463,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 179,
      "question": "How did the sales performance of REMICADE evolve from 2022 to 2024, and what does this indicate about its market position within JNJ's Immunology portfolio?",
      "original_answer": "In 2022, REMICADE had sales of $3,190 million, showing a decline of 14.9% compared to 2020. By 2024, its sales had further decreased to $1,605 million, representing a 12.8% drop from 2023. This consistent decline indicates a weakening market position of REMICADE within JNJ's Immunology portfolio over time.",
      "llm_answer": "REMICADE’s sales fell sharply – from $3.19 billion in fiscal 2022 (page 30, 2022 10‑K) to $1.84 billion in 2023 and further to $1.61 billion in 2024 (page 31, 2024 10‑K), a roughly 50 % decline over two years. The drop, attributed to growing biosimilar competition (page 32, 2024 10‑K), signals that REMICADE is losing market share and has become a much smaller contributor within J&J’s Immunology portfolio, overtaken by products such as STELARA and TREMFYA.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the declining trend in REMICADE sales and attributes it to biosimilar competition, which aligns with the ground truth's implication of a weakening market position. It also correctly notes that REMICADE is being overtaken by other products like STELARA and TREMFYA, adding contextual insight not in the original answer but plausibly inferred. However, there are key numerical inaccuracies: the 2024 sales figure is stated as $1.61 billion, while the ground truth reports $1,605 million ($1.605 billion) — a minor difference, acceptable under formatting flexibility. More significantly, the LLM claims $1.84 billion in 2023, but the ground truth does not provide 2023 sales directly; instead, it states that 2024 sales declined 12.8% from 2023. Back-calculating from $1,605 million as a 12.8% drop implies 2023 sales of approximately $1,841 million — so the $1.84 billion figure is actually accurate. The 50% decline claim over two years (from $3.19B to $1.61B) is roughly correct (~49.2%), so acceptable. (2) The original answer references a 14.9% decline from 2020 to 2022, which the LLM omits — a minor omission affecting completeness but not core correctness. (3) Multi-hop reasoning is sound: the model synthesizes data across years and filings, correctly infers competitive pressure, and contextualizes REMICADE’s role within JNJ’s portfolio. (4) Scores reflect high qualitative and contextual accuracy, but quantitative accuracy is docked slightly because the LLM does not explicitly cite the 12.8% drop from 2023 to 2024, instead using rounded figures and a two-year percentage drop not in the source. Still, the numbers themselves are factually correct based on back-calculation, so the error is more presentational than factual.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1194,
        "completion_tokens": 485,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 180,
      "question": "How has the sales performance of REMICADE evolved between 2021 and 2024, and what factors contributed to this change?",
      "original_answer": "REMICADE's sales declined significantly from $16.8 billion in 2021 (as part of total Immunology sales) to $1,605 million in 2024, reflecting a 12.8% decrease from 2023 to 2024 alone. This decline was primarily driven by biosimilar competition in the U.S. and other global markets, which intensified over time and led to a continued reduction in REMICADE sales.",
      "llm_answer": "REMICADE’s sales fell sharply, from $3.19 billion in 2021 to $1.605 billion in 2024 – a drop of roughly 50 percent (2021 table shows $3,190 M 【page_30】; 2024 table shows $1,605 M 【page_31】).  The decline was driven almost entirely by the rollout of infliximab biosimilars in the United States and other markets, which eroded REMICADE’s market share and continued to suppress its sales (2021 narrative cites “lower sales of REMICADE…due to biosimilar competition” 【page_31】; 2024 narrative notes “Lower sales of REMICADE…was due to continued biosimilar competition” 【page_32】).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative data. The original answer states that REMICADE's sales were $16.8 billion in 2021 as part of total Immunology sales, but the LLM incorrectly reports $3.19 billion as REMICADE's standalone sales in 2021. This is a major discrepancy—$3.19 billion vs $16.8 billion—and misrepresents the scale of sales. Additionally, the LLM claims a 50% drop from 2021 to 2024, but the ground truth emphasizes a 12.8% decrease specifically from 2023 to 2024, not over the full period. The 2024 figure ($1,605 million) is correct and matches the ground truth. (2) Calculations: The LLM’s 50% decline calculation from $3.19B to $1.605B is mathematically accurate, but based on incorrect input data. The ground truth does not provide a full 2021–2024 percentage change, but does specify a 12.8% drop from 2023 to 2024, which the LLM fails to mention. (3) Multi-hop reasoning: The LLM correctly identifies biosimilar competition as the key driver of decline and supports this with citations from 2021 and 2024 narratives, showing proper synthesis across years. This demonstrates sound qualitative reasoning and correct attribution of causality. (4) The answer is contextually relevant and addresses both parts of the question—sales evolution and contributing factors—but the severe error in the 2021 sales figure undermines the correctness score. While the direction of the trend (sharp decline) and the cause (biosimilar competition) are correct, the magnitude of the decline is misrepresented due to incorrect baseline data, leading to a low quantitative accuracy score. The qualitative reasoning and relevance remain strong, hence moderate scores in those categories.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 473,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 181,
      "question": "How did the status and commercial performance of STELARA (ustekinumab) evolve between 2022 and 2024?",
      "original_answer": "In 2022, STELARA was in the filing stage for the treatment of pediatric patients with juvenile psoriatic arthritis in the U.S., indicating it was under regulatory review but not yet approved. By 2024, STELARA had achieved significant commercial success, generating $10,361 million in sales, a decrease from $10,858 million in 2023, representing a 4.6% decline in total sales. This reflects that STELARA had transitioned from a product in active regulatory development to a mature, high-revenue-generating drug facing slight sales decline, suggesting market saturation or increased competition.",
      "llm_answer": "In the 2022 filing, STELARA was still protected by its U.S. patent (set to expire in September 2023), faced no biosimilar competition and delivered roughly $9.1 billion of worldwide sales (about $5.9 billion in the United States) driven by strong uptake in Crohn’s disease and ulcerative colitis. By the 2024 filing, sales had slipped to $10.36 billion globally (U.S. $6.7 billion), a 4‑5 % year‑over‑year decline, as European biosimilar entrants eroded share and multiple FDA biosimilar BLAs were filed, with the company expecting biosimilar launches in Europe and the U.S. in 2025.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. According to the ground truth, STELARA generated $10,361 million in sales in 2024 and $10,858 million in 2023, representing a 4.6% decline. The LLM incorrectly states 2022 sales as $9.1 billion globally, while the ground truth does not provide 2022 sales but does state 2023 and 2024 figures. The LLM's claim of $10.36 billion in 2024 is numerically close to the correct $10,361 million (i.e., $10.361 billion), so this part is acceptable. However, the 2022 sales figure of $9.1 billion is not supported by the original answer and contradicts the trend (since 2023 sales were higher at $10.858B). Additionally, the LLM introduces U.S. sales breakdowns ($5.9B in 2022, $6.7B in 2024) that are not present in the ground truth and cannot be verified. (2) The calculation of a 4–5% decline is approximately correct (actual: (10,858 - 10,361)/10,858 ≈ 4.58%), so this is accurate. However, the LLM misattributes the decline to European biosimilars and upcoming FDA BLAs, while the original answer does not specify causes, only noting the decline. This adds unsupported detail. (3) The multi-hop reasoning is partially sound: the LLM attempts to show evolution from 2022 to 2024, including regulatory/patent status and commercial performance. However, it fabricates 2022 sales and U.S./ex-U.S. splits not in the source. The original answer emphasizes STELARA’s 2022 regulatory filing for pediatric use, which the LLM omits entirely, instead focusing on patent protection (not mentioned in ground truth). This is a significant omission in the qualitative evolution. (4) The contextual relevance is high—the answer addresses the commercial trajectory and status changes over time. However, due to incorrect sales figures for 2022, missing key regulatory context (pediatric filing), and introducing unverified details (geographic sales, biosimilar impact), the correctness score is reduced to 5. Quantitative accuracy is low due to the incorrect 2022 number and unsupported breakdowns. Qualitative accuracy is moderate because the overall trend (high sales, slight decline by 2024) is captured, but key details are wrong or invented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 597,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 182,
      "question": "How did the total net revenue from Restasis in the United States change between 2023 and 2024, and what was the percentage decrease in each year?",
      "original_answer": "In 2023, the United States net revenue from Restasis was $382 million, which decreased to $172 million in 2024. This represents a 38.5% decrease in 2023 compared to 2022, and a further 55.2% decrease in 2024 compared to 2023.",
      "llm_answer": "The United States net revenue from Restasis fell from $621 million in 2023 to $382 million in 2024 – a $239 million drop. That decline represents a 38.5% decrease in 2024 (versus 2023) and a 49.6% decrease in 2023 (versus 2022)【page_43】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. According to the ground truth, Restasis U.S. net revenue was $382 million in 2023 and decreased to $172 million in 2024. The LLM incorrectly states $621 million in 2023 and $382 million in 2024, reversing the correct 2023 value and inventing a higher prior value. The claimed $239 million drop and 49.6% decrease in 2023 are therefore incorrect. The LLM also misattributes the 38.5% decrease to 2024 (vs 2023), when in fact that percentage matches the ground truth for 2023 vs 2022. The 55.2% decrease in 2024 (vs 2023) from the ground truth is entirely missing and replaced with an incorrect 38.5% figure. (2) Number verification: Correct 2023 revenue is $382M (LLM has it as 2024), correct 2024 revenue is $172M (LLM says $382M). The 38.5% decrease is correctly stated in the ground truth for 2023 vs 2022, but LLM incorrectly applies it to 2024 vs 2023. The 55.2% decrease in 2024 is omitted. (3) Multi-hop reasoning is flawed: The LLM fails to correctly identify the revenue trend across years and misaligns both values and percentages across time periods. It appears to reverse or misread the data. (4) Scores justified: Correctness is low (2/10) due to major factual and numerical errors. Quantitative accuracy is poor (2/10) as most numbers and percentages are wrong. Qualitative accuracy is slightly higher (3/10) because the model attempts the right type of analysis (year-over-year change, percentage decrease) but with incorrect data. Contextual relevance is moderate (6/10) as the answer addresses the right drug, geography, and metric, but with incorrect values.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1115,
        "completion_tokens": 449,
        "total_tokens": 1564
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role and strategic importance of Master Lease Agreements evolved between 2022 and 2023 in supporting AMT's international growth and tenant relationships?",
      "original_answer": "In 2022, AMT emphasized that master lease agreements were comprehensive in nature and instrumental in building strong strategic partnerships with tenants, significantly reducing colocation cycle times and enabling rapid deployment of equipment across its international portfolio of approximately 177,000 communications sites. By 2023, AMT reiterated the importance of these agreements in providing consistent, long-term revenue and reducing non-contractual churn, while operating an expanded international portfolio of approximately 182,000 communications sites. The evolution reflects a continued strategic focus on leveraging master lease agreements to support international growth and tenant retention, with an emphasis on mitigating risks such as customer consolidation and regulatory changes.",
      "llm_answer": "In 2022 AMT said its master‑lease agreements “provide for consistent, long‑term revenue and reduce the likelihood of non‑contractual churn,” and that the comprehensive nature of many of these agreements “build and augment strong strategic partnerships…while significantly reducing colocation cycle times,” supporting its international push on a portfolio of roughly 177,000 sites【page_34】. By 2023, with the portfolio expanded to about 182,000 sites, the company again stresses the same revenue‑stability and churn‑reduction benefits but now frames the agreements as a core lever for “leveraging…our extensive international portfolio…and the relationships we have built with our carrier tenants to drive sustainable, long‑term growth,” underscoring an elevated strategic role in enabling rapid tenant deployments worldwide【page_37】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, AMT highlighted master lease agreements for reducing colocation cycle times and building strategic partnerships across ~177,000 sites; by 2023, the portfolio grew to ~182,000 sites, with continued emphasis on long-term revenue and churn reduction. The numbers (177,000 and 182,000) match exactly, and years (2022, 2023) are correct. (2) Quantitative accuracy is perfect—site counts are correctly reported with appropriate rounding ('roughly', 'about') and match the original. No calculations were required. (3) Multi-hop reasoning is sound: the model synthesizes information across two years, correctly identifying the evolution in strategic framing—from operational efficiency (2022) to a 'core lever' for growth (2023)—which reflects the elevated strategic role. The mention of 'sustainable, long-term growth' and 'rapid tenant deployments worldwide' captures the evolved emphasis. (4) Minor deduction in qualitative accuracy because the LLM omits explicit mention of risk mitigation (customer consolidation, regulatory changes) noted in the original 2023 assessment, though the strategic elevation is well conveyed. Otherwise, the answer is contextually complete, semantically equivalent, and directly addresses the evolution in role and strategic importance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 381,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role of Google Marketing Platform in the company's advertising revenue generation evolved between 2023 and 2024, particularly in relation to how advertising revenues are recognized and managed across Google Network properties?",
      "original_answer": "In 2023, Google Marketing Platform was directly involved in the recognition of advertising revenues on a gross basis for Google Network properties, meaning the full amount billed to customers was recorded as revenue. By 2024, the platform's role evolved to include a more nuanced evaluation of its principal versus agent status, with an emphasis on its control over advertising inventory before transfer to customers, further supporting the gross revenue reporting. Additionally, 2024 introduced a more detailed explanation of the platform's role in managing advertising across Google Network properties, highlighting its central function in both performance and brand advertising delivery.",
      "llm_answer": "In both the 2023 and 2024 Form 10‑K the filing describes Google Marketing Platform as one of the primary channels through which advertisers purchase inventory – “Our customers generally purchase advertising inventory through Google Ads, Google Ad Manager, Google Display & Video 360, and Google Marketing Platform, among others”【page_57】.  The accounting for those sales has not changed: performance ads are recognized on user engagement, brand ads when displayed, and ads on Google Network properties are still reported on a gross basis with the amounts paid to network partners recorded as cost of revenues【page_57】【page_58】.  Thus, the role of the Marketing Platform in generating ad revenue and the way network‑property revenues are recognized and managed remained essentially the same from 2023 to 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its conclusion that the role of Google Marketing Platform remained 'essentially the same' between 2023 and 2024, which directly contradicts the ground truth. According to the original answer, there was a meaningful evolution in the platform's role in 2024, particularly in the evaluation of principal versus agent status and a more detailed articulation of its control over advertising inventory, which supports gross revenue reporting. The LLM answer fails to capture this evolution and instead asserts no change in accounting or platform role. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable—no errors in this regard, hence a score of 10. (3) The multi-hop reasoning is flawed: the question asks for a comparison across years regarding the platform’s evolving role in revenue recognition and management. The LLM correctly identifies that revenue from Google Network properties is reported on a gross basis in both years but misses the nuanced shift in rationale and disclosure emphasis in 2024 related to control and principal-agent assessment. This is a critical omission in the qualitative synthesis required. (4) Contextual relevance is moderate—the response discusses the correct platform, company, and revenue recognition policies, and cites relevant sections, but fails to address the core of the question: the evolution of the platform's role. Thus, while contextually grounded, it lacks the necessary depth and change detection required for full accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 436,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did the volume and fair value of Federal Funds Purchased & Sec Loaned change between 2023 and 2024, and what does this indicate about BAC's short-term funding strategies?",
      "original_answer": "In 2023, the volume of Federal Funds Purchased & Sec Loaned showed a net change of $16,466 million, indicating a significant increase in short-term funding liabilities. By 2024, the fair value of this category was reported at $192,859 million, a substantial increase from the prior year. This suggests that BAC significantly expanded its reliance on short-term secured funding mechanisms in 2024, likely to support its trading and liquidity management activities.",
      "llm_answer": "- **Volume:** The average balance of Federal funds purchased and securities loaned was $301 billion in 2023 (the “Key Performance Indicators” table) and the Level‑2 fair‑value measurement – a proxy for the size of the position – fell from $570 billion in 2023 to $482 billion in 2024, implying a roughly $90 billion drop in volume. 【page_34†L31-L33】【page_155†L13-L15】【page_156†L13-L15】\n\n- **Fair value:** The fair‑value of this short‑term liability declined from $192.9 billion in 2023 to $178.6 billion in 2024 (Level‑2 amount less netting adjustments). 【page_155†L13-L15】【page_156†L13-L15】\n\n- **Implication:** The reduction in both the amount and fair‑value of Federal Funds Purchased & Securities Loaned indicates that Bank of America is scaling back its reliance on Federal Funds as a short‑term funding source, likely shifting toward other, more stable funding channels in a higher‑rate environment.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both direction and magnitude of changes in volume and fair value. The original answer states that the volume increased by $16,466 million in 2023 and the 2024 fair value was $192,859 million, indicating growth in short-term funding. In contrast, the LLM claims both volume and fair value declined—from $301B to a proxy of $482B (implying a $90B drop) and fair value falling from $192.9B to $178.6B. These numbers contradict the ground truth. The LLM misinterprets Level-2 fair value as a proxy for volume, but the original answer uses net change in volume and reports 2024 fair value directly. (2) Specific number verification: Ground truth reports 2024 fair value at $192,859 million (~$192.9B), which matches the LLM’s 2023 figure, suggesting a swap of years. The LLM incorrectly assigns $192.9B to 2023 and reports a decrease, while the truth shows an increase to that amount in 2024. The $16,466 million net increase in volume in 2023 is entirely missed. (3) Multi-hop reasoning is flawed: The LLM fails to connect the correct data points across years and misidentifies trends. It draws the opposite conclusion—reduction in reliance—while the correct interpretation is increased reliance on short-term secured funding. (4) Scores are low due to major factual and directional errors in quantitative data and resulting incorrect inference. Contextual relevance is moderate because the answer addresses the right metric and attempts implication, but reasoning is based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 424,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has PepsiCo's disclosure regarding the sensitivity of pension and retiree medical plan liabilities to market fluctuations evolved between 2022 and 2024?",
      "original_answer": "In 2022, PepsiCo mentioned that the exposure of pension and retiree medical plan assets and liabilities to risks related to market fluctuations was discussed in 'Our Critical Accounting Policies and Estimates.' By 2024, the company expanded this disclosure, explicitly linking the sensitivity of these liabilities not only to market fluctuations but also to inflationary, deflationary, and recessionary conditions. This broader context indicates a more detailed characterization of the macroeconomic risks affecting these obligations, beyond just market volatility.",
      "llm_answer": "In the 2022 Form 10‑K PepsiCo noted that the exposure of its pension and retiree‑medical‑plan assets and liabilities — along with goodwill and other intangible assets — to market‑risk fluctuations is discussed in the “Critical Accounting Policies and Estimates” section. The 2024 Form 10‑K repeats the same reference, but now mentions only the pension and retiree‑medical‑plan assets and liabilities (omitting goodwill and other intangibles) and still provides no quantitative sensitivity analysis. Thus, the disclosure has remained essentially unchanged, with a slight narrowing of the language.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core conclusion about the evolution of PepsiCo's disclosure. While it correctly identifies that in 2022, the exposure of pension and retiree medical plan liabilities to market fluctuations was discussed in the 'Critical Accounting Policies and Estimates' section, it inaccurately claims that the 2024 disclosure remained 'essentially unchanged' with only a narrowing of language. The ground truth states that by 2024, PepsiCo expanded its disclosure to explicitly link sensitivity not only to market fluctuations but also to inflationary, deflationary, and recessionary conditions—indicating a broader, more detailed risk characterization. The LLM answer misses this key expansion entirely and instead incorrectly asserts no substantive change. There are no numerical values in the question or answers, so quantitative accuracy is not applicable in a meaningful way, but since no numbers were misstated, it scores high. The qualitative accuracy is low because the model failed to capture the multi-hop evolution in disclosure depth and mischaracterized the 2024 update. Contextual relevance is moderate—the response addresses the right documents and sections but draws an incorrect inference about the nature of the change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 353,
        "total_tokens": 1646
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Adobe's approach to Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's broader document management ecosystem?",
      "original_answer": "In 2023, Adobe Scan was positioned as a free mobile scanning tool that converts paper documents into editable, searchable PDFs via Adobe Document Cloud services, emphasizing its utility for individual users. By 2024, Adobe Scan remained part of Adobe Document Cloud, but the broader ecosystem placed increased emphasis on integration with cloud-based productivity tools and AI-driven features like Content Credentials and Firefly-powered generative AI workflows, indicating a shift toward deeper integration within enterprise document workflows and enhanced digital trust mechanisms.",
      "llm_answer": "In the 2023 filing Adobe Scan was described chiefly as a free mobile app that captures paper, turns it into PDFs and adds OCR, using Adobe Document Cloud services for instant sharing (2023 p.13). By the 2024 filing the same scanning and OCR features remain, but Adobe positions Scan as a core part of the Adobe Document Cloud subscription—integrated with Acrobat, Acrobat Sign and other Document Cloud APIs to enable end‑to‑end document creation, collaboration and e‑signature workflows (2024 p.12‑13).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies Adobe Scan's 2023 positioning as a free mobile scanning tool with OCR powered by Adobe Document Cloud, citing its use for converting paper to PDFs and enabling sharing. For 2024, it accurately reflects the shift in positioning—emphasizing deeper integration within the Document Cloud ecosystem, particularly with Acrobat, Acrobat Sign, and APIs for end-to-end workflows. While the LLM answer does not explicitly mention 'AI-driven features' or 'Content Credentials' and 'Firefly-powered generative AI' from the original answer, it captures the core evolution: a move from a standalone utility app to a more integrated component of enterprise document workflows. The citation of specific page numbers (2023 p.13, 2024 p.12–13) suggests accurate sourcing. There are no numerical inaccuracies (quantitative accuracy is perfect), and all entities (Adobe Scan, Adobe Document Cloud, Acrobat, Acrobat Sign) are correctly identified. The reasoning is sound and reflects multi-hop synthesis across years and product integrations. The omission of AI-specific enhancements slightly reduces qualitative accuracy, but the central strategic shift is correctly conveyed, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 360,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Gemini's role and integration across Google's products evolved from its initial launch in 2023 to 2024, and what specific advancements were made in its multimodal capabilities?",
      "original_answer": "In 2023, Gemini was introduced as a multimodal AI model capable of understanding and operating across different types of information, including text, code, audio, images, and video. It was intended to be leveraged across Alphabet to enhance product experiences. By 2024, Gemini had evolved significantly, with the launch of Gemini 2.0, which became the most capable model yet. It was integrated into all seven of Google's two billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube—powering AI features across these platforms. Additionally, in 2024, Gemini was used in experimental research prototypes such as Project Astra and Project Mariner, showcasing broader and more advanced applications than in 2023.",
      "llm_answer": "Gemini debuted in December 2023 as a natively multimodal model (handling text, code, audio, images and video) that first powered AI‑assistive features on Pixel devices (Gemini Nano) and was accessible through Android and Chrome OS (page 7). By 2024 the upgraded Gemini 2.0 expanded its multimodal capabilities, reduced latency and cost, and was embedded across all seven of Google’s flagship products—Android, Chrome, Gmail, Maps, Play Store, Search and YouTube—as well as Google Cloud’s Vertex AI platform and new prototypes, driving AI Overviews, the Gemini app, Workspace and other AI‑driven experiences (page 6).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Gemini launched in 2023 as a multimodal model handling text, code, audio, images, and video; by 2024, Gemini 2.0 was integrated into all seven of Google's two-billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube. The mention of Vertex AI and AI Overviews adds contextual detail not in the original but does not contradict it. (2) Quantitative accuracy is perfect: no incorrect numbers, dates (2023 launch, 2024 evolution), or misstatements. The reference to Pixel devices and Gemini Nano is consistent with known rollout strategy and adds precision without error. (3) Multi-hop reasoning is sound—correctly synthesizing evolution over time, product integrations, and capability improvements. The only minor gap is that the original emphasizes experimental prototypes like Project Astra and Project Mariner, which the LLM answer mentions only generally as 'new prototypes,' slightly reducing completeness. (4) Semantic equivalence is strong; wording differs but meaning matches. Contextual relevance is excellent, directly addressing both the evolution and multimodal advancements. One point deducted from qualitative accuracy for slightly less specificity on research prototypes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 365,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Linde's relationship with helium evolved between 2022 and 2024, particularly in terms of its impact on sales and operating profit?",
      "original_answer": "In 2022, helium was listed as a supply for Linde, indicating a positive or neutral relationship. However, by 2024, the relationship had evolved, and helium was reported to negatively impact the company. Specifically, in 2024, lower volumes in global helium contributed to a 2% decrease in sales for the 'Other' segment, which includes global helium wholesale. Additionally, higher costs due to helium partially offset an insurance recovery for Linde Advanced Materials Technology (LAMT), limiting the operating profit growth in that segment despite a 44% overall increase in operating profit for 'Other'.",
      "llm_answer": "In the 2022 filing helium was only noted as part of the “Other” segment (global helium wholesale) and was not highlighted as a material driver of results [2022 page 28]. By the 2024 filing Linde said that lower helium volumes cut “Other”‑segment sales by $32 million (≈2%) and that higher helium‑related costs partially offset a $19 million (44%) rise in operating profit for the segment [2024 page 28]. This shows that helium moved from a non‑material line‑item in 2022 to a factor that directly reduced sales and added cost pressure on profit by 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of Linde's relationship with helium from 2022 to 2024: neutral/non-material in 2022 to negative impact in 2024. (2) Quantitatively, it accurately states that lower helium volumes reduced 'Other' segment sales by $32 million (≈2%) in 2024 and that operating profit in the segment rose 44% ($19 million), with helium-related costs partially offsetting this gain. These figures match the ground truth in magnitude and context, though the $19 million figure is derived from the 44% increase and not explicitly stated in the original answer—this inference is reasonable and consistent. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across 2022 and 2024 filings, identifying the shift in helium’s impact from a non-material item to a negative driver of sales and profit. (4) Entity accuracy is strong: 'Other' segment, global helium wholesale, and correct years are all properly referenced. The only minor limitation is that the original answer mentions 'Linde Advanced Materials Technology (LAMT)' specifically as the segment affected by cost-pressure, while the LLM refers more generally to the 'Other' segment. This is a slight omission but does not invalidate the overall correctness, as LAMT is part of 'Other'. Wording differs but semantic meaning and factual content are equivalent. Hence, a high score is warranted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 403,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did the net value of acquired franchise rights evolve from 2022 to 2024, and what was the magnitude of this change?",
      "original_answer": "In 2022, the net value of acquired franchise rights was $789 million, while in 2024 it decreased to $598 million. This represents a significant decline in value over the two-year period.",
      "llm_answer": "The net carrying amount of acquired franchise rights fell from $1.891 billion at the end of 2022 to $1.858 billion at the end of 2024, a reduction of roughly $33 million (about a 1.8% decline)【page_85】.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in all key aspects. The ground truth states that the net value of acquired franchise rights decreased from $789 million in 2022 to $598 million in 2024, a decline of $191 million. However, the LLM claims the value was $1.891 billion in 2022 and $1.858 billion in 2024, a much smaller decline of $33 million. These numbers are not only wrong but over twice the magnitude of the correct values. (2) The calculation in the LLM answer (a $33 million reduction, ~1.8% decline) is mathematically correct based on its incorrect inputs, but since the inputs themselves are false, the entire quantitative analysis is invalid. The correct change is a $191 million decrease, or about a 24.2% decline, which is materially different. (3) The multi-hop reasoning failed: the model did not correctly extract or synthesize the actual values from the source data. It referenced a citation (page_85), but the numbers do not align with the ground truth, suggesting either misreading of the document or confusion with another metric/company. (4) The contextual relevance is low because it addresses the right metric and time frame (2022 to 2024 for acquired franchise rights), but with entirely incorrect data. Due to severe factual and quantitative errors, the correctness score is 1 — the answer is fundamentally wrong despite attempting the right type of analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1090,
        "completion_tokens": 388,
        "total_tokens": 1479
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Chevron's natural gas delivery commitments and production volumes related to Tengizchevroil evolve from 2023 to 2024?",
      "original_answer": "In 2023, Chevron reported that its natural gas volumes included 596 million cubic feet per day consumed in operations and 7,148 million cubic feet per day as sold, which included its share from Tengizchevroil in Kazakhstan. By 2024, these figures increased to 609 million cubic feet per day consumed and 7,569 million cubic feet per day as sold, indicating a growth in both operational consumption and market delivery. This reflects an increase in Chevron’s involvement and dependency on Tengizchevroil for natural gas production and delivery commitments.",
      "llm_answer": "In the 2023 filing Chevron pledged to deliver about 746 billion cubic feet of natural gas in the United States (and 2.9 trillion cubic feet from Australia and Israel) for the 2024‑26 period, whereas the 2024 filing raised the U.S. commitment to roughly 813 billion cubic feet (and the overseas commitment to 3.2 trillion cubic feet) and shifted the delivery window to 2025‑27.  Production from its Kazakhstan affiliate Tengizchevroil was essentially unchanged – oil‑equivalent output stayed at 45 MBD and crude oil at 26 MBD, with natural‑gas output slipping only slightly from 114 MMCFD in 2023 to 113 MMCFD in 2024.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and fails to address the actual data provided in the ground truth. (1) The numbers cited (e.g., 746 billion cubic feet, 813 billion cubic feet, 114 MMCFD, 113 MMCFD) do not appear in the original answer and are factually inconsistent with the ground truth. The original answer reports Chevron’s total natural gas volumes as 596 MMCFD consumed and 7,148 MMCFD sold in 2023, increasing to 609 MMCFD consumed and 7,569 MMCFD sold in 2024 — figures the LLM completely ignores. (2) The LLM incorrectly focuses on future delivery commitments (2024–26, 2025–27) and geographic breakdowns (U.S., Australia, Israel) that are not mentioned in the original answer. It also introduces oil-equivalent and crude oil production figures (45 MBD, 26 MBD) and a minor drop in Tengizchevroil gas output from 114 to 113 MMCFD, which contradicts the ground truth showing a significant increase in total sold gas volumes tied to Tengizchevroil. (3) The multi-hop reasoning is flawed: the original answer links increased total gas volumes (consumed and sold) to growing reliance on Tengizchevroil, while the LLM incorrectly asserts that Tengizchevroil’s gas output was 'essentially unchanged' or slightly down, missing the synthesis entirely. (4) The answer is contextually misaligned — it discusses forward-looking delivery pledges and regional commitments not in the source, while failing to report the actual year-over-year operational and sales volume changes that reflect evolving Tengizchevroil contributions. The only marginally relevant aspect is the mention of Tengizchevroil in Kazakhstan, but even that is used to support an incorrect conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 455,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the role of Google Network partners in Google's advertising revenue model evolved between 2023 and 2024, based on changes in the way payments to these partners are described?",
      "original_answer": "In 2023, Google Network partners were described as part of the primary uses of cash from operating activities, specifically noting payments made to these partners as a standard operating expense. By 2024, the description evolved to categorize payments to Google Network partners under Traffic Acquisition Costs (TAC), explicitly linking them to ads displayed on partner properties and tying them directly to revenue generation. This shift indicates a more strategic and performance-based dependency on these partners within the advertising ecosystem.",
      "llm_answer": "In the 2023 filing the company grouped payments to Google Network partners together with other traffic‑acquisition costs, noting that they were “amounts paid … primarily for ads displayed on their properties” (2023 10‑K p. 59). By the 2024 filing the language had shifted to treat those payments explicitly as a cost of revenue and to explain that Google now evaluates whether it is acting as a principal or an agent on Network ads – “amounts paid to Google Network partners are recorded as cost of revenues” and the principal‑agent distinction is described in the advertising‑revenue note (2024 10‑K p. 58). This change signals a more formal, transparent role for Network partners in Google’s ad model, moving from a generic TAC expense to a clearly identified cost‑of‑revenue component with principal‑agent accounting.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in how Google treats payments to Network partners between 2023 and 2024. In 2023, payments were grouped under traffic acquisition costs (TAC), described as amounts paid for ads on partner properties (citing 2023 10-K p.59), which matches the original answer's characterization as a standard operating expense within TAC. By 2024, the LLM correctly notes the shift to recording these payments as 'cost of revenues' and references the principal-agent accounting evaluation (citing 2024 10-K p.58), indicating a more formal integration into revenue recognition—consistent with the ground truth's emphasis on strategic, performance-based dependency. (2) There are no numerical values to verify, but dates (2023, 2024) and document references (10-K pages) are accurate and properly cited. (3) The multi-hop reasoning is sound: the model synthesizes changes in accounting language across two years, connects them to broader implications for Google's advertising model, and correctly interprets the move from TAC as an operating expense to cost of revenue under updated accounting guidance. (4) The only minor deviation from the original answer is that the LLM emphasizes the 'cost of revenue' reclassification and principal-agent analysis more than the ground truth, which focuses on the TAC linkage to revenue generation. However, both descriptions reflect a more strategic role for partners, and the LLM’s interpretation is factually supported and semantically consistent. Thus, the answer is slightly more detailed but not incorrect—just a different emphasis. Hence, a score of 9 is appropriate for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 491,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the impact of public policies on Bank of America's climate-related regulatory requirements evolved from 2023 to 2024, particularly in terms of jurisdictional divergence and compliance risks?",
      "original_answer": "In 2023, Bank of America highlighted increasing global regulatory focus on climate change, noting that new or heightened regulatory requirements across state, federal, and non-U.S. jurisdictions were expected to increase legal, compliance, and public disclosure risks and costs. The company specifically mentioned jurisdictional divergence as a challenge. By 2024, this concern intensified, with the company noting that existing and pending disclosure requirements in various jurisdictions, along with jurisdictional divergence, were now actively impacting legal, compliance, and public disclosure risks and costs. This indicates a shift from anticipation of increased risk to experiencing tangible impacts due to evolving public policies.",
      "llm_answer": "In the 2023 filing Bank of America warned that a “global regulatory focus on climate change and existing and pending disclosure requirements in various jurisdictions, with jurisdictional divergence, [was] expected to impact our legal, compliance and public‑disclosure risks and costs”【page_24】. By the 2024 filing the company notes that public‑policy frameworks have continued to fragment across jurisdictions, making the compliance burden “heightened” and further increasing the potential for legal and regulatory exposure and higher compliance costs【page_24】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original ground truth. (1) It correctly identifies that in 2023, Bank of America anticipated increased legal, compliance, and disclosure risks due to global regulatory focus and jurisdictional divergence in climate-related requirements, citing the correct context from page 24. In 2024, it accurately reflects the escalation of this issue, noting that policy fragmentation has heightened compliance burdens and increased regulatory exposure—consistent with the shift from anticipated to actual impact described in the ground truth. (2) There are no numerical values to verify (e.g., dollar amounts, percentages), but the years (2023 and 2024) and document references (page 24) are correctly cited, satisfying quantitative accuracy. (3) The multi-hop reasoning—comparing the evolution of risk perception from expectation in 2023 to experienced impact in 2024—is sound and well-synthesized across the two time points. The concept of 'jurisdictional divergence' is correctly maintained as a persistent challenge. (4) While the wording differs slightly, the semantic meaning matches the original answer. The only minor shortcoming is that the LLM does not explicitly use the phrase 'tangible impacts' or directly state the shift from 'anticipation' to 'experiencing' impacts as clearly as the ground truth, which slightly affects qualitative precision. However, the meaning is effectively conveyed. Thus, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 420,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has General Motors' strategic emphasis on full-size pickup trucks evolved from 2022 to 2024, and what quantitative indicators in 2024 suggest a shift toward stronger performance and market positioning for this product line?",
      "original_answer": "In 2022, General Motors identified the success of its full-size SUVs and full-size pickup trucks as a key risk factor, indicating that their performance was critical to the company's competitive position and financial health. By 2024, this strategic emphasis had evolved into a demonstrated strength, as evidenced by a significant increase in net wholesale volumes driven by higher sales of full-size pickup trucks. Additionally, the 2024 report highlights that full-size pickup trucks contributed favorably to the company's EBIT-adjusted results, with a variable profit of approximately 160% for trucks on a weighted-average basis, reflecting improved profitability and market demand for this product line.",
      "llm_answer": "In the 2022 Form 10‑K GM listed “the success of our current line of full‑size SUVs and **full‑size pickup trucks**” as a key risk factor and strategic priority, underscoring the need to sustain and grow that product line (2022 10‑K, p. 48). By the 2024 filing the narrative had shifted to reporting the trucks as a primary growth driver: GMNA wholesale vehicle sales rose 10.1 % to 3.464 million units, with full‑size truck volumes increasing to 224 k units (23.7 % of total) versus 210 k (21.9 %) a year earlier, and the favorable mix from those trucks cited as a major contributor to higher EBIT‑adjusted (2024 10‑K, p. 35‑36; truck‑specific residual‑value table, p. 32). These quantitative changes signal a move from a strategic focus on maintaining the line to demonstrable gains in sales volume, market share and profitability for full‑size pickups.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of GM's strategic emphasis from 2022, where full-size pickup trucks were a key risk factor and strategic priority, to 2024, where they became a growth driver—this matches the original answer’s narrative of a shift from risk to strength. (2) Quantitatively, the LLM provides specific figures: GMNA wholesale sales increased 10.1% to 3.464 million units, with full-size truck volumes rising from 210k to 224k units, representing 21.9% to 23.7% of total. While the ground truth does not specify these exact numbers, it confirms a 'significant increase in net wholesale volumes' and improved EBIT-adjusted results due to favorable mix—thus the LLM adds granular detail consistent with the broader trend. The mention of EBIT-adjusted improvement and favorable mix directly corresponds to the ground truth’s 'contributed favorably to EBIT-adjusted results'. (3) The reasoning is sound: it synthesizes information across 2022 and 2024 filings, correctly infers a strategic shift based on changing language and performance indicators, and supports it with volume and mix data. (4) The only minor limitation is that the LLM does not explicitly mention the '160% variable profit on a weighted-average basis' cited in the ground truth, which is a key quantitative indicator of profitability. While it references EBIT-adjusted gains and favorable mix, omitting this specific metric slightly reduces completeness. However, the overall factual correctness, contextual relevance, and logical flow remain strong. Number formats are consistent and correctly interpreted. Therefore, the answer earns a 9/10 for correctness, with high marks across all dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 476,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the allocation to U.S. Treasury and government agency securities within the nuclear decommissioning trusts evolve from 2022 to 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2022, the allocation to U.S. Treasury and government agency securities was $21 million for Alabama Power and $293 million for Georgia Power. By 2024, this allocation decreased slightly to $20 million for Alabama Power but increased significantly to $349 million for Georgia Power. The overall trend shows a shift in focus toward Georgia Power’s portfolio, indicating a possible reallocation of safer, fixed-income assets to that subsidiary.",
      "llm_answer": "In the 2022 filing the nuclear‑decommissioning trusts held roughly $314 million of U.S. Treasury and government‑agency securities (2022 10‑K, p. 310).  That balance rose to about $369 million at year‑end 2023 (2023 10‑K, p. 276) but by year‑end 2024 the trusts’ Treasury holdings had essentially vanished, with only a $9 million residual shown in the 2024 tables (2024 10‑K, p. 275).  The steep drop indicates Southern Company is moving away from low‑risk Treasury assets toward a more diversified, higher‑yielding portfolio for its decommissioning funds.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The ground truth specifies allocations for two subsidiaries—Alabama Power and Georgia Power—separately in 2022 and 2024. In 2022, Alabama Power held $21M and Georgia Power $293M, totaling $314M, which matches the LLM's 2022 figure. However, by 2024, the ground truth shows Alabama Power decreased to $20M and Georgia Power increased to $349M, resulting in a total of $369M. The LLM incorrectly states that Treasury holdings 'essentially vanished' with only $9M in 2024, which contradicts the ground truth of $369M total. This is a major factual error. (2) The LLM cites a $9M residual in 2024, which is not supported by the ground truth and appears to be a misreading of the data. Additionally, the LLM references a 2023 value of $369M, which aligns with the correct 2024 total in the ground truth, suggesting a misattribution of year. The timeline is thus distorted: the increase to $369M occurred by 2024, not 2023. (3) The multi-hop reasoning is flawed. The question asks about the evolution from 2022 to 2024 and what the shift indicates. The ground truth indicates a strategic shift toward Georgia Power’s portfolio, not an industry-wide move away from Treasuries. The LLM incorrectly infers a broader strategy of moving to higher-yielding assets due to a supposed divestment from Treasuries, which did not occur. (4) While the LLM attempts to address the question and correctly identifies the 2022 total, the severe inaccuracies in 2024 figures and misinterpretation of the trend justify a low correctness score. The contextual relevance is moderate because it discusses the right topic and trusts, but the conclusions are based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 476,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has PepsiCo's relationship with independent bottlers evolved from 2022 to 2024 in terms of financial incentives and strategic dependency?",
      "original_answer": "In 2022, PepsiCo provided sales incentives and discounts to independent bottlers primarily through funding of advertising and other marketing activities, with accruals based on annual targets and historical experience. By 2024, the company's relationship had evolved into a more structured dependency, with bottler funding negotiated annually and specifically allocated across trade and consumer programs such as advertising support, new product launches, and vending equipment placement. Additionally, in 2024, sales through independent bottlers contributed to a significant portion of revenue, with Walmart alone accounting for approximately 14% of consolidated net revenue, highlighting increased strategic dependency on these bottlers.",
      "llm_answer": "In 2022 PepsiCo’s filing described its link to independent bottlers mainly as a financial‑incentive program – “bottler funding” paid on an annual‑target basis and accrued as a reduction of revenue (2022 p. 60). By 2024 the company still provides bottler funding but adds that it grants bottlers exclusive manufacturing and distribution rights and relies on them for key accounts such as Walmart (≈14 % of net revenue), highlighting a much deeper strategic dependency (2024 p. 9; also 2024 p. 7).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: the use of bottler funding based on annual targets in 2022, continued funding in 2024 with deeper strategic integration, and Walmart accounting for approximately 14% of net revenue in 2024. The percentage (14%) and years (2022, 2024) are correctly cited. (2) Quantitative accuracy is perfect—no calculations were required, but the 14% figure is accurately reported and matches the ground truth. Format and precision are consistent. (3) The multi-hop reasoning is sound: the model correctly infers increased strategic dependency by linking exclusive rights, reliance on bottlers for major customers like Walmart, and ongoing funding mechanisms across two years. It synthesizes information from both 2022 and 2024 filings appropriately. (4) The only minor shortcoming is that the LLM omits some specific details about how funding is allocated in 2024—such as advertising support, new product launches, and vending equipment placement—mentioned in the original answer. However, it captures the essence of structured, negotiated funding and strategic dependency. Wording differs but semantic meaning is equivalent. Contextual relevance is excellent as it directly addresses both financial incentives and strategic dependency over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 370,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has Adobe Firefly's role within Adobe's product innovation strategy evolved from 2023 to 2024, based on its positioning in the company's trademark listings and risk disclosures?",
      "original_answer": "In 2023, Adobe Firefly was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Firefly was specifically highlighted in the risk factors section as a newly released generative AI product, reflecting its strategic importance in Adobe's innovation efforts. This evolution shows a shift from being a registered brand to becoming a central part of Adobe's forward-looking product development and AI strategy, with explicit mention of its role in addressing market demands for generative AI capabilities.",
      "llm_answer": "In the 2023 Form 10‑K Adobe listed “Firefly” in its trademark schedule, positioning it as a protected brand name among many of the company’s marks 【page_94】. By the 2024 filing, Firefly is called out in the risk‑factor section as a flagship generative‑AI product that drives Adobe’s AI‑focused innovation and carries regulatory, reputational and adoption risks 【page_23】—showing its shift from a mere trademark to a central element of Adobe’s product‑innovation strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Adobe Firefly was listed in the 2023 trademark schedule and highlighted in the 2024 risk factors as a generative AI product, indicating its growing strategic importance. The years (2023 vs 2024), entities (Adobe, Firefly), and document sections (trademark list, risk factors) are accurately identified. (2) There are no numeric values requiring calculation, so quantitative accuracy is not applicable beyond correct use of years, which are accurate. (3) The multi-hop reasoning is sound—correctly inferring that movement from a trademark listing to a risk factor disclosure signifies increased strategic importance, especially in the context of AI innovation and associated risks. The LLM correctly synthesizes information across two filings and sections to show evolution in strategic positioning. (4) The only minor shortcoming is the use of 'flagship' and 'drives Adobe’s AI-focused innovation,' which slightly amplifies the original answer’s more cautious 'central part' and 'strategic importance.' While reasonable, 'flagship' is a stronger characterization not explicitly confirmed in the ground truth. Otherwise, the answer is semantically equivalent, contextually relevant, and well-supported by the evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 367,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of contractual rent escalations in driving tenant billing growth changed between 2022 and 2023, particularly in light of the increased churn and lease cancellations in 2023?",
      "original_answer": "In 2022, contractual rent escalations were highlighted as a key factor contributing to tenant billing growth, listed alongside new colocation activity and lease amendments. By 2023, while contractual rent escalations remained a stated driver of growth, the context shifted due to an elevated churn rate of approximately 3%, primarily in the U.S. & Canada segment. This churn, expected to remain elevated through 2025 due to T-Mobile's lease cancellations, introduced a countervailing force against the positive impact of rent escalations, suggesting a more challenging environment for maintaining organic revenue growth solely through escalations.",
      "llm_answer": "In 2022 the filing simply notes that most of the company’s tenant leases contain automatic rent‑escalation provisions (about a 3 % fixed increase in the United States or an inflation‑linked index) that generate recurring billing growth, and it says churn had historically been immaterial【page_32】. By 2023 the MD&A still lists “contractual rent escalations on existing tenant leases” as a primary driver of tenant‑billing growth, but now qualifies it “net of churn” and discloses that churn rose to roughly 3 % of billings – largely from T‑Mobile lease cancellations – which dampens the net impact of those escalations on overall billing growth【page_35】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: in 2022, contractual rent escalations (3% fixed or inflation-linked) were a source of recurring growth with immaterial churn; in 2023, escalations remained a driver but were now presented net of churn, which rose to ~3%, primarily due to T-Mobile lease cancellations. (2) Quantitative accuracy is perfect: the 3% churn rate and 3% escalation rate are correctly reported, with proper context on geographic concentration (U.S. & Canada). (3) Multi-hop reasoning is sound—LLM correctly synthesizes changes over time, contrasting the unqualified positive role of escalations in 2022 with the qualified 'net of churn' framing in 2023, reflecting increased headwinds. (4) The answer fully addresses the question’s focus on how the role of escalations changed due to increased churn, including causality (T-Mobile cancellations) and forward-looking implications (elevated churn through 2025, though this specific forward view is implied in the LLM answer via context). Wording differs but meaning matches exactly. No errors in entities, years, or financial logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 330,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Chevron's (CVX) relationship with Tengizchevroil evolved between 2023 and 2024 in terms of capital expenditure commitments and production involvement?",
      "original_answer": "In 2023, Chevron indicated that nearly half of its Affiliate Capex, which was expected to be $3 billion in 2024, was allocated to Tengizchevroil's FGP/WPMP Project in Kazakhstan. By 2024, Chevron continued to highlight its production involvement with Tengizchevroil, noting that production volumes included Chevron's share from affiliates such as Tengizchevroil in Kazakhstan. While 2023 focused on capital commitments for project development, 2024 emphasized ongoing production contributions from the same entity, indicating a shift from investment to operational phase.",
      "llm_answer": "In 2023 Chevron’s affiliate‑capital spending was $3.5 billion, with a modest, unspecified portion directed to its stake in Tengizchevroil; for 2024 the company now expects $3 billion of affiliate capex and says “nearly half of Affiliate Capex is for Tengizchevroil’s FGP/WPMP Project in Kazakhstan” (≈ $1.5 billion) – a sharper, more‑focused investment in the joint‑venture (see 2024 10‑K p. 50).  At the same time Chevron’s share of Tengizchevroil’s output has been essentially unchanged, remaining at about 45 thousand barrels of oil‑equivalent per day in both 2023 and 2024 (see 2024 10‑K p. 9).",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its correctness. First, it incorrectly states that Chevron's 2023 affiliate capital spending was $3.5 billion; the original answer (ground truth) states that $3 billion was *expected in 2024*, with nearly half allocated to Tengizchevroil—there is no mention of a $3.5 billion figure for 2023 in the ground truth. This misrepresents the baseline capex amount and introduces a number not supported by the source. Second, while the LLM correctly notes that 'nearly half' of the $3 billion 2024 affiliate capex is for Tengizchevroil (~$1.5 billion), this inference, though reasonable, is not explicitly confirmed in the original answer, which only states the allocation without specifying the dollar amount. The LLM adds precision (≈$1.5 billion) not present in the ground truth, which is acceptable if implied, but becomes problematic when combined with the incorrect 2023 figure. Regarding production, the LLM claims Chevron's share was 'about 45 thousand barrels per day' in both years, but this specific production volume is not mentioned in the original answer—only that 2024 production volumes included Chevron's share from affiliates like Tengizchevroil. Thus, the introduction of a precise production figure lacks support. On qualitative accuracy, the LLM captures the evolving relationship—increased focus on Tengizchevroil in capex and continued production involvement—but frames it as a 'sharper, more-focused investment', which implies a comparative increase not clearly established in the ground truth. The shift from investment to operations is implied but not explicitly confirmed. Contextually, the answer is highly relevant, addressing both capital commitments and production across 2023–2024. However, the inclusion of unsourced numerical specifics and incorrect figures reduces factual reliability. Multi-hop reasoning is attempted but compromised by data inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 526,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the specificity of UPS's bond matching approach evolved in determining the discount rate for U.S. pension and postretirement benefit plans between 2023 and 2024?",
      "original_answer": "In 2023, UPS described using a bond matching approach to select specific bonds that would satisfy projected benefit payments, emphasizing its belief that this method reflects the process they would employ to settle pension and postretirement obligations. By 2024, the language evolved to place stronger emphasis on the bond matching approach as a guide for selecting bonds that align with projected benefit cash flows, without any material change in the mechanics of the method. However, the 2024 disclosure included a more precise statement indicating that the approach 'guides' the selection process, suggesting a subtle shift in how the policy is framed operationally, even though the underlying practice remained consistent.",
      "llm_answer": "UPS’s description of the bond‑matching method did not become more detailed – it stayed the same. Both the 2023 and 2024 filings say that UPS determines the discount rate for its U.S. pension and post‑retirement plans by using a bond‑matching approach that selects specific bonds that would satisfy the projected benefit payments, reflecting the process it would use to settle those obligations.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that UPS's description of the bond-matching approach 'stayed the same' between 2023 and 2024. The ground truth indicates a subtle but meaningful evolution in language and framing: while the underlying mechanics remained consistent, the 2024 disclosure shifted to state that the bond matching approach 'guides' the selection of bonds, reflecting a more precise operational framing. This nuance is entirely missing from the LLM response, which incorrectly asserts no change in description. There are no numerical values in this question, so quantitative accuracy is not applicable—however, the model correctly identifies the entities (UPS, U.S. pension and postretirement plans, bond-matching approach) and years (2023, 2024), supporting a high contextual relevance score. The reasoning is flawed because the model fails to detect the qualitative shift in disclosure language, indicating a failure in multi-hop reasoning across the two years’ filings. As a result, the answer lacks completeness and misrepresents the evolution of UPS’s disclosure, warranting a low correctness and qualitative accuracy score despite correct entity and context identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 339,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what financial impact did this change have on the company's sales and operating profit during this period?",
      "original_answer": "In 2022, helium was a supply input for Linde, indicating a supportive role in operations. By 2024, helium had a negative impact on operations, with a $32 million, or 2%, decrease in sales for the Other segment primarily due to lower volumes in global helium and LAMT. Additionally, helium-related costs contributed to downward pressure on operating profit, partially offset by an insurance recovery for LAMT. This reflects a shift from a neutral or positive relationship to one that posed operational challenges.",
      "llm_answer": "By 2022 Linde’s helium activities were not highlighted in the disclosed segments, but the 2024 filing lists “global helium wholesale” as part of the “Other” segment (2024 p. 28). The lower helium volumes in 2024 reduced Other‑segment sales by roughly $32 million (≈2 %) and, although helium‑related costs rose, insurance recoveries more than offset them, driving Other operating profit up $19 million (≈44 %) (2024 p. 28).",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the $32 million (≈2%) decrease in sales for the Other segment in 2024 due to lower helium volumes, which aligns with the ground truth. It also accurately references the 2024 filing and correctly locates the information in the 'Other' segment. However, there is a critical error in the operating profit assessment: the LLM claims that insurance recoveries 'more than offset' rising helium-related costs, leading to a $19 million (≈44%) increase in operating profit. This contradicts the ground truth, which states that helium had a negative impact on operating profit, with costs contributing to downward pressure—only partially offset by insurance recovery. The LLM incorrectly infers a net positive outcome on profit, when the truth indicates a net negative effect. This misrepresents the financial impact and reflects flawed multi-hop reasoning. While the sales impact is accurately reported, the profit analysis is factually incorrect, undermining the overall correctness. Entity identification (Linde, 2022–2024, helium, Other segment) and context are well-handled, and number formats are acceptable. The answer is relevant and addresses the evolution and financial impact, but the key conclusion about operating profit is wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 353,
        "total_tokens": 1594
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did Bank of America's unfunded capital contributions for renewable energy investments evolve between 2023 and 2024, and what was the corresponding change in recognized tax credits related to these investments?",
      "original_answer": "In 2023, Bank of America had unfunded capital contributions for renewable energy investments of $6.2 billion, and it recognized tax credits and other tax benefits of $4.0 billion. By 2024, the unfunded capital contributions decreased to $4.6 billion, and the recognized tax credits slightly declined to $3.9 billion. This indicates a reduction in the Corporation's near-term funding commitments to renewable energy projects, even as the tax benefits remained relatively stable.",
      "llm_answer": "Bank of America’s unfunded capital contributions for renewable‑energy equity investments fell from $6.2 billion at year‑end 2023 to $4.6 billion at year‑end 2024 – a reduction of about $1.6 billion【page_132】.  In the same period, the tax credits and other tax benefits recognized on those renewable‑energy investments declined from $4.0 billion in 2023 to $3.9 billion in 2024, a drop of roughly $0.1 billion【page_132】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key facts from the ground truth: unfunded capital contributions decreased from $6.2 billion in 2023 to $4.6 billion in 2024, and recognized tax credits declined from $4.0 billion to $3.9 billion. These values match the original answer exactly. (2) Quantitative accuracy is perfect: the $1.6 billion reduction in unfunded contributions ($6.2B - $4.6B) and the $0.1 billion drop in tax credits ($4.0B - $3.9B) are accurately calculated and reported. Number formats are consistent and acceptable. (3) The multi-hop reasoning is sound—information from two years and two financial metrics (unfunded contributions and tax credits) is correctly synthesized to describe the evolution across time. The LLM correctly links the two metrics across both years and reports changes accurately. (4) The answer is semantically equivalent to the ground truth, with slightly more emphasis on numerical changes but retaining all core information and implications. All entities (Bank of America, renewable energy investments, tax credits, correct years) are accurately identified. No factual, numerical, or reasoning errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 332,
        "total_tokens": 1573
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has General Motors' approach to fleet sales involving commercial fleet customers evolved from 2022 to 2024, particularly in terms of sales channels and profitability considerations?",
      "original_answer": "In 2022, General Motors highlighted that fleet transactions, especially sales to daily rental car companies, were generally less profitable compared to retail sales, and these vehicles were sold either directly or through the dealer network. By 2024, the company emphasized that fleet sales, including those to commercial fleet customers, were completed through the dealer network and in some cases directly with fleet customers, suggesting a more structured and possibly optimized approach to fleet sales. This evolution indicates a strategic shift toward balancing fleet sales with profitability by leveraging both direct and dealer-based channels.",
      "llm_answer": "In the 2022 filing GM noted that it sells vehicles to commercial‑fleet customers **both directly and through its dealer network** and that “certain fleet transactions, particularly sales to daily rental‑car companies, are generally **less profitable** than retail sales to end customers”【page_8】. By the 2024 filing the company still serves fleet customers, but stresses that **fleet sales are completed through the dealer network and, in some cases, directly with fleet customers**, without reiterating the profitability gap, suggesting a shift away from emphasizing lower‑margin fleet deals【page_103】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, GM sold fleet vehicles both directly and through dealers, and noted lower profitability for rental-car fleet sales compared to retail. By 2024, the company continued using both channels but emphasized that fleet sales were conducted through the dealer network and sometimes directly—consistent with the original answer. The observation that GM stopped reiterating the profitability gap suggests a strategic shift, which is a reasonable inference. (2) There are no numerical values requiring calculation (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised; dates (2022, 2024) are correct. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across two years and two filings, comparing channel strategies and profitability disclosures. The conclusion about a strategic shift is logically supported. (4) The only minor shortcoming is that the LLM does not explicitly state that the 2024 approach reflects a 'more structured or optimized' strategy as mentioned in the ground truth, slightly reducing qualitative completeness. However, the implication of strategic evolution is present. Wording differences do not affect semantic equivalence. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 385,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did PepsiCo's relationship with Sabra evolve between 2022 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2022, PepsiCo owned the Sabra brand as part of its joint venture portfolio. However, by 2024, PepsiCo no longer had full ownership but instead held a 50% equity stake, which was remeasured at fair value, resulting in a pre-tax gain of $122 million. This indicates that PepsiCo divested a portion of its ownership in Sabra during the intervening period, marking a strategic shift in its relationship with the brand.",
      "llm_answer": "In 2022 PepsiCo still owned a 50 % equity interest in the Sabra joint‑venture and, after re‑measuring that stake to fair value, recorded a pre‑tax gain of $122 million (about $92 million after‑tax) in its FLNA division【page_73】. By the 2024 filing, Sabra is no longer mentioned in the disclosed sections (pages 71‑75), indicating that PepsiCo has exited or otherwise reduced its ownership, so the equity‑revaluation gain disappears and no further financial impact from Sabra is reported.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the timeline and ownership structure. The original answer states that in 2022, PepsiCo *owned* Sabra as part of its joint venture portfolio, implying more than a 50% stake initially, and by 2024 held a 50% stake after divesting part of its ownership. In contrast, the LLM claims PepsiCo already had a 50% stake in 2022, which contradicts the ground truth. This misrepresents the evolution of the relationship. (2) Quantitatively, the $122 million pre-tax gain is correctly reported, as is the approximate after-tax figure (though this detail is not in the ground truth, it doesn't contradict it). However, the key percentage change — from full or majority ownership to 50% — is inverted in timing and direction. The LLM incorrectly assumes the 50% stake existed in 2022 and implies exit by 2024, while the truth is the 50% stake resulted from the 2023 transaction reported in the 2024 filing. (3) The multi-hop reasoning is flawed: the LLM infers from absence on pages 71–75 in 2024 that PepsiCo exited Sabra, but the ground truth confirms continued 50% ownership. This misinterpretation of document silence leads to an incorrect conclusion. The actual evolution — partial divestiture with remeasurement gain — is misrepresented as a full exit. (4) Despite these major errors, the answer is contextually relevant and attempts to address both the relationship change and financial impact. It correctly identifies the $122M gain and ties it to equity remeasurement, showing partial understanding. However, due to core factual and directional errors in ownership timeline, the correctness score is low. Quantitative accuracy is moderate due to correct dollar amount but incorrect framing. Qualitative accuracy suffers from flawed logic and entity-state tracking.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 499,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Adobe's treatment of Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's product ecosystem?",
      "original_answer": "In 2023, Adobe Scan was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Scan was explicitly positioned as part of Adobe Document Cloud, which includes Acrobat, Acrobat Sign, and other apps and API services that support digital document and signature workflows. This evolution shows a shift from mere trademark recognition to a more integrated and strategically emphasized role within Adobe’s broader document management and productivity offerings.",
      "llm_answer": "In the 2023 Form 10‑K (exhibit pages 94‑98) Adobe Scan is not described or highlighted at all, appearing only in the generic exhibit listings. By the 2024 Form 10‑K (page 13), Adobe Scan is called out as a free mobile‑scanning app that “captures paper documents … and transforms them into full‑featured PDFs via Adobe Document Cloud services,” and is listed alongside Acrobat and Acrobat Reader as a separate, cloud‑enabled offering within the Adobe Document Cloud suite. This shift shows Adobe moving Scan from an unmentioned component to a distinct, integrated product positioned as a free, stand‑alone app within the Document Cloud ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2023, Adobe Scan was not described in detail but only appeared in trademark listings (exhibits 94–98 of the 10-K), which matches the original answer’s point about it being a listed trademark. In 2024, it accurately notes that Adobe Scan was explicitly described on page 13 as a free mobile app integrated with Adobe Document Cloud, transforming paper documents into PDFs—this reflects the strategic integration emphasized in the ground truth. (2) There are no numeric values to verify, so quantitative accuracy is not applicable beyond correct referencing of document pages (e.g., page 13, exhibits 94–98), which are factually consistent with typical 10-K structures. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly inferring a shift in strategic positioning from passive trademark listing to active product integration within Document Cloud. (4) The only minor shortcoming is that the LLM does not explicitly name Acrobat Sign or API services as part of the Document Cloud suite, slightly reducing completeness compared to the original answer. However, mentioning Acrobat and Acrobat Reader as part of the ecosystem captures the core idea. Wording differs but semantic meaning and factual content are equivalent. Thus, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 410,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has General Motors' financial exposure and nature of obligations to Stellantis evolved from 2022 to 2024, particularly regarding indemnifications and historical liabilities?",
      "original_answer": "In 2022, General Motors continued to have supply-related transactions with Stellantis following the sale of the Opel/Vauxhall business, indicating an ongoing operational relationship. By 2024, the nature of GM's exposure to Stellantis had shifted from operational supplies to financial guarantees and indemnifications tied to legacy liabilities. Specifically, GM had agreed to indemnify Stellantis for certain emissions-related lawsuits, Takata-related recalls, and potential penalties from European regulatory investigations into end-of-life vehicle practices. Additionally, as of December 31, 2024, GM had accrued an immaterial amount related to these matters, showing a continued but reduced financial exposure compared to earlier liabilities. This reflects a transformation from active supply chain involvement to a more passive, indemnification-based financial relationship.",
      "llm_answer": "In the 2022 filing GM said that its wholly‑owned Seller would indemnify Stellantis for any losses arising from inaccurate representations, warranty breaches, emissions‑related claims and other product‑liability matters, but it could not estimate the amount and only noted that the obligations were subject to time limits, thresholds and caps【page_89】. By the 2024 filing the same indemnification framework remains, but GM now discloses that it has already paid an immaterial amount for certain Stellantis recalls (including Takata inflator recalls) and that the maximum future undiscounted payments for the indemnification agreements total about $3.7 billion (2024) – up from $3.5 billion a year earlier – while still being unable to estimate any material loss【page_93】【page_94】. This shows that GM’s exposure has become more quantified and now includes specific historical recall liabilities, though the core nature of the indemnities has not changed.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core theme of GM's evolving indemnification obligations to Stellantis, correctly identifying emissions-related claims, product liability, and Takata recalls as key components. It appropriately notes the continuation of indemnification terms from 2022 to 2024 and the immaterial accruals. However, there are significant quantitative inaccuracies: the LLM claims GM disclosed 'maximum future undiscounted payments' of $3.7 billion in 2024 (up from $3.5 billion), but this figure does not appear in the ground truth and contradicts the statement that exposure is immaterial. The ground truth emphasizes that GM accrued only an immaterial amount and implies limited financial exposure, whereas the LLM suggests a $3.7B liability, which is a material figure and factually inconsistent. This undermines the quantitative accuracy. The entity identification (GM, Stellantis, Takata, emissions lawsuits) and timeline (2022 to 2024) are correct. The reasoning partially reflects the shift from operational to indemnification-based exposure but overemphasizes financial magnitude. The LLM introduces a 'maximum future undiscounted payments' metric not present in the ground truth, likely misinterpreting or fabricating a number. While the qualitative shift is acknowledged, the financial characterization is misleading. Semantic equivalence fails on the key point of materiality. Contextual relevance is high as the answer addresses indemnifications, historical liabilities, and evolution over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1465,
        "completion_tokens": 415,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has PepsiCo's relationship with co-packers evolved between 2022 and 2024, particularly in terms of operational dependency and strategic involvement?",
      "original_answer": "In 2022, PepsiCo described its relationship with co-packers as part of a 'highly distributed network of plants, warehouses and distribution centers' that are owned or leased by these third parties, indicating an operational dependency. By 2024, the company's language shifted to emphasize co-packers as part of 'strategic alliances or joint ventures in which we have an equity interest,' suggesting a more active and ownership-based strategic involvement. This evolution reflects a shift from a primarily operational partnership to a more integrated and strategic stake in co-packers.",
      "llm_answer": "In the 2022 Form 10‑K PepsiCo disclosed that, beyond its owned and long‑term‑leased plants, it “utilizes a highly distributed network of plants, warehouses and distribution centers that are owned or leased by our contract manufacturers, **co‑packers**, strategic alliances or joint ventures” to meet its production needs【page_27】. The 2024 Form 10‑K repeats the same language, indicating that PepsiCo still relies on co‑packers as part of that distributed network and continues to involve them through strategic alliances and equity‑joint‑venture interests, with no material change in its operational dependency or strategic role【page_30】.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core conclusion, despite citing correct document sources and using accurate phrasing from the filings. The original answer (ground truth) states that PepsiCo's language evolved between 2022 and 2024—from describing co-packers as part of a 'highly distributed network' (indicating operational dependency) to framing them within 'strategic alliances or joint ventures in which we have an equity interest' (indicating deeper strategic involvement). However, the LLM claims the 2024 10-K 'repeats the same language' as 2022 and concludes there was 'no material change,' which directly contradicts the ground truth. This represents a critical failure in multi-hop reasoning: the model should have detected a shift in emphasis or wording across years, but instead assumed consistency. While all cited page numbers and entity names (PepsiCo, co-packers, 10-K forms) are accurate, and there are no numerical inaccuracies (hence full quantitative accuracy), the qualitative analysis is flawed. The model failed to identify the evolution in strategic framing, misrepresenting the nature of the relationship's progression. Contextual relevance is moderate because the response discusses the right topic and cites relevant sections, but it draws the opposite conclusion of the ground truth, severely undermining correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 375,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did SPG's financial relationship with ABG evolve between 2023 and 2024, particularly in terms of gains recognized and strategic investments?",
      "original_answer": "In 2023, SPG recognized multiple non-cash pre-tax gains related to its relationship with ABG, including $59.1 million from deemed disposals due to ABG's capital transactions and $157.1 million from the sale of a portion of its ABG interests. Additionally, SPG recorded a $145.8 million gain from the dilution of its ownership in SPARC Group. In 2024, SPG disclosed a pre-tax gain of $18.8 million from the sale of a portion of its ABG interest in December 2021, along with a strategic partnership with ABG to become the core licensee and operating partner for Reebok in the U.S., indicating a shift toward deeper operational collaboration rather than just financial transactions.",
      "llm_answer": "In 2023 Simon Property reduced its ABG holding, selling a portion of its interest for a cash pre‑tax gain of $157.1 million and, after ABG’s capital‑transaction‑driven dilution, recorded a non‑cash pre‑tax gain of $59.1 million, cutting its ownership from 12.3% to ≈9.6%【page_65】【page_64】. By 2024 Simon exited the partnership entirely, selling its remaining ABG stake for $1.2 billion and recognizing a $414.8 million pretax cash gain (plus a $10.3 million non‑cash gain from a concurrent dilution), thereby ending its strategic investment in ABG【page_73】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies the $157.1 million gain from the sale of a portion of SPG's ABG interest and the $59.1 million non-cash gain from ABG's capital transactions in 2023, it incorrectly claims that SPG exited its ABG investment entirely in 2024 for $1.2 billion with a $414.8 million gain. This contradicts the ground truth, which states that in 2024, SPG only disclosed an $18.8 million gain from the sale of a portion of its ABG interest in *December 2021* (not 2024), and emphasized a new strategic partnership with ABG for Reebok, indicating continued and deepening collaboration—not an exit. The $414.8 million gain and $1.2 billion sale are entirely fabricated and not supported by the original answer. Additionally, the claim of a $10.3 million non-cash gain from dilution in 2024 is incorrect. (2) Quantitative accuracy is severely compromised: the only correct numbers are the 2023 gains ($157.1M and $59.1M). The 2024 figures ($414.8M gain, $1.2B sale, $10.3M gain) are all false. The ground truth reports only an $18.8M gain in 2024, related to a 2021 transaction. (3) The multi-hop reasoning is flawed: instead of recognizing the shift from financial gains to strategic operational partnership in 2024, the model incorrectly infers a full exit, reversing the actual strategic direction. It fails to mention the Reebok partnership, a key qualitative shift. (4) Scores reflect major factual errors in numbers and strategic interpretation, though the answer is contextually relevant in discussing SPG-ABG financial evolution and attempts to address gains and investments. However, the core 2024 narrative is factually inverted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 468,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Lockheed Martin's involvement in Sikorsky helicopter programs evolved from 2022 to 2024, particularly in terms of production volume and program scope?",
      "original_answer": "In 2022, Lockheed Martin's RMS segment experienced a $560 million increase in product costs, partly due to higher production volume on various Sikorsky helicopter programs. By 2024, RMS explicitly listed Sikorsky helicopter programs—such as those related to the Black Hawk, Seahawk, and CH-53K King Stallion—as key components of its portfolio, indicating a continued and potentially expanded focus. This evolution reflects a shift from being a cost driver to being a clearly defined strategic product line within the RMS segment.",
      "llm_answer": "In the 2022 filing Lockheed Martin said that higher production volume on several Sikorsky platforms – the Black Hawk, Seahawk, CH‑53K King Stallion and Combat‑Rescue Helicopter – lifted RMS product sales by about $735 million and added roughly $560 million of product‑costs【page_42】【page_43】. By the 2024 filing the same helicopter families remain core RMS programs, but the scope has broadened to include the VH‑92A Marine One presidential helicopter, with the final aircraft delivered in 2024, reflecting an expansion beyond pure volume growth to a new high‑profile program【page_4】【page_5】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the $560 million increase in product costs is correctly cited from the 2022 filing, and the $735 million lift in sales is an additional detail not in the original answer but does not contradict it—this figure likely represents the revenue impact while $560M reflects cost increase, both plausible and consistent. The mention of final VH-92A delivery in 2024 is factually correct and supports the claim of expanded program scope. (2) The entities—Lockheed Martin, RMS segment, Sikorsky programs (Black Hawk, Seahawk, CH-53K, Combat Rescue Helicopter, VH-92A)—are all accurately named and correctly associated with the relevant timeframes. (3) The reasoning is sound: the LLM correctly infers evolution not just in volume (2022) but in strategic scope (2024), identifying the addition of the high-profile VH-92A program as evidence of broadened focus—this constitutes valid multi-hop synthesis across years and programs. (4) The original answer notes a shift from cost driver to strategic product line; the LLM enhances this by specifying a new program (VH-92A) as proof of expansion, adding value without error. The only minor gap is that the original emphasizes the 'listing as key components' in 2024, while LLM focuses on VH-92A delivery—both valid, but LLM slightly narrows the scope of evidence. Overall, the answer is factually correct, well-supported, and contextually complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 405,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Walmart's ownership stake and financial investment in Alert Innovation evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, increasing its ownership to approximately 100%. By fiscal 2024, there was no mention of Walmart retaining ownership of Alert Innovation, indicating that the company had fully exited its stake, likely through a sale or divestiture.",
      "llm_answer": "In fiscal 2023 Walmart completed a $0.4 billion acquisition of Alert Innovation, which gave it roughly 100 % ownership of the company【page_45】.  The 2024 filing does not record any additional purchase or sale of Alert Innovation – the “Purchases and Sales of Subsidiary Stock” table lists only Flipkart and PhonePe and makes no mention of Alert Innovation – indicating that Walmart retained the full 100 % stake and the $0.4 billion investment remained unchanged through fiscal 2024【page_65】.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states the $0.4 billion acquisition and 100% ownership in fiscal 2023, which matches the ground truth. However, it incorrectly concludes that Walmart retained the full stake in fiscal 2024, directly contradicting the ground truth that Walmart had exited its stake. The absence of Alert Innovation in the 'Purchases and Sales of Subsidiary Stock' table does not confirm continued ownership—it could also indicate a divestiture not detailed in that specific table. The LLM misinterprets silence in the filing as evidence of no change, which is a flawed inference. (2) Quantitatively, all numbers ($0.4 billion, 100%) are accurate and correctly formatted. (3) The multi-hop reasoning fails: while the model identifies relevant data points (acquisition in 2023, absence in 2024 table), it draws the opposite conclusion of the ground truth. It does not recognize that lack of mention in a transaction table may signal a divestiture, especially when prior ownership was full. This reflects a critical error in financial document interpretation. (4) Contextual relevance is moderate—the answer addresses the right companies and timeframes and cites relevant sections, but the core conclusion about ownership evolution is factually incorrect. The answer should have inferred exit from absence post-acquisition, not continued ownership.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1195,
        "completion_tokens": 379,
        "total_tokens": 1574
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did SPG's utilization and management of the Supplemental Facility evolve between 2023 and 2024, particularly in terms of borrowing activity and repayment strategy?",
      "original_answer": "In 2023, SPG utilized the Supplemental Facility as part of its broader capital strategy, borrowing €750.0 million under this facility, which was later repaid on November 17, 2023, following the issuance of senior unsecured bonds. By 2024, there was no outstanding balance under the Supplemental Facility, indicating a full repayment and a shift away from its use. This evolution shows a strategic reduction in reliance on the Supplemental Facility, with SPG opting instead to refinance through long-term unsecured notes, such as the $1.0 billion issuance in September 2024.",
      "llm_answer": "In 2023 Simon Property Group carried a €750 million balance on its Supplemental Facility, which it refinanced and fully repaid in November 2023 – the repayment was funded with proceeds from a €750 million senior unsecured bond issuance and the related Euro‑denominated interest‑rate swaps were terminated (see page 61). By 2024 the company had not drawn on the Supplemental Facility at all; the facility remained available with a $3.5‑$4.5 billion borrowing capacity but no new borrowings were recorded, indicating a shift from active borrowing to a standby‑liquidity posture (see pages 68‑69).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the €750 million borrowing under the Supplemental Facility in 2023 and its full repayment in November 2023, funded by a €750 million senior unsecured bond issuance—this matches the ground truth. It accurately states that by 2024, there were no new borrowings and no outstanding balance, aligning with the original answer's claim of zero utilization. The mention of the facility’s $3.5–$4.5 billion capacity and its shift to a standby-liquidity role adds contextual detail not in the ground truth but does not contradict it. (2) All numbers—€750 million, November 2023 repayment, no 2024 drawdowns—are factually correct and consistent with the original. Currency formats (€ vs $) are appropriately used. The 2024 $1.0 billion bond issuance in the original answer is not mentioned in the LLM response, which is a minor omission but does not impair the core accuracy regarding the Supplemental Facility’s utilization. (3) The multi-hop reasoning is sound: the model connects the 2023 borrowing, repayment timing, funding source (bond proceeds), and the 2024 inactivity to infer a strategic shift—this synthesis is valid and supported. (4) The LLM answer conveys the same core evolution: from active use in 2023 to full repayment and non-use in 2024, indicating reduced reliance. The added detail about the facility’s availability enhances rather than detracts. The only minor gap is the lack of reference to the $1.0 billion September 2024 unsecured note issuance, which the original answer cites as evidence of refinancing strategy. However, the LLM still correctly infers the strategic pivot. Thus, the answer is highly accurate, complete on key points, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 472,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has Linde's treatment of helium in its industrial gases business evolved between 2023 and 2024, particularly in terms of its positioning as a primary product and associated supply strategies?",
      "original_answer": "In 2023, helium was explicitly listed as one of Linde's primary products within its industrial gases business, specifically called out alongside gases like oxygen, nitrogen, and hydrogen. The 2023 filing also described helium's distribution through merchant delivery, with contracts typically lasting three to seven years and without minimum purchase requirements. By 2024, helium was no longer specifically named as a distinct product in the industrial gases segment. Instead, it was subsumed under more general descriptions of gas supply methods and contracts, suggesting a reduced emphasis on helium as a standalone offering. This shift indicates a strategic repositioning of helium within Linde's broader gas portfolio, aligning it more closely with other merchant gases rather than maintaining its prior distinct status.",
      "llm_answer": "Both the 2023 and 2024 10‑K filings continue to list helium as a core “process gas” in Linde’s industrial‑gases portfolio 【page_100】【page_87】.  In each year helium is highlighted as a product that is most often supplied through the merchant bulk‑liquid channel—shipped long distances under three‑to‑seven‑year supply agreements that do not contain minimum‑purchase or volume commitments—while also being available via on‑site plants under long‑term total‑requirement contracts.  The 2024 filing repeats this description, showing no material change in helium’s positioning or supply strategy from 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that helium was listed as a core 'process gas' in both 2023 and 2024 filings, and that there was no material change. According to the ground truth, helium was explicitly named as a primary product in 2023 alongside oxygen, nitrogen, and hydrogen, but in 2024 it was no longer specifically mentioned as a distinct product and was instead subsumed under general gas descriptions—indicating a strategic repositioning. The LLM incorrectly asserts continuity, directly contradicting the documented shift. While the description of supply methods (merchant delivery, contract lengths, no minimums) is consistent with the 2023 data and correctly formatted, the failure to detect the removal of helium as a named product in 2024 represents a critical qualitative error. This undermines the multi-hop reasoning required to assess evolution between years. The answer is contextually relevant to the question and uses plausible formatting with citation placeholders, but the central conclusion is false. Quantitative elements (e.g., 3–7 year contracts) are accurately reported where present, hence a moderate score there, but overall correctness is low due to the failure to identify a key strategic change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 348,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the allocation of assets in the U.S. Retiree Health Care Plan evolve between 2022 and 2023, particularly in terms of fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had $248 in fixed income securities and cash equivalents and $137 in equity securities, totaling $385. In 2023, the plan's allocation changed to $210 in fixed income securities and cash equivalents and $54 in equity securities, totaling $264. This indicates a decrease in both categories, with a more significant reduction in equity securities.",
      "llm_answer": "The U.S. Retiree Health Care Plan moved sharply toward bonds and cash. In 2022 the plan was about 65 % fixed‑income (≈ $182 million) and 35 % equity (≈ $98 million) 【page_48】, but by 2023 the mix had shifted to roughly 80 % fixed‑income (≈ $210 million) and 20 % equity (≈ $54 million) 【page_47】. The weighted‑average allocation table confirms the same change – fixed‑income rose from 65 % to 80 % and equity fell from 35 % to 20 % 【page_45】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, in 2022 the plan had $248 in fixed income securities and cash equivalents and $137 in equity securities (totaling $385), not $182 and $98 as stated by the LLM. The 2023 figures are partially correct: $210 in fixed income and $54 in equity match the ground truth, but the percentages cited (80%/20%) are based on an incorrect total if using the LLM's own 2022 numbers. (2) Calculations are flawed: the LLM claims 65% fixed income in 2022 (≈$182M), but $182/$385 ≈ 47.3%, not 65%. Similarly, $248/$385 ≈ 64.4%, which rounds to 64%, not 65%. While the 2023 percentages (210/264 ≈ 79.5% → 80%; 54/264 ≈ 20.5% → 20%) are approximately correct based on ground truth totals, the LLM uses incorrect 2022 totals to derive its percentages. (3) The reasoning is partially sound in identifying a shift toward fixed income and away from equities, which aligns with the ground truth trend. However, the multi-hop synthesis is flawed because it misrepresents the 2022 allocation values and thus distorts the magnitude of change. (4) Contextually, the answer addresses the evolution of asset allocation and focuses on fixed income and equity securities as asked. Despite incorrect base numbers, the directional conclusion (shift toward fixed income) is correct. However, the significant numerical errors in the 2022 breakdown severely undermine factual accuracy, warranting a low correctness score. The model appears to have misread or miscalculated the 2022 allocation values, leading to cascading errors in percentages and comparisons.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 446,
        "total_tokens": 1659
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial performance and strategic positioning of Trodelvy evolve between 2022 and 2023, particularly in terms of revenue generation and regulatory milestones?",
      "original_answer": "In 2022, Trodelvy generated $380 million in total product sales, primarily in the U.S., indicating its early commercial presence. By 2023, there was a strategic shift in Trodelvy's positioning as it received significant regulatory approvals: FDA approval for treating HR+/HER2- metastatic breast cancer and EC approval for a similar indication. These developments suggest a strong enhancement in its market potential and therapeutic footprint, although specific revenue figures for 2023 are not provided.",
      "llm_answer": "Trodelvy’s sales surged 56 % year‑over‑year, climbing from $680 million in 2022 to $1.06 billion in 2023 as demand expanded across new and existing geographies【page_40†L31-L38】【page_41†L1-L3】.  The 2023 filing highlights the drug’s strategic advance – it received both FDA and European Commission approvals for use as a monotherapy in HR‑positive/HER2‑negative breast cancer (adding a new label to its earlier triple‑negative indication) and, although the Phase 3 EVOKE‑01 trial missed its overall‑survival primary endpoint, it showed an encouraging trend in a patient subgroup【page_38†L13-L20】【page_39†L4-L9】.  No comparable new regulatory events were reported for Trodelvy in the 2022 filing, underscoring that the key label expansions occurred in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in financial figures. The ground truth states that Trodelvy generated $380 million in 2022, but the LLM claims $680 million, which is nearly double the correct amount. Consequently, the reported 56% year-over-year growth and $1.06 billion in 2023 revenue are entirely incorrect, as no 2023 revenue figures are provided in the original answer. These quantitative errors severely undermine the factual correctness of the response. (2) The calculation of 56% growth from $680M to $1.06B is mathematically accurate (approximately 55.9%), but since the base numbers are wrong, the entire financial narrative is false. The original answer explicitly states that 2023 revenue figures are not available, making the LLM's precise dollar amounts and growth rate fabricated. (3) On qualitative aspects, the LLM correctly identifies key regulatory milestones in 2023: FDA and European Commission approvals for HR+/HER2- metastatic breast cancer, which aligns with the ground truth. It also correctly notes that no comparable regulatory events occurred in 2022, supporting the idea of a strategic shift in 2023. However, the mention of the EVOKE-01 trial missing its primary endpoint introduces information not present in the original answer, adding unsupported detail. (4) Despite the incorrect numbers, the LLM captures the strategic evolution of Trodelvy through regulatory approvals, which is contextually relevant and addresses part of the question correctly. However, the severe quantitative inaccuracies—especially inventing revenue data—result in a low correctness score. The model fails the core multi-hop requirement of accurately synthesizing financial and regulatory data across years, with the financial data being completely inconsistent with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 495,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Chevron's downstream-related earnings and investment relationship with GS Caltex evolve from 2022 to 2024, and what does this indicate about the strategic importance of the joint venture?",
      "original_answer": "In 2022, Chevron reported higher downstream-related earnings from GS Caltex in Korea, contributing to improved income from equity affiliates. By 2024, Chevron maintained a 50% ownership stake in GS Caltex Corporation, which operates as a joint venture with GS Energy, importing, producing, and marketing petroleum products, petrochemicals, and lubricants. Additionally, in 2024, Chevron reported $13,850 million in sales and other operating revenues with affiliated companies, including GS Caltex, compared to $16,286 million in 2022. This indicates that while the joint venture remained strategically important, the level of downstream-related revenue with affiliated companies slightly decreased over the period.",
      "llm_answer": "In 2022 Chevron’s downstream segment contributed about $1.97 billion of equity earnings, with the 50 %‑owned GS Caltex joint‑venture accounting for roughly $874 million of that; by 2024 total downstream equity earnings had slipped to about $1.02 billion and GS Caltex’s share fell to only $58 million, even though Chevron still carries a roughly $4.1 billion investment in the JV. The steep drop in earnings but the continued sizable stake shows the joint‑venture is still viewed as a strategic foothold for Chevron in Korea and the broader Asian downstream market, despite its diminished short‑term profitability.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, Chevron reported higher downstream earnings from GS Caltex in 2022 and maintained a 50% ownership stake in 2024, but there is no mention of a drop in GS Caltex's equity earnings from $874 million to $58 million. In fact, the ground truth states that Chevron reported $13,850 million in sales and other operating revenues with affiliated companies in 2024 versus $16,286 million in 2022, indicating a decline in affiliated revenues but not a collapse in equity earnings to $58 million. The LLM introduces specific figures for downstream equity earnings and GS Caltex's contribution that are not present in the ground truth and appear fabricated. (2) The numbers cited—$1.97 billion total downstream equity earnings in 2022, $874 million from GS Caltex, $1.02 billion in 2024, and $58 million from GS Caltex—are entirely absent from the original answer and contradict the only revenue figures provided: $16,286 million (2022) and $13,850 million (2024) in sales and other operating revenues with affiliated companies. These are not equity earnings and are much larger in magnitude, indicating a fundamental misrepresentation of financial metrics. The $4.1 billion investment figure is also not mentioned in the ground truth. (3) The multi-hop reasoning is flawed. While the LLM attempts to infer strategic importance from sustained investment despite declining earnings, this narrative is built on false quantitative premises. The actual ground truth emphasizes continued strategic importance due to maintained ownership and ongoing operations, not declining profitability. (4) The contextual relevance is moderate because the answer addresses the evolution of the Chevron-GS Caltex relationship and attempts to assess strategic importance. However, due to severe quantitative and qualitative inaccuracies, the overall correctness score is very low. The answer creates a misleading narrative unsupported by the source data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 543,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the financial performance and production status of the CH-53K program evolve from 2022 to 2024, particularly in terms of risk retirements and production volume?",
      "original_answer": "In 2022, the CH-53K program contributed to higher operating profit for Sikorsky helicopter programs, with approximately $140 million in increased profit driven by higher risk retirements and production volume. By 2024, while the CH-53K remained a key product within RMS, the overall operating profit for RMS declined significantly—by 73%—partially due to lower profit booking rate adjustments across the portfolio. Although specific profit figures for CH-53K were not disclosed in 2024, the broader profit decline suggests that the gains from risk retirements observed in 2022 may have diminished as the program matured and entered higher-volume production.",
      "llm_answer": "In the 2022 Form 10‑K the CH‑53K was noted as a source of **higher risk‑retirements** that lifted RMS operating profit (about $140 million of the profit increase) – the filing highlighted risk‑retirement gains rather than a production surge for the helicopter【page_50】. By the 2024 Form 10‑K the story had shifted: the CH‑53K’s **production volume rose**, contributing roughly $140 million of net‑sale revenue in 2024, while risk‑retirement benefits were no longer called out as a primary driver of profit【page_40】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies that in 2022 the CH-53K program contributed approximately $140 million in higher operating profit due to risk retirements (supported by the 2022 10-K, page 50), it incorrectly states that in 2024 the program generated 'roughly $140 million of net-sale revenue'—this figure is not present in the ground truth and misrepresents the financial data. The original answer notes that no specific profit figures for CH-53K were disclosed in 2024, and that RMS operating profit declined by 73%, but the LLM falsely introduces a $140 million net-sale revenue figure not mentioned in the ground truth or supported by typical 10-K disclosures for this program. (2) The quantitative accuracy is low because the reuse of '$140 million' in 2024 as 'net-sale revenue' is unsupported and misleading—it conflates profit impact with sales revenue, which are distinct metrics. The 73% decline in RMS operating profit, a key quantitative point in the ground truth, is omitted entirely. (3) The reasoning is partially sound in identifying a shift from risk retirements to production volume as a focus, aligning with program maturation. However, the model fails to correctly synthesize the broader context: the decline in RMS profit suggests diminishing incremental gains from risk retirements, not a clean handoff to production-driven revenue. The multi-hop synthesis is flawed because it invents a revenue figure instead of acknowledging data gaps and inferring cautiously. (4) Contextual relevance is high because the answer addresses both risk retirements and production volume across 2022–2024 and references the correct program and segment (RMS). However, the introduction of an unsupported financial figure severely undermines factual correctness, warranting a low overall score despite relevant structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 512,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has PayPal's approach to seller protection programs evolved between 2022 and 2023, particularly in terms of risk exposure and strategic emphasis?",
      "original_answer": "In 2022, PayPal highlighted that its seller protection programs carried risk exposure tied to regional variations and regulatory changes, with historical transaction loss rates ranging between 0.09% and 0.15% of TPV. By 2023, the company placed a stronger strategic emphasis on these programs as a competitive differentiator, explicitly linking them to merchant trust and platform growth. While 2022 focused on risk management and potential loss implications, 2023 framed seller protection as part of a broader value proposition to attract and retain merchants, integrating it with analytics, risk management, and other merchant services.",
      "llm_answer": "In 2022 PayPal treated seller‑protection mainly as a risk‑management cost, reporting that losses from its buyer and seller protection programs averaged only 0.09 %–0.15 % of total payment volume and were reflected in its transaction‑loss allowances (2022 10‑K Customer protection programs, p. 51; Allowance for transaction and credit losses, p. 53). By 2023 the company had made seller‑protection a strategic pillar, stressing proprietary, data‑driven protection programs that actively reduce merchant losses, investing in technology and positioning these programs alongside its broader risk‑management and merchant‑value offerings (2023 10‑K Protecting merchants and consumers, p. 9; Merchant value proposition, p. 7; Strategy, p. 10).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution in PayPal's approach to seller protection between 2022 and 2023. In 2022, it accurately describes the focus on risk management and quantifies the loss rate as 0.09%–0.15% of TPV, matching the ground truth. In 2023, it correctly identifies the shift toward strategic emphasis, framing seller protection as a competitive differentiator tied to merchant trust and platform value. The use of terms like 'strategic pillar,' 'data-driven protection programs,' and integration with broader merchant services aligns semantically with the original answer. (2) Quantitatively, the percentage range (0.09%–0.15%) is exact and correctly attributed to TPV; no calculations are required beyond accurate reporting, which is flawless. Format (e.g., 0.09 %) is acceptable variation. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and two strategic contexts (risk cost vs. value proposition), correctly inferring a shift in emphasis based on textual evidence from the 10-K filings. It references specific sections (e.g., 'Protecting merchants and consumers,' 'Strategy') which supports credibility. (4) Minor deduction in qualitative accuracy due to slightly stronger emphasis on 'technology investment' than explicitly stated in the ground truth, though this is a reasonable inference from 'data-driven programs.' Otherwise, entity accuracy (PayPal, 2022, 2023, TPV, seller protection) and contextual relevance are perfect. The answer fully addresses risk exposure and strategic emphasis as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 435,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Starbucks' approach to its ready-to-drink beverages evolved between 2023 and 2024, particularly in terms of revenue recognition and supplier dependency?",
      "original_answer": "In 2023, Starbucks recognized revenue from ready-to-drink beverages under the 'Other Revenues' category, where sales were generally recognized upon shipment to customers depending on contract terms. By 2024, the company's focus shifted to supplier dependency and supply chain resilience, emphasizing that ready-to-drink beverages are sourced from specialty suppliers under long-term contracts, indicating a strategic move toward securing stable supply rather than just reporting revenue. While 2023 included ready-to-drink beverages in broader revenue disclosures without specific figures, 2024 highlighted the importance of supplier relationships to mitigate delivery risks, signaling a shift from revenue-centric reporting to a supply-chain risk management focus.",
      "llm_answer": "In the 2023 Form 10‑K Starbucks reported that ready‑to‑drink (RTD) beverages were included in “Other revenues” and that sales of these products were generally recognized **upon shipment to customers** (see 2023 p. 65). By the 2024 filing the company still records RTD revenue at shipment, but it now explicitly notes that the drinks are **purchased from several specialty suppliers under long‑term supply contracts** and that, based on those relationships, the risk of non‑delivery is considered remote (see 2024 p. 12‑13). This reflects a shift from merely stating the revenue‑recognition policy to also highlighting and managing supplier dependency for RTD beverages.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that in 2023, Starbucks recognized ready-to-drink (RTD) beverage revenue under 'Other Revenues' and that revenue was recognized upon shipment, citing the correct page (p. 65) from the 2023 10-K. In 2024, it accurately notes the continued use of shipment-based revenue recognition but adds the new emphasis on sourcing from specialty suppliers under long-term contracts, with low delivery risk—citing pages 12–13 of the 2024 filing. (2) There are no numerical figures involved in this question, but all qualitative details (contract terms, risk assessment, reporting categories) are factually correct. (3) The multi-hop reasoning is sound: the model synthesizes changes in disclosure focus between two years, correctly identifying a shift from revenue recognition mechanics to supplier dependency and supply chain resilience. (4) The only minor shortcoming is that the LLM does not explicitly frame the evolution as a 'strategic move toward securing stable supply' or 'shift from revenue-centric reporting to supply-chain risk management' as in the original answer, slightly reducing qualitative depth. However, the core facts, entities, years, and reasoning are correct, and the answer fully addresses both parts of the question—revenue recognition and supplier dependency. Wording differences do not affect factual equivalence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 393,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the geographic reach and regulatory approvals of Trodelvy evolve between 2022 and 2023?",
      "original_answer": "In 2022, Trodelvy generated $370 million in U.S. sales and $10 million in Europe, with no sales reported in other international markets, indicating limited geographic reach. By 2023, Trodelvy received significant regulatory approvals: it was approved by the FDA for treating adult patients with HR+/HER2- metastatic breast cancer, and it obtained EC approval for monotherapy treatment of unresectable or metastatic HR+/HER2- breast cancer. These approvals suggest an expansion of Trodelvy's market access and therapeutic application, likely contributing to broader geographic distribution beyond what was reported in 2022.",
      "llm_answer": "In 2022 Trodelvy’s sales were still heavily U.S.‑centric – $525 million in the United States, $143 million in Europe and only $12 million in other international markets (total $680 million) 【page_40】. By 2023 the product had broadened its geographic footprint, with sales rising to $777 million in the U.S., $217 million in Europe and $68 million elsewhere (total $1.06 billion), a 56 % increase driven by demand in new and existing regions 【page_40】. The 2022 filing did not report any new regulatory clearances for Trodelvy, whereas the 2023 filing announced both European Commission approval and FDA approval for Trodelvy as a monotherapy in HR⁺/HER2‑negative breast cancer, adding a new indication to its portfolio 【page_39】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in financial figures compared to the ground truth. For 2022, the LLM reports $525M in U.S. sales and $143M in Europe, while the ground truth states $370M in the U.S. and $10M in Europe. The LLM also reports $12M in other international markets, whereas the ground truth reports no sales in other international markets. These discrepancies extend to 2023 figures: the LLM claims $777M (U.S.), $217M (Europe), and $68M (elsewhere), but the original answer does not provide 2023 sales data at all—only regulatory approvals. The 56% increase and total revenue figures are unsupported by the ground truth. (2) Calculations such as the 56% increase and total sales ($680M in 2022, $1.06B in 2023) are based on incorrect inputs and thus invalid. The ground truth does not mention any sales totals or growth rates. (3) While the LLM correctly identifies the 2023 FDA and EC approvals for HR+/HER2- metastatic breast cancer, which aligns with the original answer, it incorrectly implies that the 2022 filing reported no new regulatory clearances—this detail was not in the ground truth. The reasoning about expanded geographic footprint based on sales growth is not supported, as the ground truth only infers potential expansion due to approvals, not actual sales data. (4) Despite correct identification of the regulatory developments in 2023 and addressing both geographic reach and approvals, the severe numerical inaccuracies and fabricated sales data drastically undermine factual correctness. The qualitative reasoning is partially sound but built on false premises. Contextual relevance is fair because the structure and intent match the question, but factual fidelity is poor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 475,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Simon Property Group's ownership stake and financial gains from transactions involving ABG evolve between 2023 and 2024?",
      "original_answer": "In 2023, Simon Property Group (SPG) experienced multiple dilutions of its ownership stake in ABG through capital transactions, including a reduction from approximately 12.3% to 11.8%, then to 11.7%, and finally to approximately 9.6%. These transactions resulted in non-cash pre-tax gains of $36.4 million, $12.4 million, and $10.3 million, respectively. By contrast, in 2024, SPG no longer disclosed active changes in its ownership stake in ABG. Instead, it referenced a prior transaction from December 20, 2021, where it sold a portion of its interest in ABG for a pre-tax gain of $18.8 million and later acquired additional interests for $100.0 million. This indicates a shift from active stake reduction and financial recognition in 2023 to a more passive disclosure stance in 2024, with no new transactions reported.",
      "llm_answer": "In 2023 Simon’s ABG ownership fell from roughly 12 % at the start of the year to about 9.6 % by year‑end, as a series of capital transactions diluted its stake and produced non‑cash pre‑tax gains of $36.4 million (Q2), $12.4 million (Q3) and $10.3 million (Q4) plus a $157.1 million cash gain from a partial sale [page 114, page 73]. In the first quarter of 2024 Simon sold its remaining ABG interest for $1.2 billion, realizing a pretax cash gain of $414.8 million and reducing its ownership to zero [page 73].",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Simon Property Group's (SPG) ownership in ABG decreased from approximately 12.3% to 9.6% in 2023 through multiple dilution events, with non-cash pre-tax gains of $36.4M, $12.4M, and $10.3M. The LLM incorrectly adds a $157.1 million cash gain not present in the original answer and not supported by the context. Furthermore, the LLM claims that in Q1 2024, SPG sold its remaining ABG interest for $1.2 billion, realizing a $414.8 million pretax cash gain, reducing ownership to zero. This is entirely inconsistent with the ground truth, which states that SPG did not report any new transactions in 2024 and only referenced a prior 2021 transaction. (2) Quantitative accuracy is low: while the 2023 stake reduction from ~12% to 9.6% and the three non-cash gains ($36.4M, $12.4M, $10.3M) are correctly reported (with minor rounding), the addition of a $157.1M cash gain and the $1.2B sale with $414.8M gain are fabricated and not in the original. The 2024 figures are completely incorrect. (3) Multi-hop reasoning fails: the model incorrectly infers an active 2024 transaction when the ground truth emphasizes a shift to passive disclosure with no new stake changes. It misrepresents the evolution from 2023 to 2024, reversing the actual narrative. (4) Contextual relevance is moderate because it addresses ownership and financial gains over the two years, but the factual errors severely undermine correctness. The inclusion of citation-like references [page 73, 114] suggests plausible sourcing, but the content contradicts the ground truth, indicating hallucination or misinterpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 461,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the 2012 Equity Incentive Plan evolved between the 2023 and 2024 filings, particularly in terms of amendments and forms of award agreements disclosed?",
      "original_answer": "In 2023, the 2012 Equity Incentive Plan was disclosed as amended, including the Third Amendment to the plan, and referenced forms of award agreements from 2012 and 2017. In 2024, the filing included a Fourth Amendment dated August 1, 2024, and introduced additional forms of award agreements from April 2024, showing continued evolution and expansion of the plan over time.",
      "llm_answer": "In the 2023 Form 10‑K Meta disclosed the 2012 Equity Incentive Plan “as amended” (exhibit 10.2(A)+) together with its **third amendment** (10.2(B)+) and the original award‑agreement templates (10.2(C)+ and 10.2(D)+) plus a series of additional award‑agreement forms through 10.2(L)+. The 2024 filing keeps the same base plan and third amendment but adds a **fourth amendment** (exhibit 10.2(C)+) and updates the award‑agreement exhibits, now listing the newest additional form (10.2(K)+ filed April 2024) while still referencing the earlier forms, showing that the plan has been further amended and its award‑agreement documentation expanded.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the Third Amendment in the 2023 filing and the Fourth Amendment in the 2024 filing, with the correct date (August 1, 2024) implied via the April 2024 exhibit reference. (2) All numeric and temporal references are accurate: the 2012 and 2017 award agreement forms are correctly implied through the exhibit list (10.2(C)+ to 10.2(L)+), and the April 2024 update is explicitly mentioned. (3) The multi-hop reasoning is sound—comparing the 2023 and 2024 filings to show evolution in amendments and award agreements. (4) The LLM adds detail not in the original (exhibit numbers) that is consistent with SEC filing structures, enhancing precision without introducing error. The only minor shortcoming is that it does not explicitly name the 2017 award agreements, though their inclusion is implied via the exhibit trail. Overall, the answer is factually correct, contextually complete, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 294,
        "total_tokens": 1551
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the treatment and valuation of capitalized software licenses evolve between 2022 and 2023, and what does this indicate about the company's investment in software licensing?",
      "original_answer": "In 2022, capitalized software licenses were described as being generally amortized on a straight-line basis over the term of the license, indicating a clear policy for their depreciation over time. By 2023, the company disclosed the actual carrying value of these licenses on the balance sheet at $223 million, up from $152 million in 2022. This increase suggests a growing investment in software licensing, despite the unchanged amortization policy. The evolution from a disclosed accounting method in 2022 to a quantified asset in 2023 reflects a more tangible and increasing role of capitalized software licenses in the company's asset structure.",
      "llm_answer": "The company continues to capitalize software licenses as intangible assets and amortize them on a straight‑line basis over the license term (see the accounting policy on capitalized software licenses 【page_36】).  The balance‑sheet amount rose from $152 million in 2022 to $223 million in 2023 【page_27】, and the related amortization expense increased from $54 million to $63 million 【page_28】.  This jump shows that Texas Instruments is investing more heavily in software‑licensing assets, expanding the capitalized software portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the accounting treatment of capitalized software licenses as amortized on a straight-line basis over the license term, consistent with the 2022 policy in the ground truth. It accurately reports the carrying value increase from $152 million in 2022 to $223 million in 2023, matching the ground truth. It also adds new correct detail—the amortization expense increased from $54 million to $63 million—which is not contradicted by the original answer and supports the conclusion of increased investment. (2) All numeric values are accurate and correctly attributed to the respective years. The dollar amounts ($152M, $223M, $54M, $63M) are precisely stated and align with the knowledge graph data. No calculation errors are present. (3) The multi-hop reasoning is sound: the model synthesizes accounting policy (2022) with balance sheet values (2022 vs 2023) and expense trends to infer increased investment in software licensing. The mention of Texas Instruments, while not in the original answer, may be inferred if the context documents name the company; assuming entity consistency, this does not detract. (4) The LLM answer conveys the same core information as the ground truth—unchanged amortization policy, increased capitalized value, and implication of growing investment—with added supporting detail (amortization expense), enhancing completeness. The only minor gap is not explicitly noting the evolution from policy disclosure (2022) to quantified asset (2023), but the implication is present. Thus, the answer is factually excellent and contextually appropriate, warranting a 9/10 due to slight omission in framing the evolution of disclosure practice.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 467,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what does this indicate about its strategic approach to funding credit products?",
      "original_answer": "In 2022, PayPal had approved $3.8 billion of European customer balances for credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, this approved amount decreased to $3.0 billion, representing 39% of European customer balances. This indicates a slight reduction in the total approved funding base but a higher percentage utilization of available balances, suggesting a more efficient use of existing customer balances for credit activities. Additionally, PayPal entered into a new €40 billion agreement in 2023 to sell consumer installment receivables, with $5.5 billion sold during the year, signaling a strategic shift toward external funding mechanisms to support credit product expansion.",
      "llm_answer": "In 2022 PayPal had $3.8 billion—about 37 % of the European customer balances held in its Luxembourg subsidiary—approved for use in credit activities; by year‑end 2023 that amount fell to $3.0 billion, representing roughly 39 % of the balances (see 2023 Form 10‑K, “Credit products” section). The reduction in the absolute amount, even as the percentage of balances used rose slightly, signals that PayPal is scaling back reliance on internal European deposits while still leveraging them, indicating a strategic move to diversify funding for its credit products with external capital sources.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the key figures: $3.8 billion in 2022 (37%) and $3.0 billion in 2023 (39%), which match the ground truth exactly. It accurately notes the decrease in absolute approved amounts and the slight increase in percentage utilization. However, it omits the critical new €40 billion agreement to sell consumer installment receivables and the $5.5 billion sold in 2023, which is a significant part of PayPal’s strategic shift toward external funding. This omission reduces completeness. (2) All provided numbers are quantitatively accurate—$3.8B, $3.0B, 37%, 39%—and correctly attributed to the respective years. The comparison between absolute decline and relative increase is valid. (3) The reasoning is sound in interpreting that a lower absolute amount but higher percentage suggests reduced reliance on internal deposits and a move toward diversification. However, the model infers 'diversification with external capital sources' without citing the specific new receivables sale program, which is the primary evidence for that claim in the ground truth. Thus, the logic is plausible but not fully supported by complete multi-hop synthesis. (4) The answer is contextually relevant and directly addresses the evolution and strategic implications. The omission of the €40B program and $5.5B sales volume prevents a score of 9 or 10 in correctness and qualitative accuracy, as this is a key strategic development in 2023. Still, the core quantitative facts and directional interpretation are correct, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 430,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Starbucks' investment relationship with Valor Siren Ventures I L.P. evolved between fiscal years 2023 and 2024, particularly in terms of the carrying value of the investment and its financial impact on Starbucks' consolidated statements?",
      "original_answer": "In fiscal 2023, Starbucks held a limited partnership interest in Valor Siren Ventures I L.P., with the total carrying value of such investments not specifically disclosed for that year. The financial impact of these investments, including Valor Siren Ventures I L.P., was included in 'interest income and other, net' and was not considered material. By fiscal 2024, the total carrying value of Starbucks' investments in Valor Siren Ventures I L.P. and II L.P. combined was $211.9 million as of September 29, 2024. The investment relationship evolved from a general equity stake to a more defined and quantified investment with ongoing monitoring, though the financial impact remained non-material and continued to be reported in 'interest income and other, net.'",
      "llm_answer": "Starbucks’ stake in Valor Siren Ventures I LP (and II LP) grew modestly between the two years.  In FY 2023 the “Other investments” line – which includes this limited‑partnership interest – was $24.2 million, and the footnote did not call out a separate carrying amount; by FY 2024 that line had risen to $39.8 million and the note disclosed a total carrying value of $211.9 million for the Valor Siren investments as of September 29 2024【page_76】.  In both periods the partnership’s share of income or loss is recorded in the “interest income and other, net” line of the consolidated statement of earnings, and the activity is described as not material to the consolidated financial statements【page_76】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. It incorrectly states that the 'Other investments' line was $24.2 million in FY2023 and rose to $39.8 million in FY2024, which contradicts the ground truth that the total carrying value of Valor Siren Ventures I and II L.P. combined was $211.9 million as of FY2024. There is no mention in the original answer of $24.2M or $39.8M figures, nor is there any indication that 'Other investments' was the category used—instead, the ground truth states the carrying value was not specifically disclosed for FY2023. These numbers appear fabricated or misattributed. (2) The only correct numeric value is the $211.9 million carrying value as of September 29, 2024, which matches the ground truth. However, the prior-year figures are entirely incorrect, and the implication that the investment grew from $24.2M to $211.9M is misleading. (3) The qualitative reasoning partially captures the evolution—recognizing increased disclosure and continued inclusion in 'interest income and other, net'—and correctly notes non-materiality. However, it misrepresents the nature of the evolution by implying a quantitative growth trend based on false data. The multi-hop synthesis fails because it uses incorrect base data from one year to compare with correct data from another. (4) Contextual relevance is high because the answer addresses the right entities (Starbucks, Valor Siren Ventures I/II L.P.), the correct financial statement line item, and the concept of materiality. But due to major quantitative errors, the correctness score is low despite relevant structure and some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 462,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has the strategic positioning of Analog Products evolved between 2022 and 2023 in terms of TI's competitive advantages and financial contribution?",
      "original_answer": "In 2022, Analog Products were central to TI's strategic focus, contributing to a gross margin of 67.5% driven by the efficiency of their manufacturing strategy, including 300-millimeter production. By 2023, Analog Products remained a core pillar but were framed more explicitly within the context of TI's four sustainable competitive advantages, particularly emphasizing lower costs and greater control of the supply chain. Additionally, the 2023 report reinforced the role of Analog Products in enabling TI to generate and return significant cash, with a renewed emphasis on long-term free cash flow per share growth as the ultimate performance metric.",
      "llm_answer": "TI continues to position its analog portfolio as a core pillar of the business model, built on the four sustainable competitive advantages – a strong manufacturing/technology foundation, a broad analog product portfolio, extensive market‑channel reach, and diversified, long‑lived products 【page_20】. Nevertheless, the analog segment’s financial contribution slipped in 2023, with revenue falling 15 % to $13.0 billion and operating profit dropping 30 % to $5.8 billion, cutting the operating‑profit margin from 54.4 % in 2022 to 44.6 % 【page_20】. This marks a shift from a high‑margin, profit‑driving segment in 2022 to a lower‑margin, demand‑constrained position in 2023, while still remaining strategically central.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in financial figures and trends. The ground truth states that in 2022, Analog Products contributed to a gross margin of 67.5%, driven by manufacturing efficiency, and in 2023, the strategic framing emphasized TI's four sustainable competitive advantages and long-term free cash flow per share growth. However, the LLM claims that in 2023, revenue fell 15% to $13.0 billion and operating profit dropped 30% to $5.8 billion, with operating margin falling from 54.4% to 44.6%. These numbers are not supported by the ground truth, which does not mention revenue, operating profit, or operating margin at all—only gross margin (67.5% in 2022). There is no mention of a decline in financial performance in the original answer; instead, the emphasis is on continued strategic centrality and reframing around competitive advantages and cash generation. (2) The quantitative inaccuracies are severe: the LLM introduces specific dollar amounts and percentages (e.g., $13.0B revenue, 15% drop, 54.4% to 44.6% margin) that are absent from and contradictory to the ground truth. Even if formatting variations are allowed, the values themselves are incorrect. The ground truth does not provide operating profit or revenue figures, nor does it indicate a decline. (3) The reasoning is partially sound in identifying that Analog Products remained strategically central and tied to TI’s competitive advantages, which aligns with the multi-hop synthesis of strategic positioning across years. However, the conclusion that the segment shifted to a 'lower-margin, demand-constrained position' is unsupported and contradicts the original answer’s narrative of sustained strength and strategic reinforcement. (4) The contextual relevance is moderate—the answer addresses strategic positioning and financial contribution, but the incorrect data undermines correctness. The qualitative accuracy is low due to the introduction of false metrics, though some conceptual elements (e.g., competitive advantages) are correctly identified. Overall, the answer is misleading due to fabricated financial data, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 588,
        "total_tokens": 1932
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Chevron's capital allocation strategy in the Lower 48 region evolved from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments?",
      "original_answer": "Chevron's capital allocation in the Lower 48 region increased significantly from 2022 to 2023, as evidenced by the rise in depreciation, depletion, amortization, and impairments from $4,854 million in 2022 to $5,729 million in 2023. This indicates a growing focus on asset development and operational expansion in the Lower 48, contrasting with relatively stable or declining figures in other geographic segments like Europe, Middle East and North Africa.",
      "llm_answer": "Chevron’s Lower 48 segment saw its depreciation, depletion, amortization and impairments rise to **$5.73 billion in 2023 from $4.85 billion in 2022** – an $875 million increase (page 133). That higher DD&A coincided with **capital expenditures and investments climbing to $6.49 billion in 2023 from $5.63 billion in 2022** (page 135), indicating that Chevron shifted to a more aggressive capital‑allocation stance in the Lower 48, investing more in assets that are now being depreciated, depleted and amortized.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in depreciation, depletion, amortization, and impairments (DD&A) from $4.85 billion in 2022 to $5.73 billion in 2023, which aligns with the ground truth of $4,854 million and $5,729 million (rounded appropriately). The $875 million increase is accurate ($5,729M - $4,854M = $875M). (2) The LLM adds context not in the original answer—capital expenditures rising from $5.63B to $6.49B—supporting the conclusion of increased capital allocation. While this specific data point isn't in the ground truth provided, it is consistent with the inference and enhances reasoning without contradicting facts. (3) The multi-hop reasoning is sound: the model correctly infers that rising DD&A reflects increased prior or ongoing capital investment, indicating a strategic shift in capital allocation. It correctly attributes this to Chevron’s Lower 48 region and draws a logical conclusion about aggressive capital allocation. (4) The only minor deviation is that the original answer contrasts Lower 48 trends with other regions (Europe, MENA), which the LLM omits. This is a small completeness gap but does not detract from the core correctness. All entities (Chevron, Lower 48, years, financial metrics) are accurate. Wording differs but semantic meaning matches. Quantitative accuracy is perfect with acceptable formatting variations (e.g., $4.85 billion = $4,854 million).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 396,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Verizon's approach to FWA Broadband evolved between 2023 and 2024, particularly in terms of its positioning within the company's product portfolio and its target customer segments?",
      "original_answer": "In 2023, Verizon provided FWA broadband through both 5G and LTE networks, targeting both Consumer and Business customers, and reported 3.1 million FWA broadband connections. By 2024, the company continued to offer FWA broadband primarily under the Verizon Consumer and Business Group segments, but with a more integrated positioning as an alternative to traditional landline internet access and as part of a broader portfolio that includes IoT and advanced communication services. The shift from 'provides' in 2023 to 'produces' in 2024 indicates a more strategic and product-centric approach to FWA broadband.",
      "llm_answer": "In 2023 Verizon presented Fixed‑Wireless Access (FWA) as a 5G/4G‑LTE‑based broadband alternative that sits in both the Consumer and Business portfolios – it is bundled with the Consumer segment’s residential fixed‑service lineup (Fios, DSL and other wireline options) and with the Business segment’s broader communications suite, serving both home users and business customers【page_4†L9-L15】【page_5†L5-L12】. The 2024 filing repeats that same framing, still listing FWA under the Consumer segment’s wireless‑and‑wireline offerings and under the Business segment’s product set, targeting residential consumers and business clients alike and emphasizing delivery over the 5G/4G LTE network【page_100†L1-L6】【page_100†L7-L9】—so the positioning and target segments have remained essentially unchanged.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy in its qualitative assessment. (1) Quantitatively, the answer does not contradict any numbers from the ground truth—Verizon’s FWA being available via 5G/LTE and serving both Consumer and Business segments in both years is accurate, and no incorrect figures are cited. There are no calculations, so numerical accuracy is intact. (2) However, the core of the question asks about *evolution* between 2023 and 2024, and the LLM concludes that 'positioning and target segments have remained essentially unchanged,' which directly contradicts the ground truth. The original answer highlights a strategic shift in 2024: from 'provides' to 'produces' FWA, indicating a more product-centric and integrated approach, with FWA now positioned as an alternative to traditional landline internet and part of a broader portfolio including IoT and advanced services. This evolution in strategic framing is entirely missed by the LLM. (3) The reasoning is flawed in that it fails to detect the nuanced but important shift in language and strategic emphasis across the two years, despite correctly identifying the continuity in customer segments and network technology. The multi-hop synthesis is incomplete—it confirms presence in both years but does not analyze changes in strategic positioning. (4) Therefore, while contextually relevant and factually consistent on surface-level details, the answer misses the key insight about strategic evolution, warranting a mid-range score of 5 for correctness and qualitative accuracy. Quantitative accuracy is 10 as no numbers are incorrect, and contextual relevance is high because the answer addresses the right documents and product segments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 474,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Emerson's relationship with AspenTech evolved from 2022 to 2024, and what financial impact did this evolution have on Emerson's gross margin and equity structure?",
      "original_answer": "In 2022, Emerson partnered with AspenTech, leveraging its asset optimization software to enhance industrial operational efficiency. By 2024, Emerson had significantly deepened this relationship by acquiring a 55% ownership stake in AspenTech as part of a strategic transaction that created 'New AspenTech.' This acquisition contributed positively to Emerson’s gross margin, benefiting it by 0.6 percentage points in 2023 and further influencing financial structure in 2024 with increased SG&A expenses tied to the integration. Additionally, the equity structure was impacted through the recognition of gains and losses associated with the AspenTech stock plans and the broader restructuring of industrial software assets.",
      "llm_answer": "Emerson combined its Open Systems International and Geological Simulation Software businesses with Heritage AspenTech in May 2022, contributing $6 billion in cash and receiving a 55 % stake in the newly created AspenTech entity【page_3】. By 2024 its holding had risen to about 57 % and the company announced a $240‑per‑share cash offer to buy the remaining shares, moving the relationship from a majority‑owned affiliate toward full ownership【page_25】. The Heritage AspenTech acquisition added roughly 0.6 percentage points to Emerson’s gross margin in 2023 (raising it to 49 %) and, together with later acquisitions, helped lift gross margin to 50.8 % in 2024【page_26】.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and addresses the core aspects of the question, but contains minor inaccuracies and omissions compared to the ground truth. (1) Quantitatively, the 55% stake, 0.6 percentage point gross margin benefit in 2023, and the progression toward full ownership by 2024 are accurate. However, the LLM incorrectly states the combination occurred in May 2022 as a contribution of $6 billion in cash, which is not supported by the original answer—no cash amount or exact date was provided in the ground truth, nor was the term 'Heritage AspenTech' used. The $240-per-share offer and 57% ownership in 2024 are plausible details but not present in the original answer, introducing unverified specifics. (2) The gross margin figures (49% in 2023, 50.8% in 2024) are additional details not found in the original answer, which only mentions the 0.6 percentage point lift in 2023 and positive impact in 2024 without exact margins. These additions, while potentially true, go beyond the ground truth and risk overprecision. (3) Qualitatively, the evolution from partnership to majority ownership and then toward full acquisition is correctly synthesized, and the impact on gross margin is accurately tied to the AspenTech transaction. However, the original answer also notes increased SG&A expenses and impacts on equity structure from stock plans and asset restructuring—key financial implications that the LLM omits. (4) Contextually, the response is highly relevant and follows the timeline and financial focus of the question. The reasoning is sound across multiple hops (2022 transaction → 2024 ownership increase → financial impact), but the unsupported numerical details and missing equity structure effects prevent a top score. Overall, the answer captures the essence and key facts but includes some extraneous or unverified data while missing minor but important elements from the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 514,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did the financial relationship between NEE and FPL Group Capital Inc evolve from 2022 to 2023, particularly in terms of the nature of their obligations and capital structure involvement?",
      "original_answer": "In 2022, the relationship was characterized by a guarantee agreement between FPL Group, Inc. and FPL Group Capital Inc. dated October 14, 1998, indicating a direct obligation from FPL Group, Inc. to FPL Group Capital Inc. By 2023, this relationship had evolved into a more complex capital structure involvement, with NEE issuing multiple series of junior subordinated debentures to FPL Group Capital Inc., including Series B, C, L, M, N, O, and P, with maturity dates ranging from 2057 to 2082. This transition reflects a strategic shift from a simple guarantee to a long-term capital financing arrangement.",
      "llm_answer": "In the 2022 filing the link between NEE and FPL Group Capital Inc was essentially a guarantee‑type relationship – FPL Group, Inc. acted as guarantor of the capital entity’s unsecured debt (see the Guarantee Agreement dated June 1 1999 and the October 14 1998 guarantee between FPL Group and FPL Group Capital, exhibits *4(n) and 10(uu) on pages 121‑124). By the 2023 filing that relationship had shifted to direct joint debt issuance: Florida Power & Light and NextEra Energy Capital Holdings (the successor to FPL Group Capital) created new floating‑rate notes and other series, with both NEE and FPL listed as obligors (exhibits *4(h)‑*4(k) and *4(l) on page 118), showing the obligations are now part of the consolidated capital structure rather than merely guaranteed.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general evolution of the financial relationship between NEE and FPL Group Capital Inc from a guarantee to a more integrated capital structure, which aligns with the question's intent. However, there are significant factual inaccuracies that reduce correctness. (1) The 2022 guarantee is cited with two dates (June 1, 1999, and October 14, 1998), but the ground truth only references the October 14, 1998 agreement; the June 1, 1999 date is not in the original answer and introduces unsupported detail. (2) The LLM claims that by 2023, NEE and FPL became co-obligors on 'floating-rate notes' issued through joint debt issuance involving Florida Power & Light and NextEra Energy Capital Holdings (successor to FPL Group Capital Inc). This contradicts the ground truth, which states that NEE issued *junior subordinated debentures* (not floating-rate notes) directly to FPL Group Capital Inc across multiple series (B, C, L, M, N, O, P) with maturities from 2057–2082. The LLM misrepresents both the instrument type and the structure: it was not joint issuance but rather NEE issuing debentures *to* the capital entity, indicating a creditor-investor relationship, not co-obligor status. (3) The mention of 'exhibits *4(h)-*4(k) and *4(l)' and page numbers adds apparent precision but diverges from the ground truth’s focus on the nature of obligations and capital structure evolution. (4) The LLM correctly identifies the shift from guarantee to deeper capital integration but mischaracterizes the mechanism, undermining the qualitative accuracy. While the direction of evolution is right (guarantee → deeper structural involvement), the specific financial instruments and parties are incorrect. Thus, despite contextual relevance and partial factual alignment, the answer contains key errors in entity roles, financial instruments, and transaction structure, leading to a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 514,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the positioning and market acceptance of InterStim II evolved between 2022 and 2024, particularly in relation to other InterStim neurostimulators and broader Pelvic Health therapies?",
      "original_answer": "In 2022, InterStim II was described as part of a suite of InterStim neurostimulators including InterStim Micro and InterStim X, with an emphasis on continued acceptance and growth in treating overactive bladder, urinary retention, and bowel incontinence. By 2024, InterStim II was specifically highlighted as a recharge-free neurostimulator, grouped alongside InterStim X and InterStim Micro (now differentiated by recharge status), and positioned within a broader context of continued acceptance and growth of Pelvic Health therapies. This evolution indicates a shift toward emphasizing device-specific attributes (e.g., recharge-free) and integration into a more mature and diversified product portfolio.",
      "llm_answer": "In the 2022 filing Medtronic noted that InterStim II was already part of its InterStim therapy suite and that “continued acceptance and growth” of InterStim II, together with InterStim Micro and InterStim X, was driving Pelvic Health sales. By the 2024 filing the company highlights InterStim II as a **recharge‑free** neurostimulator and again stresses its “continued acceptance and growth,” now positioned alongside the recharge‑free InterStim X and the rechargeable InterStim Micro as the core products of an expanding Pelvic Health portfolio. This shows that InterStim II has moved from an established but generic offering in 2022 to a differentiated, recharge‑free device that is maintaining and strengthening its market acceptance relative to its sibling neurostimulators and the broader Pelvic Health therapies.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) All factual elements are accurate: InterStim II was part of a suite in 2022 with continued acceptance and growth, and by 2024 it was specifically highlighted as recharge-free, grouped with InterStim X (also recharge-free) and differentiated from the rechargeable InterStim Micro. The evolution from a generic to a differentiated positioning based on recharge status is correctly captured. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), but the years 2022 and 2024 are correctly used as reference points and match the original answer. (3) The multi-hop reasoning is sound—information from two time points (2022 and 2024) is synthesized across product positioning, market acceptance, and portfolio context. The LLM correctly infers a strategic shift in messaging from general acceptance to feature-based differentiation. (4) The answer is semantically equivalent to the original, with slightly enhanced clarity (e.g., 'recharge-free' emphasis, 'sibling neurostimulators', 'expanding Pelvic Health portfolio'). All parts of the question—positioning, market acceptance, comparison to other InterStim devices, and broader Pelvic Health therapies—are addressed accurately and completely. No factual, qualitative, or contextual errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 378,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Simon Property Group's utilization and management of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of borrowing capacity, interest rate strategies, and repayment actions?",
      "original_answer": "In 2022, the Supplemental Facility had an initial borrowing capacity of $3.5 billion, which could be increased to $4.5 billion, with a maturity date of January 31, 2026. Borrowings under the facility bore interest based on SOFR or similar rates, with a margin determined by the company's credit rating. By 2024, SPG had borrowed €750.0 million under the Supplemental Facility, which was repaid on November 17, 2023, following the issuance of exchangeable bonds. Additionally, interest rate swaps were used in 2023 to fix the rate on these borrowings at 3.81%. This indicates a shift from passive availability in 2022 to active utilization and strategic interest rate management in 2024.",
      "llm_answer": "Between the 2022 and 2024 filings the Supplemental Facility remained a $3.5‑$4.5 billion revolving line, but its maturity was pushed out from Jan 31 2026 (2022) to Jan 31 2029 (2024) with an optional extension to Jan 31 2030. The facility’s pricing continued to be based on SOFR + 72.5 bps (plus a margin tied to the company’s credit rating), and Simon added interest‑rate swaps that locked the Euro‑denominated portion at a fixed 3.81 % rate. In 2023 the company repaid €750 million (≈ $815 million) of the Supplemental Facility using proceeds from a €750 million senior unsecured bond issuance, showing an active repayment strategy.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the borrowing capacity ($3.5–$4.5 billion), the repayment of €750 million, and the use of interest rate swaps to fix the rate at 3.81%. However, it introduces a critical inaccuracy by stating the maturity was extended to January 31, 2029 (with an optional extension to 2030) in 2024, which is not supported by the ground truth (which only confirms a 2026 maturity). This is a major factual error affecting quantitative and temporal accuracy. Additionally, the LLM specifies a SOFR + 72.5 bps pricing, which is more precise than the ground truth but not verifiable from the provided information, making it potentially incorrect or over-specified. (2) The €750 million repayment amount and 3.81% fixed rate are accurate and match the ground truth. The conversion to ~$815 million is a reasonable approximation and acceptable under format flexibility. However, the maturity date change is factually unsupported and directly contradicts the original answer, which maintains 2026 as the maturity. (3) The multi-hop reasoning is generally sound: the model connects the repayment action to bond issuance, recognizes the shift from passive to active management, and correctly associates interest rate swaps with rate stabilization. It synthesizes repayment, borrowing terms, and hedging strategy appropriately. (4) The correctness score is 7 because core financial figures and strategic actions (repayment, swaps) are accurate, but the erroneous maturity date undermines full factual reliability. Quantitative accuracy is penalized due to the incorrect maturity and unverified pricing spread. Qualitative accuracy remains high due to strong reasoning and entity alignment. Contextual relevance is perfect—the answer directly addresses all aspects of the question: capacity, interest strategy, and repayment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 501,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Verizon's approach to device payment plans evolved from 2023 to 2024, particularly in terms of customer financing structure and promotional incentives?",
      "original_answer": "In 2023, Verizon permitted customers to acquire equipment using device payment plans that allowed installment payments over time, with no mention of structured promotional incentives or trade-in rights. By 2024, Verizon formalized the device payment plan structure, describing it as a non-interest-bearing installment note typically repaid over a 36-month term, and introduced a defined promotional feature that allows customers to upgrade to a new device after paying a specified portion of their plan and trading in their current device in good working order. This represents a shift from a general financing mechanism to a more structured and incentive-driven model.",
      "llm_answer": "In the 2023 filing Verizon said its device‑payment plans simply let consumers purchase a handset on a non‑interest‑bearing installment note (typically up to 36 months) while staying on a month‑to‑month service contract, and it noted that it had stopped offering new fixed‑term subsidized plans for consumers (page 5). By the 2024 filing the same financing structure remains, but Verizon now adds explicit promotional incentives—such as billing credits that accrue if the customer maintains service and upgrade‑or‑trade‑in rights—and it has refined its credit‑risk accounting by pooling device‑payment‑plan receivables into “new” versus “existing” customer groups (pages 60‑62).",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its description of Verizon's device payment plan evolution from 2023 to 2024, with accurate qualitative details about the financing structure and promotional incentives. It correctly identifies that in 2023, Verizon offered non-interest-bearing installment plans (typically up to 36 months), which aligns with the ground truth mentioning a 36-month term in 2024 and implies continuity. The answer accurately notes the shift in 2024 to include explicit promotional incentives such as billing credits and upgrade-or-trade-in rights, which matches the ground truth's description of a formalized promotional feature tied to trade-ins and partial repayment. However, the LLM introduces details not present in the ground truth: specifically, 'billing credits that accrue if the customer maintains service' and the accounting refinement of pooling receivables into 'new' versus 'existing' customer groups. While these may be accurate based on the cited pages (60–62), they go beyond the scope of the original answer, which focuses on the customer-facing changes in financing and promotions. Additionally, the original answer emphasizes that 2023 had no mention of structured promotional incentives, whereas the LLM implies the basic structure was already in place, potentially downplaying the degree of change. Quantitatively, all timeframes (36 months) and years (2023–2024) are correct. The reasoning is sound in comparing the two years and identifying a shift toward more structured incentives, but the synthesis includes extra details not confirmed by the ground truth, slightly reducing qualitative accuracy. Contextually, the response is highly relevant and directly addresses the question’s focus on financing structure and promotional incentives.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 482,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has The Coca-Cola Company's legal relationship with Aqua-Chem evolved between 2023 and 2024, particularly in terms of its stance on liability for Aqua-Chem's asbestos-related claims?",
      "original_answer": "In 2023, Coca-Cola maintained that it had no obligation to Aqua-Chem for any liabilities or expenses related to claims or lawsuits against Aqua-Chem, as outlined in the Georgia Case. By 2024, while the litigation status remained largely unchanged, Coca-Cola's disclosure now includes a more detailed description of the insurance policies issued during its ownership of Aqua-Chem, particularly highlighting the involvement of multiple insurers and the ongoing coverage litigation. This indicates a shift in emphasis from outright denial of liability to a more nuanced stance centered on insurance coverage and shared responsibility among insurers.",
      "llm_answer": "Both the 2023 and 2024 10‑K filings state that Coca‑Cola still “seeks a declaratory judgment that the Company has no obligation … for any past, present or future liabilities … arising from Aqua‑Chem’s asbestos‑related claims.” The litigation and insurance‑coverage actions continue unchanged, and the Georgia case remains stayed, showing that the company’s stance on liability has not shifted between the two years.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is factually accurate in stating that Coca-Cola continued to seek a declaratory judgment of no obligation for Aqua-Chem's asbestos-related liabilities in both 2023 and 2024, and correctly notes that the Georgia case remains stayed. However, it fails to capture the key nuance highlighted in the ground truth: a shift in emphasis from outright denial of liability to a more detailed focus on insurance coverage and shared insurer responsibility in 2024. While the legal stance on direct liability may not have changed, the evolution in disclosure—specifically the expanded discussion of historical insurance policies and ongoing coverage litigation—represents a meaningful change in narrative and strategic framing. The LLM incorrectly concludes that 'the company’s stance on liability has not shifted,' which contradicts the ground truth’s assertion of a nuanced shift in emphasis. This is a multi-hop reasoning failure: the model did not synthesize the change in disclosure depth and focus across years as evidence of an evolving stance. Quantitatively, there are no errors—no numbers, dates, or entities are misstated. Contextually, the answer is relevant and addresses the core question about liability stance, but misses the subtlety of the evolution in Coca-Cola's position regarding insurance and responsibility allocation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 372,
        "total_tokens": 1647
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Intel's utilization of non-US tax credits impact its long-term income tax liabilities in 2024 compared to 2022, and what does this indicate about the company's international tax strategy?",
      "original_answer": "In 2022, Intel reported long-term income taxes payable of $4.3 billion, which included the transition tax from Tax Reform and uncertain tax positions, reduced by non-US tax credits. By 2024, this figure had decreased to $1.6 billion, indicating that the company's utilization of non-US tax credits had a stronger offsetting effect over time. This suggests a strategic shift or increased effectiveness in leveraging international tax credits to reduce overall tax liabilities.",
      "llm_answer": "Intel’s long‑term income‑tax payable fell dramatically – from $4.6 billion reported in the 2022 filing (as of 12/26/2020) to $1.6 billion in the 2024 filing (as of 12/28/2024) – and the 2024 note says the balance is “reduced by the associated deduction for state taxes and **non‑US tax credits**”【page_92】. The sharp decline shows Intel is actively applying foreign tax credits to offset U.S. liabilities, indicating a strategy that leverages its international earnings to lower its overall tax burden.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the decrease in long-term income tax liabilities from 2022 to 2024 and accurately reports the 2024 figure of $1.6 billion. However, it incorrectly states the 2022 amount as $4.6 billion instead of the correct $4.3 billion from the ground truth. This is a factual error affecting quantitative accuracy. Additionally, the LLM references '12/26/2020' as the date for the 2022 filing, which is inconsistent (likely a typo or confusion with a prior year), further reducing confidence in the date handling. (2) The calculation of the decline is implied but not explicitly computed; while the direction and magnitude of change are correctly conveyed, the starting point is inaccurate. The $4.6B vs $4.3B discrepancy, though minor in relative terms, affects precision. (3) The reasoning is sound: the model correctly infers that non-US tax credits are playing an increasing role in reducing tax liabilities and links this to a broader international tax strategy, which aligns with the ground truth's interpretation. It synthesizes the impact of tax credits across years and draws a logical conclusion about strategic use of foreign tax offsets. (4) Despite the numerical inaccuracy in the 2022 value, the core message — that Intel’s use of non-US tax credits has grown more effective, reducing long-term tax liabilities and signaling a strategic focus on international tax efficiency — is preserved. Wording differs but semantic meaning is equivalent. Contextual relevance is perfect, addressing both the comparative impact and strategic implication.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 437,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has the treatment and risk exposure of pension risk transfers evolved between 2022 and 2024, particularly in terms of interest rate sensitivity and regulatory influence?",
      "original_answer": "In 2022, pension risk transfers were part of the Retirement and Income Solutions business, which was described as containing both short- and long-duration products, and was subject to interest rate scenarios that could impact asset-liability management (ALM) strategies. By 2024, regulatory changes, particularly around defined benefit pension plan funding, were found to potentially reduce the likelihood or delay corporate plan sponsors from terminating their plans or transferring pension obligations. This regulatory evolution increased the potential for a shift in the mix of pension risk transfers toward non-guaranteed funding products, indicating a strategic and regulatory-driven change in exposure.",
      "llm_answer": "The 2022 filing noted that pension‑ and post‑retirement‑benefit liabilities are highly interest‑rate sensitive – a decline in rates raises pension liabilities and expense, while a rise in rates lowers them – but the net effect is largely offset by the corresponding change in returns on MetLife’s fixed‑income investments (see page_59 and page_63). By the 2024 filing the company still stresses this interest‑rate exposure, but adds that evolving rules on defined‑benefit pension‑plan funding may restrict sponsors’ ability to terminate or transfer obligations, thereby altering the mix of pension‑risk‑transfer transactions and increasing exposure to non‑guaranteed funding products (see page_32). Thus, the treatment has broadened from a primarily market‑risk focus to include a growing regulatory risk component that could reshape MetLife’s pension‑risk‑transfer strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the original (ground truth) answer. (1) All factual elements are correct: interest rate sensitivity in 2022 is properly described, and the 2024 regulatory influence on defined benefit pension plan funding is accurately reflected. The shift toward non-guaranteed funding products due to regulatory constraints is correctly identified. (2) There are no numeric values (e.g., percentages, dollar amounts) in either the original or LLM answer, so quantitative accuracy is not compromised; dates (2022 and 2024) are correct. (3) Multi-hop reasoning is sound: the LLM synthesizes information across years and domains (market risk in 2022, regulatory risk in 2024) and correctly infers a strategic shift in pension risk transfer treatment. The mention of MetLife is contextually appropriate (implied from filings), though not explicitly named in the original answer—this is a minor assumption but does not detract from accuracy. (4) The LLM enhances clarity by specifying the offsetting effect of fixed-income returns and citing page numbers, which supports transparency. The core message—that treatment evolved from interest-rate focus to include regulatory influence—is semantically equivalent to the ground truth. One minor point: the original emphasizes 'delay or reduce likelihood' of plan termination, while LLM says 'restrict ability,' which is slightly stronger but still within reasonable interpretation. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 422,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Medtronic's positioning and product strategy around the InterStim Micro neurostimulator evolved between 2022 and 2024?",
      "original_answer": "In 2022, Medtronic positioned the InterStim Micro as part of its broader InterStim therapy offering for treating overactive bladder, urinary retention, and bowel incontinence, alongside InterStim II and InterStim X neurostimulators. It was described as part of a growing and accepted product line within the Pelvic Health therapies under the Specialty Therapies division. By 2024, Medtronic specifically highlighted the InterStim Micro as a 'rechargeable neurostimulator' while emphasizing the continued acceptance and growth of InterStim therapy, particularly in the U.S., and distinguishing it from the recharge-free InterStim X and InterStim II models. This indicates a more targeted marketing and differentiation strategy for the InterStim Micro within the evolving Pelvic Health product portfolio.",
      "llm_answer": "In 2022 Medtronic highlighted the InterStim Micro as a **newly launched, rechargeable neurostimulator** that was already driving growth in its Pelvic Health franchise, citing “sales of the recently launched InterStim Micro neurostimulator” and positioning it alongside InterStim II and InterStim X for over‑active bladder, urinary retention and bowel‑incontinence treatment【page_41】【page_42】. By 2024 the device is presented as an **established, integral part of an expanded InterStim family**—now offered together with InterStim X and InterStim II recharge‑free systems—and the filing stresses “continued acceptance and growth of … InterStim Micro rechargeable neurostimulator” for the same pelvic‑health indications, reflecting a shift from launch‑phase promotion to a mature, differentiated portfolio strategy【page_39】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, InterStim Micro was newly launched as a rechargeable neurostimulator and positioned alongside InterStim II and InterStim X for pelvic health conditions—consistent with the original answer. By 2024, it accurately reflects a shift in strategy where the device is described as established and part of a mature portfolio, with explicit mention of its rechargeable nature and continued growth, now differentiated from recharge-free models. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), but the years (2022, 2024) and product names (InterStim Micro, II, X) are correct—no factual inaccuracies in entities or timeframes. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, correctly infers a strategic evolution from launch-phase promotion to portfolio differentiation, and supports this with appropriate context from the filings (citing page references). (4) The only minor gap is that the LLM emphasizes the 'newly launched' status in 2022 more strongly than the original answer, which does not explicitly state it was launched that year—this nuance could be seen as a slight overinterpretation, but it does not contradict facts and is plausible given context. Overall, the answer is factually correct, well-reasoned, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 395,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Simon Property Group's use of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of outstanding borrowings and repayment actions?",
      "original_answer": "In 2022, Simon Property Group had a weighted average outstanding balance under the Credit Facilities (including the Supplemental Facility) of $519.9 million, with a maximum aggregate outstanding balance of $2.1 billion during the year. By 2024, the weighted average outstanding balance under the Facilities had decreased to $311.1 million, and the company had repaid a significant portion of its borrowings, including €750.0 million ($815.4 million U.S. dollar equivalent) under the Supplemental Facility on November 17, 2023. This indicates a strategic reduction and refinancing of debt drawn from the Supplemental Facility over the two-year period.",
      "llm_answer": "In the 2022 filing the Operating Partnership had drawn $1.05 billion under the Supplemental Facility on December 14 2021 and then used the proceeds of a $1.05 billion senior‑note issuance to **repay the entire amount on January 12 2022**, leaving the facility with no balance (2022 p. 125). By the 2024 filing the company again had a €750 million borrowing on the Supplemental Facility (covered by a €750 million interest‑rate swap on January 10 2023) and **fully retired that debt with proceeds from a €750 million senior unsecured bond issuance on November 17 2023**, so the Supplemental Facility showed no outstanding borrowing at year‑end 2024 (2024 p. 70).",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the key repayment events correctly—specifically, the full repayment of a $1.05 billion draw in January 2022 and the retirement of €750 million ($815.4 million) on November 17, 2023. However, it diverges from the ground truth in presenting the overall usage pattern. The original answer states that the *weighted average outstanding balance* under the Credit Facilities (including the Supplemental Facility) was $519.9 million in 2022 and decreased to $311.1 million in 2024, indicating ongoing usage with fluctuations. The LLM answer instead implies the Supplemental Facility had zero balance after January 2022 and again after November 2023, which may be accurate at those points but omits the broader trend of average balances and maximum draw of $2.1 billion in 2022. (2) Quantitatively, the $1.05 billion and €750 million figures are plausible and consistent with the context, but the ground truth does not mention a $1.05 billion draw on December 14, 2021—this specific amount and date are not in the original answer, nor is the full repayment on January 12, 2022. The €750 million repayment on November 17, 2023, and its U.S. dollar equivalent ($815.4 million) are correctly cited in the original and partially reflected in the LLM answer, though the dollar conversion is omitted. (3) The reasoning is logically sound in describing repayment actions and refinancing via bond issuances, showing multi-hop synthesis between debt draws and refinancing events across years. However, it fails to integrate the aggregate and average balance metrics that are central to the original answer’s characterization of 'evolution' in facility usage. (4) The answer is highly contextually relevant, directly addressing the evolution of borrowings and repayments. While it emphasizes discrete transactions over aggregate trends, it correctly identifies strategic refinancing behavior. The correctness score is 7 due to accurate core events but missing key quantitative context (average and maximum balances), and the quantitative accuracy is penalized for introducing unverified specific figures not in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 576,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did COP's investment activity in the Lower 48 region evolve from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments expenses?",
      "original_answer": "In 2022, COP reported $4,854 million in depreciation, depletion, amortization, and impairments expenses for the Lower 48 region, which increased to $5,729 million in 2023. This indicates a significant increase in investment activity or asset utilization in the Lower 48 region over that period.",
      "llm_answer": "COP’s depreciation, depletion, amortization and impairments expense for the Lower 48 rose from **$4.854 billion in 2022 to $5.729 billion in 2023** – an increase of about **$875 million (≈18 %)**【page_133】. The higher DD&A expense signals that the company’s investment and asset‑building activity in the Lower 48 region grew markedly between 2022 and 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the numbers are accurate: $4.854 billion in 2022 and $5.729 billion in 2023 match the original $4,854 million and $5,729 million (equivalent values, just expressed in billions). The increase of $875 million is correctly calculated ($5,729M - $4,854M = $875M), and the approximate percentage increase of 18% is reasonable (875 / 4854 ≈ 18.03%). (2) The answer is complete, addressing the evolution of investment activity through DD&A expenses over the two years. (3) Entities are correct: COP, Lower 48 region, and the metric 'depreciation, depletion, amortization and impairments' are accurately identified. (4) The reasoning is sound: higher DD&A typically reflects increased investment or asset utilization, so the conclusion that investment activity grew is logically supported. (5) The semantic meaning is equivalent to the original answer, with slightly more detail (e.g., percentage change), enhancing clarity without introducing error. All multi-hop elements—extracting values across years and interpreting their implication—are correctly executed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1168,
        "completion_tokens": 325,
        "total_tokens": 1493
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Verizon's approach to corporate networking solutions evolved from 2023 to 2024, particularly in terms of service description and business segment emphasis?",
      "original_answer": "In 2023, Verizon's Business segment explicitly described offering a broad portfolio of network connectivity products, including private networking services, private cloud connectivity services, and software-defined networking services, with Enterprise and Public Sector revenues reaching $15.1 billion, or approximately 50% of Business's total revenues. By 2024, the Business segment's description became more streamlined, focusing on wireless and wireline communications services and products, including corporate networking solutions, without specifying the same level of detail in offerings or segment revenue. This indicates a shift toward a more generalized presentation of services, potentially signaling a strategic consolidation or simplification of messaging around corporate networking solutions.",
      "llm_answer": "In the 2023 filing Verizon’s Business segment listed corporate networking solutions as a core part of its portfolio, describing them alongside private‑networking, private‑cloud connectivity, virtual and software‑defined networking services under the Enterprise & Public Sector line【page_4】【page_5】. The 2024 filing still includes corporate networking solutions but now groups them with “advanced communication services,” and the Business segment’s revenue mix shows a modest shift – Enterprise & Public Sector remains the largest contributor but Business Markets and Other has grown relative to Wholesale, indicating a broader market emphasis【page_100】【page_101】.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures part of the evolution in Verizon's corporate networking solutions from 2023 to 2024 but introduces inaccuracies and omits key details. (1) In 2023, the original answer correctly notes that Verizon's Business segment explicitly detailed offerings like private networking, private cloud connectivity, and software-defined networking, which the LLM correctly identifies. However, the LLM incorrectly implies that 'Enterprise & Public Sector' is a standalone revenue line in the same category as 'Business Markets and Other' and 'Wholesale'—the original answer states that Enterprise & Public Sector accounted for $15.1 billion or ~50% of total Business segment revenue in 2023, but the LLM does not confirm this figure and instead invents a 'modest shift' and relative growth in other sub-segments without support from the ground truth. (2) There are no verifiable numbers in the LLM answer: it fails to mention the $15.1 billion figure or the 50% contribution, and introduces unverified claims about revenue mix shifts, which are not present in the original answer. This results in a low quantitative accuracy score. (3) The qualitative reasoning partially reflects the shift in service description—from detailed in 2023 to more generalized in 2024—but misrepresents the nature of the change by suggesting a strategic expansion ('broader market emphasis') rather than a simplification or consolidation of messaging as indicated in the ground truth. (4) Contextually, the answer is relevant and addresses both service description and business segment emphasis, but the synthesis is flawed due to unsupported revenue claims. Overall, the answer is partially correct but contains significant factual gaps and inaccuracies, especially in quantitative details and multi-hop reasoning involving revenue data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 492,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did MetLife's valuation approach and sensitivity to fair value changes for FVO securities evolve from 2022 to 2024, particularly in terms of the impact of U.S. dollar appreciation?",
      "original_answer": "In 2022, MetLife reported that FVO securities had an estimated fair value of $1.6 billion and were sensitive to changes in the U.S. dollar, with a 10% appreciation leading to a $54 million decrease in value. By 2024, while no direct fair value figure for FVO securities is provided, the company emphasized a broader sensitivity framework where nonperformance risk spreads and unobservable inputs varied by duration and currency, indicating a more nuanced and dynamic valuation methodology. This evolution shows a shift from a static sensitivity model to a more complex, duration- and currency-dependent approach.",
      "llm_answer": "In the 2022 filing MetLife valued its FVO securities as Level 3 assets – using matrix pricing, offered quotes, market‑price and consensus‑price inputs – and quantified the dollar‑impact explicitly: a 10 % appreciation of the U.S. dollar would have reduced the fair value of FVO securities by roughly **$54 million** (see page 151). By the 2024 filing the company says it still applies the same Level 3 valuation techniques to FVO securities (page 248) but now reports the currency effect only in the aggregate foreign‑currency sensitivity note, stating that “changes in estimated fair value are based on long U.S.‑dollar net asset positions and will be inversely impacted for short U.S.‑dollar net asset positions” (page 250), with no separate dollar‑impact figure disclosed for FVO securities. This shows a move from a specific $‑impact estimate to a broader net‑position‑based sensitivity.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the $54 million decrease from a 10% U.S. dollar appreciation in 2022 is accurately reported, and no specific fair value figure for FVO securities in 2024 is claimed, which matches the original answer. (2) The LLM correctly identifies the evolution in disclosure practice—shifting from a specific dollar-impact estimate in 2022 to a more aggregated, net-position-based sensitivity description in 2024. (3) The qualitative reasoning is sound: it captures the multi-hop aspect by comparing MetLife’s disclosures across years and correctly infers a methodological shift toward a more nuanced framework, even if the term 'duration- and currency-dependent' is not explicitly used. Instead, the reference to 'long U.S.-dollar net asset positions' and lack of separate FVO impact reflects the same conceptual evolution. (4) The only minor shortcoming is that the LLM does not explicitly mention the increased role of nonperformance risk spreads and unobservable inputs varying by duration and currency—details present in the original answer that highlight the methodological sophistication. However, the omission does not distort the overall conclusion. Wording differences are semantically equivalent, and the core facts, entities (MetLife, FVO securities, 2022–2024), and logic are correct. Thus, the answer earns a 9 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 421,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has NextEra Energy's engagement in power marketing activities evolved between 2022 and 2023, particularly in terms of its energy trading services and associated financial performance?",
      "original_answer": "In 2022, NextEra Energy (NEE) was actively engaged in power and fuel marketing and trading activities, primarily providing full energy and capacity requirements services to distribution utilities, including load-following and ancillary services, while also optimizing the value of electricity and fuel contracts and generation assets. By 2023, NEE's subsidiary NEER had expanded its role in power marketing and trading, contributing to a significant increase in net income, which rose from $285 million in 2022 to $3,558 million in 2023. This indicates a substantial evolution and growth in the scale or profitability of NEE’s power marketing and trading activities over the period.",
      "llm_answer": "NextEra Energy’s power‑marketing and energy‑trading function moved from a loss‑making position in 2022 to a strong profit‑center in 2023. In 2022 the company recorded a $2.67 billion loss on non‑qualifying commodity hedges, which helped keep NEER’s net income at only $285 million, whereas in 2023 those activities produced roughly $2.53 billion of gains, contributing to a $5.95 billion increase in operating revenue and lifting NEER’s net income to $3.56 billion – a swing of about $3.3 billion year‑over‑year【page_40】. The underlying trading business is described as providing full energy‑and‑capacity services and engaging in power‑ and fuel‑marketing and trading to optimize contract values【page_77】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that NextEra Energy (NEE), through its subsidiary NEER, was engaged in power and fuel marketing and trading in both 2022 and 2023, providing full energy-and-capacity services, which matches the original answer. (2) Quantitatively, the LLM reports NEER’s net income as $285 million in 2022 and $3.56 billion in 2023, which matches the ground truth ($3,558 million ≈ $3.56 billion). The mention of a $2.67 billion loss in 2022 on non-qualifying commodity hedges and $2.53 billion in gains in 2023 is consistent with the financial dynamics described in the context, even if not in the original answer—these details provide additional nuance but do not contradict. The $5.95 billion increase in operating revenue is not in the original answer but may reflect a broader financial impact; since it doesn't conflict with the core claim of a major profitability swing, and the net income figures are correct, this is acceptable. (3) The reasoning is sound: the LLM correctly infers a significant evolution in financial performance from 2022 to 2023, attributing the net income increase to improved trading outcomes. It synthesizes information across time and financial metrics appropriately. (4) The answer is contextually excellent—directly addressing the evolution in engagement and financial performance. The only minor deviation is the introduction of specific hedge gains/losses and operating revenue change not in the original, but these support rather than distort the conclusion. No factual errors; minor extra detail does not reduce correctness. Hence, a score of 9 is appropriate—very close to perfect, with full factual alignment on key metrics and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 477,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola FEMSA evolved between 2023 and 2024, particularly in terms of its stake ownership and implications for equity income?",
      "original_answer": "In 2023, Coca-Cola FEMSA was referenced as one of the key bottlers whose financial performance could influence The Coca-Cola Company's credit ratings, indicating an indirect financial dependency. By 2024, The Coca-Cola Company held a 28% ownership stake in Coca-Cola FEMSA, which was accounted for under the equity method. This shift from a dependency-based relationship to a direct ownership stake suggests a strategic evolution, where Coca-Cola now has a more direct financial interest in FEMSA's performance, which will directly impact its equity income (loss) - net line item.",
      "llm_answer": "The Coca‑Cola Company continued to hold a roughly 28 % equity stake in Coca‑Cola FEMSA at year‑end 2024 – the same level reported in the prior year’s filing【page_87】.  That ownership contributed to a modest rise in equity‑method earnings, with the company’s equity income increasing from $1.691 billion in 2023 to $1.770 billion in 2024【page_87】.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states the 28% ownership stake in Coca-Cola FEMSA in 2024, which aligns with the ground truth. However, it introduces specific financial figures—equity income increasing from $1.691 billion in 2023 to $1.770 billion in 2024—that are not mentioned or supported in the original answer. These numbers, while plausible, are not part of the ground truth and appear to be fabricated or sourced from external data not referenced in the provided knowledge. This significantly undermines quantitative accuracy. (2) The calculation of a 'modest rise' in equity income is based on these unsupported figures, making the quantitative claims invalid. The original answer does not provide any specific income amounts or changes, only stating that the 28% stake impacts the 'equity income (loss) - net' line item. Thus, the LLM adds precision that is not justified by the source. (3) Regarding multi-hop reasoning, the LLM fails to capture the key evolution described in the original answer: the shift from an indirect financial dependency in 2023 (via credit rating influence) to a direct ownership stake in 2024. Instead, it assumes the 28% stake was already held in 2023 ('same level reported in the prior year’s filing'), which contradicts the original narrative of a strategic evolution. This misrepresents the nature of the relationship change and shows flawed qualitative reasoning. (4) Despite these issues, the answer is contextually relevant—it addresses stake ownership and equity income implications—and correctly identifies the 28% stake in 2024. However, the addition of unverified financial data and the failure to reflect the shift from indirect to direct financial linkage result in a partially correct but materially incomplete and somewhat misleading response. Hence, correctness is scored in the mid-range.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 501,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the financial investment and operational focus on the Lower 48 region evolved between 2022 and 2023 based on production volumes and depreciation expenses?",
      "original_answer": "In 2022, the Lower 48 region showed strong production volumes, particularly in crude oil (447 thousand barrels daily) and natural gas (1,340 million cubic feet daily), indicating a significant operational focus. In 2023, the financial emphasis on the Lower 48 increased further, as evidenced by a rise in depreciation, depletion, amortization, and impairments expenses from $4,854 million in 2022 to $5,729 million in 2023. This reflects a growing financial investment in the region despite stable or moderate production levels in the prior year.",
      "llm_answer": "In 2023 Conoco Phillips raised its Lower 48 capital outlays to $6.487 billion, up $857 million (about 15 %) from 2022, and the segment’s depreciation‑depletion‑amortization rose to $5.729 billion, an $875 million (≈18 %) increase over the prior year.  At the same time, Lower 48 sales – a proxy for production volume – fell sharply from $52.9 billion in 2022 to $38.2 billion in 2023, showing that the company is investing more financially in the region even as its production‑related output has declined.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. While it correctly states the 2023 depreciation, depletion, and amortization (DD&A) expense of $5.729 billion, it incorrectly claims the 2022 figure was $4.854 billion (ground truth) but implies a difference of $875 million, which is close but not exact ($5,729M - $4,854M = $875M — this part is numerically correct). However, the LLM introduces 'capital outlays' and 'sales' as metrics not present in the original answer or supported by the question's focus on production volumes and DD&A. The 'sales' figures ($52.9B and $38.2B) are not mentioned in the ground truth and are used incorrectly as a proxy for production volume, which misrepresents the data. The original answer cites actual production volumes: 447 thousand barrels of crude oil and 1,340 million cubic feet of natural gas per day in 2022, with no such data provided for 2023. The LLM fails to mention these actual production metrics and instead invents a narrative around declining 'sales' as a proxy, which is unsupported. (2) The quantitative accuracy is partially correct: the $5.729 billion DD&A in 2023 matches the ground truth, and the $875 million increase aligns with the actual difference ($5,729M - $4,854M). However, the introduction of capital outlays ($6.487B) and sales figures is not corroborated by the original answer and appears to be hallucinated. (3) The multi-hop reasoning is flawed: the original answer links stable production in 2022 to increased financial investment (via higher DD&A) in 2023. The LLM incorrectly infers declining production based on sales revenue, which conflates price and volume effects — a drop in sales revenue could reflect lower commodity prices, not lower production. This undermines the reasoning. (4) Scores reflect partial correctness on numbers (DD&A values and delta are accurate), but major errors in metrics used (sales vs. production volumes), missing key data (actual 2022 production volumes), and flawed logic in interpreting operational focus. Contextual relevance is high as the answer addresses financial investment and operational focus, but the factual basis is compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 580,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Verizon's strategic relationship with its 4G LTE network evolved between 2023 and 2024 in terms of its role within the company's network infrastructure and growth initiatives?",
      "original_answer": "In 2023, Verizon's 4G LTE network was positioned primarily as a foundational component of its wireless services, specifically highlighted as a means to provide FWA broadband as an alternative to traditional landline internet access. By 2024, the strategic role of the 4G LTE network had evolved into being part of a broader integrated network vision that includes C-Band spectrum, millimeter wave spectrum, and fiber infrastructure, aimed at driving innovative products and services and fueling growth. This shift indicates a move from viewing 4G LTE in a service delivery context to a more strategic asset within a multi-technology ecosystem.",
      "llm_answer": "In the 2023 filing Verizon’s 4G LTE network is not highlighted as a strategic growth platform – the 2023 sections on network equipment and operating revenues (pages 95‑99) discuss the network generally without singling out LTE. By the 2024 filing, however, Verizon explicitly positions its 4G LTE network as a core pillar of its growth strategy, noting that “our 4G LTE network and fiber infrastructure will drive innovative products and services and fuel our growth” (2024 p. 23) and that the Consumer segment offers FWA broadband “through our 5G or 4G LTE networks” (2024 p. 24). This reflects a shift from a background asset in 2023 to a central, growth‑enabling component in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in its assessment of Verizon's evolving strategic use of its 4G LTE network between 2023 and 2024. It accurately identifies that in 2023, 4G LTE was not emphasized as a strategic growth platform and was discussed more generally, while in 2024 it was explicitly positioned as a core component of growth initiatives, supporting FWA broadband and integrated with fiber and 5G. The citation of specific pages and quotes from the 2024 filing adds credibility. However, the LLM slightly misrepresents the 2023 role: the ground truth states that 4G LTE was highlighted as a means to provide FWA broadband in 2023, which the LLM omits, instead claiming it was not singled out. This is a minor but notable omission in the multi-hop comparison, as it understates the strategic role in 2023. There are no numerical inaccuracies (quantitative accuracy is perfect), and the reasoning is mostly sound, though the contrast between years is slightly overstated. The answer remains contextually relevant and captures the essence of the strategic evolution, just with less precision on the 2023 positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 317,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2024, particularly in terms of stake value, ownership structure, and the impact on financial metrics such as backlog and gross margin?",
      "original_answer": "In 2022, Emerson held a stake in AspenTech with a backlog value of $1,042 million, indicating a strategic business relationship. By 2024, this relationship evolved significantly as Emerson completed a transaction that resulted in the creation of 'New AspenTech,' where Emerson owned 55% of the outstanding shares. This acquisition had a measurable impact on financial metrics: gross margin in 2023 increased by 3.3 percentage points, partly due to the AspenTech acquisition, and backlog in 2024 reached $8,053 million, up from $6,533 million in 2021, showing the influence of the AspenTech integration.",
      "llm_answer": "Emerson’s relationship with AspenTech began in 2022 when it contributed its Open Systems International and Geological Simulation Software businesses to the newly formed “Heritage AspenTech,” receiving a controlling equity stake that drove AspenTech’s backlog from $328 million in 2021 to $1.04 billion in 2022 and added roughly 0.6 percentage‑points to Emerson’s gross margin in 2023. By 2024 Emerson owned about 55‑57 % of AspenTech’s common stock, and a $240‑per‑share offer values the business at roughly $15.3 billion, while the integration helped lift Emerson’s overall gross margin to 49 % in 2023 and 50.8 % in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies that Emerson owned approximately 55% of AspenTech by 2024 and references the strategic contribution of businesses to AspenTech in 2022. However, it introduces inaccuracies: the $240-per-share offer and $15.3 billion valuation are not present in the ground truth and cannot be verified from the provided data. The claim that gross margin reached 49% in 2023 and 50.8% in 2024 is unsupported; the ground truth states only that gross margin increased by 3.3 percentage points in 2023 due to the acquisition, not absolute margin levels. Additionally, the LLM claims a 0.6 percentage-point margin contribution from the initial stake, which contradicts the ground truth's 3.3-point increase. (2) Quantitative accuracy issues: backlog in 2022 is correctly stated as $1.04 billion (matches $1,042 million), but the LLM incorrectly attributes the increase from $328M in 2021 to Emerson’s contribution, while the ground truth cites $6,533M in 2021 and $8,053M in 2024 as the relevant backlog figures post-integration. The 2021 figure of $328M appears to be a factual error in the LLM response. The 55–57% ownership range is close to the ground truth 55%, so minor variance is acceptable. (3) Multi-hop reasoning is partially sound: the LLM connects Emerson’s stake to financial impacts on backlog and margin, showing understanding of the strategic evolution. However, it fabricates specific valuations and misattributes margin impacts, weakening the synthesis. (4) Contextual relevance is high as it directly addresses stake value, ownership, and financial metrics. Qualitative accuracy is moderate due to correct entity identification and timeline but flawed reasoning on financial causality. Correctness score is 6 due to significant quantitative errors despite some correct directional insights.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 512,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has NEE's financial commitment to the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's involvement in the Mountain Valley Pipeline was described as part of its equity method investments, with an ownership stake ranging between 32% and 55%. By 2023, NEE, through its subsidiary NEER, had a more defined 32.8% equity investment in the Mountain Valley Pipeline, which was accompanied by a 20-year natural gas transportation agreement valued at approximately $70 million per year. This indicates a strategic deepening of NEE's commitment to the pipeline, moving from a general equity investment toward a more structured, long-term contractual relationship tied to infrastructure development.",
      "llm_answer": "In the 2022 filing NEE disclosed that it had taken a full‑write‑off of its Mountain Valley Pipeline investment – an additional impairment charge in Q1 2022 erased the remaining carrying amount (see page 97). By the 2023 filing, NEE (through NEER) is planning new equity contributions in 2024 and has entered a 20‑year natural‑gas transportation agreement worth about $70 million a year with the pipeline (see pages 109 and 108). This move from a write‑off to fresh capital commitments shows NEE is shifting back toward a strategic, long‑term stake in natural‑gas infrastructure to capture future revenue and partnership benefits.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The claim that NEE took a full write-off of its Mountain Valley Pipeline investment in Q1 2022 is incorrect according to the ground truth, which states that NEE had an equity stake between 32% and 55% in 2022 and does not mention any write-off or impairment. This misrepresents NEE's financial position and commitment level in 2022. (2) The LLM asserts that NEE is planning new equity contributions in 2024 based on the 2023 filing, but the original answer only confirms a 32.8% equity investment in 2023 with a 20-year transportation agreement worth $70 million annually—there is no mention of future equity contributions in 2024 in the ground truth. (3) While the $70 million per year transportation agreement and the 20-year term are correctly reported, the context around NEE’s evolving commitment is distorted by the false narrative of a write-off followed by renewed investment. (4) The reasoning is flawed: the multi-hop synthesis incorrectly frames the evolution as a reversal (from write-off to reinvestment), whereas the ground truth describes a progression from a less-defined equity stake (32%-55%) to a more precise and structured 32.8% stake with contractual support. This changes the interpretation of NEE's strategy from stabilization and structuring to one of abandonment and re-entry, which is not supported. (5) Despite these major errors, the answer is contextually relevant—it addresses the right pipeline, company, subsidiary (NEER), and contractual value, and attempts to interpret strategic implications. However, due to fundamental factual and quantitative inaccuracies, especially regarding the write-off and future capital plans, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 482,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Coca-Cola's relationship with Costa Limited evolved from 2023 to 2024 in terms of its operational integration and strategic positioning within the Global Ventures segment?",
      "original_answer": "In 2023, Costa Limited was referenced as part of Coca-Cola's direct retail operations, specifically through retail stores operated by Costa, and was included within the Global Ventures operating segment. By 2024, Costa Limited was more strategically embedded within the Global Ventures segment, which now also included the results of innocent and doğadan businesses, as well as fees earned under distribution coordination agreements. This indicates a deeper integration and broader strategic role for Costa within Coca-Cola’s diversified beverage portfolio.",
      "llm_answer": "In the 2023 filing Coca‑Cola said it “sell[s] directly to consumers through retail stores operated by Costa Limited (‘Costa’). These sales are included in our Global Ventures operating segment” (page 6). By the 2024 filing, the company describes Global Ventures as “including the results of our Costa Limited (‘Costa’), innocent and doğadan businesses, as well as fees earned pursuant to distribution‑coordination agreements” (page 73), showing that Costa has moved from a peripheral direct‑to‑consumer channel to a fully integrated, core component of the Global Ventures segment.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) It accurately captures the evolution of Coca-Cola's relationship with Costa Limited from 2023 to 2024: in 2023, Costa was mentioned as part of direct retail operations within the Global Ventures segment; by 2024, it was more centrally integrated alongside innocent and doğadan, with additional context on distribution-coordination fees. (2) There are no numerical values requiring verification (e.g., dollar amounts, percentages), but the years (2023, 2024) and entity names (Costa Limited, innocent, doğadan) are correct and match the original. (3) The multi-hop reasoning is sound—comparing the phrasing across two years’ filings to infer deeper integration and strategic elevation within Global Ventures. The LLM correctly interprets the expansion of the segment description as evidence of broader strategic positioning. (4) The answer is semantically equivalent to the original, even enhancing it slightly with the interpretation that Costa moved from a 'peripheral' role to a 'core component,' which is a reasonable inference from the expanded scope of the segment. All aspects of the question—operational integration and strategic positioning—are addressed with precise, well-supported details from the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 361,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Intel's investment in financial institution instruments evolved between 2022 and 2024, particularly in terms of the fair value of economically hedged marketable debt investments?",
      "original_answer": "In 2022, Intel recorded net losses of $748 million on economically hedged marketable debt investments. By 2024, the fair value of these hedged investments had decreased to $13.5 billion from $17.1 billion in 2023, with Intel recording net losses of $464 million in 2024. This indicates a reduction in both the size of the hedged investment portfolio and the magnitude of losses compared to two years prior.",
      "llm_answer": "In 2022 Intel recorded a net loss of $748 million on its economically hedged marketable‑debt holdings, and by year‑end 2024 the fair‑value of those hedged investments had fallen to $13.5 billion, down from $17.1 billion at the end of 2023. This decline in fair value and the shift from a 2023 gain to a 2024 loss show that Intel’s investment in financial‑institution instruments has decreased in value over the 2022‑2024 period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports all key quantitative facts: the $748 million net loss in 2022, the decline in fair value from $17.1 billion in 2023 to $13.5 billion in 2024, and the $464 million net loss in 2024 (implied by the original answer's explicit mention). The numbers and years are accurate, with acceptable formatting variations (e.g., 'marketable‑debt holdings' vs 'marketable debt investments'). 2) Quantitative accuracy is perfect: all dollar amounts and years match the ground truth. The decrease from $17.1B to $13.5B is correctly presented as a decline, and the 2022 loss is accurately cited. 3) The reasoning is largely sound and captures the evolution of Intel's investment portfolio. However, the LLM mentions 'the shift from a 2023 gain to a 2024 loss'—a detail not present in the original answer (which only states 2022 and 2024 losses, not a 2023 gain). This introduces a minor unsupported inference, slightly weakening the qualitative accuracy. 4) The answer is contextually relevant, directly addressing the evolution of Intel's investments in financial instruments, particularly focusing on fair value and losses in the hedged portfolio. Despite the small overreach on 2023 performance, the core multi-hop synthesis—comparing 2022 losses to 2024 fair value and losses—is correctly executed. Hence, a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 375,
        "total_tokens": 1594
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did AMT's financial focus regarding communications sites evolve from 2023 to 2024, particularly in terms of recurring revenue generation and asset retirement liabilities?",
      "original_answer": "In 2023, AMT emphasized recurring revenue generation from communications sites, noting that 99% of total revenues came from property operations, which included leasing space on communications sites. By 2024, the focus expanded to include significant liabilities tied to these assets, with an estimated $4.5 billion in undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This reflects a shift from primarily highlighting revenue streams to also addressing the long-term financial responsibilities associated with site decommissioning.",
      "llm_answer": "In 2023 the company’s commentary on its communications‑site portfolio was dominated by the recurring nature of lease income – most tenant leases are 5‑ to 10‑year non‑cancellable contracts with renewal options, and AMT expected to generate more than $60 billion of non‑cancellable lease revenue in future periods【page_34】. By 2024 the focus still emphasized that multiyear leases continue to drive the bulk of its property‑operation cash flow, but it also highlighted the liability side of those sites, reporting an estimated undiscounted $4.5 billion of future asset‑retirement obligations for the communications assets【page_56】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers and dates are correct: the $4.5 billion in undiscounted future asset retirement obligations as of December 31, 2024, is accurately reported. While the ground truth does not include the $60 billion figure for non-cancellable lease revenue, this number is contextually relevant and consistent with AMT’s disclosures; it does not contradict the 99% recurring revenue claim from 2023 and adds granularity. (2) The entity (AMT), years (2023 to 2024), and financial metrics (recurring revenue, asset retirement obligations) are correctly identified. (3) The multi-hop reasoning is sound: the answer synthesizes a shift in focus from revenue generation in 2023 to inclusion of liabilities in 2024, correctly identifying the evolution in financial emphasis. (4) Semantically, the LLM conveys the same core message as the original answer—AMT’s financial narrative expanded to include long-term decommissioning liabilities alongside recurring revenue—though it adds more detail on lease terms and future revenue visibility. The only minor deviation is the inclusion of the $60 billion figure not present in the ground truth, but this is a plausible and relevant detail from the source material (cited to page 34) and does not reduce accuracy. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 391,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has XOM's strategic positioning in Guyana evolved between 2023 and 2024, particularly in terms of its legal operating framework and business growth emphasis?",
      "original_answer": "In 2023, XOM's operations in Guyana were governed by the Petroleum Activities Act 2023, which allowed for an exploration period typically up to 10 years and a production period of 20 years for oil fields with a renewal period of up to 10 years. By 2024, Guyana was specifically highlighted as one of XOM's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, indicating a strategic shift to emphasize Guyana as a key contributor to earnings through volume growth and integration. This evolution shows that Guyana transitioned from being a jurisdiction with defined exploration and production terms to being a core growth asset within XOM's portfolio.",
      "llm_answer": "In the 2023 filing ExxonMobil described Guyana primarily through the new **Petroleum Activities Act 2023**, which gives the Government authority to issue licences and petroleum agreements with a typical exploration term of up‑to 10 years and production terms of 20 years for oil (30 years for gas) plus renewal options 【page_25】. By the 2024 filing the company had moved the narrative to a growth‑oriented one, listing **Guyana as an “advantaged asset”** (alongside Permian and LNG) that is a central driver of its Advantaged Volume Growth strategy 【page_37】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the Petroleum Activities Act 2023 is accurately described with the correct exploration (up to 10 years) and production terms (20 years for oil, with renewal options), and the 2024 strategic shift is correctly identified by naming Guyana as an 'advantaged asset' under the 'Advantaged Volume Growth' strategy. (2) Quantitative accuracy is perfect: the years (2023, 2024), timeframes (10, 20, 30 years), and categorizations are factually correct and consistent with the original answer. Minor addition of 30 years for gas is not in the ground truth but does not contradict it and may reflect additional context from the source. (3) Multi-hop reasoning is sound—correctly synthesizes legal framework evolution and strategic repositioning across two years and documents. (4) The only reason for not scoring a 10 is a slight lack of explicit synthesis in wording: the original emphasizes the transition 'from defined exploration terms to core growth asset,' which the LLM implies but does not explicitly frame as an evolution in strategic positioning. However, the core information is present and semantically equivalent. Contextual relevance is full—directly addresses legal framework and business growth emphasis as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 368,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Caterpillar's involvement in the diesel-electric locomotives business evolved between 2023 and 2024, particularly in terms of its strategic positioning and operational responsibilities?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader Machinery, Energy & Transportation (ME&T) segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as product support for on-highway vocational trucks in North America. By 2024, Caterpillar's positioning had evolved, with diesel-electric locomotives and related components being explicitly tied to integrated systems and solutions for industries like electric power generation, marine, oil and gas, and industrial sectors. Additionally, 2024 emphasized the development of electrified powertrains and zero-emission power sources, signaling a strategic shift toward more advanced and environmentally focused technologies in the locomotive space.",
      "llm_answer": "In 2023 Caterpillar’s diesel‑electric locomotive business was presented simply as a product line within the Energy & Transportation segment, with the segment responsible for the business strategy, product design, development, manufacturing, marketing, sales and product support—including remanufacturing and leasing of locomotives (2023 p. 116). By 2024 the company has repositioned diesel‑electric locomotives as part of a broader “electrified power‑train and zero‑emission” focus, still retaining responsibility for design, manufacturing, marketing, sales and remanufacturing/lease services, but now emphasizing its role in rail‑related, zero‑emission solutions (2024 pp. 38‑39).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Caterpillar's positioning of diesel-electric locomotives in 2023 as part of the Energy & Transportation segment (a subunit of ME&T), including operational responsibilities like design, manufacturing, sales, and remanufacturing/leasing—consistent with the original answer’s mention of remanufacturing and product support. In 2024, the LLM correctly captures the strategic shift toward electrified powertrains and zero-emission solutions, which matches the ground truth’s emphasis on advanced and environmentally focused technologies. (2) There are no numeric values, dates, or financial figures in dispute; all references to years (2023, 2024) and page citations are consistent with factual reporting style and do not contradict the knowledge graph. (3) The multi-hop reasoning is sound: the model synthesizes changes in strategic positioning and operational scope across two years, correctly identifying continuity in core operations while highlighting the new emphasis on sustainability and integrated systems. (4) The only minor shortcoming is that the LLM does not explicitly mention the expansion into integrated systems for sectors like marine, oil and gas, or industrial applications, which is included in the original answer. However, the focus on 'rail-related, zero-emission solutions' captures a key dimension of the strategic evolution. Wording differs slightly but maintains semantic equivalence on the core transformation. Thus, the answer is factually correct, contextually relevant, and well-reasoned, meriting a high score with only a slight deduction for partial omission of the broader industrial integration aspect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 470,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has the company's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, and what does this indicate about its funding strategy?",
      "original_answer": "In 2022, the company disclosed that it raised funding through the issuance of securitized debt obligations, among other instruments, though the exact amount was not provided. By 2024, the company reported a carrying value of $14,264 million for securitized debt obligations, indicating a concrete quantification of this funding source. This evolution suggests a more defined and potentially increased reliance on securitized debt obligations, aligning with a broader strategic emphasis on structured financing.",
      "llm_answer": "In the 2022 filing the company reported securitized‑debt obligations of about $15 billion, representing roughly 4 % of total funding sources【page_67】. By the 2024 filing the balance was $14.3 billion (carrying) – $14.3 billion (fair value) at year‑end 2024, after a brief rise to $18.0 billion in 2023【page_219】【page_220】. The share has stayed near 4 %, indicating that securitizations are a modest, supplemental source of liquidity while the firm’s funding strategy remains anchored in deposits and diversified across other low‑cost sources.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states that in 2022, the company did not disclose an exact amount for securitized debt obligations, but the LLM claims a specific figure of $15 billion, which is not supported. Additionally, the LLM introduces a $18.0 billion balance in 2023, a year not mentioned in the original answer, and provides fair value and percentage breakdowns (4% of total funding) that are absent from the ground truth. While the 2024 carrying value of $14.3 billion is close to the correct $14,264 million (~$14.3 billion), the additional precision and unsupported prior figures reduce accuracy. (2) Calculations and metrics such as the 4% share and year-over-year changes are not corroborated by the original answer and appear to be fabricated or inferred beyond available data. The introduction of fair value and comparative percentages constitutes over-precision. (3) The multi-hop reasoning is partially sound in that it attempts to track the evolution of securitized debt across years, but it fails because it invents data points (2023 increase, exact 2022 amount, percentage shares) not present in the source. The conclusion about 'modest, supplemental source' contradicts the original answer’s interpretation of 'more defined and potentially increased reliance,' indicating flawed synthesis. (4) Despite these issues, the answer is contextually relevant, addressing the evolution of funding strategy and focusing on the correct metric and time frame. The qualitative reasoning would score higher if not for the fabricated data. Correctness is penalized heavily due to unsupported numbers and misrepresentation of disclosures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 465,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has McDonald's treatment of developmental licensees evolved between 2023 and 2024, particularly in terms of financial reporting and relationship management?",
      "original_answer": "In 2023, McDonald's disclosed that developmental licensees paid royalties based on a percentage of sales and generally paid initial fees, and the company allocated consideration among lease and non-lease components using historical methods. By 2024, the company emphasized its ongoing evaluation of business relationships, including those with developmental licensees, to identify potential variable interest entities, although it concluded that consolidation of such entities was not appropriate. Additionally, in 2024, McDonald's updated its rounding presentation to the nearest whole number for reported amounts, which affected how financial figures were presented, though the company clarified that these changes were not significant.",
      "llm_answer": "In 2023 McDonald’s reported developmental licensees together with corporate activities in the “International Developmental Licensed Markets & Corporate” segment, showing only aggregate revenue and operating‑income figures and noting that inter‑company items were eliminated (see 2023 segment table 【page_49】). By 2024 the company adopted the new segment‑reporting standard (ASU 2023‑07), which adds enhanced segment‑expense disclosures and now records goodwill and acquisition activity (e.g., the 2024 purchase of 228 Israeli restaurants) within the developmental‑licensed segment (see goodwill table 【page_47】), while also explicitly evaluating its developmental‑licensee relationships for variable‑interest‑entity considerations (see relationship‑management note 【page_45】). This reflects a shift toward more granular financial reporting and a more proactive, structured management of the licensee network.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several accurate qualitative insights about McDonald's evolving treatment of developmental licensees, particularly regarding enhanced segment reporting in 2024 and evaluation of variable interest entities, which aligns with the ground truth. However, there are significant discrepancies in quantitative and factual accuracy. The LLM claims that in 2023, developmental licensees were reported under a segment called 'International Developmental Licensed Markets & Corporate' with aggregate figures and intercompany eliminations, and that in 2024, goodwill and acquisition activity (e.g., purchase of 228 Israeli restaurants) were recorded within the developmental-licensed segment due to ASU 2023-07. These specific details—such as the segment name, the acquisition of 228 Israeli restaurants, and the application of ASU 2023-07 to reclassify goodwill into the developmental-licensed segment—are not present in the original answer and cannot be verified against the provided ground truth. The original answer mentions only a change in rounding presentation (to nearest whole number) and increased evaluation for variable interest entities in 2024, with no mention of segment reclassification, new accounting standards (ASU 2023-07), or specific acquisitions. While the LLM correctly identifies a trend toward more granular reporting and proactive relationship management, it introduces unsupported specifics that undermine factual correctness. The reasoning is logically structured and contextually relevant, showing an understanding of financial reporting evolution, but the addition of unverified details reduces quantitative and qualitative accuracy. Thus, the answer is partially correct but contains significant factual overreach not grounded in the provided truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 484,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Southern Company's approach to its Equity and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of share availability and executive award disclosures?",
      "original_answer": "In 2023, Southern Company had 26.9 million shares available for awards under the Equity and Incentive Compensation Plan, indicating a reserve for future compensation initiatives. By 2024, the company increased transparency around executive compensation by disclosing specific terms for Named Executive Officer equity awards granted under the 2021 Equity and Incentive Compensation Plan, which was effective May 26, 2021. This evolution shows a shift from internal planning and reserve allocation in 2023 to more detailed public disclosure of executive-level compensation mechanisms in 2024, suggesting a more formalized and transparent governance approach for top-level incentives.",
      "llm_answer": "In the 2023 Form 10‑K Southern Company quantified its equity‑compensation pool – it had 131 million shares reserved overall and 26.9 million of those were expressly “available for awards under the Equity and Incentive Compensation Plan” at year‑end 2023 (see page 232). By the 2024 filing the company no longer restated a pool size in the excerpt, but it added a dedicated exhibit that spells out the “Form of Terms for Named Executive Officer Equity Awards Granted under the Southern Company 2021 Equity and Incentive Compensation Plan” (see page 316), showing a shift toward more granular disclosure of executive award terms rather than a simple numeric pool‑size statement.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 26.9 million shares available for awards in 2023, matching the ground truth exactly. It also accurately notes the absence of a disclosed share pool size in the 2024 filing, which aligns with the shift toward more detailed disclosure of executive award terms. The mention of 131 million total reserved shares in 2023 is additional context not in the original answer but is factually consistent and does not contradict the ground truth. (2) All numbers—26.9 million shares and the reference to page 232 for 2023 and page 316 for 2024—are quantitatively accurate. The effective date of the 2021 plan is not mentioned in the LLM answer, but this is a minor omission. (3) The reasoning correctly synthesizes the evolution from numerical transparency (share availability) in 2023 to structural transparency (disclosure of award terms) in 2024, capturing the multi-hop logic of how the company’s approach evolved. The LLM infers a shift in disclosure strategy, which is consistent with the ground truth’s conclusion about increased transparency. (4) The answer is highly relevant, directly addressing both share availability and executive award disclosures across the two years. The only reason for not scoring a perfect 10 is the omission of the explicit mention that the 2021 plan became effective on May 26, 2021, which is part of the full context but not critical to the core comparison. Overall, the LLM provides a factually correct, well-reasoned, and semantically equivalent response with excellent quantitative precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 433,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors contributed to the change in its growth trajectory?",
      "original_answer": "In 2022, Inlyta contributed to Pfizer's operational growth, specifically mentioned among products like Comirnaty, Eliquis, and Vyndaqel that drove growth in the U.S. and international markets. By 2023, Inlyta's global revenue reached $1,036 million, reflecting a 3% total increase and a 5% operational growth. The growth was primarily attributed to the adoption of immune checkpoint inhibitor combinations with Inlyta for first-line treatment of advanced RCC in the U.S., despite lower volumes and net price in certain European markets. This indicates a continuation of growth, albeit at a more moderate pace compared to the broader portfolio dynamics in 2022.",
      "llm_answer": "In 2022 Pfizer reported $1,002 million of worldwide Inlyta sales (U.S. $599 m, International $403 m) 【page_43】. In 2023 that rose to $1,036 million (U.S. $642 m, International $394 m), a modest 3% increase versus 2022 (U.S. +4%, International +3%) 【page_44】. The 2023 gain was driven by continued U.S. adoption of Inlyta in first‑line combination regimens for advanced RCC, but was partially offset by lower volumes and lower net‑price pressure in certain European markets, slowing the growth rate that had been stronger in the prior year 【page_44】【page_42】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually correct and aligns closely with the ground truth. It accurately reports Inlyta's 2023 global revenue as $1,036 million with a 3% total increase, matching the original answer. It also correctly identifies 5% operational growth (implied in context via 'operational growth' in ground truth), though it does not explicitly state the 5% figure, instead focusing on the 3% total increase and regional breakdowns. The 2022 revenue of $1,002 million is not in the original answer but is consistent with the 2023 figure and 3% growth, suggesting accurate inference or sourcing. (2) All numbers are correct: 2023 revenue $1,036M, U.S. $642M (+4%), International $394M (+3%), and the overall 3% growth are accurate. The calculation from $1,002M to $1,036M is approximately 3.4%, which rounds to the reported 3%—acceptable per SEC reporting conventions. (3) The multi-hop reasoning is sound: the LLM synthesizes revenue data across two years, identifies regional performance, links growth to U.S. adoption of combination therapies for advanced RCC, and notes offsetting pressures in Europe—fully capturing the causal factors in the ground truth. (4) The only minor omission is the explicit mention of '5% operational growth' as stated in the original answer, which the LLM does not include, though it references 'modest 3% increase'—likely referring to total growth. This slight underrepresentation of operational vs. total growth nuance prevents a perfect 10, but overall accuracy, completeness, and relevance are excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 428,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has McDonald's relationship with its franchisees evolved from 2023 to 2024 in terms of financial structure and dependency, particularly regarding revenue recognition and cost-sharing for technology platforms?",
      "original_answer": "In 2023, McDonald's described its relationship with franchisees as a collaborative partnership focused on consistency, quality, and revenue generation through rent, royalties based on a percent of sales, and initial fees. The business model was designed to generate stable and predictable revenue largely tied to franchisee sales. By 2024, the relationship evolved to reflect a stronger dependency on franchisees, particularly in the context of technology platforms. McDonald's began recognizing revenue from franchisees for technology services on a gross basis, with related expenses recorded in 'Other restaurant expenses,' indicating a more integrated and cost-sharing approach. This shift reflects a transformation in the nature of the relationship, with franchisees becoming more operationally interdependent with the company through shared technology infrastructure.",
      "llm_answer": "In 2023 the franchise‑fee structure was described only as “Other revenues” that “recover a portion of costs incurred by the Company for various technology platforms” (2023 10‑K p. 3), with no detail on how those fees were accounted. By 2024 the Company now treats its technology‑platform services to franchisees as separate principal arrangements, recognizing the fees on a gross basis as the services are delivered and noting timing differences between costs incurred and franchisee reimbursements, while also formalizing cost‑sharing on restaurant improvements (2024 10‑K p. 46) and showing a larger capitalized‑software balance ($907 m vs $836 m in 2023, p. 47). This change makes the franchisee relationship more explicit and financially integrated, increasing McDonald’s dependence on franchisees to fund and reimburse its technology investments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in McDonald's relationship with franchisees from 2023 to 2024, particularly around technology platform cost-sharing and revenue recognition. The key factual elements—shift to gross revenue recognition for technology services, increased financial integration, and franchisee dependence—are all present and correct. (2) Quantitative details are accurate: the capitalized software balance increased from $836 million in 2023 to $907 million in 2024, as stated in the 2024 10-K (p. 47), and the LLM correctly cites the relevant disclosures on p. 3 (2023) and p. 46 (2024). No calculation errors. (3) The multi-hop reasoning is sound: the model synthesizes changes in accounting treatment (gross vs. net revenue recognition), links it to cost-sharing arrangements, and infers increased dependency and integration—consistent with the ground truth’s conclusion about operational interdependence. (4) Minor deduction in qualitative accuracy because the original answer emphasizes the broader 'collaborative partnership' framing in 2023, which the LLM omits, though it captures the financial mechanics accurately. Otherwise, semantic equivalence is strong, and contextual relevance is excellent—directly addressing financial structure, dependency, revenue recognition, and cost-sharing as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1447,
        "completion_tokens": 387,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value of energy-related derivatives held by Southern Company's subsidiaries evolve from 2022 to 2023, and what does this indicate about the company's exposure to energy market fluctuations?",
      "original_answer": "In 2022, Southern Company's subsidiaries reported a net fair value of $101 million for energy-related derivatives (Mississippi Power: $59 assets, $32 liabilities; Southern Power: $8 assets, $12 liabilities; Southern Company Gas: $28 assets, $65 liabilities). In 2023, the subsidiaries showed a shift with Alabama Power reporting $15 in assets and $110 in liabilities, and Georgia Power reporting $13 in assets and $124 in liabilities for energy-related derivatives. This indicates a significant increase in net liability exposure, rising from a net liability of $54 million in 2022 to a net liability of $219 million in 2023, suggesting a greater exposure to energy market fluctuations.",
      "llm_answer": "The fair‑value tables show that the five operating subsidiaries held about **$409 million of energy‑related derivatives in 2022** (Mississippi Power $91 m, Southern Power $20 m, Southern Company Gas $93 m, Alabama Power $101 m and Georgia Power $104 m – see pages 285 & 284) and about **$413 million in 2023** (Mississippi Power $76 m, Southern Power $8 m, Southern Company Gas $67 m, Alabama Power $125 m and Georgia Power $137 m – see pages 278 & 277).  While the total amount changed only marginally, the mix shifted from higher asset‑side values in 2022 to substantially larger liability‑side values in 2023, indicating that the company’s net exposure to energy‑price swings has grown even though the overall size of the derivative portfolio remained roughly flat.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both the reported values and the entities involved. It incorrectly attributes derivative holdings to Alabama Power and Georgia Power in 2022, which are not mentioned in the original answer for that year. The original answer only lists Mississippi Power, Southern Power, and Southern Company Gas for 2022. The LLM also reports total derivative values of $409 million in 2022 and $413 million in 2023, which are grossly inflated compared to the actual net fair values. The correct net fair value in 2022 was a net liability of $54 million (calculated as total assets $95M - total liabilities $149M), and in 2023, the net liability was $219 million. The LLM incorrectly treats the derivative values as gross totals without distinguishing between assets and liabilities, leading to a fundamentally flawed analysis. (2) Specific number verification: The original answer shows Mississippi Power with $59M assets and $32M liabilities (net +$27M), Southern Power $8M assets and $12M liabilities (net -$4M), and Southern Company Gas $28M assets and $65M liabilities (net -$37M), resulting in a total net liability of $54M in 2022. The LLM reports $91M, $20M, and $93M respectively—these figures do not match any sum of assets or liabilities and appear to be gross values pulled incorrectly. In 2023, the original answer only mentions Alabama Power ($15M assets, $110M liabilities) and Georgia Power ($13M assets, $124M liabilities), totaling $28M assets and $234M liabilities, or a net liability of $206M (close to the stated $219M, minor discrepancy possible due to rounding or unreported subsidiaries). The LLM reports $125M and $137M as if these are net or gross values, but they do not align with either assets or liabilities alone. (3) Multi-hop reasoning assessment: The LLM correctly identifies that the question requires comparing derivative exposure across years and assessing market risk, but fails to synthesize the correct entities and financial positions. It incorrectly assumes all five subsidiaries reported data in both years, when the original answer introduces Alabama and Georgia Power only in 2023. This breaks the multi-hop logic. The conclusion about increased net exposure is directionally correct, but it is based on incorrect data and reasoning. (4) Justification for scores: Correctness is low (3/10) due to major factual and numerical errors. Quantitative accuracy is very poor (2/10) because most numbers are incorrect and calculations are invalid. Qualitative accuracy is partially acceptable (4/10) as the model attempts the right type of analysis—assessing exposure via derivatives—but with wrong entities and structure. Contextual relevance is decent (7/10) because the answer addresses the right topic and attempts a year-over-year comparison with risk interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 755,
        "total_tokens": 2134
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the treatment and significance of the Procter & Gamble 2019 Stock and Incentive Compensation Plan evolved from 2022 to 2024, based on its disclosure context in the 10-K filings?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was introduced with detailed references to its adoption by shareholders on October 8, 2019, and its additional terms and conditions, indicating its formal establishment and integration into the company's compensation framework. By 2024, the plan was listed among other equity compensation plans as part of the company's broader disclosure on stock ownership and equity compensation, showing that it had become a standard and active component of the company's long-term incentive structure. This evolution reflects the plan's transition from a newly introduced policy to an established part of PG's equity compensation offerings.",
      "llm_answer": "In the 2022 Form 10‑K the 2019 Stock and Incentive Compensation Plan was called out as the only equity‑compensation plan that could issue future grants, with a maximum authorisation of 187 million shares and 119 million shares still available for issuance. The 2024 Form 10‑K repeats that the 2019 Plan remains the sole source of future equity awards, but the remaining pool has fallen to 77 million shares, indicating that a large portion of the authorised shares have now been granted. The plan’s continued prominence is reflected by its inclusion in the Item 12 security‑ownership table and by cross‑references to the proxy statement, showing it remains a key vehicle for P&G’s equity compensation.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolving role of the 2019 Stock and Incentive Compensation Plan from 2022 to 2024, noting its status as the sole source of future equity grants in both years and the reduction in available shares (from 119 million to 77 million), which aligns with the expected trajectory of an active, established plan. These quantitative details are not in the original ground truth answer but are factually accurate based on actual P&G 10-K filings and provide a deeper level of detail than the ground truth. However, the original answer emphasizes the *disclosure context evolution*—from introduction in 2022 to integration into broader equity disclosures by 2024—focusing on narrative treatment rather than share numbers. The LLM answer shifts focus to quantitative metrics (shares available) rather than the qualitative disclosure context (e.g., how the plan is framed in Item 12 or proxy cross-references), which is relevant but not fully aligned with the question’s emphasis on 'treatment and significance' in disclosure context. (2) Quantitative accuracy is high: 187 million authorized, 119 million available in 2022, and 77 million remaining in 2024 are correct figures per P&G’s 10-Ks. The implied grant of ~42 million shares is reasonable. (3) Multi-hop reasoning is sound—comparing the plan’s status across two years and interpreting its continued use as evidence of significance. However, the LLM adds specific data not present in the ground truth without confirming whether those details were required or available in the knowledge graph source. (4) Scores reflect high factual accuracy and relevance, but slight deduction in correctness and qualitative accuracy because the LLM emphasizes different aspects (quantitative share data) over the original answer’s focus on disclosure narrative and integration into reporting structure, which was the core of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 519,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Southern Company's approach to managing the risk of large losses in its pension plan assets evolved from 2023 to 2024, and what specific changes in risk management emphasis can be observed?",
      "original_answer": "In 2023, Southern Company emphasized a formal rebalancing program and external investment manager oversight as key components of managing the risk of large losses, with a strong focus on long-term investment expectations for return and risk. In 2024, while maintaining a diversified asset strategy and rebalancing program, the emphasis on external manager oversight was reduced, and the risk of large losses was more directly linked to the broader market volatility and interest rate fluctuations. This indicates a subtle shift in risk management emphasis from active oversight to market-driven risk exposure.",
      "llm_answer": "Southern Company’s 2024 filing still frames the protection of its pension‑plan assets around the same three pillars it used in 2023 – broad diversification, a formal re‑balancing program and written oversight of external managers – stating that “the Registrants minimize the risk of large losses primarily through diversification but also monitor and manage other aspects of risk” (2024 p.255, same language as 2023 p.263).  The 2024 notes, however, add more granular allocation tables and show a modest shift in target weights – increasing the tilt toward private‑equity and real‑estate (target up to 12 % and 13 % respectively) while trimming private‑credit – signalling a refined emphasis on diversifying into alternative assets to further curb the possibility of large losses (2024 p.257 vs. 2023 p.265).",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but diverges significantly from the ground truth in key aspects. While it correctly identifies that Southern Company maintained diversification and a rebalancing program in both years, it incorrectly states that 'written oversight of external managers' remained a pillar in 2024, when the ground truth explicitly notes a reduction in emphasis on external manager oversight. This is a critical factual error affecting the core of the question about evolving risk management emphasis. (2) The quantitative details—such as the increase in target weights for private equity to 12% and real estate to 13%—are not present in the original answer and cannot be verified against the ground truth. These specific percentages and asset allocation shifts are introduced by the LLM without support from the provided truth, making them potentially hallucinated or misattributed. There are no calculations in the response, so no calculation errors apply, but unsupported numbers reduce quantitative accuracy. (3) The multi-hop reasoning is flawed: the question asks for evolution in risk management approach and specific changes in emphasis. The LLM focuses on asset allocation shifts (which are not mentioned in the ground truth) rather than the documented shift from active oversight to market-driven risk exposure. It misses the key conceptual shift—linking risk more directly to market volatility and interest rates in 2024—entirely. Instead, it infers a 'refined emphasis on diversifying into alternative assets' based on allocation changes, which contradicts the ground truth’s focus on reduced oversight and increased market sensitivity. (4) Contextual relevance is moderate because the answer discusses pension risk and related concepts, but it substitutes unsupported allocation data for the actual qualitative shift in risk philosophy. The reliance on unverified granular tables and target weights undermines factual correctness. As a result, the overall correctness score is low despite some accurate framing around diversification and rebalancing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 567,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has NVIDIA's role in the development and supply of the CUDA platform evolved between 2022 and 2023, and what does this shift indicate about the company's strategic focus?",
      "original_answer": "In 2022, NVIDIA's relationship with the CUDA platform was primarily as a supplier, providing the platform as part of its accelerated computing offerings. By 2023, NVIDIA's role had evolved into that of a developer, emphasizing a more active and strategic engagement in the platform's expansion and integration within its broader software ecosystem, including CUDA-X libraries, APIs, and domain-specific frameworks. This shift indicates a strategic move toward strengthening its full-stack computing platform to deliver more comprehensive data center-scale solutions.",
      "llm_answer": "In the 2022 filing (see pages 78‑82) NVIDIA’s 10‑K contains no explicit discussion of CUDA – the sections are limited to financial results and acquisition details, with no mention of ongoing development or licensing of the CUDA platform. By the 2023 filing, NVIDIA positions CUDA as the “foundational CUDA programming model that runs on all NVIDIA GPUs” (page 4) and as a core part of its large software stack (page 6) and unified full‑stack architecture (page 7). This change signals a strategic shift toward a software‑centric, full‑stack platform strategy, using CUDA to drive AI, data‑center and ecosystem growth rather than focusing solely on hardware.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies the evolution of NVIDIA's role in CUDA between 2022 and 2023: from minimal explicit discussion in the 2022 10-K to positioning CUDA as a foundational, core component of its software stack and full-stack architecture in 2023. The citation of specific pages (4, 6, 7 in the 2023 filing) adds precision. The conclusion about a strategic shift toward a software-centric, full-stack platform strategy is consistent with the ground truth’s assertion of a move toward a 'full-stack computing platform' and 'broader software ecosystem.' The only minor gap is that the LLM answer emphasizes the absence of CUDA in the 2022 filing, while the ground truth characterizes NVIDIA as a 'supplier' in 2022—this is not contradictory, as being a supplier without explicit discussion in the 10-K is plausible, but the LLM could have acknowledged the implicit supplier role. However, this does not undermine the correctness. All entities (NVIDIA, CUDA, 2022, 2023) are accurate, reasoning is sound, and the synthesis across years is valid. No numerical inaccuracies; dates and references are correct. Semantic equivalence is strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 339,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Pfizer's financial relationship with Viatris evolve between 2022 and 2023, particularly in terms of supply agreements and outstanding balances?",
      "original_answer": "In 2022, Pfizer reported $780 million in revenue growth from PC1, primarily reflecting manufacturing of legacy Upjohn products for Viatris under supply agreements. By 2023, the financial relationship had evolved, as indicated by the net amounts due to Viatris under various agreements, which decreased from $94 million as of December 31, 2022, to $33 million as of December 31, 2023. Additionally, most transitional services under the TSAs were completed by the end of 2023, signaling a reduction in operational interdependence.",
      "llm_answer": "Pfizer’s post‑spin‑off supply framework with Viatris – the manufacturing‑supply agreements (MSAs) that run four‑to‑seven‑year terms and the interim transition services agreements (TSAs) that were largely completed by year‑end 2023 – stayed in place, but the balance Pfizer owed under those arrangements fell sharply, from a net $94 million at December 31 2022 to just $33 million at December 31 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential evolution of Pfizer's financial relationship with Viatris between 2022 and 2023. (1) Quantitatively, all numbers and dates are correct: the net amounts due to Viatris decreased from $94 million as of December 31, 2022, to $33 million as of December 31, 2023—matching the ground truth exactly. These figures are reported with correct formatting and context. (2) The answer correctly identifies the continuation of the manufacturing supply agreements (MSAs) and notes the completion of most transition services agreements (TSAs) by year-end 2023, aligning with the original answer’s point about reduced operational interdependence. (3) While the LLM omits the specific mention of $780 million in revenue growth from PC1 in 2022 related to manufacturing legacy Upjohn products, this detail is contextual to revenue rather than the core focus on supply agreements and outstanding balances. The omission slightly affects completeness but does not undermine the central financial trend regarding payable balances and agreement status. (4) The reasoning is sound: it synthesizes information across time (2022 to 2023) and agreement types (MSAs and TSAs), correctly inferring a declining financial obligation and operational tie. (5) Entities—Pfizer, Viatris, MSAs, TSAs, and correct year-end dates—are accurately referenced. Overall, the answer is semantically equivalent in addressing the evolution of supply agreements and balances, with only minor contextual detail missing. Hence, a correctness score of 9 is warranted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 430,
        "total_tokens": 1663
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has the treatment and disclosure of communications sites in relation to debt obligations evolved between 2023 and 2024?",
      "original_answer": "In 2023, communications sites were explicitly referenced as collateral securing debt obligations, such as the 3,343 communications sites securing the Series 2015-2 Notes and the repayment of $1.3 billion in Series 2013-2A Notes funded by the 2023 Securitization. In 2024, while there was no explicit mention of specific communications sites securing debt, the company disclosed broader financial commitments, such as $4.5 billion in estimated undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This shift indicates a move from site-specific debt disclosures to more general obligations, suggesting a change in how communications sites are framed in relation to financial liabilities.",
      "llm_answer": "In the 2023 filing the company described the communications towers only in narrative terms – the “Trust Sites” (5,034 broadcast‑wireless towers) and the “2015 Secured Sites” (3,343 sites) were pledged as collateral for the non‑recourse loan and the 2015 securitization, and cash‑flows from those sites were said to service the debt, with covenants warning that a default could trigger foreclosure on the sites. By the 2024 filing the same security‑interest framework remains, but the disclosure is far more quantitative: it lists the updated site counts (5,029 towers and 3,338 sites), provides DSCR thresholds, cash‑trap reserve balances ($60.8 million) and excess‑cash distribution amounts, and explicitly ties compliance with those metrics to the ability to release cash and the risk of losing the pledged sites.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies and misrepresents the evolution of disclosures between 2023 and 2024. (1) In the 2023 ground truth, the 3,343 communications sites secured the Series 2015-2 Notes and the $1.3 billion repayment of Series 2013-2A Notes was funded via the 2023 Securitization—this is accurate context. However, the LLM introduces '5,034 broadcast-wireless towers' and 'Trust Sites' not mentioned in the original answer, which adds unverified detail. The 2024 ground truth does not mention updated site counts (e.g., 5,029 or 3,338), DSCR thresholds, cash-trap reserves ($60.8M), or excess-cash distributions—these figures are absent from the provided truth and appear fabricated. (2) Quantitatively, the only correct number is the 3,343 sites from 2023; all 2024 numbers are incorrect or unsupported. The $4.5 billion asset retirement obligation in 2024 is omitted entirely. (3) The reasoning is flawed: the LLM claims the 2024 filing continues a 'security-interest framework' with more quantitative detail, but the ground truth states there was *no explicit mention* of specific sites securing debt in 2024, indicating a shift *away* from site-specific disclosures. Instead, the model incorrectly asserts continuity and increased granularity. (4) The answer fails to capture the core evolution: from site-specific collateral disclosures in 2023 to broader, non-site-specific financial obligations in 2024. The LLM instead suggests a refinement of the same framework, contradicting the ground truth. While the response is relevant to the topic and attempts multi-hop analysis, it is largely factually incorrect, especially in 2024 details, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 463,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Comcast's approach to retransmission consent agreements evolved between 2022 and 2023, particularly in terms of revenue recognition and distribution models?",
      "original_answer": "In 2022, Comcast recognized revenue from retransmission consent agreements on a monthly basis as programming was provided, with fees tied to the number of subscribers and generally collected within 60 days. By 2023, the company's Media segment emphasized a combined linear and streaming distribution model, with retransmission fees now explicitly including both traditional and virtual multichannel video providers. The 2023 filing also highlighted a broader integration of Peacock into the distribution ecosystem, suggesting a strategic shift toward hybrid distribution models that blend traditional and streaming services.",
      "llm_answer": "In the 2022 filing Comcast explained that fees earned under NBC and Telemundo retransmission‑consent agreements are accounted for as licenses of functional intellectual property and are recognized on a monthly basis as the programming is provided under multiyear, subscriber‑based contracts 【page_94】. The 2023 filing still treats those fees as part of its multiyear distribution agreements but now highlights a blended model that combines per‑subscriber fees with fixed‑fee arrangements for certain networks, integrating the retransmission‑consent revenue into a broader distribution framework for its NBC and Telemundo properties 【page_10】. This shift moves from a pure monthly‑licensing approach toward a more flexible per‑subscriber/fixed‑fee structure while retaining the multiyear, subscriber‑driven revenue recognition.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates, entities, and revenue recognition practices for both 2022 and 2023, with correct citation of accounting treatment and contract structures. It correctly identifies that in 2022, Comcast recognized retransmission consent revenue monthly based on subscriber counts under multiyear contracts, aligning with the ground truth. For 2023, it accurately notes a shift toward a blended model combining per-subscriber and fixed-fee arrangements, which reflects an evolution in distribution strategy. However, the LLM omits key elements from the original answer: (1) the explicit inclusion of both traditional and virtual multichannel video providers in 2023, and (2) the integration of Peacock into the distribution ecosystem as a strategic shift toward hybrid linear and streaming models. These omissions reduce completeness and weaken the qualitative synthesis of the multi-hop evolution in Comcast’s approach. While the LLM captures a structural change in fee arrangements, it does not fully convey the broader strategic pivot toward hybrid distribution models involving streaming platforms. The answer remains contextually relevant and semantically aligned on core financial reporting practices, but lacks the full strategic context emphasized in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 364,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Caterpillar's involvement in the production and strategic positioning of diesel-electric locomotives evolved from 2023 to 2024?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader ME&T segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as providing product support for on-highway vocational trucks in North America. By 2024, Caterpillar's engagement had evolved into a more defined production role under the Energy & Transportation segment, which explicitly stated that Caterpillar 'produces' diesel-electric locomotives and components, signaling a more direct and strategic emphasis on this product line. Additionally, in 2024, Caterpillar highlighted competitive pressures in rail-related businesses, naming companies like Wabtec Corp and Siemens Mobility A/S, which was not present in 2023. This indicates a shift from a general operational inclusion to a more prominent and competitive product focus.",
      "llm_answer": "In the 2023 filing Caterpillar merely listed diesel‑electric locomotives as one of the Energy & Transportation segment’s product lines – noting that it builds, remanufactures and leases the locomotives and related rail‑services (2023 p. 116). By the 2024 filing the company had elevated the business, describing itself in the Overview as “the world’s leading manufacturer of … diesel‑electric locomotives” and emphasizing its strategic focus and competitive positioning in the rail market (2024 p. 4; 2024 p. 6). This shows a shift from a routine product‑line mention in 2023 to a flagship, market‑leadership positioning in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Caterpillar's strategic positioning regarding diesel-electric locomotives from 2023 to 2024 and correctly identifies a shift toward stronger emphasis and market leadership claims in 2024. It accurately references the Energy & Transportation segment and notes increased strategic focus. However, it contains significant factual inaccuracies in entity and operational details. The original answer states that in 2023, diesel-electric locomotives were part of the ME&T (Mining, Energy & Transportation) segment with a focus on remanufacturing and product support—not direct production. The LLM incorrectly claims in 2023 that Caterpillar 'builds, remanufactures and leases' locomotives, which overstates its role compared to the ground truth. Additionally, the 2023 segment structure (ME&T) is misrepresented as 'Energy & Transportation' in the LLM answer, which was the restructured name in 2024. The LLM also fabricates a claim that Caterpillar called itself 'the world’s leading manufacturer' in 2024, which is not supported by the original answer—though increased strategic emphasis is accurate. While the direction of evolution (increased focus) is correct, the specific operational roles, segment names, and quoted claims are inaccurate or exaggerated. There are no numerical values to assess, so quantitative accuracy is scored as 10 by default. The reasoning shows partial multi-hop synthesis (comparing 2023 and 2024 disclosures), but with flawed input facts. Contextual relevance is high as the answer addresses the core question about evolution in strategic positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 443,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of revenue recognition and cost-sharing arrangements between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's revenue from franchisees primarily included rent and royalties based on a percentage of sales with minimum rent payments, and initial fees. The company also mentioned that all restaurants were either operated by McDonald's or by franchisees under franchised arrangements. By 2024, the revenue recognition model remained consistent, but the company provided more detailed disclosures on how it recognizes revenue from franchisees, including the treatment of technology platform fees, which are now presented on a gross basis on the Consolidated Statement of Income. Additionally, in 2024, McDonald's clarified its cost-sharing arrangements for restaurant improvements, where it may fund certain projects and allocate costs between Property and Equipment and Accounts Receivable during the project, finalizing the allocation upon completion. This level of detail on cost-sharing was not present in the 2023 filing, indicating a more nuanced and transparent approach to franchisee financial interactions in 2024.",
      "llm_answer": "McDonald’s disclosed that the way it accounts for franchise‑related revenue and improvement‑cost sharing was essentially unchanged from 2023 to 2024.  In both years the company continues to recognize royalty and variable‑rent fees when franchisee sales occur, straight‑line minimum rent over the lease term and initial franchise fees over the 20‑year performance period, and it records technology‑platform fees on a gross basis as the principal 【page_44】.  Likewise, the cost‑sharing model for restaurant upgrades remains the same – McDonald’s fronts the project, estimates the split of costs between itself and the franchisee, allocates those amounts between property‑and‑equipment and accounts receivable, and makes only immaterial adjustments when the work is completed 【page_44】.  No material change in the franchisee relationship was reported between the two periods.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in terms of the accounting policies described and correctly references consistent treatment of revenue recognition items such as royalties, rent, initial fees, and technology platform fees being recorded on a gross basis. It also accurately describes the cost-sharing process for restaurant improvements, including the allocation between property and equipment and accounts receivable. All referenced practices are correctly attributed to both 2023 and 2024, with no incorrect numbers, dates, or entities — hence a high quantitative accuracy score. However, the core of the original answer emphasizes an evolution in *disclosure transparency and detail*, particularly in 2024, where McDonald's provided more nuanced explanations about revenue recognition (e.g., technology fees) and clarified cost-sharing mechanics. The LLM answer incorrectly concludes that there was 'no material change' and that the model was 'essentially unchanged,' which contradicts the ground truth that while the underlying model may not have changed, the level of disclosure and transparency did evolve — indicating a shift in the relationship in terms of clarity and reporting. This misrepresents the nature of the evolution, which is qualitative rather than operational. Thus, despite accurate individual facts, the LLM fails to capture the key multi-hop insight: that the *relationship evolved in transparency and detail of reporting*, not necessarily in mechanics. This results in a moderate correctness and qualitative accuracy score. Contextual relevance is high because the answer addresses the right topics and uses appropriate financial terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1475,
        "completion_tokens": 454,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Southern Company's approach to executive equity compensation evolved between 2023 and 2024, particularly regarding plan documentation and award terms?",
      "original_answer": "In 2023, Southern Company disclosed that stock-based compensation, primarily in the form of performance share units (PSUs) and restricted stock units (RSUs), was granted under the Equity and Incentive Compensation Plan to employees ranging from line management to executives. By 2024, the company formalized the terms for Named Executive Officer equity awards under the same plan, indicating a more structured approach to executive compensation. Additionally, the 2024 filing included detailed documentation practices, such as the designation of specific exhibits for equity award terms, which was not present in the 2023 filing. This reflects a shift toward greater specificity and transparency in executive equity compensation documentation.",
      "llm_answer": "In the 2023 filing Southern Company described its equity awards mainly in the notes – PSUs and RSUs were granted with a three‑year performance or service period, most vesting on a schedule (one‑third each year for RSUs) and becoming fully vested immediately on retirement or a change‑in‑control event (see page 277‑278). By the 2024 filing the company moved this information into the “Material Contracts” section, listing a suite of specific plans (e.g., Supplemental Executive Retirement Plan, Executive Change‑in‑Control Severance Plans, Deferred Compensation and Equity & Incentive Compensation Plans) and even attaching a “Form of Terms for Named Executive Officer Equity Awards” (page 315‑316), indicating a more formal, contract‑based documentation of award terms and a broader set of executive‑focused equity arrangements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies that in 2023, Southern Company granted PSUs and RSUs under the Equity and Incentive Compensation Plan with specific vesting terms (e.g., one-third annually, immediate vesting upon retirement or change-in-control), which matches the original answer's description of stock-based compensation for executives and employees. The 2024 evolution is accurately described: the company formalized Named Executive Officer award terms and introduced a 'Form of Terms for Named Executive Officer Equity Awards' as an exhibit (page 315-316), reflecting a shift toward structured, contract-based documentation. This corresponds to the ground truth's point about detailed documentation practices not present in 2023. The LLM adds valuable context not in the original answer—such as the movement of information to the 'Material Contracts' section and mention of other executive plans (e.g., SERP, change-in-control severance)—which are consistent with increased formalization and transparency. All entities (Southern Company, PSUs, RSUs, Equity and Incentive Compensation Plan, Named Executive Officers) and years (2023 vs 2024) are correct. There are no numerical inaccuracies; dates and percentages are not quantitatively miscalculated. The reasoning is sound: it infers a shift from general disclosure in notes to formalized, standalone award terms, demonstrating correct multi-hop synthesis across years and document structures. The only minor shortcoming is that the original answer emphasizes the 'same plan' continuity (Equity and Incentive Compensation Plan), which the LLM mentions but does not explicitly highlight as a point of consistency—instead focusing on broader executive arrangements. However, this does not detract from factual correctness. Overall, the LLM provides a more detailed and contextually rich answer that remains semantically equivalent and factually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 529,
        "total_tokens": 1925
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Procter & Gamble's strategic reliance on membership club stores evolved from 2022 to 2024, and what does this shift indicate about the company's broader retail channel strategy?",
      "original_answer": "In 2022, Procter & Gamble identified membership club stores as one of its key retail channels, listing them among a broad set of distribution partners such as mass merchandisers, grocery stores, and e-commerce platforms. However, by 2024, the company's language shifted to emphasize dependency on these membership club stores, indicating a deeper strategic alignment or increased reliance on this channel. This evolution suggests that membership club stores have become more central to P&G's distribution and retail execution strategy, likely reflecting growth in this channel's importance to consumer purchasing behavior and overall market dynamics.",
      "llm_answer": "In the 2022 filing P&G still listed **membership‑club stores** as one of its “key customers” alongside mass merchandisers, grocery and drug stores (see 2022 Item 1, page 4). By the 2024 filing the discussion of retail trends shifts to “evolving sales channels… e‑commerce and mobile or social‑commerce applications” as the primary growth drivers (see 2024 MD&A, page 7), signaling that the company is de‑emphasizing traditional club‑store reliance in favor of a broader, digitally‑focused channel mix. This evolution reflects a strategic pivot from a heavy dependence on membership‑club outlets toward a more diversified, omnichannel retail strategy that leans on online and direct‑to‑consumer sales.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim. While it correctly identifies that membership club stores were listed among key customers in 2022 (per Item 1, page 4), it misrepresents the 2024 filing by asserting that P&G is de-emphasizing club stores in favor of e-commerce and digital channels. The ground truth states the opposite — that P&G's language in 2024 indicates *increased* reliance on membership club stores, not reduced. The LLM incorrectly interprets the mention of e-commerce growth as a sign of de-emphasizing club stores, when the original answer suggests club stores have become more central. (2) There are no numeric values in this question, so quantitative accuracy is not applicable; however, the years (2022, 2024) and document references (Item 1, MD&A) are correctly cited, hence a score of 10. (3) The multi-hop reasoning is flawed: the model fails to synthesize the correct directional shift (increased vs decreased reliance) and draws an unsupported conclusion about strategic de-emphasis. It does not recognize that mentioning e-commerce growth does not negate increased dependence on club stores — both can be true, but the original answer emphasizes growing strategic importance of club stores specifically. (4) Contextual relevance is moderate because the answer discusses retail channel strategy and cites relevant sections, but it contradicts the ground truth on the key point of strategic evolution. The conclusion about an 'omnichannel pivot away from club stores' is unsupported and directly conflicts with the documented shift toward greater reliance on them.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 444,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did AMT's involvement with Nigeria Letters of Credit evolve between 2023 and 2024, and what does this indicate about its financial obligations related to this instrument?",
      "original_answer": "In 2023, AMT had a $3.4 million obligation under the Nigeria Letters of Credit as part of its variable rate debt portfolio. However, by 2024, this obligation was no longer present, as indicated by the $0 carrying value in both denominated currency and USD. This indicates that AMT fully settled or otherwise exited its financial obligations tied to Nigeria Letters of Credit within this period.",
      "llm_answer": "In the 2023 Form 10‑K AMT disclosed that it had drawn $3.4 million of Nigeria Letters of Credit, which bore interest at SOFR + spread and were payable 270 days after each draw (see pages 60‑61). By the 2024 filing the same line shows a “‑” for the 2024 column, indicating no carrying value and therefore the letters have been repaid or otherwise extinguished (see page 117). This evolution means the company’s exposure to that interest‑bearing subsidiary debt fell from a modest $3.4 million liability in 2023 to zero in 2024, eliminating the related interest‑expense obligation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the $3.4 million obligation in 2023 and its absence (reported as '-' indicating $0) in 2024 match the original answer. The format variations (e.g., $3.4 million) are acceptable. (2) The answer correctly identifies the evolution of AMT's involvement—full settlement or extinguishment of the Nigeria Letters of Credit between 2023 and 2024. (3) The reasoning is sound: it references the correct documents (2023 and 2024 10-Ks), explains the financial instrument (SOFR + spread, 270-day maturity), and infers from the '–' notation in the 2024 filing that the liability was extinguished, which is consistent with a $0 carrying value. (4) The conclusion that exposure and interest expense were eliminated is logically derived and semantically equivalent to the original answer. The only minor shortcoming is that the LLM adds detail (e.g., interest terms, maturity) not present in the ground truth, which, while plausible and consistent, slightly exceeds the confirmed facts. However, this does not introduce inaccuracy. All parts of the question—evolution and implications for financial obligations—are fully addressed with correct multi-hop synthesis across years and filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 360,
        "total_tokens": 1610
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the valuation methodology and composition of GD's Retirement Annuity Contracts change between 2022 and 2024, and what does this indicate about the company's approach to reporting these assets?",
      "original_answer": "In 2022, GD reported Retirement Annuity Contracts as part of Level 3 assets with a fair value of $35 million as of December 31, 2021, and this value remained relatively stable through December 31, 2020 at $38 million. The contracts were disclosed within a detailed table showing actual returns, unrealized gains and losses, and net purchases or sales. By 2024, Retirement Annuity Contracts were still categorized under Level 3 assets but were now described as being valued using NAV (net asset value) as a practical expedient, excluded from the formal fair value hierarchy. This indicates a shift in GD's reporting methodology from detailed fair value disclosures to a more simplified NAV-based approach, aligning with broader changes in how these contracts are categorized and disclosed.",
      "llm_answer": "In the 2022 10‑K GD classified its retirement‑annuity contracts as Level 3 assets—valued using unobservable inputs and internal estimates—showing a fair‑value balance of $38 million at 12/31/2020 (and $35 million at 12/31/2021)【page_94】【page_96】. The 2024 10‑K still places these contracts in Level 3 (unobservable) assets, but the balance fell to $22 million at 12/31/2024 (down from $25 million in 2023)【page_94】【page_93】. The unchanged Level 3 methodology coupled with the declining contract amount indicates GD continues to apply a consistent, judgment‑heavy reporting framework while the lower values reflect a shrinking exposure or reallocation of its retirement‑annuity assets.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies that GD classified Retirement Annuity Contracts as Level 3 assets in 2022 with a fair value of $38 million at 12/31/2020 and $35 million at 12/31/2021 (matching the ground truth), it incorrectly states that in 2024 the balance was $22 million at 12/31/2024, down from $25 million in 2023. The original answer does not mention any values for 2023 or 2024, nor does it indicate a decline in value—this is an unsupported addition. More critically, the LLM fails to report the key methodological change: in 2024, GD began using NAV as a practical expedient and excluded these contracts from the formal fair value hierarchy, which is the central point of the original answer. Instead, the LLM claims the methodology remained 'unchanged,' which directly contradicts the ground truth. (2) Quantitative accuracy is partially correct for 2020 and 2021 values but introduces false data for 2023 and 2024 with no support in the original answer. These invented figures severely undermine accuracy. (3) The multi-hop reasoning is flawed: the model correctly identifies the 2022 classification but fails to recognize and synthesize the shift in valuation approach by 2024. It misses the critical transition from detailed fair value disclosures to a NAV-based practical expedient, which is the core of the question. (4) Contextual relevance is fair—the response addresses the general topic of valuation methodology and trends in asset values, but due to major omissions and inaccuracies in both quantitative data and qualitative methodology changes, the overall correctness score is low. The conclusion about 'consistent, judgment-heavy reporting' is incorrect given the actual shift in methodology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 485,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the composition and value of restricted cash for securitization investors changed between 2022 and 2024, particularly in terms of its fair value hierarchy classification?",
      "original_answer": "In 2022, the company reported restricted cash for securitization investors as part of consolidated VIEs, with the assets and liabilities presented on the consolidated balance sheets. By 2024, the restricted cash for securitization investors was valued at $441 million, with the entire amount classified under Level 1 of the estimated fair value hierarchy, indicating a shift toward more transparent or market-based valuation methods. This reflects a more defined and standardized valuation approach in 2024 compared to 2022, where the fair value hierarchy was not explicitly detailed for this category.",
      "llm_answer": "Restricted cash for securitization investors continues to be reported as cash held for the company’s securitization VIEs (the asset is described in the VIE note)【page_179】.  In the prior‑period filing the balance was $458 million and its fair value was measured at the same amount, fully classified in Level 1 of the fair‑value hierarchy【page_220】.  By 2024 the balance had slipped to $441 million, still measured at fair value equal to its carrying amount and entirely Level 1【page_219】, indicating only a modest reduction in value with no change in hierarchy classification.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the 2024 restricted cash value is accurately reported as $441 million, and the prior-period (2022) balance is correctly stated as $458 million, with both amounts fully classified in Level 1 of the fair value hierarchy. The slight reduction in value is correctly characterized as 'modest.' (2) The LLM correctly identifies that fair value equals carrying amount in both years and that there is no change in classification—consistent with the ground truth's emphasis on increased transparency by 2024. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, identifies the continuity in reporting and hierarchy classification, and infers stability in valuation methodology, which supports the ground truth's conclusion about a more standardized approach emerging by 2024. (4) The only minor shortcoming is that the LLM does not explicitly note that the 2022 filing did *not* detail the fair value hierarchy for this category (implying an improvement in disclosure), which was a key qualitative point in the original answer. However, the LLM’s statement that the prior-period amount was 'fully classified in Level 1' may slightly overstate the transparency in 2022, though it does not contradict source data if such classification was retrospectively applied. Overall, the answer is factually correct, comprehensive, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 411,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial recognition and asset management between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's relationship with franchisees was primarily characterized by the acquisition of restaurants from franchisees, resulting in goodwill that was either fully or partially written off depending on the time of sale relative to acquisition. The Company used a discounted cash flow methodology to determine the fair value of acquired restaurants. By 2024, the relationship had transformed into a more dependency-based model, particularly in the area of technology platform services. McDonald's now provides distinct technology-related goods and services to franchisees, recognizing revenue on a gross basis and corresponding expenses within 'Other restaurant expenses.' This marks a shift from asset acquisition and goodwill management toward ongoing service-based financial interactions with franchisees.",
      "llm_answer": "McDonald’s kept the same accounting for franchise‑e revenues in 2024 as it did in 2023 – royalties and variable rent are still recognized when the underlying sales occur, minimum rent is amortized straight‑line over the franchise term, and technology‑platform fees to franchisees are presented on a gross basis【page_44】; the cost‑sharing arrangement for restaurant improvements also remained unchanged【page_44】.  At the same time the company deepened its asset relationship with franchisees by purchasing more franchised restaurants (including a large acquisition in Israel), which lifted consolidated goodwill from $3.04 bn at year‑end 2023 to $3.15 bn at year‑end 2024 and added $162 m of new goodwill in the International Developmental Licensed segment, while capitalized software rose to $907 m【page_47】【page_45】.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct quantitative details but fundamentally misrepresents the evolution of McDonald's relationship with franchisees between 2023 and 2024, contradicting the ground truth. (1) Correct elements include references to revenue recognition for royalties, rent, and technology fees, as well as goodwill increasing from $3.04B to $3.15B and $162M in new goodwill in the International Developmental Licensed segment—these numbers align with the source data. Capitalized software rising to $907M is also accurate. (2) However, the LLM claims McDonald’s 'kept the same accounting' and 'deepened its asset relationship' by purchasing more franchised restaurants in 2024, which directly contradicts the ground truth stating that 2023 was the period of acquisition-driven goodwill, while 2024 marked a shift toward service-based, technology-platform dependency. The ground truth describes a qualitative transformation in the nature of the relationship—from asset acquisition and goodwill write-offs in 2023 to gross revenue recognition from technology services in 2024—but the LLM incorrectly frames 2024 as a continuation or intensification of 2023’s asset-buying behavior. (3) This reflects a failure in multi-hop reasoning: the model synthesizes real numbers but misinterprets the directional shift in strategy over time. It misses the core conceptual evolution—away from asset management toward service-based financial interactions. (4) While numerically plausible and contextually relevant due to correct citations and financial figures, the answer is qualitatively inaccurate in portraying the strategic shift, warranting a low correctness score despite partial factual support.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 461,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the treatment of the 2019 Stock and Incentive Compensation Plan evolved between 2022 and 2024 in Procter & Gamble's disclosures, particularly regarding its relationship with other compensation plans and its role in equity compensation?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was disclosed as part of a broader set of compensation plans, with specific reference to its adoption by shareholders in 2019 and its regulation in conjunction with other plans like the 2014 Stock and Incentive Compensation Plan. By 2024, the 2019 Plan was still included in the list of active equity compensation plans, but it was now referenced in the context of security ownership and the total shares available for issuance, indicating a shift from adoption and governance details to its role in the company's overall equity compensation structure. This reflects a transformation in how the plan is positioned within the company's disclosures, moving from procedural governance to a more strategic ownership framework.",
      "llm_answer": "In the 2022 Form 10‑K the 2019 Stock and Incentive Compensation Plan was described as the **only** equity‑compensation plan that could issue future grants, with a maximum authorisation of 187 million shares and **119 million shares still available** for issuance. The 2024 filing repeats that the 2019 Plan remains the sole plan with future‑grant authority (still capped at 187 million shares) but notes that the **available pool has fallen to 77 million shares**, reflecting a reduced capacity for new equity awards; its relationship to the other plans (1992, 2001, 2003, 2009, 2014) remains unchanged, and it continues to be governed by the Compensation and Leadership Development Committee and listed among the company’s equity‑compensation exhibits.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative Accuracy: The claim that the 2019 Plan had 187 million authorized shares and 119 million available in 2022, then 77 million available in 2024, is not supported by the ground truth and introduces specific numbers absent from the original answer. The ground truth does not provide any share counts or numerical details about authorization or availability, so these figures are fabrications or hallucinations. This results in a low quantitative accuracy score. (2) Completeness: While the question asks about the evolution of the plan's treatment in disclosures—particularly its relationship with other plans and its role in equity compensation—the LLM focuses narrowly on share availability and grant authority, missing the broader narrative shift described in the original answer. (3) Entity Accuracy: The mention of older plans (1992, 2001, etc.) and the Compensation Committee is plausible but not confirmed in the ground truth, which only references the 2014 Plan specifically. However, these are not outright errors, just unverified details. (4) Reasoning: The LLM attempts multi-hop reasoning by comparing 2022 and 2024 disclosures, but it mischaracterizes the evolution. The original answer emphasizes a shift from procedural/governance language (adoption, regulation alongside other plans) to strategic/ownership framing (shares available, security ownership), whereas the LLM reduces this to a change in share pool size. This misrepresents the nature of the evolution. (5) Semantic Equivalence: The LLM conveys a different kind of change—quantitative depletion of shares—rather than the qualitative shift in disclosure focus (from governance to strategic structure). Thus, despite some relevant context (e.g., the 2019 Plan being central to equity compensation), the core insight is incorrect. The answer is contextually relevant and structured well, but factually flawed in key aspects.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 536,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Salvatore Ferragamo's presence in Simon Property Group's international outlet locations evolved between 2022 and 2023?",
      "original_answer": "In 2022, Salvatore Ferragamo was listed as a tenant in three of Simon Property Group's international outlet locations in Japan: Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Sano Premium Outlets. By 2023, Salvatore Ferragamo appeared in only one of SPG's outlet locations, specifically Las Vegas Outlets North in Nevada, USA. This indicates a significant reduction in Salvatore Ferragamo's presence across SPG's outlet portfolio, shifting from multiple locations in Japan to a single location in the U.S.",
      "llm_answer": "In the 2022 filing Salvatore Ferragamo was listed as a tenant at several international Premium Outlets – Punta Norte (Mexico City), Yeoju and Siehung (South Korea), Johor (Malaysia) and the Montreal outlet in Canada (SPG 2022 p. 43). The 2023 filing’s international outlet tables (pages 32‑36) contain no Ferragamo entries, showing the brand is no longer reported as a tenant in SPG’s international outlet locations.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of factual content and multi-hop reasoning. (1) Quantitatively, the original answer states that Salvatore Ferragamo was present in three Japanese outlets in 2022 (Gotemba, Kobe-Sanda, Sano) and one U.S. location in 2023 (Las Vegas Outlets North). The LLM incorrectly claims presence in Mexico, South Korea, Malaysia, and Canada in 2022—none of which are supported by the ground truth—and states no Ferragamo entries in 2023 international tables, missing the U.S. location entirely. These are major factual errors involving wrong countries, properties, and absence of correct data. (2) The LLM references 'SPG 2022 p. 43' and '2023 filing pages 32–36', suggesting document-based reasoning, but the entities and locations cited do not align with the ground truth, indicating either misreading or incorrect data retrieval. (3) The multi-hop reasoning fails: the question asks for evolution between 2022 and 2023, requiring accurate comparison across years and geographies. The LLM incorrectly identifies 2022 locations and omits the 2023 U.S. presence, leading to a false conclusion of complete withdrawal rather than a shift from Japan to the U.S. (4) While the answer attempts to address the temporal evolution and uses a plausible structure (citing filings and pages), the core facts are wrong, severely undermining correctness. Minor credit is given for attempting international comparison and recognizing Ferragamo’s reduced visibility, but the specific entities and geography are entirely inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 423,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about its operational focus in the region?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region, suggesting a potential shift or stabilization in operational focus rather than aggressive growth.",
      "llm_answer": "COP’s consolidated natural‑gas reserves in the Asia Pacific/Middle East slipped modestly, falling from 312 BCF at year‑end 2023 (305 BCF developed + 7 BCF undeveloped) to 296 BCF at year‑end 2024 (289 BCF developed + 7 BCF undeveloped)【page 145】. At the same time, the company’s equity‑affiliate gas holdings—​all of which are located in this region【page 147】—rose from about 5,275 BCF to 5,870 BCF (equity‑affiliate column on page 145), indicating a strategic shift toward expanding its gas portfolio through affiliate projects and a stronger operational focus on the Asia Pacific/Middle East market.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the consolidated natural gas reserves for COP in the Asia Pacific/Middle East region: 312 BCF in 2023 and 296 BCF in 2024, matching the ground truth. However, it introduces new data not present in the original answer—specifically, the breakdown into developed and undeveloped reserves and the claim about equity-affiliate holdings increasing from 5,275 BCF to 5,870 BCF. This information, while possibly in the source document, is not part of the ground truth answer and leads to a different conclusion. (2) The quantitative values for consolidated reserves are accurate (312 → 296 BCF), but the equity-affiliate numbers are not mentioned in the original answer, making their inclusion unsupported in the context of evaluating against the ground truth. There are no calculation errors in the numbers provided, but the addition of unverified data compromises accuracy. (3) The multi-hop reasoning is flawed because the LLM infers a 'strategic shift toward expanding its gas portfolio through affiliate projects' based on equity-affiliate data, which is not referenced in the ground truth. The original answer concludes a 'minor reduction in reserves' suggesting 'stabilization or shift rather than aggressive growth'—a more cautious interpretation. The LLM overreaches by introducing a new data stream and drawing a stronger, unsupported conclusion about operational focus. (4) While the core consolidated reserve numbers are correct and contextually relevant, the inclusion of extraneous, unvalidated data and the resulting misalignment in interpretation significantly reduce factual correctness. The answer is partially correct but diverges critically in reasoning and conclusion, warranting a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 476,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Comcast's approach to wireless gateways evolved from 2022 to 2024, particularly in terms of strategic emphasis and investment?",
      "original_answer": "In 2022, Comcast offered wireless gateways as part of its broadband services, combining modem and Wi-Fi router capabilities to enhance in-and-out-of-home coverage. The focus was on customer-facing features like the xFi whole-home application and advanced security. By 2024, the company elevated its strategic emphasis by shifting from merely offering wireless gateways to actively investing in their deployment as part of its broader network infrastructure upgrades. This included plans to increase capacity and deliver multigigabit symmetrical speeds, signaling a deeper integration of wireless gateways into its long-term network strategy.",
      "llm_answer": "In 2022 Comcast presented wireless gateways mainly as a product feature—an integrated modem‑router that, together with xFi Pods and the xFi whole‑home app, lets customers personalize, manage and secure their in‑home Wi‑Fi network【page_7】. By 2024 the company has elevated gateways to a strategic investment priority, classifying them under “Customer premise equipment” and explicitly budgeting for their continued deployment as a core part of its Connectivity & Platforms capital plan to support network upgrades, line extensions and scalable infrastructure【page_51】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) All entities—Comcast, wireless gateways, xFi app, Customer premise equipment, Connectivity & Platforms capital plan—are correctly identified and contextually accurate. The years 2022 and 2024 are properly used to reflect the evolution in strategy. (2) There are no numeric values (e.g., dollar amounts, percentages, speeds) in either the original or LLM answer that conflict; thus, quantitative accuracy is fully preserved. (3) The multi-hop reasoning is sound: the model correctly synthesizes a shift from customer-facing product features in 2022 to strategic infrastructure investment in 2024, citing budget classification and capital planning as evidence. The mention of 'continued deployment' and integration into capital plans reflects the deeper strategic integration noted in the ground truth. (4) Semantic equivalence is strong—while the LLM uses slightly different phrasing (e.g., 'strategic investment priority' vs 'elevated strategic emphasis'), the meaning is consistent. The only minor gap is that the LLM does not explicitly mention 'multigigabit symmetrical speeds' or 'in-and-out-of-home coverage' from the original, which slightly reduces completeness in qualitative detail, but the core evolution in strategic emphasis and investment is accurately conveyed. Hence, correctness is high but not perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 387,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the G600's market presence and production evolution changed between 2022 and 2024, particularly in terms of cumulative deliveries and its role within Gulfstream's product lineup?",
      "original_answer": "In 2022, the G500 and G600 had cumulative deliveries totaling almost 150 by year-end 2021, and were described as replacements for the G450 and G550 models with improvements in speed, fuel efficiency, cabin volume, and flight controls. By 2024, cumulative deliveries of the G500 and G600 had more than doubled to over 300 by year-end 2024. Additionally, the G600 was no longer described in the context of being a new product introduction, indicating it had become a more established part of Gulfstream's lineup, while the focus shifted to newer models like the G800 and G400.",
      "llm_answer": "In the 2022 filing Gulfstream highlighted that the G600 – launched in 2019 as a clean‑sheet, large‑cabin jet that replaces the older G550 – together with the G500 had delivered almost 150 aircraft by year‑end 2021【page_6】. By the 2024 filing the combined G500/G600 deliveries had more than doubled to over 300 aircraft at year‑end 2024, showing a strong growth in the G600’s market presence, and it remains a flagship large‑cabin model in Gulfstream’s all‑new product family alongside newer jets such as the G700, G800 and G400【page_5】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports that the G500 and G600 had nearly 150 cumulative deliveries by year-end 2021 (per 2022 filing) and over 300 by year-end 2024 (per 2024 filing), accurately reflecting the doubling in deliveries. These numbers match the ground truth exactly in value and context. (2) All quantitative data—'almost 150' and 'over 300'—are correctly cited with appropriate timeframes. The claim that deliveries 'more than doubled' is mathematically sound (300 > 2×150), so the calculation and comparison are accurate. (3) The reasoning across years and filings is sound: the LLM correctly infers increased market presence from delivery growth and identifies the G600's evolving role. However, there is a minor discrepancy in qualitative characterization: the LLM states the G600 'remains a flagship large-cabin model,' while the ground truth emphasizes that it is no longer framed as a new product and that focus has shifted to newer models like the G800 and G400. This slightly overstates the G600's current strategic emphasis. Additionally, the LLM mentions the G700, which is not referenced in the original answer, potentially introducing extraneous detail. (4) Despite this nuance, the core facts, multi-hop synthesis across 2022 and 2024 data, and overall interpretation are correct. The answer addresses both cumulative deliveries and product lineup evolution accurately, with only minor overstatement in the qualitative framing. Hence, full marks for quantitative accuracy and contextual relevance, near-perfect qualitative accuracy, and a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 436,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has AIG's financial relationship with Corebridge evolved between 2023 and 2024, particularly in terms of equity ownership and income recognition?",
      "original_answer": "In 2023, AIG held 52.2% of Corebridge common stock and was in the process of selling down its stake, with the intention to fully divest over time. By 2024, AIG had transitioned to accounting for its remaining interest in Corebridge using the equity method, recognizing pre-tax income based on dividends received and changes in Corebridge's stock price from June 9, 2024. This represents a shift from direct ownership control to a more passive investment approach, indicating a significant change in the nature of AIG's financial relationship with Corebridge.",
      "llm_answer": "In 2023 AIG still owned a controlling stake in Corebridge—52.2 % of the company as of December 31, 2023, and Corebridge’s results were fully consolidated in AIG’s earnings【page_27】. During 2024 AIG sold down its interest, holding 48.4 % at the June 9 de‑consolidation date and only 22.7 % by year‑end after a $3.8 billion sale to Nippon, and it de‑consolidated Corebridge, recording a $4.8 billion loss as discontinued operations【page_108】; thereafter Corebridge is accounted for under the equity‑method, with dividends and fair‑value changes reported as net investment income (e.g., $601 million equity‑method income for June 10‑Dec 31 2024)【page_109】【page_110】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a more detailed and precise account than the original ground truth, with all key facts and numbers correct. (1) Quantitatively: The percentages (52.2% as of Dec 31, 2023; 48.4% at de-consolidation on June 9, 2024; 22.7% by year-end 2024), dollar amounts ($3.8 billion sale to Nippon, $4.8 billion loss, $601 million equity-method income for June 10–Dec 31, 2024), and dates (June 9 de-consolidation) are all factually correct and supported by the cited pages. (2) Completeness: The LLM addresses both equity ownership evolution and income recognition, going beyond the original answer by specifying the exact ownership percentages at key points, the de-consolidation event, the accounting treatment change, and the resulting income recognition ($601M). (3) Entity and term accuracy: All entities (AIG, Corebridge, Nippon) and financial terms (equity method, de-consolidation, discontinued operations, net investment income) are correctly used. (4) Reasoning: The multi-hop synthesis is sound—connecting the stake reduction, de-consolidation, accounting change, and income recognition over time. The only minor gap is that the original answer emphasizes AIG’s 'intention to fully divest over time,' which is implied but not explicitly restated in the LLM answer; however, the 22.7% year-end stake and $3.8B sale strongly support this trajectory. Overall, the LLM answer enhances the ground truth with greater specificity and remains fully factually aligned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 412,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Tesla's production strategy for the Solar Roof evolved between 2022 and 2024, particularly in terms of manufacturing dependencies and operational challenges?",
      "original_answer": "In 2022, Tesla was actively producing the Solar Roof at Gigafactory New York, which was specifically highlighted as a dedicated facility for the development and production of Solar Roof and other solar products. The company offered financing options tied to the Solar Roof, indicating a strategic push to integrate the product into its broader energy ecosystem. By 2024, Tesla's disclosures shifted to emphasize increased complexity and risk in ramping production of the Solar Roof, with explicit mention of 'delays in launching and/or ramping production of our energy storage products and Solar Roof.' The 2024 filing also highlighted broader operational dependencies, including the need to achieve 'design tolerances, high quality and output rates' across its manufacturing facilities, and noted potential disruptions due to supply chain coordination, localized procurement challenges, and the need for cost-effective scaling. This indicates a transition from a focused production setup in 2022 to a more complex and risk-laden ramp-up phase in 2024.",
      "llm_answer": "In 2022 Tesla said it would develop and build the Solar Roof largely in‑house at its Buffalo‑based Gigafactory New York, using its own design‑engineering expertise and internal manufacturing capacity 【page_9】. By the 2024 filing the company is flagging that Solar Roof production has been slower to ramp, now hinging on external suppliers for key parts and facing “bottlenecks and other unexpected challenges” that could delay or limit output 【page_17】. This reflects a shift from a primarily internal‑manufacturing plan to a strategy that must manage greater supply‑chain dependencies and operational risks.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Gigafactory New York (Buffalo-based) as the 2022 production site and notes Tesla's in-house strategy, matching the original answer. By 2024, it accurately reflects increased production challenges, including reliance on external suppliers and operational bottlenecks, which corresponds to the ground truth's mention of supply chain coordination issues, procurement challenges, and production delays. (2) There are no numeric values to verify, so quantitative accuracy is unaffected; dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and correctly infers a strategic shift from internal manufacturing to greater supply chain dependency. The use of terms like 'bottlenecks and other unexpected challenges' (from page 17) aligns with the 2024 filing’s emphasis on delays and ramp-up risks. (4) Minor deduction in qualitative accuracy because the LLM omits specific details about financing options and cost-effective scaling mentioned in the original, but the core evolution in strategy and operational challenges is correctly captured. Overall, the answer is semantically equivalent and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 355,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Qualcomm's strategic involvement with on-device artificial intelligence (AI) evolved from 2023 to 2024, particularly in terms of its business focus and investment approach?",
      "original_answer": "In 2023, Qualcomm was actively producing on-device AI technologies as part of its broader portfolio of foundational technologies, including wireless connectivity and low-power computing. The company positioned on-device AI as a key innovation driver across industries beyond mobile handsets, such as automotive and IoT. By 2024, Qualcomm's focus on on-device AI had evolved from being a core product offering to a more investment-centric strategy. The company continued to invest heavily in advancing on-device AI through research and development, acquisitions, and strategic transactions, signaling a shift toward long-term growth and ecosystem development rather than immediate product commercialization. This transition reflects a deeper commitment to enabling third-party integration of its AI technologies rather than solely selling AI-based products directly.",
      "llm_answer": "In the 2023 filing Qualcomm described on‑device AI as a core part of its “foundational technologies” – a capability it was already scaling across mobile handsets, automotive and IoT markets (see 2023 Note 1, page 65). By the 2024 filing the company says it is now allocating substantial R&D and capital to on‑device AI **and** using acquisitions and other strategic transactions to accelerate AI‑enabled products beyond handsets (see 2024 “Risks Related to New Initiatives,” page 20). This reflects a shift from a primarily technology‑development focus to a more aggressive investment‑and‑acquisition‑driven approach to grow its AI business.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Qualcomm's 2023 focus on on-device AI as a core part of its foundational technologies, already being scaled across mobile, automotive, and IoT (citing the correct context from the 2023 filing). In 2024, it accurately captures the strategic shift toward increased investment via R&D, acquisitions, and strategic transactions to accelerate AI-enabled products beyond handsets. The characterization of a shift from technology development to an investment-and-acquisition-driven approach is semantically equivalent to the ground truth's description of a move toward a more investment-centric strategy focused on ecosystem development. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification—only qualitative descriptions of strategy over time—so quantitative accuracy is not applicable in a numerical sense, but the years (2023, 2024) and references to specific filing sections are correctly used. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly inferring a strategic evolution based on changes in language and emphasis. The only minor shortcoming is that the LLM answer emphasizes 'accelerating AI-enabled products' whereas the ground truth highlights a move away from immediate product commercialization toward ecosystem enablement. This is a subtle but notable nuance—the LLM slightly overemphasizes product development in 2024, while the original answer stresses enabling third-party integration. However, the overall direction of strategic evolution is correctly captured. (4) Contextual relevance is excellent, directly addressing both business focus and investment approach as asked. The citation of specific filing sections adds credibility and precision. The answer is concise, factually correct, and reflects strong qualitative understanding, warranting a 9/10 in correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 538,
        "total_tokens": 1923
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the presence of Dolce & Gabbana in SPG-operated properties evolved between 2022 and 2023, and what does this indicate about SPG's brand positioning strategy in its premium outlet locations?",
      "original_answer": "In 2022, Dolce & Gabbana was listed as a tenant in multiple SPG-operated premium outlets in Japan, including Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Rinku Premium Outlets. By 2023, Dolce & Gabbana was only listed at Las Vegas Outlets North Premium NV in the U.S. This indicates a strategic shift from a multi-location presence in Japan to a more exclusive, flagship-style positioning in a key U.S. market, suggesting a reevaluation of brand placement and target demographics.",
      "llm_answer": "In the 2022 filing Dolce & Gabbana was listed as a tenant at several international premium‑outlet centers—Gotemba, Kobe‑Sanda and Rinku in Japan and Punta Norte in Mexico【page_42†L2-L4】【page_43†L1】. By the 2023 filing the brand appears in the U.S. Las Vegas Premium Outlets tenant roster【page_34†L1】, showing SPG is moving high‑end luxury labels into its domestic premium‑outlet portfolio to reinforce an upscale, luxury‑focused positioning for these locations.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies Dolce & Gabbana's presence in SPG-operated properties in 2022 and 2023, but introduces an inaccuracy by including Punta Norte in Mexico, which is not mentioned in the ground truth. The 2022 locations in Japan (Gotemba, Kobe-Sanda, Rinku) are correctly listed. In 2023, the LLM correctly identifies Las Vegas Premium Outlets but refers to it as 'Las Vegas Premium Outlets' instead of 'Las Vegas Outlets North Premium NV'—a minor naming discrepancy. (2) There are no numeric values requiring calculation, so quantitative accuracy is high, though the inclusion of an extra location (Punta Norte) affects factual precision. (3) The multi-hop reasoning is partially sound: the LLM infers a strategic shift toward U.S. domestic luxury positioning, which aligns with the ground truth’s interpretation of a move toward exclusive, flagship-style placement. However, the conclusion is weakened by the erroneous inclusion of a Mexican location, suggesting incomplete or inaccurate data synthesis. (4) The answer is contextually relevant and captures the strategic implication about SPG reinforcing an upscale brand positioning. Despite the extra tenant location and slight name variation, the core evolution and strategic interpretation are reasonably accurate, warranting a score of 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 374,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did COP's investment in exploration activities in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the company's strategic focus in that region?",
      "original_answer": "In 2023, COP reported $49 million in exploration expenditures in the Asia Pacific/Middle East region, while in 2024, the company disclosed a total of $0 in new exploration activities in that region. This indicates a complete withdrawal or pause in exploration efforts in the Asia Pacific/Middle East, suggesting a strategic shift away from that region in favor of other geographic areas.",
      "llm_answer": "In 2023 ConocoPhillips recorded $49 million of exploration spending in its consolidated Asia Pacific/Middle East operations plus $46 million through equity affiliates – roughly $95 million in total (2023 10‑K, p. 156). The 2024 filing shows no exploration expense listed for the Asia Pacific/Middle East region (2024 10‑K, p. 144), indicating that the company has essentially halted new exploration there and is shifting its focus toward developing existing assets or other regions.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly inflates the 2023 exploration expenditure by including $46 million from equity affiliates, which is not reflected in the ground truth. The original answer states that COP reported $49 million in exploration expenditures in 2023 and $0 in 2024—this matches the $49 million figure for consolidated operations but contradicts the inclusion of equity affiliate spending. The total of $95 million is unsupported by the ground truth and introduces a significant quantitative error. (2) The 2024 figure of $0 is correctly identified, aligning with the ground truth and indicating accurate extraction from the 2024 10-K. However, the addition of equity affiliate amounts without clarification distorts the core financial metric in question—'exploration expenditures'—which the ground truth specifies as $49M direct spending, not including affiliates. (3) The reasoning about strategic shift is sound and logically follows from the drop to $0 in reported spending; the conclusion about halting exploration and shifting focus is semantically aligned with the ground truth’s interpretation of a 'complete withdrawal or pause.' This shows correct multi-hop synthesis between years and appropriate inference. (4) Despite correct directional logic and relevance to the question, the quantitative inaccuracy of nearly doubling the 2023 figure undermines the factual foundation. The entity (COP), years (2023–2024), region (Asia Pacific/Middle East), and metric (exploration spending) are correctly identified. The answer is contextually relevant and draws a reasonable conclusion, but the incorrect financial figure reduces overall correctness. Hence, correctness_score is 6 due to partial factual accuracy with a major numerical error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 479,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Comcast's financial stake and debt involvement in Universal Beijing Resort evolved from 2022 to 2024?",
      "original_answer": "In 2022, Universal Beijing Resort was introduced as a new entity in Comcast's disclosures, noting its opening in September 2021 and highlighting the increased depreciation and amortization expenses across the company, though no specific financial stake or debt figures were provided at that time. By 2024, Comcast explicitly stated its 30% ownership interest in Universal Beijing Resort and detailed the debt financing structure, including $3.4 billion of debt outstanding as of December 31, 2024, down from $3.5 billion in 2023. Additionally, the assets and liabilities of Universal Beijing Resort were reported as $7.3 billion and $7.0 billion respectively in 2024, compared to $7.8 billion and $7.2 billion in 2023.",
      "llm_answer": "Comcast’s equity ownership in Universal Beijing Resort has stayed at a 30 % stake – the same percentage reported in the 2022 filing【CMCSA_10k_2022.pdf page_48】.  The resort’s financing has been trimmed modestly, with total debt falling from roughly $3.5 billion (including about $3.1 billion of term‑loan principal) reported in 2022 to $3.4 billion of debt (about $3.0 billion of term‑loan principal) at year‑end 2024【CMCSA_10k_2024.pdf page_86】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Comcast's 30% ownership stake and the reduction in debt from $3.5 billion to $3.4 billion, aligning with the ground truth. However, it incorrectly states that the 30% stake was reported in the 2022 filing, which contradicts the original answer stating that no specific financial stake was disclosed in 2022—this is a significant factual error. Additionally, the LLM claims $3.5 billion debt was reported in 2022, but the ground truth indicates that the $3.5 billion figure was from 2023, not 2022. The 2022 filing did not provide specific debt figures. (2) Quantitative inaccuracies include misattributing the $3.5 billion debt to 2022 instead of 2023 and introducing term-loan principal amounts ($3.1B in 2022, $3.0B in 2024) not present in the ground truth, which undermines numerical precision. While the $3.4 billion 2024 debt figure is correct, the baseline comparison is flawed. (3) The reasoning partially supports multi-hop synthesis by comparing 2022 and 2024 disclosures, but fails to accurately reflect the evolution because it assumes financial details (stake and debt) were known in 2022 when they were not. The original answer emphasizes that specifics emerged only by 2024, making the LLM’s portrayal of continuity misleading. (4) Despite these issues, the answer is contextually relevant and captures the downward trend in debt and current ownership level. The qualitative reasoning is sound in structure but based on incorrect premises. Scores reflect partial correctness with significant factual and temporal inaccuracies affecting overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 444,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did Duke Energy's net derivatives balance and associated settlement activity evolve from 2022 to 2023, and what does this indicate about the company's exposure or management of derivative instruments?",
      "original_answer": "In 2022, Duke Energy's net derivatives balance at the end of the year was $29 million, with settlements totaling $32 million. In 2023, the net derivatives balance decreased to $13 million, while settlements increased significantly to $68 million. This indicates a shift in the company's management of derivative instruments, with a larger reduction in the net balance despite higher settlement activity in 2023.",
      "llm_answer": "In 2023 Duke Energy’s net derivative position dropped to **$13 million**, down from **$29 million** at the end of 2022, while the amount of derivative settlements more than doubled – **$68 million** of settlements in 2023 versus **$32 million** in 2022 (with purchases also falling from $74 million to $42 million)【page_192】. The larger settlement outflows and the lower net balance indicate the company actively unwound or settled derivative contracts, thereby reducing its net exposure to derivative‑related market risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key quantitative figures from the ground truth: Duke Energy's net derivatives balance decreased from $29 million in 2022 to $13 million in 2023, and settlements increased from $32 million to $68 million. These numbers match the original answer exactly, with acceptable formatting (e.g., $13 million). (2) Quantitative accuracy is perfect—no calculation or number errors. The additional detail about purchases falling from $74 million to $42 million is not in the ground truth but does not contradict it and may come from the cited source (page_192); however, since the question did not ask about purchases, this is supplementary. (3) The multi-hop reasoning is sound: the model correctly infers that higher settlement activity combined with a lower net balance indicates active unwinding of derivative positions, which aligns with the original answer’s conclusion about reduced exposure and active management. The interpretation goes slightly beyond the ground truth by explicitly stating 'reducing its net exposure to derivative-related market risk,' but this is a reasonable and logical extension. (4) Scores reflect near-perfect factual accuracy, complete coverage of the question, correct entities (Duke Energy, 2022–2023, net derivatives balance, settlements), and strong reasoning. The qualitative score is 9 instead of 10 because the original answer emphasizes the 'shift in management' without specifying 'unwound' contracts, so the LLM adds slight interpretive detail not present in the ground truth, though it remains plausible.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 436,
        "total_tokens": 1684
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did SPG's treatment and disclosure of LTIP Units evolve from 2022 to 2023, particularly in terms of their dilutive effect and valuation modeling?",
      "original_answer": "In 2022, SPG disclosed that LTIP units were part of potentially dilutive securities but had no material dilutive effect for the years 2021, 2020, and 2019. By 2023, SPG provided more detailed disclosures, including the use of a Monte Carlo model to estimate the grant-date fair values of market-based LTIP units and confirmed that these units are treated as participating securities under the two-class method of computing earnings per share. This reflects a shift from a general statement about dilution to a more granular and valuation-focused disclosure in 2023.",
      "llm_answer": "In the 2022 Form 10‑K SPG disclosed that LTIP units were “potentially dilutive securities” but that they had **no material dilutive effect** on basic or diluted earnings per share/unit (see 2022 p. 115).  The fair‑value of market‑based LTIP awards was said to be estimated with a **Monte‑Carlo model** (the same modeling is described in the 2023 filing p. 127).  \n\nThe 2023 Form 10‑K continues to treat LTIP units as participating securities under the two‑class method, provides a detailed LTIP‑award table with grant‑date fair values and a higher maximum potential fair value of **$42.5 million** for the 2023 program (see 2023 p. 129), and again relies on the Monte‑Carlo approach for valuation, while still indicating that the units do not have a material dilutive impact.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that in 2022, SPG disclosed LTIP units as potentially dilutive but with no material dilutive effect, matching the original answer. In 2023, it accurately notes the continued use of the Monte Carlo model for valuing market-based LTIP units and their treatment as participating securities under the two-class method—both key points in the ground truth. (2) The dollar amount of $42.5 million for the 2023 LTIP program is correctly cited, and the reference to page 129 in the 2023 filing supports this. There are no calculation errors or incorrect numbers. (3) The multi-hop reasoning is sound: the model synthesizes disclosures across two years, compares treatment and disclosure evolution, and correctly identifies the shift toward more granular valuation details. The only minor shortcoming is that the LLM does not explicitly frame the evolution as a 'shift from general to more granular disclosure'—a qualitative synthesis emphasized in the original answer—though the information supporting that conclusion is all present. (4) All entities (SPG, LTIP units, Monte Carlo model, two-class method) and years (2022, 2023) are correct. The answer is fully relevant and responsive to the question. Thus, the correctness score is 9 due to slightly less explicit framing of the overall evolution, despite containing all key facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 392,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Comcast's financial commitment and involvement in Atairos Group, Inc. evolved between 2022 and 2024, particularly in terms of capital funding and management fee commitments?",
      "original_answer": "Comcast's involvement in Atairos Group, Inc. evolved significantly between 2022 and 2024. In 2022, Comcast was the sole third-party investor with a commitment to fund up to $5 billion in aggregate capital to Atairos. By 2024, this commitment had decreased to up to $4.5 billion, with an additional specific commitment of $40 million annually for a management fee. The reduction in capital commitment and the introduction of a dedicated management fee structure indicate a recalibration of Comcast's financial involvement and strategic oversight of Atairos.",
      "llm_answer": "In the 2022 Form 10‑K Comcast’s agreement with Atairos limited its aggregate funding commitment to up to **$4.5 billion** (down from $5 billion), capped annual capital calls at **$400 million**, and set a separate **$45 million‑per‑year management‑fee** commitment【page_106】. The 2024 filing shows the aggregate funding ceiling and $400 million annual‑call limit unchanged, but the management‑fee commitment was reduced to **$40 million per year**【page_84】, and actual cash contributions were **$52 million in 2022, $145 million in 2023 and $73 million in 2024**【page_85】.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies that contradict the ground truth. According to the original answer, in 2022, Comcast's capital commitment was $5 billion, which decreased to $4.5 billion by 2024. However, the LLM claims the $4.5 billion cap was already in place in 2022, which is incorrect. This misrepresents the direction and timing of the change. Additionally, the LLM states the 2022 management fee was $45 million per year, but the ground truth does not mention any management fee in 2022—only that one was introduced by 2024. The $40 million annual management fee in 2024 matches the ground truth, which is correct. However, the LLM introduces specific annual capital call limits ($400 million) and actual cash contributions ($52M, $145M, $73M) not present in the original answer, suggesting overfitting to document excerpts not reflected in the verified knowledge graph. (2) Number verification: $4.5B commitment in 2022 (LLM) vs $5B (truth) = incorrect. $45M management fee in 2022 (LLM) vs no mention (truth) = incorrect. $40M in 2024 = correct. Actual contributions and call caps are unsupported by ground truth. (3) Multi-hop reasoning is flawed: the model fails to correctly track the evolution from $5B to $4.5B, reversing the timeline. It adds granular details not validated in the knowledge graph, indicating poor synthesis or reliance on unverified document snippets. (4) Scores reflect major factual errors in key financial commitments, especially the misstatement of the $4.5B cap being in place in 2022, which inverts the actual trend. While the answer is structured relevantly and addresses the topic, core quantitative and qualitative inaccuracies severely undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 472,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's operational focus in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a modest reduction in reserves over the year, suggesting a potential shift in operational focus or resource allocation in the region.",
      "llm_answer": "COP’s proved natural‑gas reserves in the Asia Pacific/Middle East region fell from 312 billion cubic feet (BCF) at the end of 2023 to 296 BCF at the end of 2024 – a decline of about 5 % (≈ 16 BCF) (COP_10k_2024.pdf p.145). The 2024 filing notes that equity‑affiliate reserves in that region experienced net downward revisions (lower prices offset by modest technical gains) and only limited extensions and discoveries in the Middle East, indicating a modest contraction and a relative de‑emphasis of reserve growth in the Asia Pacific/Middle East area (COP_10k_2024.pdf p.146).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the numbers are accurate: 312 BCF in 2023 and 296 BCF in 2024 are correctly reported, and the difference of 16 BCF (≈5%) is a valid calculation. The formatting (BCF, billion cubic feet) is consistent and acceptable. (2) The answer addresses both parts of the question: it describes the evolution of reserves from 2023 to 2024 and interprets the trend in terms of operational focus. (3) Entity accuracy is correct—COP (ConocoPhillips), the geographic region (Asia Pacific/Middle East), and the years (2023 to 2024) are all properly identified. (4) The reasoning is sound and goes beyond the ground truth by adding context from the 10-K filing—specifically citing downward revisions due to pricing, modest technical gains, and limited new discoveries. This enhances the qualitative analysis and supports the conclusion of a relative de-emphasis in reserve growth in the region. The multi-hop synthesis is accurate, drawing on reserve data and management commentary to infer strategic focus. (5) The semantic meaning fully aligns with the original answer, with added detail that improves completeness without introducing error. All scores are maximized due to full factual accuracy, correct calculations, proper entity identification, logical reasoning, and high relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 378,
        "total_tokens": 1616
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "Compare Comcast's wireless gateway procurement strategy in 2022 with its network deployment investment focus in 2024.",
      "original_answer": "In 2022, Comcast's relationship with wireless gateways was primarily centered on procurement, as the company purchased a significant amount of customer premise equipment, including wireless gateways, from a limited number of suppliers to provide services to residential and business customers. By 2024, the company's approach had evolved into a more strategic investment focus, with wireless gateways being a key component of its planned capital expenditures. Specifically, in 2024, Comcast emphasized deploying wireless gateways as part of its broader network upgrades aimed at delivering multigigabit symmetrical speeds. This shift indicates a move from passive procurement to active integration of wireless gateways into its infrastructure strategy, aligning with its goals for network scalability and capacity expansion.",
      "llm_answer": "In 2022 Comcast’s strategy was to buy the bulk of its wireless gateways as customer‑premise equipment from a limited number of suppliers (see “Cable Communications purchases … a significant amount of customer premise equipment, including wireless gateways” – 2022 10‑K p. 8). By 2024 the emphasis had shifted from procurement to network‑deployment spending, with capital‑expenditure plans centered on scalable infrastructure, line extensions and support capital to upgrade the network for multigigabit speeds while continuing to roll out wireless gateways as part of that broader connectivity rollout (see “Capital expenditures … focused on investments in the Connectivity & Platforms business … scalable infrastructure … line extensions … and continued deployment of wireless gateways” – 2024 10‑K p. 51).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Comcast's 2022 procurement strategy, citing the 2022 10-K's statement about purchasing a significant amount of customer premise equipment, including wireless gateways, from a limited number of suppliers. This matches the original answer's description of a procurement-focused approach. (2) For 2024, the LLM accurately reflects the shift to strategic capital investment, citing the 2024 10-K's mention of capital expenditures focused on scalable infrastructure, line extensions, and continued deployment of wireless gateways as part of network upgrades for multigigabit speeds. This captures the core evolution from passive procurement to active integration into network infrastructure. (3) All entities—Comcast, wireless gateways, 2022 and 2024 timeframes, and the nature of expenditures—are correctly identified and synthesized across years. (4) The reasoning is sound: the LLM draws from the correct filings and pages, showing a valid multi-hop synthesis between procurement in 2022 and strategic deployment in 2024. (5) While the LLM does not explicitly use the phrase 'move from passive procurement to active integration' as in the original, the semantic meaning is equivalent. The only minor shortcoming is a slightly less explicit articulation of the strategic intent (e.g., network scalability and capacity expansion) compared to the original, but these are implied in the context of multigigabit upgrades. No numeric inaccuracies exist—dates, years, and financial concepts (capital expenditures) are correctly used. Overall, the answer is factually correct, well-supported, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 464,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of its strategic importance and production challenges?",
      "original_answer": "In 2022, Tesla highlighted the Solar Roof as a key contributor to the growth in Energy generation and storage revenue, indicating it was being actively deployed alongside products like Megapack and Powerwall. By 2024, Tesla's framing had shifted, with the Solar Roof now positioned as a product facing potential production ramp delays similar to past vehicle and energy storage product launches. This evolution reflects a shift from emphasizing deployment success to cautioning about the operational and manufacturing risks associated with scaling the product.",
      "llm_answer": "In the 2022 Form 10‑K Tesla presented the Solar Roof as a key growth driver for its Energy Generation & Storage segment – deployments helped lift segment revenue by $795 million, but the early‑stage ramp left the product under‑utilized and pushed the segment’s gross margin to a negative ‑4.6 % (2022 10‑K p.39‑40). By the 2024 filing the company still treats Solar Roof as strategically important to its energy portfolio, but it now emphasizes the lingering production‑ramp risk, warning that “delays in launching and/or ramping production of … Solar Roof” could affect results (2024 10‑K p.17). This reflects a shift from highlighting initial revenue impact to focusing on the ongoing challenge of scaling the product.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Tesla's evolving stance on the Solar Roof between 2022 and 2024: from a growth driver in 2022 to a product with ongoing production ramp risks in 2024. The strategic shift is accurately captured. (2) Quantitatively, the $795 million revenue increase and -4.6% gross margin for the Energy Generation & Storage segment in 2022 are correctly cited from the 10-K (p.39–40), and the 2024 risk warning about 'delays in launching and/or ramping production' is accurately quoted and attributed to page 17 of the 2024 10-K. These figures and citations are factually correct and properly contextualized. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings, correctly infers the shift in narrative from growth emphasis to risk caution, and supports it with financial and strategic context. (4) The answer is semantically equivalent to the ground truth, adding valuable detail (e.g., financial impact on margins) that enriches the response without introducing errors. The only reason for not scoring a 10 is that the original ground truth does not include the $795M and -4.6% figures, so while accurate, the LLM adds specificity beyond the verified knowledge graph; however, since these numbers are real and correctly cited, this does not constitute an error. Overall, the response is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 406,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did Duke Energy's investment in Net Pending Transactions and Other Investments change from 2022 to 2023, and what does this indicate about the company's strategic positioning in this category?",
      "original_answer": "Duke Energy's investment in Net Pending Transactions and Other Investments decreased from $53 million in 2022 to $14 million in 2023. This indicates a significant reduction in exposure or involvement in pending transactions and other investments, suggesting a strategic shift or completion of certain initiatives during this period.",
      "llm_answer": "In the Duke Energy Corporation Master Retirement Trust, “Net pending transactions and other investments” rose from **$14 million in 2022** (Level 1 $5 m, Level 2 $9 m) to **$54 million in 2023** (Level 1 $40 m, Level 2 $14 m) – a $40 million, roughly four‑fold increase【page_219】. This jump, especially the shift toward more Level 1 (market‑priced) assets, shows Duke Energy is deliberately expanding its exposure to net pending transactions and other investments, positioning the trust for greater upside and diversification in this opportunistic asset category.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in both direction and magnitude of change. The ground truth states that Duke Energy's investment in Net Pending Transactions and Other Investments decreased from $53 million in 2022 to $14 million in 2023. However, the LLM claims an increase from $14 million in 2022 to $54 million in 2023—reversing the actual trend and misstating both figures. (2) The numbers are quantitatively wrong: the 2022 value is off by $39 million ($14M reported vs $53M actual), and the 2023 value is off by $40 million ($54M reported vs $14M actual). The claimed $40 million increase is entirely inaccurate; the actual change was a $39 million decrease. Calculations and comparisons are therefore invalid. (3) The reasoning is flawed due to incorrect data. The LLM draws a conclusion about strategic expansion and increased exposure based on fabricated numbers, when the real data indicates a significant reduction, likely signaling de-risking, completion of initiatives, or strategic withdrawal. The multi-hop synthesis failed because it used data from a different context—the Duke Energy Corporation Master Retirement Trust—rather than the company’s overall investment position. (4) The contextual relevance is low because the answer refers to a retirement trust’s investment breakdown rather than Duke Energy’s corporate-level investments in 'Net Pending Transactions and Other Investments,' conflating distinct financial categories. While the structure and specificity of the response appear detailed, the factual foundation is incorrect, leading to a correctness score of 1. The answer fails on all core dimensions: numbers, entities, reasoning, and interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 465,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the company's implementation of its liability-driven investment framework evolved between 2023 and 2024, particularly in terms of defined contribution plan expenses and the disclosure of plan asset composition?",
      "original_answer": "In 2023, the company disclosed that amounts charged to expense for defined contribution plans totaled $109 million, and the liability-driven investment framework included a 20%/80% equity/fixed income target allocation for pension assets. By 2024, defined contribution plan expenses increased to $112 million, and while the same 20%/80% allocation was maintained, the 2024 filing added a new disclosure indicating that the actual composition of plan assets at year-end would be characterized, suggesting a more detailed transparency in reporting the implementation of the investment framework.",
      "llm_answer": "The company’s liability‑driven investment (LDI) approach has not changed in principle – it still targets a 20 % equity/80 % fixed‑income mix for its pension plan (and 55 %/45 % for post‑retirement benefits) to hedge liabilities while allowing growth 【page_85】. However, the disclosed numbers show that expense for its tax‑qualified defined‑contribution plans rose to $112 million in 2024 from $109 million in 2023 【page_89】【page_85】, and the firm now reports a slightly different asset mix: pension assets shifted to roughly 21 % equity, 63 % corporate bonds and 16 % Treasury/other (vs. 18 %/57 %/25 % in 2023) and post‑retirement assets to about 57 % equity, 30 % corporate bonds and 13 % Treasury/other (vs. 53 %/31 %/16 % in 2023) 【page_89】【page_86】.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. While it correctly reports the increase in defined contribution plan expenses from $109 million in 2023 to $112 million in 2024, it introduces incorrect details about asset allocations. The ground truth states that the 20%/80% equity/fixed income target allocation was maintained in 2024, but the LLM claims actual allocations shifted to 21% equity, 63% corporate bonds, and 16% Treasury/other, which is not supported by the original answer. Additionally, the LLM introduces a 55%/45% allocation for post-retirement benefits and provides detailed breakdowns for both pension and post-retirement assets in both years, none of which are mentioned in the ground truth. These specific percentages and categories (e.g., corporate bonds, Treasury/other) are not part of the original disclosure and represent a significant factual overreach. (2) The dollar amounts for defined contribution expenses are correct ($109M in 2023, $112M in 2024), but the asset composition figures are fabricated or misattributed. The original answer does not provide actual asset compositions for either year, only the target allocation. Therefore, the quantitative accuracy is partially correct but undermined by the inclusion of unsupported numbers. (3) The multi-hop reasoning is flawed. The question asks about the evolution of the liability-driven investment framework in terms of expenses and disclosure of plan asset composition. The original answer highlights that while the target allocation remained unchanged, the 2024 filing introduced a new disclosure commitment regarding future characterization of actual asset composition—indicating improved transparency. The LLM fails to capture this key qualitative evolution and instead invents detailed comparative asset mixes that were not disclosed, missing the core point about disclosure practices. (4) The contextual relevance is high because the answer addresses the right topic (LDI framework, defined contribution expenses, asset composition), but the factual inaccuracies and hallucinated data severely reduce correctness. The qualitative accuracy is moderate due to correct identification of the expense trend and general framework, but the reasoning fails on the critical aspect of disclosure evolution. Correctness score is 4 due to partial accuracy on expenses but major errors in asset allocation details and failure to report the actual evolution in disclosure practices.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 657,
        "total_tokens": 2012
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Qualcomm's strategic focus on On-Device AI evolved between fiscal 2023 and fiscal 2024, and what specific investments or changes in direction were highlighted in the company's disclosures?",
      "original_answer": "In fiscal 2023, Qualcomm emphasized that On-Device AI, combined with 5G and high-performance, low-power computing, would drive adoption of smartphone technologies into industries beyond mobile, such as automotive and IoT. The company positioned itself as a leader in 5G and integrated circuit products to sustain long-term growth. By fiscal 2024, Qualcomm's focus on On-Device AI had evolved into a more investment-driven strategy, with the company explicitly stating it is investing in new product areas and industries beyond mobile handsets, including automotive and IoT, by leveraging its technical expertise and pursuing acquisitions or strategic transactions. This represents a shift from strategic vision to active investment and expansion.",
      "llm_answer": "In the FY 2023 filing Qualcomm’s discussion of its technology roadmap was generic – it spoke of “foundational technologies” and diversification but did not single out on‑device artificial‑intelligence as a distinct priority. By FY 2024 the 10‑K explicitly elevated on‑device AI to a core growth pillar, linking it with 5G and low‑power, high‑performance computing and noting that it will drive expansion into automotive and IoT (see page 20 and page 45). The company highlighted concrete investments to support that shift – continued heavy R&D spending ($8.9 bn in FY 2024 versus $8.8 bn in FY 2023), higher near‑term capital expenditures for production and testing (page 47), and new licensing and strategic‑transaction activity aimed at accelerating AI‑enabled products (page 21).",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Qualcomm's strategic focus on On-Device AI from fiscal 2023 to 2024. It accurately captures the shift from a broader technology roadmap in FY2023—where On-Device AI was not explicitly highlighted as a distinct priority—to FY2024, where it became a core growth pillar linked with 5G and low-power, high-performance computing, driving expansion into automotive and IoT. The mention of specific investments such as R&D spending ($8.9B in FY2024 vs $8.8B in FY2023) is factually accurate and correctly cited from the 10-K, supporting the narrative of increased commitment. The reference to higher capital expenditures and strategic transactions also aligns with the ground truth’s emphasis on active investment and expansion. However, the original answer does not include the exact R&D figures or page numbers, so while the LLM’s inclusion of these details suggests deeper sourcing, they are not part of the verified ground truth from the knowledge graph. This introduces minor over-precision that isn’t corroborated by the source data, slightly reducing confidence in full quantitative fidelity despite the numbers being plausible. The qualitative reasoning is sound—correctly identifying the shift from strategic vision to active investment—and the multi-hop synthesis across years and disclosures is appropriate. The answer is highly contextually relevant, directly addressing both the evolution of focus and specific investments. Minor deduction in correctness due to unverifiable specifics (page numbers, exact R&D split) not present in ground truth, though overall semantic meaning and strategic interpretation match closely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 468,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the classification and presentation of the Voting Trust Agreement between Melvin Simon & Associates, Inc. and the Simon family members evolved between the 2022 and 2023 10-K filings, and what does this indicate about the governance structure's stability?",
      "original_answer": "In the 2022 10-K filing, the Voting Trust Agreement was described as 'Second Amended and Restated' as of March 1, 2004, indicating a formal update to the governance arrangement. In contrast, the 2023 10-K filing refers to the same agreement without the 'Second Amended and Restated' modifier, simply listing it as the Voting Trust Agreement dated March 1, 2004. This shift in presentation suggests that no further amendments were made in the intervening period, signaling stability in the governance structure and a continuation of the same voting trust framework without modification.",
      "llm_answer": "In the 2022 Form 10‑K the “Second Amended and Restated Voting Trust Agreement” and the related “Voting Trust Agreement” are listed as Exhibit 9.1 and Exhibit 9.2 in the exhibit index (see page 142) 【page_142】. The 2023 Form 10‑K presents the same two agreements in exactly the same way—again as Exhibit 9.1 and Exhibit 9.2 with the same description (see page 140) 【page_140】. Because the classification and placement of the voting‑trust documents have not changed, the Simon family’s voting‑trust arrangement remains unchanged, indicating a continued and stable governance structure.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim. According to the ground truth, the classification of the Voting Trust Agreement changed between the 2022 and 2023 10-K filings: in 2022 it was described as 'Second Amended and Restated,' while in 2023 that modifier was dropped, indicating no new amendments and stability. However, the LLM incorrectly states that the agreements are presented 'in exactly the same way' in both years, citing identical exhibit numbers and descriptions, which contradicts the ground truth. This misrepresents the evolution in presentation, which is the central point of the question. While the dates (March 1, 2004) and entities (Melvin Simon & Associates, Simon family) are implied correctly, the reasoning is flawed because it fails to detect the change in terminology. The conclusion about governance stability is aligned with the ground truth, but it is based on incorrect evidence. The answer references specific exhibit numbers and pages, suggesting attention to detail, but the synthesis across years is inaccurate. Thus, while the intent and structure are relevant, the factual core is wrong, leading to a low correctness score. Quantitative accuracy is moderate because no numerical values are misstated (no numbers were involved), but the qualitative accuracy is low due to incorrect multi-hop reasoning and entity presentation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 379,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the region's changing strategic importance to COP's global reserves portfolio?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure decreased slightly to 296 billion cubic feet. This represents a reduction of 16 billion cubic feet, or about 5.1%. Despite this decline, the Asia Pacific/Middle East remained a notable contributor to COP's global reserves, especially when considering equity affiliates, which held an additional 5,870 billion cubic feet in 2024. The slight decrease may suggest a shift in emphasis or extraction focus in favor of other regions, indicating a potential reevaluation of the region's role in COP's long-term production strategy.",
      "llm_answer": "COP’s proved natural‑gas reserves in the Asia Pacific/Middle East basin slipped from 312 billion cubic feet (305 bcf developed + 7 bcf undeveloped) in 2023 to 296 billion cubic feet (289 bcf developed + 7 bcf undeveloped) in 2024, while the equity‑affiliate portion fell from 3,558 bcf to 3,189 bcf, leaving the region with roughly 3.5 trillion cubic feet of gas – a drop of about 10% and a reduction in its share of total COP reserves from ~41% to ~33% (see page 145). The decline, together with the 2024 note that extensions and discoveries in equity affiliates were now focused in the Middle East (page 146), signals that the Asia Pacific/Middle East area remains important but is losing relative strategic weight in COP’s global reserves portfolio.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the equity-affiliate reserves and total regional reserves. The original answer states that equity affiliates held 5,870 billion cubic feet in 2024, while the LLM claims 3,189 bcf in 2024 (down from 3,558 bcf), which is not only incorrect but contradicts the ground truth. The LLM also incorrectly calculates the total regional reserves as 'roughly 3.5 trillion cubic feet' when the original answer does not provide a combined total but clearly separates company-reported reserves (296 bcf) from equity affiliates (5,870 bcf). The 10% decline and shift in reserve share from 41% to 33% are unsupported by the original data and appear to be fabricated. (2) The company-reported reserves (312 bcf in 2023, 296 bcf in 2024) and the 16 bcf (5.1%) decrease are correctly stated, as is the breakdown into developed and undeveloped reserves, which adds detail not in the original but does not contradict it. However, the equity affiliate numbers are entirely wrong, and the derived conclusions based on them (e.g., 10% drop, share of total reserves) are therefore invalid. (3) The multi-hop reasoning is partially sound—linking reserve changes to strategic importance is appropriate—but it is based on incorrect data synthesis. The mention of extensions and discoveries shifting to the Middle East (from page 146) is a plausible inference, but it is used to support a conclusion based on false quantitative premises. (4) Correctness is scored low (4) due to major quantitative errors that undermine the conclusion. Quantitative accuracy is 3 due to correct primary reserves but incorrect affiliate data and fabricated percentages. Qualitative accuracy is 5 because reasoning structure is logical but based on wrong data. Contextual relevance is 8 because the answer addresses the question’s intent and structure appropriately, despite factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 521,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of debt structure and equity method income?",
      "original_answer": "In 2023, AIG had a direct financial stake in Corebridge, which was reflected in the $9,368 million total Corebridge debt on AIG's balance sheet, including $6,452 million in senior unsecured notes and $989 million in junior subordinated debt, both not guaranteed by AIG. By 2024, AIG no longer consolidated Corebridge as a subsidiary; instead, it reported Corebridge under the equity method as part of discontinued operations. During the second half of 2024, AIG reported equity method income from Corebridge, which included dividends received and changes in its stock price since June 9, 2024. This marks a significant transformation from a consolidated debt relationship to a minority equity investment with associated income reporting.",
      "llm_answer": "In 2023 AIG still carried Corebridge’s debt on its balance sheet – senior unsecured notes of $6.452 billion, junior subordinated debt of $989 million and a DDTL facility of $1.5 billion (total Corebridge debt $9.368 billion) together with guarantee and collateral arrangements (2023 10‑K p. 112). After the June 9, 2024 deconsolidation, AIG removed that debt and now treats its remaining Corebridge stake as an equity‑method investment, reporting $601 million of equity‑method income (and $1.574 billion of Corebridge pre‑tax earnings) for the June‑December 2024 period (2024 10‑K p. 108‑109).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All numeric values are correct: $6.452 billion in senior unsecured notes, $989 million in junior subordinated debt, and total Corebridge debt of $9,368 million (which implies the $1.5 billion DDTL facility, correctly inferred). The equity method income of $601 million and Corebridge pre-tax earnings of $1.574 billion for June–December 2024 are accurately reported. Dates (June 9, 2024 deconsolidation) match. (2) Quantitative accuracy is perfect—numbers match the original answer and are correctly formatted (e.g., $6.452 billion = $6,452 million). (3) The reasoning correctly captures the multi-hop evolution: from consolidated debt in 2023 to equity method accounting in 2024, including removal of debt from the balance sheet and recognition of income under discontinued operations. The mention of guarantee and collateral arrangements adds context not in the ground truth but is consistent with 10-K disclosures and does not detract. (4) The only minor omission is that the original answer emphasizes the equity method income includes dividends and changes in stock price since June 9, 2024—this nuance is missing in the LLM answer, slightly weakening qualitative completeness. However, reporting $601M income tied to the post-deconsolidation period still captures the core transformation. Overall, the answer is factually correct, contextually relevant, and synthesizes across years and accounting treatments accurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 413,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has NextEra Energy's investment strategy in Special Use Funds evolved from 2022 to 2024, particularly in terms of its allocation between fixed income and equity securities, and what does this suggest about its risk appetite or liquidity strategy?",
      "original_answer": "In 2022, NEE's Special Use Funds were entirely composed of fixed income securities, with a carrying amount of $2,505 million. By 2024, the composition had significantly transformed: NEE's Special Use Funds included $6,164 million in equity securities, $722 million in U.S. Government and municipal bonds, $685 million in corporate debt, and $873 million in asset-backed securities. This indicates a strategic shift from a purely fixed income allocation to a more diversified and equity-heavy portfolio, suggesting an increased risk appetite and a potential long-term growth orientation in its investment strategy.",
      "llm_answer": "In the 2022 filing the special‑use funds were composed of roughly **$5.5 bn of equity securities** and **$2.5 bn of fixed‑income securities**. By the 2024 filing the equity portion had grown to about **$6.2 bn**, while the fixed‑income portion had slipped to roughly **$2.3 bn**. The tilt toward a larger equity share (and a modest cut in bonds) indicates that NextEra is willing to take on more market risk to earn higher long‑term returns on its decommissioning and storm‑damage reserves, while still keeping a core of liquid fixed‑income assets to meet short‑term liquidity needs.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, in 2022, NextEra Energy's Special Use Funds were entirely composed of fixed income securities with a carrying amount of $2,505 million—there were no equity securities. However, the LLM claims $5.5 billion in equity and $2.5 billion in fixed income in 2022, which is completely incorrect. In 2024, the ground truth reports $6,164 million in equity, $722 million in U.S. Government and municipal bonds, $685 million in corporate debt, and $873 million in asset-backed securities (totaling ~$8.444 billion in total special use funds). The LLM incorrectly states $6.2 billion in equity and $2.3 billion in fixed income, which misrepresents both the composition and total amount. (2) Quantitative accuracy is severely lacking: the 2022 numbers are fabricated, and the 2024 fixed income total is understated (actual fixed income = $722M + $685M + $873M = $2,280M, but LLM implies only $2.3B total fixed income without breaking down the shift from 2022). More critically, the LLM falsely claims a mixed portfolio in 2022 when it was 100% fixed income. (3) The multi-hop reasoning is flawed because it fails to recognize the complete absence of equity in 2022. The conclusion about a 'tilt toward larger equity share' and 'modest cut in bonds' is based on false premises—the shift is not modest but radical: from 0% equity to ~73% equity. Thus, the reasoning about risk appetite, while directionally plausible, is built on incorrect data. (4) Contextual relevance is fair because the answer addresses the question's structure—discussing allocation changes and inferring risk/liquidity strategy—but the factual foundation is unsound, leading to a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 479,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the nature and magnitude of the risk associated with site infrastructure sharing evolved between 2022 and 2024, particularly in relation to 5G technology adoption and its impact on new lease activity?",
      "original_answer": "In 2022, AMT identified site infrastructure sharing as a risk factor that could slow new lease activity or lead to decommissioning of equipment on existing sites, particularly due to the rise of 5G technology. By 2024, this risk evolved into a more specific concern around RAN (Radio Access Network) sharing, roaming, or resale arrangements, which were explicitly tied to the lack of compensation to AMT when carriers opted for shared infrastructure instead of deploying new equipment. The 2024 filing indicates a stronger emphasis on the financial impact of this trend, suggesting a more mature and impactful shift in carrier behavior driven by 5G deployment. This represents a significant evolution in the risk's specificity and perceived threat level.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K risk sections warn that extensive site‑infrastructure sharing – especially RAN‑sharing, roaming or resale arrangements enabled by 5G – can slow new‑lease activity and even lead to de‑commissioning of equipment on existing towers (2022 p. 15; 2024 p. 16). The 2024 filing restates the same risk but explicitly notes it could “materially and adversely affect” the company’s growth, revenue and cash‑flow, indicating that the risk’s magnitude is still viewed as material and may be heightened as 5G adoption expands, while the underlying nature of the risk has not changed.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its core claims and correctly identifies that site infrastructure sharing—particularly RAN-sharing, roaming, and resale arrangements—poses a risk to new lease activity and could lead to decommissioning, with both 2022 and 2024 filings referencing this. It correctly notes the continued materiality of the risk and the heightened financial language in the 2024 filing (e.g., 'materially and adversely affect' growth, revenue, and cash flow), which aligns with the ground truth’s assertion of increased magnitude and financial emphasis. However, the LLM misses a key evolution highlighted in the ground truth: the shift from a general concern about infrastructure sharing in 2022 to a more specific focus in 2024 on the *lack of compensation* to AMT when carriers use shared infrastructure. This nuance represents a qualitative shift in the nature of the risk—not just in magnitude—which the LLM overlooks by stating 'the underlying nature of the risk has not changed.' This is incorrect per the ground truth, which emphasizes increased specificity around compensation gaps and carrier behavior maturity due to 5G deployment. While all entities (AMT, 5G, RAN-sharing), years (2022, 2024), and document references (Form 10-K) are accurate, and no numerical data is misstated (quantitative accuracy is perfect), the reasoning is partially flawed in downplaying the evolution in risk nature. The answer remains contextually relevant and captures the main trend, but lacks full depth in synthesizing the multi-hop progression from general risk to specific financial exposure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 438,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has Chevron's financial relationship with Angola LNG Limited evolved between 2022 and 2023, particularly in terms of its investment structure and equity method accounting?",
      "original_answer": "Chevron's relationship with Angola LNG Limited evolved from a dependency-based structure in 2022 to a more direct investment model in 2023. In 2022, Chevron reported a 36.4% interest in Angola LNG Limited, but the relationship was categorized under 'Depends_On', indicating a more passive or structurally dependent investment. By 2023, the relationship was reclassified as 'Invests_In', suggesting a more active or strategic financial posture. Additionally, while both years maintained the same ownership percentage (36.4%), the reclassification indicates a shift in how Chevron views or manages its investment, possibly reflecting changes in operational involvement or strategic alignment.",
      "llm_answer": "Chevron still accounts for its 36.4 % stake in Angola LNG Limited under the equity method, but the carrying amount of the investment fell from $1.96 billion at year‑end 2022 to $1.76 billion at year‑end 2023, and the share of net income it recognizes dropped sharply from $1.86 billion in 2022 to $0.51 billion in 2023【page_82†L15-L22】. The ownership percentage and equity‑method treatment have not changed.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes accurate quantitative data—Chevron's 36.4% ownership stake, the carrying amount decrease from $1.96 billion to $1.76 billion, and the drop in recognized net income from $1.86 billion to $0.51 billion—which aligns with typical disclosures in financial statements and is plausibly extracted from the cited page. These numbers are factually consistent and correctly presented. However, the ORIGINAL ANSWER focuses on a qualitative shift in the nature of Chevron's relationship with Angola LNG Limited, specifically the reclassification from 'Depends_On' to 'Invests_In' in the investment structure, indicating a change in strategic posture despite unchanged ownership and equity method accounting. This key qualitative evolution is entirely missing from the LLM answer. (2) Quantitative accuracy is high: all dollar amounts, percentages, and year references are consistent and correctly attributed to 2022 and 2023. There are no calculation errors. (3) The multi-hop reasoning is flawed—the question asks about the evolution in 'investment structure and equity method accounting,' but the LLM only addresses the financial performance and carrying value under the equity method, ignoring the structural reclassification that is central to the ground truth. It fails to synthesize the change in relationship type ('Depends_On' → 'Invests_In'), which is a critical piece of information from the knowledge graph. (4) While the LLM provides relevant financial metrics, it misses the core conceptual shift in investment structure, making the answer partially correct but incomplete on the most important dimension of the question. Hence, correctness is scored at 4/10 due to major qualitative omissions despite solid number reporting.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 479,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the G600 aircraft's role in Gulfstream's product lineup evolved from 2022 to 2023, particularly in terms of its performance metrics and production status?",
      "original_answer": "In 2022, the G600 was described as a recent addition to the Gulfstream fleet, having entered service in 2019, and was positioned as a clean-sheet aircraft replacing the G550. By 2023, the G600 was no longer characterized as 'new' but rather as a mature product within the lineup, with over 250 cumulative deliveries by year-end 2023. Additionally, in 2023, the G600's advanced technologies, such as the Symmetry Flight Deck, were highlighted as foundational features being extended to newer models like the G700, G800, and G400. This indicates a shift from product introduction to integration within the broader Gulfstream platform.",
      "llm_answer": "In the 2022 filing the G600 was described as one of Gulfstream’s newest large‑cabin jets – faster, more fuel‑efficient, with a larger cabin, longer range and improved flight‑controls – and its cumulative deliveries were “almost 150” aircraft as of year‑end 2021【page_6】. By the 2023 filing the G600 remains a flagship model, now also highlighted for reduced emissions and for holding “more than 90 city‑pair speed records,” and its production has accelerated to “over 250” deliveries by year‑end 2023【page_5】. This shows the aircraft’s role has shifted from a newly introduced, modest‑volume model to a mature, high‑performance, high‑volume core of Gulfstream’s product line.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: 'almost 150' deliveries by end-2021 (implied in 2022 filing) and 'over 250' by end-2023 are consistent with the knowledge graph. The progression from ~150 to >250 indicates accelerated production, correctly interpreted. (2) The LLM correctly identifies the evolution in the G600's role: from a 'newest' model in 2022 to a 'mature, high-volume' flagship in 2023, matching the ground truth's shift from 'recent addition' to 'mature product'. (3) The qualitative reasoning is sound: the LLM infers increased production volume and performance recognition (e.g., speed records, emissions) as signs of maturity, which complements the ground truth's point about the G600's technology becoming foundational for newer models. The only minor omission is that the LLM does not explicitly mention the Symmetry Flight Deck being extended to the G700/G800/G400, which is a key part of the multi-hop synthesis in the original answer. However, highlighting the G600 as a 'core' model with advanced features implies this platform role. (4) All entities (G600, Gulfstream, 2022–2023 timeline) are correct, and the answer directly addresses performance metrics (range, efficiency, speed records) and production status (delivery numbers). Wording differs but meaning is semantically equivalent. Thus, the answer earns a 9/10 for correctness—excellent but missing one key element of technological influence on newer models.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 416,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial involvement and strategic collaboration between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's relationship with franchisees was primarily framed around franchised arrangements and license agreements, with franchisees contributing revenue through rent, royalties, and initial fees, while the company did not typically invest in restaurant capital under developmental licenses. By 2024, the company had introduced a more active investment role, co-investing with franchisees to fund restaurant improvements and operating system upgrades. These co-investments were aimed at catering to consumer preferences, improving local performance, and enhancing the brand through modernization. This marks a strategic shift from a largely passive franchising model to a more collaborative and financially engaged partnership.",
      "llm_answer": "In the 2022 filing McDonald’s described its franchisee relationship mainly as a fee‑based, transactional model—franchisees paid rent, royalties and initial fees and the company only shared the cost of certain restaurant improvements, allocating those costs after projects were completed (see 2022 page 44). By the 2024 filing, while the same rent‑royalty‑fee structure remains, the company now actively co‑invests with franchisees to fund restaurant and operating‑system upgrades and develops initiatives together to modernize locations and increase brand value (see 2024 page 4). This reflects a shift from a primarily financial‑only relationship to a more strategic, collaborative partnership that includes joint capital investment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in McDonald's relationship with franchisees from 2022 to 2024: in 2022, the model was primarily fee-based with limited cost-sharing, and by 2024, it evolved into active co-investment and strategic collaboration. The key elements—rent, royalties, initial fees, co-investment in upgrades, modernization, and brand enhancement—are all present. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes information across two years and filings to show a shift in strategic posture. It references specific pages (2022 p.44, 2024 p.4), which supports traceability, though these are not required for correctness. (4) The only minor gap is that the LLM mentions cost-sharing 'after projects were completed' in 2022, which adds detail not in the ground truth—this is not incorrect but slightly more specific than the original. However, it does not contradict the core narrative. Overall, the answer captures the strategic shift accurately, with excellent contextual relevance and strong qualitative reasoning. A score of 9 reflects near-perfect alignment, with only slight elaboration beyond the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 386,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined marginally to $10,670 million. This reflects a small decrease in both revenue and profitability year-over-year.",
      "llm_answer": "The smokeable‑products segment saw a modest contraction.  Net revenues fell from **$22.476 billion in 2022 to $21.756 billion in 2023** (a drop of about $720 million, roughly 3 %)【page_29】.  Operating income (OCI) slipped only slightly, from **$10.688 billion in 2022 to $10.670 billion in 2023** (down $18 million, essentially flat)【page_29】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: net revenues of $22,476 million (reported as $22.476 billion) in 2022 and $21,756 million (reported as $21.756 billion) in 2023 are correctly stated, as are operating income figures of $10,688 million ($10.688 billion) in 2022 and $10,670 million ($10.670 billion) in 2023. The calculated drop of $720 million in revenue and $18 million in operating income are accurate. The approximate 3% decline in revenue is correctly inferred. (2) The answer is complete, addressing both net revenues and operating income across both years as required by the question. (3) Entity accuracy is correct—'smokeable products' is the right segment, and years 2022 and 2023 are properly referenced. (4) The reasoning is sound: the LLM correctly synthesizes year-over-year performance, notes the slight contraction, and characterizes the operating income as essentially flat, which aligns with the marginal decline. The use of billion-scale formatting is semantically equivalent to million-scale figures in the original. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1177,
        "completion_tokens": 331,
        "total_tokens": 1508
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the role of Opdivo within BMY's product development and commercialization strategy evolved from 2022 to 2024, particularly in terms of its collaborative framework and new therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was primarily positioned within a joint development and commercialization framework with Ono, where profits, losses, and development costs were shared—either equally for combination therapies or under an 80-20 split for single-party compounds. Additionally, Opdivo was part of a broader alliance that included other products like Yervoy and Orencia, with structured co-promotion and supply responsibilities. By 2024, Opdivo's role had evolved significantly, marked by a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. This reflects a shift from a co-development focus to a more independent product introduction strategy, with BMY taking the lead in expanding Opdivo’s therapeutic applications in key oncology markets.",
      "llm_answer": "In the 2022 filing Opdivo was presented as BMS’s flagship immuno‑oncology asset that BMS commercializes worldwide except in Japan, South Korea and Taiwan, where it is jointly developed and marketed with Ono (with profit‑sharing and royalty arrangements) and it also underpins a joint‑development program with Nektar on the Opdivo‑NKTR‑214 combination (see 2022 p. 113‑114). By the 2024 filing the product had moved from a single‑indication, partnership‑driven asset to a multi‑indication cornerstone of BMS’s IO strategy, gaining FDA, EC and Japanese approvals for new uses—including resectable NSCLC, first‑line urothelial carcinoma, MSI‑H/dMMR colorectal cancer—and a new sub‑cutaneous formulation (Opdivo Qvantig) that was highlighted as a recent launch (see 2024 p. 44‑45, 46). The underlying Ono co‑commercialization framework remains unchanged, but Opdivo’s role has expanded to drive broader therapeutic growth and diversification of its delivery formats.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but has minor discrepancies in emphasis and detail. (1) Quantitatively, all dates and approvals mentioned are accurate: the March 2024 FDA approval for first-line urothelial carcinoma (in combination with cisplatin and gemcitabine) is correctly noted, and the 2022 collaborative framework with Ono is accurately described in terms of geography and profit-sharing. The mention of new approvals in 2024 for resectable NSCLC, MSI-H/dMMR colorectal cancer, and the subcutaneous formulation (Opdivo Qvantig) is consistent with BMY's expanded commercialization strategy. (2) However, the LLM introduces a partnership with Nektar on Opdivo-NKTR-214 not mentioned in the original answer or supported by the knowledge graph used for ground truth, which reduces factual precision. Additionally, while the original answer emphasizes a strategic shift toward independent product introduction led by BMY, the LLM states the Ono framework 'remains unchanged'—which is factually correct—but misses the nuance that BMY has increasingly taken the lead in global approvals, signaling reduced reliance on joint decision-making. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years (2022 to 2024), identifies the evolution in therapeutic approvals, and contextualizes Opdivo’s growing role within BMY’s oncology portfolio. (4) Despite minor overreach on the Nektar collaboration and slight underemphasis on the strategic shift from co-development to independent expansion, the answer captures the core evolution in Opdivo’s role. Wording differs but semantic meaning is largely equivalent, supporting a high correctness score with a small deduction for unsupported details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1467,
        "completion_tokens": 478,
        "total_tokens": 1945
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has AMT's disclosure regarding interest rate benchmarks for debt instruments evolved between 2022 and 2024, particularly in terms of referenced rates and associated covenants?",
      "original_answer": "In 2022, AMT's debt instruments referenced LIBOR, EURIBOR, and a defined base rate for USD and EUR denominated borrowings, with the 2021 credit facilities tied to debt ratings and commitment fees ranging from 0.080% to 0.300%. By 2024, AMT disclosed that new drawings under letters of credit in Nigeria bore interest at SOFR (Secured Overnight Financing Rate) plus a spread, indicating a shift away from LIBOR-based instruments. Additionally, while 2022 disclosures detailed specific covenants and optional renewal periods for various credit facilities, the 2024 disclosure focused on the consequences of covenant non-compliance without specifying interest rate structures or renewal terms, suggesting a simplification or evolution in the presentation of covenant-related disclosures.",
      "llm_answer": "In the 2022 Form 10‑K AMT said its bank borrowings were floating‑rate loans tied to traditional inter‑bank benchmarks – LIBOR for U.S. dollars, EURIBOR for euros (or a base‑rate alternative) – and its Indian facilities were linked to the bank’s marginal cost‑of‑funds rate (MCLR) or the overnight Mumbai inter‑bank offer rate, with the loan agreements simply noting “reporting, financial and operating covenants” and limits on additional debt. By the 2024 filing the company is referencing newer benchmarks – the Nigeria letters of credit bear interest at SOFR plus a spread – and it lists fixed coupon rates for its securitized notes (e.g., 5.490%/5.735% for the 2023 securities and 3.652%/4.459% for the 2018 securities), while also spelling out detailed covenants such as debt‑service‑coverage‑ratio thresholds, cash‑trap DSCR, minimum‑DSCR triggers, amortization periods and pre‑payment penalties. This shows a shift from broad LIBOR/EURIBOR‑based references and generic covenants to more precise benchmark rates (SOFR, fixed coupons) and explicit covenant mechanics.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution in AMT's interest rate benchmark disclosures from LIBOR/EURIBOR in 2022 to SOFR in 2024, which aligns with the ground truth. It correctly identifies the shift away from LIBOR and the use of SOFR for Nigeria letters of credit. However, there are significant factual inaccuracies: (1) The mention of Indian facilities tied to MCLR or overnight MIBOR is not present in the original answer and introduces an entity (India) and rates not supported by the ground truth; (2) The specific fixed coupon rates (e.g., 5.490%/5.735% for 2023 securities, 3.652%/4.459% for 2018) are detailed in the LLM answer but absent in the original, making them unverified and potentially incorrect additions; (3) The 2024 disclosure in the ground truth does not include detailed covenants like DSCR thresholds or prepayment penalties—instead, it notes a *lack* of specific covenant terms in favor of discussing consequences of non-compliance, which contradicts the LLM’s claim of more 'explicit covenant mechanics.' This misrepresents the direction of covenant disclosure evolution. While the core idea of a shift from LIBOR to SOFR is correct, the inclusion of unsupported details, especially around Indian facilities and specific covenants, undermines factual accuracy. The reasoning is partially sound in identifying benchmark transitions but fails in multi-hop synthesis by introducing unverified entities and mischaracterizing covenant disclosure trends. Quantitative accuracy is low due to unsupported percentages and rates. Contextual relevance is high as the response stays focused on the question’s scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1472,
        "completion_tokens": 445,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has McDonald's relationship with franchisees evolved in terms of real estate ownership and co-investment strategy between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's emphasized Systemwide coordination and alignment to manage ESG initiatives, including environmental sustainability and responsible sourcing, which required franchisee cooperation. However, the specific role of franchisees in real estate ownership was not detailed. By 2024, the company explicitly outlined its conventional franchise model, where it typically owns or secures long-term leases on land and buildings, while franchisees invest in equipment, signs, seating, and décor. This co-investment model was described as enabling McDonald's to achieve high restaurant performance levels. The shift from a general emphasis on franchisee collaboration in 2022 to a clearly defined real estate and co-investment strategy in 2024 reflects a more structured and strategic approach to franchise relationships.",
      "llm_answer": "In the 2022 filing McDonald’s described its franchise model as one in which the Company “generally owns or secures a long‑term lease on the land and building for conventional franchised and Company‑operated restaurant sites” (page 35), using that ownership to secure long‑term occupancy and control costs. By the 2024 filing the same ownership structure remains (“the Company generally owns or secures a long‑term lease on the land and building…”) (page 3), but the Company now explicitly adds that it “may co‑invest with franchisees to fund improvements to their restaurants or operating systems” (page 4), signaling a shift toward a collaborative capital‑investment approach alongside its real‑estate ownership.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, McDonald's generally owned or secured long-term leases on land and buildings, citing the appropriate structure from the 2022 filing. In 2024, it accurately notes the continuation of this real estate model and adds the new detail about co-investment with franchisees for restaurant improvements, which reflects the evolution in strategy. (2) There are no numerical values to verify, but the dates (2022 and 2024) and document references (page numbers) are correctly attributed, supporting factual precision. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings to show a shift from a stable real estate ownership model to one that now explicitly includes co-investment—a nuanced but important strategic evolution. The LLM captures the core of the shift described in the ground truth: from general franchisee collaboration in ESG (implied in 2022) to a clearly defined co-investment framework in 2024. (4) The only minor shortcoming is that the LLM does not mention the 2022 emphasis on ESG and systemwide alignment, which contextualizes the broader franchisee relationship evolution. While not strictly necessary for the real estate and co-investment focus, including it would have made the answer fully comprehensive. However, the LLM still captures the key structural evolution in real estate and investment strategy, making it factually correct and contextually relevant. Hence, a high score of 9 is warranted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 430,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the status and documentation of the 2015 Stock Compensation Plan for Non-Employee Directors change between 2022 and 2023, and what does this evolution indicate about Altria's governance approach to director compensation?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was disclosed with 703,256 shares available for issuance under the plan. By 2023, the plan was formally amended and restated effective October 26, 2022, and was incorporated by reference from Altria's September 30, 2022, Form 10-Q filing. This indicates a formal update to the plan’s structure and governance, suggesting Altria refined its director compensation framework mid-cycle, potentially to align with evolving governance standards or internal compensation strategies.",
      "llm_answer": "- 2022 Form 10‑K: The 2015 Stock Compensation Plan for Non‑Employee Directors was listed among the approved equity‑compensation plans with **703,256 shares** available for future issuance (Item 12 table, p. 114) and was referenced in the exhibit list as **Exhibit 10.22** (p. 116).  \n\n- 2023 Form 10‑K: The same plan appears again as an approved plan but now shows **589,927 shares** available (Item 12 table, p. 107) and is specifically described as **“amended and restated effective October 26 2022”** in Exhibit 10.22 (p. 110).  \n\n**Interpretation:** Altria’s governance team is actively revisiting director compensation – formally amending the plan, reducing the share pool, and documenting the change in the filing – indicating a disciplined, transparent approach that aligns director pay with evolving corporate and shareholder expectations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key facts: in 2022, 703,256 shares were available under the 2015 Stock Compensation Plan for Non-Employee Directors, and by 2023, the plan was amended and restated effective October 26, 2022. The share count in 2023 (589,927) is accurate as a reduction from the prior year, though the ground truth does not specify this number — it only confirms the amendment and restatement. The LLM adds precision by including the updated share balance, which is consistent with typical plan usage and does not contradict the ground truth. (2) All numbers and dates are correct: 703,256 shares in 2022, October 26, 2022, as the amendment date, and the correct exhibit number (10.22) in both years. The 2023 share count of 589,927 is plausible and reflects actual usage or allocation, even if not explicitly stated in the ground truth; no calculation errors are present. (3) The multi-hop reasoning is sound: the model synthesizes data from both the 2022 and 2023 10-Ks, identifies the change in status (amended and restated), and infers governance implications. It correctly references incorporation by reference from the September 30, 2022, 10-Q, aligning with standard SEC filing practices. (4) The interpretation about Altria’s disciplined and transparent governance approach is logically derived and consistent with the ground truth’s conclusion about refining the compensation framework. The only minor limitation is that the ground truth emphasizes the incorporation by reference from the 10-Q, which the LLM does not explicitly mention, but it does reference the amendment date and exhibit update, capturing the essential documentation change. Overall, the answer is factually accurate, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 481,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the impact of roaming and resale arrangements among wireless service providers on AMT's leasing activity evolved from 2022 to 2024, and what does this indicate about the competitive pressures affecting new lease growth?",
      "original_answer": "In 2022, AMT noted that roaming or resale arrangements among wireless service providers, particularly with the rise of 5G technology, could slow new lease activity if carriers opted to share infrastructure rather than deploy new equipment. By 2024, this concern evolved into a broader risk involving RAN sharing and resale arrangements, which not only threatened new lease activity but also led to potential decommissioning of existing equipment due to redundancy. This indicates a growing competitive pressure where infrastructure sharing is becoming a more viable and widespread alternative to leasing, directly impacting AMT’s revenue growth prospects.",
      "llm_answer": "Both the 2022 and 2024 10‑K filings warn that “extensive sharing of site infrastructure through RAN sharing, roaming or resale arrangements among wireless service providers… may cause new lease activity to slow if carriers utilize shared equipment rather than deploy new equipment, or may result in the de‑commissioning of equipment” (2022 p. 15; 2024 p. 15). The wording is essentially unchanged, indicating that competitive pressure from carriers’ network‑sharing and resale strategies remains a persistent headwind that continues to limit AMT’s ability to grow new leases.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in quoting the 10-K filings from 2022 and 2024 and correctly identifies that both years cite similar language regarding the risks of RAN sharing, roaming, and resale arrangements on new lease activity and potential decommissioning. The quantitative accuracy is perfect: no numerical errors, and the cited page numbers (p. 15 for both years) are consistent with the source context. Contextual relevance is strong—the response directly addresses the evolution of the impact on AMT's leasing activity and links it to competitive pressures. However, the qualitative accuracy is slightly lower because the LLM incorrectly implies there is no meaningful evolution in the risk between 2022 and 2024 by stating the 'wording is essentially unchanged' and that the pressure 'remains a persistent headwind.' In contrast, the ground truth highlights a significant evolution: in 2022, the concern was primarily about slowed new lease activity due to infrastructure sharing, but by 2024, the risk expanded to include actual decommissioning of existing equipment due to redundancy, indicating a deepening threat. This reflects a qualitative shift in risk severity that the LLM answer underemphasizes. Thus, while the core facts are correct, the synthesis of how the impact evolved—key to the multi-hop reasoning—is incomplete, leading to a correctness score of 7 rather than higher.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 387,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has McDonald's relationship with its franchisees evolved between 2022 and 2024, particularly in terms of strategic investment and operational expectations?",
      "original_answer": "In 2022, McDonald's highlighted the impact of the COVID-19 pandemic on franchise operations, emphasizing risks related to labor availability, supply chain disruptions, and the importance of executing its 'Accelerating the Arches' strategy to maintain growth. The focus was on franchisees' ability to adapt to changing consumer behavior and operational restrictions. By 2024, McDonald's had shifted toward a more active investment role, co-investing with franchisees to modernize restaurants and improve local performance. The company emphasized franchisee reinvestment in their businesses and introduced structured co-investment initiatives designed to increase the value of the McDonald's brand through restaurant modernization and enhanced consumer appeal. This marks a shift from pandemic-driven operational challenges to a more strategic, investment-backed growth approach.",
      "llm_answer": "In the 2022 filing McDonald’s said its growth relied on franchisees ‑ who must independently fund major, capital‑intensive reinvestment initiatives and stay aligned with the company’s operating, value‑promotional and capital‑intensive plans, with the risk that a lack of financing could hurt performance (2022 Risk Factors pp. 28‑30). By the 2024 filing the relationship has become more collaborative: franchisees still must meet rigorous standards, but McDonald’s now co‑invests with them to finance restaurant‑modernization and system‑upgrade projects that are designed to boost revenue and brand value (2024 p. 4).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in McDonald's relationship with franchisees from 2022 to 2024: in 2022, franchisees were expected to independently fund capital-intensive initiatives, with risks tied to financing and operational alignment, which matches the original answer's emphasis on pandemic-related challenges and franchisee adaptation. By 2024, the shift to co-investment is accurately described, including McDonald's active role in financing modernization projects to boost revenue and brand value—consistent with the 'structured co-investment initiatives' and 'restaurant modernization' mentioned in the ground truth. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised; dates (2022 and 2024) are correct and consistently used. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and two filings, correctly contrasting the shift from independent franchisee funding to a collaborative, co-investment model. It references specific sections (e.g., Risk Factors pp. 28–30 in 2022, p. 4 in 2024), adding credibility. (4) The only minor shortcoming is that the LLM answer does not explicitly mention the 'Accelerating the Arches' strategy or the pandemic-driven context (labor, supply chain) emphasized in 2022, which slightly reduces qualitative completeness. However, the core evolution in strategic investment and operational expectations is accurately captured. Wording differs but semantic meaning is equivalent. Contextual relevance is excellent as it directly addresses both strategic investment and operational expectations over the specified time frame.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 477,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did NextEra Energy's investment strategy in equity securities within its Special Use Funds evolve from 2022 to 2024?",
      "original_answer": "In 2022, NextEra Energy held $8,922 million in Special Use Funds, with no explicit breakdown of equity securities provided in the filing. By 2024, the company disclosed a more detailed composition, with $6,164 million specifically allocated to equity securities under Special Use Funds. This evolution suggests a strategic shift toward transparency and a potentially greater emphasis on equity investments within these funds. While the total amount in Special Use Funds decreased, the explicit allocation to equities in 2024 indicates a more defined and possibly more aggressive investment posture compared to 2022.",
      "llm_answer": "In 2022 the equity portion of NextEra Energy’s nuclear‑decommissioning “special‑use” funds generated a $1.028 billion unrealized loss, indicating a relatively modest equity allocation that was largely held directly (Level 1) 【page_91†L31-L38】. By 2024 the company had expanded that equity exposure to $6.2 billion, with Level 1 holdings rising to $2.6 billion and Level 2 commingled‑fund holdings growing to $3.3 billion, turning the position into a $917 million unrealized gain 【page_89†L9-L15】【page_91†L31-L38】. This reflects a strategic shift toward a larger, more diversified equity portfolio within the special‑use funds.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains both correct and incorrect information. It correctly identifies the $6.2 billion equity allocation in 2024 (close to the ground truth $6,164 million), and cites a shift toward greater equity exposure and diversification, which aligns with the original answer’s conclusion about a strategic shift. However, it introduces specific data for 2022—namely a $1.028 billion unrealized loss and implied equity allocation—that are not present in the ground truth. The original answer explicitly states that no breakdown of equity securities was provided in 2022, making the LLM’s detailed 2022 figures unsupported. (2) Quantitative accuracy is partially correct: $6.2 billion in 2024 is a reasonable approximation of $6,164 million. However, the LLM fabricates Level 1 and Level 2 holdings ($2.6B and $3.3B) and unrealized gains/losses not present in the ground truth. There is no mention of unrealized losses or gains in the original answer, nor any breakdown by valuation level. (3) The reasoning shows sound multi-hop logic in identifying a strategic evolution toward larger equity investments and improved diversification, and the use of footnotes (e.g., page references) suggests grounding in source material. However, the reasoning is based on incorrect 2022 data, undermining the validity of the comparison. The original answer emphasizes increased transparency as a key evolution, which the LLM omits, instead focusing on performance and unrealized gains. (4) The contextual relevance is high—the answer addresses the evolution of investment strategy in equity securities within Special Use Funds and correctly identifies a strategic shift. However, due to the inclusion of unsupported quantitative details for 2022 and the omission of the transparency narrative, the overall correctness is reduced. The answer is directionally accurate but factually flawed in key areas.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 516,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined to $10,670 million. This indicates a marginal decrease in both revenue and profitability year-over-year.",
      "llm_answer": "The smokeable‑products segment saw a modest contraction. Net revenues fell from **$22.476 billion in 2022 to $21.756 billion in 2023** (a drop of about $720 million, ≈3 %) and **operating income slipped from $10.688 billion to $10.670 billion** (down roughly $18 million, ≈0.2 %)【page_29】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $22,476 million (=$22.476 billion) in 2022 and $21,756 million (=$21.756 billion) in 2023 for net revenues; $10,688 million (=$10.688 billion) and $10,670 million (=$10.670 billion) for operating income—format variations are acceptable and semantically equivalent. (2) The calculations are correct: a drop of $720 million (22,476 - 21,756) is ≈3%, and a decrease of $18 million (10,688 - 10,670) is ≈0.2%. (3) The reasoning is sound and synthesizes year-over-year performance correctly, identifying a marginal decline in both revenue and profitability. (4) The answer addresses both parts of the question—net revenues and operating income—across 2022 and 2023, with proper entity and metric identification. (5) The semantic meaning is identical to the original answer, with added clarity via percentage changes. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1162,
        "completion_tokens": 284,
        "total_tokens": 1446
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the utilization of Accenture plc Class A Ordinary Shares evolved between 2022 and 2023, particularly in terms of share purchase programs and their intended usage?",
      "original_answer": "In 2022, Accenture disclosed an aggregate available authorization of $3,129,296 for publicly announced open-market share purchase programs and other share purchase programs involving Accenture plc Class A Ordinary Shares and Accenture Canada Holdings Inc. exchangeable shares. By 2023, the company clarified that Class A Ordinary Shares acquired through these programs were being held as treasury shares and intended for employee benefits, such as equity awards. Additionally, in fiscal 2024, shares were acquired via share withholding for payroll tax obligations under employee equity share plans, which were separate from the publicly announced share purchase authorization. This indicates a shift in focus toward internal employee compensation mechanisms while maintaining a formal buyback program.",
      "llm_answer": "In fiscal 2022 Accenture repurchased 12.2 million Class A ordinary shares—9.6 million through its publicly announced open‑market program and 2.5 million via employee‑withholding purchases—and held them as treasury to fund equity awards and other employee‑benefit plans, with the Board raising the total repurchase authority to $6.13 million (page 94). The 2023 filing indicates that the same open‑market purchase program and its employee‑benefit usage continued under the existing authority (page 93), although a detailed 2023 purchase volume is not disclosed.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Accenture had an aggregate available authorization of $3,129,296 (approximately $3.13 million), not $6.13 million as claimed by the LLM. The LLM incorrectly states that the Board raised the repurchase authority to $6.13 million, which is not supported by the original answer and misrepresents the scale and direction of the authorization. Additionally, the LLM introduces specific repurchase volumes (12.2 million shares, with 9.6 million via open-market and 2.5 million via employee withholding), which are not present in the ground truth and appear to be fabricated or hallucinated. The original answer does not provide any share repurchase volume for 2022 or 2023. (2) The fiscal year 2024 detail in the original answer—regarding share withholding for payroll tax obligations being separate from the public buyback—is omitted in the LLM response, which instead conflates employee-withholding purchases with the formal buyback program without clarifying their distinction. (3) The multi-hop reasoning is flawed: while the LLM correctly identifies that repurchased shares are held as treasury for employee benefits (a point in the original answer for 2023), it incorrectly projects this usage back into 2022 with unsupported quantitative detail and misstates the authorization amount. It fails to capture the evolution described in the original—i.e., a clarification in 2023 about usage and the separation of withholding from public buybacks in 2024. (4) The contextual relevance is moderate because the LLM addresses share purchase programs and intended usage for employee benefits, which are central to the question. However, due to major quantitative errors and missing key qualitative distinctions (especially the separation of share withholding in 2024), the overall correctness is low. Minor note: citing page numbers (e.g., page 94) is irrelevant since the ground truth does not reference pages, suggesting the LLM may be drawing from a different source or hallucinating details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 563,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the nature and structure of AMT's operating covenants evolved between 2022 and 2024, particularly in terms of the types of debt instruments involved and associated interest rate benchmarks?",
      "original_answer": "In 2022, AMT's operating covenants were tied to a variety of credit facilities and loans that referenced LIBOR and EURIBOR as the interest rate benchmarks. These included the 2021 Multicurrency Credit Facility, the 2021 Credit Facility, and several term loans. By 2024, AMT's disclosures indicate a shift in the interest rate benchmark to SOFR, specifically for letters of credit drawn in Nigeria, which were subject to a rate equal to SOFR at the time of drawing plus a spread. This reflects a transition away from LIBOR-based covenants toward SOFR-based structures, signaling a strategic and regulatory evolution in how AMT manages its debt obligations and associated covenants.",
      "llm_answer": "In the 2022 filing AMT’s operating covenants were tied to its 2021 revolving credit facilities and term loans (the 2021 Multicurrency Credit Facility, Credit Facility, Term Loan and the EUR‑ and USD‑delayed‑draw term loans). These agreements imposed standard reporting, financial‑information and “other restrictions” (e.g., limits on additional debt, guarantees and asset sales) and the borrowings were priced at LIBOR (for USD) or EURIBOR (for EUR) + 1.125 % (see page_113 and page_114).  \n\nBy the 2024 filing the covenant framework had shifted to the securitization structures (the Loan Agreement and the 2015 Indenture) and other subsidiary debt, adding DSCR‑based cash‑trap, reserve‑account and amortization triggers and prohibiting new indebtedness, while the debt instruments now carry mostly fixed rates (e.g., 3.029 % on the 2015 notes, 3.652 %/4.459 % on the 2018 securities, 5.490 %/5.735 % on the 2023 securities) and new benchmarks such as SOFR + spread for Nigeria letters of credit (see page_117 and page_116).",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in AMT's operating covenants from LIBOR/EURIBOR-based instruments in 2022 to SOFR-based benchmarks and fixed-rate structures in 2024, particularly highlighting the Nigeria letters of credit using SOFR + spread. It correctly identifies key debt instruments like the 2021 Multicurrency Credit Facility and 2021 Credit Facility in 2022, and references securitization structures (Loan Agreement, 2015 Indenture) and fixed-rate notes in 2024. However, there are minor quantitative inaccuracies: the LLM states that borrowings in 2022 were priced at LIBOR/EURIBOR + 1.125%, which is not confirmed in the ground truth and introduces a specific spread not present in the original answer. Additionally, the detailed fixed rates (e.g., 3.029%, 3.652%, etc.) are introduced without confirmation in the ground truth, which does not mention fixed rates or these specific percentages. While the shift toward fixed rates may be plausible, the original answer emphasizes the benchmark transition from LIBOR to SOFR as the key evolution, not a move to fixed rates. The LLM overemphasizes structural changes in covenants (e.g., DSCR triggers, reserve accounts) that are not mentioned in the ground truth, potentially conflating general covenant tightening with the specific benchmark transition. Despite these additions, the core multi-hop reasoning—linking the change in interest rate benchmarks across years and instruments—is sound and contextually relevant. The answer addresses both parts of the question: types of debt instruments and interest rate benchmarks. Semantic equivalence is mostly preserved, though some details exceed or misrepresent the ground truth. Hence, a score of 8 is appropriate—core facts correct, but with some unsupported specifics and minor misdirection.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 494,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Disney+ Hotstar's subscriber base evolve between the 2023 and 2024 SEC filings, and what impact did the consolidation of Star+ into Disney+ in Latin America have on Disney's international streaming strategy?",
      "original_answer": "In the 2023 SEC filing, Disney+ Hotstar reported approximately 36 million paid subscribers as of September 28, 2024. The 2024 filing noted that in certain Latin American countries prior to July 2024, Disney offered both Disney+ and Star+ as separate services, but these were merged into a single Disney+ product offering by the end of June 2024. This consolidation suggests a strategic shift toward streamlining international service offerings, potentially aligning with the model used for Disney+ Hotstar by integrating diverse content into a unified brand to enhance user experience and operational efficiency.",
      "llm_answer": "Disney+ Hotstar’s paid subscriber base rose to roughly 36 million by September 28 2024 【page_7】, up from a smaller share of the 66.1 million international subscriber base reported in the 2023 filing 【page_58】—showing continued growth of the Hotstar service. In June 2024 Disney merged Star+ into Disney+ across Latin America, creating a single Disney+ product that streamlines the brand, expands content (including sports), and reinforces Disney’s strategy of a unified, globally‑branded streaming platform 【page_57】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the timeline: it states that Disney+ Hotstar had 36 million subscribers 'by September 28, 2024' and references this as growth from the 2023 filing, but the ground truth clarifies that the 36 million figure was reported in the 2023 filing as of September 28, 2023 (not 2024). This misrepresents the time period and implies growth that isn't supported by the data provided. Additionally, the claim that Disney+ Hotstar grew from a 'smaller share of the 66.1 million international subscriber base' is speculative and not directly supported by the ground truth, which does not break down how much of that 66.1 million belonged to Hotstar. (2) Quantitatively, the 36 million figure is correct, and the June 2024 consolidation date aligns with the ground truth (end of June 2024). However, the use of the 66.1 million international subscribers from the 2023 filing is misleading without context and introduces a false comparison. The date error (2024 vs. 2023) for the 36 million figure is a critical quantitative inaccuracy. (3) The reasoning around the Star+ consolidation is sound and correctly identifies the strategic intent—streamlining services, expanding content, and unifying branding—which aligns with the ground truth's interpretation of a strategic shift toward integrated offerings. This shows good multi-hop synthesis between the operational change and its strategic implications. (4) Despite the key date/number error, the answer is contextually relevant and addresses both parts of the question: subscriber evolution and strategic impact. The qualitative reasoning about Disney’s global streaming strategy is accurate and well-articulated. However, the quantitative inaccuracies and incorrect temporal framing reduce overall correctness significantly, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 504,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the number of employees covered under collective labor agreements changed from 2022 to 2023, and what does this indicate about the company's labor agreement strategy?",
      "original_answer": "In 2022, the company expected to negotiate agreements covering approximately 3,000 employees in the following year. In 2023, the company projected negotiations covering 2,100 employees for the upcoming year. This indicates a reduction in the number of employees involved in labor renegotiations, suggesting a shift in the company's labor agreement strategy, possibly due to fewer expiring agreements or proactive resolution of collective bargaining terms.",
      "llm_answer": "The 2022 filing said the company expected to renegotiate 21 collective‑bargaining agreements covering roughly 3,000 employees and noted that about one‑fifth of its workforce (≈62 agreements) was union‑covered【page_77】. The 2023 filing again reports that roughly one‑fifth of employees were covered by 62 collective agreements, showing essentially no change in the number of workers under such agreements【page_79】. This unchanged proportion indicates General Dynamics is maintaining a stable labor‑agreement strategy—keeping the share of union‑covered employees steady while regularly renegotiating the existing agreements without material disruption.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the number of employees expected to be covered in renegotiations decreased from 3,000 in 2022 to 2,100 in 2023, indicating a strategic shift. However, the LLM claims that the proportion of union-covered employees remained stable at one-fifth with 62 agreements in both years, which contradicts the ground truth focus on renegotiation scope. The ground truth does not mention 62 agreements or one-fifth workforce coverage, making these details hallucinated or misattributed. (2) Quantitatively, the 3,000 and 2,100 employee figures are correct in the context of expected renegotiations, but the LLM incorrectly shifts focus to total union-covered employees (62 agreements, one-fifth) not mentioned in the original answer, introducing false precision and irrelevant metrics. There is no verification that these numbers appear on the cited pages, and they distort the actual trend. (3) The multi-hop reasoning is flawed: instead of comparing the projected number of employees in renegotiations across years (3,000 → 2,100), the model infers stability from total union coverage, which is not supported by the ground truth. This leads to an incorrect conclusion about a 'stable strategy' when the truth suggests a reduction and possible strategic shift. (4) Contextual relevance is moderate because the answer addresses labor agreements and employee counts, but it fails to capture the core dynamic—reduction in renegotiation scope—thus missing the key implication about strategy change. The answer is factually misaligned and synthesizes incorrect conclusions from potentially misread data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 461,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did NextEra Energy's investment in U.S. Government and municipal bonds evolve from 2022 to 2024, and what was the change in total value across these years?",
      "original_answer": "In 2022, NextEra Energy's investment in U.S. Government and municipal bonds totaled $137 million. By 2024, this investment had increased significantly to $161 million under 'Other investments' for NEE. This represents a growth of $24 million, or approximately 17.5%, indicating a strategic increase in this asset class over the two-year period.",
      "llm_answer": "In 2022 NextEra Energy held **$137 million** of U.S. Government and municipal bonds (Level 1 $131 m + Level 2 $6 m)【page_101】. By the end of 2024 that investment had risen to **$722 million** (Level 1 $663 m + Level 2 $59 m)【page_89】. The total holding therefore increased by roughly **$585 million** over the period.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual errors. While it correctly states the 2022 investment value of $137 million, it incorrectly reports the 2024 value as $722 million, which is drastically higher than the ground truth of $161 million. This leads to a false increase of $585 million instead of the correct $24 million. The percentage growth is therefore also wrong (actual: ~17.5%, LLM implies ~427%). (2) Number verification: 2022 value matches ground truth ($137M), but 2024 value does not ($722M reported vs $161M actual). The cited breakdown (Level 1 + Level 2) may reflect data from the filing, but it misattributes the category—those amounts correspond to different investment types or classifications, not U.S. Government and municipal bonds under 'Other investments' for NEE. Calculations based on incorrect inputs are invalid. (3) Multi-hop reasoning fails: the model identifies two years and attempts a comparison, but uses incorrect data for 2024, likely due to misreading the financial table or confusing investment categories. It fails to correctly extract the 'Other investments' line item for U.S. Government and municipal bonds. (4) Correctness and quantitative accuracy are severely penalized due to wrong core numbers. Qualitative accuracy is low because of flawed entity/metric mapping. Contextual relevance is moderate since the answer addresses the right company, time frame, and general topic, but with critical errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1168,
        "completion_tokens": 403,
        "total_tokens": 1571
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the role of Opdivo in Bristol-Myers Squibb's product portfolio evolved between 2022 and 2024, particularly in terms of its manufacturing strategy and therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was referenced as a product with both internal manufacturing capability and reliance on third-party manufacturers to meet demand, highlighting its strategic importance in BMY's supply chain. By 2024, Opdivo received a new FDA approval in March for combination therapy with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma, indicating an expansion of its therapeutic applications. This evolution reflects both continued manufacturing investment and increased clinical positioning of Opdivo within BMY's oncology portfolio.",
      "llm_answer": "In the 2022 filing BMS described Opdivo as a mature immuno‑oncology product for which the company “has the capability to manufacture Opdivo internally and has arrangements with third‑party manufacturers to meet demand” (page 27). By the 2024 filing Opdivo’s portfolio importance had expanded dramatically, with new FDA and EU approvals for first‑line urothelial carcinoma (March 2024), neoadjuvant resectable NSCLC (Oct 2024), the sub‑cutaneous Opdivo Qvantig formulation (Dec 2024) and Opdivo + Yervoy for MSI‑high colorectal cancer (Dec 2024) (pages 44‑45), cementing Opdivo as a core IO asset while BMS continues to rely on its flexible internal‑and‑third‑party manufacturing network to supply these additional indications.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Opdivo's manufacturing strategy in 2022 as involving both internal and third-party manufacturing, consistent with the ground truth. It also accurately notes the continuation of this flexible manufacturing model in 2024. The therapeutic expansion is mostly correct, but includes additional approvals not mentioned in the ground truth: neoadjuvant NSCLC (Oct 2024), subcutaneous formulation (Dec 2024), and Opdivo + Yervoy for MSI-high colorectal cancer (Dec 2024). While these may be factually accurate based on external knowledge, the original answer only specifies the March 2024 FDA approval for urothelial carcinoma. Including unmentioned approvals introduces information beyond the provided ground truth, which is derived from specific SEC filings. (2) Quantitatively, the March 2024 approval date matches the ground truth. However, the LLM adds specific months (Oct, Dec 2024) for other approvals not present in the original answer, which only references March 2024. This introduces date-level precision not supported by the ground truth, reducing quantitative accuracy. (3) The multi-hop reasoning is strong: the LLM synthesizes manufacturing strategy across years and links it to evolving therapeutic positioning. It correctly infers that expanded indications reinforce Opdivo’s strategic importance, aligning with the original answer’s conclusion. However, the inclusion of extra approvals weakens strict factual alignment. (4) Despite the overstatement of approvals, the core evolution—expanded clinical use and sustained manufacturing flexibility—is accurately captured. The answer remains highly relevant and well-supported, warranting a high correctness score with a minor deduction for unsupported specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 482,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Disney's relationship with National Geographic magazine evolved between 2023 and 2024 in terms of its business structure and strategic positioning within the company's portfolio?",
      "original_answer": "In 2023, National Geographic magazine was explicitly described as part of the Entertainment segment under Content Sales/Licensing, and was noted as being 73% owned by Disney. By 2024, the magazine was still reported under Content Sales/Licensing, but the emphasis on its ownership percentage was removed, and it was described more as a publication 'published' by the company rather than a business in which Disney has a direct equity stake. This shift indicates a more operational rather than ownership-focused relationship in 2024 compared to 2023.",
      "llm_answer": "In the 2023 filing Disney said the National Geographic magazine (and its online business) is part of the Entertainment segment’s Content Sales/Licensing line and is owned 73 % by the company【page_78】. The 2024 filing still reports the magazine under Content Sales/Licensing (and notes it is published by Disney)【page_7】, but now places it alongside National Geographic Channels in the Linear Networks portfolio【page_5】, showing the same 73 % ownership while emphasizing tighter integration of the magazine within a broader, cross‑platform National Geographic brand strategy.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several key inaccuracies that deviate from the ground truth. (1) Quantitatively, the LLM incorrectly states that Disney still reports 73% ownership of National Geographic magazine in the 2024 filing. The ground truth explicitly states that the ownership percentage was *removed* in 2024, indicating a shift in disclosure and strategic framing. This is a critical factual error. (2) The claim that the magazine is placed alongside National Geographic Channels in the Linear Networks portfolio in 2024 is not supported by the ground truth, which makes no mention of such a reclassification—only that the magazine remains under Content Sales/Licensing but with a changed emphasis in language (from ownership to publication). (3) The qualitative reasoning is flawed: instead of identifying a shift from ownership-focused to operationally-focused language (indicating a more integrated or less equity-emphasized role), the LLM suggests tighter integration under a cross-platform strategy, which contradicts the ground truth’s implication of reduced emphasis on equity stake. (4) Contextually, the answer addresses the right segments and years, and correctly identifies the Content Sales/Licensing category in both years, showing relevance. However, the core conclusion about the evolution of the business relationship is incorrect—the trend is toward de-emphasizing ownership, not reinforcing integration with linear networks. Minor positive: correct citation of 73% ownership in 2023 and correct segment placement in both years. Overall, partially correct facts but significant errors in interpretation and key details, leading to a misleading synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 454,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has PayPal's description of its transaction management databases' capabilities evolved between 2023 and 2024, particularly in relation to global payment processing in different currencies?",
      "original_answer": "In 2023, PayPal described its transaction management databases as part of a platform that allowed consumers to withdraw funds in 56 currencies. By 2024, the company updated this figure to 57 currencies, indicating a slight expansion in the global reach of its transaction processing capabilities. Additionally, while both years emphasize the role of these databases in enabling customers to utilize PayPal's suite of products, the 2024 filing introduced a more consumer-centric framing, placing 'consumers' ahead of 'merchants' in describing the ecosystem served by the platform. These changes suggest a refinement in how PayPal positions its transaction management systems within its broader global payments infrastructure.",
      "llm_answer": "In the 2023 filing PayPal simply noted that it “has developed … transaction‑management databases … to enable our customers to utilize our suite of products and services,” without tying those databases to a specific global‑currency scope. By the 2024 filing the same language appears, but it is now placed alongside a detailed statement that the platform can send payments in roughly 200 markets and ≈ 140 currencies (down from ≈ 150 in 2023) and withdraw funds in 57 currencies (up from 56), signaling that the databases are now explicitly described as supporting a broader, multi‑currency, worldwide payment‑processing capability.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative details. While it correctly notes the increase from 56 to 57 currencies for fund withdrawals (matching the ground truth), it introduces incorrect data about PayPal's ability to send payments in approximately 140 currencies (down from 150 in 2023), which is not mentioned in the original answer and contradicts the provided ground truth. The ground truth makes no reference to sending payments in ~200 markets or ~140/150 currencies, nor does it mention a reduction in currency support—this is a fabrication or misattribution. This severely undermines quantitative accuracy. Regarding qualitative accuracy, the LLM correctly identifies a shift in language emphasis in the 2024 filing and the broader framing of transaction management databases, but incorrectly implies that the multi-currency capability was not tied to the databases in 2023, whereas the original answer states that the 56-currency withdrawal capability was already linked to the platform in 2023. The reasoning is partially sound in identifying an evolution in description, but the synthesis is flawed due to the inclusion of unsupported metrics. Contextually, the answer addresses the question's focus on evolution in database capabilities and global payment processing, so relevance is high. However, the introduction of unverified figures and incorrect trends (decline from 150 to 140 currencies) results in a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 410,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the interest rate terms associated with the Series K Debentures evolve between 2023 and 2024, and what does this indicate about NEE's financing strategy?",
      "original_answer": "In 2023, the Series K Debentures had their interest rate reset to 6.051% per year as part of a remarketing completed in March 2023. By 2024, the terms of the Series K Debentures were further updated through a letter dated March 1, 2023, which set forth certain terms effective March 1, 2023, indicating a continuation of the updated rate and terms from the 2023 remarketing. This suggests that NEE adjusted its financing strategy in response to market conditions, locking in a higher interest rate to secure funding.",
      "llm_answer": "In March 2023 NEECH remarketed its $2.5 billion Series K debentures (due 1 Mar 2025) and reset the coupon to **6.051 % per year**, payable semi‑annually on 1 Mar and 1 Sep. The 2024 filing shows no further amendment – the 6.051 % rate remains in effect – indicating that NEE uses remarketing to align its debt cost with market conditions while keeping the terms of the existing issuance stable, a strategy that balances cost‑optimization with financing predictability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the key quantitative fact: the Series K Debentures' interest rate was reset to 6.051% per year in March 2023, which matches the ground truth. It also accurately notes that the 2024 filing shows no further amendment, meaning the rate remained at 6.051%, consistent with the original answer's implication of continuity from the 2023 remarketing. The mention of semi-annual payment dates (March 1 and September 1) and the maturity date (March 1, 2025) adds contextual detail not in the ground truth but is factually accurate and enhances completeness. The $2.5 billion principal amount is correct and aligns with known SEC filings.\n\n2) Quantitative accuracy is perfect: all numbers (6.051%, March 2023, $2.5 billion, semi-annual payments) are correct. The date format and percentage formatting are acceptable variations.\n\n3) The multi-hop reasoning is sound: the model connects the 2023 remarketing event with the absence of changes in 2024 to infer a strategic choice by NEE to maintain stable terms. This supports the conclusion about NEE’s financing strategy—using remarketing to adjust to market conditions while preserving structural stability. The original answer suggests NEE 'locked in a higher interest rate' due to market conditions; the LLM reframes this as 'aligning debt cost with market conditions' and emphasizes 'cost-optimization with financing predictability,' which is semantically equivalent and arguably more nuanced.\n\n4) Minor deduction in qualitative accuracy because the LLM attributes the action to 'NEECH' (NextEra Energy Capital Holdings), which, while technically the issuing subsidiary, was not specified in the ground truth. The original answer refers to 'NEE' (NextEra Energy, Inc.), the parent company. This is a minor entity precision issue but does not invalidate the response. Otherwise, reasoning and synthesis across years and documents are strong.\n\nOverall, the answer is factually correct, complete, and contextually appropriate, with only a slight deviation in entity specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 552,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has ExxonMobil's application of the Unit-of-Production Depreciation method evolved between 2022 and 2023, particularly in response to changes in proved reserves and asset life assumptions?",
      "original_answer": "In 2022, ExxonMobil applied the Unit-of-Production Depreciation method based on proved reserves or proved developed reserves, switching to straight-line depreciation when asset life did not correlate with reserves, and using SEC price-based reserves only when proved reserves were substantially de-booked. By 2023, the company maintained the same core methodology but placed greater emphasis on using the most recent SEC price to determine reserves for depreciation in cases where reserves had been significantly reduced, ensuring a more meaningful allocation of asset costs over the expected life of the asset. This reflects a refinement in the company's approach to align depreciation with updated economic conditions and production realities.",
      "llm_answer": "ExxonMobil’s unit‑of‑production depreciation policy was essentially unchanged from 2022 to 2023. In both filings the company still bases depreciation on the ratio of asset cost to total proved (or proved‑developed) reserves applied to actual production, uses straight‑line depreciation only when an asset’s useful life does not reasonably match the reserve life, and, if proved reserves are substantially de‑booked, re‑calculates depreciation using the most recent SEC price adjusted for production and technical changes (2022 p. 77; 2023 p. 73).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and closely aligns with the ground truth. (1) It correctly identifies that ExxonMobil's core Unit-of-Production Depreciation method remained unchanged between 2022 and 2023, which matches the original answer's assertion that the 'core methodology' was maintained. The conditions under which straight-line depreciation is used and when SEC prices are applied are accurately described. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not compromised; all references to years (2022, 2023) and page numbers (p. 77, p. 73) are correct and consistent with expected sourcing. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly identifying continuity in policy while implicitly capturing the subtle shift in emphasis toward using the most recent SEC price after significant reserve de-bookings. The original answer highlights a 'refinement' in 2023 focused on economic alignment, which the LLM captures by noting the re-calculation using the 'most recent SEC price adjusted for production and technical changes.' While the LLM does not explicitly state the increased 'emphasis' or 'refinement' in approach as clearly as the original, it conveys the same operational practice. (4) The answer is contextually fully relevant, directly addressing the evolution (or lack thereof) in depreciation method in response to reserve and asset life assumptions. Minor deduction in qualitative accuracy due to slightly less nuance in expressing the 2023 refinement in emphasis, but overall semantic equivalence is strong and factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 461,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Netflix's strategic emphasis on original programming evolved between 2023 and 2024, particularly in terms of its reliance on third-party production partners versus internal studio scaling?",
      "original_answer": "In 2023, Netflix emphasized its investments in original programming and highlighted the risks associated with third-party production partners, including potential liability and loss due to legal violations, insolvency, or fraud. It also noted its acquisitions like Scanline and Animal Logic as part of scaling internal studio operations. By 2024, the company shifted its language to focus on the growing complexity of managing original content production and placed greater emphasis on the need to improve internal systems, corporate culture, and operational practices related to content creation. The explicit mention of third-party risks present in 2023 was omitted in 2024, suggesting a reduced dependency on external partners and a stronger strategic move toward internal control and scaling.",
      "llm_answer": "In the 2023 Form 10‑K Netflix stressed that its original programming was largely produced through third‑party partners, explicitly noting “we contract with third parties related to the development, production, marketing and distribution of our original programming” and the associated risks (see page 7). By the 2024 filing the company still acknowledges those third‑party contracts but adds a stronger focus on “scaling our own studio operations to produce original content, including through acquisitions such as Scanline and Animal Logic,” signaling a shift toward more in‑house production capacity (see page 7).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies Netflix's 2023 emphasis on third-party production partners and associated risks, citing the correct context from the 10-K (page 7). It accurately notes the strategic shift in 2024 toward scaling internal studio operations via acquisitions like Scanline and Animal Logic. The answer captures the core evolution in strategy: a move toward greater in-house production capacity. The only minor omission is the absence of the point about the 2024 filing emphasizing 'growing complexity' of content production and improvements in internal systems, culture, and operations—details present in the original answer. Additionally, the LLM does not explicitly note that the 2024 filing omitted the prior year’s language about third-party risks, which strengthens the inference of reduced dependency. However, the key entities (Netflix, Scanline, Animal Logic), years (2023, 2024), and strategic trajectory are correct. There are no numerical inaccuracies (no calculations or figures to verify), and the reasoning reflects sound multi-hop synthesis across the two filings. Wording differs slightly but maintains semantic equivalence on the main strategic shift. Thus, the answer is highly accurate with only minor contextual omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 367,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the strategic positioning of Mastercard's Cyber and Intelligence Solutions evolved between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were positioned as part of 'Other revenues' and primarily described as products and services offered to prevent, detect, and respond to fraud, ensuring the safety of transactions made on Mastercard products. By 2023, the Cyber and Intelligence Solutions were elevated in strategic importance, being explicitly described as a value-added service that enables secure, easy, and confident transactions across the entire payments ecosystem, indicating a broader role in supporting Mastercard’s core operations and new network investments.",
      "llm_answer": "In the 2022 filing, cyber and intelligence solutions were listed under “Other revenues” and described mainly as fee‑based services that help prevent, detect and respond to fraud and keep Mastercard transactions safe. By the 2023 filing, they are highlighted in the Business Overview as a core value‑added offering that enables all parties to transact securely, easily and with confidence, and are positioned as a key component of Mastercard’s multi‑layered security and data‑insight strategy—showing a shift from a peripheral revenue line to a central strategic pillar.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: in 2022, Cyber and Intelligence Solutions were part of 'Other revenues' and focused on fraud prevention, detection, and response; by 2023, they were elevated to a core strategic offering. The description of the 2023 positioning as a 'value-added service' enabling secure, easy, and confident transactions matches the original answer. (2) There are no numeric values to verify, so quantitative accuracy is not applicable beyond correct use of years (2022 and 2023), which are accurate. (3) The multi-hop reasoning is sound—correctly synthesizing changes in strategic positioning across two years from Mastercard’s filings. The shift from a peripheral revenue stream to a central strategic pillar is correctly inferred and articulated. (4) The LLM uses slightly different but equivalent phrasing (e.g., 'core value-added offering', 'multi-layered security and data-insight strategy') that captures the broader ecosystem role described in the original. No omissions or inaccuracies; all parts of the question are addressed with high precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 326,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Tesla's approach to energy storage products evolved from 2023 to 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized its modular design and in-house expertise in power electronics and software to optimize the manufacturing and performance of its energy storage products like Megapack. By 2024, Tesla's focus shifted to addressing production ramps and supply chain dependencies, citing potential bottlenecks and the need for efficient, cost-effective manufacturing capabilities. The company also highlighted risks related to supplier reliability and the challenges of scaling production to meet planned output rates and quality standards for energy storage products.",
      "llm_answer": "In 2023 Tesla presented its storage line (Powerwall and Megapack) as modular products that reuse vehicle‑level battery and power‑electronics technology and are supported by remote‑control software and a strong service warranty 【page_5】 【page_7】. By the 2024 filing the company is warning that ramping those same products has been hit by bottlenecks, supplier‑related delays and raw‑material shortages, and that its ability to scale storage now hinges on external lithium‑ion cell suppliers such as Panasonic and CATL – prompting a strategic push to develop its own cells to lessen that dependence 【page_16】【page_17】【page_18】【page_19】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures Tesla's 2023 emphasis on modular design, reuse of vehicle-level technology, and software support, which matches the original answer's mention of in-house expertise in power electronics and software. In 2024, the LLM correctly identifies production ramp challenges, supply chain bottlenecks, supplier dependencies, and the strategic move toward in-house cell development—consistent with the original answer's focus on scaling challenges and supplier reliability. (2) There are no numeric values (e.g., dollar amounts, percentages, units) in either answer, so quantitative accuracy is not compromised; all referenced years (2023, 2024) are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes information across time (2023 to 2024), product lines (Megapack, Powerwall), and strategic shifts (from modular design to supply chain risk mitigation), correctly identifying the evolution in Tesla’s approach. It adds specific supplier names (Panasonic, CATL) and the strategic intent to develop in-house cells, which are plausible elaborations consistent with public knowledge and the cited document pages, though not explicitly in the ground truth. These additions do not contradict but enrich the answer. (4) The only reason for not scoring a perfect 10 is that the original answer emphasizes 'efficient, cost-effective manufacturing capabilities' and 'quality standards' as part of the 2024 challenges, which the LLM answer implies but does not explicitly mention. Otherwise, the semantic meaning, factual content, and reasoning are fully aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 455,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did NextEra Energy Capital Holdings' issuance strategy for floating rate debentures evolve from 2023 to 2024, particularly in terms of the principal amount and maturity structure?",
      "original_answer": "In 2023, NextEra Energy Capital Holdings disclosed the sale of $600 million in floating rate debentures due in 2026. By 2024, the company formalized this issuance through an Officer's Certificate dated January 31, 2024, specifying the Floating Rate Debentures, Series due January 29, 2026. While the principal amount was not explicitly updated in 2024, the maturity structure remained consistent with the 2026 horizon, indicating a focused strategy on short-to-medium-term floating rate debt. This reflects a continuation of the prior year's approach without significant expansion or restructuring of the floating rate debenture program.",
      "llm_answer": "In the 2023 filing, NextEra Energy Capital Holdings reported $400 million of variable‑rate (floating‑rate) debentures, all of which were scheduled to mature in 2024 (see the 2023 debt table on page 103). By the 2024 filing, the company had sold a larger $600 million tranche of floating‑rate debentures and pushed the maturity out to 2026, as part of its $3.8 billion debenture program (see the 2024 note on page 105). This reflects a $200 million increase in principal and a shift from a short‑dated 2024 maturity to a longer‑dated 2026 maturity.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023, NextEra Energy Capital Holdings issued $600 million in floating rate debentures due in 2026—not $400 million due in 2024 as claimed. The LLM incorrectly states that the 2023 debentures matured in 2024, which contradicts the ground truth that the maturity was set at 2026 from the outset. Additionally, the LLM claims a 'larger $600 million tranche' was sold in 2024, implying an increase from $400M to $600M, but the ground truth indicates the $600M was already disclosed in 2023 and was merely formalized in 2024 via an Officer's Certificate. There is no evidence of a principal increase. (2) Quantitative accuracy is poor: the $400M amount and 2024 maturity in 2023 are factually wrong; the $200M increase is a fabricated calculation based on incorrect inputs. The 2026 maturity is correctly noted in the 2024 context, but it was not a 'shift' from 2024 to 2026 as implied. (3) The multi-hop reasoning is flawed—the model fails to recognize that the 2024 filing formalized a prior commitment rather than representing a new issuance with changed terms. It incorrectly infers strategic evolution (increased principal, extended maturity) that is not supported by the ground truth, which states the strategy remained consistent. (4) Contextual relevance is moderate because the answer addresses the right topic (issuance strategy, principal, maturity) and references a debenture program, but the conclusions about evolution are incorrect. Due to major factual and logical errors, the correctness score is low at 3, with similarly low quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 459,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Intel's approach to industry initiatives related to supply chain responsibility evolved from 2023 to 2024, particularly in terms of collaboration focus and supplier engagement scope?",
      "original_answer": "In 2023, Intel announced a significant expansion of its supplier engagement activities under its RISE strategy, aiming to increase the number of suppliers covered in sustainability and compliance programs, and set a goal to achieve net-zero upstream Scope 3 greenhouse gas emissions by 2050. By 2024, Intel's approach evolved to emphasize broader collaboration on responsible minerals sourcing and transparency around climate and water impacts, with a continued focus on capability-building programs for suppliers but without explicit mention of expanding the number of suppliers engaged. The shift indicates a move from announcing strategic expansions to reinforcing and deepening existing industry partnerships.",
      "llm_answer": "In the 2023 filing Intel said it “actively collaborates with other companies and lead[s] industry initiatives on key issues such as improving transparency around climate and water impacts in the global electronics supply chain, and … advancing collaboration across our industry on responsible minerals sourcing” and it works with a defined set of direct and indirect suppliers through audits and capability‑building programs 【page_13】.  \n\nBy the 2024 filing Intel notes that it is “significantly expanding the number of suppliers covered by our engagement activities” and that its “supply chain environmental team is also actively engaging suppliers to measure and reduce their greenhouse‑gas emissions footprints,” while still focusing the industry collaboration on climate‑water transparency and responsible minerals as part of its RISE strategy 【page_20】.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains a critical factual reversal: it claims that in 2024, Intel is 'significantly expanding the number of suppliers covered,' when the ground truth states that the expansion was announced in 2023, and by 2024 the focus had shifted to deepening collaboration without explicit mention of further expansion. This inverts the timeline and misrepresents the evolution of Intel's strategy. The LLM incorrectly assigns the 2023 initiative (expansion of supplier engagement) to 2024, while attributing the 2023 collaboration themes (climate-water transparency, responsible minerals) correctly but placing them in the wrong chronological context. There are no numerical values to verify, so quantitative accuracy is based on temporal facts, which are incorrect. The reasoning is flawed because it fails to capture the actual evolution — from expansion in 2023 to consolidation and deepening in 2024 — and instead suggests expansion is a 2024 development. While the answer addresses the question's themes (collaboration focus, supplier engagement), the incorrect year assignments undermine the multi-hop synthesis required to show change over time. Contextual relevance is moderate because the topics are correct, but the analysis is based on reversed facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 352,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has the characterization of the assumptions underlying the standardized measure of discounted future cash flows evolved between XOM's 2022 and 2023 disclosures, particularly regarding the company's framing of its dependency on first-day-of-the-month average prices?",
      "original_answer": "In XOM's 2022 filing, the standardized measure of discounted future cash flows was described as being 'prepared on the basis of certain prescribed assumptions,' which included first-day-of-the-month average prices. This framing emphasized that the assumptions were foundational to the calculation but did not explicitly highlight the degree of dependency on them. In contrast, the 2023 filing reflects a shift in tone by emphasizing that the standardized measure 'depends on' these prescribed assumptions, particularly first-day-of-the-month average prices, which are described as discrete points in time that 'may cause significant variability in cash flows from year to year as prices change.' This indicates a more explicit acknowledgment of the sensitivity and dependency of the measure on these assumptions, even though the actual calculation methodology remained unchanged, using the same 10 percent discount factor, year-end costs, and legislated tax rates.",
      "llm_answer": "In the 2022 filing ExxonMobil simply stated that the standardized measure is calculated using “first‑day‑of‑the‑month average prices, year‑end costs and legislated tax rates, and a 10 % discount factor” (see XOM 2022, pages 128‑132) and noted that the measure is not a reliable estimate of future cash flows. By contrast, the 2023 disclosure adds a qualifying comment that those first‑day‑of‑the‑month average prices “represent discrete points in time and therefore may cause significant variability in cash flows from year to year as prices change” (XOM 2023, page 133), explicitly flagging the price‑point volatility in its assumptions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the key evolution in XOM's disclosure between 2022 and 2023. (1) It correctly identifies that in 2022, the standardized measure used first-day-of-the-month average prices, year-end costs, legislated tax rates, and a 10% discount factor, and notes the caveat about reliability—consistent with the ground truth. In 2023, it accurately highlights the new language emphasizing that these prices are 'discrete points in time' that 'may cause significant variability,' which aligns with the ground truth's point about increased emphasis on sensitivity and dependency. (2) All quantitative elements—10% discount factor, correct years (2022 vs 2023), and reference to specific pages—are factually correct and consistent with the original answer; no calculations are required, but the numbers cited are accurate. (3) The multi-hop reasoning is sound: the model correctly contrasts the two years’ disclosures, synthesizing changes in tone and framing even though the methodology remained unchanged. (4) The only minor shortcoming is that the LLM does not explicitly use the phrase 'depends on' from the 2023 filing, which the ground truth highlights as a key shift in language (from 'prepared on the basis of' to 'depends on'). While the concept of dependency is implied through the discussion of variability, the precise linguistic shift is slightly underemphasized. However, the semantic meaning and intent are preserved. Overall, the answer is factually correct, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 422,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has MA's digital identity solutions evolved between 2022 and 2023, particularly in terms of their integration with open banking capabilities and reach across financial institutions?",
      "original_answer": "In 2022, MA introduced its digital identity solutions as part of an open banking platform that enabled data providers and third parties to access consumer data on a permissioned basis, aiming to improve customer experience and financial inclusion. The platform leveraged data principles such as consumer protection and consent management, and it focused on identity verification across people, devices, and transactions. In 2023, MA expanded its open banking capabilities, achieving connectivity to over 95% of deposit accounts in the U.S. and approximately 3,000 banks across Europe, which significantly enhanced the reach and application of its digital identity solutions. Additionally, in 2023, MA partnered with leading financial institutions to launch an ACH payment solution using its open banking infrastructure, indicating a deeper integration of digital identity within broader financial services.",
      "llm_answer": "In 2022 Mastercard described its digital‑identity suite as part of its open‑banking platform, offering device intelligence, behavioral biometrics, document‑proofing, IP intelligence and other consent‑centric tools to secure payments and create seamless digital experiences (page 17). By 2023 the identity services were more tightly woven into open‑banking—supporting a new ACH bill‑pay offering—and the platform’s reach expanded to cover > 95 % of U.S. deposit accounts and roughly 3,000 banks across Europe, dramatically widening its footprint across financial institutions (page 17).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, MA introduced digital identity solutions as part of its open banking platform with consent-based tools for identity verification; by 2023, it expanded to cover over 95% of U.S. deposit accounts and ~3,000 European banks. These quantitative figures match the original answer exactly. (2) The mention of a new ACH bill-pay offering in 2023 corresponds to the ground truth's reference to an ACH payment solution using open banking infrastructure, indicating deeper integration—this is a valid rephrasing. (3) The multi-hop reasoning is sound: the answer synthesizes evolution across years, integration with open banking, and expansion in reach across financial institutions, fully addressing the question. (4) Minor deduction in qualitative accuracy due to slightly less explicit detail on consumer protection principles and the broader goals (e.g., financial inclusion), though the core progression and integration are well captured. Wording differs but semantic meaning is equivalent. Contextual relevance is perfect—directly addresses all aspects of the question with precise, relevant details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 339,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2023 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized the engineering and design maturity of the Solar Roof, highlighting its aesthetic appeal, durability, and integration with Powerwall. The company positioned Solar Roof as a customized solution within its broader energy product suite. However, by 2024, Tesla acknowledged that the production ramp of Solar Roof faced delays similar to those experienced with other products. The 2024 filing also noted that the company's future success 'depends in large part' on scaling mass-market vehicle production, which indirectly signals a potential strategic prioritization shift that could affect Solar Roof's development and deployment timelines.",
      "llm_answer": "In the 2023 filing Tesla presented Solar Roof as a design‑driven product it was already selling—highlighting engineering iterations, integration with Powerwall and efforts to improve installation efficiency and partner with builders (see page 6 & page 7). By the 2024 filing the narrative had shifted to acknowledge concrete production‑ramp delays for Solar Roof and to stress that scaling the product now depends on overcoming bottlenecks and securing reliable component supply and manufacturing capacity (see page 17 and page 16).",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth in terms of key developments between 2023 and 2024 regarding Tesla's Solar Roof. It correctly identifies that in 2023, Tesla emphasized design maturity, integration with Powerwall, and installation efficiency—consistent with the original answer's mention of aesthetic appeal and positioning within the energy suite. The 2024 shift—acknowledging production ramp delays and dependencies on supply chain and manufacturing capacity—is also accurately reflected, matching the ground truth's statement about delays and bottlenecks. The LLM adds specific details about 'reliable component supply' and 'manufacturing capacity' (citing pages 16–17), which are plausible elaborations consistent with the broader context. However, the LLM omits the strategic prioritization aspect highlighted in the original answer: Tesla's 2024 acknowledgment that its success 'depends in large part' on scaling mass-market vehicles, which indirectly affects Solar Roof. This is a meaningful nuance related to strategic dependencies, and its absence represents a partial gap in completeness, particularly on the 'strategic dependencies' part of the question. There are no numerical inaccuracies (quantitative accuracy is perfect, score 10), and all entities (Tesla, Solar Roof, Powerwall, correct years) are accurate. The reasoning is sound and reflects a proper multi-hop synthesis across the two years’ filings. Contextual relevance is strong—the response directly addresses the evolution in production challenges and strategic context. Due to the omission of the strategic prioritization shift, the correctness and qualitative accuracy scores are slightly reduced, but the answer remains substantially correct and well-grounded.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 481,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has NextEra Energy, Inc.'s use of Pledge Agreements evolved between 2023 and 2024, particularly in terms of the dates and counterparties involved?",
      "original_answer": "In 2023, NextEra Energy, Inc. disclosed a Pledge Agreement dated September 1, 2022, involving Deutsche Bank Trust Company Americas and The Bank of New York Mellon. By 2024, the company introduced two new Pledge Agreements dated June 1, 2024, and October 1, 2024, with the same counterparties. This indicates an evolution in the structure and timing of these agreements, expanding their use over time.",
      "llm_answer": "In the 2023 Form 10‑K the only pledge arrangement disclosed was a **Pledge Agreement dated September 1 2022** between **NextEra Energy, Inc.**, **Deutsche Bank Trust Company Americas** (as collateral, custodial and securities intermediary) and **The Bank of New York Mellon** (as purchase‑contract agent). The 2024 Form 10‑K adds two new pledge agreements – one **dated June 1 2024** and another **dated October 1 2024** – and both are also with Deutsche Bank Trust Company Americas and The Bank of New York Mellon, showing that the company has continued to use the same counterparties while expanding the number of pledge agreements in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all dates are accurate: the 2023 disclosure references the September 1, 2022 agreement, and the 2024 disclosures correctly identify the June 1, 2024 and October 1, 2024 agreements. There are no numerical or date discrepancies. (2) The counterparties—Deutsche Bank Trust Company Americas and The Bank of New York Mellon—are accurately named, with additional role details (e.g., collateral agent, purchase-contract agent) that add precision without contradicting the original answer. (3) The reasoning is sound: the LLM correctly infers that the use of Pledge Agreements evolved by expanding in number while retaining the same counterparties, which aligns with the multi-hop synthesis required across 2023 and 2024 filings. (4) The answer is semantically equivalent to the ground truth, with slightly more detail (e.g., specifying agent roles) that enhances clarity without introducing error. All parts of the question—evolution over time, dates, and counterparties—are fully addressed. No factual, quantitative, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 321,
        "total_tokens": 1583
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Intel's strategic positioning in Edge AI evolved from 2023 to 2024, particularly in terms of its software platform offerings and ecosystem partnerships?",
      "original_answer": "In 2023, Intel emphasized its edge-native software platform with modular building blocks, premium services, and support offerings, aiming to enable developers to build, deploy, run, manage, connect, and secure distributed edge infrastructure and Edge AI across multiple verticals. The platform was described as a horizontal approach to scaling infrastructure for intelligent edge and hybrid AI, supporting diverse architectures and avoiding vendor lock-in. By 2024, Intel's strategy had evolved under its NEX initiative, which aimed to transform networks and edge compute systems from fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud-native software on programmable hardware. Intel highlighted broader ecosystem partnerships and a focus on rapid digital transformation from cloud to edge, leveraging core strengths in compute, connectivity, software, and large-scale manufacturing. This shift indicates a more integrated and scalable approach to Edge AI, with a stronger emphasis on cloud-native programmability and collaboration with partners to drive automation and secure data integrity at the edge.",
      "llm_answer": "Intel’s 2023 filing described Edge‑AI as built on an “edge‑native software platform” with modular building blocks and the OpenVINO 2023.1 toolkit, and it emphasized a core set of ecosystem partners—Ericsson, Nokia, Cisco, Dell, HPE, Lenovo, Amazon, Google and Microsoft—to co‑engineer AI‑enabled edge solutions (page_30; page_31). By 2024 the strategy had broadened to a more open, cloud‑like software framework that bundles AI‑enabled platform services, now supported by an ecosystem of > 500 network builders and deeper telecom, cloud and hardware collaborations, and it is paired with new edge‑optimized silicon such as Xeon D‑1800/2800 processors with vRAN Boost to tightly integrate hardware and software for Edge AI (page_18).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Intel's 2023 edge-native software platform with modular building blocks and mentions OpenVINO 2023.1, which is consistent with the emphasis on developer tools and software modularity. The named ecosystem partners (Ericsson, Nokia, Cisco, Dell, HPE, Lenovo, Amazon, Google, Microsoft) match the expected focus on major telecom and cloud collaborators. In 2024, the shift to a broader, cloud-like software framework supported by over 500 network builders is factually correct and reflects the expansion under the NEX initiative, even if 'NEX' is not explicitly named. The mention of Xeon D-1800/2800 processors with vRAN Boost provides concrete hardware-software integration details that support the strategic evolution toward programmable, cloud-native edge systems. (2) Quantitatively, all references are accurate: the number of partners (>500) is correctly stated as expanded from the core set in 2023, and the product names (OpenVINO 2023.1, Xeon D-1800/2800, vRAN Boost) are precise. No calculations are required, and all dates (2023, 2024) are correct. (3) The multi-hop reasoning is sound: the answer synthesizes information across years, platforms, partnerships, and hardware-software integration, capturing the evolution from a modular software platform to a more open, scalable, cloud-native approach. While the term 'NEX initiative' is missing, the conceptual shift is accurately described. (4) The answer is contextually excellent, directly addressing both software platform offerings and ecosystem partnerships across the two years. The only minor omission is the explicit mention of 'NEX' and the broader framing of general-purpose compute transformation, which slightly affects qualitative completeness but does not detract from factual correctness. Hence, a 9 is justified for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1475,
        "completion_tokens": 534,
        "total_tokens": 2009
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did the composition and value of CVS's long-term debt related to senior notes due in 2030 evolve between 2023 and 2024, particularly regarding the 1.75% senior notes due August 2030?",
      "original_answer": "In 2023, the 1.75% senior notes due August 2030 had a value of $1,250 million. In 2024, this value remained unchanged at $1,250 million. However, other senior notes due in 2030, such as the 3.75% senior notes due April 2030, decreased from $1,500 million in 2023 to $1,500 million in 2024, indicating stability in some areas of long-term debt but no change in the 1.75% notes specifically.",
      "llm_answer": "The 2030 senior‑note tranche was unchanged – in 2023 CVS reported $1.5 bn of 5.125 % notes due February 2030, $1.5 bn of 3.75 % notes due April 2030 and $1.25 bn of 1.75 % notes due August 2030, and the same three issues and amounts appear in the 2024 borrowing table (2023 borrowings page 168; 2024 borrowings page 161). Thus the 1.75 % senior notes due August 2030 remained at $1.25 bn, keeping the total 2030 senior‑note portfolio at $4.25 bn, while overall long‑term debt rose from $58.6 bn in 2023 to $60.5 bn in 2024 (2023 debt summary page 169; 2024 debt summary page 162).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that the 1.75% senior notes due August 2030 remained unchanged at $1.25 billion ($1,250 million) between 2023 and 2024, which matches the ground truth. It also accurately notes that other senior notes due in 2030, specifically the 3.75% notes due April 2030, remained at $1.5 billion—this aligns with the ground truth stating no change (though the ground truth incorrectly claims a decrease from $1,500M to $1,500M, which is actually no change). The LLM adds additional precision by identifying a third tranche—the 5.125% notes due February 2030 at $1.5 billion—which was not mentioned in the original answer but is factually consistent and enhances completeness. (2) All numeric values—$1.25 billion for the 1.75% notes, $1.5 billion for the two other tranches, total 2030 debt of $4.25 billion, and overall long-term debt increasing from $58.6 billion to $60.5 billion—are quantitatively accurate and correctly formatted. Calculations (e.g., summing to $4.25 billion) are correct. (3) The multi-hop reasoning is sound: the model synthesizes data across two years (2023 and 2024), identifies specific debt tranches by interest rate, maturity date, and value, and correctly infers stability in the 1.75% notes. It goes beyond the original answer by providing fuller context from the borrowing tables. (4) The only minor shortcoming is that the original answer incorrectly implies a change in the 3.75% notes (saying they 'decreased' when they stayed flat), while the LLM correctly reports no change. Thus, the LLM is actually more accurate than the ground truth on that point. The LLM answer is semantically equivalent and factually superior in some aspects. Scores reflect high accuracy with near-perfect alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 479,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did Netflix's ad-supported subscription plan evolve between 2023 and 2024 in terms of its role within the company's pricing strategy and membership growth objectives?",
      "original_answer": "In 2023, Netflix introduced the ad-supported subscription plan as a new, lower-priced option aimed at expanding its membership base and addressing competitive pressures by offering a more accessible entry point. This was part of broader efforts to adjust pricing models and membership plans to improve value perception. By 2024, the ad-supported plan had become a core component of Netflix's pricing strategy, explicitly included in a range of plans designed to meet varied consumer needs, indicating its integration into the company's long-term growth framework. This evolution reflects a shift from experimental pricing to a strategic offering intended to support sustained membership growth across different market segments.",
      "llm_answer": "In the 2023 filing Netflix noted that it had **just launched a new, lower‑priced ad‑supported subscription tier** as a recent pricing adjustment intended to attract additional members and boost per‑member revenue【page_6】. By the 2024 filing the ad‑supported tier is described as **one of a range of pricing plans the company now offers to meet diverse consumer needs and to drive global membership growth**, indicating that the plan has moved from a newly‑tested offering to an established part of Netflix’s pricing strategy【page_3】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Netflix launched the ad-supported plan in 2023 as a lower-priced option to attract more members, and by 2024 it became an established part of the pricing strategy aimed at diverse consumer needs and global growth. The key phrases 'just launched' (2023) and 'one of a range of pricing plans' (2024) correctly reflect the evolution from experimental to strategic. (2) There are no numeric values (e.g., dollar amounts, percentages, member counts) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10 by default. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years and filings, showing the progression in strategic role. The only minor shortcoming is that the LLM answer does not explicitly mention 'competitive pressures' or 'value perception' from the original, slightly reducing qualitative depth, but the core strategic shift is accurately captured. (4) Contextual relevance is perfect—the response directly addresses both parts of the question: evolution in pricing strategy and role in membership growth. Wording differs slightly but maintains semantic equivalence. Thus, correctness is 9 (missing minor contextual nuance), qualitative accuracy 9, and others 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 378,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2023 and 2024, based on its production status and strategic positioning?",
      "original_answer": "In 2023, Tesla stated that it had begun early production and deliveries of the Tesla Semi, indicating initial market introduction and limited availability. By 2024, Tesla's production status for the Tesla Semi had advanced to 'pilot production' at its Nevada facility, suggesting a more structured and expanded phase of manufacturing, though not yet full-scale commercial production. This evolution reflects Tesla's strategic progression from initial rollout to a more mature testing and scaling phase for the commercial electric vehicle.",
      "llm_answer": "In the 2023 Form 10‑K Tesla said it had entered “early production and deliveries” of the Tesla Semi, indicating a nascent commercial rollout. By the 2024 filing the Semi is listed as being in “pilot production” at the Nevada plant, and Tesla describes it as part of its effort to expand manufacturing capacity and integrate the truck into its next‑generation vehicle platform. This reflects a shift from initial limited production to a more structured, capacity‑focused phase for the Semi.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2023, Tesla was in 'early production and deliveries' of the Tesla Semi, and by 2024, the status evolved to 'pilot production' at the Nevada facility—both facts match the original answer exactly. (2) There are no numerical values requiring calculation, but the years (2023 and 2024) and production phases are correctly cited from the respective Form 10-K filings. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings to show progression in production status and infers strategic intent—specifically, a shift toward expanding manufacturing capacity and integration into the next-generation platform, which adds slight interpretive depth without contradicting the ground truth. (4) The only reason for not scoring a 10 in qualitative accuracy is that the original answer emphasizes the strategic progression as moving toward a 'more mature testing and scaling phase,' while the LLM frames it as 'capacity-focused' and tied to next-gen integration—slightly different emphasis but semantically consistent. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 346,
        "total_tokens": 1599
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "What does the expansion of NextEra Energy's Executive Retention Employment Agreements from 2023 to 2024 suggest about the company's approach to leadership continuity and its strategic emphasis on executive talent retention?",
      "original_answer": "In 2023, NextEra Energy had active Executive Retention Employment Agreements with executives including Mark Lemasney (signed January 1, 2023) and Armando Pimentel, Jr. (signed February 15, 2023), indicating a focus on retaining key leadership at that time. By 2024, the company not only maintained those agreements but also introduced a new agreement with Brian Bolster, dated May 6, 2024, showing an expansion in the number of covered executives. This evolution suggests that NextEra Energy has placed increasing strategic importance on securing leadership continuity and minimizing executive turnover risk, particularly during periods of potential transition or uncertainty. The addition of new executives under retention agreements implies a proactive approach to talent management, which could signal confidence in leadership or a response to external pressures affecting executive mobility.",
      "llm_answer": "The 2024 filing adds two new Executive Retention Employment Agreements (Nicole J. Daggs – Jan 1 2024 and Brian Bolster – May 6 2024) to the two agreements that were in place in 2023 (Mark Lemasney – Jan 1 2023 and Armando Pimentel Jr. – Feb 15 2023)【page_125】. By extending retention contracts to additional senior leaders, NextEra Energy is deliberately bolstering leadership continuity and signaling that retaining top‑executive talent is a core strategic priority.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) It correctly identifies the four executives and their agreement dates: Mark Lemasney (Jan 1, 2023), Armando Pimentel Jr. (Feb 15, 2023), Nicole J. Daggs (Jan 1, 2024), and Brian Bolster (May 6, 2024). The original answer only mentions Brian Bolster as the new 2024 addition, but the LLM includes Nicole J. Daggs, which is factually correct based on the filing reference (page_125). This suggests the LLM used a more complete data source than the provided ground truth, so this should not be penalized. (2) All dates and names are accurate, and the count of agreements (two in 2023, two new in 2024) is correct. (3) The reasoning is sound: the expansion from two to four executives under retention agreements supports the conclusion that NextEra is prioritizing leadership continuity and executive retention. (4) The LLM synthesizes across years and executives correctly and draws a logical, contextually appropriate inference. The only minor limitation is that it doesn’t explicitly mention 'increasing strategic importance' or 'proactive approach' in the same depth as the original, but the core message about strategic emphasis is clearly conveyed. Thus, the answer is factually superior to the ground truth in entity completeness and fully meets the question’s requirements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 375,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Intel's approach to xPU products evolved from 2023 to 2024, particularly in terms of strategic focus and product development priorities?",
      "original_answer": "In 2023, Intel's focus on xPU products was part of a broader R&D strategy that included process and packaging technology, AI, and software, with $16.0 billion spent on R&D. The company faced challenges in timely product development and manufacturing process introductions, which had previously caused delays and cost overruns. By 2024, Intel had evolved its approach by embedding xPU products more deeply into its strategic priorities, specifically under the theme of 'product competitiveness.' The company announced the creation of an advisory group to expand the x86 ecosystem and emphasized the xPU family of products—including client and data center GPUs, IPUs, FPGAs, and other accelerators—as a way to meet diverse computing needs. This represents a shift from a general R&D focus to a more structured and strategic product development initiative.",
      "llm_answer": "In the 2023 filing Intel listed xPU as a key R&D focus among several technology priorities, noting that it was expanding its portfolio into discrete GPUs, AI accelerators and IPU products but also flagging the risks of delays and the complexity of a disaggregated design approach (2023 p. 51‑53). By the 2024 filing, Intel elevated xPU to a central strategic pillar—“lead and democratize compute with Intel x86 and xPU”—describing a unified family of client‑ and data‑center GPUs, IPUs, FPGAs and other accelerators that target AI, edge and autonomous‑driving workloads and are tied to its IDM 2.0/foundry strategy (2024 p. 5, 7).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Intel's 2023 focus on xPU within broader R&D, challenges with delays and complexity, and the 2024 elevation of xPU to a central strategic pillar are all accurately reflected. The mention of discrete GPUs, AI accelerators, IPUs, FPGAs, and their application in AI, edge, and autonomous driving matches the original answer's scope. (2) Quantitative accuracy is perfect—while no specific dollar figures (e.g., $16.0B R&D) are mentioned in the LLM answer, none are misstated, and the omission does not detract from correctness as the focus is on strategic evolution rather than financials. The absence of the exact R&D figure is a minor completeness gap but not a factual error. (3) Multi-hop reasoning is sound: the LLM correctly synthesizes the shift from 2023’s R&D context to 2024’s strategic product focus, citing structural changes like the x86/xPU strategic pillar and integration with IDM 2.0/foundry strategy. The reference to an advisory group in the original is not mentioned, but the core idea of ecosystem expansion is captured through 'democratize compute' and ecosystem alignment. (4) Semantic equivalence is strong—wording differs but meaning matches: 'embedded more deeply into strategic priorities' (original) vs. 'elevated to a central strategic pillar' (LLM) convey the same evolution. Contextual relevance is excellent, directly addressing strategic focus and product development priorities across both years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 421,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Netflix's approach to advertising technology evolved between 2023 and 2024, particularly in terms of organizational development and infrastructure investment?",
      "original_answer": "In 2023, Netflix emphasized its limited experience with advertising and outlined several dependencies, particularly on third-party service providers for ad management and the need to attract and retain advertisers. The company also highlighted risks related to developing the necessary advertising technology infrastructure. By 2024, Netflix shifted toward a more proactive stance, emphasizing its ability to 'develop and expand an advertising sales and advertising technology organization team' and 'develop the technology and related infrastructure to support advertising and drive value to advertisers.' This indicates a strategic evolution from reliance on external providers to internal development and investment in ad tech capabilities.",
      "llm_answer": "In the 2023 filing Netflix described its ad business as “new” and noted that it had “limited experience and operating history offering advertising on our service” and that the offering was subject to many risks 【page_9】. By the 2024 filing the company was talking about actively building the capability – it highlighted its “relationship with third‑party service providers for the management, operation, sale and technology to support advertisements,” its “ability to develop and expand an advertising sales organization team,” and its “ability to develop the technology and related infrastructure to support advertising” 【page_10】. Thus, Netflix moved from a nascent, risk‑focused ad offering in 2023 to a more mature strategy that includes a dedicated sales organization and significant infrastructure investment in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original (ground truth) answer. (1) It correctly captures Netflix's 2023 stance of limited experience and reliance on third-party providers, as well as the risks related to ad tech infrastructure. In 2024, it accurately reflects the shift toward internal development of advertising sales teams and technology infrastructure. The key phrases like 'develop and expand an advertising sales organization team' and 'develop the technology and related infrastructure' are correctly cited from the source. (2) There are no numeric values (e.g., dollar amounts, percentages) in the question or ground truth, so quantitative accuracy is not applicable—however, the years 2023 and 2024 are correctly used, and no incorrect dates or figures are introduced. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and two different strategic postures (from risk-focused to proactive investment), correctly identifying the evolution in organizational development and infrastructure. (4) The only minor shortcoming is that the LLM slightly underemphasizes the contrast between external dependency in 2023 and internal capability building in 2024, though the core idea is present. Wording differences (e.g., 'nascent, risk-focused ad offering' vs. original's 'limited experience') are semantically equivalent and acceptable. Overall, the answer is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 407,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Tesla's approach to free Supercharging programs evolved between 2023 and 2024, particularly in terms of revenue recognition and program structure?",
      "original_answer": "In 2023, Tesla's free Supercharging programs were included under Automotive Sales Revenue as part of the revenue associated with new vehicle deliveries, indicating they were bundled with vehicle sales and recognized over time. By 2024, Tesla began deferring revenue related to features such as FSD (Supervised), internet connectivity, and free Supercharging, recognizing these as liabilities to be amortized over time rather than immediately upon vehicle delivery. This structural shift reflects a more formalized and segmented approach to monetizing these features, including free Supercharging, which allows Tesla to better align revenue recognition with service delivery.",
      "llm_answer": "In the 2023 filing Tesla said that unlimited free Supercharging is a “stand‑ready” service that is recognized on a straight‑line basis over the expected ownership life of the vehicle, while any limited free‑Supercharging incentives are recognized when the customer actually uses them or the incentive expires. The 2024 filing keeps the same accounting treatment, but now reports a detailed deferred‑revenue schedule for the free‑Supercharging (and related) services – showing a beginning balance of $3.5 bn, additions of $1.34 bn, revenue recognized of $1.19 bn and an ending balance of $3.6 bn, with $872 m of revenue recognized in 2024 versus $469 m in 2023. Thus, the program structure (unlimited plus limited free‑Supercharging) remains unchanged, but Tesla has moved to more granular deferred‑revenue tracking and larger recognized revenue for the program in 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth does not mention specific deferred revenue balances ($3.5B beginning, $3.6B ending), additions ($1.34B), or recognized revenue amounts ($872M in 2024 vs $469M in 2023). These numbers are entirely absent from the original answer and appear to be fabricated or hallucinated. There is no support in the ground truth for any of these specific figures. (2) The qualitative description partially aligns with the original answer—both note a shift toward deferring revenue and amortizing it over time, which reflects improved tracking and alignment with service delivery. However, the LLM incorrectly states that the 'accounting treatment' remained the same, while the original answer clearly indicates a change in 2024 where Tesla began deferring revenue for features like free Supercharging rather than recognizing it upfront. This contradicts the core claim of continuity. (3) The multi-hop reasoning is partially sound—linking revenue recognition policy to program structure across years—but fails on key synthesis: the original answer emphasizes a structural shift in revenue recognition (from bundled to deferred), while the LLM downplays this change and instead emphasizes continuity with added reporting granularity. (4) Despite incorrect numbers and a mischaracterization of the accounting change, the LLM captures the general direction of more formalized tracking and increasing revenue recognition, which maintains some contextual relevance. However, the hallucinated financial data severely undermines factual correctness, warranting a moderate score of 6 for overall correctness—some core concepts are right, but key facts and calculations are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 485,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has NextEra Energy's approach to issuing Series O Junior Subordinated Debentures evolved between 2023 and 2024, particularly in terms of coupon structure and maturity dates, and what might this shift indicate about their financing strategy?",
      "original_answer": "In 2023, NextEra Energy issued the Series O Junior Subordinated Debentures due on May 1, 2079, with no explicit coupon rate disclosed in the filing. This indicates a potentially fixed or deferred interest structure typical for long-dated junior subordinated instruments. By 2024, the Series O Debentures were issued with a defined coupon rate of 5.55% and a significantly shorter maturity date of November 1, 2029. This represents a strategic shift toward issuing more conventional debt instruments with shorter durations and clearly defined interest costs. This evolution suggests a possible recalibration of NextEra’s capital structure strategy, favoring shorter-term, more predictable financing over long-dated, potentially lower-yielding instruments.",
      "llm_answer": "In the 2023 filing the only Series O referenced is the older **Series O Junior Subordinated Debentures** that mature on **May 1 2079** (a very long‑dated, fixed‑rate instrument)【page_123】. By the 2024 filing NextEra introduced a new **Series O Debenture** that matures on **November 1 2029**, and the exhibit no longer lists a fixed coupon, implying a shift to a shorter‑dated, potentially floating‑rate or lower‑coupon structure【page_122】. This change suggests the company is moving toward shorter‑term, more flexible financing to reduce duration risk and better align debt costs with current market conditions.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key quantitative elements. The 2024 Series O Debentures are stated to have a coupon rate of 5.55% in the ground truth, but the LLM incorrectly claims the exhibit 'no longer lists a fixed coupon' and implies a floating-rate or lower-coupon structure, which contradicts the disclosed 5.55% fixed rate. Additionally, the maturity date for the 2024 issuance is correctly identified as November 1, 2029, which matches the ground truth, but the 2023 maturity date (May 1, 2079) is correct. However, the coupon information for 2023 is misrepresented — while the ground truth notes 'no explicit coupon rate disclosed,' the LLM interprets this as implying a floating or lower-coupon structure, which is speculative and not supported. (2) The dates are accurate, but the coupon details are incorrect in both years: missing in 2023 (should note 'no explicit coupon disclosed') and falsely implied absent in 2024 when 5.55% is explicitly given. This is a critical error in financial characterization. (3) The multi-hop reasoning is partially sound — the model correctly identifies a shift from long-dated to short-dated instruments and infers strategic intent around duration risk. However, the reasoning is undermined by incorrect financial terms (coupon structure), leading to flawed conclusions about 'flexible' or 'floating-rate' design. The ground truth indicates a move to *more conventional, fixed-rate* debt, not less. (4) The contextual relevance is high — the answer addresses the evolution, compares years, and attempts strategic interpretation. Qualitative accuracy is moderate due to correct identification of instruments and maturities but flawed financial interpretation. Quantitative accuracy is low due to incorrect handling of coupon data, which is central to the question. Correctness score reflects partial accuracy with major flaws in key financial facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 523,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has ExxonMobil's consideration of OPEC investment activities evolved in its impairment assessment framework from 2022 to 2023, particularly in relation to long-term oil supply dynamics?",
      "original_answer": "In 2022, ExxonMobil explicitly stated that OPEC investment activities and production policies had an impact on world oil supplies and were considered in the context of impairment assessments. By 2023, while the company still acknowledged OPEC's influence on global oil supply, the discussion of OPEC was embedded more broadly within a comprehensive cash flow assessment framework that included forward-looking variables such as greenhouse gas emission costs and net-zero targets. This indicates a shift from a direct focus on OPEC's role to a more integrated view of macroeconomic and environmental factors affecting long-term asset valuation.",
      "llm_answer": "In the 2022 filing, ExxonMobil first noted that “OPEC investment activities and production policies also have an impact on world oil supplies” and that this factor is part of the long‑term supply‑side assumptions used when testing assets for impairment. The 2023 filing repeats the same language, showing that the company continues to treat OPEC’s investment and production decisions as a key input to its long‑term oil‑supply outlook and related impairment assessments, with no substantive change in how it is incorporated.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that ExxonMobil's treatment of OPEC in its impairment assessment remained unchanged from 2022 to 2023. The ground truth states that while OPEC was explicitly discussed in 2022 as a direct factor in impairment assessments, by 2023 the discussion was embedded within a broader, more integrated framework that included forward-looking environmental and macroeconomic variables such as greenhouse gas costs and net-zero targets—indicating an evolution in the assessment approach. The LLM incorrectly asserts that the 'same language' is repeated in 2023 and that there is 'no substantive change,' which contradicts the ground truth. There are no numerical values in the question or answers, so quantitative accuracy is not applicable in a traditional sense, but the dates (2022 and 2023) are correctly referenced, warranting full marks there. However, the qualitative accuracy is low because the model fails to capture the shift in reasoning and synthesis across years, misrepresenting the evolution of ExxonMobil’s framework. Contextual relevance is moderate because the answer addresses the right topic and documents but draws the wrong conclusion about change over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 342,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Netflix's approach to its ad-supported subscription plan evolved from 2023 to 2024, based on the level of detail and strategic emphasis provided in the filings?",
      "original_answer": "In 2023, Netflix's ad-supported subscription plan was mentioned in the context of uncertainty and risk, particularly around consumer adoption and the lack of operating history with such offerings, which could lead to discrepancies between forecasts and actual results. By 2024, the ad-supported plan was presented as part of the company's broader pricing strategy, explicitly included in the description of plans offered to meet a variety of consumer needs. This shift indicates a move from a risk-focused perspective to a more confident, strategic positioning of the ad-supported plan as a core part of Netflix's business model.",
      "llm_answer": "In the 2023 filing Netflix merely flagged the ad‑supported tier as a “pricing strategy” with little operating history, stressing the difficulty of forecasting consumer adoption and its impact on revenue. By the 2024 filing the ad‑supported plan is presented as a core element of Netflix’s pricing portfolio—explicitly called out in the business overview and forward‑looking statements—showing far more detail and strategic emphasis on its rollout.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in Netflix's approach from 2023 to 2024: in 2023, the ad-supported tier was mentioned with uncertainty around forecasting and limited operating history, and by 2024, it was positioned as a core part of the pricing strategy. The key themes of increased strategic emphasis, inclusion in forward-looking statements, and business overview are consistent with the original answer. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly inferring a shift in tone and strategic positioning. The only minor shortcoming is that the LLM does not explicitly mention the 'risk-focused perspective' language from 2023 or the intent to meet 'a variety of consumer needs' as stated in the original, which slightly reduces qualitative completeness. However, the essence—that the plan moved from uncertain experiment to strategic offering—is preserved. (4) The answer is fully contextually relevant, directly addressing how the level of detail and strategic emphasis evolved over time. Overall, this is a semantically equivalent, well-reasoned response with only negligible omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 382,
        "total_tokens": 1656
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Amazon's approach to shipping offers evolved between 2022 and 2024, particularly in terms of cost drivers and strategic focus on fulfillment efficiency?",
      "original_answer": "In 2022, Amazon highlighted that shipping costs were expected to increase as customers increasingly adopted its shipping offers, used faster delivery methods, and as the company expanded its fulfillment network. Shipping costs in 2021 were $76.7 billion, and the company anticipated continued growth in these costs. The strategic emphasis was on mitigating these increases through higher sales volumes, network optimization, supplier negotiations, and operational efficiencies. By 2024, the focus had shifted: while the company still invested in expanding its fulfillment network, it emphasized fulfillment network efficiencies as a key cost offset. The 2024 report notes that increased sales and network investments drove up fulfillment costs, but these were partially offset by efficiency gains. This marks a strategic evolution from a customer-driven cost increase in 2022 to a more operations-centric efficiency focus by 2024.",
      "llm_answer": "Amazon’s shipping offers remained a core price‑and‑convenience lever, but the cost story shifted from 2022 to 2024. In 2022 the company warned that higher carrier rates, wage incentives and fulfillment‑network inefficiencies were driving rising shipping and fulfillment costs, and it focused on offsetting those pressures with higher sales volumes, better supplier terms and operational efficiencies (2022 p.23‑25). By 2024, although shipping costs continued to grow as customers used faster, more expensive delivery options, Amazon emphasized that expanded fulfillment‑network capacity and lower transportation costs were partially offsetting the cost increase, reflecting a strategic pivot toward scaling and optimizing fulfillment efficiency while still leveraging shipping offers to drive sales (2024 p.24‑27).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: the 2022 context correctly identifies rising shipping and fulfillment costs due to carrier rates, wage incentives, and network inefficiencies, with mitigation strategies including higher sales volumes, supplier negotiations, and operational efficiencies—consistent with the original answer’s emphasis. By 2024, the shift toward fulfillment network expansion and efficiency gains as a cost offset is accurately portrayed. (2) Quantitative accuracy is perfect: while the LLM does not repeat the $76.7 billion figure from 2021 mentioned in the original answer, it does not make any numerical claims that contradict the ground truth, and no incorrect figures are introduced. The absence of the specific dollar amount is a minor omission but does not detract from correctness since the trend (rising costs) is properly conveyed. (3) Multi-hop reasoning is sound—the model synthesizes information across 2022 and 2024 timeframes, correctly identifying the evolution from customer-driven cost increases to operations-focused efficiency gains. The strategic pivot is logically inferred and well-articulated. (4) Semantic equivalence is strong: the LLM uses slightly different phrasing (e.g., 'lower transportation costs' instead of 'network investments'), but the meaning remains consistent with the original. The citation of page numbers (2022 p.23–25, 2024 p.24–27) suggests document grounding, enhancing credibility. The only reason for not scoring a 10 is the omission of the specific $76.7 billion shipping cost figure from 2021, which was part of the original context, though it is not strictly required for answering the evolution question. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 502,
        "total_tokens": 1941
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did Duke Energy's utilization and reporting of the Master Retirement Trust evolve between 2023 and 2024, particularly in terms of asset allocation and disclosure practices?",
      "original_answer": "In 2023, Duke Energy's Master Retirement Trust was described in terms of its investment objective, focusing on achieving sufficient returns for plan benefits, with specific mention of VEBA trusts and their target and actual asset allocations. By 2024, the reporting evolved to include a more detailed breakdown of how different subsidiaries were allocated portions of the trust, such as Duke Energy Progress at 15% and Duke Energy Florida at 18%. Additionally, 2024 introduced a reconciliation of beginning and ending balances for pension and post-retirement assets, including Level 3 fair value disclosures, which was not present in 2023. This reflects a shift toward more granular and transparent reporting on trust assets and their valuation methodologies.",
      "llm_answer": "In 2023 Duke Energy’s Master Retirement Trust continued to hold roughly 98 % of its assets for qualified pension plans and 2 % for other post‑retirement benefits, with target allocations of 45 % global equity, 35 % debt, 7 % real‑estate/cash for the RCBP assets and 14 % equity, 80 % debt for the DELPP assets; actual holdings were essentially on target (e.g., 45 % equity, 35 % debt for RCBP and 14 % equity, 79 % debt for DELPP) and VEBA trusts were heavily weighted to debt and cash (30 % debt, 18 % cash) (pages 217‑218, 219). By 2024 the trust still served the same plan mix, but the actual mix shifted – RCBP equity fell to 44 % (with private‑equity 1 %), real‑estate/cash rose to 10 % and hedge‑funds to 5 %; DELPP equity rose to 15 % and cash to 4 %, while VEBA trusts moved to 34 % U.S. equity and 13 % cash (pages 226‑227, 227). The 2024 filing added more granular target‑vs‑actual tables for each asset class, a detailed fair‑value hierarchy discussion, a Level‑3 reconciliation and a note that securities‑lending was discontinued, expanding the depth of disclosure compared with the 2023 filing.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer provides a detailed and largely accurate comparison of Duke Energy's Master Retirement Trust reporting between 2023 and 2024, with strong contextual relevance and correct entity identification. However, there are significant quantitative inaccuracies that reduce confidence in the numerical precision. The ground truth does not mention specific percentages like 98% for qualified pension plans or 2% for other benefits, nor does it specify target allocations (e.g., 45% global equity, 35% debt) for RCBP and DELPP plans in 2023—these figures are absent from the original answer. Similarly, the 2024 shifts in asset allocations (e.g., RCBP equity falling to 44%, private equity at 1%, hedge funds at 5%) are not present in the ground truth, which instead emphasizes structural changes in disclosure such as subsidiary-level allocations (e.g., Duke Energy Progress at 15%, Duke Energy Florida at 18%) and the introduction of Level 3 fair value reconciliations. These specific subsidiary allocations are entirely missing from the LLM response. While the LLM correctly identifies increased granularity and enhanced disclosures in 2024—including fair value hierarchy and Level 3 reconciliation—its focus on granular asset class shifts appears to hallucinate detailed percentages not supported by the ground truth. The qualitative reasoning is sound in identifying a trend toward more transparent and detailed reporting, and the multi-hop synthesis across years is appropriate. Contextual relevance is excellent, as the response directly addresses evolution in utilization and disclosure practices. However, due to unsupported numerical claims, the quantitative accuracy is moderate, pulling down the overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1474,
        "completion_tokens": 470,
        "total_tokens": 1944
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has Google's financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of the cost structure and payment obligations?",
      "original_answer": "In 2022, Google's cost of revenues included significant Traffic Acquisition Costs (TAC) paid to Google Network partners, primarily for ads displayed on their properties, with a noted higher cost percentage compared to Google Search properties due to the substantial share of advertiser revenues paid out as TAC. By 2024, Google Network partners were referenced in the context of operating cash outflows, indicating that payments to these partners had become a primary use of operating cash. This shift suggests a transformation in the nature of the financial relationship, from a cost-of-revenue model to a more direct operational cash flow obligation, reflecting a potential increase in the scale or structure of Google's dependency on these partners.",
      "llm_answer": "In the 2022 filing, Google’s cost of revenues was split into Traffic‑Acquisition Costs (TAC), which “include amounts paid to Google Network partners primarily for ads displayed on their properties” and caused the cost‑of‑revenues margin on network‑ad sales to be “significantly higher” than on search ads (see 2022 p. 32). By 2024 the same TAC component remains, and the 10‑K now lists “payments to distribution and Google Network partners” as one of the primary cash outflows from operating activities, noting that TAC costs rose alongside higher network‑ad revenue (see 2024 p. 42 and 2024 p. 41), indicating that the payment obligations to network partners have stayed substantial and grown with the business.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, Traffic Acquisition Costs (TAC) were a component of cost of revenues, specifically paid to Google Network partners for ad placements, and notes the higher cost margin compared to search ads—this matches the original answer’s emphasis on TAC as a significant cost with a higher percentage for network properties. (2) For 2024, the LLM correctly observes that TAC payments are now highlighted as a primary operating cash outflow, citing rising TAC alongside increased network-ad revenue, which reflects the shift toward operational cash flow obligations described in the ground truth. (3) All entities—Google, Google Network partners, TAC, cost of revenues, operating cash outflows—are accurately identified and correctly contextualized across both years. (4) The reasoning is sound: the LLM synthesizes information across two years and two financial statements (income statement in 2022, cash flow statement in 2024), demonstrating multi-hop understanding. The only minor shortcoming is that it does not explicitly frame the evolution as a 'transformation in the nature of the financial relationship' or use the phrase 'dependency,' which slightly weakens the qualitative synthesis compared to the original’s interpretive depth. However, the factual and conceptual core is preserved. (5) No numeric inaccuracies: while exact dollar amounts aren't cited, the trends (TAC rising with network-ad revenue) are correctly reported and consistent with the source. Wording differences are acceptable under semantic equivalence. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 466,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the treatment and financial impact of offsetting swap positions evolve between 2022 and 2023, particularly in terms of fair value changes and settlements reported in the consolidated income?",
      "original_answer": "In 2022, UPS reported fair value changes and settlements of interest rate swaps, foreign currency exchange forwards, and investment market price forward contracts not designated as hedges, with specific figures for 2021 and 2020 provided (e.g., $163M net gain in 2021 and $124M net gain in 2020). In 2023, the company continued to report these derivatives at fair value with unrealized gains and losses in earnings, but the disclosure now included data for 2023 and 2022, showing a shift in focus to more recent periods. The explicit mention of terminating contracts or entering into offsetting swap positions remained consistent, but the financial impact in 2023 was not quantified in the excerpt, indicating a change in transparency around current-year derivative impacts.",
      "llm_answer": "UPS treats offsetting swap and forward contracts that are no longer designated as hedges as “non‑designated” derivatives, recording their fair‑value changes and settlement results directly in the statement of consolidated income (shown under investment income and other). In 2022 the company recognized a $69 million loss from these positions, while in 2023 the loss was only $7 million, indicating a much smaller adverse impact from offsetting swaps and forwards 【page_132】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative Accuracy: The LLM claims UPS recognized a $69 million loss in 2022 and a $7 million loss in 2023 from non-designated derivatives. However, the ground truth states that specific figures were provided for 2021 ($163M net gain) and 2020 ($124M net gain), but does not quantify the 2023 financial impact, noting a lack of transparency in current-year reporting. The $69M loss in 2022 and $7M loss in 2023 are not supported by the original answer and contradict the explicit statement that 2023 impacts were not quantified. (2) Completeness: The LLM fails to capture the key point about the evolution in disclosure focus—shifting from older years (2020, 2021) in 2022 to including 2023 and 2022 in 2023—but instead invents precise loss figures not present in the source. It omits the critical observation that 2023 data was not quantified, which is central to the original answer’s conclusion about reduced transparency. (3) Entity Accuracy: While the company (UPS) and derivative types (swaps, forwards) are correctly identified, the financial metrics (losses in 2022 and 2023) are incorrect. (4) Reasoning: The multi-hop synthesis is flawed—the original answer emphasizes a change in reporting transparency, not a quantifiable reduction in losses. The LLM incorrectly infers a favorable trend based on fabricated numbers rather than analyzing disclosure practices. (5) Semantic Equivalence: The LLM’s answer is not semantically equivalent; it replaces a nuanced discussion of disclosure evolution with a false quantitative comparison. The mention of accounting treatment (fair value through income) is correct but insufficient to offset major factual errors. Thus, the correctness score is low due to invented figures and failure to reflect the actual analytical point of the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 509,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "What does the increased prominence of the Directors' Savings Plan in Duke Energy's 2024 disclosures indicate about the company's director compensation strategy compared to 2023?",
      "original_answer": "In 2023, the Directors' Savings Plan was referenced primarily through historical amendments listed in exhibit references (e.g., Exhibit 10.12), with no detailed description of its structure or strategic role in compensation. In contrast, the 2024 filing provides a substantive description of the plan, explaining how outside directors may defer annual compensation, the phantom investment options available, and how balances are adjusted accordingly. This increased prominence indicates a shift toward emphasizing the plan as a core component of director compensation and deferral flexibility, suggesting a more strategic and transparent approach to director-level financial incentives in 2024.",
      "llm_answer": "The 2024 filing places the Directors’ Savings Plan front‑and‑center in its equity‑compensation section—listing it in the plan‑summary table and describing how outside directors can defer retainers into an unfunded, performance‑linked account that is paid out when their term ends【page_239】—whereas the 2023 filing only mentioned the plan in an amendment footnote among many exhibits【page_245】. This heightened visibility signals that Duke Energy is leaning more heavily on a deferred‑compensation, performance‑based structure for its directors in 2024 than it did in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) It correctly identifies that in 2023, the Directors' Savings Plan was only mentioned in a footnote (specifically an amendment among exhibits, as in the original), while in 2024 it received a detailed description, including deferral of retainers and payout timing. The mention of 'performance-linked account' aligns with the phantom investment options and balance adjustments in the original. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2023 vs 2024) are correct. (3) The multi-hop reasoning is sound: the model correctly contrasts the treatment of the plan across two years and infers a strategic shift toward deferred, performance-based compensation. The conclusion about increased strategic emphasis is logically supported. (4) The only minor gap is that the LLM answer does not explicitly mention 'transparency' as a dimension of the strategic shift, which is noted in the original. However, 'front-and-center' and detailed description imply increased transparency. Wording differs slightly (e.g., 'unfunded, performance-linked account' vs 'phantom investment options'), but these are semantically equivalent in the context of non-qualified deferred compensation plans. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 399,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has American Express's approach to developing value propositions evolved between 2022 and 2024, particularly in response to competitive pressures and changing customer behaviors?",
      "original_answer": "In 2022, American Express highlighted the challenge of developing compelling value propositions in the face of growing competition, particularly from alternative payment providers and digital wallets, which threatened to fragment customer spending and reduce the competitiveness of its offerings. The company emphasized the need to evolve its value propositions to retain relevance and attract customers amid rising Card Member rewards costs and shifting consumer preferences, especially in mobile and online payments. By 2024, the company's strategy had evolved to focus on expanding leadership in premium consumer and commercial payments, particularly targeting Millennial and Gen-Z consumers, and enhancing digital capabilities through investments in AI, automation, and the Amex app. It also emphasized the importance of strategic partnerships, dining platform expansion (including Tock and Rooam), and global merchant coverage growth as key enablers of its value proposition strategy. This represents a shift from a reactive stance on competition to a more proactive, innovation-driven approach.",
      "llm_answer": "In the 2022 filing American Express warned that “if we are not able to differentiate ourselves from our competitors, develop compelling value propositions for our customers… we may not be able to compete effectively” and that rising competition and the shift toward alternative payment methods were already forcing the company to evolve those propositions, even at the cost of higher rewards and service expenses【page_26】. By the 2024 filing the tone has shifted to a proactive, growth‑focused plan: the firm now emphasizes expanding its premium consumer leadership (especially with Millennials and Gen‑Z), launching new benefits and digital‑channel experiences, leveraging data, AI and strategic partnerships (e.g., dining, B2B) to build a multiproduct ecosystem, and explicitly tying these initiatives to “develop and market new benefits and value propositions that appeal to Card Members” in response to competitive pressure and changing customer behavior【page_93】【page_92】. This reflects a move from a defensive, risk‑focused stance in 2022 to an aggressive, innovation‑driven strategy in 2024 for shaping value propositions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original ground truth. (1) All factual elements are correct: the 2022 context highlights competitive pressures from alternative payment providers and rising rewards costs, and the 2024 evolution reflects a proactive strategy centered on premium positioning, digital innovation, and strategic partnerships. The mention of Millennials and Gen-Z, AI, data, digital channels, and ecosystem development matches the original. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or answers, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes information across 2022 and 2024 filings, identifying a shift in tone and strategy from defensive/reactive to proactive/innovation-driven. It accurately captures the evolution in value proposition development in response to competition and customer behavior. (4) Semantic equivalence is strong—wording differs slightly but meaning is preserved. The only minor gap is that the LLM omits specific examples like Tock and Rooam mentioned in the original, though it correctly references 'dining' partnerships. This small omission prevents a perfect 10 on qualitative accuracy, but overall the answer is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1566,
        "completion_tokens": 378,
        "total_tokens": 1944
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Exxon Mobil's approach to long-term debt financing evolved between 2022 and 2024, particularly regarding the composition of its long-term notes?",
      "original_answer": "In 2022, Exxon Mobil disclosed a broader range of debt instruments, including the 0.142% Notes due 2024, 0.524% Notes due 2028, 0.835% Notes due 2032, and the 1.408% Notes due 2039. By 2024, the company no longer listed the 0.142% Notes due 2024, indicating that those obligations had matured or been repaid. However, the 1.408% Notes due 2039 remained in the disclosure, suggesting a continued emphasis on long-term financing instruments with distant maturity dates. This shift reflects a strategic evolution in the company's capital structure, focusing more heavily on extended-term debt while retiring shorter-duration obligations.",
      "llm_answer": "In the 2022 Form 10‑K Exxon Mobil listed four outstanding senior notes – a 0.142 % note due 2024 together with notes due 2028, 2032 and 2039 – showing a mix of very short‑term, ultra‑low‑coupon debt and longer‑dated issues【page_1】. By the 2024 filing the 0.142 % note had disappeared, leaving only the 0.524 % (2028), 0.835 % (2032) and 1.408 % (2039) notes, indicating the company retired the short‑dated, low‑rate instrument and is now relying on a longer‑maturity debt profile【page_1】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All numeric values—interest rates (0.142%, 0.524%, 0.835%, 1.408%) and maturity years (2024, 2028, 2032, 2039)—are correctly reported, matching the original answer exactly. The disappearance of the 0.142% Note due 2024 in the 2024 filing is accurately noted, indicating proper retirement or maturity. (2) The composition of long-term notes is correctly summarized for both years, with precise attribution to the respective Form 10-K filings. No calculation errors are present. (3) The multi-hop reasoning—comparing debt disclosures across 2022 and 2024 to infer a strategic shift toward longer-term debt—is sound and well-supported. The conclusion that Exxon Mobil is moving toward a longer-maturity debt profile is logically derived and consistent with the evidence. (4) The only minor shortcoming is that the LLM does not explicitly state that the continued presence of the 1.408% Notes due 2039 'suggests a continued emphasis on long-term financing,' a nuance present in the original answer. However, the implication is clearly conveyed through the observation of retiring short-term debt. Wording differs slightly (e.g., 'ultra-low-coupon', 'very short-term') but adds interpretive context without distorting facts. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 389,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has American Express's approach to corporate card solutions evolved between 2022 and 2024, particularly in terms of strategic emphasis and product differentiation?",
      "original_answer": "In 2022, American Express emphasized evolving card value propositions and differentiating corporate card and accounts payable expense management solutions as part of its broader commercial payments strategy. By 2024, the company continued to focus on commercial payments but introduced a more integrated global network approach, aiming to increase merchant acceptance and provide enhanced fraud protection and marketing insights. This shift indicates a move from internal product development focus in 2022 to a more externally integrated ecosystem strategy by 2024.",
      "llm_answer": "American Express has kept corporate cards at the core of its commercial‑payments pillar, stating that it will “evolve our card value propositions, further differentiate our corporate card and accounts‑payable expense‑management solutions and design innovative products and features” (2022 10‑K p. 8). By 2024 the company repeats that language but adds a clearer focus on financing, banking and broader payment‑solution innovations, signaling a deeper push to differentiate the corporate‑card suite with integrated financial‑service features (2024 10‑K p. 8).",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its use of direct quotes and correctly identifies American Express's continued emphasis on corporate card solutions from 2022 to 2024. It accurately reflects the strategic continuity in evolving value propositions and differentiating corporate card and expense management solutions, citing the correct document pages (2022 and 2024 10-K, p. 8). There are no numeric inaccuracies, so quantitative accuracy is perfect. However, the LLM answer misses a key evolution highlighted in the ground truth: the shift toward an integrated global network strategy focused on increasing merchant acceptance and delivering fraud protection and marketing insights in 2024. Instead, it emphasizes 'financing, banking and broader payment-solution innovations' and 'integrated financial-service features,' which, while plausible, are not explicitly supported in the ground truth. This represents a deviation in qualitative accuracy—the reasoning captures continuity but not the correct directional shift in strategy (from internal product development to external ecosystem integration). The answer remains contextually relevant and addresses the core of the question, but lacks full completeness in capturing the 2024 strategic evolution as defined in the original answer. Thus, while the core facts are correct, the synthesis across years is partially incomplete, warranting a 7 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 397,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Amazon's financial relationship with AWS Services evolved between 2022 and 2024, particularly in terms of cash flow generation and strategic emphasis?",
      "original_answer": "In 2022, AWS Services were primarily discussed in the context of competitive pressures and risks, with an emphasis on the challenges of operating in a rapidly evolving and intensely competitive market. By 2024, AWS had transitioned into a key financial contributor, with Amazon reporting $115.9 billion in operating cash flow for that year, up from $84.9 billion in 2023, driven in part by AWS and other enterprise services. This reflects a shift from viewing AWS as a risk-laden venture to a core revenue generator funding broader corporate initiatives.",
      "llm_answer": "In the 2022 filing Amazon already treated AWS as a distinct, strategically‑important business – it listed Adam Selipsky as CEO of Amazon Web Services (page 5) and discussed cloud‑service competition (pages 6‑7) – but gave little quantitative detail on the cash it generated. By the 2024 filing AWS accounted for 17 % of total net sales, growing to $107.6 billion (a 19 % YoY increase) (page 24), and the rise in operating cash flow to $115.9 billion (page 22) was largely driven by that segment, while the MD&A stresses continued heavy capital spending on AWS technology infrastructure as a core growth engine (page 21). This shows a shift from emphasizing AWS’s strategic leadership to relying on it as a major cash‑flow contributor and focal point of ongoing investment.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the LLM correctly states that AWS generated $107.6 billion in revenue in 2024 (19% YoY increase) and that operating cash flow reached $115.9 billion in 2024 — consistent with the ground truth, which confirms $115.9B in 2024 OCF and $84.9B in 2023. While the ground truth does not specify AWS's exact revenue, the $107.6B figure for AWS in 2024 is plausible and contextually supported. The 17% of total net sales attribution is additional but reasonable detail. (2) The LLM slightly misattributes the $115.9B operating cash flow as being solely driven by AWS, whereas the ground truth states it was 'driven in part by AWS and other enterprise services' — a minor overstatement but not factually incorrect given AWS's major role. (3) Qualitatively, the reasoning is sound: it captures the evolution from 2022 (strategic emphasis, competition, leadership) to 2024 (cash generation, infrastructure investment), correctly identifying the shift in narrative and strategic role. (4) Contextual relevance is excellent — the answer directly addresses cash flow generation and strategic emphasis across 2022–2024, synthesizing multi-hop information from different sections and years of the filings. The only minor issue is the lack of explicit mention of 2022 cash flow figures (none were provided in original either), and the answer implies AWS was not quantitatively detailed in 2022, which is accurate. Overall, the answer is factually strong, well-reasoned, and semantically equivalent to the ground truth with only slight nuance differences.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 443,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did the scope or focus of trend analyses used in evaluating the historical consistency of regulatory asset balances evolve between 2023 and 2024?",
      "original_answer": "In 2023, trend analyses were used to evaluate the historical consistency of regulatory asset balances in general, without specific reference to asset retirement obligations. By 2024, the scope of the trend analyses remained focused on regulatory asset balances, but the audit procedures expanded to include a specific evaluation of the ongoing regulatory recoverability of asset retirement obligations related to coal ash, indicating a shift in focus toward more specialized regulatory compliance areas.",
      "llm_answer": "In the 2023 filing the auditors noted that they “utilized trend analyses to evaluate the historical consistency of regulatory asset balances” for the **Florida subsidiary only**, using the analysis simply to test that the subsidiary’s regulatory‑asset balances were consistent with prior periods. By the 2024 filing the same language appears, but the trend‑analysis step is now part of a **consolidated‑company audit** and is coupled with broader inquiries into recent regulatory orders, coal‑ash retirement obligations and storm‑ and fuel‑cost recoverability, indicating that the focus of the trend analysis was broadened from a single subsidiary to the entire company’s regulatory‑asset portfolio.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that deviate from the ground truth, despite using plausible financial auditing language. (1) The original answer does not mention the Florida subsidiary or any subsidiary-specific focus in 2023, nor does it indicate that the 2024 audit became consolidated; these are fabrications not present in the ground truth. (2) The ground truth states that the scope of trend analyses remained on regulatory asset balances, but in 2024 expanded to include evaluation of the recoverability of asset retirement obligations related to coal ash. The LLM incorrectly frames this as a shift from a subsidiary to a consolidated audit and adds unmentioned elements like 'storm- and fuel-cost recoverability', which are not in the original. (3) The multi-hop reasoning is flawed: the evolution described should focus on a change in analytical depth (general consistency → specific recoverability of coal ash obligations), not a change in audit scope (subsidiary → consolidated). (4) While the years (2023, 2024) and general topic (trend analyses of regulatory assets) are correct, the core evolution in focus is misrepresented. There are no numerical values, so quantitative accuracy is scored as 10 by default. The answer is contextually relevant but conveys a different and incorrect narrative about how the trend analysis evolved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 377,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did Costco's strategy regarding the penetration of private-label items evolve between 2022 and 2023 in response to cost and pricing pressures?",
      "original_answer": "In 2022, Costco responded to higher-than-recent inflation in merchandise costs by employing several strategies, including absorbing some cost increases internally, purchasing earlier and in larger volumes, and selectively passing on cost increases to members, all of which were aimed at maintaining pricing authority while managing gross margin pressures. In 2023, Costco continued to emphasize increasing the penetration of its private-label items as part of its broader merchandising and pricing strategy to adapt to ongoing cost increases and competitive pressures. This indicates a shift from a more reactive approach in 2022 to a more strategic and sustained emphasis on private-label offerings in 2023 to maintain competitive pricing and member value.",
      "llm_answer": "Costco said that the higher‑inflation environment in 2022 led it to “adjust … our pricing and merchandise mix, including increasing the penetration of our private‑label items” as a way to offset cost pressures【page_22】.  In the 2023 filing the company reiterated the same tactic – noting that its “merchandising and pricing strategies in response to cost increases” continue to rely on “increasing the penetration of our private‑label items” to protect margins and keep prices competitive【page_23】.  Thus, the strategy of expanding private‑label share was introduced in 2022 and was maintained (and emphasized) in 2023 as a core response to ongoing cost and pricing pressures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. (1) It correctly identifies that Costco began increasing private-label penetration in 2022 as a response to inflation and continued this strategy in 2023, which matches the original answer's timeline and intent. (2) There are no numeric values (e.g., percentages, dollar amounts) in either the question or ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across 2022 and 2023 filings to show evolution in strategy, correctly characterizing the shift from a reactive to a sustained strategic emphasis. The only minor shortcoming is that the LLM slightly downplays the broader 2022 tactics (e.g., absorbing costs, bulk purchasing) mentioned in the original answer, focusing narrowly on private-label expansion, which was introduced but not the sole strategy. However, the core evolution—increasing private-label penetration as a continued and emphasized strategy—is accurately conveyed. (4) The answer is highly contextually relevant, directly addressing how the strategy evolved in response to cost and pricing pressures. Wording differs but semantic meaning matches. Thus, the correctness score is 9 due to slight incompleteness in covering all 2022 strategies, but not enough to detract from the accurate portrayal of the central evolution in private-label strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 397,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the financial outlook for Paxlovid evolved between 2023 and 2024 based on Pfizer's remaining performance obligations?",
      "original_answer": "In 2023, Pfizer did not disclose specific remaining performance obligations for Paxlovid. However, by the end of 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a clear financial commitment from customers for future delivery of the product. This evolution suggests increased contractual certainty and forward-looking revenue expectations for Paxlovid between the two years.",
      "llm_answer": "Pfizer’s 2024 Form 10‑K says the remaining performance‑obligation balance for Paxlovid is about **$1 billion** (page 109). By contrast, at the end of 2023 the company carried **$5.1 billion of deferred revenue for Paxlovid and Comirnaty combined**—$2.6 billion in current liabilities and $2.5 billion in non‑current liabilities (page 110)—indicating that the future revenue pipeline for Paxlovid has contracted sharply from 2023 to 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and reasoning errors despite referencing correct document sources. (1) QUANTITATIVE INACCURACY: The claim that Pfizer had $5.1 billion in deferred revenue for Paxlovid and Comirnaty combined at the end of 2023 is not supported by the ground truth, which states that Pfizer did not disclose specific remaining performance obligations (RPOs) for Paxlovid in 2023. The $5.1 billion figure may exist in the 10-K but is not attributable solely or specifically to Paxlovid’s future performance obligations, making the comparison invalid. The 2024 RPO of $1 billion is correctly cited. (2) COMPLETENESS: The answer fails to reflect the actual evolution described in the ground truth—increased contractual certainty from 2023 to 2024—instead asserting a 'sharp contraction' in revenue pipeline, which contradicts the ground truth. (3) ENTITY & METRIC CONFUSION: The LLM conflates 'deferred revenue' (a balance sheet liability) with 'remaining performance obligations' (a forward-looking revenue metric), which are related but not interchangeable without proper context. It also combines Paxlovid with Comirnaty without evidence that the deferred revenue split is known. (4) REASONING FAILURE: The conclusion that the revenue pipeline 'contracted sharply' is logically flawed because there is no disclosed Paxlovid-specific RPO for 2023 to compare against the 2024 $1 billion figure. The ground truth emphasizes the emergence of a clear $1 billion obligation in 2024 where none was previously specified, indicating improved visibility, not a decline. (5) SEMANTIC NON-EQUIVALENCE: The LLM's interpretation directly contradicts the ground truth's meaning. While it cites correct document pages and some numbers, the synthesis and conclusion are factually incorrect. Minor credit is given for correctly identifying the $1 billion 2024 RPO and referencing the appropriate filing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 513,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has American Express's use and assumptions around the Reasonable and Supportable (R&S) Period evolved between 2022 and 2024 in estimating credit loss reserves, and what does this indicate about the company's approach to financial risk management?",
      "original_answer": "In 2022, American Express explicitly described its use of the R&S Period as a key component in estimating reserves for credit losses on Card Member loans, incorporating historical loss experience and current/future economic conditions over that period. The reserves stood at $3.3 billion as of December 31, 2021, and the R&S Period was a central assumption in modeling expected credit losses. By 2024, while the R&S Period was still referenced, it was no longer introduced as a newly explained concept and instead appeared embedded within a more mature and established process, indicating it had become a standard part of the company's financial risk modeling framework. This evolution suggests a shift from introducing the methodology (2022) to relying on it as a foundational element in credit loss estimation (2024).",
      "llm_answer": "In the 2022 10‑K (see page 95) American Express explained that it projects lifetime expected credit losses over a “reasonable and supportable” period (the R&S Period) by blending historical loss experience with current and future economic conditions, and that losses beyond that horizon are estimated by reverting to long‑term average loss rates. The 2024 filing (see page 97) repeats the same methodology and assumptions for the R&S Period, showing no material change in how the period is defined or applied. This continuity signals a disciplined, forward‑looking risk‑management framework that relies on consistent, judgment‑driven modeling to capture credit risk over a supportable horizon.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in describing American Express's use of the Reasonable and Supportable (R&S) Period in both 2022 and 2024, with correct references to the methodology involving historical loss experience, current and future economic conditions, and reversion to long-term averages beyond the R&S Period. All entities (American Express, R&S Period, credit loss reserves) and years (2022, 2024) are correctly identified, and there are no numerical inaccuracies—though no specific dollar amounts (e.g., $3.3 billion as of December 31, 2021) are mentioned, which were present in the original answer. The LLM correctly notes continuity in the methodology between 2022 and 2024, but misses a key qualitative evolution emphasized in the ground truth: in 2022, the R&S Period was presented as a newly highlighted or explicitly explained concept, while by 2024 it had become an embedded, standard part of the framework—indicating maturation in risk management practice. The LLM interprets this as 'no material change' and emphasizes consistency, which is not incorrect, but fails to capture the shift in presentation and integration that signifies institutionalization of the approach. This omission affects the depth of the qualitative analysis and the multi-hop synthesis of how the *role* of the R&S Period evolved, even if the technical application remained stable. Thus, while the answer is contextually relevant and quantitatively sound, it lacks full completeness in capturing the conceptual evolution described in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 424,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Amazon's approach to debt financing evolved between 2022 and 2024, particularly with respect to the 0.800% Note due 2025?",
      "original_answer": "In 2022, Amazon's filings referenced the 0.800% Note due 2025 as part of its broader debt structure, originally introduced in the Officers' Certificate dated June 3, 2020. By 2024, Amazon not only continued to reference the 0.800% Note due 2025 in its filings but also introduced new debt instruments with different interest rates and maturity dates, such as the 4.600% Note due 2025. This indicates a shift in Amazon's debt financing strategy, incorporating a wider range of interest rates and maturities to potentially manage cash flow and interest rate risk more effectively.",
      "llm_answer": "In the 2022 Form 10‑K, Amazon’s low‑cost debt program is reflected by the 0.800 % Note due 2025 listed in the Officers’ Certificate dated June 3 2020 (Exhibit 4.5) 【page_73】. By the 2024 Form 10‑K, the same 0.800 % Note still appears (Exhibit 4.6) 【page_75】, but the company has added a newer Officers’ Certificate dated December 1 2022 that includes a 4.600 % Note due 2025 (Exhibit 4.8) 【page_75】. This shows Amazon’s debt strategy has broadened from relying on ultra‑low‑interest notes to issuing higher‑coupon notes while still retaining the original low‑rate issue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 0.800% Note due 2025 is correctly referenced in both 2022 and 2024 filings, originating from the Officers’ Certificate dated June 3, 2020, and the new 4.600% Note due 2025 is tied to a December 1, 2022 Officers’ Certificate. These dates, percentages, and exhibit numbers (Exhibit 4.5, 4.6, 4.8) are factually consistent with the knowledge graph. (2) Quantitative accuracy is perfect: interest rates (0.800%, 4.600%), maturity year (2025), and dates (June 3, 2020; December 1, 2022) are all correct. (3) Multi-hop reasoning is sound—LLM correctly synthesizes data across 2022 and 2024 filings, identifies continuity of the low-rate note, and observes the addition of a higher-rate instrument, indicating an evolution in strategy. (4) The answer captures the core conclusion of the original answer—Amazon has broadened its debt financing strategy—though it uses slightly more interpretive language (e.g., 'ultra-low-interest', 'higher-coupon') which is reasonable but not in the original. Minor deduction in qualitative accuracy for slight editorialization, but overall reasoning and synthesis are strong. Contextual relevance is excellent as it directly addresses Amazon’s debt evolution with respect to the specified note.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 369,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the treatment or disclosure of the Twenty-third Supplemental Indenture evolved between the 2022 and 2024 SEC filings, and what does this indicate about its ongoing relevance or status?",
      "original_answer": "In the 2022 filing (DUK_10k_2022.pdf), the Twenty-third Supplemental Indenture was explicitly listed and dated June 1, 1978, incorporated by reference to Exhibit 2(c), File No. 2-61611. However, in the 2024 filing (DUK_10k_2024.pdf), there is no direct mention or continued reference to the Twenty-third Supplemental Indenture. Instead, the focus shifts to more recent supplemental indentures, such as the Forty-ninth Supplemental Indenture dated March 14, 2024. This indicates that the Twenty-third Supplemental Indenture was not reaffirmed or highlighted in the most recent disclosure, suggesting it may have diminished in operational or reporting significance over time.",
      "llm_answer": "In the 2022 Form 10‑K the “Twenty‑third Supplemental Indenture” is shown twice – once as a 1968 instrument (4.3.4 “dated February 1, 1968”) and again as a 1978 instrument (4.4.19 “dated June 1, 1978”) 【page_247†L13-L15】【page_249†L19-L21】. The 2024 filing only retains the 1978 entry (4.4.19 “dated June 1, 1978”) and the 1968 reference is no longer listed 【page_250†L19-L21】. This change implies the older 1968 indenture has been retired or is no longer material, while the 1978 indenture remains active and continues to be disclosed as part of Duke Energy’s outstanding debt.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. First, the claim that the Twenty-third Supplemental Indenture was listed twice in the 2022 filing—once as dated February 1, 1968, and again as June 1, 1978—is incorrect. The ground truth confirms only the June 1, 1978 date is associated with the Twenty-third Supplemental Indenture, incorporated by reference to Exhibit 2(c), File No. 2-61611. There is no mention of a 1968 date for this indenture in the 2022 filing, and the LLM appears to have misattributed or conflated exhibit numbers or indentures (e.g., possibly confusing it with another exhibit like 4.3.4). This introduces a false entity (the 1968 Twenty-third Supplemental Indenture) that does not exist in the ground truth. Second, while the LLM correctly notes that the 1978 indenture is still referenced in the 2024 filing, the ground truth states that the Twenty-third Supplemental Indenture is *not mentioned at all* in the 2024 filing. Instead, the 2024 filing references the *Forty-ninth* Supplemental Indenture (March 14, 2024), indicating the Twenty-third is no longer actively disclosed. Thus, the LLM incorrectly concludes the 1978 indenture remains active and disclosed, when in fact it is absent from the 2024 report. This misrepresents the evolution and current status. The reasoning is partially sound in comparing disclosures across years, but the factual foundation is flawed, leading to an incorrect conclusion about ongoing relevance. The answer is contextually relevant to the question and attempts multi-hop analysis, but the core facts—dates, entities, and presence/absence in filings—are wrong. Quantitative accuracy is moderate: the 1978 date is correct, but the 1968 date is not. Qualitative accuracy suffers due to incorrect entity mapping and flawed synthesis. Contextual relevance is acceptable as the structure and intent align with the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 517,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the repurchase activity for Class C Capital Stock evolve from 2022 to 2024, and what was the total value of shares repurchased in each year?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023 the amount increased to $62.2 billion, and in 2024 it remained high at $62.0 billion. This demonstrates a consistent and significant level of share repurchase activity over the three-year period, with a slight peak in 2023 followed by a minor decline in 2024.",
      "llm_answer": "Alphabet’s share‑repurchase program continued to include Class C capital stock each year. In 2022 the company repurchased a total of $59.3 billion of Class A and Class C shares (the Class C portion was not broken out)【page_82】. In 2023 it repurchased 450 million Class C shares for $52.9 billion【page_84】, and in 2024 it repurchased 306 million Class C shares for $50.2 billion【page_84】. Thus, after the $59.3 billion combined buy‑back in 2022, the dollar value and number of Class C shares repurchased fell modestly from 2023 to 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative details for 2023 and 2024. The ground truth states that Alphabet repurchased $62.2 billion in 2023 and $62.0 billion in 2024 of Class A and Class C shares combined, but the LLM claims $52.9 billion and $50.2 billion respectively for Class C shares alone, which contradicts the ground truth. These figures are not only lower but incorrectly attributed solely to Class C, while the original answer does not break out Class C separately after 2022. (2) The 2022 figure of $59.3 billion is correct and matches the ground truth as a combined amount for Class A and Class C. However, the LLM introduces specific numbers for Class C repurchases in 2023 and 2024 that are not present in the original answer and contradict its overall totals. There is no mention in the ground truth of 450 million or 306 million shares repurchased, nor of $52.9B or $50.2B for Class C alone. (3) The reasoning is flawed in the multi-hop synthesis: the LLM incorrectly infers that because Class C repurchases declined from 2023 to 2024, the overall trend declined, while the ground truth shows total repurchases remained high and nearly flat at ~$62B each year. This misrepresents the evolution of repurchase activity. (4) Contextually, the answer is relevant and addresses the question structure appropriately—discussing each year and total value—but fails on factual correctness. The citation of page numbers suggests document grounding, but the data extracted is inconsistent with the provided ground truth. Thus, while the framing is sound, the core financial facts are incorrect, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 460,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "What changes occurred in the treatment and documentation of the American Express Company Salary/Bonus Deferral Plan between the 2022 and 2024 SEC filings?",
      "original_answer": "In the 2022 filing, the Salary/Bonus Deferral Plan was referenced through historical amendments, including Exhibit 10.16 (1988 plan) and Exhibit 10.17 (1994 amendment). The 2024 filing reintroduces the plan through Exhibit 10.13, referencing the same 1988 plan, and also includes Exhibit 10.14, which references the 1994 amendment. Notably, the 2024 filing adds Exhibit 10.16, which incorporates the 1997 amendments to the plan. This indicates that while the foundational documentation remained consistent, the 2024 filing expanded the disclosure to include a broader historical record of amendments, providing more context on the plan's evolution.",
      "llm_answer": "In the 2022 Form 10‑K the Salary/Bonus Deferral Plan was listed as Exhibit 10.16 (the original plan), with its 1994 amendment as Exhibit 10.17 and a later 1997 amendment as Exhibit 10.19 【page_165】. In the 2024 filing the same plan and amendments are still incorporated by reference to the same historic documents, but the exhibit numbers were shifted – the original plan is now Exhibit 10.13, the 1994 amendment is Exhibit 10.14 and the 1997 amendment is Exhibit 10.16 【page_171】. This reflects a renumbering of the exhibit schedule rather than a change in the underlying documentation.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) According to the ground truth, the 2022 filing referenced the 1988 plan as Exhibit 10.16 and the 1994 amendment as Exhibit 10.17—there is no mention of a 1997 amendment (Exhibit 10.19) in the 2022 filing. However, the LLM claims the 1997 amendment was included in 2022 via Exhibit 10.19, which contradicts the original answer and introduces a false data point. (2) The ground truth states that the 1997 amendment was *added* in the 2024 filing via Exhibit 10.16, marking a new disclosure. The LLM incorrectly frames this as a renumbering of existing exhibits rather than recognizing the substantive addition of previously unreported amendment documentation. (3) While the LLM correctly identifies the current exhibit numbers in the 2024 filing (10.13, 10.14, 10.16), it misrepresents the nature of the change: the core issue is not renumbering but expanded disclosure. (4) The reasoning is flawed because it fails to recognize the multi-hop distinction—what was *newly added* in 2024 versus what existed in 2022. The conclusion that this reflects only renumbering is incorrect and misses the key point about enhanced historical documentation. (5) Contextually, the answer is relevant and well-structured, addressing exhibit numbers and years appropriately, hence the moderate contextual relevance score. However, due to major errors in entity accuracy (presence of 1997 amendment in 2022) and reasoning, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 417,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has Starbucks' exposure to interest rate swaps evolved between 2022 and 2024, particularly in terms of their balance sheet classification and magnitude of liability?",
      "original_answer": "In 2022, Starbucks reported an interest rate swap liability of $34.0 million under 'Other long-term liabilities'. By 2024, the company's interest rate swap position had shifted significantly, with a liability of $19.2 million under 'Other long-term liabilities' and an additional $41.4 million liability from interest rate swaps reported for the prior year (2023), indicating a decrease in liability from the previous year but a continued significant exposure. This reflects a transformation in the company's interest rate swap position, with a shift in balance sheet classification and a notable reduction in total swap liability.",
      "llm_answer": "In the 2022 filing Starbucks recorded interest‑rate‑swap liabilities both as a short‑term (accrued) item of $12 million and as other long‑term liabilities of $34 million – about $46 million in total (SBUX 2022 Note 4, p. 68). By the 2024 filing the swaps appear only in other long‑term liabilities and the liability has fallen to $19.2 million on the September 29, 2024 balance sheet (down from $41.4 million a year earlier) (SBUX 2024 Note 4, p. 72). Thus, the exposure has shifted from a split current/long‑term classification to a purely long‑term classification and the recorded liability has been reduced by roughly 60 %.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and addresses the evolution of Starbucks' interest rate swap exposure between 2022 and 2024 with strong qualitative reasoning and contextual relevance. However, there are minor quantitative inaccuracies. The original answer states that in 2022, Starbucks reported a $34.0 million liability solely under 'Other long-term liabilities'—but the LLM claims an additional $12 million short-term (accrued) liability, which is not present in the ground truth. This leads to an incorrect total of $46 million in 2022, introducing a factual discrepancy. The 2024 figures are accurate: $19.2 million liability reported, down from $41.4 million in 2023. The LLM correctly notes the shift in balance sheet classification from split (current/long-term) to purely long-term, though this classification detail was not explicitly confirmed in the ground truth. The 60% reduction claim is approximately correct (from $41.4M to $19.2M is a ~54% decrease), so the rounding is acceptable. The multi-hop reasoning—comparing classifications and magnitudes across years—is sound and well-articulated. All entities (Starbucks, interest rate swaps, balance sheet classifications, years) are correct. The answer is highly relevant and synthesizes temporal changes effectively. The main issue is the unsupported $12 million short-term liability in 2022, which reduces quantitative accuracy despite otherwise strong performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 394,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the treatment of the Directors' Savings Plan evolved between 2022 and 2024, and what does this suggest about Duke Energy's approach to director compensation governance and deferral mechanisms?",
      "original_answer": "In 2022, the Directors' Savings Plan was formally introduced in the 10-K filing with a specific amendment dated December 16, 2021, indicating active documentation and policy updates around director deferrals. By 2024, the plan is referenced in the context of phantom investment options and deferred compensation mechanics, with an emphasis on unfunded accounts tied to the Duke Energy Common Stock Fund. This evolution suggests a shift from policy establishment to operational transparency, highlighting how deferrals are structured and invested, which may reflect a broader governance strategy to align director compensation with long-term shareholder interests and company stock performance.",
      "llm_answer": "In the 2022 Form 10‑K the Directors’ Savings Plan is mentioned only as an “Amended and Restated” plan (originally dated 2014) with a subsequent amendment effective December 16 2021, without a detailed description of how it works. By the 2024 Form 10‑K the plan is disclosed in the equity‑compensation tables and explained as a non‑qualified deferred‑compensation arrangement that lets outside directors defer all or part of their retainers, credits the unfunded account with phantom‑stock performance (including the Duke Energy Common Stock Fund), and pays out when a director’s board service ends. This evolution shows Duke Energy moving toward greater transparency and formal governance of director pay, using a performance‑linked deferral mechanism to align director incentives with shareholder interests.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the December 16, 2021 amendment date is accurately cited, and the evolution from minimal disclosure in 2022 to detailed description in 2024 is correctly portrayed. The LLM correctly identifies the plan as a non-qualified deferred-compensation arrangement with phantom stock credits, specifically including the Duke Energy Common Stock Fund. (2) Quantitative accuracy is perfect: no numerical errors, and the dates (2014 original plan, 2021 amendment) match the source. (3) The multi-hop reasoning is sound—comparing disclosures across 2022 and 2024 filings to infer increased transparency and governance. The conclusion about aligning director incentives with shareholder interests via performance-linked deferrals is logically supported and consistent with the original answer. (4) The only minor shortcoming is that the LLM mentions the plan was 'originally dated 2014' and 'Amended and Restated,' which, while likely true, is not present in the ground truth and slightly extends beyond the provided context. However, this does not contradict the original answer and may reflect accurate external knowledge. Overall, the answer is factually correct, comprehensive, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 370,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the positioning and associated risk profile of Costco's Kirkland Signature brand evolved between 2022 and 2023?",
      "original_answer": "In 2022, Costco emphasized the Kirkland Signature brand as a strategic asset, highlighting its high quality, competitive pricing, and contribution to higher margins. The company planned to continue increasing the sales penetration of these private-label items. However, by 2023, the risk disclosures included broader mentions of how supply chain disruptions, foreign exchange fluctuations, and catastrophic events could negatively impact the business—including private-label brands like Kirkland Signature. While the 2022 filing focused on growth and brand strength, the 2023 filing introduced a more risk-focused lens, indicating that the brand's expansion and reliance could expose Costco to greater operational and financial volatility.",
      "llm_answer": "In the 2022 Form 10‑K Costco highlighted Kirkland Signature as a core private‑label brand that “are high quality, offered at prices that are generally lower than national brands, and help lower costs, differentiate our merchandise offerings, and generally earn higher margins” and said it expects to “continue to increase the sales penetration of our private‑label items” (2022 10‑K p. 7). By the 2023 filing the company no longer discusses Kirkland separately; the brand is folded into the broader private‑label discussion and the risk narrative focuses on general sourcing and commodity‑price risks – e.g., “We depend heavily on our ability to purchase quality merchandise in sufficient quantities at competitive prices” and “Suppliers may be unable to timely supply us with quality merchandise at competitive prices” (2023 10‑K p. 15). This shift shows Kirkland’s positioning remains central to Costco’s value proposition, but its risk profile is now treated as part of overall supply‑chain and pricing risks rather than a distinct brand‑specific risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the 2022 emphasis on Kirkland Signature as a high-quality, margin-enhancing private-label brand with plans to increase sales penetration, citing the exact language and page from the 2022 10-K. This matches the original answer's characterization of 2022 positioning. (2) For 2023, the LLM accurately notes that Kirkland is no longer discussed separately but is included in broader private-label risk disclosures, with increased focus on supply chain, sourcing, and pricing risks—consistent with the ground truth's claim of a more risk-focused lens. The cited quotes from the 2023 10-K (p. 15) are factually correct and support the analysis. (3) The multi-hop reasoning is sound: the model synthesizes changes in tone and focus between two years’ filings, correctly inferring that while Kirkland remains strategically important, its risk profile is now embedded in systemic risks rather than being highlighted as a standalone growth asset. (4) The only minor shortcoming is that the LLM does not explicitly state that this shift implies greater operational and financial volatility due to increased reliance on the brand—slightly less emphasis on the 'exposure' aspect mentioned in the original answer. However, the implication is present through the discussion of supply-chain dependency. All entities (Costco, Kirkland Signature, 2022 vs 2023, 10-K filings) are correct. No numerical inaccuracies; dates and references are precise. Wording differs slightly but maintains semantic equivalence. Thus, the answer is excellent with only a small gap in fully articulating the risk exposure implication.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 461,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve from 2022 to 2024, and what were the key changes in terms of volume and sources of additions?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. Over this period, the company experienced revisions and production activities that impacted reserves, with minimal extensions and discoveries contributing to the region. In 2024, there were no sales or significant reserve additions in this region, indicating a reduction in focus or activity compared to earlier years.",
      "llm_answer": "ConocoPhillips’ proved natural‑gas reserves in the Asia Pacific/Middle East fell in its own operations from about 330 BCF at year‑end 2022 (326 BCF developed + 4 BCF undeveloped) to roughly 303 BCF at year‑end 2024【page_145】, a decline driven by revisions, production and the disposition of its Indonesia assets. In contrast, the equity‑affiliate portion in the same region grew from 5,753 BCF in 2022 to 5,870 BCF in 2024【page_145】, reflecting upward price‑related revisions, technical revisions and extensions/discoveries in the Middle East (and earlier affiliate purchases)【page_146】. Overall, total Asia Pacific/Middle East natural‑gas reserves rose modestly to about 6,166 BCF, with the net increase coming almost entirely from affiliate additions rather than the company’s direct reserves.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies compared to the ground truth. The original answer states that COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 326 BCF in 2022 to 296 BCF in 2024. However, the LLM claims reserves fell from 330 BCF (splitting into 326 developed + 4 undeveloped) to 303 BCF, which introduces an incorrect total for 2022 and an incorrect final figure for 2024. The ground truth does not mention any breakdown into developed/undeveloped or affiliate reserves, nor does it report a total of 6,166 BCF. (2) The quantitative inaccuracies are critical: the LLM invents a split of reserves (326 + 4 = 330) not present in the original, misreports the 2024 reserve level (303 vs. actual 296), and fabricates equity-affiliate reserves growing from 5,753 to 5,870 BCF—numbers entirely absent from the ground truth. These are not formatting differences but fabricated data. (3) The reasoning is flawed in terms of multi-hop synthesis: the question asks about COP's natural gas reserves, and the original answer focuses solely on the company's direct reserves. The LLM incorrectly shifts focus to include equity affiliates and total regional reserves, which were not part of the original data or question scope. It also attributes the decline to 'disposition of its Indonesia assets,' which is not mentioned in the ground truth. (4) While the LLM recognizes a decline and cites revisions and production as factors—partially aligning with the original—the introduction of unverified data, incorrect totals, and irrelevant affiliate information severely undermines factual correctness. The contextual relevance is moderate because it addresses reserve evolution but does so with incorrect data and scope. Scores reflect major factual deviations, especially in numbers and entity focus.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 502,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has FedEx's strategic relationship with the Boeing 767F evolved between 2022 and 2024, particularly in terms of fleet ownership and modernization focus?",
      "original_answer": "In 2022, FedEx directly owned 114 Boeing 767F aircraft, indicating a significant owned asset position in its fleet strategy. By 2024, while no updated ownership figures were disclosed, FedEx emphasized the Boeing 767-300 Freighter (B767F) as a key component of its aircraft modernization programs. The company described these aircraft as significantly more fuel-efficient per unit than older models and noted that expenditures for these aircraft are necessary for long-term operating savings and fleet replacement, with limited flexibility to delay purchases without incurring significant costs.",
      "llm_answer": "In 2022 FedEx owned a fleet of 114 Boeing 767‑300 freighters (all owned, none leased) and had active purchase commitments for additional 767Fs – 14 slated for delivery in 2023 and another 14 in 2024【page_40】. By the 2024 filing the company’s strategy had shifted to using the 767F as a core element of its aircraft‑modernization program, with $611 million of deposits for new aircraft and a reduced pipeline of only 14 further 767Fs (11 in 2025 and 3 in 2026) as it replaces older, less‑efficient planes【page_117】【page_116】. This reflects a move from expanding the fleet to focusing on modernizing it with fuel‑efficient 767‑300 freighters.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies FedEx's ownership of 114 Boeing 767-300F aircraft in 2022, which matches the ground truth. However, it adds specific details not present in the original answer, such as 'all owned, none leased' and exact delivery schedules (14 in 2023, 14 in 2024, 11 in 2025, 3 in 2026), which are not confirmed in the ground truth. The $611 million deposit figure is also absent from the original answer and cannot be verified against the provided truth. (2) While the 114 aircraft number is accurate, the additional quantitative claims (delivery pipeline, deposits) introduce unsupported precision. The ground truth states that no updated ownership figures were disclosed for 2024, but the LLM implies continuity and specificity that isn't justified. (3) The qualitative reasoning about a strategic shift from fleet expansion to modernization is a reasonable interpretation and aligns with the ground truth’s emphasis on the 767F’s role in modernization and fuel efficiency. The synthesis of modernization focus and replacement of older models is sound and addresses the multi-hop aspect of the question. (4) The answer is highly contextually relevant, directly addressing fleet ownership and modernization focus. However, the correctness score is reduced due to the inclusion of unverified numerical details not present in the ground truth, even though the core narrative about strategic evolution is consistent. The answer goes beyond the original data with specific forward-looking delivery numbers and financial deposits, which risks factual overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 437,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did Starbucks' involvement with roasted coffee evolve from 2022 to 2024 in terms of inventory value and production infrastructure?",
      "original_answer": "In 2022, Starbucks reported an inventory value of roasted coffee at $310.3 million, reflecting its role in holding roasted coffee as part of its merchandise. By 2024, the company had expanded its infrastructure dedicated to roasting, with facilities in York, PA; Minden, NV (Carson Valley); Kunshan, China; and Kent, WA, indicating a significant increase in its direct involvement in the roasting process. This represents a shift from primarily holding roasted coffee inventory to actively producing and distributing it at scale.",
      "llm_answer": "In fiscal 2022 Starbucks reported $310.3 million of roasted‑coffee inventory on its balance sheet and $838.5 million of roasting equipment (Note 5 and PP&E schedule)【page_71】. By the 2024 filing the company emphasizes a broadened production footprint – it owns large roasting plants in York, PA (1.96 M sq ft), Minden, NV (1.08 M sq ft), Kunshan, China (0.63 M sq ft) and Kent, WA (0.51 M sq ft) – together providing over 4 million sq ft of roasting, warehousing and distribution capacity, indicating an expanded roasting infrastructure (the 2024 excerpt does not disclose a new roasted‑coffee inventory figure)【page_33】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2022 roasted coffee inventory value of $310.3 million, matching the ground truth. It also accurately lists the roasting facilities in York, PA; Minden, NV; Kunshan, China; and Kent, WA, confirming correct entity and location identification. However, the LLM introduces a figure of $838.5 million for roasting equipment from the PP&E schedule, which is not mentioned or implied in the original answer and is not directly relevant to the question about inventory value and production infrastructure evolution—this is an overreach in quantitative detail not supported by the ground truth. (2) The square footage details (1.96M, 1.08M, etc.) and total capacity over 4 million sq ft are not present in the original answer; while they may be factually correct from the filing, they add precision not required and slightly shift focus toward infrastructure scale rather than the strategic shift emphasized in the ground truth. The absence of a 2024 inventory figure is correctly noted and aligns with the original answer’s limitation. (3) The multi-hop reasoning is sound: the model connects 2022 inventory data with 2024 infrastructure developments to infer increased involvement in roasting. However, the original answer emphasizes a qualitative shift—from holding inventory to active production—while the LLM focuses more on physical capacity, slightly missing the strategic interpretation. (4) The correctness score is 8 because core facts (inventory value, locations, timeline) are accurate and the reasoning supports the conclusion of expanded involvement, but the addition of unsupported equipment value and excessive facility metrics reduces precision. Quantitative accuracy is 9 due to correct key numbers but inclusion of extraneous, unverified figures. Qualitative accuracy is 8 due to solid reasoning but less emphasis on the strategic shift. Contextual relevance is 10 as all information pertains directly to the question’s scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 535,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has PepsiCo's utilization of the 2.750% Senior Notes due 2025 evolved between 2023 and 2024, based on the specific debt instruments referenced in the filings?",
      "original_answer": "In 2023, the 2.750% Senior Notes due 2025 were listed among other notes in a Board of Directors Resolutions document that authorized officers to establish terms for several senior notes, including the 2.750% Senior Notes due 2025. By 2024, PepsiCo not only retained the 2.750% Senior Notes due 2025 in its list of authorized instruments but also introduced a new 2.750% Senior Notes due 2030. This indicates that PepsiCo extended its debt strategy involving this interest rate to a longer-term horizon, signaling a strategic evolution in its financing approach.",
      "llm_answer": "In the 2023 Form 10‑K, PepsiCo’s board approved the issuance of a new 2.750 % senior note due 2025 (see the Board of Directors Resolutions in Exhibit 4.65 on page 129). By the 2024 Form 10‑K, that same 2.750 % senior note due 2025 is listed among the company’s outstanding senior‑note portfolio (see the consolidated debt schedule in Exhibit 4.64 on page 130), indicating the instrument has moved from authorization in 2023 to being an active component of PepsiCo’s financing in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in its quantitative details: the 2.750% Senior Notes due 2025 were authorized in 2023 (via Board Resolutions in Exhibit 4.65) and appeared in the 2024 filing as part of the outstanding senior-note portfolio (Exhibit 4.64), confirming issuance. All dates, percentages, and document references (e.g., Form 10-K, exhibit numbers, page numbers) are correct and align with the ground truth. The reasoning correctly traces the evolution from authorization to active financing instrument, which is a valid interpretation of the note’s utilization. However, the LLM omits a key element from the original answer: the introduction of a new 2.750% Senior Notes due 2030 in 2024, which signals a strategic extension of the same interest rate to a longer-term horizon. This omission reduces completeness and slightly weakens the qualitative synthesis of PepsiCo’s broader debt strategy evolution. While the LLM captures the core progression of the 2025 note, it does not fully reflect the strategic implication of extending the 2.750% rate to a new long-term instrument. Thus, while factually sound and contextually relevant, the answer falls short on full multi-hop synthesis involving the new 2030 note, warranting a score of 8 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 360,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did FedEx's planned utilization of the B777F aircraft change from 2022 to 2024, and what does this indicate about its strategic role in the fleet?",
      "original_answer": "In 2022, FedEx planned to operate 4 B777F aircraft in 2024 and 2 in 2025. By 2024, the updated plan showed 2 B777F aircraft operating in 2025, with no further plans beyond that year. This indicates a reduction in the strategic emphasis on the B777F fleet, moving from a gradually decreasing role to a complete phase-out, suggesting a shift in aircraft preference or operational strategy.",
      "llm_answer": "In the 2022 Form 10‑K FedEx said it was committed to **eight B777F freighters** – 2 slated for 2023, 4 for 2024 and 2 for 2025【page_114】. By the 2024 filing the commitment had been **scaled back to only two B777F aircraft**, both now expected in 2025【page_117】. FedEx still characterizes the B777F as a fuel‑efficient, long‑term modernization platform, but the reduced quantity shows the type is being positioned as a more limited, targeted component of its fleet‑renewal strategy.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant quantitative inaccuracy: it states that FedEx committed to eight B777F aircraft in 2022, with 2 in 2023, 4 in 2024, and 2 in 2025. However, the ground truth indicates that in 2022, FedEx planned for 4 B777Fs in 2024 and 2 in 2025 — totaling 6 aircraft, not 8. There is no mention of 2 aircraft in 2023 in the ground truth. This misrepresents the original plan. The 2024 update correctly notes only 2 B777Fs planned for 2025, aligning with the ground truth. (2) The calculation of total aircraft and year-by-year distribution is therefore incorrect in the initial plan. The LLM overstates the original commitment by two aircraft and introduces a 2023 delivery not present in the ground truth. (3) Despite this, the qualitative reasoning is sound: the LLM correctly identifies a reduction in B777F commitments from 2022 to 2024 and interprets this as a strategic downgrading of the aircraft’s role, which matches the ground truth’s conclusion about reduced strategic emphasis and likely phase-out. The synthesis across years and filings is logical and contextually appropriate. (4) The contextual relevance is perfect — the answer directly addresses both parts of the question: the change in utilization and its strategic implication. The qualitative accuracy is high due to correct interpretation of intent and trend, but quantitative accuracy is reduced due to incorrect numbers and timeline. Correctness score is 7 because the core trend (reduction) is accurate, but key details (number of planes, years) are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 431,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did Starbucks' foreign currency - other derivative liabilities and their impact on net gains/(losses) included in AOCI evolve from 2022 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2022, Starbucks reported foreign currency - other derivative liabilities of $0.3 million under accrued liabilities, while in 2024, the net gains included in AOCI related to foreign currency - other were $11.5 million. This indicates a significant shift from a minimal liability position in 2022 to a more substantial unrealized gain in 2024, suggesting increased exposure to or hedging of foreign currency fluctuations.",
      "llm_answer": "Starbucks’ designated “foreign‑currency‑other” derivative liabilities grew from roughly $0.3 million at fiscal‑year‑end 2022 (Oct 2 2022) to $2.0 million at fiscal‑year‑end 2023 (Oct 1 2023) and then to about $8.8 million by September 29 2024【page_68†L31-L38】【page_72†L31-L38】. At the same time, the net unrealized gain for these hedges recorded in AOCI fell from $55.3 million in 2022【page_66†L31-L38】 to $39.6 million in 2023 and to $11.5 million in 2024【page_70†L31-L38】. The rising liability balance shows Starbucks is expanding its foreign‑currency‑other hedge positions, while the shrinking AOCI gain indicates the hedges are increasingly offsetting currency movements, suggesting a diminishing net exposure to foreign‑exchange fluctuations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and trends compared to the ground truth. The original answer states that in 2022, Starbucks had foreign currency - other derivative liabilities of $0.3 million, and in 2024, the net gains in AOCI were $11.5 million. However, the LLM claims liabilities grew to $8.8 million by 2024 and provides intermediate values for 2023 ($2.0 million), which are not present in the ground truth. Additionally, the LLM reports AOCI gains of $55.3 million in 2022 and $39.6 million in 2023, decreasing to $11.5 million in 2024, while the original answer only mentions the 2024 AOCI gain of $11.5 million with no data for prior years. These numbers are entirely fabricated or misattributed. (2) The only correct quantitative point is the $11.5 million net gain in AOCI in 2024, matching the ground truth. The $0.3 million liability in 2022 is also correctly cited. All other figures (e.g., $2.0 million in 2023, $8.8 million in 2024, $55.3M and $39.6M AOCI values) are unsupported by the original answer and contradict its minimal information. (3) The multi-hop reasoning is flawed. The original answer infers increased exposure to foreign currency fluctuations due to a shift from a small liability to a large unrealized gain. In contrast, the LLM incorrectly concludes *diminishing* net exposure based on declining AOCI gains, which contradicts the implication of growing liabilities and large unrealized gains. The reasoning is internally consistent with its own data but built on false inputs. (4) Contextual relevance is high because the LLM addresses the evolution of liabilities and AOCI impacts and attempts to interpret exposure implications. However, due to severe quantitative errors and incorrect synthesis, the qualitative accuracy and overall correctness are low. Minor formatting variations are acceptable, but invented data points and trends are not.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 521,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has PepsiCo's engagement with the 2.625% Senior Notes due 2026 evolved between 2023 and 2024, particularly in terms of its broader debt instrument disclosures?",
      "original_answer": "In 2023, the 2.625% Senior Notes due 2026 were listed among other notes in a section that included Board of Directors Resolutions authorizing officers to establish terms for various senior notes. By 2024, PepsiCo not only retained the 2.625% Senior Notes due 2026 in its disclosures but also introduced a significantly expanded list of senior notes, including newer maturities such as the 3.000% Senior Notes due 2027 and the 2.625% Senior Notes due 2029. This indicates a broader and more diversified set of debt instruments, suggesting an active capital markets strategy involving the issuance of notes with different maturities and rates.",
      "llm_answer": "In the 2023 Form 10‑K PepsiCo disclosed the 2.625 % Senior Notes due 2026 in a Board‑of‑Directors resolution authorizing the terms (2023 p. 129‑130) and listed the notes among a relatively modest set of senior‑note issuances. In the 2024 Form 10‑K the same resolution and listing reappear (2024 p. 129‑130), but the debt schedule now includes a much larger array of senior notes and even references a new 2024 Indenture (2024 p. 131), showing that while PepsiCo’s commitment to the 2.625 % notes persists, its overall debt‑instrument disclosures have expanded to cover a broader portfolio of financing arrangements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2.625% Senior Notes due 2026 were disclosed in both 2023 and 2024 filings in the context of Board of Directors resolutions authorizing terms for senior notes, and the 2024 disclosure includes a broader set of notes. The page references (2023 p. 129–130, 2024 p. 129–131) and mention of the 2024 Indenture are consistent with expected document structure and support the claim. (2) Quantitative elements—interest rate (2.625%), maturity year (2026), and the introduction of new instruments like the 2027 and 2029 notes—are correctly represented, even if the LLM does not explicitly name the 3.000% due 2027 and 2.625% due 2029, it accurately captures the expansion in scope. (3) The multi-hop reasoning is sound: the model correctly infers that the continued inclusion of the 2026 notes alongside an expanded debt portfolio indicates ongoing engagement and a broader capital markets strategy. (4) The answer is contextually relevant and directly addresses the evolution of PepsiCo’s engagement with the notes and broader disclosure trends. The only minor shortcoming is the lack of explicit mention of the specific new notes (e.g., 3.000% due 2027, 2.625% due 2029) highlighted in the ground truth, which slightly reduces completeness in qualitative detail, but the core conclusion about expanded disclosures remains valid. Hence, a score of 9 is warranted for correctness, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 424,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Cisco's exposure to and reliance on overcoming technical hurdles evolved from 2022 to 2024, particularly in relation to its strategic investments and product development timelines?",
      "original_answer": "In 2022, Cisco acknowledged facing technical hurdles that could delay successful execution of its vision, especially in areas like product planning, timing, and resource allocation, which could lead to loss of market share and earnings. By 2024, the company's exposure to technical hurdles had transformed into a more specific dependency on overcoming these challenges in a timely manner to maintain competitive advantage, particularly in delivering complex software subscription offerings and introducing new technologies such as those related to artificial intelligence, security, observability, and cloud. The 2024 disclosures emphasize that failure to overcome these hurdles could not only result in loss of market share but also reputational damage, legal liability, and reduced customer retention. This represents a shift from internal execution risk to a broader operational and strategic dependency.",
      "llm_answer": "In the 2022 filing Cisco warned that “challenges with regard to product planning and timing, technical hurdles that we fail to overcome in a timely fashion” could delay product introductions and that its long‑term engineering, sales and marketing investments “may achieve delayed, or lower than expected, benefits” (2022 p. 25). By the 2024 filing the same risk language reappears, but it is now linked explicitly to the larger strategic spend on AI, cloud, security, software‑subscription offerings and recent acquisitions (e.g., Splunk), with the company noting it must “commit significant resources… before knowing whether our investments will result in products the market will accept” and that any failure to overcome those hurdles “could delay product introductions and harm our business” (2024 p. 20‑21). Thus, Cisco’s exposure to technical hurdles remains a core risk, but its reliance on overcoming them has grown as its strategic investments and product‑development timelines have become more central to its growth strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original (ground truth) answer. (1) It correctly identifies Cisco's evolving exposure to technical hurdles from 2022 to 2024, noting the continuity of risk language while highlighting its increased strategic importance. The key entities—Cisco, AI, cloud, security, software subscriptions, Splunk—are all correctly identified, and the years (2022, 2024) are accurate. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the answers, so quantitative accuracy is not applicable in a numerical sense; however, the citation of page numbers (p. 25 for 2022, pp. 20–21 for 2024) matches typical 10-K disclosure formats and supports authenticity, with no incorrect figures present. (3) The multi-hop reasoning is sound: the model synthesizes risk disclosures across two years, connects them to strategic investments (e.g., AI, cloud, acquisitions like Splunk), and infers an escalation in reliance on overcoming technical hurdles despite consistent wording. It captures the shift from internal execution risk to broader strategic dependency, though it does not explicitly mention 'reputational damage, legal liability, or reduced customer retention'—a minor omission from the 2024 risks noted in the ground truth. (4) The answer is contextually excellent, directly addressing how Cisco’s exposure and reliance evolved in relation to strategic investments and product development timelines. Wording differs slightly but maintains semantic equivalence. The only reason for not scoring a 10 is the omission of the expanded consequences in 2024 (reputational and legal risks), which are part of the qualitative evolution. Overall, this is a strong, factually correct, and well-reasoned response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1495,
        "completion_tokens": 483,
        "total_tokens": 1979
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the role of Google Ad Manager in driving Google Network revenues change between 2022 and 2023, based on the specific mentions of its performance and positioning across those years?",
      "original_answer": "In 2022, Google Ad Manager was explicitly cited as one of the key drivers behind the $8.6 billion year-over-year increase in Google Network revenues, alongside AdMob and AdSense. By 2023, while Google Ad Manager remained a core advertising platform used by customers, it was listed among several platforms (including Google Ads, Display & Video 360, and the Marketing Platform) without specific attribution to revenue growth. This indicates a shift from being a standout growth contributor in 2022 to being part of a broader suite of advertising tools in 2023, suggesting a more integrated but less singularly emphasized role.",
      "llm_answer": "In the 2022 filing, Google Ad Manager was singled out as a key growth engine – the increase in Google Network revenue was “primarily driven by strength in AdMob, Google Ad Manager, and AdSense”【page_35】. By the 2023 filing, the product is mentioned only as one of several channels (Google Ads, Google Ad Manager, Display & Video 360, etc.) through which advertisers buy inventory, without any explicit claim that it is driving network‑revenue growth【page_57】. This reflects a shift from being highlighted as a primary revenue driver to being treated as a routine component of the broader ad‑selling suite.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the original answer. (1) It correctly identifies that in 2022, Google Ad Manager was explicitly cited as a key driver of Google Network revenue growth alongside AdMob and AdSense, with the $8.6 billion year-over-year increase being attributed to these platforms in the ground truth (though the exact dollar figure is not repeated in the LLM answer, it is not required for correctness as the focus is on the role of the platform, not the number itself). (2) The LLM accurately notes that in 2023, Google Ad Manager was no longer singled out for growth but listed among other platforms like Google Ads and Display & Video 360, without explicit linkage to revenue growth. (3) The multi-hop reasoning—comparing the change in emphasis across two years and inferring a shift in strategic positioning—is sound and well-supported by the source references (page_35 for 2022, page_57 for 2023). (4) All entities (Google Ad Manager, AdMob, AdSense, Google Ads, Display & Video 360) and years (2022 vs 2023) are correctly identified. The answer captures the core insight: a shift from being a highlighted growth driver to a component of a broader suite. No factual inaccuracies, omissions, or reasoning flaws are present. Minor omission of the $8.6B figure does not detract from correctness as the question focuses on the 'role' and 'positioning,' not quantitative impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 394,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did Starbucks' derivative liabilities related to foreign currency - other evolve from 2022 to 2024, and what was the magnitude of change?",
      "original_answer": "In 2022, Starbucks reported derivative liabilities related to foreign currency - other at $0.3 million under accrued liabilities. By 2024, this amount had increased to $4.7 million under the same category. This indicates a significant increase in the company's liabilities tied to foreign currency derivatives over the two-year period.",
      "llm_answer": "Starbucks’ derivative liabilities for “foreign currency – other” were only $0.3 million in fiscal 2022 (accrued liabilities)【page_68】. By September 29 2024 they had risen to $4.7 million of accrued liabilities plus $4.1 million of other long‑term liabilities – a total of $8.8 million【page_72】. That represents an increase of roughly $8.5 million over the two‑year period.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2022 derivative liability amount ($0.3 million) and the 2024 amount under accrued liabilities ($4.7 million), which matches the ground truth. However, it introduces an additional $4.1 million in 'other long-term liabilities' in 2024 not mentioned in the original answer, leading to a total of $8.8 million, which is not supported by the ground truth. The original answer states the 2024 amount is $4.7 million under the same category (accrued liabilities), with no mention of long-term liabilities. (2) The calculation of an $8.5 million increase is based on incorrect totals: the actual increase from $0.3M to $4.7M is $4.4 million, not $8.5 million. This represents a significant quantitative error. (3) The multi-hop reasoning is partially sound—correctly tracking the change over time—but fails in synthesis by incorporating an unsupported liability category. The model appears to misinterpret the 2024 filing by aggregating across liability categories without confirmation from the source. (4) Scores reflect that core data (2022 and accrued portion of 2024) are correct, but major errors in totals and calculations reduce correctness. Contextual relevance is high as the response addresses the evolution and magnitude of change, albeit inaccurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1175,
        "completion_tokens": 364,
        "total_tokens": 1540
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has PepsiCo's issuance of the 4.600% Senior Notes due 2045 evolved between 2023 and 2024, and what does this indicate about the company's debt structure strategy?",
      "original_answer": "In 2023, the 4.600% Senior Notes due 2045 were listed among other senior notes in the Board of Directors Resolutions that authorized PepsiCo's officers to establish terms for various notes, including the 4.600% Senior Notes due 2045. By 2024, the 4.600% Senior Notes due 2045 remained part of the company's debt structure, but were now referenced alongside a broader range of newly introduced senior notes, such as the 4.000% Senior Notes due 2047 and Floating Rate Notes due 2026. This indicates that while the 4.600% Senior Notes due 2045 remained a part of PepsiCo's long-term debt strategy, the company expanded its debt portfolio with additional instruments, suggesting a more diversified approach to long-term financing in 2024.",
      "llm_answer": "PepsiCo’s board authorized the issuance of 4.600 % senior notes due 2045 in its 2023 Form 10‑K (see page 130) and the same authorization appears unchanged in the 2024 Form 10‑K (also page 130). The note’s continued presence without amendment shows the company is maintaining a long‑dated, fixed‑rate senior‑note program, using the 4.600 % 2045 issue to diversify its maturity profile and lock in relatively low borrowing costs for the long term.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 4.600% Senior Notes due 2045 and their presence in both the 2023 and 2024 Form 10-K filings, with accurate page references (130 in both years), which aligns with the ground truth. The percentage (4.600%), maturity year (2045), and the fact that the notes were authorized in 2023 and still referenced in 2024 are all factually correct. (2) Quantitative accuracy is perfect: all dates, percentages, and document references are accurate. There are no numerical or date errors. (3) However, the reasoning and qualitative accuracy are partially flawed. The LLM claims the authorization 'appears unchanged' and interprets this as PepsiCo maintaining a long-dated, fixed-rate program, but it fails to capture the key evolution highlighted in the ground truth: in 2024, the 4.600% notes were referenced alongside *newly introduced* senior notes (e.g., 4.000% due 2047, Floating Rate Notes due 2026), indicating a broadening and diversification of the debt portfolio. The LLM misses this multi-hop insight — that the company expanded its debt instruments — and instead concludes only that the program is 'unchanged', which contradicts the ground truth. (4) The answer is contextually relevant and well-structured, but the failure to identify the strategic expansion in 2024 limits its correctness. While the core fact about the 2045 notes is accurate, the interpretation of PepsiCo's debt strategy is incomplete and less nuanced than the original answer, which explicitly notes the diversification. Hence, correctness is reduced to 6 due to missing key strategic evolution, despite strong quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 453,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved between 2022 and 2024, and what does this indicate about its strategic focus in the region?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas in the Asia Pacific/Middle East region. By 2024, this figure had decreased slightly to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region over the two-year period. The decline, although modest, suggests a potential shift in strategic focus, possibly due to market dynamics or operational adjustments in the region.",
      "llm_answer": "Between 2022 and 2024 ConocoPhillips’ direct natural‑gas reserves in Asia Pacific/Middle East fell from 326 BCF to 296 BCF, while its equity‑affiliate holdings rose from about 5,753 BCF to 5,870 BCF, lifting the total regional gas position from roughly 6,080 BCF to 6,170 BCF – a modest net gain driven by affiliate growth【page_145】. The 10‑K notes that the company added affiliate interest in Asia Pacific and pursued extensions and discoveries through its equity affiliates in the Middle East, indicating a strategic emphasis on expanding partner‑based exposure and leveraging LNG market dynamics rather than expanding its own operating base in the region【page_146】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces data not present in the ground truth—specifically equity-affiliate holdings (5,753 BCF to 5,870 BCF) and total regional gas position (6,080 BCF to 6,170 BCF). These figures are not mentioned in the original answer and contradict the ground truth, which only reports a decline from 326 BCF to 296 BCF in COP's natural gas position. The original answer interprets this as a straightforward reduction in reserves, with no mention of affiliate growth or net gains. (2) The quantitative values for COP's direct reserves (326 BCF in 2022, 296 BCF in 2024) are correct and match the ground truth. However, the addition of unverified affiliate numbers and the resulting total (6,170 BCF) introduces significant inaccuracies. The calculation of a 'net gain' is therefore factually unsupported by the provided ground truth. (3) The reasoning is flawed in multi-hop synthesis: while the LLM attempts to infer strategic focus (partner-based exposure, LNG dynamics), this interpretation relies on fabricated or unsupported data. The original answer suggests a potential strategic shift due to market or operational factors, but does not specify a pivot to affiliate investments. (4) The contextual relevance is high—the answer addresses the evolution of COP's position and infers strategic focus—but the factual foundation is partially incorrect, leading to a misleading conclusion. The inclusion of affiliate data, while possibly present in the 10-K, is not part of the verified knowledge graph and thus cannot be considered correct in this evaluation context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 436,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Google Play's role in Google's non-advertising revenue strategy evolved from 2022 to 2023, based on the specific revenue sources mentioned in the filings?",
      "original_answer": "In 2022, Google Play was specifically mentioned as generating revenues from 'sales of apps and in-app purchases and digital content sold in the Google Play store.' By 2023, Google Play's revenue focus had evolved to be more narrowly described as primarily coming from 'apps and in-app purchases,' and it was grouped under the broader category of 'platforms' within non-advertising revenue sources. This indicates a shift in emphasis toward core app-based monetization within Google's strategic narrative around Play.",
      "llm_answer": "In the 2022 10‑K, Google Play was called out as a non‑advertising revenue platform that earned money from “sales of apps and in‑app purchases and digital content sold in the Google Play store” (2022 p.7) and was grouped under “platforms … revenues from Google Play from the sales of apps and in‑app purchases” (2022 p.8). The 2023 filing still lists Google Play as a key non‑advertising source, but now describes it only as generating “revenues from Google Play from the sales of apps and in‑app purchases” (2023 p.6), dropping the explicit mention of digital‑content sales—showing a narrowed, more app‑focused role in Google’s non‑advertising revenue strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in Google Play's revenue description from 2022 to 2023: in 2022, revenue sources included 'sales of apps and in-app purchases and digital content sold in the Google Play store,' while in 2023, the description narrows to 'sales of apps and in-app purchases,' with no explicit mention of digital content. This matches the original answer’s claim of a strategic narrowing. (2) There are no numerical values to verify, so quantitative accuracy is not applicable in a traditional sense—but all cited years (2022, 2023), document references (page numbers), and quoted phrases are factually correct and properly attributed, satisfying the standard for precision. (3) The multi-hop reasoning is sound: the model correctly compares two filings across years, identifies a change in wording, and infers a strategic shift in emphasis—core to the question. (4) The only reason for not scoring a perfect 10 is a minor omission: the LLM does not explicitly mention that Google Play was grouped under the broader 'platforms' category in 2023, which is part of the original answer’s reasoning about strategic framing. However, it does reference 'platforms' in the 2022 context and implies continuity, so the gap is small. Overall, the answer is semantically equivalent, contextually precise, and factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 390,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has the projected utilization of the Cessna SkyCourier 408 evolved from 2022 to 2024, and what does this indicate about FedEx's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FedEx projected the Cessna SkyCourier 408 to have a total of 49 aircraft in operation across the years 2023 to thereafter. By 2024, this projection was reduced to a total of 31 aircraft for the years 2025 through 2029. However, in the 2024 report, the relationship to the Cessna SkyCourier 408 shifted from 'Increases' to 'Depends_On', indicating a change in strategic importance. This suggests a moderated but still significant reliance on the aircraft model over time.",
      "llm_answer": "The 2022 Form 10‑K showed FedEx planning to acquire 49 Cessna SkyCourier 408s through 2026 – 11 in 2023, 12 in 2024, another 12 in 2025 and 14 in 2026 (see page 114). By the 2024 filing the schedule had been revised to 31 SkyCourier 408s, with a larger 2025 commitment of 17 aircraft (up from 12) and 14 slated for 2026 (see page 117). The higher‑than‑original 2025 delivery target and continued 2026 commitment indicate that FedEx is deepening its strategic reliance on the SkyCourier to expand its regional and feeder‑service capacity.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, FedEx projected 49 aircraft for operation from 2023 onward, but the LLM incorrectly specifies delivery schedules (11 in 2023, 12 in 2024, etc.) that are not present in the original answer and not supported by the knowledge graph. Similarly, the 2024 revision to 31 aircraft is correctly noted in quantity but mischaracterized with specific delivery numbers (17 in 2025, 14 in 2026), which are not in the ground truth and contradict its broader timeframe (2025–2029). (2) Quantitative accuracy is low: while the totals 49 and 31 are correct, the breakdown by year (e.g., 11, 12, 12, 14) and the claim of a 'higher-than-original 2025 delivery target' are fabricated and unsupported. The original answer does not specify annual delivery numbers, so these precise figures are erroneous. (3) The reasoning is flawed: the LLM concludes that FedEx is 'deepening its strategic reliance' due to increased 2025 deliveries, but the ground truth states the strategic relationship changed from 'Increases' to 'Depends_On', indicating a *moderated* reliance, not a deepening one. This misinterprets the direction of strategic change. (4) Contextual relevance is moderate—the answer addresses the evolution of aircraft numbers and strategic reliance, but the incorrect data and reversed conclusion undermine its validity. The multi-hop synthesis fails because it invents granular data and misrepresents the strategic shift. Overall, the answer is partially responsive but factually and logically incorrect on key points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 442,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of segmentation and the types of casualty lines analyzed?",
      "original_answer": "In 2022, AIG used expected loss ratio methods primarily for the three latest accident years in the U.S. Excess Casualty line, segmenting analysis by attachment point and further differentiating between automobile and non-automobile claims, including special treatment for latent exposures like construction defects and mass torts. In 2023, AIG continued to apply expected loss ratio methods but shifted focus to U.S. Workers' Compensation, where the company grouped business by risk-sharing features such as high deductibles and retrospective rating, and analyzed separately by state, industry, and claim handling entity. The increase in large deductible business also affected the reporting pattern of claims, indicating a broader application context for the method. This reflects a strategic evolution in where and how expected loss ratio methods are applied across different casualty lines.",
      "llm_answer": "AIG’s 2022 filing already explained that it applies expected‑loss‑ratio techniques mainly to its excess‑casualty business, splitting the analysis between automobile‑related and non‑automobile claims, then further separating non‑automobile latent exposures (e.g., construction‑defect and mass‑tort claims) and also by attachment‑point bands (losses capped at $10 million versus those above $10 million) 【page_261】. The 2023 filing repeats the same segmentation for excess casualty 【page_204】 and adds a broader statement that expected‑loss‑ratio methods may be given significant weight for any line written in excess of a deductible in the most recent five accident years 【page_200】, but the underlying segmentation and focus on excess‑casualty lines have not materially changed.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies AIG's use of expected loss ratio methods in 2022 for U.S. Excess Casualty, including segmentation by attachment point and differentiation between automobile and non-automobile claims, as well as special treatment for latent exposures like construction defects and mass torts. These details align with the ground truth and are supported by the cited pages. However, the LLM answer incorrectly states that the 2023 filing 'repeats the same segmentation for excess casualty,' which contradicts the ground truth indicating a strategic shift in 2023 from Excess Casualty to U.S. Workers' Compensation as the primary line of focus. The LLM fails to mention this key evolution entirely. Instead, it claims the focus and segmentation 'have not materially changed,' which is factually incorrect. While it does note a broader statement in 2023 about expected loss ratio methods being given significant weight for lines written over a deductible in the last five accident years, this does not compensate for missing the core shift in application context. (2) Quantitatively, the LLM accurately reflects segmentation thresholds (e.g., $10 million attachment point) and accident year ranges (latest three in 2022, reference to five in 2023), with no calculation errors. These numeric elements are consistent with the source material. (3) The multi-hop reasoning is flawed: the question asks for an evolution between 2022 and 2023, requiring comparison across years and identification of changes in segmentation and casualty lines analyzed. The LLM fails this synthesis by asserting continuity rather than change, thus missing the central analytical point. (4) The contextual relevance is moderate because the answer discusses the right company, method, and general domain, but it misrepresents the directional shift in strategy, leading to a substantively incorrect conclusion about the evolution of AIG’s methodology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 527,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the classification and reporting of unallocated products evolve between fiscal years 2022 and 2024, particularly in terms of how they are categorized within Nike's consumer construct?",
      "original_answer": "In fiscal year 2022, unisex products were classified within Men's, and certain products not allocated to Men's, Women's, NIKE Kids', and Jordan Brand were included in 'Others' with adjustments not allocated by consumer. By fiscal year 2024, 'Others' continued to include products not allocated to Men's, Women's, Kids', and Jordan Brand, but there was no specific mention of unisex product classification within Men's, suggesting a potential shift or integration of unisex products within broader categories.",
      "llm_answer": "In the 2022 filing Nike introduced a new consumer‑construct – Men’s, Women’s, Kids’ and Jordan Brand – and said that, beginning in FY 2022, unisex items would be folded into the Men’s segment while any product that could not be placed in Men’s, Women’s, Kids’ or Jordan was reported as “Others” (the unallocated line)【page_35】. The 2024 filing still uses that same construct, defining “Others” as products not allocated to Men’s, Women’s, Kids’ or Jordan Brand, so unallocated products continue to be shown under “Others” (with unisex items still counted in Men’s)【page_37】.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains a critical factual inaccuracy regarding the classification of unisex products in fiscal year 2024. The original answer (ground truth) notes that while in FY2022 unisex products were explicitly classified within Men's, by FY2024 there was no specific mention of this practice, suggesting a potential shift or integration into broader categories. However, the LLM answer incorrectly asserts that 'unisex items still counted in Men’s' in FY2024, which contradicts the ground truth that such a classification was no longer explicitly stated. This misrepresents the evolution of reporting and reflects flawed multi-hop reasoning. Quantitatively, there are no numerical errors (dates and structure are accurate), so quantitative accuracy is high. Contextually, the answer is relevant and addresses the consumer construct and 'Others' category correctly. However, the qualitative reasoning is flawed because it fails to recognize the absence of evidence (no mention of unisex-in-Men's in 2024) as a signal of potential change, instead assuming continuity without support. Thus, while the structure and some facts are correct, the core inference about unisex product classification evolution is incorrect, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 355,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did PepsiCo's engagement with the 3.500% Senior Notes due 2025 evolve between 2023 and 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2023, PepsiCo's 3.500% Senior Notes due 2025 were listed among other notes, indicating they were part of the company's existing debt structure. By 2024, the 3.500% Senior Notes due 2025 were still present, but they were now accompanied by a broader range of new notes, including longer-term instruments such as the 3.500% Senior Notes due 2040 and the 3.550% Senior Notes due 2034. This suggests that PepsiCo expanded its debt portfolio in 2024, introducing more long-term financing options while maintaining its commitment to the 3.500% Senior Notes due 2025. The addition of new notes indicates a strategic shift toward diversifying its debt maturity structure.",
      "llm_answer": "PepsiCo’s 2023 Form 10‑K disclosed a board‑of‑directors resolution authorizing officers to establish the terms of a 3.500 % senior note due 2025 (see Exhibit 4.65 on page 129 and Exhibit 4.64 on page 130)【page_129】【page_130】. The 2024 Form 10‑K repeats the same resolution (Exhibit 4.64 on page 130)【page_130】, showing the company continued to pursue or retain that issuance. This steady authorization signals a deliberate debt‑management strategy that leans on medium‑term senior notes to lock in low borrowing costs and diversify PepsiCo’s debt‑maturity profile.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies the 3.500% Senior Notes due 2025 and references the correct years (2023 and 2024) and documents (Form 10-K), with accurate exhibit citations (Exhibits 4.64 and 4.65). The percentage (3.500%) and maturity year (2025) are factually correct, satisfying quantitative accuracy. However, the LLM misrepresents the nature of the information: the board resolution authorizing officers to set terms does not confirm that the notes were issued or actively managed; it only shows authorization was in place. The original answer correctly observes that the 2025 notes remained in the debt portfolio but emphasizes a key evolution—PepsiCo added longer-term notes (e.g., due 2034 and 2040) in 2024, indicating a strategic diversification of maturities. The LLM fails to mention these new instruments, missing a critical multi-hop insight about debt strategy evolution. Instead, it infers a 'steady authorization' as evidence of active debt management, which is a weaker interpretation. The conclusion about 'locking in low borrowing costs' is speculative and not directly supported by the ground truth. While the LLM addresses PepsiCo’s continued engagement with the 2025 notes, it omits the broader strategic shift toward long-term financing, resulting in partial completeness and flawed qualitative reasoning. Contextually, the answer is relevant and focused, but lacks the comparative analysis across years that the question demands.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 400,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did COP's financial disclosures regarding the Lower 48 region evolve between 2022 and 2024, particularly in terms of capital expenditures and future cash inflow revisions?",
      "original_answer": "In 2022, COP reported capital expenditures for the Lower 48 region at $3,129 million, indicating significant active investment in the area. By 2024, the company disclosed that certain amounts in the Lower 48 had been revised to reflect additional future cash inflows and future production costs, although no new capital expenditure figure was provided. This shift suggests a transition from active investment to a focus on revising financial projections based on updated expectations for production and cost dynamics in the region.",
      "llm_answer": "In the 2022 Form 10‑K ConocoPhillips said it spent about **$3.1 billion** on capital expenditures in the Lower 48 segment and logged **$13.1 billion** of “revisions of previous quantity estimates” that adjust future cash‑flow forecasts for that region【page_149】. By the 2024 Form 10‑K the company’s Lower 48 outlays had risen to roughly **$30 billion** (the sum of $12.1 billion of proved property acquisition, $10.9 billion of unproved acquisition, $6.3 billion of development and $0.55 billion of exploration)【page_157】, and the reserve‑quantity revisions were increased to about **$14.2 billion**, reflecting an upward revision to future cash‑inflow estimates for the Lower 48【page_158】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. The original answer states that COP reported $3,129 million (i.e., $3.129 billion) in capital expenditures for the Lower 48 in 2022, which the LLM approximates as $3.1 billion — this is acceptable and accurate within rounding. However, the LLM claims that in 2024, capital expenditures rose to roughly $30 billion based on a sum of line items from page 157. This is incorrect: those line items refer to different categories of spending (proved/unproved property acquisition, development, exploration), but they are not all capital expenditures for the Lower 48 alone, nor do they sum to a disclosed total for that region. The ground truth explicitly states that no new capital expenditure figure was provided for 2024. Additionally, the LLM invents a $13.1 billion and $14.2 billion 'revisions of previous quantity estimates' figure tied to future cash flows, which is not present in the original answer. While reserve revisions may affect cash flow projections, the original answer does not quantify these revisions in dollar terms, nor does it state that such figures were reported in 2022 or 2024. (2) The calculation of $12.1B + $10.9B + $6.3B + $0.55B = ~$30B is mathematically correct, but the underlying assumption — that these are all Lower 48 capital expenditures in 2024 — is unsupported by the ground truth. The original answer makes clear that no 2024 capex number was disclosed. (3) The multi-hop reasoning fails: the LLM incorrectly synthesizes data from different contexts (possibly misreading segment-level disclosures or conflating global with regional figures). It fabricates quantitative financial disclosures not present in the ground truth, particularly the dollar amounts for future cash inflow revisions. The evolution described — increasing capex and upward revisions — contradicts the ground truth narrative of a shift from active investment to revised projections without new capex data. (4) The correctness score is low due to major factual and quantitative errors. The contextual relevance is moderate because the answer addresses the right company, region, and general theme (capex and future cash flow revisions), but the details are largely incorrect. Quantitative accuracy is very low due to invented figures. Qualitative accuracy is slightly higher because the model attempts the right kind of analysis (tracking changes over time in financial disclosures), but the reasoning is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 660,
        "total_tokens": 1972
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did Comcast's financial commitments and governance arrangements with Atairos Group evolve between 2023 and 2024, particularly regarding capital obligations and control structures?",
      "original_answer": "In 2023, Comcast had a Fourth Amended and Restated Shareholders Agreement with Atairos Group, Inc., which was further amended in June 2023. This agreement outlined Comcast's role as the sole third-party investor and included governance terms among Atairos-related entities. By 2024, the relationship evolved into a more formalized investment framework under the equity method accounting. In this framework, Comcast reduced its capital commitment from up to $5 billion to $4.5 billion, limited annual capital calls to $400 million, and agreed to separately fund $40 million annually for management fees. Additionally, the 2024 filing clarified that Comcast absorbs approximately 99% of Atairos’ losses and receives approximately 86% of residual returns, while Atairos’ management companies (led by Comcast’s former CFO) retained all voting rights. These changes reflect a recalibration of financial exposure and a clearer delineation of control.",
      "llm_answer": "In the 2023 filing Comcast’s relationship with Atairos was governed by the Fourth Amended and Restated Shareholders Agreement (and its June 2 2023 amendment) that left the former‑CFO‑led management companies with all voting rights while Comcast was the sole third‑party investor (page 100). By the 2024 filing Comcast’s funding commitment had been trimmed to a $4.5 billion aggregate limit (down from $5 billion) with annual capital calls capped at $400 million and a $40 million annual management‑fee commitment, and the company now classifies Atairos as a variable‑interest entity, confirming it has no voting control and only limited consent rights (pages 84‑85).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures all key quantitative elements correctly: the reduction in Comcast's capital commitment from $5 billion to $4.5 billion, the $400 million annual capital call cap, and the $40 million annual management fee are all correctly reported. The date of the June 2023 amendment is accurately referenced, and the governance structure—specifically that voting rights remain with the former-CFO-led management companies—is correctly identified. The LLM also correctly notes the classification change in 2024, where Atairos is treated as a variable-interest entity with Comcast having no voting control but significant financial exposure. The only minor omission is that the original answer specifies Comcast absorbs approximately 99% of losses and receives 86% of residual returns, which the LLM answer does not mention. This is a relevant detail regarding financial commitment evolution and risk allocation, though the core capital obligations and control structures are well-covered. The reasoning is sound, with correct synthesis across 2023 and 2024 filings, and the entities, years, and financial terms are accurate. Wording differs but meaning is semantically equivalent on the main points. Thus, the answer is excellent but slightly less complete than the ground truth on the economic rights breakdown.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 372,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did FedEx's projected utilization of the Cessna SkyCourier 408 change between 2022 and 2023 filings, and what does this indicate about its strategic role in the fleet compared to other aircraft?",
      "original_answer": "In the 2022 filing, FedEx projected a total of 49 Cessna SkyCourier 408 aircraft to be in service through 2027. By the 2023 filing, this projection dropped significantly to only 31 Cessna SkyCourier 408 aircraft through 2029. This indicates a strategic reduction in the planned reliance on the Cessna SkyCourier 408, especially when compared to other aircraft types like the B767F and B777F, which saw more stable or less reduced projections. This shift suggests FedEx may have reassessed the aircraft's role in its long-term fleet strategy.",
      "llm_answer": "In the 2022 Form 10‑K FedEx disclosed that it owned only one Cessna 408 (still being modified) and was planning to acquire **49 SkyCourier 408s** – 11 in 2023, 12 in 2024, 12 in 2025 and 14 in 2026. The 2023 filing trimmed the total to **31 SkyCourier 408s** – 17 slated for delivery in 2025 and 14 in 2026 – reflecting a revised, still‑significant but more focused build‑out. This change shows FedEx is positioning the SkyCourier as a dedicated regional‑feeder aircraft to supplement its larger long‑haul freighters (B777F, B767F) and medium‑capacity turboprops, emphasizing high‑frequency, short‑haul service rather than core long‑haul capacity.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the reduction in projected Cessna SkyCourier 408 aircraft from 49 in the 2022 filing to 31 in the 2023 filing, which matches the ground truth. However, there is a discrepancy in the delivery timeline: the 2022 filing mentions 49 aircraft to be delivered through 2027, but the LLM specifies annual breakdowns (11 in 2023, etc.) that are not present in the ground truth and may be fabricated or misattributed. Similarly, the 2023 filing states the total is now 31 through 2029, but the LLM claims 17 in 2025 and 14 in 2026 without mentioning 2029, which omits a key temporal shift (extension of timeline). These details affect quantitative precision. (2) The core numbers—49 and 31—are correct, and the direction and magnitude of change (reduction of 18 aircraft) are accurate. However, the LLM introduces specific delivery year allocations not found in the ground truth, which risks overprecision and potential inaccuracy. (3) The reasoning about strategic role is sound: the LLM correctly infers that the SkyCourier is being positioned as a regional feeder aircraft supplementing larger freighters like B777F and B767F, aligning with the ground truth’s implication of reduced strategic emphasis compared to other aircraft. The synthesis across years and aircraft types is logical and contextually appropriate. (4) The answer is highly relevant and captures the essence of the strategic shift. While it adds plausible detail (delivery schedule), this introduces minor inaccuracies. Overall, the answer is factually strong on the main point (reduction from 49 to 31) and correct in interpretation, warranting a high score but not perfect due to unsupported specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 466,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Nike's approach to the Air Max product line evolved from 2022 to 2024, particularly in terms of revenue transparency and technological innovation emphasis?",
      "original_answer": "In 2022, Nike included Air Max in a general list of technologies within the revenue disaggregation table, indicating its presence in the product portfolio but without specific revenue figures. By 2024, while no direct revenue numbers were disclosed, Nike emphasized Air Max as a central example of its innovation strategy, highlighting its integration into broader product categories and consumer applications. This shift reflects a strategic move from passive acknowledgment to positioning Air Max as a key innovation driver, despite the continued lack of standalone financial metrics for the product line.",
      "llm_answer": "In the 2022 Form 10‑K Nike reported only aggregate footwear revenue and gave no separate line‑item for Air Max, so the Air Max contribution was not disclosed in detail (see Note 16 – Revenues, page page_88). By the 2024 filing Nike is explicitly highlighting Air Max as one of its core technology platforms and notes its Air‑Sole manufacturing subsidiary that supplies new cushioning components, underscoring a stronger focus on innovation for the Air Max line (see product‑development discussion, page page_6, and manufacturing section, page page_7).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. (1) Quantitatively, no specific revenue figures are claimed for Air Max in either year, which matches the original answer—Nike did not disclose standalone revenue in 2022 or 2024. The reference to aggregate footwear revenue in 2022 and lack of a line-item is correct. (2) The LLM correctly identifies the shift in emphasis by 2024, noting Nike's explicit highlighting of Air Max as a core technology platform and referencing innovation through the Air-Sole manufacturing subsidiary. This reflects the strategic pivot toward innovation emphasis as stated in the ground truth. (3) The multi-hop reasoning is sound: the answer synthesizes information across years (2022 vs 2024), documents (Form 10-K sections), and dimensions (revenue transparency and technological focus). (4) Minor deduction in qualitative accuracy due to slightly less nuanced framing than the original—while the LLM mentions innovation focus, it doesn't fully articulate the conceptual shift from 'passive acknowledgment' to 'innovation driver' as clearly as the ground truth. However, the core meaning is preserved. Wording differences are acceptable under semantic equivalence. All entities (Nike, Air Max, Air-Sole, Form 10-K, correct years) are accurate. Contextual relevance is perfect—directly addresses both revenue transparency and technological innovation evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 391,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Comcast's capital expenditure strategy regarding Epic Universe evolve from 2023 to 2024, particularly in terms of specific investment amounts and thematic park development priorities?",
      "original_answer": "In 2023, Comcast specifically noted an increase in capital expenditures directly related to the development of Epic Universe in Orlando, with a total of $8.2 billion allocated to Connectivity & Platforms, which included investments in scalable infrastructure and line extensions. By 2024, the company continued to emphasize investment in existing and new attractions at Universal theme parks, including Epic Universe, as part of its broader capital expenditure plan for 2025. While specific figures for Epic Universe alone were not disclosed in 2024, the company indicated an ongoing commitment to theme park development, particularly in expanding attractions and enhancing capacity. The evolution shows a shift from initial infrastructure and development focus in 2023 to a more sustained investment strategy in 2024 that includes both infrastructure and guest experience enhancements.",
      "llm_answer": "In 2023 Comcast said its total capital spending rose to about $8.2 billion and that part of the increase was “related to the development of Epic Universe in Orlando,” reflecting early‑stage work and land‑acquisition for the new park. By the 2024 filing, total capex was essentially unchanged at roughly $8.3 billion, but the company highlighted that theme‑park attraction spending grew and now included “costs associated with the construction of Epic Universe,” shifting the priority from acquisition and planning in 2023 to actual building of the park in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $8.2 billion capital expenditure in 2023 related to Epic Universe, aligning with the ground truth. It also accurately notes that 2024 capex was approximately $8.3 billion, which is consistent with the continued investment trend. However, the original answer does not specify the total 2024 capex figure—only that investment in theme parks including Epic Universe continued—so the $8.3 billion figure, while plausible, is not explicitly confirmed in the ground truth, introducing a minor inaccuracy. (2) The shift from 'early-stage work and land acquisition' in 2023 to 'construction' in 2024 is a reasonable interpretation of the evolution from infrastructure focus to building, though the original answer emphasizes 'scalable infrastructure and line extensions' rather than land acquisition, which slightly misaligns the priority framing. (3) The multi-hop reasoning is sound: the model correctly infers a strategic shift based on changes in language between filings and connects capital allocation to development phases. However, it adds specificity (e.g., 'land-acquisition') not present in the original, which may overinterpret. (4) Despite minor overprecision on the 2024 capex number and slight mischaracterization of 2023 activities, the core facts—increased investment focus on Epic Universe, evolution from development planning to construction, and sustained capex levels—are correct and contextually well-applied, warranting high scores in qualitative accuracy and full marks for relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 427,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did FedEx's utilization of the ATR 72-600F aircraft evolve between 2022 and 2023 as reflected in their fleet projections for the same planning periods?",
      "original_answer": "In 2022, FedEx projected operating 11 ATR 72-600F aircraft in 2023, 6 in 2024, 6 in 2025, and only 1 in 2026. By 2023, the projections for the same time periods changed significantly, with 7 ATR 72-600F aircraft planned for 2025 and only 3 for 2026. This indicates a notable reduction in planned usage of the ATR 72-600F by FedEx over time.",
      "llm_answer": "In the 2022 filing FedEx listed six ATR‑72‑600F aircraft in its fleet and a commitment to receive 11 additional ATR‑72‑600F in 2023 – a total of 24 of the type were slated for delivery through the 2027 planning horizon【page_40】. By the 2023 filing the forward‑looking commitment schedule had shifted, showing only ten ATR‑72‑600F slated for delivery in 2025‑2026 and no further 2023 deliveries were listed【page_117】, indicating that the 2023 expansion was now expected to be in service and future growth of the type was more modest.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, FedEx projected operating 11 ATR 72-600F aircraft in 2023, decreasing to 6 in 2024 and 2025, and only 1 in 2026. By 2023, the projections changed to 7 for 2025 and 3 for 2026. The LLM answer incorrectly states that FedEx had six ATR 72-600F in its fleet in 2022 and committed to 11 additional in 2023, totaling 24 through 2027 — none of which aligns with the ground truth. The ground truth reflects planned operations (not deliveries or commitments), and the numbers cited in the LLM response (e.g., 24 aircraft through 2027, 10 deliveries in 2025–2026) are not supported. (2) Quantitative accuracy is low: the LLM misrepresents fleet size, delivery schedules, and planning horizons. For example, the ground truth shows a reduction from 11 to 1 aircraft projected over time, while the LLM suggests ongoing deliveries into 2027, contradicting the downward trend. (3) The reasoning is partially sound in that it identifies a shift in projections between 2022 and 2023 filings and attempts multi-hop synthesis across years, but it misinterprets the nature of the data (operational fleet projections vs. delivery commitments). (4) Contextual relevance is high because the answer addresses the evolution of ATR 72-600F utilization and compares 2022 and 2023 filings, but factual correctness undermines the response. The core conclusion about reduced future usage is directionally correct, but the supporting data is wrong, leading to a partially correct but misleading answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 434,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did Nike's approach to estimating product return reserves evolve between fiscal 2022 and fiscal 2024, and what does this indicate about changes in their revenue recognition methodology?",
      "original_answer": "In fiscal 2022, Nike disclosed that the estimated cost of inventory for expected product returns was $269 million, and these reserves were recorded in Prepaid expenses and other current assets. By fiscal 2024, while the specific dollar amount of the product return reserve was not disclosed, Nike described a more formalized estimation process, stating that it calculates anticipated reductions in revenue—such as sales returns—by determining the 'most likely amount' it will be entitled to receive. This indicates a shift toward a more probabilistic and forward-looking revenue estimation methodology, aligning with the broader revenue recognition framework where variable consideration is estimated at the time revenues are recognized.",
      "llm_answer": "In the 2022 Form 10‑K Nike only disclosed a $1.015 billion sales‑related reserve (including a $194 million inventory cost for expected returns) and said it records the “most likely” amount as a reduction to revenue. By the 2024 filing the company spells out a detailed methodology—using historical return rates, specific identification of outstanding returns, and estimates of discretionary returns and post‑invoice discounts, and separating contractual from discretionary components—adjusting revenue when actual returns differ. This evolution shows Nike has moved to a more granular, ASC 606‑aligned revenue‑recognition approach that more precisely estimates variable consideration (returns) at the time of sale.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. The ground truth states that in fiscal 2022, the estimated cost of inventory for expected product returns was $269 million, but the LLM claims a $194 million inventory cost and a $1.015 billion sales-related reserve, which is not mentioned in the original answer. These figures are unsupported by the provided truth and contradict it. (2) The LLM incorrectly asserts that in 2022, Nike already used the 'most likely amount' method as a reduction to revenue, while the original answer indicates this more formalized 'most likely amount' approach was described in the 2024 filing, not 2022. This misrepresents the evolution timeline. (3) While the LLM correctly infers a shift toward a more granular, ASC 606-aligned methodology in 2024, this reasoning is based on incorrect premises. The mention of 'historical return rates', 'discretionary returns', and 'post-invoice discounts' is more detailed than the original answer provides, suggesting possible hallucination. (4) Despite these errors, the LLM captures the general direction of change—toward a more sophisticated, forward-looking revenue recognition model aligned with variable consideration under ASC 606—so the conceptual interpretation is partially valid. However, due to major quantitative errors and incorrect attribution of methodology timing, the correctness score is low. Quantitative accuracy is severely compromised. Qualitative accuracy is moderate due to correct high-level inference despite flawed inputs. Contextual relevance is high as the response stays focused on the question's theme.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 450,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the planned fleet composition of the Cessna SkyCourier 408 change between 2022 and 2023 for the years 2025 and beyond, and what does this indicate about the company's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FDX projected a total of 12 Cessna SkyCourier 408 aircraft to be in operation by 2025 and planned to maintain that number through 2026. By 2023, the company increased its planned fleet count for 2025 to 17 but reduced it to 14 for 2026. This indicates a short-term increase in strategic reliance on the Cessna SkyCourier 408, followed by a moderate decline in planned usage by 2026, suggesting a recalibration of fleet strategy.",
      "llm_answer": "The 2022 filing showed a commitment to **12 Cessna SkyCourier 408s for delivery in 2025 and none “thereafter”**【page_114】. The 2023 filing raised the 2025 commitment to **17 SkyCourier 408s, still with zero deliveries beyond 2025**【page_117】. This modest increase for 2025 indicates FedEx is expanding its near‑term use of the SkyCourier, but the unchanged “thereafter” figure suggests the aircraft is not slated to become a long‑term, core component of its fleet.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase from 12 to 17 Cessna SkyCourier 408 aircraft planned for 2025 between the 2022 and 2023 filings, which matches the ground truth. However, it incorrectly states that there were zero deliveries 'beyond 2025' or 'thereafter' in both years, while the ground truth indicates that in 2022, FDX planned to maintain 12 aircraft through 2026, and in 2023, the plan was reduced to 14 for 2026. This means the LLM misrepresents the post-2025 fleet composition, claiming no long-term use when in fact there was a planned continuation (albeit reduced). (2) The numbers for 2025 (12 and 17) are accurate, but the claim of 'zero thereafter' is factually incorrect based on the ground truth, which specifies 12 in 2026 (2022 plan) and 14 in 2026 (2023 plan). This is a significant quantitative error. (3) The multi-hop reasoning is partially sound—comparing the 2025 figures across years is correct—but fails in synthesizing the full fleet trajectory beyond 2025. The conclusion that the aircraft is not a long-term core component is speculative and contradicted by the actual plans to operate 14 aircraft in 2026. (4) The contextual relevance is high as the answer addresses fleet changes and strategic implications, but the factual inaccuracies in the post-2025 plans reduce correctness and qualitative accuracy. The answer captures the short-term increase but misses the nuanced recalibration indicated in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 407,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Mastercard's real-time account-based payments infrastructure evolved from 2023 to 2024, particularly in terms of operational scale and integrated security capabilities?",
      "original_answer": "In 2023, Mastercard operated or was implementing real-time payments infrastructure in 13 markets globally, offering instant payments with enhanced data and messaging capabilities. The company emphasized a distributed network architecture that enabled intelligent routing and applied value-added services like fraud scoring and tokenization in real time. By 2024, Mastercard expanded its capabilities by enhancing its ACH and real-time account-based payment systems to provide more secure, simple, and smart payment solutions across its global network. The company also reinforced its multi-layered security approach, integrating additional protections and partnerships to safeguard the payments ecosystem. These developments indicate a strategic shift toward strengthening both the scale and security of its real-time payments infrastructure.",
      "llm_answer": "In 2023 Mastercard reported that its real‑time account‑based payments capability was operating or being rolled out in **13 markets** and was supported by a multi‑layered security framework built into its core network (see 2023 Form 10‑K, p. 11). By the 2024 filing the company describes real‑time ACH (batch and real‑time) as a **core component of its global payments network that now spans more than 150 currencies and 210 countries**, and it explicitly ties these capabilities to dedicated security solutions that leverage Mastercard’s secure‑data architecture (see 2024 Form 10‑K, p. 72). This shows the infrastructure has broadened from a limited set of markets to a worldwide scale while embedding security more tightly into the real‑time payment services.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 13 markets in 2023 from the ground truth, which is accurate. However, it introduces a significant inaccuracy by claiming that by 2024, Mastercard's real-time ACH capabilities span 'more than 150 currencies and 210 countries'—a figure not present in the original answer and not supported by the provided ground truth. While Mastercard did expand its infrastructure, the original answer does not specify such a scale, only noting broader enhancements and integration. This overstatement of scale undermines quantitative accuracy. (2) The citation of Form 10-K pages (p. 11 for 2023, p. 72 for 2024) suggests document grounding, but the 2024 data expansion is overstated. The 13-market figure for 2023 is correct. No calculations are made, so no arithmetic errors, but the implied growth from 13 markets to 210 countries is misleading—these are not equivalent units (markets vs. countries) and likely reflect different scopes (e.g., network reach vs. real-time payments deployment). (3) The multi-hop reasoning is partially sound: the model correctly infers growth in scale and tighter security integration from 2023 to 2024. It synthesizes the evolution of infrastructure and security, aligning with the original answer’s emphasis on expanded capabilities and reinforced security. However, the leap to 210 countries overreaches the evidence in the ground truth, indicating a failure in precise synthesis. (4) The correctness score is 7 because the core direction of evolution—increased scale and deeper security integration—is accurate, and the 2023 data point is correct. However, the exaggerated 2024 metrics reduce quantitative accuracy to 6. Qualitative accuracy is 8 due to sound reasoning framework despite overstatement. Contextual relevance is high (9) as the answer directly addresses both operational scale and security evolution as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 514,
        "total_tokens": 1922
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did Nike's use of foreign exchange forwards and options evolve between 2022 and 2024, particularly in terms of their impact on financial liabilities and hedging strategy?",
      "original_answer": "In 2022, foreign exchange forwards and options had a net gain of $8 million after tax, impacting various income categories such as revenues, cost of sales, and other (income) expense, net. By 2024, the liabilities associated with these instruments increased to $110 million under accrued liabilities and $5 million under deferred income taxes and other liabilities, indicating a shift in how these derivatives were managed or reported. This reflects a strategic evolution in Nike's hedging activities and financial exposure management.",
      "llm_answer": "Nike trimmed the notional amount of foreign‑exchange forwards and options used as cash‑flow hedges from roughly $18.5 billion in 2022 to $16.2 billion in 2024, while the notional of undesignated forwards rose from about $3 billion to $4.4 billion.  The change lowered derivative liabilities – from a modest net‑liability position in 2022 (no net liability and $486 million of collateral received) to $115 million of accrued liabilities for designated hedges and only $5 million for undesignated hedges in 2024 – and signals a shift toward more balance‑sheet‑oriented forward contracts to offset fair‑value changes of assets and liabilities, while still maintaining a cash‑flow‑hedge program for forecasted transactions (up to a 24‑month horizon).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that foreign exchange forwards and options had a net gain of $8 million after tax in 2022 and that by 2024, liabilities were $110 million under accrued liabilities and $5 million under deferred income taxes and other liabilities. However, the LLM claims derivative liabilities were $115 million for designated hedges and $5 million for undesignated hedges in 2024, which misrepresents the categorization (accrued liabilities vs. deferred taxes) and total amount. Additionally, the LLM introduces specific notional values—$18.5 billion in 2022 and $16.2 billion in 2024 for cash-flow hedges, and $3 billion to $4.4 billion for undesignated forwards—which are not present in the original answer and cannot be verified against the ground truth. The claim about 'collateral received' ($486 million) is also absent from the original and appears fabricated. (2) The only partially correct number is the $5 million liability in 2024, which aligns with the 'deferred income taxes and other liabilities' in the original, but the $110 million under accrued liabilities is misrepresented as $115 million in a different context. The original does not mention notional amounts or collateral, so these are unsupported additions. (3) The reasoning attempts multi-hop synthesis by inferring a strategic shift toward balance-sheet-oriented contracts, which loosely aligns with the original's mention of a shift in management/reporting. However, this inference is based on incorrect data, undermining the logic. The original emphasizes the impact on financial liabilities and hedging strategy evolution through reported liability increases, while the LLM incorrectly frames it as a reduction in liabilities. (4) Despite factual errors, the LLM stays contextually relevant by addressing the evolution of hedging strategy and linking it to financial liabilities. The qualitative reasoning is plausible but built on false premises. Hence, the correctness score is low due to major quantitative inaccuracies, though the direction of strategic evolution is partially aligned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 586,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has the product category classification of Puffs within the Baby, Feminine & Family Care segment evolved between 2022 and 2023?",
      "original_answer": "In 2022, Puffs was categorized under the Family Care sub-category, which included Paper Towels, Tissues, and Toilet Paper. By 2023, Puffs remained in the Family Care category, but the specific mention of 'Tissues' replaced 'Tissues' with a more general listing without sub-category breakdowns, indicating a simplification or consolidation of how the segment details were reported.",
      "llm_answer": "In the 2022 Form 10‑K, Puffs is listed under the “Family Care (Paper Towels, Tissues, Toilet Paper)” sub‑category of the Baby, Feminine & Family Care segment【page_19】. The 2023 Form 10‑K places Puffs in the identical “Family Care” sub‑category of the same segment【page_19】, so its product‑category classification did not change.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually correct in stating that Puffs remained in the Family Care sub-category within the Baby, Feminine & Family Care segment from 2022 to 2023, and correctly cites the same segment name and page reference. However, it misses a key nuance present in the ground truth: the evolution in reporting detail. In 2022, the sub-category explicitly listed 'Tissues' as part of Family Care, but in 2023, the breakdown became more general without specific sub-category mentions (e.g., 'Tissues' was no longer highlighted), indicating a simplification or consolidation in reporting. The LLM incorrectly concludes that 'its product-category classification did not change,' which overlooks this shift in disclosure granularity. While the categorical placement is accurate, the answer fails to capture the qualitative evolution in how the category was reported, which is central to the question about 'evolution' between years. This constitutes a significant omission in reasoning and completeness, particularly for a question asking about change over time. Quantitative accuracy is perfect—no numbers, dates, or entities are incorrect. Contextual relevance is high as the response directly addresses the topic with proper sourcing. The qualitative accuracy is reduced due to incomplete synthesis of the reporting change, despite correct entity and segment identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1173,
        "completion_tokens": 380,
        "total_tokens": 1554
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the positioning of Tampax within P&G's product portfolio evolved between 2022 and 2023, particularly in terms of its categorization and associated product lines?",
      "original_answer": "In 2022, Tampax was categorized under 'Feminine Care' within the 'Baby, Feminine & Family Care' segment, which also included 'Baby Care' and 'Family Care' sub-categories. By 2023, the product category was refined, and Tampax was associated solely with 'Menstrual Care' under the same broader segment. This reflects a more focused positioning of Tampax, separating it from general 'Family Care' items and aligning it more specifically with menstrual health needs.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K place Tampax in the **Baby, Feminine & Family Care** segment, under the **Feminine‑Care** sub‑category (Menstrual Care). In each year the brand is listed together with the other feminine‑care brands – Always and Always Discreet – and is grouped with the Bounty family‑care brand in the segment’s brand list, showing that its categorization and associated product lines have remained unchanged from 2022 to 2023【page_18】【page_19】.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that Tampax's categorization remained unchanged between 2022 and 2023, directly contradicting the ground truth. While the answer correctly identifies that Tampax was in the 'Baby, Feminine & Family Care' segment in both years (contextually relevant), it fails to recognize the key evolution in sub-category classification. The ground truth states that in 2022, Tampax was under 'Feminine Care' within the broader segment, but in 2023 it was repositioned under a more specific 'Menstrual Care' sub-category, reflecting a strategic refinement. The LLM incorrectly asserts no change occurred, citing both years as 'Feminine-Care (Menstrual Care)', which misrepresents the evolution. There are no numeric values to assess, so quantitative accuracy is neutral (scored 10 by default for absence of error). However, the qualitative accuracy is low due to failure in multi-hop reasoning—synthesizing changes across two years and categories. The model relies on surface-level similarity (same segment, similar brand groupings) but misses the nuanced repositioning. Contextual relevance is moderate because it discusses the right segment and brands, but the conclusion is misleading. Thus, the correctness score is low (3) due to a major factual inaccuracy in the central claim.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 367,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Oracle's strategy and positioning of Oracle Engineered Systems evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue contribution and research investment expectations?",
      "original_answer": "In fiscal 2022, Oracle highlighted that its hardware business, which includes Oracle Engineered Systems, involved point-of-sale revenue recognition for hardware and related software, with the majority of products sold through indirect channels. By fiscal 2023, Oracle introduced a more forward-looking strategy, explicitly stating plans to continue investing in research and development to improve existing hardware products and develop new offerings. Additionally, in fiscal 2023, Oracle noted that hardware represented 6% of total revenues, a figure not specified in 2022, indicating a clearer emphasis on the segment's strategic positioning.",
      "llm_answer": "In fiscal 2022 Oracle’s Engineered Systems hardware generated $3.2 billion of revenue – roughly 9 % of total revenue – and the segment’s margin slipped as the company de‑emphasized non‑strategic hardware lines (page 51). By fiscal 2023 the hardware business accounted for only about 6 % of total revenue, reflecting a further reduction in its contribution as Oracle leans more heavily on cloud and license growth (page 41), while the company explicitly says it will “continue to make investments in research and development to improve existing hardware products and services and to develop new hardware products and services” (page 41). This signals a shift toward a smaller, more strategic role for Engineered Systems, but with a sustained R&D commitment.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The ground truth does not mention a specific revenue figure of $3.2 billion for Oracle Engineered Systems in fiscal 2022, nor does it state that hardware accounted for 9% of total revenue that year. The only revenue percentage provided in the ground truth is 6% for fiscal 2023. The LLM invents a 9% figure and a $3.2 billion amount with no support from the original answer, which constitutes a major factual error. (2) While the 6% revenue contribution in fiscal 2023 matches the ground truth, the LLM incorrectly frames this as a 'further reduction' from 9% in 2022, implying a trend not present in the original data—since the 2022 percentage was not disclosed. This leads to flawed comparative analysis. (3) On qualitative aspects, the LLM correctly identifies the multi-hop element that Oracle in fiscal 2023 committed to continued R&D investment in hardware, which marks a strategic evolution from 2022's more operational description. This shows sound reasoning in identifying a shift in strategic tone. However, the synthesis is undermined by the fabricated numbers. (4) Contextually, the response is well-structured and directly addresses the question about evolution in strategy, revenue contribution, and R&D—hence high relevance. But due to the invention of unsupported financial figures and incorrect year-over-year comparison, the correctness and quantitative accuracy scores are low. Minor note: citation of 'page 41/51' suggests access to source documents but does not excuse factual misrepresentation against the verified ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 454,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did Honeywell's investment in private funds for its Non-U.S. pension plans evolve between 2022 and 2023, particularly in terms of allocation and classification across fair value hierarchy levels?",
      "original_answer": "In 2022, Honeywell reported $1,105 million invested in private funds for its U.S. pension plans, with the amount classified under Level 3 of the fair value hierarchy. By 2023, the company reported $115 million in private fund investments for its Non-U.S. pension plans, with $41 million classified under Level 2 and $74 million under Level 3 of the fair value hierarchy. This represents a significant decrease in overall private fund allocation, particularly in U.S. plans, and a shift in classification for the remaining private fund investments under the Non-U.S. plans.",
      "llm_answer": "Honeywell’s non‑U.S. pension plans increased their private‑fund holdings from **$90 million in 2022** to **$115 million in 2023**.  In 2022 the private‑fund assets were **$54 million classified as Level 2** and **$36 million as Level 3** (none at Level 1); by 2023 the mix had shifted to **$41 million at Level 2** and **$74 million at Level 3**, indicating a larger share of the private‑fund exposure moved into the less‑observable Level 3 category【page_110】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. The original answer states that in 2022, Honeywell reported $1,105 million invested in private funds for its *U.S.* pension plans (not Non-U.S.), all classified under Level 3. However, the LLM incorrectly claims $90 million in Non-U.S. private fund investments in 2022, with $54 million in Level 2 and $36 million in Level 3—none of which is supported by the ground truth. In 2023, the LLM correctly reports $115 million in Non-U.S. private fund investments, with $41 million in Level 2 and $74 million in Level 3, matching the ground truth. (2) Quantitative accuracy is poor: the 2022 figures are entirely fabricated ($90M total vs. no reported Non-U.S. private fund investments in 2022 in the original), and the breakdown into Level 2 and Level 3 is incorrect. The only correct numbers are the 2023 Non-U.S. totals. (3) Multi-hop reasoning is flawed—the question asks about evolution in *Non-U.S.* plans between 2022 and 2023, but the LLM invents 2022 Non-U.S. data that does not exist in the original. The original shows a shift from U.S. to Non-U.S. reporting or a reallocation, but the LLM misrepresents this as a growth in Non-U.S. holdings. (4) Contextual relevance is moderate because the answer discusses the right topic (private fund allocation in Non-U.S. pension plans, fair value hierarchy levels) and correctly reports 2023 data, but the incorrect 2022 data and misattribution of U.S. figures to Non-U.S. plans undermine the validity. The conclusion about a shift to Level 3 is partially reasonable given 2023 data, but based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 445,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the status and management of the 2014 USD Notes evolve between 2023 and 2024, and what specific actions were taken regarding this debt in 2024?",
      "original_answer": "In 2023, the 2014 USD Notes were classified as short-term debt, net of unamortized discount and debt issuance costs, with a maturity date of April 2024. By 2024, the company reported that in April 2024, $1 billion of principal related to the 2014 USD Notes matured and was paid in full. This indicates that the company transitioned the obligation from a near-term liability in 2023 to a fully settled debt instrument in 2024.",
      "llm_answer": "In the 2023 filing the 3.375 % senior “2014 USD Notes” (due April 2024) were still outstanding and were presented as short‑term debt, net of unamortized discount and issuance costs, on the consolidated balance sheet 【page_97†L31-L38】.  In 2024 the company’s debt‑management actions led those notes to mature and the full $1 billion principal was paid off in April 2024, effectively retiring the 2014 USD Notes 【page_58†L1-L4】.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the 2014 USD Notes were outstanding in 2023, classified as short-term debt, matured in April 2024, and the $1 billion principal was paid in full. The inclusion of the coupon rate (3.375%) adds precision not in the original but does not contradict it. (2) Quantitative elements—$1 billion principal, April 2024 maturity and payment date—are factually correct and match the ground truth. Format variations (e.g., $1 billion) are acceptable. (3) Multi-hop reasoning is sound: the answer correctly synthesizes the status in 2023 (from 2023 filing) with the 2024 action (from 2024 filing), showing the transition from liability to settlement. (4) Contextual relevance is high—the response directly addresses both parts of the question: the evolution between 2023 and 2024 and the specific 2024 action taken. Citations from relevant pages further support accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 282,
        "total_tokens": 1496
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has the treatment and documentation of Lowe's Officer Indemnification Agreements evolved between 2022 and 2024, and what does this indicate about the company's executive risk management and governance continuity?",
      "original_answer": "Between 2022 and 2024, Lowe's maintained the same form of Officer Indemnification Agreement, first filed as Exhibit 10.43 on April 2, 2019, and refiled without amendment in both the 2022 and 2024 10-K filings. This indicates that the company did not modify the terms or structure of these agreements over this period, suggesting consistent governance practices and a stable approach to executive risk management and retention. Investors can interpret this continuity as a sign of predictable leadership protections and aligned corporate governance priorities.",
      "llm_answer": "In the 2022 Form 10‑K Lowe’s presented a stand‑alone Officer Indemnification Agreement as Exhibit 10.43 (dated April 2 2019) 【page_79】. By contrast, the 2024 Form 10‑K exhibit schedule (pages 77‑78) no longer lists a separate officer indemnification document, indicating that the indemnification terms have been folded into updated corporate‑governance or indemnity policies rather than filed as a distinct exhibit. This shift shows that Lowe’s continues to protect its executives but has moved to a more integrated, streamlined documentation approach, reflecting ongoing executive risk management and governance continuity.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the Officer Indemnification Agreement was no longer listed as a separate exhibit in the 2024 10-K. The ground truth confirms that the same form (Exhibit 10.43, dated April 2, 2019) was refiled without amendment in both the 2022 and 2024 10-Ks. The LLM incorrectly infers a change in documentation practice, claiming the agreement was 'folded into updated corporate-governance or indemnity policies,' which is not supported by the data. (2) Quantitatively, the LLM correctly identifies the exhibit number (10.43) and the original filing date (April 2, 2019), which are accurate. However, it misrepresents the presence of the exhibit in the 2024 filing, introducing a false conclusion about its absence. There are no calculations, but the dates and exhibit numbers are partially correct. (3) The multi-hop reasoning fails because the model incorrectly synthesizes the evolution of the agreement over time. Instead of recognizing continuity, it assumes integration due to absence in the exhibit list, which contradicts the ground truth that the agreement was refiled identically. This breaks the logical chain required for accurate inference. (4) While the LLM attempts to interpret governance implications (risk management, continuity), its conclusion is based on a false premise. The contextual relevance is moderate because it addresses executive risk and governance, but the factual foundation is flawed, leading to a misleading interpretation. Thus, the correctness score is low due to major factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 436,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the market share and category positioning of Always Discreet in the adult incontinence market change between the 2022 and 2023 Procter & Gamble 10-K filings?",
      "original_answer": "In the 2022 filing, Always Discreet was explicitly stated to have over 10% market share in the key adult incontinence markets where Procter & Gamble competes. However, in the 2023 filing, while Always Discreet is still listed as a major brand in the Feminine Care category under the Baby, Feminine & Family Care segment, no specific market share figure is provided for the brand. This suggests a shift in how the brand's performance is communicated, moving away from a quantified market share disclosure to a more general category association.",
      "llm_answer": "- 2022 10‑K: P&G said it “also competes in the adult‑incontinence sub‑category behind **Always Discreet**, with **about 15 %** market share in the markets in which we compete.”【page_18】\n\n- 2023 10‑K: The same language is used, but the share is now described as “with **over 10 %** market share in the key markets in which we compete.”【page_18】\n\n**Result:** The filing shows a modest decline in Always Discreet’s reported share (from roughly 15 % to just over 10 %), while its positioning remains unchanged – it is still the leading brand in adult incontinence that P&G trails.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in the 2022 filing, Always Discreet had 'over 10%' market share, not 'about 15%' as claimed by the LLM. Furthermore, the 2023 filing does not provide any specific market share figure for Always Discreet, contrary to the LLM's claim that it was updated to 'over 10%'. Thus, the reported 'decline' from 15% to just over 10% is entirely fabricated. (2) The quantitative accuracy is very low because both percentages cited by the LLM are incorrect or misrepresented. The 15% figure does not appear in the 2022 filing per the ground truth, and the 2023 filing contains no market share number at all. There is no valid basis for claiming a 'modest decline'. (3) The multi-hop reasoning is flawed: the LLM incorrectly assumes that both years contain market share disclosures and that a comparison can be drawn, when in fact only 2022 included a quantified share (and even that was 'over 10%', not 15%). The conclusion that positioning remained unchanged is partially aligned with the ground truth (brand still listed as major), but the reasoning is undermined by incorrect data. (4) Contextual relevance is moderate because the answer addresses the right topic (market share and positioning of Always Discreet across two years) and correctly identifies the brand's role in adult incontinence, but the core factual claims about market share values and trends are false. The answer creates a narrative not supported by the source documents.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 422,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has Oracle's strategic positioning of Engineered Systems evolved between 2022 and 2023, particularly in terms of their role within the hardware business and implications for Oracle's cloud transformation narrative?",
      "original_answer": "In 2022, Oracle Engineered Systems were described as pre-integrated products central to both cloud and on-premise data center infrastructure, emphasizing their technical advantages such as improved performance, scalability, and simplified maintenance. However, by 2023, Oracle elevated the strategic importance of Engineered Systems by positioning them as part of a broader hardware business that now includes servers, storage, and operating systems, all tightly integrated and accounted for as combined performance obligations. The 2023 filing also highlighted that hardware revenues, including Engineered Systems, represented 6% of total revenues in both fiscal 2023 and 2024, and underscored ongoing R&D investments to enhance these offerings. This evolution suggests that Oracle is leveraging Engineered Systems not just as technical solutions but as foundational components in its hybrid cloud and on-premise strategies, aligning them more closely with its cloud transformation narrative while acknowledging the lower-margin nature of the hardware business.",
      "llm_answer": "In the 2022 filing Oracle presented Engineered Systems as “core to our cloud‑based and on‑premise data‑center infrastructure offerings,” stressing that they are pre‑integrated platforms that can be delivered on‑premise, as OCI services or in hybrid models (see 2022 p.13). By the 2023 filing the same products are mentioned only as part of the hardware segment—​a business that now accounts for roughly 6 % of total revenue and is described as lower‑margin, supplying the underlying infrastructure for OCI rather than being a primary growth story (see 2023 p.43). This reflects a shift from positioning Engineered Systems as a headline driver of Oracle’s cloud transformation to treating them as a supporting hardware component that underpins the cloud business.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the 6% of total revenue for hardware (including Engineered Systems) in fiscal 2023 is accurately reported, and the reference to fiscal years 2022 and 2023 matches the question's scope. There are no calculation errors. (2) The LLM correctly identifies the shift in strategic positioning—from Engineered Systems being a 'core' component of both cloud and on-premise infrastructure in 2022 to being subsumed under a broader, lower-margin hardware segment in 2023 that supports OCI. This reflects proper synthesis across filings. (3) The reasoning is sound: the model infers a strategic downgrading in narrative prominence (from 'headline driver' to 'supporting component'), which is consistent with the ground truth’s observation that Engineered Systems are now part of combined performance obligations within hardware and not emphasized as standalone growth engines. (4) The only minor gap is that the LLM omits mention of R&D investments in 2023 and the explicit inclusion of servers, storage, and operating systems in the expanded hardware definition—details present in the original answer. However, this does not undermine the core correctness. The answer remains semantically equivalent in its key claims and effectively addresses the evolution in strategic positioning, role within hardware, and implications for cloud transformation. Wording differences are acceptable and do not affect factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1474,
        "completion_tokens": 418,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the disclosure regarding the 2020 Stock Plan's relationship with the 2011 Stock Plan evolve between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, the 2020 Stock Plan disclosure included the detail that 5,530,106 shares previously available under the 2011 Stock Plan were carried forward and made available for award grants under the 2020 Stock Plan. However, in the 2023 10-K filing, this specific reference to the 2011 Stock Plan and the carry-forward of shares was omitted. This indicates a shift in how the company chose to present the lineage and transition between the two stock plans, focusing only on the 2020 Stock Plan without linking it to its predecessor in the disclosed text.",
      "llm_answer": "In the 2022 Form 10‑K the filing explicitly linked the two plans – it said the 2020 Stock Plan “is the successor to the 2011 Stock Plan” and that the 5,530,106 shares that were still available under the 2011 Plan “are available for award grants under the 2020 Stock Plan”【page_59】. By the 2023 Form 10‑K, that language was dropped; the 2020 Stock Plan is described only in terms of the grants it permits, with no reference to the 2011 Plan or the transfer of shares【page_61】. This shows the company removed the explicit successor‑relationship disclosure in the later filing.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately reports that in the 2022 10-K, 5,530,106 shares from the 2011 Stock Plan were carried forward under the 2020 Stock Plan, with correct qualitative description of the relationship (e.g., 'successor to the 2011 Stock Plan'). (2) The quantitative accuracy is perfect: the number 5,530,106 is correctly cited, and the years (2022 and 2023) are accurate. (3) The multi-hop reasoning is sound—comparing disclosures across two filings, identifying the presence and subsequent omission of specific language linking the two stock plans. (4) The LLM correctly concludes that the company removed the explicit reference to the predecessor plan in the 2023 filing, which aligns with the ground truth's interpretation of a shift in disclosure strategy. Semantic equivalence is maintained, with slightly more precise phrasing (e.g., 'successor') that is consistent with the original meaning. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 295,
        "total_tokens": 1578
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How has Honeywell's allocation strategy toward private funds evolved between 2022 and 2023, and what might this indicate about the company's capital deployment priorities?",
      "original_answer": "In 2022, Honeywell reported $1,244 million invested in private funds, as disclosed in the 2022 10-K filing. By 2023, this amount increased slightly to $1,265 million, as noted in the 2023 10-K filing. This represents a modest increase of approximately 1.7%, suggesting that Honeywell maintained a relatively stable allocation strategy toward private funds despite broader reductions in total assets under the U.S. plans. This slight upward trend may indicate a strategic decision to preserve or slightly expand exposure to alternative investments, potentially to capitalize on expected higher returns or diversification benefits from private fund investments.",
      "llm_answer": "Honeywell’s pension‑plan holdings of private‑fund assets rose slightly from 2022 to 2023 – the U.S. plans held $1,258 million of private funds in 2022 versus $1,265 million in 2023, and the non‑U.S. plans held $90 million versus $115 million over the same period【page_109】【page_110】.  The increase, while still within the company’s stated 10‑20% “other investments” (private‑equity) target, shows Honeywell is nudging more capital into private‑fund strategies, indicating a modest but growing priority to seek higher‑return, less‑liquid opportunities and further diversify its portfolio beyond traditional public‑market assets.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in the quantitative details. According to the ground truth, Honeywell reported $1,244 million in private fund investments in 2022 and $1,265 million in 2023. However, the LLM states $1,258 million for 2022 (incorrect), and separates U.S. and non-U.S. plans ($90M and $115M), which is not supported by the original answer or the cited knowledge graph truth. The ground truth does not break down private fund allocations by U.S. vs. non-U.S. plans, nor does it report $1,258M or $90M/$115M figures. This introduces factual errors in both magnitude and structure. (2) The 2023 number ($1,265 million) is correct, but the 2022 number is wrong, leading to an incorrect basis for comparison. The actual increase is from $1,244M to $1,265M (~1.7%), but the LLM implies a smaller increase from $1,258M, which understates the relative growth. Additionally, the mention of non-U.S. plans adding $25M is unsupported in the ground truth. (3) The reasoning about strategic intent—increased focus on higher-return, less-liquid assets and diversification—is plausible and aligns semantically with the original answer’s interpretation, showing sound qualitative logic. The reference to a 10–20% target for 'other investments' may be contextually accurate but is not present in the ground truth, so it cannot be verified and slightly detracts from accuracy. (4) Despite incorrect numbers and unsupported breakdowns, the LLM captures the directional trend (slight increase) and infers a reasonable strategic motive, which maintains partial correctness. Contextual relevance is high as it directly addresses the evolution and implications of allocation strategy. However, the quantitative inaccuracies significantly reduce overall correctness, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 492,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the status and disclosure of Class B-2 Common Stock evolve between 2023 and 2024, particularly regarding its outstanding status and relationship to other stock classes?",
      "original_answer": "In 2023, Class B-2 Common Stock was subject to conversion rate adjustments tied to the U.S. litigation escrow account under the U.S. retrospective responsibility plan, which caused dilution in as-converted shares. Additionally, it was noted that no shares of Class B-2 were outstanding prior to the Class B-1 exchange offer. By 2024, the 10-K filing only referenced Class B-2 Common Stock in relation to its lack of outstanding shares prior to the Class B-1 exchange offer, with no further updates or disclosures regarding its conversion mechanics or dilution impacts, suggesting a reduced emphasis or potential discontinuation of its active role in the capital structure.",
      "llm_answer": "In the 2023 filing the EPS table shows a dash for Class B‑2 common stock – the company had **no B‑2 shares outstanding**, and a footnote explicitly states that “no shares of class B‑2 common stock were outstanding prior to the class B‑1 common stock exchange offer”【page_59】. By the 2024 filing, after the May 2024 exchange offer, Class B‑2 is disclosed as a new class: the EPS table reports **49 million weighted‑average shares (basic and diluted)** for B‑2【page_59】, the equity note lists **120 million shares issued and outstanding as of September 30, 2024**【page_87】, and the narrative explains that B‑2 shares were issued in the exchange offer and now sit alongside Class B‑1 as part of “class B common stock” with a defined conversion rate to Class A common stock【page_89】.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect and contradicts the ground truth in both direction and fact. (1) According to the original answer, Class B-2 Common Stock was not newly introduced in 2024; rather, it existed in 2023 with disclosures about its conversion mechanics and dilution effects tied to litigation escrow. The LLM falsely claims that in 2024, Class B-2 was 'disclosed as a new class' with 49 million weighted-average shares and 120 million shares issued and outstanding as of September 30, 2024 — this is unsupported by the ground truth, which states there were no updates in 2024 beyond a reference to no shares being outstanding prior to the Class B-1 exchange offer. (2) The quantitative claims (49 million, 120 million) are entirely fabricated and have no basis in the provided truth; the ground truth contains no such numbers. (3) The multi-hop reasoning is flawed: instead of recognizing that disclosures about Class B-2 diminished from 2023 to 2024, the LLM incorrectly infers increased prominence in 2024. It also misrepresents the sequence of events — claiming shares were issued in a May 2024 exchange offer, while the ground truth implies the relevant exchange offer occurred prior to 2023. (4) Contextual relevance is low but not zero because the answer discusses stock classes and exchange offers, which are topically relevant, but the factual foundation is entirely wrong. The LLM appears to have hallucinated data from document pages not validated against the knowledge graph. Thus, the correctness score is 1 due to complete factual inaccuracy despite addressing the general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 439,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the financial obligations related to the Target Circle program change between 2022 and 2024, and what does this indicate about the program's evolution?",
      "original_answer": "In 2022, the deferred revenue related to the Target Circle program was $89 million as of January 29, 2022, while in 2024, the deferred revenue related to the program was $117 million as of February 3, 2024. This indicates a significant increase in the company's liability tied to unredeemed rewards, suggesting growth in program participation or changes in redemption patterns. However, by February 1, 2025, the deferred revenue had dropped to $19 million, signaling a sharp decline, which may reflect either a surge in reward redemptions or a strategic change in how the program's liabilities are recognized or managed.",
      "llm_answer": "In FY 2022 Target recorded a $89 million deferred‑revenue liability for the Target Circle loyalty program. By FY 2024 that liability had grown to $117 million. The rise in the deferred‑revenue balance signals that the program has expanded—more members and earned rewards are being accrued, increasing Target’s future reward obligations.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM correctly identifies the deferred revenue amounts for FY 2022 ($89 million) and FY 2024 ($117 million), matching the ground truth in both values and fiscal years. These numbers are accurately presented with acceptable formatting variations (e.g., $89 million vs $89 million). However, the LLM omits the critical data point from February 1, 2025, where deferred revenue dropped sharply to $19 million—a key part of the program's evolution. This omission significantly affects completeness and reasoning. 2) Quantitatively, all provided numbers are correct. The increase from $89M to $117M is accurate and correctly interpreted as growth in obligations. No calculation errors. 3) The reasoning correctly infers that rising deferred revenue indicates program expansion and greater future obligations. However, it fails to address the subsequent sharp decline to $19M, which is essential for a full understanding of the program’s evolution—potentially due to increased redemptions or accounting changes. This missing link breaks the multi-hop synthesis required by the question, which asks about changes *between 2022 and 2024* and what that indicates about the program’s trajectory. While the answer captures the upward trend, it misses the reversal, leading to an incomplete conclusion. 4) Despite the omission, the answer remains contextually relevant and accurately interprets the meaning of deferred revenue in the context of loyalty programs. The explanation about growing membership and accrued rewards is reasonable and aligned with the implications in the ground truth. The score is reduced primarily due to missing a key data point that alters the overall narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 457,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the fair value of Netflix's 4.375% Senior Notes change between December 31, 2022, and December 31, 2023, and what does this indicate about investor perception or market conditions?",
      "original_answer": "The fair value of Netflix's 4.375% Senior Notes decreased from $980 million on December 31, 2022, to $996 million on December 31, 2023. This indicates a shift in investor perception or market conditions, as the fair value moved closer to the principal amount at par, suggesting a stabilization or improved outlook for the company's debt.",
      "llm_answer": "The Level 2 fair value of Netflix’s 4.375 % senior notes rose from **$980 million at December 31 2022 to $996 million at December 31 2023** – a $16 million (about 1.6 %) increase【page_56】. This price gain means investors were willing to pay more for the notes, suggesting lower market yields or an improved perception of Netflix’s credit quality, i.e., stronger demand for its debt in the prevailing market conditions.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error: it states that the fair value of Netflix's 4.375% Senior Notes *increased* from $980 million to $996 million, but the ground truth states it *decreased* from $980 million to $996 million. This is a direct contradiction — an increase cannot be correct if the value decreased. Despite using the same numbers, the direction of change is reversed, which fundamentally undermines the answer's correctness. (2) Numeric values (dates, dollar amounts: $980M and $996M) are accurate and properly formatted. However, the calculation of a '$16 million (about 1.6%) increase' is incorrect in context because the change should be a *decrease*, not an increase. The percentage calculation itself is approximately correct (16/980 ≈ 1.63%), but applied to the wrong directional change. (3) The multi-hop reasoning is partially sound — the model attempts to interpret the change in fair value in terms of investor perception and market conditions. However, because it misreads the direction of the change, the conclusion is inverted: higher prices (closer to par) should indicate *improved* perception, but only if the value is rising toward par from below. In this case, the original answer notes the value moved *closer to par*, implying it was below par and rose — but the LLM incorrectly frames an increase when the truth is a decrease. This suggests confusion in reasoning or a typo with 'decreased' vs 'increased'. (4) Contextual relevance is high — the answer addresses both parts of the question (change in fair value and its implication), uses appropriate financial logic, and cites a source. However, the reversal of the trend destroys factual correctness. A score of 4 is justified due to correct numbers but incorrect direction and interpretation, leading to a significantly flawed conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1199,
        "completion_tokens": 502,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the equity structure related to Class C Common Stock evolve between 2023 and 2024, particularly in terms of share issuance and equity classification?",
      "original_answer": "In 2023, Visa conducted an exchange offer where 241 million shares of Class B-1 common stock were tendered, and in exchange, approximately 48 million shares of Class C common stock were issued. This indicates active restructuring of stock classes tied to the Visa Europe retrospective responsibility plans. By 2024, the balance of Class C common stock remained at 10 shares issued and outstanding, as stated in the equity section of the balance sheet. This suggests that while there was active movement and restructuring involving Class C shares in 2023, the 2024 disclosures indicate a stabilization or conclusion of that phase of equity restructuring.",
      "llm_answer": "In 2023 Visa reported only 10 million Class C common‑stock shares outstanding (see the equity table on page 42). In 2024 the company issued roughly 48 million new Class C shares as part of the May 2024 B‑1 exchange offer (page 40), which raised the weighted‑average Class C share count to 16 million by year‑end (page 59), while the shares continued to be classified as a distinct Class C common‑stock category (page 58).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors in both direction and magnitude of share issuance and timing. (1) Quantitatively, it incorrectly states that in 2023 only 10 million Class C shares were outstanding, whereas the ground truth indicates that approximately 48 million were issued in 2023 as part of the exchange offer. The LLM also reverses the timeline, claiming 48 million were issued in 2024, when the ground truth confirms the issuance occurred in 2023. Additionally, the LLM cites a year-end weighted average of 16 million shares in 2024, which contradicts the ground truth stating only 10 shares (not million) were issued and outstanding in 2024. (2) The entity accuracy is partially correct—Visa is the right company, and the classes (Class B-1 and Class C) are correctly identified—but the years and share counts are fundamentally wrong. (3) The reasoning is flawed: the LLM suggests ongoing issuance in 2024, while the ground truth indicates stabilization with only 10 shares remaining, implying the restructuring concluded. The multi-hop synthesis fails because it misaligns the sequence of events between 2023 and 2024. (4) Contextually, the answer addresses equity structure evolution and classification, so relevance is moderate, but the incorrect data renders the conclusion invalid. The claim that Class C shares remained a distinct category is consistent, but this minor accuracy does not offset the core errors. Overall, the answer inverts the factual narrative and thus scores very low on correctness and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 425,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Lowe's engagement with Rough Plumbing evolved from 2022 to 2024, particularly in terms of its business classification and service offerings?",
      "original_answer": "In 2022, Rough Plumbing was classified under the 'Building Products' category, indicating it was primarily offered as a product within Lowe's merchandise divisions. By 2024, Lowe's had expanded its engagement with Rough Plumbing by integrating it into both installation services and protection plans, signaling a shift from a pure product offering to a more service-oriented approach. This evolution reflects a strategic move to bundle Rough Plumbing with labor and extended protection, contributing to the approximately 5% of total sales attributed to installed sales in 2024.",
      "llm_answer": "In the 2022 Form 10‑K, Rough Plumbing was mentioned only as a sub‑category of the “Building Products” merchandise division – a product‑only classification (see 2022 page 55). By the 2024 filing, Rough Plumbing is listed as a distinct product line in Lowe’s product assortment and is also highlighted as a service category for both installed‑sales contracts and extended protection plans (see 2024 pages 6 and 7), showing that the company now treats Rough Plumbing not just as a product but also as a service‑driven offering.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies that in 2022, Rough Plumbing was classified under 'Building Products' as a product-only offering (citing 2022 page 55), and by 2024, it evolved into a service-driven offering with inclusion in installed-sales contracts and extended protection plans (citing 2024 pages 6 and 7). All entities (Lowe's, Rough Plumbing), years (2022 to 2024), and classifications are correct. The shift from product-only to service-integrated is accurately described. The only minor omission is the specific quantitative impact—namely, that installed sales accounted for approximately 5% of total sales in 2024, which was included in the original answer. However, this does not detract significantly from the overall correctness, as the core evolution in business classification and service offerings is fully captured. No numerical inaccuracies are present, and the reasoning demonstrates sound multi-hop synthesis across two years of filings. The answer is contextually precise and directly addresses the question's focus on classification and service evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 322,
        "total_tokens": 1598
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the introduction and subsequent status of Class B-2 common stock evolve between 2023 and 2024, and what does this indicate about its role in the company's capital structure?",
      "original_answer": "In 2023, Class B-2 common stock was newly introduced with 77 million shares outstanding, indicating its initial incorporation into the company's equity structure. By 2024, the company disclosed that no shares of Class B-2 common stock were outstanding prior to the Class B-1 common stock exchange offer, suggesting a strategic shift where Class B-2 shares may have been replaced or restructured as part of a broader capital realignment. This indicates a transformation in the role of Class B-2 common stock within the company’s capital structure.",
      "llm_answer": "In 2023 Visa reported **no Class B‑2 common‑stock shares outstanding** (the footnote on the earnings‑per‑share table notes “‑” for B‑2 and the equity note says “No shares of class B‑2 common stock were outstanding prior to the class B‑1 exchange offer”). In May 2024 the company completed a B‑1 exchange offer and **issued a new B‑2 series** (≈120 million B‑2 shares, shown as 49 basic‑average shares and 77 million as‑converted Class A equivalents in the 2024 statements) while retiring the tendered B‑1 shares, reducing total class B shares from 245 to 125. This evolution shows B‑2 was created as a **transitional, exchange‑offer class** that replaces retired B‑1 shares and carries a special conversion‑rate impact, making it a small but strategically distinct component of Visa’s capital structure rather than a primary source of equity.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Class B-2 common stock was introduced in 2023 with 77 million shares outstanding. However, the LLM claims that in 2023, there were *no* Class B-2 shares outstanding, directly contradicting the original answer. Conversely, the LLM states that Class B-2 was *issued in May 2024* as a new series, which conflicts with the ground truth stating that by 2024, *no shares were outstanding prior to the exchange offer*, implying the class existed but was eliminated or not issued. The LLM reverses the timeline: it claims B-2 was created in 2024, while the truth states it was introduced in 2023 and absent before the 2024 exchange. (2) Quantitatively, the LLM incorrectly reports ≈120 million B-2 shares issued in 2024 and references 49 basic-average shares and 77 million as-converted Class A equivalents. The ground truth only confirms 77 million shares outstanding in 2023 and no mention of 120 million or 49 average shares. These numbers are unsupported and appear fabricated or misinterpreted. The reduction in total Class B shares from 245 to 125 is not in the ground truth and cannot be verified, further undermining quantitative accuracy. (3) The multi-hop reasoning is flawed: the LLM misidentifies the sequence of events—introduction vs. elimination of Class B-2—and incorrectly infers that B-2 was created in 2024 as part of the exchange offer. The ground truth suggests B-2 existed in 2023 and was no longer outstanding in 2024, indicating a removal or conversion, not a creation. The LLM’s conclusion that B-2 was a 'transitional, exchange-offer class' replacing B-1 is speculative and contradicts the stated timeline. (4) Contextual relevance is moderate—the answer discusses capital structure evolution and uses appropriate financial terminology—but the core facts are inverted, leading to a fundamentally incorrect narrative. The answer addresses the question’s intent but fails on factual correctness, especially on key dates and share counts, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 562,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has the financial liability associated with the Target Circle program changed between 2022 and 2024, and what does this indicate about the program's growth or evolution?",
      "original_answer": "In 2022, the Target Circle program was described primarily in terms of its benefits to customers, such as earning 1% rewards on non-RedCard purchases, but no specific liability figure was disclosed. By 2024, the deferred revenue related to the Target Circle program had grown to $117 million as of February 3, 2024, indicating a significant increase in the program's financial liability and suggesting substantial growth or expansion of the program. This increase reflects a greater number of participants or increased transactional activity within the program.",
      "llm_answer": "The 2022 Form 10‑K only describes the Target Circle loyalty program and does not disclose a specific liability for it (see the program description on pages 3‑5). By the 2024 filing, Target reports a $19 million deferred‑revenue liability for Target Circle in Accrued and Other Current Liabilities (page 50), indicating that the program has expanded enough to generate a measurable financial obligation and that rewards earned by members have grown.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in the deferred revenue amount. The ground truth states that the deferred revenue liability for Target Circle was $117 million as of February 3, 2024, but the LLM incorrectly reports it as $19 million. This is a significant quantitative discrepancy that undermines the answer's factual accuracy. (2) The date and context of the 2022 disclosure are correctly noted—no specific liability was disclosed, which aligns with the original answer. However, the 2024 figure is wrong, and no mention is made of the growth from no disclosed liability to $117 million, which is central to the question. The $19 million figure appears to be either a misreading of the filing or confusion with another liability. (3) The reasoning about program expansion is logically sound and directionally correct—increased liability implies growth in rewards and participation—but it is based on incorrect data, weakening the multi-hop synthesis. The model correctly infers that a newly reported liability indicates program growth, which shows appropriate qualitative reasoning. (4) Contextual relevance is fair because the answer addresses both years and the evolution of the program, but the major numerical error severely limits correctness. Quantitative accuracy is very low due to the incorrect dollar amount. Qualitative accuracy is moderate because the logic and entity identification (Target Circle, deferred revenue, fiscal years) are correct. Correctness score is low because financial liability figures are central to the question and must be accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 438,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has NVDA's exposure to and concern about pollution limits evolved between 2023 and 2024, particularly in terms of regulatory impact on operations and customer data center expansion?",
      "original_answer": "In 2023, NVDA highlighted that pollution limits and related climate regulations could increase direct and indirect costs, including compliance, energy, and capital expenditures, and could require changes to manufacturing processes and supply chain operations. By 2024, the company expanded its concern to include not only cost increases but also the potential for land and permitting constraints tied to pollution limits, which could impair customers' ability to expand data center capacity—an essential market for NVDA's products. This indicates a growing concern that regulatory tightening around pollution could directly affect demand for NVDA's offerings.",
      "llm_answer": "In the 2023 Form 10‑K, NVIDIA warned that new or proposed pollution‑limit regulations could increase direct manufacturing and compliance costs and generate indirect cost pressures through its suppliers and customers【NVDA_10k_2023.pdf page_22】. By the 2024 filing, the company broadened the risk, noting that such regulations – especially those that limit energy or water availability – could also restrict customers’ ability to expand data‑center capacity, potentially curbing demand for NVIDIA’s products【NVDA_10k_2024.pdf page_22】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2023, NVDA identified pollution limits as a source of increased direct and indirect costs, including compliance and supply chain impacts; by 2024, the concern expanded to include operational constraints on customers' data center expansion due to energy and water availability, which could affect demand. The cited pages (22 for both years) are consistent with typical risk factor sections in 10-Ks. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable beyond correct use of years (2023, 2024), which are accurate. (3) The multi-hop reasoning is sound—correctly synthesizing how NVDA’s risk disclosure evolved from internal cost concerns to external demand-side risks via customer constraints. The answer captures the core progression in regulatory impact: from cost pressures to capacity and permitting limitations affecting customer expansion. (4) The only minor shortcoming is that the LLM does not explicitly mention 'land and permitting constraints' or 'capital expenditures' from the 2023 risk, though 'compliance costs' and 'indirect cost pressures' cover much of the same ground. Also, 'energy or water availability' is a precise addition in 2024, which is semantically aligned with the original answer’s emphasis on pollution limits affecting resource access. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning with only slight omissions in granular detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 439,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the composition and valuation of the company's Guaranteed Senior Notes evolve between 2023 and 2024, particularly in terms of issuance, repayment, and fair value inputs?",
      "original_answer": "In 2023, the company's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. These notes were valued using Level 3 inputs. In 2024, the Japanese subsidiary repaid $77 of these Guaranteed Senior Notes. The fair value of long-term debt, including Guaranteed Senior Notes, was approximately $5,412 at the end of 2024, compared to $5,738 at the end of 2023. This indicates a reduction in the overall fair value of long-term debt, partially driven by repayments on the Guaranteed Senior Notes.",
      "llm_answer": "In 2023 Costco’s Japanese subsidiary introduced four Guaranteed Senior Notes – roughly $500 of face amount – which were recorded under “Other long‑term debt” at $484 and valued using Level 3 fair‑value inputs. By the 2024 filing the subsidiary had repaid $77 of those notes, leaving about $423 of principal outstanding and “Other long‑term debt” had risen to $919 (reflecting the net issuance plus amortization of discounts/premiums), still measured with Level 3 inputs; the total fair‑value of the company’s long‑term debt fell from about $5.74 billion in 2023 to $5.41 billion in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely correct in its factual content but introduces minor inaccuracies and additional details not present in the ground truth. The issuance of four Guaranteed Senior Notes totaling approximately $500 in 2023 at fixed rates (not specified in the LLM answer) using Level 3 inputs is correctly stated, though the ground truth does not mention the notes being recorded at $484 under 'Other long-term debt'—this detail is plausible but not verifiable from the original answer and represents an over-specification. The repayment of $77 in 2024 is accurate. The fair value of total long-term debt declining from $5,738 million (~$5.74 billion) to $5,412 million (~$5.41 billion) is correctly reflected with acceptable rounding. (2) Quantitatively, the $500 issuance, $77 repayment, and fair value figures are accurate within acceptable rounding. However, the LLM introduces a specific book value ($484) and updated 'Other long-term debt' balance ($919), which are not in the original answer and cannot be verified—this affects quantitative precision. The use of 'about $423 of principal outstanding' is a reasonable calculation ($500 - $77), but the original answer does not specify remaining principal, so this is an inference. (3) The multi-hop reasoning is sound: the model correctly links the 2023 issuance, 2024 repayment, and overall change in fair value of long-term debt, attributing part of the decline to repayments. It maintains correct entity identification (Japanese subsidiary, Guaranteed Senior Notes, Level 3 inputs) and correct years. (4) The answer is contextually relevant and addresses all key aspects of the question—issuance, repayment, fair value inputs, and valuation evolution—though it adds unconfirmed accounting details. The core facts and synthesis are correct, warranting a high score, but the inclusion of unsupported specifics prevents a perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 517,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Netflix's investment in streaming service improvements and associated risk exposure evolve from 2022 to 2024, based on the specific personnel and cybersecurity-related changes disclosed in those years?",
      "original_answer": "In 2022, Netflix disclosed a $384 million increase in personnel-related costs driven by headcount growth to support production activity and improve the streaming service. By 2024, the focus had evolved to include significant emphasis on cybersecurity, with detailed descriptions of enterprise-wide security programs, third-party risk management, and the potential financial impact of cyber incidents. The company highlighted the risk of unauthorized data releases and digital content theft, noting that such events could adversely affect business operations and financial results. This represents a shift from purely growth-oriented investment in streaming to a more risk-aware posture as the service matured.",
      "llm_answer": "In the 2022 filing Netflix said it boosted technology‑and‑development spending by 24% to $2.27 billion, with a $384 million increase in personnel costs to grow headcount that supports “continued improvements in our streaming service.” By the 2024 filing the company had added a dedicated Vice President of Security and Privacy Engineering and described a formal, enterprise‑wide cybersecurity program, risk‑quantification model and board oversight, indicating that its risk exposure has shifted to emphasize cyber‑security while still maintaining investment in streaming‑service enhancements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the $384 million increase in personnel costs in 2022 is accurately cited, and while the $2.27 billion total technology-and-development spend and 24% increase are not in the original answer, they do not contradict it and may reflect additional context from the filing. These additions are plausible and do not degrade accuracy. (2) The entity identification is correct—Netflix, 2022 and 2024 timeframes, personnel costs, and cybersecurity developments are properly attributed. (3) The multi-hop reasoning is sound: the answer traces the evolution from investment in streaming improvements (via headcount growth in 2022) to heightened focus on cybersecurity by 2024, citing structural changes like the VP of Security and Privacy Engineering and enterprise-wide programs, which aligns with the original answer’s emphasis on formalized risk management and board oversight. (4) Semantically, the core message—that Netflix shifted from growth-focused investment to a more risk-aware posture—is preserved. The only minor gap is that the LLM answer does not explicitly mention the risk of digital content theft or unauthorized data releases impacting financial results, which is a small omission in completeness. However, the mention of enterprise-wide cybersecurity programs and risk quantification implies this awareness. Overall, the answer is factually correct, well-reasoned, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 418,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did The Bank of New York Mellon Corporation's approach to restricted stock unit agreements evolve between the 2023 and 2024 filings, particularly in terms of the lifecycle management of these equity instruments and their implications for executive compensation strategy?",
      "original_answer": "In the 2023 filing, the '2024 Form of Restricted Stock Unit Agreement' was newly introduced and explicitly stated as 'Filed herewith,' indicating it was a current and newly adopted form for that year. This suggests the company was actively updating its equity compensation framework to align with strategic goals for executive retention and incentives. By the 2024 filing, this '2024 Form' was no longer newly filed but instead was referenced as 'Previously filed,' signaling it had become an established part of the company's compensation structure. Additionally, in 2024, the company introduced the '2025 Form of Restricted Stock Unit Agreement,' which was marked as 'Filed herewith,' showing a forward-looking update to the equity compensation strategy. This evolution indicates a consistent, proactive approach to managing executive compensation frameworks, with new forms being introduced annually and the prior year’s forms transitioning into reference documents. This reflects a mature, iterative process in shaping executive incentives and aligning them with long-term corporate objectives.",
      "llm_answer": "In the 2023 Form 10‑K the company disclosed its RSU program only by reference – the 2023 Form of Restricted Stock Unit Agreement appears as Exhibit 10.24 and is incorporated from a prior quarterly filing【page_19】. By the 2024 filing the Bank filed a fresh 2024 Form of Restricted Stock Unit Agreement directly as Exhibit 10.29 (and even a 2025 version)【page_20】, signalling a shift to a more explicit, updated lifecycle framework for granting, vesting and settling RSUs that better aligns the equity awards with its executive compensation strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains a significant factual error in the timeline and nature of the filings, which undermines the correctness of the multi-hop reasoning. According to the ground truth, the '2024 Form of Restricted Stock Unit Agreement' was introduced and filed as 'Filed herewith' in the 2023 filing, not the 2024 filing. However, the LLM incorrectly states that the 2024 Form was filed in the 2024 Form 10-K as Exhibit 10.29, reversing the actual sequence. This misrepresents the evolution: the 2024 Form was already current in 2023, not newly filed in 2024. Additionally, the LLM claims the 2023 Form was only referenced and not newly filed, but the ground truth does not confirm this — it focuses on the introduction and subsequent referencing of the 2024 Form. The introduction of the 2025 Form in the 2024 filing is correctly noted, which supports the forward-looking strategy. While the general theme of evolving toward a more explicit lifecycle framework is contextually relevant and aligns with the strategic implication in the original answer, the reversed chronology and incorrect exhibit details (Exhibit 10.24 vs. 10.29, timing of filing) introduce major inaccuracies. The reasoning is partially sound in identifying a shift, but the factual foundation is flawed. Quantitative accuracy is moderate: years (2023, 2024, 2025) are correct, but their association with filing events is not. Qualitative accuracy suffers due to incorrect entity-event mapping. Contextual relevance is high as the answer addresses lifecycle management and executive compensation strategy as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 432,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the status and structure of the 4.90% Senior Notes evolved from 2023 to 2024, particularly in terms of their carrying amount and maturity timeline?",
      "original_answer": "In 2023, the 4.90% Senior Notes were newly issued in November 2023, with a principal amount of $750 million, a discount of $3.4 million, and a maturity date of April 15, 2029. Interest payments were scheduled semi-annually starting April 15, 2024. By 2024, these notes remained outstanding, with a carrying amount of $743 million as of January 28, 2024. The maturity date remained unchanged at April 2029, and the notes continued to be listed among the company’s long-term debt obligations. The carrying amount slightly decreased, reflecting the initial discount and amortization progress over the year.",
      "llm_answer": "The 4.90 % senior notes were unchanged in composition between the two filings. In the 2023 Form 10‑K the company reported a $750 million series due September 2026 with a net carrying amount of $745 million and a $750 million series due April 2029 with a net carrying amount of $743 million【page_59†L...】. The 2024 Form 10‑K shows the same two series still outstanding – the September 2026 notes at $745 million (still $745 million on 1/28/24 and $747 million by 2/2/25) and the April 2029 notes at $743 million (still $743 million on 1/28/24 and $744 million by 2/2/25)【page_62†L...】 – and their maturity dates (Sept 2026 and Apr 2029) have not been altered.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that the 4.90% Senior Notes were newly issued in November 2023 with a principal of $750 million, a discount of $3.4 million, and a maturity date of April 15, 2029. However, the LLM incorrectly claims there are two series: one due September 2026 and another due April 2029. The September 2026 series is not mentioned in the ground truth and is therefore a hallucination. Additionally, the LLM states the April 2029 notes had a carrying amount of $743 million in 2023, but the ground truth indicates this was the carrying amount as of January 28, 2024 — not in 2023. The 2023 carrying amount should reflect the initial issuance with a $3.4 million discount, implying a $746.6 million carrying amount at issuance, not $743 million. (2) Quantitative accuracy is poor: the maturity date is partially correct (April 2029 matches), but the erroneous inclusion of a September 2026 series and incorrect carrying amounts in time (e.g., $743M in 2023) undermines correctness. The LLM also cites future carrying amounts (e.g., $744M by 2/2/25), which are not relevant to the question about 2023–2024 evolution. (3) Multi-hop reasoning is flawed: the model fails to correctly track the evolution of a single note series over time, instead inventing a dual-series structure and misattributing carrying amounts across years. It does not acknowledge the issuance event in November 2023 or the semi-annual interest starting April 2024, both key structural elements. (4) Contextual relevance is moderate — the answer discusses carrying amounts and maturities as requested, but misidentifies the notes and timeframes, leading to a mostly incorrect synthesis. The reference to specific pages suggests document grounding, but the extracted facts do not align with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 503,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did the issuance and repayment of Guaranteed Senior Notes by Costco's Japanese subsidiary evolve between 2023 and 2024?",
      "original_answer": "In 2023, Costco's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. In 2024, the subsidiary repaid $77 of these Guaranteed Senior Notes. Additionally, the proceeds from the issuance of these notes were referenced in the 2024 filing as a source of financing activity, indicating continued financial engagement with this instrument.",
      "llm_answer": "Costco’s Japan subsidiary issued four Guaranteed Senior Notes in November 2023 for roughly $500 total (interest 1.40%‑2.12%, maturing 2033‑2043)【page_52】, and the 2024 financing‑activities disclosure notes that the cash‑flow statement includes the proceeds from those notes【page_30】. In July 2024 the subsidiary repaid $77 of the Guaranteed Senior Notes, lowering the outstanding balance【page_52】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: in 2023, Costco's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 million at interest rates between 1.400% and 2.120%, and in 2024, $77 million was repaid. These numbers match the original answer exactly, with acceptable formatting variations (e.g., $500 vs $500 million). The mention of maturities (2033–2043) and November 2023 issuance adds contextual detail not in the ground truth but does not contradict it. (2) Quantitative accuracy is perfect: all dollar amounts ($500 total issuance, $77 repayment), interest rates (1.40%–2.12%), and dates (November 2023, July 2024) are correct and consistent with the source. (3) The multi-hop reasoning is sound—information is synthesized across time (2023 issuance and 2024 repayment) and documents (referencing both the issuance and the 2024 financing activities). The use of proceeds being noted in the 2024 cash flow statement correctly reflects continued financial engagement. (4) The only minor shortcoming is the addition of specific months (November 2023, July 2024) and maturities (2033–2043), which were not present in the ground truth; however, these do not conflict with it and may reflect additional data from the filing. Overall, the answer is semantically equivalent, factually correct, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 396,
        "total_tokens": 1594
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the risk associated with competitors developing after-market parts for DHR's products evolved from 2022 to 2023, particularly in terms of its impact on the company's business and financial statements?",
      "original_answer": "In 2022, the risk of competitors developing after-market parts was described as a direct threat that could 'detract from our sales,' with an emphasis on how commoditization and private-label offerings could reduce market prices and erode DHR's competitive position. By 2023, the framing of this risk shifted to being 'Impacted By' such competition, with a broader contextualization within cost containment trends in the healthcare industry and pricing pressures from managed care and government reimbursement policies. While the core risk remained, it was presented as one of several external pressures rather than a primary threat, suggesting a relative de-emphasis in severity or a strategic recalibration in how the company perceives this risk.",
      "llm_answer": "In the 2022 filing the company warned that “competitors may also develop after‑market services and parts for our products which may detract from our sales,” noting that such competition “may adversely impact our business and financial statements” (2022 p. 23). The 2023 filing repeats the same concern—again stating that “competitors may also develop after‑market services and parts for our products which may detract from our sales” (2023 p. 20)—but now embeds it within a broader discussion of innovation and cost pressures, without indicating that the risk has intensified or diminished. Thus, the risk of after‑market parts remains a consistent competitive threat that could erode sales and adversely affect Danaher’s business and financial results.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in quoting the exact language from both the 2022 and 2023 filings, correctly identifying the risk of competitors developing after-market parts and its potential impact on sales and financial statements. All entities (DHR/Danaher), years (2022, 2023), and document references (page numbers) are accurate, satisfying entity and quantitative accuracy. The answer correctly notes that the same warning text appears in both years, which aligns with the ground truth. However, the LLM misses the nuanced evolution in risk framing described in the original answer: in 2023, the risk was repositioned as 'Impacted By' rather than a direct threat, and embedded within broader industry cost and pricing pressures, indicating a relative de-emphasis or strategic recalibration. The LLM interprets this consistency in wording as 'a consistent competitive threat' without acknowledging the shift in contextual framing, which downplays the evolution in how the company presents the risk. This omission affects qualitative accuracy, as the multi-hop reasoning required to detect a change in tone and contextual integration is incomplete. Nonetheless, the answer remains contextually relevant and factually sound on the surface, earning high marks for accuracy and relevance but losing points for missing the deeper interpretive shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 375,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Netflix's approach to membership plans evolved from 2022 to 2024, particularly in terms of pricing strategy and service features, and what business challenges were these changes intended to address?",
      "original_answer": "In 2022, Netflix experienced a 19% revenue increase driven by an 11% growth in average paying memberships and a 7% rise in average monthly revenue per membership, partly due to price increases and favorable foreign exchange rates. However, paid net membership additions dropped by 50% compared to the prior year, signaling early signs of member acquisition challenges. By 2024, Netflix responded by introducing a lower-priced ad-supported subscription plan and enforcing terms of use to limit multi-household usage. These changes were aimed at addressing fluctuating member acquisition, retention pressures, and increasing competition in the streaming and broader entertainment market. The company acknowledged that macroeconomic conditions, content competition, and consumer sensitivity to pricing adjustments could negatively impact membership growth and profitability.",
      "llm_answer": "In 2022 Netflix’s membership strategy was built around a tiered, country‑specific price band that ranged from roughly $2 to $27 per month and included a newly launched lower‑priced ad‑supported tier; modest price hikes were used to lift average monthly revenue per paying member and to offset slowing subscriber additions, competitive pressure and inflationary headwinds (see page_24 and page_23). By 2024 the company had formalized the ad‑supported tier, kept testing price variations across markets, and broadened the plan portfolio with new features such as advertising, games and live programming to drive additional per‑member revenue and sustain growth amid intensified competition and a saturated market (see page_6 and page_7).",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies and misstatements. It incorrectly claims that Netflix launched a lower-priced ad-supported tier in 2022, when in fact the ad-supported plan was introduced in late 2022 and fully rolled out in 2023, not as part of the 2022 strategy. The original answer correctly identifies that the 2022 strategy relied on price increases and favorable FX, not the ad-tier. The LLM also fabricates a price range of $2 to $27 without support from the ground truth, which does not specify exact pricing bands. Additionally, the LLM mentions 'games and live programming' as features added by 2024, which are not referenced in the original answer and thus introduce unsupported details. (2) Quantitative accuracy is low: the original answer includes specific metrics—19% revenue growth, 11% membership growth, 7% increase in ARPU, and 50% drop in net additions—but the LLM omits all of these figures, failing to report any correct numbers. The absence of these key data points significantly undermines factual precision. (3) Reasoning is partially sound: the LLM correctly infers that pricing adjustments and new tiers were responses to competitive and macroeconomic pressures, and it acknowledges the strategic intent to address slowing growth. However, it fails to correctly sequence the evolution—especially the timing of the ad-tier launch—and misattributes 2023–2024 changes to 2022, breaking the multi-hop timeline. (4) Despite factual errors, the answer remains contextually relevant by addressing pricing strategy, service features, and business challenges. It captures the general direction of Netflix’s evolution, even if specifics are inaccurate. Thus, while the structure and intent align with the question, the lack of correct data and misrepresentation of key developments limit correctness to a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 505,
        "total_tokens": 1921
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Boeing's approach to in-orbit incentive payments evolved between 2022 and 2023, particularly in terms of risk exposure and financial recognition?",
      "original_answer": "In 2022, Boeing highlighted the financial risks associated with in-orbit incentive payments, particularly in the context of potential program cancellations or failure to meet performance criteria, which could trigger termination provisions or loss of payments. The company noted that these risks were part of ongoing fixed-price development programs like Commercial Crew, KC-46A Tanker, and VC-25B. By 2023, Boeing had recorded $1,585 million in additional losses on its five most significant fixed-price development programs, which included those mentioned in 2022, and explicitly stated that in-orbit incentive payments were at risk if satellites failed to meet performance criteria over up to 15 years post-acceptance. The company also emphasized that the net present value of these fees was recognized as revenue during the construction period, increasing financial exposure if performance issues arose. This represents a shift from general risk acknowledgment in 2022 to a more specific quantification of losses and a detailed explanation of revenue recognition practices tied to in-orbit performance in 2023.",
      "llm_answer": "In the 2022 Form 10‑K (see page 45) Boeing listed the loss of satellite in‑orbit incentive payments as a contingent financial risk – a possible exposure that could arise from schedule delays, technical problems or contract termination, but it did not describe how such fees are accounted for. By the 2023 filing (see page 15) Boeing now records the net present value of the in‑orbit incentive fees as revenue in the construction period, while still emphasizing that the payments remain at risk for up to 15 years and could be reversed or require refunds if the satellite fails to meet performance criteria.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in its description of Boeing's evolving approach to in-orbit incentive payments between 2022 and 2023, with correct entity identification (Boeing), time periods (2022 and 2023), and financial concepts (net present value recognition during construction, 15-year performance risk). Quantitatively, the LLM does not include the $1,585 million loss figure mentioned in the ground truth for 2023, which is a notable omission affecting completeness. However, no incorrect numbers are presented, so quantitative accuracy remains high. The reasoning is sound: it correctly contrasts 2022's general risk disclosure with 2023's more specific accounting policy, showing evolution in financial recognition and risk exposure. The answer captures the core multi-hop insight—shift from risk acknowledgment to active revenue recognition with reversal risk—but omits the explicit quantification of losses on the five major programs, which is a key element in the original answer. This missing detail prevents a top score, but the response remains semantically aligned and contextually precise, fully addressing the question’s focus on risk exposure and financial recognition evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 337,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly described as being posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/invrelations/directors-code-of-conduct.pdf, and the company stated its intention to disclose amendments or waivers on the website. In 2024, while the Code remained accessible, it was referenced more generally as part of a broader list of governance materials available on the company’s website, including committee charters and governance guidelines, without repeating the direct URL. The change indicates a shift from detailed disclosure of access to a more consolidated and implicit reference, suggesting a streamlined but less direct approach to public access in 2024.",
      "llm_answer": "In the 2023 Form 10‑K the Directors’ Code of Conduct was called out in the “Code of Ethics” section, with a specific URL ( https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors‑code‑of‑conduct.pdf ) and a statement that any amendments or waivers would be posted on the website. In the 2024 Form 10‑K the Code is listed together with other governance documents in the “Available Information” section, confirming it remains publicly accessible on the company’s website but without the explicit link or amendment‑waiver language. This reflects a shift from a detailed, URL‑specific disclosure to a broader, integrated presentation of the Directors’ Code of Conduct among the company’s governance materials.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All factual elements are accurate: in 2023, the Directors' Code of Conduct was disclosed with a specific URL and a statement about posting amendments or waivers; in 2024, it was referenced more generally among other governance documents without the direct link or amendment-waiver language. (2) There are no numeric values requiring calculation, but the years (2023 and 2024) are correctly used and contextually appropriate. (3) The multi-hop reasoning is sound—comparing disclosure practices across two years and synthesizing changes in presentation and accessibility from two different 10-K filings. The model correctly identifies the shift from explicit, URL-specific disclosure to a more consolidated, implicit reference. (4) The answer is contextually relevant, directly addressing the evolution in disclosure and accessibility between the two years. Wording differs slightly (e.g., mentioning the 'Code of Ethics' section in 2023 and 'Available Information' in 2024), but these details align with typical 10-K structures and enhance precision without deviating from the truth. No factual inaccuracies, omissions, or reasoning flaws are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 345,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role and deployment strategy of Mobileye Drive™ evolved between 2022 and 2023?",
      "original_answer": "In 2022, Mobileye launched the SAE L4 Self-Driving System (SDS), Mobileye Drive™, and secured multiple collaborations for commercial use, including with Udelv for autonomous cargo delivery and with Transdev for self-driving mobility services. Additionally, Mobileye achieved its first consumer L4 design win with Geely. By 2023, Mobileye’s strategy had evolved to focus on supplying the Mobileye Drive™ self-driving system to transportation network companies, public transit operators, and suppliers of AV-ready vehicle platforms, with plans to bundle it with Moovit’s urban mobility and transit intelligence application. This shift indicates a more defined go-to-market strategy targeting fleet deployment and mobility-as-a-Service (MaaS) ecosystems.",
      "llm_answer": "In 2022 Mobileye Drive™ was launched as a Level‑4 (SAE L4) self‑driving system that Mobileye used to build robotaxi and vehicle‑as‑a‑service (VaaS) offerings – partnering with Udelv, Transdev and securing a consumer L4 design win with Geely – and positioning the company as an end‑to‑end service provider for autonomous‑mobility fleets. By 2023 the strategy had shifted to supplying Mobileye Drive™ as a standalone self‑driving product to transportation‑network companies, public‑transit operators and AV‑ready vehicle platform suppliers, often bundled with Moovit’s mobility platform, moving from a service‑provider model to a product‑supply/go‑to‑market model.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Mobileye Drive™ was launched as an SAE L4 system in 2022, with partnerships including Udelv and Transdev, and a design win with Geely. In 2023, the strategy shifted to supplying the system as a standalone product to transportation network companies, public transit operators, and AV platform suppliers, often bundled with Moovit. (2) There are no numeric values requiring calculation, but all dates (2022, 2023) and entity names (Udelv, Transdev, Geely, Moovit) are accurate. (3) The multi-hop reasoning is sound: the answer correctly synthesizes information across time (2022 to 2023), entities (partnerships), and strategic shifts (from service provider to product supplier). (4) The LLM captures the evolution in deployment strategy precisely, including the pivot to a product-supply model and integration with Moovit, which aligns with the ground truth's emphasis on targeting MaaS ecosystems. Wording differs slightly but meaning is preserved. All evaluation dimensions are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 316,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the structure and distribution rate of the Tower Preferred Interests evolved from 2022 to 2024?",
      "original_answer": "In 2022, the Tower Preferred Interests were divided into two series: the September series (Class A-1) totaling $1,500 with a 5.0% initial preferred distribution, and the December series (Class A-2) totaling $4,500 with a 4.75% initial preferred distribution. These distributions reset every five years. By 2024, the structure was amended in August 2024 to reclassify all 2019 Tower preferred interests into Fixed Rate Class A Limited Membership Interests (Tower Fixed Rate Interests) paying a 5.90% preferred distribution. Additionally, a portion of these fixed-rate interests will transition annually into Floating Rate Class A Limited Membership Interests (Tower Floating Rate Interests), which will pay a distribution equal to SOFR plus 250 basis points. This represents both a structural and rate evolution in the Tower Preferred Interests.",
      "llm_answer": "In the 2022 filing the Tower Holdings preferred interests were two separate series – a September Class A‑1 ($1.5 bn) paying a 5.0% preferred distribution and a December Class A‑2 ($4.5 bn) paying 4.75%, both slated for a reset in December 2024. By the 2024 filing the company had amended those interests, consolidating them into Fixed‑Rate Class A Limited Membership Interests that now pay 5.90% and a new Floating‑Rate Class A Limited Membership Interests that pay SOFR + 250 bps, with a portion moving to the floating class each year over a five‑year period. This raised the fixed‑rate distribution to 5.90% and added a variable‑rate component.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of the Tower Preferred Interests from 2022 to 2024. (1) Quantitatively, the dollar amounts ($1.5 bn and $4.5 bn) correctly reflect the $1,500 and $4,500 in millions from the ground truth (i.e., $1.5 billion = $1,500 million), and the distribution rates (5.0%, 4.75%, 5.90%, SOFR + 250 bps) are all correct. The reset timing is mentioned as December 2024, which aligns with the 'every five years' reset in the original answer, though the original specifies the structural amendment occurred in August 2024, which the LLM omits. (2) The LLM correctly identifies the reclassification into Fixed-Rate and Floating-Rate Class A Limited Membership Interests and the annual transition over a five-year period, which is consistent with the ground truth. (3) The reasoning is sound: it synthesizes the 2022 structure with the 2024 changes, correctly noting consolidation, rate changes, and the introduction of a floating-rate component. (4) Minor omission: the LLM refers to '2019 Tower preferred interests' being reclassified, which is not mentioned in the ground truth—this is an inaccuracy, though not central. Also, the August 2024 amendment date is missing. Otherwise, the answer is semantically equivalent, well-structured, and fully relevant to the question on structural and rate evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 375,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the investment approach and unrealized gains/(losses) for Level 3 assets related to the Balanced Index Fund evolve from 2022 to 2023?",
      "original_answer": "In 2022, the company disclosed unrealized losses for Level 3 assets still held at year-end, including ($16) million for corporate fixed income securities and ($11) million for mortgage-backed and asset-backed fixed income securities. By 2023, these values shifted to unrealized gains of $2 million for corporate fixed income securities and $6 million for mortgage-backed and asset-backed fixed income securities. This indicates a significant turnaround in the performance of these assets. Additionally, while the Balanced Index Fund's composition remained at approximately 60% equities and 40% debt securities in both years, the valuation methodology in 2023 explicitly referenced a market approach based on quoted market prices (Level 1), suggesting a more transparent and standardized valuation process.",
      "llm_answer": "The OPB plan’s balanced‑index fund (about 60 % equities, 40 % debt) continued to be valued using a **market approach that relies on the quoted price of an identical Level 1 instrument**【page_96】.  For the Level 3 assets underlying that fund, unrealized results swung from a **$90 net loss in 2022** to a **$14 net gain in 2023** – corporate fixed‑income moved from a $16 loss to a $2 gain, mortgage‑backed securities from an $11 loss to a $6 gain, and other categories likewise improved【page_96】.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. While it correctly reports the unrealized loss of $16 million for corporate fixed income and $11 million for mortgage-backed/asset-backed securities in 2022, and the 2023 gains of $2 million and $6 million respectively, it introduces a fabricated 'net loss of $90 in 2022' and 'net gain of $14 in 2023'. The actual net loss in 2022 was ($27) million ($16M + $11M), and the net gain in 2023 was $8 million ($2M + $6M), not $90 and $14 as stated. This major calculation error undermines factual correctness. (2) The composition of the Balanced Index Fund (60% equities, 40% debt) is accurately reported for both years. The valuation methodology shift to Level 1 quoted prices is correctly noted and aligns with the ground truth. However, the mention of 'other categories likewise improved' is unsupported by the original answer, which only specifies two asset classes. (3) The multi-hop reasoning is partially sound—information is synthesized across years and asset types, and the turnaround in performance is correctly inferred. However, the erroneous net figures suggest flawed aggregation across Level 3 assets. (4) Despite the incorrect net values, the answer captures the directional shift from losses to gains and the increased use of Level 1 inputs, which are key qualitative points. The contextual relevance is high as it directly addresses the evolution of investment approach and unrealized gains/losses. However, the severe quantitative inaccuracies limit the correctness score to 6.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 431,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has BNY Mellon's emphasis on accounting developments in its forward-looking statements evolved between 2023 and 2024, and what does this reveal about the changing influence of accounting standards on its strategic priorities?",
      "original_answer": "In 2023, BNY Mellon included accounting developments among a broader list of potential influences on forward-looking statements, noting they 'may impact our businesses' without specific elaboration. By 2024, the company expanded this language, explicitly stating that accounting developments 'may impact our businesses, regulatory, technology, market, economic or accounting developments and the impacts of such developments on our businesses.' This shift indicates a more integrated view of accounting changes as part of strategic risk and planning considerations. The inclusion of terms like 'capital plans including dividends and repurchases' and 'efficiency savings' in 2024 further suggests that accounting developments are increasingly tied to concrete business decisions and performance metrics.",
      "llm_answer": "In the 2023 Form 10‑K, accounting developments are only listed among a broad set of “regulatory, technology, market, economic or accounting developments” that could affect the business (see 2023 forward‑looking statements, p. 3). By the 2024 filing, BNY Mellon isolates “changes in accounting standards…could have a material impact on our reported financial condition, results of operations, cash flows and other financial data” as a distinct risk in its forward‑looking discussion (see 2024 forward‑looking statements, p. 5). This move from a peripheral mention to a highlighted risk shows that accounting standards have become a more prominent driver of the firm’s strategic priorities and risk‑management focus.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its description of the evolution between 2023 and 2024 filings, correctly identifying that accounting developments were initially listed among other broad factors in 2023 and then elevated to a more prominent, standalone risk in 2024. The dates (2023 and 2024), document types (Form 10-K), and page references (p. 3 and p. 5) are consistent with the ground truth context and do not contradict the original answer. There are no numeric values requiring verification, so quantitative accuracy is scored as 10. However, the LLM diverges slightly in interpretation: while the original answer emphasizes that the 2024 language integrates accounting developments into strategic business decisions like 'capital plans including dividends and repurchases' and 'efficiency savings,' the LLM instead claims accounting standards are now discussed as a 'distinct risk' with material impact on financial reporting. This reframing is plausible but shifts focus from strategic integration (as per ground truth) to risk disclosure, missing the nuance that accounting changes are now tied to forward-looking business planning, not just financial reporting risks. Thus, while the core factual progression (increased emphasis) is correct, the qualitative interpretation of what this reveals about strategic priorities is partially misaligned. The multi-hop reasoning is sound in comparing two years’ disclosures, but the synthesis does not fully capture the strategic linkage to capital allocation and efficiency metrics emphasized in the ground truth. Contextual relevance is high as the response directly addresses the question’s focus on evolving emphasis and strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 463,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the evolution of risks related to store safety and cybersecurity in 2023 potentially impact the associate experience, as compared to the engagement-focused initiatives highlighted in 2022?",
      "original_answer": "In 2022, HD emphasized internal initiatives to improve the associate experience through engagement surveys, a digital engagement platform, and recognition programs, which historically showed that four out of five associates were emotionally committed. However, in 2023, the company highlighted external risks such as increased store shrink, particularly from organized retail crime, and cybersecurity threats that could compromise associate data and store safety. These risks were noted to potentially erode trust, impact associate morale and retention, and damage the company's reputation. This shift indicates that while HD was actively fostering associate engagement in 2022, the emergence or escalation of external risks in 2023 introduced new challenges that could undermine those earlier gains in associate experience.",
      "llm_answer": "In the 2023 filing the company warned that a failure to keep stores safe (e.g., rising organized‑retail crime and “shrink”) and the growing cyber‑threat landscape could erode associate confidence, morale and retention – safety incidents or data‑breaches can increase stress, raise costs and damage the brand, directly hurting the associate experience. By contrast, the 2022 filing emphasized proactive engagement programs – culture‑driven values, pulse‑check and Voice‑of‑Associate surveys, a digital engagement platform and recognition initiatives – that were designed to boost associate commitment and satisfaction. Thus, while 2022 focused on building a positive associate experience, the 2023 risk evolution introduced factors that could negatively impact that experience if the safety and cybersecurity threats materialize.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original answer. (1) All factual elements are correct: the 2022 initiatives (engagement surveys, digital platform, recognition programs) and the 2023 risks (organized retail crime, shrink, cybersecurity threats) are correctly identified and contextualized. The impact on associate experience—morale, retention, trust—is accurately described in both years. (2) There are no numeric values, percentages, or financial figures in the question or ground truth, so quantitative accuracy is not applicable beyond correct use of terms like 'shrink' and 'cyber-threats,' which are used appropriately. (3) The multi-hop reasoning is sound: the model correctly contrasts proactive engagement efforts in 2022 with emerging external risks in 2023 and synthesizes how the latter could undermine the former. The logic that safety and cybersecurity issues could erode gains in associate experience is consistent with the ground truth. (4) The only minor shortcoming is the omission of the specific statistic from 2022 that 'four out of five associates were emotionally committed,' which adds empirical support to the engagement narrative. While this detail is missing, the overall qualitative and contextual accuracy remains high. The answer is semantically equivalent and fully relevant to the question, with clear, logical structure and precise use of terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 389,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the role of the 'learning curve' in influencing cost and production estimates evolved between 2022 and 2023, particularly in relation to program profitability and risk management?",
      "original_answer": "In 2022, the 'learning curve' was identified as a risk factor that could negatively impact program profitability due to production complexities, rework, and delays—especially in programs like the 787—potentially leading to additional losses and abnormal production costs. By 2023, the 'learning curve' was no longer framed solely as a risk but was integrated into the company's cost estimation process, factored into production rate assumptions, supplier performance trends, and internal labor efficiency projections. This shift indicates that Boeing began treating the learning curve as a predictable and manageable component of production planning rather than an unpredictable risk.",
      "llm_answer": "In the 2022 filing the learning‑curve effect was called out as a specific risk factor that could drive lower margins or trigger reach‑forward losses, underscoring its potential to hurt program profitability (page_42). By 2023 the learning curve is folded into the broader set of assumptions used in the quarterly‑reviewed program‑accounting and cost‑estimation process, showing a shift toward a more systematic, risk‑managed approach to forecasting production costs and margins (page_49).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) It correctly identifies that in 2022, the learning curve was a risk factor affecting profitability, citing potential lower margins and reach-forward losses, which aligns with the original answer's emphasis on rework, delays, and abnormal costs—particularly on programs like the 787 (though the 787 example is omitted, the conceptual impact is preserved). (2) For 2023, the LLM correctly states that the learning curve was integrated into the cost-estimation and program-accounting process, reflecting a shift toward systematic management, consistent with the ground truth's description of its inclusion in production rate assumptions, supplier trends, and labor efficiency. (3) The multi-hop reasoning is sound: the model synthesizes changes in framing and usage of the learning curve across two years, correctly inferring a strategic shift from risk to managed input. (4) Minor deduction in qualitative accuracy due to omission of specific elements (e.g., 'supplier performance trends', 'internal labor efficiency') mentioned in the original, but the overall meaning and evolution are preserved. No numeric inaccuracies; dates (2022, 2023) and contextual references (page numbers) are correctly attributed. Semantic equivalence is strong, and relevance to the question on evolution, profitability, and risk management is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 393,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the treatment or disclosure of the Dividend Reinvestment Plan evolved between the 2023 and 2024 SEC filings, particularly in relation to officer or director participation and associated trading arrangements?",
      "original_answer": "In the 2023 filing, the Dividend Reinvestment Plan was mentioned in the context of officer or director participation alongside the employee stock purchase plan and 401(k) plan, with specific reference to elections to have shares withheld for tax purposes or to pay the exercise price of stock awards. The disclosure also included a detailed description of how these elections may be structured under Rule 10b5-1 or non-Rule 10b5-1 trading arrangements as defined in Item 408(c) of Regulation S-K. In the 2024 filing, the Dividend Reinvestment Plan was again referenced in the context of officer or director participation, but the detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements was omitted, indicating a simplification or standardization of the disclosure without the earlier level of specificity regarding trading frameworks.",
      "llm_answer": "In the 2023 Form 10‑K the company only disclosed that some officers and directors had elected to participate in its dividend‑reinvestment plan (along with other equity plans) and did not elaborate on the trading‐arrangement implications. By the 2024 filing, Item 9B was expanded to say that those elections may be made to satisfy the affirmative‑defense conditions of Rule 10b5‑1 **or** may constitute non‑Rule 10b5‑1 trading arrangements, giving a more detailed description of the possible insider‑trading structures tied to the plan.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its description of the evolution between the 2023 and 2024 filings, reversing the direction of change in disclosure detail. According to the ground truth, the 2023 filing included a detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements in the context of the Dividend Reinvestment Plan, while the 2024 filing omitted this detailed discussion, indicating a simplification. However, the LLM claims the opposite: that the 2023 filing lacked elaboration and the 2024 filing added detail by expanding Item 9B to include Rule 10b5-1 and non-Rule 10b5-1 structures. This misrepresents the actual progression and shows a critical failure in multi-hop reasoning and synthesis across the two filings. There are no numeric values to assess for quantitative accuracy, so that score is neutral (10 by default, as no numbers were misstated). The entities (Dividend Reinvestment Plan, Rule 10b5-1, officers/directors) are correctly identified, but their treatment across years is inverted. Contextual relevance is low because the answer describes a disclosure enhancement in 2024 that did not occur, thus failing to address the actual evolution. The semantic meaning is not equivalent to the ground truth, resulting in a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 361,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has The Home Depot's investment in creating an interconnected shopping experience evolved from fiscal 2021 to fiscal 2023, and what specific changes were made in the way this experience is tailored to customers?",
      "original_answer": "In fiscal 2021, The Home Depot invested $2.6 billion in capital expenditures focused on supporting an interconnected customer experience. By fiscal 2023, the company had advanced this strategy by leveraging enhanced merchandising information technology tools to build an interconnected shopping experience tailored to customers' shopping intent and location. This represents a shift from general investment in interconnectedness to a more refined, data-driven personalization strategy.",
      "llm_answer": "The Home Depot’s spend on the “interconnected, frictionless” shopping experience rose from **$2.6 billion in fiscal 2021**【page_6†L31-L34】to **$3.2 billion in fiscal 2023**【page_5†L31-L34】—a roughly $0.6 billion increase. In 2021 the focus was on data‑driven merchandising tools that linked digital and in‑store channels to each shopper’s **intent and location**【page_8†L13-L18】. By 2023 the company expanded that vision with a broader set of digital upgrades (enhanced website and mobile apps, richer product pages, personalized marketing messages) and physical‑store enhancements (way‑finding signage, self‑service lockers, curb‑side pickup, electronic shelf‑labeling, redesigned service desks, expanded self‑checkout and mobile‑app store navigation) to make the experience **more personalized and location‑specific** for customers【page_7†L1-L7】【page_8†L1-L12】【page_9†L1-L9】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative claim that The Home Depot's investment increased from $2.6 billion in fiscal 2021 to $3.2 billion in fiscal 2023. The ground truth does not support the $3.2 billion figure or any specific increase in capital expenditure by 2023; it only confirms the $2.6 billion investment in 2021 and describes strategic evolution, not increased spending. This is a major error that undermines the answer’s correctness. (2) The calculation of a '$0.6 billion increase' is therefore incorrect, as the 2023 investment amount is not stated in the ground truth. The LLM fabricates a numeric value not present in the original answer, violating quantitative accuracy. (3) Qualitatively, the LLM correctly identifies the shift toward a more personalized, data-driven experience using intent and location, and mentions relevant enhancements like mobile apps, signage, and checkout improvements. These details align with the idea of tailoring the experience, though they are presented as evidence of increased spending, which is unsupported. The multi-hop reasoning is partially sound—linking technology and store upgrades to personalization—but incorrectly ties them to a financial increase not in the ground truth. (4) Contextually, the answer is relevant and addresses both parts of the question: evolution over time and changes in tailoring. However, the inclusion of false financial data severely compromises factual correctness. While the direction of strategic evolution is plausibly described, the answer misrepresents the evidence. Thus, the correctness score is low due to the critical error in financial figures, despite some accurate qualitative insights.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 476,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the financial relationship between DHR and Aldevron evolved between 2022 and 2023, particularly in terms of capital investment and acquisition-related expenditures?",
      "original_answer": "In 2022, DHR anticipated capital expenditures of approximately $1.5 billion, with a portion of this spending attributed to increased manufacturing capacity for products related to the Aldevron Acquisition, among others. This reflects a growing capital commitment tied to Aldevron. By 2023, the financial relationship had evolved significantly, as evidenced by the net cash consideration paid to Aldevron amounting to $9,561 million, indicating that Aldevron had transitioned from being primarily a capital investment target to a core component of DHR's consolidated assets. This represents a substantial shift in the nature of their relationship from a dependency to a stakeholding and integration model.",
      "llm_answer": "Danaher’s spending on Aldevron has moved from a one‑time purchase to ongoing capital upgrades.  In the 2023 filing the company reports property‑plant‑and‑equipment purchases of $136 million versus $87 million in 2022 (page 72), indicating a higher level of investment in the business’s assets.  By contrast, the only acquisition‑related outlay for Aldevron was the original $9.6 billion cash purchase and its $28 million transaction cost recorded in 2021 (pages 73‑74); no new acquisition fees appear in the 2022‑2023 disclosures.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the financial relationship evolution between DHR and Aldevron from 2022 to 2023. (1) Quantitatively, the LLM incorrectly states that the only acquisition-related outlay for Aldevron was in 2021 ($9.6 billion), but the ground truth indicates that the $9,561 million net cash consideration was paid in 2023, not 2021. This is a critical error in both timing and amount. Additionally, the LLM cites $136 million and $87 million in PP&E purchases as evidence of increased investment in Aldevron, but the original answer does not mention these figures or attribute them specifically to Aldevron, making this claim unsupported. (2) The original answer emphasizes that in 2022, DHR anticipated $1.5 billion in total capital expenditures, with a portion linked to Aldevron capacity expansion—this context is missing in the LLM response. (3) Qualitatively, the LLM mischaracterizes the evolution: it frames spending as shifting from 'one-time purchase to ongoing capital upgrades,' but the ground truth shows a shift from preparatory capital investment in 2022 to full acquisition integration in 2023 via a $9.56B cash payment, not ongoing upgrades. The LLM incorrectly implies continued post-acquisition investment is the main trend, when in fact the major event was the completion of the acquisition in 2023. (4) The reasoning is flawed because it draws conclusions about Aldevron-specific investments from general PP&E numbers without evidence of attribution, and it misplaces the key acquisition expenditure in time. While the answer attempts to address the question's focus on capital investment and acquisition spending, it does so with incorrect data and logic, leading to a low correctness score. Contextual relevance is moderate because the structure and intent align with the question, but factual content is largely inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 515,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the structure and total value of Telco LLC's preferred interests evolved from 2022 to 2024, and what changes were made to the distribution rates and reset schedules during this period?",
      "original_answer": "In 2022, Telco LLC had $2,000 in nonconvertible cumulative preferred interests (Telco Class A-1) with an initial preferred distribution rate of 4.25% annually, subject to reset every seven years. By 2024, Telco LLC expanded its preferred interests with the issuance of an additional $5,250 in preferred interests (Telco Class A-2 and A-3) in April 2023, bringing the total cumulative preferred interests to $7,250. The new preferred interests (Class A-2 and A-3) carried a significantly higher initial preferred distribution rate of 6.85% annually, with the first reset scheduled for November 1, 2027, and every seven years thereafter. This represents both a structural expansion in the capital stack and a strategic shift toward higher-yielding preferred instruments.",
      "llm_answer": "In the 2022 filing Telco LLC had only one series of preferred interests – the September 2020 issuance of $2 billion (‑‑$2,000 mm) of non‑convertible cumulative preferred interests (Telco Class A‑1) that paid an initial 4.25% annual distribution and were subject to a reset every seven years【page_130】.  \n\nBy the 2024 filing the structure had been expanded to three series – the original Class A‑1 plus new Class A‑2 and A‑3 issued in April 2023 for an additional $5.25 billion, bringing total Telco preferred interests to $7.25 billion as of 12/31/2024【page_87】.  Class A‑1 still pays 4.25% with a seven‑year reset, while the new Class A‑2/A‑3 pay a higher 6.85% initial distribution and reset on Nov 1 2027 and every seven years thereafter.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: in 2022, Telco LLC had $2,000 million ($2 billion) in Class A-1 preferred interests with a 4.25% annual distribution rate and a seven-year reset schedule. In April 2023, an additional $5,250 million ($5.25 billion) in Class A-2 and A-3 preferred interests were issued at a 6.85% rate, bringing the total to $7,250 million ($7.25 billion) by 2024. (2) Quantitative accuracy is perfect: $2,000 + $5,250 = $7,250; the percentages (4.25%, 6.85%) and reset dates (seven-year cycle, first reset Nov 1, 2027 for new series) match exactly. Format variations (e.g., $2 billion vs $2,000 mm) are acceptable and common in financial reporting. (3) The multi-hop reasoning is sound—information is correctly synthesized across 2022 and 2024 filings, with proper temporal sequencing of the April 2023 issuance and its impact on structure and total value. (4) The answer addresses all parts of the question: evolution of structure and total value, changes in distribution rates, and reset schedules. The qualitative analysis correctly identifies a structural expansion and shift to higher-yielding instruments, aligning with the strategic implication in the original answer. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 371,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has AIG's use of Expected Loss Ratio Methods evolved between 2022 and 2024, particularly in terms of the types of insurance lines and the rationale for their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to their high-severity nature. By 2024, AIG expanded the use of Expected Loss Ratio Methods to include U.S. Workers' Compensation, a long-tail line of business, where it was used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different insurance lines with varying claim characteristics.",
      "llm_answer": "In 2022 AIG applied Expected Loss Ratio (ELR) methods chiefly to long‑tail U.S. Workers’ Compensation and to high‑severity aviation exposures, and used ELR for the latest accident‑year reserves when development data were limited (2022 p. 271; 2022 p. 273). By 2024 the firm had expanded ELR use to both long‑ and short‑tail lines—including excess‑of‑deductible business—grounding the ratios on premium‑based projections that are adjusted for rate changes, loss‑trend, inflation and market conditions, reflecting a broader, more systematic rationale (2024 p. 149; 2024 p. 151).",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the 2022 application of the Expected Loss Ratio (ELR) method. The ground truth states that in 2022, AIG used ELR primarily for the latest accident year and in aviation exposures (high-severity), but did not mention U.S. Workers' Compensation at that time. However, the LLM claims ELR was applied to 'long-tail U.S. Workers’ Compensation' in 2022, which contradicts the original answer and represents a major misstatement of the timeline. This error undermines the multi-hop comparison between 2022 and 2024. The 2024 expansion to U.S. Workers' Compensation is correctly identified in the original answer, and the LLM correctly notes broader use across long- and short-tail lines by 2024, including excess-of-deductible business, and references premium-based projections adjusted for rate changes, loss trends, inflation, and market conditions—this aligns with the evolution rationale. (2) There are no explicit numerical values (e.g., percentages, dollar amounts) in either the question or answers, so quantitative accuracy is not compromised by miscalculations. Page references (e.g., 2022 p. 271) appear consistent with source documentation format, though not verifiable here. (3) The multi-hop reasoning is partially sound: the model attempts to compare ELR usage across years and lines of business, but incorrectly attributes 2024 developments (use in Workers' Compensation) to 2022, breaking the logical evolution. This misattribution disrupts the synthesis required for accurate trend analysis. (4) Contextual relevance is high—the response addresses the evolution of ELR methods, insurance lines, and rationale. However, due to the incorrect assignment of Workers' Compensation usage in 2022, the qualitative accuracy is reduced significantly despite otherwise detailed and relevant content. Correctness score reflects partial accuracy with a major factual flaw in temporal attribution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 529,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has Target's approach to its owned brands evolved from 2023 to 2024, particularly in terms of strategic emphasis and product portfolio development?",
      "original_answer": "In 2023, Target emphasized expanding its owned brands portfolio as a core strategic element to drive relevancy and market share growth. By 2024, the company shifted focus to producing a broad range of owned and exclusive brands, listing over 40 distinct brands across various categories, indicating a more concrete execution phase of brand development and diversification.",
      "llm_answer": "In the 2023 filing Target’s strategy simply **“strengthen[ed] our owned brands portfolio”** as a core way to deliver newness, style and value (Item 1 – Strategy). By the 2024 filing the company is **showing the portfolio in detail**—listing dozens of exclusive labels and stating that **about one‑third of merchandise sales now come from owned and exclusive brands**—and it ties that growth to its **global‑sourcing team that identifies, evaluates and partners with suppliers “most notably for our owned brands.”** This reflects a move from a high‑level strategic intent in 2023 to a broader, operationally‑driven expansion and diversification of the owned‑brand product mix in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution from 2023's high-level strategic emphasis on strengthening owned brands to 2024's more detailed, execution-focused approach with explicit mention of portfolio expansion. (2) The quantitative claim that 'about one-third of merchandise sales now come from owned and exclusive brands' is consistent with Target's 2024 disclosures and adds precision not in the original answer, but does not contradict it—this is a valid enhancement based on actual filings. There are no calculation errors. (3) The multi-hop reasoning is sound: it synthesizes information across two years' filings, correctly identifying the shift from strategic intent to operational execution, and supports it with evidence about supplier partnerships and sourcing teams. (4) The only reason for not scoring a 10 is minor: the original answer emphasizes the count of 'over 40 distinct brands,' which the LLM omits, though mentioning 'dozens of exclusive labels' is a reasonable approximation. Otherwise, the LLM provides richer context (e.g., global-sourcing team) that enhances accuracy. All entities (Target, 2023, 2024, owned/exclusive brands) are correct. Semantic equivalence is strong, with slightly better detail in the LLM response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 366,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "What does IBM's continued listing of the 0.875% Notes due 2030 in 2024 alongside the new 2.900% Notes due 2030 suggest about its debt financing strategy and the market conditions for long-term borrowing?",
      "original_answer": "In 2023, IBM listed the 0.875% Notes due 2030 (trading symbol IBM30A) among its registered securities, indicating its initial issuance of this long-term debt instrument. By 2024, IBM not only maintained the 0.875% Notes due 2030 in its capital structure but also introduced a new 2.900% Notes due 2030 (trading symbol IBM30C). The significant increase in the interest rate—from 0.875% to 2.900%—for the same maturity year suggests that IBM may have pursued additional financing in 2024 under less favorable interest rate conditions, or it may be targeting different investor segments with varied risk-return profiles. This dual listing could also indicate a strategic effort to diversify its debt portfolio and manage refinancing risks by having multiple instruments maturing in the same year but with different coupon rates.",
      "llm_answer": "IBM’s 2024 filing still shows the ultra‑low‑coupon 0.875 % notes due 2030 that were on its books in 2023 (IBM_10k_2023.pdf p. 1) and adds a new series of 2.900 % notes also due 2030 (IBM_10k_2024.pdf p. 1). This signals a strategy of keeping a tranche of very cheap long‑dated debt while issuing fresh long‑term paper at the higher yields now required by the market, indicating that IBM is diversifying its maturity mix and that investor demand for high‑quality, long‑term bonds remains strong despite rising overall rates.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key facts: IBM continued listing the 0.875% Notes due 2030 in 2024 and issued a new 2.900% Notes due 2030. The percentages (0.875% and 2.900%), maturity year (2030), and the multi-year context (2023 to 2024) are all accurate. There are no calculation errors, and the numbers match the ground truth exactly. (2) Quantitative accuracy is perfect—interest rates, years, and the sequence of filings are correctly reported. Format variations (e.g., spacing in percentages) do not affect meaning. (3) The reasoning is sound: the LLM correctly infers that IBM is maintaining cheap debt while issuing new debt at higher rates, reflecting current market conditions. It accurately suggests diversification of maturity mix and implies continued investor demand for high-quality long-term bonds. The only minor omission is not explicitly mentioning 'refinancing risk' or 'targeting different investor segments,' which are in the original answer. However, the core strategic implications—diversification and adapting to higher yields—are well captured. (4) The answer is contextually highly relevant, directly addressing IBM’s debt financing strategy and market conditions for long-term borrowing. It synthesizes information across two years of filings and draws appropriate inferences. The slight deduction in qualitative accuracy is due to the absence of nuanced strategic motives present in the ground truth, but the overall reasoning remains strong and factually aligned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 418,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the composition of AT&T's long-term debt instruments evolve between 2022 and 2024, particularly regarding the 4.000% Global Notes due June 1, 2049 and the addition of new long-term notes?",
      "original_answer": "In 2022, AT&T listed the 4.000% Global Notes due June 1, 2049 (T 49A) among other long-term debt instruments, but did not include the 4.300% Global Notes due November 18, 2034. By 2024, the 4.000% Global Notes due 2049 remained registered under the same symbol (T 49A), and the company added the 4.300% Global Notes due 2034 (T 34C). This indicates that AT&T expanded its long-term debt portfolio by introducing new maturities while maintaining existing long-dated obligations like the 2049 notes.",
      "llm_answer": "In the 2022 Form 10‑K, AT&T’s long‑term debt schedule listed a 4.000 % Global Note due June 1 2049 (T 49A) among a broad set of fixed‑rate notes ranging from 2026 to 2067【page_2】. By the 2024 filing, that 4.000 % 2049 issue no longer appears; instead the debt register now includes newer issuances such as floating‑rate notes due March 6 2025, 3.550 % notes due Nov 18 2025, 3.500 % notes due Dec 17 2025, and a series of notes maturing from 2026 through 2033【page_1】. This reflects a shift from the older 2049 instrument to a more recent mix of long‑term notes with varied coupons and nearer maturities.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. According to the ground truth, the 4.000% Global Notes due June 1, 2049 (T 49A) were still present in AT&T's long-term debt portfolio in 2024. However, the LLM incorrectly states that this instrument 'no longer appears' in the 2024 filing, which directly contradicts the original answer. Additionally, the ground truth confirms the addition of the 4.300% Global Notes due November 18, 2034 (T 34C) in 2024, but the LLM fails to mention this specific new issuance and instead lists various other notes (e.g., floating-rate notes due March 6, 2025, 3.550% notes due Nov 18, 2025, etc.) that are not referenced in the original answer, suggesting fabrication or misattribution. (2) Quantitatively, the LLM misrepresents the presence of the 4.000% 2049 notes (wrongly claiming they were removed) and introduces unverified debt instruments with incorrect coupons and maturities not supported by the ground truth. The dates and percentages listed (e.g., 3.550%, 3.500%, March 6, 2025) have no alignment with the original answer, which only specifies the 4.300% notes due 2034 as newly added. (3) The multi-hop reasoning is flawed: the model fails to correctly track the continuity of the 2049 notes and the specific new addition in 2024. Instead of showing expansion while maintaining long-dated obligations, it incorrectly infers a 'shift' away from long-dated debt, which is the opposite of what the ground truth indicates. (4) Contextual relevance is moderate because the answer addresses the general topic of AT&T's long-term debt evolution and attempts to compare 2022 and 2024, but the core facts are incorrect, undermining the validity of the conclusion. Due to major factual and quantitative errors, the correctness score is low despite the structurally appropriate framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 499,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the financial impact of the Heritage AspenTech acquisition evolve between 2023 and 2024, particularly in terms of intangibles amortization and restructuring costs?",
      "original_answer": "In 2023, the intangibles amortization related to the Heritage AspenTech acquisition was $258, while in 2024, this figure decreased to $97. Additionally, restructuring costs were $72 in 2023 and increased to $228 in 2024. This indicates a reduction in the amortization burden but a significant rise in restructuring expenses over the two years.",
      "llm_answer": "In 2023 the Heritage AspenTech deal contributed $258 million of intangibles amortization and only $1 million of restructuring expense (the $258 million is noted as AspenTech‑related amortization, and the $1 million appears in the AspenTech segment of the $72 million total restructuring cost)【page_55】. By 2024 total intangibles amortization had risen to $1,077 million; after allocating $560 million to the NI acquisition, roughly $517 million remained for other intangibles—including AspenTech—while overall restructuring costs jumped to $228 million, with AspenTech‑related restructuring increasing to $8 million【page_55】.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, intangibles amortization for the Heritage AspenTech acquisition decreased from $258 million in 2023 to $97 million in 2024. However, the LLM claims it was $258 million in 2023 (correct) but then incorrectly states that total intangibles amortization in 2024 rose to $1,077 million, with $517 million remaining for 'other intangibles including AspenTech'—this implies AspenTech amortization increased, contradicting the ground truth decrease to $97 million. Additionally, the LLM claims AspenTech-related restructuring costs were $1 million in 2023 and $8 million in 2024, but the ground truth states total restructuring costs were $72 million in 2023 and $228 million in 2024—there is no breakdown by segment in the original answer, so attributing only $1M and $8M to AspenTech is unsupported and misleading. (2) Number verification: $258 million amortization in 2023 is correct; however, 2024 amortization is wrong (LLM implies ~$517M vs. correct $97M). Restructuring: LLM says $1M and $8M for AspenTech; ground truth says $72M and $228M total—these are not equivalent. (3) Multi-hop reasoning is flawed: the LLM attempts to allocate portions of total amortization and restructuring to AspenTech based on other acquisitions (e.g., NI), but this introduces speculation and misrepresents the direct comparison required between 2023 and 2024 for the Heritage AspenTech acquisition specifically. The original answer provides clear, direct figures without needing allocation. (4) Scores justified: correctness is low due to major numerical and interpretive errors; quantitative accuracy is poor due to incorrect values and unsupported allocations; qualitative accuracy is low due to faulty reasoning and entity misattribution; contextual relevance is moderate because the answer addresses the right topic and acquisition but with incorrect data synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 527,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has AIG's use of expected loss ratio methods for workers' compensation evolved between 2022 and 2024, particularly in relation to the segmentation of business types and the impact of large deductible accounts?",
      "original_answer": "In 2022, AIG applied expected loss ratio methods primarily to guaranteed cost business in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that the proportion of large deductible business had increased, slowing the reporting pattern of claims. By 2024, AIG continued to use expected loss ratio methods but placed greater emphasis on segmentation by deductible size and claim handling (AIG vs. third-party administrators), and explicitly highlighted the increasing influence of large deductible accounts on slowing claim emergence. Additionally, 2024 disclosures emphasized limitations in claim count data due to aggregation and reinsurance exclusions, which were not as prominently noted in 2022.",
      "llm_answer": "AIG’s reserving approach for U.S. workers’ compensation has stayed the same – it blends loss‑development, frequency‑severity and expected‑loss‑ratio techniques and splits the portfolio into guaranteed‑cost and excess‑of‑deductible blocks, with further break‑outs by state, industry and deductible size (2022 p. 258; 2024 p. 151).  What has shifted is the mix of business: the share of large‑deductible, risk‑sharing accounts has grown, slowing claim emergence and causing AIG to rely more heavily on expected‑loss‑ratio assumptions for the excess‑of‑deductible segment (especially in the most recent accident years), even though the overall segmentation framework remains unchanged.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its description of AIG's reserving methods and correctly identifies the continued use of expected loss ratio techniques across 2022 and 2024, segmentation by business type (guaranteed cost vs. excess of deductible), and the growing share of large deductible accounts slowing claim emergence. It accurately notes the increased reliance on expected loss ratio assumptions for excess-of-deductible business in recent accident years, aligning with the ground truth. Quantitatively, there are no numbers, dates, or percentages in dispute, and the cited page numbers (2022 p. 258; 2024 p. 151) are consistent with plausible sourcing, so quantitative accuracy is high. However, the LLM omits key qualitative developments emphasized in the 2024 disclosures: specifically, the greater segmentation by claim handling (AIG vs. third-party administrators) and the explicit discussion of limitations in claim count data due to aggregation and reinsurance exclusions—points not highlighted in 2022 but noted as a shift in the ground truth. While the LLM mentions segmentation by deductible size, it does not fully capture the evolution in granularity or the new data limitations acknowledged in 2024. Thus, while the core facts about business mix and methodology reliance are correct, the answer lacks completeness in conveying how the *application* and *transparency* of the expected loss ratio methods evolved. This results in a strong but not fully accurate qualitative assessment. Contextual relevance is high as the response directly addresses the evolution of methods, segmentation, and impact of large deductible accounts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 450,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has Target's approach to cybersecurity threat investigation and response evolved from 2023 to 2024, particularly in terms of its Cyber Fusion Center operations and collaboration with external organizations?",
      "original_answer": "In 2023, Target operated its Cyber Fusion Center as part of its threat investigation and response capabilities, and emphasized collaboration with organizations across industries to share threat intelligence and best practices. By 2024, Target not only maintained its Cyber Fusion Center but also introduced a more structured incident response program with a coordinated escalation model to inform management and the Board of Directors during security incidents. Additionally, in 2024, Target expanded its external engagement by incorporating regular training and compliance activities for team members, and by leveraging third-party vendors to assess and test its cybersecurity program. This represents a more comprehensive and mature approach to cybersecurity threat response and collaboration.",
      "llm_answer": "In the 2023 filing Target described its cyber‑fusion center as the hub that “investigates and responds to threats” and noted that it “shares threat intelligence and collaborates with organizations across different industries” (2023 Form 10‑K p. 17). By the 2024 filing the core function of the fusion center is unchanged, but Target now stresses a more proactive threat‑intelligence program, regular internal and independent validation of its controls, and an expanded, formalized partnership model for exchanging intelligence and fighting cybercrime with external industry groups (2024 Form 10‑K p. 21). This reflects an evolution toward deeper, more structured collaboration while maintaining the same investigative‑response capability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Target maintained its Cyber Fusion Center from 2023 to 2024, continued industry collaboration, and enhanced its program in 2024. The LLM correctly identifies the evolution toward a more structured and proactive approach, including formalized external partnerships and validation of controls. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2023, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly identifying continuity in core operations while highlighting advancements in structure, validation, and collaboration. The mention of 'regular internal and independent validation' aligns with the ground truth's reference to third-party assessments and compliance training. (4) The only minor gap is that the LLM answer does not explicitly mention the 'coordinated escalation model to inform management and the Board of Directors'—a key addition in 2024 per the original answer. While 'proactive threat-intelligence program' and 'formalized partnership model' capture aspects of maturity, the absence of Board-level escalation slightly reduces completeness. However, the overall semantic meaning and evolution are accurately conveyed. Wording differences are acceptable and do not affect factual correctness. Contextual relevance is perfect—the response directly addresses both Cyber Fusion Center operations and external collaboration as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 443,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did Eli Lilly's financial relationship with Baqsimi evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual arrangements?",
      "original_answer": "In 2023, Eli Lilly reported $579.0 million in revenue specifically attributed to the sale of the rights for Baqsimi. By 2024, Baqsimi was included within broader collaboration and other revenue disclosures, reflecting its integration into revenue from collaborations and other arrangements, which included the 2023 sales of rights for both the olanzapine portfolio and Baqsimi. This shift indicates a move from direct product revenue to a more complex revenue recognition model under collaborative arrangements, suggesting a strategic evolution in how the company accounts for and manages its financial relationship with Baqsimi.",
      "llm_answer": "In 2023 Eli Lilly booked Baqsimi’s $579 million one‑time rights‑sale as product revenue – it appears in the $677.6 million Baqsimi line of net product revenue. In the 2024 filing that same rights‑sale is no longer shown in product sales but is included in “collaboration and other revenue” (part of the $4.3 billion of such revenue), indicating the transaction is now treated as an upfront payment under a collaboration/licensing arrangement rather than as ordinary product sales.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the $579 million one-time rights sale for Baqsimi in 2023 and its reclassification in 2024 under 'collaboration and other revenue'. The figure of $4.3 billion for that category in 2024 is contextually accurate as a broader bucket, though not explicitly stated in the original answer—this is a reasonable inference from filings and does not contradict the ground truth. (2) The quantitative details are correct: $579 million in 2023 is accurately reported, and the shift in presentation between years is properly noted. The mention of $677.6 million in net product revenue for Baqsimi in 2023 is an additional detail not in the original answer; however, it does not conflict with it and may reflect a more granular breakdown from the actual 10-K. (3) The reasoning correctly captures the multi-hop evolution: from direct product revenue recognition in 2023 to inclusion in collaborative arrangements in 2024, indicating a change in accounting treatment consistent with licensing or collaboration models. (4) The answer is semantically equivalent to the original, with slightly more specificity in financial line items. The only minor limitation is the introduction of the $677.6 million figure, which, while plausible, isn't in the ground truth and could be misleading if unverified—but it doesn't undermine the core correctness. Overall, the response is factually sound, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 413,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did AT&T's approach to managing its capital structure through preferred interests evolve from 2023 to 2024, particularly regarding the repurchase of Mobility Preferred Interests and the expansion of Tower Holdings and Telco LLC preferred interests?",
      "original_answer": "In 2023, AT&T repurchased the remaining 213 million Mobility Preferred Interests for $5,414, removing $2,650 from 'Accounts payable and accrued liabilities' and $2,670 from 'Other noncurrent liabilities.' This repurchase was primarily funded by the issuance of $5,250 in new Telco LLC preferred interests, which carried a 6.85% annual distribution rate. By 2024, AT&T had shifted focus toward expanding its Tower Holdings preferred interests, where $6,000 in 2019 Tower preferred interests were restructured into fixed and floating rate classes with a 5.90% base rate and SOFR + 250 bps, respectively. Additionally, the total Telco LLC preferred interests increased to $7,250, including the original $2,000 (Telco Class A-1) and the 2023 additions. This reflects a strategic pivot from repurchasing legacy preferred interests to leveraging new preferred structures with more flexible redemption and distribution terms to manage capital and liquidity.",
      "llm_answer": "In 2023 AT&T’s capital‑structure strategy was to eliminate a legacy preferred‑interest liability – it repurchased the entire 213 million Mobility preferred interests (≈ $5.4 billion) and, after the April 2023 Telco preferred issuance, left no Mobility preferred securities on its balance sheet 【page_86】【page_87】. By 2024 the focus had shifted to expanding and reshaping its preferred‑interest program: the 2019 Tower Holdings interests were amended (August 2024) into fixed‑rate and floating‑rate series, and AT&T entered an agreement to issue an additional $2.25 billion of Telco Class A‑4 preferred interests in early 2025 to fund further redemptions 【page_87】【page_88】. This marks a move from repurchasing existing preferred interests to using new and re‑structured preferred securities as a financing tool.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution in AT&T's capital structure strategy from 2023 to 2024 accurately and is semantically aligned with the ground truth. In 2023, it correctly identifies the repurchase of 213 million Mobility Preferred Interests for approximately $5.4 billion and notes the elimination of these legacy interests from the balance sheet, supported by the issuance of Telco LLC preferred interests. However, the LLM omits the exact amount of the 2023 Telco issuance ($5,250 or $5.25 billion) and does not specify the 6.85% distribution rate, which are key quantitative details in the original answer. Instead, it references a future $2.25 billion issuance of Telco Class A-4 in early 2025, which is factually correct per the source (page 88) but shifts focus slightly from the 2024 expansion already realized. The original answer states that total Telco LLC preferred interests reached $7,250 by 2024 (including prior and 2023 issuances), while the LLM only implies growth without stating the cumulative figure. Regarding Tower Holdings, the LLM correctly notes the August 2024 restructuring of the 2019 Tower preferred interests into fixed and floating rate classes and mentions the base rate implicitly but omits the specific 5.90% fixed rate and SOFR + 250 bps terms, reducing quantitative precision. The reasoning is sound: it correctly infers a strategic pivot from repurchasing legacy interests to using new structured preferred instruments for financing. Entity names (Mobility, Tower Holdings, Telco LLC), years (2023–2024), and document references are accurate. The answer is highly contextually relevant, addressing both parts of the multi-hop question—evolution over time and specific actions on preferred interests. While minor but notable financial specifics are missing or generalized, the overall narrative and strategic interpretation match the ground truth, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1466,
        "completion_tokens": 520,
        "total_tokens": 1986
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Emerson's relationship with AspenTech evolve from 2023 to 2024, and what financial impacts did this transformation have on Emerson's gross margin and ownership structure?",
      "original_answer": "In 2023, Emerson had a business relationship with AspenTech as part of its Software and Control offerings. By 2024, this relationship transformed into a more significant strategic position, as Emerson acquired a 55% ownership stake in 'New AspenTech' (formerly Heritage AspenTech) following a transaction that included approximately $6.0 billion in cash. This change in relationship had a measurable financial impact: the AspenTech acquisition contributed to a 3.3 percentage point increase in gross margin in 2023 and was part of broader changes that led to a 1.8 percentage point increase in gross margin in 2024. Additionally, the ownership stake marked a structural shift in Emerson’s involvement with AspenTech, moving from a partner to a majority shareholder.",
      "llm_answer": "In 2023 Emerson owned roughly 55 percent of AspenTech after the Heritage AspenTech transaction, and that acquisition contributed about 0.6 percentage‑points to Emerson’s gross‑margin, which rose to 49.0 percent (up 3.3 pp) that year【page_26】. By 2024 Emerson’s stake had increased to about 57 percent and it announced a cash offer to acquire all of the remaining AspenTech shares, moving toward full ownership, while its gross‑margin improved further to 50.8 percent (up 1.8 pp)【page_25】【page_26】.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it incorrectly states that Emerson owned 55% of AspenTech in 2023 'after the Heritage AspenTech transaction'—while the ground truth confirms the 55% stake and $6.0 billion cash transaction, the LLM misattributes the timing and implies ownership was already established in 2023 as a starting point, whereas the acquisition was the transformative event of that year. More critically, the LLM claims the acquisition contributed '0.6 percentage-points' to gross margin in 2023, which directly contradicts the ground truth stating a 3.3 percentage-point increase due to AspenTech. The 3.3 pp increase is correctly cited in the LLM answer as the total gross margin rise, but it misassigns the AspenTech contribution. Similarly, for 2024, the LLM correctly notes a 1.8 pp increase in gross margin but incorrectly implies AspenTech's contribution was only part of it without specifying the correct attribution. (2) The numerical errors are significant: the 0.6 pp contribution is unsupported and incorrect; the 57% ownership in 2024 is not in the ground truth (which states 55% post-acquisition with no mention of increase); and the full acquisition offer is mentioned but not in the original answer, introducing unverified forward-looking information. (3) The multi-hop reasoning is partially sound—linking ownership change to margin impact—but flawed in execution due to incorrect data synthesis. The model conflates total margin increases with AspenTech's specific contribution and invents a stake increase to 57%. (4) Contextual relevance is high as the answer addresses the evolution of the relationship and financial impacts on margin and ownership. However, due to major quantitative errors and incorrect entity details, the correctness score is low despite relevant structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 501,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has AIG's Japan pension plans' contribution to non-U.S. pension obligations evolved between 2022 and 2024, and what change occurred in the weighted average discount rate applied to these plans during this period?",
      "original_answer": "In 2022, AIG's Japan pension plans accounted for 61% of total non-U.S. pension assets, with an expected long-term rate of return of 1.85%. By 2024, the Japan pension plans' share of non-U.S. projected benefit obligations decreased to 50% as of December 31, 2024, from 54% in 2023, and the weighted average discount rate increased to 1.81% in 2024 from 1.48% in 2023. This indicates a relative decline in the size of the Japan pension plans within AIG's non-U.S. pension structure, accompanied by a notable increase in the discount rate applied, likely reflecting changes in market conditions or investment strategy.",
      "llm_answer": "AIG’s Japan pension plans continued to account for roughly one‑half of the company’s total non‑U.S. pension obligations – about 50 % at December 31, 2024 (down slightly from 54 % in 2023) and the same ≈ 50 % share reported for the prior period (December 31, 2021)【page_183†L15-L19】【page_310†L7-L10】.  At the same time, the weighted‑average discount rate used for the Japan plans rose sharply, from about 0.5 % (0.52 % at year‑end 2021) to 1.81 % at year‑end 2024【page_310†L7-L10】【page_183†L31-L34】.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in numbers and time periods compared to the ground truth. It incorrectly states that Japan's share of non-U.S. pension obligations was approximately 50% in 2021, but the original answer does not provide data for 2021—only 2022 (61% of non-U.S. pension *assets*, not obligations) and 2023–2024 for obligations. The LLM conflates assets with obligations and misrepresents the 2021 figure, which is not in the ground truth. Additionally, the LLM claims the discount rate rose from 0.52% in 2021 to 1.81% in 2024, but the ground truth only provides discount rate data for 2023 (1.48%) and 2024 (1.81%). There is no mention of a 0.52% rate in 2021 in the original answer, making this a significant factual error. (2) The only correct quantitative elements are the 50% share in 2024 and 54% in 2023 for Japan’s share of non-U.S. projected benefit obligations, and the 1.81% discount rate in 2024. However, the 2022 data point (61% of *assets*) is omitted, and the discount rate change is misrepresented by extending it to 2021 with incorrect values. (3) The multi-hop reasoning is partially sound—the model correctly identifies the trend of declining relative size in obligations and an increasing discount rate—but it fails to distinguish between pension *assets* and *obligations* in 2022 and fabricates a longer time series than supported. (4) The contextual relevance is high because the answer addresses both parts of the question—evolution of contribution and change in discount rate—and attempts to synthesize trends. However, due to significant quantitative inaccuracies and incorrect data points, the correctness score is limited to 6, with a lower quantitative accuracy score of 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 475,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Amazon's disclosure about the impact of competitive stores on its business evolve between the 2022 and 2023 10-K filings, particularly in terms of the framing of external market conditions?",
      "original_answer": "In the 2022 10-K filing, Amazon described competitive stores as a general factor among many that could impact sales and operating results, listing them alongside internal capabilities such as inventory management and customer satisfaction. The 2022 filing included the phrase: 'the introduction of competitive stores, websites, products, services, price decreases, or improvements' as a potential cause of sales fluctuations. In contrast, the 2023 filing retained the same core language but embedded it within a broader context that emphasized external economic and geopolitical conditions, stating that revenue and operating profit growth 'depends on the continued growth of demand for the products and services offered by us or our sellers, and our business is affected by, among other things, general economic, business, and geopolitical conditions worldwide.' This indicates a shift toward framing competitive pressures as part of a larger set of external risks rather than a standalone concern.",
      "llm_answer": "- In the 2022 10‑K Amazon listed “the introduction of competitive stores, websites, products, services, price decreases, or improvements” as a risk factor and framed the broader market backdrop in concrete terms, noting that demand can be hit by “global economic conditions such as recessionary fears or rising inflation” (see page 8).  \n- In the 2023 10‑K the same competitive‑store risk appears, but Amazon now situates it within a more general macro‑economic narrative, stating that its revenue growth “depends on the continued growth of demand… and our business is affected by general economic and business conditions worldwide” and that a “softening of demand… may result in decreased revenue or growth” (see page 9).  \n\nThus, the disclosure shifted from citing specific economic headwinds (recessionary fears, inflation) to a broader framing of overall economic conditions and demand‑softening trends.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the core language about 'competitive stores, websites, products, services, price decreases, or improvements' in both the 2022 and 2023 10-Ks and accurately notes that this language persists across years. It correctly captures the shift in framing: from a more specific list of internal and external factors in 2022 (including recessionary fears and inflation) to a broader macroeconomic narrative in 2023 centered on general economic conditions and demand softening. (2) There are no numeric values, dates, or financial figures in the question or ground truth, so quantitative accuracy is not applicable in a traditional sense—but the LLM correctly references page numbers (8 and 9), which are plausible and consistent with typical 10-K structures, though not verifiable from the provided data. No calculations are required. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings and correctly infers a shift in narrative emphasis—from specific competitive and economic headwinds to a more generalized macroeconomic framing. The only minor shortcoming is that the LLM slightly overstates the 2022 framing as focusing on 'specific economic headwinds' when the ground truth emphasizes that competitive stores were listed among many factors, not necessarily subsumed under economic conditions. The 2022 mention of 'recessionary fears or rising inflation' is correctly attributed, but the LLM implies a stronger separation between competitive factors and macro conditions than explicitly stated. (4) The answer is contextually relevant, directly addressing the evolution in disclosure and framing. Overall, the semantic meaning matches the ground truth with high fidelity, warranting a correctness score of 9—excellent but not perfect due to slight nuance loss in how 2022’s factors were categorized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1489,
        "completion_tokens": 522,
        "total_tokens": 2012
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has Target's exposure to port security risks evolved between 2023 and 2024, particularly in terms of geographic focus and operational impact?",
      "original_answer": "In 2023, Target specifically highlighted California ports as a key area affected by port security issues, mentioning that these ports were where the company received a significant portion of its imported merchandise. By 2024, Target broadened its focus, referring to 'major U.S. ports' without specifically naming California, indicating a more generalized concern across multiple locations. Additionally, in 2023, the company noted it had made alternative arrangements due to past disruptions, while in 2024, the emphasis shifted to potential future impacts, including increased costs and inventory supply issues, due to ongoing global conflicts and labor disputes.",
      "llm_answer": "In the 2023 filing Target listed port‑security as one of a broad set of external risks, warning that “periodic closings and ship diversions…congestion disrupting … ports around the world, **including at major U.S. ports** where we receive a significant portion of the products we source from outside the U.S.” (2023 Form 10‑K, p. 15). The 2024 filing still cites port‑security but narrows the geographic focus to “**California ports** where we receive a significant portion of the products we source from outside the U.S.” (2024 Form 10‑K, p. 13), and again notes that such disruptions can interrupt merchandise flow, raise costs and adversely affect results of operations. Thus, Target’s exposure has shifted from a generic U.S.–port risk to a more specific California‑port risk, while the operational impact—supply‑chain disruptions and cost pressures—remains unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that reverse the actual evolution described in the ground truth. (1) It incorrectly states that Target narrowed its geographic focus from 'major U.S. ports' in 2023 to 'California ports' in 2024, when the truth is the opposite: in 2023, Target specifically mentioned California ports, and in 2024, it broadened to 'major U.S. ports' without specifying California. This reversal of direction is a critical error in both entity accuracy and reasoning. (2) The citations provided in the LLM answer misrepresent the actual disclosures—attributing 'major U.S. ports' to 2023 and 'California ports' to 2024 contradicts the ground truth, which has California ports named in 2023 and generalized U.S. ports in 2024. (3) The multi-hop reasoning fails because the model incorrectly interprets the trend over time, leading to an opposite conclusion about the evolution of geographic focus. (4) While the operational impacts (supply chain disruptions, cost increases) are correctly noted as consistent concerns, this does not compensate for the fundamental misrepresentation of the directional change in geographic risk focus. The contextual relevance is moderate because the answer addresses port security risks and operational impacts, but the core factual error undermines correctness. Quantitative accuracy is low because there are no numerical values, but the temporal and geographic assertions are factually wrong. Qualitative accuracy is poor due to incorrect synthesis across years and misidentification of the risk evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 430,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did Emerson's financial relationship with Heritage AspenTech evolve between 2023 and 2024, particularly in terms of acquisition-related amortization and restructuring costs?",
      "original_answer": "In 2023, Emerson reported $258 million in intangibles amortization related to the Heritage AspenTech acquisition. By 2024, this specific amortization was no longer reported, indicating that the focus had shifted away from AspenTech as a newly acquired entity. Additionally, restructuring costs increased significantly from $72 million in 2023 to $228 million in 2024, suggesting that Emerson undertook more extensive restructuring activities in 2024, potentially reflecting integration efforts or strategic realignments following the AspenTech acquisition.",
      "llm_answer": "In 2023 Emerson recorded $258 million of intangible amortization that was specifically tied to the Heritage AspenTech acquisition and only $1 million of AspenTech‑related restructuring costs. By 2024 the Heritage AspenTech amortization is no longer broken out (total intangible amortization rose to $1,077 million, with $560 million attributed to the NI acquisition) while AspenTech restructuring expenses increased to $8 million【page_55】.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but introduces significant inaccuracies. The $258 million intangibles amortization related to the Heritage AspenTech acquisition in 2023 matches the ground truth and is correct. However, the claim that only $1 million in AspenTech-related restructuring costs occurred in 2023 is not supported by the original answer, which states total restructuring costs were $72 million in 2023 (without breaking out AspenTech-specific amounts). Similarly, the LLM claims AspenTech restructuring rose to $8 million in 2024, but the original answer reports total restructuring costs increased to $228 million in 2024—again without specifying how much was AspenTech-related. Thus, the LLM fabricates AspenTech-specific restructuring figures not present in the ground truth. (2) The mention of total intangible amortization rising to $1,077 million in 2024 with $560 million tied to the NI acquisition is extraneous and not part of the original answer, which focuses solely on the absence of AspenTech amortization in 2024. These additional numbers, while possibly factual from the filing, distort the focus and introduce unverified specifics. (3) The multi-hop reasoning is flawed: the original answer infers a shift in focus from AspenTech due to the absence of acquisition-related amortization in 2024 and links rising restructuring costs to integration efforts. The LLM fails to make this synthesis and instead incorrectly narrows restructuring costs to AspenTech with unsupported figures, missing the broader strategic implication. (4) While the LLM correctly identifies the drop in AspenTech-specific amortization reporting from 2023 to 2024 and gets the 2023 amortization number right, it invents AspenTech-specific restructuring costs and omits the key point about the significant overall increase in restructuring costs from $72M to $228M. This undermines both quantitative and qualitative accuracy. The answer remains contextually relevant as it addresses the evolution of financial relationship, but correctness is compromised by fabrication and omission.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 568,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has AIG's use of Expected Loss Ratio methods evolved between 2022 and 2024, particularly in terms of the weight given to this method across different lines of business and accident years?",
      "original_answer": "In 2022, AIG applied Expected Loss Ratio methods primarily for more recent accident years in lines such as D&O, E&O, EPLI, and professional liability, where losses are low frequency and high severity. The method was also used in conjunction with IBNR factor methods for low frequency/high severity losses, with factors continually reevaluated based on emerging claim experience and market factors. By 2024, AIG continued to use Expected Loss Ratio methods but expanded their application to include U.S. Workers' Compensation, a long-tail line of business, where they were used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different risk profiles and a more integrated approach to reserving in complex portfolios.",
      "llm_answer": "In the 2022 Form 10‑K AIG explained that it combines loss‑development, expected‑loss‑ratio and frequency‑severity techniques, using the expected‑loss‑ratio approach mainly for D&O, E&O, EPLI and professional‑liability lines and giving it more weight in the newest accident years while relying on development methods for older years. By the 2024 filing the company says the expected‑loss‑ratio method now receives “significant weight” for business written in excess of a deductible and for the most recent five accident years across its lines, with the ratios explicitly adjusted for rate changes, loss‑trend, inflation and market conditions—showing a broader, heavier reliance on the method in the later period.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the evolution of AIG's use of the Expected Loss Ratio (ELR) method between 2022 and 2024 with strong qualitative accuracy. In 2022, it correctly identifies that ELR was primarily used for recent accident years in D&O, E&O, EPLI, and professional liability—lines characterized by low frequency and high severity—and that more weight was given to ELR for newer years while older years relied on loss development methods. This aligns with the ground truth. By 2024, the LLM notes an expanded role for ELR, including 'significant weight' for recent accident years and excess-of-deductible business, with adjustments for rate changes, inflation, and market conditions. While the ground truth specifically mentions the inclusion of U.S. Workers' Compensation (a long-tail line) in 2024 and the integration of ELR with loss development and frequency/severity methods, the LLM does not explicitly reference Workers' Compensation, which is a notable omission. However, the broader trend of increased reliance and expanded application across lines and accident years is accurately conveyed. The LLM introduces the detail about the 'most recent five accident years' and 'excess of a deductible' which are not in the original answer; these may reflect accurate details from the 10-K not captured in the ground truth, but cannot be verified as fully consistent with the knowledge graph. There are no numerical inaccuracies (quantitative accuracy is high), and all dates (2022, 2024) are correct. The reasoning is sound and reflects multi-hop synthesis across years and lines of business. The answer is highly contextually relevant. The score is reduced slightly (from 9 to 8) due to the omission of the specific example of Workers' Compensation and the lack of mention of IBNR factor methods being reevaluated in 2022, which were part of the original synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 510,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has the monetization strategy for Amazon's film groups evolved between 2022 and 2023, based on changes in capitalized video and music content costs and associated expenses?",
      "original_answer": "Amazon's monetization strategy for film groups evolved between 2022 and 2023, as evidenced by an increase in both the capitalized video and music content costs and the associated expenses. In 2022, the capitalized costs were $16.7 billion with total video and music expenses of $16.6 billion, while in 2023, these figures increased to $17.4 billion and $18.9 billion, respectively. This indicates a more aggressive investment in content and a corresponding rise in monetization efforts.",
      "llm_answer": "In 2022 Amazon’s film‑group portfolio carried $16.7 billion of capitalized video‑and‑music content and generated $16.6 billion of video‑and‑music expense; by the end of 2023 those figures had risen to $17.4 billion and $18.9 billion respectively【page_49】. The modest increase in capitalized assets (≈ 4 %) together with a larger jump in expense (≈ 14 %) indicates Amazon is expanding the size of its film‑group content library and leaning more heavily on amortized/licensing costs to monetize that content.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All numeric values are correct: capitalized costs increased from $16.7B in 2022 to $17.4B in 2023, and associated expenses rose from $16.6B to $18.9B—matching the original answer exactly. The percentage changes cited (≈4% and ≈14%) are approximately correct: (17.4 - 16.7)/16.7 ≈ 4.19% and (18.9 - 16.6)/16.6 ≈ 13.86%, so rounding to whole percentages is reasonable. (2) The answer addresses all parts of the question: it identifies the relevant financial metrics (capitalized content costs and expenses), covers both years (2022 and 2023), and draws a logical conclusion about Amazon’s evolving monetization strategy. (3) Entity accuracy is strong: Amazon is correctly identified, the time periods are accurate, and the financial metrics (capitalized video and music content, associated expenses) are properly named and contextualized. (4) The reasoning is sound and adds value beyond the original answer by interpreting the disparity between asset growth and expense growth—suggesting Amazon is relying more on amortization or licensing for monetization. This is a reasonable inference given the larger jump in expenses relative to capitalized costs, indicating increased content utilization. The only minor shortcoming is that the original answer frames the shift as 'more aggressive investment' and 'rise in monetization efforts,' while the LLM infers a strategic pivot toward amortization/licensing. While plausible, this specific emphasis isn't explicitly confirmed in the ground truth, making the interpretation slightly more speculative. However, it does not contradict the facts and enhances the analysis. Thus, the answer earns a 9/10 for correctness—excellent but not perfectly aligned in interpretive nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 485,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has Philip Morris International's financial relationship with RBH evolved between 2022 and 2024, particularly in terms of its stake and associated impairment?",
      "original_answer": "In 2022, Philip Morris maintained a trademark relationship with RBH, continuing to report volume of brands sold by RBH such as HEETS and other heated tobacco units. By 2024, PMI held an equity investment in RBH, which became subject to a significant impairment charge of $2,316 million due to unresolved allocation of a $32.5 billion Canadian tobacco litigation settlement among RBH, ITL, and JTIM. This reflects a shift from a trademark and brand licensing relationship to a more direct equity investment facing financial impairment.",
      "llm_answer": "In the 2022 Form 10‑K PMI only noted that it had de‑consolidated its Canadian subsidiary Rothmans, Benson & Hedges (RBH) and continued to report the volume of RBH‑sold brands, with no impairment of its RBH equity stake disclosed 【page_32】. By the 2024 filing PMI still owned an equity investment in RBH, but because of the unresolved settlement‑allocation litigation it concluded the investment’s fair value was below its carrying amount and recorded a $2.316 billion non‑cash impairment (a $1.49‑per‑share charge) 【page_30】【page_32】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Philip Morris International's (PMI) financial relationship with Rothmans, Benson & Hedges (RBH) from 2022 to 2024. In 2022, PMI had de-consolidated RBH and only reported volumes of RBH-sold brands like HEETS, with no equity impairment disclosed — this aligns with the ground truth. By 2024, PMI held an equity investment in RBH that was impaired by $2.316 billion (i.e., $2,316 million), which matches the ground truth amount exactly, despite the format difference ($2.316 billion vs $2,316 million). The reason — unresolved allocation of the $32.5 billion Canadian tobacco litigation settlement among RBH, ITL, and JTIM — is accurately reflected in the context of impairment, though the LLM does not explicitly name ITL and JTIM, which slightly reduces completeness. (2) Quantitatively, all numbers are correct: the $2.316 billion impairment is equivalent to $2,316 million, and the per-share charge of $1.49 is an additional detail not in the ground truth but does not contradict it. The years (2022 and 2024) and entities (PMI, RBH) are accurate. (3) The multi-hop reasoning is sound: the model correctly infers a shift from a de-consolidated, brand-licensing relationship in 2022 to an equity investment facing impairment in 2024, synthesizing information across filings. The only minor gap is the omission of the specific parties (ITL, JTIM) in the litigation context, which slightly weakens the qualitative depth. (4) The answer is contextually fully relevant, directly addressing stake evolution and impairment. The correctness score is 9 due to high factual accuracy and strong reasoning, with only a minor omission in entity detail preventing a perfect 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 472,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the sensitivity of LLY's net product revenue to changes in sales return, rebate, and discount liabilities evolve between 2023 and 2024, based on the disclosures in the respective 10-K filings?",
      "original_answer": "In 2023, LLY disclosed that a 5% change in its consolidated sales return, rebate, and discount liability would result in a $615 million change in revenue. In 2024, while the company continued to describe the accounting policy for revenue recognition and accruals for rebates and discounts, it did not provide an updated sensitivity figure. This omission suggests that the company did not disclose a revised estimate for the impact of liability changes on revenue in 2024, indicating a lack of updated quantitative disclosure compared to 2023.",
      "llm_answer": "The 2023 filing notes that a 5 % change in the consolidated sales‑return, rebate and discount liability would shift net product revenue by roughly $615 million (page 53). The 2024 filing says the same 5 % change would affect revenue by about $600 million (page 54), showing a modest reduction in the revenue‑sensitivity from 2023 to 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that the 2024 10-K filing disclosed a $600 million sensitivity impact from a 5% change in liabilities. According to the ground truth, no such updated quantitative figure was provided in the 2024 filing. This is a major factual error. The 2023 figure of $615 million is correctly cited. (2) The quantitative accuracy is low because the $600 million figure for 2024 is false; there is no basis for this number in the ground truth. The comparison between $615M and $600M implying a 'modest reduction' is therefore invalid. (3) The reasoning is flawed: instead of recognizing the absence of updated sensitivity data in 2024—a key point of evolution—the model fabricates a figure and draws an incorrect conclusion about decreasing sensitivity. This fails the multi-hop requirement to compare disclosure practices across years. (4) Contextual relevance is high because the answer addresses the right topic, company (LLY), metric (revenue sensitivity to liabilities), and time frame (2023–2024), but the core factual inaccuracy severely undermines correctness. The answer should have noted the omission in 2024 rather than inventing a number.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 334,
        "total_tokens": 1568
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has the role and revenue contribution of Bulk shipments evolved from 2022 to 2024, based on Union Pacific's disclosures?",
      "original_answer": "In 2022, Bulk shipments had an average revenue per car of $3,305 in 2021 (referenced in the 2022 filing), showing a 6% increase from 2020. By 2024, Bulk shipments had grown in strategic importance, contributing 32% of total freight revenues, with detailed operations covering grain, fertilizer, and coal markets, including international connections to Mexico and access to Canadian interline routes. This indicates a transformation in the Bulk segment's role from a revenue-per-unit perspective to a more strategically embedded and revenue-significant component of Union Pacific's operations.",
      "llm_answer": "In the 2022 filing Union Pacific described Bulk shipments as a core commodity group and said it expected volume to outpace industrial production that year, but it did not break out a specific revenue share for Bulk (2022 Outlook – page 33). By the 2024 filing the company quantifies Bulk’s importance: Bulk shipments generated roughly $7.3 billion – 32 % of total freight revenues of $22.8 billion (2024 Freight Revenues – page 6). Thus, Bulk’s role has shifted from a qualitative, growth‑focused segment in 2022 to a clearly defined, one‑third share of overall freight revenue in 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Bulk shipments contributed 32% of total freight revenues in 2024, which matches the ground truth. However, it introduces a specific dollar amount of $7.3 billion for Bulk revenue and $22.8 billion for total freight revenue in 2024, which are not present in the original answer and cannot be verified from the provided ground truth. These figures may be accurate in the actual filing, but since they are absent from the ground truth, their inclusion constitutes a quantitative overreach. Additionally, the ground truth references 2021 average revenue per car ($3,305) and a 6% increase from 2020, but the LLM answer omits this entirely, failing to address the evolution from a revenue-per-unit perspective. (2) The calculation of 32% of $22.8 billion equating to ~$7.3 billion is mathematically correct, but the introduction of unverified absolute figures reduces quantitative accuracy. The absence of the $3,305 per-car revenue metric from 2021 (disclosed in the 2022 filing) is a significant omission. (3) The qualitative reasoning is sound: the LLM correctly infers a shift from qualitative emphasis in 2022 (growth expectations) to quantitative significance in 2024 (32% revenue share), demonstrating valid multi-hop synthesis across years. It captures the strategic evolution even without referencing the operational details (grain, fertilizer, coal, Mexico/Canada routes) from the ground truth. (4) Contextual relevance is high—the answer directly addresses the evolution of Bulk shipments’ role and revenue contribution. While the core revenue percentage is correct and the narrative arc is logical, the addition of unsupported dollar figures and omission of key metrics from the ground truth prevent a higher score. Thus, correctness is partially compromised on quantitative precision and completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 505,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the interest rate of IBM's Notes due 2028 evolve between 2023 and 2024, and what does this indicate about IBM's debt strategy?",
      "original_answer": "In 2023, IBM had 1.750% Notes due 2028 (IBM 28A) listed, and in 2024, the same 1.750% Notes due 2028 (IBM 28A) were still present in the disclosures. This indicates that the interest rate for this specific issuance remained unchanged over the two years. However, IBM introduced new notes with different interest rates in 2024, such as the 2.900% Notes due 2030 and the 3.150% Notes due 2033, suggesting a broader strategy to issue debt at higher rates for longer maturities.",
      "llm_answer": "In IBM’s 2023 filing the 2028 notes were listed at 0.300 % (IBM 28B) and 1.750 % (IBM 28A) 【page_1】, and the 2024 filing shows the same two notes with identical rates of 0.300 % and 1.750 % 【page_1】. The unchanged rates indicate IBM is keeping its long‑term borrowing costs stable, locking in low‑cost financing and signaling a deliberate strategy to maintain a low‑interest, long‑dated debt profile.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that in 2023, IBM had two 2028 notes: one at 0.300% (IBM 28B) and another at 1.750% (IBM 28A). However, the ground truth confirms only the 1.750% Notes due 2028 (IBM 28A) were present in both 2023 and 2024. There is no mention of a 0.300% note for 2028 in the original answer, making this a significant factual error. The claim of two notes with unchanged rates is therefore false. (2) The quantitative accuracy is low because the 0.300% rate is entirely fabricated in this context. While the 1.750% rate is correct, the addition of a non-existent tranche distorts the financial picture. No calculations were required, but the comparison across years is based on incorrect data. (3) The reasoning is partially sound in interpreting stable rates as a signal of a stable debt strategy, but it fails the multi-hop requirement by not acknowledging IBM’s broader strategy of issuing new debt at higher rates for longer maturities (e.g., 2.900% Notes due 2030 and 3.150% due 2033), which is a key part of the ground truth. The LLM instead concludes a general strategy of low-cost financing without recognizing the shift toward higher-cost, longer-term debt. (4) Contextual relevance is moderate because the answer addresses the interest rate evolution and attempts to infer strategy, but the incorrect entities and missing strategic context reduce its accuracy. The conclusion is plausible but based on flawed premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 404,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did AT&T's capital structure strategy regarding preferred interests evolve from 2023 to 2024, particularly in relation to the Mobility Preferred Interests and the introduction of new preferred instruments?",
      "original_answer": "In 2023, AT&T repurchased all of its Mobility Preferred Interests, which had a redemption value of approximately $5,340 million and paid annual cash distributions of $373 million. This marked a significant shift in strategy, as the company eliminated this class of preferred interests. In 2024, AT&T introduced structural modifications to other preferred instruments, including the restructuring of its Tower Holdings preferred interests to include both fixed and floating rate components, and the expansion of Telco LLC preferred interests to a total of $7,250 million. This evolution indicates a strategic pivot from Mobility-based preferred capital to more diversified and strategically tailored preferred instruments tied to infrastructure and telecommunications assets.",
      "llm_answer": "In 2023 AT&T eliminated its legacy Mobility Preferred Interests by repurchasing the remaining 213 million interests in April 2023, removing that liability from its capital structure (see Note 16, p. 55; Note 12, p. 87). By 2024 the company shifted to new preferred financing – it issued two million Series B Cumulative Perpetual Preferred Membership Interests in Mobility II (Mobility II Redeemable Noncontrolling Interests) in June 2023 and, in October 2024, agreed to issue $2.25 billion of non‑convertible cumulative preferred interests in Telco LLC (Class A‑4) in Q1 2025 (see p. 88) – reflecting a move from retiring legacy preferred equity to using redeemable, reset‑rate preferred securities for financing flexibility.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies that AT&T repurchased its Mobility Preferred Interests in 2023, but introduces inaccuracies regarding new issuances. The claim that AT&T issued 'two million Series B Cumulative Perpetual Preferred Membership Interests in Mobility II' in June 2023 is not supported by the ground truth and appears to be fabricated or misattributed. Additionally, the LLM states that AT&T 'agreed to issue $2.25 billion of non-convertible cumulative preferred interests in Telco LLC (Class A-4) in Q1 2025' — while this partially aligns with the expansion of Telco LLC preferred interests, the ground truth reports a total of $7,250 million, not $2.25 billion as a new issuance, and no specific mention of Class A-4 or Q1 2025 timing is in the original. (2) Quantitative inaccuracies include: the $2.25 billion figure does not match the $7,250 million total in the original; the redemption value of $5,340 million and annual distributions of $373 million from the original are omitted entirely in the LLM answer, weakening completeness and accuracy. The 213 million interests repurchased and April 2023 timing may be factually correct but are not in the ground truth, suggesting possible hallucination or source mismatch. (3) Multi-hop reasoning is partially sound — the model recognizes a strategic shift from retiring old preferred interests to issuing new ones — but fails to accurately represent the nature of the new instruments. The ground truth emphasizes restructuring Tower Holdings with fixed/floating rates and expanding Telco LLC to $7,250 million total, not a single $2.25 billion tranche. The LLM mischaracterizes the evolution by focusing on instruments not mentioned in the original (Mobility II Redeemable Noncontrolling Interests). (4) Scores reflect partial factual correctness: contextual relevance is high because the answer addresses the strategic evolution theme; qualitative accuracy is moderate due to correct directional insight but flawed entity and instrument mapping; quantitative accuracy is low due to missing key figures and introducing unsupported ones.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 582,
        "total_tokens": 1972
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has Amazon's characterization of the competitive threat from websites evolved between 2022 and 2023, and what specific changes in language indicate a shift in the nature of this competition?",
      "original_answer": "In 2022, Amazon described competitive websites as part of a broader list of fluctuating business factors, indicating a general awareness of competitive pressures. By 2023, Amazon's language evolved to reflect a more direct and strategic competitive stance, specifically highlighting the introduction of 'competitive stores, websites, products, services, price decreases, or improvements' as a central concern. This shift indicates a more focused and intensified competitive threat from digital platforms, suggesting an evolution from a general operational risk to a more strategic and dynamic competitive challenge.",
      "llm_answer": "In the 2022 Form 10‑K Amazon treated competition from other sites as a generic market pressure – it listed “the introduction of competitive stores, **websites**, products, services, price decreases, or improvements” and linked the risk to “changes in usage or adoption rates of the Internet, e‑commerce, electronic devices, and web services.” By the 2023 filing the wording was altered to stress a technology‑driven threat, saying the risk now comes from “the extent to which new and existing technologies, or industry trends, **restrict online advertising or affect our ability to customize advertising or otherwise tailor our product and service offerings**,” indicating a shift from simple website competition to competition based on platform‑technology and advertising capabilities.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable; however, since there are no numbers to misstate, it is scored as 10 by default. The main issue lies in qualitative accuracy and factual correctness. The LLM incorrectly claims that in 2023, Amazon shifted its risk language to focus on 'new and existing technologies... restrict online advertising or affect our ability to customize advertising,' which is not supported by the ground truth. The original answer states that in 2023, Amazon continued to emphasize competitive stores, websites, products, services, price decreases, or improvements—indicating a more strategic framing of the same competitive elements, not a shift toward technology-driven advertising risks. The LLM invents a new focus on advertising customization and platform-technology threats that are not present in the provided ground truth. This represents a significant factual deviation. Additionally, the LLM mischaracterizes the 2022 language by implying it was more generic, when both years reference similar competitive elements—the difference being the emphasis and framing. The answer fails to correctly identify the evolution described in the ground truth: from a general operational risk to a more focused, strategic concern over competitive digital offerings. While the answer addresses the question's structure and attempts multi-hop reasoning (comparing 2022 and 2023 language), the synthesis is based on incorrect or fabricated content, undermining the reasoning. Contextual relevance is moderate because the response discusses Amazon’s competitive environment and cites risk factors from 10-Ks, but the specific evolution described is inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 465,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has PM's relationship with KT&G evolved from 2022 to 2024, particularly in terms of its strategic reliance on KT&G's heat-not-burn products within PMI's smoke-free product portfolio?",
      "original_answer": "In 2022, PM had a global collaboration agreement with KT&G that allowed PMI to exclusively distribute KT&G's smoke-free products, including heat-not-burn products like LIL Mini and LIL Plus, outside of South Korea. This agreement was initially for three years, indicating a strategic partnership aimed at expanding KT&G's products globally. By 2024, this relationship had evolved such that KT&G's heat-not-burn products were no longer just distributed by PMI but were integrated into PMI's broader smoke-free product portfolio, specifically being listed among PMI's own heat-not-burn offerings. This indicates a deeper strategic reliance on KT&G's product line within PMI's own commercialization efforts, suggesting a shift from a distribution partnership to a more embedded supplier or technology partner role for KT&G.",
      "llm_answer": "In the 2022 filing PMI described a three‑year “global collaboration agreement” with KT&G that gave PMI exclusive rights to distribute KT&G’s smoke‑free products—including its LIL heat‑not‑burn devices—outside South Korea, while still allowing PMI to sell its own products (see page_51). By the 2024 filing the relationship had shifted to a licensing model: KT&G‑licensed heat‑not‑burn brands (Fiit and Miix) are now counted as part of PMI’s HTU (heat‑not‑burn) lineup and are included in the company’s smoke‑free revenue, indicating a deeper strategic reliance on KT&G’s heat‑not‑burn products within PMI’s smoke‑free portfolio (see pages_40‑41).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the 2022 three-year global collaboration agreement granting PMI exclusive distribution rights for KT&G's smoke-free products (including LIL devices) outside South Korea, citing the correct context and page reference. By 2024, it accurately notes the evolution into a licensing model where KT&G's heat-not-burn brands (specifically named as Fiit and Miix) are now part of PMI's HTU lineup and included in smoke-free revenue—indicating deeper integration. (2) There are no numeric values requiring calculation (e.g., dates like 2022 and 2024 are correct; the three-year agreement duration is consistent), so quantitative accuracy is perfect. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points and two companies, correctly inferring a strategic shift from distribution to licensing and portfolio integration. The only minor deviation from the original answer is that the LLM specifies 'Fiit and Miix' as the licensed brands, while the ground truth refers more generally to LIL Mini and LIL Plus—though these may be related product lines. This does not constitute an error but reflects potentially more granular data. (4) The answer is contextually excellent, directly addressing the evolution of PM's strategic reliance on KT&G’s heat-not-burn products within PMI’s portfolio. The conclusion about deeper strategic reliance is logically supported. Thus, the answer earns a 9/10 for correctness due to slight variation in product naming but remains factually and semantically equivalent in substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 447,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did IBM's use of the PWCC Plan for funding employee awards evolve between 2022 and 2024, particularly in terms of its administration and scope?",
      "original_answer": "In 2022, the PWCC Plan was described as being used solely to fund awards for employees of PwCC who joined IBM after the acquisition, and it was stated that the plan would continue to be used for this purpose. By 2024, while the plan's administration and terms remained substantively identical to the 2001 Plan, IBM emphasized that the PWCC Plan 'has been and will continue to be used solely' for funding awards for former PwCC employees, indicating a reaffirmation rather than a change in scope. However, the shift in language from 'has been and will continue to be' in 2022 to a more definitive tone in 2024 suggests a stronger commitment to maintaining the plan’s current usage without expansion.",
      "llm_answer": "Both the 2022 and 2024 Form 10‑K describe the PWCC Acquisition Long‑Term Performance Plan as “adopted … in connection with the company’s acquisition of PricewaterhouseCoopers Consulting” and note that **the plan is administered under the same framework as the 2001 Long‑Term Performance Plan (i.e., by the Executive Compensation and Management Resources Committee of the Board)**【page_28】. In each filing the plan is said to **“be used solely to fund awards for employees of PwCC who have become employed by the company as a result of the acquisition” and that “awards for senior executives … will not be funded from the PWCC Plan”【page_28】【page_18】. Thus, between 2022 and 2024 IBM’s use of the PWCC Plan did not change – its administration remained with the same committee and its scope continued to be limited to non‑senior‑executive PwCC employees.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in terms of entity identification, administration, and scope of the PWCC Plan in both 2022 and 2024. It correctly states that the plan was administered under the same framework as the 2001 Long-Term Performance Plan by the Executive Compensation Committee, and that it was used solely for funding awards for former PwCC employees, excluding senior executives. These points align with the ground truth. The quantitative and entity accuracy is perfect—no incorrect dates, numbers, or misattributed facts. However, the LLM answer misses a key qualitative nuance emphasized in the original answer: the evolution in language tone between 2022 and 2024, particularly IBM’s shift to a more definitive commitment (from 'will continue to be used' to 'has been and will continue to be used solely'), which signals a stronger reaffirmation of the plan’s limited use. While the LLM correctly concludes there was no change in administration or scope, it does not address the subtle but important evolution in IBM’s stated commitment, which was central to the question about how the use of the plan 'evolved.' This omission affects the depth of the reasoning and synthesis across years, slightly weakening the multi-hop analysis. Despite this, the answer remains contextually relevant and factually sound, earning high marks for accuracy and relevance but a slightly lower score for qualitative reasoning completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 396,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did AT&T's financial obligations and strategic approach to Mobility Preferred Interests evolve between 2023 and 2024, and what does this shift indicate about its broader capital structure management?",
      "original_answer": "In 2023, AT&T repurchased all remaining Mobility Preferred Interests for a total of $5,414 million, which included accrued and unpaid distributions, effectively eliminating this financial obligation. By 2024, there was no mention of Mobility Preferred Interests in the disclosures, indicating a complete exit from this instrument. This contrasts with AT&T's treatment of other preferred interests, such as the Tower Holdings and Telco LLC preferred interests, which remained outstanding and were even expanded or restructured in 2024. This shift indicates a strategic move to reduce certain long-term liabilities while maintaining or adjusting other capital instruments for flexibility, suggesting a selective approach to managing its capital structure.",
      "llm_answer": "In 2023 AT&T eliminated its legacy Mobility Series A preferred interests – repurchasing the 213 million shares in April 2023 and reclassifying the obligation as a liability, which showed up as a one‑time increase in interest expense and removed the equity‑like preferred‑interest claim (see page 25 and page 86). By 2024 the company had no Series A interests outstanding but had issued a much smaller “Mobility II” Series B redeemable non‑controlling interest (2 million shares paying 6.8% cash distributions) that is recorded as a redeemable liability and does not restrict cash movements or dividend policy (see page 88). The move from repurchasing a large, legacy preferred‑equity tranche to issuing a modest, callable preferred‑interest instrument reflects AT&T’s broader strategy to streamline its capital structure, replace costly equity‑type obligations with more flexible, lower‑cost debt‑like securities, and preserve financial flexibility.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) According to the ground truth, AT&T repurchased all remaining Mobility Preferred Interests in 2023 for $5,414 million, effectively eliminating the obligation, with no mention of such instruments in 2024. However, the LLM claims that AT&T issued a new 'Mobility II' Series B redeemable interest in 2024, which contradicts the original answer and suggests a continuation or replacement instrument that is not supported by the ground truth. (2) The LLM cites specific numbers such as '213 million shares' repurchased in April 2023 and a new issuance of '2 million shares' with a '6.8% cash distribution'—none of which appear in the ground truth and are therefore unverified or incorrect. The ground truth does not mention share counts, specific percentages, or new issuances. (3) The reasoning is flawed in its multi-hop synthesis: instead of showing a complete exit from Mobility Preferred Interests (as confirmed in both 2023 and 2024 disclosures), the LLM portrays a refinancing or restructuring into a new instrument, which misrepresents the strategic shift. (4) While the broader theme of capital structure streamlining is contextually relevant and aligns with the ground truth’s interpretation, the specific narrative of replacing old with new preferred interests is factually incorrect. The ground truth emphasizes elimination, not substitution. Thus, despite some thematic relevance, the answer fails on key quantitative and qualitative dimensions due to fabrication of details and incorrect entity/timeline representation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 441,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has IBM's relationship with stock exchange regulations evolved in terms of regulatory exposure for its debt securities between 2022 and 2024?",
      "original_answer": "In 2022, IBM described stock exchange regulations as one of several factors influencing the value of its debt securities, placing it among other external variables beyond the company's control. By 2024, IBM's language shifted to indicate a more direct regulatory exposure, stating it is 'subject to' stock exchange regulations, which implies a heightened recognition of their binding impact on the company's financing activities. This evolution reflects a stronger acknowledgment of regulatory influence in 2024 compared to the more general mention in 2022.",
      "llm_answer": "In IBM’s 2022 Form 10‑K the company explicitly listed “governmental and **stock‑exchange regulations**” as one of the external factors that can affect the value of its debt securities (see the risk‑factor paragraph on page 22). The 2024 Form 10‑K’s discussion of debt‑security risks no longer mentions stock‑exchange regulation, showing that IBM’s disclosed regulatory exposure for its debt securities has been reduced or omitted in the later filing.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim and contradicts the ground truth. While it correctly identifies IBM and the relevant years (2022 and 2024), it falsely states that IBM removed mention of stock-exchange regulations in its 2024 10-K, concluding that regulatory exposure has been reduced or omitted. This is the opposite of the ground truth, which states that IBM's language evolved from a general reference in 2022 (regulations as an influencing factor) to a stronger, more direct acknowledgment in 2024 by stating it is 'subject to' stock exchange regulations—indicating increased, not decreased, regulatory exposure. The LLM's reasoning is therefore fundamentally flawed, failing the multi-hop synthesis required to compare the qualitative shift in language across filings. There are no numerical values in this question, so quantitative accuracy is scored as 10 by default. However, the qualitative inaccuracy and reversal of the actual trend severely undermine the answer's correctness and relevance. The answer also misrepresents the source evidence, potentially misreading or misinterpreting the 2024 filing. As a result, the correctness score is low despite correct entity and year identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 342,
        "total_tokens": 1594
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Disney's financial relationship with A&E evolve from 2022 to 2024, particularly in terms of equity income contribution?",
      "original_answer": "In 2022, Disney's equity investment in A&E was a significant component of its equity income, with A&E being one of the most notable equity method investees alongside CTV Specialty Television. By 2024, Disney's equity in the income of investees had decreased by $207 million, specifically due to lower income generated from A+E. This indicates a material decline in the financial contribution from A&E to Disney over the two-year period.",
      "llm_answer": "In the 2022 Form 10‑K Disney’s 50 % stake in A+E was highlighted as a major equity‑method investment, with its share of A+E earnings feeding the “Equity in the income of investees, net” line (the amount was materially larger than in later years). By fiscal 2024 that equity‑income contribution had fallen to $575 million, a $207 million decline from the prior year, reflecting weaker A+E earnings and a one‑time $56 million gain from a content‑license termination that was booked in restructuring charges.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Disney's 50% stake in A+E as a major equity-method investment in 2022 and notes a $207 million decline in equity income by 2024, aligning with the ground truth. However, it introduces a specific figure of $575 million for 2024 equity income, which is not present in the original answer and cannot be verified from the provided ground truth. Additionally, the mention of a one-time $56 million gain from a content-license termination is new information not found in the original answer, potentially introducing unsupported detail. (2) The $207 million decrease is accurately reported and matches the ground truth. However, the $575 million figure for 2024 and the implied 2023 value (~$782 million) are not corroborated by the original answer, which only states the decline amount without providing absolute values. This affects quantitative accuracy. (3) The reasoning is sound in identifying a decline in A&E's contribution and linking it to lower earnings, demonstrating correct multi-hop synthesis between Disney’s equity income and A&E’s performance. The addition of the $56 million gain, while possibly factual, goes beyond the scope of the original answer and weakens strict factual alignment. (4) The answer is highly relevant and captures the core trend of declining financial contribution from A&E. Scores reflect high qualitative and contextual accuracy, with a moderate deduction in quantitative accuracy due to unverified specific figures and extra details not in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 425,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did the carrying value of securitized debt obligations change from 2022 to 2023, and what does this indicate about the company's long-term funding strategy?",
      "original_answer": "In 2022, the long-term funding, which primarily consists of securitized debt obligations and senior and subordinated notes, stood at $42.3 billion as of December 31, 2021, with a significant portion driven by securitized debt obligations. By December 31, 2023, the carrying value of securitized debt obligations alone decreased to $18.043 billion. This indicates a strategic shift or reduction in reliance on securitized debt obligations as part of the company's long-term funding structure over this period.",
      "llm_answer": "The carrying value of securitized debt obligations rose from **$16.973 billion at December 31 2022** to **$18.043 billion at December 31 2023**, an increase of roughly **$1.07 billion**【page_211】【page_210】. This uptick, coupled with the company’s sizable shelf‑registration capacity for additional securitizations, signals that Capital One is deliberately expanding its securitization program to diversify and strengthen its long‑term funding mix beyond deposits and conventional notes.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude of change in the carrying value of securitized debt obligations. The original answer states that by December 31, 2023, the carrying value was $18.043 billion, down from $42.3 billion in long-term funding as of December 31, 2021, with securitized debt being a major component. The LLM incorrectly claims the value increased from $16.973 billion in 2022 to $18.043 billion in 2023, implying growth, whereas the ground truth indicates a significant reduction in securitized debt obligations, signaling a strategic pullback. The $16.973 billion figure for 2022 is not supported by the original answer, which does not provide a specific 2022 value but implies a decline from $42.3 billion (2021) to $18.043 billion (2023). (2) The calculation of a $1.07 billion increase is therefore based on incorrect inputs and is invalid. The correct trend is a decrease of approximately $24.257 billion over the two-year period (from $42.3B in 2021 to $18.043B in 2023), though exact 2022 value is not provided. (3) The multi-hop reasoning fails: the LLM misidentifies the trend and draws an opposite conclusion about the company's long-term funding strategy. Instead of recognizing a reduction in reliance on securitized debt, it claims expansion, which contradicts the ground truth. (4) Scores reflect major factual and quantitative errors (correctness: 2), severe miscalculations and wrong data points (quantitative accuracy: 2), flawed logic and incorrect synthesis (qualitative accuracy: 3), but partial relevance in discussing securitization as a funding strategy (contextual relevance: 6).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 454,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has Disney's approach to scripted programming evolved between 2022 and 2024, particularly in terms of its international general entertainment channels and its strategic shift toward DTC platforms?",
      "original_answer": "In 2022, Disney operated approximately 220 General Entertainment channels outside the U.S., primarily under the Fox, National Geographic, and Star brands, featuring a mix of scripted, reality, and documentary programming across multiple languages and regions. By 2024, there was a notable strategic shift, with increased emphasis on DTC platforms and less focus on traditional linear channels. The 2024 report highlights that Disney, along with Fox Corporation and Warner Bros. Discovery, planned a joint venture (Venu Sports) to distribute sports content via a DTC platform, signaling a broader move toward streaming. Additionally, Disney announced plans to launch a new DTC offering in early fall 2025 that would include live linear streams of ESPN channels and ESPN+. This reflects a strategic pivot from scripted linear content toward live and sports-driven DTC offerings, indicating a transformation in Disney’s programming and distribution priorities.",
      "llm_answer": "In 2022 Disney’s scripted series were still being delivered mainly through its worldwide linear network – roughly 220 general‑entertainment channels (Fox, Star and National Geographic) that aired a mix of scripted, reality and documentary shows – and the filing warned that a growing focus on direct‑to‑consumer (DTC) would erode that licensing‑based model【page_12】. By 2024 the company has pivoted the bulk of that scripted inventory to streaming, folding Star+ into Disney+, using the Star tile on Disney+ to showcase general‑entertainment (including scripted) titles and adding ad‑supported and sports tiles, so that new scripted programming is now monetized primarily on its DTC platforms rather than on international linear channels【page_7】.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) Quantitatively, the number '220 general-entertainment channels' is accurate and matches the original answer. The years 2022 and 2024 are correctly used as reference points. (2) The LLM correctly identifies Disney’s shift from linear channels (Fox, Star, National Geographic) to DTC platforms, and accurately reflects the strategic pivot, including the integration of Star+ into Disney+ and the use of the Star tile for scripted content on Disney+. (3) However, the LLM omits key details present in the ground truth: it does not mention the Venu Sports joint venture with Fox Corporation and Warner Bros. Discovery, nor does it reference the planned 2025 DTC launch with live ESPN streams, which are important elements of Disney’s strategic shift toward live and sports-driven DTC offerings. This omission affects completeness and slightly weakens the multi-hop synthesis, particularly around Disney’s broader DTC strategy beyond scripted content. (4) Despite these omissions, the core reasoning about the shift from licensing-based linear models to DTC monetization of scripted content is sound and semantically equivalent to the original. The answer is highly relevant and accurately captures the evolution in scripted programming strategy. Minor deduction due to missing strategic elements in the 2024 outlook.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 383,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Tesla's financial and operational challenges related to energy storage products evolve from 2022 to 2023, particularly in terms of accounts receivable and production scaling dependencies?",
      "original_answer": "In 2022, Tesla disclosed significant long-term government rebates receivable related to its energy storage products, with a balance of $627 million as of December 31, 2021, indicating extended collection periods of up to a year or more. By 2023, the focus shifted from financial implications of receivables to operational dependencies, as Tesla highlighted production scaling risks for energy storage products, including bottlenecks, supplier constraints, and facility ramp delays at factories in Nevada, Texas, and other locations. These changes reflect a shift from financial exposure tied to receivables to broader production and supply chain dependencies affecting the company's ability to meet cost and profitability targets.",
      "llm_answer": "In the 2022 Form 10‑K Tesla warned that its accounts‑receivable balance— which includes sales of energy‑generation and storage products— can swing widely because payments from financing partners, regulatory‑credit sales and government rebates often take weeks or months to clear, creating a notable financial exposure (see 2022 p. 64). By the 2023 filing the focus had shifted to operational risk: the company said that expanding energy‑storage production now depends on securing enough lithium‑ion cells, raw‑material supplies and successfully ramping new factories and installation capacity, and that any shortfall could force curtailments or higher‑cost sourcing (see 2023 p. 16‑18).",
      "correctness_score": 9,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution from financial to operational challenges in Tesla's energy storage business from 2022 to 2023. It accurately identifies extended payment cycles in 2022 related to government rebates and financing partners as a source of financial exposure, and the shift in 2023 to production scaling risks such as supply of lithium-ion cells, raw materials, and factory ramp-up. However, it omits the specific $627 million receivable balance as of December 31, 2021, disclosed in the 2022 filing, which is a key quantitative detail in the ground truth. While it references 'widely swinging' receivables and timing issues, the absence of this concrete figure reduces quantitative precision. (2) The ground truth includes a specific dollar amount ($627 million) tied to long-term government rebates receivable, which the LLM answer does not mention. This is a factual omission affecting quantitative accuracy, though no incorrect numbers are stated. All other qualitative financial and operational descriptions align with the filings. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across the 2022 and 2023 10-Ks, identifying a shift in risk focus from accounts receivable timing (financial) to production and supply chain dependencies (operational). It correctly attributes these changes to Tesla and the energy storage product line across the two years. (4) The correctness score is 9 because the core factual narrative and synthesis are accurate and well-supported, with only a minor but notable omission of a key financial figure. Quantitative accuracy is 8 due to the missing $627M data point. Qualitative accuracy is 9 due to strong reasoning and entity/year/metric correctness. Contextual relevance is 10 as the answer directly addresses all aspects of the question with high precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 507,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in relation to its bottling partners and fountain retailers?",
      "original_answer": "In 2022, Coca-Cola's relationship with syrups was primarily defined by its sales to both consolidated and unconsolidated bottling partners, with revenue and volume recognition dependent on the ownership structure of those partners. Specifically, concentrate and syrup sales were not recognized until finished products were sold to third parties in the case of consolidated bottlers, while recognition occurred immediately for unconsolidated bottlers. By 2023, the company's description of syrups shifted to emphasize their role as a dependency within a broader operational framework, particularly in relation to fountain retailers. In 2023, the company clarified that it manufactures fountain syrups and sells them directly to fountain retailers or authorized wholesalers and bottlers, highlighting a more integrated and strategic role for syrups in its finished beverage delivery system. This represents a shift from a primarily volume-driven metric to a more operationally embedded component of the business model.",
      "llm_answer": "In the 2022 filing Coca‑Cola described syrups mainly as a component of its concentrate business that it sells to bottling partners, with revenue recognized when those partners sell the finished beverages (see the revenue‑recognition discussion of syrups on page 43). By the 2023 filing the company emphasizes a broader syrup role: it now manufactures fountain syrups in the United States and sells them directly to fountain retailers, while outside the United States its bottling partners are authorized to produce and distribute fountain syrups to retailers or wholesalers (page 37), and the share of net operating revenue from concentrate operations (which includes syrups) grew from 56 % in 2022 to 58 % in 2023 (page 38), reflecting an expanded importance of syrups in the business model.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers and percentages are correct: the increase in concentrate operations' share of net operating revenue from 56% in 2022 to 58% in 2023 is accurately reported, and the references to specific pages (43, 37, 38) support the claims. There are no calculation or date errors. (2) The answer correctly identifies the shift in Coca-Cola’s syrup strategy between 2022 and 2023, noting the change from a concentrate-sales model primarily through bottling partners to a more direct and strategic role involving fountain syrup sales. It accurately distinguishes between U.S. (direct sales) and international (bottling partners authorized to produce and distribute) operations in 2023. (3) The multi-hop reasoning is sound: it synthesizes information across years, geographies, and business relationships (bottling partners, fountain retailers), and correctly infers increased strategic importance from the revenue share increase. (4) The only minor shortcoming is that the LLM does not explicitly mention the accounting distinction in revenue recognition between consolidated and unconsolidated bottlers in 2022, which is a nuanced but important part of the original answer. However, it captures the broader evolution in the role of syrups. Wording differs but semantic meaning and factual content are equivalent on all key points. Thus, the answer is excellent but not perfect, warranting a 9/10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1455,
        "completion_tokens": 418,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did Disney's investment in Other Mortgage- and Asset-Backed Securities (MBS & ABS) evolve from fiscal year 2022 to fiscal year 2024, and what was the trend in its proportion relative to the overall fair value hierarchy?",
      "original_answer": "In fiscal year 2022, Disney's investment in Other MBS & ABS was valued at $96 million, representing 1% of the total plan asset mix. By fiscal year 2024, this investment increased to $120 million, maintaining a 1% share of the total plan asset mix. While the absolute value of the investment grew moderately, its proportional representation within the portfolio remained stable.",
      "llm_answer": "Disney’s “Other mortgage‑ and asset‑backed securities” holding grew from **$84 million** at FY 2022 year‑end (page 104) to **$120 million** in FY 2023 and **$166 million** in FY 2024 (page 107).  Although the dollar amount rose, the line consistently accounted for **about 1 % of the total fair‑value hierarchy** (≈$84 million of $7.5 billion in FY 2022, $120 million of $8.1 billion in FY 2023 and $166 million of $11.0 billion in FY 2024), showing a modest absolute increase but a stable portfolio share.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the reported values for Disney's investment in Other MBS & ABS. According to the ground truth, the investment was $96 million in FY 2022, not $84 million as stated by the LLM. Additionally, the LLM claims the value increased to $166 million in FY 2024, whereas the correct amount is $120 million. The LLM also introduces a figure for FY 2023 ($120 million), which is not part of the original question or ground truth, and incorrectly presents it as an intermediate value. (2) The percentage share is correctly noted as about 1%, which aligns with the ground truth stating it 'maintained a 1% share'. However, the LLM's supporting calculations use incorrect total fair value figures (e.g., $7.5B, $8.1B, $11.0B), which are not in the original answer and appear fabricated. There is no mention in the ground truth of total plan assets being in the billions or specific totals per year. (3) The reasoning is partially sound in observing that the proportion remained stable despite absolute growth, which matches the ground truth's conclusion. However, the multi-hop synthesis is flawed because the LLM relies on incorrect source data (possibly misreading the 10-K), introduces an extra year (FY2023), and fabricates total portfolio values to justify percentages. (4) The contextual relevance is high because the answer addresses the evolution of investment and its proportional trend, but the severe quantitative errors undermine the correctness. The core conclusion about stable proportion is preserved, but the incorrect base numbers make the overall answer misleading. Thus, the correctness score is low due to major factual discrepancies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 467,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the focus areas of Skunk Works' advanced development programs evolve between 2022 and 2023 in relation to next-generation military aircraft capabilities?",
      "original_answer": "In 2022, Skunk Works' Advanced Development Programs focused on future systems including unmanned and manned aerial systems and next-generation capabilities for hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. By 2023, the focus had evolved to emphasize air dominance, hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. The shift highlights an increased emphasis on air dominance as a core next-generation capability while maintaining focus on hypersonics and ISR. This represents a refinement of priorities rather than a complete overhaul of focus areas.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K filings describe Skunk Works (the Advanced Development Programs) in the same terms – it is “focused on future systems, including unmanned and manned aerial systems and next‑generation capabilities for air dominance, hypersonics, intelligence, surveillance, reconnaissance, situational awareness and air mobility,” and it “continues to explore technology advancement and insertion into our existing aircraft” while pursuing “network‑enabled activities” to boost effectiveness 【page_4†L1-L9】【page_4†L10-L13】. The wording is essentially unchanged, showing that the program’s focus areas did not evolve between 2022 and 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core conclusion, despite citing document excerpts. (1) The original answer (ground truth) states that there was a shift in focus between 2022 and 2023—specifically, an increased emphasis on air dominance—while the LLM claims the focus areas did not evolve, citing identical wording in the 10-K filings. This directly contradicts the ground truth, which identifies a refinement in priorities. (2) There are no numeric values to verify, so quantitative accuracy is not applicable; however, the years (2022 and 2023) are correctly referenced. (3) The multi-hop reasoning failed: the model should have compared the actual focus areas between years as synthesized in the ground truth, but instead relied on verbatim text similarity to conclude no change, missing the nuanced evolution in emphasis. (4) While the LLM correctly identifies Skunk Works and the general capability areas, it fails to capture the key evolution—increased focus on air dominance—making the answer misleading. The contextual relevance is moderate because it discusses the right program and time frame but draws an incorrect inference from the data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 326,
        "total_tokens": 1656
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Tesla's approach to the Powerwall product evolved from 2022 to 2023, particularly in terms of integration strategy and production emphasis?",
      "original_answer": "In 2022, Tesla emphasized cross-selling Powerwall with residential solar energy products due to better availability and growing grid stability concerns. The company was also focused on improving installation capabilities and price efficiencies for Solar Roof, which is closely related to Powerwall integration. By 2023, Tesla had advanced its integration strategy by designing both Solar Roof and solar energy systems to specifically integrate with Powerwall, indicating a more deliberate and engineered approach to product synergy. This evolution reflects a shift from a sales and availability focus to a deeper technical and strategic integration within Tesla's energy ecosystem.",
      "llm_answer": "In the 2022 filing Tesla said it was **ramping Powerwall production**, improving its availability and using the product to **cross‑sell with residential solar** while building new capacity (e.g., the Megafactory) to meet demand【page_34】. By the 2023 filing the focus had shifted to **integrating Powerwall with Solar Roof and offering bundled solar‑Powerwall financing**, positioning it as part of an integrated home‑energy solution rather than emphasizing pure production growth【page_5】【page_7】【page_9】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Tesla's 2022 focus on ramping Powerwall production, improving availability, and cross-selling with residential solar—matching the original answer's emphasis on availability and grid stability concerns. It also notes infrastructure expansion (e.g., Megafactory), which is consistent with production emphasis. In 2023, the shift to deeper integration with Solar Roof and bundled financing reflects the original answer’s point about engineered integration and strategic synergy. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and connects production strategy (2022) to integration and bundling (2023). The only minor gap is that the original answer emphasizes 'improving installation capabilities and price efficiencies for Solar Roof' as part of the integration context, which the LLM answer omits. This doesn't undermine the core accuracy but slightly reduces completeness in qualitative terms. (4) Contextual relevance is perfect—the response directly addresses both parts of the question: integration strategy and production emphasis across 2022–2023. Wording differs but semantic meaning is equivalent. Minor omission prevents a perfect 10, but 9 is justified for high correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 403,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Gilead's strategic positioning around Biktarvy evolved between 2022 and 2024, particularly in terms of its role within the company's HIV portfolio and associated commercial risks?",
      "original_answer": "In 2022, Biktarvy was prominently positioned as a key revenue-generating product within Gilead’s HIV portfolio, highlighted as a single-tablet regimen combining bictegravir, emtricitabine, and tenofovir alafenamide (TAF), emphasizing its convenience and efficacy. By 2024, while Biktarvy remained a core product, the company faced heightened commercial risk as it became more dependent on HIV products containing TAF. A shift in treatment paradigms or reduced preference for nucleoside-based therapies could significantly impact Biktarvy’s sales and, by extension, Gilead’s financial stability. This reflects a transition from a focus on product innovation to increased vulnerability due to overreliance on a narrow therapeutic class.",
      "llm_answer": "In the 2022 filing Gilead presented Biktarvy as a flagship, revenue‑generating, once‑daily single‑tablet regimen that sits at the core of its HIV portfolio (see page 5). By the 2024 filing the company’s tone has shifted to stress that HIV products—including Biktarvy—account for a substantial share of sales but now face heightened commercial risks such as intense competition, generic erosion, pricing‑and‑reimbursement pressures, and the possibility that shifts away from TAF‑based regimens could erode demand (see pages 18 and 20). This reflects an evolution from positioning Biktarvy as a primary growth driver to acknowledging its exposure to broader market and regulatory headwinds.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Biktarvy's role in 2022 as a flagship, revenue-generating, once-daily single-tablet regimen central to Gilead’s HIV portfolio, matching the original answer’s emphasis on convenience and efficacy. By 2024, it accurately reflects the increased commercial risks, including competition, generic erosion, pricing pressures, and the specific vulnerability related to TAF-based therapies—directly corresponding to the ground truth’s concern about overreliance on TAF and shifting treatment paradigms. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), but the years (2022 and 2024) and product details (Biktarvy, TAF-based regimens) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two time points and correctly infers a strategic shift—from innovation-driven growth to increased risk exposure—based on evolving market dynamics. (4) The only minor shortcoming is that the LLM does not explicitly state the transition from 'product innovation' to 'vulnerability due to narrow therapeutic class' in the same conceptual terms as the ground truth, though the meaning is semantically equivalent. Wording differences are acceptable under semantic equivalence, so this does not warrant a major deduction. Overall, the answer is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 397,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did the composition of the U.S. Retrospective Responsibility Plan change between 2022 and 2023, particularly regarding the mechanisms referenced in relation to the U.S. Litigation Escrow Agreement?",
      "original_answer": "In 2022, the U.S. Retrospective Responsibility Plan included mechanisms such as the U.S. Litigation Escrow Agreement, the conversion feature of Class B common stock, indemnification obligations of Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. By 2023, the composition evolved to include a new element — 'makewhole agreements relating to the Class B-1 common stock exchange offer' — while retaining the U.S. Litigation Escrow Agreement and other previously listed mechanisms. This indicates an expansion of the plan to incorporate additional financial safeguards or compensatory measures.",
      "llm_answer": "In the 2022 Form 10‑K the U.S. Retrospective Responsibility Plan was described as consisting of six mechanisms – a U.S. litigation escrow agreement, the conversion feature of the company’s class B common stock, the indemnification obligations of Visa U.S.A. members, an interchange‑judgment‑sharing agreement, a loss‑sharing agreement and an omnibus agreement 【page_71】.  \n\nThe 2023 filing shows the same six mechanisms but adds a distinct “make‑whole” agreement (tied to the class B‑1 exchange offer) and expands the conversion feature to cover class B‑1 and B‑2 shares, thereby broadening the plan’s components while retaining the escrow, indemnification, interchange‑judgment‑sharing, loss‑sharing and omnibus agreements 【page_72】【page_74】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the six original mechanisms in the 2022 U.S. Retrospective Responsibility Plan, including the U.S. Litigation Escrow Agreement, conversion feature of Class B common stock, indemnification obligations, interchange judgment sharing agreement, loss-sharing agreement, and omnibus agreement. (2) For 2023, it accurately notes the addition of 'makewhole agreements relating to the Class B-1 common stock exchange offer' (referred to as a 'make-whole' agreement), which matches the ground truth. (3) The LLM adds a detail not present in the original answer — that the conversion feature was expanded to cover Class B-1 and B-2 shares — which is consistent with typical plan evolution and may be supported by the source (pages 72, 74), though this specific expansion is not mentioned in the ground truth. This does not contradict but adds granularity, so it doesn't reduce correctness. (4) All entities (Visa U.S.A., Class B/B-1/B-2 stock, agreements) and years (2022 vs 2023) are correct. (5) The reasoning is sound, demonstrating multi-hop synthesis between two years’ filings and correctly identifying both continuity and change. (6) The only reason for not scoring a 10 is that the original answer emphasizes the *retention* of all prior mechanisms and the *addition* of one new element, while the LLM slightly reframes it as broadening the conversion feature — a plausible interpretation but a minor expansion beyond the ground truth’s scope. Overall, the answer is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 442,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has the strategic importance of Biktarvy evolved for GILD from 2022 to 2024, based on its patent protection timeline and the company's risk disclosures around HIV product dependency?",
      "original_answer": "In 2022, Biktarvy was listed with a U.S. patent expiration in 2033 and no expiration listed in the E.U., indicating strong long-term protection and likely a key revenue driver. By 2024, although patent details were not explicitly mentioned, the company highlighted heightened risk around its HIV products, including Biktarvy, due to market competition and potential shifts in treatment paradigms. This suggests that despite long-term patent protection, Biktarvy's strategic position has become more vulnerable due to external market and regulatory pressures.",
      "llm_answer": "In the 2022 filing Gilead highlighted that Biktarvy’s core compound patents run through 2033 in both the United States and the European Union (see the patent‑expiration table on page 11) and even added a pediatric low‑dose tablet approval (page 10), signaling a long‑term, protected revenue stream. The 2024 filing still lists dependence on HIV products as a material risk (page 18) and the same 2033 expiration horizon persists, showing that Biktarvy remains a central, heavily protected pillar of Gilead’s portfolio and its strategic importance has stayed high from 2022 to 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains accurate quantitative information regarding Biktarvy's patent expiration in 2033 in both the U.S. and EU, which aligns with the ground truth's mention of 2033 U.S. protection and absence of an EU expiration in 2022. However, the ground truth states that in 2024, patent details were *not explicitly mentioned*, while the LLM incorrectly asserts that the 'same 2033 expiration horizon persists' in the 2024 filing—this is unsupported and contradicts the original answer, which notes a lack of explicit patent updates. This misrepresents the evolution of strategic importance. The LLM also omits the key qualitative shift highlighted in the ground truth: increased risk disclosures around market competition and changing treatment paradigms in 2024, which signal growing vulnerability despite patent protection. Instead, the LLM concludes that strategic importance 'has stayed high,' directly conflicting with the ground truth's implication of increased risk and reduced strategic security. While the entity (GILD, Biktarvy), years (2022–2024), and core metric (patent expiration) are correct, the reasoning fails to synthesize the multi-hop insight that strong IP protection is being offset by rising external risks. Thus, despite accurate numbers, the qualitative interpretation and overall correctness are significantly flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 374,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "Have there been any modifications to the financial guarantees provided by AT&T for Illinois Bell Telephone Company between 2022 and 2023, particularly in terms of guarantee structure or referenced documentation?",
      "original_answer": "The financial guarantee relationship between AT&T and Illinois Bell Telephone Company remained structurally unchanged between 2022 and 2023. In 2022, AT&T's guarantee for Illinois Bell Telephone Company was referenced under Exhibit 4-d to Form 10-K for the period ending December 31, 2011. In 2023, the same guarantee was still in place and referenced under the identical exhibit number (Exhibit 4-d) and filing history (Form 10-K for the period ending December 31, 2011). There is no indication of modifications to the guarantee structure, terms, or documentation between the two years.",
      "llm_answer": "The 2023 Form 10‑K adds a specific reference to AT&T’s “Guaranty of certain obligations of … Illinois Bell Telephone Company” (Exhibit 4‑d), a guarantee that is not mentioned in the 2022 filing. No other changes to the guarantee’s terms or structure are disclosed, indicating the guarantee itself remains the same but its documentation is now explicitly referenced.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in a critical aspect: it claims that the 2023 Form 10-K 'adds' a specific reference to the guarantee (Exhibit 4-d) that was not present in the 2022 filing. This contradicts the ground truth, which states that the same guarantee was referenced under Exhibit 4-d in both years and that there was no change in documentation or structure. The ground truth confirms the guarantee has been consistently referenced since the 2011 Form 10-K and remained unchanged through 2022 and 2023. Therefore, the claim that the guarantee is 'not mentioned in the 2022 filing' is false. While the LLM correctly identifies Exhibit 4-d and the entity involved, the core reasoning is flawed—instead of recognizing continuity, it infers a change in documentation. This represents a significant error in multi-hop reasoning, as the model failed to correctly synthesize the longitudinal consistency of the exhibit reference across filings. Quantitative accuracy is partially preserved (correct exhibit number and company), but the temporal and documentary analysis is incorrect. Contextual relevance is moderate because the answer addresses the right topic and document type, but the conclusion is misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 341,
        "total_tokens": 1595
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "What does the consistent Class C to Class A common stock conversion rate between 2022 and 2023 suggest about the potential impact on Class A common stockholders' voting power in significant corporate transactions?",
      "original_answer": "In 2022, the Class C common stock had a conversion rate of 4.0000 into Class A common stock, and this rate remained unchanged in 2023. Despite the as-converted Class A common stock value increasing slightly from 38 million in 2022 to 39 million in 2023, the unchanged conversion rate suggests that the relative voting power dilution for Class A common stockholders remained stable. This stability implies that there was no structural change in how Class C stockholders could influence significant corporate decisions through their voting rights tied to Class A equivalents.",
      "llm_answer": "The conversion rate for Class C common stock into Class A common stock remained at 4.0000 in both 2022 and 2023 (see page_87). Because the rate did not change, any conversion of Class C shares would not increase the dilution of voting power beyond what was already anticipated, so Class A shareholders’ voting power in significant corporate transactions remains essentially unchanged (see page_30; page_32).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the Class C to Class A conversion rate as 4.0000 in both 2022 and 2023, matching the ground truth exactly. It accurately notes the stability of the conversion rate, which is the key quantitative and structural fact. While the LLM does not explicitly mention the as-converted Class A stock value increasing from 38 million to 39 million, this omission does not undermine the core reasoning about voting power stability. (2) All numeric values (conversion rate of 4.0000) and years (2022, 2023) are correct. No calculations are required beyond recognizing consistency over time, which the model handles accurately. (3) The multi-hop reasoning is sound: the model correctly infers that a stable conversion rate implies no additional dilution of voting power for Class A shareholders in significant corporate transactions. It logically connects the unchanged conversion mechanics to the conclusion of stable voting influence, which aligns with the ground truth’s implication of no structural change. (4) The answer is contextually fully relevant, directly addressing the question about impact on voting power. The only minor shortcoming is the omission of the slight increase in as-converted Class A value (38M to 39M), which slightly reduces completeness but does not affect the correctness of the conclusion. Hence, a score of 9 is justified—excellent accuracy with a minor gap in full contextual detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 400,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Tesla's relationship with the Solar Roof evolve from 2022 to 2023 in terms of production focus and strategic dependencies?",
      "original_answer": "In 2022, Tesla directly produced the Solar Roof at Gigafactory New York, indicating active involvement in its manufacturing. However, by 2023, Tesla's disclosures shifted to emphasizing dependencies and risks associated with scaling production, including potential delays, supply chain constraints, and challenges in launching and ramping products like the Solar Roof. This reflects a transition from a production-centric view to a more cautionary outlook on strategic execution risks.",
      "llm_answer": "In the 2022 filing Tesla said that its Solar Roof was a core part of the energy‑generation business and was **designed, engineered and produced at Gigafactory New York in Buffalo** (see 2022 p. 9) with in‑house design expertise, financing options and dedicated warranties (2022 p. 7‑8). By the 2023 filing the company no longer highlights a dedicated Solar Roof plant; instead it groups Solar Roof with its energy‑storage products as a line that could **experience production‑ramp delays**, indicating that the focus has shifted to managing Solar Roof through its broader manufacturing capacity and supply‑chain dependencies rather than a specific facility (2023 p. 16).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Tesla produced the Solar Roof at Gigafactory New York in Buffalo, citing the correct context (design, engineering, production) and referencing in-house capabilities and warranties. This matches the original answer's claim of direct production involvement. In 2023, the LLM correctly notes the shift in tone and focus—no longer highlighting a dedicated facility but instead grouping Solar Roof with energy-storage products and emphasizing risks like production-ramp delays and supply-chain dependencies. These points reflect the strategic shift from production focus to execution risks. (2) There are no numerical values to verify, but the years (2022, 2023) and document references (page numbers) are accurately used and consistent with a factual basis. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, compares the change in language and strategic emphasis, and correctly infers a shift in Tesla’s approach. The conclusion about moving from a facility-specific to a broader manufacturing dependency is logically supported. (4) The only reason for not giving a perfect 10 is minor: the original answer explicitly mentions 'strategic dependencies' including supply chain constraints and launch challenges, which the LLM touches on but could have emphasized more directly. However, the core meaning is preserved, and the answer remains semantically equivalent and factually correct. All parts of the question—production focus and strategic dependencies—are adequately addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 447,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in terms of their relationship to finished beverage production and distribution channels?",
      "original_answer": "In 2022, Coca-Cola described syrups as intermediate products used primarily in fountain beverage production, where bottling partners or fountain retailers mix them with water and sweeteners to create finished beverages for immediate consumption. The company emphasized that syrups were a key part of the concentrate operations, which generally yield lower net operating revenues but higher gross profit margins compared to finished product operations. By 2023, the company expanded its description to emphasize that fountain syrup sales in the U.S. were directly managed by Coca-Cola and sold to both fountain retailers and authorized wholesalers or bottling partners. Additionally, the 2023 filing highlighted that fountain syrup operations were specifically included in the North America operating segment, indicating a more structured and regionally focused approach to syrup distribution. This evolution reflects a strategic shift toward tighter control and segmentation of syrup-related revenue streams within the broader beverage production ecosystem.",
      "llm_answer": "In both years Coca‑Cola’s syrups are still sold by the concentrate business to its bottling partners, who blend the syrups (or concentrates) with water and sweeteners to make the finished beverages, and in the United States the company also sells fountain syrups directly to fountain retailers, wholesalers or bottlers (2022 p. 6‑7; 2023 p. 37). But the 2023 filing shows the concentrate segment – which includes syrups – grew to 58 % of net operating revenue and 83 % of unit‑case volume, up from 56 % and 82 % in 2022 (2023 p. 38), indicating that syrups have become a larger share of the company’s revenue and volume and thus a more pivotal feedstock for finished‑beverage production and its distribution channels.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of syrups in Coca-Cola's business model between 2022 and 2023 with generally accurate qualitative insights, but contains significant quantitative inaccuracies that affect overall correctness. (1) Correct elements: The answer correctly identifies that syrups are intermediate products sold by the concentrate business to bottling partners and that in the U.S., Coca-Cola sells fountain syrups directly to retailers, wholesalers, or bottlers—consistent with both years’ disclosures. It also appropriately highlights the growing importance of the concentrate segment, which includes syrups, in the company’s revenue and volume mix. (2) Quantitative issues: The claim that the concentrate segment grew to 58% of net operating revenue and 83% of unit-case volume in 2023 (from 56% and 82% in 2022) is not supported by the ground truth. The original answer does not mention these specific percentages or any such growth in the concentrate segment’s share of revenue or volume. These figures appear to be fabricated or misattributed, which severely undermines quantitative accuracy. (3) Multi-hop reasoning: The LLM attempts synthesis across years and correctly infers increased strategic importance of syrups based on distribution changes and segment reporting, aligning with the ground truth’s theme of tighter control and segmentation. However, it substitutes unsupported metrics for the actual structural changes (e.g., direct management of U.S. fountain syrup sales and inclusion in the North America operating segment) emphasized in the original. (4) Contextual relevance is high—the response stays focused on the role of syrups in production and distribution channels and draws a reasonable conclusion about their increasing strategic role. Despite the incorrect numbers, the directional interpretation (increased focus on syrups) is consistent with the ground truth. Thus, the answer is partially correct but penalized for introducing unverified statistics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1454,
        "completion_tokens": 536,
        "total_tokens": 1990
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the company's operational focus on Africa/Eurasia evolved between 2022 and 2024, particularly in terms of its geographic reporting structure and financial contribution?",
      "original_answer": "In 2022, Africa/Eurasia was reported as part of the Oral, Personal and Home Care segment with an operating profit of $203 million, indicating a relatively minor financial contribution compared to other regions. By 2024, the company maintained Africa/Eurasia as a distinct reportable operating segment within the Oral, Personal and Home Care geographic structure. Additionally, in 2024, the company realigned its skin health business, shifting it from Europe to North America, signaling a strategic refinement in geographic reporting. This change suggests a more nuanced operational focus in how the company organizes and evaluates its regional performance, including in Africa/Eurasia.",
      "llm_answer": "The company continues to treat Africa/Eurasia as a distinct, fifth geographic operating segment of its Oral, Personal and Home Care business. In 2022 the segment generated about $1.08 billion of net sales and $228 million of operating profit (with $30 million of capex); by 2024, after the company recast historic segment data to reflect a skin‑health reporting realignment, Africa/Eurasia contributed roughly $1.10 billion of net sales and $253 million of operating profit (capex down to $12 million). The geographic reporting structure (five regions) remained unchanged, with only the skin‑health business shifting between Europe and North America.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative data. The ground truth states that Africa/Eurasia had an operating profit of $203 million in 2022, but the LLM claims $228 million. Similarly, the 2024 operating profit is stated as $253 million in the LLM answer, which is not supported by the original answer (which does not provide a 2024 operating profit figure). The LLM also introduces net sales figures ($1.08B in 2022, $1.10B in 2024) and capex data ($30M and $12M) that are absent from the ground truth and cannot be verified. (2) These numerical discrepancies are critical because they misrepresent the financial contribution of the region. There is no mention in the original answer of net sales or capex for Africa/Eurasia, nor any recasting of historical data for skin health affecting Africa/Eurasia’s numbers—only a realignment of skin health from Europe to North America. The LLM incorrectly implies that the skin-health realignment affected Africa/Eurasia’s reported figures, when the original answer specifies the shift was between Europe and North America only. (3) While the LLM correctly identifies that Africa/Eurasia remained a distinct geographic segment and that the overall five-region structure was unchanged, it fails to accurately describe the evolution of the reporting structure. The original answer emphasizes that in 2022, Africa/Eurasia was part of the broader Oral, Personal and Home Care segment, not necessarily a 'fifth distinct' segment at that time, suggesting a potential change in segmentation status by 2024. The LLM assumes continuity in segmentation status without acknowledging this nuance. (4) Despite incorrect numbers and some mischaracterization of the reporting changes, the LLM captures the general idea of a stable geographic structure and a skin health realignment, hence moderate contextual relevance. However, due to major quantitative errors and flawed multi-hop reasoning (especially around data recasting and financials), the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 556,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Johnson & Johnson's strategic presentation of its Orthopaedics business evolved between 2023 and 2024, particularly in terms of global sales performance and emphasis on enabling technologies?",
      "original_answer": "In 2023, JNJ's Orthopaedics segment was presented primarily through quantifiable sales figures, with global revenue reaching $8,942 million, showing a 4.1% increase from the prior year. The 2023 data emphasized steady growth, particularly in the U.S. ($5,525 million, up 3.8%) and modest international growth ($3,417 million, up 4.6%). By 2024, the strategic framing of Orthopaedics shifted from financial metrics to a qualitative emphasis on innovation and enabling technologies. The 2024 filing described Orthopaedics as a portfolio 'supported by products and enabling technologies' across hips, knees, trauma, spine, and sports medicine, without revisiting specific revenue figures. This reflects a strategic pivot from highlighting quantitative performance to underscoring technological leadership and product diversification within the segment.",
      "llm_answer": "In the 2023 Form 10‑K Johnson & Johnson treated Orthopaedics as a discrete MedTech sub‑segment, reporting $8.9 billion of worldwide sales for the year (up 4.1 % versus 2022) and even breaking the business out by region and by product groups such as knees, trauma and spine (see 2023 p. 90‑91). By the 2024 filing the company shifted to a more narrative‑driven presentation, describing the Orthopaedics portfolio as a suite of products and “enabling technologies” that support hips, knees, trauma, spine, sports and other areas, with no detailed sales numbers disclosed (see 2024 p. 7‑8).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the $8.9 billion figure matches the ground truth $8,942 million (rounded appropriately), and the 4.1% growth is correctly stated. Regional and product-level breakdowns are not required by the question and their absence does not detract from correctness. (2) The shift in strategic presentation from 2023 to 2024 is accurately captured: the 2023 focus on discrete financial reporting and regional/product segmentation, and the 2024 pivot to a narrative emphasizing 'enabling technologies' across hips, knees, trauma, spine, and sports medicine without disclosing sales figures. (3) Multi-hop reasoning is sound—correctly synthesizing changes in disclosure style and content across two years and filings. (4) Minor deduction in qualitative accuracy due to slightly less explicit emphasis on the U.S. vs. international growth details present in the original, though these are not central to the core question about strategic presentation evolution. Wording differs but semantic meaning and factual content are equivalent. Contextual relevance is perfect—directly addresses both parts of the question: sales performance in 2023 and shift toward enabling technologies in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 353,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Visa's approach to managing litigation liabilities through loss sharing agreements evolved between 2022 and 2023, particularly in terms of the scope of U.S. covered litigation and liability allocation?",
      "original_answer": "In 2022, Visa detailed specific amendments to its loss sharing agreement, including the October 2015 amendment that expanded the scope of U.S. covered litigation to include opt-out actions from the Rule 23(b)(3) Settlement Class in MDL 1720 that arose out of similar facts or circumstances. This amendment was part of a broader framework involving the omnibus agreement, under which Visa assumed 66.6667% of any monetary liability in covered settlements or judgments, with Mastercard assuming 33.3333%. In 2023, Visa consolidated its approach under the U.S. Retrospective Responsibility Plan, which now encompasses the loss sharing agreement as part of a broader set of mechanisms designed to address potential liabilities from U.S. covered litigation. Notably, the 2023 filing emphasizes that U.S. covered litigation now includes matters that have been 'settled or otherwise fully or substantially resolved,' indicating a shift toward resolution and consolidation of past liabilities. The evolution from a focus on specific amendments and liability sharing with Mastercard in 2022 to a more comprehensive and retrospective liability framework in 2023 suggests a strategic pivot toward finalizing and managing legacy litigation exposure.",
      "llm_answer": "In both the 2022 and 2023 filings Visa’s loss‑sharing framework continues to be governed by the 2015 amendment that defines “U.S. covered litigation” as the Interchange MDL 1720 and any post‑amendment opt‑out actions that are factually similar (see 2022 p. 73; 2023 p. 73). The 2023 filing expands the agreement’s trigger to expressly include liabilities arising from the U.S. litigation‑escrow arrangement and the conversion feature of Visa’s class B common stock (see 2023 p. 72), but the allocation of those liabilities remains based on each member’s membership proportion – with Visa bearing roughly two‑thirds of any settlement or judgment under the omnibus agreement (see 2022 p. 71; 2023 p. 72). This reflects a broader set of covered mechanisms while keeping the proportional liability structure unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures some key elements correctly but misses critical aspects of the evolution in Visa's approach between 2022 and 2023, leading to a partially correct response. (1) Quantitatively, the 66.6667% (two-thirds) liability allocation to Visa and 33.3333% to Mastercard is accurately represented as 'roughly two-thirds,' and the reference to the 2015 amendment is correct. Page references (e.g., 2022 p.73, 2023 p.72) appear consistent with source formatting. (2) However, the LLM incorrectly states that the 2023 filing expands the agreement’s trigger to include liabilities from the 'U.S. litigation-escrow arrangement' and 'conversion feature of Visa’s class B common stock'—this is not mentioned in the ground truth and appears to be a misinterpretation or hallucination based on peripheral filing content. The ground truth emphasizes that in 2023, Visa shifted to the U.S. Retrospective Responsibility Plan, which consolidates past liabilities and now includes matters that are 'settled or otherwise fully or substantially resolved'—a key qualitative shift toward resolution that the LLM fails to mention. (3) The multi-hop reasoning is partially sound: it correctly identifies continuity in the loss-sharing structure and references the 2015 amendment. However, it misses the strategic pivot from a focus on active liability sharing with Mastercard (2022) to a retrospective, consolidated framework (2023), which is the core of the evolution. (4) While the answer is contextually relevant and uses accurate terminology, the omission of the U.S. Retrospective Responsibility Plan and the misrepresentation of the 2023 expansion undermine factual completeness and reasoning accuracy, warranting a score of 6 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1528,
        "completion_tokens": 471,
        "total_tokens": 1999
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did CL's investment in Guaranteed Investment Contracts evolve between 2022 and 2024, and what does this shift indicate about the company's pension plan asset strategy?",
      "original_answer": "In 2022, CL held $1 million in Guaranteed Investment Contracts under its United States Pension Plans and $55 million under its International Pension Plans. By 2024, the company had completely phased out Guaranteed Investment Contracts from its United States Pension Plans, reducing the International allocation to $34 million. This represents a significant shift away from Guaranteed Investment Contracts in the U.S. and a moderate decrease internationally, indicating a strategic reallocation of pension plan assets.",
      "llm_answer": "In the 2022 filing the pension plans held roughly $52 million of guaranteed investment contracts – about $1 million in the U.S. plan and $51 million internationally (2022‑10‑K, p. 100). By year‑end 2024 that exposure had fallen to $30 million, all in the international plan with the U.S. holding eliminated (2024‑10‑K, p. 102). The drop signals a strategic move away from insurance‑linked GICs toward a higher weighting in other fixed‑income and diversified assets, consistent with the plans’ target allocation that emphasizes fixed‑income securities.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM answer captures the overall trend correctly: CL eliminated Guaranteed Investment Contracts (GICs) in the U.S. pension plan and reduced international holdings by 2024, indicating a strategic shift. However, the quantitative figures are inaccurate. According to the ground truth, in 2022, CL held $1M in U.S. and $55M in International GICs (total $56M), but the LLM reports $1M U.S. and $51M international (total $52M). By 2024, the ground truth states international dropped to $34M (U.S. $0), but LLM reports $30M all in international. These discrepancies affect factual precision.\n\n2) Calculations: The LLM’s implied 2022 total ($52M) is off by $4M from the correct $56M. The 2024 figure ($30M vs $34M) is off by $4M. While the direction of change is correct, the magnitude is misstated. The U.S. elimination is correctly noted in both years.\n\n3) Multi-hop reasoning is sound: the model correctly synthesizes data across 2022 and 2024 filings, identifies the elimination in the U.S., and interprets the reduction as part of a broader asset allocation strategy. The conclusion about shifting toward other fixed-income and diversified assets aligns with the ground truth’s indication of strategic reallocation.\n\n4) Entity accuracy is strong: CL (Colgate-Palmolive) is correctly implied, years (2022, 2024) are accurate, and the metric (GICs in pension plans) is properly contextualized. The mention of target allocation and fixed-income emphasis adds relevant qualitative insight not in the ground truth but plausibly inferred.\n\nJustification: The answer earns a 7 due to correct reasoning and structure but loses points on quantitative accuracy. The errors in reported amounts are significant enough to reduce confidence in financial precision, though not enough to invalidate the overall conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 490,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the strategic positioning and functionality of the Mastercard Developer Platform evolved between 2022 and 2024, particularly in terms of its role in enabling integration of digital assets and new technologies?",
      "original_answer": "In 2022, the Mastercard Developer Platform was described as a single access point that enables customers and partners to leverage Mastercard's digital assets and services, with an emphasis on ease of integration into new and existing solutions. By 2024, the platform continued to serve this role but expanded its strategic positioning by explicitly aligning with emerging technologies such as blockchain and digital currencies. In 2024, the platform was referenced in the context of enabling integration with the Mastercard Multi-Token Network™, which supports programmable payments and facilitates secure, scalable, and interoperable blockchain-based transactions. This evolution shows a shift from a general digital integration platform to one that specifically supports next-generation financial technologies and programmable commerce solutions.",
      "llm_answer": "In the 2022 Form 10‑K, Mastercard described the Developer Platform mainly as a “single access point” that lets customers and partners “simplify access to, and integration of, our digital assets,” providing tools and APIs so its services can be embedded in new or existing solutions【page_14】. By the 2024 filing, the platform is positioned as a strategic gateway for emerging tech – it now underpins “new blockchain‑based business models,” integrates with the Mastercard Multi‑Token Network to enable programmable payments and crypto purchases, and supports experimentation with future technologies through Mastercard Foundry, expanding its role from simple API access to a hub for digital‑asset and technology integration【page_14】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, the Mastercard Developer Platform was described as a 'single access point' for integration of digital assets, which matches the original answer. By 2024, it evolved to support blockchain-based models and integration with the Mastercard Multi-Token Network, enabling programmable payments and crypto purchases—this is consistent with the ground truth’s emphasis on programmable commerce and blockchain interoperability. (2) There are no numeric values, dates, or calculations in the question or answers that conflict; all years (2022, 2024) and proper nouns (Mastercard Developer Platform, Mastercard Multi-Token Network™, Mastercard Foundry) are correctly identified. The LLM refers to 'Mastercard Foundry' as part of the innovation support, which adds contextual detail not in the original but does not contradict it and is plausibly aligned with Mastercard's innovation initiatives. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two time points (2022 and 2024) and identifies the evolution in strategic positioning—from general integration to enabling next-gen financial tech. The only minor gap is that the original answer emphasizes 'secure, scalable, and interoperable blockchain-based transactions' and the 'strategic positioning' shift more explicitly, which the LLM implies but doesn’t fully articulate in those terms. (4) The answer is contextually excellent, directly addressing the evolution in functionality and strategic role regarding digital assets and new technologies. Wording differs slightly but maintains semantic equivalence. No hallucinations or inaccuracies—just a slight omission of 'secure, scalable, interoperable' descriptors, which prevents a perfect 10. Thus, correctness is 9/10, with high marks across all other dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 516,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the company's investment in U.S. common stocks within its pension plans evolved between 2022 and 2024, and what does this indicate about its strategic asset allocation?",
      "original_answer": "In 2022, the company reported no investments in U.S. common stocks within its pension plans, while by 2024, there was still no allocation to U.S. common stocks in the U.S. pension plan. However, the international pension plan maintained a $2 million investment in U.S. common stocks in both years. This indicates a continued strategic decision to avoid direct exposure to U.S. common stocks in the domestic pension portfolio while maintaining a minimal presence in the international portfolio.",
      "llm_answer": "The 2022 filing shows the pension‑plan tables list U.S. common‑stock holdings as “‑” (i.e., zero) for the U.S. plan, while the 2024 filing records a $1 million balance of U.S. common stocks in the U.S. plan (and $2 million in the International plan) 【page_100†L31-L38】【page_99†L31-L38】. This modest addition coincides with a higher target equity allocation for the U.S. defined‑benefit plans—up from about 21 % to roughly 26 % of assets—signaling a strategic tilt toward greater equity exposure in the company’s asset mix 【page_100†L1-L8】【page_99†L1-L8】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the company had no investment in U.S. common stocks in its U.S. pension plan in both 2022 and 2024. However, the LLM claims that the 2024 filing shows a $1 million balance in U.S. common stocks for the U.S. plan, which contradicts the original answer. Additionally, the international plan maintained a $2 million investment in both years, but the LLM implies a change or ongoing presence without clarifying the consistency across years. (2) The quantitative inaccuracies are critical: the LLM incorrectly reports $1 million in U.S. common stocks for the U.S. plan in 2024, while the ground truth states there was no allocation in either year. The claimed increase in target equity allocation from 21% to 26% is not corroborated by the original answer and introduces unsupported data. (3) The multi-hop reasoning is flawed because the LLM infers a strategic shift toward greater equity exposure based on incorrect data. Since the actual data shows no investment in U.S. common stocks in the U.S. pension plan over the period, the conclusion about a 'strategic tilt' is invalid. The synthesis across years and plans fails because it misrepresents the core facts. (4) Despite the incorrect facts, the answer is contextually relevant—it addresses the evolution of investments and attempts to interpret strategic asset allocation. However, due to major quantitative and qualitative errors, the overall correctness score is low. Minor formatting variations in numbers are acceptable, but here the numbers themselves are factually wrong, warranting a score of 2 out of 10 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 460,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did Disney's strategic focus on cruise ships evolve between 2022 and 2023, particularly in terms of capital investment plans and operational risk considerations?",
      "original_answer": "In 2022, Disney highlighted cruise ships as a key part of its capital investment strategy within the Parks & Experiences segment, noting that a majority of its capital spending was directed toward theme parks, resorts, and cruise ships. This indicated a growth-oriented approach focused on expanding physical assets. By 2023, the emphasis had shifted toward operational risks associated with cruise ships, particularly in the context of external disruptions like hurricanes and global events (e.g., the impact of Hurricane Milton on Walt Disney World operations). The 2023 filing framed cruise ships more as an operational exposure rather than a growth engine, signaling a shift from investment to risk mitigation. This evolution reflects a recalibration of strategic focus from asset expansion to managing volatility and external threats.",
      "llm_answer": "In the 2022 Form 10‑K Disney grouped cruise ships only as a component of its overall Parks & Experiences capital‑spending program, noting that “cruise ships” were among the major areas of investment but giving no specific expansion plan (see 2022 page 17). By the 2023 filing the company moved to a more aggressive stance, announcing a concrete plan to add more vessels to its fleet and warning that the higher launch costs and the risk of asset impairments—exemplified by the Star Wars Galactic Starcruiser write‑down—could affect profitability (see 2023 page 22).",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) It incorrectly states that Disney adopted a 'more aggressive stance' in 2023 with plans to add more vessels, whereas the original answer indicates a strategic shift away from growth and toward risk mitigation, not expansion. This misrepresents the core evolution of Disney's strategy. (2) The mention of 'concrete plan to add more vessels' and 'higher launch costs' is unsupported by the ground truth, which emphasizes operational risks like hurricanes and external disruptions, not fleet expansion or launch costs. (3) The reference to the Star Wars Galactic Starcruiser write-down as an example of asset impairment risk is factually plausible but misaligned with the context—this event relates to a land-based attraction, not cruise ships, and thus misattributes operational risk to the cruise segment. (4) The 2022 description is partially correct—cruise ships were mentioned as part of capital spending—but the LLM omits the key point that a majority of capital investment was directed toward theme parks, resorts, and cruise ships collectively, under a growth-oriented strategy. (5) The multi-hop reasoning fails: instead of identifying a shift from investment to risk management, the LLM suggests increased investment intent in 2023, which is the opposite of the ground truth. While the answer addresses the question's structure and references the correct document types and segments (Parks & Experiences), the factual and conceptual errors severely undermine correctness. Quantitative accuracy is low due to absence of correct numerical data or accurate characterization of financial plans. Qualitative accuracy suffers from incorrect entity linking and flawed reasoning. Contextual relevance is moderate because the answer discusses cruise ships and capital spending in the right timeframe and segment, but with incorrect conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 520,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Mastercard's use of short duration foreign exchange derivative contracts evolved between 2022 and 2024, particularly in terms of their role in managing foreign exchange risk during daily settlement activities?",
      "original_answer": "In 2022, Mastercard used short duration foreign exchange derivative contracts to manage foreign exchange risk associated with daily settlement activities, aiming to reduce exposure to volatility from currency fluctuations on anticipated receipts and disbursements. By 2024, the company continued this practice, maintaining the same stated objective of minimizing volatility in gains and losses due to foreign exchange fluctuations. However, the context changed as the company actively adjusted its hedging strategies involving euro-denominated debt, de-designating and re-designating portions of it in 2023 and 2024, which indicates a more dynamic approach to managing foreign exchange exposure across the period. The continuity in the use of short duration contracts contrasts with the evolving structure of the company’s broader foreign exchange risk management strategy.",
      "llm_answer": "Mastercard still uses short‑duration foreign‑exchange derivative contracts as non‑designated economic hedges to offset the few‑day FX exposure that exists between a payment transaction and its settlement, with the resulting gains or losses recorded in general‑and‑administrative expense【page_111】. The 2024 filing repeats the same description of this practice【page_106】, but the financial impact has grown – the G&A expense associated with these contracts rose from $21 million in 2022 to $32 million in 2024, indicating a larger notional amount of short‑duration FX contracts being employed【page_107】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Mastercard uses short-duration foreign exchange derivative contracts to manage FX risk in daily settlement activities and notes continuity between 2022 and 2024, which aligns with the ground truth. It adds specific financial data — G&A expense rising from $21M in 2022 to $32M in 2024 — suggesting increased usage, which is a reasonable inference from the filings. However, this quantitative detail is not present in the original ground truth, and while plausible, it introduces a claim (increased notional amount due to higher expense) that may not be directly supported or emphasized in the knowledge graph. (2) The numbers ($21M in 2022, $32M in 2024) are treated as factually accurate per the model’s source pages, but the ground truth does not include these figures, so their correctness cannot be fully verified against the provided truth. If these numbers are indeed in the cited pages, they are likely accurate, but the original answer does not mention them, creating a discrepancy in focus. The calculation (increase in expense) is arithmetically correct, but the causal inference (higher expense = larger notional) is interpretive and not explicitly confirmed in the ground truth. (3) The multi-hop reasoning is partially sound: the model connects the use of short-duration contracts across years and infers strategic implications from financial impacts. However, it misses the key qualitative evolution noted in the ground truth — the de-designation and re-designation of euro-denominated debt hedging in 2023–2024, which reflects a dynamic shift in broader FX strategy. This omission reduces completeness in capturing how the *overall* FX risk management evolved, even if short-duration contracts remained stable. (4) The contextual relevance is high because the answer directly addresses the role of short-duration contracts in settlement risk and compares 2022 to 2024. The qualitative accuracy is good due to correct entity identification (Mastercard, short-duration FX derivatives, G&A expense) and proper characterization of their use as non-designated hedges. The correctness score is 7 because core facts about the contracts’ use are accurate and enriched with plausible data, but the answer substitutes a financial trend for a strategic nuance (de-/re-designation activity) that was central to the ground truth’s narrative of evolving strategy, resulting in partial omission of key context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 655,
        "total_tokens": 2041
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Salesforce's strategic relationship with enterprise cloud companies evolved from 2023 to 2024, particularly in terms of investment focus and ecosystem integration?",
      "original_answer": "In 2023, Salesforce maintained a portfolio of strategic investments in enterprise cloud companies, technology startups, and system integrators, with a focus on digitally transforming industries and expanding its solution ecosystem. These investments were described as ranging from early to late-stage companies, including those concurrent with initial public offerings. By 2024, Salesforce's relationship with enterprise cloud companies shifted from primarily investing to a broader strategic dependency, leveraging these partners as part of its ecosystem to accelerate reach into new markets and industries. The 2024 filing emphasized the Salesforce Platform's role in enabling third-party developers and ISVs to create and deliver cloud-based applications through the AppExchange, indicating a deepened integration and dependency on enterprise cloud partners beyond mere financial investment.",
      "llm_answer": "In its 2023 filing Salesforce said it “manages a portfolio of strategic investments … focused primarily on enterprise‑cloud companies, technology startups and system integrators” that are intended to “expand our solution ecosystem” (CRM 10‑K 2023 p. 23). By the 2024 filing the company still plans to make such investments, but it now stresses turning those relationships into an integrated partner‑driven cloud platform—leveraging the open Salesforce Platform, the AppExchange marketplace and close work with ISVs and SIs to embed third‑party applications, data and services across its offerings (CRM 10‑K 2024 p. 8; p. 6). Thus the relationship has shifted from a primarily investment‑focused stance in 2023 to a broader ecosystem‑integration strategy in 2024, using those investments to deepen the partner‑centric cloud marketplace.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately captures the evolution of Salesforce's strategic relationship with enterprise cloud companies from 2023 to 2024: in 2023, the focus was on strategic investments in enterprise cloud companies, startups, and system integrators to expand the solution ecosystem; by 2024, the emphasis shifted to deeper ecosystem integration via the Salesforce Platform and AppExchange, leveraging partnerships beyond financial investment. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes information across two years of 10-K filings, identifying a shift in strategy from investment-centric to integration- and platform-centric collaboration, citing specific mechanisms like AppExchange, ISVs, and SIs. (4) The LLM includes precise citations (CRM 10-K 2023 p. 23; CRM 10-K 2024 pp. 8, 6), which align with the type of evidence expected, and uses terminology consistent with the original (e.g., 'solution ecosystem', 'integrated partner-driven cloud platform'). Wording differs slightly but meaning is preserved. All aspects of the question—investment focus and ecosystem integration across 2023 and 2024—are addressed thoroughly and accurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 390,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the company's approach to accrual rates for vendor funding programs evolve between fiscal 2023 and fiscal 2024, particularly in terms of sensitivity to projected purchase volumes?",
      "original_answer": "The company's approach to accrual rates for vendor funding programs remained methodologically consistent between fiscal 2023 and fiscal 2024, with no material changes in the recognition methodology over the past three fiscal years. However, in fiscal 2023, the company specifically highlighted sensitivity to 'graduated purchase volumes' that could impact accrued amounts, emphasizing the importance of projected volumes in determining accrual rates. In fiscal 2024, this explicit reference to 'graduated purchase volumes' was omitted, suggesting a potential simplification or stabilization in how accrual rates were adjusted throughout the year, despite continued monitoring of historical purchase trends and vendor confirmations.",
      "llm_answer": "The company’s policy for vendor‑fund accruals was essentially unchanged – it still builds accrual rates from the specific terms of each vendor agreement, reviews historical purchase trends and volumes throughout the year and adjusts the rates as needed. Both FY 2023 and FY 2024 disclosures note that “amounts accrued throughout the year could be impacted if actual purchase volumes differ from projected purchase volumes, especially in the case of programs that provide for increased funding when graduated purchase volumes are met” and that “we have not made any material changes in the methodology used to recognize vendor funds”【page_33】【page_34】.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent with the disclosures cited (pages 33 and 34), correctly stating that there were no material changes in methodology and that both years reference sensitivity to projected purchase volumes, including graduated volume thresholds. However, it contradicts the ground truth by asserting that both FY2023 and FY2024 included the specific language about 'graduated purchase volumes,' when the original answer explicitly states that this phrase was omitted in FY2024. This omission is a key qualitative distinction indicating a shift in disclosure emphasis, which the LLM fails to recognize. While the core methodology is accurately described as unchanged, the LLM incorrectly implies continuity in disclosure language, missing the nuance that the explicit sensitivity reference was present only in FY2023. This undermines the multi-hop reasoning required to assess evolution in approach—particularly around how sensitivity to projected volumes was communicated. There are no numerical inaccuracies (hence high quantitative score), and the response is contextually relevant, but the qualitative inaccuracy in representing the evolution of disclosure reduces overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 338,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the strategic relationship between LLY and Boehringer Ingelheim evolved from 2022 to 2024, particularly in terms of legal involvement and collaborative dependency on the Jardiance product?",
      "original_answer": "In 2022, LLY was not a direct party to the Jardiance patent litigation initiated by Boehringer Ingelheim (BI) against generic drug manufacturers under the Hatch-Waxman Act, indicating a more arms-length relationship in legal matters. By 2024, LLY's business became significantly dependent on the Jardiance collaboration, as the product was selected under the Inflation Reduction Act (IRA) for government-set pricing with a 66% discount compared to the 2023 list price, directly impacting LLY's revenue projections and business strategy. This shift reflects a deeper strategic entanglement and dependency on BI's partnership for navigating regulatory and pricing pressures.",
      "llm_answer": "In the 2022 filing, Lilly described its partnership with Boehringer Ingelheim (BI) as a co‑marketing and development arrangement for Jardiance, noting that BI had initiated a U.S. patent suit (which Lilly was not a party to) and that under their agreement BI would defend and indemnify Lilly in five pending Jardiance product‑liability lawsuits【page_102】; the discussion was therefore centered on legal exposure and indemnification. By the 2024 filing, the relationship is still active, but the focus has shifted to the product’s regulatory and pricing landscape—Jardiance, as a joint BI‑Lilly product, was selected for government‑set pricing under the Inflation Reduction Act, highlighting a continued collaborative dependency on the drug’s revenue while legal involvement is no longer emphasized【page_45】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: in 2022, LLY was not a party to the Hatch-Waxman litigation initiated by BI, and BI was responsible for indemnifying LLY in product-liability lawsuits; by 2024, the focus shifted to Jardiance being subject to government-set pricing under the Inflation Reduction Act (IRA) with significant revenue implications. The 66% discount mentioned in the original answer is implied in the LLM’s reference to government-set pricing and its impact, though not explicitly stated—this is a minor omission. (2) No numeric inaccuracies: the years (2022, 2024), legal contexts, and financial implications are correctly represented without erroneous figures. Format and references to page numbers support accuracy. (3) Multi-hop reasoning is sound: the LLM correctly synthesizes information across time (2022 to 2024), entities (LLY, BI), legal domains (patent vs. product liability), and regulatory shifts (IRA pricing). It captures the evolution from legal indemnification concerns to strategic dependency via pricing policy. (4) Semantic equivalence is strong—while the LLM does not explicitly mention the '66% discount', it accurately conveys the consequence (government-set pricing impacting revenue and strategy) and the deepening collaborative dependency. The answer is fully contextually relevant, directly addressing legal involvement and collaborative dependency as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 404,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How did Disney's capital investment strategy toward cruise ships evolve from 2022 to 2023, particularly in relation to its broader Parks & Experiences business?",
      "original_answer": "In 2022, Disney's 10-K filing highlighted cruise ships as part of its broader Experiences segment but did not specifically emphasize capital investment in them, instead noting general risks from macroeconomic conditions such as inflation, supply chain delays, and currency fluctuations that could impact the implementation of business plans, including those for parks and resorts. By 2023, Disney explicitly listed cruise ships as part of its significant capital investments, indicating a strategic elevation in focus. The 2023 filing stated that the majority of the company’s capital spend was directed toward parks and experiences, including 'new attractions, cruise ships, capital improvements and systems infrastructure.' This shift demonstrates a clear prioritization of cruise ships as a key growth area within the broader Experiences segment.",
      "llm_answer": "In the 2022 filing Disney treated cruise‑ship spending as one of several uncertain, project‑specific capital outlays – for example, it highlighted the new Lighthouse Point destination and warned that “we must often invest substantial amounts … cruise ships … before we know the extent to which these products will earn consumer acceptance” (pages 22 & 25). By the 2023 filing the company had moved to a more integrated, strategic stance, placing cruise‑ship construction squarely within its Parks & Experiences capital plan and noting that “the majority of the Company’s capital spend has been at our parks and experiences business…principally for … cruise ships” (page 12) while listing Disney Cruise Line as a core Experience (page 11). This reflects a shift from a cautious, project‑by‑project approach in 2022 to a deliberate, core‑business focus on cruise‑ship investment within Parks & Experiences in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in Disney's capital investment strategy toward cruise ships from 2022 to 2023, noting the shift from a cautious, project-specific approach to a more integrated and strategic focus within Parks & Experiences. The key factual elements—cruise ships not being a highlighted capital investment in 2022, macroeconomic risks mentioned, and the explicit inclusion of cruise ships in major capital spending in 2023—are all present. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; all references to years (2022, 2023) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings, correctly infers a strategic shift based on changes in language and categorization, and supports claims with specific page references (though page numbers are not part of the ground truth, they do not contradict it and suggest document fidelity). (4) The LLM adds contextual detail not in the original—such as quoting the 'substantial amounts' language and naming Lighthouse Point—which enriches the answer without introducing inaccuracies. The only minor gap is that the original emphasizes broader risks (inflation, supply chain) affecting implementation, while the LLM focuses more on consumer acceptance risk; both are valid aspects, but the LLM slightly downplays the macroeconomic context. Overall, the answer is semantically equivalent, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 443,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Mastercard Foundry's role in fostering innovation evolved between 2022 and 2024, particularly in relation to its engagement with emerging technologies and fintech partnerships?",
      "original_answer": "In 2022, Mastercard Foundry (formerly known as Mastercard Labs) was primarily described as a vehicle for bringing customers and partners access to thought leadership, innovation methodologies, new technologies, and early-stage fintech players. By 2024, its role had evolved into a more active innovation engine, with continued emphasis on identifying and experimenting with future technologies, start-ups, and trends. Specifically, in 2024, Foundry was positioned as a key enabler of blockchain-based business models and programmable payments through the Mastercard Multi-Token Network™, indicating a strategic shift toward deeper integration with next-generation financial technologies.",
      "llm_answer": "In the 2022 filing, Mastercard Foundry (formerly Mastercard Labs) was portrayed mainly as a thought‑leadership hub that “identifies and experiments with future technologies, start‑ups and trends” and gives customers and partners access to new‑technology insights and early‑stage fintech players【page_14】. By the 2024 filing, Foundry’s role had become more hands‑on – it still provides that thought‑leadership and fintech access, but now runs concrete programs such as the five‑day “Launchpad” app‑prototyping workshop and in‑lab usability‑testing and concept‑design services【page_16】, showing a deeper, program‑driven engagement with emerging technologies and fintech partners【page_14】.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Mastercard Foundry's role between 2022 and 2024. It accurately captures the shift from a thought-leadership-focused entity in 2022 to a more hands-on, program-driven innovation engine in 2024, citing specific initiatives like the 'Launchpad' workshop and in-lab design services, which reflect deeper engagement with emerging technologies and fintech partners. These details support the qualitative evolution described in the original answer. However, the LLM omits the key strategic advancement highlighted in the ground truth: Foundry’s role in enabling blockchain-based business models and programmable payments via the Mastercard Multi-Token Network™ in 2024. This is a significant omission in terms of the specific technological focus (blockchain, programmable payments) that represents a core part of the evolution. Despite this, the answer correctly identifies the broader trend of increased operational engagement and provides concrete examples from the filings (with correct page references), demonstrating sound multi-hop reasoning across years and functions. All entities (Mastercard Foundry, former name Mastercard Labs), years (2022, 2024), and descriptions are accurate. There are no numerical inaccuracies (quantitative accuracy is 10), and the answer is highly relevant to the question. The qualitative accuracy is slightly reduced due to the missing blockchain and Multi-Token Network™ component, which limits full completeness in the innovation evolution narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 432,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial and strategic nature of the collaboration with Boehringer Ingelheim evolved between 2022 and 2024, particularly in terms of regulatory designations and pricing pressures?",
      "original_answer": "In 2022, the collaboration with Boehringer Ingelheim included the development of a therapy that had received Breakthrough Therapy and Fast Track designations from the FDA, indicating early-stage regulatory support and potential expedited development. By 2024, the collaboration faced significant pricing pressures under the Inflation Reduction Act, with Jardiance—part of the LLY-Boehringer Ingelheim partnership—selected for government-set pricing effective in 2026, subject to a 66% discount compared to the 2023 U.S. list price. This marks a shift from regulatory facilitation to regulatory-driven financial constraints.",
      "llm_answer": "In the 2022 filing the Boehringer Ingelheim partnership was presented as a development‑focused alliance – empagliflozin (Jardiance) was being pursued for new heart‑failure and chronic‑kidney‑disease uses and had earned FDA Breakthrough‑Therapy, Fast‑Track and priority‑review designations (2022 10‑K p. 39). By the 2024 filing the emphasis had shifted to pricing risk: Jardiance was named one of the first ten drugs subject to the Inflation‑Reduction‑Act government‑set price, with HHS announcing a 66 % discount for 2026, creating significant revenue‑erosion pressure on the collaboration (2024 10‑K p. 45). This marks a transition from a regulatory‑milestone‑driven strategy to one dominated by pricing‑and‑reimbursement challenges.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: in 2022, the collaboration involved regulatory designations (Breakthrough Therapy, Fast Track, and Priority Review) for empagliflozin (Jardiance) in new indications, as confirmed in the 2022 10-K. By 2024, the focus shifted due to the Inflation Reduction Act, with Jardiance selected for government-set pricing requiring a 66% discount effective in 2026, as stated in the 2024 10-K. (2) Quantitative accuracy is perfect: the 66% discount figure matches the ground truth, and the years (2022, 2024, 2026) are correctly cited. Format variations (e.g., '66 %' vs '66%') are acceptable. (3) Multi-hop reasoning is sound: the answer synthesizes information across two years of filings, correctly identifying the shift from regulatory facilitation (2022) to pricing pressure (2024), and links Jardiance to the LLY-Boehringer Ingelheim partnership. (4) The answer fully addresses both parts of the question—evolution in regulatory designations and pricing pressures—and provides contextually rich, relevant details. Wording differs slightly (e.g., 'revenue-erosion pressure' vs 'financial constraints') but meaning is preserved. All entities (Boehringer Ingelheim, Jardiance, Inflation Reduction Act, HHS) are correctly identified. No omissions or inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 379,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has the strategic positioning of the CH-53K King Stallion heavy lift helicopter evolved within Lockheed Martin's Rotary and Mission Systems segment from 2023 to 2024?",
      "original_answer": "In 2023, the CH-53K King Stallion heavy lift helicopter was described as part of Lockheed Martin's near-to-mid-term growth elements, specifically under the Rotary and Mission Systems (RMS) segment, alongside radar surveillance systems. By 2024, the CH-53K remained a highlighted program within RMS, but the emphasis shifted to framing it within a broader context of advancing all-domain mission solutions and digital technologies such as AI/ML and autonomy. While no specific revenue figures are provided, the helicopter's positioning evolved from being a growth driver among several others to being part of a more integrated, technologically advanced portfolio aimed at improving interoperability and supporting multi-domain solutions.",
      "llm_answer": "In the 2023 Form 10‑K the CH‑53K King Stallion was highlighted as a growth‑stage asset in the Rotary and Mission Systems (RMS) portfolio – it appears in the list of “radar surveillance systems and CH‑53K King Stallion heavy lift helicopter” and the filing notes a December 2021 Israeli Letter of Offer that awarded 12 helicopters (first four in 2022, the remainder in 2023) (page 29; page 31). By the 2024 filing the helicopter is positioned as a core, mature RMS major program – it is described among “Sikorsky helicopter programs … the CH‑53K King Stallion … in service with U.S. and foreign governments” and is again listed as a growth driver, reflecting a shift from an emerging growth focus to an established, in‑service platform with continued strategic importance (page 3; page 4).",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its factual content and references to the 10-K filings, with accurate use of dates, program details, and entity names. It correctly identifies the CH-53K as part of the Rotary and Mission Systems (RMS) segment in both 2023 and 2024, and notes its evolution from a growth-stage asset to an in-service, established program. The mention of the Israeli Letter of Offer and delivery timeline (first four in 2022, remainder in 2023) is factually accurate and adds useful context, though this detail is not in the ground truth—however, it does not contradict it. Quantitatively, all dates and numbers (e.g., 12 helicopters, 2021 offer, 2022/2023 deliveries) are accurate as presented, earning a high score on quantitative accuracy. However, the qualitative assessment is slightly lower because the LLM focuses on maturity and service status rather than the ground truth’s emphasis on strategic repositioning within a broader portfolio of digital technologies, AI/ML, and multi-domain interoperability. The shift from 'near-to-mid-term growth element' to being part of 'all-domain mission solutions' is underemphasized; instead, the LLM frames the evolution as a transition from 'emerging' to 'mature,' which is plausible but not fully aligned with the original answer’s focus on technological integration and strategic portfolio context. This represents a partial synthesis failure in multi-hop reasoning—while the facts are correct, the conceptual evolution in strategic positioning is not fully captured. Contextual relevance is high because the answer directly addresses the question’s focus on strategic positioning over time and uses appropriate evidence from the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 462,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "What does the change in LLY's diabetes product portfolio co-commercialized with Boehringer Ingelheim between 2022 and 2024 indicate about the companies' shifting strategic priorities or market focus?",
      "original_answer": "In 2022, LLY and Boehringer Ingelheim were jointly developing and commercializing a broader portfolio of diabetes products, including Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, and Basaglar. By 2024, the portfolio had narrowed to include only Jardiance, Glyxambi, Synjardy, and Trijardy XR. This indicates a strategic refocusing, potentially driven by lifecycle management, shifting market demand, or prioritization of products with stronger commercial performance or longer patent protection. The removal of Trajenta, Jentadueto, and Basaglar may reflect declining market relevance, generic competition, or a strategic decision to streamline the collaboration around products with greater growth potential or therapeutic differentiation.",
      "llm_answer": "In the 2022 filing Lilly’s partnership with Boehringer Ingelheim covered a broad diabetes suite – Basaglar (insulin), Trajenta (linagliptin), Jentadueto (metformin‑sitagliptin) together with Jardiance, Glyxambi, Synjardy and Trijardy XR 【page_5】【page_7】. By the 2024 filing the collaboration is limited to just Jardiance, Glyxambi, Synjardy and Trijardy XR, dropping the insulin and DPP‑4 products 【page_8】. This narrowing signals that the two companies are shifting away from older insulin/DPP‑4 lines and concentrating on newer SGLT2‑inhibitor and fixed‑dose combination therapies that carry stronger cardiovascular‑outcome and growth potential.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. (1) All entities—LLY (Lilly), Boehringer Ingelheim, product names, and years (2022 vs 2024)—are correctly identified. The list of products in 2022 (Basaglar, Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR) and the narrowed 2024 portfolio (Jardiance, Glyxambi, Synjardy, Trijardy XR) match the original answer exactly. (2) There are no numeric values requiring calculation, but the temporal comparison across 2022 and 2024 is correctly interpreted. (3) The multi-hop reasoning is sound: the model synthesizes changes in the product portfolio over time and infers strategic intent—shifting from older insulin/DPP-4 inhibitors (Basaglar, Trajenta, Jentadueto) toward SGLT2 inhibitors and fixed-dose combinations (Jardiance and related combos), which reflects lifecycle management and growth prioritization. (4) The LLM adds value by specifying therapeutic classes (insulin, DPP-4, SGLT2) and highlighting cardiovascular outcomes as a driver, which is a reasonable and contextually supported extension of the ground truth. The only minor limitation is that it does not explicitly mention potential reasons like generic competition or patent protection, though 'growth potential' and 'stronger cardiovascular-outcome' imply similar strategic logic. Overall, the answer is semantically equivalent, highly accurate, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 394,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial performance and strategic importance of the JASSM program evolve between 2023 and 2024, particularly in terms of production activity and its contribution to backlog?",
      "original_answer": "In 2023, JASSM was a product under the Missiles and Fire Control (MFC) segment, contributing to the company's portfolio of tactical missiles, but there was no specific mention of significant changes in its production volume or backlog contribution. By 2024, JASSM experienced a production ramp-up, contributing to a $1.2 billion increase in tactical and strike missile programs within MFC. Additionally, JASSM was specifically cited as a key contributor to the increase in backlog alongside PAC-3 and GMLRS. This indicates a notable rise in both production activity and strategic importance for JASSM in 2024.",
      "llm_answer": "In 2023 the Joint Air‑to‑Surface Standoff Missile (JASSM) entered a production ramp‑up that added $145 million of net sales to the Missiles‑and‑Fire‑Control (MFC) segment and helped lift year‑end backlog to $32.2 billion, as higher orders on JASSM (along with LRASM and GMLRS) were cited as a key driver of the backlog increase 【page_40】. By 2024 the ramp‑up continued and grew in scale, contributing roughly $1.2 billion of incremental MFC sales and pushing the segment’s backlog to $38.8 billion, with the 2024 backlog rise explicitly attributed to “higher orders on PAC‑3, JASSM and GMLRS” 【page_40】. Thus, JASSM’s production activity and backlog contribution expanded markedly from 2023 to 2024, underscoring its rising strategic importance.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that in 2023, there was no specific mention of a production ramp-up or financial contribution from JASSM, but the LLM claims a $145 million increase in net sales in 2023, which is not supported by the original answer. Additionally, the LLM introduces specific backlog figures ($32.2B in 2023 and $38.8B in 2024) and attributes them to JASSM, LRASM, and GMLRS in 2023 and PAC-3, JASSM, and GMLRS in 2024, which are not present in the original answer. While the original confirms that JASSM contributed to a $1.2 billion increase in 2024, the LLM incorrectly applies this figure to 'incremental MFC sales' without specifying it's part of a broader tactical and strike missile category. (2) The $1.2 billion figure for 2024 is correctly cited, but the $145 million figure for 2023 is entirely fabricated and not in the original. The backlog numbers and their attribution to specific programs in 2023 are unsupported. (3) The reasoning is partially sound in identifying a ramp-up in 2024 and increased strategic importance, which aligns with the original. However, the multi-hop synthesis is flawed because it invents precise financial data and misattributes backlog drivers for 2023, failing to reflect the original's key point that JASSM was not highlighted as significant in 2023. (4) The contextual relevance is high because the answer addresses production activity, backlog contribution, and strategic importance across both years. However, the correctness score is low due to major quantitative inaccuracies and unsupported specifics, which undermine the factual reliability of the response. The qualitative accuracy is moderate because the general trend (increased importance in 2024) is correct, but the reasoning is based on incorrect data for 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 512,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has JPM's focus in evaluating credit risk for Business Banking Loans evolved between 2023 and 2024, and what implications does this shift have for identifying early signs of borrower distress?",
      "original_answer": "In 2023, JPM focused on Business Banking Loans as part of its broader prime consumer credit strategy, emphasizing loan performance and scoring models within the 'Consumer, excluding credit card loan portfolio' segment. By 2024, the focus shifted toward delinquency rates as the primary credit quality indicator, particularly noting that loans more than 30 days past due serve as early warnings of financial difficulty. This evolution suggests a more proactive stance in identifying early signs of borrower distress, aligning Business Banking Loans with broader consumer loan risk frameworks where early delinquency tracking enhances risk mitigation. The shift indicates a strategic move toward earlier intervention and more granular performance monitoring.",
      "llm_answer": "JPM’s 2023 and 2024 10‑K filings show the same credit‑risk framework for its business‑banking (scored auto and business‑banking) loans: delinquency rates remain the primary early‑warning signal, while geographic distribution is used as a secondary gauge of portfolio health. Because the firm has not introduced a new metric, early signs of borrower distress continue to be identified through 30‑plus‑day delinquencies and by monitoring regional concentration risks rather than a shift to a different risk indicator.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that JPM's credit-risk framework remained unchanged between 2023 and 2024. The ground truth states a clear evolution—from a focus on loan performance and scoring models within the 'Consumer, excluding credit card loan portfolio' in 2023 to an emphasis on delinquency rates (specifically 30+ days past due) as the primary indicator in 2024. The LLM incorrectly claims there was no shift, stating that delinquency rates were already the primary early-warning signal in both years, which contradicts the documented change. (2) Quantitatively, the LLM correctly references 30-plus-day delinquencies, which aligns with the ground truth’s mention of 'loans more than 30 days past due.' There are no numerical inaccuracies in the metrics cited, hence a high score for quantitative accuracy. (3) The multi-hop reasoning is flawed—the question requires synthesis of changes across two years and implications for borrower distress identification. The LLM fails this by denying any evolution in focus, thus missing the core of the multi-hop analysis. It also incorrectly groups 'scored auto and business-banking' loans without evidence from the original answer, introducing extraneous details. (4) Contextual relevance is moderate because the answer discusses relevant concepts (delinquency, geographic distribution, early warning), but it misrepresents the strategic shift, leading to an incorrect conclusion about continuity rather than change. This fundamental error undermines the qualitative and overall correctness scores.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 434,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did Target Corporation's SPP II plan terms evolve between the 2022 and 2023 filings, and what does this suggest about the company's executive compensation framework?",
      "original_answer": "In the 2022 filing, the SPP II plan was described under the 2016 Plan Statement, as amended and restated effective April 3, 2016. However, in the 2023 filing, the SPP II plan was updated to the 2022 Plan Statement, as amended and restated effective May 1, 2022. This indicates that Target Corporation revised the SPP II plan within this timeframe, reflecting a shift in the structure or terms of the plan. Such changes could signal adjustments in the company's executive compensation strategy, potentially aligning incentives more closely with updated business objectives or governance standards.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K exhibit lists reference the same “Target Corporation SPP II (2016 Plan Statement) (as amended and restated effective April 3, 2016)” (see page 68 of each filing). The unchanged reference shows that the SPP II terms were not revised between the two years, suggesting that Target’s executive‑compensation framework is anchored in a stable, long‑term incentive structure rather than frequent plan modifications.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect. (1) It claims that both the 2022 and 2023 filings reference the same '2016 Plan Statement, as amended and restated effective April 3, 2016', but the ground truth states that the 2023 filing updated the plan to the '2022 Plan Statement, as amended and restated effective May 1, 2022'. This is a direct factual contradiction. (2) The dates (April 3, 2016 vs. May 1, 2022) are critical quantitative elements and are misrepresented—the LLM incorrectly asserts no change occurred, while the ground truth confirms a material update. (3) The multi-hop reasoning fails: the question requires comparing plan terms across two years to infer evolution in executive compensation strategy. The LLM incorrectly concludes stability due to unchanged documentation, when in fact the plan was revised, undermining the entire logical foundation. (4) The conclusion about 'stable, long-term incentive structure' is therefore unsupported and misleading. While the response is relevant to the topic of executive compensation, its factual inaccuracies severely limit usefulness. The answer fails on correctness, quantitative precision, reasoning, and alignment with the evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 335,
        "total_tokens": 1600
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial obligations related to Incyte under the Olumiant collaboration evolve from 2022 to 2024, particularly regarding potential future milestone payments?",
      "original_answer": "In 2022, Incyte was eligible to receive up to $100.0 million in additional development-related regulatory milestones and another $100.0 million in sales-based milestones under the Olumiant agreement. By 2024, there is no mention of remaining regulatory milestones, suggesting they were either paid out or no longer applicable, and only ongoing royalty payments based on sales tiers (up to 20%) and a low teens royalty for sales exceeding a threshold in the context of COVID-19 treatment are explicitly referenced. This indicates a shift from a structure with both regulatory and sales milestones to one focused primarily on sales-based compensation.",
      "llm_answer": "In the 2022 filing (see page 72), Eli Lilly noted that, as of Dec 31 2021, Incyte could still earn up to **$100 million in success‑based regulatory milestones and another $100 million in sales‑based milestones** under the Olumiant deal – a total of roughly $200 million of potential future payments. By the 2024 filing (see page 73), the Olumiant description no longer references any remaining milestone obligations, indicating that those potential payments have been satisfied, restructured or are no longer expected.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $100 million in potential regulatory milestones and $100 million in sales-based milestones from 2022, matching the ground truth. It accurately notes the absence of milestone obligations in the 2024 filing, indicating a shift to sales-based compensation only. The total potential $200 million is correctly implied. (2) All numeric values are accurate: $100 million (regulatory), $100 million (sales milestones), and the combined $200 million are correctly reported. Dates (as of Dec 31, 2021, referenced in 2022 filing) are consistent with typical SEC reporting lags and align with the context. (3) The multi-hop reasoning is sound: the model correctly infers evolution by comparing disclosures across 2022 and 2024 filings, concluding that milestone obligations are no longer mentioned, suggesting resolution or restructuring. The core shift from milestone-based to royalty-based compensation is correctly inferred, though the LLM does not explicitly mention the 'up to 20%' royalty tiers or 'low teens' royalty for COVID-19 sales, which are part of the ground truth. This is a minor omission affecting completeness but not the central conclusion. (4) The answer is highly relevant, directly addressing the evolution of financial obligations. The scores reflect near-perfect quantitative accuracy and strong qualitative reasoning, with a minor deduction in qualitative accuracy for not fully detailing the 2024 royalty structure mentioned in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 418,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has Cisco's financial exposure in the APJC region evolved between fiscal 2022 and fiscal 2023, based on its segment reporting and asset balances?",
      "original_answer": "In fiscal 2022, Cisco reported its business performance across geographic segments including APJC, though specific financial figures for APJC were not disclosed in the provided data. By fiscal 2023, Cisco's balance sheet showed that its assets in the APJC region stood at $5,382 million as of July 29, 2023, following additions from acquisitions and foreign currency translation adjustments. This indicates a more detailed financial disclosure regarding APJC in 2023 compared to 2022, where segment-level asset values were not explicitly itemized.",
      "llm_answer": "Cisco’s APJC business still represents roughly an $8 billion revenue stream – $8,027 million in FY 2022 (the most recent segment figure disclosed)【page_105】.  The intangible‑asset exposure tied to that region grew only marginally, with goodwill allocated to APJC increasing from $5,360 million at July 30 2022 to $5,382 million at July 29 2023 – a $22 million rise【page_76】.  Together, these data show that Cisco’s financial exposure in APJC remained essentially flat between FY 2022 and FY 2023, with only a slight uptick in goodwill.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Cisco did not disclose specific financial figures for APJC in fiscal 2022 segment reporting, but the LLM claims $8,027 million in revenue for APJC in FY 2022, which is not supported by the original answer. This is a major error. Additionally, while the LLM correctly reports APJC goodwill of $5,382 million as of July 29, 2023, it incorrectly states the prior year goodwill was $5,360 million at July 30, 2022 — this figure is not mentioned in the ground truth, which only notes that segment-level asset values were not itemized in 2022. (2) The calculation of a $22 million increase in goodwill is based on unsupported data and cannot be verified against the ground truth. The revenue figure of $8,027 million appears to be hallucinated or drawn from an external source not reflected in the provided knowledge. (3) The multi-hop reasoning is flawed: the LLM assumes that because goodwill increased slightly and revenue remained stable, financial exposure was flat — but the ground truth emphasizes a change in disclosure practices (from no segment asset breakdown in 2022 to reporting $5,382M in 2023), not stability. The model fails to recognize that the evolution lies in transparency, not in the magnitude of exposure. (4) Despite these issues, the answer is contextually relevant — it addresses Cisco’s APJC financial exposure over the two fiscal years and attempts to use asset and segment data. However, due to key factual errors and incorrect synthesis, the correctness score is low. Quantitative accuracy is partially correct only for the 2023 asset figure ($5,382M), but the rest is unsupported. Qualitative accuracy suffers from incorrect assumptions and missing the core point about disclosure evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 493,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the strategic collaboration between LLY and Boehringer Ingelheim, specifically regarding Jardiance, evolved from 2022 to 2024 in response to regulatory changes?",
      "original_answer": "In 2022, Jardiance revenue was growing significantly, with a 30% increase in the U.S. and 28% outside the U.S., driven by increased demand and volume respectively. By 2024, the collaboration was significantly impacted by the Inflation Reduction Act (IRA), which introduced government-set pricing for certain drugs, including Jardiance. In August 2023, Jardiance was selected as one of the first ten medicines subject to government-set prices, and in August 2024, a 66% discount was applied compared to the 2023 U.S. list price, significantly affecting revenue projections and business strategy.",
      "llm_answer": "In the 2022 Form 10‑K Lilly reported that Jardiance – a product it co‑markets with Boehringer Ingelheim – generated about $1.5 billion of revenue and was described in Note 4 as a joint collaboration, with the newly enacted Inflation Reduction Act (IRA) only raising the prospect of future price‑setting (see 2022 p. 44‑45). By the 2024 filing the IRA’s pricing provisions had taken effect: the Department of Health and Human Services named Jardiance, the Lilly‑Boehringer partnership product, as one of the first ten drugs subject to Medicare‑set pricing and announced a 66 % discount for 2026, meaning the collaboration now must operate under government‑set price constraints that will erode revenue (see 2024 p. 45).",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the strategic collaboration between LLY and Boehringer Ingelheim on Jardiance and the impact of the Inflation Reduction Act (IRA). It accurately notes that in 2022, the IRA was only a future concern, while by 2024, government-set pricing had taken effect. However, there is a key discrepancy in timing: the original answer states that the 66% discount was applied in August 2024, whereas the LLM answer incorrectly states it will take effect in 2026. This is a significant factual error affecting quantitative and temporal accuracy. Additionally, while the $1.5 billion revenue figure for Jardiance in 2022 is plausible and consistent with public data, it is not mentioned in the original answer, which focuses on growth percentages (30% in U.S., 28% outside U.S.) rather than absolute revenue—making this an addition not grounded in the provided truth. (2) The 66% discount is correctly cited in magnitude but misaligned in timing (2026 vs. actual 2024 implementation), which undermines quantitative accuracy. The mention of revenue amount ($1.5B) is unsupported in the original answer, though not necessarily false. (3) The reasoning is otherwise sound: the LLM correctly traces the evolution from regulatory anticipation in 2022 to implementation in 2024, demonstrates multi-hop understanding across years and regulatory developments, and correctly identifies the entities and collaboration structure. (4) Despite the date error and unverified revenue figure, the core narrative of IRA’s impact on the collaboration is preserved, and the answer remains highly relevant and logically structured—justifying a high qualitative and contextual score. The correctness score is reduced to 8 due to the material timing inaccuracy in when the discount was applied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 491,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did GM's emphasis on the financial and reputational risks of product safety recalls evolve between 2022 and 2023, particularly concerning global platforms like the Chevrolet Bolt EV and the company's positioning in EV/AV technologies?",
      "original_answer": "In 2022, GM specifically highlighted the Chevrolet Bolt EV recall as an example of how global platform-related recalls could significantly increase costs due to their scale. The focus was on the financial burden and logistical complexity tied to such large-scale campaigns. By 2023, while the concern around global platforms remained, GM expanded its risk disclosure to emphasize the reputational damage to brand image and equity, particularly in relation to its leadership aspirations in EV and AV technologies. This evolution suggests a shift from a primarily cost-centric concern to a broader strategic risk tied to innovation and market positioning.",
      "llm_answer": "In the 2022 10‑K GM warned that product‑safety recalls—especially on a global platform—could generate sizable repair costs and erode brand equity, noting that safety concerns around advanced technologies such as EVs and AVs could hurt its ability to lead the industry. By the 2023 filing the company sharpened that warning, naming the Chevrolet Bolt EV recall as a concrete global‑platform example and stressing that such recalls threaten its reputation and its ambition to “lead the disruption” in the market through EV and autonomous‑vehicle technologies. This shift shows a move from a broad risk description to a more pointed focus on a specific EV platform and the strategic importance of its EV/AV leadership.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2022 focus on financial costs and brand equity, the 2023 emphasis on reputation and leadership in EV/AV technologies, and the use of the Chevrolet Bolt EV recall as a specific example in 2023. The evolution from broad to more strategic risk framing is correctly captured. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years, identifies the shift in GM's risk disclosure focus, and ties it to the Bolt EV recall and strategic positioning in EV/AV. The only minor shortcoming is that the original answer notes the 2022 filing already mentioned the Bolt EV recall, while the LLM implies it was first named in 2023. This is a slight inaccuracy in entity-year linkage, though the overall trend description remains valid. (4) The answer is contextually excellent—directly addresses the evolution in GM's risk emphasis, covers both financial and reputational aspects, and connects it to global platforms and innovation goals. The wording differs but the semantic meaning matches closely. Hence, a 9 on correctness and qualitative accuracy, with full marks for relevance and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 391,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the Guaranteed Senior Notes issued by Costco's Japanese subsidiary evolve between 2022 and 2024, and what does this indicate about the company's long-term financing strategy?",
      "original_answer": "In 2022, the Guaranteed Senior Notes issued by Costco's Japanese subsidiary were described in general terms, indicating only their existence and that they were valued using Level 3 inputs. By 2024, the company provided significantly more detailed information, disclosing that in November 2023, the subsidiary issued four new Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%, with maturities extending from 2033 to 2043. Additionally, in July 2024, the subsidiary repaid $77 of these notes. This evolution indicates a more transparent and strategic approach to long-term financing, with a focus on fixed-rate debt and extended maturities to manage future liquidity needs.",
      "llm_answer": "In the 2022 filing the Company’s “Other long‑term debt” – which is comprised of Guaranteed Senior Notes issued by Costco’s Japanese subsidiary – was $590 million【page_52】. By the 2024 filing the subsidiary had issued four new Guaranteed Senior Notes worth roughly $500 million in November 2023, repaid $77 million in July 2024, and the “Other long‑term debt” balance had risen to $919 million【page_52】. This increase indicates that Costco is increasingly using its Japanese subsidiary to raise low‑cost, long‑dated debt in Japan, diversifying its financing sources and extending the maturity profile of its long‑term capital structure.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, the 2022 filing only mentioned the existence of Guaranteed Senior Notes valued using Level 3 inputs, with no specific dollar amount provided. However, the LLM claims the 'Other long-term debt' was $590 million in 2022, which is not supported by the ground truth. Similarly, the 2024 balance of $919 million is not mentioned in the ground truth and appears to be fabricated or misattributed. While the $500 million issuance in November 2023 and the $77 million repayment in July 2024 are correctly reported, the overall quantitative picture is misleading due to unsupported figures. (2) The calculation of the net change in debt is implied but incorrect due to false baselines: adding $500M and subtracting $77M does not explain a rise from $590M to $919M, and the ground truth does not support these totals. (3) The reasoning is partially sound—using a Japanese subsidiary for long-term, fixed-rate financing in local markets aligns with the strategic interpretation in the ground truth. The LLM correctly infers a strategy of diversification and maturity extension. However, it fails to mention the key evolution in disclosure transparency (from minimal to detailed reporting), which is a central point in the original answer. (4) Despite missing the transparency angle and introducing false numbers, the LLM captures the core strategic implication about long-term financing, hence moderate scores on qualitative accuracy and a passing correctness score due to partial alignment on the $500M issuance and $77M repayment. Contextual relevance is high as the response stays focused on the question and attempts multi-hop synthesis across years and filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 479,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the value of Cisco's available-for-sale debt investments change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, Cisco reported gains from available-for-sale debt investments at $9 million, indicating a relatively minor role in their investment portfolio. By 2023, the total value of these investments dropped significantly from $15,592 million to $9,865 million, a decrease of $5,727 million. This indicates a strategic reduction in the company's holdings of available-for-sale debt instruments, suggesting a shift in investment focus or risk management approach.",
      "llm_answer": "Cisco’s available‑for‑sale debt investments rose from $11.9 billion at July 30, 2022 to $15.6 billion at July 29, 2023 – an increase of roughly $3.6 billion【page_50†L9-L13】【page_47†L9-L13】. The growth signals that Cisco is deliberately expanding its high‑quality, investment‑grade debt portfolio to generate additional interest income and preserve liquidity for its capital‑allocation strategy, including dividends, share repurchases and strategic acquisitions.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude. The ground truth states that Cisco's available-for-sale debt investments decreased from $15,592 million in 2022 to $9,865 million in 2023 — a drop of $5,727 million. The LLM claims an increase from $11.9 billion to $15.6 billion, which contradicts the actual data. Additionally, the LLM cites gains of $9 million in 2022 as context, but fails to mention the significant decline in investment value, instead asserting growth. (2) Number verification: $15,592M → $9,865M = $5,727M decrease (correct in ground truth); LLM reports $11.9B → $15.6B = $3.7B increase — all figures are incorrect. The dates cited (July 30, 2022 and July 29, 2023) may align with fiscal year-ends, but the values do not match the ground truth. (3) Multi-hop reasoning failed: the question requires comparing two years’ investment values and interpreting strategic implications. The LLM incorrectly infers expansion, while the truth indicates a strategic reduction. It also omits the mention of gains in 2022 being minor ($9M), which contextualizes the portfolio's role. (4) Correctness and quantitative accuracy are severely compromised due to wrong numbers and direction of change. Qualitative accuracy is low because the reasoning is based on false premises. Contextual relevance is slightly higher only because the answer addresses the general topic of investment strategy, albeit with incorrect conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 406,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has JPMorgan Chase's exposure to system damage risks evolved from 2023 to 2024, particularly in relation to third-party vendor attacks and data recovery challenges?",
      "original_answer": "In 2023, JPMorgan Chase highlighted risks related to system damage primarily through unauthorized access, zero-day vulnerabilities, and disruptions from distributed denial-of-service attacks. The company emphasized the risk of undetected vulnerabilities due to incomplete system enhancements and the potential for data loss or manipulation. By 2024, the exposure evolved to include more specific emphasis on ransomware attacks targeting third-party vendors and the risk of losses exceeding cyber insurance coverage. Additionally, JPMorgan Chase noted increased complexity in recovering from data theft or destruction, with a new concern around the inability to prevent systems from processing fraudulent transactions. These changes indicate a growing awareness of external cyber threats and their financial implications.",
      "llm_answer": "In the 2023 filing JPMorgan Chase warned that its operations could be seriously disrupted by cyber‑attacks—including attacks on third‑party vendors—and that “the inability, or extended delays in the ability, to fully recover and restore data that has been stolen, manipulated or destroyed” was a material risk (2023 pp. 23‑27). The 2024 filing repeats those exposures but adds a heightened focus on “enhancing early detection of attacks against third‑party vendors” and “upgrading coverage and capabilities … to recover from outages that could be caused by a malware or ransomware attack,” while again acknowledging that prolonged data‑recovery delays remain a significant concern (2024 pp. 25‑29).",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of factual content and context. (1) It accurately captures JPMorgan Chase's continued exposure to system damage risks from 2023 to 2024, particularly around third-party vendor attacks and data recovery challenges. The mention of 'inability or extended delays in... recover[ing] data' matches the 2023 risk description in the original answer. In 2024, the LLM correctly identifies an increased focus on early detection of third-party vendor attacks and improved recovery capabilities for ransomware/malware incidents, which reflects the evolving emphasis noted in the ground truth. (2) There are no numeric values, dates, or financial figures in the question or answers, so quantitative accuracy is not applicable—no errors here. (3) The multi-hop reasoning is sound: the model synthesizes information across two years and identifies both continuity and evolution in risk exposure. However, the LLM answer omits a key element from the original: the 2024 concern about losses potentially exceeding cyber insurance coverage and the new risk of systems processing fraudulent transactions due to undetected compromises. These are important nuances in the evolution of risk that are missing, slightly reducing completeness and qualitative accuracy. (4) Despite these omissions, the answer remains contextually relevant and factually accurate on the core points, warranting high scores in contextual relevance and overall correctness, though not perfect due to the missing details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 425,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "What operational investments has Costco made by 2024 to support the private-label growth strategy mentioned in its 2022 filing?",
      "original_answer": "In 2022, Costco emphasized increasing the penetration of its private-label items as a merchandising strategy to manage inflationary pressures and maintain competitive pricing. By 2024, Costco had made tangible operational investments to support this strategy, including the operation of various processing, packaging, and manufacturing facilities dedicated to the production of private-label items. These facilities, referenced in the 2024 filing, represent a significant evolution from the earlier strategic focus, demonstrating a shift from sourcing private-label products externally to building internal production capabilities to scale the initiative.",
      "llm_answer": "Costco’s 2022 filing notes that a key driver of growth is “increasing the penetration of our private‑label items” (2022 MD&A, p. 22). By 2024 the retailer has backed that strategy with major operational investments – it now operates 890 warehouses covering roughly 130.9 million sq ft of floor space (plus 31.9 million sq ft of distribution‑logistics facilities) and has added dedicated processing, packaging and manufacturing plants to produce its private‑label products (2024 Properties, p. 20).",
      "correctness_score": 9,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. It accurately captures the strategic intent from the 2022 filing—increasing private-label penetration—and correctly identifies that by 2024, Costco made operational investments in dedicated processing, packaging, and manufacturing facilities to support this strategy, which matches the core claim in the original answer. The qualitative reasoning and multi-hop synthesis across the 2022 strategy and 2024 operational execution are sound. However, the LLM introduces specific quantitative details—890 warehouses, 130.9 million sq ft of warehouse space, and 31.9 million sq ft of distribution-logistics facilities—that, while potentially accurate, are not present in the ground truth and are not directly tied to the private-label production facilities. These numbers may be contextually relevant to Costco’s overall operations but are not explicitly linked to the private-label strategy in the provided truth, making their inclusion potentially misleading or unsupported in this context. Thus, while the key operational investment (dedicated plants) is correctly identified, the additional quantitative details reduce the precision of the quantitative accuracy score. The answer remains semantically equivalent in intent and core factual content, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 375,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How did UnitedHealth Group's approach to Medicaid managed care contract bidding evolve between 2022 and 2023, particularly in terms of assumptions and risks associated with bid accuracy?",
      "original_answer": "In 2022, UnitedHealth Group emphasized the risk of losing Medicaid members if it failed to renew state Medicaid managed care contracts, highlighting the importance of contract renewals to retain enrolled members. By 2023, the company placed greater emphasis on the assumptions behind its bids, noting that if these assumptions—such as enrollment, utilization, and medical costs—were materially incorrect due to unforeseen program changes or competitor pricing, it could materially affect results of operations and cash flows. This reflects an evolution from a focus on contract renewal risk to a more detailed discussion of the assumptions and competitive dynamics involved in the bidding process itself.",
      "llm_answer": "In the 2022 filing UnitedHealth said its Medicaid‑managed‑care bids are built on assumptions about enrollment, utilization, medical‑cost trends and other factors, and that a material error in any of those assumptions—whether from unexpected program changes, policy shifts after the bid is filed or a competitor’s lower rate—could adversely affect earnings. The 2023 filing keeps the same reliance on those assumptions but adds a new, explicit risk: chronic failure to meet the benchmark premiums could lead to termination of the state contracts, underscoring a heightened focus on the consequences of bid inaccuracy.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy that affects the core of the multi-hop reasoning. (1) Correct elements: The mention of assumptions about enrollment, utilization, and medical-cost trends in 2022 is consistent with the original answer, as is the risk from unexpected program changes or competitor pricing. The contextual focus on bid accuracy and its impact on earnings is relevant. (2) Quantitative accuracy: There are no numeric values to verify, so this aspect is neutral; no errors in dates (2022 vs 2023) or entities (UnitedHealth Group, Medicaid managed care). (3) Multi-hop reasoning failure: The key flaw is the claim that the 2023 filing introduced a 'new, explicit risk' about 'chronic failure to meet benchmark premiums' leading to contract termination. This is not supported by the ground truth. Instead, the original answer states that the evolution was from emphasizing member retention via contract renewal (2022) to focusing more deeply on the accuracy of bid assumptions themselves (2023). The LLM misrepresents the nature of the evolution by introducing a specific contractual consequence (termination due to benchmark failure) that is not in the original. (4) The answer is contextually relevant and well-structured, but the qualitative inaccuracy in representing the shift in UnitedHealth’s disclosed risks undermines the correctness. The evolution is portrayed as a change in risk type (new termination risk), whereas the truth is a deepening of focus on bid assumption sensitivity. Thus, while some facts are correct, the synthesis is flawed, warranting a mid-range score of 5 for correctness and qualitative accuracy, full marks for quantitative accuracy (no numbers wrong), and high relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 477,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did MET's investment in Municipals evolve from 2022 to 2023, particularly in terms of its valuation hierarchy classification?",
      "original_answer": "In 2022, MET's investment in Municipals was valued at $14,212 million and primarily categorized under 'Estimated Fair Value' without a detailed breakdown of valuation hierarchy levels. By 2023, the investment in Municipals decreased to $159 million and was explicitly classified under 'Level 2' of the fair value hierarchy. This indicates a significant reduction in the size of the Municipals investment and a more transparent categorization within the fair value hierarchy in 2023.",
      "llm_answer": "MET’s municipal securities were recorded entirely in the Level 2 fair‑value hierarchy in both years. At December 31 2022 the company held $159 million of municipals in pension assets and $15 million in other post‑retirement assets (total ≈ $174 million) 【page_308】, and by December 31 2023 those amounts had slipped to $147 million and $8 million respectively (total ≈ $155 million), still classified as Level 2 with no Level 1 or Level 3 exposure【page_308】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, MET's investment in Municipals was $14,212 million in 2022, not approximately $174 million as stated in the LLM answer. The 2023 value is reported as $159 million in the ground truth, while the LLM reports approximately $155 million—both figures are close but still inconsistent, and more importantly, the direction of change is wrong: the ground truth shows a massive decrease from $14,212M to $159M, whereas the LLM implies only a small decline from $174M to $155M. (2) The LLM incorrectly states that municipal investments were classified under Level 2 in both years. The ground truth explicitly says that in 2022, the valuation was under 'Estimated Fair Value' without a detailed hierarchy breakdown—meaning no explicit Level 2 classification existed then. The shift to Level 2 in 2023 is a key point missed by the LLM, which instead claims consistent Level 2 classification across both years. (3) The multi-hop reasoning is flawed: the question asks about evolution in valuation hierarchy classification and size, requiring synthesis of changes in both amount and categorization. The LLM fails to recognize the shift from non-specific fair value to explicit Level 2, misrepresents the magnitude of the investment, and introduces a breakdown into pension and other post-retirement assets not mentioned in the original answer or relevant to the question. (4) While the LLM attempts to address the topic and references a page for support, the core numbers and classification logic are incorrect, leading to a low correctness score. Contextual relevance is moderate because it discusses the right company and general topic, but the substance is factually unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 480,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has Microsoft's approach to Office 365 subscriptions evolved in terms of licensing flexibility and customer agreement models from fiscal year 2022 to 2024?",
      "original_answer": "In fiscal year 2022, Office 365 subscriptions were primarily managed under volume licensing programs and were recognized as part of unearned revenue, invoiced annually at the beginning of each contract period and recognized ratably over the coverage period. By fiscal year 2024, Microsoft introduced more structured and flexible customer agreement models, including the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products and Services Agreement, which allowed customers to subscribe to cloud services seamlessly and directly, with options for monthly or annual subscriptions and no organization-wide commitment. This represents a shift toward enhanced customer-centric licensing flexibility.",
      "llm_answer": "In FY 2022, Office 365 subscriptions were treated as a single integrated cloud service that was invoiced at the start of each annual term and recognized ratably over the subscription period (2022 10‑K p. 64‑63). By FY 2024, Microsoft expanded the licensing framework, offering Office 365 (now part of Microsoft 365) through a suite of more flexible, digital agreements—including Enterprise Agreements, Microsoft Customer Agreements, Microsoft Online Subscription Agreements and Microsoft Products & Services Agreements—that let customers subscribe on a month‑or‑year basis, use non‑expiring contracts and optionally add Software Assurance, providing greater licensing flexibility (2024 10‑K p. 16‑17).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in FY 2022, Office 365 subscriptions were invoiced annually and recognized ratably, consistent with the original answer and supported by the cited 2022 10-K pages (note: page order '64-63' is a minor typo but does not affect accuracy). By FY 2024, Microsoft introduced more flexible agreement models, including the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products & Services Agreement, allowing monthly or annual subscriptions without organization-wide commitments. The LLM correctly identifies this shift toward customer-centric licensing. (2) Quantitative accuracy is perfect: fiscal years 2022 and 2024 are correctly referenced, and there are no numerical errors. Citation of 2024 10-K pages 16–17 is accurate. (3) Multi-hop reasoning is sound—information is synthesized across two fiscal years and multiple agreement types, demonstrating evolution in licensing models. The mention of 'non-expiring contracts' and 'Software Assurance' adds detail not in the original answer but is factually correct and enhances completeness without introducing error. (4) Semantic equivalence is strong; the core message about increased licensing flexibility and shift in customer agreement models is preserved. The only minor shortcoming is the inclusion of 'Enterprise Agreements' as part of the 2024 model, which is not mentioned in the ground truth and could imply continuity rather than evolution—potentially slightly overstating continuity of older models. However, this does not materially misrepresent the overall trend. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 488,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the composition of MET's Level 3 Fixed Maturity Securities AFS change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, MET's Level 3 Fixed Maturity Securities AFS included $1 million in Corporate bonds, $1 million in Foreign Bonds, and $11 million in Equity Securities. By 2023, the Level 3 composition shifted significantly, with $54 million in Corporate bonds, $2 million in Foreign Bonds, and $828 million in Other Investments. This indicates a strategic shift toward increasing exposure in Other Investments while maintaining a relatively small position in Level 3 fixed maturity securities overall. The significant increase in Other Investments within Level 3 suggests a more aggressive approach to portfolio diversification or risk management.",
      "llm_answer": "In 2022 the Level 3 slice of MetLife’s Fixed‑Maturity Securities AFS was $58 million, made up almost entirely of corporate securities ($55 m) with a tiny “other” component ($3 m) 【page_308】. By year‑end 2023 the Level 3 balance had risen to $64 million and the mix had broadened to $54 m of corporate securities, $2 m of foreign‑bond holdings and $8 m of other securities 【page_308】. The modest increase and the addition of foreign‑bond and other illiquid assets indicate the company is gently diversifying its Level 3 exposure, seeking a bit more yield from less‑transparent securities while still keeping corporate holdings as the core.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, MET's Level 3 Fixed Maturity Securities AFS included $1M in Corporate bonds, $1M in Foreign Bonds, and $11M in Equity Securities (totaling $13M), not $58M as claimed. The LLM incorrectly states a $55M corporate securities component and $3M 'other' in 2022, which contradicts the ground truth. In 2023, the ground truth reports $54M in Corporate bonds, $2M in Foreign Bonds, and $828M in Other Investments (totaling $884M), whereas the LLM reports only $8M in 'other securities'—a massive understatement. The LLM's total Level 3 amounts ($58M in 2022, $64M in 2023) are completely incorrect and misrepresent the scale of the portfolio, especially the surge in Other Investments. (2) Calculations and values are fundamentally wrong: the LLM omits the $828M 'Other Investments' in 2023, instead reporting $8M, and mischaracterizes Equity Securities as 'other' or 'corporate securities'. The shift from $11M Equity to $828M Other Investments is a critical strategic move that the LLM fails to capture. (3) Multi-hop reasoning is flawed: the LLM concludes a 'gentle diversification' and 'modest increase', but the ground truth indicates a dramatic strategic shift toward high-risk, high-diversification 'Other Investments', suggesting a more aggressive strategy. The LLM fails to recognize the replacement of Equity Securities with a massive 'Other Investments' position. (4) Despite incorrect numbers and reasoning, the answer is contextually relevant—it attempts to describe composition changes and infer strategy. However, due to severe quantitative and qualitative errors, the conclusion is misleading. The correctness score is low due to major factual and numerical discrepancies that undermine the entire analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 495,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How has Microsoft's strategic positioning of Office 365 evolved between 2022 and 2024, particularly in terms of its role within the broader cloud services portfolio and its response to competitive pressures from AI-driven offerings?",
      "original_answer": "In 2022, Office 365 was explicitly listed as a key component of Microsoft's service and other revenue, positioned alongside Azure, Dynamics 365, and Xbox as a core cloud-based solution. By 2024, Office 365 had evolved into a more integrated part of Microsoft’s broader AI-infused cloud services portfolio, reflecting the company's strategic shift to infuse generative AI capabilities into commercial offerings. The 2024 filing notes that Microsoft is devoting significant resources to develop and deploy AI models, platforms, and infrastructure to meet customer needs, indicating that Office 365 is now part of this AI-enhanced competitive strategy. This shift was driven by increasing competitive pressures from companies entering the AI market and offering alternative models such as free applications funded by advertising or open-source AI models, which Microsoft must counter with enhanced, integrated cloud experiences.",
      "llm_answer": "In the 2022 Form 10‑K Microsoft presented Office 365 as a core subscription‑based cloud offering, grouped with Azure, Dynamics 365 and Xbox in its “service and other revenue” line (see Service and other revenue includes Office 365 – page 62) and treated it as a single, highly integrated performance obligation whose revenue is recognized ratably over the contract period (see Office 365 revenue recognition – page 63; Office 365 subscriptions listed in unearned revenue – page 64). By the 2024 filing the company positions Office 365 as a mature pillar of its broader cloud ecosystem that is now being infused with generative‑AI capabilities to meet rising AI‑driven competition, emphasizing company‑wide AI investment and the need to embed AI into cloud products such as Office 365 (see transformation from on‑premises to Office 365 – page 19; AI infusion across cloud offerings and competitive pressures – page 21).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual information is correct: Office 365 was indeed positioned in 2022 as part of Microsoft's 'service and other revenue' alongside Azure, Dynamics 365, and Xbox, and the revenue recognition details (ratable recognition, unearned revenue) are accurately described. By 2024, the strategic shift toward AI integration is correctly identified, with Office 365 being infused with generative AI as part of a broader cloud ecosystem. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable beyond correct referencing of page numbers and years—both of which are accurate and consistent with the source structure. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years (2022 to 2024), identifies the evolution in strategic positioning, and links it to competitive pressures from AI-driven offerings, including the mention of AI infusion and competitive response. (4) The only minor shortcoming is that the LLM does not explicitly name the competitive alternatives mentioned in the ground truth (e.g., free applications funded by advertising or open-source AI models), though it does reference 'rising AI-driven competition' and 'competitive pressures,' which captures the essence. This slight omission prevents a perfect 10 on qualitative accuracy. Overall, the answer is semantically equivalent, contextually precise, and factually robust.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1482,
        "completion_tokens": 417,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did UnitedHealth Group's recognition and handling of credit-related impairments evolve between 2022 and 2023, particularly in terms of their evaluation methodology and financial impact?",
      "original_answer": "In 2022, UnitedHealth Group evaluated available-for-sale debt securities for credit-related impairments by analyzing expected cash flows, underlying credit quality, and credit ratings of issuers, concluding that there was no significant credit deterioration since purchase and that unrealized losses were primarily due to interest rate increases. The allowance for credit losses was not material. By 2023, the company formalized its impairment recognition process by distinguishing between credit-related and non-credit-related impairments, recording credit-related impairments as an allowance against investment income and non-credit-related impairments through other comprehensive income. Additionally, the company emphasized a more structured evaluation framework that includes present value of expected cash flows, the extent of fair value decline relative to amortized cost, and issuer-specific financial conditions. This reflects a more detailed and segmented approach to impairment recognition and financial reporting.",
      "llm_answer": "In the 2022 filing UnitedHealth said it only tested available‑for‑sale debt securities for credit‑related impairment when fair value was below amortized cost, looking at the expected cash‑flows, the issuers’ credit quality and ratings, and noted that the allowance for credit losses was “not material”【page_57】. By the 2023 filing the company had broadened the assessment – it now considers the present value of expected cash‑flows relative to amortized cost, the size of the fair‑value shortfall, the issuer’s financial condition, near‑term prospects and any specific events, and records any impairment as an allowance offset to investment and other income, still without a material credit‑loss allowance disclosed【page_47】. This reflects a more detailed, forward‑looking evaluation while the financial impact remained negligible.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution in UnitedHealth Group's impairment evaluation methodology between 2022 and 2023. In 2022, the company assessed credit-related impairments only when fair value was below amortized cost, focusing on expected cash flows, credit quality, and ratings, and concluded the allowance was not material—this aligns with the ground truth. In 2023, the LLM accurately notes a more structured approach, including present value of expected cash flows, extent of fair value decline, issuer financial condition, and near-term prospects. It correctly states that impairments are recorded as an allowance against investment income and that the allowance remained not material. The only minor omission is the explicit distinction between credit-related and non-credit-related impairments being recorded through different financial statements (allowance vs. other comprehensive income), which is mentioned in the original but only partially reflected in the LLM answer. (2) There are no numerical values to verify, but all qualitative financial impacts (e.g., 'not material') are correctly reported. (3) The multi-hop reasoning is sound—comparing methodology changes across two years and synthesizing disclosures from different filings. The LLM correctly infers a more forward-looking, detailed framework in 2023. (4) The answer is highly factually accurate, contextually complete, and semantically equivalent to the ground truth, with only a slight gap in fully articulating the accounting treatment segmentation, warranting a 9/10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1474,
        "completion_tokens": 443,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did the allocation and valuation of Fixed Maturity Securities AFS in MET's pension and other postretirement benefit plans evolve from 2022 to 2023?",
      "original_answer": "In 2022, Fixed Maturity Securities AFS accounted for 84% of U.S. Pension Benefits and 95% of U.S. Other Postretirement Benefits. By 2023, the total estimated fair value of Fixed Maturity Securities AFS was $6,714 million for Pension Benefits and $1,274 million for Other Postretirement Benefits. This indicates a shift from a primarily percentage-based allocation in 2022 to a more detailed valuation breakdown in 2023, showing both the scale and composition of MET's holdings.",
      "llm_answer": "In 2023 the pension plan’s Fixed‑Maturity Securities AFS made up about 82 % of its assets (the 2023 target was 85 %) versus a 2022 target of 83 % (the 2022 actual allocation was not disclosed), and the other‑post‑retirement plan’s allocation slipped to 94 % from 96 % in 2022 (both years’ targets were 95 %)【page_307】.  At year‑end the fair‑value of these securities fell slightly in the pension plan from $6.802 billion in 2022 to $6.714 billion in 2023, while the other‑post‑retirement plan’s balance rose from $1.256 billion to $1.274 billion over the same period【page_308】.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes mostly correct information but introduces details not present in the ground truth, particularly regarding 'target' allocations (e.g., 2022 target of 83%, 2023 target of 85%) which are absent from the original answer and not requested in the question. The actual 2022 allocations in the original answer are explicitly stated (84% for U.S. Pension, 95% for Other Postretirement), but the LLM claims the 2022 actual allocation was 'not disclosed', which contradicts the ground truth. This is a significant factual discrepancy. (2) Quantitatively, the LLM correctly reports the 2023 fair values: $6.714 billion (Pension) and $1.274 billion (Other Postretirement), matching the original. However, it incorrectly states the 2022 Pension fair value as $6.802 billion and Other Postretirement as $1.256 billion — these specific numbers are not in the ground truth, which only provides percentages for 2022, not dollar amounts. Thus, the LLM fabricates 2022 valuation figures unsupported by the original answer. (3) The multi-hop reasoning is partially sound — it attempts to compare 2022 and 2023 allocations and valuations — but fails because it substitutes actual disclosed percentages with unverified targets and invents dollar figures for 2022. The original answer emphasizes a shift from percentage-based reporting in 2022 to valuation-based disclosure in 2023, which the LLM does not acknowledge, instead treating both years as having comparable valuation data. (4) Despite these issues, the LLM captures the general trend: a slight decrease in Pension allocation and a small increase in Other Postretirement value. The contextual relevance is high as it directly addresses the evolution of allocation and valuation. Due to incorrect 2022 dollar figures and misrepresentation of disclosed data, the quantitative accuracy is reduced to 7, and overall correctness is 7 due to partial factual accuracy with notable errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 528,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Lowe's strategic positioning of the Kitchens & Bath product category evolve between 2022 and 2023, and what does this suggest about its relative importance in the company's product portfolio?",
      "original_answer": "In 2022, Kitchens & Bath was grouped under the Home Décor division alongside categories like Appliances, Décor, Flooring, and Paint, suggesting a more design-focused positioning. By 2023, Kitchens & Bath was listed among core construction and renovation categories such as Lumber, Building Materials, and Rough Plumbing, indicating a strategic repositioning toward home improvement and remodeling. This shift suggests that Lowe's placed greater strategic emphasis on Kitchens & Bath as a key growth area tied to higher-value home projects, aligning with its broader 'Total Home' strategy.",
      "llm_answer": "In the 2022 filing, Kitchens & Bath was only referenced as one of the sub‑categories bundled inside the “Home Décor” segment, which together represented about 35 % of total net sales. By the 2023 filing, Lowe’s lists Kitchens & Bath as a standalone product line in its assortment and ties it to dedicated installation services and protection‑plan offerings, highlighting it as a distinct, high‑visibility category. This evolution shows the company has moved the category from a broad, aggregated segment to a strategically emphasized pillar of its product portfolio.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the strategic repositioning of Kitchens & Bath from being part of the Home Décor segment in 2022 to a more prominent, standalone category in 2023, which aligns with the ground truth. It accurately captures the shift in strategic emphasis and ties it to Lowe's broader product portfolio evolution. However, the 35% figure for Home Décor's share of total net sales is not present in the original answer (ground truth), making this a factual addition not supported by the provided knowledge graph. This affects quantitative accuracy, as the percentage is specific and unverified in the source. While the LLM correctly infers increased strategic importance and mentions installation services and protection plans (contextually plausible), these details are not in the ground truth and slightly extend beyond the provided evidence. The reasoning is sound and the multi-hop synthesis—comparing category grouping across years—is well executed. The answer addresses both parts of the question: evolution between 2022 and 2023, and implications for strategic importance. Despite minor overreach in unsupported specifics, the core facts and interpretation are consistent with the original answer, warranting a high correctness score with a deduction for the unverified percentage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 362,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Mondelez International's strategic focus on Cheese & Grocery evolved between 2022 and 2024, and what does this suggest about its prioritization of snack categories for long-term growth?",
      "original_answer": "In 2022, Mondelez directly produced Cheese & Grocery products, generating $1,990 million in total net revenues from this category. By 2024, the company no longer reported direct production in this category and instead indicated only a strategic stake in Cheese & Grocery, positioning it as an adjacent category within its broader snacking portfolio. This shift suggests a refocusing on core snack categories like biscuits and chocolate, while maintaining a presence in Cheese & Grocery through a lighter footprint. The change aligns with Mondelez's stated strategy of prioritizing long-term growth in core snacking segments and managing costs amid inflationary pressures.",
      "llm_answer": "In the 2022 filing (pages 127‑131 contain no discussion of cheese & grocery, indicating it was not highlighted as a strategic focus), the segment was not emphasized. By the 2024 filing the Business overview explicitly lists cheese & grocery as an “adjacent, locally relevant” category alongside its core chocolate, biscuits and baked‑snack businesses [page_34]. This suggests that cheese & grocery remains a peripheral part of the portfolio, while Mondelez continues to prioritize its core snack categories as the primary engine for long‑term growth.",
      "correctness_score": 5,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct in describing the shift in strategic focus on Cheese & Grocery from 2022 to 2024, noting that it was not emphasized in 2022 and was labeled as an 'adjacent, locally relevant' category in 2024. However, it completely omits the key quantitative information from the ground truth—specifically, that Mondelez generated $1,990 million in net revenues from Cheese & Grocery in 2022 and that by 2024 it no longer reported direct production in the category. This omission severely undermines the answer's completeness and factual accuracy. (2) The quantitative accuracy is very low because the answer fails to mention any financial figures, despite the ground truth including a precise revenue number ($1,990 million), which is central to assessing the scale and strategic importance of the category. The absence of this data point means the user cannot assess the significance of the shift. (3) The reasoning is sound in interpreting the change in language between filings and correctly infers that core snacks remain the growth priority. It correctly identifies the multi-hop element—comparing strategic emphasis across years—and draws a reasonable conclusion about prioritization. However, it does not fully synthesize the operational change (from direct production to strategic stake), which is a key factual shift. (4) Contextual relevance is high because the answer addresses the evolution of strategic focus and links it to long-term growth priorities, directly responding to the question’s intent. Despite missing critical data, the qualitative interpretation aligns with the ground truth. The main failure is the lack of numerical and operational specifics needed for a fully accurate response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 475,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Abbott's presentation of its enteral feeding product lineup, specifically the positioning of Jevity relative to Freego™ products, change between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, Jevity was listed first among enteral feeding products, followed by Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite®, Oxepa®, Freego™ (Enteral Pump), and Freego™ sets. In the 2023 filing, Jevity remained listed first, but the Freego™ (Enteral Pump) and Freego™ sets were now mentioned immediately after Jevity, before the Glucerna and Osmolite® product lines. This change in listing order suggests a shift in product emphasis within the enteral feeding category, with Freego™ products receiving more prominent placement alongside Jevity in 2023 compared to 2022.",
      "llm_answer": "In the 2022 10‑K (page 4) Abbott’s enteral‑feeding list reads “Jevity … Freego™ (Enteral Pump) and Freego™ sets …,” and the 2023 10‑K (page 4) repeats the same sequence, still placing Jevity before the Freego™ products. Thus, the relative positioning of Jevity versus Freego™ was unchanged between the two filings.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that the relative positioning of Jevity and Freego™ products was unchanged between the 2022 and 2023 10-K filings. The ground truth shows a clear reordering: in 2022, Jevity was listed first, but Freego™ (Enteral Pump) and Freego™ sets appeared at the end of the enteral product list, after Glucerna and Osmolite®. In 2023, Freego™ products were moved immediately after Jevity, before Glucerna and Osmolite®, indicating a more prominent positioning. The LLM incorrectly states that the sequence is the same in both years, which contradicts the documented change. While the entities (Jevity, Freego™, Abbott, 10-K filings) and years are correctly identified, and there are no numerical inaccuracies (hence high quantitative accuracy), the reasoning is flawed. The model failed to detect the multi-hop change in product listing order, which is central to the question. This represents a failure in qualitative accuracy and synthesis across the two filings. The answer is contextually relevant (it addresses the right documents and products) but draws an incorrect conclusion, severely limiting its usefulness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 327,
        "total_tokens": 1561
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MET's investment in municipals evolve from 2022 to 2023 in terms of fair value and classification, and what does this suggest about the company's credit risk management strategy?",
      "original_answer": "In 2022, MET held $14,212 million in municipals, classified under the 'fixed maturity securities AFS' category, with a fair value that included $2,464 million in gross unrealized gains and only $13 million in gross unrealized losses. By 2023, this investment had significantly declined to just $159 million, now categorized under the 'fixed maturity securities AFS' and classified entirely within Level 2 of the fair value hierarchy, indicating a shift in MET's positioning. This dramatic reduction suggests a strategic move to reduce credit exposure to municipals, likely as part of a broader risk management adjustment to limit potential losses in this asset class.",
      "llm_answer": "In the 2022 filing MetLife reported municipal securities of $174 million in fair value – $159 million held in its U.S. pension‑benefit plans and $15 million in other post‑retirement plans – and all of these were measured at **Level 2** in the fair‑value hierarchy (observable market inputs). By year‑end 2023 the municipal holdings had fallen to $155 million ($147 million in pension assets and $8 million in other post‑retirement assets), still classified entirely as **Level 2** (page 308). The modest decline in exposure, together with the continued use of Level 2 valuation, indicates that MetLife is deliberately trimming its municipal‑bond position while keeping it in a transparent, market‑observable category, reflecting a cautious credit‑risk management approach that favors lower‑risk, well‑priced assets.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, MET held $14,212 million in municipals in 2022, not $174 million as stated by the LLM. The LLM incorrectly reports 2022 municipal holdings as $174 million (split between pension and other plans), while the correct total is over 80 times larger at $14,212 million. The 2023 value is reported as $155 million by the LLM versus the correct $159 million—close but still inaccurate. More critically, the LLM fails to mention the massive reduction from $14,212M to $159M, which is central to the strategic interpretation in the original answer. (2) The LLM misrepresents the classification: it claims all municipals were Level 2 in 2022, but the ground truth does not specify hierarchy levels for 2022—only that in 2023 they were entirely Level 2. The LLM also introduces a breakdown by pension and post-retirement plans not present in the original answer, which may reflect confusion with a different part of the filing. (3) The reasoning is flawed due to incorrect data: describing a 'modest decline' is completely inaccurate when the actual decline is a 99% reduction. This undermines the entire analysis of credit risk strategy. The original answer correctly infers a strategic de-risking move; the LLM’s conclusion of a 'cautious trimming' is inconsistent with the scale of divestment. (4) Contextual relevance is moderate—the LLM addresses fair value, classification, and risk strategy as asked—but due to severe quantitative errors and mischaracterization of the data, the qualitative and correctness scores are very low. Semantic equivalence fails on core facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 455,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2022 and 2023, particularly in terms of their notional value and the impact on fixed-rate debt management?",
      "original_answer": "In 2022, Abbott had interest rate hedge contracts totaling approximately $2.2 billion, which were used to manage exposure to changes in the fair value of fixed-rate debt by converting fixed-rate obligations into variable-rate obligations. By 2023, Abbott continued to use these contracts for the same purpose, and the notional value remained consistent at approximately $2.2 billion. However, in 2023, the company provided more detailed disclosures about the impact of these contracts on the carrying value of fixed-rate debt, indicating a more refined approach to interest rate risk management.",
      "llm_answer": "Abbott’s portfolio of interest‑rate hedge contracts fell from roughly $2.9 billion at the end of 2022 to about $2.2 billion in 2023 after $700 million of contracts (and the underlying debt) matured in 2023 【page_65】.  The fair‑value liability for those hedges also declined, from $156 million in 2022 to $95 million in 2023 【page_66】, and the contracts remain designated as fair‑value hedges that offset changes in the fair value of the fixed‑rate debt, effectively converting that portion of the debt to a variable‑rate exposure 【page_64】.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative details. According to the ground truth, Abbott's notional value of interest rate hedge contracts was approximately $2.2 billion in both 2022 and 2023, with no change in notional amount. However, the LLM claims the portfolio fell from $2.9 billion in 2022 to $2.2 billion in 2023, which contradicts the ground truth. This error affects the core of the question about the evolution of notional value. The LLM also introduces specific figures for fair-value liability ($156M in 2022, $95M in 2023) and mentions $700M of contracts maturing, none of which are present in the original answer and cannot be verified against the ground truth. (2) While the final notional value in 2023 ($2.2 billion) matches, the starting point (2022) is incorrect in the LLM answer. The calculation of a $700M reduction from $2.9B to $2.2B is numerically correct but based on false premises. The ground truth states the notional value remained consistent, so there should be no reduction. (3) The qualitative reasoning about the purpose of the hedges—converting fixed-rate debt to variable-rate exposure via fair-value hedges—is accurate and aligns with the original answer. The LLM correctly identifies the ongoing use and designation of the contracts. However, it fails to mention the key qualitative evolution noted in the ground truth: that Abbott provided more detailed disclosures in 2023, indicating a more refined risk management approach. This omission weakens the multi-hop synthesis required to assess 'evolution' beyond just notional value. (4) Despite correct terminology and contextual relevance to debt management, the major numerical error in the 2022 notional amount and the unsupported claim of a decline reduce the correctness score significantly. The answer is partially right on purpose and 2023 value but wrong on trend and magnitude of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 522,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did 3M's issuance and management of fixed rate registered notes evolve between 2022 and 2024, particularly in terms of repayment activity and interest rate strategies?",
      "original_answer": "In 2022, 3M had a significant amount of fixed rate registered notes, including $600 million of 10-year notes due 2030 with a coupon rate of 3.05%, and $650 million of 30-year notes due 2050 with a coupon rate of 3.70%. The company also issued $3.25 billion in fixed rate registered notes in August 2019, including $1.0 billion of 10-year notes due 2029 and $1.0 billion of 30-year notes due 2049. In 2024, 3M repaid $1.1 billion in medium-term notes that matured, and in 2023, it repaid $500 million in fixed-rate registered notes. Additionally, interest rate swaps initiated in 2021 converted portions of the fixed-rate notes due 2049 and 2050 into floating-rate debt through mid-2028, indicating a strategic shift toward managing interest rate exposure. This shows a decrease in the amount of fixed-rate debt outstanding and a shift toward floating-rate instruments through swaps.",
      "llm_answer": "Between 2022 and 2024 3M moved from holding a portfolio of fixed‑rate registered notes with coupons of roughly 1.86 %‑2.67 % (including a $1 bn 2.50 % issue due 2029) to actively retiring its maturing fixed‑rate securities – it repaid €500 m and $600 m of medium‑term notes in 2022, retired $500 m of fixed‑rate registered notes in 2023, and in 2024 repaid $1.1 bn of medium‑term notes that matured (see page 69). At the same time the company continued to issue new fixed‑rate notes at modest rates (≈2.0 %‑2.7 % for 2025‑2029 issues) while the weighted effective rate on its fixed‑rate debt rose to about 3.07 % from 2.80 % (pages 68 & 88) and it used interest‑rate swaps to convert portions of long‑dated fixed‑rate debt into floating‑rate exposure (pages 89 & 69).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and dates, particularly regarding the coupon rates and issuance details of 3M's fixed-rate notes. The ground truth states that in 2022, 3M had $600M of 10-year notes due 2030 at 3.05% and $650M of 30-year notes due 2050 at 3.70%, and had issued $3.25B in 2019 including $1B due 2029 and $1B due 2049. The LLM incorrectly claims coupon rates of 1.86%-2.67%, citing a $1B 2.50% note due 2029, which does not match the original data. Additionally, the LLM mentions repayment of €500M and $600M in 2022, but the ground truth states no such repayments occurred in 2022; instead, $500M in fixed-rate notes were repaid in 2023 and $1.1B in medium-term notes in 2024. The LLM incorrectly attributes 2022 repayments that are not in the original answer. (2) The quantitative inaccuracies are severe: wrong principal amounts (e.g., €500M not mentioned in truth), incorrect timing of repayments, and fabricated coupon rates. The claim that the weighted effective rate rose from 2.80% to 3.07% is unsupported by the ground truth, which does not provide such figures. The LLM also claims new issuances in the 2.0%-2.7% range for 2025-2029, but the ground truth does not mention any new issuances between 2022 and 2024. (3) The qualitative reasoning partially captures the strategic use of interest rate swaps to convert fixed-rate debt (due 2049 and 2050) into floating-rate through mid-2028, which aligns with the ground truth. This shows correct multi-hop synthesis of the swap strategy. However, the conclusion that 3M continued issuing new fixed-rate notes is contradicted by the original answer, which only references past issuances and recent repayments, indicating a reduction in fixed-rate debt. (4) The contextual relevance is high because the answer addresses repayment activity and interest rate strategies as asked. However, due to major quantitative errors and incorrect assertions about new issuances and repayment timing, the correctness score is low. The qualitative accuracy is moderate due to correct identification of swap usage but flawed overall narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 575,
        "total_tokens": 1993
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has the role of securities issuances in Schwab's capital structure evolved between 2023 and 2024, particularly in relation to its overall funding sources and capital management strategy?",
      "original_answer": "In 2023, securities issuances by CSC were identified as a primary source of capital, directly supporting the company's capital management strategy, which included balance sheet growth and financial support to subsidiaries. By 2024, while still listed as one of several funding sources, securities issuances were positioned among a broader set of liquidity tools, including FHLB borrowings, repurchase agreements, and CDs, indicating a more diversified funding approach. This shift suggests a strategic evolution where securities issuances remain important but are more integrated within a wider capital structure framework.",
      "llm_answer": "In 2023 Schwab said that “the Company’s primary sources of capital are funds generated by the operations of subsidiaries **and securities issuances by CSC in the capital markets**” and that it would also use commercial‑paper or other capital‑markets issuances to support margin‑loan growth and meet regulatory capital needs (2023 p. 59; 2023 p. 57). By 2024 the discussion pivots to client‑generated cash and deposits as the main funding source, with a deliberate reduction of supplemental funding (e.g., brokered CDs, FHLB borrowings) and active hedging of existing senior notes rather than issuing new debt, while still retaining a shelf‑registration that allows securities issuances when needed (2024 p. 52‑54). Thus, securities issuances moved from a core component of Schwab’s capital structure in 2023 to a more ancillary, liquidity‑management tool in 2024, reflecting a shift toward internal cash generation and lower‑cost funding within its capital‑management strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2023, securities issuances by CSC were a primary source of capital, citing specific page references and linking them to capital management objectives like supporting margin loans and regulatory capital. In 2024, it accurately notes a strategic pivot toward client-generated deposits and cash as the main funding source, with reduced reliance on external tools like FHLB borrowings and brokered CDs. The shelf registration detail correctly reflects that securities issuances remain available but are no longer emphasized. (2) There are no numerical values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—no errors in dates or financial figures. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, compares shifts in funding strategy, and infers a strategic evolution from external issuances to internal funding. The conclusion that securities issuances moved from 'core' to 'ancillary' is a slightly stronger characterization than the original answer’s 'more integrated within a wider framework,' but it is still a reasonable interpretation given the reduced emphasis. (4) The answer is fully contextually relevant, directly addressing the evolution in capital structure and funding sources. Minor deduction in qualitative accuracy due to slightly more assertive framing of the shift (e.g., 'ancillary' vs. 'among several'), but overall factual and conceptual alignment is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 430,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did Coca-Cola's contingent payment obligations related to fairlife evolve from 2022 to 2024, and what does this indicate about fairlife's performance against its financial targets?",
      "original_answer": "In 2022, Coca-Cola disclosed that it had a $270 million liability for contingent milestone payments related to its acquisition of fairlife, based on fairlife achieving certain financial targets through 2024. The company also noted that the first milestone payment of $100 million was made in 2021 after fairlife met its 2020 targets. By 2024, the remaining contingent payment was described as a milestone payment contingent on fairlife achieving certain financial targets through 2024 and was payable in 2025. This indicates that fairlife had met at least one set of financial targets (2020), triggering the initial $100 million payment, and that the company remained on track to potentially meet the remaining targets through 2024, as the obligation was still active and had not been rescinded or adjusted downward.",
      "llm_answer": "In the 2022 Form 10‑K Coca‑Cola reported a $270 million contingent‑consideration liability for fairlife (and noted that a $100 million milestone was paid in 2021) that is payable only if fairlife meets its 2024‑targeted financial goals. By the 2024 filing that liability had ballooned to $3.0 billion at year‑end 2023 and $6.1 billion at year‑end 2024, with a $275 million milestone paid in 2023, showing that fairlife’s operating results have kept the milestone payment on track (and even increased its fair‑value estimate), indicating that fairlife is meeting or exceeding the financial targets that trigger the contingent payments.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, Coca-Cola had a $270 million contingent liability in 2022 related to fairlife's financial targets through 2024, with a $100 million payment already made in 2021. The LLM incorrectly states that the liability 'ballooned' to $3.0 billion by year-end 2023 and $6.1 billion by year-end 2024, which is not supported by the original answer or known filings. Additionally, the LLM claims a $275 million milestone was paid in 2023, which is false—the original answer only confirms the $100 million payment in 2021 and no further payments. (2) Quantitative accuracy is extremely low: all key numbers ($3.0B, $6.1B, $275M payment in 2023) are fabricated or grossly incorrect. The only correct figures are the $270M liability in 2022 and the $100M payment in 2021. (3) The multi-hop reasoning is fundamentally flawed. The original answer indicates the $270M obligation remained active through 2024, suggesting fairlife was on track, but does not suggest any increase in liability. The LLM incorrectly infers growing liabilities as evidence of outperformance, which contradicts standard accounting for contingent consideration (where increases could reflect revised estimates but not necessarily 'exceeding' targets). (4) Contextual relevance is low because the answer invents financial data and misrepresents the evolution of the obligation. The conclusion about performance is based on false premises. The only relevant elements are the correct mention of the $270M liability and the 2021 payment, but the rest of the response is misleading and factually wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 451,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Infrastructure (OCI) evolved between 2022 and 2024, particularly in terms of its global market positioning and integration with enterprise IT solutions?",
      "original_answer": "In 2022, Oracle's financial disclosures emphasized revenue contributions from cloud and license businesses, which generated $36.052 billion, representing 85% of total revenues, with no explicit strategic language about Oracle Cloud Infrastructure's positioning. By 2024, Oracle significantly elevated OCI's role, describing it as a core component of Oracle Cloud Services alongside SaaS, and emphasizing its ability to provide 'comprehensive and integrated applications and infrastructure services' that enable customers to choose deployment models best suited to their needs. This reflects a clear strategic shift toward positioning OCI as a central pillar in Oracle’s enterprise IT offerings, not just a contributor to cloud revenue.",
      "llm_answer": "In the 2022 filing Oracle noted that it was deliberately shifting resources away from non‑strategic hardware and “placing emphasis on the marketing and sale of our growing cloud‑based infrastructure technologies” – i.e., OCI – while most of the revenue lift came from the Americas (68 %) with growing shares from EMEA (22 %) and APAC (10 %)【page_47】. By the 2024 filing OCI is positioned as a core pillar of “Oracle Cloud Services,” described as delivering “comprehensive and integrated applications and infrastructure services” that are sold worldwide and tightly coupled with SaaS and on‑premise offerings to support hybrid enterprise‑IT solutions【page_72】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of Oracle's strategic emphasis on OCI between 2022 and 2024: from a growing infrastructure focus in 2022 to a core pillar of Oracle Cloud Services by 2024. The qualitative shift in language—from revenue contributions to strategic positioning—is accurately reflected. (2) Quantitatively, the LLM introduces regional revenue distribution (Americas 68%, EMEA 22%, APAC 10%) not present in the original answer. Since this data is not contradicted by the ground truth and comes from a plausible part of the filing (page 47), it does not count as an error but adds detail beyond the original. However, the ground truth emphasizes the $36.052 billion cloud and license revenue (85% of total) in 2022, which the LLM omits. This is a minor omission affecting completeness but not the core correctness. (3) The multi-hop reasoning is sound: the LLM synthesizes strategic language shifts across years and connects OCI to broader enterprise IT integration, including hybrid deployments and SaaS coupling, which matches the original’s conclusion. (4) Semantic equivalence is strong—'core pillar', 'comprehensive and integrated applications and infrastructure services', and global deployment are all consistent with the ground truth. The answer is slightly more detailed with regional data, but the central narrative and strategic evolution are correctly conveyed. Minor deduction from 10 due to omission of the $36.052B figure and its 85% share, which is a key quantitative anchor in the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 435,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has the treatment and risk profile of PALs evolved between 2023 and 2024, particularly in terms of credit loss allowance and collateralization?",
      "original_answer": "In 2023, there was a slight decrease in PALs, and the allowance for credit losses was influenced by improved credit quality metrics and lower projected loss rates. By 2024, all PALs were fully collateralized by securities with fair values exceeding borrowings, and no allowance for credit losses for PALs was required as they were all subject to the collateral maintenance practical expedient under ASC 326. This indicates a strengthening in the risk profile and treatment of PALs over the period.",
      "llm_answer": "Schwab’s Personal Asset Loans (PALs) continued to be treated as fully collateralized in both years – the securities pledged against the loans had fair values in excess of the borrowings – and, under ASC 326’s collateral‑maintenance practical expedient, no credit‑loss allowance was required for PALs in either 2023 or 2024. Thus the allowance for PALs remained zero and the risk profile stayed low and unchanged across the two years【page_88】.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct in stating that PALs were fully collateralized and that no allowance for credit losses was required in 2024 under ASC 326's collateral maintenance practical expedient. However, it incorrectly claims this treatment was the same in 2023, directly contradicting the ground truth. The original answer specifies that in 2023, there was a slight decrease in PALs and the allowance for credit losses was still influenced by credit quality and projected loss rates—implying that the allowance was actively managed and not yet eliminated. Only in 2024 did the policy shift such that no allowance was required due to full collateralization and application of the practical expedient. Thus, the LLM fails to capture the evolution in treatment and risk profile over time, incorrectly asserting that the status was unchanged. This is a critical error in multi-hop reasoning and temporal comparison. While entity names (PALs, ASC 326) and the zero allowance outcome in 2024 are accurate, the core of the question—how the risk profile evolved—is misrepresented. The answer is contextually relevant and quantitatively plausible (no incorrect numbers cited), but the qualitative reasoning is flawed, leading to a misleading conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 349,
        "total_tokens": 1584
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Nike's relationship with the Asia Pacific & Latin America (APLA) region evolved between fiscal years 2023 and 2024, particularly in terms of operational structure and strategic emphasis?",
      "original_answer": "In fiscal year 2023, Nike's relationship with APLA was characterized by direct operational involvement, with the region being one of the geographies where certain employees were represented by trade unions, indicating a more localized and embedded workforce structure. By fiscal year 2024, Nike transitioned parts of its APLA operations to third-party distributors, signaling a strategic shift away from direct control toward a more outsourced model. This evolution reflects a broader restructuring effort to optimize the business model and reduce operational complexity in certain international markets.",
      "llm_answer": "In FY 2023 Nike’s filing only notes that workers in the APLA geographies are among the few union‑represented employees (see page 9), but it does not describe a distinct operating‑segment structure or a strategic shift for the region. By FY 2024 Nike has formalized APLA as its own geographic operating segment and, per Note 15 (page 89), is transitioning NIKE‑Brand businesses in certain APLA countries to third‑party distributors (see Note 18), indicating a move toward an outsourced, partnership‑focused model while still growing the region’s revenue (up to $6.7 bn in FY 2024 from $6.4 bn in FY 2023, page 90). This reflects an evolution from a largely internal, workforce‑focused presence to a more structured, strategically‑driven approach that leverages external distribution partners.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift from direct operations in APLA in FY2023 to transitioning to third-party distributors in FY2024, aligning with the ground truth. It accurately notes union representation in FY2023 and the strategic move toward outsourcing in FY2024. However, it introduces a claim not present in the original answer — that APLA was 'formalized as its own geographic operating segment' in FY2024 — which is not mentioned in the ground truth and may represent an overinterpretation or unsupported inference. (2) Quantitatively, the LLM cites revenue increasing from $6.4B to $6.7B in APLA between FY2023 and FY2024. While these figures may be accurate to the actual filings, they are not included in the provided ground truth answer, which focuses on structural and strategic changes rather than financial performance. This addition, while potentially valid, introduces information beyond the scope of the verified answer, reducing strict factual alignment. (3) The multi-hop reasoning is partially sound: the model connects union representation (workforce structure) in FY2023 to operational model changes in FY2024, and correctly infers strategic implications from the shift to third-party distributors. However, the synthesis includes extra details (segment formalization, revenue figures) that were not part of the knowledge graph's ground truth, suggesting the model may have relied on external knowledge or overextended its interpretation. (4) The contextual relevance is high, as the answer directly addresses the evolution in operational structure and strategic emphasis. The core reasoning about shifting from direct control to outsourcing matches the ground truth. However, the added details reduce factual precision relative to the verified answer, warranting a score of 7 for correctness — capturing the key evolution but including unverified elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 515,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How did Abbott's positioning and strategic emphasis on Pedialyte evolve between 2022 and 2023, particularly in relation to its U.S. Pediatric Nutritional business and product portfolio expansion?",
      "original_answer": "In 2022, Pedialyte was highlighted as a key growth driver within Abbott's U.S. Pediatric Nutritional business, with sales increasing 10.3% for the year, alongside Similac and PediaSure. By 2023, Pedialyte was formally included in Abbott's product portfolio under the Nutritional Products segment, listed among major brands such as Ensure, Glucerna, and PediaSure, signaling a more structured integration into Abbott's broader nutritional offerings. This reflects a strategic evolution from being a contributor to growth in 2022 to being a formally recognized and embedded part of the company's core U.S. Pediatric Nutritional product lineup in 2023.",
      "llm_answer": "In the 2022 filing Abbott emphasized Pedialyte as a primary growth driver for its U.S. Pediatric Nutritionals business, noting that the segment’s sales rose 10.3 % in 2021 “reflecting growth in Pedialyte, Similac and PediaSure”【page_31】. By the 2023 filing the company still lists Pedialyte among its core offerings, but it is presented as one product within a much broader, diversified nutritional portfolio that now spans numerous infant‑formula, pediatric‑ and adult‑nutrition brands, signaling a shift from highlighting Pedialyte alone to positioning it as part of an expanded product suite【page_4】【page_3】.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Pedialyte as a key growth driver in 2022 and its integration into a broader portfolio in 2023, aligning with the ground truth. However, there is a factual error in the quantitative claim: the LLM states that the 10.3% sales increase was in 2021, citing page 31, while the ground truth (and correct data from Abbott's 2022 filing) indicates that the 10.3% growth for Pedialyte, Similac, and PediaSure occurred in 2022, not 2021. This misattribution of the year undermines quantitative accuracy. (2) The numbers themselves (10.3%) are accurate, but the time period is incorrect, which is a significant but not central error—since the focus is on Abbott’s strategic emphasis in 2022–2023, misdating the growth to 2021 weakens precision. (3) The multi-hop reasoning is strong: the model correctly synthesizes information across 2022 and 2023 filings, noting the shift from highlighting Pedialyte as a standalone growth driver to embedding it within a broader portfolio, including adult nutrition brands. It accurately infers strategic evolution based on presentation changes in the filings. (4) Contextual relevance is excellent—the answer directly addresses Abbott’s positioning and strategic emphasis on Pedialyte in relation to its U.S. Pediatric Nutritional business and portfolio expansion. Despite the year error, the core qualitative insight about strategic integration is correct and well-supported. Hence, correctness is high but not perfect due to the date inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 420,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did RTX's financial position regarding its 7.100% notes due 2027 evolve from 2022 to 2023, and what does this indicate about its debt management strategy?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $6 million for its 7.100% notes due 2027. By 2023, RTX had a stake in the same notes with an aggregate principal balance of $135 million. This indicates a significant increase in RTX's exposure to this particular debt instrument, suggesting a shift in its debt management strategy, possibly involving refinancing or restructuring.",
      "llm_answer": "RTX kept the 7.100 % notes due 2027 at a constant $135 million at year‑end – the 2022 10‑K shows a $135 million balance (page 94) and the 2023 10‑K reports the same $135 million balance for both 2023 and 2022 (page 84). The unchanged amount indicates that RTX chose not to retire or refinance this low‑coupon tranche, reflecting a debt‑management approach that preserves existing inexpensive financing while focusing its refinancing and repayment efforts on other debt issuances.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both numbers and reasoning. According to the ground truth, RTX's aggregate principal balance for the 7.100% notes due 2027 was $6 million in 2022 and increased to $135 million in 2023. The LLM incorrectly claims the balance was $135 million in both years, directly contradicting the ground truth. This error fundamentally misrepresents the evolution of RTX's financial position. (2) Quantitative accuracy is severely lacking: the 2022 figure is off by $129 million, and the 2023 figure, while matching the ground truth, is presented as unchanged when it actually increased significantly. The LLM also cites specific 10-K page numbers (94 and 84) that are not verifiable here but conflict with the known truth. (3) The multi-hop reasoning is flawed: instead of identifying a major increase in exposure, the LLM concludes there was no change and infers a strategy of preserving low-cost debt, which contradicts the ground truth implication of a strategic shift via increased exposure. The model fails to recognize or report the tenfold increase, which is central to the correct interpretation. (4) Contextual relevance is low because the answer addresses the right instrument and general topic of debt management, but with incorrect data and therefore misleading analysis. While the question is addressed in structure, the factual foundation is entirely wrong, leading to an incorrect conclusion about RTX's strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 406,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Nike's relationship with Converse evolved in terms of revenue performance and strategic positioning between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Converse revenues decreased by 15% on a currency-neutral basis, driven by declines in North America and Western Europe, with both wholesale and direct-to-consumer channels experiencing drops in unit sales and average selling price. By fiscal 2024, Converse was described as a wholly-owned subsidiary that operates on a stand-alone basis, indicating a strategic shift toward maintaining it as a distinct brand within Nike’s portfolio. This evolution reflects a move from a financially struggling entity in 2023 to a more strategically positioned brand in 2024, despite the earlier revenue contraction.",
      "llm_answer": "Nike’s Converse brand saw its total revenue fall from $2.43 billion in fiscal 2023 to $2.08 billion in fiscal 2024 – a 14 % decline (15 % on a currency‑neutral basis), with footwear revenues down 16 % while apparel rose modestly (+3 %) and equipment jumped (+32 %) (see page 46).  Despite the sales drop, Nike continues to position Converse as a stand‑alone, reportable operating segment – a wholly‑owned subsidiary that designs, markets, licenses and sells casual sneakers, apparel and accessories, and operates its own direct‑to‑consumer network (81 U.S. stores and 54 overseas stores) as part of Nike’s broader brand portfolio (see pages 5 & 4).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the revenue decline is correctly stated as 14% (and 15% on a currency-neutral basis), matching the original answer. The specific revenue figures ($2.43B in FY2023 to $2.08B in FY2024) are precise and consistent with a 14% drop. Footwear down 16%, apparel +3%, equipment +32% — these breakdowns add contextual detail not in the original answer but do not contradict it; they enhance completeness without introducing errors. (2) The entity identification is correct: Nike, Converse, fiscal years 2023 and 2024, and the description of Converse as a wholly-owned, stand-alone subsidiary are all accurate. (3) The reasoning is sound: the answer captures the evolution from financial decline in 2023 to strategic positioning in 2024 by emphasizing Converse’s continued operation as a distinct, reportable segment within Nike’s portfolio. (4) While the original answer highlights the strategic shift more explicitly, the LLM conveys the same semantic meaning by noting Converse’s standalone status and direct-to-consumer operations. The only minor gap is that the LLM does not explicitly mention the geographic drivers of decline (North America and Western Europe) or the drop in unit sales and average selling price, which were in the original. However, the core facts — revenue performance and strategic positioning — are correctly and comprehensively addressed. Thus, the answer earns a 9 for correctness due to slight incompleteness in causal detail, but remains factually and logically robust.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 432,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Coca-Cola's financial risk assessment regarding digital evolution changed from 2022 to 2024, particularly in terms of its impact on sales growth and margin improvement?",
      "original_answer": "In 2022, Coca-Cola viewed digital evolution as a risk factor that could negatively impact its business if it failed to implement digital transformation initiatives effectively, potentially leading to a loss in sales and brand relevance. By 2024, the company shifted its stance, identifying digital evolution as a strategic dependency, emphasizing that its future success would rely on expanding digital capabilities to increase sales and improve margins. The 2024 filing explicitly states that failure to digitalize operations could adversely impact financial performance, indicating a stronger financial linkage to digital initiatives than in 2022.",
      "llm_answer": "In the 2022 Form 10‑K (page 19) Coca‑Cola warned that if it does not successfully **digitalize** the system, “our ability to increase sales and improve margins may be negatively affected.” By the 2024 filing (page 18) the company still flags the same sales‑growth risk, but the margin impact is now described as a risk to “reduce costs” rather than “improve margins,” reflecting a shift from margin‑improvement concerns to cost‑reduction concerns while the digital‑evolution risk to sales growth remains unchanged.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct in identifying that Coca-Cola discussed digital evolution as a risk in both 2022 and 2024 filings, with references to sales growth and margin/cost impacts. The citation of specific pages (2022 10-K p.19, 2024 p.18) and direct quotes are consistent with typical SEC filing analysis, and there are no numeric inaccuracies (quantitative accuracy is high, hence score of 10). However, the qualitative interpretation is flawed. The original answer (ground truth) states that Coca-Cola's stance evolved from viewing digital evolution as a risk to business if not implemented, to a strategic dependency for future success—indicating a significant shift in strategic framing. The LLM answer incorrectly characterizes this shift as merely a change from 'improve margins' to 'reduce costs', which misrepresents the broader strategic repositioning. In fact, 'improving margins' and 'reducing costs' are related but not equivalent shifts; the core change is in the company's dependency on digital transformation, not just a rewording of financial outcomes. The LLM fails to capture the multi-hop synthesis that the company’s financial risk assessment evolved from a defensive concern (risk of inaction) to an offensive strategic imperative (dependency for growth and margins). This is a significant omission in reasoning, leading to a qualitative accuracy score of 4. Contextually, the answer addresses the question’s focus on sales growth and margin improvement, so relevance is moderate (7), but the misinterpretation of the nature of the change limits usefulness. Correctness is partially accurate on surface-level wording but incorrect on the deeper strategic shift, warranting a 4/10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 464,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Services evolved from fiscal year 2022 to 2024, particularly in terms of research and development investment and the positioning of cloud offerings relative to on-premise solutions?",
      "original_answer": "In fiscal year 2022, Oracle invested $7.2 billion in research and development, highlighting its commitment to enhancing Oracle Cloud Services, including Oracle SaaS and OCI, as part of a broader strategy to offer flexible and interoperable deployment models. Oracle positioned cloud services as a key differentiator against competitors by emphasizing rapid deployment, security, and integration. By fiscal year 2024, Oracle continued to emphasize cloud services but restructured its messaging to position Oracle Cloud Software-as-a-Service and Oracle Cloud Infrastructure as central to enabling customers to 'choose the best option that meets their specific business needs.' While the 2024 report does not specify the R&D investment amount, the increased focus on cloud-first positioning and integration with customer-specific needs indicates a strategic deepening of Oracle's commitment to cloud services over on-premise offerings.",
      "llm_answer": "Oracle’s FY 2022 filing disclosed a $7.2 billion R&D spend to enhance its portfolio and develop new technologies, and noted that cloud services and license‑support revenues already accounted for roughly 71 % of total revenue, signaling a major shift from on‑premise to cloud offerings【page_6】【page_8】. By FY 2024, Oracle’s commentary stresses Oracle Cloud Services (SaaS and OCI) as a core, integrated platform delivered via cloud, on‑premise, and hybrid models, highlighting flexible, interoperable deployment and continued heavy R&D focus on cloud capabilities, thereby cementing an even stronger cloud‑first strategy relative to traditional on‑premise solutions【page_6】.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Oracle's $7.2 billion R&D investment in FY2022, matching the ground truth. It also accurately reflects the strategic shift toward cloud services, including the emphasis on SaaS and OCI, and the positioning of flexible deployment models (cloud, on-premise, hybrid). However, the LLM introduces a specific percentage—'71% of total revenue' from cloud services and license-support—that is not present in the original answer and cannot be verified from the provided ground truth, which weakens quantitative accuracy slightly. (2) The dollar amount ($7.2 billion) is correct and properly attributed to FY2022. The absence of an FY2024 R&D figure in the original answer is respected in the LLM response by not specifying a number, though it implies continued 'heavy R&D focus,' which aligns semantically with the original's assertion of deepened strategic commitment. The unverified 71% revenue figure is the only unsupported numeric claim. (3) The multi-hop reasoning is sound: the LLM synthesizes information across FY2022 and FY2024 to show evolution in strategy, correctly inferring a stronger cloud-first orientation over time. It connects R&D investment to cloud development and interprets Oracle’s shifting messaging around deployment flexibility and integration. The only gap is the unsupported revenue percentage, which may stem from external data or misattribution. (4) Despite the extraneous statistic, the core of the answer matches the original in intent, factual content, and direction. The strategic evolution, R&D emphasis, and cloud-first positioning are all accurately conveyed with strong contextual relevance. Hence, a score of 8 is justified—minor factual overreach but otherwise correct and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 482,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the status and availability of shares under the Norwest Corporation Directors' Formula Stock Award Plan evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Norwest Corporation Directors' Formula Stock Award Plan was described as a plan under which shares of common stock were awarded to non-employee directors, with the ability to defer receipt of awards until a future year. However, it was noted that no future stock awards or deferrals could be made under this plan. In 2024, the 10-K filing further clarified that no future awards or deferrals would be made under the plan and that column (a) of the equity compensation table reflected all shares issuable under the plan upon distribution of outstanding awards or deferred compensation benefits. This indicates that by 2024, the plan was fully closed to any new activity and only existing obligations remained. The number of shares issuable in 2024 related to this plan was minimal (only 391 shares), showing that the plan had effectively concluded its active phase.",
      "llm_answer": "The Norwest Corporation Directors’ Formula Stock Award Plan remained a non‑shareholder‑approved plan that does not permit any future stock awards or deferrals in both years — the 2023 filing notes “No future stock awards or deferrals may be made under this plan”【page_12】and the 2024 filing repeats the same language【page_15】. However, the pool of shares that could still be issued under the plan fell from 509 shares in 2023 (the footnote lists 509 shares issuable)【page_11】to 391 shares in 2024【page_14】.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, it correctly states the number of shares issuable under the plan in 2023 (509) and 2024 (391), matching the ground truth's implication of a minimal remaining balance and decline over time. The ground truth does not specify the 2023 share count explicitly but confirms the 2024 count as 391; the LLM’s inclusion of 509 in 2023 is consistent with the knowledge graph data and represents a minor detail not contradicted by the original. (2) The LLM accurately captures that no future awards or deferrals were permitted in both years, citing consistent language from the filings, which matches the original answer’s claim that the plan was closed to new activity. (3) The reasoning is sound: it infers the plan’s inactive status and declining share liability, correctly synthesizing information across two years and filings. (4) The answer addresses the evolution of the plan’s status and availability of shares, fully responding to the multi-hop aspect of the question. The only minor limitation is that it does not explicitly state the plan was 'fully closed' or 'only existing obligations remained' in 2024, but this is implied by the cited language and share reduction. Overall, the answer is factually correct, well-supported, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 373,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has McDonald's disclosure around food safety concerns evolved between 2022 and 2023, particularly in relation to supply chain risks and cost volatility?",
      "original_answer": "In 2022, McDonald's characterized food safety concerns primarily as reputational risks that could impact brand perception and financial results due to incidents like food-borne illness or contamination. The focus was on the potential damage to consumer trust and the company's image. By 2023, the framing had evolved to emphasize food safety concerns as contributors to supply chain volatility, specifically in relation to commodity cost fluctuations. The 2023 filing noted that food safety issues, along with other macroeconomic and regulatory factors, could exacerbate volatility in the prices of key ingredients like beef, chicken, and pork, thereby affecting profitability. This indicates a shift in emphasis from reputational impact to financial exposure through supply chain disruption and cost pressures.",
      "llm_answer": "In the 2022 filing McDonald’s treated food‑safety as a separate risk – noting that food‑borne illness or product‑recall events could hurt its brand and that commodity‑price volatility for beef, chicken and pork is “particularly volatile … due to … food‑safety concerns, product recalls, government regulation” (2022 p.33) – while supply‑chain interruptions were described in a distinct risk factor that could raise costs or limit product availability (2022 p.30). By the 2023 filing the language is more integrated: the company says its ability to meet “expectations for safe food … including … in the supply chain, restaurants or delivery” and stresses reliance on independent suppliers to meet high standards (2023 p.31, p.35), yet it still flags that commodity‑cost volatility remains driven by food‑safety concerns (2023 p.33). This shows an evolution from a generic food‑safety warning to a clearer linkage of food‑safety risk with supply‑chain exposure and cost volatility.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in McDonald's disclosures between 2022 and 2023: in 2022, food safety was framed as a reputational risk, while in 2023 it was more integrated with supply chain and cost volatility concerns. The LLM accurately reflects that in 2022, food safety was mentioned as one of several factors contributing to commodity price volatility (citing beef, chicken, pork), and in 2023, the linkage between food safety, supply chain standards, and cost pressures was strengthened. (2) There are no numerical values, dates, or financial figures in the question or answer that require verification—only years (2022, 2023), which are correct. Page references (e.g., p.33, p.31) are included and consistent with typical 10-K formatting, though not verifiable without source documents; their presence does not detract from accuracy. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, distinguishes between the framing of risks, and correctly infers a shift from siloed to integrated risk disclosure. It notes the continued mention of food-safety-driven cost volatility in 2023, which matches the ground truth. (4) The only minor shortcoming is that the LLM does not explicitly state the *shift in emphasis* from reputational impact (2022) to financial exposure via supply chain (2023) as clearly as the original answer. However, this is implied through the description of 'clearer linkage of food-safety risk with supply-chain exposure and cost volatility.' Thus, the answer is semantically equivalent with only slight nuance missing. All entities (McDonald's, supply chain, cost volatility, beef/chicken/pork) are correct. The contextual relevance is perfect—directly addressing the evolution in disclosure focus.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1450,
        "completion_tokens": 498,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the carrying value and interest rate of TMO's 1.750% 7-Year Senior Notes evolved between 2023 and 2024?",
      "original_answer": "In 2023, TMO's 1.750% 7-Year Senior Notes, due on October 15, 2028, had a carrying value of $700 million and an effective interest rate of 1.89%. In 2024, both the carrying value and effective interest rate remained unchanged at $700 million and 1.89% respectively. This indicates that there was no change in the financial structure or valuation of this particular debt instrument over the period.",
      "llm_answer": "In 2023 the 1.750 % 7‑year senior notes (due 10/15/2028) were carried at $700 million with an effective interest rate of 1.89 %【page_62】. The 2024 filing shows the same notes still carried at $700 million and still reporting a 1.89 % effective rate【page_47】. Thus, both the carrying amount and the interest rate remained unchanged from 2023 to 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the carrying value of $700 million and effective interest rate of 1.89% are correctly reported for both 2023 and 2024. The maturity date (October 15, 2028) is also correctly included. Minor formatting differences (e.g., spacing in '1.750 %' or '10/15/2028') do not affect factual accuracy. (2) The answer is complete, addressing both the carrying value and interest rate across both years, and correctly states that there was no change. (3) Entity accuracy is correct: TMO (Thermo Fisher Scientific) is properly identified via context, the debt instrument is accurately named, and the years 2023 and 2024 are correctly referenced. (4) The reasoning is sound: the model correctly synthesizes data from two different filings (cited with page numbers), compares the values across years, and draws the correct conclusion that both metrics remained unchanged. The semantic meaning is equivalent to the original answer, with no factual or interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1177,
        "completion_tokens": 306,
        "total_tokens": 1483
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did RTX's exposure to its 7.000% notes due 2038 change between 2022 and 2023, and what does this suggest about its approach to managing long-term debt maturities?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $11 million for its 7.000% notes due 2038. By 2023, this amount had increased significantly to $148 million. This suggests that RTX either issued additional tranches of this note or restructured its debt to extend maturities, indicating a strategic shift toward increasing exposure to this particular long-term debt instrument.",
      "llm_answer": "RTX’s 7.000 % notes due 2038 were $148 million at the end of 2022 and remained $148 million at the end of 2023 (2023 10‑K, Note 10 table shows $148 million for both years)【page_85】. The unchanged balance indicates the company neither added to nor retired this tranche, suggesting a deliberate strategy to keep its exposure to this long‑dated, higher‑coupon debt stable while managing overall maturities through other issuances and repayments.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core quantitative claim. According to the ground truth, RTX's exposure to the 7.000% notes due 2038 was $11 million in 2022 and increased to $148 million in 2023. The LLM incorrectly states the balance was $148 million in both 2022 and 2023, reversing the actual trend. This error fundamentally undermines the answer's validity. (2) The dollar amounts and years are directly contradicted by the ground truth: the $148 million figure applies only to 2023, not 2022. The LLM also cites 'Note 10 table' and 'page_85' as support, but this conflicts with the verified data in the knowledge graph, suggesting either misreading of the source or incorrect data retrieval. (3) The multi-hop reasoning fails because the model did not correctly identify the change over time, which is central to the question. The conclusion that RTX 'kept its exposure... stable' is incorrect given the 13-fold increase in the note balance. The ground truth suggests a strategic increase in long-term debt exposure, while the LLM infers stability — a directly contradictory interpretation. (4) The contextual relevance is moderate because the answer addresses the right topic (debt management strategy) and references an appropriate section (Note 10), but the factual foundation is wrong. Due to major quantitative and reasoning errors, the correctness score is low at 2, with similarly low scores for quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 407,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did McDonald's financial relationship with its franchisees evolve between 2022 and 2023, particularly regarding the collection of rent and royalties?",
      "original_answer": "In 2022, McDonald's disclosed that it had deferred approximately $1 billion in rent and royalties from franchisees, primarily during the first half of 2020, due to the impact of government restrictions related to COVID-19. By the end of 2021, the company had collected substantially all of these deferred amounts. In contrast, the 2023 filing reflects a return to standard operations, with no mention of ongoing deferrals or pandemic-related financial accommodations. Instead, the 2023 report outlines the normalization of franchise operations, including a detailed breakdown of restaurant ownership types, which indicates that franchisees were operating under regular financial obligations without pandemic-era relief measures.",
      "llm_answer": "In the 2022 filing McDonald’s explained that, because of COVID‑19, it had **deferred roughly $1 billion of rent and royalty payments from franchisees** in the first half of 2020 and had “collected substantially all of these deferrals as of December 31, 2021” (2022 10‑K, p. 51). The 2023 filing no longer mentions any deferrals; instead it states that **rental income (minimum rent straight‑line and variable rent) and royalties are recognized when earned – i.e., at the time underlying sales occur** (2023 10‑K, p. 44). Thus, the franchisee relationship shifted from a pandemic‑driven cash‑collection pause in 2022 to a normalized, on‑schedule collection of rent and royalties in 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) All key facts are accurately reported: the $1 billion deferral in rent and royalties from franchisees occurred in the first half of 2020 due to COVID-19, and substantially all of it was collected by December 31, 2021, as confirmed in the 2022 10-K (p. 51). The 2023 filing shows no ongoing deferrals, indicating a return to normal operations. (2) Quantitative accuracy is precise: the $1 billion figure is correctly cited, and the timeline (2020 deferral, collection completed by end of 2021, reported in 2022, normalized in 2023) is factually sound with no calculation or date errors. (3) The multi-hop reasoning is strong: the model correctly synthesizes information across two years of filings, contrasting the post-deferral status in 2022 with the normalized revenue recognition policy in 2023. It accurately infers that the absence of deferral mentions and the reaffirmation of standard rent and royalty recognition (on p. 44 of the 2023 10-K) signify a return to regular financial operations. (4) The answer is contextually relevant, directly addressing the evolution of McDonald's financial relationship with franchisees regarding rent and royalties between 2022 and 2023. Wording differs slightly from the original answer but maintains full semantic equivalence and adds specific citation details (page numbers, quotes), enhancing accuracy. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 407,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has The Coca-Cola Company's financial stake in Embotelladora Andina S.A. evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning with respect to this equity investment?",
      "original_answer": "In 2022, Coca-Cola recognized a gain of $39 million from the partial sale of its ownership interest in Embotelladora Andina S.A., indicating a strategic refranchising or divestiture move while retaining an equity stake. By 2024, Coca-Cola still held a financial stake in Andina, with a carrying value of $90 million and a fair value of $168 million, showing that the company maintained its involvement but with a relatively modest valuation compared to other equity investments. This indicates a partial exit strategy rather than a complete divestiture, with ongoing but reduced exposure.",
      "llm_answer": "In the 2022 filing Coca‑Cola noted that, after selling a portion of its holding in 2019, it still retained a “remaining ownership interest” in Embotelladora Andina S.A. that is accounted for under the equity‑method (no dollar amount was disclosed)【page_76】. By the 2024 filing the same equity‑method investment is shown with a carrying amount of $90 million and a fair‑value of $168 million, indicating that the stake has appreciated and that Coca‑Cola continues to hold a minority, strategic interest rather than moving toward full acquisition or disposal【page_87】. This suggests the company views Andina as a valuable partner and is preserving its influence while benefiting from the investment’s upside.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the key figures—$90 million carrying value and $168 million fair value in 2024—are correctly reported. The 2022 gain of $39 million from partial sale is implied in the original answer but not explicitly mentioned in the LLM response; however, the LLM correctly notes the retained ownership interest post-sale, referencing the equity-method accounting, which is consistent with the partial divestiture. The absence of the $39M figure is a minor omission but does not distort the overall financial evolution. (2) The LLM correctly identifies the continuation of the stake into 2024 with updated values, and the appreciation from carrying to fair value is accurately highlighted. (3) Reasoning is sound: the conclusion that Coca-Cola maintains a strategic minority interest rather than pursuing full exit or acquisition is logically derived from the sustained equity-method accounting and valuation data. The interpretation of ongoing influence and strategic partnership aligns semantically with the ground truth’s 'partial exit strategy' and 'ongoing but reduced exposure.' (4) All entities—The Coca-Cola Company, Embotelladora Andina S.A., years 2022 and 2024, carrying and fair values—are correctly identified. The answer fully addresses both parts of the question: evolution of the stake and strategic implications. Only slight deduction in quantitative accuracy due to missing explicit mention of the $39M gain in 2022, though the context of partial sale is acknowledged. Overall, the answer is factually correct, well-reasoned, and contextually complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 449,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has Oracle's strategic investment in cloud infrastructure evolved from 2022 to 2024, particularly regarding internal development efforts and the positioning of Oracle Cloud Infrastructure in its product portfolio?",
      "original_answer": "In 2022, Oracle emphasized internal development as a core strategy, dedicating significant resources to research and development to maintain and improve its existing product suite, including cloud technologies. The company highlighted its global R&D workforce and the importance of innovation in response to evolving market demands. By 2024, this focus had evolved into a more product-specific strategy with the explicit introduction of Oracle Cloud Infrastructure (OCI) as a central offering within Oracle Cloud Services. OCI was positioned as a comprehensive and integrated infrastructure solution, indicating a shift from general cloud development to a structured, customer-facing product portfolio. This evolution demonstrates a strategic deepening of Oracle's cloud infrastructure commitment, aligning internal R&D with the delivery of a defined, market-ready suite of cloud services.",
      "llm_answer": "Oracle’s 2022 filing stresses that its cloud platform is built and operated internally – Oracle Cloud Operations is managed by Oracle employees, the company is expanding data‑center capacity, and the bulk of its cloud products are developed in‑house (2022 p.15‑16). By the 2024 filing the same internal‑development emphasis remains, but Oracle now explicitly brands Oracle Cloud Infrastructure (OCI) as a core pillar of its Oracle Cloud Services suite, positioning OCI alongside SaaS as an integrated, strategic offering in its product portfolio (2024 p.72‑73).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Oracle's continued emphasis on internal development from 2022 to 2024, citing in-house cloud operations, data center expansion, and internal product development in 2022, and the sustained focus in 2024. The evolution toward positioning Oracle Cloud Infrastructure (OCI) as a core, branded component of Oracle Cloud Services is accurately captured, with correct contextual framing as a strategic shift in product portfolio structure. (2) There are no numeric values (e.g., dollar amounts, percentages, headcount) in either the original or LLM answer, so quantitative accuracy is not applicable in a numerical sense; however, the cited page numbers (2022 p.15–16, 2024 p.72–73) are consistent with document-based evidence and do not introduce factual errors, supporting accuracy. (3) The multi-hop reasoning is sound: the model synthesizes information across two years, connects internal development efforts to strategic product positioning, and correctly infers a progression from general cloud development to a structured OCI-centric portfolio. (4) The only minor shortcoming is that the LLM answer does not explicitly mention the 'global R&D workforce' or 'innovation in response to market demands' from the 2022 context, which slightly reduces qualitative completeness, but the core strategic evolution is correctly and concisely conveyed. Wording differs but semantic meaning matches. All entities—Oracle, OCI, Oracle Cloud Services, SaaS, internal development—are correctly identified and contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 439,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did TMO's involvement with The Binding Site Group evolve between 2023 and 2024, and what does this indicate about the company's integration and strategic focus post-acquisition?",
      "original_answer": "In 2023, TMO acquired The Binding Site Group for $2.70 billion as part of its Specialty Diagnostics segment, expanding its portfolio in diagnostics for blood cancers and immune disorders. By 2024, the company had integrated the acquisition into its asset base, with The Binding Site Group contributing to the 19-year weighted-average amortization period for customer relationships among definite-lived intangible assets. This evolution indicates a strategic focus on long-term value creation through integration of acquired innovation into its core diagnostics offerings.",
      "llm_answer": "In 2023 Thermo Fisher completed a $2.7 billion acquisition of The Binding Site Group, adding the U.K.‑based diagnostics business to its Specialty Diagnostics segment (cash $2.412 bn, debt $307 mn; customer relationships $868 mn, product technology $162 mn, goodwill $1.741 bn)【page_66】. By the 2024 filing the company no longer discusses any new activity with The Binding Site Group, instead highlighting fresh deals such as the Olink acquisition, which signals that The Binding Site Group has been fully integrated into Thermo Fisher’s operations and the firm’s post‑acquisition focus has shifted to leveraging that platform while pursuing additional strategic growth opportunities【page_65】.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2023 acquisition of The Binding Site Group by TMO (Thermo Fisher) for $2.7 billion, aligning with the ground truth. It adds more granular detail not in the original answer—such as the breakdown of consideration ($2.412B cash, $307M debt) and intangible asset allocation (customer relationships $868M, product technology $162M, goodwill $1.741B)—which are factually consistent with typical SEC disclosures and do not contradict the ground truth. These details enhance completeness but were not required for full accuracy. However, the LLM fails to mention the key 2024 integration point from the ground truth: The Binding Site Group’s contribution to the 19-year weighted-average amortization period for customer relationships, which is a critical indicator of integration into long-term asset planning. This omission affects completeness and reasoning. (2) All numeric values cited by the LLM are quantitatively accurate or plausibly rounded (e.g., $2.7B vs $2.70B is acceptable). The sum of the components ($2.412B + $307M = $2.719B) is close to $2.7B, with minor rounding differences acceptable in financial reporting. (3) The reasoning is partially sound: the inference that reduced discussion implies full integration is logical and contextually supported by the shift in focus to Olink. However, this is a weaker proxy than the actual evidence in the ground truth—the amortization period—which directly reflects integration into financial statements. The LLM uses circumstantial evidence rather than definitive financial integration metrics, weakening the multi-hop reasoning. (4) Despite missing the key amortization point, the LLM captures the strategic focus on leveraging the platform and moving to new acquisitions, which aligns semantically with 'long-term value creation' and 'strategic growth.' Thus, while the conclusion is directionally correct, it lacks the precise financial grounding of the original. Scores reflect high accuracy with a moderate deduction for missing a key multi-hop fact essential to the strategic interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 563,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2022 and 2024, particularly in terms of website links and scope of application?",
      "original_answer": "In 2022, the Directors' Code of Conduct was posted on BNY Mellon's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf, and it applied to all directors. By 2024, while the scope of application remained the same—applying to all directors—the URL for the Directors' Code of Conduct had changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf. This indicates a change in the website structure or domain branding, likely reflecting a broader rebranding from 'BNY Mellon' to 'BNY', while maintaining the same governance policy content and disclosure intent.",
      "llm_answer": "In the 2022 Form 10‑K the Directors’ Code of Conduct was described as applying to “all directors of BNY” and was referenced only with a relative link – bnymellon/documents/pdf/investor‑relations/directors‑code‑of‑conduct.pdf. By the 2024 filing the same code still applies to “all directors of BNY Mellon,” but the company now provides a full, publicly‑clickable URL – https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/in relations/directors‑code‑of‑conduct.pdf – making the disclosure more direct and accessible while the scope of application remains unchanged.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. First, it incorrectly states that in 2022 the Directors' Code of Conduct applied to 'all directors of BNY'—the original answer specifies 'all directors' without mentioning 'BNY', and the rebranding to 'BNY' was not reflected in the 2022 scope. Second, the LLM claims the 2022 filing used a 'relative link', but the ground truth confirms a full URL was provided. Third, the 2024 URL in the LLM answer is incorrect: it cites 'bnymellon.com' and a malformed path ('in relations'), whereas the correct 2024 URL uses 'bny.com' as per the rebranding. The LLM also fails to note the domain change from 'bnymellon.com' to 'bny.com', a key point in the original answer about rebranding. (2) While the years (2022, 2024) and the fact that the scope remained unchanged are correct, the URLs are factually wrong, and the description of link types (relative vs. absolute) is inaccurate. (3) The multi-hop reasoning is partially sound—comparing disclosure changes over time and recognizing consistent scope—but fails in synthesizing the correct URLs and the significance of the domain change. (4) The contextual relevance is high as the answer addresses website accessibility and scope evolution, but factual errors in critical details (URLs, branding, link types) reduce correctness significantly. Thus, the answer is partially correct but contains major factual flaws in quantitative and qualitative aspects.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 403,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has McDonald's relationship with franchisees evolved in terms of financial reporting and strategic emphasis between 2022 and 2023?",
      "original_answer": "In 2022, McDonald's noted that the results of operations from restaurant businesses purchased and sold in transactions with franchisees were not material to the consolidated financial statements, indicating a limited financial impact from such transactions. By 2023, the company explicitly included franchisees and licensees as key stakeholders in its business model, emphasizing their role alongside company-operated restaurants in a detailed breakdown of restaurant ownership types. This shift reflects a more strategic and transparent focus on franchisees as integral to McDonald's global business structure.",
      "llm_answer": "In the 2022 filing McDonald’s reported franchise‑related revenues – rent, royalties, minimum‑rent payments and initial fees – on a gross basis and also included technology‑platform services (including Dynamic Yield SaaS) as franchisee revenue, while noting that franchisee advertising contributions were not consolidated because the company lacked control【page_44】【page_45】. By the 2023 filing the Dynamic Yield revenue is gone after its sale, the same gross‑basis accounting for franchise fees and technology services remains, but goodwill rose to $3.0 bn (from $2.9 bn) as McDonald’s continued to purchase restaurants from franchisees, and advertising spend for company‑operated restaurants increased, reflecting a strategic emphasis on expanding company‑owned locations and deeper franchisee collaboration【page_44】【page_45】.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some accurate details but diverges significantly from the ground truth in focus and key points. (1) Correct elements include references to franchise-related revenues being reported on a gross basis in 2022 and the continuation of that accounting in 2023, as well as the increase in goodwill from $2.9B to $3.0B, which aligns with McDonald's purchasing restaurants from franchisees. The mention of increased advertising spend for company-operated restaurants is contextually plausible. (2) Quantitatively, the $2.9B to $3.0B goodwill increase is accurate and correctly framed. However, the LLM introduces Dynamic Yield SaaS revenue as part of franchisee revenue in 2022 and claims it was removed in 2023 due to a sale—this detail is not present in the original answer and may be factually unsupported in the context of the question about franchisee relationships. There is no mention in the ground truth about the sale of Dynamic Yield affecting reporting, so this is an unsupported addition. (3) The reasoning is flawed in its focus: the original answer emphasizes a strategic shift in how McDonald's positions franchisees in its business model—from a financial non-materiality in 2022 to a stakeholder-integration narrative in 2023. The LLM instead focuses on revenue line items and goodwill changes without capturing this evolution in strategic emphasis or transparency. It fails to note that in 2022, transactions with franchisees were deemed immaterial, and in 2023, franchisees were explicitly named as key stakeholders—a core multi-hop insight. (4) While the LLM answer is relevant and includes some correct financial reporting details, it misses the central theme of evolving strategic emphasis and stakeholder integration, instead introducing potentially extraneous information about Dynamic Yield. Thus, it is partially correct but lacks the essential synthesis required by the question, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 523,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the accounting treatment or status of the contingent consideration liabilities related to the Clif Bar acquisition evolve between 2023 and 2024, particularly in terms of fair value measurement and purchase price allocation adjustments?",
      "original_answer": "In 2023, the contingent consideration liabilities related to the Clif Bar acquisition were actively measured at fair value using a Monte Carlo simulation, with $548 million classified as long-term liabilities at December 31, 2023. These liabilities were tied to performance targets in 2025 and 2026 and were subject to fair value adjustments recorded in selling, general, and administrative expenses. By 2024, there is no direct mention of the contingent consideration liabilities; instead, the 2024 filing references purchase price allocation adjustments for Clif Bar during 2023. This indicates that the contingent consideration may have been finalized or reclassified as part of the purchase price allocation process, though the 2024 disclosure does not provide updated figures or valuation methods for these liabilities.",
      "llm_answer": "In the 2023 Form 10‑K the Clif Bar contingent‑consideration was shown as a distinct liability of **$548 million**, measured at fair value using Level 3 (Monte‑Carlo) inputs, with changes recorded in SG&A (see page 99). By the 2024 filing the separate contingent‑consideration balance is no longer disclosed; instead, the related amount appears only in the **purchase‑price‑allocation adjustments** for the Clif Bar acquisition (noted in the intangible‑asset schedule on page 87), indicating the liability has been re‑measured/settled and incorporated into the acquisition accounting rather than retained as a stand‑alone fair‑value liability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $548 million contingent consideration liability in 2023, its fair value measurement using Monte Carlo simulation (noted as Level 3 inputs), and the recording of changes in SG&A—matching the ground truth. The 2024 status is accurately described as no longer disclosed as a standalone liability, with only purchase price allocation adjustments referenced, indicating re-measurement or settlement. (2) All numeric values—$548 million, years 2023 and 2024—are correct and contextually accurate. No calculations are required, but the reporting of figures aligns precisely with the original answer. (3) The multi-hop reasoning is sound: the model correctly infers from the absence of the liability in 2024 and the presence of purchase price allocation adjustments that the contingent consideration was likely finalized and incorporated into acquisition accounting. This synthesis across two filings (2023 and 2024) is logically valid and consistent with the ground truth. (4) The only minor shortcoming is the lack of explicit mention that the performance targets were tied to 2025 and 2026, which adds context to why the liability existed in 2023. However, this does not detract from the core accuracy regarding accounting treatment evolution. Wording differs slightly but maintains semantic equivalence. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 397,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has AMD's strategic emphasis on Vulkan API support evolved between 2022 and 2024, and what does this reveal about its approach to maintaining competitiveness in the discrete GPU market?",
      "original_answer": "In 2022, AMD highlighted its support for Vulkan as part of its Radeon™ series discrete GPUs, which were built on the RDNA 2 architecture and aimed at delivering high-performance gaming and creation workloads. By 2024, AMD continued to support Vulkan but shifted its focus toward the newer RDNA 3 architecture, which underpins the Radeon RX 7000 Series GPUs. This evolution suggests AMD is maintaining its commitment to Vulkan while advancing its GPU capabilities to meet the growing demands of immersive gaming and AI/ML computing. This strategic continuity in API support combined with architectural innovation indicates AMD’s effort to stay competitive by offering both backward compatibility and cutting-edge performance enhancements.",
      "llm_answer": "In the 2022 Form 10‑K AMD said its Radeon discrete GPUs “support current‑generation application programming interfaces (APIs) like DirectX 12 Ultimate and **Vulkan**.” By the 2024 filing the company repeats that support but now couples Vulkan with “high‑refresh‑rate displays,” immersive‑gaming, VR and AI/ML capabilities, positioning it as a key part of the Radeon RX 7000‑Series platform. This shift from a simple compatibility statement to a broader, feature‑rich emphasis shows AMD is deliberately aligning its GPUs with the latest industry‑standard API (Vulkan) to stay competitive in the fast‑evolving discrete‑GPU market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies AMD's support for Vulkan in both 2022 and 2024, referencing the appropriate GPU series (Radeon and RX 7000 Series) and architectural evolution (implied by shift to newer features). The years (2022 and 2024) are correct, and no monetary figures or percentages are involved, so quantitative accuracy is perfect. (2) The answer captures the evolution from basic Vulkan compatibility in 2022 to a more integrated role in 2024 alongside high-refresh-rate displays, VR, and AI/ML—consistent with the ground truth’s emphasis on immersive gaming and AI/ML computing. (3) The multi-hop reasoning is sound: it synthesizes AMD’s API support across two years and infers strategic intent (staying competitive via industry-standard API alignment). The only minor omission is not explicitly naming the RDNA 2 to RDNA 3 architectural transition, which is mentioned in the original answer and provides technical context for the performance enhancements. However, the LLM implies this through reference to the RX 7000 Series and new capabilities. (4) Despite this slight gap, the LLM conveys the same strategic narrative—continuity in Vulkan support combined with performance innovation—making the answer semantically equivalent and contextually strong. Hence, correctness is docked slightly but remains high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 384,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How did RTX's integration-related charges impact its operating profit trends between 2022 and 2023, particularly with the introduction of the Powder Metal Matter charge in 2023?",
      "original_answer": "In 2022, RTX reported a decrease in Acquisition Accounting Adjustments, which contributed positively to its operating profit. However, in 2023, there was a significant $2.9 billion charge associated with the Powder Metal Matter, which became a major driver of the $1.9 billion decrease in Operating Profit compared to 2022. This reflects a notable shift from a declining trend in integration-related charges in 2022 to a significant new expense in 2023 that directly impacted profitability.",
      "llm_answer": "RTX’s operating profit rose modestly in 2022 because integration‑related acquisition‑accounting adjustments fell, adding about $0.4 bn and lifting profit to $5.5 bn (≈8.2% margin) 【page_39】. In 2023 the company recorded a $2.9 bn Powder Metal Matter charge at Pratt & Whitney (net of partner share), which drove a $1.9 bn year‑over‑year decline in operating profit to $3.6 bn and cut the margin to 5.2% 【page_39】【page_41】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key numbers are correct: the $2.9 billion Powder Metal Matter charge in 2023 and the $1.9 billion year-over-year decline in operating profit are explicitly stated and match the original answer. The operating profit figures of $5.5 billion in 2022 and $3.6 billion in 2023 are consistent with a $1.9 billion decrease. The margin drop from 8.2% to 5.2% is additional but plausible context supported by the data. The mention of a $0.4 billion benefit from declining acquisition adjustments in 2022 is not in the original answer but does not contradict it and may reflect further detail from the source (page 39). (2) Calculations are sound: $5.5B - $3.6B = $1.9B, and the charge being larger than the profit decline is logically consistent (as the charge is a primary driver, not the sole cause). (3) Multi-hop reasoning is strong: the answer correctly synthesizes trends across 2022 and 2023, links the Powder Metal Matter charge to the profit decline, and identifies Pratt & Whitney as the business unit involved (a detail not in the original answer but likely from the cited page). (4) The only minor gap is that the original emphasizes the shift in trend—from decreasing integration charges in 2022 to a major new charge in 2023—slightly more explicitly, while the LLM implies it through contrast. However, the core message about the reversal in integration-related cost trends is preserved. Wording differs but semantic meaning and factual content are equivalent. All entities (RTX, 2022, 2023, Powder Metal Matter, operating profit) are correct. Citations to page_39 and page_41 suggest document grounding. No factual errors detected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 470,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has MDLZ's relationship with Clif Bar evolved between 2023 and 2024, particularly in terms of acquisition-related financial activities?",
      "original_answer": "In 2023, MDLZ acquired Clif Bar, as noted in the 2023 10-K filing, with specific reference to the August 1, 2022 acquisition and related financial impacts such as integration costs and contingent consideration adjustments. By 2024, the relationship had evolved to include purchase price allocation adjustments for Clif Bar during the prior year, as detailed in the 2024 10-K filing. This indicates that the company had moved beyond the initial acquisition phase into a period of financial recalibration and consolidation of the Clif Bar acquisition.",
      "llm_answer": "In the 2023 filing MDLZ highlighted that its August 2022 acquisition of Clif Bar was still generating a measurable impact – it added about $529 million of incremental net revenue (constant‑currency) and the company recorded purchase‑price‑allocation adjustments for the brand as part of its acquisition‑related accounting. By the 2024 filing the Clif Bar brand appears only as an indefinite‑life intangible asset (grouped with other acquired brands) and no new acquisition‑related costs are shown, indicating the acquisition has been fully integrated into MDLZ’s ongoing asset base.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding the acquisition date and financial figures. The ground truth states that MDLZ acquired Clif Bar on August 1, 2022, which was disclosed in the 2023 10-K — this part is consistent with the LLM answer mentioning the August 2022 acquisition. However, the LLM introduces a specific figure of $529 million in incremental net revenue, which is not present in the original answer and cannot be verified from the provided ground truth. This number is therefore unsupported and likely incorrect, undermining quantitative accuracy. (2) There is no mention in the ground truth about the exact amount of revenue contributed by Clif Bar, so including $529 million constitutes a fabrication or hallucination. Additionally, while the LLM correctly notes purchase price allocation adjustments in 2023, it misattributes them to the 2023 filing as if they were new adjustments during that year, whereas the ground truth clarifies these were adjustments related to the prior year acquisition, now being finalized or reported in the 2024 filing. (3) The reasoning around integration progression — from active acquisition accounting in 2023 to full integration reflected in 2024 as part of indefinite-life intangibles — is logically sound and aligns with the multi-hop evolution described in the original answer. The synthesis across years and filings shows appropriate qualitative understanding of post-acquisition financial lifecycle. (4) Despite the incorrect number, the overall direction of the narrative — that Clif Bar moved from active acquisition accounting to consolidation — matches the ground truth, supporting a moderate correctness score. Contextual relevance is high because the response directly addresses the evolution of the relationship and financial activities. However, the inclusion of an unverified dollar amount significantly reduces quantitative accuracy, warranting a score of 4 for that dimension. Qualitative accuracy is stronger due to correct entity identification (MDLZ, Clif Bar), correct timeline framing, and reasonable inference about integration status in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 581,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Gulfstream's approach to energy efficient engines evolved from 2023 to 2024, and what specific aircraft developments reflect this shift?",
      "original_answer": "In 2023, Gulfstream emphasized its leadership in the use of sustainable aviation fuel (SAF) and energy efficient engines, focusing on continuous R&D investment to develop technologically advanced business jets. However, no new aircraft model powered by energy efficient engines was introduced that year. By 2024, Gulfstream had transitioned from announcement and development phases to actual production of energy efficient engines, as evidenced by the introduction of the G700, which features 'all-new engines' designed for high-speed performance and efficiency. This marks a tangible evolution from strategic positioning in 2023 to operational realization in 2024.",
      "llm_answer": "In 2023 Gulfstream framed its strategy around R&D and leadership in sustainable aviation fuel, saying it would bring all‑new, high‑speed, fuel‑efficient engines to the next‑generation G700 slated for early‑2024 entry into service. By 2024 the focus had shifted to deployment – the G700 entered service in March 2024, the newly launched G800 and G400 also use all‑new, lower‑emission engines, and Gulfstream highlighted operational SAF milestones such as the world’s first 100 % SAF trans‑Atlantic flight, reflecting a move from development to real‑world use of energy‑efficient propulsion.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution from R&D focus in 2023 to deployment in 2024 and correctly identifies the G700's entry into service with new efficient engines. However, it introduces significant inaccuracies: (1) The G800 and G400 are not mentioned in the original answer as being launched in 2024 or featuring all-new engines—this is unsupported by the ground truth and represents a factual overreach. (2) While the G700 entering service in March 2024 may be factually accurate, the original answer does not specify the date, so including it introduces precision not confirmed by the source. (3) The mention of a 'world’s first 100% SAF trans-Atlantic flight' is not present in the original answer and cannot be verified from the provided knowledge graph, making it extraneous and potentially misleading. These additions compromise quantitative and qualitative accuracy. The core multi-hop reasoning—shifting from strategic R&D in 2023 to operational realization in 2024 via the G700—is sound and aligns with the ground truth, supporting a moderate correctness score. Contextual relevance is high as the response directly addresses the evolution and aircraft developments. However, the inclusion of unverified aircraft models and SAF milestones reduces factual reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 358,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has AMD's relationship with semi-custom SoC products evolved from 2022 to 2024, particularly in terms of revenue structure and strategic positioning?",
      "original_answer": "In 2022, AMD's relationship with semi-custom SoC products was characterized by dependency, with revenue derived from both non-recurring engineering fees and sales of the products themselves, and success was directly tied to third-party product performance. By 2024, AMD's relationship evolved to one of active production and broader strategic integration, as semi-custom SoC products became part of a more diversified product portfolio that includes AI accelerators, GPUs, APUs, and DPUs. This shift indicates a more central and controlled role for AMD in the development and commercialization of these products, aligning them more closely with long-term industry trends and internal innovation strategies.",
      "llm_answer": "In the 2022 filing AMD described semi‑custom SoC revenue as “non‑recurring engineering fees … and revenue received in connection with sales of our semi‑custom SoC products,” stressing that the income depends on the customer’s product being launched and succeeding, with no control over the third‑party’s marketing. By the 2024 filing AMD lists “semi‑custom System‑on‑Chip (SoC) products” as a distinct product category and accounts the related “custom products” (primarily in the Gaming segment) using a cost‑plus, over‑time revenue‑recognition method, treating them as a strategic, recurring growth engine rather than a one‑off fee. This shows a shift from a largely opportunistic, non‑recurring revenue stream in 2022 to a more integrated, strategically positioned and systematically recognized line of business in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution of AMD's relationship with semi-custom SoC products from 2022 to 2024. In 2022, it accurately describes the revenue structure as based on non-recurring engineering (NRE) fees and product sales, with success dependent on third-party product performance—mirroring the original answer's emphasis on dependency and lack of control. By 2024, it correctly identifies a strategic shift: semi-custom SoCs are now treated as a distinct, recurring business line with cost-plus, over-time revenue recognition, indicating deeper integration and strategic importance. (2) There are no numeric values in the question or answers that require verification; all references to years (2022, 2024) and financial terms (NRE fees, cost-plus, revenue recognition) are used correctly and consistently with the original. (3) The multi-hop reasoning is sound—comparing AMD’s disclosures across two years and inferring a strategic evolution based on changes in revenue recognition and product categorization. The LLM correctly synthesizes information from different time points and interprets the implications of accounting method changes as indicators of strategic repositioning. (4) The only minor shortcoming is that the LLM answer does not explicitly mention the broader product portfolio integration (e.g., AI accelerators, GPUs, APUs, DPUs) highlighted in the original answer, which provides additional context for AMD’s strategic diversification. However, the core insight about increased strategic integration and shift from opportunistic to systematic revenue is fully preserved. Thus, the answer is semantically equivalent in substance, with only slight omission of contextual breadth. Scores reflect high accuracy, with a 9 on correctness due to this minor completeness gap.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 505,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the company's structure of preferred share authorization evolved between fiscal years 2023 and 2024, and what does this indicate about its capital strategy?",
      "original_answer": "The company's preferred share authorization structure remained unchanged between fiscal years 2023 and 2024, with 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value authorized in both years. Additionally, no Preferred Shares or A Preferred Shares were issued or outstanding in either year. This indicates that the company has not utilized or pursued any changes in its preferred share structure as part of its capital strategy during this period.",
      "llm_answer": "The authorized share capital remained the same in both years – Medtronic was authorized to issue 127.5 million $0.20‑par Preferred Shares and 500 thousand $1.00‑par “A” Preferred Shares (with none issued or outstanding in either FY 2023 or FY 2024). This unchanged preferred‑share framework shows the company is preserving a latent equity‑raising option but is not actively using preferred equity, underscoring a capital strategy that relies on ordinary‑share repurchases and other cash returns rather than issuing new preferred stock.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that the preferred share authorization remained unchanged between FY 2023 and FY 2024, with 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value authorized in both years. It also accurately notes that no shares were issued or outstanding in either year—this matches the ground truth exactly. (2) All numeric values (127.5 million, $0.20 par, 500 thousand, $1.00 par) are correct and consistently reported; no calculations were required, but the synthesis of authorization and issuance status is accurate. (3) The multi-hop reasoning is sound: the model correctly infers from the lack of changes and zero issuance that the company is not actively using preferred shares, which aligns with the ground truth’s conclusion about capital strategy. The LLM adds a slight interpretive layer—'preserving a latent equity-raising option' and 'relies on ordinary-share repurchases'—which is reasonable and contextually supported but not explicitly stated in the ground truth. This minor extrapolation does not introduce error but adds nuance. (4) The answer is fully contextually relevant, addresses both parts of the question (evolution of structure and capital strategy implication), and maintains semantic equivalence with the original answer. The only reason for not scoring a 10 is the slight addition of interpretive content not present in the ground truth, though it is logically sound and not misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 414,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the framing of reputational risk related to adverse publicity evolved between 2022 and 2024 in BK's risk disclosures, particularly in terms of associated impacts or linked concerns?",
      "original_answer": "In 2022, BK identified adverse publicity as a risk that could negatively affect its business, financial condition, and results of operations, and linked it with government scrutiny and other reputational harm. By 2024, the framing of this risk remained present but was expanded to include broader reputational impacts from sustainability concerns such as climate change and diversity, in addition to being tied to new operational models like the platforms operating model transition. This indicates a broadening of the contexts in which adverse publicity could negatively impact BK's reputation and business outcomes.",
      "llm_answer": "In the 2022 Form 10‑K the company listed reputational risk in a single, generic bullet – “our businesses may be negatively affected by adverse events, publicity, government scrutiny or other reputational harm” (BK 2022 p. 5). By the 2024 filing the same wording is retained (BK 2024 p. 4) but is now supplemented by separate risk statements that climate‑change and broader sustainability concerns “could … damage our reputation” (BK 2024 p. 4‑5), linking adverse publicity to ESG‑related issues. Thus the framing has broadened from a generic reputational‑harm clause to an explicit connection between adverse publicity and environmental/social concerns.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, BK framed reputational risk generically, citing adverse publicity, government scrutiny, and reputational harm (citing the correct document location, p. 5). In 2024, it notes the retention of that language and the addition of explicit links between sustainability concerns—specifically climate change—and reputational damage (pp. 4–5), which matches the original answer’s claim about broadening to include ESG/sustainability issues. (2) There are no numeric values to verify, so quantitative accuracy is not applicable beyond correct years (2022, 2024), which are accurate. (3) The multi-hop reasoning is sound: the model synthesizes changes across two filings, identifies continuity (retention of original language) and evolution (addition of ESG-related risks), and correctly infers a broadening in framing. The only minor omission is that the original answer also mentions the link to the 'platforms operating model transition' as a new context for reputational risk in 2024, which the LLM answer does not address. This missing element prevents a perfect 10 on correctness and qualitative accuracy. (4) Despite this, the LLM captures the core evolution—linking adverse publicity to ESG and sustainability issues—and does so with precise citations and logical flow, making it contextually highly relevant and factually strong overall.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 399,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How did Amazon's financial investment and valuation approach toward Anthropic, PBC evolve from 2023 to 2024, particularly in terms of investment classification and the factors affecting its valuation?",
      "original_answer": "In 2023, Amazon disclosed a $1.25 billion convertible note investment in Anthropic, PBC, classified as available-for-sale and reported at fair value with unrealized gains and losses included in 'Accumulated other comprehensive income (loss).' The note was categorized as a Level 3 asset, and Amazon had an agreement to invest an additional $2.75 billion in a second convertible note by Q1 2024. By 2024, the investment was still classified as available-for-sale but was noted to be part of a broader portfolio of convertible debt investments in private companies, primarily referencing Anthropic, PBC. The 2024 filing emphasized increased complexity in valuing private company investments due to the lack of readily available market data and global economic uncertainty, indicating a shift toward acknowledging heightened valuation risk. While the classification remained consistent, the 2024 disclosure placed more emphasis on the challenges of valuation rather than the mechanics of the investment itself.",
      "llm_answer": "In 2023 Amazon disclosed that it had invested $1.25 billion in a convertible note from Anthropic, PBC, which it classified as an available‑for‑sale Level 3 asset measured at fair value, with unrealized gains and losses reported in accumulated other‑comprehensive income and an option to invest up to $2.75 billion in a second note (page 50). By the 2024 filing the Anthropic investment remained an available‑for‑sale convertible‑debt investment measured at fair value, but Amazon emphasized that valuing private‑company securities such as Anthropic is inherently more complex because of limited market data and heightened uncertainty from current global economic conditions, which affect the fair‑value estimate (page 32).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $1.25 billion 2023 investment, classification as available-for-sale Level 3 asset, reporting of unrealized gains/losses in accumulated other comprehensive income, and the $2.75 billion option (correctly described as an option, though the original specifies it as an agreement to invest by Q1 2024). The 2024 classification remains the same, and the increased emphasis on valuation complexity due to lack of market data and global economic uncertainty is accurately reflected. (2) Quantitative accuracy is perfect: all dollar amounts ($1.25B, $2.75B) and years (2023, 2024) are correct, with no calculation errors. (3) Multi-hop reasoning is sound—information is synthesized across two years and correctly attributes changes in disclosure tone and focus. The only minor shortcoming is that the LLM refers to an 'option' to invest $2.75 billion, whereas the original specifies a binding agreement to invest by Q1 2024, which slightly weakens the qualitative precision. (4) Contextual relevance is excellent—the answer directly addresses the evolution in investment classification and valuation approach, focusing on the shift in disclosure emphasis from mechanics to valuation risk. Overall, the answer is factually complete and semantically equivalent to the ground truth with only a minor nuance missing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 390,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the nature of the risks related to the protection of MDLZ's intellectual property, including know-how, evolved between 2023 and 2024?",
      "original_answer": "In 2023, MDLZ emphasized the importance of protecting its intellectual property rights, particularly trademarks, patents, copyrights, and know-how, through a combination of legal mechanisms such as patent and trademark laws, licensing agreements, and third-party nondisclosure agreements. The company expressed concern that failure to protect these rights or any legal changes reducing intellectual property protections—especially in response to developments in artificial intelligence technologies—could significantly harm its competitiveness and financial condition. In 2024, while the company maintained its emphasis on the significance of intellectual property rights, it did not specifically mention artificial intelligence as a factor affecting protection. Instead, the 2024 disclosure focused on the broader risks of legal or regulatory non-compliance and the potential for civil or criminal penalties, reputational damage, and financial loss due to litigation or enforcement actions. This shift indicates a broadening of the risk context without the specific emphasis on AI-related threats present in 2023.",
      "llm_answer": "Both the 2023 and 2024 filings stress that MDLZ’s competitiveness depends on protecting its trademarks, patents, copyrights, trade‑secrets, recipes, technology, know‑how and licensing agreements, and they warn that failures‑to‑protect (including challenges from AI‑driven technologies or changes in law) could materially harm the business. The 2024 filing adds a more explicit statement that the company may be “unaware of potential third‑party claims” and could face costly litigation, injunctions or license‑fee obligations, but the underlying nature of the IP‑protection risk remains essentially unchanged. (2023 p. 26‑27; 2024 p. 27)",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy in its qualitative analysis that undermines the correctness of the conclusion. (1) The answer correctly identifies that both 2023 and 2024 filings emphasize the importance of protecting MDLZ's intellectual property, including trademarks, patents, copyrights, know-how, and trade secrets, which aligns with the ground truth. It also correctly notes that failure to protect IP could materially harm the business. However, the key evolution between 2023 and 2024 is misrepresented: the LLM claims the 'underlying nature of the IP-protection risk remains essentially unchanged,' which directly contradicts the ground truth. In reality, there was a notable shift—2023 specifically highlighted AI-driven technologies as a risk to IP protection, while 2024 removed that emphasis and instead broadened the risk to include legal/regulatory non-compliance, reputational damage, and enforcement actions. This evolution is central to the question and was missed by the LLM. (2) There are no numerical values in the response or ground truth, so quantitative accuracy is not applicable; the score of 10 reflects no errors in this dimension. (3) The multi-hop reasoning is flawed: the model fails to synthesize the change in emphasis from AI-specific risks in 2023 to broader compliance and litigation risks in 2024. Instead, it incorrectly asserts continuity. The citation of page numbers (2023 p. 26–27; 2024 p. 27) suggests document grounding, but the interpretation is inaccurate. (4) Contextual relevance is high because the answer addresses IP protection and cites relevant risk factors, but the failure to capture the nuanced shift in risk framing reduces its overall correctness. Thus, while the answer contains accurate elements, it misses the core analytical point of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 500,
        "total_tokens": 1937
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has Goldman Sachs' treatment of Non-Employee Director Equity Award Agreements evolved between the 2023 and 2024 SEC filings, particularly in terms of referenced agreements and their timelines?",
      "original_answer": "In 2023, Goldman Sachs referenced Non-Employee Director Equity Award Agreements through Exhibit 10.17, which pointed to an amendment dated November 28, 2008. By 2024, the company continued to disclose these agreements under the same exhibit number (10.18), but the referenced source shifted to Exhibit 10.69 from the 2008 Annual Report, indicating a formalization or consolidation of prior amendments. This evolution shows a continuation of the policy with deeper historical documentation being emphasized in the later filing.",
      "llm_answer": "In the 2023 Form 10‑K the only non‑employee director equity‑award reference was a single entry – “Amendments to Certain Non‑Employee Director Equity Award Agreements,” incorporated by reference to Exhibit 10.69 covering the fiscal year ended November 28 2008. The 2024 filing expands that disclosure: it still cites the 2008 amendment (Exhibit 10.69) but also adds a “Form of Non‑Employee Director RSU Award Agreement (pre‑2015)” (Exhibit 10.21 for the fiscal year ended December 31 2014) and lists the RSU award forms (Exhibits 10.32 and 10.33). Thus, Goldman Sachs moved from referencing only the historic 2008 amendment to also referencing the underlying pre‑2015 RSU award agreement from the 2014 fiscal year.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The 2023 filing is incorrectly described: the ground truth states that in 2023, Goldman Sachs referenced the Non-Employee Director Equity Award Agreements via Exhibit 10.17 pointing to the November 28, 2008 amendment, not Exhibit 10.69 as the LLM claims. Exhibit 10.69 is correctly noted as part of the 2008 Annual Report, but the LLM misattributes its use to the 2023 filing as the sole reference, which contradicts the ground truth. (2) The LLM claims the 2024 filing cites Exhibit 10.69 *and* adds Exhibits 10.21, 10.32, and 10.33, including a 'Form of Non-Employee Director RSU Award Agreement (pre-2015)' from 2014. However, the ground truth states that in 2024, the company continued under Exhibit 10.18 (not 10.17 or others) and shifted the reference to Exhibit 10.69 from the 2008 Annual Report — there is no mention of adding new exhibits from 2014 or new RSU forms. (3) The multi-hop reasoning is flawed: the LLM invents a narrative of expansion and addition of pre-2015 agreements, while the actual evolution described in the ground truth is a consolidation or formalization by referencing deeper historical documentation under the same exhibit structure (10.17 → 10.18). (4) Dates are partially correct (November 28, 2008 is accurate), but the LLM incorrectly introduces December 31, 2014 as a fiscal year end for Goldman Sachs without verification. Overall, the answer misrepresents the exhibits, their numbering, their evolution, and the nature of the changes between years, leading to a low correctness score. While the general theme of 'referencing historical agreements' is contextually relevant, the specific facts and reasoning are largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 476,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has BKNG's relationship with travel service providers evolved between 2022 and 2023 in terms of revenue recognition and contractual responsibilities?",
      "original_answer": "In 2022, BKNG described its relationship with travel service providers as one where it connects consumers to providers through its platforms, emphasizing its role as an intermediary without taking responsibility for delivering the travel services. The company highlighted that it earns revenues primarily from facilitating reservations and also mentioned the impact of cancellations during the pandemic recovery phase. By 2023, BKNG provided more detailed accounting treatment around its contracts with travel service providers, specifying that it recognizes revenue on a net basis due to its role as an agent, and further clarified its revenue recognition timing as occurring at the point when travelers begin using the arranged services. This reflects a shift from a general description of the relationship to a more structured and accounting-driven dependency on travel service providers, particularly in how it recognizes commissions and transaction revenues.",
      "llm_answer": "In 2022 Booking Holdings began shifting more of its business to a merchant model, facilitating payments to travel‑service providers and recognizing “merchant revenues” on a net basis (commissions, transaction‑net amounts, credit‑card rebates) while deducting incentives and loyalty points at the time they are granted【page_50】. By the 2023 filing the company spells out that its contracts still give providers the right to market availability without transferring delivery responsibility, but revenue is now recognized on a net basis at the point post‑booking services are completed (or at booking for merchant transactions), with cash received in advance recorded as “Deferred merchant bookings” and incentives recorded as reductions when granted【page_83】【page_84】. Thus, the relationship has evolved to a more explicit, timing‑focused revenue‑recognition framework and clearer accounting for deferred payments and incentives.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its description of BKNG's evolving revenue recognition and contractual responsibilities between 2022 and 2023, with accurate qualitative details and proper citation of accounting treatments. It correctly identifies the shift to net revenue recognition, timing of revenue recognition (at service completion or booking), treatment of incentives, and the use of deferred revenue accounts. The quantitative accuracy is high—no specific numerical values are in dispute, and all referenced accounting concepts (net basis, deferred revenue, timing) align with the ground truth. However, the LLM introduces the term 'merchant model' and 'merchant revenues' as a central shift, which is not emphasized in the original answer; the ground truth focuses on BKNG clarifying its role as an agent and thus recognizing revenue on a net basis, not necessarily a structural shift to a merchant model. This introduces a potential mischaracterization of the nature of the evolution—framing it more as a business model change rather than an accounting clarification. Additionally, while the LLM mentions 'Deferred merchant bookings' and specific page citations, these details, though plausible, slightly overreach the scope of the original answer, which emphasizes the increased specificity in accounting policy rather than operational model shifts. The multi-hop reasoning is sound in connecting changes in revenue recognition timing and contract accounting across years, but the emphasis on the 'merchant model' distorts the primary narrative of enhanced accounting transparency. Thus, while factually consistent in key aspects, the answer diverges in emphasis and framing, warranting a 7 for correctness and qualitative accuracy. Contextual relevance remains high as it directly addresses revenue recognition and contractual dynamics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1474,
        "completion_tokens": 499,
        "total_tokens": 1973
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "What specific changes occurred in the structure of Goldman Sachs' executive life insurance policy disclosures between the 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs included the Goldman Sachs & Co. LLC Executive Life Insurance Policy and Certificate with Metropolitan Life Insurance Company (Exhibit 10.11) and a form of the policy with Pacific Life & Annuity Company (Exhibit 10.12). In the 2024 10-K filing, these exhibits were not only retained but renumbered to 10.12 and 10.13 respectively, indicating a reorganization of exhibit numbering. This renumbering and retention of the policies in the 2024 filing demonstrates a structural update in how the policies are presented within the filing, rather than a substantive change in the policies themselves.",
      "llm_answer": "In the 2023 Form 10‑K the executive‑life‑insurance disclosures appeared as Exhibit 10.11 (Metropolitan Life policy) and Exhibit 10.12 (Pacific Life policy) 【page_5†L10-L13】. In the 2024 Form 10‑K those same items were moved down one slot—Metropolitan Life became Exhibit 10.12 and Pacific Life became Exhibit 10.13—after a new General Guarantee Agreement was inserted as Exhibit 10.11 【page_246†L10-L14】. The change is therefore a renumbering of the exhibit schedule, not a change in the policy content.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately identifies the exhibit numbers for the executive life insurance policies in both the 2023 and 2024 10-K filings: Exhibit 10.11 and 10.12 in 2023 (Metropolitan Life and Pacific Life, respectively), and their renumbering to 10.12 and 10.13 in 2024. (2) The quantitative details—exhibit numbers and their renumbering—are precisely correct, with no calculation or numeric errors. (3) The reasoning is sound and correctly infers that the change is structural (renumbering due to insertion of a new Exhibit 10.11, the General Guarantee Agreement) rather than substantive, demonstrating accurate multi-hop synthesis between the two filings. (4) The answer is contextually relevant, directly addressing the question about structural changes in disclosure format. Minor wording differences (e.g., 'moved down one slot' vs 'renumbered') do not affect semantic equivalence—the core information about exhibit reorganization is preserved and accurately conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 298,
        "total_tokens": 1582
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has the strategic importance and manufacturing approach for FBAR filters evolved between 2022 and 2024, particularly in terms of internal fabrication and competitive positioning?",
      "original_answer": "In 2022, FBAR filters were highlighted as a key product utilizing Broadcom’s proprietary processes, fabricated internally to protect IP and accelerate time to market, alongside vertical-cavity surface emitting lasers and side emitting lasers. The internal fabrication was specifically emphasized as a means to maintain competitive advantage by safeguarding innovation. By 2024, FBAR filters remained part of the internal fabrication strategy, but the context expanded to include a more comprehensive list of competitors in the semiconductor space, such as Qorvo, Qualcomm, and Skyworks, indicating a more intense competitive environment. This suggests that while the internal manufacturing strategy for FBAR filters remained consistent, the competitive pressure in wireless communications increased significantly, requiring Broadcom to reinforce its IP protections and innovation cycle.",
      "llm_answer": "In the 2022 filing Broadcom highlighted FBAR filters as a key proprietary technology – they are produced in‑house at its U.S. and Singapore III‑V fabs to protect IP, accelerate time‑to‑market, and are explicitly cited as a competitive differentiator (“high‑speed proprietary design expertise, FBAR technology”)【page_13】. By the 2024 filing the discussion of internal manufacturing is broader, referring only to “fabrication capabilities for devices manufactured internally” without singling out FBAR filters, indicating the technology has become a mature part of the portfolio while the company’s competitive positioning now emphasizes overall proprietary design and high‑speed solutions rather than FBAR alone【page_13】.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that FBAR filters were a key proprietary technology in 2022, fabricated internally in the U.S. and Singapore using III-V fabs to protect IP and accelerate time-to-market, which aligns with the ground truth. It also correctly notes that in 2024, the mention of FBAR filters specifically in the context of internal fabrication is no longer highlighted, suggesting maturation of the technology. However, the LLM answer diverges from the ground truth by concluding that FBAR filters are no longer emphasized, while the original answer states they remained part of the internal fabrication strategy—just within a broader competitive context. The LLM incorrectly implies a strategic downgrading or de-emphasis of FBAR, whereas the ground truth indicates continuity in manufacturing approach but increased competitive pressure. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable beyond correct use of years (2022, 2024), which are accurate. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes information across two years and infers strategic shifts. However, it fails to incorporate the key point from the ground truth that FBAR filters are still part of the internal fabrication strategy in 2024 and that the competitive landscape now explicitly includes Qorvo, Qualcomm, and Skyworks—critical context for competitive positioning. The LLM omits this entirely, weakening the qualitative accuracy. (4) The correctness score is 6 due to partial factual alignment—core elements about internal fabrication and IP protection are correct, but the evolution in competitive positioning is misrepresented. Qualitative accuracy is 6 due to flawed reasoning about strategic de-emphasis. Quantitative accuracy is 10 (no numbers, but years correct). Contextual relevance is 8 because the response stays on topic and addresses strategic importance and manufacturing, though with incomplete competitive context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 550,
        "total_tokens": 1960
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BMY's strategic positioning of Krazati evolved between 2023 and 2024, particularly in terms of clinical development focus and financial valuation?",
      "original_answer": "In 2023, Krazati was positioned as part of BMY’s oncology portfolio with specific clinical trials listed: KRYSTAL-17 for 1L NSCLC TPS<50%, KRYSTAL-10 for 2L CRC, and KRYSTAL-12* for 2L+ Mutated NSCLC. By 2024, BMY had acquired Mirati for $4.8 billion, securing full rights to Krazati, which had already received FDA and EMA approvals for second-line NSCLC and FDA approval for advanced KRAS-mutated colorectal cancer. Additionally, Krazati was now being developed in combination with a PD-1 inhibitor for first-line NSCLC, indicating a significant expansion in its clinical and commercial strategy.",
      "llm_answer": "In the 2023 filing Krazati was still a late‑stage pipeline asset, slated for three registrational trials – KRYSTAL‑17 (first‑line NSCLC), KRYSTAL‑10 (second‑line colorectal cancer) and KRYSTAL‑12 (second‑line‑plus KRAS‑mutated NSCLC) (see pages 12 & 14). By the 2024 filing, after the $4.8 billion Mirati acquisition, Krazati had become an FDA/EMA‑approved product for second‑line NSCLC and KRAS‑mutated colorectal cancer, with a new development focus on a first‑line NSCLC combination with a PD‑1 inhibitor, and its acquired marketed product rights were valued at roughly $640 million of definite‑life intangible assets (see pages 93 & 94).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Krazati's 2023 clinical development included KRYSTAL-17 (1L NSCLC), KRYSTAL-10 (2L CRC), and KRYSTAL-12 (2L+ KRAS-mutated NSCLC); by 2024, after BMY's $4.8 billion acquisition of Mirati, Krazati gained FDA/EMA approval for second-line NSCLC and FDA approval for KRAS-mutated colorectal cancer. The shift to combination therapy with a PD-1 inhibitor in first-line NSCLC is correctly noted. (2) Quantitatively, the $4.8 billion acquisition cost is accurate. The $640 million valuation of definite-life intangible assets for Krazati is not in the original answer but appears to be an additional detail from the filing; since it does not contradict the ground truth and is likely correct based on source documents, it does not penalize the score. No calculation errors. (3) Multi-hop reasoning is sound: the model correctly links BMY’s acquisition of Mirati to full control of Krazati, connects approval milestones across jurisdictions, and identifies the strategic shift in clinical focus. (4) The answer is contextually complete and directly addresses both clinical development evolution and financial valuation aspects of the question. The only minor limitation is that the original answer does not mention the $640M intangible asset valuation, so including it introduces a detail not confirmed by the ground truth, but it does not appear incorrect. Thus, the response earns a 9/10 for correctness—excellent but with a slight overreach on unverified financial detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 429,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has the relationship between BKNG and travel service providers evolved between 2022 and 2023, particularly in terms of how BKNG manages financial obligations and incentives related to these providers?",
      "original_answer": "In 2022, BKNG primarily competed with travel service providers, highlighting the intense and evolving nature of the competitive landscape in the online travel market. By 2023, BKNG's relationship with travel service providers shifted to a more dependent model, as evidenced by the increase in the 'Deferred merchant bookings' liability on its balance sheet, which reflects amounts estimated to be payable to travel service providers. Additionally, BKNG introduced more incentive programs, such as referral bonuses, rebates, and loyalty points, which are recognized as a reduction of revenue, indicating a strategic shift toward enhancing partnerships and incentivizing collaboration with travel service providers rather than solely competing with them.",
      "llm_answer": "In 2022 Booking Holdings described its ties to travel‑service providers mainly as a broad, mutually‑beneficial partnership that expands the providers’ distribution and marketing reach (2022 p. 6‑7). By 2023 the company has moved to a more granular, liability‑focused model: prepaid traveler funds are recorded as “deferred merchant bookings” that represent amounts payable to providers, and a suite of incentive programs—including referral bonuses, rebates, credits and loyalty‑point awards—are explicitly accounted for as reductions of revenue when granted (2023 p. 84‑83). This reflects an evolution from a high‑level partnership narrative to detailed management of financial obligations and provider incentives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the original answer, with only minor differences in framing. (1) The key facts are correct: the shift from a partnership/competitive dynamic in 2022 to a more liability- and incentive-focused model in 2023 is accurately described. The mention of 'deferred merchant bookings' as a liability and the treatment of incentives (referral bonuses, rebates, loyalty points) as revenue reductions aligns exactly with the ground truth. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised; all references to years (2022, 2023) and financial terms are correct. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes changes in BKNG’s relationship with providers over time, drawing from balance sheet items and accounting policies across two years. The only minor shortcoming is that the original answer emphasizes a shift 'from competition to dependence,' while the LLM frames 2022 as a 'mutually-beneficial partnership'—a slightly more positive characterization than the 'competitive' tone in the original. However, this does not contradict the data and may reflect interpretation of the same narrative. (4) Contextual relevance is excellent: all parts of the question—evolution of the relationship, financial obligations, and incentives—are addressed with precise, document-supported details. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 425,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Broadcom's involvement in the development of Custom Touch Controllers evolved from 2022 to 2024, particularly in terms of their role in the product lifecycle?",
      "original_answer": "In 2022, Broadcom was described as supplying Custom Touch Controllers as part of its semiconductor solutions for the wireless market. By 2024, the company's role had evolved to include producing these controllers as part of its broader custom silicon solutions, reflecting a deeper engagement in their development. This shift indicates a strategic move from being a component supplier to an active producer involved in the design and creation process.",
      "llm_answer": "In the 2022 filing Broadcom simply listed “custom touch controllers” as a product family within its wireless segment, indicating a component‑supply role (see page_7). By the 2024 filing the company has folded those controllers into its Mobile Device Connectivity Solutions, describing them as processing touch‑screen signals in handsets and tablets and positioning them as an integrated part of the solution set—showing a broader, end‑to‑end involvement across the product‑development lifecycle (see page_6).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth in terms of Broadcom's evolving role in Custom Touch Controllers from 2022 to 2024. In 2022, the company's role was correctly characterized as a component supplier, listing 'custom touch controllers' as a product within its wireless segment (per page_7 reference). By 2024, the answer accurately reflects a strategic shift by integrating these controllers into 'Mobile Device Connectivity Solutions' and describing their function in processing touch-screen signals, indicating deeper involvement in the product lifecycle (per page_6). This mirrors the ground truth's assertion of a move from supplier to active producer in design and development. All entities (Broadcom, Custom Touch Controllers, correct years) are accurate. There are no numeric values to verify, so quantitative accuracy is scored as 10. The reasoning is sound and demonstrates multi-hop synthesis across two years of filings. The only minor shortcoming is that the LLM does not explicitly use the term 'custom silicon solutions' as in the original answer, which slightly weakens the linkage to the broader strategic framing—but the semantic meaning of increased integration and lifecycle involvement is preserved. Hence, qualitative accuracy is 9. Contextual relevance is perfect, directly addressing the evolution in Broadcom’s role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 381,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Union Pacific's approach to freight cars evolved from 2023 to 2024, particularly in terms of asset acquisition strategy?",
      "original_answer": "In 2023, Union Pacific primarily leased freight cars as part of its operational strategy, reflecting a reliance on leased assets for rail operations. By 2024, the company's strategy shifted toward acquiring freight cars, including lease buyouts of $143 million in 2024 compared to $57 million in 2023, indicating a more aggressive stance on asset ownership to support replacement and growth opportunities.",
      "llm_answer": "In 2023 Union Pacific’s freight‑car strategy was lease‑heavy – it reported $1.64 billion of operating‑lease assets and $1.25 billion of operating‑lease liabilities (page 68) and only $57 million of lease‑buyouts within its $728 million “locomotives and freight cars” capital spend (page 33). By 2024 the company shifted toward ownership, raising total spending on locomotives and freight cars to $788 million (up from $728 million) and increasing lease‑buyouts to $143 million, while cutting operating‑lease liabilities to $1.27 billion (page 31), indicating a move from leasing to acquiring more owned freight‑car assets.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the shift in Union Pacific's strategy from leasing in 2023 to increased acquisition in 2024, including the key metric of lease buyouts rising from $57M to $143M. (2) Quantitatively, all cited numbers are correct: $57M and $143M for lease buyouts in 2023 and 2024 respectively; $728M and $788M in capital spending on locomotives and freight cars; and operating lease liabilities decreasing to $1.27B in 2024 (though the 2023 liability figure of $1.25B is accurate, the slight increase to $1.27B in 2024 appears inconsistent with the stated strategy shift—this may reflect reporting nuances but does not contradict the overall trend of reduced leasing reliance). The $1.64B operating lease assets in 2023 is additional context not in the original answer but is factually consistent. (3) The multi-hop reasoning is sound: the model synthesizes data across years, distinguishes between lease liabilities and buyouts, and infers a strategic shift toward ownership. (4) The answer is semantically equivalent to the ground truth, with added detail (e.g., total capital spend) that enhances completeness without introducing error. One minor point: the original answer emphasizes the strategic intent (replacement and growth), which is slightly underemphasized in the LLM response, but the inference is still clear. Hence, a score of 9 is justified—excellent accuracy with negligible omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 407,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "What were the financial and operational impacts of Nike's structural changes in APLA between FY2022 and FY2023, particularly regarding the transition of certain businesses to third-party distributors?",
      "original_answer": "In FY2022, Nike directly operated within APLA as part of its geographic operating segments, which included associated costs and foreign currency impacts such as non-recurring impairment charges due to the anticipated release of non-cash cumulative foreign currency translation losses from transitioning certain businesses to third-party distributors. By FY2023, Nike had shifted its relationship with APLA from direct operations to a strategic stake, where the company now oversees results through third-party distributors. This transition is reflected in the 2023 filing noting that APLA includes results for the NIKE and Jordan brands and referencing Note 18 on divestitures related to the transition. Operationally, this change represents a strategic shift to reduce direct operational overhead in APLA, likely aiming to improve financial efficiency and focus on brand management rather than local execution.",
      "llm_answer": "Nike’s Asia Pacific & Latin America (APLA) segment grew its total revenue from $5.96 bn in FY 2022 to $6.43 bn in FY 2023, with wholesale sales rising from $3.53 bn to $3.74 bn and direct‑to‑consumer sales from $2.43 bn to $2.70 bn (see FY 2022 vs. FY 2023 tables on pages 88 & 87).  EBIT for APLA also improved modestly, increasing from $1.90 bn to $1.93 bn (page 90), reflecting the operational benefit of moving certain APLA businesses to third‑party distributors—a transition highlighted in Note 18 (footnote 1 on page 87).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to align with the ground truth in both factual content and reasoning. (1) The financial figures cited—such as APLA revenue of $5.96B in FY2022 and $6.43B in FY2023, along with breakdowns of wholesale and DTC sales and EBIT increases—are not supported by the original answer and appear fabricated or misattributed. The ground truth does not provide any specific revenue or EBIT numbers for APLA in either fiscal year, nor does it mention growth in those metrics. (2) The claim that EBIT improved from $1.90B to $1.93B due to the transition to third-party distributors is unsupported; the original answer references non-recurring impairment charges related to foreign currency translation losses, not EBIT improvements. (3) The qualitative shift described in the original answer—moving from direct operations to a strategic stake with oversight via third-party distributors, resulting in a structural reduction in operational overhead—is entirely missing from the LLM response. Instead, the LLM incorrectly frames the transition as an operational efficiency gain reflected in rising revenues and stable EBIT, which contradicts the nature of the change described in the ground truth. (4) The LLM references Note 18 correctly in context, but uses it to justify incorrect financial claims rather than the divestiture and non-cash foreign currency impacts emphasized in the original. The multi-hop reasoning required—linking the structural change to financial impacts like impairment charges and strategic rationale—is absent. While the answer is contextually relevant by addressing APLA and the transition, its factual inaccuracies and incorrect numerical data severely undermine its validity. Minor credit is given for referencing the correct region and noting a transition tied to Note 18.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 494,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Broadcom's involvement with InP lasers evolved from 2022 to 2024, particularly in terms of their internal fabrication strategy and competitive positioning?",
      "original_answer": "In 2022, Broadcom disclosed using internal fabrication facilities for products based on proprietary processes, including vertical-cavity surface emitting lasers and side emitting lasers using GaAs and InP lasers for fiber optic communications. By 2024, Broadcom continued this strategy but began emphasizing the competitive landscape more explicitly, listing companies like Coherent Corp., Lumentum Holdings Inc., and others as competitors in semiconductor solutions. This indicates a strategic shift toward highlighting InP laser capabilities as part of its competitive differentiation in the market.",
      "llm_answer": "In 2022 Broadcom said it kept the production of its GaAs‑ and InP‑based vertical‑cavity surface‑emitting and side‑emitting lasers for fiber‑optic communications in its own III‑V wafer fabs in the United States and Singapore, using internal fabrication to protect IP and accelerate time‑to‑market while outsourcing commodity CMOS processes (AVGO 2022 10‑K, p. 13). The 2024 filing repeats that same internal‑fabrication strategy for InP lasers, indicating the approach has not changed and that Broadcom continues to rely on its proprietary fab capability to differentiate itself in a market that includes many integrated device manufacturers, fabless firms and specialist optical‑laser companies such as Lumentum and MACOM (AVGO 2024 10‑K, p. 15; competition list in 2022 p. 13).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Broadcom used internal III-V wafer fabs in the U.S. and Singapore in 2022 for GaAs and InP lasers (AVGO 2022 10-K, p. 13), and this strategy continued into 2024 (AVGO 2024 10-K, p. 15). The mention of outsourcing commodity CMOS processes adds contextual detail not in the original but is consistent with Broadcom's strategy and does not detract from accuracy. (2) There are no numeric values requiring calculation, but dates (2022, 2024) and entity names (Lumentum, MACOM) are correctly cited. The original answer mentions Coherent Corp. and Lumentum as competitors; the LLM includes Lumentum and MACOM—MACOM is not in the original but is a plausible competitor and does not constitute a major error. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes information across two years of 10-K filings to show continuity in internal fabrication and evolving competitive positioning. It correctly infers that continued reliance on proprietary fabrication serves as a differentiator, which is consistent with the strategic emphasis in the 2024 filing. (4) The LLM slightly expands the list of competitors beyond the original (adding MACOM, omitting Coherent Corp.), which is a minor deviation but not a significant factual error given the competitive landscape. Otherwise, the answer captures the evolution in Broadcom’s strategic communication—maintaining internal fabrication while increasingly framing it within competitive differentiation. Wording differs but semantic meaning matches. Thus, the answer earns a 9 for correctness—excellent but not perfect due to minor competitor list variance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 466,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the ownership structure of Swoosh, LLC in relation to NIKE's Class A and Class B Common Stock evolved between 2022 and 2023, and what implications does this have for shareholder influence?",
      "original_answer": "In 2022, Swoosh, LLC beneficially owned approximately 77% of NIKE's Class A Common Stock, which would translate to approximately 16% ownership of Class B Common Stock if all shares were converted. In 2023, the ownership structure remained consistent with Swoosh, LLC still beneficially owning approximately 77% of Class A Common Stock, with a commensurate ownership percentage of approximately 16% in Class B Common Stock if all shares were converted. Despite the consistency in ownership percentages, the continued concentration of ownership in Swoosh, LLC implies sustained influence by Travis Knight, who has a significant role in managing the Class A Common Stock owned by Swoosh, LLC, potentially affecting shareholder decisions and market dynamics.",
      "llm_answer": "In the 2022 filing Nike disclosed that Swoosh LLC owned about 77 % of the company’s Class A shares – a stake that would become roughly 16 % of the Class B pool if all were converted (2022 Form 10‑K, p. 25). The 2023 filing repeats the same figures – Swoosh LLC still holds about 77 % of Class A (and would be ~16 % of Class B on conversion) (2023 Form 10‑K, p. 26). Because Class A shares elect three‑quarters of the board, this unchanged concentration gives Swoosh LLC (and the Knight family) decisive voting power, limiting the influence of other shareholders unless a conversion to Class B occurs, which would dilute that control.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: 77% ownership of Class A Common Stock and ~16% implied ownership of Class B upon conversion for both 2022 and 2023 are accurately reported, matching the original answer. The citation of Form 10-K pages adds precision. (2) The answer correctly identifies that the ownership structure remained consistent between the two years, fulfilling the multi-hop requirement across time periods. (3) Entity accuracy is strong: Swoosh, LLC, NIKE’s share classes, and the Knight family (implied through 'Knight family' reference) are correctly identified. (4) Reasoning is sound—LLM correctly infers that the concentrated ownership in Class A, which elects three-quarters of the board, gives Swoosh, LLC decisive voting power, thus limiting influence of other shareholders. This aligns with the original answer’s point about sustained influence by Travis Knight. The only minor shortcoming is that the LLM attributes influence to the 'Knight family' generally, while the ground truth specifically names Travis Knight as having a significant management role. This slight shift in specificity prevents a perfect 10 on qualitative accuracy, but the core implication about control and shareholder influence is correctly conveyed. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 390,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did PMI's strategic positioning of Reduced-Risk Products evolve from 2022 to 2023, particularly in terms of portfolio integration and market availability?",
      "original_answer": "In 2022, PMI classified Reduced-Risk Products (RRPs) as a distinct category, including heated tobacco units, heat-not-burn devices, e-vapor, and oral nicotine products, with separate net revenue reporting. By 2023, RRPs were integrated into a broader category called Smoke-Free Products (SFPs), which now also included wellness and healthcare offerings. Additionally, PMI reported that its smoke-free products were available in 84 markets by the end of 2023, a notable expansion from the unspecified market availability in 2022. This evolution reflects a strategic shift toward consolidating RRPs under a unified smoke-free vision and expanding their global footprint.",
      "llm_answer": "In the 2022 filing PMI described reduced‑risk products (RRPs) as a broad, developing “smoke‑free” suite—including heat‑not‑burn, e‑vapor and oral nicotine—led by its IQOS brand and treated as a separate product category (PM 2022 p. 95). By the 2023 filing, after acquiring Swedish Match, PMI emphasized that the ZYN oral‑nicotine franchise was being combined with IQOS into a unified smoke‑free portfolio, that Swedish Match results would be folded into the four geographic segments, and that its smoke‑free products were now sold in 84 markets (PM 2023 p. 28‑29).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: PMI treated RRPs as a separate category in 2022, and by 2023 integrated them into a broader smoke-free portfolio, now including ZYN following the Swedish Match acquisition. The market availability of 84 markets in 2023 is correctly reported, matching the ground truth. (2) Quantitative accuracy is perfect: the number '84 markets' is correctly cited, and no other numerical errors exist. Format and sourcing (page references) are consistent with accurate retrieval. (3) Multi-hop reasoning is sound: the answer synthesizes information across 2022 and 2023 filings, correctly identifying the strategic shift post-acquisition of Swedish Match and the integration of ZYN with IQOS. It captures the portfolio integration and market expansion aspects of the question. (4) The only minor shortcoming is that the LLM does not explicitly mention the inclusion of 'wellness and healthcare offerings' in the 2023 Smoke-Free Products category as noted in the ground truth, which slightly reduces completeness in qualitative accuracy. However, the emphasis on ZYN and IQOS integration captures the core of the portfolio evolution. Wording differs but semantic meaning is equivalent on all major points. Contextual relevance is excellent as it directly addresses both portfolio integration and market availability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 388,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Caterpillar's strategic role in the reciprocating engines business evolved from 2022 to 2024, and what impact has this had on its revenue composition and gross margin potential?",
      "original_answer": "In 2022, Caterpillar primarily sold reciprocating engines through its global dealer network and through subsidiary Perkins Engines Company Limited, which operated 90 distributors across 171 countries. By 2024, Caterpillar expanded its involvement by including the remanufacturing of Caterpillar reciprocating engines and components, as well as offering remanufacturing services for other companies. This evolution from a seller to a full lifecycle service provider likely improved gross margin potential, as remanufacturing typically involves lower material costs compared to new engine production and leverages existing asset value. The shift also diversified revenue composition by incorporating service-based income streams alongside traditional product sales.",
      "llm_answer": "In 2022 Caterpillar portrayed its reciprocating‑engine business as a core, volume‑driven line sold principally through its worldwide dealer network and its Perkins, FG Wilson and MaK subsidiaries, emphasizing broad distribution rather than targeted profitability (2022 p. 9). By 2024 the engines were positioned as a strategic growth driver within the Energy & Transportation segment, with sales moving from flat well‑servicing to growth in large data‑center generator sets and gas‑compression applications, and with stronger price‑realization and a more favorable product mix lifting segment profit and gross‑margin potential (2024 p. 37‑38, 40).",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually plausible and contextually relevant, but diverges significantly from the ground truth in terms of Caterpillar's strategic evolution in the reciprocating engines business from 2022 to 2024. (1) Correct elements: The answer correctly identifies Caterpillar’s distribution channels (dealer network, Perkins, FG Wilson, MaK) and notes a strategic shift by 2024 toward higher-value applications like data centers and gas compression, which aligns with improved price realization and gross margin potential. It also correctly situates the engines within the Energy & Transportation segment. (2) Quantitative accuracy: No specific numbers (e.g., revenue figures, distributor counts) are misstated because the LLM avoids citing them; thus, there are no numeric inaccuracies. However, it omits key quantitative details present in the ground truth (e.g., Perkins operating 90 distributors in 171 countries in 2022). (3) Multi-hop reasoning: The LLM synthesizes information across years and segments, showing awareness of strategic repositioning. However, it fails to capture the core evolution highlighted in the ground truth — the shift from selling engines to offering remanufacturing services and full lifecycle support. Instead, it emphasizes product mix and end-market expansion, which, while potentially true, are not the central strategic evolution per the original answer. (4) The omission of remanufacturing — a critical addition in 2024 that directly impacts gross margins through lower material costs — undermines the qualitative accuracy. This is a significant gap in reasoning, as the margin improvement in the ground truth stems from service-based, asset-light revenue, not just pricing or product mix. While the LLM’s explanation for margin improvement is reasonable, it does not reflect the actual strategic pivot described in the truth. Thus, despite strong contextual framing and no factual errors, the answer misses a key multi-hop insight (from product sales → remanufacturing/services), resulting in a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 553,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How did BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of the mechanisms and transparency commitments outlined for informing stakeholders of changes?",
      "original_answer": "BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct remained consistent between 2022 and 2023, with the company reaffirming its commitment to post any amendments or waivers on its website in both years. There was no change in the specific mechanism or transparency commitment described across the two years, indicating a stable governance communication strategy.",
      "llm_answer": "In the 2022 Form 10‑K BNY Mellon said that its Directors’ Code of Conduct is posted on its website and that any amendments or waivers to that code “will be disclosed on our website” 【page_11】. The 2023 filing repeats the same commitment—using the corporate website to publish any changes—but updates the URL to a new location, reaffirming that the website remains the primary, publicly‑accessible mechanism for informing stakeholders of any amendments or waivers 【page_13】. The evolution is therefore a refinement of the web link rather than a change in the disclosure approach.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and aligns closely with the ground truth. It accurately identifies that BNY Mellon maintained a consistent mechanism—posting amendments or waivers to the Directors' Code of Conduct on its website—in both 2022 and 2023. The only noted evolution was a URL update, which is a minor technical refinement rather than a change in disclosure policy or transparency commitment. This matches the ground truth's assertion of a stable governance communication strategy. All entities (BNY Mellon, Directors' Code of Conduct, 2022 and 2023 Form 10-K filings) are correctly identified, and the reasoning across years is sound. The answer adds slightly more detail (URL change) not explicitly in the ground truth, but this does not contradict it and may reflect actual filing differences. There are no calculation or date inaccuracies. The answer fully addresses the question about mechanisms and transparency commitments. The qualitative score is 9 because while the core reasoning is correct, the ground truth emphasizes 'no change in the specific mechanism or transparency commitment,' whereas the LLM highlights the URL update as an 'evolution,' which could be interpreted as overemphasizing a minor technical detail. However, this does not undermine factual correctness. Semantic equivalence is maintained.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 369,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Nike's strategic approach to the APLA market evolved between FY22 and FY23, particularly in terms of operational structure and market participation?",
      "original_answer": "In FY22, Nike operated directly in APLA, maintaining a significant presence through its NIKE Direct operations and wholesale distribution, with APLA contributing to the 14% growth in the NIKE Direct business. By FY23, Nike began transitioning certain businesses within APLA to third-party distributors, signaling a strategic shift away from direct market participation in some parts of the region. This change indicates a move toward a more distributed, partner-driven model in APLA, altering the way Nike engages with that market.",
      "llm_answer": "Nike’s FY‑22 filing disclosed that it had entered definitive agreements to sell its Argentina, Uruguay and Chile legal entities and would shift those APLA markets from a combined wholesale‑and‑direct‑to‑consumer operating model to a third‑party distributor model, a change it said would curb short‑term revenue growth but improve profitability (FY 22 overview, p. 32). By FY 23 the divestiture was in progress – the operating‑segment note still references the transition to distributors – and APLA revenue rose to $6.4 bn (from $5.96 bn) with NIKE Direct sales continuing to increase, reflecting a mix of distributor participation and an expanding direct‑to‑consumer presence (FY 23 segment note, p. 89; revenue tables, p. 87‑90).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Nike's strategic shift in APLA from direct operations to third-party distributors, specifically noting the divestiture of legal entities in Argentina, Uruguay, and Chile in FY22, which matches the original answer's claim of a transition away from direct market participation. The FY23 update confirms the transition was in progress, consistent with the knowledge graph. (2) Quantitatively, the LLM provides specific revenue figures: APLA revenue increased from $5.96B in FY22 to $6.4B in FY23. While the original answer does not include these numbers, they are plausible and internally consistent; no calculation errors are present, and the values are cited from appropriate sections of the filings (segment note, revenue tables). The $0.44B increase is reasonable and supports the narrative of continued growth despite structural changes. (3) The multi-hop reasoning is sound: the model synthesizes information across FY22 and FY23 filings, connects operational changes (shift to distributors) with financial outcomes (revenue growth), and correctly interprets the coexistence of distributor models and expanding DTC presence. (4) The only minor limitation is that the original answer emphasizes the broader strategic shift and its implication for operational structure without citing exact revenue numbers, while the LLM adds granular data not in the ground truth. This does not reduce accuracy but slightly exceeds the scope. Wording differs but semantic meaning is equivalent or richer. All entities (Nike, APLA, FY22, FY23, NIKE Direct, third-party distributors) are correct. The answer fully addresses both operational structure and market participation as required by the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 483,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the impact of Favorable Price Realization on Caterpillar's sales and profitability evolved from 2022 to 2024?",
      "original_answer": "In 2022, favorable price realization contributed to a $9.223 billion increase in total sales and revenues, driven by higher end-user demand and changes in dealer inventories. By 2024, favorable price realization continued to play a key role, partially offsetting a $2.251 billion decrease in sales volume and contributing to an increase in profit from $10.335 billion in 2023 to $10.792 billion in 2024. This indicates that while Caterpillar faced declining sales volume in 2024, the company leveraged pricing strategies more effectively to maintain profitability.",
      "llm_answer": "In the 2022 filing (covering FY 2021), favorable price realization was a key driver of growth – it helped lift sales by 22 % and was a major factor in the 51 % jump in operating profit (see pages 34‑36). By 2024, sales fell about 3 % year‑over‑year, but favorable price realization still added to results, partially offsetting the volume decline and more than offsetting its profit impact, keeping operating profit margin above 20 % (see page 30).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the 2022 filing covers FY 2021, when it should reflect FY 2022. The claimed 22% sales increase and 51% operating profit jump due to favorable price realization are not supported by the ground truth, which specifies a $9.223 billion sales increase in 2022 but does not quantify the profit impact. In 2024, the LLM claims a 3% YoY sales decline and mentions profit margin above 20%, but the ground truth states a $2.251 billion volume decrease and an absolute profit increase from $10.335B to $10.792B—no margin percentage is mentioned. (2) The quantitative inaccuracies are severe: none of the percentages (22%, 51%, 3%, 20%) match or can be derived from the ground truth. The dollar figures from the ground truth ($9.223B sales boost, $10.335B to $10.792B profit increase) are entirely missing in the LLM response. (3) The multi-hop reasoning is flawed: the LLM fails to connect favorable price realization to the specific financial impacts across 2022–2024 as required. It misattributes time periods and omits the key point that price realization offset volume declines to grow profits in 2024. (4) Despite incorrect numbers and misaligned years, the LLM captures the general qualitative trend—price realization helped offset volume declines and supported profitability—giving it partial credit for contextual relevance and basic reasoning direction, but not factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 408,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has General Motors' approach to EV manufacturing capacity evolved between 2023 and 2024, particularly in terms of strategic focus and supply chain development?",
      "original_answer": "In 2023, General Motors emphasized significant investments in EV manufacturing capacity based on expectations for future EV demand, acknowledging the risks and uncertainties associated with such investments, including high fixed costs and limitations on closing facilities. By 2024, GM's strategy had evolved to include a stronger emphasis on developing a resilient, scalable, and sustainable North American-focused EV supply chain. This included advancing strategic sourcing initiatives to secure supply through investments in raw materials suppliers and the execution of multi-year supply agreements. The shift indicates a more structured and regionally focused approach to EV manufacturing, aiming to mitigate supply chain risks and ensure long-term scalability.",
      "llm_answer": "In the 2023 filing GM stressed that it would make “significant investments” to expand EV‑manufacturing capacity and was building a “more resilient, scalable and sustainable North‑American‑focused EV supply chain” through strategic sourcing, multi‑year supply agreements and raw‑material offtake contracts. By the 2024 filing the emphasis had shifted to a broader EV strategy that still calls for scaling production but now focuses on lowering battery‑cell and pack costs, improving range and energy‑density, and efficiently sourcing battery materials while leveraging existing ICE scale and software platforms—showing a move from pure capacity‑building and raw‑material contracts toward a cost‑and‑technology‑driven scaling approach.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in terms of dates (2023 and 2024) and correctly identifies General Motors (GM) as the entity, satisfying entity accuracy. There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable but assumed correct—scored as 10. The answer addresses both years and discusses strategic evolution, maintaining contextual relevance. However, while the original answer emphasizes a shift toward a 'resilient, scalable, and sustainable North American-focused EV supply chain' with specific actions like investments in raw materials suppliers and multi-year agreements, the LLM answer introduces new elements not present in the ground truth—specifically 'lowering battery-cell and pack costs, improving range and energy-density, and efficiently sourcing battery materials while leveraging existing ICE scale and software platforms.' These technology- and cost-driven priorities are not mentioned in the original answer and represent an overextension of the documented strategy. The core evolution—shifting from broad capacity investment to a more structured, supply-chain-focused approach—is partially captured, but the LLM reframes the 2024 focus in a way that adds unverified technical and cost-reduction objectives. This affects qualitative accuracy, as the reasoning and synthesis do not fully align with the source: the multi-hop logic is plausible but not supported by the ground truth. Thus, while the answer is relevant and contains some correct elements (e.g., strategic sourcing, supply agreements), it misrepresents the nature of the strategic shift, warranting a correctness score of 7 for capturing the general direction but missing the precise emphasis on supply chain resilience and regional focus as the primary evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 493,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved from 2022 to 2024, based on remaining performance obligations disclosed in the 10-K filings?",
      "original_answer": "In 2022, Pfizer's 10-K filing did not disclose specific remaining performance obligations related to Paxlovid. However, by 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a significant ongoing financial commitment tied to future delivery of the product. This shows a clear evolution from an undefined obligation in 2022 to a quantified $1 billion commitment in 2024.",
      "llm_answer": "Pfizer reported roughly $2.5 billion of remaining performance‑obligation revenue for Paxlovid at the end of 2022, but that amount had fallen to about $1 billion by December 31 2024, indicating a sizable reduction in the future contracted revenue for the oral COVID‑19 treatment【page_7†L38-L38】【page_109†L38-L38】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it states that Pfizer reported $2.5 billion in remaining performance obligations for Paxlovid at the end of 2022, which directly contradicts the ground truth stating that no specific obligations were disclosed for Paxlovid in the 2022 10-K. The $1 billion figure for December 31, 2024, is correct. However, the claim of a reduction from $2.5B to $1B is therefore based on a false premise. (2) The citations provided (page_7†L38-L38 and page_109†L38-L38) do not support the asserted 2022 figure if the ground truth is accurate, indicating potential hallucination or misattribution. (3) Qualitatively, the reasoning is flawed: the evolution is misrepresented as a decrease in commitment, whereas the ground truth shows an emergence of a defined commitment where none was previously specified. This reflects a failure in multi-hop reasoning—instead of recognizing the absence of data in 2022 as a lack of disclosure, the model invents a number, leading to an incorrect trend interpretation. (4) Contextually, the answer addresses the right topic (Paxlovid's performance obligations over time) and correctly identifies the 2024 figure, so it retains partial relevance. However, the core factual error undermines the conclusion. Minor note: 'December 31 2024' is acceptable formatting, though the 2024 10-K would report obligations as of that date in early 2025, which is not addressed but not penalized here.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1194,
        "completion_tokens": 412,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Caterpillar's approach to monitoring supplier financial viability evolved between 2022 and 2023, particularly in terms of risk mitigation strategies and contractual agreements?",
      "original_answer": "In 2022, Caterpillar indicated that it uses 'a variety of agreements with suppliers to protect our intellectual property and processes to monitor and mitigate risks of the supply base causing a business disruption,' including monitoring supplier financial viability. By 2023, Caterpillar maintained the same monitoring approach but placed a more explicit emphasis on 'supplier financial viability' as a key risk factor, listing it as the first risk under its supply chain disclosures. Additionally, in 2023, Caterpillar reinforced its global strategic sourcing models to build long-term supplier relationships and leverage enterprise spend, suggesting a potentially more structured or prioritized focus on supplier financial health compared to 2022.",
      "llm_answer": "Both the 2022 and 2023 Form 10‑K describe the same framework: Caterpillar “uses a variety of agreements with suppliers to protect our intellectual property and processes to monitor and mitigate risks… The risks monitored include supplier financial viability, the ability to increase or decrease production levels, business continuity, quality and delivery” (see page 9). The 2023 filing repeats this language and the same 90‑day termination right for dealer agreements, showing that the company’s risk‑mitigation strategy and contractual approach to monitoring supplier financial health have remained essentially unchanged from 2022 to 2023.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses key qualitative evolution in Caterpillar's approach between 2022 and 2023, which is central to the question. (1) The LLM correctly identifies that both years reference the same boilerplate language about using supplier agreements and monitoring risks, including financial viability, and accurately cites the 90-day termination clause. These factual elements are consistent with the filings and correctly reported. (2) Quantitative accuracy is perfect—no numbers, dates, or financial figures are misstated, and the citation to page 9 is plausible (though not verifiable from the provided data). (3) However, the reasoning is flawed in concluding that the strategy 'remained essentially unchanged.' The ground truth highlights a meaningful shift in emphasis: in 2023, Caterpillar explicitly listed 'supplier financial viability' as the first risk in its supply chain disclosures, signaling heightened priority, and reinforced strategic sourcing models to build long-term relationships and leverage enterprise spend—indicative of a more structured focus on supplier financial health. The LLM fails to detect or report this evolution, instead interpreting repeated language as evidence of no change, which overlooks the nuanced but important shift in risk prioritization and strategic framing. (4) This omission significantly reduces correctness and qualitative accuracy, as the core of the question asks about evolution in risk mitigation strategies. While the answer is factually sound in what it reports, it lacks the deeper synthesis required to capture the change in emphasis and strategic posture, resulting in a partially correct response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 458,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Visa's approach to Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of its strategic positioning and integration within its value-added services?",
      "original_answer": "In 2022, Visa positioned Risk and Identity Solutions as part of a broader set of value-added services aimed at supporting clients, but without detailed elaboration on specific capabilities or strategic direction. By 2024, Risk and Identity Solutions were embedded within a more structured value-added services framework, with a clear three-pillar strategy: (1) services for Visa transactions, (2) network-agnostic services for non-Visa transactions, and (3) services beyond payments. This evolution reflects a more strategic and comprehensive integration of Risk and Identity Solutions into Visa's broader service portfolio, with an emphasis on scalability and business outcomes.",
      "llm_answer": "In the 2022 filing Visa only mentioned risk and identity solutions as one of its generic “value‑added services” (e.g., “We provide value added services … risk and identity solutions” 【page_5】). By the 2024 filing the company has repositioned this offering as a flagship, AI‑driven “Visa Protect” suite—adding new products such as Visa Deep Authorization, Visa Protect for A2A payments and a scheme‑agnostic Visa Advanced Authorization—and integrated it into a broader, network‑agnostic value‑added‑services strategy that now includes more than 200 coordinated products (see the Value‑Added Services overview 【page_11】 and the detailed Risk and Identity Solutions description 【page_12】). This marks a shift from a peripheral service listing to a central, technology‑focused component of Visa’s portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the evolution of Visa's Risk and Identity Solutions from a generic value-added service in 2022 to a more central, structured offering by 2024. The mention of 'Visa Protect' suite, AI-driven capabilities, and specific products like Visa Deep Authorization and Visa Advanced Authorization reflects accurate qualitative synthesis from the filings. While the original answer does not name 'Visa Protect' or the specific products, the LLM answer adds detail that is consistent with the broader strategic shift described in the ground truth—namely, the move toward a more integrated, scalable, and network-agnostic framework. The three-pillar strategy from the original answer is not explicitly mentioned, but the LLM captures the essence of that evolution through its description of network-agnostic services and expansion beyond Visa transactions. There are no numeric inaccuracies (quantitative accuracy is perfect), and all years (2022, 2024) and entities (Visa, value-added services) are correct. The reasoning is sound, demonstrating multi-hop understanding across years and strategic positioning. The slight deduction in qualitative accuracy is due to the introduction of specific product names not present in the ground truth, which, while plausible, go beyond the provided information. However, this does not undermine the factual correctness of the overall strategic evolution. Contextual relevance is excellent, as the response directly addresses the question about strategic positioning and integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 438,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has the company's exposure to shelf space limitations as a risk factor evolved between 2022 and 2023, particularly in relation to changes in retail customer policies and the expansion of alternative retail channels?",
      "original_answer": "In 2022, the company noted that it had been and could continue to be negatively affected by changes in retail customer policies such as limitations on access to shelf space and delisting of products. By 2023, the company was actively impacted by these limitations and described them as part of a broader set of evolving retail dynamics, including the growth of eCommerce and alternative retail channels such as subscription services and direct-to-consumer businesses. This evolution indicates a shift from potential risk to an actively experienced challenge, with the company planning to invest more in digital and analytics capabilities to adapt.",
      "llm_answer": "In the 2022 Form 10‑K the company warned that “changes in the policies or practices of our retail trade customers…such as inventory de‑stocking, fulfillment requirements, **limitations on access to shelf space**, delisting of our products” could hurt sales, and it noted that the rapid growth of e‑commerce and new channels (subscriptions, direct‑to‑consumer) were already creating pricing pressure and could strain retailer relationships【page_11】. The 2023 filing repeats the same shelf‑space‑limitation risk but stresses that “the retail landscape…continues to evolve as a result of the **continued growth of eCommerce** and the **increased presence of alternative retail channels**…which have created and may continue to create pricing pressures and/or adversely affect our relationships with our key retailers”【page_31】. Thus, while the exposure to shelf‑space constraints remains, the 2023 discussion frames it as a heightened risk because the expansion of e‑commerce and alternative channels has intensified the pressure on shelf‑space access and retailer dynamics.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, shelf space limitations were presented as a potential risk tied to retail customer policies, and in 2023, this evolved into an active challenge amid broader retail dynamics. The mention of e-commerce growth, subscription services, and direct-to-consumer channels as contributing factors matches the original answer. (2) There are no numeric values, dates, or financial figures in the question or ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly tracing the evolution from a forward-looking risk (2022) to a current, intensified challenge (2023). It accurately links the expansion of alternative retail channels to increased pressure on shelf space and retailer relationships. The only minor shortcoming is that the LLM does not explicitly state the company's planned response (investing in digital and analytics capabilities), which is included in the ground truth, making the answer slightly less complete. (4) Despite this omission, the LLM captures the core evolution in risk exposure and contextual drivers, maintaining strong semantic equivalence. Thus, the answer is contextually relevant, factually correct, and well-reasoned, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1447,
        "completion_tokens": 390,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Oracle's approach to hybrid deployments evolved between fiscal years 2023 and 2024, particularly in terms of product offerings and strategic emphasis?",
      "original_answer": "In fiscal 2023, Oracle emphasized hybrid deployments as part of its broader deployment models, including on-premise, cloud-based, and hybrid options such as Oracle Exadata Cloud@Customer and Dedicated Region offerings. The company highlighted its commitment to providing customers with choice and flexibility in how they deploy Oracle technologies. By fiscal 2024, Oracle continued to support hybrid deployments but introduced more specific product integrations and services tailored for hybrid environments, indicating a strategic shift toward deeper integration and support for customer-managed cloud and on-premise IT environments. This evolution reflects Oracle's ongoing investment in making hybrid deployments more interoperable and extensible with other IT and cloud environments.",
      "llm_answer": "In FY 2023 Oracle framed hybrid‑deployment as a set of distinct products – for example, Exadata Cloud@Customer, Dedicated Region instances and multicloud options – and positioned “choice and flexibility” in hybrid models as a core growth driver 【page_6】. By FY 2024 the filing no longer lists those individual offerings; instead it describes hybrid deployment simply as one of the flexible, interoperable on‑premise/cloud models that underpin its broader Oracle Cloud Services portfolio, signalling a shift toward a unified, cloud‑first strategy that integrates hybrid capabilities across its entire suite 【page_72】.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable; however, since there are no numbers to misstate, it is scored as 10 by default. Contextually, the answer addresses Oracle's hybrid deployment evolution between FY2023 and FY2024, which is relevant. However, the qualitative accuracy is low due to a significant factual error: the LLM claims that in FY2024, Oracle 'no longer lists' specific hybrid offerings like Exadata Cloud@Customer and Dedicated Region, and instead has shifted to a 'unified, cloud-first strategy' where hybrid is subsumed into broader cloud services. This contradicts the ground truth, which states that Oracle *continued to support* hybrid deployments and *introduced more specific product integrations and services* for hybrid environments in FY2024—indicating deeper investment, not de-emphasis. The LLM incorrectly interprets the strategic evolution as a move away from hybrid-specific products, when the original answer describes an advancement toward greater integration and support. This misrepresents the direction of Oracle's strategy and fails the multi-hop reasoning test by drawing an opposite conclusion from the evidence. While the mention of Exadata Cloud@Customer and Dedicated Region in FY2023 aligns with the original, the FY2024 characterization is factually incorrect, undermining the core of the answer. Thus, despite correct entity and year identification, the reasoning and factual synthesis are flawed, warranting a correctness score of 4 for partial accuracy with major errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 425,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved between 2022 and 2024, based on remaining performance obligations and contracted revenue expectations?",
      "original_answer": "In 2022, Pfizer indicated that Paxlovid had the potential to provide ongoing revenue streams, though it acknowledged that post-pandemic revenues might not match the levels seen during the pandemic. By 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, with contracted revenue expected to be recognized from 2025 through 2028. This reflects a continued but reduced financial commitment compared to the pandemic period, as the company anticipates delivery and revenue recognition over a multi-year horizon rather than immediate high-volume sales.",
      "llm_answer": "Pfizer’s 2024 Form 10‑K shows that the company had roughly **$1 billion of remaining performance‑obligation (contracted‑revenue) for Paxlovid** as of 31 Dec 2024【page_109】. The 2022 filing did not disclose a comparable RPO amount, but Paxlovid generated **$18.9 billion of revenue in 2022**【page_23】, indicating that the future contractual revenue expectation was substantially larger at that time. Thus, Pfizer’s financial commitment to Paxlovid has been reduced, with the amount of revenue still expected from existing contracts falling to about one‑quarter of its earlier scale.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but has a minor overstatement in reasoning that affects completeness. (1) Quantitatively, all numbers are accurate: $1 billion in remaining performance obligations (RPO) as of December 31, 2024, is correctly cited from the 2024 10-K, and $18.9 billion in Paxlovid revenue in 2022 is factually correct. The format variations are acceptable. (2) The LLM correctly identifies that the 2022 filing did not disclose a specific RPO for Paxlovid, which is consistent with the original answer. (3) The reasoning compares current contracted revenue ($1B) to prior annual revenue ($18.9B), concluding a reduction to 'about one-quarter' of earlier scale. However, this comparison is slightly misleading—comparing a multi-year forward-looking RPO ($1B total from 2025–2028) to a single year’s revenue ($18.9B in 2022) overstates the decline. The original answer correctly frames the $1B as spread over several years, not as an annual figure, and avoids implying a direct ratio. (4) Despite this, the core conclusion—that Pfizer’s financial commitment has reduced and is now spread over a longer horizon—is supported by both the LLM and ground truth. The LLM captures the evolution in commitment and cites correct sources. It misses the nuance that the $1B is expected to be recognized over 2025–2028, which the original answer includes. This omission slightly weakens completeness and reasoning, but does not invalidate the overall correctness. Hence, high scores across the board with a small deduction in correctness and qualitative accuracy for the imprecise comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 444,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Caterpillar's relationship with its independent dealers evolved between 2022 and 2023, particularly in terms of contractual obligations and strategic emphasis?",
      "original_answer": "In 2022, Caterpillar described its relationship with independent dealers in general terms as part of its global sales and marketing strategy. By 2023, the company formalized and detailed these relationships through standardized sales and service agreements, granting dealers the right to purchase, sell, and service Caterpillar products within specified territories. In exchange, dealers were obligated to develop and promote Caterpillar products, maintain adequate sales and support personnel, and keep detailed financial records accessible to Caterpillar. This represents a shift from a general partnership model to a more structured contractual framework, indicating a strategic emphasis on formalizing dealer relationships to enhance control and accountability.",
      "llm_answer": "In the 2022 filing Caterpillar simply described its sales model as “a global network of independent dealers…building long‑term relationships with customers” (see 2022 p. 4). By the 2023 filing the company says those relationships are now memorialized in standard sales‑and‑service agreements that grant dealers the right to purchase, sell, service and use Caterpillar trademarks, but also obligate them to develop and promote sales, staff adequate sales‑and‑support personnel, participate in product‑improvement programs, keep detailed financial and inventory records, and are terminable at‑will with 90‑day notice (see 2023 p. 10). This shift reflects a move from a broad, network‑focused description to a more formal, contract‑driven partnership with an explicit strategic emphasis on dealer‑driven growth and accountability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Caterpillar evolved from a general description of dealer relationships in 2022 to formalized standard sales-and-service agreements in 2023. The contractual rights (to purchase, sell, service, use trademarks) and obligations (promote sales, maintain staff, keep records) are accurately detailed. The mention of at-will termination with 90-day notice, while not in the original answer, is consistent with formalization and does not contradict the ground truth—it adds a specific term that plausibly supports the shift toward greater control. (2) There are no numbers, dates, or financial figures in this question, so quantitative accuracy is not applicable in the traditional sense, but all references to years (2022, 2023) and document locations (p. 4, p. 10) are correctly cited and contextually appropriate. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, identifying a shift in tone and structure from general partnership to formal contractual framework. The conclusion about strategic emphasis on accountability and dealer-driven growth is a reasonable interpretation supported by both the original and LLM answers. (4) The only reason for not scoring a perfect 10 is that the original answer emphasizes the strategic shift toward 'control and accountability,' while the LLM slightly reframes it as 'dealer-driven growth and accountability'—a nuance that is plausible but introduces a subtle emphasis not explicitly in the ground truth. However, this does not constitute an error. Overall, the answer is factually correct, comprehensive, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 473,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How did the company's financial allocation or operational focus related to Africa/Eurasia evolve from 2022 to 2023, based on capital expenditures and restructuring charges?",
      "original_answer": "In 2022, the company reported capital expenditures for Africa/Eurasia at $33 million, showing a steady increase from $13 million in 2021 and $8 million in 2020. However, in 2023, the company indicated that approximately 10% of the cumulative pretax charges from the 2022 Global Productivity Initiative would relate to initiatives undertaken in Africa/Eurasia, signaling a shift in focus toward restructuring and cost optimization in the region rather than continued capital investment. This reflects a strategic evolution from growth-oriented capital allocation to operational restructuring within Africa/Eurasia.",
      "llm_answer": "The company’s most recent capital‑expenditure data show a relatively sizable investment in Africa/Eurasia – $33 million was spent on the region (up from $13 million the year before)【page_117】.  Yet the portion of the Global Productivity Initiative’s restructuring costs allocated to Africa/Eurasia dropped markedly, falling from 11 % of total charges in 2022 to only 5 % in 2023【page_48】.  This indicates that while capital spending in the region remained strong, the focus on restructuring and cost‑saving activities there was sharply reduced.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, capital expenditures for Africa/Eurasia were $33 million, with no data provided for 2023 capital expenditures. Instead, the 2023 focus shifted to restructuring, with approximately 10% of cumulative pretax charges from the 2022 Global Productivity Initiative relating to Africa/Eurasia. However, the LLM incorrectly states that the portion of restructuring costs allocated to Africa/Eurasia dropped from 11% in 2022 to 5% in 2023, which contradicts the original answer stating a 10% allocation in 2023 with no prior percentage given for 2022. Additionally, the LLM implies that capital spending remained strong in 2023, but the original answer does not provide 2023 capex data, only noting a shift toward restructuring. (2) Quantitative inaccuracies include the fabricated percentages (11% in 2022 and 5% in 2023) and the incorrect implication of continued high capital spending in 2023. The $33 million capex figure for 2022 is correct, but the claim of being 'up from $13 million the year before' misattributes 2021 data as 2022's prior year without clarifying the timeline. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the shift from capital investment (capex) in 2022 to restructuring focus in 2023. Instead, it incorrectly suggests both high capex and reduced restructuring in 2023, reversing the strategic evolution described in the ground truth. (4) The contextual relevance is moderate because the answer discusses the right region and initiatives, but the core conclusion about reduced restructuring focus is factually wrong, leading to a low correctness score despite some relevant terminology and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 479,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Qualcomm's strategic focus on 5G technologies evolved from 2022 to 2024, particularly in terms of investment emphasis and commercialization outcomes?",
      "original_answer": "In 2022, Qualcomm was heavily investing in 5G technologies as part of its broader strategy to expand beyond mobile handsets into areas like automotive and IoT, with an emphasis on developing leading and cost-effective 5G-based technologies and products. The company acknowledged significant risks around the success of these investments due to potential regulatory hurdles, competition, and the long design-in cycles typical of new industries like automotive. By 2024, Qualcomm had transitioned from a primarily investment phase to a more mature stage where it had developed a leading patent portfolio in 5G NR and was actively licensing these technologies. The company reported generating the majority of its QTL revenues from OFDMA-based products, including multimode 3G/4G/5G devices such as smartphones, indicating a successful commercialization phase. This shift shows that Qualcomm moved from strategic investment and development in 5G across multiple industries to a position of market leadership and monetization in 5G technologies.",
      "llm_answer": "In the 2022 Form 10‑K Qualcomm stressed that it was “investing significant resources toward advancements primarily in support 5G‑based technologies” and that its growth “depends significantly on our ability to develop and patent 5G technologies, and to develop and commercialize products using 5G technologies” – a stage still focused on development and the risk that those investments might not yet yield returns (2022 10‑K, p. 21). By the 2024 filing the narrative had shifted to concrete 5G commercialization: the company highlights Snapdragon 5G modem‑RF platforms, sub‑6 GHz and mmWave RFFE components, and a leading 5G‑NR patent portfolio, showing that its 5G investments have moved into product roll‑outs across mobile, automotive and IoT markets while still funding ongoing R&D (2024 10‑K, pp. 11‑13).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures Qualcomm's strategic evolution from 2022 to 2024: in 2022, the focus was on heavy investment and development of 5G technologies with acknowledged risks, as stated in the 2022 10-K (p. 21), and by 2024, the narrative shifted to commercialization, including product rollouts (Snapdragon 5G modem-RF platforms, RFFE components) and a leading 5G NR patent portfolio, per the 2024 10-K (pp. 11–13). (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings, correctly identifying the shift from R&D investment to commercialization and monetization, particularly through licensing and product integration in mobile, automotive, and IoT. The mention of ongoing R&D shows nuance, acknowledging that investment continues even as commercialization advances. (4) The LLM omits explicit mention of QTL revenues being primarily from OFDMA-based products and the specific reference to multimode 3G/4G/5G devices, which are key commercialization outcomes in the ground truth. This is a minor omission affecting completeness but does not undermine the core correctness. Wording differs but semantic meaning is equivalent. Contextual relevance is perfect—directly addresses investment emphasis and commercialization outcomes as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1465,
        "completion_tokens": 418,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Pfizer's financial and strategic positioning of Paxlovid evolved between 2022 and 2024, particularly in terms of revenue contribution and contractual commitments?",
      "original_answer": "In 2022, Paxlovid generated $76 million in revenue, marking its initial contribution as a newly launched product targeting high-risk COVID-19 patients. By 2024, while direct revenue figures for Paxlovid are not explicitly stated, Pfizer disclosed approximately $1 billion in remaining performance obligations tied to future Paxlovid deliveries under existing contracts. This indicates a strategic shift from initial market entry to securing longer-term contractual commitments, despite potential market or regulatory challenges reflected in the context of government returns and adjustments in 2024.",
      "llm_answer": "In 2022 Paxlovid produced $18.9 billion of revenue (≈19% of total $101.2 billion) and most of its sales came from government contracts – the U.S. government accounted for 23% of Pfizer’s total revenue that year【page_108†L30-L38】. By 2024 Paxlovid revenue had fallen to $5.7 billion (≈9% of total $63.6 billion) as the product moved to commercial markets, the U.S. government share dropped to 6% and the company recorded about $1 billion of remaining performance‑obligation contracts for future Paxlovid deliveries【page_108†L0-L8】【page_107†L31-L38】. This reflects a strategic shift from a government‑driven, EUA‑supplied product in 2022 to a commercially‑oriented portfolio with a smaller, but still material, pipeline of contractual commitments by 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in key financial figures. According to the ground truth, Paxlovid generated $76 million in revenue in 2022, but the LLM claims $18.9 billion—over 240 times higher. This is a critical error that undermines the entire response. Similarly, the 2024 revenue is stated as $5.7 billion in the LLM answer, while the ground truth does not provide a 2024 revenue figure at all, only $1 billion in remaining performance obligations. The LLM incorrectly presents this obligation as actual revenue and misrepresents its meaning. (2) Calculations and percentages are therefore also incorrect: claiming Paxlovid was 19% of Pfizer’s total revenue in 2022 ($18.9B of $101.2B) and 9% in 2024 ($5.7B of $63.6B) is based on fabricated revenue numbers. The ground truth does not support these proportions. (3) The qualitative reasoning partially captures a strategic shift—from government contracts toward commercial markets and ongoing contractual obligations—which aligns with the ground truth's mention of a shift to longer-term commitments despite market challenges. The mention of $1 billion in remaining performance obligations for future Paxlovid deliveries in 2024 matches the ground truth and shows correct synthesis of contractual evolution. However, the reasoning is built upon false quantitative foundations. (4) Contextually, the answer addresses both revenue contribution and contractual commitments as asked, and correctly identifies the shift in strategic positioning, earning moderate relevance. However, due to severe quantitative inaccuracies, the correctness and accuracy scores are low. Minor note: citation tags like 【page_108†L30-L38】 suggest document retrieval but do not compensate for factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 481,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the company's exposure to credit market tightness as a supply chain risk evolved between 2022 and 2023, and what does this indicate about its changing vulnerability to external financial conditions?",
      "original_answer": "In 2022, tighter credit or capital markets were described as a risk that 'negatively impacts' suppliers, with a direct concern that this could disrupt the supply of raw and packaging materials. By 2023, the framing shifted to indicate that the company's operations are 'impacted by' these conditions, suggesting a broader recognition of ongoing vulnerability. This evolution reflects a continuation of concern over credit market conditions but with a more integrated perspective on how such financial constraints affect not just suppliers, but the company's overall supply chain resilience.",
      "llm_answer": "In 2022 the company listed “the impact on our suppliers of tighter credit or capital markets” as a supply‑chain risk (2022 p. 16). By 2023 the discussion had broadened to note that “disruptions and volatility in the global capital markets, including rising interest rates, may increase the cost of capital and adversely impact our access to capital,” indicating that the firm now sees credit‑market tightness as a direct financing risk as well as a supplier issue (2023 p. 13). This shift reflects a growing vulnerability to external financial conditions, moving from a supplier‑focused exposure to a broader sensitivity to overall credit market conditions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the 2022 risk framing around suppliers being impacted by tighter credit markets (citing 2022 p.16), and the 2023 evolution where the company acknowledges broader financial risks including increased cost of capital and reduced access to capital (citing 2023 p.13). These details are factually correct and contextually appropriate. (2) There are no numerical values to verify (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable in a traditional sense—but all dates and page references are accurate, and no incorrect numbers are introduced. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings and correctly infers a shift from supplier-focused risk to a broader organizational vulnerability. The conclusion about 'growing vulnerability' and 'broader sensitivity' matches the ground truth's interpretation of an 'integrated perspective' on financial constraints. (4) The only minor gap is that the LLM emphasizes the company’s own financing risk (e.g., access to capital) slightly more than the original answer, which focuses on supply chain resilience through supplier impacts. While this is a valid interpretation, the original answer stresses the continuity of supplier risk with an evolved understanding of systemic vulnerability, whereas the LLM frames it as a shift toward direct financing concerns. This subtle difference in emphasis prevents a perfect 10 on qualitative accuracy, but the core reasoning remains strong. Overall, the answer is factually correct, complete, and contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 456,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2022 to 2024, based on disclosed figures and agreements?",
      "original_answer": "In 2022, Paxlovid was under Emergency Use Authorization (EUA) in the U.S. and had received conditional marketing authorization (CMA) in the EU and full approval in Japan, indicating early-stage regulatory and commercial momentum. By 2024, Pfizer disclosed that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, reflecting firm orders from long-term contracts with customers. This shows a significant financial commitment to Paxlovid, with delivery expected from 2025 through 2028, subject to renegotiation. Additionally, 2024 included a $771 million favorable final adjustment related to a prior revenue reversal tied to Paxlovid EUA-labeled treatment courses returned by the U.S. government, indicating ongoing financial adjustments and evolving contractual dynamics.",
      "llm_answer": "In the 2022 Form 10‑K, Paxlovid was newly authorized (EUA Dec 2021, CMA Jan 2022, EU approval Feb 2022) and Pfizer only disclosed that it had entered into supply agreements with governments and other customers, without quantifying the related financial commitment. By the 2024 Form 10‑K, the company reported $2.2 billion of deferred revenue and $1 billion of remaining performance‑obligation contracts for Paxlovid (down from $5.1 billion of deferred revenue a year earlier), recognized $5.7 billion of Paxlovid revenue in 2024, and detailed amended U.S. government contracts and non‑cash adjustments that reflect the transition from large advance‑payment and inventory‑return arrangements to commercial sales.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The ground truth states that as of December 31, 2024, remaining performance obligations for Paxlovid were approximately $1 billion — this part is correctly reported. However, the LLM claims $2.2 billion of deferred revenue and $5.1 billion a year earlier, which are not supported by the original answer and introduce unsupported figures. The original does not mention deferred revenue at all. The LLM also states that $5.7 billion of Paxlovid revenue was recognized in 2024, which is a major addition not present in the ground truth and cannot be verified from the provided information. (2) The $771 million favorable adjustment related to returned EUA-labeled treatment courses from the U.S. government — a key financial event in 2024 — is entirely omitted from the LLM answer, representing a major factual gap. This adjustment is central to understanding the evolving contractual dynamics. (3) While the LLM correctly identifies the regulatory timeline (EUA, CMA) and notes increased contractual disclosure by 2024, it fabricates financial metrics (deferred revenue, revenue recognized) that were not in the ground truth, undermining the multi-hop synthesis. The reasoning appears structured but is based on incorrect or invented data. (4) The contextual relevance is high because the answer attempts to trace the evolution of financial commitments and contractual obligations over time, aligning with the question’s intent. However, due to major quantitative errors and omission of a key adjustment event, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the framework of analysis is sound, but the factual foundation is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 487,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has the financial liability and risk exposure related to Aearo Technologies' respirator mask/asbestos litigation evolved from 2023 to 2024?",
      "original_answer": "In 2023, MMM had an accrual of $574 million for respirator mask/asbestos liabilities excluding Aearo, and Aearo was in bankruptcy proceedings, which resulted in a stay of litigation. By 2024, MMM, through Aearo, had accruals of $51 million specifically for Aearo-related asbestos, silica-related, and coal mine dust claims. Additionally, Aearo’s liability was limited by its agreement with Cabot, where Cabot assumed responsibility for claims involving exposure prior to January 1, 1997, as long as Aearo continued to pay a quarterly fee of $100,000. This represents a shift from a broader liability exposure under bankruptcy protection in 2023 to a more defined and limited liability framework in 2024, with Aearo actively managing its share of liability through contractual arrangements and cost-sharing with other co-defendants.",
      "llm_answer": "In 2023, after the June 2023 dismissal of Aearo’s bankruptcy, 3M recorded a $62 million accrual for Aearo’s respirator‑mask asbestos, silica and coal‑dust product liabilities and defense costs. By year‑end 2024 that accrual had fallen to $51 million, but the underlying risk exposure remains unchanged – Aearo’s liability is still limited by its 1995 Cabot agreement (the $100 k quarterly fee) to respirators sold on/after Jan 1 1997, with the possibility of additional exposure only if the arrangement is altered or Cabot cannot meet its obligations.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023, Aearo was still in bankruptcy proceedings with a stay of litigation — not dismissed in June 2023 as claimed. The $62 million accrual figure for Aearo in 2023 is incorrect; the ground truth states that 3M had a $574 million accrual for respirator mask/asbestos liabilities excluding Aearo, and does not specify a $62 million accrual for Aearo in 2023. The only accurate number is the $51 million accrual in 2024 for Aearo-related claims, which matches the original answer. The $100,000 quarterly fee and Cabot agreement details are correctly mentioned, though the reference to a '1995 agreement' is not in the original and slightly misrepresents the timing (original says agreement covers pre-1997 exposure). (2) Quantitative accuracy is low: the $62 million figure is unsupported and contradicts the ground truth, which does not report any specific Aearo accrual in 2023. The decrease from $62M to $51M is therefore based on false premises. The original answer does not state that the accrual 'fell' — it presents the 2024 $51M as a new, specific accrual under a different liability framework. (3) Multi-hop reasoning is flawed: the model incorrectly asserts that Aearo’s bankruptcy was dismissed in June 2023, which reverses the actual legal status (bankruptcy was ongoing in 2023, providing a stay of litigation). This undermines the entire timeline and risk assessment. The conclusion that 'risk exposure remains unchanged' contradicts the original answer, which describes a shift to a more defined and limited liability framework in 2024. (4) Contextual relevance is moderate — the answer addresses the right topic (Aearo’s liability evolution) and mentions key elements like the Cabot agreement and accrual amounts, but due to major factual and reasoning errors, the overall correctness is low. The synthesis fails on critical points, warranting a low score despite some relevant context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 540,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did the retail share of Skoal, a product of MO, change between 2023 and 2024, and how does this compare to its shipment volume trend between 2020 and 2021?",
      "original_answer": "The retail share of Skoal decreased from 9.3% in 2023 to 7.6% in 2024, indicating a decline in market presence. In contrast, Skoal's shipment volume was also declining between 2020 and 2021, dropping from 208.5 million packs/cans in 2020 to 197.4 million packs/cans in 2021. Both metrics show a consistent downward trend, suggesting a potential long-term challenge for the product's performance in the market.",
      "llm_answer": "Skoal’s retail share slipped from 9.3 % in 2023 to 7.6 % in 2024 – a decline of roughly 1.7 percentage points. In the earlier period, Skoal’s shipment volume fell from 208.5 million cans/packs in 2020 to 197.4 million in 2021, a drop of about 11 million units (≈5 %). Both intervals show a downward trend, with the recent change reflected in share‑percentage and the earlier change reflected in absolute shipment volume.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: retail share decreased from 9.3% in 2023 to 7.6% in 2024; shipment volume dropped from 208.5 million to 197.4 million between 2020 and 2021. The LLM correctly calculates the 1.7 percentage point decline in share and approximates the shipment drop as ~11 million units (exact: 11.1 million), noting ≈5% decline, which is accurate (11.1 / 208.5 ≈ 5.3%). (2) The answer is complete, addressing both sub-questions: the 2023–2024 retail share trend and the 2020–2021 shipment volume trend. (3) Entities are correct: Skoal, MO (implied), correct time periods, and appropriate metrics (retail share, shipment volume). (4) The reasoning is sound and synthesizes multi-hop data correctly—linking recent market share decline with earlier shipment decline to highlight a consistent downward trend, even though the metrics and timeframes differ. (5) The semantic meaning is equivalent to the original answer, with added clarity on the magnitude of changes. Wording differences (e.g., 'slipped', 'fell') do not affect factual accuracy. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 334,
        "total_tokens": 1544
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Qualcomm's approach to multimedia technologies evolved from 2022 to 2024, particularly in terms of engineering focus areas and integration into product offerings?",
      "original_answer": "In 2022, Qualcomm emphasized engineering expertise in multimedia technologies such as camera, video, display, and computer vision as part of a broader set of capabilities including modem, RF, and sensor perception technologies. The focus was on enhancing existing products and developing new technologies for industries beyond mobile handsets, such as automotive and IoT. By 2024, the company's description of its multimedia technology efforts remained consistent, but there was a notable expansion in the integration of AI, particularly generative AI, into its research and development strategy. Additionally, in 2024, Qualcomm placed greater emphasis on enabling developers to design and deploy applications across multiple device categories and industries, signaling a more deliberate diversification strategy. This evolution reflects a shift from primarily hardware-centric multimedia innovation in 2022 to a more platform-oriented, AI-enhanced approach by 2024.",
      "llm_answer": "In the 2022 filing Qualcomm described its multimedia work mainly as a core R&D capability – engineers focused on “multimedia (camera, video, display and computer‑vision)” and its patent portfolio included video‑ and audio‑codecs and streaming protocols that were built into consumer‑oriented chipsets such as smartphones, tablets, wearables and XR devices【page_14】. By the 2024 filing the scope had broadened: the same multimedia expertise is now paired with AI‑driven perception, a dedicated NPU and generative‑AI research, and Qualcomm is packaging those capabilities into a wider range of platforms – from mobile SoCs to automotive digital‑cockpit and ADAS/AD solutions and IoT products – while emphasizing developer‑friendly integration across multiple device categories【page_14】. This reflects a shift from a primarily consumer‑handset focus to a more diversified, AI‑enabled multimedia strategy that spans automotive and IoT markets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Qualcomm's 2022 focus on multimedia technologies (camera, video, display, computer vision) as part of core R&D and integration into consumer devices like smartphones, tablets, wearables, and XR is accurately reported. By 2024, the expansion to include AI-driven perception, NPU, and generative AI research is correctly identified. The shift toward broader platform integration across automotive (digital cockpit, ADAS/AD) and IoT is consistent with the original answer. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) Multi-hop reasoning is sound: the model synthesizes information across years and domains (engineering focus, product integration, market diversification) and correctly infers a strategic evolution from hardware-centric to platform-oriented, AI-enhanced multimedia. (4) Semantic equivalence is strong—while the LLM uses slightly different phrasing (e.g., 'AI-driven perception', 'dedicated NPU'), it captures the essence of the strategic shift described in the ground truth. The only minor gap is that the LLM does not explicitly mention 'developer enablement' as a strategic emphasis in 2024, though it does reference 'developer-friendly integration', which partially covers this point. This small omission prevents a perfect 10 but does not undermine the overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1482,
        "completion_tokens": 419,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did 3M's financial relationship with the Aearo Entities evolve between 2023 and 2024, particularly in terms of equity investment and intercompany balances?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities, which resulted in the removal of a $0.7 billion asset balance in equity and other investments and a $0.6 billion net liability for former intercompany amounts from its consolidated balance sheet as of December 31, 2023. By 2024, the Aearo Entities were no longer consolidated, and instead, 3M now 'has a stake in' them, indicating a shift from full consolidation to a retained equity interest. This reflects a significant change in the financial structure and relationship between 3M and the Aearo Entities.",
      "llm_answer": "In 2023, after the court‑ordered reconsolidation of the Aearo Entities, 3M removed a $0.7 billion equity‑investment asset and a $0.6 billion net intercompany liability that had previously been shown on its balance sheet 【page_101】. The 2024 filing again references the reconsolidation of the Aearo Entities but makes no further mention of any separate equity‑investment or intercompany balances, showing that those items have been fully absorbed into the consolidated statements 【page_50】.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the $0.7 billion equity investment asset and $0.6 billion net intercompany liability removed from 3M's balance sheet in 2023, matching the ground truth numerically and contextually. These quantitative elements are accurate and properly attributed to the reconsolidation event. (2) However, the LLM misinterprets the 2024 situation. The ground truth states that by 2024, the Aearo Entities were *no longer consolidated*, and 3M now holds a retained equity stake—indicating a move *away* from consolidation. In contrast, the LLM claims the 2024 filing 'references the reconsolidation' and that balances were 'fully absorbed into the consolidated statements,' which is factually incorrect. Reconsolidation occurred in 2023; by 2024, the entities were deconsolidated again, and 3M holds a stake. This is a critical qualitative error in reasoning and entity relationship understanding. (3) The multi-hop reasoning fails: the model does not correctly trace the evolution from pre-2023 deconsolidation → 2023 reconsolidation → 2024 deconsolidation with retained interest. Instead, it incorrectly assumes consolidation continued into 2024. (4) While numbers are correct (hence quantitative accuracy = 10) and the response is contextually relevant (8), the qualitative inaccuracy in describing the nature of the 2024 relationship severely undermines the correctness, warranting a 4/10 overall score due to a major factual misrepresentation of the financial relationship's evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 419,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Visa's Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of their strategic positioning within the company's broader value-added services portfolio?",
      "original_answer": "In 2022, Visa's Risk and Identity Solutions were described as tools that 'transform data into insights for near real-time decisions' and included named products like Visa Advanced Authorization and Visa Secure. These solutions were positioned primarily around fraud prevention and payment security, with an emphasis on helping clients protect account holder data and prevent fraud in the context of omnichannel commerce. By 2024, Risk and Identity Solutions had been elevated as one of five core categories within a more expansive value-added services portfolio that now includes Open Banking Solutions and Advisory Services. The 2024 report highlights that Visa offered more than 200 products and services as of September 30, 2024, many designed to work together for 'high impact business outcomes,' indicating a broader strategic integration of Risk and Identity Solutions within a more diversified services ecosystem.",
      "llm_answer": "In the 2022 filing Visa’s Risk and Identity Solutions were described as a set of fraud‑mitigation and authentication tools (e.g., Visa Advanced Authorization, Visa Secure, Visa Advanced Identity Score, Visa Consumer Authentication Service) that sat alongside Issuing, Acceptance, Open Banking and Advisory services as one of its value‑added services【page_12_2022】. By the 2024 filing the suite has been rebranded as the “Visa Protect” portfolio and expanded with AI‑driven offerings—Visa Deep Authorization, Visa Protect for A2A Payments and Visa Risk Manager with scheme‑agnostic Advanced Authorization—plus AI/ML‑based authentication and provisioning intelligence, extending protection to real‑time non‑card (A2A) flows and positioning Risk and Identity Solutions as a core, differentiated pillar of Visa’s five‑category value‑added services strategy【page_11_2024】【page_12_2024】.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually strong in many areas but introduces information not present in the ground truth, affecting qualitative accuracy. (1) Correct elements: The 2022 description accurately reflects Risk and Identity Solutions as fraud-mitigation tools with correct product names (Visa Advanced Authorization, Visa Secure), and their placement within value-added services. The evolution into a more strategic role by 2024 is correctly framed, including the expansion of capabilities. (2) Quantitative accuracy is perfect: no specific numbers (dates, dollar amounts, counts) are misstated; the mention of September 30, 2024 from the ground truth is not contradicted. (3) Multi-hop reasoning is generally sound—synthesizing changes between 2022 and 2024 filings—but the claim that the suite was 'rebranded as Visa Protect' and includes specific new products like 'Visa Deep Authorization' and 'Visa Protect for A2A Payments' is not supported by the provided ground truth, which does not mention a rebrand or these specific product names. This represents a significant factual overreach. (4) The ground truth emphasizes structural evolution—elevation to one of five core categories within a broader portfolio of 200+ services—but does not confirm AI-driven expansion or scheme-agnostic features. While the strategic thrust aligns, the LLM adds unverified detail, likely hallucinated or inferred beyond the source. Thus, while the core evolution is captured, the addition of unsupported product names and branding changes reduces qualitative accuracy. Contextual relevance remains high as the response directly addresses the strategic positioning and evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1460,
        "completion_tokens": 451,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did RTX's disclosure and quantification of Acquisition Accounting Adjustments' impact on operating profit evolve between 2023 and 2024?",
      "original_answer": "In 2023, RTX provided specific quantified impacts of Acquisition Accounting Adjustments on operating profit, showing a negative impact of $1,998 million in 2023, compared to $1,893 million in 2022 and $2,203 million in 2021. By 2024, RTX shifted its disclosure approach by providing qualitative policy context about the components of these adjustments, but did not include updated quantitative figures for the current year's impact on operating profit. This represents a move from concrete numerical disclosure to a more conceptual explanation of acquisition accounting practices without continuing the year-over-year quantification.",
      "llm_answer": "In the 2023 Form 10‑K RTX disclosed acquisition‑accounting adjustments only as a single line‑item that reduced operating profit by **$1.998 billion**, accompanied by a brief description of the types of adjustments. In the 2024 filing the company kept the same line‑item but added a detailed breakdown – showing total adjustments of **$2.058 billion** (about **$60 million more** than 2023) and allocating the impact to Collins Aerospace ($833 million), Pratt & Whitney ($312 million) and Raytheon ($913 million) – thereby providing a more granular quantification of the impact on operating profit.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it claims RTX disclosed a $2.058 billion adjustment in 2024, but the ground truth states that RTX did *not* provide updated quantitative figures for 2024—this number is fabricated. The $60 million increase and segment breakdowns (Collins Aerospace, Pratt & Whitney, Raytheon) are also not present in the original answer and contradict the fact that RTX stopped providing year-over-year quantification in 2024. (2) The original answer clearly states that in 2024, RTX shifted to *qualitative* disclosure only, with no new numerical data, whereas the LLM claims a more granular *quantitative* breakdown was provided, which is the opposite of the truth. (3) The reasoning is flawed: instead of recognizing a reduction in disclosure detail (from numbers to policy context), the model incorrectly infers increased transparency with fabricated data. (4) Entity accuracy is partially correct (RTX, correct 2023 figure of ~$1.998B), but the core evolution narrative is reversed. The answer fails the multi-hop requirement to compare disclosure practices across years based on actual filing content. Only contextual relevance is slightly above zero because the topic (acquisition accounting adjustments at RTX) is relevant and the 2023 number is approximately correct, though misrepresented as 'billion' instead of 'million' (though semantically close due to $1,998 million = $1.998 billion).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 408,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Microsoft's Office 365 Commercial revenue contribution to the Microsoft Cloud evolved between fiscal years 2022 and 2023, and what does this indicate about its growth trajectory within the broader cloud ecosystem?",
      "original_answer": "In fiscal year 2022, Office 365 Commercial was explicitly cited as a key growth driver within the Productivity and Business Processes segment, contributing to an 18% overall revenue increase for the company. By fiscal year 2023, Office 365 Commercial was included in a newly disclosed consolidated Microsoft Cloud revenue figure, which reached $111.6 billion in FY2023, up from $91.4 billion in FY2022. This indicates that Office 365 Commercial continued to grow as part of a broader, increasingly transparent cloud revenue portfolio that now includes Azure, LinkedIn (commercial portion), Dynamics 365, and other cloud services.",
      "llm_answer": "Microsoft’s Office 365 Commercial (reported as “Office products and cloud services”) rose from $44.97 billion in FY 2022 to $48.85 billion in FY 2023, yet its share of total Microsoft Cloud revenue slipped from roughly 49 % (44.97 / 91.4 bn) to about 44 % (48.85 / 111.6 bn)【page_93】. This indicates that Office 365 is still growing in absolute terms, but the broader cloud portfolio—especially Azure and other cloud services—is expanding faster, shifting the overall cloud growth trajectory toward a more diversified mix【page_42】.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the growth trajectory of Office 365 Commercial within Microsoft Cloud and notes its relative declining share due to faster growth in other cloud services like Azure, which aligns with the ground truth's emphasis on diversification. However, the specific revenue figures for Office 365 Commercial ($44.97B in FY2022 and $48.85B in FY2023) are not present in the original answer and cannot be verified from the provided ground truth. The original answer does not break out Office 365 Commercial revenue explicitly but instead refers to its role in driving the Productivity and Business Processes segment and inclusion in the broader Microsoft Cloud revenue. (2) The calculations of percentages (49% and 44%) are mathematically accurate based on the numbers provided by the LLM, but since the numerator (Office 365 revenue) is not confirmed in the ground truth, these figures introduce unsupported precision. The Microsoft Cloud totals ($91.4B and $111.6B) are correct as per the original answer. (3) The multi-hop reasoning is sound: the model infers that while Office 365 is growing, its relative contribution is decreasing due to faster expansion in other cloud segments—this is a valid interpretation consistent with the strategic narrative in the original answer. (4) Despite the unsupported specific revenue numbers, the qualitative insight and contextual relevance are strong, accurately reflecting the shift toward a more diversified cloud portfolio. The correctness score is reduced due to the introduction of unverified quantitative data, even though the overall direction and logic of the answer are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 455,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did Merck's alliance revenue related to Lynparza evolve between 2023 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2023, alliance revenue for Lynparza was part of Merck's broader alliance revenue reporting, which included profits based on product sales net of cost of sales and commercialization costs. By 2024, alliance revenue related to Lynparza specifically grew by 9%, driven by higher demand in most international markets. This growth indicates a positive shift in Lynparza's market performance during the period.",
      "llm_answer": "Merck’s Lynparza‑related alliance revenue grew from $1,199 million in 2023 to $1,311 million in 2024 – a rise of roughly 9 percent.  The company said the increase was “largely due to higher demand in most international markets” for the drug under its AstraZeneca collaboration.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Lynparza-related alliance revenue grew by approximately 9% from 2023 to 2024, which aligns with the ground truth. It provides specific dollar amounts ($1,199 million in 2023 and $1,311 million in 2024), and the calculated growth rate is accurate: (1,311 - 1,199) / 1,199 ≈ 0.0934 or 9.34%, which rounds to ~9%, matching the reported figure. These numbers are not in the original answer but are consistent with a 9% growth and plausible given the context; no contradiction with ground truth exists. (2) The quantitative accuracy is perfect: the figures are precise, the percentage change is correctly approximated, and the years are accurate. Format variations (e.g., 'million' vs 'M') are acceptable and correctly interpreted. (3) The reasoning is sound: the LLM identifies the increase and correctly attributes it to 'higher demand in most international markets,' directly reflecting the causal factor in the ground truth. It also correctly references the AstraZeneca collaboration, which is contextually accurate for Lynparza (co-developed and co-commercialized by AstraZeneca and Merck). This shows proper multi-hop synthesis across alliance structure, revenue trends, and market dynamics. (4) The only reason for not scoring a 10 in qualitative accuracy is that the original answer does not specify exact dollar amounts—those may be inferred but are not confirmed in the ground truth. However, since they are consistent with a 9% growth and do not contradict, this is a minor issue. The answer is fully contextually relevant, addressing both the evolution of revenue and the contributing factors as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1166,
        "completion_tokens": 454,
        "total_tokens": 1620
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the treatment and disclosure of the Procter & Gamble 2014 Stock and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of its regulatory context and inclusion in equity compensation reporting?",
      "original_answer": "In 2023, the 2014 Stock and Incentive Compensation Plan was disclosed in the context of regulatory documentation and was referenced alongside other compensation plans and agreements, such as the 2009 and 2019 plans, indicating its active role in executive compensation. By 2024, the plan was included in a broader list of equity compensation plans for reporting on stock issuances upon exercise of options, suggesting a shift from regulatory disclosure to a focus on ownership structure and equity compensation transparency. This evolution indicates a more integrated view of the 2014 plan within the company’s overall equity compensation framework.",
      "llm_answer": "Both the 2023 and 2024 Form 10‑K list the Procter & Gamble 2014 Stock and Incentive Compensation Plan together with the other equity‑compensation plans in Item 12’s table, but, like in 2023, the footnote makes clear that only the 2019 plan can issue future grants. The plan’s terms and the Compensation and Leadership Development Committee’s regulations are still disclosed by incorporation‑by‑reference to Exhibits 10‑24, 10‑25 and 10‑26, and the filing points to the Proxy Statement filed under Regulation 14A for additional detail—so the regulatory context and reporting treatment of the 2014 plan remain essentially unchanged from 2023 to 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is factually consistent in terms of entities, dates, and regulatory references (e.g., correct mention of Form 10-K, Item 12, Exhibits 10-24 to 10-26, Regulation 14A, and the 2019 plan being the only one allowing future grants), which supports a high quantitative and entity accuracy score. However, the core of the question asks about the *evolution* in treatment and disclosure of the 2014 plan between 2023 and 2024, particularly regarding regulatory context and equity compensation reporting. The LLM concludes that the treatment 'remains essentially unchanged,' which directly contradicts the ground truth, which identifies a meaningful shift—from regulatory-focused disclosure in 2023 to a broader integration into equity compensation transparency and ownership structure reporting in 2024. The LLM fails to recognize or report this evolution, likely due to overreliance on surface-level consistency (e.g., both years listing the plan in Item 12). This represents a critical failure in multi-hop reasoning and qualitative synthesis. While the LLM accurately reports *what* is disclosed, it misses the *significance* and *shift in context* of that disclosure. Thus, despite correct details, the answer is semantically divergent from the ground truth in its conclusion, warranting a low correctness and qualitative accuracy score. Contextual relevance is moderate because the answer addresses the right documents and sections but misinterprets the trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 404,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the treatment of the 1992 Stock Plan evolved between the 2023 and 2024 10-K filings, particularly in terms of its role within the company's equity compensation structure?",
      "original_answer": "In the 2023 10-K filing, the 1992 Stock Plan was referenced as an adopted plan with specific terms and conditions incorporated by reference to prior filings. However, in the 2024 10-K filing, the 1992 Stock Plan is listed among other equity compensation plans in a consolidated table that outlines shares authorized for issuance upon the exercise of options, warrants, and rights. This indicates a shift from a standalone referenced plan to one being tracked alongside newer plans, suggesting its role has transitioned from active adoption to a more passive stake within the broader equity compensation framework.",
      "llm_answer": "In the 2023 Form 10‑K the Procter & Gamble 1992 Stock Plan is simply listed as one of the company’s equity‑compensation plans (see Exhibit 10‑3) without any comment on its ability to issue new awards【page_69】. In the 2024 Form 10‑K the plan still appears in the aggregated equity‑compensation table, but the filing now explicitly notes that “only the Procter & Gamble 2019 Stock and Incentive Compensation Plan … allows for future grants of securities,” indicating that the 1992 Stock Plan is now treated as a legacy plan that only contributes to outstanding options/RSUs and is not used for new grants【page_68】.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the treatment of the 1992 Stock Plan in both the 2023 and 2024 10-K filings: in 2023, it was listed without commentary on new awards, and in 2024, it was included in the aggregated equity-compensation table with an explicit note that only the 2019 plan allows future grants. This matches the ground truth's assertion of a shift from active adoption to a passive, legacy role. (2) There are no numeric values (e.g., dollar amounts, share counts) in either the question or answers, so quantitative accuracy is not applicable in that sense, but all dates (1992, 2023, 2024, 2019) are correct and consistently used—hence a score of 10. (3) The reasoning is sound: the LLM correctly infers from the 2024 filing that the 1992 plan is no longer used for new grants, which represents a valid multi-hop synthesis between the presence of the plan in disclosures and the explicit statement about future grant eligibility. The only minor shortcoming is that the LLM does not explicitly mention the 'incorporated by reference' aspect from the 2023 filing as noted in the ground truth, slightly reducing completeness in qualitative terms. (4) The answer is fully contextually relevant, directly addressing the evolution of the plan’s role within the equity compensation structure. Overall, the LLM captures the essential evolution accurately and clearly, warranting a 9/10 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 406,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the company's emphasis on large-scale transformations evolved between 2023 and 2024, particularly in terms of client spending patterns and revenue conversion timelines?",
      "original_answer": "In 2023, the filing noted that clients were reducing or deferring spending on smaller contracts with shorter durations and that there was a slowdown in client spending, especially for consulting services. However, clients were still prioritizing large-scale transformations, which convert to revenue over a longer period. In 2024, the filing reiterated that clients continued to prioritize large-scale transformations, emphasizing the ongoing shift toward longer-duration contracts. While there was no explicit quantitative metric provided in either year, the repeated emphasis in both filings on the extended revenue conversion timeline for large-scale transformations indicates a strategic reinforcement of this focus, especially amid ongoing economic volatility.",
      "llm_answer": "The company’s focus on large‑scale transformation work has stayed steady, but the backdrop has changed. In the 2023 filing Accenture noted that “clients continue to prioritize large‑scale transformations, which convert to revenue over a longer period.” By the 2024 filing the same priority is reaffirmed, but it adds that “some of these conditions slowed the pace and level of client spending, particularly for smaller contracts with a shorter duration… Clients continue to prioritize large‑scale transformations, which convert to revenue over a longer period” —showing that spending on smaller, short‑term deals has contracted while transformation projects now generate revenue over an even longer horizon. 【page_21】",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution between 2023 and 2024: in 2023, clients were prioritizing large-scale transformations despite a slowdown in spending on smaller, short-duration contracts; in 2024, this trend continued, with explicit mention of slowed spending on smaller deals and reaffirmed focus on long-term transformations. The key qualitative points—client spending patterns shifting away from short-term contracts and the extended revenue conversion timeline—are all present. (2) There are no numeric values in the original or LLM answer, so quantitative accuracy is not applicable beyond correct handling of time periods (2023 vs 2024), which is accurate. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly identifying continuity in strategic emphasis while noting the deepening context in 2024 about spending slowdowns. The only minor shortcoming is that the LLM implies the 2024 filing states transformation projects now convert revenue over an 'even longer horizon,' which is not explicitly stated—the original answer notes the timeline is long but doesn't indicate it has lengthened. This slight overinterpretation prevents a perfect 10. (4) The answer is fully contextually relevant, directly addressing client spending patterns and revenue conversion timelines as asked. Overall, the response is factually correct, well-supported, and semantically equivalent to the ground truth with only minor interpretive overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 430,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How did Accenture's issuance of Class A Ordinary Shares for employee compensation change from fiscal 2023 to 2024, and what was the impact on the company's equity structure?",
      "original_answer": "In fiscal 2023, Accenture acquired Class A Ordinary Shares primarily through share withholding for payroll tax obligations related to employee equity awards. In fiscal 2024, the company issued 7,970 Class A Ordinary Shares specifically for employee share programs, while also purchasing 12,181 treasury shares. This shift reflects a more active use of Class A Ordinary Shares for compensation purposes in 2024. The equity structure was impacted as Class A Ordinary Shares increased from 15,656,591 in 2023 to 15,664,561 in 2024, while treasury shares decreased in value from $(3,408,491) million to $(6,678,037) million, indicating a significant reallocation of shares for employee programs.",
      "llm_answer": "Accenture raised the amount of Class A Ordinary Shares it issued for employee‑share programs from **7,970 shares in fiscal 2023** to **8,883 shares in fiscal 2024** – an increase of 913 shares【page_70】.  The associated equity contribution grew from roughly **$1.94 billion of additional paid‑in capital and a $1.35 billion increase to total shareholders’ equity** in FY 2023 to **$2.15 billion of additional paid‑in capital and a $1.50 billion increase to total shareholders’ equity** in FY 2024, expanding the overall equity base and slightly diluting existing shareholders【page_71】.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Accenture did not issue 7,970 shares in 2023 for employee programs; instead, it acquired shares via withholding for tax obligations. The issuance of 7,970 Class A Ordinary Shares occurred in 2024, not an increase from 7,970 in 2023 to 8,883 in 2024 as claimed. The LLM incorrectly states increasing issuance when the ground truth shows a shift from share acquisition (2023) to issuance (2024). Additionally, the dollar amounts mentioned ($1.94B, $2.15B, etc.) are not present in the original answer and appear fabricated. (2) Quantitative accuracy is severely lacking: the share numbers are wrong (7,970 in 2023 vs. actual no issuance in that context), the increase of 913 shares is based on false premises, and the financial figures (e.g., $1.94 billion additional paid-in capital) have no support in the ground truth. The original answer discusses changes in total shares outstanding and treasury shares but provides no dollar values for equity contributions. (3) The multi-hop reasoning is flawed. The LLM fails to recognize the qualitative shift from share withholding/acquisition in 2023 to issuance in 2024, instead portraying a simple numerical increase. It also introduces unsupported impacts like 'slight dilution' and specific equity account changes not mentioned in the ground truth. The synthesis across years is incorrect. (4) Contextual relevance is moderate because the answer addresses employee share programs and equity structure changes, but the incorrect data and reasoning undermine its usefulness. The mention of 'page_70' and 'page_71' suggests citation, but the content does not align with the verified facts. Overall, major factual and conceptual errors lead to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 492,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did MDLZ's exposure to Canadian-denominated debt instruments change between 2022 and 2023, and how does this shift compare to the company's overall trend in managing foreign currency-denominated debt during this period?",
      "original_answer": "In 2022, MDLZ reported a decrease in Canadian notes of $3 million, continuing a trend of declining balances from $17 million in 2019 to $7 million in 2020 and $3 million in 2021. However, in 2023, the company experienced an increase in Canadian notes by $8 million, reversing the previous downward trajectory. This shift contrasts with the broader pattern of fluctuating foreign currency exposure, where Euro notes decreased significantly from $211 million in 2021 to $81 million in 2023, while Swiss franc notes also showed volatility. The reversal in Canadian notes indicates a notable deviation from the prior year's trend of reducing exposure to this currency denomination.",
      "llm_answer": "MDLZ’s net‑investment‑hedge notional for Canadian‑dollar notes increased to **$453 million in 2023 from $443 million at year‑end 2022** (≈ $10 million or 2 % higher)【page_97】, and the after‑tax result on those notes turned from a **$25 million gain in 2022 to an $8 million loss in 2023**【page_98】.  This modest rise in Canadian exposure occurred while the company was broadly reshaping its foreign‑currency debt mix – Euro‑denominated notes grew (3,516 → 3,410 million) and Swiss‑franc notes fell sharply (386 → 638 million)【page_97】, and overall hedging outcomes shifted from gains to losses across currencies, indicating a general rebalancing and weaker performance of its foreign‑currency debt hedges in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitatively, the LLM claims MDLZ's Canadian-dollar note notional increased from $443M to $453M in 2023, implying a $10M rise. However, the ground truth states that Canadian notes decreased to $3M in 2022 and then increased by only $8M in 2023—meaning the actual balance went from $3M to $11M, not hundreds of millions. The LLM’s figures are off by an order of magnitude. Additionally, the LLM cites Euro notes growing from 3,516 to 3,410 million (a decrease, not increase), and Swiss franc notes rising from 386 to 638 million (an increase), whereas the ground truth notes a sharp decline in Euro notes from $211M to $81M over 2021–2023 and volatility in Swiss franc notes—again, the LLM’s numbers do not align. (2) The LLM confuses 'net-investment-hedge notional' with actual debt balances, which are distinct concepts; the question asks about exposure to Canadian-denominated debt instruments, not hedge positions. (3) Qualitatively, the reasoning is flawed: while the LLM identifies a reversal in Canadian exposure, it mischaracterizes the scale and context. It also incorrectly frames Euro and Swiss franc trends, contradicting the ground truth. (4) Contextually, the answer addresses the right topic—foreign currency debt management—and attempts multi-hop synthesis across currencies and years, but due to incorrect data sources or misinterpretation of the filings, the conclusions are invalid. The mention of hedging gains/losses adds context not directly requested, but distracts from the core question about debt exposure levels. Overall, major factual and conceptual errors lead to a low correctness score despite some structural relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 472,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Accenture's approach to engaging with growth-stage companies evolved from 2023 to 2024, particularly in terms of strategic involvement and investment activity?",
      "original_answer": "In 2023, Accenture Ventures was described as primarily partnering with growth-stage companies that create innovative enterprise technologies. By 2024, the relationship evolved from a partnership model to a more direct investment approach, indicating a deeper financial and strategic commitment. This shift from 'partners with' to 'invests in' growth-stage firms suggests Accenture is taking a more active role in shaping innovation ecosystems through capital allocation, aligning with its broader innovation strategy supported by $1.3 billion in R&D spending in fiscal 2023 and $1.2 billion in fiscal 2024.",
      "llm_answer": "In its 2023 filing Accenture noted that Accenture Ventures “partners with and invests in growth‑stage companies that create innovative enterprise technologies,” positioning the unit as a strategic partner and investor (page_17). By the 2024 filing the firm emphasized a deeper integration of those companies into its broader innovation ecosystem—linking them to Accenture Labs, its global delivery network, and a larger R&D budget of $1.2 billion in FY 24—signaling a more active, investment‑focused engagement (page_17).",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) Quantitatively, all numbers and dates are accurate: the $1.2 billion R&D spending in FY24 is correctly cited, and while the $1.3 billion from FY23 is omitted, this is a minor omission rather than an error. (2) The shift from 'partners with' to a more investment-focused approach is accurately conveyed, though the LLM slightly misrepresents the 2023 stance by stating Accenture Ventures both 'partners with and invests in' growth-stage companies, whereas the ground truth specifies that in 2023 the emphasis was on 'partnering'—the investment role was not highlighted until 2024. This overstates the continuity and understates the evolution. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes information across years, connects Accenture Ventures to Accenture Labs and the delivery network, and links increased integration to strategic engagement. (4) Contextual relevance is excellent—the response directly addresses the evolution in strategic involvement and investment activity. The answer captures the essence of deeper integration and active engagement, even if it slightly softens the contrast between 2023 and 2024. Thus, the correctness score is 8 due to minor overstatement of 2023 investment activity, but quantitative accuracy remains perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 373,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Merck's financial and strategic involvement in the Lynparza collaboration with AstraZeneca evolved from 2022 to 2024, particularly in terms of asset amortization and alliance revenue growth?",
      "original_answer": "In 2022, Merck was amortizing an intangible asset balance of $1.1 billion related to Lynparza, which included capitalized milestone payments, and was expected to be amortized through 2028. By 2024, the focus shifted from asset amortization to revenue growth, with alliance revenue from Lynparza increasing by 9% due to higher demand in international markets. Additionally, in early 2025, Lynparza received a new approval in China for adjuvant treatment in early breast cancer, indicating an expansion in its therapeutic footprint and strategic importance to Merck.",
      "llm_answer": "Merck’s Lynparza asset, which captures the capitalized sales‑based and regulatory milestone payments, was recorded at about **$1.1 billion at the end of 2021 and is being amortized on a straight‑line basis through 2028**【page_102】.  The profit‑share portion of the deal – reported as alliance revenue – **rose from $1.116 billion in 2022 to $1.311 billion in 2024** (a 9 % increase in 2024 and roughly an 18 % gain versus 2022)【page_53】, indicating that Merck’s financial stake and commercial upside in the AstraZeneca‑Lynparza partnership have grown while the amortization schedule for the underlying intangible asset remains unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually correct and aligns closely with the ground truth. It accurately reports the $1.1 billion intangible asset balance related to Lynparza being amortized through 2028, consistent with the original answer. The alliance revenue increase is correctly quantified: from $1.116 billion in 2022 to $1.311 billion in 2024, representing a 9% increase in 2024 (which matches the '9% due to higher demand' in the ground truth). The calculation of ~18% growth from 2022 to 2024 is mathematically accurate ((1.311 - 1.116)/1.116 ≈ 17.5%, rounded to 18%), though this specific comparison wasn't in the original answer, it doesn't contradict it. (2) All numbers, dates, and percentages are correct: $1.1 billion asset, straight-line amortization through 2028, revenue figures for 2022 and 2024, and the 9% growth in 2024 are all supported. Format variations (e.g., $1.116 billion vs $1.116B) are acceptable and semantically equivalent. (3) The multi-hop reasoning is sound: the model correctly synthesizes information about asset amortization (a balance sheet/expense topic) and revenue growth (an income statement topic) across time (2022 to 2024), showing evolution in Merck's financial involvement. It correctly infers that while amortization continues on a fixed schedule, the growing alliance revenue reflects increasing commercial success. (4) The only minor omission is the mention of the early 2025 China approval for adjuvant treatment in early breast cancer, which adds strategic context about therapeutic expansion. While this detail enhances the strategic narrative, its absence does not undermine the core financial and strategic evolution described. The LLM captures the key financial evolution—shift from amortization focus to revenue growth—accurately. Thus, the answer is highly accurate, complete on financials, and contextually relevant, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 539,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has AVGO's strategic emphasis on ValueOps changed between 2023 and 2024, and what does this indicate about its evolving role in the Distributed Software portfolio?",
      "original_answer": "In 2023, ValueOps was listed as one of several key offerings under AVGO's Distributed Software portfolio, positioned alongside other solutions like DevOps and AIOps without specific elaboration on its strategic role. By 2024, ValueOps was elevated to be one of the three core domains—alongside DevOps and AIOps—that AVGO's distributed software solutions are 'organized in the domains of,' with an explicit emphasis on delivering 'end-to-end visibility across all stages of the digital lifecycle.' This indicates a strategic shift where ValueOps became more central to AVGO's value proposition, aligning it more deeply with business outcomes and customer experiences. The change reflects a broader evolution from being a feature in the portfolio to a foundational pillar supporting enterprise digital transformation.",
      "llm_answer": "In both the 2023 and 2024 10‑K filings Broadcom continues to list ValueOps as one of the three core domains of its Distributed Software portfolio and describes it in the same way—as a “value‑stream management” solution that aligns business and development teams and improves time‑to‑value (2023 p.10‑11; 2024 p.10‑11). The wording and placement are essentially unchanged, indicating that ValueOps remains a stable, foundational pillar of the Distributed Software suite rather than a newly‑emphasized or de‑emphasized focus.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim. According to the ground truth, AVGO's strategic emphasis on ValueOps changed significantly between 2023 and 2024: in 2023, ValueOps was one of several offerings without special prominence, but in 2024 it was elevated to a core domain alongside DevOps and AIOps, with explicit emphasis on end-to-end visibility across the digital lifecycle. The LLM incorrectly states that the wording and placement were 'essentially unchanged' and that ValueOps was already one of the three core domains in 2023, which contradicts the ground truth. This misrepresents the evolution of ValueOps from a portfolio component to a foundational pillar. There are no numeric values to verify, so quantitative accuracy is not applicable (scored 10 by default for absence of errors). Qualitative accuracy is very low due to incorrect reasoning and failure to identify the strategic shift. Contextual relevance is moderate because the answer addresses the right topic and company, but with incorrect synthesis across years. The model failed the multi-hop reasoning required to compare the strategic positioning of ValueOps across two filings and draw the correct inference about its evolving role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 343,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did FedEx's strategic approach to Network 2.0 within the DRIVE transformation evolve between 2023 and 2024, particularly in terms of expected cost savings and implementation risks?",
      "original_answer": "In 2023, FedEx emphasized the strategic importance of Network 2.0 as part of its DRIVE transformation, noting that significant investments were being made with the expectation of achieving operational efficiencies, network flexibility, and alignment of the cost base with demand. However, the filing acknowledged that the failure to successfully execute Network 2.0 within the expected time frame and cost could adversely affect future results. By 2024, FedEx shifted focus to the integration complexities of Network 2.0, including risks related to harmonizing operating practices, maintaining customer and service provider agreements, addressing labor and cultural differences, and managing unforeseen expenses. The 2024 filing also noted that the actual amount and timing of cost savings and permanent cost reductions might differ from expectations, and that asset impairment charges, tax impacts, and litigation risks could arise. This reflects a transition from strategic planning and investment justification in 2023 to operational integration and financial risk mitigation in 2024.",
      "llm_answer": "In the 2023 filing FedEx presented Network 2.0 as a cornerstone of its DRIVE transformation that was expected to deliver “operational efficiencies, network flexibility, alignment of our cost base with demand, and cost‑savings and reductions to our permanent cost structure,” while cautioning that the actual amount and timing of those savings could differ from its estimates (see 2023 p. 32). By the 2024 filing the discussion had become far more risk‑focused – FedEx now enumerates specific integration, labor‑status, regulatory, cultural and legal hurdles and warns that the program could cost more, generate less‑than‑expected savings and take longer to complete, making execution risk a central concern (see 2024 p. 28‑29 & 31).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of FedEx's strategic approach to Network 2.0 between 2023 and 2024 as described in the ground truth. (1) It correctly identifies that in 2023, FedEx emphasized operational efficiencies, cost alignment, and permanent cost reductions through Network 2.0 as part of DRIVE, while cautioning about uncertainty in the timing and amount of savings—consistent with the original answer. In 2024, it accurately reflects the shift toward heightened focus on integration risks, including labor, cultural, regulatory, and legal challenges, as well as potential cost overruns and delays. (2) There are no numeric values (e.g., dollar amounts, percentages, dates) in either the question or ground truth, so quantitative accuracy is not applicable in a numerical sense; however, the cited page numbers (2023 p. 32; 2024 pp. 28–29 & 31) are treated as contextual references and match typical disclosure locations, which supports fidelity to source material. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly identifying the shift from strategic justification to risk mitigation. The only minor shortcoming is that the LLM omits explicit mention of 'asset impairment charges' and 'tax impacts' noted in the 2024 filing, which are part of the financial risks in the ground truth. This slight omission prevents a perfect 10 on qualitative accuracy. (4) The answer is fully contextually relevant, directly addressing both expected cost savings and implementation risks across the two years. Overall, the response is factually correct, well-reasoned, and semantically equivalent to the ground truth with only minor detail omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1464,
        "completion_tokens": 469,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did the financial impact from equity method investment contracts evolve between 2022 and 2023, and what does this indicate about MDLZ's engagement with these investments?",
      "original_answer": "In 2022, MDLZ reported a net liability of $3 million related to equity method investment contracts. By 2023, this position had shifted to a gain of $7 million from equity method investment contracts, indicating a reversal in financial impact and potentially more active or favorable engagement with these investments. This evolution highlights a strategic or operational shift in how MDLZ managed these equity method investments over the two years.",
      "llm_answer": "In 2022 MDLZ’s equity‑method investment contracts showed a small negative fair‑value position of $(3) million and no gain or loss was recorded (see page 96). By 2023 the company reported a $7 million pre‑tax gain from those contracts (see page 98). The swing from a neutral/negative impact to a modest positive contribution indicates that MDLZ’s equity‑method investment – chiefly its JDE Peet’s exchangeable‑bond position – remained active and delivered a small upside in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the financial impact shift: from a $3 million net liability (negative fair-value position) in 2022 to a $7 million pre-tax gain in 2023, matching the ground truth. The numbers, years, and direction of change are accurate. 2) Quantitatively, all figures are correct: $(3) million in 2022 and $7 million gain in 2023. The LLM adds contextual detail (page references and mention of JDE Peet’s exchangeable bond), which aligns with typical 10-K disclosures and does not contradict the ground truth. 3) The reasoning is sound: the shift from a negative/neutral impact to a positive gain indicates more favorable engagement, which the LLM interprets as 'active and delivered a small upside'—a reasonable inference. The original answer notes a 'strategic or operational shift,' while the LLM specifies the JDE Peet’s instrument, adding precision without overreach. 4) The LLM slightly exceeds the ground truth in specificity (naming JDE Peet’s), which is acceptable if supported by source documents. However, the original answer does not mention the lack of gain/loss recording in 2022 or the pre-tax nature in 2023, so those details, while potentially accurate, are not verifiable from the ground truth alone. Still, they do not detract from correctness. Overall, the answer is factually aligned, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 380,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did Broadcom's (AVGO) estimated cost to complete for the VMware Cloud Foundation July 2024 releases evolve from fiscal year 2023 to fiscal year 2024, and what does this indicate about the development progress relative to expectations?",
      "original_answer": "The estimated cost to complete for the VMware Cloud Foundation July 2024 releases remained unchanged at $38 million from fiscal year 2023 to fiscal year 2024. This consistency in the cost estimate indicates that the development progress for this product was proceeding largely as planned, with actual expenditures aligning with earlier projections. The lack of an increase or decrease in the estimated cost to complete suggests that Broadcom (AVGO) did not encounter significant unexpected expenses or delays in the development timeline for this specific release.",
      "llm_answer": "Broadcom’s estimate for the remaining work on the VMware Cloud Foundation July 2024 releases was $38 million in the FY 2023 filing and remained $38 million in the FY 2024 filing 【page_69】.  The unchanged cost‑to‑complete figure signals that the program is progressing on schedule and that Broadcom does not anticipate any additional overruns beyond its original expectations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Broadcom's estimated cost to complete for the VMware Cloud Foundation July 2024 releases was $38 million in both fiscal years 2023 and 2024, which matches the ground truth exactly. All numeric values and fiscal years are accurate. (2) The dollar amount ($38 million) is consistent across both years, and no calculation is required beyond comparison—this is handled correctly. Format is acceptable with '$38 million' matching ground truth semantics. (3) The reasoning is sound: the unchanged cost is correctly interpreted as indicating on-schedule progress and absence of budget overruns, aligning with the ground truth's conclusion about development proceeding as planned. The LLM infers that no additional overruns are expected, which is logically equivalent to the original answer’s statement about actual expenditures aligning with projections. (4) The only minor shortcoming is that the LLM does not explicitly mention the absence of both delays *and* underspending (i.e., it doesn’t note that lack of decrease also implies no acceleration), but this does not detract significantly from the overall correctness. The core multi-hop synthesis—comparing cost-to-complete across two fiscal years and interpreting stability—is executed accurately. Thus, full marks for quantitative accuracy and contextual relevance, near-perfect qualitative accuracy, and a 9/10 overall due to slight incompleteness in nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 404,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has the strategic positioning of FedEx Office's Ship and Go kiosk evolved between 2023 and 2024, and what does this indicate about the company's approach to e-commerce logistics and returns management?",
      "original_answer": "In 2023, the Ship and Go kiosk was described primarily as a self-serve shipping solution available in approximately 1,300 locations, allowing customers to generate labels via mobile or QR code and drop off packages securely. While it mentioned facilitating e-commerce returns, the integration was not emphasized. By 2024, the description of Ship and Go remained consistent in terms of presence (still in approximately 1,300 locations) and core functionality, but there was a notable shift in emphasis: it was now more explicitly tied to FedEx Returns Technology and Consolidated Returns, highlighting its role in in-store printing of return labels and enabling customers to drop off returns without a box or label. This evolution indicates a strategic shift toward positioning Ship and Go not just as a shipping tool, but as a key node in FedEx's broader e-commerce returns infrastructure.",
      "llm_answer": "- 2023 Form 10‑K (FedEx Office description on page 15) presented the Ship and Go kiosk primarily as a self‑serve shipping station in roughly 1,300 FedEx Office locations, letting customers generate a label via a mobile label or QR code and drop packages in a secure bin.  \n- 2024 Form 10‑K (same section on page 15) still highlights the kiosk’s 1,300‑location footprint but now couples it with FedEx Returns Technology and Consolidated Returns, emphasizing label‑less, box‑free returns and positioning the kiosk as part of an end‑to‑end e‑commerce and returns solution.  \n\nThis evolution shows FedEx moving the kiosk from a simple shipping convenience to a broader e‑commerce logistics hub, reinforcing its strategy to capture more online‑shopping volume and simplify the returns process for merchants and consumers.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all key aspects. (1) Quantitatively, the number of locations (approximately 1,300) is accurately reported for both 2023 and 2024, with no incorrect figures or miscalculations. (2) The answer correctly identifies the evolution in strategic positioning: from a self-serve shipping tool in 2023 to an integrated component of FedEx's returns infrastructure in 2024, explicitly tied to FedEx Returns Technology and Consolidated Returns. (3) The multi-hop reasoning is sound—by comparing the 2023 and 2024 10-K descriptions, the model correctly infers a strategic shift in emphasis, even though the physical footprint remained stable. (4) The conclusion that FedEx is positioning the kiosk as part of a broader e-commerce logistics and returns solution is semantically equivalent to the ground truth and well-supported by the evidence. All entities (FedEx Office, Ship and Go, FedEx Returns Technology, Consolidated Returns), years (2023, 2024), and functional changes (label-less, box-free returns) are accurately identified and synthesized. Wording differs slightly but meaning is preserved. No omissions or inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 332,
        "total_tokens": 1773
      },
      "error": null
    }
  ],
  "evaluation_summary": {
    "total_questions": 1000,
    "successful_evaluations": 1000,
    "failed_evaluations": 0,
    "average_correctness_score": 6.87,
    "average_quantitative_accuracy": 7.62,
    "average_qualitative_accuracy": 7.11,
    "average_contextual_relevance": 8.88,
    "score_distribution": {
      "excellent": 467,
      "good": 148,
      "fair": 219,
      "poor": 166
    }
  },
  "original_experiment_metadata": {
    "model": "gpt-oss-120b-reasoning",
    "experiment": "e5_page_window_relevance_asc",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions": 1000,
    "successful": 1000,
    "failed": 0,
    "elapsed_seconds": 8768.91,
    "timestamp": "2026-02-02T18:06:34.647002"
  }
}